{"meta":{"query_hash":"7437e4e67cc8","filters":{"topic":"Chronic Myeloid Leukemia Treatments"},"cohort_total":1136,"direct_labels_cover":0,"predictions_cover":1136,"exported":1136,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/7437e4e67cc8","api":"https://metacan.xera.ac/api/v1/cohort?topic=Chronic+Myeloid+Leukemia+Treatments"},"results":[{"id":"W1023475980","doi":"","title":"Regulation of KISS1 in Uveal Melanoma Cell Lines Treated With Imatinib Mesylate by MicroRNAs, SP1 and DRIP-130","year":2010,"lang":"en","type":"article","venue":"Investigative Ophthalmology & Visual Science","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Imatinib mesylate; Medicine; Mesylate; Cancer research; Imatinib; Chemistry","score_opus":0.01606515778792145,"score_gpt":0.30124870404081333,"score_spread":0.2851835462528919,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1023475980","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976291,0.00009499002,7.0367685e-7,0.00024772948,0.00006111972,0.0004969766,0.000015035278,0.000022999979,0.0014313387],"genre_scores_gemma":[0.9956507,0.000004771761,0.003730153,0.00005172048,0.000026442107,0.000025735097,0.000033027492,0.000018512483,0.0004589477],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99816287,0.00008492951,0.00038840444,0.00061701424,0.00033463107,0.00041212767],"domain_scores_gemma":[0.99882156,0.0001413207,0.00028360626,0.00026943715,0.00020049722,0.0002835526],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.00042956433,0.0002559341,0.00044446156,0.0002442546,0.00011272464,0.00001758851,0.00017711797,0.00016297944,0.000109068205],"category_scores_gemma":[0.00023362339,0.00019313129,0.000027870581,0.0008494469,0.004310612,0.00024089233,0.00008819296,0.00032576162,0.000010777478],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009234854,0.00013535218,0.3219872,0.000024748579,0.000011235517,0.000097284,0.0003973319,0.0000017873845,0.67705643,0.000016520076,0.00001867233,0.00016105914],"study_design_scores_gemma":[0.0016418572,0.0009881832,0.4140737,0.00006367609,0.000027159436,0.0004497622,0.000070633374,0.00044401095,0.5819184,0.0002046336,0.000009619102,0.00010834523],"about_ca_topic_score_codex":0.00084439997,"about_ca_topic_score_gemma":0.00003608171,"teacher_disagreement_score":0.09513803,"about_ca_system_score_codex":0.00018471901,"about_ca_system_score_gemma":0.00063833006,"threshold_uncertainty_score":0.9983991},"labels":[],"label_agreement":null},{"id":"W112559982","doi":"10.1182/blood.v122.21.92.92","title":"ENESTnd Update: Nilotinib (NIL) Vs Imatinib (IM) In Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) and The Impact Of Early Molecular Response (EMR) and Sokal Risk At Diagnosis On Long-Term Outcomes","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Nilotinib; Discontinuation; Internal medicine; Imatinib mesylate; Imatinib; Myeloid leukemia; Gastroenterology; Oncology","score_opus":0.008635732933922944,"score_gpt":0.2706753204529666,"score_spread":0.26203958751904366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W112559982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99422675,0.001997608,0.0000023283603,0.00017166388,0.00003392581,0.003386222,0.000105194085,0.000042388598,0.000033903794],"genre_scores_gemma":[0.99761546,0.0011917786,0.00009605363,0.000100178804,0.00004165296,0.0007028108,0.00009599196,0.00010131129,0.000054752803],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964321,0.00056443195,0.0008409701,0.0007923679,0.0005831528,0.00078694336],"domain_scores_gemma":[0.9969607,0.0011854622,0.0004914869,0.00094763417,0.00009739195,0.00031730058],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005460545,0.00066962733,0.0011942057,0.00037719385,0.00012139258,0.00006413595,0.00024073894,0.00023254017,0.00020733498],"category_scores_gemma":[0.00051247835,0.00041880083,0.00020111192,0.00041659301,0.00051618606,0.0002500221,0.00020540308,0.00052901614,0.00004252789],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009824982,0.0017905238,0.97856987,0.00014987473,0.0005789409,0.0003428791,0.0009753854,0.00015248466,0.0011607198,0.0000049260816,0.000047090318,0.0064023505],"study_design_scores_gemma":[0.16874434,0.008290455,0.8157186,0.0005874836,0.00042594585,0.00003444218,0.000021829532,0.00021116408,0.005624371,0.000015032461,0.000003875464,0.00032247315],"about_ca_topic_score_codex":0.0060482025,"about_ca_topic_score_gemma":0.0010718,"teacher_disagreement_score":0.16285126,"about_ca_system_score_codex":0.004470751,"about_ca_system_score_gemma":0.0014393274,"threshold_uncertainty_score":0.9998264},"labels":[],"label_agreement":null},{"id":"W129265093","doi":"10.1182/blood.v122.21.4025.4025","title":"Bosutinib As Therapy For Chronic Phase Chronic Myeloid Leukemia Following Failure With Imatinib Plus Dasatinib and/Or Nilotinib: 36-Month Update","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Bosutinib; Nilotinib; Dasatinib; Medicine; Internal medicine; Imatinib; Gastroenterology; Imatinib mesylate; Myeloid leukemia; Tyrosine-kinase inhibitor; Cancer","score_opus":0.014754208368096456,"score_gpt":0.2843805241773604,"score_spread":0.269626315809264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W129265093","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857772,0.0045015,0.00024020115,0.0012080483,0.00018018064,0.0062559056,0.00007165917,0.0004282586,0.0013370367],"genre_scores_gemma":[0.9822891,0.0007658426,0.009703229,0.0007890338,0.00096833607,0.0021573424,0.0005108469,0.00028523017,0.0025310703],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99592954,0.00008727435,0.0008312164,0.0011811316,0.00066240795,0.001308458],"domain_scores_gemma":[0.9973436,0.00031977994,0.00040625024,0.0011758036,0.00017489826,0.0005796867],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00034396126,0.00086883834,0.0012323787,0.00020182924,0.00039124535,0.00017498781,0.00035011265,0.0003318743,0.0014945763],"category_scores_gemma":[0.00016343378,0.0006083212,0.0003450972,0.00039391848,0.00020922272,0.00048331547,0.000116809606,0.0005064086,0.00037775908],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027380059,0.01576765,0.017505415,0.0072233747,0.028710946,0.0039078984,0.012724538,0.00026270893,0.2319655,0.0016700838,0.048317473,0.60456437],"study_design_scores_gemma":[0.7010741,0.049553085,0.0073265377,0.0032935485,0.0047466517,0.0030401882,0.00168376,0.007575487,0.11424727,0.00047903802,0.10364019,0.0033401456],"about_ca_topic_score_codex":0.00040737653,"about_ca_topic_score_gemma":0.00027375942,"teacher_disagreement_score":0.673694,"about_ca_system_score_codex":0.0022029395,"about_ca_system_score_gemma":0.0053332304,"threshold_uncertainty_score":0.9996368},"labels":[],"label_agreement":null},{"id":"W1484884408","doi":"10.1200/jco.2012.30.15_suppl.6505","title":"Switch to nilotinib versus continued imatinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with detectable BCR-ABL after 2 or more years on imatinib: ENESTcmr 12-month (mo) follow-up.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Princess Margaret Cancer Centre","funders":"","keywords":"Nilotinib; Imatinib; Medicine; Discontinuation; Internal medicine; Imatinib mesylate; Myeloid leukemia; Clinical endpoint; Oncology; Gastroenterology; Clinical trial","score_opus":0.05594910151100691,"score_gpt":0.3982784705581594,"score_spread":0.3423293690471525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1484884408","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99518836,0.00046068837,0.000028830573,0.00045830966,0.0012562558,0.0017111611,0.000021125621,0.00003427874,0.0008410031],"genre_scores_gemma":[0.99350864,0.00015820109,0.0032696316,0.0009093167,0.0012652857,0.00017116865,0.0000240341,0.00013722094,0.0005565291],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99283254,0.00056129403,0.0033659053,0.000675727,0.001148125,0.0014164108],"domain_scores_gemma":[0.9935903,0.0022489517,0.002010221,0.0006667162,0.00037045954,0.0011133405],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024898709,0.0006511961,0.003054674,0.0005609224,0.00005599488,0.000029302182,0.000429074,0.00069345493,0.00053693843],"category_scores_gemma":[0.002328415,0.00043091242,0.00037889977,0.00070043025,0.00027690083,0.0004754381,0.00013769347,0.0021503635,0.00015032559],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.38338798,0.007965658,0.32804444,0.00024372515,0.0011204208,0.0032488897,0.001627584,0.00072163355,0.00035301826,0.000009254829,0.0015550992,0.2717223],"study_design_scores_gemma":[0.28308886,0.13447192,0.56054235,0.001757433,0.000680405,0.00019463534,0.00023383551,0.000331627,0.00051151944,0.00000548038,0.01761974,0.00056219776],"about_ca_topic_score_codex":0.00034737718,"about_ca_topic_score_gemma":0.004922728,"teacher_disagreement_score":0.27116007,"about_ca_system_score_codex":0.01654366,"about_ca_system_score_gemma":0.011688766,"threshold_uncertainty_score":0.9998143},"labels":[],"label_agreement":null},{"id":"W1490900965","doi":"10.1002/ajh.23788","title":"Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia","year":2014,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":107,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Bosutinib; Medicine; Internal medicine; Gastroenterology; Imatinib; Neutropenia; Dysgeusia; Adverse effect; myalgia; Myeloid leukemia; Nilotinib; Toxicity","score_opus":0.017983480108602515,"score_gpt":0.33338896278461944,"score_spread":0.3154054826760169,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1490900965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994545,0.0016412165,0.00025674357,0.0014616485,0.00048392,0.00081751635,0.0000108697695,0.00001254937,0.00077056873],"genre_scores_gemma":[0.9979045,0.0005722423,0.0006942091,0.00022868125,0.00048671482,0.00003824408,0.00002169684,0.00003947719,0.000014238538],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9957369,0.0007742548,0.0019461164,0.00033189214,0.0005351801,0.00067567587],"domain_scores_gemma":[0.99510103,0.0022602074,0.0016942554,0.00063006935,0.00011953384,0.00019487609],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014689362,0.00035568583,0.0018907886,0.00049260154,0.000053110416,0.000009822674,0.00050093315,0.00014121199,0.00023877922],"category_scores_gemma":[0.0011252151,0.00025413436,0.00034144765,0.0007676852,0.00073878025,0.00012558125,0.00005886464,0.0009172849,0.00002099305],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38022208,0.00870288,0.0061655277,0.00049778813,0.0013543427,0.0052091996,0.006160586,0.00062695314,0.0056726416,0.0026909395,0.0024187793,0.5802783],"study_design_scores_gemma":[0.91766834,0.060525455,0.0018741017,0.0007614834,0.000506705,0.0036897573,0.0017794812,0.0018584204,0.0029770287,0.00012485981,0.007875064,0.0003593192],"about_ca_topic_score_codex":0.00038016302,"about_ca_topic_score_gemma":0.0003731914,"teacher_disagreement_score":0.579919,"about_ca_system_score_codex":0.0030434867,"about_ca_system_score_gemma":0.0035407378,"threshold_uncertainty_score":0.99999106},"labels":[],"label_agreement":null},{"id":"W1493840214","doi":"10.1002/ejhf.58","title":"Ageing is a Risk Factor in Imatinib Mesylate Cardiotoxicity","year":2014,"lang":"en","type":"article","venue":"European Journal of Heart Failure","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Clinical Research Institute; University of Ottawa","funders":"Canadian Institutes of Health Research; University of Ottawa","keywords":"Cardiotoxicity; Imatinib mesylate; Medicine; Imatinib; Heart failure; Pharmacology; Tyrosine kinase; Tyrosine-kinase inhibitor; Cardiomyopathy; Internal medicine; Cancer; Chemotherapy","score_opus":0.012721174352402026,"score_gpt":0.2529556180842846,"score_spread":0.24023444373188255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1493840214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948535,0.0002463815,0.00013781458,0.0029306666,0.00014524993,0.00015734091,0.000014178312,0.000021162452,0.0014937181],"genre_scores_gemma":[0.98953587,0.000046771955,0.009256921,0.00048169098,0.00043850177,4.31549e-7,0.0000010886736,0.00004736297,0.00019136052],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978034,0.000688407,0.0006258362,0.00018761095,0.00039964626,0.0002950872],"domain_scores_gemma":[0.998894,0.00009952387,0.00033397326,0.00032082762,0.000109445755,0.00024224623],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011246345,0.00019486918,0.00055252825,0.00019490143,0.00006065886,0.000029391176,0.00013132638,0.000038770857,0.00039801857],"category_scores_gemma":[0.00040496778,0.00014916937,0.000280017,0.00016689286,0.000040217805,0.0001271605,0.00005007174,0.00074604753,0.00023288828],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010917824,0.00068489625,0.65317696,0.00043460508,0.0013725698,0.01060608,0.009230076,0.0004167499,0.08488531,0.000019919456,0.110802524,0.1272785],"study_design_scores_gemma":[0.009393105,0.0011247084,0.7911064,0.0008136864,0.00016769547,0.0017901722,0.0001463,0.0002558088,0.0071995016,0.000025635718,0.18773623,0.00024072482],"about_ca_topic_score_codex":0.000020122581,"about_ca_topic_score_gemma":0.0000088121005,"teacher_disagreement_score":0.13792944,"about_ca_system_score_codex":0.00028365117,"about_ca_system_score_gemma":0.00013291641,"threshold_uncertainty_score":0.608295},"labels":[],"label_agreement":null},{"id":"W1498704631","doi":"10.1002/9781444300857.ch37","title":"Chronic Myeloid Leukemia","year":2008,"lang":"en","type":"other","venue":"","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre","funders":"","keywords":"Myeloid leukemia; Bone marrow transplantation; Medicine; Oncology; Bone marrow; Intensive care medicine; Internal medicine","score_opus":0.01523801012347451,"score_gpt":0.26068401371356104,"score_spread":0.24544600359008653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1498704631","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006845316,0.012854975,0.00004242285,0.00015316434,0.00038435712,0.0008025679,0.000024513563,0.0009956722,0.98467386],"genre_scores_gemma":[0.00035903853,0.006343671,0.0015346837,0.00036297302,0.0028800617,0.00005944998,0.0003206261,0.0011354613,0.98700404],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99819475,0.000018327024,0.0002656544,0.000594483,0.0004355276,0.0004912616],"domain_scores_gemma":[0.99856067,0.00002167815,0.00014420864,0.00099371,0.000023215187,0.00025654875],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000030575364,0.0005069309,0.0007554096,0.000311779,0.000036558744,0.000007943131,0.00015534958,0.0006370845,0.065839395],"category_scores_gemma":[0.000020572066,0.0004051763,0.00024536965,0.00017456802,0.00013177418,0.000018599441,0.00007338338,0.00041438296,0.010606005],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012614351,0.00003361441,0.00019406326,0.00022571154,0.00041085595,0.0005571239,0.000013808181,4.552906e-7,0.00007077894,0.00006720815,0.9855556,0.012858191],"study_design_scores_gemma":[0.003866759,0.00022476124,0.0003219455,0.0005443312,0.00021384125,0.00069113227,0.0000045122983,0.000022299995,0.00030843966,0.0000040738655,0.9934566,0.0003412768],"about_ca_topic_score_codex":0.0014462486,"about_ca_topic_score_gemma":0.00036629834,"teacher_disagreement_score":0.05523339,"about_ca_system_score_codex":0.006812861,"about_ca_system_score_gemma":0.0036693907,"threshold_uncertainty_score":0.99984},"labels":[],"label_agreement":null},{"id":"W1505654720","doi":"10.1002/9781118778166.ch30","title":"In Sickness and in Health: A Shotgun Marriage That Is Flourishing","year":2014,"lang":"en","type":"other","venue":"","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drug discovery; Flourishing; Commercialization; Pharmaceutical industry; Scientific discovery; Drug industry; Engineering ethics; Data science; Business; Engineering; Medicine; Computer science; Marketing; Psychology; Pharmacology; Biology; Bioinformatics","score_opus":0.02120324101416811,"score_gpt":0.2943283443440429,"score_spread":0.27312510332987483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1505654720","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012339629,0.008781199,0.000056467336,0.008471451,0.0004942094,0.0020777727,0.000032187116,0.00019093101,0.9675562],"genre_scores_gemma":[0.016270977,0.0014770064,0.00097217155,0.0059347693,0.00033448887,0.000050548573,0.000050102324,0.00038845267,0.97452146],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985601,0.00007080038,0.00029095658,0.0004713771,0.00022982681,0.000376971],"domain_scores_gemma":[0.9992269,0.000065817556,0.00013254893,0.00041488255,0.0000049241994,0.00015487205],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000279132,0.00029727232,0.00078448217,0.0004307445,0.0000113865335,0.000016245112,0.00007961068,0.00032563446,0.010234285],"category_scores_gemma":[0.000031326184,0.00024658983,0.000043868644,0.00013099822,0.000036754525,0.00003620499,0.00006652681,0.00036528314,0.00015490773],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007192413,0.00013445807,0.022044811,0.0017710873,0.00009671811,0.0003878274,0.00093030784,3.3625216e-7,0.000008805981,0.000049359656,0.9654006,0.009103797],"study_design_scores_gemma":[0.009792022,0.00012565884,0.0075298925,0.0046136053,0.00004628251,0.00010177929,0.000114679075,0.00019336189,0.000059859598,0.00009161046,0.9769595,0.00037169442],"about_ca_topic_score_codex":0.020368095,"about_ca_topic_score_gemma":0.01331776,"teacher_disagreement_score":0.014514919,"about_ca_system_score_codex":0.00087355374,"about_ca_system_score_gemma":0.000316367,"threshold_uncertainty_score":0.9999986},"labels":[],"label_agreement":null},{"id":"W1525555980","doi":"10.1038/leu.2015.168","title":"BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase","year":2015,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Dasatinib; Imatinib; Medicine; Nilotinib; Internal medicine; Myeloid leukemia; Tyrosine-kinase inhibitor; Oncology; Imatinib mesylate; Mutation; Biology; Cancer; Genetics","score_opus":0.04711676767517604,"score_gpt":0.3224659356603377,"score_spread":0.2753491679851617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1525555980","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99205613,0.0012826674,0.0011047613,0.00023775309,0.00019720799,0.0040127737,0.00005300401,0.0002901137,0.00076556095],"genre_scores_gemma":[0.977075,0.00024639294,0.012036728,0.000110439825,0.00076635194,0.0025276577,0.0010733729,0.00019800955,0.005966084],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99580723,0.00006457478,0.0011302673,0.0010874566,0.00070463767,0.0012058294],"domain_scores_gemma":[0.99767107,0.00023352864,0.0004214536,0.0008533834,0.00022702228,0.00059353135],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00035733116,0.0008355803,0.0010820233,0.00040281698,0.00024987178,0.00006405065,0.0002397555,0.00030987192,0.00025590236],"category_scores_gemma":[0.00016029908,0.0006145873,0.00015826694,0.0006398921,0.00013366893,0.00033302835,0.000083483705,0.00034882722,0.00019031404],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.058281973,0.0043533826,0.012346215,0.00899437,0.0046369736,0.009753504,0.034569576,0.09851523,0.026454821,0.00020722965,0.0033882014,0.7384985],"study_design_scores_gemma":[0.5074535,0.03990821,0.012340507,0.004574588,0.0013363628,0.0025202562,0.0013484457,0.11022129,0.23419507,0.00012708551,0.08308564,0.0028890583],"about_ca_topic_score_codex":0.00080570154,"about_ca_topic_score_gemma":0.005948204,"teacher_disagreement_score":0.7356095,"about_ca_system_score_codex":0.16278246,"about_ca_system_score_gemma":0.03273449,"threshold_uncertainty_score":0.9996306},"labels":[],"label_agreement":null},{"id":"W1533032912","doi":"10.2353/jmoldx.2009.080095","title":"Laboratory Practice Guidelines for Detecting and Reporting BCR-ABL Drug Resistance Mutations in Chronic Myelogenous Leukemia and Acute Lymphoblastic Leukemia","year":2008,"lang":"en","type":"article","venue":"Journal of Molecular Diagnostics","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Chronic myelogenous leukemia; Mutation; Standardization; Lymphoblastic Leukemia; Drug resistance; ABL; Cancer research; Medicine; Leukemia; Biology; Genetics; Computer science; Gene","score_opus":0.03137821926947709,"score_gpt":0.33127114660437573,"score_spread":0.29989292733489864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1533032912","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9691171,0.025157467,0.0037486735,0.0012318344,0.00015264387,0.0004974566,0.0000149761945,0.000019568579,0.00006026315],"genre_scores_gemma":[0.8914843,0.011170953,0.095833905,0.0009798887,0.00031414628,0.000032750584,0.000011039058,0.000072471,0.000100552345],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99695504,0.000096091215,0.0018396936,0.00030662742,0.0004314334,0.0003711088],"domain_scores_gemma":[0.99356097,0.0018669285,0.0022585448,0.00026119375,0.001819049,0.00023330128],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0011151137,0.0002614449,0.00064573775,0.00024891752,0.00019914821,0.00003314918,0.00008919126,0.0001352646,0.0000023753414],"category_scores_gemma":[0.05108557,0.00024514133,0.00010627387,0.00032020314,0.00013770106,0.00021801546,0.00005561856,0.00038722582,0.0000010551553],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0050669974,0.0011223906,0.06456419,0.0049580405,0.0071395496,0.2512799,0.014340121,0.039282516,0.52999014,0.00046174764,0.031887796,0.049906638],"study_design_scores_gemma":[0.119900785,0.007945018,0.11425465,0.021762902,0.021204632,0.17642857,0.0077621164,0.032866076,0.42168674,0.0028887107,0.068843596,0.004456207],"about_ca_topic_score_codex":0.000053457592,"about_ca_topic_score_gemma":0.00008638678,"teacher_disagreement_score":0.114833795,"about_ca_system_score_codex":0.004424475,"about_ca_system_score_gemma":0.0057828086,"threshold_uncertainty_score":0.9998535},"labels":[],"label_agreement":null},{"id":"W1559606456","doi":"10.1186/1710-1492-10-s2-a9","title":"Acute generalized exanthematous pustulosis from imatinib","year":2014,"lang":"en","type":"article","venue":"Allergy Asthma and Clinical Immunology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto; McGill University","funders":"","keywords":"Acute generalized exanthematous pustulosis; Imatinib; Medicine; Dermatology; Internal medicine","score_opus":0.01894874415679589,"score_gpt":0.31481451143248473,"score_spread":0.29586576727568886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1559606456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99200493,0.0016230994,0.00032583068,0.0019511917,0.00051179907,0.00019753141,0.000010336666,0.000117103584,0.0032581561],"genre_scores_gemma":[0.9832426,0.0058494085,0.00599437,0.002056704,0.0004173464,0.00004469479,0.0001833139,0.00005136819,0.0021602379],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99791104,0.0002608046,0.000728857,0.00056667195,0.00014187774,0.00039073805],"domain_scores_gemma":[0.9982119,0.0007160103,0.000188897,0.0006529127,0.00004600313,0.00018427099],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00023756121,0.0002596736,0.00085042656,0.000053412936,0.00009805916,0.000016293117,0.00015429419,0.00042693905,0.0010676356],"category_scores_gemma":[0.00029391804,0.000206708,0.00023248182,0.00007826382,0.00035956714,0.00005361425,0.00017546765,0.000396387,0.00038736692],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008492297,0.0045673894,0.05714185,0.000051584353,0.041172087,0.0009784197,0.00089587003,0.000002958962,0.027594905,0.014124958,0.015170582,0.8298071],"study_design_scores_gemma":[0.061809085,0.0059777033,0.5635954,0.00025593129,0.0011385755,0.0010791918,0.00023307685,0.0033474988,0.004283834,0.006415655,0.35082445,0.0010395957],"about_ca_topic_score_codex":0.00034949713,"about_ca_topic_score_gemma":0.00007878092,"teacher_disagreement_score":0.8287675,"about_ca_system_score_codex":0.00006898512,"about_ca_system_score_gemma":0.00009782488,"threshold_uncertainty_score":0.9998455},"labels":[],"label_agreement":null},{"id":"W1565948695","doi":"10.1002/ajh.23707","title":"<i>BCR/ABL</i> level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase","year":2014,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Imatinib; Medicine; Internal medicine; Myeloid leukemia; Gastroenterology; Imatinib mesylate; Immunology; Surgery; Oncology","score_opus":0.012166135326978689,"score_gpt":0.3005888551829361,"score_spread":0.2884227198559574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1565948695","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889594,0.0063481,0.0026905588,0.0008364183,0.00029218764,0.0007662532,0.000030877345,0.00003064265,0.000045605917],"genre_scores_gemma":[0.9942299,0.00032016254,0.00444374,0.00040894095,0.00011809098,0.00013004243,0.000012545085,0.000104823535,0.00023171827],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99617636,0.0006913551,0.0013057457,0.00050841534,0.0004928442,0.0008252617],"domain_scores_gemma":[0.99633706,0.0013325112,0.0012407784,0.0006210347,0.00016193921,0.00030668388],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013929895,0.00045715965,0.0016656339,0.0004485062,0.00014945453,0.000029768176,0.000295793,0.00015836363,0.000086016764],"category_scores_gemma":[0.00069592404,0.00038697565,0.00069979293,0.00033132968,0.0003270889,0.00021623344,0.00010862799,0.00048031023,0.000035337926],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1271709,0.002333487,0.33828935,0.0003984709,0.005122649,0.01125725,0.010644477,0.00049720175,0.42429024,0.00013773805,0.0014976659,0.07836057],"study_design_scores_gemma":[0.2395026,0.057692997,0.13572286,0.0033439507,0.0033698191,0.01664471,0.0036466827,0.0066803494,0.51273805,0.0013273718,0.016413292,0.0029173163],"about_ca_topic_score_codex":0.00036583043,"about_ca_topic_score_gemma":0.00026551218,"teacher_disagreement_score":0.20256647,"about_ca_system_score_codex":0.002246198,"about_ca_system_score_gemma":0.00061791233,"threshold_uncertainty_score":0.9998582},"labels":[],"label_agreement":null},{"id":"W1584179619","doi":"10.1002/cncr.29240","title":"Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic‐ or accelerated‐phase chronic myeloid leukemia: Results with 24 months of follow‐up","year":2015,"lang":"en","type":"article","venue":"Cancer","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; National Institutes of Health; Teva Pharmaceutical Industries","keywords":"Medicine; Internal medicine; Gastroenterology; Neutropenia; Myeloid leukemia; Confidence interval; Adverse effect; Surgery; Chemotherapy","score_opus":0.03353811094204888,"score_gpt":0.2990981108762727,"score_spread":0.2655599999342238,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1584179619","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99587256,0.002147388,0.000011116057,0.00013572225,0.00008314772,0.0011184778,0.00033587942,0.000012328269,0.00028339995],"genre_scores_gemma":[0.99842995,0.0003326838,0.000099348435,0.000022862292,0.00003996354,0.00005032557,0.00011041554,0.000031596923,0.0008828449],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977902,0.00007974726,0.0007198794,0.00044934414,0.0006200671,0.00034075798],"domain_scores_gemma":[0.9979393,0.000105123734,0.00061950355,0.000725527,0.00045141805,0.0001591678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023751709,0.00030139988,0.0010445914,0.00027130323,0.000034939727,0.000005243106,0.00018859867,0.00012493426,0.00010951256],"category_scores_gemma":[0.00013394753,0.00016144762,0.00009976014,0.0017633507,0.0002778099,0.00010703129,0.000082701394,0.0002529427,6.470731e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18738681,0.0022058534,0.705381,0.0012855764,0.011238775,0.00009778786,0.0043434696,0.035801046,0.0027197646,0.00002279106,0.0013798545,0.048137262],"study_design_scores_gemma":[0.19233619,0.0062892125,0.7754351,0.0015039886,0.004109837,0.0000050900344,0.00009528981,0.0032432089,0.01601952,0.0000013491766,0.000700662,0.0002605825],"about_ca_topic_score_codex":0.0023502875,"about_ca_topic_score_gemma":0.008669127,"teacher_disagreement_score":0.07005407,"about_ca_system_score_codex":0.003881688,"about_ca_system_score_gemma":0.0045699137,"threshold_uncertainty_score":0.99994224},"labels":[],"label_agreement":null},{"id":"W1591412289","doi":"10.1002/9781444300857.ch32","title":"Acute Lymphoblastic Leukemia in Adults","year":2008,"lang":"en","type":"other","venue":"","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Lymphoblastic Leukemia; Philadelphia chromosome; Tyrosine kinase; Induction therapy; Transplantation; Medicine; Leukemia; Stem cell; Oncology; Cancer research; Biology; Immunology; Genetics; Internal medicine; Chromosomal translocation; Gene; Chemotherapy","score_opus":0.00877627404205995,"score_gpt":0.24686887005313196,"score_spread":0.23809259601107202,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1591412289","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0032688489,0.001185745,0.000016718499,0.000044162167,0.00024993543,0.0007507986,0.000033100707,0.00036241784,0.9940883],"genre_scores_gemma":[0.003726003,0.0032927932,0.0012003597,0.00034598578,0.0003544992,0.000060947514,0.00023092912,0.0006165621,0.9901719],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984778,0.000016377828,0.00027853882,0.00051208684,0.00031873965,0.00039646053],"domain_scores_gemma":[0.999085,0.00003154309,0.000105152954,0.0005949283,0.00001535231,0.00016798492],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000021003452,0.0004012726,0.0006761695,0.00044542324,0.000012533779,0.000004088006,0.00011667979,0.00050441845,0.012416795],"category_scores_gemma":[0.000027207874,0.00032273275,0.0001257225,0.000219764,0.000071613635,0.000016620967,0.00005277416,0.00024605702,0.0031450137],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020764953,0.000088410954,0.0012040284,0.00023675125,0.0003786881,0.003231711,0.000071807364,0.0000012969144,0.000012004663,0.000029169876,0.9915105,0.0030279984],"study_design_scores_gemma":[0.031111322,0.0004398246,0.0035262222,0.0058351923,0.00044827335,0.001750048,0.000029888277,0.0004644103,0.00016610842,0.000009377673,0.9554731,0.0007462366],"about_ca_topic_score_codex":0.0034211946,"about_ca_topic_score_gemma":0.0012352237,"teacher_disagreement_score":0.03603739,"about_ca_system_score_codex":0.0061528715,"about_ca_system_score_gemma":0.0020981443,"threshold_uncertainty_score":0.99992245},"labels":[],"label_agreement":null},{"id":"W1592984486","doi":"10.1159/000375150","title":"Lymphoproliferative Disorders in Patients with Chronic Myeloid Leukemia: A Single-Center Case Series","year":2015,"lang":"en","type":"review","venue":"Acta Haematologica","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Lymphoproliferative disorders; Medicine; Myeloid leukemia; Immunology; Leukemia; Myeloid; Disease; Lymphoma; Pathology","score_opus":0.031898892346222715,"score_gpt":0.28644841435975826,"score_spread":0.25454952201353553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1592984486","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.025103625,0.9646025,0.0000016184554,0.00012768882,0.00021796934,0.0064706346,0.00019394996,0.00021379595,0.0030682627],"genre_scores_gemma":[0.030201418,0.9657875,0.00036904236,0.000079410194,0.000112516886,0.0012315256,0.001399858,0.00020096258,0.0006178123],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958707,0.00031974897,0.0010743568,0.001183606,0.0006032479,0.00094835955],"domain_scores_gemma":[0.9975191,0.0001757459,0.00067747454,0.0010769181,0.00018234081,0.00036846477],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001856624,0.0012222849,0.004273356,0.0003955162,0.00012579803,0.00005690726,0.00030611947,0.00087845797,0.00020034646],"category_scores_gemma":[0.00018864204,0.00076209434,0.00038820016,0.00070217776,0.00034677438,0.00028163462,0.00026809366,0.0008454095,0.00017192346],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015955628,0.0039073266,0.024407791,0.03618372,0.0024978274,0.030809293,0.0007395032,0.0000022666645,1.3924239e-7,0.000073488336,0.0039258245,0.8958573],"study_design_scores_gemma":[0.013894468,0.004021877,0.00011654704,0.017313287,0.0016858765,0.055216737,0.000078024794,0.000004203555,9.3468293e-7,0.00002342891,0.90661055,0.0010340489],"about_ca_topic_score_codex":0.00012313729,"about_ca_topic_score_gemma":0.0013445313,"teacher_disagreement_score":0.90268475,"about_ca_system_score_codex":0.013430586,"about_ca_system_score_gemma":0.0043736477,"threshold_uncertainty_score":0.999483},"labels":[],"label_agreement":null},{"id":"W1605939038","doi":"10.1038/77819","title":"SCL and LMO1 alter thymocyte differentiation: inhibition of E2A-HEB function and pre-Tα chain expression","year":2000,"lang":"en","type":"article","venue":"Nature Immunology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":209,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec; BioPhage Pharma (Canada); Université de Montréal; Montreal Clinical Research Institute","funders":"","keywords":"Transcription factor; Biology; CD8; Cell biology; Cellular differentiation; Thymocyte; T cell; Gene; Immunology; Genetics; Antigen; Immune system","score_opus":0.0042712647826951165,"score_gpt":0.2339531923296735,"score_spread":0.22968192754697836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1605939038","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98626375,0.012000901,0.00004219223,0.0005597553,0.00018061271,0.0003311532,0.000008135181,0.00004512653,0.0005683554],"genre_scores_gemma":[0.997034,0.0013260804,0.00017133255,0.00020201257,0.000107826156,0.0000214717,0.0001346216,0.000016078655,0.0009865924],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9991419,0.000066076725,0.00021340763,0.00027914977,0.00013153523,0.00016795611],"domain_scores_gemma":[0.999538,0.000050836334,0.000088221605,0.00023337906,0.00004943893,0.00004010565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006752372,0.00015201925,0.00026776388,0.00010814648,0.00006323696,0.000006994321,0.000027189551,0.0004954549,0.0005717857],"category_scores_gemma":[0.000031476906,0.00012039837,0.00003666754,0.00008917882,0.00011346874,0.0000991633,0.000037551425,0.00043582235,0.0000092180435],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003526645,0.00031892658,0.015340876,0.00018627725,0.0002958139,0.00002255465,0.00065138255,0.0000023347013,0.8469583,0.00033340577,0.00065956835,0.13170391],"study_design_scores_gemma":[0.010090629,0.0010797491,0.8201139,0.00047698675,0.00021245865,0.00025984528,0.000049861108,0.00016576637,0.16380286,0.0007814548,0.002795701,0.00017080214],"about_ca_topic_score_codex":0.000022979064,"about_ca_topic_score_gemma":0.000006942195,"teacher_disagreement_score":0.804773,"about_ca_system_score_codex":0.00013078464,"about_ca_system_score_gemma":0.00004427626,"threshold_uncertainty_score":0.6260653},"labels":[],"label_agreement":null},{"id":"W1606151478","doi":"10.14740/wjon912e","title":"Polymorphism T81C in H-RAS Oncogene Is Associated With Disease Progression in Imatinib (TKI) Treated Chronic Myeloid Leukemia Patients","year":2015,"lang":"en","type":"article","venue":"World Journal of Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Myeloid leukemia; Medicine; Genotype; Single-nucleotide polymorphism; Imatinib; Internal medicine; Gastroenterology; Chronic myelogenous leukemia; Odds ratio; Immunology; Leukemia; Gene; Biology; Genetics","score_opus":0.02470908974637585,"score_gpt":0.31303497544156433,"score_spread":0.28832588569518847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1606151478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99252737,0.0019465798,0.0000022493525,0.001604723,0.00023981021,0.0007073912,0.000016018399,0.000024122093,0.0029317678],"genre_scores_gemma":[0.99744165,0.00012959736,0.00045428946,0.00047467684,0.00019303415,0.000036772617,0.00007826475,0.000055965236,0.0011357793],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99679685,0.0003496471,0.001138521,0.00034083062,0.0007494001,0.00062478194],"domain_scores_gemma":[0.9973785,0.00018734919,0.0010504498,0.00029851325,0.00036872615,0.0007164248],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00066860707,0.00035236415,0.0010939005,0.00093570823,0.0000406527,0.000014246818,0.00020974696,0.0001990006,0.00022758778],"category_scores_gemma":[0.00042912082,0.00025715173,0.00013809622,0.0010317641,0.00015453478,0.00021094612,0.00007276764,0.0007800921,0.00003277461],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.006747766,0.0029780632,0.9147309,0.00004517601,0.00030549619,0.007152314,0.0010021959,0.0001549544,0.00045630065,0.000009073961,0.0035102016,0.06290757],"study_design_scores_gemma":[0.10667377,0.011409931,0.86560404,0.0031714356,0.00056378735,0.00039423627,0.00013531711,0.0007115517,0.0010028394,0.00013142386,0.009768038,0.00043364696],"about_ca_topic_score_codex":0.00018554735,"about_ca_topic_score_gemma":0.001658388,"teacher_disagreement_score":0.099926,"about_ca_system_score_codex":0.0277815,"about_ca_system_score_gemma":0.008363775,"threshold_uncertainty_score":0.9999881},"labels":[],"label_agreement":null},{"id":"W1640770146","doi":"10.3747/co.v13i6.124","title":"Recommendations of the Canadian Consensus Group on the Management of Chronic Myeloid Leukemia","year":2006,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Toronto; Vancouver Hospital and Health Sciences Centre; Queen Elizabeth II Health Sciences Centre; Université de Montréal; Hôpital Maisonneuve-Rosemont; Princess Margaret Cancer Centre; Vancouver General Hospital; University of British Columbia; BC Cancer Agency; University Health Network; Dalhousie University; Royal Victoria Hospital; McGill University Health Centre","funders":"","keywords":"Medicine; Myeloid leukemia; Bioinformatics; Computational biology; Cancer research; Biology","score_opus":0.06426344845818455,"score_gpt":0.34155699529452205,"score_spread":0.2772935468363375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1640770146","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8666412,0.0018007017,0.000012694872,0.023407385,0.0022667835,0.0020449627,0.000111322035,0.000029980829,0.10368492],"genre_scores_gemma":[0.9983125,0.00019574823,0.00013573945,0.00014765587,0.0001418991,0.00008152322,0.00006213704,0.000014831518,0.0009079848],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99878824,0.0001263265,0.00038893276,0.0002018452,0.00020314567,0.00029148403],"domain_scores_gemma":[0.9988745,0.00018816811,0.00022855513,0.0005577643,0.000075458025,0.00007554234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023050839,0.0001426527,0.00027038288,0.000093715455,0.00014772484,0.000003417197,0.00020599923,0.00008992057,0.0002551843],"category_scores_gemma":[0.000023399136,0.000085186926,0.00012278487,0.00025202424,0.00029306972,0.000008854026,0.00006689563,0.0002790108,0.00003967008],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028708938,0.0025423754,0.024480337,0.0010108389,0.0012264393,0.00009749545,0.0005394661,0.0002860881,0.001139099,0.23978122,0.31512326,0.4134863],"study_design_scores_gemma":[0.005237311,0.0007650068,0.10910719,0.0006373908,0.0005116946,0.000057256788,0.00024167543,0.00043828404,0.0016019243,0.00084367575,0.88041306,0.00014556677],"about_ca_topic_score_codex":0.018856358,"about_ca_topic_score_gemma":0.10226902,"teacher_disagreement_score":0.5652898,"about_ca_system_score_codex":0.008027531,"about_ca_system_score_gemma":0.0019074816,"threshold_uncertainty_score":0.99578047},"labels":[],"label_agreement":null},{"id":"W1667009823","doi":"10.1007/978-1-4615-1173-1_11","title":"Model Studies of Cyclophosphamide Resistance in Human Myeloid Leukemia","year":2002,"lang":"en","type":"review","venue":"Cancer treatment and research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; University of Alberta","funders":"National Cancer Institute","keywords":"Cyclophosphamide; Myeloid leukemia; Medicine; Context (archaeology); Cancer research; Adjuvant; Oncology; Myeloid; Chemotherapy; Internal medicine; Biology","score_opus":0.2719716428221121,"score_gpt":0.48483120716492856,"score_spread":0.21285956434281644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1667009823","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005635462,0.9881103,1.522638e-7,0.00007537489,0.0000550526,0.0021424466,0.00008970834,0.000023967254,0.0038675137],"genre_scores_gemma":[0.0008067225,0.94373494,0.00016339497,0.000005601922,0.00013443228,0.0015778035,0.00007190794,0.000081383565,0.053423807],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968084,0.00021491219,0.00081324676,0.0008482242,0.0005895427,0.0007256734],"domain_scores_gemma":[0.99826676,0.00037546517,0.00021101806,0.000718362,0.00021963293,0.0002087516],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003876096,0.0005772339,0.0028698018,0.0006687701,0.00017778866,0.000016959626,0.00017958322,0.0003618303,0.00008648884],"category_scores_gemma":[0.00006883062,0.00038193841,0.00032955955,0.0007772579,0.0005945021,0.000054749537,0.00014932071,0.0006162697,0.000019139196],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014030277,0.00048307132,0.000553292,0.04424552,0.0024155192,0.00046954767,0.001630459,0.000010897328,0.000013078978,0.0002824256,0.0023039272,0.94745195],"study_design_scores_gemma":[0.007892161,0.0008947043,0.00010577782,0.079215646,0.0021750357,0.00003269766,0.00022522446,0.00007639134,0.00011842681,0.00043504636,0.90824544,0.0005834607],"about_ca_topic_score_codex":0.00052774133,"about_ca_topic_score_gemma":0.0008722124,"teacher_disagreement_score":0.9468685,"about_ca_system_score_codex":0.015438735,"about_ca_system_score_gemma":0.002497934,"threshold_uncertainty_score":0.99986327},"labels":[],"label_agreement":null},{"id":"W1668902290","doi":"10.1182/blood.v124.21.4559.4559","title":"Bosutinib As Third-Line Therapy in Patients (Pts) with Chronic Phase Chronic Myeloid Leukemia (CP CML) Following Failure with Imatinib Plus Dasatinib and/or Nilotinib: 48-Month Update of a Phase 1/2 Study","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Bosutinib; Nilotinib; Dasatinib; Medicine; Internal medicine; Imatinib; Gastroenterology; Imatinib mesylate; Myeloid leukemia","score_opus":0.012911871954017174,"score_gpt":0.2859074742347657,"score_spread":0.27299560228074854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1668902290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99306065,0.00077869516,0.00006396757,0.00013794765,0.00009981774,0.005070016,0.00006611158,0.00020139496,0.0005214029],"genre_scores_gemma":[0.99669677,0.00015419273,0.001468481,0.0001849715,0.0002683802,0.00042761432,0.00033857123,0.00021636221,0.00024468405],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99484414,0.0003011382,0.0012608102,0.0013015317,0.001212618,0.0010797861],"domain_scores_gemma":[0.9969591,0.0002375105,0.00074926217,0.0014168599,0.00019442577,0.0004428269],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007251057,0.0009805466,0.0018129543,0.00039238093,0.00020285482,0.00006517506,0.00040343378,0.00024972935,0.00025133294],"category_scores_gemma":[0.00019964353,0.0006586304,0.0001859123,0.0008577083,0.0002501116,0.00036233437,0.00015222021,0.0007267572,0.000047747704],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08544714,0.11581515,0.532602,0.0026873637,0.013720892,0.0034595602,0.020209935,0.00048718965,0.015187825,0.00016964073,0.0008334852,0.20937979],"study_design_scores_gemma":[0.8122565,0.13708866,0.022611456,0.0022282582,0.0023209865,0.00022400872,0.0010333786,0.0020908285,0.01713099,0.000019821391,0.001710356,0.0012847455],"about_ca_topic_score_codex":0.0006300498,"about_ca_topic_score_gemma":0.0016298539,"teacher_disagreement_score":0.7268094,"about_ca_system_score_codex":0.001840642,"about_ca_system_score_gemma":0.0035798817,"threshold_uncertainty_score":0.9995865},"labels":[],"label_agreement":null},{"id":"W1775596629","doi":"10.1182/blood.v118.21.606.606","title":"Complete Molecular Response (CMR) Rate with Nilotinib in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) without CMR After ≥ 2 Years on Imatinib: Preliminary Results From the Randomized ENESTcmr Trial of Nilotinib 400 Mg Twice Daily (BID) Vs Imatinib","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; McMaster University Medical Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Nilotinib; Medicine; Imatinib; Internal medicine; Imatinib mesylate; Clinical endpoint; Myeloid leukemia; Oncology; Gastroenterology; Randomized controlled trial","score_opus":0.017162198750396762,"score_gpt":0.2530342717225034,"score_spread":0.23587207297210666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1775596629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98921686,0.0005470257,0.000032119948,0.0001265351,0.00014883556,0.008494045,0.000590157,0.0001218376,0.00072259904],"genre_scores_gemma":[0.99509585,0.000084271654,0.002032717,0.0002891492,0.00019639365,0.0012646455,0.0006435031,0.00024262207,0.00015084304],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9915462,0.0024574208,0.0022045905,0.0014529678,0.0012312672,0.0011075372],"domain_scores_gemma":[0.9937038,0.0022903413,0.0013123049,0.0021541256,0.000227437,0.00031202077],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0026020596,0.00102079,0.0024732822,0.00045705927,0.00009252766,0.00004603694,0.00064705405,0.0003482231,0.00018405268],"category_scores_gemma":[0.0011668232,0.0006909915,0.00034584675,0.0008319159,0.0007249902,0.00025339358,0.00020909627,0.0010233494,0.00008934498],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9813762,0.00408448,0.0032875233,0.00014954172,0.00090109336,0.0009961523,0.004073662,0.00019560101,0.003810445,0.0000125902425,0.00003935699,0.0010733609],"study_design_scores_gemma":[0.8874999,0.036622982,0.060079366,0.0029008107,0.0014329101,0.000039803268,0.00011109424,0.00092072575,0.009559194,0.000027098435,0.0001259435,0.0006801417],"about_ca_topic_score_codex":0.0028923561,"about_ca_topic_score_gemma":0.00073650345,"teacher_disagreement_score":0.093876265,"about_ca_system_score_codex":0.0025599254,"about_ca_system_score_gemma":0.0038289104,"threshold_uncertainty_score":0.9995541},"labels":[],"label_agreement":null},{"id":"W1821529798","doi":"10.3109/10428194.2015.1071486","title":"Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate","year":2015,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Myeloid leukemia; Toxicity; Internal medicine; Incidence (geometry); Oncology","score_opus":0.012498052574899658,"score_gpt":0.2532419150282752,"score_spread":0.24074386245337553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1821529798","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98936814,0.0061699385,0.000039059032,0.00008134634,0.0000778198,0.0023928618,0.0000664734,0.00019280743,0.0016115437],"genre_scores_gemma":[0.99386865,0.003028407,0.0012757068,0.00013098148,0.0001098879,0.00025726232,0.00031577877,0.0001857178,0.00082761724],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942728,0.00018990583,0.0011848982,0.0017885168,0.0012508209,0.0013130162],"domain_scores_gemma":[0.9965975,0.00014133735,0.00063634047,0.0011500521,0.00039128787,0.0010834754],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00045022852,0.0012801634,0.001740018,0.0006407043,0.00025010455,0.00012832505,0.0003469751,0.0005380009,0.00004346057],"category_scores_gemma":[0.000040978277,0.00096139713,0.000097007374,0.0011536534,0.00081074337,0.0007846593,0.00047011333,0.00028964938,0.000013422872],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.024475222,0.001465325,0.5199269,0.0045400094,0.0020054039,0.00404126,0.0019448994,0.0005506984,0.0029880027,0.00039113584,0.00081378245,0.4368573],"study_design_scores_gemma":[0.20603713,0.0078027146,0.75647265,0.0044493447,0.0010803118,0.0010510667,0.0003655062,0.008177505,0.011432176,0.00004315947,0.0018081153,0.001280306],"about_ca_topic_score_codex":0.0027709315,"about_ca_topic_score_gemma":0.0005149972,"teacher_disagreement_score":0.43557703,"about_ca_system_score_codex":0.02823736,"about_ca_system_score_gemma":0.006026295,"threshold_uncertainty_score":0.999995},"labels":[],"label_agreement":null},{"id":"W1827459324","doi":"10.1002/ajh.24120","title":"Age and d<scp>PCR</scp> can predict relapse in <scp>CML</scp> patients who discontinued imatinib: The <scp>ISAV</scp> study","year":2015,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":209,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Regione Lombardia; Associazione Italiana per la Ricerca sul Cancro","keywords":"Imatinib; Medicine; Cancer research; Myeloid leukemia","score_opus":0.014613517413403032,"score_gpt":0.26853034137151954,"score_spread":0.2539168239581165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1827459324","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99409366,0.001430367,0.000030083367,0.00047904564,0.00049385976,0.0012312448,0.000033806642,0.00004776534,0.002160194],"genre_scores_gemma":[0.99717706,0.00022042665,0.00056472805,0.0005915304,0.00022063503,0.000066336506,0.000027321677,0.00010876682,0.0010231948],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946041,0.0009122574,0.0017206441,0.00063067704,0.0010280426,0.0011042608],"domain_scores_gemma":[0.99305767,0.0029221948,0.0019397278,0.00083788694,0.00039102818,0.00085148215],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012056748,0.0006382298,0.00224883,0.00052658573,0.00015084668,0.0000664887,0.0006029198,0.00018320113,0.0000063207353],"category_scores_gemma":[0.006998259,0.00043627678,0.00024359743,0.00079323037,0.0011071841,0.0002558519,0.00029744057,0.0012715561,0.000030408677],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005075192,0.0015815814,0.9386661,0.000062029634,0.00078301894,0.0033632028,0.027671048,0.000020131734,0.000058260666,0.00007288049,0.025058428,0.0026125486],"study_design_scores_gemma":[0.031550918,0.013932719,0.8249524,0.0007293915,0.0012195156,0.00721972,0.107304946,0.00022364805,0.0005443212,0.0005222928,0.01168429,0.00011580281],"about_ca_topic_score_codex":0.00064556807,"about_ca_topic_score_gemma":0.0004717082,"teacher_disagreement_score":0.11371368,"about_ca_system_score_codex":0.0007483898,"about_ca_system_score_gemma":0.0008717009,"threshold_uncertainty_score":0.9998089},"labels":[],"label_agreement":null},{"id":"W1870322611","doi":"10.18632/oncotarget.405","title":"AHI-1: a novel signaling protein and potential therapeutic target in human leukemia and brain disorders","year":2011,"lang":"en","type":"review","venue":"Oncotarget","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Michael Smith Health Research BC; Canadian Institutes of Health Research; Cancer Research Society","keywords":"Myeloid leukemia; Cancer research; Cancer; Fusion gene; Medicine; Leukemia; Gene; Biology; Genetics; Immunology","score_opus":0.03309629368636536,"score_gpt":0.3106691322543715,"score_spread":0.27757283856800613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1870322611","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008296307,0.9873816,0.00010856479,0.000089660454,0.00008717727,0.0030247339,0.000051457395,0.00007288734,0.0008876333],"genre_scores_gemma":[0.003969205,0.9899278,0.0025473917,0.00016761085,0.00024081908,0.00044662604,0.00040537756,0.00020624576,0.0020889065],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99720347,0.0001590074,0.00079725176,0.0009295903,0.00028592226,0.00062476087],"domain_scores_gemma":[0.99878186,0.00008995883,0.00035286476,0.00048973935,0.000025688618,0.00025986848],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004193391,0.000780315,0.002141378,0.00038446637,0.00012426471,0.00004478347,0.00017747263,0.00058414275,0.0002740181],"category_scores_gemma":[0.000052869775,0.0006384302,0.00028281336,0.0002734367,0.00020866944,0.00010945915,0.00016114958,0.0008786432,0.00001952296],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002177561,0.0011619295,0.002203374,0.045913592,0.0019926785,0.00046416422,0.0012958446,0.0000032005487,0.0019920818,0.0013838104,0.0006065567,0.942765],"study_design_scores_gemma":[0.0063699167,0.00062385603,0.00048972486,0.014707743,0.0011941672,0.0002721751,0.000043869255,0.00007747488,0.00001935312,0.000763707,0.97456014,0.0008778533],"about_ca_topic_score_codex":0.0005811819,"about_ca_topic_score_gemma":0.00008078045,"teacher_disagreement_score":0.9739536,"about_ca_system_score_codex":0.001419713,"about_ca_system_score_gemma":0.0011444914,"threshold_uncertainty_score":0.99960667},"labels":[],"label_agreement":null},{"id":"W1905318784","doi":"10.1111/j.1600-0609.2009.01357.x","title":"BCR‐ABL positive cells and chronic myeloid leukemia in immune suppressed organ transplant recipients","year":2009,"lang":"en","type":"article","venue":"European Journal Of Haematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec","funders":"","keywords":"Myeloid leukemia; Chromosomal translocation; clone (Java method); Immunology; Population; Biology; Immune system; ABL; Leukemia; Cancer research; Tyrosine kinase; Medicine; Receptor; Gene; Genetics","score_opus":0.008542085462240891,"score_gpt":0.23313671559384858,"score_spread":0.2245946301316077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1905318784","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929762,0.0028106074,0.00012660076,0.00096293254,0.00029205126,0.00024491284,0.000009785266,0.000018819737,0.0025580742],"genre_scores_gemma":[0.9974155,0.0011583903,0.00071716367,0.00028587962,0.00013810037,6.3580336e-7,0.000014612108,0.000040797448,0.00022894637],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9975718,0.0005051134,0.0009501776,0.00027858472,0.0002461876,0.00044812122],"domain_scores_gemma":[0.99885774,0.00011210172,0.00041145494,0.00027472898,0.00010382057,0.00024017872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005648711,0.00027634721,0.0009071794,0.000332313,0.000055867553,0.000017202077,0.00021178034,0.00007970564,0.00014441878],"category_scores_gemma":[0.000057948615,0.00022563836,0.00013168146,0.00019115546,0.00013018896,0.00012927216,0.000034766905,0.00062862516,0.00006777949],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053010904,0.0009962807,0.018916281,0.00029560228,0.0009082667,0.25727436,0.007950858,0.0002078539,0.66707236,0.000338115,0.0022884125,0.03845053],"study_design_scores_gemma":[0.040111996,0.008337463,0.5629038,0.0032809984,0.0006820541,0.12203169,0.00022661472,0.00025146018,0.25881636,0.00012373328,0.0026211825,0.00061264547],"about_ca_topic_score_codex":0.000012402369,"about_ca_topic_score_gemma":0.000006966016,"teacher_disagreement_score":0.5439875,"about_ca_system_score_codex":0.0011553414,"about_ca_system_score_gemma":0.00056449673,"threshold_uncertainty_score":0.9201265},"labels":[],"label_agreement":null},{"id":"W190699452","doi":"10.1182/blood.v124.21.813.813","title":"The Risk of Relapse in CML Patients Who Discontinued imatinib Can Be Predicted Based on Patients Age and the Results of dPCR Analysis","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Imatinib; Discontinuation; Medicine; Imatinib mesylate; Internal medicine; Minimal residual disease; Digital polymerase chain reaction; Oncology; Myeloid leukemia; Population; Gastroenterology; Surgery; Immunology; Leukemia; Polymerase chain reaction; Biology","score_opus":0.00492055600604591,"score_gpt":0.21244616561744578,"score_spread":0.20752560961139987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W190699452","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970593,0.00003121944,0.0000037240973,0.00021371894,0.000032977365,0.0007862058,0.0006011809,0.00001070546,0.0012609567],"genre_scores_gemma":[0.9992197,0.000052629184,0.00010252981,0.00006003936,0.000016383216,0.00003692425,0.00036794913,0.000015996484,0.00012785877],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997938,0.0004247436,0.00066053413,0.0002726193,0.00049217936,0.00021196147],"domain_scores_gemma":[0.9974708,0.0010120912,0.00055613654,0.00076610205,0.00012184964,0.00007303117],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006199531,0.00017400322,0.0005581261,0.00015037437,0.000073532996,0.000009797939,0.0001450698,0.00007535237,0.0000053325616],"category_scores_gemma":[0.002478663,0.000089748784,0.00015353585,0.00048590975,0.00024596023,0.000023940467,0.000052474454,0.00018715189,3.976231e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023726772,0.0013892382,0.99134207,0.00004231617,0.00086731947,0.0000036039771,0.0015366204,0.000062180494,0.000012825911,0.000020848605,0.00015234959,0.0021979406],"study_design_scores_gemma":[0.073658474,0.0007377245,0.91743326,0.00018708504,0.0024036434,1.2889468e-7,0.00005395002,0.004588323,0.00076140754,0.000025718611,0.000079136196,0.000071142655],"about_ca_topic_score_codex":0.0017703162,"about_ca_topic_score_gemma":0.0014533803,"teacher_disagreement_score":0.07390881,"about_ca_system_score_codex":0.000077739554,"about_ca_system_score_gemma":0.000069494236,"threshold_uncertainty_score":0.36598492},"labels":[],"label_agreement":null},{"id":"W1919069136","doi":"10.1111/bjh.13801","title":"Factors influencing long‐term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib","year":2015,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Teva Pharmaceutical Industries; Pfizer","keywords":"Bosutinib; Medicine; Internal medicine; Imatinib; Tolerability; Cumulative incidence; Adverse effect; Discontinuation; Oncology; Gastroenterology; Myeloid leukemia; Nilotinib; Cohort","score_opus":0.055125360430511784,"score_gpt":0.34971217641064417,"score_spread":0.29458681598013237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1919069136","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99001145,0.008605076,0.000077080265,0.00023616433,0.00021367184,0.00073487574,0.000024850482,0.000021558606,0.00007529057],"genre_scores_gemma":[0.9987537,0.0003291182,0.00061304,0.00007679521,0.00012976759,0.000011682012,0.000012898246,0.000040872623,0.000032072618],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99623245,0.00025425793,0.0019801373,0.00041639133,0.0005095282,0.00060725835],"domain_scores_gemma":[0.99741936,0.00035141254,0.000812837,0.00038654867,0.00039605147,0.00063381874],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00093178835,0.00033236414,0.0019559087,0.00038892918,0.000058868594,0.000035737765,0.00026564664,0.00023959242,0.00016317687],"category_scores_gemma":[0.0015728992,0.00029081033,0.00016046969,0.0003911562,0.0003019808,0.00022830217,0.00014776397,0.000664503,0.000005798089],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030248152,0.006718738,0.3893031,0.008504567,0.0021039736,0.2080156,0.019239925,0.0007919008,0.0694615,0.00014176816,0.0029734315,0.26249737],"study_design_scores_gemma":[0.09921631,0.017189601,0.6594245,0.012361742,0.0006402276,0.18097238,0.0012085978,0.00027108387,0.027109403,0.00013232668,0.0006727742,0.00080106384],"about_ca_topic_score_codex":0.0005556455,"about_ca_topic_score_gemma":0.0022449265,"teacher_disagreement_score":0.2701214,"about_ca_system_score_codex":0.0038695084,"about_ca_system_score_gemma":0.004595523,"threshold_uncertainty_score":0.99995446},"labels":[],"label_agreement":null},{"id":"W1933922259","doi":"10.1186/s13256-015-0674-9","title":"Inclusion body myositis in a patient with chronic myeloid leukemia treated with dasatinib: a case report","year":2015,"lang":"en","type":"article","venue":"Journal of Medical Case Reports","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Mount Sinai Hospital","funders":"","keywords":"Medicine; Dasatinib; Inclusion body myositis; Surgical oncology; Myeloid leukemia; Myositis; Inclusion (mineral); Internal medicine; Oncology; Pathology; Imatinib","score_opus":0.015318399490158318,"score_gpt":0.2877430312843122,"score_spread":0.2724246317941539,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1933922259","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955667,0.0013989072,0.00011006376,0.001151684,0.00019455195,0.00065439695,0.0000027986684,0.00004175009,0.0008791287],"genre_scores_gemma":[0.9980382,0.000085042775,0.0009656169,0.00021441521,0.00043660816,0.000028451574,0.000029413899,0.00006732209,0.00013494909],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9930591,0.00017765639,0.0020788803,0.00050127663,0.00364806,0.0005350573],"domain_scores_gemma":[0.9948174,0.00014331716,0.0018624251,0.00070708833,0.0006599021,0.0018098833],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0023659903,0.00041004497,0.0010939881,0.0004146648,0.00013696337,0.000027534668,0.00007776434,0.00034953607,0.00022585175],"category_scores_gemma":[0.0013691486,0.0002467661,0.000152151,0.0006136507,0.00020776155,0.00022867268,0.00025587418,0.001166037,0.000003168052],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0012766726,0.0005369219,0.022149825,0.0001002057,0.00028748158,0.9623186,0.0011946737,0.000082119215,0.000056587127,0.0000014407846,0.0009956419,0.010999836],"study_design_scores_gemma":[0.011801932,0.007186925,0.001300457,0.002314984,0.0005048467,0.97208184,0.00057446485,0.00047776062,0.0008025582,0.000014080348,0.002686779,0.00025335854],"about_ca_topic_score_codex":0.0047793337,"about_ca_topic_score_gemma":0.0019980415,"teacher_disagreement_score":0.02084937,"about_ca_system_score_codex":0.008522037,"about_ca_system_score_gemma":0.015460045,"threshold_uncertainty_score":0.99999845},"labels":[],"label_agreement":null},{"id":"W1947838475","doi":"10.1182/blood-2015-06-648667","title":"Pediatric chronic myeloid leukemia is a unique disease that requires a different approach","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":216,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Child and Family Research Institute; BC Children's Hospital","funders":"National Cancer Institute; Ariad Pharmaceuticals; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Chronic myelogenous leukemia; Disease; Pediatrics; Transplantation; Myeloid leukemia; Hematopoietic stem cell transplantation; Dasatinib; Leukemia; Intensive care medicine; Immunology; Imatinib; Internal medicine","score_opus":0.03734855655750234,"score_gpt":0.2647348544438029,"score_spread":0.22738629788630055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1947838475","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98472613,0.008084486,0.00012186049,0.00037088498,0.00014756584,0.0009865335,0.00004360704,0.00027397525,0.0052449396],"genre_scores_gemma":[0.9936429,0.0008028603,0.0005804737,0.00036365844,0.0010728621,0.0002441849,0.0001789206,0.0000841449,0.0030299444],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99756914,0.00008306873,0.00033220032,0.0006729222,0.00071736635,0.00062532286],"domain_scores_gemma":[0.9976447,0.000051442625,0.00014335464,0.0009899393,0.00008822912,0.001082333],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014913725,0.00042801004,0.0005228023,0.00018686506,0.0000781404,0.00003997513,0.00023434292,0.00017085577,0.0001461804],"category_scores_gemma":[0.00011587851,0.00033170494,0.0002239317,0.00029419028,0.00008194905,0.00012962932,0.00017296112,0.00033067196,0.00018568935],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001012833,0.0068718786,0.9456397,0.0022485945,0.0012846682,0.0017592127,0.0027148526,0.00004278695,0.00090956944,0.00056695833,0.03263945,0.004309481],"study_design_scores_gemma":[0.14740908,0.0044594887,0.77573645,0.00077771547,0.01477371,0.0014082036,0.000758926,0.0046745846,0.024376918,0.0019395882,0.020603124,0.0030822337],"about_ca_topic_score_codex":0.000129257,"about_ca_topic_score_gemma":0.000010040982,"teacher_disagreement_score":0.1699033,"about_ca_system_score_codex":0.0027855018,"about_ca_system_score_gemma":0.0033307378,"threshold_uncertainty_score":0.9999135},"labels":[],"label_agreement":null},{"id":"W1963599260","doi":"10.1016/j.clml.2013.05.012","title":"A Critical Review of Trials of First-Line BCR-ABL Inhibitor Treatment in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase","year":2013,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Nilotinib; Dasatinib; Imatinib; Medicine; Tyrosine-kinase inhibitor; Myeloid leukemia; Tyrosine kinase; Internal medicine; Clinical trial; Oncology; Pharmacology; Cancer","score_opus":0.08339020883833671,"score_gpt":0.40468084065048987,"score_spread":0.32129063181215317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1963599260","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03453264,0.9481316,0.000010328543,0.000116572286,0.00067897077,0.015329782,0.0007914922,0.000109341956,0.000299253],"genre_scores_gemma":[0.0039011587,0.9870268,0.00079458876,0.0002013891,0.0014093161,0.0033433922,0.0025995504,0.0004454562,0.00027831012],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.97481763,0.0029476918,0.0155993095,0.0028516355,0.0018072586,0.0019764432],"domain_scores_gemma":[0.9737307,0.015116298,0.0055747894,0.003555898,0.00084847776,0.0011738343],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.004199227,0.0027319135,0.023061924,0.0012469382,0.00009528667,0.000047116104,0.0010980085,0.0024080405,0.0013682025],"category_scores_gemma":[0.01612781,0.0019103616,0.0041233012,0.002418895,0.0014208136,0.00040906185,0.0004469083,0.0014309981,0.0003049506],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0012766888,0.0037968385,0.0014530773,0.13511117,0.0013322195,0.00069233036,0.00003675393,0.000007868361,0.0000015779951,0.0000281229,0.0012297214,0.85503364],"study_design_scores_gemma":[0.10736105,0.019088862,0.010906312,0.4723766,0.008458938,0.000099800214,0.000007992053,0.0001613787,0.000041013078,0.000023107728,0.3799087,0.0015662299],"about_ca_topic_score_codex":0.0017538834,"about_ca_topic_score_gemma":0.00073305285,"teacher_disagreement_score":0.8534674,"about_ca_system_score_codex":0.096985005,"about_ca_system_score_gemma":0.05879513,"threshold_uncertainty_score":0.9995447},"labels":[],"label_agreement":null},{"id":"W1963980838","doi":"10.1007/s10024-004-1116-7","title":"c-kit Expression and Mutational Analysis in Medulloblastoma","year":2004,"lang":"en","type":"article","venue":"Pediatric and Developmental Pathology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medulloblastoma; Imatinib mesylate; Cancer research; Biology; Chronic myelogenous leukemia; Proto-Oncogene Proteins c-kit; Receptor tyrosine kinase; Tyrosine kinase; Metastasis; Imatinib; Leukemia; Pathology; Cancer; Medicine; Stem cell; Stem cell factor; Signal transduction; Myeloid leukemia; Immunology; Genetics; Haematopoiesis","score_opus":0.00825220137488142,"score_gpt":0.24548157317436314,"score_spread":0.23722937179948173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1963980838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981495,0.00076246803,0.00018785599,0.00014484912,0.000032023843,0.00014100397,0.000005496584,0.000020524427,0.0005562432],"genre_scores_gemma":[0.98639274,0.00033325024,0.012858626,0.00016691146,0.000043908272,0.000022763305,0.00006237292,0.0000073723736,0.00011203993],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99916446,0.000019528221,0.00021389098,0.00029397235,0.00012738537,0.00018076532],"domain_scores_gemma":[0.9997243,0.00005201565,0.00004355231,0.0000568092,0.000015715732,0.00010759131],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009079451,0.00011907031,0.00024939328,0.0003695262,0.000048861126,0.0000057304337,0.000023028178,0.00009348323,0.000079220925],"category_scores_gemma":[0.000046504396,0.00010279256,0.00002793233,0.0003967702,0.000056807592,0.000051610343,0.000062428284,0.00009694869,0.00002125207],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007922575,0.00010861493,0.9951521,0.00002930796,0.0000485197,0.0008770842,0.0010585899,0.000016755563,0.000836615,0.000045676217,0.000028199622,0.0017193008],"study_design_scores_gemma":[0.004293314,0.00008517863,0.9932663,0.000007874009,0.00020829691,0.00093921146,0.00024516336,0.000016909875,0.00045329085,0.00034522754,0.000032708012,0.00010655449],"about_ca_topic_score_codex":0.00003423588,"about_ca_topic_score_gemma":0.00004544926,"teacher_disagreement_score":0.01267077,"about_ca_system_score_codex":0.00026770693,"about_ca_system_score_gemma":0.00023310154,"threshold_uncertainty_score":0.4191759},"labels":[],"label_agreement":null},{"id":"W1964003009","doi":"10.1002/ajh.21850","title":"Comprehensive evaluation of time‐to‐response parameter as a predictor of treatment failure following imatinib therapy in chronic phase chronic myeloid leukemia: Which parameter at which time‐point does matter?","year":2010,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Imatinib; Internal medicine; Oncology; Hazard ratio; Myeloid leukemia; Proportional hazards model; Receiver operating characteristic; Nilotinib; Survival analysis; Confidence interval","score_opus":0.014152098318423739,"score_gpt":0.31747014263009415,"score_spread":0.3033180443116704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1964003009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957954,0.0006497877,0.000031908057,0.0017088292,0.00018475659,0.001508593,0.00003480492,0.000018508274,0.000067396584],"genre_scores_gemma":[0.99632174,0.00009690012,0.0029446958,0.00018286299,0.000103000864,0.00012415944,0.000034743098,0.000076099204,0.00011581489],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9952704,0.0009875109,0.0017323717,0.00052025315,0.0008526417,0.00063682557],"domain_scores_gemma":[0.99437857,0.0018372716,0.0016913897,0.000825348,0.0009387842,0.0003286598],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010947909,0.00053754984,0.0023486218,0.00071039685,0.000057512192,0.000013091896,0.00030600265,0.00023533653,0.0033562288],"category_scores_gemma":[0.00079684245,0.00037030532,0.00047047524,0.000750153,0.00036282695,0.00017130392,0.00008826369,0.00057938724,0.00026591506],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.015946414,0.00146177,0.019242108,0.00018351551,0.0032306644,0.00031566067,0.003398331,0.0009892617,0.92405975,0.000004189698,0.0007610465,0.03040728],"study_design_scores_gemma":[0.15367258,0.119878106,0.041827157,0.002834549,0.0042904457,0.015245821,0.0014773883,0.028394267,0.6276967,0.00034060937,0.0028684288,0.0014739821],"about_ca_topic_score_codex":0.00023205258,"about_ca_topic_score_gemma":0.0002527119,"teacher_disagreement_score":0.2963631,"about_ca_system_score_codex":0.006657645,"about_ca_system_score_gemma":0.006098682,"threshold_uncertainty_score":0.9998749},"labels":[],"label_agreement":null},{"id":"W1964395789","doi":"10.1074/jbc.m304575200","title":"Characterization of a Myeloid Tyrosine Phosphatase, Lyp, and Its Role in the Bcr-Abl Signal Transduction Pathway","year":2003,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"National Cancer Institute; National Institutes of Health","keywords":"Protein tyrosine phosphatase; Signal transduction; breakpoint cluster region; Cell biology; Chemistry; Tyrosine kinase; Cancer research; Biology; Biochemistry; Receptor","score_opus":0.01746224700469707,"score_gpt":0.2367406023877741,"score_spread":0.21927835538307705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1964395789","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969969,0.0022983484,0.000025835838,0.00022376672,0.000026498572,0.00011522788,0.000021743514,0.00000385768,0.00028785734],"genre_scores_gemma":[0.9989032,0.0007033241,0.000093818766,0.00008422501,0.00011419347,0.0000038595617,0.00004408877,0.000004998129,0.0000482781],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990979,0.000058688594,0.00041328793,0.00011894238,0.00017870715,0.00013250965],"domain_scores_gemma":[0.9994426,0.0000585544,0.00026385527,0.00008457801,0.00008110336,0.00006935026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036671414,0.00011451655,0.00028979513,0.000023646879,0.000023420784,0.0000068281806,0.000069638336,0.00014378461,0.00035247215],"category_scores_gemma":[0.00014084805,0.00006426749,0.000077416036,0.00014121414,0.00005579146,0.000058139638,0.0000069306507,0.00024996937,0.0000010323206],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026493563,0.0002866168,0.004462533,0.000061281164,0.000029794995,0.000050894167,0.00011558888,0.000001600906,0.99296516,0.000021736618,0.000008166751,0.0017316748],"study_design_scores_gemma":[0.0021625764,0.00034939134,0.022690985,0.00010991457,0.00004138632,0.0008875796,0.00015093113,0.00002188663,0.97226447,0.00005828269,0.0012013557,0.00006125401],"about_ca_topic_score_codex":0.0000015757487,"about_ca_topic_score_gemma":1.601635e-7,"teacher_disagreement_score":0.020700721,"about_ca_system_score_codex":0.00011132222,"about_ca_system_score_gemma":0.00012122531,"threshold_uncertainty_score":0.3859323},"labels":[],"label_agreement":null},{"id":"W1965169783","doi":"10.1111/bjh.12187","title":"<i><scp>BCR</scp>‐<scp>ABL</scp>1</i> transcript at 3 months predicts long‐term outcomes following second generation tyrosine kinase inhibitor therapy in the patients with chronic myeloid leukaemia in chronic phase who failed Imatinib","year":2012,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Imatinib; Medicine; Tyrosine kinase; Internal medicine; Tyrosine-kinase inhibitor; Myeloid leukemia; ABL; Gastroenterology; Oncology; Immunology; Receptor; Cancer","score_opus":0.017634749593782983,"score_gpt":0.26789628347300787,"score_spread":0.2502615338792249,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965169783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96187794,0.034985222,0.000063525025,0.00013906769,0.0007674207,0.0018497395,0.00007604809,0.000035659443,0.00020536415],"genre_scores_gemma":[0.99664354,0.0011937469,0.00020766487,0.0005454578,0.00055993174,0.00015424681,0.00025647003,0.00011625845,0.00032269795],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99491906,0.0005501683,0.0017354502,0.0005207001,0.00095566444,0.0013189585],"domain_scores_gemma":[0.99739003,0.0005903285,0.0009065744,0.0005066375,0.00021462579,0.0003917969],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009751982,0.0006209532,0.0018000857,0.00045188985,0.00022671241,0.00011180437,0.00042805925,0.0004141123,0.00009979083],"category_scores_gemma":[0.00046030758,0.00049020536,0.0004189611,0.00050593243,0.00021702639,0.0010191115,0.00006462454,0.0010945684,0.000018449316],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025238015,0.0030033803,0.94768953,0.00047668727,0.00080884044,0.016324284,0.004594099,0.00008428031,0.009291828,0.000013000612,0.008530039,0.008931631],"study_design_scores_gemma":[0.10429909,0.004295694,0.8484126,0.0025422603,0.0004988253,0.018218637,0.00035590833,0.00023010331,0.018272955,0.00001323489,0.002606815,0.00025388732],"about_ca_topic_score_codex":0.00013289257,"about_ca_topic_score_gemma":0.003442669,"teacher_disagreement_score":0.10404671,"about_ca_system_score_codex":0.0033634023,"about_ca_system_score_gemma":0.0011498523,"threshold_uncertainty_score":0.99975497},"labels":[],"label_agreement":null},{"id":"W1965435352","doi":"10.3747/co.21.1736","title":"Patient preferences for stopping tyrosine kinase inhibitors in chronic myeloid leukemia","year":2014,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"Leukemia and Lymphoma Society; American Society of Hematology","keywords":"Medicine; Discontinuation; Interquartile range; Myeloid leukemia; Nilotinib; Disease; Internal medicine; Tyrosine-kinase inhibitor; Family medicine; Imatinib; Cancer","score_opus":0.06222247984834014,"score_gpt":0.3561808516265632,"score_spread":0.2939583717782231,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965435352","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98944217,0.004738964,0.00031385705,0.00037701728,0.0018146733,0.00144855,0.000015034459,0.00008356348,0.0017661949],"genre_scores_gemma":[0.9973843,0.0003450913,0.000574969,0.00012372193,0.0007744466,0.0005068248,0.00016692706,0.000032959982,0.00009077616],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99799997,0.000119413664,0.0005540551,0.0005297117,0.00021574319,0.0005810967],"domain_scores_gemma":[0.99884975,0.00029580374,0.00020592444,0.00035001666,0.00010589137,0.00019259255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027884138,0.00027551592,0.0005991477,0.00023111654,0.000073020936,0.000011527924,0.000115364935,0.00020296093,0.00009983563],"category_scores_gemma":[0.00032757386,0.00023799467,0.00012809737,0.00021840545,0.00012220338,0.00007697563,0.00009393347,0.000366086,0.00005839052],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032761254,0.00055832247,0.02102127,0.00049512397,0.000047914575,0.000016189904,0.0006735568,0.00012708177,0.0049589756,0.00034235476,0.004555324,0.96687627],"study_design_scores_gemma":[0.022769248,0.008760585,0.04226471,0.001379709,0.00024090786,0.000061626306,0.0002498925,0.00915628,0.011024848,0.00066774257,0.9028563,0.00056816294],"about_ca_topic_score_codex":0.000076739816,"about_ca_topic_score_gemma":0.00027766186,"teacher_disagreement_score":0.9663081,"about_ca_system_score_codex":0.011208195,"about_ca_system_score_gemma":0.0020627535,"threshold_uncertainty_score":0.9925876},"labels":[],"label_agreement":null},{"id":"W1965448482","doi":"10.1080/10428190802668873","title":"HLA risk markers for chronic myelogenous leukemia in Eastern Canada","year":2009,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University","funders":"","keywords":"Human leukocyte antigen; Chronic myelogenous leukemia; Immunology; Odds ratio; Antigen; Medicine; Leukemia; Population; Oncology; Internal medicine","score_opus":0.008109764680904099,"score_gpt":0.22981611971363863,"score_spread":0.22170635503273453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965448482","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98316157,0.006434698,0.00013006992,0.0004120589,0.000699336,0.0027297072,0.00024926802,0.0003192335,0.0058640735],"genre_scores_gemma":[0.9875944,0.0020268734,0.0012540474,0.002725844,0.0009052132,0.00037296693,0.00044386403,0.00023008398,0.0044466928],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99219227,0.00022873835,0.0017021224,0.0021248776,0.0011646841,0.0025872819],"domain_scores_gemma":[0.9955858,0.0006109683,0.00067323016,0.0016734026,0.00024231762,0.0012142675],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0006884848,0.0015175366,0.001997686,0.0005852881,0.00059216964,0.0001579268,0.0006825768,0.00091056316,0.00012615285],"category_scores_gemma":[0.00034885344,0.0014764235,0.00050900056,0.0009692981,0.00033337064,0.0003901962,0.00019215161,0.0004306889,0.000066907654],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.005399802,0.0003746852,0.044370115,0.00086572324,0.000940342,0.0032026442,0.0011270902,0.001582036,0.002826897,0.0004161194,0.019059012,0.9198355],"study_design_scores_gemma":[0.11402038,0.0038405391,0.65769356,0.0015559075,0.0014914069,0.004143486,0.00095733424,0.084617995,0.0057382854,0.0008780991,0.12180335,0.0032596313],"about_ca_topic_score_codex":0.41914842,"about_ca_topic_score_gemma":0.21720411,"teacher_disagreement_score":0.9165759,"about_ca_system_score_codex":0.16297175,"about_ca_system_score_gemma":0.059374757,"threshold_uncertainty_score":0.99975735},"labels":[],"label_agreement":null},{"id":"W1966143894","doi":"10.1053/hupa.2002.126190","title":"T-cell blast crisis of chronic myelogenous leukemia manifesting as a large mediastinal tumor","year":2002,"lang":"en","type":"article","venue":"Human Pathology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Chronic myelogenous leukemia; Fluorescence in situ hybridization; Medicine; Leukemia; Lymphoma; Bone marrow; CD5; Acute lymphocytic leukemia; Pathology; breakpoint cluster region; Cancer research; Immunology; Biology; Internal medicine; Lymphoblastic Leukemia; Gene","score_opus":0.023424472584120257,"score_gpt":0.2678311827445751,"score_spread":0.24440671016045487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966143894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9643121,0.002081047,0.000049849576,0.00009955477,0.00021704116,0.00042961712,0.00002592771,0.00013272042,0.03265218],"genre_scores_gemma":[0.9951922,0.00007143475,0.0006232091,0.00041555244,0.00044364348,0.000053479056,0.00005382998,0.0000724365,0.0030741736],"study_design_codex":"bench_or_experimental","study_design_gemma":"case_report","domain_scores_codex":[0.9975351,0.00011940525,0.00061890896,0.0005936639,0.00033642445,0.0007964674],"domain_scores_gemma":[0.9985644,0.00010425337,0.00032265738,0.0006777953,0.0001128933,0.0002180032],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00025334727,0.00034045757,0.00069679803,0.00022196042,0.00018183426,0.000008073932,0.00021532626,0.00018919355,0.0061559086],"category_scores_gemma":[0.00013355531,0.00032600525,0.00018206994,0.00018435053,0.00019809356,0.000052454143,0.00015218771,0.0004410935,0.0014856881],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060301565,0.009155982,0.07128,0.004451586,0.0008697292,0.17571183,0.023025326,0.00013727542,0.64363736,0.004179019,0.05613211,0.010816761],"study_design_scores_gemma":[0.16355422,0.05661953,0.14056851,0.002944578,0.006739092,0.3644322,0.010153592,0.011314603,0.20639716,0.0027390195,0.028823584,0.0057139355],"about_ca_topic_score_codex":0.00009849267,"about_ca_topic_score_gemma":0.00004635628,"teacher_disagreement_score":0.43724018,"about_ca_system_score_codex":0.0015349587,"about_ca_system_score_gemma":0.00037878938,"threshold_uncertainty_score":0.9999192},"labels":[],"label_agreement":null},{"id":"W1967060888","doi":"10.3109/10428194.2011.559670","title":"Does pretreatment fluorescence<i>in situ</i>hybridization for<i>BCR–ABL</i>predict imatinib-associated hematologic toxicity in chronic myeloid leukemia?","year":2011,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Fluorescence in situ hybridization; Imatinib; Myeloid leukemia; Medicine; Chronic myelogenous leukemia; Philadelphia chromosome; Internal medicine; Gastroenterology; breakpoint cluster region; Leukemia; Hematology; Haematopoiesis; Myeloid; Immunology; Cancer research; Stem cell; Biology; Chromosomal translocation; Chromosome; Receptor","score_opus":0.015208323174291393,"score_gpt":0.24080128363944112,"score_spread":0.22559296046514973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1967060888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879866,0.0019748525,0.0001868572,0.00011661304,0.00061159796,0.003922049,0.00017901084,0.0005797327,0.00444268],"genre_scores_gemma":[0.99032074,0.002266841,0.0029495952,0.0005807716,0.00030207747,0.0013550202,0.0008122415,0.00024956572,0.0011631424],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9914571,0.0003665078,0.0022975202,0.0024006236,0.0010501057,0.0024281484],"domain_scores_gemma":[0.9959474,0.00062140106,0.00087224244,0.0014861383,0.0002753083,0.0007975104],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00096327596,0.0016187727,0.0024312711,0.0008983957,0.0004204144,0.00013028932,0.00066655333,0.0012567195,0.00018146109],"category_scores_gemma":[0.00060992903,0.0012489383,0.00056223664,0.001497757,0.0005786255,0.00074655836,0.00036224237,0.0004065085,0.00008271152],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.012633619,0.0063639153,0.60066205,0.0055638263,0.0030030925,0.008394918,0.015999805,0.00087050523,0.110166594,0.0034633812,0.0057123806,0.2271659],"study_design_scores_gemma":[0.117856026,0.0034471462,0.6260915,0.0039092144,0.0011904403,0.0014967748,0.0012733436,0.036257423,0.2010589,0.0024287316,0.00200386,0.0029866586],"about_ca_topic_score_codex":0.006099627,"about_ca_topic_score_gemma":0.0036619524,"teacher_disagreement_score":0.22417924,"about_ca_system_score_codex":0.10008414,"about_ca_system_score_gemma":0.012427078,"threshold_uncertainty_score":0.99965596},"labels":[],"label_agreement":null},{"id":"W1967890376","doi":"10.1371/journal.pone.0061858","title":"Inhibition of BCR/ABL Protein Expression by miR-203 Sensitizes for Imatinib Mesylate","year":2013,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Chongqing Medical University; University of Chicago","keywords":"Imatinib mesylate; Imatinib; breakpoint cluster region; RNA interference; ABL; microRNA; Cancer research; K562 cells; Philadelphia chromosome; Chemistry; Biology; Cell biology; Cell culture; RNA; Signal transduction; Gene; Tyrosine kinase; Genetics; Chromosomal translocation; Biochemistry; Myeloid leukemia","score_opus":0.029298473808793433,"score_gpt":0.24437352984829058,"score_spread":0.21507505603949714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1967890376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99486876,0.00022188353,0.000100324934,0.00069591694,0.000013631271,0.0030175396,0.000064309934,0.00007787343,0.00093978463],"genre_scores_gemma":[0.9712856,0.000024886343,0.024274401,0.000107136526,0.00008267965,0.0007196268,0.00028171888,0.00004057287,0.0031833965],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998834,0.00003366683,0.0003216243,0.00023982409,0.0003316795,0.00023917007],"domain_scores_gemma":[0.99915797,0.00007171569,0.00016550435,0.000297789,0.00019912851,0.00010790795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009130925,0.000156423,0.0003871416,0.000058011414,0.00004460558,0.00000987321,0.000035058794,0.000106574036,0.00043603682],"category_scores_gemma":[0.00016893922,0.00012921901,0.00007091196,0.00007282596,0.000046382404,0.00012417352,0.000032334978,0.00009764103,0.00012730501],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001397064,0.0011654882,0.00019412168,0.00071701733,0.00014664588,0.0000034072648,0.00020219297,2.0673342e-7,0.9914043,0.000009766395,0.0052229892,0.00079414994],"study_design_scores_gemma":[0.0044901785,0.00045633508,0.00027571508,0.0017528959,0.00016594729,0.000003248626,0.000057706726,0.0006145538,0.99165756,0.00031246402,0.000101177626,0.00011223577],"about_ca_topic_score_codex":0.00010179963,"about_ca_topic_score_gemma":0.000001724067,"teacher_disagreement_score":0.024174077,"about_ca_system_score_codex":0.00020011842,"about_ca_system_score_gemma":0.00007712907,"threshold_uncertainty_score":0.52693987},"labels":[],"label_agreement":null},{"id":"W1968225752","doi":"10.1111/jvim.12189","title":"Masitinib-Associated Minimal Change Disease with Acute Tubular Necrosis Resulting in Acute Kidney Injury in a Dog","year":2013,"lang":"en","type":"article","venue":"Journal of Veterinary Internal Medicine","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Texas Heart Institute","keywords":"Medicine; Acute kidney injury; Acute tubular necrosis; Necrosis; Disease; Internal medicine; Intensive care medicine; Kidney","score_opus":0.029714791111862423,"score_gpt":0.32258444278072207,"score_spread":0.29286965166885964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968225752","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98710793,0.00027045765,0.000010034643,0.011029763,0.00038812886,0.0008019409,0.000044929595,0.000021232074,0.00032558516],"genre_scores_gemma":[0.99530053,0.0004917547,0.00070211774,0.0022583941,0.00055451255,0.000096570875,0.00004028368,0.000058378748,0.00049747375],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968265,0.00016231212,0.0012949316,0.00033956653,0.00079404435,0.00058259733],"domain_scores_gemma":[0.99766064,0.00010868091,0.00077622867,0.00031230052,0.0002690229,0.0008731324],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00054919405,0.00040044347,0.0010636337,0.0008064468,0.00003488628,0.000024320634,0.0002986068,0.0001317953,0.00049082824],"category_scores_gemma":[0.0005583614,0.0002720948,0.00013688502,0.00049193687,0.00016989643,0.0005034941,0.000119870194,0.0009165548,0.000022762903],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037092604,0.0022989223,0.602171,0.0004088653,0.0028200482,0.1742984,0.0064499793,0.0000021484846,0.1526816,0.0000047320427,0.008951301,0.01282039],"study_design_scores_gemma":[0.031874385,0.02798599,0.9074999,0.018436246,0.0009403812,0.009738898,0.0003365962,0.00063881365,0.00061094464,0.00004229084,0.0015398031,0.0003557291],"about_ca_topic_score_codex":0.0012353258,"about_ca_topic_score_gemma":0.00001053873,"teacher_disagreement_score":0.30532894,"about_ca_system_score_codex":0.0015864705,"about_ca_system_score_gemma":0.00041673623,"threshold_uncertainty_score":0.9999731},"labels":[],"label_agreement":null},{"id":"W1968232397","doi":"10.1111/bjh.12618","title":"Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of <scp>SWOG</scp> S0325, an intergroup randomized <scp>PHASE II</scp> trial in newly diagnosed chronic phase chronic myeloid leukaemia","year":2013,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"National Cancer Institute","keywords":"Imatinib; Medicine; Internal medicine; Toxicity; Imatinib mesylate; Gastroenterology; Hematology; Phases of clinical research; Chemotherapy; Oncology; Surgery; Myeloid leukemia","score_opus":0.01681967084386809,"score_gpt":0.30572050564883335,"score_spread":0.28890083480496526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968232397","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97606593,0.01684672,0.00038374242,0.00045411236,0.0010586937,0.0042710234,0.0002485679,0.00010707954,0.00056410965],"genre_scores_gemma":[0.9911696,0.0031234568,0.0031065028,0.00029941148,0.0007663237,0.0004390432,0.00034868158,0.00021649254,0.00053049845],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98676425,0.0031209893,0.0057633906,0.0012064256,0.0013604907,0.00178447],"domain_scores_gemma":[0.98707324,0.005714371,0.0040785386,0.0012266112,0.00091445394,0.0009927904],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0037675765,0.0010897627,0.005742996,0.0013958932,0.00027559465,0.00021710231,0.001210521,0.0010028762,0.00027444333],"category_scores_gemma":[0.018222721,0.0010621841,0.0012566464,0.00086326874,0.0012008072,0.0012740203,0.0003844603,0.0021222325,0.00006866308],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38103488,0.025690075,0.0004919029,0.002424081,0.006901484,0.18924604,0.013342167,0.00027777793,0.24476437,0.00048786763,0.044521075,0.090818286],"study_design_scores_gemma":[0.8760308,0.013683086,0.0004405565,0.0037678797,0.0010865796,0.056284133,0.0015156281,0.0011708861,0.044096757,0.00062146457,0.0010136262,0.0002886002],"about_ca_topic_score_codex":0.0020135676,"about_ca_topic_score_gemma":0.0010443351,"teacher_disagreement_score":0.49499592,"about_ca_system_score_codex":0.00209538,"about_ca_system_score_gemma":0.00547011,"threshold_uncertainty_score":0.9991828},"labels":[],"label_agreement":null},{"id":"W1968698908","doi":"10.1016/j.bmcl.2006.11.077","title":"Inhibition of Src kinase activity by 7-ethynyl-4-phenylamino-3-quinolinecarbonitriles: Identification of SKS-927","year":2006,"lang":"en","type":"article","venue":"Bioorganic & Medicinal Chemistry Letters","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Chemistry; Quinoline; Aniline; Amine gas treating; Stereochemistry; Kinase; Proto-oncogene tyrosine-protein kinase Src; Inhibitory postsynaptic potential; Structure–activity relationship; Aromatic amine; Aniline Compounds; Biochemistry; In vitro; Organic chemistry; Internal medicine","score_opus":0.007450620211774933,"score_gpt":0.23002168004746237,"score_spread":0.22257105983568745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968698908","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958635,0.0006773559,0.00047377258,0.0017089235,0.000114820126,0.00038297905,0.00010243761,0.00007288129,0.0006033367],"genre_scores_gemma":[0.99828476,0.000050874733,0.00013148443,0.00023624404,0.00043447252,0.000021944848,0.00049632083,0.000046070134,0.00029782348],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973184,0.000051042367,0.0009134543,0.0005162148,0.0008293242,0.00037158365],"domain_scores_gemma":[0.99816275,0.00011052825,0.0007451432,0.00066367333,0.00016160114,0.00015630877],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032012913,0.00034247598,0.0006831633,0.00009142884,0.000048423513,0.000007932565,0.00015580734,0.00023407338,0.00021277588],"category_scores_gemma":[0.00018058793,0.00032865413,0.00018535882,0.00041697823,0.0003970563,0.00009289499,0.000050004644,0.0003128066,0.000012974582],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021643187,0.0004967713,0.0025920332,0.0009714246,0.00010185822,0.00005470882,0.00008476447,0.0000016628492,0.99059,0.0000040082687,0.0041486314,0.00073772797],"study_design_scores_gemma":[0.0038272315,0.00007045387,0.011471863,0.00039038048,0.00040078614,0.000075293974,0.000106760584,0.00005641597,0.9832063,0.000019717829,0.00016580355,0.00020899791],"about_ca_topic_score_codex":0.00044341147,"about_ca_topic_score_gemma":0.0000021942653,"teacher_disagreement_score":0.00887983,"about_ca_system_score_codex":0.0008620756,"about_ca_system_score_gemma":0.00029752115,"threshold_uncertainty_score":0.99991655},"labels":[],"label_agreement":null},{"id":"W1968747503","doi":"10.1182/blood-2013-05-501569","title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","year":2013,"lang":"en","type":"review","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1989,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Institute for Health and Care Research","keywords":"Medicine; Myeloid leukemia; Internal medicine; Intensive care medicine","score_opus":0.05498044835877869,"score_gpt":0.32031545548990364,"score_spread":0.26533500713112496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968747503","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000092152195,0.98470247,0.00010691771,0.00030388645,0.00039248235,0.0063425587,0.00026459224,0.00009427352,0.0077836094],"genre_scores_gemma":[0.000008552712,0.97978634,0.0033311066,0.000057264166,0.0006996775,0.0015869165,0.001406245,0.00020227184,0.012921633],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971624,0.00015948183,0.0011350277,0.00065168133,0.00033318013,0.000558229],"domain_scores_gemma":[0.9969982,0.00038915157,0.00074803864,0.0015888286,0.00011206692,0.00016371079],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00044292657,0.0006597318,0.0016646205,0.00017379742,0.00016870149,0.000036635043,0.00062682194,0.00025030295,0.0006903856],"category_scores_gemma":[0.000021394915,0.00041727908,0.00087587454,0.00033352128,0.00012081277,0.00006647246,0.00027965105,0.0005335509,0.0008798081],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000048082325,0.00029446295,0.0000010043389,0.031723697,0.004581503,0.000035376936,0.000025837444,0.0000014780857,7.959319e-7,0.0001786351,0.049975615,0.9131768],"study_design_scores_gemma":[0.004696822,0.00030465415,0.000012695401,0.017135575,0.018643562,0.0001768339,0.000034828925,0.000017854063,0.000008790918,0.000010114312,0.9586474,0.0003109274],"about_ca_topic_score_codex":0.000119031254,"about_ca_topic_score_gemma":0.0000111378395,"teacher_disagreement_score":0.9128659,"about_ca_system_score_codex":0.0025097136,"about_ca_system_score_gemma":0.0014078422,"threshold_uncertainty_score":0.99989814},"labels":[],"label_agreement":null},{"id":"W1969451930","doi":"10.1038/sj.leu.2402969","title":"Quantitative PCR identifies a minimal deleted region of 120 kb extending from the Philadelphia chromosome ABL translocation breakpoint in chronic myeloid leukemia with poor outcome","year":2003,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Emergent BioSolutions (Canada); University Health Network; University of Toronto; Ontario Institute for Cancer Research","funders":"American Society of Hematology","keywords":"Haploinsufficiency; Chromosomal translocation; Biology; ABL; Derivative chromosome; Breakpoint; breakpoint cluster region; Fluorescence in situ hybridization; Comparative genomic hybridization; Genetics; Myeloid leukemia; Fusion gene; Chromosome; Chromosome 9; Chromosome 22; Molecular biology; Gene; Cancer research; Phenotype","score_opus":0.037264299172111,"score_gpt":0.28984141519557416,"score_spread":0.25257711602346317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969451930","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99173224,0.0037382427,0.001106883,0.0010050953,0.0001924855,0.0014170068,0.00004744485,0.000115137234,0.0006454657],"genre_scores_gemma":[0.9963987,0.00048983685,0.001788778,0.0002976653,0.00015889997,0.00018544454,0.00019624435,0.00011058112,0.00037386286],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9959984,0.00031237295,0.0012571953,0.00090226426,0.0007745371,0.00075525034],"domain_scores_gemma":[0.997453,0.00062394363,0.00057558017,0.00096237264,0.00019506595,0.00019004056],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00050258747,0.0006104105,0.001058604,0.00030616435,0.00017210463,0.00004975022,0.00035675307,0.00031333568,0.00021052311],"category_scores_gemma":[0.0003154145,0.00044019803,0.00025606394,0.0010015357,0.00044358443,0.00038438823,0.000047415884,0.00073826953,0.00006766789],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0120511195,0.0011974304,0.14083505,0.002469435,0.0042495024,0.0039761914,0.02764728,0.008914349,0.76780623,0.0103846155,0.0038354383,0.016633358],"study_design_scores_gemma":[0.07243189,0.005422638,0.63446814,0.00829593,0.0024011964,0.002310289,0.009057818,0.020450853,0.2374396,0.0017887665,0.0032756932,0.0026571925],"about_ca_topic_score_codex":0.0051539424,"about_ca_topic_score_gemma":0.0025520232,"teacher_disagreement_score":0.53036666,"about_ca_system_score_codex":0.013268883,"about_ca_system_score_gemma":0.003670581,"threshold_uncertainty_score":0.999805},"labels":[],"label_agreement":null},{"id":"W1969666177","doi":"10.1158/1538-7445.am10-2602","title":"Abstract 2602: The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity","year":2010,"lang":"en","type":"article","venue":"Cancer Research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba","funders":"","keywords":"Sunitinib; Tyrosine kinase; Lapatinib; Cardiotoxicity; Dasatinib; Medicine; Imatinib; Tyrosine-kinase inhibitor; Pharmacology; Nilotinib; Kinase; Gefitinib; Erlotinib; Sorafenib; Cancer; Internal medicine; Chemistry; Biochemistry; Receptor; Toxicity; Breast cancer; Epidermal growth factor receptor; Trastuzumab","score_opus":0.05392565443431722,"score_gpt":0.35480449594693425,"score_spread":0.300878841512617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969666177","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940184,0.0015315574,0.000008145573,0.0012016889,0.00012131264,0.0012688878,0.00023951534,0.000030706815,0.0015798049],"genre_scores_gemma":[0.99753416,0.00062541774,0.00008510408,0.00014339387,0.00018913732,0.00013171088,0.00003755128,0.000054294873,0.0011992264],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99766,0.00009353472,0.0002959394,0.0005155981,0.00084568124,0.0005892395],"domain_scores_gemma":[0.9981747,0.00020300859,0.00010595351,0.000766364,0.00045766195,0.00029227778],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066915445,0.0002377331,0.00044046083,0.00011613193,0.00018629352,0.000041392315,0.00021095015,0.00017956637,0.0008268526],"category_scores_gemma":[0.00013394088,0.00015291676,0.00006932049,0.0005613582,0.0010502372,0.000068858186,0.0001278457,0.0013757938,0.000018060215],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000784042,0.00020535594,0.04899987,0.00023757375,0.00031543136,0.00015336042,0.00057139806,0.00002158487,0.9297511,0.000026086505,0.018088916,0.0008452738],"study_design_scores_gemma":[0.0046459152,0.000364351,0.10083046,0.0002631926,0.00009160411,0.000015143781,0.0001571859,0.00032580213,0.8859608,0.00001446996,0.0071349316,0.00019611091],"about_ca_topic_score_codex":0.0065122363,"about_ca_topic_score_gemma":0.00062138285,"teacher_disagreement_score":0.05183059,"about_ca_system_score_codex":0.0007035263,"about_ca_system_score_gemma":0.0011645163,"threshold_uncertainty_score":0.9844597},"labels":[],"label_agreement":null},{"id":"W1969894871","doi":"10.1080/10428190310001615666","title":"Subdural Hematomas during CML Therapy with Imatinib Mesylate","year":2004,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Imatinib mesylate; Mesylate; Medicine; Imatinib; Subdural Hematomas; Oncology; Internal medicine; Myeloid leukemia; Surgery; Hematoma; Chemistry","score_opus":0.009542626261534072,"score_gpt":0.23355689386411407,"score_spread":0.22401426760258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969894871","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98623633,0.003774794,0.00006425163,0.0004417179,0.0002479439,0.0014239666,0.00003412672,0.0008222551,0.0069545885],"genre_scores_gemma":[0.9906052,0.0017076471,0.0030691759,0.0011634711,0.00045722668,0.00027525076,0.00015202959,0.00030577587,0.0022642296],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9942943,0.00009716848,0.0010803613,0.0016222025,0.001184088,0.0017219082],"domain_scores_gemma":[0.99664533,0.00014637996,0.0004597623,0.0015052356,0.00022387915,0.0010194011],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00026959725,0.0013405186,0.0015602253,0.00044462414,0.00067798723,0.00020964259,0.00043389606,0.0005982373,0.00024244648],"category_scores_gemma":[0.00006387871,0.0010485386,0.0003968842,0.0008802352,0.000614744,0.0006093073,0.00021514048,0.00027870413,0.00028793962],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.04830943,0.006034901,0.17225511,0.0058578085,0.011673008,0.04859112,0.02523507,0.0021385716,0.16962545,0.014311476,0.004167665,0.4918004],"study_design_scores_gemma":[0.24495387,0.0029438455,0.4843164,0.0023323952,0.00089484133,0.03903173,0.0014477142,0.001113894,0.20930457,0.001309939,0.00921106,0.0031397382],"about_ca_topic_score_codex":0.0022324806,"about_ca_topic_score_gemma":0.00011981516,"teacher_disagreement_score":0.48866066,"about_ca_system_score_codex":0.018151678,"about_ca_system_score_gemma":0.007275259,"threshold_uncertainty_score":0.9999346},"labels":[],"label_agreement":null},{"id":"W1970504379","doi":"10.1038/sj.leu.2403649","title":"Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease","year":2005,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":136,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute; Cancer Research Society","keywords":"Haematopoiesis; Stem cell; Immunology; CD38; Biology; Myelopoiesis; CD34; Cancer research; Myeloid leukemia; Myeloid; Progenitor cell; Leukemia; Population; Medicine; Cell biology","score_opus":0.016088792945409554,"score_gpt":0.23343800847961527,"score_spread":0.21734921553420572,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970504379","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99204826,0.005325616,0.000043901073,0.00024675057,0.00010656273,0.0013044605,0.00008988846,0.00005982763,0.0007747422],"genre_scores_gemma":[0.99501014,0.00046336596,0.000196678,0.00016690262,0.00013937346,0.00007349053,0.000040622446,0.000070424816,0.003838999],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971873,0.0000928396,0.00079570385,0.00066355953,0.0007275746,0.0005330106],"domain_scores_gemma":[0.99772954,0.00008051744,0.00043313822,0.0013747583,0.00013173523,0.00025033642],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020253067,0.00045887183,0.0007810849,0.00012669427,0.00014747649,0.000015727606,0.00038445447,0.00015595823,0.000046410776],"category_scores_gemma":[0.000020086476,0.00032008198,0.00028331755,0.00024794575,0.00035614756,0.00010990586,0.0003413799,0.00043087316,0.00001270259],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042271623,0.000517875,0.011102995,0.0018097885,0.00027714626,0.00001712323,0.0012198914,0.009594755,0.96305674,0.00021630332,0.0007547482,0.011009896],"study_design_scores_gemma":[0.01367544,0.00041565395,0.15055493,0.0016042823,0.0013363359,0.000062814994,0.00012731695,0.049550015,0.78049165,0.00010290967,0.0013913439,0.0006873241],"about_ca_topic_score_codex":0.0001845516,"about_ca_topic_score_gemma":0.000053026844,"teacher_disagreement_score":0.18256512,"about_ca_system_score_codex":0.0101513,"about_ca_system_score_gemma":0.0028131162,"threshold_uncertainty_score":0.99992514},"labels":[],"label_agreement":null},{"id":"W1971390992","doi":"10.1016/j.cellsig.2012.05.015","title":"Signaling pathways in chronic myeloid leukemia and leukemic stem cell maintenance: Key role of stromal microenvironment","year":2012,"lang":"en","type":"review","venue":"Cellular Signalling","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Stem cell; Stromal cell; Cancer research; Myeloid leukemia; Imatinib; Cancer stem cell; Haematopoiesis; Leukemia; Tumor microenvironment; Biology; Hematopoietic stem cell; Cancer; Medicine; Immunology; Cell biology; Internal medicine; Tumor cells","score_opus":0.02734511367323812,"score_gpt":0.23796707492789163,"score_spread":0.21062196125465352,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971390992","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.091081254,0.90626705,0.00018285612,0.000001780784,0.00012489971,0.001838292,0.00006099211,0.000052758627,0.0003900965],"genre_scores_gemma":[0.117002666,0.8805387,0.0007500669,0.000010303188,0.000423468,0.00015086433,0.00034182356,0.00025099213,0.0005310991],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9947635,0.00026675645,0.0018713779,0.0011585483,0.00064128137,0.001298568],"domain_scores_gemma":[0.9973283,0.0002594478,0.0010880522,0.00083787437,0.00004460642,0.00044172956],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007444869,0.0011666705,0.0035355214,0.00049364974,0.00009731907,0.000033500928,0.00040000604,0.00083104265,0.0002248778],"category_scores_gemma":[0.000008467928,0.0010482694,0.00073051784,0.00035454743,0.00020969464,0.00013259797,0.00029970013,0.0013836127,0.00011918559],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000868676,0.00030432153,0.00017330007,0.060057726,0.00063669577,0.0005352347,0.0011533456,0.0003935363,0.27633712,0.000054694206,0.000013390659,0.66025376],"study_design_scores_gemma":[0.014984545,0.0018189426,0.00005767312,0.14941527,0.014150513,0.0008900739,0.0018558032,0.0028024584,0.15011768,0.000079098434,0.65976965,0.0040582786],"about_ca_topic_score_codex":0.00009758179,"about_ca_topic_score_gemma":0.0000057481693,"teacher_disagreement_score":0.6597563,"about_ca_system_score_codex":0.014556549,"about_ca_system_score_gemma":0.0030434106,"threshold_uncertainty_score":0.99919677},"labels":[],"label_agreement":null},{"id":"W1971589784","doi":"10.1016/j.bbmt.2009.11.026","title":"Response to Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Myelogenous Leukemia Relapsing in Chronic and Advanced Phase Following Allogeneic Hematopoietic Stem Cell Transplantation","year":2009,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Chronic myelogenous leukemia; Dasatinib; Internal medicine; Imatinib; Hematopoietic stem cell transplantation; Tyrosine-kinase inhibitor; Oncology; Transplantation; Nilotinib; Gastroenterology; Leukemia; Odds ratio; Immunology; Cancer; Myeloid leukemia","score_opus":0.0069516396142854766,"score_gpt":0.24269610254690654,"score_spread":0.23574446293262108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971589784","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99387026,0.004600043,0.00013688067,0.00011688011,0.00004639622,0.0011497864,0.00004309764,0.000024997225,0.000011682537],"genre_scores_gemma":[0.9960449,0.002924918,0.0005888831,0.00008041377,0.000018016057,0.000037918533,0.00027309245,0.000020947322,0.00001095404],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985456,0.0001430507,0.0004299616,0.0004327968,0.00013033091,0.00031824785],"domain_scores_gemma":[0.99951607,0.000096302334,0.00010804773,0.00014744817,0.000029678047,0.00010247078],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022423871,0.00025390336,0.0004443634,0.0003170958,0.000052623815,0.0000065724043,0.000046657675,0.00017057205,0.0000037153516],"category_scores_gemma":[0.000003885605,0.00021943089,0.000042627533,0.00024114863,0.000059784907,0.00011351075,0.0000035109701,0.00014098112,6.543289e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016806627,0.0004089873,0.057725564,0.0003189807,0.00004921827,0.00018522203,0.0023114432,0.0000963861,0.88632035,0.0000053115023,4.345736e-7,0.035771478],"study_design_scores_gemma":[0.10797204,0.020406771,0.40339407,0.0016938159,0.00042549963,0.00011342859,0.000092073875,0.00004500674,0.4654278,0.00002538419,0.000015862075,0.00038827863],"about_ca_topic_score_codex":0.00006212806,"about_ca_topic_score_gemma":0.00020701239,"teacher_disagreement_score":0.42089257,"about_ca_system_score_codex":0.0004580541,"about_ca_system_score_gemma":0.00038604107,"threshold_uncertainty_score":0.8948132},"labels":[],"label_agreement":null},{"id":"W1971880154","doi":"10.1182/blood-2010-06-291641","title":"Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":158,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Philadelphia chromosome; Chronic myelogenous leukemia; ABL; Medicine; Biology; Leukemia; Immunology; Internal medicine; Genetics; Chromosomal translocation; Gene; Tyrosine kinase","score_opus":0.028175711886128364,"score_gpt":0.28298799367047694,"score_spread":0.25481228178434856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971880154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967553,0.00007732601,0.0002126515,0.0015726686,0.00030191272,0.00055593724,0.00003969959,0.000013402598,0.00047112026],"genre_scores_gemma":[0.9928087,0.000044015313,0.00652069,0.00011997551,0.00006650055,0.000017237919,0.000088411114,0.000013498372,0.00032097602],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99926805,0.000010719071,0.00027806356,0.00013018327,0.00021669091,0.000096310796],"domain_scores_gemma":[0.99915093,0.000068618145,0.0002478984,0.00024977888,0.00024789406,0.000034898025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009970389,0.00006950487,0.00014169556,0.00006798468,0.00004074313,0.000005824419,0.00011973435,0.000035066987,0.000113688904],"category_scores_gemma":[0.000254809,0.000051477968,0.00003256537,0.00021267684,0.00003497668,0.00003566694,0.000032034935,0.00007755531,0.000003050719],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012566628,0.0025955993,0.91843855,0.00080315664,0.00040714204,0.0000018819987,0.0015868371,0.00008605814,0.058554374,0.005884725,0.002159631,0.009356349],"study_design_scores_gemma":[0.0067111365,0.0003137383,0.8950218,0.00024182381,0.00019941335,0.00002131849,0.00007543534,0.0003508326,0.09168604,0.000195957,0.005099687,0.00008284522],"about_ca_topic_score_codex":0.00022376026,"about_ca_topic_score_gemma":0.00081343553,"teacher_disagreement_score":0.03313167,"about_ca_system_score_codex":0.00009574693,"about_ca_system_score_gemma":0.00036610346,"threshold_uncertainty_score":0.20992106},"labels":[],"label_agreement":null},{"id":"W1973415773","doi":"10.1002/cncr.23607","title":"No significance of derivative chromosome 9 deletion on the clearance kinetics of <i>BCR</i>/<i>ABL</i> fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia","year":2008,"lang":"en","type":"article","venue":"Cancer","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Imatinib mesylate; breakpoint cluster region; ABL; Imatinib; Medicine; Fluorescence in situ hybridization; Philadelphia chromosome; Myeloid leukemia; Fusion gene; Fusion transcript; Molecular biology; Cancer research; Internal medicine; Tyrosine kinase; Biology; Chromosomal translocation; Chromosome; Gene; Genetics; Receptor","score_opus":0.03888736965436139,"score_gpt":0.301315502515052,"score_spread":0.2624281328606906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1973415773","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99063456,0.0025565801,0.00064711325,0.0013761624,0.000119409255,0.004125505,0.00046563006,0.00003159837,0.000043447537],"genre_scores_gemma":[0.9897055,0.0046477793,0.0020587877,0.0005249495,0.00010168855,0.0011470952,0.000027774988,0.00010074408,0.00168568],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971784,0.00035486958,0.0008337401,0.00057795196,0.0005828254,0.0004722655],"domain_scores_gemma":[0.9971047,0.0008133223,0.00049581827,0.00089325657,0.0005426082,0.00015030723],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00030942567,0.00047077154,0.0009421034,0.00015973387,0.00009680313,0.000005155841,0.00028659642,0.00019143702,0.000330773],"category_scores_gemma":[0.0003044595,0.00028719092,0.0002859919,0.00068185956,0.0004090118,0.000048516365,0.000025883704,0.00015633734,0.000009049109],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14017007,0.00035972614,0.00016026977,0.00027217492,0.00035374358,0.000054253538,0.0017765326,0.001826372,0.85062206,0.000015523749,0.00056306005,0.003826222],"study_design_scores_gemma":[0.012106573,0.018839816,0.010065818,0.0010045628,0.00017294449,0.000039274877,0.000088937166,0.00021864932,0.9383494,0.000009588497,0.018845899,0.00025849295],"about_ca_topic_score_codex":0.000166531,"about_ca_topic_score_gemma":0.000099280776,"teacher_disagreement_score":0.1280635,"about_ca_system_score_codex":0.002976828,"about_ca_system_score_gemma":0.0030173457,"threshold_uncertainty_score":0.99995804},"labels":[],"label_agreement":null},{"id":"W1973595070","doi":"10.1182/blood-2013-12-544015","title":"Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Nilotinib; Imatinib; Medicine; Dasatinib; Internal medicine; Imatinib mesylate; Oncology; Myeloid leukemia","score_opus":0.006477699996470823,"score_gpt":0.2363842598865341,"score_spread":0.22990655989006328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1973595070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976848,0.00012421166,0.00018231708,0.0003407168,0.0000447718,0.0011504106,0.000013057944,0.00007803478,0.00038168087],"genre_scores_gemma":[0.9959586,0.0000032270977,0.0021320751,0.0011887988,0.000060320846,0.00020264961,0.000059493854,0.00007880823,0.00031597368],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979976,0.00013101118,0.000364083,0.00053435785,0.00048173507,0.00049121573],"domain_scores_gemma":[0.99860984,0.000093344875,0.0001278536,0.0007738588,0.00011116458,0.00028393124],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016386513,0.0003315414,0.0005507936,0.00019670812,0.000035747395,0.000026615802,0.00014818348,0.00012312984,0.00012365587],"category_scores_gemma":[0.00031264246,0.00026356097,0.000077614575,0.00028946146,0.00004174073,0.000073309704,0.0000933802,0.00021276028,0.00015570696],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030635486,0.0015033197,0.99202985,0.00011466893,0.00016690645,0.00034411726,0.00045117133,0.0000057966918,0.00079992105,0.000004228501,0.000023448862,0.0014929987],"study_design_scores_gemma":[0.02535532,0.0013740287,0.96400446,0.0007465152,0.00027246022,0.000018684808,0.000018667333,0.000015298794,0.007862055,0.000007332893,0.000053035626,0.00027216374],"about_ca_topic_score_codex":0.000030842966,"about_ca_topic_score_gemma":0.00015233795,"teacher_disagreement_score":0.028025435,"about_ca_system_score_codex":0.00023371709,"about_ca_system_score_gemma":0.0001302022,"threshold_uncertainty_score":0.99998164},"labels":[],"label_agreement":null},{"id":"W1974046893","doi":"10.1038/leu.2012.196","title":"Ex vivo expansion of normal and chronic myeloid leukemic stem cells without functional alteration using a NUP98HOXA10homeodomain fusion gene","year":2012,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute; BC Cancer Agency; Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Fondation de France; Terry Fox Foundation","keywords":"Stem cell; Haematopoiesis; Biology; Myeloid leukemia; Myeloid; Cancer research; CD34; Hematopoietic stem cell; Cell biology; Ex vivo; Leukemia; Fusion gene; Cord blood; Immunology; In vivo; Gene; Genetics","score_opus":0.02291217344348628,"score_gpt":0.25289705516832994,"score_spread":0.22998488172484366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974046893","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99238473,0.0021170438,0.0037942075,0.00002324249,0.0005490458,0.00068584003,0.000023897326,0.00008019906,0.00034176424],"genre_scores_gemma":[0.9937873,0.00025913052,0.003511475,0.00011833111,0.0009560091,0.000024607349,0.00007692663,0.00007069547,0.0011955563],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975859,0.00010178739,0.0006114613,0.00045726763,0.0006086438,0.00063495],"domain_scores_gemma":[0.99866194,0.00008562309,0.0003052665,0.00049483695,0.00011245753,0.00033989197],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036171474,0.0003859431,0.00056916795,0.0002313126,0.00017271112,0.000022175203,0.00008434765,0.0002702293,0.00035880518],"category_scores_gemma":[0.000014385975,0.0003480229,0.00013491244,0.00025832388,0.00013963337,0.00045869907,0.0001333701,0.0003062604,0.000057426263],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042166267,0.00008751763,0.017071454,0.00027379644,0.00010397978,0.000013835849,0.0005605758,0.00066069077,0.9747648,0.000043031974,0.00027226194,0.005726399],"study_design_scores_gemma":[0.008845761,0.00047472698,0.025675757,0.00043422534,0.00039435545,0.00070584327,0.0001790006,0.022182932,0.93977875,0.000013564025,0.0009228059,0.00039228436],"about_ca_topic_score_codex":0.00024997618,"about_ca_topic_score_gemma":0.0000129686305,"teacher_disagreement_score":0.034986053,"about_ca_system_score_codex":0.0067052986,"about_ca_system_score_gemma":0.0015901711,"threshold_uncertainty_score":0.9998972},"labels":[],"label_agreement":null},{"id":"W1974862201","doi":"10.1038/sj.leu.2403928","title":"Imatinib dose increase up to 1200 mg daily can induce new durable complete cytogenetic remissions in relapsed Ph+ chronic myeloid leukemia patients","year":2005,"lang":"en","type":"letter","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Imatinib; Myeloid leukemia; Medicine; Internal medicine; Leukemia; Imatinib mesylate; Myeloid; Hematology; Cancer research; Oncology; Immunology","score_opus":0.025523139557030814,"score_gpt":0.2673035791016141,"score_spread":0.2417804395445833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974862201","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8484586,0.001733396,0.000018371908,0.12803745,0.0018846699,0.0070867385,0.0010624642,0.00065364223,0.011064701],"genre_scores_gemma":[0.18834744,0.000924655,0.006412532,0.57407707,0.017649928,0.001430069,0.019572787,0.0018553713,0.18973014],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9888549,0.00047764325,0.0025649306,0.0028397162,0.0022039379,0.003058887],"domain_scores_gemma":[0.9926828,0.0005180474,0.00097271486,0.0036097302,0.00033808433,0.0018786083],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.00042574338,0.0022183731,0.0028741302,0.0014101786,0.00037736943,0.00015853398,0.0014235966,0.0028890881,0.0026256323],"category_scores_gemma":[0.0007813388,0.0021833142,0.0006469942,0.001738375,0.00022427259,0.00020060953,0.00070437544,0.006613335,0.0023184484],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00062208105,0.00013837666,0.0034837152,0.0007341485,0.00039648666,0.0022497955,0.0011143967,0.00059042894,0.0051807794,0.00000426948,0.9716255,0.01386004],"study_design_scores_gemma":[0.040468916,0.001285321,0.028965103,0.0051639862,0.0010126744,0.00041964496,0.000062565545,0.00081354525,0.0018810577,0.00006723678,0.91726977,0.002590197],"about_ca_topic_score_codex":0.020663433,"about_ca_topic_score_gemma":0.002190121,"teacher_disagreement_score":0.6601111,"about_ca_system_score_codex":0.08722208,"about_ca_system_score_gemma":0.029539675,"threshold_uncertainty_score":0.9990556},"labels":[],"label_agreement":null},{"id":"W1975012883","doi":"10.1016/j.pep.2008.10.023","title":"Cloning, expression, purification and functional characterization of the oligomerization domain of Bcr–Abl oncoprotein fused to the cytoplasmic transduction peptide","year":2008,"lang":"en","type":"article","venue":"Protein Expression and Purification","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Blood Services","funders":"National Natural Science Foundation of China; University of South Alabama","keywords":"Fusion protein; Tyrosine kinase; Biology; Cytoplasm; Signal transduction; ABL; K562 cells; Transduction (biophysics); Cell biology; Protein kinase domain; breakpoint cluster region; Molecular biology; Chemistry; Biochemistry; Recombinant DNA; Cell; Gene; Mutant","score_opus":0.01653897866449224,"score_gpt":0.2288962637677391,"score_spread":0.21235728510324686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975012883","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9776948,0.00019518934,0.017002419,0.0022112539,0.00010229944,0.0026297078,0.000025247542,0.00003803398,0.00010103525],"genre_scores_gemma":[0.99551815,0.00027256762,0.0024678945,0.000067185014,0.00011573063,0.00045346175,0.00019180146,0.00002578433,0.0008874499],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981909,0.00021552322,0.00056298205,0.00039051267,0.00048155105,0.00015856065],"domain_scores_gemma":[0.99864775,0.000035978926,0.0005048081,0.0005033281,0.00021074123,0.00009738203],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032402153,0.0001952817,0.00026048606,0.00013952906,0.00035518757,0.0000143230445,0.00010345147,0.00014786034,0.00007182778],"category_scores_gemma":[0.00012472594,0.00012396964,0.000063606436,0.00039002902,0.00017634465,0.00020354548,0.00003918357,0.00016910107,0.000004734799],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004711354,0.0001394685,0.002246531,0.00013402889,0.000015199756,3.8024734e-7,0.0018494996,0.000024026827,0.99184525,0.0002441444,0.000058513375,0.002971844],"study_design_scores_gemma":[0.0013392558,0.000116061616,0.18289118,0.00042255817,0.00003275179,0.000043575274,0.00012867122,0.00020922466,0.81158245,0.00007615839,0.0030588321,0.00009929023],"about_ca_topic_score_codex":0.000035532736,"about_ca_topic_score_gemma":0.0000026650291,"teacher_disagreement_score":0.18064465,"about_ca_system_score_codex":0.0001036402,"about_ca_system_score_gemma":0.00015992885,"threshold_uncertainty_score":0.5055335},"labels":[],"label_agreement":null},{"id":"W1975447781","doi":"10.1007/s11010-013-1841-1","title":"Cell-penetrating fusion peptides OD1 and OD2 interact with Bcr–Abl and influence the growth and apoptosis of K562 cells","year":2013,"lang":"en","type":"article","venue":"Molecular and Cellular Biochemistry","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Chongqing Medical University; Chongqing University; National Natural Science Foundation of China","keywords":"K562 cells; Chronic myelogenous leukemia; Biology; ABL; Fusion protein; Cytoplasm; breakpoint cluster region; Cell biology; Phosphorylation; Cell culture; Apoptosis; Signal transduction; Molecular biology; Cancer research; Tyrosine kinase; Leukemia; Biochemistry; Immunology; Receptor; Recombinant DNA; Genetics; Gene","score_opus":0.002907826825619656,"score_gpt":0.18856004840696872,"score_spread":0.18565222158134906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975447781","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948751,0.003923181,0.000053464315,0.00015769734,0.000007460514,0.00028958597,0.0000042105266,0.0000118758735,0.00067745434],"genre_scores_gemma":[0.9986388,0.00023090585,0.00082013523,0.00013832457,0.000015546106,0.000018224508,0.000016296348,0.000020627385,0.00010115184],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990436,0.000026489244,0.00019233311,0.00035354387,0.00017247016,0.00021157858],"domain_scores_gemma":[0.9993643,0.000054814194,0.000102392994,0.00025008962,0.000063041094,0.00016534733],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007741947,0.00021895907,0.0002302882,0.000026838003,0.00008750799,0.000057119792,0.00005753075,0.000099980796,0.000015747428],"category_scores_gemma":[0.000030189209,0.00014692768,0.000029269664,0.00007353692,0.00026343847,0.00005666337,0.000119848366,0.0001641153,8.448534e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000031737018,0.000039512677,0.015595332,0.00057427346,0.000054792705,0.000019995405,0.00019574525,6.998297e-7,0.9827987,0.0000050054155,0.000022427294,0.0006617658],"study_design_scores_gemma":[0.001279644,0.00018464327,0.0027038555,0.00026116066,0.00015565296,0.00009223497,0.00052251236,0.0000985763,0.99451745,0.000025431898,0.000008833084,0.0001499838],"about_ca_topic_score_codex":0.00034144215,"about_ca_topic_score_gemma":7.7342133e-7,"teacher_disagreement_score":0.012891476,"about_ca_system_score_codex":0.000027378446,"about_ca_system_score_gemma":0.000053544958,"threshold_uncertainty_score":0.59915364},"labels":[],"label_agreement":null},{"id":"W1975706178","doi":"10.1203/01.pdr.0000153871.45184.19","title":"Effects of 17-Allylamino-17-Demethoxygeldanamycin (17-AAG) on Pediatric Acute Lymphoblastic Leukemia (ALL) with Respect to Bcr-Abl Status and Imatinib Mesylate Sensitivity","year":2005,"lang":"en","type":"article","venue":"Pediatric Research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital","funders":"Hospital for Sick Children","keywords":"Imatinib mesylate; Imatinib; Medicine; Cancer research; ABL; Pharmacology; Context (archaeology); Internal medicine; Myeloid leukemia; Biology; Tyrosine kinase; Receptor","score_opus":0.02600349625462167,"score_gpt":0.34009772365541496,"score_spread":0.3140942274007933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975706178","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990264,0.0021345685,0.00017922687,0.000640809,0.00009070632,0.0027482333,0.00006910094,0.00013692601,0.0037364603],"genre_scores_gemma":[0.9809658,0.0041061323,0.0068600527,0.00026596265,0.0015861817,0.0002051804,0.00005027782,0.00014894332,0.0058114636],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99221057,0.0009401703,0.0008448218,0.001380637,0.0026048843,0.0020189055],"domain_scores_gemma":[0.9908679,0.0058691893,0.0002744885,0.001119675,0.0006174112,0.0012513506],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0028321352,0.0006709087,0.0011990672,0.0019038871,0.00026425955,0.00008435148,0.0002825128,0.00033151585,0.00014458889],"category_scores_gemma":[0.002331779,0.00053308863,0.00017282025,0.0026597104,0.00020711767,0.0002260622,0.0004353147,0.0011943763,0.00025177858],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.039355937,0.0062093437,0.5845356,0.0118308645,0.003662443,0.016679069,0.009890937,0.004944224,0.035220172,0.00048630327,0.21037367,0.07681143],"study_design_scores_gemma":[0.036165908,0.015426209,0.9119793,0.0003896579,0.00403054,0.00061674934,0.00021744017,0.0047715064,0.020040851,0.00014157114,0.00452124,0.0016990378],"about_ca_topic_score_codex":0.00084396027,"about_ca_topic_score_gemma":0.00020582945,"teacher_disagreement_score":0.3274437,"about_ca_system_score_codex":0.0040830025,"about_ca_system_score_gemma":0.0029691174,"threshold_uncertainty_score":0.9997401},"labels":[],"label_agreement":null},{"id":"W1975748957","doi":"10.1172/jci31095","title":"FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome–positive acute lymphocytic leukemia","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Investigation","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":332,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"National Cancer Institute; D. Warren Brown Family Foundation; Associazione Italiana per la Ricerca sul Cancro; Fonds de Recherche du Québec - Santé; Ministero della Salute; Ohio State University; American-Italian Cancer Foundation","keywords":"Chronic myelogenous leukemia; Cancer research; Philadelphia chromosome; Leukemia; Dasatinib; Progenitor cell; Medicine; Myeloid leukemia; Immunology; Imatinib; Stem cell; Biology","score_opus":0.052966102490439086,"score_gpt":0.3724998987889664,"score_spread":0.3195337962985273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975748957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885501,0.0010585866,0.0069648162,0.0017785968,0.00060354423,0.0007935711,0.000025110403,0.00004122284,0.0001844258],"genre_scores_gemma":[0.9751416,0.00080403837,0.017908908,0.0013203319,0.0043586697,0.000009968781,0.000057564444,0.000072075876,0.0003268616],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99567133,0.0001374466,0.0025130366,0.00049251487,0.0006430841,0.0005425667],"domain_scores_gemma":[0.9941901,0.001825123,0.0020256576,0.00029916584,0.0006019193,0.0010580163],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019728423,0.00039742683,0.0012352354,0.00030178356,0.00017443122,0.00005864014,0.00019138194,0.00040623426,0.000039643903],"category_scores_gemma":[0.0016837156,0.00032845672,0.00050500385,0.00033525022,0.00034844587,0.0004257705,0.000065123626,0.00069268147,0.000014492576],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.040540878,0.0013855944,0.08851001,0.0025010624,0.033264495,0.010105006,0.023757182,0.010278113,0.18856521,0.0026337237,0.063520275,0.53493845],"study_design_scores_gemma":[0.22629975,0.047916822,0.27623734,0.009210135,0.019934017,0.023964,0.0026204314,0.09475636,0.2671276,0.023654034,0.0054314914,0.0028480296],"about_ca_topic_score_codex":0.00033601542,"about_ca_topic_score_gemma":0.00005452785,"teacher_disagreement_score":0.5320904,"about_ca_system_score_codex":0.013905698,"about_ca_system_score_gemma":0.012144341,"threshold_uncertainty_score":0.99991673},"labels":[],"label_agreement":null},{"id":"W1977131009","doi":"10.1002/cyto.a.10063","title":"Immunoreactivity of Stat5 phosphorylated on tyrosine as a cell‐based measure of Bcr/Abl kinase activity","year":2003,"lang":"en","type":"article","venue":"Cytometry Part A","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; National Institutes of Health","keywords":"Molecular biology; Flow cytometry; Imatinib mesylate; Biology; DAPI; ABL; Chronic myelogenous leukemia; Tyrosine kinase; STAT5; Chemistry; Leukemia; Cancer research; Cell biology; Phosphorylation; Immunology; Imatinib; Signal transduction; Myeloid leukemia; Biochemistry; Apoptosis","score_opus":0.02228093840885184,"score_gpt":0.28042456865662435,"score_spread":0.25814363024777254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1977131009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98481154,0.0007309489,0.00012175164,0.00004509945,0.00014744238,0.00064752914,0.000084931744,0.00006260121,0.0133481305],"genre_scores_gemma":[0.99864227,0.000047141006,0.00031522376,0.00007927029,0.000023246508,0.000033441953,0.000045432946,0.00005161073,0.0007623383],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978036,0.00018418011,0.00041420353,0.00045091362,0.00073299493,0.00041409177],"domain_scores_gemma":[0.99787027,0.00031285413,0.00038342067,0.00097559195,0.00023924446,0.00021861063],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004973097,0.0003435184,0.0008327854,0.00036018246,0.000057657035,0.0000072329294,0.00011738019,0.00021364825,0.0006995873],"category_scores_gemma":[0.0006663957,0.0003043485,0.00025318714,0.0012251788,0.0001695008,0.00009022694,0.000027871736,0.0003840566,0.00009060766],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00487996,0.007538502,0.04318691,0.0006530577,0.0005292329,0.00020711175,0.0001950135,0.00007219664,0.93586874,0.00009182244,0.0010858926,0.005691541],"study_design_scores_gemma":[0.00873613,0.0015758573,0.03191414,0.00033764716,0.00026732116,0.000018645427,0.00004288445,0.0001031877,0.95434886,0.000017069278,0.0024275258,0.00021074673],"about_ca_topic_score_codex":0.00028683472,"about_ca_topic_score_gemma":0.0000056404583,"teacher_disagreement_score":0.018480085,"about_ca_system_score_codex":0.0008521174,"about_ca_system_score_gemma":0.0010499462,"threshold_uncertainty_score":0.9999409},"labels":[],"label_agreement":null},{"id":"W1979362816","doi":"10.1002/gcc.20082","title":"<i>MLL</i> translocations with concurrent 3′ deletions: Interpretation of FISH results","year":2004,"lang":"en","type":"article","venue":"Genes Chromosomes and Cancer","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Hospital for Sick Children","keywords":"Chromosomal translocation; Fish <Actinopterygii>; Fluorescence in situ hybridization; Breakpoint; Biology; Metaphase; Molecular biology; Karyotype; Cytogenetics; Genetics; Gene; Chromosome","score_opus":0.013679589246351872,"score_gpt":0.27480385663314283,"score_spread":0.26112426738679095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979362816","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98405623,0.010741413,0.00082861877,0.003047209,0.00011503909,0.00042322543,0.00021474157,0.000033768167,0.0005397768],"genre_scores_gemma":[0.9923099,0.006567299,0.00034455155,0.000310629,0.00006833647,0.00011043525,0.000115459115,0.000012601208,0.000160769],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993318,0.000008449086,0.00020279514,0.0001953946,0.00014095263,0.00012061158],"domain_scores_gemma":[0.9995925,0.000017301612,0.000076022276,0.0001502954,0.00009459012,0.000069283094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000028957798,0.000107433865,0.00019037919,0.000041655887,0.000043652322,0.0000071324216,0.00003207903,0.000040125633,0.00004711471],"category_scores_gemma":[0.0000062343256,0.00008095055,0.000037805297,0.00013415613,0.00009805021,0.000059636666,0.000007809697,0.000054551718,0.0000020333891],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015632104,0.00088112446,0.007866318,0.0012496128,0.0010985452,0.00006532916,0.008997347,0.006004089,0.019961707,0.0009874979,0.0017902221,0.949535],"study_design_scores_gemma":[0.15579514,0.009023856,0.18074483,0.013102368,0.0048763687,0.0011750284,0.004160345,0.0038933367,0.41603845,0.0007662034,0.2083091,0.0021149607],"about_ca_topic_score_codex":0.00038625716,"about_ca_topic_score_gemma":0.00063633686,"teacher_disagreement_score":0.94742006,"about_ca_system_score_codex":0.00023522734,"about_ca_system_score_gemma":0.00040165335,"threshold_uncertainty_score":0.33010677},"labels":[],"label_agreement":null},{"id":"W1979633868","doi":"10.3747/co.21.1660","title":"Bilineal T lymphoblastic and myeloid blast transformation in chronic myeloid leukemia with TP53 mutation—an uncommon presentation in adults","year":2013,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Myeloid; Medicine; Myeloid leukemia; Cancer research; Fluorescence in situ hybridization; Lymphoblast; Bone marrow; Lymph node; Immunology; Biology; Genetics; Gene; Cell culture; Chromosome","score_opus":0.02827886034914285,"score_gpt":0.32895639057355397,"score_spread":0.3006775302244111,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979633868","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958909,0.00051135046,0.00021476336,0.00038550957,0.00021192977,0.0019204752,0.00000908673,0.0000619124,0.00079405075],"genre_scores_gemma":[0.9979758,0.00040951156,0.00031497024,0.000046260608,0.00016159796,0.00052988576,0.0004959522,0.000032643504,0.00003337977],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99797195,0.00017173013,0.0006351822,0.00047985284,0.0002789197,0.00046237872],"domain_scores_gemma":[0.9990736,0.00018313425,0.00017128095,0.00025318368,0.00011111447,0.00020763619],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018072373,0.00029164486,0.00048076012,0.00044165953,0.000051981373,0.000024279107,0.00009436359,0.00019634156,0.0001344693],"category_scores_gemma":[0.000056734018,0.00024491228,0.000036371002,0.00044258163,0.00016210071,0.00051023415,0.000027736107,0.0003723521,0.00007216669],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026491813,0.0016575258,0.17607895,0.0016705962,0.000088129855,0.00016858238,0.013950786,0.0049729,0.0022356065,0.00025961408,0.00015578064,0.79611236],"study_design_scores_gemma":[0.04736428,0.0058019944,0.75525445,0.0012460434,0.00013705647,0.00044146544,0.0021293806,0.18481664,0.0010698978,0.00024898758,0.0010362231,0.00045360296],"about_ca_topic_score_codex":0.0013440669,"about_ca_topic_score_gemma":0.009714236,"teacher_disagreement_score":0.79565877,"about_ca_system_score_codex":0.0081977,"about_ca_system_score_gemma":0.0019557609,"threshold_uncertainty_score":0.9987233},"labels":[],"label_agreement":null},{"id":"W1979706247","doi":"10.1038/leu.2013.40","title":"Gads (Grb2-related adaptor downstream of Shc) is required for BCR-ABL-mediated lymphoid leukemia","year":2013,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto; Ontario Institute for Cancer Research","funders":"Canadian Institutes of Health Research","keywords":"GRB2; Signal transducing adaptor protein; Downstream (manufacturing); Cancer research; Leukemia; Lymphoid leukemia; breakpoint cluster region; Biology; Cell biology; Immunology; Signal transduction; Receptor; Genetics; Business","score_opus":0.015447981150308895,"score_gpt":0.25329396121420267,"score_spread":0.23784598006389376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979706247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852385,0.0010201131,0.000103175174,0.0007004572,0.0005217404,0.0029902104,0.00032011658,0.00040007452,0.0087056095],"genre_scores_gemma":[0.9790997,0.00029624428,0.0033740134,0.0011108512,0.00032067232,0.0006075443,0.0010109029,0.00018855713,0.013991499],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9956546,0.000073556344,0.0013728639,0.0009950754,0.0007782272,0.0011256728],"domain_scores_gemma":[0.99631834,0.00049016875,0.00058308896,0.0014796018,0.00051808206,0.0006107171],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00029019802,0.00071415893,0.001286858,0.00033782783,0.00015060669,0.000043001713,0.0004390482,0.00074906164,0.0026138653],"category_scores_gemma":[0.00053039525,0.0006245859,0.0005388614,0.00072023744,0.00032619407,0.0003709078,0.000147147,0.0003924171,0.0012155247],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025883124,0.0011273356,0.039147776,0.0021789176,0.004295309,0.00024169424,0.003733404,0.00019847688,0.43306452,0.0008049553,0.44635612,0.06626318],"study_design_scores_gemma":[0.15549515,0.0066812993,0.066395134,0.0042514727,0.0042593875,0.0015188786,0.001775772,0.07816955,0.5698607,0.0029726275,0.104321286,0.004298734],"about_ca_topic_score_codex":0.0030667335,"about_ca_topic_score_gemma":0.00003168724,"teacher_disagreement_score":0.34203485,"about_ca_system_score_codex":0.01004095,"about_ca_system_score_gemma":0.00443753,"threshold_uncertainty_score":0.99962056},"labels":[],"label_agreement":null},{"id":"W1980294911","doi":"10.1038/sj.leu.2402486","title":"Bcr-abl-positive cells secrete angiogenic factors including matrix metalloproteinases and stimulate angiogenesis in vivo in Matrigel implants","year":2002,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":92,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Blood Services; University of Alberta","funders":"National Heart, Lung, and Blood Institute","keywords":"Matrigel; Angiogenesis; Chronic myelogenous leukemia; Hepatocyte growth factor; Matrix metalloproteinase; Cancer research; CD34; Biology; Bone marrow; Neovascularization; Immunology; Stem cell; Leukemia; Cell biology; Receptor","score_opus":0.027155013535768484,"score_gpt":0.27273693512783276,"score_spread":0.24558192159206427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1980294911","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99338466,0.004398389,0.000013043862,0.000055054395,0.000105348845,0.0010999261,0.00015619227,0.00009286717,0.00069453294],"genre_scores_gemma":[0.99669975,0.0006784271,0.0009056353,0.000095022944,0.00007009905,0.000054141936,0.000049387134,0.00007939242,0.0013681459],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973483,0.00010860096,0.00061802566,0.00072591135,0.00039490417,0.0008042214],"domain_scores_gemma":[0.9988443,0.00023265713,0.00016620997,0.00043767397,0.00004102979,0.00027812642],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020793978,0.00050846196,0.00083984627,0.00065837253,0.00009871631,0.000040166604,0.00015576303,0.0002980848,0.00060077105],"category_scores_gemma":[0.00006728836,0.00046273498,0.00021064361,0.00073231384,0.00008621508,0.00022824669,0.00017571672,0.00029447975,0.00008454371],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009055261,0.00047933473,0.4656941,0.00069002766,0.0011354644,0.0072787795,0.0059343707,0.0019354647,0.5080435,0.00006148649,0.0011015532,0.006740388],"study_design_scores_gemma":[0.026399283,0.00093590387,0.33203632,0.0015680186,0.0010364312,0.0008630218,0.0008790936,0.02881503,0.604238,0.0001869818,0.0012492641,0.0017927062],"about_ca_topic_score_codex":0.0036717039,"about_ca_topic_score_gemma":0.00040310036,"teacher_disagreement_score":0.13365778,"about_ca_system_score_codex":0.0038927842,"about_ca_system_score_gemma":0.00020821429,"threshold_uncertainty_score":0.9999311},"labels":[],"label_agreement":null},{"id":"W1980473329","doi":"10.1038/sj.leu.2402444","title":"Elucidating critical mechanisms of deregulated stem cell turnover in the chronic phase of chronic myeloid leukemia","year":2002,"lang":"en","type":"review","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":126,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Stem cell; Haematopoiesis; clone (Java method); Biology; Progenitor cell; Stem cell theory of aging; Myeloid leukemia; Myeloid; Cancer research; Autocrine signalling; Immunology; Cell biology; Leukemia; Genetics; Stem cell factor; Cell culture; Gene","score_opus":0.04371995112838308,"score_gpt":0.33159713711425187,"score_spread":0.2878771859858688,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1980473329","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0025540297,0.9911364,0.0003423839,0.000024839987,0.0003360895,0.0029413318,0.00017491273,0.00008730562,0.0024027613],"genre_scores_gemma":[0.046673838,0.95011884,0.00044178366,0.00006379299,0.0005347875,0.00031403845,0.00043961935,0.0002777348,0.0011355502],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.992735,0.00061653287,0.0028943,0.0011888398,0.0013235734,0.0012417142],"domain_scores_gemma":[0.99464333,0.001307277,0.0013596357,0.0022292077,0.00019609189,0.00026446278],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00086591474,0.0012780568,0.0045571127,0.0006153537,0.00010331545,0.00003537233,0.00106548,0.0012971639,0.0010016615],"category_scores_gemma":[0.00014079636,0.00090761535,0.0012824401,0.0014902749,0.00042629472,0.00016127017,0.00020981781,0.0020404535,0.00017346353],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00008633078,0.00089958584,0.000002907439,0.10046662,0.0006615132,0.00073589385,0.0007035205,0.000067301284,0.0010460872,0.00076859933,0.001079553,0.8934821],"study_design_scores_gemma":[0.046742957,0.008127008,0.000035225486,0.18377788,0.018246438,0.0035177725,0.00054895965,0.007571066,0.018834803,0.0004697497,0.70867395,0.0034541741],"about_ca_topic_score_codex":0.00026096473,"about_ca_topic_score_gemma":0.00007146292,"teacher_disagreement_score":0.89002794,"about_ca_system_score_codex":0.029207947,"about_ca_system_score_gemma":0.010433123,"threshold_uncertainty_score":0.99999934},"labels":[],"label_agreement":null},{"id":"W1980590287","doi":"10.1016/j.leukres.2012.07.013","title":"Dasatinib inhibits leukaemic cell survival by decreasing PRH/Hhex phosphorylation resulting in increased repression of VEGF signalling genes","year":2012,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Wellcome Trust","keywords":"Dasatinib; Psychological repression; Phosphorylation; Cell biology; Proto-oncogene tyrosine-protein kinase Src; Transcription factor; Cancer research; Biology; Myeloid leukemia; Chemistry; Signal transduction; Molecular biology; Gene; Tyrosine kinase; Gene expression; Biochemistry","score_opus":0.06927618701549326,"score_gpt":0.36445768919430604,"score_spread":0.2951815021788128,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1980590287","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878513,0.005350321,0.00005783185,0.000056021312,0.00010245878,0.0010401175,0.000017531398,0.00006891538,0.005455464],"genre_scores_gemma":[0.9955761,0.00050131994,0.0024754754,0.000024286854,0.00027743328,0.00008010645,0.00026519113,0.00008654577,0.00071358506],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99462926,0.0008074044,0.00096314575,0.00066829415,0.0016815112,0.0012503878],"domain_scores_gemma":[0.9967445,0.0014123584,0.00029665956,0.0007029771,0.00037790427,0.00046561536],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0047717863,0.0003218027,0.0006244883,0.0005283073,0.00021142382,0.000037949776,0.00025773837,0.00037908964,0.00012416749],"category_scores_gemma":[0.0016370172,0.00030004553,0.000119986114,0.001125195,0.00018597745,0.00037927492,0.0002712763,0.0011394443,0.000060425686],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012891439,0.00040674995,0.21547471,0.00044341473,0.000040364463,0.00003462237,0.0015270418,0.00012988097,0.77067316,0.000026872043,0.0005392636,0.009414805],"study_design_scores_gemma":[0.009741751,0.00024159478,0.033650715,0.0015738603,0.0000525417,0.000027846607,0.0008951644,0.0068833977,0.9458498,0.000050599345,0.00073029567,0.00030248147],"about_ca_topic_score_codex":0.008245244,"about_ca_topic_score_gemma":0.00007731701,"teacher_disagreement_score":0.181824,"about_ca_system_score_codex":0.005883746,"about_ca_system_score_gemma":0.001904261,"threshold_uncertainty_score":0.99994516},"labels":[],"label_agreement":null},{"id":"W1980663284","doi":"10.1016/j.leukres.2008.07.015","title":"Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels","year":2008,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; BC Cancer Agency","funders":"BC Cancer Agency; Michael Smith Health Research BC","keywords":"Imatinib; Myeloid leukemia; Internal medicine; Medicine; Odds ratio; Gastroenterology; Trough (economics); Trough level; Oncology","score_opus":0.061519008866460737,"score_gpt":0.34157451335812333,"score_spread":0.2800555044916626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1980663284","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99471396,0.0019287235,0.00012076542,0.00032135754,0.000027985332,0.002419511,0.00020930731,0.000059563503,0.00019882125],"genre_scores_gemma":[0.99285,0.0028661394,0.0032667888,0.00007929457,0.00006133118,0.0002454015,0.000040538267,0.00009915381,0.00049132033],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9950973,0.00070642796,0.0008221332,0.00090391934,0.0015533123,0.0009169043],"domain_scores_gemma":[0.99715024,0.00089431665,0.00028315285,0.00077583664,0.000492167,0.0004042803],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012258935,0.00045673797,0.00088522874,0.00077665533,0.0003141538,0.000055765213,0.0002251417,0.0003008168,0.00007713517],"category_scores_gemma":[0.0009617398,0.0003723259,0.000073936,0.0010309834,0.00081301894,0.00018603752,0.00019258009,0.0010524674,0.000022117527],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.06916568,0.00029272021,0.21385354,0.00094097375,0.0007254977,0.004215035,0.010304663,0.0027297942,0.6630527,0.0001208785,0.00049402204,0.034104496],"study_design_scores_gemma":[0.03687789,0.006045182,0.53410447,0.0011943665,0.00007250478,0.00094262185,0.0008136121,0.008398668,0.4108248,0.00007672095,0.00018146122,0.00046771142],"about_ca_topic_score_codex":0.002128836,"about_ca_topic_score_gemma":0.00051480765,"teacher_disagreement_score":0.32025093,"about_ca_system_score_codex":0.007669998,"about_ca_system_score_gemma":0.007481933,"threshold_uncertainty_score":0.99987286},"labels":[],"label_agreement":null},{"id":"W1981083415","doi":"10.1016/j.ccr.2005.10.015","title":"The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein","year":2005,"lang":"en","type":"article","venue":"Cancer Cell","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":472,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"National Institutes of Health; National Cancer Institute; University of Pennsylvania","keywords":"Chronic myelogenous leukemia; Cancer research; Protein phosphatase 2; breakpoint cluster region; Progenitor cell; Imatinib mesylate; ABL; Biology; Imatinib; Leukemia; Stem cell; Cell biology; Phosphorylation; Immunology; Signal transduction; Phosphatase; Myeloid leukemia; Tyrosine kinase; Receptor; Genetics","score_opus":0.014746787630949913,"score_gpt":0.26112393852160914,"score_spread":0.24637715089065923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1981083415","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.983938,0.001247768,0.0000048464067,0.009876699,0.0002518135,0.0015041678,0.000080661455,0.00003520232,0.00306087],"genre_scores_gemma":[0.99341196,0.000091460206,0.000028593959,0.0009357337,0.00028205596,0.00036283798,0.000008785242,0.000041044048,0.004837518],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99819523,0.00018087027,0.0003503361,0.00036912263,0.00050985935,0.00039457672],"domain_scores_gemma":[0.9985228,0.0001598504,0.00028063677,0.0008341637,0.00014269825,0.000059831367],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020138462,0.00026510004,0.00031530726,0.000025970387,0.00022567021,0.000020830013,0.00029604163,0.00011505208,0.00070008734],"category_scores_gemma":[0.000050650408,0.00013228299,0.0001564398,0.00032983514,0.00025109883,0.00018347781,0.00013299052,0.00047931768,0.000026092619],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039824503,0.0015037099,0.0069896355,0.00046447632,0.00081965624,0.000029137795,0.008793907,0.0015679528,0.8257056,0.00013656511,0.1430647,0.0069422508],"study_design_scores_gemma":[0.0037950613,0.000111176996,0.019745184,0.00022450059,0.00013035264,0.000010524919,0.00073104084,0.00047157262,0.90581113,0.000052808424,0.06876132,0.00015533988],"about_ca_topic_score_codex":0.003710965,"about_ca_topic_score_gemma":0.0017284711,"teacher_disagreement_score":0.08010555,"about_ca_system_score_codex":0.0023274366,"about_ca_system_score_gemma":0.00097319396,"threshold_uncertainty_score":0.76654655},"labels":[],"label_agreement":null},{"id":"W1981154777","doi":"10.1038/leu.2013.253","title":"Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease","year":2013,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":135,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; Princess Margaret Cancer Centre","funders":"National Center for Advancing Translational Sciences; National Institute of Allergy and Infectious Diseases; National Cancer Institute; National Heart, Lung, and Blood Institute","keywords":"Medicine; Internal medicine; Hazard ratio; Transplantation; Minimal residual disease; Gastroenterology; Confidence interval; Population; Hematopoietic stem cell transplantation; Oncology; Surgery; Leukemia","score_opus":0.018221627587227725,"score_gpt":0.2633497789427754,"score_spread":0.24512815135554766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1981154777","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979698,0.000355896,0.0000025726195,0.00037318992,0.000057869063,0.00088305894,0.0002694233,0.000021363277,0.00006682574],"genre_scores_gemma":[0.99862856,0.00024928074,0.00033893966,0.00011550791,0.00008042217,0.0000475031,0.00041771852,0.000032876058,0.00008920446],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983069,0.000083711195,0.0004610118,0.0004875328,0.0003178036,0.00034309804],"domain_scores_gemma":[0.9988349,0.00013468055,0.00014169651,0.00028506285,0.00017756473,0.00042609574],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00010540927,0.00032350858,0.0005367259,0.00014434308,0.0000518571,0.00001950225,0.000057228302,0.00013868994,0.00012991222],"category_scores_gemma":[0.00013109368,0.00026041802,0.00008766553,0.0001150917,0.00019520233,0.00018976117,0.00007072121,0.00021706749,0.0000064475566],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006338627,0.00021807503,0.9733164,0.00036794887,0.00014827093,0.00029181814,0.0020641512,0.000023921364,0.015821842,0.0000011971014,0.0005811667,0.00082659465],"study_design_scores_gemma":[0.009677356,0.0006335273,0.9840257,0.0005828115,0.000213785,0.000020635753,0.000077832236,0.00074571813,0.0037278994,0.00003276176,0.000039850736,0.00022213368],"about_ca_topic_score_codex":0.0021417546,"about_ca_topic_score_gemma":0.0002533772,"teacher_disagreement_score":0.012093944,"about_ca_system_score_codex":0.0012599195,"about_ca_system_score_gemma":0.0003516292,"threshold_uncertainty_score":0.9999848},"labels":[],"label_agreement":null},{"id":"W1981170979","doi":"10.1002/pbc.22172","title":"The treatment of pediatric Philadelphia positive (Ph+) leukemias in the imatinib era","year":2009,"lang":"en","type":"article","venue":"Pediatric Blood & Cancer","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Stollery Children's Hospital","funders":"Children's Cancer Research Fund","keywords":"Medicine; Imatinib; Chronic myelogenous leukemia; Blood cancer; Internal medicine; Imatinib mesylate; Hematopoietic cell; Oncology; Transplantation; Philadelphia chromosome; Hematopoietic stem cell transplantation; Leukemia; Lymphoblastic Leukemia; Cancer; Pediatrics; Haematopoiesis; Stem cell; Myeloid leukemia; Chromosomal translocation","score_opus":0.017233621311286113,"score_gpt":0.29481852455798685,"score_spread":0.2775849032467007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1981170979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9447299,0.046214677,0.000002356045,0.0055857874,0.00023061396,0.0013287876,0.000068357374,0.000043116557,0.0017963692],"genre_scores_gemma":[0.93626434,0.0598172,0.00013660798,0.0005072653,0.0026895849,0.00025438739,0.000029772562,0.0000285989,0.0002722663],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99760264,0.00012442374,0.000633757,0.00042998086,0.00061863876,0.00059057603],"domain_scores_gemma":[0.9982165,0.00055203633,0.0003150213,0.00067178387,0.00012040096,0.00012421918],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025298228,0.00036896256,0.00051718013,0.00018997023,0.00017645703,0.000029001374,0.00028618693,0.00014089962,0.00009111818],"category_scores_gemma":[0.00006220055,0.00020049531,0.00025481754,0.0010476821,0.00006645259,0.00008057711,0.00001936784,0.00030763028,0.000027728012],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026257574,0.014661071,0.8161156,0.0005026098,0.0015847521,0.0012089298,0.025686648,0.00035945434,0.00056871644,0.0010577742,0.024144359,0.11148432],"study_design_scores_gemma":[0.024885496,0.0054005403,0.9551514,0.000060976447,0.0072443243,0.00017627,0.0005065908,0.0001691737,0.0016503946,0.0004217719,0.0037937667,0.00053928816],"about_ca_topic_score_codex":0.0008851818,"about_ca_topic_score_gemma":0.00016488145,"teacher_disagreement_score":0.13903579,"about_ca_system_score_codex":0.0009556848,"about_ca_system_score_gemma":0.0012254305,"threshold_uncertainty_score":0.8175962},"labels":[],"label_agreement":null},{"id":"W1981256536","doi":"10.1177/1078155214522143","title":"Clinical efficacy of generic imatinib","year":2014,"lang":"en","type":"article","venue":"Journal of Oncology Pharmacy Practice","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Imatinib; Medicine; Myeloid leukemia; Imatinib mesylate; Internal medicine; Oncology; Pharmacology","score_opus":0.09526435613282552,"score_gpt":0.48579286121924914,"score_spread":0.3905285050864236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1981256536","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95709515,0.0008932887,0.00062320783,0.009562429,0.0015043734,0.0002621677,0.0000015950172,0.00001542939,0.030042386],"genre_scores_gemma":[0.94088906,0.001884387,0.051221613,0.0039989245,0.0016588749,0.0000020975663,0.0000026087882,0.00002791004,0.0003145526],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967498,0.00093513884,0.0015058102,0.00016525897,0.00041851852,0.00022545354],"domain_scores_gemma":[0.9905034,0.005681243,0.0025940256,0.00026952187,0.0006506493,0.00030121166],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0036003396,0.00015060812,0.00085948646,0.00014490508,0.000037307782,0.000006132381,0.00019644725,0.00011111942,0.00042531046],"category_scores_gemma":[0.008803049,0.000115358525,0.00032472736,0.00018584501,0.00015513894,0.0003351988,0.000058717695,0.0009236034,0.00009003225],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016460847,0.009900431,0.045717202,0.00015818546,0.0029353064,0.0016977667,0.0005459034,0.0001086242,0.015447685,0.00014559073,0.042779934,0.86410254],"study_design_scores_gemma":[0.042075038,0.004664287,0.017163578,0.00007822248,0.002640223,0.00936022,0.00009105286,0.0007531423,0.0028757772,0.00002252861,0.9201768,0.000099127734],"about_ca_topic_score_codex":0.000015552052,"about_ca_topic_score_gemma":5.320328e-7,"teacher_disagreement_score":0.8773969,"about_ca_system_score_codex":0.0005008395,"about_ca_system_score_gemma":0.0018158521,"threshold_uncertainty_score":0.99954623},"labels":[],"label_agreement":null},{"id":"W1981631249","doi":"10.1158/1078-0432.ccr-05-0429","title":"Intermittent Exposure of Primitive Quiescent Chronic Myeloid Leukemia Cells to Granulocyte-Colony Stimulating Factor <i>In vitro</i> Promotes their Elimination by Imatinib Mesylate","year":2006,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":92,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Imatinib mesylate; Medicine; Myeloid leukemia; Granulocyte colony-stimulating factor; Imatinib; Mesylate; Pharmacology; CD34; Leukemia; Haematopoiesis; Immunology; Chemotherapy; Internal medicine; Stem cell; Chemistry; Biology","score_opus":0.073390416314338,"score_gpt":0.4188013356411297,"score_spread":0.3454109193267917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1981631249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99308705,0.001455816,0.00005556443,0.0012812121,0.00022985958,0.0030868805,0.0002473258,0.000053027183,0.00050328975],"genre_scores_gemma":[0.996983,0.00039736443,0.00039184224,0.00012851278,0.00039775582,0.00048228403,0.00013541654,0.00007208599,0.0010117695],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9948091,0.0005987374,0.0015374707,0.0009178137,0.0011576435,0.0009792183],"domain_scores_gemma":[0.99660903,0.0015211127,0.000299649,0.00064795336,0.0005996088,0.00032264416],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018722926,0.00035591,0.000981886,0.00029621084,0.000112224734,0.000037766265,0.00035751614,0.000307625,0.00023849314],"category_scores_gemma":[0.0007087557,0.00028911734,0.00026933107,0.0006798652,0.00037749799,0.000117840835,0.00030009114,0.0012348535,0.000054582037],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033742106,0.0013050747,0.04262607,0.0007822068,0.00017826264,0.00007197278,0.0009589562,0.0002723563,0.7682173,0.000017551603,0.003366378,0.17882964],"study_design_scores_gemma":[0.009290663,0.0032970845,0.20459878,0.0012574795,0.000056019144,0.000004367841,0.0001790652,0.002881616,0.77645785,0.00005478176,0.0016044806,0.0003178299],"about_ca_topic_score_codex":0.0025642174,"about_ca_topic_score_gemma":0.0005036325,"teacher_disagreement_score":0.1785118,"about_ca_system_score_codex":0.007817077,"about_ca_system_score_gemma":0.0023024548,"threshold_uncertainty_score":0.9999561},"labels":[],"label_agreement":null},{"id":"W1981908108","doi":"10.3747/co.v18i3.782","title":"Digital Necrosis Induced by Erlotinib Treatment in Metastatic Adenocarcinoma of the Lung","year":2011,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Erlotinib; Metastatic melanoma; Adenocarcinoma; Lung; Melanoma; Internal medicine; Oncology; Adjuvant; Necrosis; Cancer research; Pathology; Cancer; Epidermal growth factor receptor","score_opus":0.13535105616876406,"score_gpt":0.3715425654161556,"score_spread":0.23619150924739155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1981908108","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910385,0.002478866,0.0000052469295,0.00017964297,0.0004892644,0.0009790867,0.000051234623,0.00001995222,0.004758187],"genre_scores_gemma":[0.999147,0.000080347454,0.00008207299,0.000032161952,0.00002918797,0.00014350182,0.00004506335,0.00001998184,0.0004207074],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987461,0.000092359754,0.00041315053,0.00028156175,0.00016228945,0.00030452156],"domain_scores_gemma":[0.9991627,0.00011189256,0.00018403155,0.0003937876,0.00004225177,0.00010535243],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000078044286,0.00020040222,0.0005076645,0.00009123,0.000027562539,0.000004454123,0.00014437469,0.00008003277,0.00020575666],"category_scores_gemma":[0.00008591964,0.00012715752,0.00014934919,0.00023212773,0.00011899186,0.000064263804,0.00007691287,0.0001816503,0.000028255727],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031932816,0.0045422423,0.871759,0.000103124825,0.00026935074,0.000039761937,0.0038214661,3.029026e-7,0.0011859434,0.000076581986,0.0020042916,0.11587859],"study_design_scores_gemma":[0.024377873,0.004838926,0.93230253,0.00028786968,0.0010411612,0.00015153193,0.0007270051,0.00025525357,0.017102335,0.00018724172,0.018404644,0.00032362653],"about_ca_topic_score_codex":0.00024038949,"about_ca_topic_score_gemma":0.00006569448,"teacher_disagreement_score":0.115554966,"about_ca_system_score_codex":0.0019618976,"about_ca_system_score_gemma":0.0006909553,"threshold_uncertainty_score":0.5185333},"labels":[],"label_agreement":null},{"id":"W1982454931","doi":"10.1074/jbc.m301339200","title":"Dok-R Binds c-Abl and Regulates Abl Kinase Activity and Mediates Cytoskeletal Reorganization","year":2003,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"National Cancer Institute; Canadian Institutes of Health Research; University of Toronto","keywords":"Tyrosine kinase; Cell biology; SH3 domain; ABL; Proto-oncogene tyrosine-protein kinase Src; Tyrosine phosphorylation; SH2 domain; Phosphorylation; Biology; Receptor tyrosine kinase; Tyrosine; Signal transduction; Kinase; Chemistry; Molecular biology; Biochemistry","score_opus":0.013358535961616447,"score_gpt":0.24796991982510763,"score_spread":0.23461138386349117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982454931","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99739224,0.0015507434,0.000013763375,0.00029766667,0.000036501333,0.00006181792,0.000003827217,0.000014156642,0.00062929554],"genre_scores_gemma":[0.99783087,0.0010586346,0.00075025036,0.000049860024,0.00014882235,0.0000010414444,0.000007924268,0.000009203845,0.0001433991],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992087,0.000040002888,0.00025704477,0.00017860398,0.00014849495,0.00016715575],"domain_scores_gemma":[0.9992116,0.0001347216,0.0002248779,0.000108787,0.000098627424,0.00022135273],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024408585,0.00015153682,0.00034181704,0.000024930081,0.000051792813,0.000017240973,0.000043371565,0.00022751531,0.00023237836],"category_scores_gemma":[0.0009000278,0.0000968947,0.000056528424,0.00010383661,0.00016153268,0.00006594169,0.00003126085,0.00026809156,0.0000015699793],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015479479,0.00015193877,0.059088573,0.000081099904,0.00008587939,0.00015231017,0.00002865797,7.1542746e-7,0.93801224,0.000009851837,0.00009892726,0.0021350195],"study_design_scores_gemma":[0.0027072178,0.00039877923,0.07707135,0.00008683712,0.00010138639,0.0021934307,0.000065328,0.000019909692,0.91630286,0.00030383997,0.00062621164,0.00012286901],"about_ca_topic_score_codex":0.0000030386923,"about_ca_topic_score_gemma":1.7232857e-7,"teacher_disagreement_score":0.021709386,"about_ca_system_score_codex":0.00017234322,"about_ca_system_score_gemma":0.000116116746,"threshold_uncertainty_score":0.39512512},"labels":[],"label_agreement":null},{"id":"W1982694110","doi":"10.1182/blood-2007-07-100990","title":"Toward distinguishing LSCs from HSCs","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Population; Biology; Stem cell; Medicine; Cell biology; Environmental health","score_opus":0.027464495307856322,"score_gpt":0.2775396428704698,"score_spread":0.25007514756261345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982694110","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9647543,0.0007265074,0.00028303647,0.00018463326,0.00019826951,0.00016801884,0.000013813809,0.00014728002,0.033524174],"genre_scores_gemma":[0.9923661,0.000018732495,0.005597277,0.00028890144,0.00080951804,0.000004014116,0.000083874766,0.000027336162,0.00080425007],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99897903,0.000009393882,0.00020957862,0.00024750954,0.00025146612,0.0003030439],"domain_scores_gemma":[0.9992854,0.0001311875,0.00005661868,0.00031708274,0.000038785387,0.00017090718],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015006331,0.00013126817,0.00021022596,0.00004138794,0.00004512953,0.000016185188,0.00008069061,0.00008857161,0.00024383735],"category_scores_gemma":[0.00031852518,0.00011464541,0.00007374187,0.0001075216,0.000028297583,0.000037331498,0.000047455276,0.0001670094,0.00018667265],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030388375,0.0028686225,0.89517176,0.00017153168,0.0012298748,0.007154693,0.003838902,0.0000013803973,0.02687797,0.0005640439,0.003423372,0.058393974],"study_design_scores_gemma":[0.03129624,0.00051027385,0.7726455,0.0005500986,0.0017949705,0.0005116761,0.00062952866,0.0000555109,0.14361483,0.00074982265,0.047058698,0.0005828887],"about_ca_topic_score_codex":0.0005893314,"about_ca_topic_score_gemma":0.000056605146,"teacher_disagreement_score":0.12252629,"about_ca_system_score_codex":0.00021111009,"about_ca_system_score_gemma":0.00012028439,"threshold_uncertainty_score":0.4675104},"labels":[],"label_agreement":null},{"id":"W1983005412","doi":"10.1158/1535-7163.mct-07-0179","title":"Combi-targeting concept: an optimized single-molecule dual-targeting model for the treatment of chronic myelogenous leukemia","year":2008,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Health Canada; Royal Victoria Hospital","funders":"","keywords":"Imatinib; Chronic myelogenous leukemia; Cancer research; ABL; Imatinib mesylate; breakpoint cluster region; Apoptosis; Tyrosine kinase; Leukemia; Tyrosine-kinase inhibitor; Chemistry; Pharmacology; Biology; Immunology; Cancer; Cell biology; Signal transduction; Receptor; Biochemistry","score_opus":0.05143331692213097,"score_gpt":0.3044808825892281,"score_spread":0.25304756566709713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983005412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8361911,0.07361062,0.08546695,0.0007228864,0.00033768278,0.0031660686,0.00014058505,0.0001710931,0.00019296442],"genre_scores_gemma":[0.9801382,0.006114308,0.01127658,0.0008787488,0.0002946756,0.0004836889,0.00022053675,0.00016805824,0.00042520114],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9975414,0.00009928524,0.0006238526,0.00056476274,0.00045586523,0.00071479235],"domain_scores_gemma":[0.9982865,0.00016220193,0.00033003013,0.0007706899,0.00028135153,0.00016925164],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014067978,0.000491558,0.0007476545,0.00007487124,0.00037540597,0.000019428084,0.00021846415,0.00020203758,0.000055648663],"category_scores_gemma":[0.000018771476,0.00036349235,0.00042433137,0.00021469107,0.00033455563,0.00006449804,0.00003430948,0.00017417567,0.0000029648274],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013168335,0.0021155295,0.00027203446,0.00014518667,0.0030673246,0.0002380062,0.010703099,0.2760259,0.6714983,0.000114532726,0.00020688868,0.03429636],"study_design_scores_gemma":[0.013907948,0.0029240234,0.000042437234,0.00006923681,0.0013515188,0.00007185775,0.0002037118,0.5973822,0.37917647,0.000045474826,0.004447342,0.00037781996],"about_ca_topic_score_codex":0.00029447733,"about_ca_topic_score_gemma":0.000026234053,"teacher_disagreement_score":0.32135627,"about_ca_system_score_codex":0.004279111,"about_ca_system_score_gemma":0.001941521,"threshold_uncertainty_score":0.9998817},"labels":[],"label_agreement":null},{"id":"W1983384821","doi":"10.1137/04061578x","title":"Periodic Oscillations of Blood Cell Populations in Chronic Myelogenous Leukemia","year":2006,"lang":"en","type":"article","venue":"SIAM Journal on Mathematical Analysis","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University; McGill University","funders":"","keywords":"Mathematics; Oscillation (cell signaling); Mathematical analysis; Nonlinear system; Chronic myelogenous leukemia; Period (music); Differential equation; Leukemia; Physics; Immunology","score_opus":0.022396744017515294,"score_gpt":0.2856888920847192,"score_spread":0.2632921480672039,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983384821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892628,0.00064237014,0.0022592163,0.00029253872,0.00002430826,0.00021832516,0.000012263944,0.000022647928,0.007265521],"genre_scores_gemma":[0.9917381,0.000055507204,0.0066183726,0.00002931465,0.00014863847,0.0000091647635,0.000039766262,0.000022155238,0.0013390254],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9977191,0.000081770384,0.0010190004,0.00023724361,0.00059632515,0.00034655092],"domain_scores_gemma":[0.998822,0.00014470397,0.00034184978,0.00040181013,0.00011914311,0.0001704947],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00031023615,0.00021778005,0.00080912316,0.0009238341,0.00013228599,0.000029723244,0.00012235057,0.00012307604,0.0017551688],"category_scores_gemma":[0.00009587664,0.00016701061,0.000605205,0.0015237684,0.00008974579,0.000064068015,0.000024834784,0.00038999325,0.000110101064],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050026603,0.014297302,0.41859558,0.0020973247,0.012064981,0.00317812,0.0025672473,0.42859772,0.06881005,0.0425396,0.0009941808,0.0057576303],"study_design_scores_gemma":[0.026785085,0.0036987609,0.64589393,0.0016543058,0.055354033,0.0022976205,0.00067435624,0.14844905,0.012996768,0.099951655,0.0006797798,0.001564686],"about_ca_topic_score_codex":0.00012449219,"about_ca_topic_score_gemma":0.00018096644,"teacher_disagreement_score":0.28014866,"about_ca_system_score_codex":0.0018888214,"about_ca_system_score_gemma":0.00071910006,"threshold_uncertainty_score":0.99915737},"labels":[],"label_agreement":null},{"id":"W1983399256","doi":"10.3816/clm.2007.s.005","title":"The Challenges of Targeting Chronic Myeloid Leukemia Stem Cells","year":2007,"lang":"en","type":"review","venue":"Clinical Lymphoma & Myeloma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute; University of British Columbia; Canada Research Chairs; Leukemia and Lymphoma Society of Canada; Michael Smith Health Research BC; Terry Fox Foundation; Cancer Research Society","keywords":"Myeloid leukemia; Stem cell; Cancer research; Leukemia; Medicine; Biology; Immunology; Cell biology","score_opus":0.09710067136416807,"score_gpt":0.3856242570326927,"score_spread":0.28852358566852465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983399256","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005684561,0.9883473,0.00000835614,0.000093093506,0.002265458,0.002536958,0.00005194864,0.00021985623,0.005908587],"genre_scores_gemma":[0.00029284036,0.9924697,0.0003806176,0.00008805352,0.0031122207,0.00018592483,0.00009436215,0.0003446279,0.0030316266],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98902833,0.0009127938,0.0055052876,0.0017421626,0.0012270262,0.0015843721],"domain_scores_gemma":[0.98536485,0.008002576,0.0027631645,0.0027591255,0.00034367025,0.00076658494],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.004178631,0.0014371513,0.0063001867,0.0002800379,0.00033894638,0.000054377044,0.0013325799,0.0021144005,0.000114096794],"category_scores_gemma":[0.0006119753,0.00091400027,0.0035261214,0.0006656615,0.0011338491,0.000093886236,0.0006405423,0.0012977532,0.0011349873],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00012816345,0.00027585888,0.000018823739,0.016101593,0.0016275931,0.00039316,0.00003471363,2.6094088e-7,0.0000026667806,0.00065767043,0.0025931092,0.9781664],"study_design_scores_gemma":[0.0037533692,0.0010657872,0.00040546613,0.020718131,0.002983588,0.000429913,0.000079300225,0.000025059042,0.00007368909,0.00003482997,0.9697247,0.0007061299],"about_ca_topic_score_codex":0.000039843064,"about_ca_topic_score_gemma":0.000026894513,"teacher_disagreement_score":0.97746027,"about_ca_system_score_codex":0.008188662,"about_ca_system_score_gemma":0.011248783,"threshold_uncertainty_score":0.9998378},"labels":[],"label_agreement":null},{"id":"W1983717821","doi":"10.1038/sj.emboj.7601485","title":"Bcr‐Abl stabilizes β‐catenin in chronic myeloid leukemia through its tyrosine phosphorylation","year":2007,"lang":"en","type":"article","venue":"The EMBO Journal","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":215,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Cancer Institute; Associazione Italiana per la Ricerca sul Cancro; Fondazione Italiana per la Ricerca sul Cancro; Ministero dell’Istruzione, dell’Università e della Ricerca","keywords":"Library science; Medicine; Humanities; Art; Computer science","score_opus":0.026330294916087214,"score_gpt":0.29826162047072724,"score_spread":0.27193132555464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983717821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98075616,0.008919591,0.0004966477,0.0013264345,0.0004846558,0.0005412065,0.000003879934,0.00006121967,0.0074101933],"genre_scores_gemma":[0.99353516,0.0018310643,0.0007233042,0.00035184209,0.0010860082,0.000011124417,0.000016967455,0.000057860976,0.0023866496],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974131,0.00010816106,0.0007677257,0.0002980974,0.0006449775,0.0007679098],"domain_scores_gemma":[0.99871516,0.00022562961,0.00030243272,0.00039905694,0.00016143278,0.00019628173],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015496006,0.00030994666,0.0004449795,0.00015467117,0.00026441584,0.00005688693,0.00026937455,0.00014445736,0.0012791604],"category_scores_gemma":[0.00019889728,0.0002049922,0.00016963831,0.00052560243,0.00012949358,0.0003139196,0.00007268128,0.0010588105,0.00030857534],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0103420345,0.0017697947,0.07174113,0.00077572616,0.0020161727,0.006165346,0.027908618,0.009308945,0.6206797,0.005799481,0.028093936,0.21539915],"study_design_scores_gemma":[0.041702155,0.002550769,0.3972456,0.0018998563,0.00082059903,0.011305682,0.0024565163,0.0051594353,0.48821267,0.0050743525,0.042322837,0.0012495471],"about_ca_topic_score_codex":0.00020905248,"about_ca_topic_score_gemma":0.00025749585,"teacher_disagreement_score":0.32550445,"about_ca_system_score_codex":0.010959918,"about_ca_system_score_gemma":0.001859974,"threshold_uncertainty_score":0.9996338},"labels":[],"label_agreement":null},{"id":"W1984939312","doi":"10.1038/clpt.2011.42","title":"Environmental and Genetic Factors Affecting Transport of Imatinib by OATP1A2","year":2011,"lang":"en","type":"article","venue":"Clinical Pharmacology & Therapeutics","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"National Cancer Institute; American Lebanese Syrian Associated Charities","keywords":"Imatinib; Pharmacology; Bioavailability; Rosuvastatin; Organic anion-transporting polypeptide; Transporter; Drug; Chemistry; Medicine; Internal medicine; Biochemistry; Gene","score_opus":0.08487687495840779,"score_gpt":0.3675479273089365,"score_spread":0.2826710523505287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984939312","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974951,0.001206776,0.00004744065,0.00013189725,0.000362567,0.00045644867,0.00003336142,0.0000385407,0.00022786665],"genre_scores_gemma":[0.9940376,0.0016892464,0.0009385421,0.0030972753,0.00008502484,0.0000075119005,0.000022320226,0.000035867983,0.00008660558],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985516,0.00012801915,0.00059969194,0.0003230631,0.00013048528,0.00026716216],"domain_scores_gemma":[0.9990739,0.00035147453,0.0001962085,0.00018330339,0.000012382885,0.00018269315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015561124,0.00020548848,0.00049527775,0.00003527608,0.000046450867,0.0000011798553,0.00009653021,0.00021568169,0.00083678716],"category_scores_gemma":[0.000004440343,0.00017069123,0.00015380766,0.00004194227,0.00055342563,0.000029794444,0.000033025834,0.00035633225,0.000018375707],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039551253,0.0012699335,0.8913983,0.000045209523,0.0010912678,0.00005127503,0.0011319875,2.795747e-7,0.09697889,4.031812e-7,0.00033416992,0.0073027737],"study_design_scores_gemma":[0.0066499426,0.0014604738,0.91921955,0.000016003525,0.0023398048,0.00004598652,0.00020226401,0.00007617699,0.06840345,0.0000147995515,0.0014115395,0.00016001318],"about_ca_topic_score_codex":0.000012457023,"about_ca_topic_score_gemma":8.733072e-7,"teacher_disagreement_score":0.028575432,"about_ca_system_score_codex":0.00008784921,"about_ca_system_score_gemma":0.00007915699,"threshold_uncertainty_score":0.9162233},"labels":[],"label_agreement":null},{"id":"W1986010889","doi":"10.1111/ejh.12052","title":"Rash with the multitargeted kinase inhibitors nilotinib and dasatinib: meta‐analysis and clinical characterization","year":2012,"lang":"en","type":"review","venue":"European Journal Of Haematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Canadian Dermatology Foundation; Dermatology Foundation; American Society of Hematology","keywords":"Nilotinib; Dasatinib; Medicine; Rash; Incidence (geometry); Internal medicine; Tyrosine-kinase inhibitor; Adverse effect; Dermatology; Myeloid leukemia; Imatinib; Cancer","score_opus":0.0988586204046646,"score_gpt":0.3572264443656417,"score_spread":0.2583678239609771,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986010889","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013468398,0.9851069,0.00018176228,0.0003856609,0.00018223978,0.00053218834,0.0000203058,0.000015599819,0.00010698203],"genre_scores_gemma":[0.009281563,0.9888556,0.0009712556,0.00015397108,0.00040683197,0.0000050877243,0.000102306745,0.000092149865,0.00013125448],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99468756,0.0028985848,0.0015560241,0.00032606322,0.00025633292,0.00027545443],"domain_scores_gemma":[0.9961351,0.00068186776,0.002308379,0.0003970995,0.00016266707,0.00031487053],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022006761,0.0004462042,0.004553707,0.00039572135,0.000088003886,0.000029894698,0.00016950905,0.00013516012,0.00010395262],"category_scores_gemma":[0.00019121736,0.0002104277,0.0010155129,0.00038092525,0.0003568336,0.00009755687,0.00011841455,0.00086830126,0.000025213187],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024587917,0.0004867246,0.005692035,0.0058424203,0.37923938,0.01090297,0.0005021005,3.090645e-7,0.00000508341,0.000031139512,0.00029736178,0.5967546],"study_design_scores_gemma":[0.0020713743,0.0005664185,0.0037336976,0.0008814806,0.54393464,0.020452825,0.000030797684,0.000004848182,0.0000018147826,3.5061657e-7,0.42810497,0.00021678588],"about_ca_topic_score_codex":0.0000026519483,"about_ca_topic_score_gemma":0.00000551621,"teacher_disagreement_score":0.5965378,"about_ca_system_score_codex":0.00006037177,"about_ca_system_score_gemma":0.00025785936,"threshold_uncertainty_score":0.8580992},"labels":[],"label_agreement":null},{"id":"W1986422421","doi":"10.1002/stem.5530160809","title":"Differences between normal and cml stem cells: Potential targets for clinical exploitation","year":2009,"lang":"en","type":"review","venue":"Stem Cells","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Biology; Progenitor cell; Stem cell; Haematopoiesis; Myeloid; Myeloid leukemia; Immunology; Progenitor; Cancer research; Cell biology","score_opus":0.10745318010217181,"score_gpt":0.36973187853923467,"score_spread":0.26227869843706286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986422421","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001958749,0.9924048,0.0003025379,0.0000368392,0.0010299088,0.0035218252,0.0003612374,0.00009215308,0.0002919588],"genre_scores_gemma":[0.0007753796,0.9911663,0.0008068827,0.000048830778,0.0014990272,0.00017054402,0.00033994642,0.000093007795,0.005100063],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962408,0.00029100294,0.0015247958,0.0009291403,0.00044331042,0.00057096203],"domain_scores_gemma":[0.9974389,0.00080393645,0.000743116,0.0005254052,0.00010428624,0.00038436402],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005395555,0.000691957,0.0031388307,0.00017886875,0.00012185626,0.00006139132,0.00022706053,0.00075510493,0.00005456857],"category_scores_gemma":[0.000009393939,0.000520733,0.000845943,0.00013988055,0.00010624394,0.000104148545,0.00008710443,0.0005136206,0.00015421794],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000041115756,0.00012537387,0.0001021871,0.011760639,0.0005704673,0.00004900946,0.00006433044,1.1638603e-7,0.0000028272186,0.0000049959,0.0028358006,0.9844431],"study_design_scores_gemma":[0.004263053,0.0016934106,0.00021062803,0.009802785,0.0076208482,0.00004281891,0.000104979496,0.000025700914,0.00014297645,0.000017603757,0.9753966,0.0006786013],"about_ca_topic_score_codex":0.000011379202,"about_ca_topic_score_gemma":0.0000025732606,"teacher_disagreement_score":0.9837645,"about_ca_system_score_codex":0.0004504407,"about_ca_system_score_gemma":0.00069573626,"threshold_uncertainty_score":0.99972445},"labels":[],"label_agreement":null},{"id":"W1986691999","doi":"10.1016/s1098-3015(10)70208-4","title":"PCN30 COSTS RELATED TO ADVERSE EVENTS IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH TYROSINE KINASE INHIBITORS IN CANADA","year":2008,"lang":"en","type":"article","venue":"Value in Health","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Myeloid leukemia; Tyrosine kinase; Medicine; Adverse effect; Tyrosine-kinase inhibitor; Oncology; Internal medicine; Cancer research; Pharmacology; Cancer; Receptor","score_opus":0.014335736900875546,"score_gpt":0.24540235617157014,"score_spread":0.23106661927069458,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986691999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99587506,0.0005820914,3.5946618e-7,0.00047863435,0.00018030108,0.002584946,0.00003497724,0.000044265733,0.00021939108],"genre_scores_gemma":[0.9982257,0.00035663552,0.00013401077,0.0005546146,0.000034914974,0.00013357386,0.00022672775,0.0000749877,0.00025887557],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960906,0.0002814711,0.0011416253,0.0007168436,0.00070975634,0.0010596984],"domain_scores_gemma":[0.9984458,0.00011270744,0.00023710307,0.0005430042,0.00007590966,0.0005854678],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003033501,0.00041958492,0.0008075496,0.0006378079,0.000077003875,0.000001634072,0.00014542222,0.00015361371,0.000050421037],"category_scores_gemma":[0.0001439226,0.0003813819,0.000045998426,0.0019246856,0.000045968667,0.00011935021,0.00006017088,0.00063038856,0.00004553448],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00061670213,0.00032703354,0.97791183,0.0001556048,0.000024076628,0.001126051,0.0006887994,0.016244734,0.000043273238,0.0000048992474,0.00037510812,0.002481915],"study_design_scores_gemma":[0.022532985,0.0013755584,0.96953595,0.0029521775,0.000012081179,0.000065728396,0.00011384078,0.0023735578,0.00038463235,0.000002785671,0.00033920235,0.00031151847],"about_ca_topic_score_codex":0.9804895,"about_ca_topic_score_gemma":0.9110663,"teacher_disagreement_score":0.119519085,"about_ca_system_score_codex":0.14683512,"about_ca_system_score_gemma":0.027316036,"threshold_uncertainty_score":0.9998638},"labels":[],"label_agreement":null},{"id":"W1987355354","doi":"10.1038/bmt.2009.11","title":"Recurrence of lymphoid blast crisis over 20 years after successful sibling allo-SCT for CML: short lived complete cytogenetic response to imatinib","year":2009,"lang":"en","type":"letter","venue":"Bone Marrow Transplantation","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Blast Crisis; Medicine; Imatinib; Sibling; Immunology; Oncology; Leukemia","score_opus":0.027089673585731007,"score_gpt":0.29299277021572184,"score_spread":0.26590309662999084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987355354","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9570326,0.00058681075,0.0025863037,0.032268193,0.00034136075,0.0034363861,0.0035029142,0.000107210675,0.0001382207],"genre_scores_gemma":[0.87240565,0.0008755384,0.016851323,0.095759034,0.001229821,0.0010259195,0.010506465,0.00029509937,0.00105115],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9964215,0.00022092878,0.0010071408,0.0008705398,0.0008494221,0.00063046295],"domain_scores_gemma":[0.9981779,0.00051413156,0.00026435065,0.0006470159,0.00022233343,0.00017429751],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041125604,0.0005906824,0.001007909,0.0006914529,0.000060360995,0.000044579425,0.00022777513,0.0005832678,0.00022741036],"category_scores_gemma":[0.0000638648,0.0006248576,0.00039464535,0.00038089827,0.000068032896,0.000108989494,0.000019191531,0.00046221737,0.00004410315],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11705265,0.00087015674,0.018464444,0.013273256,0.0022728024,0.00921073,0.0100098355,0.0005739831,0.25484246,0.0000026068287,0.5569739,0.016453192],"study_design_scores_gemma":[0.061459932,0.011553319,0.4458075,0.020245548,0.017715596,0.0037492628,0.00041650393,0.0023998397,0.08218859,0.00019011683,0.3480824,0.006191402],"about_ca_topic_score_codex":0.00018603208,"about_ca_topic_score_gemma":0.00011037289,"teacher_disagreement_score":0.42734304,"about_ca_system_score_codex":0.0007220582,"about_ca_system_score_gemma":0.00054832455,"threshold_uncertainty_score":0.99962026},"labels":[],"label_agreement":null},{"id":"W1987706750","doi":"10.1016/j.bbmt.2015.04.005","title":"Allogeneic Hematopoietic Stem Cell Transplantation Is an Effective Salvage Therapy for Patients with Chronic Myeloid Leukemia Presenting with Advanced Disease or Failing Treatment with Tyrosine Kinase Inhibitors","year":2015,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; BC Cancer Agency","funders":"American Society of Hematology","keywords":"Medicine; Internal medicine; Hematopoietic stem cell transplantation; Myeloid leukemia; Transplantation; Oncology; Univariate analysis; Tyrosine-kinase inhibitor; Odds ratio; Disease; Multivariate analysis; Cancer","score_opus":0.011810804537200237,"score_gpt":0.24462475816678844,"score_spread":0.2328139536295882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987706750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942126,0.0014481669,0.00081507355,0.00003771287,0.000034835874,0.0030951754,0.0002900046,0.00005293981,0.000013480745],"genre_scores_gemma":[0.9945166,0.0015353767,0.0016320331,0.00002971159,0.00005093228,0.00047075056,0.0016739756,0.00004996279,0.00004064116],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998605,0.00008534366,0.00028390152,0.00053556205,0.00018419328,0.00030595835],"domain_scores_gemma":[0.9990723,0.00011846488,0.00021271229,0.0002008477,0.00015477077,0.00024089972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000080673024,0.00035844266,0.00044912615,0.00011217592,0.00009735419,0.000011662069,0.00004931225,0.00010924024,0.000004376499],"category_scores_gemma":[0.0000017811868,0.00021046631,0.00005071267,0.00012740618,0.00014813045,0.00019250737,0.0000027313538,0.00007008803,4.3941296e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1031716,0.0023236936,0.7024453,0.003836176,0.001276752,0.00024819002,0.010391555,0.00040530215,0.1345667,0.00001802393,0.0000032319754,0.041313436],"study_design_scores_gemma":[0.13366766,0.064872004,0.11908294,0.0010837311,0.0047999374,0.0001516261,0.0004631402,0.00020515588,0.6749486,0.000019543662,0.00005849915,0.00064719527],"about_ca_topic_score_codex":0.00009176358,"about_ca_topic_score_gemma":0.00020024671,"teacher_disagreement_score":0.5833624,"about_ca_system_score_codex":0.00024682024,"about_ca_system_score_gemma":0.00053742295,"threshold_uncertainty_score":0.85825676},"labels":[],"label_agreement":null},{"id":"W1987854357","doi":"10.1002/path.2178","title":"Decreased expression level of SH2 domain‐containing protein tyrosine phosphatase‐1 (Shp1) is associated with progression of chronic myeloid leukaemia","year":2007,"lang":"en","type":"article","venue":"The Journal of Pathology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute; National Institutes of Health","keywords":"Protein tyrosine phosphatase; Tyrosine; Chronic myeloid leukaemia; SH2 domain; Cancer research; Myeloid; Biology; Medicine; Chemistry; Biochemistry","score_opus":0.03296901226954663,"score_gpt":0.3064877813777634,"score_spread":0.27351876910821676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987854357","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926196,0.0038622152,0.0023278769,0.00023855975,0.00007564679,0.00066811906,0.000041164436,0.000013538438,0.00015329808],"genre_scores_gemma":[0.99457747,0.000087131215,0.0049271877,0.00009010345,0.00012888885,0.0000068837344,0.000028056229,0.000039302002,0.0001149598],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99738026,0.00028102586,0.0010404463,0.00018493066,0.0006719596,0.00044140572],"domain_scores_gemma":[0.9965574,0.00033685425,0.0020189704,0.00043498774,0.00047304583,0.00017873709],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024908183,0.00026237743,0.00086101174,0.00020712684,0.000088136214,0.0000037778618,0.00026555982,0.00023126461,0.00014577605],"category_scores_gemma":[0.00040598388,0.00014631602,0.00015145677,0.00031169978,0.0003646091,0.000105401894,0.000080012614,0.0005312151,0.000002749985],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011263342,0.0009364057,0.012289102,0.00017398634,0.00036600532,0.0024621615,0.0017761043,0.000020322359,0.96007675,0.000063352985,0.0003558691,0.010216624],"study_design_scores_gemma":[0.016800469,0.008609968,0.043032914,0.0041145077,0.0004894478,0.003005064,0.0005689177,0.000033219712,0.9229311,0.00015744074,0.000103697574,0.00015327432],"about_ca_topic_score_codex":0.000038062808,"about_ca_topic_score_gemma":0.000036762376,"teacher_disagreement_score":0.037145644,"about_ca_system_score_codex":0.00094324,"about_ca_system_score_gemma":0.001086042,"threshold_uncertainty_score":0.5966594},"labels":[],"label_agreement":null},{"id":"W1988322375","doi":"10.1016/j.vph.2009.02.003","title":"On the ability of imatinib mesylate to inhibit smooth muscle cell proliferation without delaying endothelialization: An in vitro study","year":2009,"lang":"en","type":"article","venue":"Vascular Pharmacology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Hôpital Saint-François d'Assise","funders":"Natural Sciences and Engineering Research Council of Canada; Centre québécois sur les matériaux fonctionnels","keywords":"Imatinib mesylate; Intimal hyperplasia; Medicine; Pharmacology; Endothelium; Tyrosine kinase; Cancer research; Cell growth; Tyrosine-kinase inhibitor; Restenosis; Platelet-derived growth factor receptor; Imatinib; Chemistry; Receptor; Internal medicine; Smooth muscle; Growth factor; Cancer; Biochemistry","score_opus":0.020204850580704158,"score_gpt":0.3148543097322759,"score_spread":0.29464945915157176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988322375","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953505,0.00005981259,0.00025296054,0.00058028894,0.00010420776,0.0032424661,0.000005602676,0.00004276419,0.00036141026],"genre_scores_gemma":[0.99759376,0.00001172893,0.00044597627,0.00162671,0.00008791419,0.00017464656,0.000020665273,0.000019734707,0.000018883753],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998155,0.00049410603,0.00042022226,0.00037868117,0.00029963447,0.00025235218],"domain_scores_gemma":[0.9991948,0.00009212841,0.00011105895,0.00039988037,0.0000992039,0.00010290502],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007775892,0.00018135908,0.00036876928,0.00015580574,0.00006919259,0.000009372733,0.00012264664,0.00006834904,0.00023971779],"category_scores_gemma":[0.000079156925,0.00013233956,0.000079196085,0.0003334674,0.000032664655,0.00007263625,0.000029508368,0.00019799163,0.000021992493],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00081361533,0.0032505707,0.005099222,0.00003700875,0.000084624575,0.00003283737,0.004051366,0.0016593148,0.9772959,0.000026282776,0.00008410957,0.0075651826],"study_design_scores_gemma":[0.021487227,0.0040362077,0.08386863,0.00004488783,0.0005196893,0.000008790394,0.0005161695,0.01437323,0.8741987,0.00020751226,0.00046299587,0.00027599008],"about_ca_topic_score_codex":0.00009023345,"about_ca_topic_score_gemma":0.000016181984,"teacher_disagreement_score":0.10309719,"about_ca_system_score_codex":0.0004144688,"about_ca_system_score_gemma":0.00019470116,"threshold_uncertainty_score":0.53966504},"labels":[],"label_agreement":null},{"id":"W1990020715","doi":"10.1038/leu.2008.84","title":"Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib","year":2008,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":354,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Dasatinib; Medicine; Imatinib; Chronic myelogenous leukemia; Internal medicine; Gastroenterology; Neutropenia; Imatinib mesylate; Leukemia; Oncology; Chemotherapy; Myeloid leukemia","score_opus":0.022184882067737867,"score_gpt":0.27956515176368274,"score_spread":0.25738026969594485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990020715","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944185,0.001202267,0.000045336437,0.00015895293,0.00007591945,0.002917719,0.000057843517,0.00014278998,0.0009806454],"genre_scores_gemma":[0.99076104,0.00022889121,0.0039574956,0.00041068357,0.00016746162,0.00063835515,0.00012470406,0.0001622736,0.0035490815],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951293,0.0002026025,0.0010208708,0.001284744,0.0009952936,0.0013672088],"domain_scores_gemma":[0.99743295,0.00027431335,0.00033939804,0.0013209609,0.00019909065,0.0004332667],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002927289,0.00078218494,0.0011947969,0.00064857275,0.00022678907,0.00003737899,0.00044461025,0.00029183223,0.0002551586],"category_scores_gemma":[0.00023080024,0.0005807923,0.00007777153,0.0019843257,0.0003386978,0.00030264602,0.00010790952,0.0008288924,0.00014514072],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.13566715,0.002358692,0.7639591,0.0023070492,0.00071723317,0.013558595,0.012859497,0.019659707,0.024205325,0.00004948822,0.0025466408,0.0221115],"study_design_scores_gemma":[0.09871811,0.011149656,0.8609933,0.004171972,0.00013868335,0.00035502933,0.00015325024,0.00054845866,0.019371321,0.000013164067,0.0031224347,0.0012646202],"about_ca_topic_score_codex":0.0015113321,"about_ca_topic_score_gemma":0.015882285,"teacher_disagreement_score":0.09703418,"about_ca_system_score_codex":0.0498163,"about_ca_system_score_gemma":0.021064734,"threshold_uncertainty_score":0.99966437},"labels":[],"label_agreement":null},{"id":"W1990237215","doi":"10.1155/2010/530130","title":"Locking Src/Abl Tyrosine Kinase Activities Regulate Cell Differentiation and Invasion of Human Cervical Cancer Cells Expressing E6/E7 Oncoproteins of High-Risk HPV","year":2010,"lang":"lv","type":"article","venue":"Journal of Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Concordia University; McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"HeLa; Proto-oncogene tyrosine-protein kinase Src; Tyrosine kinase; Cancer research; Cell growth; Epithelial–mesenchymal transition; Cell biology; Cancer cell; Catenin; Cell; Motility; Cell cycle; Kinase; Cancer; Signal transduction; Biology; Medicine; Wnt signaling pathway; Internal medicine; Metastasis; Biochemistry","score_opus":0.017783390976891182,"score_gpt":0.29251343422018145,"score_spread":0.27473004324329026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990237215","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944211,0.0026716422,0.00011631457,0.00031300102,0.0017361686,0.0004212031,0.000054482636,0.0000083115065,0.00025775388],"genre_scores_gemma":[0.9947257,0.0021681748,0.0016364914,0.000038756978,0.0010881763,0.0000068798627,0.000011188958,0.00005575094,0.00026888342],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9965965,0.0004211963,0.0015644446,0.00034549192,0.00062444387,0.00044788964],"domain_scores_gemma":[0.99423385,0.0005035457,0.0041426807,0.00041336546,0.00041271854,0.00029382698],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007300605,0.0003862499,0.0016036853,0.0004389672,0.00018270116,0.000026226537,0.00023056242,0.00065204105,0.0008390036],"category_scores_gemma":[0.00011141804,0.00032096263,0.00024191012,0.00018596824,0.00045999134,0.00028562782,0.0001962297,0.0014175582,0.000001964212],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011993109,0.0014889641,0.020684918,0.0009041189,0.00035342862,0.00016491293,0.0023028108,0.00010694732,0.9258036,0.00003634367,0.00022857584,0.046726063],"study_design_scores_gemma":[0.013972234,0.005076996,0.1065599,0.0014035567,0.0016271311,0.00013490279,0.00052818813,0.00032302685,0.86959827,0.00021967605,0.0003402011,0.00021591775],"about_ca_topic_score_codex":0.002825817,"about_ca_topic_score_gemma":0.0012425851,"teacher_disagreement_score":0.08587499,"about_ca_system_score_codex":0.0013829242,"about_ca_system_score_gemma":0.0014178478,"threshold_uncertainty_score":0.99992424},"labels":[],"label_agreement":null},{"id":"W1991071027","doi":"10.1038/oncsis.2014.37","title":"Chaetocin antileukemia activity against chronic myelogenous leukemia cells is potentiated by bone marrow stromal factors and overcomes innate imatinib resistance","year":2014,"lang":"en","type":"article","venue":"Oncogenesis","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan","funders":"","keywords":"Chronic myelogenous leukemia; Cancer research; Bone marrow; Stromal cell; Imatinib; Stem cell; Haematopoiesis; Imatinib mesylate; Biology; Immunology; Leukemia; Cell biology; Myeloid leukemia","score_opus":0.00901262803584609,"score_gpt":0.23364956640223508,"score_spread":0.22463693836638898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1991071027","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938621,0.002404996,0.00010385637,0.00030429938,0.00023223419,0.0008318702,0.0004609116,0.00024185418,0.0015578783],"genre_scores_gemma":[0.99257797,0.0014441466,0.00065918727,0.00039177708,0.00018827796,0.000053660086,0.00027023998,0.0001487333,0.0042659966],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9964097,0.00019604788,0.00059990137,0.0010912302,0.00070842175,0.0009946936],"domain_scores_gemma":[0.99775296,0.00021226701,0.00043279096,0.0009810043,0.00012450635,0.00049647264],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003277753,0.00076549104,0.0011960856,0.00021654142,0.00034421997,0.000072562834,0.00023638614,0.00043544755,0.00024116872],"category_scores_gemma":[0.00008604998,0.0006806182,0.0002764547,0.00040568318,0.00025441372,0.00024217195,0.00018193047,0.00039014695,0.00007334936],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043614372,0.00023217699,0.028736675,0.0005636948,0.00053808355,0.00013458484,0.00039936922,0.00001440012,0.9381392,0.0000091178745,0.008546806,0.022249771],"study_design_scores_gemma":[0.010960678,0.0007520206,0.14046702,0.00045377493,0.00070696516,0.00006650154,0.000105442996,0.0017235222,0.824033,0.000021547208,0.019647405,0.0010620718],"about_ca_topic_score_codex":0.0007722442,"about_ca_topic_score_gemma":0.00027568123,"teacher_disagreement_score":0.114106126,"about_ca_system_score_codex":0.0053248536,"about_ca_system_score_gemma":0.0011133438,"threshold_uncertainty_score":0.9995645},"labels":[],"label_agreement":null},{"id":"W1991548013","doi":"10.1182/blood-2014-05-574293","title":"Distinguishing CML LSCs from HSCs using CD26","year":2014,"lang":"en","type":"letter","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Cancer research; Immunology","score_opus":0.03662174043846369,"score_gpt":0.27509064071148187,"score_spread":0.23846890027301818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1991548013","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.67167294,0.0050229793,0.0004938466,0.27989388,0.0035922749,0.0022276607,0.0006249003,0.0010962263,0.03537529],"genre_scores_gemma":[0.05887803,0.00008547578,0.024326054,0.8456897,0.05522507,0.000065110464,0.0073607564,0.0006852151,0.0076845894],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972791,0.00009121158,0.0004892752,0.0008055606,0.0006809198,0.00065392494],"domain_scores_gemma":[0.9979639,0.0003152893,0.00034250887,0.0011392237,0.00009410763,0.00014498748],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012075115,0.00056755013,0.00096463354,0.0001296564,0.00012046097,0.00008197655,0.00027851583,0.0010613293,0.00043110206],"category_scores_gemma":[0.00042706708,0.00051652256,0.0002894866,0.00012776454,0.00007610035,0.00004999185,0.00014148885,0.0018713757,0.00022768487],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027298354,0.00035272856,0.013764418,0.0007073039,0.001884101,0.010427064,0.0002799389,0.0000033143403,0.0012075485,0.0000037492903,0.97025347,0.0010890702],"study_design_scores_gemma":[0.008217668,0.00014454014,0.0009698802,0.0020021645,0.004978732,0.000661713,0.000011426435,0.00027012522,0.00082199817,0.00013173779,0.98112243,0.0006675758],"about_ca_topic_score_codex":0.0019166489,"about_ca_topic_score_gemma":0.000017792001,"teacher_disagreement_score":0.61279494,"about_ca_system_score_codex":0.00074114563,"about_ca_system_score_gemma":0.0005232787,"threshold_uncertainty_score":0.9997286},"labels":[],"label_agreement":null},{"id":"W1991958842","doi":"10.1016/j.leukres.2004.11.012","title":"Engineering 3-alkyltriazenes to block bcr-abl kinase: a novel strategy for the therapy of advanced bcr-abl expressing leukemias","year":2005,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada; Royal Victoria Hospital; McGill University Health Centre; Royal Victoria Regional Health Centre","funders":"","keywords":"Autophosphorylation; Tyrosine kinase; K562 cells; Cancer research; ABL; Chronic myelogenous leukemia; Leukemia; breakpoint cluster region; Philadelphia chromosome; Molecular biology; Biology; Chemistry; Kinase; Cell biology; Biochemistry; Immunology; Signal transduction; Protein kinase A; Receptor","score_opus":0.10583180042391337,"score_gpt":0.3902554435472102,"score_spread":0.2844236431232968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1991958842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9831013,0.0067798863,0.0018581215,0.002201249,0.00020300238,0.004221733,0.00006992727,0.0001685717,0.0013962089],"genre_scores_gemma":[0.9766894,0.0010126746,0.015189906,0.00024911622,0.0010058293,0.0010120511,0.000035888857,0.00016666396,0.0046384595],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9953982,0.00010324213,0.0007680404,0.0008514437,0.0014244182,0.0014546285],"domain_scores_gemma":[0.99513394,0.0021589242,0.00014778823,0.0014242704,0.00069091463,0.00044419453],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017025121,0.00047610237,0.00074451,0.0005125951,0.0003686468,0.00010675619,0.00073470286,0.00029360465,0.00018034787],"category_scores_gemma":[0.0010748464,0.00034978616,0.0002933135,0.0011226018,0.00020282756,0.000237529,0.00024009407,0.0009432632,0.000075113356],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026649015,0.00038678816,0.00018223087,0.00035712743,0.0004527029,0.000041249245,0.0012888045,0.08656076,0.7134175,0.00053014397,0.0049536778,0.18916415],"study_design_scores_gemma":[0.030129973,0.002069684,0.0036565433,0.0012579699,0.00011732468,0.00016470057,0.0013713497,0.06347519,0.64630485,0.000068197674,0.25064346,0.00074074813],"about_ca_topic_score_codex":0.0005619948,"about_ca_topic_score_gemma":0.0000689003,"teacher_disagreement_score":0.24568978,"about_ca_system_score_codex":0.006083079,"about_ca_system_score_gemma":0.0032990903,"threshold_uncertainty_score":0.9998954},"labels":[],"label_agreement":null},{"id":"W1992194693","doi":"10.1016/s0140-6736(00)02150-4","title":"White cells 2: impact of understanding the molecular basis of haematological malignant disorders on clinical practice","year":2000,"lang":"en","type":"review","venue":"The Lancet","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; breakpoint cluster region; Leukemia; Cancer research; Tyrosine kinase; Myeloid leukemia; Myeloid; Chronic myeloid leukaemia; Immunology; Bioinformatics; Oncology; Internal medicine; Biology","score_opus":0.15098813284618318,"score_gpt":0.4353633937973449,"score_spread":0.2843752609511617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992194693","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008086921,0.98166484,0.00008251343,0.0013592133,0.00013371932,0.00167382,0.00016628682,0.000030475747,0.01408045],"genre_scores_gemma":[0.008358948,0.99075806,0.00023990503,0.00024713762,0.0001788169,0.000030255478,0.0000385381,0.000048609334,0.000099735014],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967448,0.001006769,0.0010193499,0.00036370681,0.00048562392,0.00037972716],"domain_scores_gemma":[0.994751,0.002684578,0.00093385996,0.0015133321,0.00003361023,0.000083638915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012748275,0.00039983512,0.003234332,0.00006724592,0.000053976975,0.000012049229,0.00052561687,0.00030999907,0.00031725137],"category_scores_gemma":[0.0005275387,0.00015954183,0.0013130301,0.00032246424,0.00035877738,0.000026081794,0.0000850162,0.0008133963,0.000057124154],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036559184,0.002793215,0.0016449577,0.023659825,0.016260354,0.0009126006,0.00080059026,0.00020578489,0.0000047482704,0.0070805266,0.033783015,0.90919846],"study_design_scores_gemma":[0.0068045165,0.0039065764,0.00045909255,0.036122657,0.01707425,0.00090038526,0.00036030528,0.000073089235,0.000018500881,0.00092692336,0.9327113,0.0006424273],"about_ca_topic_score_codex":0.000052755488,"about_ca_topic_score_gemma":0.0000031792563,"teacher_disagreement_score":0.90855604,"about_ca_system_score_codex":0.0006474561,"about_ca_system_score_gemma":0.00069644843,"threshold_uncertainty_score":0.6505927},"labels":[],"label_agreement":null},{"id":"W1993474153","doi":"10.1038/leu.2009.156","title":"Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value","year":2009,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Dasatinib; Imatinib; Medicine; Internal medicine; Myeloid leukemia; Oncology; Imatinib mesylate; Gastroenterology","score_opus":0.00565248787314487,"score_gpt":0.2579140445945823,"score_spread":0.2522615567214374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1993474153","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956075,0.00082214887,0.00016561548,0.00039533785,0.00008376104,0.0023791974,0.0001498327,0.00017622528,0.00022041542],"genre_scores_gemma":[0.9972736,0.00004838073,0.0009561076,0.00034274478,0.000058843118,0.0001531142,0.00067125016,0.00012197278,0.00037393358],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99505115,0.0006472997,0.001008629,0.0011713931,0.00090468297,0.0012168463],"domain_scores_gemma":[0.9977179,0.0005231404,0.0003789679,0.00089698925,0.00011896894,0.00036402297],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009907355,0.00077740074,0.0011454996,0.0007282475,0.00014896912,0.00006975035,0.00026072553,0.00051265565,0.000041366657],"category_scores_gemma":[0.0010371787,0.0007224074,0.00018582755,0.0012729208,0.00018415657,0.0004125608,0.000112061905,0.0010961066,0.00001928091],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.14130336,0.0041031106,0.69222903,0.00085328834,0.0029116462,0.0140042715,0.00826545,0.02125656,0.062315114,0.00083273486,0.00081259425,0.05111281],"study_design_scores_gemma":[0.110892,0.010508221,0.80261016,0.002210269,0.00043180937,0.00005267914,0.00017358616,0.06906588,0.0029480443,0.0001737079,0.00007721701,0.0008564534],"about_ca_topic_score_codex":0.00054757803,"about_ca_topic_score_gemma":0.0010747514,"teacher_disagreement_score":0.11038109,"about_ca_system_score_codex":0.092053756,"about_ca_system_score_gemma":0.009262124,"threshold_uncertainty_score":0.9995227},"labels":[],"label_agreement":null},{"id":"W1994072538","doi":"10.1016/s0145-2126(01)00181-3","title":"The kinase inhibitor STI571 reverses the Bcr–Abl induced point mutation frequencies observed in pre-leukemic P190Bcr–Abl transgenic mice","year":2002,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital","funders":"Medical Research Council","keywords":"ABL; Chronic myelogenous leukemia; Point mutation; Cancer research; Biology; Leukemia; Philadelphia chromosome; breakpoint cluster region; Transgene; Genetically modified mouse; Tyrosine-kinase inhibitor; Tyrosine kinase; Molecular biology; Mutation; Immunology; Chromosomal translocation; Cancer; Genetics; Signal transduction; Receptor; Gene","score_opus":0.11712964894598563,"score_gpt":0.34268559322263736,"score_spread":0.22555594427665174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1994072538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98459893,0.00332363,0.000008797244,0.0058719823,0.000349485,0.0028419443,0.000023243067,0.00013354198,0.0028484392],"genre_scores_gemma":[0.98701125,0.001745378,0.00024608284,0.00035048512,0.00045151947,0.0007143405,0.00005030036,0.000103021346,0.009327611],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9931692,0.0012785507,0.0009574188,0.0009262247,0.0020353557,0.001633249],"domain_scores_gemma":[0.994744,0.0026527522,0.00017370304,0.0015862155,0.00049065525,0.00035265234],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0031010024,0.00049043895,0.00056350505,0.00041527947,0.00091223145,0.0002169081,0.0009043817,0.00041526216,0.00050404534],"category_scores_gemma":[0.002397787,0.0003099964,0.00026678471,0.0019513419,0.0007066226,0.00039138127,0.00021638897,0.0025850679,0.0005391219],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046706926,0.0015703461,0.01085658,0.0014382194,0.0011872319,0.0026376355,0.04136257,0.000762245,0.76563835,0.002295516,0.07375489,0.093825705],"study_design_scores_gemma":[0.08785182,0.007487716,0.33666107,0.0054275603,0.0010150917,0.0019356076,0.028406551,0.056437183,0.39116552,0.0062985895,0.07371587,0.003597402],"about_ca_topic_score_codex":0.009040733,"about_ca_topic_score_gemma":0.0033901015,"teacher_disagreement_score":0.37447283,"about_ca_system_score_codex":0.014200926,"about_ca_system_score_gemma":0.0025710606,"threshold_uncertainty_score":0.9999352},"labels":[],"label_agreement":null},{"id":"W1995955815","doi":"10.1159/000205160","title":"Chronic Myeloid Leukaemia in Yorkshire: A Case Control Study","year":2009,"lang":"en","type":"article","venue":"Acta Haematologica","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada","funders":"","keywords":"Chronic myeloid leukaemia; Medicine; Myeloid leukaemia; Case-control study; Hobby; Disease; Internal medicine","score_opus":0.021398496207285806,"score_gpt":0.2936129670299987,"score_spread":0.2722144708227129,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995955815","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98961365,0.001355105,0.000012353898,0.0027717317,0.00008800656,0.0022237687,0.000009858817,0.00023066388,0.0036948589],"genre_scores_gemma":[0.9982585,0.00005223585,0.00019887053,0.00084554695,0.00012794042,0.00012865264,0.000010329512,0.000024664743,0.00035327137],"study_design_codex":"case_report","study_design_gemma":"observational","domain_scores_codex":[0.9975485,0.00017686523,0.00060196116,0.0006549688,0.00032606008,0.0006916433],"domain_scores_gemma":[0.9984986,0.00023276464,0.0001575072,0.00082770427,0.000051135783,0.00023229122],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003330081,0.00038558667,0.0010092413,0.00018967134,0.00011381011,0.000029781788,0.00019673523,0.00024525326,0.0005831392],"category_scores_gemma":[0.0003047457,0.00029286087,0.00014573938,0.00043835744,0.0000759057,0.00012307697,0.000047909503,0.0005198633,0.00017902287],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021480776,0.006572898,0.30286852,0.00020652502,0.00077048026,0.57215613,0.0027848333,0.000050773415,0.003505705,0.0007258148,0.004509362,0.10370088],"study_design_scores_gemma":[0.0642162,0.012770467,0.8019324,0.0004294489,0.00096551614,0.11063132,0.0020993757,0.001361595,0.001036946,0.0005295072,0.0029643069,0.001062915],"about_ca_topic_score_codex":0.00019865883,"about_ca_topic_score_gemma":0.00046692524,"teacher_disagreement_score":0.4990639,"about_ca_system_score_codex":0.0016123492,"about_ca_system_score_gemma":0.00046805906,"threshold_uncertainty_score":0.9999524},"labels":[],"label_agreement":null},{"id":"W1996081258","doi":"10.1007/s00280-008-0730-x","title":"Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults","year":2008,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; BC Children's Hospital; Izaak Walton Killam Health Centre","funders":"","keywords":"Imatinib; Imatinib mesylate; Medicine; Pharmacokinetics; NONMEM; Tyrosine-kinase inhibitor; Pharmacology; Population; Myeloid leukemia; Internal medicine; Dosing; Metabolite; Oncology; Cancer","score_opus":0.01325244747741804,"score_gpt":0.30946617371609253,"score_spread":0.2962137262386745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996081258","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97014207,0.028817927,0.0000015076596,0.0003141288,0.000105573985,0.00051332475,0.000035515317,0.000014315441,0.000055629265],"genre_scores_gemma":[0.9160732,0.082915045,0.00012154945,0.0006059517,0.00011360369,0.00003307601,0.000025944624,0.000016923646,0.00009469658],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99924475,0.000037022328,0.00022700844,0.00024061199,0.00007634031,0.00017427835],"domain_scores_gemma":[0.9996983,0.00002596359,0.000095915064,0.000054560347,0.000033928274,0.00009134495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006436807,0.00014735946,0.0003556052,0.00008713787,0.000036278805,0.0000019774582,0.000027456439,0.00007579589,0.00019651788],"category_scores_gemma":[0.000003826494,0.00013275184,0.000021239784,0.00010484841,0.00008748236,0.00006008479,0.000018505634,0.00012491693,3.819279e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001341229,0.00012275961,0.86044705,0.00018422873,0.00035338633,0.000015856262,0.0017876066,0.000007717843,0.10022319,0.000014349968,0.00018975548,0.035312884],"study_design_scores_gemma":[0.019075487,0.00012484717,0.8705437,0.000042658765,0.00016998503,0.00024787695,0.000008660484,0.0015615693,0.107788436,0.000016748438,0.00030391672,0.000116069525],"about_ca_topic_score_codex":0.0003577214,"about_ca_topic_score_gemma":0.000008901336,"teacher_disagreement_score":0.054097116,"about_ca_system_score_codex":0.00006782956,"about_ca_system_score_gemma":0.000051053372,"threshold_uncertainty_score":0.5413463},"labels":[],"label_agreement":null},{"id":"W1996346809","doi":"10.1182/blood-2009-05-222471","title":"Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Michael Smith Health Research BC; Canadian Cancer Society Research Institute; Cancer Research Society; Bristol-Myers Squibb","keywords":"Imatinib mesylate; Progenitor cell; CD34; Stem cell; Myeloid leukemia; Haematopoiesis; Cancer research; Imatinib; ABL; Medicine; Immunology; Biology; Internal medicine; Tyrosine kinase; Receptor; Genetics","score_opus":0.04221781815748588,"score_gpt":0.2902911563868482,"score_spread":0.24807333822936234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996346809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975598,0.00020188931,0.0000057789634,0.00024422116,0.00043675004,0.001115158,0.000024492501,0.0000865406,0.0003253812],"genre_scores_gemma":[0.9946559,0.000041673542,0.0012161141,0.00010540475,0.00017376344,0.00008400458,0.0000057734846,0.00005445011,0.0036629068],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99819523,0.00010037778,0.0005215459,0.000405879,0.00043737423,0.00033957092],"domain_scores_gemma":[0.9984806,0.00014687989,0.00019944315,0.00074522314,0.00012286087,0.00030495579],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025715886,0.00027640696,0.0006381912,0.00009236997,0.000053410295,0.000017742763,0.00017052,0.00017007231,0.0001090084],"category_scores_gemma":[0.00010118779,0.00016404338,0.00014923581,0.00011209681,0.0001551154,0.000049149072,0.000101609025,0.000412017,0.0001206662],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005620764,0.0038325323,0.5108142,0.0003852069,0.0012224377,0.00026587828,0.0011175582,0.0000011514434,0.47108006,0.000022502287,0.00034592437,0.0052918014],"study_design_scores_gemma":[0.012297336,0.0022676687,0.1531585,0.00050812383,0.00096512755,0.0001858239,0.00012416925,0.000031440675,0.8294956,0.000003973081,0.00072004506,0.00024218146],"about_ca_topic_score_codex":0.000043789532,"about_ca_topic_score_gemma":0.000034664376,"teacher_disagreement_score":0.35841554,"about_ca_system_score_codex":0.0000524483,"about_ca_system_score_gemma":0.0003616497,"threshold_uncertainty_score":0.6689495},"labels":[],"label_agreement":null},{"id":"W1996490450","doi":"10.1038/sj.leu.2403785","title":"Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro","year":2005,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Imatinib mesylate; Cancer research; Population; Myeloid leukemia; Biology; Phosphoinositide 3-kinase; Haematopoiesis; Immunology; Leukemia; Imatinib; K562 cells; Pharmacology; Stem cell; Medicine; PI3K/AKT/mTOR pathway; Cell biology; Signal transduction","score_opus":0.012521974893370829,"score_gpt":0.27002299353954295,"score_spread":0.25750101864617214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996490450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9842945,0.000771563,0.000016674392,0.0032301906,0.000111960115,0.00091910857,0.0000292137,0.000043326774,0.010583515],"genre_scores_gemma":[0.98773485,0.00011078757,0.004368778,0.00096432946,0.00017311431,0.000075478114,0.000016403275,0.000034906654,0.0065213214],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99814534,0.00008052651,0.00052582484,0.0003849168,0.00043221412,0.00043120518],"domain_scores_gemma":[0.99883485,0.00017987816,0.00017763994,0.0005842331,0.00008312513,0.00014028858],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028707,0.00023816264,0.00045395835,0.000119871846,0.00005410165,0.000012436138,0.00023187656,0.00010089099,0.00012742703],"category_scores_gemma":[0.0001328925,0.00016962197,0.00011294194,0.00037391484,0.00011822868,0.00007508065,0.00008820584,0.000308038,0.00018459291],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031502543,0.0004011841,0.0011227358,0.00026260223,0.00021772679,0.00015056584,0.009038265,0.000663452,0.93569046,0.0002840573,0.014126109,0.034892596],"study_design_scores_gemma":[0.0033618156,0.00010620844,0.016468382,0.00038678487,0.000075221076,0.000013643471,0.00036091774,0.00021992456,0.956582,0.00003550585,0.022212734,0.00017686722],"about_ca_topic_score_codex":0.00021503256,"about_ca_topic_score_gemma":0.00017996348,"teacher_disagreement_score":0.03471573,"about_ca_system_score_codex":0.0040288703,"about_ca_system_score_gemma":0.0008260613,"threshold_uncertainty_score":0.9997945},"labels":[],"label_agreement":null},{"id":"W1997062198","doi":"10.1038/leu.2012.331","title":"CBL-B is required for leukemogenesis mediated by BCR-ABL through negative regulation of bone marrow homing","year":2012,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"Canadian Institutes of Health Research","keywords":"Homing (biology); Bone marrow; Haematopoiesis; Neutrophilia; breakpoint cluster region; Leukemia; Biology; Cancer research; Spleen; Immunology; ABL; Transplantation; Myeloid; Myeloid leukemia; Chronic myelogenous leukemia; Stem cell; Medicine; Internal medicine; Signal transduction; Cell biology; Receptor; Genetics; Tyrosine kinase","score_opus":0.026546077606185665,"score_gpt":0.2824213171881071,"score_spread":0.25587523958192143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997062198","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895882,0.0029430294,0.0017679532,0.0006759645,0.00036313088,0.0015431797,0.00024658293,0.00014920508,0.002722732],"genre_scores_gemma":[0.9766536,0.00016173898,0.016184594,0.0007073773,0.00040622146,0.00017971013,0.0006185315,0.00010370443,0.004984538],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975113,0.00007163531,0.00073369505,0.0004546138,0.0005157877,0.0007129696],"domain_scores_gemma":[0.99793273,0.00048714946,0.00047720317,0.00064643926,0.00021604545,0.00024042209],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034941503,0.00037555737,0.00078774197,0.000120221164,0.00012698787,0.000012239114,0.00012238113,0.00034108662,0.00042289458],"category_scores_gemma":[0.00051704125,0.00034620127,0.00026187117,0.00041345126,0.0001594657,0.00046157886,0.00006382349,0.00016128973,0.00008880048],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021334342,0.00047244044,0.026011473,0.0009898606,0.001175383,0.000013125378,0.008510973,0.000029357276,0.787225,0.00046669363,0.15594266,0.017029557],"study_design_scores_gemma":[0.016978065,0.0005008068,0.02445244,0.00043006692,0.0008922185,0.00007446646,0.0005437754,0.0021458128,0.91855335,0.00062808517,0.034239743,0.0005611723],"about_ca_topic_score_codex":0.00056151964,"about_ca_topic_score_gemma":0.0000122978445,"teacher_disagreement_score":0.13132831,"about_ca_system_score_codex":0.004300895,"about_ca_system_score_gemma":0.0007403414,"threshold_uncertainty_score":0.99989897},"labels":[],"label_agreement":null},{"id":"W1997254819","doi":"10.1038/leu.2014.245","title":"Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia","year":2014,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":133,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University; University of Toronto","funders":"National Institute for Health and Care Research; National Cancer Institute; National Institutes of Health; National Heart, Lung, and Blood Institute; Huntsman Cancer Institute; University of Utah; American Society of Hematology","keywords":"Myeloid leukemia; Cancer research; breakpoint cluster region; Tyrosine kinase; Philadelphia chromosome; STAT protein; Biology; STAT3; Medicine; Signal transduction; Internal medicine; Cell biology; Chromosomal translocation; Biochemistry; Receptor","score_opus":0.016181650942108654,"score_gpt":0.2565663677557162,"score_spread":0.2403847168136075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997254819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924181,0.0014959932,0.000043557568,0.00088274234,0.00017606062,0.0009860416,0.00002026342,0.00019037651,0.0037868721],"genre_scores_gemma":[0.996928,0.0007883398,0.00041255873,0.0006515085,0.00024579154,0.000139143,0.00012329269,0.000085551714,0.0006258454],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9967409,0.00029350232,0.000729197,0.00088641135,0.0005658661,0.0007841534],"domain_scores_gemma":[0.99790466,0.00033161824,0.0002385749,0.0011080336,0.00009527982,0.00032185562],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007727223,0.0005268897,0.00083020405,0.00029067465,0.00015646702,0.00006763853,0.000205671,0.00037465422,0.00024959774],"category_scores_gemma":[0.00034450582,0.00046294185,0.00013226617,0.00043055112,0.00031185793,0.0002284491,0.00016456183,0.00070899946,0.00010925902],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065611843,0.0012005556,0.051346872,0.0023532563,0.00082409906,0.0010056561,0.004516968,0.00040075483,0.6872133,0.007842126,0.004500888,0.23223436],"study_design_scores_gemma":[0.07726216,0.0064254096,0.6530685,0.0032792646,0.00043049364,0.0003818198,0.00062668434,0.008028521,0.21704009,0.01002778,0.021148382,0.0022808937],"about_ca_topic_score_codex":0.0022025905,"about_ca_topic_score_gemma":0.00045052345,"teacher_disagreement_score":0.60172164,"about_ca_system_score_codex":0.011708109,"about_ca_system_score_gemma":0.0019904533,"threshold_uncertainty_score":0.9997822},"labels":[],"label_agreement":null},{"id":"W1997397403","doi":"10.1182/blood-2008-03-147744","title":"Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":233,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Imatinib; Myeloid leukemia; Genotype; Single-nucleotide polymorphism; Pharmacogenetics; Imatinib mesylate; Haplotype; Allele; Medicine; Leukemia; Internal medicine; Immunology; Oncology; Biology; Genetics; Gene","score_opus":0.01370123802848771,"score_gpt":0.24894842035048703,"score_spread":0.23524718232199932,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997397403","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936861,0.0031650502,0.000057161727,0.0005674498,0.000049285092,0.00132836,0.00023420871,0.00020863027,0.0007038036],"genre_scores_gemma":[0.9880315,0.00013053023,0.0055008936,0.00042612737,0.000093820134,0.00021924805,0.000116686206,0.00013084908,0.0053503523],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9966824,0.00019078943,0.00058596337,0.0007972305,0.0008998432,0.00084377965],"domain_scores_gemma":[0.99803984,0.00018395841,0.0002718111,0.00093790586,0.00018187331,0.0003845832],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00030950474,0.0004913716,0.0008701339,0.00033524007,0.00017305027,0.000022127524,0.00024002492,0.00020936145,0.00011709184],"category_scores_gemma":[0.00066937384,0.00043545495,0.00013321344,0.00085110386,0.00016222984,0.00011096275,0.000094445495,0.00041685387,0.000087539374],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020182261,0.0033994012,0.25216565,0.00044799506,0.002759461,0.068148375,0.004698798,0.0005214671,0.6427685,0.00008096295,0.0037858416,0.0010412615],"study_design_scores_gemma":[0.06663539,0.0016001313,0.53871536,0.001991193,0.00058510894,0.0006936874,0.0001346765,0.00007558693,0.38745892,0.000023551365,0.0012306982,0.0008557105],"about_ca_topic_score_codex":0.0002822603,"about_ca_topic_score_gemma":0.0012539771,"teacher_disagreement_score":0.28654972,"about_ca_system_score_codex":0.0069217277,"about_ca_system_score_gemma":0.0036397865,"threshold_uncertainty_score":0.99980974},"labels":[],"label_agreement":null},{"id":"W1997569947","doi":"10.1002/ajh.20882","title":"Inv (11)(p15q21) in donor‐derived Ph‐negative cells in a patient with chronic myeloid leukemia in relapse successfully treated with imatinib mesylate post allogeneic stemcell transplantation","year":2007,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Imatinib mesylate; Medicine; Myeloid leukemia; Transplantation; Philadelphia chromosome; Hematopoietic stem cell transplantation; Internal medicine; Imatinib; Stem cell; Dysplasia; Oncology; Gastroenterology; Immunology; Chromosomal translocation; Biology","score_opus":0.005524933062993245,"score_gpt":0.2350075105700737,"score_spread":0.22948257750708045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997569947","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980744,0.00037442974,0.00016494945,0.00025555328,0.00005316081,0.0008306075,0.000011954843,0.000017790631,0.00021716679],"genre_scores_gemma":[0.9969107,0.00036672427,0.0023461937,0.00020903564,0.000023268702,0.000030092737,0.000031076826,0.00006136198,0.000021554606],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99657184,0.0003270621,0.0014659122,0.00045032214,0.00042463865,0.0007602395],"domain_scores_gemma":[0.9974994,0.00046516446,0.0012699615,0.0002871562,0.00023108925,0.0002472044],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00044566143,0.00045197274,0.0015138394,0.001114732,0.00003501553,0.00001167354,0.00018885102,0.00014611635,0.000051340525],"category_scores_gemma":[0.000040938397,0.0003274487,0.00009807461,0.0011979955,0.00046554607,0.00021791298,0.000020574404,0.00072834536,0.000008648023],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028981078,0.0010563503,0.8149564,0.00045984605,0.0005579805,0.06454349,0.017021907,0.0050332663,0.055682186,0.000040839815,0.000016409896,0.011650232],"study_design_scores_gemma":[0.07341983,0.032422878,0.4572143,0.00487656,0.0006031253,0.046920896,0.011912608,0.00068798714,0.37069333,0.000037794245,0.000084789004,0.0011259025],"about_ca_topic_score_codex":0.0055237343,"about_ca_topic_score_gemma":0.030618064,"teacher_disagreement_score":0.35774213,"about_ca_system_score_codex":0.0045936573,"about_ca_system_score_gemma":0.002243234,"threshold_uncertainty_score":0.99991775},"labels":[],"label_agreement":null},{"id":"W1997954121","doi":"10.1182/blood-2002-05-1324","title":"Primitive interleukin 3 null hematopoietic cells transduced with BCR-ABL show accelerated loss after culture of factor-independence in vitro and leukemogenic activity in vivo","year":2002,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Haematopoiesis; Biology; In vitro; Cancer research; Immunology; In vivo; Interleukin 3; Virology; Molecular biology; Stem cell; Cell biology; Interleukin 21; Genetics; Cytotoxic T cell","score_opus":0.015093356074047885,"score_gpt":0.23177468367043821,"score_spread":0.21668132759639033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997954121","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979612,0.00054359855,0.0000138342875,0.000055552286,0.000024564177,0.00085514394,0.000068220164,0.000031647112,0.00044618722],"genre_scores_gemma":[0.9989629,0.00017643446,0.00028621042,0.000054359567,0.000020269863,0.0000788218,0.000005744001,0.00003847413,0.00037683407],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982482,0.000091675574,0.00033149912,0.0005462076,0.00036577508,0.00041663166],"domain_scores_gemma":[0.99925554,0.00006601299,0.00011727312,0.00034670703,0.00007004439,0.0001443963],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00008075767,0.00035104324,0.0006609083,0.00017800655,0.00001979014,0.000018191955,0.000115517105,0.00024853396,0.0004066285],"category_scores_gemma":[0.000018791172,0.00027550955,0.00007700304,0.00038191862,0.00012908905,0.00019813392,0.00003929985,0.0004911719,0.000009140464],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015520809,0.0022369463,0.040469795,0.00038535445,0.00022515502,0.0013720493,0.00977294,0.00000387811,0.942949,0.0000011028651,0.000010167048,0.0010215131],"study_design_scores_gemma":[0.016610071,0.0005044345,0.048943408,0.00050872535,0.00017696538,0.00026864972,0.00028909105,0.0001511851,0.9322829,0.0000042659653,0.000012304074,0.00024797305],"about_ca_topic_score_codex":0.00023929533,"about_ca_topic_score_gemma":0.00037450725,"teacher_disagreement_score":0.015057989,"about_ca_system_score_codex":0.00048649174,"about_ca_system_score_gemma":0.00017518656,"threshold_uncertainty_score":0.9999697},"labels":[],"label_agreement":null},{"id":"W1998770217","doi":"10.1158/1078-0432.ccr-05-2282","title":"Synergistic Interactions between DMAG and Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitors in Bcr/abl+ Leukemia Cells Sensitive and Resistant to Imatinib Mesylate","year":2006,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Imatinib mesylate; Cancer research; Imatinib; K562 cells; MAPK/ERK pathway; Kinase; Chemistry; Biology; Leukemia; Myeloid leukemia; Immunology; Cell biology","score_opus":0.0918782453012303,"score_gpt":0.44457176942121357,"score_spread":0.3526935241199833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998770217","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941394,0.0005287603,0.000008699697,0.0021826648,0.00017014824,0.0020847542,0.00013887741,0.000049602775,0.0006971111],"genre_scores_gemma":[0.9952566,0.00015648545,0.00043760453,0.000087685745,0.00062650075,0.0003541531,0.000051560142,0.00006034367,0.0029690776],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99592596,0.0006841348,0.0009873434,0.0009544171,0.00066830614,0.00077983894],"domain_scores_gemma":[0.99655616,0.0018175308,0.00013565212,0.0004947789,0.00037789662,0.00061798515],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015999197,0.0002983406,0.0007405379,0.00043551566,0.00019547425,0.000076340984,0.00011231797,0.00022711535,0.00009288159],"category_scores_gemma":[0.0014992177,0.00026325794,0.00009176321,0.00084828655,0.0005525641,0.00012538524,0.0003040304,0.0013780863,0.00005345034],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070190798,0.0006147755,0.043998316,0.0005213622,0.0003058044,0.002120593,0.0007075186,0.000043248783,0.88907534,0.00011547037,0.009192169,0.046286352],"study_design_scores_gemma":[0.014401448,0.0022619308,0.2887534,0.003641208,0.00020482493,0.000015769328,0.00059426564,0.00042610514,0.6704957,0.0004556537,0.018053947,0.00069578446],"about_ca_topic_score_codex":0.023137975,"about_ca_topic_score_gemma":0.0038834244,"teacher_disagreement_score":0.24475507,"about_ca_system_score_codex":0.0031821239,"about_ca_system_score_gemma":0.0013892896,"threshold_uncertainty_score":0.99998194},"labels":[],"label_agreement":null},{"id":"W1998936478","doi":"10.1038/leu.2008.221","title":"Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase","year":2008,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":201,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Cancer Institute","keywords":"Dasatinib; Medicine; Internal medicine; Chronic myelogenous leukemia; Imatinib; Neutropenia; Tolerability; Gastroenterology; Imatinib mesylate; Myeloid leukemia; Oncology; Nilotinib; Immunology; Leukemia; Adverse effect; Chemotherapy","score_opus":0.015000299361486464,"score_gpt":0.26624099219016034,"score_spread":0.2512406928286739,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998936478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99654835,0.0004176753,0.000026405609,0.00005235849,0.00005498561,0.0016726393,0.000060486636,0.000056576035,0.0011105381],"genre_scores_gemma":[0.99745864,0.0003298521,0.0013587892,0.0001135329,0.0000663993,0.00008163855,0.00016473758,0.000074109616,0.00035229317],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996794,0.00009828153,0.001093309,0.00070161227,0.00063069386,0.0006821089],"domain_scores_gemma":[0.998325,0.0003069254,0.0003356085,0.00067210663,0.00010511203,0.00025524854],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002148243,0.0004891697,0.0010649961,0.00038864888,0.00008809961,0.000010634128,0.00018158878,0.00021413084,0.00023885039],"category_scores_gemma":[0.000200892,0.00035825215,0.00007489072,0.00080764305,0.0003555468,0.00017977887,0.00010135133,0.00053884386,0.000022003715],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12025755,0.0050192093,0.75228655,0.0028653264,0.00079561496,0.0053088292,0.013355121,0.0029126836,0.01768565,0.000141764,0.0012172969,0.0781544],"study_design_scores_gemma":[0.14958778,0.0038462353,0.83684385,0.001881494,0.00011408244,0.00015072936,0.00011232001,0.0027114127,0.0033282342,0.000006775683,0.00095217035,0.00046493008],"about_ca_topic_score_codex":0.0015358563,"about_ca_topic_score_gemma":0.001423404,"teacher_disagreement_score":0.08455728,"about_ca_system_score_codex":0.012410152,"about_ca_system_score_gemma":0.0050938637,"threshold_uncertainty_score":0.99988693},"labels":[],"label_agreement":null},{"id":"W1999257052","doi":"10.1182/blood-2007-05-088815","title":"Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8)","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":108,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"Wilmot Cancer Institute, University of Rochester Medical Center; National Cancer Institute; Leukemia and Lymphoma Society","keywords":"Haematopoiesis; Leukemia; Stem cell; Progenitor cell; Myeloid leukemia; Biology; Cancer research; Myeloid; Immunology; Cell biology","score_opus":0.019713133837099175,"score_gpt":0.2547638598019159,"score_spread":0.23505072596481674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1999257052","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99143744,0.005855053,0.000017288554,0.000090625304,0.00008310155,0.0010662868,0.000032577736,0.000048217367,0.0013694055],"genre_scores_gemma":[0.9985115,0.00035596787,0.0005119468,0.00011514759,0.00016300328,0.000023211524,0.000018421912,0.000041233085,0.00025959613],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983823,0.00007374797,0.00039026028,0.0004040845,0.00034699662,0.0004026492],"domain_scores_gemma":[0.998708,0.00039432224,0.00018524873,0.00035639553,0.00012170782,0.0002343235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044620852,0.000279947,0.0004782287,0.00010088969,0.00013420105,0.00002226983,0.000102178434,0.00018560483,0.000015077411],"category_scores_gemma":[0.000044560522,0.0001984735,0.00006545105,0.00024306588,0.0001403852,0.000073330564,0.00007686093,0.00032280904,0.0000059302665],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000514632,0.0009623456,0.046457715,0.00026245302,0.0013494451,0.00011242604,0.0017552011,3.6615097e-7,0.93187344,0.00016193652,0.0009621014,0.015587936],"study_design_scores_gemma":[0.011941762,0.0010115182,0.059505586,0.0000974461,0.0008125794,0.00034768964,0.00043773482,0.000028617196,0.92449117,0.000038011203,0.0010700728,0.00021778942],"about_ca_topic_score_codex":0.00039179708,"about_ca_topic_score_gemma":0.000028770522,"teacher_disagreement_score":0.015370147,"about_ca_system_score_codex":0.00034878153,"about_ca_system_score_gemma":0.0003682918,"threshold_uncertainty_score":0.80935144},"labels":[],"label_agreement":null},{"id":"W1999328539","doi":"10.1182/blood-2013-07-516807","title":"The core autophagy protein ATG4B is a potential biomarker and therapeutic target in CML stem/progenitor cells","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":199,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; University of British Columbia; BC Cancer Agency","funders":"Canadian Institutes of Health Research","keywords":"Progenitor cell; Autophagy; Stem cell; Gene knockdown; Cancer research; Progenitor; Biology; Cell biology; Cell culture; Apoptosis; Genetics","score_opus":0.015068472542162587,"score_gpt":0.24480314064500647,"score_spread":0.22973466810284388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1999328539","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948634,0.0029230977,0.000019402376,0.0005570615,0.0001188845,0.0010913893,0.000010232618,0.000047100984,0.00036945252],"genre_scores_gemma":[0.996482,0.00004323289,0.0004244681,0.00028630157,0.00014032435,0.00012717668,0.0000062604463,0.00003455281,0.0024556743],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99875975,0.0000765052,0.0002467368,0.00031780027,0.00025207354,0.00034712197],"domain_scores_gemma":[0.9993055,0.000058639722,0.00007792533,0.00041017414,0.00003573297,0.00011204735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023706658,0.00019373842,0.0002479213,0.00005550583,0.00010500951,0.000031778272,0.00010959298,0.000117058014,0.00008263613],"category_scores_gemma":[0.000015490248,0.00012549307,0.00007122844,0.0001314348,0.000093708186,0.000026178952,0.000059298098,0.00015216129,0.00006464797],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009553358,0.002435968,0.05017759,0.00044237377,0.0015296085,0.0004931198,0.0015258441,0.0000020383052,0.8495797,0.00032953144,0.0012601422,0.09126873],"study_design_scores_gemma":[0.047996257,0.0015096222,0.12169237,0.0003848991,0.00097377505,0.0004915927,0.0002654541,0.006439146,0.7784631,0.0011074183,0.040006533,0.000669782],"about_ca_topic_score_codex":0.00008989365,"about_ca_topic_score_gemma":0.000015794116,"teacher_disagreement_score":0.09059895,"about_ca_system_score_codex":0.00009965803,"about_ca_system_score_gemma":0.00015736834,"threshold_uncertainty_score":0.51174587},"labels":[],"label_agreement":null},{"id":"W2000298515","doi":"10.1182/blood-2014-06-581173","title":"Disruption of IKAROS activity in primitive chronic-phase CML cells mimics myeloid disease progression","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre; University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Myeloid; Medicine; Cancer research; Disease; Imatinib; Myeloid leukemia; Immunology; Biology; Internal medicine","score_opus":0.012481730666794935,"score_gpt":0.301793895850643,"score_spread":0.28931216518384806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000298515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997629,0.0003104559,0.0001516585,0.00014030305,0.000086154316,0.0009819237,0.000044872624,0.000052801995,0.00060281524],"genre_scores_gemma":[0.99876386,0.00012317195,0.00057368336,0.000032035492,0.0001654373,0.00008635939,0.00008143721,0.000032829677,0.00014119304],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99855405,0.00010190875,0.00028663984,0.0003891072,0.00034465175,0.0003236572],"domain_scores_gemma":[0.99893856,0.000087837594,0.00019147166,0.00047901197,0.00006005369,0.00024307625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018270142,0.00021754994,0.00038535075,0.000120908284,0.000039006187,0.000008446814,0.000086268985,0.00011282721,0.00005076384],"category_scores_gemma":[0.00012842895,0.00018578254,0.00011470109,0.00018781929,0.00010116834,0.00011593525,0.00006730672,0.00020740897,0.000028129762],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019351026,0.016150106,0.06289319,0.0011645535,0.00017925879,0.00021802587,0.0005159326,0.000031815354,0.78772116,0.00011318983,0.00007119423,0.12900648],"study_design_scores_gemma":[0.03856679,0.0017989816,0.1985456,0.0010940378,0.00059839,0.000017970504,0.00002665457,0.0028451432,0.75559604,0.00004546525,0.0005962989,0.00026864675],"about_ca_topic_score_codex":0.000045877903,"about_ca_topic_score_gemma":0.000027297405,"teacher_disagreement_score":0.13565241,"about_ca_system_score_codex":0.00057921605,"about_ca_system_score_gemma":0.00049631845,"threshold_uncertainty_score":0.7575992},"labels":[],"label_agreement":null},{"id":"W2002298886","doi":"10.1038/tpj.2014.54","title":"ABCB1 polymorphisms predict imatinib response in chronic myeloid leukemia patients: a systematic review and meta-analysis","year":2014,"lang":"en","type":"review","venue":"The Pharmacogenomics Journal","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Fundação de Amparo à Pesquisa do Estado de São Paulo","keywords":"Imatinib; Myeloid leukemia; Imatinib mesylate; Tyrosine-kinase inhibitor; Single-nucleotide polymorphism; Medicine; Genotype; Tyrosine kinase; Allele; Oncology; Dasatinib; Internal medicine; Pharmacology; Immunology; Biology; Genetics; Gene; Receptor; Cancer","score_opus":0.05647927720534315,"score_gpt":0.3544688033806148,"score_spread":0.2979895261752717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002298886","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016625972,0.9924358,0.00004198436,0.00042011557,0.00011885003,0.0064201807,0.00029482137,0.000035777717,0.00006620141],"genre_scores_gemma":[0.00025074903,0.99623847,0.00010505928,0.0012057323,0.00024843038,0.0007237904,0.00015656909,0.00017749278,0.00089369057],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9898168,0.003933769,0.0038069177,0.00076145545,0.00084501907,0.0008360383],"domain_scores_gemma":[0.9931293,0.001368384,0.0033094129,0.0014212686,0.00020944062,0.0005621549],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.006841006,0.0012463549,0.013589554,0.0010297775,0.00026596824,0.00013303643,0.00094543473,0.00029300913,0.0009895412],"category_scores_gemma":[0.0005973596,0.0006746735,0.0047810255,0.0012460358,0.00018378241,0.0001399343,0.00029653605,0.0021391578,0.00018577575],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002528577,0.00013003715,0.0000047240364,0.6336948,0.35936564,0.00023967671,0.0001399683,0.000031287844,0.0000038227786,0.000004542797,0.00062628754,0.005506308],"study_design_scores_gemma":[0.0024308993,0.00026181355,0.0000065677846,0.042893358,0.90686756,0.0028247016,0.0000048762918,0.00020658055,0.0000011619261,0.000007927725,0.044012345,0.00048222917],"about_ca_topic_score_codex":0.000028593118,"about_ca_topic_score_gemma":0.0000070778456,"teacher_disagreement_score":0.5908015,"about_ca_system_score_codex":0.013605704,"about_ca_system_score_gemma":0.003888227,"threshold_uncertainty_score":0.9999237},"labels":[],"label_agreement":null},{"id":"W2002379912","doi":"10.1080/1042819021000035707","title":"Association of Familial Leukemia with HLA Cw3: Is it Real?","year":2002,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sudbury Regional Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Leukemia; Myeloid leukemia; Anticipation (artificial intelligence); Human leukocyte antigen; Immunology; Medicine; Haplotype; Genetics; Allele; Biology; Antigen; Gene","score_opus":0.014329316963668234,"score_gpt":0.23759822062964506,"score_spread":0.22326890366597682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002379912","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94164413,0.0014073589,0.000039517647,0.000884912,0.0003750502,0.0011421173,0.00015355407,0.00034522222,0.05400813],"genre_scores_gemma":[0.94221747,0.0052544265,0.0014057579,0.0025238,0.0006317686,0.00014081562,0.00017936173,0.00024550423,0.0474011],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9929296,0.00020708887,0.001589002,0.001674381,0.0019517911,0.0016481477],"domain_scores_gemma":[0.99532634,0.0005402121,0.0011045313,0.0016296201,0.00052112475,0.00087819534],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00053772057,0.0012588805,0.001970854,0.00053942495,0.0004269687,0.00012311486,0.000507198,0.0011599517,0.0013865274],"category_scores_gemma":[0.00023191489,0.001094694,0.0005122269,0.0011625836,0.00049043784,0.0005478869,0.00024940076,0.00034627866,0.0005497714],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00570425,0.0018270202,0.22976017,0.002489411,0.0066598514,0.0028846685,0.016842304,0.00020973329,0.01779822,0.0011802892,0.40677297,0.3078711],"study_design_scores_gemma":[0.18821345,0.005809147,0.4569766,0.0033219438,0.0065056053,0.0058567734,0.004447745,0.038840443,0.057855934,0.0004270825,0.22675738,0.0049879164],"about_ca_topic_score_codex":0.005870122,"about_ca_topic_score_gemma":0.00032481187,"teacher_disagreement_score":0.30288318,"about_ca_system_score_codex":0.05069135,"about_ca_system_score_gemma":0.005281811,"threshold_uncertainty_score":0.9995263},"labels":[],"label_agreement":null},{"id":"W2004492241","doi":"10.1182/blood-2006-09-046839","title":"Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":372,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Dasatinib; Imatinib; Medicine; Internal medicine; Neutropenia; Myeloid leukemia; Adverse effect; Imatinib mesylate; Nilotinib; Gastroenterology; Oncology; Chemotherapy","score_opus":0.029391149409079758,"score_gpt":0.3000116606126729,"score_spread":0.27062051120359315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004492241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99731946,0.0006914541,0.000008637828,0.000047419868,0.000032136842,0.0015760952,0.000031120246,0.00007181914,0.0002218775],"genre_scores_gemma":[0.998264,0.000090296795,0.0012099036,0.00008795743,0.00003793128,0.000091228605,0.00007986511,0.00005223544,0.00008658025],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971616,0.00012811653,0.00084256945,0.00067338516,0.00046116524,0.0007331516],"domain_scores_gemma":[0.9986202,0.00035803867,0.00023929971,0.00045411245,0.00009278445,0.00023558075],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00049287913,0.00042335154,0.00075740466,0.0004701993,0.00007269709,0.00003583057,0.00014579397,0.00020303129,0.00013231335],"category_scores_gemma":[0.000261179,0.0002894327,0.000041020365,0.0008098349,0.0001622827,0.00010848178,0.000067841895,0.00037666078,0.000013220283],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033040475,0.0072351703,0.81232303,0.00071701995,0.0003872999,0.006109823,0.00202588,0.000026092774,0.12381383,0.000027172055,0.000030544474,0.01426367],"study_design_scores_gemma":[0.08733264,0.005205348,0.8171641,0.0008012248,0.00019461979,0.00012191577,0.00030483067,0.00008332213,0.08833933,0.00001076127,0.00004230999,0.00039956663],"about_ca_topic_score_codex":0.00031584967,"about_ca_topic_score_gemma":0.0008100308,"teacher_disagreement_score":0.054292165,"about_ca_system_score_codex":0.0017984748,"about_ca_system_score_gemma":0.0018621661,"threshold_uncertainty_score":0.9999558},"labels":[],"label_agreement":null},{"id":"W2004871448","doi":"10.1007/s12156-008-0059-z","title":"The role of Lyn kinase in the development of imatinib resistance in chronic myelogenous leukemia","year":2008,"lang":"en","type":"article","venue":"Oncology Reviews","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"LYN; Medicine; Chronic myelogenous leukemia; Imatinib; Leukemia; Nilotinib; Cancer research; Immunology; Internal medicine; Proto-oncogene tyrosine-protein kinase Src; Receptor; Myeloid leukemia","score_opus":0.03950615215564697,"score_gpt":0.32384904725769126,"score_spread":0.2843428951020443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004871448","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80170673,0.17565483,0.0000041580006,0.000323312,0.000049850198,0.0016775968,0.000002186245,0.0000065646245,0.02057479],"genre_scores_gemma":[0.9483175,0.04303657,0.006953423,0.00021817688,0.00006410358,0.00059442694,0.00001866972,0.00002148193,0.0007756383],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99763554,0.00043468006,0.0011803227,0.00022301181,0.00020727127,0.00031914667],"domain_scores_gemma":[0.9984462,0.00040399504,0.00046361628,0.00060239364,0.00004510637,0.000038690752],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016060063,0.00017119647,0.00082957005,0.00007291478,0.00009168647,0.0000014203887,0.00031060886,0.000120766534,0.00004293871],"category_scores_gemma":[0.00029845317,0.00009291336,0.00010343441,0.00038983417,0.00026491203,0.000025346748,0.00005538964,0.00028976152,0.0000439295],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009546275,0.0013862713,0.061990853,0.0017357295,0.00020542138,0.0005756816,0.042231984,0.000017931603,0.023024566,0.0013622927,0.004469124,0.8620455],"study_design_scores_gemma":[0.0037236142,0.00038843387,0.07893831,0.00080065586,0.000059143786,0.00012426429,0.0004301844,0.000022706092,0.0037405267,0.0001658185,0.91148686,0.00011944407],"about_ca_topic_score_codex":0.000089338864,"about_ca_topic_score_gemma":0.007139426,"teacher_disagreement_score":0.90701777,"about_ca_system_score_codex":0.0046686474,"about_ca_system_score_gemma":0.0047360356,"threshold_uncertainty_score":0.99915224},"labels":[],"label_agreement":null},{"id":"W2004999590","doi":"10.3747/co.v15i2.224","title":"An Approach to the Management of Chronic Myeloid Leukemia in British Columbia","year":2008,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute; University of British Columbia; Michael Smith Health Research BC","keywords":"Medicine; Myeloid leukemia; Immunology","score_opus":0.058235382983990835,"score_gpt":0.3380898324092474,"score_spread":0.27985444942525656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004999590","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873029,0.002391562,0.00016140427,0.000104376355,0.0004882272,0.0013725791,0.000014226368,0.00004249661,0.008122248],"genre_scores_gemma":[0.9952025,0.0017343881,0.0013053278,0.00010523617,0.00024509168,0.0003428315,0.00009674748,0.000026640073,0.00094125746],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9983205,0.00010657255,0.00042382942,0.0004449106,0.0002801409,0.00042405157],"domain_scores_gemma":[0.999056,0.000032976382,0.00010239659,0.000578547,0.000059891434,0.00017022199],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002452365,0.000130287,0.00045985435,0.00006931894,0.00008963914,0.000012972733,0.00028802024,0.00011080392,0.00016982199],"category_scores_gemma":[0.000013153324,0.00015177172,0.00008257732,0.00040299582,0.00016985755,0.000050967054,0.000121423654,0.00031050981,0.000057464833],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014886215,0.0046209143,0.17108119,0.00089060335,0.00030680647,0.0007487218,0.0016642632,0.0006596618,0.00017168591,0.000107789674,0.03399939,0.7856001],"study_design_scores_gemma":[0.0091632735,0.0015769234,0.79255474,0.00036926116,0.00017995496,0.0010108701,0.00051928806,0.0024694724,0.000047003665,0.000031215917,0.19184698,0.00023105128],"about_ca_topic_score_codex":0.003658975,"about_ca_topic_score_gemma":0.010320063,"teacher_disagreement_score":0.78536904,"about_ca_system_score_codex":0.007248891,"about_ca_system_score_gemma":0.0012391185,"threshold_uncertainty_score":0.9965621},"labels":[],"label_agreement":null},{"id":"W2005245904","doi":"10.1016/j.bcmd.2006.06.002","title":"The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years","year":2006,"lang":"en","type":"article","venue":"Blood Cells Molecules and Diseases","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Imatinib; Imatinib mesylate; Medicine; Internal medicine; Myeloid leukemia; Philadelphia chromosome; Chronic myelogenous leukemia; Gastroenterology; Oncology; Surgery; Leukemia; Chromosomal translocation; Biology","score_opus":0.008202529627470641,"score_gpt":0.22982200540861888,"score_spread":0.22161947578114824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005245904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995388,0.002420107,0.000004034011,0.000068625246,0.000005582431,0.0017905477,0.0002832129,0.000022551603,0.00001736817],"genre_scores_gemma":[0.9988592,0.00020956717,0.00021338239,0.000021811897,0.000009955114,0.00013151986,0.00030269686,0.000031927462,0.00021989642],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988216,0.00007728796,0.0002736327,0.00032166732,0.00021895801,0.00028680894],"domain_scores_gemma":[0.9992826,0.00011654288,0.00015735887,0.0002295951,0.000072727365,0.00014118876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000071658076,0.0002104304,0.00029112736,0.00006051245,0.00011878913,0.0000232323,0.000049021546,0.000043501037,0.0000063988473],"category_scores_gemma":[0.000017786779,0.00012505053,0.00003193739,0.00012944316,0.0001366887,0.000032990534,0.00004133691,0.00004781138,4.3906638e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11878194,0.006017905,0.4857147,0.0010762599,0.0007583443,0.000369602,0.00026423132,0.00087468035,0.38136286,0.000010713132,0.00023993276,0.0045288135],"study_design_scores_gemma":[0.07717434,0.008312007,0.8290112,0.0006438656,0.0011322452,0.0000096356225,0.000021571352,0.0024136922,0.08071121,0.000016525504,0.0003072725,0.00024642798],"about_ca_topic_score_codex":0.00009655695,"about_ca_topic_score_gemma":0.00006322662,"teacher_disagreement_score":0.3432965,"about_ca_system_score_codex":0.000122021615,"about_ca_system_score_gemma":0.00018722376,"threshold_uncertainty_score":0.5099413},"labels":[],"label_agreement":null},{"id":"W2007148967","doi":"10.1053/shem.2002.35979","title":"Chronic myeloid leukemia: Current therapies and the potential role of farnesyltransferase inhibitors","year":2002,"lang":"en","type":"review","venue":"Seminars in Hematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Myeloid leukemia; Busulfan; Imatinib mesylate; Chronic myelogenous leukemia; Transplantation; Immunology; Toxicity; Leukemia; Oncology; Pharmacology; Imatinib; Internal medicine; Hematopoietic stem cell transplantation","score_opus":0.01578019992684772,"score_gpt":0.29008924812173104,"score_spread":0.27430904819488333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007148967","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001973442,0.9949314,0.000003923995,0.00012593772,0.00043132473,0.0021100498,0.0000314848,0.000039077764,0.00035333823],"genre_scores_gemma":[0.0042260126,0.99469256,0.000065988206,0.000014026423,0.0002677005,0.0004020872,0.00009314935,0.00008846509,0.0001499967],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99660933,0.0004291508,0.0013448949,0.00069650525,0.00033421034,0.0005859078],"domain_scores_gemma":[0.9979845,0.0006185114,0.0004494199,0.00077731424,0.00005144383,0.000118784155],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003789362,0.00071095116,0.0038517676,0.00041409704,0.000072978044,0.000011857303,0.00029846933,0.00070098304,0.00017753942],"category_scores_gemma":[0.00011027269,0.00044610098,0.0006351477,0.00042311923,0.0010617184,0.000045143235,0.00014798703,0.0012061723,0.000033943852],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000078370555,0.00012026156,0.00010490795,0.018026516,0.00039842565,0.00019945909,0.0005801192,0.0000010243147,0.00000430884,0.0010682213,0.00023087308,0.9791875],"study_design_scores_gemma":[0.009101295,0.00035992495,0.000012042665,0.047776986,0.0027198342,0.007394877,0.00025201595,0.000105752544,0.00009519444,0.00059572695,0.9310399,0.0005464315],"about_ca_topic_score_codex":0.000095818716,"about_ca_topic_score_gemma":0.0000319688,"teacher_disagreement_score":0.9786411,"about_ca_system_score_codex":0.0014971977,"about_ca_system_score_gemma":0.0011657025,"threshold_uncertainty_score":0.9997991},"labels":[],"label_agreement":null},{"id":"W2007928017","doi":"10.1182/blood-2012-02-409763","title":"Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"National Cancer Institute; National Blood Foundation; Genentech; Astellas Pharma; Office of Naval Research; Be The Match Foundation; Eisai; CellGenix; Medical College of Wisconsin; HistoGenetics; National Heart, Lung, and Blood Institute; Blue Cross and Blue Shield Association; National Institute of Allergy and Infectious Diseases; Celgene; Biogen; Health Resources and Services Administration; Astellas Pharma US; Amgen; IC Design Education Center","keywords":"Medicine; Internal medicine; Chronic myelogenous leukemia; Imatinib; Gastroenterology; Graft-versus-host disease; Leukemia; Cohort; Tyrosine-kinase inhibitor; Hematopoietic stem cell transplantation; Transplantation; Surgery; Cancer; Myeloid leukemia","score_opus":0.009481520573364446,"score_gpt":0.232201296206451,"score_spread":0.22271977563308654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007928017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99534893,0.0006955745,0.00020512466,0.00031387171,0.00038673935,0.00244943,0.000255584,0.00012551674,0.00021920758],"genre_scores_gemma":[0.99653023,0.000035056823,0.0008146909,0.00058461487,0.0006776434,0.00039588616,0.00043696197,0.000103688304,0.00042123167],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974389,0.000058261125,0.0005640141,0.00055529963,0.0004076693,0.00097583927],"domain_scores_gemma":[0.99839866,0.00025720132,0.00019411185,0.00050739764,0.00025043474,0.0003921731],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019855879,0.00045369248,0.00058153167,0.00015212671,0.0007736985,0.000060118087,0.0001523652,0.00018167747,0.00026494492],"category_scores_gemma":[0.00010143761,0.00037184273,0.00023436228,0.00027562628,0.00011521316,0.00026436435,0.00008198172,0.00038005254,0.00011379747],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016995862,0.0049255975,0.23437378,0.0042634155,0.0022039306,0.00024340468,0.0785671,0.00022629206,0.67046106,0.00017207183,0.002006522,0.0008572634],"study_design_scores_gemma":[0.02351065,0.00085192174,0.18478204,0.0012776477,0.0011719263,0.0003105901,0.00093235297,0.00005410787,0.7864128,0.000018096887,0.0001542335,0.0005236758],"about_ca_topic_score_codex":0.000064771506,"about_ca_topic_score_gemma":0.000022827133,"teacher_disagreement_score":0.11595172,"about_ca_system_score_codex":0.002437476,"about_ca_system_score_gemma":0.00073252805,"threshold_uncertainty_score":0.99987334},"labels":[],"label_agreement":null},{"id":"W2008502942","doi":"10.5858/arpa.2011-0136-oa","title":"Design and Analytic Validation of BCR-ABL1 Quantitative Reverse Transcription Polymerase Chain Reaction Assay for Monitoring Minimal Residual Disease","year":2011,"lang":"en","type":"article","venue":"Archives of Pathology & Laboratory Medicine","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Reverse transcription polymerase chain reaction; Reverse transcriptase; Real-time polymerase chain reaction; Computational biology; Polymerase chain reaction; Chronic myelogenous leukemia; Reliability engineering; Minimal residual disease; Computer science; Biology; Leukemia; Immunology; Engineering; Messenger RNA; Genetics","score_opus":0.0564768793298593,"score_gpt":0.31272764003674597,"score_spread":0.2562507607068867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2008502942","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98597395,0.001675677,0.010830751,0.0003323695,0.00018242931,0.00080774527,0.00007738037,0.000028569442,0.000091133006],"genre_scores_gemma":[0.9779657,0.00038730996,0.021235406,0.000044628992,0.000115728515,0.00006427944,0.00009469271,0.000026714399,0.0000655525],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998288,0.00042108155,0.0005143507,0.00036452137,0.00019802015,0.00021407094],"domain_scores_gemma":[0.99836355,0.00066925236,0.0003402647,0.0002977931,0.00014543944,0.00018367423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071364373,0.00019958211,0.0005248169,0.00035682906,0.000056734887,0.0000010926324,0.00006373628,0.000081446386,0.000019342711],"category_scores_gemma":[0.0007582213,0.00017153478,0.000057006262,0.00019453702,0.0006415374,0.00012275974,0.000014240268,0.00013625289,8.8848606e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063079786,0.0002571544,0.0209246,0.00043668246,0.00021281812,0.00018758143,0.012414168,0.0000060260745,0.95679206,0.00045473102,0.000052277814,0.001953904],"study_design_scores_gemma":[0.01527223,0.0075242408,0.33502126,0.0014734713,0.0027821301,0.00006334213,0.0055279806,0.0009172774,0.6298604,0.0011948189,0.000060384187,0.0003024749],"about_ca_topic_score_codex":0.0000618995,"about_ca_topic_score_gemma":0.000002486121,"teacher_disagreement_score":0.3269317,"about_ca_system_score_codex":0.00007155574,"about_ca_system_score_gemma":0.0003320923,"threshold_uncertainty_score":0.6994985},"labels":[],"label_agreement":null},{"id":"W2008801723","doi":"10.3747/co.v15i3.233","title":"Drug-Induced Immune Thrombocytopenic Purpura Secondary to Sunitinib","year":2008,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Sunitinib; Medicine; Thrombocytopenic purpura; Tyrosine-kinase inhibitor; Immune thrombocytopenia; Immune system; Drug; Pharmacology; Immunology; Internal medicine; Cancer; Platelet","score_opus":0.12912491502553852,"score_gpt":0.3961701709201712,"score_spread":0.2670452558946327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2008801723","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96825296,0.0018879183,0.000013929,0.0022649486,0.0020980274,0.0010718013,0.00001733014,0.00015157767,0.024241507],"genre_scores_gemma":[0.9955494,0.0004382529,0.00038997762,0.0006143668,0.00052208226,0.00018099447,0.0001678868,0.00004837518,0.002088657],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979814,0.00012486461,0.0005114382,0.0005011466,0.0002775135,0.00060363504],"domain_scores_gemma":[0.9985251,0.00015427395,0.00013247538,0.0006414284,0.00015274729,0.00039401156],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00018531243,0.0002960486,0.0008045955,0.00020576904,0.00017658545,0.000007332763,0.00023270937,0.00015675221,0.0021081367],"category_scores_gemma":[0.0001488282,0.00026719488,0.00018279647,0.00033216216,0.00012408636,0.000089193774,0.00020351043,0.0006486363,0.002128529],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013425658,0.0056000273,0.036461554,0.0004425487,0.0007726279,0.0034565274,0.009160696,0.0000047841495,0.052061632,0.0006108052,0.14270036,0.74738586],"study_design_scores_gemma":[0.0140603045,0.00199603,0.17218073,0.00018723034,0.00022549409,0.002656747,0.00037396766,0.000025160534,0.016883424,0.00005696148,0.7908991,0.00045485768],"about_ca_topic_score_codex":0.00008866972,"about_ca_topic_score_gemma":0.00006401422,"teacher_disagreement_score":0.746931,"about_ca_system_score_codex":0.0022129882,"about_ca_system_score_gemma":0.0022206057,"threshold_uncertainty_score":0.999978},"labels":[],"label_agreement":null},{"id":"W2009563819","doi":"10.1016/s1098-3015(10)65228-x","title":"PCN70 UTILITYVALUES FOR HEALTH STATES FOR CHRONIC MYELOGENOUS LEUKAEMIA (CML): ESTIMATES FROM LAYPERSONS IN AUSTRALIA, THE UNITED KINGDOM (UK) AND CANADA","year":2007,"lang":"en","type":"article","venue":"Value in Health","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Kingdom; Family medicine; Chronic myelogenous leukemia; Environmental health; Gerontology; Leukemia; Immunology; Biology","score_opus":0.0916650070418641,"score_gpt":0.3684696056787971,"score_spread":0.276804598636933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009563819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9828533,0.0035318907,0.00035506568,0.008893089,0.00023699668,0.0034786556,0.0006035845,0.000040565617,0.0000068787945],"genre_scores_gemma":[0.99109226,0.00043085605,0.005021804,0.0021852322,0.00017504403,0.00016656975,0.00078936137,0.00005127738,0.00008759551],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969622,0.00013657745,0.0008578999,0.00054420636,0.0002910824,0.0012080214],"domain_scores_gemma":[0.9966511,0.0022170688,0.00026259595,0.00043330915,0.000066967455,0.0003689272],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017507287,0.0003118353,0.00070172956,0.00023306232,0.00025774186,0.000021063901,0.00015482107,0.00012509373,0.000022653106],"category_scores_gemma":[0.00033021875,0.0002472439,0.00006166216,0.0003658833,0.00012502474,0.000041378305,0.00003687515,0.0003538838,0.0000012033673],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0037954433,0.00095615094,0.89319164,0.008361341,0.00065508566,0.00024296423,0.01887809,0.020204224,0.00031415222,0.0022607788,0.018925948,0.032214183],"study_design_scores_gemma":[0.035382923,0.005744204,0.74692184,0.0039971042,0.00020547828,0.00015815183,0.0045676753,0.15015039,0.0013470397,0.00516085,0.045321025,0.0010433428],"about_ca_topic_score_codex":0.9910551,"about_ca_topic_score_gemma":0.93741935,"teacher_disagreement_score":0.14626983,"about_ca_system_score_codex":0.011054204,"about_ca_system_score_gemma":0.008104096,"threshold_uncertainty_score":0.999998},"labels":[],"label_agreement":null},{"id":"W2010818649","doi":"10.3747/co.v16i0.404","title":"Targeted Therapies for Renal Cell Carcinoma: More Gains from Using Them Again","year":2009,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Sunitinib; Imatinib; Sorafenib; Nilotinib; Chronic myelogenous leukemia; Dasatinib; Concomitant; Tyrosine-kinase inhibitor; Renal cell carcinoma; Tyrosine kinase; Oncology; Bevacizumab; Targeted therapy; Temsirolimus; Internal medicine; Pharmacology; Leukemia; Cancer; Chemotherapy; Myeloid leukemia; Hepatocellular carcinoma; PI3K/AKT/mTOR pathway","score_opus":0.1574497299406017,"score_gpt":0.3932410952658096,"score_spread":0.2357913653252079,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010818649","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988803,0.0064986027,0.00088930305,0.0010904667,0.00065906474,0.0008032085,0.00009057227,0.000075729906,0.0010900463],"genre_scores_gemma":[0.99254113,0.00010650753,0.005471707,0.00044430658,0.00075536553,0.000041725547,0.00043056958,0.000028321941,0.00018038008],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986292,0.000070249094,0.00030546126,0.00039969353,0.00016207546,0.00043329404],"domain_scores_gemma":[0.99908745,0.00017643953,0.00014955687,0.00033789012,0.00009754412,0.00015111518],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010856194,0.00024400454,0.0004933346,0.00007588824,0.00009784572,0.000008721165,0.0001231492,0.00017651239,0.00021683594],"category_scores_gemma":[0.000046748755,0.00019958531,0.00017548265,0.000110921785,0.00008232514,0.000045313696,0.000029167775,0.00024475512,0.000029722345],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035585673,0.008304967,0.114518985,0.00031154283,0.00062328804,0.0005245323,0.01563633,0.0000974301,0.2754073,0.0005532237,0.05712597,0.52333784],"study_design_scores_gemma":[0.07977922,0.007445407,0.23433697,0.00044124108,0.002498602,0.00023223618,0.002815313,0.028573882,0.09160051,0.004997068,0.5457243,0.0015552504],"about_ca_topic_score_codex":0.000046608417,"about_ca_topic_score_gemma":0.000008171823,"teacher_disagreement_score":0.5217826,"about_ca_system_score_codex":0.0015950028,"about_ca_system_score_gemma":0.0006869488,"threshold_uncertainty_score":0.8138853},"labels":[],"label_agreement":null},{"id":"W2012153991","doi":"10.1038/sj.leu.2404609","title":"Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies","year":2007,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":358,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Terry Fox Research Institute; BC Cancer Agency","funders":"","keywords":"CD38; Imatinib mesylate; Myeloid leukemia; Stem cell; Haematopoiesis; Cancer research; Biology; CD34; Myeloid; breakpoint cluster region; Leukemia; Imatinib; Immunology; Cell biology; Receptor; Genetics","score_opus":0.012187320014432932,"score_gpt":0.25831486054924735,"score_spread":0.24612754053481442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012153991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9806381,0.007542918,0.00081501034,0.00041414416,0.00051781913,0.0017847143,0.00009549234,0.00034398562,0.0078478055],"genre_scores_gemma":[0.9699125,0.00030801893,0.006044204,0.0006018627,0.0004496383,0.000073974785,0.00007819103,0.0001489406,0.02238264],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99600255,0.000114863615,0.00094598916,0.00089743384,0.000900808,0.0011383329],"domain_scores_gemma":[0.9968264,0.0005161409,0.00037743527,0.0014054901,0.00033938608,0.00053511886],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007028898,0.0006517421,0.0010232087,0.00039374077,0.000174016,0.000041323743,0.00054901355,0.00047202758,0.00020447212],"category_scores_gemma":[0.00010274552,0.0005784337,0.0003080234,0.00094192766,0.00022664422,0.00017593878,0.00022327233,0.00069915113,0.00014317056],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026513906,0.00018428404,0.0069752033,0.0011132674,0.00078362576,0.0006361609,0.0034756889,0.00054780196,0.92557526,0.00065558474,0.022189304,0.035212435],"study_design_scores_gemma":[0.007052118,0.00062307925,0.060014635,0.0007790599,0.00017806645,0.00006704868,0.0006852782,0.00006251096,0.8931037,0.000102897335,0.036739282,0.0005923291],"about_ca_topic_score_codex":0.0010237314,"about_ca_topic_score_gemma":0.0021015422,"teacher_disagreement_score":0.05303943,"about_ca_system_score_codex":0.016331285,"about_ca_system_score_gemma":0.0035656355,"threshold_uncertainty_score":0.9996667},"labels":[],"label_agreement":null},{"id":"W2012962381","doi":"10.1056/nejmoa040258","title":"Granulocyte–Macrophage Progenitors as Candidate Leukemic Stem Cells in Blast-Crisis CML","year":2004,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1489,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; National Heart, Lung, and Blood Institute","keywords":"Chronic myelogenous leukemia; Stem cell; Blast Crisis; Haematopoiesis; Progenitor cell; Medicine; Cancer research; Leukemia; Immunology; Cell biology; Biology","score_opus":0.01126369969363871,"score_gpt":0.26346980045142127,"score_spread":0.25220610075778255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012962381","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889012,0.0039841845,0.000099981204,0.004796507,0.001018702,0.00040145658,0.0000044984686,0.000025541385,0.00076794054],"genre_scores_gemma":[0.9930159,0.0015403721,0.00044465423,0.0006884994,0.0030816838,0.0000039882443,0.000007562606,0.00004941729,0.0011679512],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99718875,0.000098189565,0.0010388488,0.00027938015,0.00090813416,0.00048669224],"domain_scores_gemma":[0.9981765,0.00012024293,0.0004551258,0.0003315404,0.00017110558,0.00074549345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075756334,0.0003438749,0.00095993123,0.0005242464,0.000053643136,0.000012059544,0.00021590567,0.00015071368,0.00025480494],"category_scores_gemma":[0.00010712917,0.00023003817,0.00015251982,0.00046736829,0.00012388088,0.00013599721,0.00003324752,0.0008101178,0.00007321334],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019939268,0.0019089718,0.057059027,0.0010831811,0.0023966704,0.07418145,0.024570303,0.003041115,0.2694018,0.00022759513,0.044723447,0.50146717],"study_design_scores_gemma":[0.67310226,0.013031333,0.008976895,0.0047900137,0.001871352,0.02903491,0.0023809576,0.00006081959,0.20643781,0.0014210858,0.058193542,0.0006989927],"about_ca_topic_score_codex":0.0022747768,"about_ca_topic_score_gemma":0.00024575982,"teacher_disagreement_score":0.653163,"about_ca_system_score_codex":0.0021534294,"about_ca_system_score_gemma":0.0020484282,"threshold_uncertainty_score":0.93806845},"labels":[],"label_agreement":null},{"id":"W2013525273","doi":"10.1016/s0301-472x(00)00345-3","title":"Spontaneous reactivation of primitive quiescent cml cells is associated with upregulation of IL-3 expression","year":2000,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Downregulation and upregulation; Biology; Cancer research; Expression (computer science); Cell biology; Genetics; Gene; Computer science","score_opus":0.010610954511631533,"score_gpt":0.262727232714071,"score_spread":0.2521162782024395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013525273","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995533,0.00041392233,0.000012086277,0.000041017964,0.000040697763,0.0005281197,0.000020166466,0.000033293752,0.0033777324],"genre_scores_gemma":[0.9984895,0.00001538001,0.00056698924,0.00005049575,0.000012987806,0.000027596168,0.000116006195,0.000023413311,0.00069761585],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99885917,0.000059364414,0.00036447463,0.00025542674,0.00027710607,0.00018443425],"domain_scores_gemma":[0.99929464,0.00008033001,0.00025610893,0.00024786073,0.00006031591,0.00006072542],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000044734257,0.00016646164,0.00047542257,0.00006957545,0.00003199211,0.0000016869653,0.00004977688,0.0001445176,0.0013891306],"category_scores_gemma":[0.000012301065,0.00013727395,0.000065497,0.00010701027,0.0001336105,0.0000691128,0.000019370305,0.00008070097,0.000015587355],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002507605,0.0017406866,0.0022180493,0.00006565203,0.00018487294,0.0003020646,0.0036118014,0.000011044314,0.9875772,0.00038938806,0.0003518567,0.001039808],"study_design_scores_gemma":[0.0037700036,0.00095025887,0.004711783,0.0004472735,0.0000524193,0.0008493019,0.000550858,0.00010641452,0.9883676,0.000011080096,0.000083180945,0.00009981485],"about_ca_topic_score_codex":0.00007881111,"about_ca_topic_score_gemma":0.0000036526183,"teacher_disagreement_score":0.0030609434,"about_ca_system_score_codex":0.0005600032,"about_ca_system_score_gemma":0.000110543355,"threshold_uncertainty_score":0.99952376},"labels":[],"label_agreement":null},{"id":"W2013658560","doi":"10.1038/leu.2013.151","title":"Bcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic target","year":2013,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"National Cancer Institute; National Institutes of Health; Medical College of Wisconsin; National Heart, Lung, and Blood Institute; Sundhed og Sygdom, Det Frie Forskningsråd; Leukemia and Lymphoma Society","keywords":"Progenitor cell; Chronic myelogenous leukemia; Cancer research; Haematopoiesis; Bcl-xL; Bone marrow; Biology; Stem cell; CD34; Apoptosis; Stromal cell; Leukemia; Immunology; Medicine; Programmed cell death; Cell biology; Genetics","score_opus":0.03132524855511329,"score_gpt":0.3029187906383001,"score_spread":0.27159354208318676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013658560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9692618,0.0077915923,0.0061408374,0.006740231,0.0003764195,0.008980413,0.00010522413,0.000127069,0.00047637298],"genre_scores_gemma":[0.9043563,0.00047555382,0.057080936,0.0020138181,0.000393607,0.001105716,0.000203195,0.00012721929,0.034243643],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975355,0.00002731941,0.00060245005,0.0007044731,0.0003670437,0.00076321047],"domain_scores_gemma":[0.99819225,0.00015708659,0.00030044775,0.0006702551,0.00020586234,0.00047412014],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001730168,0.00036885316,0.0006607531,0.0000576466,0.00016461789,0.000043957618,0.00018122297,0.0001604787,0.00031531695],"category_scores_gemma":[0.00010118856,0.00028455397,0.00017012031,0.0001729347,0.000107118685,0.00019370108,0.000112103495,0.00012549908,0.000041203988],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003543362,0.0005896509,0.13270995,0.004476577,0.0015174715,0.00005133013,0.002994613,0.00012112735,0.004824227,0.0003366056,0.71857905,0.130256],"study_design_scores_gemma":[0.08215688,0.002354818,0.18109725,0.014607656,0.0023067633,0.00010596234,0.00082372985,0.07841592,0.06276251,0.0178089,0.5550156,0.0025440047],"about_ca_topic_score_codex":0.0001984363,"about_ca_topic_score_gemma":0.000011922101,"teacher_disagreement_score":0.16356348,"about_ca_system_score_codex":0.0011044954,"about_ca_system_score_gemma":0.0017104198,"threshold_uncertainty_score":0.99996066},"labels":[],"label_agreement":null},{"id":"W2013988353","doi":"10.1080/146532402320775991","title":"CML leukapheresis products can be enriched for CD34+ cells and simultaneously depleted of CD15+ cells using a simple Ab cocktail","year":2002,"lang":"en","type":"article","venue":"Cytotherapy","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute","funders":"National Cancer Institute","keywords":"Leukapheresis; CD34; CD15; Progenitor cell; Chemistry; Population; Andrology; Cell culture; Molecular biology; Immunology; Stem cell; Biology; Cell biology; Medicine","score_opus":0.04399780862946051,"score_gpt":0.2765147117626303,"score_spread":0.2325169031331698,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013988353","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952517,0.0017692135,0.00023972536,0.00044855813,0.000098917815,0.0017797701,0.00013842672,0.0000850432,0.00018864207],"genre_scores_gemma":[0.98979515,0.00063243794,0.0064648152,0.0006597747,0.00018186383,0.0000461177,0.00003400636,0.000117743766,0.0020680875],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981771,0.00005477048,0.00043448922,0.00055210653,0.00028722835,0.00049428875],"domain_scores_gemma":[0.99846625,0.00032878626,0.00022529325,0.0005838722,0.00021416986,0.00018160541],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000120227705,0.000342133,0.000657566,0.00012461345,0.0001196392,0.000016282234,0.00011942382,0.00016787698,0.00036533715],"category_scores_gemma":[0.000094036,0.00030612585,0.000121600344,0.0003110954,0.00011965003,0.00005301917,0.00002375211,0.00012676929,0.0000064708124],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046164618,0.00041912208,0.00090946653,0.0003832885,0.000370631,0.00005613448,0.0017287451,0.00015645305,0.9848158,0.000011059932,0.0035537446,0.00713391],"study_design_scores_gemma":[0.02276218,0.0017547915,0.00033112624,0.0001574022,0.00050295447,0.00012963316,0.0005677934,0.024212738,0.9200653,0.00011898089,0.028757827,0.0006392768],"about_ca_topic_score_codex":0.0003576487,"about_ca_topic_score_gemma":0.000091303045,"teacher_disagreement_score":0.0647505,"about_ca_system_score_codex":0.0005570584,"about_ca_system_score_gemma":0.00024277721,"threshold_uncertainty_score":0.9999391},"labels":[],"label_agreement":null},{"id":"W2014205306","doi":"10.1016/j.cancergencyto.2006.04.012","title":"Philadelphia-negative clonal hematopoiesis following imatinib therapy in patients with chronic myeloid leukemia: a report of nine cases and analysis of predictive factors","year":2006,"lang":"en","type":"article","venue":"Cancer Genetics and Cytogenetics","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; BC Cancer Agency; Leukemia & Lymphoma Society of Canada","funders":"","keywords":"Imatinib mesylate; Biology; Trisomy 8; Myeloid leukemia; Monosomy; Imatinib; Internal medicine; Cumulative incidence; Chromosome 7 (human); Incidence (geometry); Aneuploidy; Chromosomal translocation; Trisomy; Immunology; clone (Java method); Gastroenterology; Karyotype; Genetics; Medicine; Cohort; Chromosome","score_opus":0.014961633314246449,"score_gpt":0.2673222327827034,"score_spread":0.25236059946845696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014205306","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912156,0.007740455,0.00007056266,0.000030469502,0.000033371543,0.00058065815,0.00027586255,0.000008863294,0.00004414936],"genre_scores_gemma":[0.99650455,0.0023296496,0.0008195215,0.000013692431,0.000036222496,0.000043272346,0.00018583536,0.000033054825,0.000034192795],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982488,0.000030560393,0.00062352326,0.0004161312,0.00042260851,0.00025838293],"domain_scores_gemma":[0.99883497,0.00014385412,0.00039855824,0.00031505627,0.00021065201,0.0000969092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007544729,0.0002888184,0.0008197623,0.00029047416,0.00004476755,0.000008514924,0.0000611288,0.0001235373,0.000033524495],"category_scores_gemma":[0.00003120481,0.0002279438,0.00012747214,0.0006446394,0.00023811308,0.000029235354,0.00005203412,0.00010957014,4.5964317e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003111907,0.00016754113,0.9924943,0.00009780579,0.0018894651,0.000057984147,0.00046732248,0.0023797248,0.0011709698,0.0000041844887,0.000012879653,0.0009466551],"study_design_scores_gemma":[0.0055493014,0.0014309247,0.95480597,0.00015594954,0.0018918953,0.000015037781,0.00011682692,0.0010649511,0.034731686,0.000019867348,0.00003085906,0.00018672431],"about_ca_topic_score_codex":0.0012169253,"about_ca_topic_score_gemma":0.00083556195,"teacher_disagreement_score":0.0376883,"about_ca_system_score_codex":0.0005729814,"about_ca_system_score_gemma":0.0006387855,"threshold_uncertainty_score":0.9295278},"labels":[],"label_agreement":null},{"id":"W2014706039","doi":"10.1016/j.jmb.2014.04.014","title":"Structural Mechanisms Determining Inhibition of the Collagen Receptor DDR1 by Selective and Multi-Targeted Type II Kinase Inhibitors","year":2014,"lang":"en","type":"article","venue":"Journal of Molecular Biology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; National Cancer Institute; National Institutes of Health; Ontario Ministry of Economic Development and Innovation; Diamond Light Source; Wellcome Trust","keywords":"DDR1; Chemistry; Collagen receptor; Kinase; Biochemistry; Receptor; Pharmacology; Biology; Receptor tyrosine kinase; Integrin","score_opus":0.00838409365618123,"score_gpt":0.2597535798683978,"score_spread":0.25136948621221655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014706039","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99778414,0.00063921325,0.0008780014,0.00022053263,0.00025375144,0.00018623106,0.000008232696,0.0000050544095,0.000024822313],"genre_scores_gemma":[0.99404705,0.000025657375,0.005607484,0.00020983275,0.0000568731,0.0000016223719,0.00001163908,0.000014846039,0.00002497217],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990481,0.00019835396,0.00034043458,0.00013500295,0.00012522939,0.00015284492],"domain_scores_gemma":[0.9991224,0.000043528904,0.00042283174,0.00012210388,0.00021878067,0.000070369824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002048217,0.00012824427,0.00031773993,0.00007911309,0.00006891958,0.0000036155077,0.000060892413,0.00014905962,0.00002485599],"category_scores_gemma":[0.00039200377,0.00008200325,0.000088939705,0.00014444595,0.00009521842,0.000027930653,0.00006534531,0.0001570157,8.231005e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001485038,0.000033747358,0.0018528542,0.0000135342325,0.0001242229,0.00001105762,0.0001615751,0.0000062020813,0.9938698,0.00004886563,0.00020152076,0.0035281607],"study_design_scores_gemma":[0.0036788743,0.002380895,0.0019883409,0.00009877537,0.00013862357,0.0002740174,0.00006991118,0.00032498158,0.99045247,0.000330276,0.00018242163,0.00008040431],"about_ca_topic_score_codex":0.000013502558,"about_ca_topic_score_gemma":0.0000033420054,"teacher_disagreement_score":0.004729483,"about_ca_system_score_codex":0.00019766571,"about_ca_system_score_gemma":0.00016553533,"threshold_uncertainty_score":0.33439958},"labels":[],"label_agreement":null},{"id":"W2015018636","doi":"10.1182/blood-2014-12-615757","title":"IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":224,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"National Institutes of Health; National Cancer Institute; National Heart, Lung, and Blood Institute; St. Baldrick's Foundation","keywords":"Medicine; Oncology; Internal medicine; Cohort","score_opus":0.01667898044994222,"score_gpt":0.21560553882389832,"score_spread":0.19892655837395612,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015018636","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99575067,0.0027665112,0.0000046287805,0.00012786887,0.00019926539,0.0006637211,0.000084501946,0.00008543419,0.00031739005],"genre_scores_gemma":[0.99834466,0.00059608807,0.0004624853,0.00019448456,0.00011684981,0.000040516647,0.0000799882,0.000044246997,0.00012067886],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980645,0.000062951585,0.00031960692,0.0004563494,0.0007157613,0.00038078445],"domain_scores_gemma":[0.9988036,0.00004974369,0.00011221702,0.00035184083,0.00025700865,0.00042559538],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024986645,0.00030345228,0.0004081318,0.00009632327,0.00006304536,0.00003720094,0.00007880512,0.00014070804,0.000009908802],"category_scores_gemma":[0.00015501164,0.00024714318,0.000057048146,0.000074278345,0.000075412565,0.00014300479,0.000066717985,0.00018859518,0.00003228211],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009157292,0.0016966067,0.98929596,0.000314682,0.00093789643,0.00017337092,0.0015125879,0.0000018975225,0.0023766672,0.000028218468,0.00037009595,0.0023762651],"study_design_scores_gemma":[0.02905807,0.0022167638,0.9610864,0.00038810112,0.0016276764,0.00008519724,0.000033333683,0.000007859786,0.0045170123,0.000055128145,0.0006541516,0.00027032083],"about_ca_topic_score_codex":0.002207936,"about_ca_topic_score_gemma":0.00015419106,"teacher_disagreement_score":0.028209599,"about_ca_system_score_codex":0.00024493106,"about_ca_system_score_gemma":0.00026941882,"threshold_uncertainty_score":0.9999981},"labels":[],"label_agreement":null},{"id":"W2015551314","doi":"10.1007/s11010-008-9828-z","title":"Expanding the chemical diversity of CK2 inhibitors","year":2008,"lang":"en","type":"article","venue":"Molecular and Cellular Biochemistry","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institut National Du Cancer; Ligue Contre le Cancer; Institute of Cancer Research; Institut National de la Santé et de la Recherche Médicale","keywords":"Druggability; Computational biology; Docking (animal); Chemistry; Chemical biology; Chemical library; Structure–activity relationship; Chemical genetics; Context (archaeology); High-throughput screening; In vitro; Drug discovery; Biochemistry; Small molecule; Combinatorial chemistry; Biology; Gene; Medicine","score_opus":0.008903444977764286,"score_gpt":0.2130198526326273,"score_spread":0.204116407654863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015551314","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964913,0.0014658846,0.00010387556,0.00015068939,0.000021535132,0.00009527483,0.0000034028683,0.0000161062,0.001651942],"genre_scores_gemma":[0.9994789,0.000020792302,0.00012716922,0.00007887386,0.00004486815,0.000003028298,0.000030474419,0.000009639982,0.00020628737],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992937,0.000010837051,0.00012425098,0.00019303615,0.00021404141,0.0001641777],"domain_scores_gemma":[0.99953914,0.000014574211,0.00004643672,0.0002661204,0.000028247845,0.00010545816],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005416078,0.000113370465,0.00015902736,0.000014502753,0.000107975495,0.0000027592876,0.000074305055,0.000096010524,0.000027898363],"category_scores_gemma":[0.000032939937,0.00008495194,0.000102866135,0.00007999504,0.00021675556,0.000010165266,0.00020901945,0.00012353974,0.0000024301578],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000031889922,0.000059338447,0.014947126,0.000072605966,0.000067402405,0.000238721,0.0001172194,2.1034815e-7,0.9840564,0.000008153175,0.00026241725,0.00013848719],"study_design_scores_gemma":[0.0010426068,0.000025677602,0.00019971798,0.00003982847,0.000091555325,0.00021173467,0.0001058676,0.0000071206005,0.9981314,0.000018145547,0.00005020954,0.000076155375],"about_ca_topic_score_codex":0.000026879065,"about_ca_topic_score_gemma":4.5486956e-8,"teacher_disagreement_score":0.014747407,"about_ca_system_score_codex":0.00009975024,"about_ca_system_score_gemma":0.000074375086,"threshold_uncertainty_score":0.34642395},"labels":[],"label_agreement":null},{"id":"W2015564512","doi":"10.1007/s10549-010-1241-0","title":"Expression of Abl interactor 1 and its prognostic significance in breast cancer: a tissue-array-based investigation","year":2010,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Ontario Institute for Cancer Research; University of Manitoba","funders":"Canadian Institutes of Health Research","keywords":"Tissue microarray; Immunohistochemistry; Breast cancer; Protein kinase B; Cancer research; Biology; Cancer; Pathology; Oncology; Medicine; Internal medicine; Signal transduction; Genetics","score_opus":0.042785451384319106,"score_gpt":0.36029989975908927,"score_spread":0.31751444837477016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015564512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99265695,0.0016810533,0.0000017345111,0.0034955866,0.000066635694,0.0015294541,0.00047541343,0.00002364434,0.00006954413],"genre_scores_gemma":[0.99687415,0.0010612713,0.00022795735,0.000030450943,0.00012764572,0.0013523039,0.00005101457,0.000030121204,0.00024506933],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99818283,0.00009503308,0.00028395536,0.0005206662,0.0004592757,0.0004582403],"domain_scores_gemma":[0.99875945,0.00019974959,0.00009428252,0.00027039245,0.00026402008,0.00041211353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018921238,0.00024043626,0.00038236828,0.00027410802,0.00009191494,0.000030304935,0.00007353579,0.000112285816,0.00036240113],"category_scores_gemma":[0.000037594597,0.00017586158,0.00003168856,0.0003337531,0.00025940087,0.00013276744,0.000040050734,0.0003175183,0.000005943516],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019727848,0.0006689936,0.45898443,0.00032062762,0.00007094243,0.000077606055,0.00048571263,0.000005698576,0.4949542,0.000017970122,0.00007442386,0.042366605],"study_design_scores_gemma":[0.0077681066,0.00085276103,0.6934063,0.0014410481,0.000063904,0.00014785788,0.00008559917,0.00030253458,0.2954372,0.00004429708,0.000294917,0.00015551824],"about_ca_topic_score_codex":0.010335864,"about_ca_topic_score_gemma":0.0029679756,"teacher_disagreement_score":0.23442185,"about_ca_system_score_codex":0.0009737824,"about_ca_system_score_gemma":0.0014286424,"threshold_uncertainty_score":0.9962544},"labels":[],"label_agreement":null},{"id":"W2017217800","doi":"10.1080/10428190400025120","title":"Isolated central nervous system relapse in patients with chronic myeloid leukemia on imatinib mesylate","year":2005,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; Montreal Children's Hospital","funders":"","keywords":"Myeloid leukemia; Imatinib mesylate; Medicine; Imatinib; Central nervous system; Oncology; Internal medicine; Cancer research","score_opus":0.005834918914286738,"score_gpt":0.20399632849166588,"score_spread":0.19816140957737916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017217800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97019756,0.003131288,0.000029761004,0.008574533,0.001687854,0.0060214703,0.00062882295,0.0015018687,0.008226869],"genre_scores_gemma":[0.8778684,0.0012341203,0.00079843553,0.0904967,0.007321454,0.0010204187,0.008183898,0.0017473559,0.011329198],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9833366,0.00064446876,0.0033302435,0.004479092,0.0032210937,0.0049884985],"domain_scores_gemma":[0.99179626,0.0006446823,0.0019211073,0.0037739933,0.0004857404,0.0013782292],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.00052344496,0.00418097,0.0048975297,0.0018668688,0.00067700754,0.00042397075,0.0013205615,0.0052201226,0.00030081114],"category_scores_gemma":[0.00014192736,0.0035846774,0.0009545472,0.0017587444,0.00083249656,0.0007295773,0.00053142884,0.0030495909,0.0008435651],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.019446297,0.0015147334,0.037484974,0.011507095,0.0057351543,0.038244646,0.0023206992,0.0018940178,0.00016813139,0.0002748321,0.5117099,0.36969948],"study_design_scores_gemma":[0.17167877,0.007688094,0.3673608,0.016694684,0.0035615168,0.004925722,0.00020299185,0.019506756,0.00050070806,0.000032700475,0.4010327,0.0068145604],"about_ca_topic_score_codex":0.004690653,"about_ca_topic_score_gemma":0.00036316278,"teacher_disagreement_score":0.3628849,"about_ca_system_score_codex":0.2320173,"about_ca_system_score_gemma":0.02525317,"threshold_uncertainty_score":0.9999344},"labels":[],"label_agreement":null},{"id":"W2020921982","doi":"10.1016/j.leukres.2012.06.012","title":"Nilotinib and imatinib inhibit cytarabine cellular uptake: Implications for combination therapy","year":2012,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec; Université Laval; Hôtel-Dieu de Québec","funders":"","keywords":"Nilotinib; Cytarabine; Imatinib; Myeloid leukemia; Medicine; Pharmacology; Tyrosine-kinase inhibitor; Nucleoside analogue; Tyrosine kinase; Oncology; Internal medicine; Nucleoside; Chemistry; Receptor","score_opus":0.13274411959298354,"score_gpt":0.4060545935447574,"score_spread":0.2733104739517739,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020921982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864324,0.0024227684,0.0003988378,0.0040032887,0.00008512018,0.002588132,0.00003594868,0.000094128525,0.0039393976],"genre_scores_gemma":[0.9909422,0.0005638235,0.0028701874,0.000199913,0.0003588771,0.00082936726,0.0003072442,0.00006299715,0.003865427],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99785894,0.00011818824,0.00034659298,0.00037828297,0.00046446413,0.00083353155],"domain_scores_gemma":[0.9980321,0.00053190073,0.00007125671,0.0005806553,0.0004102468,0.0003738189],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001509736,0.00019547663,0.00030178772,0.00026275322,0.00034411935,0.0000469626,0.00013657527,0.00017431841,0.00014343818],"category_scores_gemma":[0.00038331325,0.0001674581,0.000084724634,0.0004417995,0.0001996149,0.00021159853,0.000089752706,0.0004318388,0.0001116112],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018011103,0.0024948842,0.12474737,0.0008282859,0.00053689355,0.000013906746,0.0036665157,0.000006066508,0.4948748,0.066439986,0.041715417,0.26287475],"study_design_scores_gemma":[0.048433416,0.0030050003,0.56925017,0.0002976095,0.00015779458,0.00023220919,0.0005603468,0.0024141376,0.17630912,0.008111158,0.19049072,0.0007383207],"about_ca_topic_score_codex":0.00013225306,"about_ca_topic_score_gemma":0.0000052999544,"teacher_disagreement_score":0.44450277,"about_ca_system_score_codex":0.0022210074,"about_ca_system_score_gemma":0.00078188506,"threshold_uncertainty_score":0.6828743},"labels":[],"label_agreement":null},{"id":"W2020949922","doi":"10.3747/co.v18i4.953","title":"E-Manuscript Article Summaries","year":2011,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Health Science Center, University of Tennessee","keywords":"Medicine; Data science; Information retrieval; Computational biology; Computer science; Biology","score_opus":0.1897963577858121,"score_gpt":0.3832508126657494,"score_spread":0.1934544548799373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020949922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9239196,0.0020676241,0.000086601685,0.00039879535,0.0015234087,0.00032656264,0.000006344235,0.00013487723,0.07153618],"genre_scores_gemma":[0.9967762,0.00018139767,0.001137639,0.00022735247,0.00023606258,0.000057424153,0.00003079119,0.000018278093,0.0013348365],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99907947,0.000043691856,0.00021224428,0.00023022082,0.000119650154,0.00031474986],"domain_scores_gemma":[0.9993706,0.000039988605,0.00005914685,0.00029198176,0.00006645799,0.00017182413],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00009763629,0.00012448257,0.0002674591,0.000062915686,0.00004849254,0.0000041031553,0.00007677476,0.00008898698,0.0024363578],"category_scores_gemma":[0.000097330805,0.00010325439,0.00007506014,0.00010460733,0.00014583764,0.000058292997,0.000062320796,0.0002028534,0.0011852988],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00074250315,0.003511096,0.43419752,0.00014879266,0.0002246285,0.00044115732,0.0045163496,2.1035473e-7,0.0014914249,0.0050458782,0.07215145,0.477529],"study_design_scores_gemma":[0.0055223433,0.0011703656,0.18576811,0.000056403293,0.00025579912,0.00020269061,0.00027024111,0.00012399637,0.006938363,0.0010812029,0.79844177,0.00016873099],"about_ca_topic_score_codex":0.000050379396,"about_ca_topic_score_gemma":0.00003928819,"teacher_disagreement_score":0.7262903,"about_ca_system_score_codex":0.0006874452,"about_ca_system_score_gemma":0.00035097846,"threshold_uncertainty_score":0.9995924},"labels":[],"label_agreement":null},{"id":"W2021904192","doi":"10.1074/jbc.m103100200","title":"TEL-JAK2 Mediates Constitutive Activation of the Phosphatidylinositol 3′-Kinase/Protein Kinase B Signaling Pathway","year":2001,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network; University of Toronto; Ontario Institute for Cancer Research","funders":"Canadian Institutes of Health Research; Cancer Research Society","keywords":"Tyrosine phosphorylation; Tyrosine kinase; MAP2K7; Biology; Cell biology; Cyclin-dependent kinase 2; MAP kinase kinase kinase; Phosphorylation; Protein kinase B; Molecular biology; Signal transduction; Cancer research; Chemistry; Protein kinase A","score_opus":0.02379234659081998,"score_gpt":0.2573389748764089,"score_spread":0.23354662828558892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2021904192","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968951,0.0006626654,0.000052939347,0.0004928281,0.00007112509,0.00020143788,0.000010485207,0.000012282306,0.0016011697],"genre_scores_gemma":[0.9988107,0.000085707725,0.00049601204,0.00010854281,0.00032291922,0.000005539986,0.000010092309,0.000007544675,0.0001529255],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986744,0.000047397403,0.0005743868,0.00016195029,0.00033861253,0.00020324759],"domain_scores_gemma":[0.99850726,0.00020828763,0.0006921714,0.00019647041,0.00025482837,0.0001409879],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024986858,0.00017852837,0.00042183688,0.000022325221,0.00006671945,0.000008361951,0.0001898456,0.00023330524,0.00040065713],"category_scores_gemma":[0.00096444343,0.00009519298,0.0002497891,0.00019208381,0.00028734622,0.000058801503,0.00005541946,0.00043674075,0.0000031888467],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047142213,0.00030126914,0.025399113,0.000059143924,0.00012261551,0.00016753572,0.00005006538,0.000021172029,0.9713418,0.000019224568,0.00006059711,0.0019860321],"study_design_scores_gemma":[0.0022213142,0.000251477,0.0058510243,0.00057397655,0.000066327244,0.00030239264,0.00019172607,0.000017560007,0.9893849,0.00017407697,0.0008715848,0.00009366964],"about_ca_topic_score_codex":0.000010002801,"about_ca_topic_score_gemma":1.6548252e-7,"teacher_disagreement_score":0.019548088,"about_ca_system_score_codex":0.00040885698,"about_ca_system_score_gemma":0.00046415735,"threshold_uncertainty_score":0.43869147},"labels":[],"label_agreement":null},{"id":"W2023142527","doi":"10.1159/000206326","title":"Chronic Myeloid Leukemia with an Unusual Simple Variant Translocation: t(22;22)(q13;q11)","year":2009,"lang":"zh","type":"article","venue":"Acta Haematologica","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Chromosomal translocation; Myeloid leukemia; Metaphase; Biology; Leukemia; Simple (philosophy); Genetics; Molecular biology; Cancer research; Chromosome; Gene; Philosophy","score_opus":0.0205351748147362,"score_gpt":0.2769190052746965,"score_spread":0.25638383045996027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2023142527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93422663,0.011875708,0.0010356462,0.008508932,0.0005927771,0.0039039883,0.00016144212,0.0010711714,0.038623717],"genre_scores_gemma":[0.99080867,0.0019798097,0.0018683663,0.0016208078,0.0012343538,0.00014722865,0.0008295672,0.00014739185,0.0013638303],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9925154,0.00047557967,0.0014917258,0.0020855193,0.0012943179,0.002137453],"domain_scores_gemma":[0.9949401,0.0003730167,0.0007033197,0.0025467414,0.00032256948,0.0011142745],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.00061439426,0.0014618599,0.0023313367,0.00033299116,0.0006744791,0.00019867628,0.0010319463,0.001094399,0.0038049063],"category_scores_gemma":[0.00019421834,0.0011138632,0.00036609964,0.0011342311,0.0005614195,0.0007477464,0.00010086911,0.0013312589,0.0007922282],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.021805232,0.015501735,0.012108056,0.0045769094,0.0098906765,0.08844125,0.016449502,0.0017496601,0.03114951,0.11736686,0.05205479,0.62890583],"study_design_scores_gemma":[0.18373592,0.1684531,0.23576309,0.010817064,0.015359941,0.090600364,0.0074299034,0.03051397,0.051793512,0.025251938,0.16496085,0.015320351],"about_ca_topic_score_codex":0.00054111483,"about_ca_topic_score_gemma":0.00039731877,"teacher_disagreement_score":0.6135855,"about_ca_system_score_codex":0.005662354,"about_ca_system_score_gemma":0.0059047714,"threshold_uncertainty_score":0.99998575},"labels":[],"label_agreement":null},{"id":"W2023450315","doi":"10.1182/blood-2008-07-169110","title":"Genetic variants in the candidate genes of the apoptosis pathway and susceptibility to chronic myeloid leukemia","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Single-nucleotide polymorphism; Biology; Myeloid leukemia; Haplotype; Allele; Genetics; Immunology; SNP; Cancer research; Genotype; Gene","score_opus":0.010089940063186628,"score_gpt":0.2385421577308934,"score_spread":0.2284522176677068,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2023450315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959461,0.0014435612,0.0000075936514,0.00087813113,0.000050857117,0.0008809284,0.000018429047,0.000015525555,0.0007588836],"genre_scores_gemma":[0.9986312,0.00021662554,0.0003571143,0.00053884805,0.00011094119,0.000029063885,0.0000042921797,0.000012184187,0.00009977092],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99862134,0.00011454687,0.00030790656,0.0003329587,0.00031330474,0.00030991272],"domain_scores_gemma":[0.9989252,0.00006506036,0.00007791047,0.0008083832,0.00003547504,0.00008793805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027768494,0.00017965912,0.00029976817,0.00005683976,0.000068708636,0.000015021563,0.00025165518,0.00008343449,0.000042035055],"category_scores_gemma":[0.00008180362,0.00010112141,0.000073349496,0.00033310198,0.00007464646,0.000029777128,0.00007058396,0.00016244604,0.000009222069],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023996978,0.0017066911,0.52652353,0.000312726,0.00028921352,0.00009009843,0.0048496784,0.00012323739,0.35161066,0.00019508312,0.00042741664,0.11363171],"study_design_scores_gemma":[0.004583905,0.0005949556,0.9300481,0.00012362543,0.00019433365,0.00007319792,0.000094134346,0.00004501512,0.06360435,0.00011180439,0.00041715012,0.00010942196],"about_ca_topic_score_codex":0.0006852781,"about_ca_topic_score_gemma":0.0008255937,"teacher_disagreement_score":0.4035246,"about_ca_system_score_codex":0.00050243706,"about_ca_system_score_gemma":0.0007281044,"threshold_uncertainty_score":0.41236115},"labels":[],"label_agreement":null},{"id":"W2024639674","doi":"10.1182/blood-2007-03-078303","title":"High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2–dependent suppression of C/EBPα-driven myeloid differentiation","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"National Cancer Institute; Pfizer","keywords":"Biology; MAPK/ERK pathway; Phosphorylation; Cancer research; Progenitor cell; Chronic myelogenous leukemia; Myeloid; breakpoint cluster region; Molecular biology; K562 cells; Haematopoiesis; ABL; Cell biology; Stem cell; Leukemia; Tyrosine kinase; Signal transduction; Immunology; Receptor; Biochemistry","score_opus":0.0247668264678103,"score_gpt":0.2709574113211005,"score_spread":0.2461905848532902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024639674","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99465185,0.00046548553,0.0014472955,0.0006437796,0.00036476043,0.002017394,0.00018194108,0.000031152784,0.00019635448],"genre_scores_gemma":[0.99717265,0.000038207603,0.0011214387,0.00005654122,0.00022244752,0.00008164845,0.000038492482,0.000036342433,0.0012322263],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981464,0.00006380829,0.00056748564,0.0002912537,0.00061089045,0.00032013218],"domain_scores_gemma":[0.99806345,0.00031006674,0.0005674596,0.00080062065,0.00018404631,0.00007437964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037005788,0.00021196918,0.00042402433,0.000071293594,0.00012510277,0.000008248718,0.00029185062,0.00016636391,0.00015503974],"category_scores_gemma":[0.00023949398,0.00011659841,0.00023059598,0.00017278596,0.00009996484,0.00006166986,0.00013259974,0.00017002375,0.0000057440348],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00092882663,0.0021671825,0.043801516,0.0007491043,0.0010545595,0.000019442767,0.0011058347,0.000068549205,0.9340532,0.00070058357,0.0006516038,0.014699642],"study_design_scores_gemma":[0.008680732,0.00024468044,0.32056808,0.00043895154,0.0006208476,0.000013428411,0.00018034076,0.00007680885,0.6687374,0.00016296115,0.00018988298,0.0000858936],"about_ca_topic_score_codex":0.00021056848,"about_ca_topic_score_gemma":0.00013813253,"teacher_disagreement_score":0.27676657,"about_ca_system_score_codex":0.00024660976,"about_ca_system_score_gemma":0.00019688683,"threshold_uncertainty_score":0.4754745},"labels":[],"label_agreement":null},{"id":"W2025239375","doi":"10.1042/bj3480063","title":"Exon-skipping in BCR/ABL is induced by ABL exon 2","year":2000,"lang":"en","type":"article","venue":"Biochemical Journal","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Exon; Minigene; ABL; Biology; breakpoint cluster region; Exon skipping; Molecular biology; RNA splicing; Fusion gene; Philadelphia chromosome; Tandem exon duplication; Alternative splicing; Cancer research; Genetics; Gene; Chromosomal translocation; Tyrosine kinase; RNA","score_opus":0.01757248956401645,"score_gpt":0.27719979586944204,"score_spread":0.2596273063054256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025239375","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912781,0.0017380449,0.000008048736,0.002041144,0.00011029456,0.00017975156,0.000007447774,0.00003468756,0.004602496],"genre_scores_gemma":[0.99517286,0.0006569407,0.00070754497,0.0012259136,0.0005145663,0.000009313692,0.000024763198,0.00003538224,0.0016527144],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981469,0.000042571777,0.0005045377,0.0003239315,0.00044785027,0.00053418864],"domain_scores_gemma":[0.9991164,0.00004899477,0.00009705877,0.0002771037,0.000047470177,0.0004129344],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00019804004,0.00023963187,0.00038145517,0.00011255673,0.00006917967,0.000040980114,0.00016981334,0.00026499492,0.005221739],"category_scores_gemma":[0.000081553095,0.00020471982,0.00014963694,0.00026104416,0.00005105661,0.000101957485,0.00003372521,0.0008161802,0.00030821178],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036244295,0.0004975915,0.0034114849,0.000037875896,0.00012938878,0.00038877482,0.00044112024,6.54376e-7,0.8490708,0.000002735667,0.08944417,0.056212977],"study_design_scores_gemma":[0.021145133,0.0006315011,0.015785225,0.0014610947,0.00020936599,0.004242856,0.0002472918,0.00031006988,0.87493616,0.00023989036,0.08001177,0.000779664],"about_ca_topic_score_codex":0.000087265355,"about_ca_topic_score_gemma":0.0000017360486,"teacher_disagreement_score":0.05543331,"about_ca_system_score_codex":0.0013108985,"about_ca_system_score_gemma":0.00032300624,"threshold_uncertainty_score":0.9956876},"labels":[],"label_agreement":null},{"id":"W2025701448","doi":"10.1111/bjh.12339","title":"Chronic myeloid leukaemia presenting with isolated thrombocythaemia, a case revealing its stem cell biology","year":2013,"lang":"en","type":"letter","venue":"British Journal of Haematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Medical Research Council; Kræftens Bekæmpelse; Aarhus Universitetshospital","keywords":"Thrombocytosis; Stem cell; Myeloid; Vincristine; Anagrelide; Medicine; Progenitor cell; Haematopoiesis; Bone marrow; Immunology; Hematology; Internal medicine; Cyclophosphamide; Biology; Cancer research; Pathology; Essential thrombocythemia; Platelet; Chemotherapy","score_opus":0.019931176247564228,"score_gpt":0.2603717279615163,"score_spread":0.24044055171395207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025701448","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90293765,0.056372736,0.00019141607,0.036352847,0.0010952634,0.0015694301,0.000097446406,0.0001180299,0.0012651997],"genre_scores_gemma":[0.8431469,0.011381389,0.004549203,0.10632886,0.016498303,0.00022985395,0.00085988175,0.0011542519,0.015851365],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9940638,0.0006501902,0.002229288,0.0009219159,0.0005875467,0.0015472588],"domain_scores_gemma":[0.9943932,0.00054282736,0.0029486993,0.0007008229,0.0010407069,0.0003737021],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.000463461,0.0008789095,0.0037028482,0.00060096435,0.00026725768,0.00012879782,0.00055907335,0.0024153474,0.0007746527],"category_scores_gemma":[0.00010994212,0.00082153647,0.0005842487,0.00037484846,0.00038972398,0.000307799,0.00022171297,0.006462008,0.00018571167],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000076642646,0.00009240484,0.0002872571,0.0025491186,0.0012123269,0.7178897,0.000112931135,0.000012105515,0.00039364042,0.0000027875235,0.27444857,0.0029224958],"study_design_scores_gemma":[0.008238016,0.0014683031,0.000025889682,0.004195076,0.0016116132,0.9098111,0.00008952934,0.00021520838,0.0014889119,0.000024758987,0.07222106,0.00061053503],"about_ca_topic_score_codex":0.0008261607,"about_ca_topic_score_gemma":0.00014143475,"teacher_disagreement_score":0.2022275,"about_ca_system_score_codex":0.0022627271,"about_ca_system_score_gemma":0.0030799308,"threshold_uncertainty_score":0.99942356},"labels":[],"label_agreement":null},{"id":"W2026601287","doi":"10.1016/j.leukres.2005.04.020","title":"Treatment of elderly patients with acute lymphoblastic leukemia—Evidence for a benefit of imatinib in BCR-ABL positive patients","year":2005,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Imatinib; Imatinib mesylate; Internal medicine; Regimen; Induction chemotherapy; Induction therapy; Chemotherapy; Oncology; Gastroenterology; Surgery; Myeloid leukemia","score_opus":0.04490805009228664,"score_gpt":0.357904061476144,"score_spread":0.31299601138385735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026601287","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944593,0.0003207517,0.000051923336,0.00016395206,0.000039429924,0.003969366,0.0002898108,0.00002514594,0.00068036845],"genre_scores_gemma":[0.9931112,0.0002596642,0.004514362,0.000027041466,0.00007565653,0.0006157306,0.0003069208,0.00007784845,0.0010115637],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99565464,0.0001366966,0.0009120223,0.0007522488,0.0015479944,0.0009963816],"domain_scores_gemma":[0.9956029,0.0015581611,0.00031375486,0.0008202739,0.0014174397,0.0002874543],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003463197,0.00041516218,0.0009650943,0.0006557995,0.00010817186,0.000020195928,0.00030441832,0.00022974111,0.00008289425],"category_scores_gemma":[0.0004448804,0.00031505956,0.00019957488,0.0008974112,0.0003441959,0.00030184095,0.00010804683,0.0002641179,0.000035135672],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034462284,0.007109353,0.71578205,0.0013107212,0.0018101077,0.0001548692,0.005884883,0.0010762658,0.0032272434,0.00034361062,0.000606578,0.22823201],"study_design_scores_gemma":[0.101489164,0.043992795,0.7925589,0.0037359118,0.00063481036,0.000029181068,0.00025508823,0.0059676166,0.05013997,0.00016648971,0.0004544835,0.00057560176],"about_ca_topic_score_codex":0.0022973635,"about_ca_topic_score_gemma":0.00043924406,"teacher_disagreement_score":0.22765641,"about_ca_system_score_codex":0.023216365,"about_ca_system_score_gemma":0.0040257936,"threshold_uncertainty_score":0.99993014},"labels":[],"label_agreement":null},{"id":"W2026893703","doi":"10.1371/journal.pone.0028395","title":"Modeling of Molecular Interaction between Apoptin, BCR-Abl and CrkL - An Alternative Approach to Conventional Rational Drug Design","year":2012,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"College of the North Atlantic; Memorial University of Newfoundland; University of Manitoba","funders":"Cancerfonden","keywords":"In silico; Chronic myelogenous leukemia; ABL; breakpoint cluster region; Computational biology; Cancer research; K562 cells; Fusion protein; Docking (animal); Biology; Chemistry; SH2 domain; Signal transducing adaptor protein; SH3 domain; Cell biology; Signal transduction; Leukemia; Biochemistry; Tyrosine kinase; Genetics; Receptor; Medicine","score_opus":0.11456791288014392,"score_gpt":0.3025271324478098,"score_spread":0.1879592195676659,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026893703","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9429895,0.00013416495,0.055529553,0.00010289165,0.000021286769,0.00056053896,0.000015241215,0.000021277918,0.00062553317],"genre_scores_gemma":[0.91995543,0.000008608418,0.07936261,0.000064898646,0.0002145153,0.000059571285,0.00020015078,0.000018799554,0.000115429575],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.998916,0.000078240846,0.0002363793,0.00020184102,0.00039635293,0.00017123431],"domain_scores_gemma":[0.99939287,0.00005865707,0.00007053999,0.00014770434,0.00014209688,0.00018812007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024116671,0.000118614014,0.0002521819,0.00010411124,0.000036330963,0.000009053213,0.000047812893,0.00004294368,0.000052261043],"category_scores_gemma":[0.00007370346,0.000115092866,0.00003427716,0.000072645045,0.000025801353,0.00023557816,0.000034668145,0.00011885973,0.000014876942],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035098945,0.039185032,0.19649984,0.0020417075,0.013214498,0.00002455227,0.022816049,0.06376402,0.64295536,0.007452656,0.00038378994,0.008152572],"study_design_scores_gemma":[0.0056319614,0.0005806275,0.008812125,0.0005707671,0.0012685505,0.000023958055,0.00051895867,0.65985227,0.3217153,0.00067277945,0.0000127246985,0.00033994846],"about_ca_topic_score_codex":0.00009727196,"about_ca_topic_score_gemma":5.9871167e-7,"teacher_disagreement_score":0.5960883,"about_ca_system_score_codex":0.00027086743,"about_ca_system_score_gemma":0.00008172382,"threshold_uncertainty_score":0.46933508},"labels":[],"label_agreement":null},{"id":"W2027412286","doi":"10.1159/000334109","title":"Prolonged Survival with Imatinib Mesylate Combined with Chemotherapy and Allogeneic Stem Cell Transplantation in de novo Ph+ Acute Myeloid Leukemia","year":2012,"lang":"en","type":"article","venue":"Acta Haematologica","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"National Natural Science Foundation of China","keywords":"Myeloid leukemia; Imatinib mesylate; Medicine; Minimal residual disease; Hematopoietic stem cell transplantation; Transplantation; Imatinib; Chemotherapy; Internal medicine; Daunorubicin; Philadelphia chromosome; Leukemia; Oncology; Immunology; Biology; Chromosomal translocation; Gene","score_opus":0.014425710205392107,"score_gpt":0.24706536456458889,"score_spread":0.23263965435919678,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027412286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99654543,0.00028707265,0.0001026702,0.0006104554,0.000031335345,0.001171334,0.000012189934,0.00011628206,0.001123237],"genre_scores_gemma":[0.99427354,0.00060375244,0.004314764,0.00029571453,0.000024532254,0.00016001318,0.00007853248,0.000051147337,0.00019802418],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99826443,0.000119336786,0.00031351688,0.0003821673,0.00027803172,0.00064253935],"domain_scores_gemma":[0.9990971,0.00013860757,0.0001757847,0.0003237061,0.00004279541,0.00022201198],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002673481,0.00036070944,0.00070400356,0.0001029739,0.000076779965,0.000020033343,0.00011286209,0.00019912742,0.00005895834],"category_scores_gemma":[0.000005217273,0.0002285337,0.000042132655,0.00023284082,0.00013209206,0.00018290922,0.000018694747,0.00027309213,0.000011629275],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015319606,0.0007500036,0.93299216,0.0007469997,0.0006673801,0.002057914,0.006552697,0.000011719615,0.037414372,0.00012933555,0.00005334258,0.0033044806],"study_design_scores_gemma":[0.04492159,0.0041429102,0.7959338,0.00046823747,0.0009925261,0.00957968,0.00065469526,0.00022192537,0.14194873,0.000033862798,0.00033436174,0.0007676829],"about_ca_topic_score_codex":0.00006639756,"about_ca_topic_score_gemma":0.00013147279,"teacher_disagreement_score":0.13705835,"about_ca_system_score_codex":0.00048064085,"about_ca_system_score_gemma":0.00031321993,"threshold_uncertainty_score":0.93193334},"labels":[],"label_agreement":null},{"id":"W2027804344","doi":"10.1016/j.jval.2012.08.1217","title":"PCN24 Treatment and Response Patterns in Chronic Myeloid Leukemia: Evidence from a Retrospective Study in Canada, Australia, and South Korea","year":2012,"lang":"en","type":"article","venue":"Value in Health","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Nilotinib; Dasatinib; Imatinib; Myeloid leukemia; Internal medicine; Pediatrics; Demography","score_opus":0.07667985724548108,"score_gpt":0.330722337570888,"score_spread":0.2540424803254069,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027804344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923587,0.0047641955,0.0000011599391,0.0005837394,0.00011312559,0.0020683103,0.00009155507,0.000013470635,0.000005785847],"genre_scores_gemma":[0.9985139,0.0008743123,0.00008358765,0.0000928947,0.00010751929,0.00016832355,0.000012507184,0.000028515198,0.00011847058],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99686474,0.0007229444,0.00064838794,0.00061938603,0.00033299671,0.0008115297],"domain_scores_gemma":[0.9984789,0.00048557136,0.00015945228,0.0004481796,0.000018117986,0.0004097632],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010330197,0.0003229593,0.0007559497,0.0002717363,0.00004842027,0.000012867548,0.0000716296,0.000102505226,0.000051426938],"category_scores_gemma":[0.00021963818,0.00028499652,0.00002557149,0.0003241736,0.0000456555,0.00014943359,0.000066577,0.00042839817,0.000006949078],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0009816588,0.00023573806,0.9785803,0.000102112135,0.000035226483,0.00028598635,0.018465519,0.00012314535,0.00008158514,0.000002699714,0.000015609818,0.0010904047],"study_design_scores_gemma":[0.0089971265,0.0019529251,0.98345464,0.0013228013,0.000036215144,0.000034411565,0.003286896,0.0006121307,0.00009152458,0.000011632058,0.000018766712,0.00018094231],"about_ca_topic_score_codex":0.99433094,"about_ca_topic_score_gemma":0.96557516,"teacher_disagreement_score":0.088664375,"about_ca_system_score_codex":0.097747535,"about_ca_system_score_gemma":0.009083157,"threshold_uncertainty_score":0.99996024},"labels":[],"label_agreement":null},{"id":"W2028959752","doi":"10.1056/nejmoa022457","title":"Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia","year":2003,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3565,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Medicine; Imatinib; Cytarabine; Internal medicine; Gastroenterology; Myeloid leukemia; Imatinib mesylate; Confidence interval; Alpha interferon; Philadelphia chromosome; Immunology; Interferon; Oncology; Biology; Chromosomal translocation","score_opus":0.019284873836844504,"score_gpt":0.29471192241794764,"score_spread":0.2754270485811031,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028959752","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97770303,0.01257369,0.0043874676,0.0029029795,0.0005441486,0.0011483341,0.000012740882,0.000038234957,0.0006893409],"genre_scores_gemma":[0.98991895,0.0015941226,0.003500759,0.00039876235,0.0037021807,0.000022604252,0.000057055197,0.000077904944,0.000727639],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972774,0.00012247176,0.0010429792,0.00037132614,0.0006243452,0.0005614731],"domain_scores_gemma":[0.9971455,0.0006275025,0.000674693,0.0004027458,0.0003255784,0.0008240051],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008770572,0.00047380966,0.001341035,0.00030668094,0.00010655224,0.000022890461,0.00016942128,0.00013162436,0.0004694565],"category_scores_gemma":[0.0006379546,0.00029563872,0.00012706341,0.00025101178,0.00028717253,0.00019120394,0.000023862518,0.0005936662,0.000006230124],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.048950307,0.0017343991,0.0075301616,0.0030771643,0.003647862,0.005614429,0.007265734,0.0013594861,0.11099955,0.000674122,0.052756283,0.7563905],"study_design_scores_gemma":[0.82644916,0.051848635,0.0026321195,0.0056643407,0.0017790844,0.0105273975,0.00043828815,0.0025423726,0.008161654,0.00023270288,0.08924342,0.00048081763],"about_ca_topic_score_codex":0.00013324432,"about_ca_topic_score_gemma":0.00021849829,"teacher_disagreement_score":0.77749884,"about_ca_system_score_codex":0.0026262447,"about_ca_system_score_gemma":0.0035026367,"threshold_uncertainty_score":0.9999496},"labels":[],"label_agreement":null},{"id":"W2029310284","doi":"10.1592/phco.24.16.1508.50958","title":"The Influence of St. John's Wort on the Pharmacokinetics and Protein Binding of Imatinib Mesylate","year":2004,"lang":"en","type":"article","venue":"Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":148,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institute of General Medical Sciences","keywords":"Imatinib mesylate; Pharmacokinetics; Pharmacology; Mesylate; Medicine; Chemistry; Imatinib; Internal medicine","score_opus":0.019557589068304675,"score_gpt":0.3302328160462573,"score_spread":0.31067522697795263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029310284","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98223877,0.009139108,0.000006176139,0.00715483,0.00017241656,0.0011484146,0.00001194474,0.00001232505,0.000116028015],"genre_scores_gemma":[0.9622534,0.035332512,0.000057402474,0.001898749,0.00021551702,0.000027258926,8.912565e-7,0.00003920269,0.00017510103],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976433,0.0005415668,0.00084892096,0.00017368505,0.00045331352,0.00033921137],"domain_scores_gemma":[0.99747235,0.0008264803,0.0010854302,0.00024017277,0.0002427744,0.0001328174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002123914,0.0003164403,0.000531621,0.00015574053,0.0004872839,0.00001924063,0.00044799055,0.000062131614,0.00022347737],"category_scores_gemma":[0.000023088756,0.00014583833,0.00015369883,0.00023222198,0.00097598817,0.00012255383,0.000048403315,0.0007741206,0.0000014886921],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048859785,0.000424936,0.00079095725,0.0000535194,0.0014067265,0.000029112298,0.003384302,0.00045928624,0.9815012,0.0002965744,0.0010882119,0.005679174],"study_design_scores_gemma":[0.0238727,0.001779394,0.003050285,0.00026889378,0.0005186535,0.00027949794,0.00034790253,0.0000615869,0.9608473,0.0014786033,0.0073132524,0.00018189127],"about_ca_topic_score_codex":0.000023852512,"about_ca_topic_score_gemma":0.0000021650606,"teacher_disagreement_score":0.026193405,"about_ca_system_score_codex":0.000120382865,"about_ca_system_score_gemma":0.00023983032,"threshold_uncertainty_score":0.5947115},"labels":[],"label_agreement":null},{"id":"W2031313479","doi":"10.1084/jem.20072316","title":"AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells","year":2008,"lang":"en","type":"article","venue":"The Journal of Experimental Medicine","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"BC Cancer Agency; Stem Cell Network; Cancer Research Society; Leukemia and Lymphoma Society; Michael Smith Health Research BC; Leukemia and Lymphoma Society of Canada; Bristol-Myers Squibb","keywords":"Progenitor cell; Cancer research; Stem cell; Imatinib; Imatinib mesylate; Chronic myelogenous leukemia; Haematopoiesis; STAT5; Biology; breakpoint cluster region; Tyrosine kinase; ABL; K562 cells; Myeloid leukemia; Leukemia; Immunology; Cell biology; Phosphorylation; Signal transduction; Receptor","score_opus":0.0237624186408181,"score_gpt":0.28660424278896146,"score_spread":0.2628418241481434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031313479","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909493,0.0074628466,0.000039911294,0.0007830866,0.00014190069,0.00047356615,0.0000052616906,0.000010361569,0.00013380864],"genre_scores_gemma":[0.99815744,0.00071144424,0.000623851,0.00011073498,0.00017757516,0.000005196632,0.0000012006562,0.000032754044,0.00017980892],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982825,0.00019304885,0.000564922,0.00016215922,0.0005526776,0.00024467637],"domain_scores_gemma":[0.99840766,0.0005227884,0.000458796,0.00024253296,0.00010208596,0.00026614807],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069577416,0.00027057983,0.0007368555,0.00016364171,0.00012354176,0.0000050225385,0.00011538898,0.00006685626,0.00008729053],"category_scores_gemma":[0.000056565023,0.0001432135,0.00006113178,0.00014099761,0.0005999118,0.0002348447,0.000042061514,0.0003225606,0.0000012019474],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017151512,0.0003116555,0.0011486707,0.000080110796,0.00032177957,0.00027611182,0.014766803,0.0000032839155,0.9638527,0.0000019326155,0.00012182818,0.0019636278],"study_design_scores_gemma":[0.011935814,0.0074733295,0.0059416154,0.0012119286,0.0003320136,0.008678091,0.005675516,0.00014578934,0.95840013,0.00000404925,0.00008199289,0.00011972591],"about_ca_topic_score_codex":0.00014845477,"about_ca_topic_score_gemma":0.0000026964512,"teacher_disagreement_score":0.009091287,"about_ca_system_score_codex":0.00028649985,"about_ca_system_score_gemma":0.00020301664,"threshold_uncertainty_score":0.58400774},"labels":[],"label_agreement":null},{"id":"W2035030872","doi":"10.1532/ijh97.04095","title":"Fluorescence In Situ Hybridization Monitoring of BCR-ABL-Positive Neutrophils in Chronic-Phase Chronic Myeloid Leukemia Patients during the Primary Stage of Imatinib Mesylate Therapy","year":2005,"lang":"en","type":"article","venue":"International Journal of Hematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan","funders":"","keywords":"Imatinib mesylate; Myeloid leukemia; Hematology; Medicine; Fluorescence in situ hybridization; Imatinib; Stage (stratigraphy); breakpoint cluster region; Internal medicine; Cancer research; Oncology; Immunology; Chemistry; Biology; Receptor; Gene","score_opus":0.011419617866952005,"score_gpt":0.29905267361095106,"score_spread":0.28763305574399906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035030872","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964387,0.0023068932,0.000052071187,0.0003744897,0.00029077634,0.00038126987,0.000019918647,0.000005979083,0.00012993871],"genre_scores_gemma":[0.9971869,0.0017853845,0.0006496604,0.000031585434,0.0002508374,0.000010816792,0.000020109743,0.000023354358,0.00004137111],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99747163,0.00012627218,0.0013191244,0.00019760203,0.0006200872,0.0002653036],"domain_scores_gemma":[0.99789846,0.00020574391,0.0011286538,0.00020520597,0.00050107227,0.000060838047],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029830023,0.00020057388,0.00061868364,0.00048738832,0.00002505605,0.000009252282,0.0003706405,0.00009827319,0.000058615475],"category_scores_gemma":[0.00012028277,0.00015404119,0.0001436732,0.00020561625,0.00013555371,0.0003000709,0.000082763174,0.0004112835,0.0000033936844],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004074254,0.0015393408,0.34470838,0.00034150525,0.00069409824,0.00079529296,0.0018630442,0.007366234,0.61013836,0.00030319643,0.000022325066,0.028154004],"study_design_scores_gemma":[0.022962818,0.00088796223,0.40796274,0.0013294839,0.000030771294,0.00054210215,0.00008003511,0.0007768511,0.5651957,0.00003102957,0.00007901545,0.000121538185],"about_ca_topic_score_codex":0.00007616678,"about_ca_topic_score_gemma":0.000036215373,"teacher_disagreement_score":0.06325437,"about_ca_system_score_codex":0.006180489,"about_ca_system_score_gemma":0.0012747272,"threshold_uncertainty_score":0.9976346},"labels":[],"label_agreement":null},{"id":"W2035068694","doi":"10.1182/blood-2010-01-263624","title":"Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"National Institutes of Health; Medical Research Council; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research","keywords":"Medicine; Internal medicine; Myeloid leukemia; Transplantation; Hematopoietic stem cell transplantation; Oncology; Imatinib; Imatinib mesylate; Hematopoietic cell; Chronic leukemia; Univariate analysis; Leukemia; Multivariate analysis; Immunology; Haematopoiesis; Acute leukemia; Stem cell; Biology","score_opus":0.011411524826883842,"score_gpt":0.2692569028110168,"score_spread":0.25784537798413293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035068694","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956032,0.00090922625,0.0005479083,0.000051150535,0.00015244428,0.002098898,0.000027362992,0.00007839886,0.0005314275],"genre_scores_gemma":[0.99435925,0.00032951383,0.004012378,0.000048612153,0.00021974643,0.00059783016,0.0002524617,0.00006723672,0.00011295119],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978631,0.00005497309,0.0005978211,0.00059286435,0.00026608177,0.0006251502],"domain_scores_gemma":[0.9991873,0.00013359533,0.00017738936,0.00028713932,0.00007170028,0.00014287642],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021369476,0.00033801366,0.0004680248,0.00035710842,0.0000823003,0.000020056126,0.000103798644,0.0002759337,0.00013706378],"category_scores_gemma":[0.00003591726,0.00033825458,0.00013423276,0.00044467315,0.000056458433,0.00016508056,0.000018740047,0.00054867816,0.000026501604],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006072432,0.001251038,0.0056829923,0.0010544229,0.00011977434,0.00015112867,0.003821648,0.0044258735,0.9740278,0.00005894795,0.000028295533,0.008770849],"study_design_scores_gemma":[0.07133543,0.0032931725,0.006202458,0.0005130505,0.00051241735,0.00031893761,0.00017441725,0.0140949385,0.9024745,0.00009212096,0.0004875349,0.0005009841],"about_ca_topic_score_codex":0.00036757332,"about_ca_topic_score_gemma":0.0035125536,"teacher_disagreement_score":0.071553245,"about_ca_system_score_codex":0.006323899,"about_ca_system_score_gemma":0.0031887745,"threshold_uncertainty_score":0.99990696},"labels":[],"label_agreement":null},{"id":"W2035278640","doi":"10.1016/j.leukres.2014.10.005","title":"Comparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors","year":2014,"lang":"en","type":"review","venue":"Leukemia Research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Pfizer","keywords":"Bosutinib; Ponatinib; Nilotinib; Dasatinib; Medicine; Tyrosine kinase; Chronic myelogenous leukemia; Tyrosine-kinase inhibitor; Internal medicine; Imatinib; Pharmacology; Oncology; Leukemia; Myeloid leukemia","score_opus":0.08836413084802916,"score_gpt":0.4135965523823236,"score_spread":0.32523242153429444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035278640","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1323287,0.85196126,0.00003117705,0.00015576441,0.00032181334,0.013638261,0.0012891165,0.0000646295,0.0002092911],"genre_scores_gemma":[0.29758438,0.6751514,0.0011170743,0.0000901774,0.005692121,0.007360357,0.009967854,0.00050110416,0.0025355082],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9887324,0.001952921,0.0033220667,0.0018891933,0.0021919792,0.0019114156],"domain_scores_gemma":[0.9917842,0.0025801093,0.0014943784,0.0026351481,0.0010591294,0.0004470449],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.0034914967,0.0015804924,0.0053696227,0.0016498887,0.00034913,0.00010437087,0.0010653405,0.001395607,0.00031466986],"category_scores_gemma":[0.00077468995,0.0011009236,0.0014525729,0.002310574,0.0010352983,0.00023034097,0.00042285744,0.0026398571,0.00011226121],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.004896398,0.0069284537,0.0001044917,0.13518871,0.004287227,0.0011881945,0.005276904,0.00037280362,0.02325279,0.0002806067,0.044180486,0.7740429],"study_design_scores_gemma":[0.07064252,0.020386403,0.00023444429,0.05183573,0.004896413,0.00039434756,0.0003128181,0.0025361145,0.042358946,0.000037157908,0.8045246,0.0018404904],"about_ca_topic_score_codex":0.0006584024,"about_ca_topic_score_gemma":0.002502901,"teacher_disagreement_score":0.77220243,"about_ca_system_score_codex":0.03627658,"about_ca_system_score_gemma":0.02130654,"threshold_uncertainty_score":0.9999008},"labels":[],"label_agreement":null},{"id":"W2038906686","doi":"10.1002/ajh.23408","title":"Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic‐phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors","year":2013,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Ariad Pharmaceuticals; Teva Pharmaceutical Industries; Pfizer","keywords":"Medicine; Internal medicine; Gastroenterology; Neutropenia; Adverse effect; Dasatinib; Myeloid leukemia; Rash; Phases of clinical research; Imatinib; Chemotherapy","score_opus":0.012338075314130881,"score_gpt":0.3062197094384318,"score_spread":0.2938816341243009,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2038906686","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99523014,0.0011329207,0.00022563372,0.0005017992,0.00028053104,0.0025257126,0.000057970996,0.000019641115,0.000025627949],"genre_scores_gemma":[0.9974998,0.000101304395,0.0018275782,0.00010624683,0.00016746207,0.00010124052,0.000023296536,0.00007869499,0.00009437575],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9956839,0.00019891305,0.0023360725,0.00045555911,0.0006396351,0.0006859232],"domain_scores_gemma":[0.9948005,0.00041399596,0.002384063,0.0006667146,0.0012239517,0.0005107729],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034176942,0.00047393117,0.0024852864,0.00065885624,0.00007824702,0.000010823732,0.00036403965,0.00010783739,0.00029450655],"category_scores_gemma":[0.000480758,0.00034058103,0.00032346987,0.0007127643,0.00037426004,0.00013827739,0.00010627951,0.00035598368,0.000012995472],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10546397,0.054115072,0.0101266755,0.0029825552,0.005764986,0.006311873,0.008727133,0.00042898982,0.32215354,0.00012278203,0.009087805,0.4747146],"study_design_scores_gemma":[0.19164225,0.5818952,0.0024285975,0.0017951024,0.002026487,0.0053767613,0.0042385687,0.0009067371,0.20671178,0.00004342105,0.002167924,0.0007671683],"about_ca_topic_score_codex":0.0007653378,"about_ca_topic_score_gemma":0.00021218407,"teacher_disagreement_score":0.5277801,"about_ca_system_score_codex":0.002757981,"about_ca_system_score_gemma":0.0022033115,"threshold_uncertainty_score":0.99990463},"labels":[],"label_agreement":null},{"id":"W2039165844","doi":"10.1080/10428190600923157","title":"Unusual fluid retention with imatinib therapy for chronic myeloid leukemia","year":2006,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Imatinib; Myeloid leukemia; Medicine; Oncology; Cancer research; Internal medicine","score_opus":0.014858361213849139,"score_gpt":0.24383367669860398,"score_spread":0.22897531548475483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2039165844","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90545136,0.024428044,0.0010688719,0.03367161,0.002619948,0.01458834,0.0019144346,0.0026213392,0.013636071],"genre_scores_gemma":[0.2654422,0.014004405,0.015206022,0.44148916,0.04714214,0.0125089865,0.063912205,0.0060401005,0.1342548],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9862258,0.0003757174,0.002689919,0.0043428955,0.0025620237,0.0038036904],"domain_scores_gemma":[0.9922982,0.00096681877,0.0017615014,0.0033030456,0.00080836134,0.0008620733],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00073491986,0.003766433,0.004204122,0.0012605971,0.0011093727,0.0005680675,0.0011509277,0.0049217795,0.00031380725],"category_scores_gemma":[0.00011867144,0.003186024,0.0015452618,0.0012212481,0.0012810422,0.00071712723,0.00035265906,0.0014938167,0.00029563965],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0033932317,0.00027272882,0.0007914859,0.0034473422,0.0025899394,0.0036044403,0.00033756925,0.00010252728,0.002942503,0.00013826939,0.82082224,0.16155773],"study_design_scores_gemma":[0.09427495,0.0053383154,0.011396533,0.002961918,0.002767249,0.0059145116,0.000108734304,0.005481183,0.008306993,0.000452209,0.8591199,0.0038774977],"about_ca_topic_score_codex":0.0037726357,"about_ca_topic_score_gemma":0.00019871171,"teacher_disagreement_score":0.64000916,"about_ca_system_score_codex":0.0981896,"about_ca_system_score_gemma":0.035849683,"threshold_uncertainty_score":0.9975056},"labels":[],"label_agreement":null},{"id":"W2039725378","doi":"10.5966/sctm.2012-0159","title":"Kinase-Independent Mechanisms of Resistance of Leukemia Stem Cells to Tyrosine Kinase Inhibitors","year":2014,"lang":"en","type":"review","venue":"Stem Cells Translational Medicine","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Stem cell; Tyrosine kinase; Cancer research; Leukemia; Kinase; Biology; Cell biology; Immunology; Signal transduction","score_opus":0.03153652321322902,"score_gpt":0.2943872599800715,"score_spread":0.26285073676684245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2039725378","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00026116526,0.9879438,0.0034264133,0.00031563753,0.0014322364,0.0042688907,0.00062534475,0.00008132932,0.0016451443],"genre_scores_gemma":[0.013870478,0.97110707,0.0031507385,0.00018304113,0.0011320461,0.00027990493,0.0007170466,0.00036574982,0.009193941],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99212253,0.00031650809,0.0032982086,0.0011885398,0.002424608,0.00064962846],"domain_scores_gemma":[0.9951177,0.00087403157,0.0015712621,0.0012956624,0.00048707312,0.00065423927],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011055392,0.0011354629,0.0053279107,0.0008941349,0.00007651065,0.0000073865153,0.0004967856,0.0007241033,0.00045785386],"category_scores_gemma":[0.000022165583,0.0008776799,0.000886661,0.001075209,0.0002857573,0.00007139141,0.00006718235,0.0006921209,0.000110568195],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010817804,0.0007548303,0.000017696435,0.21485275,0.002307645,0.00047636594,0.0010218266,0.0001582551,0.021661906,0.0034697454,0.008232005,0.7459652],"study_design_scores_gemma":[0.009391063,0.0018288767,0.000017253304,0.14433768,0.007308561,0.00008317765,0.00015351782,0.000040535688,0.057340365,0.00020573162,0.7782458,0.0010474116],"about_ca_topic_score_codex":0.00010388435,"about_ca_topic_score_gemma":0.000057132842,"teacher_disagreement_score":0.7700138,"about_ca_system_score_codex":0.0016004707,"about_ca_system_score_gemma":0.0024185681,"threshold_uncertainty_score":0.9993674},"labels":[],"label_agreement":null},{"id":"W2039731055","doi":"10.1182/blood-2003-05-1550","title":"Evidence for a positive role of SHIP in the BCR-ABL–mediated transformation of primitive murine hematopoietic cells and in human chronic myeloid leukemia","year":2003,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Haematopoiesis; Biology; Myeloid leukemia; CD34; Cancer research; Stem cell; Myeloid; Leukemia; Bone marrow; breakpoint cluster region; Molecular biology; Cell biology; Immunology; Receptor; Genetics","score_opus":0.02133377006430549,"score_gpt":0.27343440865023255,"score_spread":0.2521006385859271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2039731055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994871,0.0025026451,0.00002224093,0.0000788461,0.000011252452,0.0016800425,0.00002722489,0.0000081059,0.00079862995],"genre_scores_gemma":[0.99926126,0.00029612114,0.00018880525,0.00003478992,0.000014588435,0.00013764465,0.000033788554,0.000014907156,0.000018095432],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99872744,0.00011588509,0.00046755176,0.00020522231,0.00021876591,0.00026515266],"domain_scores_gemma":[0.9991193,0.0004060155,0.00015124402,0.00020874347,0.0000660473,0.000048692917],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000493786,0.00015575561,0.00038798613,0.00014808355,0.000027040345,0.000004857566,0.000082620754,0.000096142205,0.00002027217],"category_scores_gemma":[0.00017581879,0.00012100997,0.00006514724,0.00027054283,0.00011701717,0.00011306844,0.00001018005,0.00015344414,0.0000013184899],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060547754,0.001773719,0.026326887,0.002277471,0.00022229056,0.00004434473,0.028331606,0.000045968132,0.9373277,0.0018851095,0.00001044548,0.0011489936],"study_design_scores_gemma":[0.016448492,0.001206139,0.093734406,0.0017879608,0.0002968788,0.00006609972,0.0016148941,0.00016577732,0.88414645,0.00038616316,0.000018732238,0.00012803586],"about_ca_topic_score_codex":0.00021435066,"about_ca_topic_score_gemma":0.00025989773,"teacher_disagreement_score":0.06740752,"about_ca_system_score_codex":0.00055365457,"about_ca_system_score_gemma":0.0005512793,"threshold_uncertainty_score":0.49346432},"labels":[],"label_agreement":null},{"id":"W2039946232","doi":"10.1080/13684730412331302063","title":"Intracellular cytokine analysis of interferon-? in T cells of patients with chronic myeloid leukemia","year":2002,"lang":"en","type":"article","venue":"Cytokines Cellular & Molecular Therapy","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"Medical Research Council Canada","keywords":"Cytokine; Myeloid leukemia; Immunology; Interferon; Intracellular; Medicine; Myeloid; Leukemia; Cancer research; Biology; Cell biology","score_opus":0.009742204197778038,"score_gpt":0.21810943416776749,"score_spread":0.20836722996998944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2039946232","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917275,0.0050570956,0.0015288573,0.00004854482,0.00007861149,0.0010941379,0.000064215856,0.00004548554,0.00035555506],"genre_scores_gemma":[0.9975157,0.00094816304,0.00063115364,0.00008488658,0.000041788648,0.000049341437,0.00039550307,0.00011117532,0.0002223053],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9966339,0.00014787554,0.001059073,0.0007394758,0.0008213265,0.0005983482],"domain_scores_gemma":[0.99759185,0.00006912869,0.00052526983,0.0013249384,0.00029959437,0.00018922362],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00017684951,0.0005817005,0.0015346031,0.0011403811,0.000034198074,0.000013450057,0.00037359956,0.00025819754,0.0011423725],"category_scores_gemma":[0.000021491125,0.00047953828,0.0005225558,0.0023790533,0.0002799206,0.000107607266,0.00007815851,0.00035512281,0.000025891339],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011452137,0.0014217236,0.059912976,0.0002034093,0.0036768897,0.00031028822,0.00048192573,0.003977788,0.9217448,0.000044731965,0.000022699021,0.0070575178],"study_design_scores_gemma":[0.014300357,0.002299877,0.028258381,0.00023895862,0.0014706427,0.000004597914,0.000031600688,0.008285594,0.9436202,0.000010463006,0.001040373,0.00043894092],"about_ca_topic_score_codex":0.00020886518,"about_ca_topic_score_gemma":0.000038796414,"teacher_disagreement_score":0.031654593,"about_ca_system_score_codex":0.0013396161,"about_ca_system_score_gemma":0.00022730211,"threshold_uncertainty_score":0.9997707},"labels":[],"label_agreement":null},{"id":"W2043471542","doi":"10.1111/j.1939-165x.2012.00450.x","title":"Acute myeloblastic leukemia with associated <i><scp>BCR</scp></i>‐<i><scp>ABL</scp></i> translocation in a dog","year":2012,"lang":"en","type":"article","venue":"Veterinary Clinical Pathology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Center for Research Resources; National Institutes of Health","keywords":"Chromosomal translocation; ABL; Acute myeloblastic leukemia; Leukemia; Biology; Virology; Cancer research; Cell biology; Immunology; Genetics; Signal transduction; Gene; Tyrosine kinase","score_opus":0.04510548140523162,"score_gpt":0.342575412979838,"score_spread":0.2974699315746064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043471542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920121,0.0009786778,0.00035408587,0.00020441279,0.0009177631,0.0010856775,0.00007488864,0.00029450376,0.0040779305],"genre_scores_gemma":[0.9921489,0.0008108583,0.002055612,0.0018154999,0.0005286874,0.0002525295,0.00038087476,0.00014138431,0.0018656517],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943077,0.000925815,0.0015818895,0.001060824,0.0005232883,0.0016005067],"domain_scores_gemma":[0.9939363,0.0037051528,0.0005313533,0.0009578535,0.00015572028,0.00071364705],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015636802,0.0006680636,0.001560014,0.00031160895,0.00012703227,0.000025669455,0.0003461783,0.0010312288,0.00004565934],"category_scores_gemma":[0.0028078004,0.0005696705,0.00034206614,0.0008013514,0.000550858,0.0003460936,0.00016926532,0.0014252379,0.00057563634],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015093009,0.009255007,0.87085086,0.000536962,0.0023165043,0.02285847,0.0056900783,0.00013768871,0.057060238,0.0001979549,0.014300174,0.015286785],"study_design_scores_gemma":[0.031549454,0.017421886,0.91530645,0.000763222,0.001305766,0.008295654,0.0005287335,0.0006320099,0.001412796,0.000152372,0.022317145,0.00031449946],"about_ca_topic_score_codex":0.0000559959,"about_ca_topic_score_gemma":0.000045684577,"teacher_disagreement_score":0.05564744,"about_ca_system_score_codex":0.0015041038,"about_ca_system_score_gemma":0.0007716902,"threshold_uncertainty_score":0.99967545},"labels":[],"label_agreement":null},{"id":"W2045103043","doi":"10.1038/sj.leu.2403335","title":"Growth autonomy and lineage switching in BCR-ABL-transduced human cord blood cells depend on different functional domains of BCR-ABL","year":2004,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Haematopoiesis; Biology; Cancer research; Imatinib mesylate; K562 cells; Tyrosine kinase; ABL; Stem cell; Growth factor; Cell biology; Imatinib; Leukemia; Immunology; Signal transduction; Myeloid leukemia; Receptor","score_opus":0.015433312532936694,"score_gpt":0.24942036779335638,"score_spread":0.23398705526041969,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045103043","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961694,0.00016562069,0.00026050906,0.00016619169,0.00019609713,0.00068741123,0.000022516286,0.00008316184,0.0022490958],"genre_scores_gemma":[0.99800444,0.000064551954,0.0008159235,0.000272448,0.00021649244,0.00004962222,0.000101637124,0.000061305036,0.00041359343],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976973,0.00005454713,0.00064976944,0.00063887244,0.0004663575,0.00049316406],"domain_scores_gemma":[0.9988983,0.00015122893,0.00018888415,0.00046396418,0.00005294342,0.00024467736],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017316181,0.00042530903,0.0006913367,0.00028891393,0.00012278024,0.000023650828,0.00013358226,0.00023689005,0.00016485626],"category_scores_gemma":[0.00003643904,0.00036903846,0.00015462401,0.00021527383,0.000079637844,0.00010561932,0.00006452751,0.000621116,0.000026029735],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017825208,0.0027452374,0.06097801,0.0010221512,0.0008945539,0.00112031,0.0026545639,0.001069143,0.91868746,0.00505397,0.00015117356,0.0038408968],"study_design_scores_gemma":[0.049222037,0.00230006,0.3534568,0.0011564854,0.00064416765,0.00019981618,0.00017166388,0.00029455184,0.59048057,0.0011852524,0.00026314083,0.0006254663],"about_ca_topic_score_codex":0.0014724922,"about_ca_topic_score_gemma":0.0006277204,"teacher_disagreement_score":0.3282069,"about_ca_system_score_codex":0.003296582,"about_ca_system_score_gemma":0.00094668084,"threshold_uncertainty_score":0.99987614},"labels":[],"label_agreement":null},{"id":"W2046960502","doi":"10.1016/s0960-894x(03)00553-5","title":"Synthesis of pyrimidinopyridine–triazene conjugates targeted to abl tyrosine kinase","year":2003,"lang":"en","type":"article","venue":"Bioorganic & Medicinal Chemistry Letters","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital","funders":"","keywords":"Triazene; Chemistry; Moiety; ABL; Tyrosine kinase; Conjugate; Conjugated system; Stereochemistry; Tyrosine; Biochemistry; Tyrosine-kinase inhibitor; Organic chemistry; Receptor; Internal medicine","score_opus":0.012175608539639275,"score_gpt":0.23722173036004804,"score_spread":0.22504612182040876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046960502","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882778,0.0012175103,0.00012682703,0.007706543,0.00022048249,0.00050103664,0.000035824585,0.0001273104,0.0017866775],"genre_scores_gemma":[0.9953959,0.00008799547,0.0014340555,0.0022061523,0.00033795647,0.0000505074,0.000060174618,0.000082839484,0.0003444457],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972487,0.000057116027,0.00069380744,0.00065419456,0.0007030344,0.0006431197],"domain_scores_gemma":[0.9979218,0.00025528797,0.000236019,0.0008246218,0.00015015868,0.00061209156],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00036654298,0.000478258,0.0008778784,0.000112982874,0.000078362325,0.000012173131,0.0002533772,0.00019621852,0.0026978834],"category_scores_gemma":[0.0020100255,0.00041402734,0.00018861509,0.00061669236,0.00023906051,0.000052626634,0.000055935347,0.00030252506,0.00011136596],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002822194,0.00023255525,0.0026115137,0.00051172276,0.0002743877,0.00026695323,0.000119826254,0.0000018930459,0.9882284,0.000013677523,0.0070299096,0.00042693524],"study_design_scores_gemma":[0.0032569964,0.0001280368,0.0019480742,0.0005575383,0.0005176153,0.00033174275,0.00020507141,0.0000107175965,0.9884466,0.0000057419725,0.0042651836,0.00032669905],"about_ca_topic_score_codex":0.0000932212,"about_ca_topic_score_gemma":0.0000013115156,"teacher_disagreement_score":0.0071180854,"about_ca_system_score_codex":0.0008892361,"about_ca_system_score_gemma":0.0004951593,"threshold_uncertainty_score":0.99983114},"labels":[],"label_agreement":null},{"id":"W2047332763","doi":"10.1016/j.leukres.2009.03.002","title":"Correlation between trough imatinib plasma concentration and clinical response in chronic myeloid leukemia","year":2009,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; BC Cancer Agency; University of British Columbia","funders":"","keywords":"Reductive amination; Chemistry; Alkylation; Sodium cyanoborohydride; Iminosugar; Piperidine; Myeloid leukemia; Stereochemistry; Intramolecular force; Docking (animal); Combinatorial chemistry; Enzyme; Medicinal chemistry; Biochemistry; Cancer research; Medicine; Catalysis","score_opus":0.07239733739088638,"score_gpt":0.4088779336070712,"score_spread":0.3364805962161848,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047332763","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921024,0.0005171507,0.00010993367,0.0019815657,0.00009865669,0.0015366056,0.000014216082,0.00010514898,0.00353434],"genre_scores_gemma":[0.9962716,0.0006800768,0.0007203773,0.00014317314,0.0006142941,0.000049860013,0.00017009325,0.000042380656,0.001308146],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99451613,0.0012905789,0.0010960591,0.00088230986,0.001167179,0.0010477568],"domain_scores_gemma":[0.9959313,0.0025420755,0.00012236515,0.0007101324,0.00023457341,0.00045951613],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0045462702,0.0003200845,0.0007075133,0.0003063413,0.00022296843,0.000087535176,0.0001889718,0.0005771299,0.0001293584],"category_scores_gemma":[0.0019995407,0.00030179246,0.00013034586,0.00090593804,0.00041826375,0.00033395446,0.00010464953,0.0020207227,0.00027507966],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.037372813,0.0006252598,0.52763736,0.00044554318,0.00046602104,0.0023342345,0.0038699494,0.0014078033,0.031627875,0.0018262271,0.007917617,0.38446927],"study_design_scores_gemma":[0.020799039,0.0043822685,0.9146901,0.00047858662,0.00007780439,0.00012583725,0.00017902403,0.05317924,0.0025346766,0.00042797878,0.002827083,0.0002983923],"about_ca_topic_score_codex":0.00039732034,"about_ca_topic_score_gemma":0.000083754945,"teacher_disagreement_score":0.38705269,"about_ca_system_score_codex":0.027637744,"about_ca_system_score_gemma":0.008821594,"threshold_uncertainty_score":0.99994344},"labels":[],"label_agreement":null},{"id":"W2047725399","doi":"10.1016/j.clml.2013.03.020","title":"Subcutaneous Omacetaxine Mepesuccinate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With 2 or More Tyrosine Kinase Inhibitors Including Imatinib","year":2013,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; University of Texas MD Anderson Cancer Center; Teva Pharmaceutical Industries","keywords":"Medicine; Nilotinib; Dasatinib; Internal medicine; Adverse effect; Gastroenterology; Imatinib; Neutropenia; Clinical endpoint; Confidence interval; Myeloid leukemia; Surgery; Randomized controlled trial; Toxicity","score_opus":0.01974581216089715,"score_gpt":0.3045457770249775,"score_spread":0.2847999648640803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047725399","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893976,0.0014803438,0.00003387846,0.00046774585,0.0002949927,0.0067973738,0.00008972389,0.00068229047,0.00075609435],"genre_scores_gemma":[0.99143934,0.00041443846,0.0019073243,0.00063279056,0.0009223809,0.0009328321,0.0010714559,0.00049267797,0.0021867636],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9888446,0.00048253877,0.0034750917,0.0027300837,0.0017536053,0.0027141222],"domain_scores_gemma":[0.99252146,0.0010025991,0.0014251706,0.0025307827,0.0008419021,0.0016780538],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0008092487,0.0019676345,0.0033412552,0.00069447135,0.00043344373,0.00021958309,0.00084594765,0.0010862974,0.0013866517],"category_scores_gemma":[0.0007875328,0.0013277001,0.0005391811,0.0021663788,0.0011584716,0.00092559436,0.00049288064,0.0013289681,0.00071928994],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.022043569,0.0033712557,0.2982164,0.0010961015,0.0013178819,0.008062768,0.00040731527,0.00031876567,0.0011649553,0.0000240643,0.00264423,0.66133267],"study_design_scores_gemma":[0.13558146,0.027636489,0.81476265,0.0040251478,0.0010791839,0.0012674889,0.000098828285,0.0073201642,0.0040319846,0.000018479406,0.0022501242,0.0019279671],"about_ca_topic_score_codex":0.0023701934,"about_ca_topic_score_gemma":0.0010440876,"teacher_disagreement_score":0.65940475,"about_ca_system_score_codex":0.039960723,"about_ca_system_score_gemma":0.0121199675,"threshold_uncertainty_score":0.9995262},"labels":[],"label_agreement":null},{"id":"W2047907548","doi":"10.1182/blood-2002-04-1244","title":"Oncogenic interaction between BCR-ABL andNUP98-HOXA9 demonstrated by the use of an in vitro purging culture system","year":2002,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Cancer research; Myeloid leukemia; Bone marrow; Leukemia; Chronic myelogenous leukemia; ABL; Biology; Philadelphia chromosome; Immunology; Stem cell; K562 cells; breakpoint cluster region; Medicine; Tyrosine kinase; Chromosomal translocation; Cell biology; Signal transduction; Receptor; Genetics; Gene","score_opus":0.03926552683287885,"score_gpt":0.2641455768159855,"score_spread":0.22488004998310665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047907548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981631,0.0005873745,0.000013449632,0.00009697732,0.000054359098,0.0004668954,0.000049082875,0.00006791725,0.0005008203],"genre_scores_gemma":[0.998815,0.00004194094,0.00039148898,0.000036481124,0.00010275904,0.000021980175,0.00012956961,0.00002158442,0.00043920096],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988372,0.00012241495,0.00035128073,0.00024214231,0.0002196168,0.00022736443],"domain_scores_gemma":[0.9992543,0.00009157536,0.00015191869,0.00036004453,0.000047836864,0.00009431641],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011005985,0.00016369585,0.00033152613,0.00007445389,0.000052844738,0.00002508155,0.00009436646,0.0001295992,0.000047071313],"category_scores_gemma":[0.00004847088,0.000112409565,0.000075158154,0.00027187367,0.000040889674,0.0002052131,0.000024310515,0.00028266176,0.000029934636],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055047416,0.0042174356,0.17576884,0.00066805445,0.0018664718,0.00048049996,0.0037928459,0.00006336395,0.7667993,0.000016462867,0.0050389837,0.040737286],"study_design_scores_gemma":[0.036195148,0.0012520875,0.024342554,0.0015878896,0.0030419969,0.001535102,0.0030265443,0.011789463,0.9053739,0.000005662733,0.011230992,0.00061868236],"about_ca_topic_score_codex":0.00042427873,"about_ca_topic_score_gemma":0.000022576944,"teacher_disagreement_score":0.15142629,"about_ca_system_score_codex":0.00040317822,"about_ca_system_score_gemma":0.00005174005,"threshold_uncertainty_score":0.4583929},"labels":[],"label_agreement":null},{"id":"W2048177933","doi":"10.1016/j.bmc.2013.04.080","title":"A 2,6,9-hetero-trisubstituted purine inhibitor exhibits potent biological effects against multiple myeloma cells","year":2013,"lang":"en","type":"article","venue":"Bioorganic & Medicinal Chemistry","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto","funders":"Natural Sciences and Engineering Research Council of Canada; Leukemia and Lymphoma Society of Canada","keywords":"Kinome; Chemistry; Purine; Purine metabolism; Biochemistry; Kinase; Purine analogue; Computational biology; Combinatorial chemistry; Enzyme; Biology","score_opus":0.011946862333743246,"score_gpt":0.22077377199176842,"score_spread":0.20882690965802517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048177933","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99335086,0.0018762215,0.00005479825,0.0008389814,0.0005217484,0.0014206058,0.000020578636,0.00040647452,0.0015097455],"genre_scores_gemma":[0.99468637,0.00030211534,0.0006677311,0.0008717285,0.0015187889,0.00019336538,0.00033383598,0.00008638728,0.0013396981],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9964248,0.000059797072,0.00075430365,0.0010088795,0.00077581994,0.00097641564],"domain_scores_gemma":[0.99742025,0.00025823555,0.00025339753,0.0008925825,0.0002170223,0.0009585152],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00018828195,0.0007050313,0.00093978184,0.000088079796,0.00015017978,0.000039136077,0.00033854233,0.0005927392,0.0014199885],"category_scores_gemma":[0.00068013114,0.000530286,0.00027130375,0.00044063135,0.00034614583,0.00011458709,0.00023231945,0.0007346624,0.0012281629],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016980834,0.0005782091,0.0065011187,0.00056216365,0.00022355713,0.0007815251,0.000085861924,5.8184486e-7,0.9772175,8.046664e-7,0.0063408893,0.0075379717],"study_design_scores_gemma":[0.009720622,0.00042023163,0.029553834,0.00068626826,0.00019931555,0.0005210755,0.00012598095,0.00017477208,0.955513,0.0000091844195,0.0025938812,0.00048184066],"about_ca_topic_score_codex":0.00010293764,"about_ca_topic_score_gemma":0.0000022118397,"teacher_disagreement_score":0.023052717,"about_ca_system_score_codex":0.0012996824,"about_ca_system_score_gemma":0.0004770807,"threshold_uncertainty_score":0.99971485},"labels":[],"label_agreement":null},{"id":"W2048262171","doi":"10.1038/bmt.2011.194","title":"Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis","year":2011,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; National Heart, Lung, and Blood Institute; U.S. Public Health Service","keywords":"Medicine; Cumulative incidence; Internal medicine; Imatinib; Oncology; Transplantation; Bone marrow; Incidence (geometry); Haematopoiesis; Gastroenterology; Stem cell","score_opus":0.039016555208107234,"score_gpt":0.29027427585082166,"score_spread":0.25125772064271445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048262171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9832724,0.00007691005,0.0124336695,0.00022592419,0.000059972903,0.0033497268,0.00036157624,0.00003851498,0.00018132638],"genre_scores_gemma":[0.9907672,0.00015093132,0.004577886,0.00012603673,0.00001859022,0.0012988376,0.0029736797,0.000027887569,0.00005898503],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983922,0.00008724126,0.0005710222,0.0003627407,0.00024553746,0.00034121593],"domain_scores_gemma":[0.99887985,0.0006756867,0.00012730154,0.00021284532,0.000051274306,0.000053047235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039340305,0.00024660066,0.0004932593,0.00048616738,0.00006283033,0.000014985243,0.000102344704,0.00012674477,0.000038269667],"category_scores_gemma":[0.00006250439,0.00017636422,0.00028157784,0.0005224687,0.000031889536,0.00013395581,0.0000016870642,0.00011861818,0.0000028980883],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017150061,0.00047850545,0.97530615,0.0008637524,0.00043606272,0.00008129581,0.01740574,0.00008157273,0.002165685,0.00019268692,0.0000076723745,0.0012658429],"study_design_scores_gemma":[0.008557677,0.00034877553,0.98283094,0.00009948547,0.0033764138,0.000032333333,0.0004529811,0.00086881523,0.003025831,0.00022125056,0.000006918521,0.00017855091],"about_ca_topic_score_codex":0.00057497824,"about_ca_topic_score_gemma":0.005761486,"teacher_disagreement_score":0.016952759,"about_ca_system_score_codex":0.00020062532,"about_ca_system_score_gemma":0.00012636717,"threshold_uncertainty_score":0.71919245},"labels":[],"label_agreement":null},{"id":"W2049063681","doi":"10.1016/j.ejca.2010.02.032","title":"Bosutinib: A review of preclinical studies in chronic myelogenous leukaemia","year":2010,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Bosutinib; Chronic myelogenous leukemia; Imatinib; Cancer research; Medicine; Pharmacology; ABL; breakpoint cluster region; Leukemia; Dasatinib; Myeloid leukemia; Immunology; Tyrosine kinase; Internal medicine; Receptor","score_opus":0.17751043491524784,"score_gpt":0.47829605297896555,"score_spread":0.30078561806371773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049063681","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009999608,0.9953416,0.0000010575312,0.00016829056,0.0010616208,0.0008826559,0.000025182298,0.000010483806,0.0024090991],"genre_scores_gemma":[0.000028790206,0.99640125,0.00031842093,0.00022958186,0.0019862815,0.000019159457,0.0000103464345,0.00013636443,0.00086979696],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9940924,0.0010096487,0.003493107,0.0003581286,0.0006608272,0.00038590757],"domain_scores_gemma":[0.9946942,0.0004062013,0.0034557467,0.000663604,0.0005521515,0.00022814405],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0030615942,0.0005343824,0.0050962768,0.00030580608,0.000025841544,0.000006333956,0.00050430576,0.00015383746,0.00040120832],"category_scores_gemma":[0.0014414126,0.00034852896,0.0013259568,0.0004215421,0.0002864304,0.00006039266,0.0001587286,0.0022707651,0.00006979283],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004063782,0.00008708639,0.000029907747,0.1604876,0.0011403316,0.0016811078,0.00008518843,5.7241493e-7,0.0000027167773,0.000001916256,0.0043228087,0.8321201],"study_design_scores_gemma":[0.0014716117,0.0005842804,0.00005535068,0.39190602,0.0031581286,0.0011186535,0.000005004882,1.473737e-7,0.0000026928515,0.0000010432547,0.60155696,0.00014011875],"about_ca_topic_score_codex":0.000008394511,"about_ca_topic_score_gemma":0.000024281462,"teacher_disagreement_score":0.83198,"about_ca_system_score_codex":0.003682341,"about_ca_system_score_gemma":0.008232834,"threshold_uncertainty_score":0.99989665},"labels":[],"label_agreement":null},{"id":"W2050088310","doi":"10.1016/j.exphem.2013.05.205","title":"Effectively targeting treatment-naïve CML stem/progenitor cells from imatinib-nonresponders with combination treatments of new JAK2 and ABL inhibitors in vitro and in vivo","year":2013,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Dasatinib; Progenitor cell; Nilotinib; Stem cell; Imatinib; Pharmacology; Imatinib mesylate; CD34; Medicine; Cancer research; Bone marrow; In vivo; Tyrosine kinase; Tyrosine-kinase inhibitor; Immunology; Internal medicine; Biology; Receptor; Myeloid leukemia; Cell biology; Cancer","score_opus":0.011247807005065412,"score_gpt":0.26430419341871664,"score_spread":0.25305638641365125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050088310","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931146,0.0047171973,0.000003602753,0.00006959204,0.0000751798,0.001805617,0.000014694431,0.000025851046,0.00017366625],"genre_scores_gemma":[0.99701256,0.000042373948,0.0023702008,0.00002505751,0.000020633002,0.0002854586,0.00004398395,0.000037750437,0.00016199674],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99843055,0.00013680407,0.00044131378,0.00049308443,0.0001649637,0.00033330658],"domain_scores_gemma":[0.99920624,0.00024890964,0.00018070925,0.0001771232,0.000018510893,0.0001685222],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00005229971,0.00033488302,0.0007604701,0.00023395827,0.00003834363,0.000013726301,0.0000438362,0.00015873631,0.000109374196],"category_scores_gemma":[0.000009936619,0.00027127378,0.00004512067,0.0001427215,0.00014465436,0.0001796035,0.000048904083,0.00009739076,0.0000144412525],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025634554,0.0016951319,0.14080213,0.000068564164,0.0003006672,0.00022519323,0.006357328,0.0000010736708,0.8439761,0.000039267514,0.00009844058,0.0038726754],"study_design_scores_gemma":[0.023553517,0.001828189,0.011545755,0.00016045556,0.0000628032,0.00011630348,0.0038108893,0.00025239636,0.95844764,0.000038141112,0.000009908917,0.00017402026],"about_ca_topic_score_codex":0.0052856114,"about_ca_topic_score_gemma":0.000075117896,"teacher_disagreement_score":0.12925638,"about_ca_system_score_codex":0.00095990254,"about_ca_system_score_gemma":0.00012066106,"threshold_uncertainty_score":0.99997395},"labels":[],"label_agreement":null},{"id":"W2050240511","doi":"10.1006/bcmd.2000.0296","title":"Detailed Mapping of Methylcytosine Positions at the CpG Island Surrounding the Pa Promoter at the bcr-abl Locus in CML Patients and in Two Cell Lines, K562 and BV173","year":2000,"lang":"en","type":"article","venue":"Blood Cells Molecules and Diseases","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Grantová Agentura České Republiky; Ministerstvo Školství, Mládeže a Tělovýchovy; Université Laval","keywords":"Biology; DNA methylation; Methylation; ABL; breakpoint cluster region; Molecular biology; Chronic myelogenous leukemia; Restriction enzyme; Philadelphia chromosome; K562 cells; Promoter; CpG site; Genetics; Cancer research; Gene; Chromosomal translocation; Leukemia; Tyrosine kinase; Gene expression","score_opus":0.006462438300409976,"score_gpt":0.22743372956356528,"score_spread":0.2209712912631553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050240511","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98252875,0.015599519,0.0000028075947,0.0004856069,0.000019420284,0.0008409093,0.0001313892,0.000008348977,0.00038325257],"genre_scores_gemma":[0.99702215,0.0018002938,0.00003613491,0.00026504038,0.000030488744,0.00006619293,0.00007203462,0.000020660165,0.0006870088],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987651,0.00015520789,0.00030018698,0.00031153756,0.00020156575,0.0002664031],"domain_scores_gemma":[0.99923414,0.0002598155,0.00009020602,0.00028340795,0.00002900934,0.00010339215],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000120868506,0.00021465922,0.00027899977,0.00006229689,0.00019599221,0.00003884555,0.00007528251,0.000041462776,0.00012764355],"category_scores_gemma":[0.000024634513,0.00010946453,0.000056992867,0.00018248518,0.0002230859,0.00005028098,0.00013492297,0.00011204307,0.0000032956295],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00097136537,0.0019890636,0.9465061,0.00054658315,0.0002529488,0.00018577249,0.0021896425,0.00011244412,0.03807086,0.000014517915,0.00045986258,0.008700842],"study_design_scores_gemma":[0.02831922,0.00054831663,0.91560817,0.0008189603,0.001857666,0.0001035263,0.00064500154,0.0009821947,0.04912234,0.00024158669,0.001252117,0.00050088426],"about_ca_topic_score_codex":0.0005329946,"about_ca_topic_score_gemma":0.0014804947,"teacher_disagreement_score":0.030897912,"about_ca_system_score_codex":0.00008572706,"about_ca_system_score_gemma":0.00006102221,"threshold_uncertainty_score":0.4463834},"labels":[],"label_agreement":null},{"id":"W2050540976","doi":"10.1080/1024533031000134929","title":"Imatinib Mesylate (Gleevec™) is a Useful Agent in the Salvage Treatment of Adults with Relapsed/refractory Philadelphia Positive Acute Leukemias","year":2003,"lang":"en","type":"article","venue":"Hematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Imatinib mesylate; Medicine; Refractory (planetary science); Salvage therapy; Internal medicine; Imatinib; Chemotherapy; Transplantation; Oncology; Gastroenterology; Biology; Myeloid leukemia","score_opus":0.018694788074695653,"score_gpt":0.2783425060711104,"score_spread":0.25964771799641473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050540976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905171,0.0017151772,0.00003446254,0.0017396325,0.000084608066,0.001445911,0.0000485428,0.00004241053,0.00437219],"genre_scores_gemma":[0.9968263,0.0005343627,0.0011971559,0.000772417,0.00002313569,0.00021830942,0.00007522551,0.000049812705,0.00030329198],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99773735,0.00025667198,0.00059267186,0.0005354649,0.00034725748,0.0005306017],"domain_scores_gemma":[0.9983425,0.00032966246,0.0003046385,0.00080848194,0.0000899808,0.00012469706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014651733,0.00041121917,0.00093964866,0.0001834551,0.000064934735,0.0000071002646,0.00014136091,0.0002323621,0.00029078775],"category_scores_gemma":[0.000052353953,0.00024510524,0.0001728916,0.0003459312,0.00021848157,0.00007408494,0.000021414591,0.00024638668,0.00009714503],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029427359,0.029288096,0.48922074,0.0023020597,0.016630832,0.066406414,0.30132392,0.000063404405,0.0072751585,0.030245429,0.017653558,0.010163019],"study_design_scores_gemma":[0.24243619,0.044805806,0.2831202,0.004704898,0.008029062,0.07003396,0.01773084,0.00075604673,0.29157317,0.0016547882,0.032280464,0.0028745933],"about_ca_topic_score_codex":0.00021379523,"about_ca_topic_score_gemma":0.0001256178,"teacher_disagreement_score":0.284298,"about_ca_system_score_codex":0.0011193323,"about_ca_system_score_gemma":0.0006015572,"threshold_uncertainty_score":0.99951017},"labels":[],"label_agreement":null},{"id":"W2050728617","doi":"10.1002/pbc.22484","title":"Imatinib mesylate in children and adolescents with cancer","year":2010,"lang":"en","type":"review","venue":"Pediatric Blood & Cancer","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Memorial Sloan-Kettering Cancer Center","keywords":"Medicine; Imatinib; Imatinib mesylate; Myeloid leukemia; Tyrosine-kinase inhibitor; Oncology; Philadelphia chromosome; Tyrosine kinase; Leukemia; Cancer; Platelet-derived growth factor receptor; Internal medicine; Cancer research; Receptor; Chromosomal translocation; Growth factor; Gene; Genetics","score_opus":0.013157145554729978,"score_gpt":0.30587140216132147,"score_spread":0.2927142566065915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050728617","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.036158197,0.96077466,2.4618106e-7,0.000034400495,0.00025484915,0.0023172824,0.00027729865,0.00006443441,0.00011861189],"genre_scores_gemma":[0.0012582141,0.99482894,0.0001423661,0.00008417734,0.0019837911,0.0010352386,0.00012317387,0.00016833961,0.00037574794],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972589,0.00006166607,0.0006692939,0.00091092853,0.00045600414,0.00064320635],"domain_scores_gemma":[0.9984894,0.00003800263,0.00051001104,0.00057895883,0.000068327805,0.00031529416],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013168633,0.0007592038,0.002204858,0.00040016492,0.000054326913,0.00003032272,0.00020489724,0.00053940475,0.00028071133],"category_scores_gemma":[0.000026674124,0.0005289439,0.00020633009,0.0007272462,0.00007688925,0.00007592948,0.00011219605,0.0014064006,0.000032564672],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000042683678,0.00027100416,0.33380443,0.019439045,0.00050122326,0.00008856049,0.00005106967,4.495608e-7,1.5064357e-7,0.0000010677378,0.00029226422,0.64550805],"study_design_scores_gemma":[0.0343289,0.0006402404,0.22910036,0.0947096,0.08428056,0.0019690495,0.000006432722,0.000007834362,0.000005996415,0.000008644734,0.5520058,0.0029365497],"about_ca_topic_score_codex":0.0028405075,"about_ca_topic_score_gemma":0.0007789021,"teacher_disagreement_score":0.6425715,"about_ca_system_score_codex":0.00057134253,"about_ca_system_score_gemma":0.0030368448,"threshold_uncertainty_score":0.9997162},"labels":[],"label_agreement":null},{"id":"W2051711544","doi":"10.1016/j.leukres.2007.03.002","title":"Comparative gene expression analysis of a chronic myelogenous leukemia cell line resistant to cyclophosphamide using oligonucleotide arrays and response to tyrosine kinase inhibitors","year":2007,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Chronic myelogenous leukemia; Biology; Tyrosine kinase; ABL; Nilotinib; Cancer research; Imatinib mesylate; Molecular biology; Signal transduction; breakpoint cluster region; Kinase; Gene; Leukemia; Imatinib; Immunology; Cell biology; Genetics; Myeloid leukemia","score_opus":0.051629105179668136,"score_gpt":0.36487851310431596,"score_spread":0.31324940792464784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051711544","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930871,0.0023729156,0.0014279794,0.00021521564,0.00009370568,0.001987642,0.00010437728,0.00006837252,0.00064269506],"genre_scores_gemma":[0.9793952,0.0001590997,0.018825479,0.00014475954,0.0003109943,0.00006302937,0.00010463667,0.000091810136,0.0009049729],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9934896,0.00056160195,0.0012183656,0.0012929128,0.0018227051,0.0016148036],"domain_scores_gemma":[0.9947463,0.0012940584,0.00024783122,0.0014513995,0.0008564865,0.0014038911],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004203483,0.0005511615,0.001496719,0.003019129,0.00043612963,0.000062155304,0.0003974492,0.00033046026,0.00012580425],"category_scores_gemma":[0.0007384588,0.0005015819,0.00027254794,0.0059709325,0.0003920705,0.00012691373,0.0006406263,0.00090808683,0.000056977173],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019370152,0.00028510508,0.001985254,0.00019927224,0.0004957174,0.0007529819,0.0038299572,0.011764839,0.9590175,0.000006961996,0.0010786962,0.0012135614],"study_design_scores_gemma":[0.0049974825,0.002819561,0.024782563,0.00062971783,0.00064650975,0.000034441367,0.0012497653,0.005786404,0.95704514,0.000010092003,0.0015695702,0.0004287502],"about_ca_topic_score_codex":0.00398681,"about_ca_topic_score_gemma":0.0010776743,"teacher_disagreement_score":0.022797307,"about_ca_system_score_codex":0.027905095,"about_ca_system_score_gemma":0.0051530064,"threshold_uncertainty_score":0.9997436},"labels":[],"label_agreement":null},{"id":"W2052054991","doi":"10.1182/blood-2012-02-410688","title":"A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":176,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Canadian Cancer Society Research Institute; Ariad Pharmaceuticals; National Cancer Institute; National Institutes of Health; Pfizer; Oregon Health and Science University; Bristol-Myers Squibb","keywords":"Dasatinib; Medicine; Nilotinib; Imatinib; Internal medicine; Myeloid leukemia; Imatinib mesylate; Gastroenterology; Randomized controlled trial; Tyrosine-kinase inhibitor; Immunology; Cancer","score_opus":0.028945470028785506,"score_gpt":0.3226977424825182,"score_spread":0.2937522724537327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052054991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9807906,0.006998977,0.00003035962,0.0001548778,0.0010512938,0.0049005197,0.000053329284,0.00013975755,0.0058802557],"genre_scores_gemma":[0.9939719,0.0009143878,0.0011837849,0.0000615697,0.0021158145,0.0009377434,0.00025414393,0.00011114386,0.000449514],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9954041,0.0004541902,0.0015590966,0.00060436554,0.00079134176,0.0011868754],"domain_scores_gemma":[0.9959253,0.0017414805,0.00064496254,0.0011279765,0.0000971738,0.00046307777],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014369615,0.0006087847,0.002236428,0.00036146454,0.00008010469,0.000023586386,0.00031225942,0.00039350436,0.0012468348],"category_scores_gemma":[0.0017038457,0.0005222813,0.00061877735,0.00057240756,0.00032504462,0.000287436,0.00014375355,0.000587173,0.0002135838],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95901537,0.007804067,0.0006986758,0.0005848236,0.0016213305,0.00023872699,0.0017651393,0.000029219545,0.011455796,0.00029183537,0.0006282524,0.015866783],"study_design_scores_gemma":[0.9748926,0.0035043962,0.00046994345,0.0004782845,0.0017895292,0.0000541681,0.00009312493,0.00058978755,0.016061114,0.000021867492,0.0016357886,0.0004093538],"about_ca_topic_score_codex":0.0009030135,"about_ca_topic_score_gemma":0.00021744154,"teacher_disagreement_score":0.015877292,"about_ca_system_score_codex":0.0038803462,"about_ca_system_score_gemma":0.0040572113,"threshold_uncertainty_score":0.99994355},"labels":[],"label_agreement":null},{"id":"W2052370726","doi":"10.1158/0008-5472.can-06-2027","title":"A Src/Abl Kinase Inhibitor, SKI-606, Blocks Breast Cancer Invasion, Growth, and Metastasis <i>In vitro</i> and <i>In vivo</i>","year":2007,"lang":"en","type":"article","venue":"Cancer Research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":147,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Metastasis; Cancer research; Protein kinase B; Proto-oncogene tyrosine-protein kinase Src; Cancer; Angiogenesis; Breast cancer; Biology; Tyrosine kinase; In vivo; Kinase; Medicine; Pathology; Internal medicine; Receptor; Signal transduction; Cell biology","score_opus":0.035183164792797095,"score_gpt":0.35392657920397075,"score_spread":0.31874341441117365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052370726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98074794,0.0133257145,0.0000029767816,0.0033031236,0.00012485137,0.0010488942,0.00017811442,0.000031698473,0.0012366658],"genre_scores_gemma":[0.9899324,0.0077259378,0.00017447132,0.00055375695,0.00034669103,0.00035332996,0.000011728679,0.00006232342,0.0008393444],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9963899,0.0001677317,0.00048190085,0.0008555156,0.0009120919,0.0011928552],"domain_scores_gemma":[0.9983251,0.00037172466,0.000063303516,0.0004289904,0.0002354749,0.0005754056],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016214683,0.0003123973,0.0005848447,0.0007474101,0.0001438323,0.00006281786,0.00015528366,0.00020408569,0.00038784955],"category_scores_gemma":[0.00016278592,0.00027424973,0.00005938145,0.0013094874,0.00042476968,0.00018446374,0.0002705923,0.000927849,0.000007717245],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055507077,0.00060205406,0.18656181,0.000854165,0.00018528193,0.0023068662,0.0012832766,0.0000047643935,0.74031353,0.000049054674,0.006729267,0.0555592],"study_design_scores_gemma":[0.019994207,0.00029849046,0.05801153,0.0016865468,0.00013681097,0.00046740222,0.0008508619,0.000070649534,0.9075624,0.00019329201,0.010162989,0.00056486897],"about_ca_topic_score_codex":0.021666067,"about_ca_topic_score_gemma":0.0074770395,"teacher_disagreement_score":0.1672488,"about_ca_system_score_codex":0.0022085996,"about_ca_system_score_gemma":0.0011711954,"threshold_uncertainty_score":0.999971},"labels":[],"label_agreement":null},{"id":"W2053290453","doi":"10.1158/1078-0432.ccr-07-0835","title":"Synergistic Interactions between Vorinostat and Sorafenib in Chronic Myelogenous Leukemia Cells Involve Mcl-1 and p21CIP1 Down-Regulation","year":2007,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":65,"is_retracted":true,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute; National Institutes of Health; Leukemia and Lymphoma Society; U.S. Department of Defense","keywords":"Vorinostat; Imatinib mesylate; Sorafenib; Cancer research; Chronic myelogenous leukemia; Histone deacetylase inhibitor; Imatinib; Histone deacetylase; Pharmacology; Biology; Chemistry; Leukemia; Myeloid leukemia; Immunology; Histone; Biochemistry","score_opus":0.18198482242363437,"score_gpt":0.5002775618152996,"score_spread":0.31829273939166525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053290453","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944753,0.002812532,0.00008764485,0.0006021439,0.0002493759,0.00092620176,0.000030583462,0.000039400005,0.0007768321],"genre_scores_gemma":[0.9946236,0.0023601018,0.00026761956,0.00008181352,0.0010911175,0.000072409006,0.000053858785,0.000041653882,0.0014078481],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966742,0.00028329605,0.0008715698,0.0007423403,0.0006021784,0.00082644605],"domain_scores_gemma":[0.99553627,0.0030931046,0.00011197131,0.00047120333,0.0002429776,0.0005444772],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028727897,0.00022003449,0.00057325774,0.00040322577,0.00018663528,0.000046032477,0.00013618996,0.00027322577,0.00025112322],"category_scores_gemma":[0.0006266765,0.00019720076,0.00008086809,0.000554371,0.00073711644,0.00013521232,0.00024329821,0.0014424946,0.0000710997],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014939759,0.00028232342,0.68047285,0.0005409157,0.00031649522,0.00036538945,0.0008139541,0.00006733191,0.014939165,0.00023939513,0.0018791677,0.29858902],"study_design_scores_gemma":[0.007752796,0.0011842217,0.97143596,0.00058654044,0.00014243141,0.00001909972,0.00021013147,0.0009783524,0.0063263937,0.0006280632,0.010473642,0.00026236614],"about_ca_topic_score_codex":0.005002278,"about_ca_topic_score_gemma":0.0073330407,"teacher_disagreement_score":0.29832664,"about_ca_system_score_codex":0.005755413,"about_ca_system_score_gemma":0.0023307467,"threshold_uncertainty_score":0.9980613},"labels":[],"label_agreement":null},{"id":"W2053888937","doi":"10.1503/cmaj.111710","title":"Chronic myeloid leukemia: The race is yet to be won","year":2012,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Race (biology); Myeloid leukemia; Point (geometry); Medicine; Computer science; Gerontology; Immunology; Gender studies; Sociology; Mathematics","score_opus":0.012753997511932574,"score_gpt":0.2608639692857849,"score_spread":0.24810997177385236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053888937","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.53687406,0.0026880358,0.000055499906,0.44424066,0.002922678,0.00054551987,0.00005009858,0.000046053454,0.012577415],"genre_scores_gemma":[0.86748314,0.00042490137,0.00016649505,0.10970529,0.010228467,0.000032225355,0.000024754523,0.000051394796,0.011883329],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99621934,0.00015859795,0.0004521335,0.00018417358,0.0018666828,0.0011190856],"domain_scores_gemma":[0.99499464,0.00021453046,0.00019328525,0.00027715304,0.00025148995,0.0040688734],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0020022346,0.00020100984,0.0003256337,0.00017139026,0.000417965,0.000068526606,0.0002754978,0.00045806044,0.013093075],"category_scores_gemma":[0.0021916067,0.0001427099,0.00016611368,0.0003936496,0.0000456741,0.00016325629,0.00003586186,0.0014927128,0.0015272233],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000013365302,0.00002769782,0.047866914,0.000011669839,0.00030191118,0.00018414242,0.0018656267,0.0000031654827,0.00007450258,0.00011897678,0.9008685,0.04866353],"study_design_scores_gemma":[0.0019515941,0.000113507005,0.051220194,0.0000982033,0.000118163916,0.0011120825,0.00040713866,0.000071542556,0.00021203686,0.00001865954,0.94452983,0.0001470246],"about_ca_topic_score_codex":0.0036690356,"about_ca_topic_score_gemma":0.012898771,"teacher_disagreement_score":0.33453536,"about_ca_system_score_codex":0.031200193,"about_ca_system_score_gemma":0.014710872,"threshold_uncertainty_score":0.9992502},"labels":[],"label_agreement":null},{"id":"W2054103222","doi":"10.1016/j.stem.2012.12.011","title":"A Pan-BCL2 Inhibitor Renders Bone-Marrow-Resident Human Leukemia Stem Cells Sensitive to Tyrosine Kinase Inhibition","year":2013,"lang":"en","type":"article","venue":"Cell stem cell","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":195,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Canada's Michael Smith Genome Sciences Centre; Ontario Institute for Cancer Research; BC Cancer Agency","funders":"National Institute of Allergy and Infectious Diseases; National Institute of General Medical Sciences; Ontario Ministry of Research and Innovation; University of California, San Diego; Canadian Institutes of Health Research; Ontario Genomics Institute; China Scholarship Council; Genome Canada; National Institutes of Health; Ontario Genomics; National Cancer Institute; Government of Canada; California Institute for Regenerative Medicine","keywords":"Biology; Stem cell; Tyrosine-kinase inhibitor; Leukemia; Bone marrow; Cancer research; Tyrosine kinase; Immunology; Cell biology; Signal transduction; Cancer; Genetics","score_opus":0.014644643610817135,"score_gpt":0.23421988454862905,"score_spread":0.21957524093781192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054103222","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98248476,0.00048048,0.000102595935,0.00036115843,0.0005137223,0.0030430076,0.00005023519,0.0002926738,0.012671363],"genre_scores_gemma":[0.94983894,0.000057100333,0.0003544803,0.0008738614,0.00047427343,0.00024107081,0.00014731486,0.00016560298,0.047847345],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9957275,0.00019391318,0.0009579491,0.0011978167,0.0008622476,0.0010605709],"domain_scores_gemma":[0.99715686,0.00014604861,0.00037169218,0.0011003762,0.00033306816,0.0008919319],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00027879162,0.00074907445,0.000894717,0.000365459,0.0002484052,0.00013474157,0.00015467468,0.00038428698,0.0005406858],"category_scores_gemma":[0.000006393363,0.0007079493,0.00032404542,0.0004881859,0.00012523904,0.00027445352,0.00023693152,0.00054253056,0.005066534],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016037302,0.00038575332,0.00035509723,0.0005568932,0.00006259366,0.00084772025,0.002361986,0.00007964431,0.9365446,0.0000130968,0.056205302,0.0024269253],"study_design_scores_gemma":[0.0070593664,0.0009365801,0.0012127612,0.0005547785,0.0002785557,0.000058877315,0.0029947455,0.00018078285,0.98207927,0.0000133314325,0.0039557,0.000675275],"about_ca_topic_score_codex":0.001704669,"about_ca_topic_score_gemma":0.00010782223,"teacher_disagreement_score":0.052249603,"about_ca_system_score_codex":0.0056176716,"about_ca_system_score_gemma":0.00058743206,"threshold_uncertainty_score":0.99953717},"labels":[],"label_agreement":null},{"id":"W2054216998","doi":"10.1016/j.bmcl.2007.05.067","title":"Optimization of novel combi-molecules: Identification of balanced and mixed bcr-abl/DNA targeting properties","year":2007,"lang":"en","type":"article","venue":"Bioorganic & Medicinal Chemistry Letters","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital","funders":"Leukemia and Lymphoma Society","keywords":"Chemistry; Chronic myelogenous leukemia; ABL; DNA; Tyrosine kinase; Imatinib mesylate; DNA damage; Molecule; Imatinib; Cancer research; In vitro; Molecular biology; Biochemistry; Leukemia; Signal transduction; Genetics; Biology","score_opus":0.013409854932493168,"score_gpt":0.23149767822597928,"score_spread":0.2180878232934861,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054216998","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887724,0.0006288968,0.009119743,0.0009705014,0.00008947028,0.00027880847,0.0000091201555,0.000038331815,0.00009274543],"genre_scores_gemma":[0.99706256,0.000062024235,0.002365031,0.00017700912,0.00012509216,0.0000056456993,0.00011714205,0.000029580666,0.00005589013],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982824,0.000013295779,0.0007009576,0.00031260203,0.0004387318,0.00025201018],"domain_scores_gemma":[0.9989617,0.000053603282,0.00042478603,0.00028805627,0.00014676317,0.000125083],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042411272,0.00019880907,0.0003905737,0.00005938721,0.000043101532,0.0000059117874,0.000110163885,0.00011709434,0.000058916154],"category_scores_gemma":[0.00036373964,0.00017333985,0.000055365515,0.00023614736,0.00029346428,0.000055616805,0.000041252857,0.00014898545,0.0000012031455],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018281657,0.00016522552,0.0028366048,0.0008890503,0.00010654817,0.00001325226,0.0004349036,0.00005130276,0.99486893,0.0000013222107,0.0001757581,0.00027428608],"study_design_scores_gemma":[0.0036941012,0.000052354993,0.0066070026,0.00045123912,0.00020220765,0.00008421376,0.0008102327,0.0012257677,0.98672086,5.2153223e-7,0.000022621089,0.00012890685],"about_ca_topic_score_codex":0.000045759258,"about_ca_topic_score_gemma":6.747274e-7,"teacher_disagreement_score":0.008290201,"about_ca_system_score_codex":0.00029165822,"about_ca_system_score_gemma":0.00014357276,"threshold_uncertainty_score":0.7068594},"labels":[],"label_agreement":null},{"id":"W2055073381","doi":"10.1016/j.clml.2013.09.010","title":"A Comparison of Long-Term Outcomes of Donor Lymphocyte Infusions and Tyrosine Kinase Inhibitors in Patients With Relapsed CML After Allogeneic Hematopoietic Cell Transplantation","year":2013,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Hematopoietic cell; Tyrosine kinase; Medicine; Lymphocyte; Hematopoietic stem cell transplantation; Haematopoiesis; Immunology; Transplantation; Term (time); Oncology; Cancer research; Internal medicine; Stem cell; Biology; Receptor; Genetics","score_opus":0.017275716060362396,"score_gpt":0.29798285927303064,"score_spread":0.28070714321266826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2055073381","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99733895,0.0007462543,0.000014096542,0.000070065296,0.00014545985,0.0014807178,0.000041063515,0.00004064398,0.00012275612],"genre_scores_gemma":[0.9981558,0.00022534146,0.00092519127,0.00016310427,0.000035434277,0.00013913935,0.00018535127,0.00006382479,0.000106839274],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99622655,0.0001629662,0.0019794535,0.00064043066,0.00054205564,0.00044855542],"domain_scores_gemma":[0.9975137,0.0005646015,0.0006560546,0.0006739756,0.00023409358,0.00035756154],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022716387,0.00045457997,0.0015231601,0.00026258442,0.000046785306,0.000017008271,0.0001670823,0.0004014021,0.00014034266],"category_scores_gemma":[0.00012480315,0.00034560036,0.00024253535,0.00036968724,0.00048803768,0.00019255334,0.00009704426,0.00020375902,0.000037368303],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022858963,0.0015870002,0.9384838,0.0006131288,0.00014166374,0.00009360316,0.0005067305,0.000011077121,0.0006200752,0.000003929269,0.00003826253,0.055614833],"study_design_scores_gemma":[0.032060187,0.0015396507,0.9583008,0.00088439457,0.00045313375,0.000021082313,0.0000505909,0.000076799646,0.006296476,0.000011959236,0.0000075241696,0.0002973855],"about_ca_topic_score_codex":0.00042856776,"about_ca_topic_score_gemma":0.00014324133,"teacher_disagreement_score":0.05531745,"about_ca_system_score_codex":0.0010994789,"about_ca_system_score_gemma":0.00089114986,"threshold_uncertainty_score":0.9998996},"labels":[],"label_agreement":null},{"id":"W2055203873","doi":"10.1074/jbc.m413787200","title":"c-Abl Tyrosine Kinase Regulates Caspase-9 Autocleavage in the Apoptotic Response to DNA Damage","year":2005,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute","keywords":"DNA damage; Caspase 8; Caspase 3; Cell biology; Apoptosis; Caspase 2; Tyrosine kinase; Caspase-9; Molecular biology; Caspase; Cancer research; Chemistry; Biology; Signal transduction; DNA; Programmed cell death; Biochemistry","score_opus":0.025072942419618514,"score_gpt":0.2859718287722914,"score_spread":0.2608988863526729,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2055203873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98705554,0.00033714838,0.0000055141963,0.011141432,0.000029596742,0.00017656673,0.000005694041,0.000016708595,0.0012317775],"genre_scores_gemma":[0.9964842,0.000034887053,0.0011218442,0.0012484269,0.00043666534,0.00000651609,0.000007703367,0.000011337885,0.00064837193],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99852073,0.00012558748,0.000545311,0.00020144049,0.00029651422,0.000310395],"domain_scores_gemma":[0.99876374,0.00038578775,0.00020023728,0.0003442489,0.00008069695,0.00022526436],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009545223,0.00019385855,0.00040519866,0.000054561835,0.000045978763,0.000026668411,0.0002801313,0.00019352483,0.00037575146],"category_scores_gemma":[0.0011789915,0.00010438657,0.00016303238,0.00031250724,0.00010644746,0.00006166068,0.00005733068,0.0005060202,0.000039587747],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033905008,0.00052083825,0.00160744,0.000033563134,0.00004391087,0.0016699643,0.00024195778,0.000059810896,0.9874066,0.0000037372452,0.0030665323,0.0019551185],"study_design_scores_gemma":[0.0056116367,0.0013445872,0.19269659,0.00036180916,0.00009857404,0.0030088052,0.000524439,0.00009664688,0.7791443,0.00006306474,0.016814446,0.00023512777],"about_ca_topic_score_codex":0.00000827639,"about_ca_topic_score_gemma":0.0000017930026,"teacher_disagreement_score":0.20826235,"about_ca_system_score_codex":0.00072482263,"about_ca_system_score_gemma":0.00020249646,"threshold_uncertainty_score":0.42567608},"labels":[],"label_agreement":null},{"id":"W2055405821","doi":"10.1016/j.crvi.2003.05.004","title":"Contribution to the study of periodic chronic myelogenous leukemia","year":2004,"lang":"en","type":"review","venue":"Comptes Rendus Biologies","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":112,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Mitacs; Alexander von Humboldt-Stiftung","keywords":"Chronic myelogenous leukemia; Stem cell; Hopf bifurcation; Leukemia; Haematopoiesis; Period (music); Stability (learning theory); Bifurcation; Mathematics; Biology; Immunology; Physics; Cell biology; Computer science","score_opus":0.0587611801818841,"score_gpt":0.34198163462941766,"score_spread":0.2832204544475336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2055405821","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009027473,0.9847024,0.000010770785,0.000058478436,0.00044719272,0.0053293067,0.00015379077,0.0001755246,0.00009503922],"genre_scores_gemma":[0.024055693,0.9741229,0.00006298121,0.00002542408,0.00031337485,0.0006329155,0.00055457663,0.000052725292,0.00017945466],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997046,0.0002995706,0.0010000771,0.0007263947,0.00033241184,0.0005955481],"domain_scores_gemma":[0.9972904,0.0003959565,0.0005646027,0.0014404517,0.00018233777,0.00012629613],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029992303,0.0007070236,0.003032003,0.0002488297,0.00021058817,0.000029417757,0.0006983572,0.00047673535,0.00020322666],"category_scores_gemma":[0.00046808325,0.0003798019,0.00053869537,0.0005887301,0.0002596129,0.000023676343,0.00045718206,0.0006875126,0.00057323143],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059449285,0.00043679724,0.00014270094,0.0061437436,0.0015735576,0.00015692029,0.0003396986,0.00006570283,0.000011430592,0.000031202577,0.0013938792,0.98964494],"study_design_scores_gemma":[0.0025375953,0.005091649,0.0005292969,0.011787737,0.0028193428,0.00036599225,0.00029866965,0.0000033356077,0.000026393627,0.000009903275,0.9761221,0.0004080278],"about_ca_topic_score_codex":0.00033705233,"about_ca_topic_score_gemma":0.00007230325,"teacher_disagreement_score":0.9892369,"about_ca_system_score_codex":0.009112212,"about_ca_system_score_gemma":0.0036537952,"threshold_uncertainty_score":0.9998654},"labels":[],"label_agreement":null},{"id":"W2055980828","doi":"10.1186/gm206","title":"The pharmacogenetics of imanitib","year":2010,"lang":"en","type":"article","venue":"Genome Medicine","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; Université de Montréal","funders":"","keywords":"Pharmacogenetics; Imatinib mesylate; Medicine; Imatinib; Myeloid leukemia; Tyrosine kinase; Tyrosine-kinase inhibitor; Pharmacology; Bioinformatics; Computational biology; Drug; Candidate gene; Pharmacogenomics; Gene; Biology; Genetics; Cancer research; Internal medicine; Genotype; Cancer; Receptor","score_opus":0.01540278393439104,"score_gpt":0.29502425981610886,"score_spread":0.2796214758817178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2055980828","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9675268,0.0028514937,0.00003662723,0.0043551913,0.000732028,0.00042110868,0.0000070903966,0.000037238267,0.02403245],"genre_scores_gemma":[0.994327,0.0007433696,0.00040827144,0.00042708995,0.00086065347,0.000015218295,0.000025962925,0.000023394394,0.0031690106],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989418,0.000016575697,0.0003059862,0.00015720168,0.00033417653,0.00024430268],"domain_scores_gemma":[0.99899065,0.0001380126,0.00010105468,0.0004917221,0.00012777976,0.00015076398],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00029613223,0.00012865844,0.0002572059,0.000058347636,0.000086869004,0.000002653056,0.00015722896,0.00005159866,0.0010830933],"category_scores_gemma":[0.0001643897,0.000071008646,0.00005279116,0.00015257651,0.00043677734,0.000012774975,0.000043198954,0.00027782086,0.0000711123],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016059943,0.0001107797,0.008292252,0.000087576096,0.0002469657,0.00007990867,0.00068871235,0.000001203373,0.9487491,0.00079900183,0.002957283,0.037826587],"study_design_scores_gemma":[0.012325043,0.0011643721,0.13792904,0.00009181112,0.0007710665,0.00061250554,0.0004121114,0.00015825962,0.036872685,0.00044430196,0.8090169,0.00020191599],"about_ca_topic_score_codex":0.000057194964,"about_ca_topic_score_gemma":0.000028800001,"teacher_disagreement_score":0.91187644,"about_ca_system_score_codex":0.00007423006,"about_ca_system_score_gemma":0.00017880919,"threshold_uncertainty_score":0.99983007},"labels":[],"label_agreement":null},{"id":"W2056048301","doi":"10.1002/cncr.22936","title":"The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome‐negative cells","year":2007,"lang":"en","type":"article","venue":"Cancer","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":129,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Imatinib mesylate; Medicine; Myeloid leukemia; Internal medicine; Imatinib; Philadelphia chromosome; Gastroenterology; Odds ratio; Immunology; Oncology; Chromosomal translocation; Biology; Genetics","score_opus":0.01422227534640781,"score_gpt":0.2713631737444779,"score_spread":0.2571408983980701,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2056048301","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921942,0.003156112,0.000052546613,0.0005336724,0.00024053465,0.002888963,0.00015556312,0.00004384523,0.0007346158],"genre_scores_gemma":[0.9949298,0.0009884139,0.00028793493,0.0002727496,0.00055678707,0.0011698831,0.000071831375,0.00007512774,0.0016474548],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977139,0.00003164037,0.00045742255,0.00047481255,0.00047611608,0.0008461136],"domain_scores_gemma":[0.99863696,0.00036554364,0.00019728584,0.00036103482,0.0002552833,0.00018391611],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019342988,0.00035000185,0.00041851233,0.000111104375,0.00021260574,0.00003347844,0.0001837754,0.00014399111,0.00014082303],"category_scores_gemma":[0.00004283461,0.00023021354,0.00011434066,0.0002567056,0.0003216381,0.00011150604,0.00005174292,0.00027372182,0.000014014661],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060537276,0.00063292135,0.9247489,0.0010779406,0.0012741517,0.0001078721,0.0041988785,0.0008728755,0.0017029522,0.00025087016,0.007988051,0.051090878],"study_design_scores_gemma":[0.028118966,0.0027013777,0.84006405,0.0014322677,0.00041261944,0.000016697366,0.00056980975,0.00078757666,0.09400961,0.00012130831,0.031057412,0.00070830743],"about_ca_topic_score_codex":0.0005033204,"about_ca_topic_score_gemma":0.003573085,"teacher_disagreement_score":0.09230665,"about_ca_system_score_codex":0.008372324,"about_ca_system_score_gemma":0.0021423427,"threshold_uncertainty_score":0.99543434},"labels":[],"label_agreement":null},{"id":"W2059614461","doi":"10.1002/pbc.23031","title":"Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: A report from the Children's Oncology Group","year":2011,"lang":"en","type":"article","venue":"Pediatric Blood & Cancer","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre; Centre Hospitalier Universitaire Sainte-Justine","funders":"National Cancer Institute; National Institutes of Health","keywords":"Medicine; Imatinib; Chronic myelogenous leukemia; Internal medicine; Imatinib mesylate; Leukemia; Oncology; Gastroenterology; Myeloid leukemia","score_opus":0.02294045038282184,"score_gpt":0.2934814233140928,"score_spread":0.270540972931271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059614461","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9641458,0.030073674,0.00021740938,0.00041995925,0.00045655307,0.003350634,0.0004571373,0.0002318725,0.00064699864],"genre_scores_gemma":[0.97748405,0.004123992,0.0033627194,0.00074192556,0.010418141,0.0022813284,0.00083737844,0.00019479457,0.0005556485],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99637806,0.00009647643,0.0007593949,0.00107671,0.0004827394,0.0012066051],"domain_scores_gemma":[0.9972898,0.0002516756,0.0006676368,0.0012488809,0.00015561232,0.00038643225],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00035310586,0.0006305828,0.0008944853,0.0001253686,0.0003065952,0.000028398308,0.00047269868,0.00041506442,0.0016204192],"category_scores_gemma":[0.000066526445,0.0004242505,0.00030120005,0.000491237,0.00022184037,0.00013715232,0.00013235508,0.00072151626,0.000051859046],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0030119265,0.004013323,0.91343606,0.00030677542,0.0071330806,0.0018523306,0.0022303606,0.000046642643,0.0010273649,0.000100790836,0.012814066,0.05402731],"study_design_scores_gemma":[0.0908021,0.008771053,0.8670576,0.00014345808,0.018519612,0.005224944,0.00003410541,0.000061932864,0.0017492002,0.00016374055,0.006474799,0.000997436],"about_ca_topic_score_codex":0.011814899,"about_ca_topic_score_gemma":0.00242185,"teacher_disagreement_score":0.087790176,"about_ca_system_score_codex":0.0062930253,"about_ca_system_score_gemma":0.010096907,"threshold_uncertainty_score":0.99982095},"labels":[],"label_agreement":null},{"id":"W2059644814","doi":"10.1139/v04-060","title":"Voltammetric behavior and quantification of the anti-leukemia drug imatinib in bulk form, pharmaceutical formulation, and human serum at a mercury electrode","year":2004,"lang":"en","type":"article","venue":"Canadian Journal of Chemistry","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Chemistry; Hanging mercury drop electrode; Dropping mercury electrode; Chronic myelogenous leukemia; Imatinib mesylate; Cathodic stripping voltammetry; Voltammetry; Pharmaceutical formulation; Chromatography; Polarography; Imatinib; Electrode; Cyclic voltammetry; Electrochemistry; Analytical Chemistry (journal); Inorganic chemistry; Leukemia","score_opus":0.016295647672848048,"score_gpt":0.2818846684280266,"score_spread":0.2655890207551786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059644814","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99799997,0.0010245363,0.000004508103,0.0005959169,0.000030768348,0.00017796607,0.000017047885,0.0000024609424,0.00014681923],"genre_scores_gemma":[0.9995944,0.000054535598,0.00008439904,0.00005200182,0.000048389644,0.0000036439892,0.000010505691,0.000013855797,0.00013824922],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990219,0.000011407173,0.00042727994,0.00012681159,0.00017947913,0.00023314939],"domain_scores_gemma":[0.9991025,0.000027755917,0.00024311944,0.0001633589,0.00011245713,0.00035080593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019739277,0.00011915045,0.00024860102,0.00012418674,0.00009310161,0.000013336208,0.000091050766,0.00008712951,0.00006038433],"category_scores_gemma":[0.00010759133,0.00009496655,0.000058642207,0.00025529644,0.000108952736,0.00008526977,0.000015111819,0.00028742186,4.7653202e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000042786618,0.000059984333,0.5070435,0.00030442845,0.000064234046,0.00010887026,0.0006769932,0.0000341894,0.48962823,0.00005400101,0.00018043516,0.0018023477],"study_design_scores_gemma":[0.004343275,0.000037461705,0.50207174,0.00024376431,0.00017578494,0.0013197061,0.00007864314,0.000058797195,0.49117857,0.000112846,0.00028506975,0.00009432125],"about_ca_topic_score_codex":0.0014958971,"about_ca_topic_score_gemma":0.0023309684,"teacher_disagreement_score":0.004971733,"about_ca_system_score_codex":0.0021899713,"about_ca_system_score_gemma":0.0018225837,"threshold_uncertainty_score":0.57266986},"labels":[],"label_agreement":null},{"id":"W2060564241","doi":"10.1002/pmic.201100553","title":"Molecular and structural characterization of the <scp>SH</scp>3 domain of <scp>AHI</scp>‐1 in regulation of cellular resistance of <scp>BCR</scp>‐<scp>ABL</scp><sup>+</sup> chronic myeloid leukemia cells to tyrosine kinase inhibitors","year":2012,"lang":"en","type":"article","venue":"PROTEOMICS","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia; BC Cancer Agency","funders":"Canadian Institutes of Health Research","keywords":"SH3 domain; Tyrosine kinase; Myeloid leukemia; ABL; Cancer research; breakpoint cluster region; Chemistry; Biology; Philadelphia chromosome; Cell biology; Signal transduction; Receptor; Biochemistry; Gene","score_opus":0.006526571794354577,"score_gpt":0.21245222288886154,"score_spread":0.20592565109450695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060564241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99105847,0.0021862467,0.0012738243,0.000046342808,0.00028662733,0.0043817437,0.00032870946,0.000051942876,0.00038612],"genre_scores_gemma":[0.99204856,0.0002235162,0.005369628,0.00007181275,0.00031456898,0.00016664017,0.00032812817,0.00017674653,0.0013003884],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99385804,0.00048579657,0.002246978,0.00092768134,0.001334384,0.001147147],"domain_scores_gemma":[0.99448836,0.00075338787,0.0021899915,0.0016115056,0.0005357067,0.00042103813],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012351446,0.0008473996,0.001641214,0.0006095267,0.00013760594,0.000036283192,0.00057967205,0.00065352506,0.000008306847],"category_scores_gemma":[0.0021247058,0.0007516265,0.00036319293,0.0015622647,0.0005574074,0.00049798575,0.00041921446,0.00066099263,0.000008869461],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004475029,0.00024473405,0.025269384,0.002119989,0.00018703322,0.000011985405,0.0056334636,0.002210343,0.96332157,0.00036296048,0.00028089195,0.0003129064],"study_design_scores_gemma":[0.004937078,0.0004355858,0.055000763,0.0013806381,0.00028826372,0.000022273909,0.0008745666,0.0028233812,0.93268526,0.00029608354,0.0011759015,0.00008020004],"about_ca_topic_score_codex":0.00025675245,"about_ca_topic_score_gemma":0.000043790238,"teacher_disagreement_score":0.030636294,"about_ca_system_score_codex":0.0023237318,"about_ca_system_score_gemma":0.0011358253,"threshold_uncertainty_score":0.9994935},"labels":[],"label_agreement":null},{"id":"W2061303590","doi":"10.1046/j.1365-2141.2001.02556.x","title":"Engagement of the CrkL adaptor in interferon α signalling in BCR–ABL‐expressing cells","year":2001,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"National Cancer Institute; Medical Research Council; National Institutes of Health; U.S. Department of Veterans Affairs","keywords":"breakpoint cluster region; STAT5; Signal transducing adaptor protein; Cancer research; Chemistry; Chronic myelogenous leukemia; K562 cells; Interferon; ABL; Phosphorylation; Biology; Cell biology; Signal transduction; Leukemia; Virology; Cell; Immunology; Receptor; Tyrosine kinase; Biochemistry","score_opus":0.02612113893396738,"score_gpt":0.2746797086129177,"score_spread":0.2485585696789503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2061303590","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951955,0.0032472347,0.0001193503,0.00041450973,0.00026918473,0.00021576548,0.0000021339943,0.0000042457773,0.00053204095],"genre_scores_gemma":[0.99803233,0.0007555371,0.000906186,0.00012494414,0.00005852615,0.000003969492,9.0652486e-7,0.000017736607,0.000099875215],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.998105,0.00028705766,0.00091895135,0.00014751869,0.00025681753,0.00028465426],"domain_scores_gemma":[0.9990714,0.00017899573,0.00044495985,0.00014835759,0.0000882164,0.000068080946],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006119359,0.00011879452,0.00066805515,0.00019792597,0.000033317785,0.000012702538,0.00020782459,0.00010857235,0.00016642448],"category_scores_gemma":[0.00019380881,0.000104563886,0.00013420828,0.00020125664,0.000096743,0.000093929826,0.00008135943,0.0006374735,0.0000032184355],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003722558,0.005016614,0.27250546,0.0013998447,0.00085049827,0.32679245,0.005778193,0.0036788126,0.27469838,0.00019344654,0.007230659,0.098133065],"study_design_scores_gemma":[0.041934144,0.0020384248,0.12163235,0.03491947,0.00051396445,0.48554388,0.0036359357,0.0018511548,0.3007547,0.0009173803,0.005594658,0.00066394533],"about_ca_topic_score_codex":0.00037135658,"about_ca_topic_score_gemma":0.00048828058,"teacher_disagreement_score":0.15875141,"about_ca_system_score_codex":0.00045426394,"about_ca_system_score_gemma":0.0003291038,"threshold_uncertainty_score":0.42639914},"labels":[],"label_agreement":null},{"id":"W2062448901","doi":"10.1185/03007995.2014.944973","title":"Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase","year":2014,"lang":"en","type":"article","venue":"Current Medical Research and Opinion","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Nilotinib; Imatinib; Internal medicine; Adverse effect; Incidence (geometry); Imatinib mesylate; Quality of life (healthcare); Chronic myelogenous leukemia; Philadelphia chromosome; Bosutinib; Tyrosine-kinase inhibitor; Myeloid leukemia; Gastroenterology; Leukemia; Cancer","score_opus":0.09152452362728754,"score_gpt":0.45543503688559417,"score_spread":0.36391051325830664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062448901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933808,0.0020172573,0.00004479814,0.00068757526,0.0002869749,0.0033059653,0.00023629141,0.000020821986,0.000019512894],"genre_scores_gemma":[0.99208915,0.006213161,0.000034939414,0.000034432484,0.0002459089,0.00023229142,0.0011005347,0.000043434153,0.000006117594],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9933997,0.001022089,0.0018753791,0.00072412274,0.0018308245,0.0011478754],"domain_scores_gemma":[0.9945451,0.0029126958,0.0005704781,0.00047478548,0.000418944,0.0010779973],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003054628,0.0003648636,0.0013211723,0.0006497792,0.0001038297,0.0000054256575,0.00028444242,0.00031696257,0.00017382327],"category_scores_gemma":[0.013927859,0.00027595455,0.00021702594,0.00083412055,0.00040634003,0.00012831138,0.00015058774,0.0011581389,0.000009615326],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.03567862,0.02287272,0.24012706,0.021242617,0.0006992878,0.000050570197,0.004743189,0.00036812844,0.0019144185,0.00036677194,0.0023319,0.6696047],"study_design_scores_gemma":[0.14620647,0.03814866,0.77394164,0.021985628,0.00001887158,0.000006909671,0.00010872016,0.018546835,0.00038852193,0.00020676623,0.000078743135,0.000362241],"about_ca_topic_score_codex":0.0032984598,"about_ca_topic_score_gemma":0.0009647705,"teacher_disagreement_score":0.6692425,"about_ca_system_score_codex":0.010607484,"about_ca_system_score_gemma":0.012125456,"threshold_uncertainty_score":0.99996924},"labels":[],"label_agreement":null},{"id":"W2063319055","doi":"10.1111/j.1365-2141.2004.04955.x","title":"Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants","year":2004,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute","keywords":"Medicine; Internal medicine; Framingham Risk Score; Transplantation; Oncology; Population; Hematopoietic stem cell transplantation; Chronic myeloid leukaemia; Disease","score_opus":0.009854361523955739,"score_gpt":0.21968413883645418,"score_spread":0.20982977731249844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063319055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939785,0.004124523,0.0006481119,0.00013444044,0.00021419364,0.00082571874,0.000044594795,0.000010714894,0.000019230942],"genre_scores_gemma":[0.9965329,0.0017315384,0.0015454328,0.000043099702,0.000049779068,0.0000123969,0.000016723083,0.00004005926,0.000028072962],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981935,0.00012097778,0.0007390232,0.00026767468,0.00036578346,0.000313047],"domain_scores_gemma":[0.9981884,0.00015019285,0.0009163902,0.0002490425,0.00036682567,0.00012917716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003043282,0.00020030997,0.00077989715,0.00010656218,0.00015632351,0.000017583263,0.00015650774,0.00016903094,0.000014659401],"category_scores_gemma":[0.00007964437,0.00015151933,0.00016751113,0.00013549905,0.00019255043,0.00013213891,0.000032575117,0.00032379475,0.0000014222869],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003897528,0.0023823804,0.88877606,0.0060033426,0.0015254027,0.007036219,0.0021163337,0.0019186866,0.013715543,0.00012509523,0.00056325493,0.07194015],"study_design_scores_gemma":[0.05555196,0.0047676004,0.6348669,0.012195583,0.0026247369,0.18595567,0.00022081514,0.00007252837,0.10240193,0.0007397531,0.00012366554,0.00047883615],"about_ca_topic_score_codex":0.000099785546,"about_ca_topic_score_gemma":0.00014746837,"teacher_disagreement_score":0.25390914,"about_ca_system_score_codex":0.00045399353,"about_ca_system_score_gemma":0.0006709134,"threshold_uncertainty_score":0.61787784},"labels":[],"label_agreement":null},{"id":"W2063853379","doi":"10.1038/leu.2011.34","title":"A phase I/II study of imatinib plus reinduction therapy for c-kit-positive relapsed/refractory acute myeloid leukemia: inhibition of Akt activation correlates with complete response","year":2011,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto","funders":"","keywords":"Medicine; Imatinib; Mitoxantrone; Myeloid leukemia; Internal medicine; Cytarabine; Imatinib mesylate; Etoposide; Oncology; Refractory (planetary science); Gastroenterology; Pharmacology; Chemotherapy; Biology","score_opus":0.038890731830352694,"score_gpt":0.293776129030658,"score_spread":0.2548853972003053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063853379","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942272,0.00007654621,0.0009390827,0.00006142149,0.00014270585,0.0039511463,0.00012245688,0.000106337226,0.0003731336],"genre_scores_gemma":[0.9961567,0.000048290687,0.0022274712,0.000089732646,0.00010475306,0.00039375346,0.00037742333,0.00009428452,0.00050761143],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973091,0.00024769214,0.00088174816,0.0006179364,0.0005566598,0.00038685944],"domain_scores_gemma":[0.99717474,0.00039583107,0.0010129212,0.0007097178,0.0005658613,0.00014093751],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00049424655,0.00044364692,0.000879958,0.00038340894,0.00021878198,0.000008999546,0.0001303273,0.00029870606,0.00008579808],"category_scores_gemma":[0.00015140921,0.00036243198,0.0001717341,0.0004847313,0.00022352644,0.00041937607,0.00005798501,0.0004605152,0.0000069765015],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19922556,0.0056080148,0.0008505935,0.00019648249,0.002076047,0.00010099948,0.035529595,0.00013402097,0.7435815,0.00009926762,0.00067462487,0.011923341],"study_design_scores_gemma":[0.16457413,0.11343228,0.019277431,0.0011209988,0.0013357413,0.00016930807,0.0058592707,0.0016454958,0.69162714,0.0001813028,0.0002018019,0.00057507306],"about_ca_topic_score_codex":0.0007766375,"about_ca_topic_score_gemma":0.000027631755,"teacher_disagreement_score":0.107824266,"about_ca_system_score_codex":0.0052174567,"about_ca_system_score_gemma":0.0019934657,"threshold_uncertainty_score":0.99988276},"labels":[],"label_agreement":null},{"id":"W2064192118","doi":"10.3747/co.v16i2.301","title":"Concomitant Renal Cell Carcinoma and Chronic Myelogenous Leukemia: Use of a Targeted Approach","year":2009,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Sunitinib; Sorafenib; Imatinib; Chronic myelogenous leukemia; Nilotinib; Dasatinib; Renal cell carcinoma; Tyrosine-kinase inhibitor; Concomitant; Tyrosine kinase; Oncology; Bevacizumab; Targeted therapy; Temsirolimus; Internal medicine; Leukemia; Cancer; Chemotherapy; Myeloid leukemia; Hepatocellular carcinoma; PI3K/AKT/mTOR pathway","score_opus":0.07053278544921589,"score_gpt":0.32100040236091204,"score_spread":0.25046761691169617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2064192118","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9817256,0.014704919,0.00019374362,0.00015704945,0.00026754453,0.00080008304,0.000031749667,0.00005285386,0.0020664746],"genre_scores_gemma":[0.9965186,0.0006911572,0.0020192536,0.00010644854,0.00024369179,0.000031077027,0.00015550604,0.00002253402,0.00021169613],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9981864,0.000119946424,0.00050044,0.00048412548,0.00021978965,0.0004893182],"domain_scores_gemma":[0.99880576,0.00013922183,0.00024411803,0.00043299736,0.000121407385,0.0002565044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001440492,0.00028531352,0.00078307226,0.00015933924,0.00006430778,0.000008463727,0.00010931332,0.00026188832,0.00006613209],"category_scores_gemma":[0.000072835006,0.00024278066,0.00012473187,0.00019496214,0.00023234749,0.00007344337,0.00006844872,0.0004601202,0.000013829588],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030575553,0.0082481215,0.109979115,0.0019660578,0.0004893186,0.0011694466,0.0045427624,0.00020168883,0.25824744,0.0010217737,0.022666674,0.5884101],"study_design_scores_gemma":[0.07619435,0.034162454,0.54503214,0.00045156523,0.002699628,0.0034380963,0.0004632241,0.016993845,0.0824924,0.00030995614,0.2362576,0.0015047588],"about_ca_topic_score_codex":0.00005658253,"about_ca_topic_score_gemma":0.0000121065295,"teacher_disagreement_score":0.5869053,"about_ca_system_score_codex":0.0040056156,"about_ca_system_score_gemma":0.0022811138,"threshold_uncertainty_score":0.99981785},"labels":[],"label_agreement":null},{"id":"W2064933772","doi":"10.1016/j.bbmt.2012.11.481","title":"A Phase 1 Open Label, Multi-Center, Dose Escalation Study of Nilotinib (NLT) in Steroid Dependent / Refractory Chronic Graft-Versus-Host Disease (cGvHD)","year":2013,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Adverse effect; Prednisone; Refractory (planetary science); Trough level; Internal medicine; Single Center; Corticosteroid; Nilotinib; Dosing; Pharmacokinetics; Gastroenterology; Pharmacology; Tacrolimus; Transplantation; Imatinib","score_opus":0.04760983088244001,"score_gpt":0.3409495016617229,"score_spread":0.29333967077928286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2064933772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965906,0.00080781814,0.000038231887,0.00006009908,0.00011136609,0.0021951906,0.0001383341,0.000016778411,0.00004154168],"genre_scores_gemma":[0.9978634,0.0010288357,0.00026103551,0.000018924438,0.000025604486,0.00015254636,0.0005907328,0.00001610076,0.000042779462],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.998664,0.0001579185,0.0004971643,0.00035727772,0.00012374707,0.00019986226],"domain_scores_gemma":[0.9992854,0.000090968366,0.00021236017,0.00022073985,0.00006556397,0.00012495315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014943496,0.0001859865,0.0003955966,0.00015962783,0.000036048506,0.0000087736535,0.00011407998,0.000106043524,0.000058572947],"category_scores_gemma":[0.000020457337,0.00016115537,0.000030795884,0.00009726025,0.00008629495,0.00020257647,0.000031303345,0.00011956646,0.000004841476],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012353289,0.041967846,0.33004355,0.00097459904,0.0006629262,0.00010265705,0.0026320685,0.000006002545,0.59977305,0.000023636396,0.000015886517,0.011444482],"study_design_scores_gemma":[0.5004653,0.020353032,0.45829064,0.0005698014,0.0017343774,0.00003527715,0.00064391654,0.00054844934,0.016978512,0.000021711377,0.000029899751,0.00032911045],"about_ca_topic_score_codex":0.0012093062,"about_ca_topic_score_gemma":0.0015901155,"teacher_disagreement_score":0.58279455,"about_ca_system_score_codex":0.000097081116,"about_ca_system_score_gemma":0.0001741109,"threshold_uncertainty_score":0.65717256},"labels":[],"label_agreement":null},{"id":"W2065430663","doi":"10.1182/blood-2011-01-329797","title":"A genome-wide association study identifies novel loci associated with susceptibility to chronic myeloid leukemia","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Myeloid leukemia; Cohort; Genome-wide association study; Medicine; Internal medicine; Locus (genetics); Candidate gene; Genetic association; Oncology; Genetics; Biology; Gene; Genotype; Single-nucleotide polymorphism","score_opus":0.023632263912175405,"score_gpt":0.2481965590923387,"score_spread":0.2245642951801633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2065430663","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99442416,0.00012270676,0.000064228,0.00011184388,0.00009760984,0.0022014112,0.00003726589,0.000267774,0.0026730173],"genre_scores_gemma":[0.9942942,0.000010198238,0.00032985036,0.00022190438,0.00015778949,0.00019232542,0.00011839084,0.00007277845,0.0046025147],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970173,0.00010545555,0.00052091427,0.0007621967,0.0008946716,0.00069943815],"domain_scores_gemma":[0.9979904,0.00021243498,0.00031673847,0.0008179175,0.00036026232,0.0003022398],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007990016,0.00038108663,0.0006662497,0.00016566382,0.00016326399,0.00004793006,0.00024432666,0.00020175627,0.00048823247],"category_scores_gemma":[0.0011840534,0.00032627652,0.00013314188,0.0005801536,0.000049446342,0.00015841897,0.00014152899,0.00035373378,0.0003069541],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018868339,0.0048549166,0.9815591,0.0000460942,0.0019393013,0.00012441396,0.003753715,0.0000073662836,0.0071820724,0.0000027809813,0.00025412728,0.000087420114],"study_design_scores_gemma":[0.01720492,0.0028820795,0.9712632,0.000094923074,0.0015404229,0.000010695738,0.0006255818,0.0000070935334,0.00589387,0.00001552859,0.0001423295,0.00031940304],"about_ca_topic_score_codex":0.00094826357,"about_ca_topic_score_gemma":0.005473472,"teacher_disagreement_score":0.017016236,"about_ca_system_score_codex":0.010350785,"about_ca_system_score_gemma":0.0013742942,"threshold_uncertainty_score":0.99991894},"labels":[],"label_agreement":null},{"id":"W2066023838","doi":"10.1016/j.exphem.2003.10.010","title":"SCL: From the origin of hematopoiesis to stem cells and leukemia","year":2004,"lang":"en","type":"review","venue":"Experimental Hematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":149,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Haematopoiesis; Transcription factor; Biology; Stem cell; Regulator; Hematopoietic stem cell; Leukemia; Cell biology; Transcription (linguistics); Genetics; Gene; Lineage (genetic); Computational biology; Cancer research","score_opus":0.04608980461120263,"score_gpt":0.34932174445569886,"score_spread":0.30323193984449626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066023838","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0032120263,0.99389744,0.0000066310645,0.000062220955,0.0003374718,0.0018215505,0.00011741632,0.000053180003,0.00049208873],"genre_scores_gemma":[0.004303883,0.99256855,0.0013934663,0.00019968691,0.00014124432,0.0004397892,0.000112427,0.00013866856,0.00070229574],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976477,0.00012497447,0.00085018075,0.00069121056,0.0002854247,0.0004004917],"domain_scores_gemma":[0.9981604,0.0003526415,0.00034672496,0.00087805564,0.00002664515,0.00023552432],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000090379304,0.0006001104,0.0029290912,0.00012281701,0.00007356385,0.000013036713,0.000296258,0.00043002825,0.0003732667],"category_scores_gemma":[0.000011389844,0.00038597028,0.00038254936,0.00023096487,0.00025040732,0.000032433432,0.00030671322,0.00031946687,0.00035144002],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009974013,0.0036237002,0.0005253495,0.12856625,0.01254593,0.0048546684,0.016719101,0.0000035754845,0.0015414879,0.08698813,0.039706096,0.7039283],"study_design_scores_gemma":[0.003209329,0.00050566974,0.0000047942485,0.031018466,0.0015194631,0.002569407,0.0010264701,0.0000014301937,0.07388378,0.000043957265,0.8856441,0.00057314505],"about_ca_topic_score_codex":0.0005028759,"about_ca_topic_score_gemma":0.000011800549,"teacher_disagreement_score":0.84593797,"about_ca_system_score_codex":0.0023277511,"about_ca_system_score_gemma":0.0012494958,"threshold_uncertainty_score":0.9998592},"labels":[],"label_agreement":null},{"id":"W2067382049","doi":"10.1038/onc.2010.67","title":"Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1α-induced metabolic reprograming","year":2010,"lang":"en","type":"article","venue":"Oncogene","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":176,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute","keywords":"Biology; Imatinib mesylate; Cancer research; Transketolase; Imatinib; Myeloid leukemia; Biochemistry; Enzyme","score_opus":0.019921697606279497,"score_gpt":0.2846204596258328,"score_spread":0.26469876201955334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067382049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98820096,0.0002241628,0.000033660992,0.00062061136,0.00022273052,0.00071670226,0.00002183482,0.00018395195,0.009775395],"genre_scores_gemma":[0.9880343,0.000020781394,0.0041730287,0.00031992694,0.0002279221,0.00008861599,0.00014416616,0.0000698867,0.0069213505],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99787474,0.000058977854,0.0003557682,0.0006014289,0.00068818073,0.00042089802],"domain_scores_gemma":[0.99834216,0.00010061455,0.00028595814,0.0008991067,0.00017625696,0.00019588674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035808957,0.00028761892,0.0004594183,0.000106265295,0.00015807664,0.000037885955,0.00012133184,0.00021271281,0.00033764463],"category_scores_gemma":[0.0002900391,0.00023104521,0.000105245745,0.00038332914,0.000047641264,0.00009341777,0.000033582983,0.00038985172,0.000118481876],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013567186,0.0017409513,0.036007743,0.00009595972,0.0015876167,0.00045669577,0.0014758656,0.000018920115,0.8012947,0.0008917644,0.0011537108,0.15391937],"study_design_scores_gemma":[0.013381386,0.0007443668,0.18078864,0.00050413137,0.0009047029,0.000093817376,0.00009387247,0.00046396494,0.79120034,0.00018281232,0.011067809,0.0005741396],"about_ca_topic_score_codex":0.00010983949,"about_ca_topic_score_gemma":0.0007735496,"teacher_disagreement_score":0.15334523,"about_ca_system_score_codex":0.000590121,"about_ca_system_score_gemma":0.00035703828,"threshold_uncertainty_score":0.94217503},"labels":[],"label_agreement":null},{"id":"W2068587884","doi":"10.1007/s40271-013-0006-3","title":"The Patient Journey in Chronic Myeloid Leukemia Patients on Tyrosine Kinase Inhibitor Therapies: Qualitative Insights Using a Global Ethnographic Approach","year":2013,"lang":"en","type":"article","venue":"Patient","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Smiths Detection (Canada)","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Myeloid leukemia; Disease; Optimism; Qualitative research; Family medicine; Life expectancy; Debriefing; Intensive care medicine; Internal medicine; Psychology; Psychotherapist; Population","score_opus":0.032651636071600376,"score_gpt":0.3028228139926159,"score_spread":0.2701711779210155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068587884","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918026,0.00290829,0.00003112139,0.00014444537,0.0003938807,0.0030300436,0.00003408788,0.00007373068,0.0015818309],"genre_scores_gemma":[0.9976942,0.00020386266,0.0007570154,0.0004829524,0.00012903257,0.000522776,0.000116469615,0.000062969746,0.000030733794],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9957401,0.00054182677,0.0010018318,0.0007369955,0.0011100974,0.000869128],"domain_scores_gemma":[0.99779624,0.00025317015,0.00045614803,0.00080012484,0.00034856383,0.00034577897],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021393926,0.0005897018,0.0005875692,0.00025079143,0.00039394188,0.000096852695,0.00022155842,0.00022790821,0.000056172004],"category_scores_gemma":[0.00020403779,0.00037803984,0.00024118775,0.0009798787,0.00030421012,0.00023500632,0.00015563276,0.0005884289,0.00011269769],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005636411,0.016185816,0.13990428,0.0011663937,0.002905573,0.00027064863,0.384431,0.006949006,0.0068230485,0.0033743319,0.0109802475,0.42137322],"study_design_scores_gemma":[0.12628525,0.0615798,0.5104343,0.010340726,0.0012366419,0.0001715596,0.14004731,0.0776443,0.022414183,0.007927462,0.03457506,0.007343392],"about_ca_topic_score_codex":0.0018600954,"about_ca_topic_score_gemma":0.00016271803,"teacher_disagreement_score":0.41402984,"about_ca_system_score_codex":0.013291947,"about_ca_system_score_gemma":0.0009942015,"threshold_uncertainty_score":0.99986714},"labels":[],"label_agreement":null},{"id":"W2068834508","doi":"10.1038/leu.2010.159","title":"Insights into the stem cells of chronic myeloid leukemia","year":2010,"lang":"en","type":"review","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":120,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Stem cell; Haematopoiesis; Myeloid leukemia; Biology; Somatic evolution in cancer; Phenotype; Cancer stem cell; Hematopoietic stem cell; Leukemia; Immunology; Myeloid; Cancer research; Cancer; Genetics; Gene","score_opus":0.025212852724935363,"score_gpt":0.29107243080304046,"score_spread":0.2658595780781051,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068834508","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0020882576,0.9880554,0.000015161748,0.00003171767,0.0014642944,0.0029978927,0.000029888766,0.00017426912,0.0051431046],"genre_scores_gemma":[0.000510639,0.9842202,0.00024182531,0.00012052556,0.0015077025,0.00041763674,0.00022318368,0.00030627477,0.012452002],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99466914,0.00029992822,0.0019037983,0.0012269669,0.0010510973,0.0008490826],"domain_scores_gemma":[0.9939937,0.00070474204,0.0013657737,0.0033138427,0.00020525843,0.0004167058],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.00033906056,0.0013732802,0.004223823,0.00043533684,0.00023529262,0.000052704105,0.0012694341,0.0017822828,0.0003503074],"category_scores_gemma":[0.00005726816,0.00082085,0.0016213075,0.0009836036,0.0006071998,0.00012613519,0.00047452268,0.0032773523,0.0013779053],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00002501531,0.000071042516,0.0000025173738,0.022067538,0.0007749262,0.00017290724,0.0004383541,0.0000053399153,0.00031641993,0.00026679778,0.0031119096,0.9727472],"study_design_scores_gemma":[0.002017987,0.00036503864,0.000006891011,0.015962986,0.003906425,0.00023324927,0.000039319348,0.00008335042,0.0015610737,0.000044333025,0.9751391,0.00064023765],"about_ca_topic_score_codex":0.0006292074,"about_ca_topic_score_gemma":0.00026000253,"teacher_disagreement_score":0.972107,"about_ca_system_score_codex":0.02631578,"about_ca_system_score_gemma":0.02441042,"threshold_uncertainty_score":0.9999018},"labels":[],"label_agreement":null},{"id":"W2072432392","doi":"10.1016/j.leukres.2004.11.011","title":"Cytokinetics and mechanism of action of AKO4: a novel nitrogen mustard targeted to bcr-abl","year":2005,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada; Royal Victoria Hospital; McGill University Health Centre; Royal Victoria Regional Health Centre","funders":"","keywords":"Chlorambucil; Nitrogen mustard; breakpoint cluster region; ABL; K562 cells; Cancer research; Apoptosis; Philadelphia chromosome; Biology; Tyrosine kinase; DNA damage; Flow cytometry; Chemistry; Molecular biology; Cell biology; DNA; Biochemistry; Receptor; Signal transduction; Chemotherapy; Chromosomal translocation; Genetics","score_opus":0.08074433413515884,"score_gpt":0.37642908915909085,"score_spread":0.295684755023932,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2072432392","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955267,0.00027005217,0.0005605427,0.00081009715,0.000039488783,0.00090352236,0.000045644218,0.000027522692,0.0018164715],"genre_scores_gemma":[0.9840185,0.00016203163,0.014025769,0.000098105884,0.0001674512,0.000051556228,0.000028063818,0.000041520416,0.0014069877],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99756175,0.0000833676,0.0004194651,0.00038380473,0.0010182597,0.0005333502],"domain_scores_gemma":[0.99833,0.00020556124,0.000087897344,0.00054964883,0.00051189587,0.00031502306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006759661,0.00017635632,0.0004333032,0.0004972129,0.000068667745,0.000011027183,0.00016463242,0.00019125518,0.0002736624],"category_scores_gemma":[0.00040423629,0.00016039291,0.00007882128,0.0006579153,0.00015367658,0.00007460222,0.00020776736,0.00045583266,0.00006609295],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008670233,0.00027938507,0.0014311468,0.00036691647,0.00019482421,0.000023704471,0.00085486384,0.00008944498,0.97760147,0.0014398771,0.0012188513,0.015632497],"study_design_scores_gemma":[0.006813999,0.0013023972,0.0031255584,0.00021819113,0.00009009381,0.000084529485,0.0004815359,0.0041970927,0.9768625,0.0005757333,0.0060925614,0.00015581699],"about_ca_topic_score_codex":0.00068286824,"about_ca_topic_score_gemma":0.00012214344,"teacher_disagreement_score":0.01547668,"about_ca_system_score_codex":0.002826412,"about_ca_system_score_gemma":0.0013348307,"threshold_uncertainty_score":0.73909694},"labels":[],"label_agreement":null},{"id":"W2072875377","doi":"10.3747/co.v18i2.391","title":"Monitoring Response and Resistance to Treatment in Chronic Myeloid Leukemia","year":2011,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Jewish General Hospital","funders":"","keywords":"Medicine; Myeloid leukemia; Immunology; Intensive care medicine","score_opus":0.11192742089545413,"score_gpt":0.3860843015670953,"score_spread":0.2741568806716411,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2072875377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98708695,0.008224988,0.000012879282,0.0003012384,0.0006135852,0.00080047845,0.0000055573782,0.00005953163,0.0028947673],"genre_scores_gemma":[0.99440825,0.0017749709,0.0017675834,0.000030693776,0.00027958123,0.0003273941,0.000005415045,0.000029752135,0.0013763849],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99840754,0.00016032979,0.00033444754,0.0004908667,0.00013870405,0.00046810906],"domain_scores_gemma":[0.99903214,0.00017187666,0.00007350574,0.00039208514,0.00004300348,0.0002874182],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002579374,0.00024172643,0.00047033012,0.0002454785,0.000051707822,0.0000057484735,0.00008649688,0.00013330202,0.00009391047],"category_scores_gemma":[0.00013048854,0.0002117247,0.000055673623,0.00023511077,0.00008458404,0.000054127846,0.00007436683,0.0002098192,0.00011630287],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015693225,0.001259405,0.4277632,0.00025175995,0.00017299468,0.0013673151,0.01231214,0.0000047928406,0.016170226,0.0001930097,0.000754694,0.52405727],"study_design_scores_gemma":[0.0107288575,0.0039569708,0.78707427,0.000541516,0.00011794403,0.0000923883,0.0002699867,0.000025179594,0.01271185,0.00010126514,0.18412405,0.00025574665],"about_ca_topic_score_codex":0.0001423561,"about_ca_topic_score_gemma":0.00049233163,"teacher_disagreement_score":0.5238015,"about_ca_system_score_codex":0.024711916,"about_ca_system_score_gemma":0.0022253548,"threshold_uncertainty_score":0.97903204},"labels":[],"label_agreement":null},{"id":"W2073019201","doi":"10.1080/13684730210002319","title":"Increased IFN-? synthesis by T cells from patients on imatinib therapy for chronic myeloid leukemia","year":2002,"lang":"en","type":"article","venue":"Cytokines Cellular & Molecular Therapy","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Imatinib; Medicine; Cytokine; Myeloid leukemia; Immunology; Tyrosine-kinase inhibitor; White blood cell; Myeloid; Stem cell; Internal medicine; Cancer; Biology","score_opus":0.014267104526376168,"score_gpt":0.23014121510386867,"score_spread":0.2158741105774925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073019201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98235244,0.0112093575,0.001063267,0.00030993653,0.00032955135,0.0031510135,0.0005112817,0.0002549348,0.00081821607],"genre_scores_gemma":[0.9889282,0.0038822202,0.0012523335,0.0021488117,0.00041551556,0.0009076276,0.0013785244,0.0003430894,0.00074367557],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9960198,0.00022397809,0.0007480126,0.0012147714,0.00085389323,0.00093958393],"domain_scores_gemma":[0.9970629,0.00043326896,0.00035889517,0.0015332578,0.00020416544,0.00040750156],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00018285487,0.0009254205,0.0010379312,0.00021259581,0.00023211275,0.000082877435,0.00049213914,0.00042634975,0.001945916],"category_scores_gemma":[0.00009639396,0.0007920283,0.00068183005,0.00033848285,0.0001527853,0.00011634797,0.000046997764,0.00035656733,0.00048546022],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012417865,0.0014285566,0.00071490544,0.000054731616,0.000874618,0.00010253683,0.00019024735,0.000032802775,0.88741094,0.000016197597,0.007467912,0.100464754],"study_design_scores_gemma":[0.021217592,0.0019256566,0.00070112175,0.00018716074,0.00017432027,0.00000419229,0.000015193882,0.0018840285,0.90735835,0.00007911306,0.06578276,0.00067049527],"about_ca_topic_score_codex":0.0003329859,"about_ca_topic_score_gemma":0.00000391005,"teacher_disagreement_score":0.09979425,"about_ca_system_score_codex":0.0021175279,"about_ca_system_score_gemma":0.0002659683,"threshold_uncertainty_score":0.99945307},"labels":[],"label_agreement":null},{"id":"W2075548587","doi":"10.1182/blood.v97.3.720","title":"Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3","year":2001,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":150,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"BC Cancer Agency","keywords":"Biology; Myeloid leukemia; CD38; Interleukin 3; Progenitor cell; CD34; Leukemia; Cancer research; Population; Myeloid; Molecular biology; Growth factor; ABL; Immunology; Stem cell; Cell biology; T cell; Interleukin 21; Signal transduction; Immune system; Tyrosine kinase; Medicine; Receptor; Genetics","score_opus":0.006904935077660119,"score_gpt":0.20762307441750769,"score_spread":0.20071813933984756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075548587","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982541,0.00010615364,0.0000489549,0.000010773372,0.00007855275,0.0011506709,0.00011408639,0.00003076319,0.00020591075],"genre_scores_gemma":[0.99887717,0.00009888486,0.00034489436,0.000018923543,0.00004931047,0.000046181747,0.00042915906,0.000054419175,0.00008103267],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972375,0.00014197045,0.0007563778,0.0005106286,0.0009215679,0.00043195434],"domain_scores_gemma":[0.99833655,0.00018765133,0.0007781984,0.00034941637,0.0002432073,0.00010495016],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001414366,0.00035512753,0.00074083824,0.00035442584,0.000024667634,0.000010218623,0.00014272968,0.0002458018,0.000093607174],"category_scores_gemma":[0.00006111819,0.00028580747,0.00007952153,0.00038795083,0.00005906272,0.00022326344,0.00006647455,0.0003755505,0.000007067269],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003675319,0.0010876865,0.65014344,0.00011552729,0.00016762123,0.00013566711,0.0015504599,0.0000963778,0.34224188,0.0000016962276,0.0000046140494,0.000779718],"study_design_scores_gemma":[0.020659862,0.00068619597,0.48607865,0.0009987284,0.00013036822,0.00001299825,0.00008894511,0.000053325577,0.4911367,0.000009569485,0.0000028547977,0.00014181103],"about_ca_topic_score_codex":0.003885922,"about_ca_topic_score_gemma":0.0014688749,"teacher_disagreement_score":0.1640648,"about_ca_system_score_codex":0.009409653,"about_ca_system_score_gemma":0.0011515495,"threshold_uncertainty_score":0.9999594},"labels":[],"label_agreement":null},{"id":"W2075634944","doi":"10.2165/00003495-200767170-00014","title":"Imatinib in Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia","year":2007,"lang":"en","type":"article","venue":"Drugs","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Imatinib; Refractory (planetary science); Philadelphia chromosome; Lymphoblastic Leukemia; Oncology; Internal medicine; Pharmacotherapy; Pediatrics; Leukemia; Genetics; Chromosomal translocation; Gene","score_opus":0.01332079583642018,"score_gpt":0.29007371630028644,"score_spread":0.27675292046386624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075634944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881664,0.00026128785,0.000056112178,0.0009311937,0.00027222282,0.000702625,0.000046445613,0.00015466503,0.009409058],"genre_scores_gemma":[0.9948747,0.000096418,0.00095337763,0.0009799963,0.00025418593,0.000037977075,0.00016250716,0.00007125923,0.0025695548],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9977077,0.000046610774,0.0005842022,0.0005145619,0.00047405073,0.00067284086],"domain_scores_gemma":[0.9985023,0.00043696738,0.00016823593,0.0005309646,0.00007957332,0.0002819621],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034151637,0.00033761538,0.00054209784,0.00030600248,0.00007140202,0.000015002946,0.00015100499,0.00024541933,0.00059651263],"category_scores_gemma":[0.00017708015,0.00027231715,0.00012362874,0.0005588954,0.00012395436,0.0000952579,0.00007275529,0.00040575553,0.00041261388],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060556356,0.014815321,0.08517317,0.002681458,0.007940521,0.09595623,0.09728279,0.00021858398,0.3324621,0.0022819997,0.05470629,0.24592517],"study_design_scores_gemma":[0.17435308,0.008104429,0.5841504,0.0065058097,0.0029933252,0.0054403655,0.006153081,0.0036685157,0.18087435,0.0007004475,0.023396997,0.0036592388],"about_ca_topic_score_codex":0.0001598346,"about_ca_topic_score_gemma":0.000089636225,"teacher_disagreement_score":0.49897718,"about_ca_system_score_codex":0.0040010884,"about_ca_system_score_gemma":0.00087947724,"threshold_uncertainty_score":0.9999729},"labels":[],"label_agreement":null},{"id":"W2077014658","doi":"10.1002/pbc.21132","title":"A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: A Children's Oncology Group study","year":2007,"lang":"en","type":"article","venue":"Pediatric Blood & Cancer","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":209,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Centre Hospitalier Universitaire Sainte-Justine; BC Children's Hospital","funders":"National Cancer Institute","keywords":"Medicine; Imatinib mesylate; Sarcoma; Imatinib; Osteosarcoma; Neuroblastoma; Synovial sarcoma; Refractory (planetary science); Internal medicine; Oncology; Platelet-derived growth factor receptor; Surgical oncology; Pathology; Receptor","score_opus":0.01498889142586767,"score_gpt":0.33410369590748557,"score_spread":0.3191148044816179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077014658","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928217,0.0013656935,0.0000033480862,0.000036163747,0.00011215536,0.0053110505,0.000045632285,0.00010229906,0.00020199358],"genre_scores_gemma":[0.99763864,0.0003650144,0.0002870966,0.000088949266,0.0008375762,0.0004707247,0.000044676533,0.000094270494,0.00017304094],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962799,0.00016764572,0.0011727057,0.0008505208,0.0007704106,0.00075880653],"domain_scores_gemma":[0.99792683,0.00017607256,0.00071546837,0.0007577621,0.00013422931,0.00028961376],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007702273,0.0004951427,0.0012972673,0.00063696475,0.00012174089,0.000009103348,0.00026305267,0.00017195151,0.00035058998],"category_scores_gemma":[0.00011465974,0.0003575937,0.00009496637,0.0013620945,0.00007477187,0.00015035845,0.00016007139,0.0007168737,0.0000084586045],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005357285,0.07664606,0.9000333,0.000058462996,0.0014566571,0.0006946682,0.0066895518,0.000012557687,0.000084604704,7.044029e-7,0.00011788835,0.0088482555],"study_design_scores_gemma":[0.13691798,0.0814051,0.77570665,0.00007534171,0.0038944753,0.00023130066,0.0012968632,0.0000072621056,0.000119852906,0.0000016389146,0.000019540188,0.00032400963],"about_ca_topic_score_codex":0.0066612936,"about_ca_topic_score_gemma":0.0053951903,"teacher_disagreement_score":0.1315607,"about_ca_system_score_codex":0.00095094455,"about_ca_system_score_gemma":0.0014854076,"threshold_uncertainty_score":0.99995345},"labels":[],"label_agreement":null},{"id":"W2077285193","doi":"10.1016/j.taap.2010.08.026","title":"The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro","year":2010,"lang":"en","type":"article","venue":"Toxicology and Applied Pharmacology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":102,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Canadian Institutes of Health Research; Canada Research Chairs","keywords":"Tyrosine kinase; Kinase; Sunitinib; Cyclin-dependent kinase 9; Dasatinib; MAP kinase kinase kinase; Lapatinib; Chemistry; Tyrosine-kinase inhibitor; Pharmacology; Mitogen-activated protein kinase kinase; Biology; Biochemistry; Protein kinase A; Signal transduction; Cancer","score_opus":0.017730040865506762,"score_gpt":0.2905904223245284,"score_spread":0.27286038145902164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077285193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961204,0.000102536396,0.000015978309,0.0011233601,0.00019198528,0.0010454252,0.000036889294,0.000018140852,0.0013452886],"genre_scores_gemma":[0.99805754,0.00004533203,0.0006966497,0.00095912116,0.0000570494,0.00009650085,0.0000108911745,0.0000167449,0.000060146926],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987675,0.0000786048,0.00037585525,0.00035152514,0.00008589019,0.00034065355],"domain_scores_gemma":[0.99894285,0.0004422081,0.00015591821,0.00026109238,0.000066569984,0.0001313717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032288543,0.0001968657,0.00051771716,0.000087077,0.00006459968,0.0000025490906,0.00013195432,0.00022136477,0.00037761673],"category_scores_gemma":[0.000029408298,0.00012881214,0.000039368497,0.00025079114,0.00083010836,0.000014277412,0.00009930253,0.00054384925,0.000005251912],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054377834,0.0004926742,0.010368129,0.00006136466,0.00012186618,0.000024058221,0.00059699576,0.00004881185,0.980935,0.00021846614,0.00041840292,0.0012764795],"study_design_scores_gemma":[0.0053496608,0.0004955007,0.027235685,0.00000880354,0.00010266906,0.000015570751,0.00013661408,0.0004001111,0.96511745,0.000109837376,0.0009224967,0.00010560667],"about_ca_topic_score_codex":0.000055022327,"about_ca_topic_score_gemma":0.000110977424,"teacher_disagreement_score":0.016867554,"about_ca_system_score_codex":0.00012857758,"about_ca_system_score_gemma":0.00031405553,"threshold_uncertainty_score":0.5252807},"labels":[],"label_agreement":null},{"id":"W2078051582","doi":"10.1080/10428190601175393","title":"Phase II, randomized, multicenter, comparative study of peginterferon–α–2a (40 kD) (Pegasys®)<i>versus</i>interferon α-2a (Roferon®-A) in patients with treatment-naïve, chronic-phase chronic myelogenous leukemia","year":2007,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Gastroenterology; Internal medicine; Chronic myelogenous leukemia; PEG ratio; Philadelphia chromosome; Interferon; Adverse effect; Immunology; Leukemia; Chromosomal translocation; Biology","score_opus":0.018731130442451106,"score_gpt":0.2977675554976269,"score_spread":0.2790364250551758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078051582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9824953,0.0038638283,0.00020707365,0.000034634606,0.00092461123,0.00978334,0.0002270872,0.00036472408,0.0020993704],"genre_scores_gemma":[0.99471986,0.0007031389,0.00043605585,0.00014843605,0.0005753016,0.0007723634,0.00092753506,0.00035619564,0.0013611243],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9879124,0.000706183,0.003606848,0.002967588,0.0018314668,0.002975507],"domain_scores_gemma":[0.9925212,0.0012900194,0.0017544454,0.0024767092,0.00060993666,0.0013476644],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0011357421,0.0027223853,0.0056264075,0.0014706351,0.0007334476,0.00014685412,0.00090697024,0.0009226803,0.00027307437],"category_scores_gemma":[0.00014867372,0.0021985034,0.0008316356,0.0013780008,0.0014755289,0.00082297885,0.00058551546,0.00059209135,0.00008935074],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.76739866,0.03702735,0.012903849,0.00076682254,0.006630778,0.0020597272,0.02148111,0.0005674236,0.0028020432,0.00009258194,0.00060090044,0.14766878],"study_design_scores_gemma":[0.8686016,0.08660647,0.015625596,0.001292652,0.0029559257,0.00024061254,0.0043266774,0.0072481665,0.009777551,0.000008917589,0.0015675557,0.0017482685],"about_ca_topic_score_codex":0.008830597,"about_ca_topic_score_gemma":0.0073653217,"teacher_disagreement_score":0.14592052,"about_ca_system_score_codex":0.11424369,"about_ca_system_score_gemma":0.010720413,"threshold_uncertainty_score":0.99855095},"labels":[],"label_agreement":null},{"id":"W2078189286","doi":"10.1007/s12185-012-1142-6","title":"Polymorphisms of ERCC1 genotype associated with response to imatinib therapy in chronic phase chronic myeloid leukemia","year":2012,"lang":"en","type":"article","venue":"International Journal of Hematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Imatinib; Myeloid leukemia; Medicine; Hematology; Internal medicine; Oncology; ERCC1; Chronic myeloid leukaemia; Genotype; Dasatinib; Immunology; Biology; Genetics; Gene; DNA repair; Nucleotide excision repair","score_opus":0.022124246252064186,"score_gpt":0.33116411526778405,"score_spread":0.3090398690157199,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078189286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99341106,0.003786385,0.0002344325,0.0016117647,0.0004360503,0.0002932392,0.000017089624,0.00001300536,0.00019694625],"genre_scores_gemma":[0.9982512,0.00018198557,0.0007473542,0.00028869693,0.0002948503,0.000013493189,0.000019137018,0.00003557659,0.0001677252],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977154,0.00019047242,0.00088645704,0.00016253437,0.0006371271,0.00040801376],"domain_scores_gemma":[0.9979585,0.00041053127,0.0007177265,0.00021887945,0.00048046635,0.00021391668],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007717514,0.00021654298,0.0006946977,0.0006457658,0.000020586029,0.000008102609,0.00032066385,0.00015109713,0.00060700666],"category_scores_gemma":[0.00047449465,0.00016493788,0.00014240872,0.00026132283,0.00010884239,0.00018887571,0.00005124598,0.00035671354,0.000042993426],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.070096314,0.004356201,0.15918127,0.000091128146,0.0052952054,0.0039217453,0.0047390633,0.0006024023,0.70327467,0.0014677851,0.0021788077,0.044795427],"study_design_scores_gemma":[0.13641797,0.026129134,0.33530858,0.0035266269,0.00039475042,0.02511846,0.0003161893,0.0006679466,0.46037388,0.00025134973,0.010711481,0.00078362576],"about_ca_topic_score_codex":0.000061022318,"about_ca_topic_score_gemma":0.00006004435,"teacher_disagreement_score":0.24290076,"about_ca_system_score_codex":0.007501968,"about_ca_system_score_gemma":0.003271594,"threshold_uncertainty_score":0.996308},"labels":[],"label_agreement":null},{"id":"W2079102835","doi":"10.1371/journal.pone.0086195","title":"Growth Arrest Specific 2 Is Up-Regulated in Chronic Myeloid Leukemia Cells and Required for Their Growth","year":2014,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Key Research and Development Program of China; National Public Health Grand Research Foundation; Government of Jiangsu Province; Priority Academic Program Development of Jiangsu Higher Education Institutions; Soochow University; National Natural Science Foundation of China","keywords":"K562 cells; Myeloid leukemia; Haematopoiesis; Chemistry; CD34; Imatinib mesylate; Cancer research; Cell growth; Stem cell; Cell biology; Progenitor cell; Leukemia; Apoptosis; Chronic myelogenous leukemia; Molecular biology; Biology; Imatinib; Immunology; Biochemistry","score_opus":0.03289852313539745,"score_gpt":0.23210228520882012,"score_spread":0.19920376207342266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079102835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947072,0.001119552,0.000065789834,0.0009618727,0.0001381019,0.0015385837,0.000060415325,0.00013679307,0.0012716736],"genre_scores_gemma":[0.9936796,0.0012991813,0.0014511344,0.00033116835,0.00060902414,0.00016654072,0.0001511829,0.00010471713,0.0022074713],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99771595,0.00006481382,0.00049106247,0.0007087555,0.00037000343,0.0006493923],"domain_scores_gemma":[0.99858266,0.00026039509,0.00015082801,0.0006004911,0.00015131,0.00025434198],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00028394564,0.00039121104,0.0007805064,0.00022203637,0.00009533248,0.000035448764,0.00017318084,0.0002383214,0.00017451412],"category_scores_gemma":[0.000117571486,0.00034320095,0.00010677122,0.00031651472,0.00015693187,0.0001421231,0.00008127577,0.0002784098,0.00011535856],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012227866,0.0014066877,0.009955944,0.00237323,0.001065408,0.000040511997,0.001790938,0.0000046184005,0.96879613,0.0009986684,0.0071206666,0.0052244146],"study_design_scores_gemma":[0.02180987,0.0014088973,0.020706115,0.0015614567,0.00042030547,0.00001760643,0.000077808945,0.006895477,0.94224465,0.0018526195,0.0024127753,0.00059241493],"about_ca_topic_score_codex":0.0001809481,"about_ca_topic_score_gemma":0.00006454384,"teacher_disagreement_score":0.026551474,"about_ca_system_score_codex":0.0032354177,"about_ca_system_score_gemma":0.00048631325,"threshold_uncertainty_score":0.999902},"labels":[],"label_agreement":null},{"id":"W2079353397","doi":"10.1007/s12185-011-0766-2","title":"A novel insertion mutation of K294RGG within BCR-ABL kinase domain confers imatinib resistance: sequential analysis of the clonal evolution in a patient with chronic myeloid leukemia in blast crisis","year":2011,"lang":"en","type":"article","venue":"International Journal of Hematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institut national de la recherche scientifique","keywords":"Dasatinib; Imatinib; clone (Java method); Myeloid leukemia; Mutant; Mutation; Biology; Cancer research; Imatinib mesylate; breakpoint cluster region; Nilotinib; ABL; Molecular biology; Genetics; Virology; Tyrosine kinase; Gene; Receptor","score_opus":0.014720360303774788,"score_gpt":0.26634641643104323,"score_spread":0.25162605612726846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079353397","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960193,0.00021377594,0.0027967088,0.0003101881,0.00023597755,0.00024167942,0.000034467466,0.0000039956144,0.00014392428],"genre_scores_gemma":[0.9956499,0.000016272767,0.0041892375,0.000052942407,0.000028308541,0.0000141413875,0.00002775712,0.000013537649,0.000007930963],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99734044,0.00015010781,0.0013848649,0.00020248319,0.00074104423,0.00018104665],"domain_scores_gemma":[0.9973513,0.00010880241,0.0016113501,0.00019857392,0.0006734097,0.000056551053],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003977631,0.00017011695,0.0006463115,0.001123688,0.000019157967,0.0000054139614,0.0002345436,0.0001274785,0.00010910713],"category_scores_gemma":[0.0001788318,0.00012275789,0.00021958721,0.0007128813,0.00019449697,0.00016935081,0.000048356356,0.00031177478,9.715224e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041983325,0.0046905335,0.6478246,0.0006929741,0.01369114,0.0046275635,0.043833554,0.031480733,0.16555405,0.044318877,0.00021245045,0.0010901985],"study_design_scores_gemma":[0.031603955,0.0016911692,0.8302296,0.0030425622,0.0021022025,0.0060631135,0.0061989184,0.00832125,0.10665622,0.0036828036,0.000027800808,0.00038040732],"about_ca_topic_score_codex":0.0013076552,"about_ca_topic_score_gemma":0.007742548,"teacher_disagreement_score":0.18240498,"about_ca_system_score_codex":0.004130613,"about_ca_system_score_gemma":0.001983755,"threshold_uncertainty_score":0.9996924},"labels":[],"label_agreement":null},{"id":"W2080070416","doi":"10.5539/jmbr.v1n1p47","title":"Evaluation of Molecular Response to Imatinib in Iraqi Chronic Myeloid Leukemia Patients Using Real Time – Reveres Transcriptase-Polymerase Chain Reaction (RT-RT-PCR) – Taqman Assay","year":2011,"lang":"en","type":"article","venue":"Journal of Molecular Biology Research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"TaqMan; Real-time polymerase chain reaction; Medicine; Myeloid leukemia; Minimal residual disease; Imatinib mesylate; Reverse transcriptase; Internal medicine; Imatinib; breakpoint cluster region; Polymerase chain reaction; Gastroenterology; Leukemia; Oncology; Biology; Receptor; Gene; Genetics","score_opus":0.08216666194008686,"score_gpt":0.3930057921293431,"score_spread":0.31083913018925624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080070416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962081,0.0011312654,0.00026758696,0.00032212594,0.00014141825,0.0012609072,0.000027865348,0.000011801967,0.000628969],"genre_scores_gemma":[0.9969882,0.00012401749,0.0025077383,0.00006387849,0.00007959024,0.000034977154,0.000054726694,0.000060903225,0.000086001746],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9898344,0.005808919,0.0012245157,0.00048777444,0.0019066975,0.0007376786],"domain_scores_gemma":[0.9962401,0.00026526165,0.00052297756,0.0006529858,0.0019573478,0.00036134574],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.015057933,0.00030521015,0.0007762893,0.0016345049,0.00008774861,0.000012243322,0.00036041558,0.0003989026,0.00022894115],"category_scores_gemma":[0.0032296083,0.0002711558,0.00026820294,0.00090052903,0.00025681494,0.00014077543,0.00010389592,0.00092735665,0.000031097956],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0066534686,0.0005152411,0.0038512782,0.000066058914,0.0003594698,0.00044532327,0.0006787766,0.000111714326,0.97782886,0.000021305721,0.00013276935,0.009335764],"study_design_scores_gemma":[0.020565154,0.009705061,0.05633979,0.0011771931,0.00070236775,0.0004020097,0.00023005325,0.0030203203,0.9066261,0.00068406586,0.000151734,0.00039617214],"about_ca_topic_score_codex":0.0010510163,"about_ca_topic_score_gemma":0.000036196117,"teacher_disagreement_score":0.07120275,"about_ca_system_score_codex":0.0069926186,"about_ca_system_score_gemma":0.004842456,"threshold_uncertainty_score":0.9999741},"labels":[],"label_agreement":null},{"id":"W2080125373","doi":"10.1182/blood-2006-09-047266","title":"Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":609,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Dasatinib; Imatinib; Medicine; Myeloid leukemia; Internal medicine; Imatinib mesylate; Adverse effect; Nilotinib; Oncology; Pharmacology; Gastroenterology; Immunology","score_opus":0.017234787570403184,"score_gpt":0.2844798465666158,"score_spread":0.2672450589962126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080125373","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9766186,0.021695662,0.000005520323,0.0001821093,0.00003207509,0.00092881016,0.000045458513,0.000064023974,0.00042777642],"genre_scores_gemma":[0.99675024,0.0007576428,0.0015517967,0.0000655658,0.00017515488,0.00023507222,0.00005543488,0.000052322033,0.00035679396],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977732,0.00012273203,0.00068118854,0.0005451856,0.00033511233,0.0005425903],"domain_scores_gemma":[0.9988078,0.0002025252,0.00023064147,0.00058509415,0.000063911415,0.00011003044],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002336463,0.00037747753,0.00073625834,0.00026023664,0.00005491332,0.00002344902,0.00014062275,0.00025456442,0.00034260194],"category_scores_gemma":[0.000069300666,0.00031115036,0.00010618724,0.00036520662,0.00022031457,0.00011123443,0.00007863292,0.00028018327,0.000023773342],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019184138,0.0024291875,0.12914611,0.0009313326,0.0003478155,0.0009938875,0.00062874646,0.00005500995,0.8540903,0.00011201405,0.00026801357,0.009079174],"study_design_scores_gemma":[0.062906355,0.0030388923,0.2171823,0.0007672953,0.00027532352,0.0007217343,0.000110120316,0.00015851503,0.7129069,0.00019585273,0.0012688484,0.00046788284],"about_ca_topic_score_codex":0.00053959887,"about_ca_topic_score_gemma":0.00055404654,"teacher_disagreement_score":0.1411834,"about_ca_system_score_codex":0.001118945,"about_ca_system_score_gemma":0.0018599789,"threshold_uncertainty_score":0.9999341},"labels":[],"label_agreement":null},{"id":"W2080338202","doi":"10.1503/cmaj.081042","title":"Hydroxyurea-induced ulcers on the leg","year":2009,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Ankle; Leukemia; Diabetes mellitus; Chronic myelogenous leukemia; Surgery; Internal medicine; Endocrinology","score_opus":0.012049250785951622,"score_gpt":0.2514398920693173,"score_spread":0.23939064128336565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080338202","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6360268,0.0000721128,0.0000043363575,0.29524437,0.00057258253,0.00020505328,0.0000055302717,0.000027546159,0.0678417],"genre_scores_gemma":[0.92680573,0.00005092742,0.000020028716,0.06974277,0.0015880216,0.0000032522453,0.00000695371,0.000011995427,0.0017703192],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99736077,0.0001292857,0.0003062527,0.00014737636,0.0015404124,0.0005159022],"domain_scores_gemma":[0.9976084,0.00020567195,0.00014808787,0.00018021259,0.0001590089,0.0016985742],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001103569,0.00013740927,0.00021446966,0.00013629705,0.00030972352,0.000056686127,0.00017512028,0.0003216395,0.005328157],"category_scores_gemma":[0.0022584787,0.000089557914,0.00013759953,0.00022086881,0.000019979318,0.000053794545,0.0000043364025,0.0012968226,0.00063685526],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000057044832,0.00016094181,0.016701085,0.0000043842433,0.00047404456,0.003112823,0.00055574166,0.0000047146827,0.00019139796,0.0032933785,0.8105059,0.16493852],"study_design_scores_gemma":[0.006590137,0.0010282414,0.31076258,0.00033993696,0.00018424759,0.0020277333,0.0004684694,0.00051845075,0.00036180392,0.00094300427,0.6764429,0.0003324744],"about_ca_topic_score_codex":0.0011765313,"about_ca_topic_score_gemma":0.003147788,"teacher_disagreement_score":0.29406148,"about_ca_system_score_codex":0.006502785,"about_ca_system_score_gemma":0.0056802654,"threshold_uncertainty_score":0.9999566},"labels":[],"label_agreement":null},{"id":"W2081365397","doi":"10.1097/ftd.0b013e31823cdec9","title":"The Role of Therapeutic Drug Monitoring of Imatinib in Patients with Chronic Myeloid Leukemia and Metastatic or Unresectable Gastrointestinal Stromal Tumors","year":2011,"lang":"en","type":"review","venue":"Therapeutic Drug Monitoring","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Burnaby Hospital; University of British Columbia","funders":"","keywords":"Imatinib; Medicine; GiST; Myeloid leukemia; Imatinib mesylate; Tyrosine-kinase inhibitor; Internal medicine; Therapeutic drug monitoring; Oncology; Chronic myelogenous leukemia; Adverse effect; Pharmacology; Pharmacokinetics; Gastroenterology; Leukemia; Cancer; Stromal cell","score_opus":0.03223681275316437,"score_gpt":0.29844058175229093,"score_spread":0.26620376899912657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081365397","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.20498875,0.7924402,0.000005141622,0.0000034228287,0.00021967276,0.002123591,0.000027464044,0.000052275238,0.00013951217],"genre_scores_gemma":[0.40100905,0.59636766,0.0013714896,0.0000015306966,0.00027359085,0.00032660383,0.000026144951,0.00024760482,0.00037633325],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9952017,0.00043139118,0.0016648081,0.0007627374,0.0008760724,0.0010632722],"domain_scores_gemma":[0.9959636,0.0010915498,0.0013829308,0.001109178,0.00022558605,0.00022718936],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00075091375,0.001043775,0.002860171,0.00041067018,0.00018446802,0.00005006116,0.0006152425,0.000115905204,0.000032308686],"category_scores_gemma":[0.000061375526,0.0006188143,0.00032452715,0.0007087277,0.00040372694,0.00020419237,0.00020961637,0.0010647265,0.0000075895396],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009770095,0.00034589454,0.18658358,0.010413949,0.0013967516,0.000037920283,0.000935489,0.000012976829,0.00005469739,0.000039477563,7.5979085e-7,0.7992015],"study_design_scores_gemma":[0.047590036,0.011794659,0.40081865,0.46532857,0.025058657,0.0015653794,0.008468553,0.0003965996,0.007453486,0.0005695651,0.026057314,0.004898512],"about_ca_topic_score_codex":0.0007420706,"about_ca_topic_score_gemma":0.000033421362,"teacher_disagreement_score":0.794303,"about_ca_system_score_codex":0.002788168,"about_ca_system_score_gemma":0.002900145,"threshold_uncertainty_score":0.99962634},"labels":[],"label_agreement":null},{"id":"W2081439907","doi":"10.1038/sj.leu.2403994","title":"Response to ‘D276G mutation is associated with a poor prognosis in imatinib mesylate-resistant chronic myeloid leukemia patients’ by Leguay et al","year":2005,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Imatinib mesylate; Myeloid leukemia; Medicine; Imatinib; Mutation; Cancer research; Mesylate; Hematology; Leukemia; Internal medicine; Oncology; Biology; Genetics; Gene; Chemistry","score_opus":0.00928403131228904,"score_gpt":0.26138138869316924,"score_spread":0.2520973573808802,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081439907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9827686,0.0003441993,0.000029875577,0.012968935,0.000086118525,0.0023386388,0.00023049713,0.00026295675,0.00097019837],"genre_scores_gemma":[0.9814816,0.00004050155,0.0019114988,0.012148713,0.00005927715,0.00057021185,0.0007795859,0.0001638236,0.0028447756],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9953022,0.00039913048,0.00096455606,0.0010667627,0.0011761887,0.0010911867],"domain_scores_gemma":[0.9976576,0.00043825217,0.00039019735,0.00074368867,0.00028068648,0.0004896021],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009354987,0.00067251764,0.000865941,0.0004448937,0.00014553747,0.00008823363,0.00035051844,0.00033845336,0.0003961253],"category_scores_gemma":[0.0010921643,0.00058398943,0.0001670651,0.0011273127,0.00011215398,0.00039193494,0.00014763868,0.00072810316,0.00038042094],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.048180092,0.0034558882,0.09205131,0.00039151494,0.0021027662,0.0018928212,0.018499099,0.0030855916,0.14376387,0.00007053922,0.6349603,0.051546242],"study_design_scores_gemma":[0.10796492,0.014492218,0.5514956,0.0049688537,0.00083751715,0.00020150348,0.0005116146,0.012373732,0.14590022,0.00005595175,0.15831964,0.002878242],"about_ca_topic_score_codex":0.00092926645,"about_ca_topic_score_gemma":0.0014707253,"teacher_disagreement_score":0.47664064,"about_ca_system_score_codex":0.043140646,"about_ca_system_score_gemma":0.0048302836,"threshold_uncertainty_score":0.99966115},"labels":[],"label_agreement":null},{"id":"W2083666809","doi":"10.1038/sj.leu.2403650","title":"BCR-ABL-transduced human cord blood cells produce abnormal populations in immunodeficient mice","year":2005,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Haematopoiesis; Biology; Cord blood; CD34; Severe combined immunodeficiency; Bone marrow; Cancer research; Myeloid; Nod; Immunology; Population; Transplantation; Stem cell; Virology; Internal medicine; Medicine; Cell biology; In vivo","score_opus":0.029275919322379315,"score_gpt":0.2967654724335959,"score_spread":0.2674895531112166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083666809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907568,0.0006998501,0.000018268624,0.00053383445,0.00024141737,0.0009298842,0.00001915724,0.00016111974,0.00663965],"genre_scores_gemma":[0.99133277,0.000039255865,0.00263594,0.00043591054,0.00030424894,0.00008177092,0.00018580616,0.00006265214,0.0049216496],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.997583,0.000059362133,0.00065741956,0.0006123479,0.00042658576,0.00066130597],"domain_scores_gemma":[0.9988071,0.000035869893,0.00013430836,0.00077905774,0.00007694792,0.00016671675],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023163205,0.00033988018,0.00045419473,0.0002476824,0.00016495357,0.000030770578,0.00021187609,0.0001893753,0.00045380357],"category_scores_gemma":[0.000034377117,0.00033118183,0.00014701243,0.00046665675,0.00007539861,0.00017956595,0.000058827296,0.00051506184,0.00040377842],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005842652,0.0023680488,0.055304494,0.0003174144,0.0002749359,0.00047651067,0.0031003756,0.0034168183,0.91614014,0.00094542827,0.0033865834,0.013685012],"study_design_scores_gemma":[0.029264858,0.0011632454,0.4822194,0.0006610035,0.0009640256,0.00064544426,0.0003205301,0.0026074331,0.46364158,0.00010714204,0.017222757,0.0011825623],"about_ca_topic_score_codex":0.0016110729,"about_ca_topic_score_gemma":0.00073330605,"teacher_disagreement_score":0.45249853,"about_ca_system_score_codex":0.003377721,"about_ca_system_score_gemma":0.00070506,"threshold_uncertainty_score":0.99991405},"labels":[],"label_agreement":null},{"id":"W2084452268","doi":"10.1182/blood-2003-09-3032","title":"Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":238,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Imatinib mesylate; Imatinib; Nausea; Pharmacokinetics; Internal medicine; Gastroenterology; Vomiting; Myeloid leukemia; Philadelphia chromosome; Chromosomal translocation","score_opus":0.01754745499324663,"score_gpt":0.2983391117999296,"score_spread":0.280791656806683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084452268","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989036,0.0005872685,0.00008191389,0.00044040082,0.00006290327,0.0065286825,0.002881037,0.00013164034,0.00025012053],"genre_scores_gemma":[0.98969656,0.00012504005,0.005547055,0.00006568339,0.00036452519,0.00055422593,0.0035082453,0.00009485279,0.000043802833],"study_design_codex":"nonrandomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971316,0.00008222337,0.00082006614,0.0009770942,0.00042383306,0.0005652003],"domain_scores_gemma":[0.9979454,0.00024120773,0.00052254886,0.0008629623,0.00014291613,0.0002849368],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013502891,0.0005818872,0.0012958763,0.00017281131,0.00014524523,0.000016364851,0.00017907345,0.00023123274,0.000037315505],"category_scores_gemma":[0.00007300369,0.00042785995,0.0002473291,0.00028656633,0.00017765533,0.000108585795,0.000050442264,0.00015799952,0.000020411886],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.095302165,0.4750116,0.1803747,0.00019179563,0.09228245,0.0042465827,0.04953761,0.00079387176,0.042812537,0.00025282943,0.0005005338,0.058693327],"study_design_scores_gemma":[0.5771782,0.103172556,0.25106198,0.00032231034,0.009355553,0.0006817995,0.0003839389,0.000024851897,0.05713467,0.000093384,0.000056387085,0.00053438457],"about_ca_topic_score_codex":0.0035172212,"about_ca_topic_score_gemma":0.00034948776,"teacher_disagreement_score":0.48187605,"about_ca_system_score_codex":0.0024182135,"about_ca_system_score_gemma":0.0012967665,"threshold_uncertainty_score":0.9998173},"labels":[],"label_agreement":null},{"id":"W2088026712","doi":"10.3111/13696998.2012.693896","title":"The economic burden of pleural effusions in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","year":2012,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Lethbridge","keywords":"Medicine; Internal medicine; Confounding; Medical prescription; Myeloid leukemia; Pleural effusion","score_opus":0.007333948391764676,"score_gpt":0.23089702428171546,"score_spread":0.22356307588995078,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088026712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971484,0.0008478068,0.000004312214,0.001184993,0.00027833955,0.00032691378,0.000011589908,0.0000071718023,0.00019050346],"genre_scores_gemma":[0.9979015,0.00093681866,0.0001654003,0.00007235787,0.0007786921,0.000006888539,0.000018055433,0.000040460593,0.00007981982],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997901,0.000060752904,0.0010066843,0.00016268654,0.00040164503,0.00046717928],"domain_scores_gemma":[0.99798393,0.00026672726,0.000768365,0.00032083463,0.00008806056,0.00057206274],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007228498,0.00024622417,0.0006871079,0.00017793247,0.00006896729,0.000016857815,0.00027213304,0.00018565505,0.00022329696],"category_scores_gemma":[0.00013186657,0.00013569415,0.00012905792,0.00010944227,0.00030884412,0.00023881049,0.000072041395,0.0005918982,0.000016877491],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004772211,0.00057303207,0.9589664,0.00011049134,0.00087045005,0.00009469194,0.0006207452,0.0021586088,0.00006990546,0.00024435532,0.0011590947,0.030360026],"study_design_scores_gemma":[0.08141906,0.007911034,0.88241285,0.002341131,0.0008165782,0.00081430934,0.00055957044,0.0047035734,0.0033401435,0.000026830288,0.015064002,0.00059088727],"about_ca_topic_score_codex":0.00044195965,"about_ca_topic_score_gemma":0.00035386794,"teacher_disagreement_score":0.07664685,"about_ca_system_score_codex":0.006500185,"about_ca_system_score_gemma":0.0035519775,"threshold_uncertainty_score":0.9973137},"labels":[],"label_agreement":null},{"id":"W2088911092","doi":"10.1093/annonc/mdv097.3","title":"Comparison of Human Nucleoside Transporter Interactions with BCR-ABL Kinase Inhibitors","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Dasatinib; Bosutinib; Nilotinib; Imatinib; Pharmacology; Medicine; Cladribine; Nucleoside transporter; Imatinib mesylate; Cancer research; Myeloid leukemia; Chemistry; Biochemistry; Internal medicine; Transporter","score_opus":0.1699478740717183,"score_gpt":0.4530179599606671,"score_spread":0.28307008588894883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088911092","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9749472,0.00019606446,0.000020741509,0.0020369457,0.00012384333,0.00024844776,0.000010910121,0.000024229459,0.022391587],"genre_scores_gemma":[0.99841666,0.000013544443,0.0007112226,0.00030454504,0.000087538465,0.000015225801,0.00004738399,0.000019196237,0.0003846934],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988865,0.000050121685,0.00048266086,0.00017884902,0.00020238949,0.00019946361],"domain_scores_gemma":[0.99890065,0.00006851649,0.0002892949,0.00027263942,0.0002873748,0.00018152641],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015170335,0.00013121353,0.00062372786,0.0001415564,0.000024595995,0.0000017385793,0.00007257903,0.00009998665,0.00023857581],"category_scores_gemma":[0.00003430291,0.00010395197,0.00009379391,0.00013863931,0.00019782918,0.0000741808,0.00001647229,0.00018561407,0.00002007482],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048432127,0.012095388,0.7023426,0.00041818674,0.0016860346,0.00064707553,0.016117765,0.00014944386,0.070030995,0.0011086093,0.11139279,0.07916785],"study_design_scores_gemma":[0.025769494,0.051520534,0.14788674,0.00089314894,0.0010948575,0.0003236759,0.005769947,0.00018209158,0.5206642,0.00045925126,0.24494638,0.0004896576],"about_ca_topic_score_codex":0.0005443195,"about_ca_topic_score_gemma":0.000671193,"teacher_disagreement_score":0.55445594,"about_ca_system_score_codex":0.00018634502,"about_ca_system_score_gemma":0.0004843499,"threshold_uncertainty_score":0.42390382},"labels":[],"label_agreement":null},{"id":"W2089154194","doi":"10.1182/blood-2009-05-219550","title":"BMS-214662 induces mitochondrial apoptosis in chronic myeloid leukemia (CML) stem/progenitor cells, including CD34+38− cells, through activation of protein kinase Cβ","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Progenitor cell; Stem cell; Biology; Cell biology; Cancer research; Myeloid leukemia; Haematopoiesis; Apoptosis; CD34; Chemistry; Biochemistry","score_opus":0.027113385441561593,"score_gpt":0.2699501453277935,"score_spread":0.2428367598862319,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089154194","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99458563,0.00093224016,0.000038088438,0.0002462903,0.0003344974,0.002658342,0.000027624812,0.00013798833,0.0010392832],"genre_scores_gemma":[0.9943275,0.000182145,0.0035418116,0.000083940795,0.0010756911,0.00021934381,0.000078907215,0.00007683461,0.00041384174],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9964902,0.00014637886,0.0009777382,0.0008322964,0.0007895313,0.00076389255],"domain_scores_gemma":[0.9982352,0.00009726321,0.000510089,0.0008188203,0.0001436696,0.00019491298],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020020352,0.00055860955,0.0008854564,0.00031854038,0.00013885346,0.00003828854,0.0003301216,0.00047368006,0.00010779229],"category_scores_gemma":[0.000076079785,0.0005315651,0.00024448737,0.0008159193,0.000095788346,0.0004261936,0.00012390941,0.0006240593,0.0000521509],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003929978,0.0013640821,0.00027229334,0.00037645252,0.00020538962,0.00004789577,0.0008985788,0.000060940423,0.99099433,0.000058839203,0.00020351016,0.005124677],"study_design_scores_gemma":[0.017359806,0.0013760395,0.0009024504,0.0011206727,0.00030702894,0.00001604579,0.00028316662,0.00007173507,0.9770925,0.00010092281,0.0009519471,0.00041765408],"about_ca_topic_score_codex":0.0007902741,"about_ca_topic_score_gemma":0.00004178565,"teacher_disagreement_score":0.016966809,"about_ca_system_score_codex":0.0042563616,"about_ca_system_score_gemma":0.0022026717,"threshold_uncertainty_score":0.9997136},"labels":[],"label_agreement":null},{"id":"W2089819455","doi":"10.1038/sj.bmt.1704368","title":"The role of allogeneic bone marrow transplantation in adult patients below the age of 55 years with acute lymphoblastic leukemia in first complete remission: a donor vs no donor comparison","year":2003,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Lymphoblastic Leukemia; Surgery; Transplantation; Internal medicine; Sibling; Complete remission; Bone marrow; Gastroenterology; Acute lymphocytic leukemia; Leukemia; Pediatrics; Chemotherapy","score_opus":0.007965612029441916,"score_gpt":0.22157765734224494,"score_spread":0.21361204531280303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089819455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970858,0.0003013833,0.00015405304,0.000108939734,0.00009235661,0.0013375652,0.00017677133,0.000023246264,0.0007198607],"genre_scores_gemma":[0.99633896,0.0015273569,0.00086900557,0.000063686275,0.000017777931,0.00013643444,0.00090137,0.000044789387,0.00010061319],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99732625,0.00023017343,0.0009988371,0.0004033539,0.0006254067,0.0004159919],"domain_scores_gemma":[0.9985821,0.00038584243,0.00038601272,0.00039973334,0.00015422601,0.00009204904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032938313,0.00033039186,0.0006382367,0.00019620599,0.00011583921,0.000018006642,0.00016889574,0.00016180631,0.000041398664],"category_scores_gemma":[0.000043989934,0.00022469806,0.00011634228,0.00046827967,0.0001881113,0.00012201726,0.0000078067515,0.00025841422,0.000016799004],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03029595,0.0010503002,0.8631453,0.0019496956,0.0005131112,0.00093309477,0.0135047855,0.0040960032,0.07969854,0.00033056145,0.00015217352,0.0043304767],"study_design_scores_gemma":[0.035228856,0.0012433883,0.93036556,0.0023520933,0.001141978,0.0003552031,0.0005237062,0.0035073082,0.023916513,0.00008989011,0.00080597884,0.00046950122],"about_ca_topic_score_codex":0.0013267564,"about_ca_topic_score_gemma":0.007492023,"teacher_disagreement_score":0.06722028,"about_ca_system_score_codex":0.0008810912,"about_ca_system_score_gemma":0.00048680181,"threshold_uncertainty_score":0.9162921},"labels":[],"label_agreement":null},{"id":"W2091215976","doi":"10.1016/j.exphem.2013.07.001","title":"Genotypic and functional diversity of phenotypically defined primitive hematopoietic cells in patients with chronic myeloid leukemia","year":2013,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Haematopoiesis; Biology; Myeloid leukemia; CD34; Myeloid; Immunology; Stem cell; Bone marrow; Cancer research; Leukemia; Genotyping; Genotype; Genetics; Gene","score_opus":0.008540431702141912,"score_gpt":0.21414403893755277,"score_spread":0.20560360723541085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091215976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99672234,0.0012330827,0.000038578313,0.00004857629,0.0000802686,0.0009822848,0.000006887715,0.000030429037,0.00085753866],"genre_scores_gemma":[0.9984406,0.000009697005,0.001134381,0.00010536641,0.000018079189,0.000076968514,0.000053690088,0.000023940675,0.00013725436],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985911,0.00004417149,0.00032881976,0.0004113635,0.00027546525,0.0003490822],"domain_scores_gemma":[0.9993207,0.00007831057,0.00013179495,0.0002496407,0.0000715942,0.00014798147],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00003657107,0.00024698433,0.0005497707,0.00012459754,0.000084133615,0.0000053958465,0.000072252165,0.00014709924,0.0009411626],"category_scores_gemma":[0.000010769393,0.00020550448,0.00005332212,0.00011084287,0.0003120091,0.00011758966,0.00026811016,0.00017070696,0.00009106107],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018238054,0.0014671483,0.972124,0.000278738,0.00026364517,0.000049822593,0.0014738478,0.000010976354,0.01575621,0.005869454,0.0003836227,0.0004987307],"study_design_scores_gemma":[0.013939189,0.0013969109,0.7985539,0.00012195659,0.00005411446,0.00007912649,0.00024595243,0.00006358393,0.18524398,0.00008800454,0.000016790333,0.00019651871],"about_ca_topic_score_codex":0.00033916472,"about_ca_topic_score_gemma":0.000041159394,"teacher_disagreement_score":0.17357011,"about_ca_system_score_codex":0.0014824703,"about_ca_system_score_gemma":0.00029779796,"threshold_uncertainty_score":0.9999721},"labels":[],"label_agreement":null},{"id":"W2091403456","doi":"10.1111/j.1524-4733.2009.00573.x","title":"A Multinational Study of Health State Preference Values Associated with Chronic Myelogenous Leukemia","year":2009,"lang":"en","type":"article","venue":"Value in Health","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Chronic myelogenous leukemia; Demography; Preference; Population; Estimation; Disease; Environmental health; Leukemia; Internal medicine; Statistics; Economics","score_opus":0.05893333800666009,"score_gpt":0.3183134830426154,"score_spread":0.2593801450359553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091403456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99435145,0.0017190352,0.000063484666,0.0009005093,0.00005513762,0.0026348708,0.000028964056,0.00008978463,0.00015677349],"genre_scores_gemma":[0.99802023,0.0003125676,0.00080319395,0.00041261947,0.00003642505,0.0000456808,0.00008568347,0.000028824561,0.00025479778],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963877,0.0006182695,0.0010303095,0.00050131656,0.0007726076,0.00068979576],"domain_scores_gemma":[0.9982629,0.00022920658,0.0006818669,0.00044339328,0.00015714069,0.00022550675],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013529002,0.00026848709,0.0008622222,0.0002793991,0.0001345013,0.000008585098,0.00014392476,0.00007105301,0.000025057729],"category_scores_gemma":[0.00020498947,0.00022315118,0.000046558303,0.0006301486,0.000056984423,0.000076650664,0.000028159351,0.0003826385,0.000007191364],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0016172124,0.018395985,0.5912385,0.0016516935,0.000786329,0.00028171838,0.05183184,0.098950684,0.00023060734,0.00034238794,0.00059038796,0.23408265],"study_design_scores_gemma":[0.015972279,0.020728236,0.9522364,0.0015206706,0.000029235685,0.00003319922,0.00047042666,0.008451305,0.0000575216,0.000263943,0.00005063243,0.00018610978],"about_ca_topic_score_codex":0.020146377,"about_ca_topic_score_gemma":0.0017551327,"teacher_disagreement_score":0.36099795,"about_ca_system_score_codex":0.014296712,"about_ca_system_score_gemma":0.010821356,"threshold_uncertainty_score":0.9947864},"labels":[],"label_agreement":null},{"id":"W2091785969","doi":"10.1038/nm0107-13b","title":"In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'","year":2007,"lang":"en","type":"letter","venue":"Nature Medicine","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Imatinib mesylate; Cardiotoxicity; Imatinib; Medicine; Mesylate; Cancer; Pharmacology; Oncology; Cancer research; Internal medicine; Chemotherapy; Chemistry","score_opus":0.020456823524054084,"score_gpt":0.34109640404921976,"score_spread":0.32063958052516567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091785969","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01949291,0.016820993,0.000014808648,0.9522833,0.0031437466,0.0025413095,0.000059271573,0.00004729312,0.0055963183],"genre_scores_gemma":[0.042835444,0.00043186097,0.00015949098,0.9413869,0.0065250923,0.000117488504,0.00009090184,0.000110062385,0.008342803],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956544,0.00016488414,0.0009260132,0.0008010047,0.0017777855,0.0006759004],"domain_scores_gemma":[0.99709713,0.00032832925,0.000426393,0.0017486416,0.0002512321,0.00014825787],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00083556067,0.0006026432,0.0015963599,0.00049941416,0.000045201556,0.0000044018384,0.0005830809,0.0017557435,0.0009819252],"category_scores_gemma":[0.0005248969,0.00033190605,0.00032273235,0.0011041907,0.0002661402,0.000029917159,0.00015000989,0.0064958734,0.000023707438],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023957776,0.00005802096,0.0021052198,0.00068884296,0.00050514855,0.0010027228,0.0006895348,0.0000046555624,0.0019028208,0.000008714131,0.98942846,0.0033662561],"study_design_scores_gemma":[0.0042568077,0.00037637423,0.016061537,0.0037417088,0.00075816776,0.00017100722,0.000030023508,0.000009320628,0.007486315,0.000068028574,0.96677476,0.00026596617],"about_ca_topic_score_codex":0.0016201368,"about_ca_topic_score_gemma":0.00013651355,"teacher_disagreement_score":0.023342535,"about_ca_system_score_codex":0.002696399,"about_ca_system_score_gemma":0.0007725142,"threshold_uncertainty_score":0.99993134},"labels":[],"label_agreement":null},{"id":"W2091998318","doi":"10.1038/onc.2008.8","title":"Bcr-Abl induces autocrine IGF-1 signaling","year":2008,"lang":"en","type":"article","venue":"Oncogene","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"Canadian Institutes of Health Research","keywords":"Autocrine signalling; Biology; Chronic myelogenous leukemia; Cancer research; breakpoint cluster region; Signal transduction; Oncogene; Leukemia; Cell biology; Immunology; Cell cycle; Apoptosis; Receptor; Genetics","score_opus":0.04470236527401474,"score_gpt":0.2922226395562831,"score_spread":0.24752027428226833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091998318","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.979312,0.0009711004,0.00005668945,0.0004893141,0.0001774466,0.00028047976,0.0000068735485,0.00016049157,0.018545618],"genre_scores_gemma":[0.9846315,0.00019719594,0.0037278465,0.0005042523,0.0005052761,0.000032262255,0.00005387162,0.000040996925,0.010306816],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99872285,0.000025493297,0.00025652704,0.00031621818,0.00033272523,0.0003461649],"domain_scores_gemma":[0.9992168,0.00005277936,0.000072339186,0.00038254255,0.00006810829,0.00020746503],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00008549344,0.00019360839,0.00033229022,0.00009283663,0.00013030776,0.0000068015943,0.000095205,0.00009313224,0.0011781686],"category_scores_gemma":[0.00007180729,0.00016515653,0.0001119341,0.00021769255,0.00007171892,0.00006490933,0.000052611686,0.00017637257,0.0006569598],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034448915,0.0009973223,0.025580894,0.00014035088,0.00068536797,0.0051964265,0.0012900234,0.000090234906,0.898251,0.00012873209,0.014656169,0.052638993],"study_design_scores_gemma":[0.010131062,0.00093482144,0.01552659,0.00022332129,0.00033206644,0.003411138,0.00011595684,0.00026725186,0.8821122,0.00008907873,0.08636114,0.00049537263],"about_ca_topic_score_codex":0.00017404364,"about_ca_topic_score_gemma":0.00000861072,"teacher_disagreement_score":0.07170497,"about_ca_system_score_codex":0.000670734,"about_ca_system_score_gemma":0.00063942134,"threshold_uncertainty_score":0.9997349},"labels":[],"label_agreement":null},{"id":"W2092555277","doi":"10.1177/1078155214537926","title":"Adherence to imatinib among patients attending Saskatchewan Cancer Agency Pharmacies","year":2014,"lang":"en","type":"article","venue":"Journal of Oncology Pharmacy Practice","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Medicine; Imatinib; Imatinib mesylate; Cancer; Pharmacy; Pharmacist; Myeloid leukemia; Family medicine; Internal medicine","score_opus":0.053762430460891374,"score_gpt":0.4259535604798781,"score_spread":0.37219113001898674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2092555277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98247343,0.00032513408,0.00024408374,0.004721697,0.0019335635,0.0005110615,0.000008467641,0.00002883296,0.009753729],"genre_scores_gemma":[0.98318046,0.00044602607,0.00876063,0.0055632982,0.0009396493,0.000037627247,0.0000047092108,0.000040661675,0.00102692],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99722725,0.00046344916,0.00094652065,0.0002711055,0.00064196397,0.0004497366],"domain_scores_gemma":[0.99567384,0.0010827362,0.001557909,0.00021939725,0.00089479476,0.00057133526],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012880537,0.00026557097,0.00067187735,0.00024410126,0.00013385231,0.00003053578,0.00027543036,0.00008171705,0.0012889042],"category_scores_gemma":[0.0020355766,0.00021903127,0.0001845936,0.000314252,0.00009172838,0.0010060726,0.00010315441,0.00088681484,0.00014947409],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052176416,0.0027213416,0.30574414,0.00017267311,0.0015018696,0.00090813916,0.008146797,0.00014269233,0.027962629,0.000008024007,0.042940993,0.6045331],"study_design_scores_gemma":[0.04076126,0.0063164756,0.06868763,0.00047790082,0.0036240092,0.0019249407,0.0014251434,0.0005608437,0.021244051,0.000026359663,0.854479,0.00047238474],"about_ca_topic_score_codex":0.00033946478,"about_ca_topic_score_gemma":0.000031864205,"teacher_disagreement_score":0.811538,"about_ca_system_score_codex":0.0019661256,"about_ca_system_score_gemma":0.001617886,"threshold_uncertainty_score":0.9996241},"labels":[],"label_agreement":null},{"id":"W2092788376","doi":"10.3816/clm.2002.s.006","title":"Acute and Long-Term Toxicities Associated with Gemtuzumab Ozogamicin (Mylotarg®) Therapy of Acute Myeloid Leukemia","year":2002,"lang":"en","type":"review","venue":"Clinical Lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Gemtuzumab ozogamicin; Myeloid leukemia; Calicheamicin; Medicine; Leukemia; Pharmacology; Oncology; Internal medicine; CD33; Biology; Stem cell","score_opus":0.07021262687105202,"score_gpt":0.36695139610792527,"score_spread":0.29673876923687326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2092788376","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.133934,0.8621321,0.0000048788893,0.000033785862,0.00031862158,0.0020166514,0.0004605383,0.00017597238,0.0009234978],"genre_scores_gemma":[0.0021549205,0.9894756,0.00019226366,0.0002726379,0.00038454126,0.00013313335,0.001030791,0.00027243028,0.0060836608],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9940115,0.00048195285,0.0025604495,0.0013426262,0.00076569826,0.0008377286],"domain_scores_gemma":[0.99440134,0.0017121981,0.0017315343,0.001416167,0.00022087751,0.0005179049],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00054850476,0.0012590372,0.00659026,0.0002997285,0.00011906025,0.00004893789,0.0004970373,0.0015409802,0.00036784433],"category_scores_gemma":[0.00023904651,0.00085253885,0.0013624802,0.0005633746,0.0010109455,0.00012317054,0.0002283817,0.000728361,0.00010683116],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050609885,0.00078080466,0.003004184,0.0023395228,0.015701443,0.0015449409,0.000070500115,5.3234718e-8,0.0000023179123,0.000012955744,0.000754692,0.9752825],"study_design_scores_gemma":[0.11322604,0.02205307,0.10007585,0.13293909,0.07391068,0.007570526,0.000047292542,0.00008954991,0.00013723975,0.00005975518,0.5451201,0.004770799],"about_ca_topic_score_codex":0.00003404609,"about_ca_topic_score_gemma":0.00001835733,"teacher_disagreement_score":0.9705117,"about_ca_system_score_codex":0.0037924726,"about_ca_system_score_gemma":0.0031819625,"threshold_uncertainty_score":0.9997552},"labels":[],"label_agreement":null},{"id":"W2093253247","doi":"10.1038/leusup.2014.3","title":"STAT3 as a mediator of BCR-ABL1-independent resistance in chronic myeloid leukemia","year":2014,"lang":"en","type":"article","venue":"Leukemia Supplements","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institutes of Health; Brown University; Celgene; Gilead Sciences; Bristol-Myers Squibb","keywords":"Dasatinib; Nilotinib; Myeloid leukemia; Medicine; Cancer research; Imatinib mesylate; Imatinib; Tyrosine kinase; Leukemia; Immunology; Myeloid; Tyrosine-kinase inhibitor; Internal medicine; Cancer; Receptor","score_opus":0.010311575729924442,"score_gpt":0.272663253366069,"score_spread":0.2623516776361446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2093253247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98299825,0.001196042,0.00014132902,0.0003899009,0.00039292994,0.0015966713,0.00017116906,0.000121992496,0.012991719],"genre_scores_gemma":[0.989272,0.0005594226,0.0026067866,0.00044600634,0.00036926902,0.00027006454,0.0005871997,0.00012745505,0.0057618218],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9944406,0.00020602948,0.0014345354,0.0010487615,0.001611011,0.00125904],"domain_scores_gemma":[0.997146,0.00026118188,0.0005063068,0.0014211917,0.00017671101,0.0004886026],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008127429,0.00063793006,0.0011648235,0.00048525975,0.00010145051,0.00002994421,0.0005300932,0.0003404844,0.0029847575],"category_scores_gemma":[0.00036009995,0.00061581004,0.00026048126,0.00066017185,0.00018957026,0.00024814237,0.00026716647,0.0006789135,0.00050662574],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.009501073,0.0024792554,0.56472915,0.009114268,0.0036115446,0.0030231222,0.009242369,0.0013692278,0.17246228,0.015301626,0.16400014,0.045165956],"study_design_scores_gemma":[0.110067695,0.0038937025,0.16430427,0.0032583468,0.0009498675,0.00020076803,0.00091251545,0.0033813089,0.23620068,0.004591573,0.4698966,0.0023426688],"about_ca_topic_score_codex":0.0024684628,"about_ca_topic_score_gemma":0.004918505,"teacher_disagreement_score":0.40042487,"about_ca_system_score_codex":0.029179558,"about_ca_system_score_gemma":0.0067106197,"threshold_uncertainty_score":0.9996293},"labels":[],"label_agreement":null},{"id":"W2093322643","doi":"10.1186/1476-4598-6-67","title":"Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; Stem Cell Network; Kenneth T. and Eileen L. Norris Foundation","keywords":"Nilotinib; Imatinib; Leukemia; Cancer research; Chronic myelogenous leukemia; Imatinib mesylate; Tyrosine-kinase inhibitor; Philadelphia chromosome; Acute lymphocytic leukemia; Tyrosine kinase; Medicine; Biology; Immunology; Internal medicine; Myeloid leukemia; Cancer; Chromosomal translocation; Lymphoblastic Leukemia; Receptor","score_opus":0.019722282975176975,"score_gpt":0.2880412356463142,"score_spread":0.2683189526711372,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2093322643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98793715,0.00251684,0.0024008653,0.000084105035,0.000103761275,0.00067808665,0.000026983153,0.00004877418,0.006203449],"genre_scores_gemma":[0.9954262,0.00028371307,0.0011176647,0.00027333826,0.0000563609,0.000106847634,0.000028690845,0.00006150212,0.0026457326],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982561,0.00003017003,0.0004553195,0.00040150067,0.00036666892,0.00049028173],"domain_scores_gemma":[0.99906856,0.00005114997,0.00011826294,0.0005049333,0.00007256424,0.00018451066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013922418,0.00027832587,0.0005024389,0.000217331,0.000021852562,0.0000055919795,0.00009567127,0.00014051431,0.00018516787],"category_scores_gemma":[0.000029420224,0.00024216423,0.00016076803,0.00030287454,0.000073264826,0.00006250635,0.000036417565,0.00010604919,0.000024351148],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037630887,0.002594581,0.04219218,0.00067626033,0.0017386589,0.0054058167,0.0036092147,0.05745341,0.78116465,0.002312025,0.00066834665,0.09842178],"study_design_scores_gemma":[0.023519883,0.0010709736,0.009844801,0.00046290728,0.00043395764,0.00008526498,0.00015590827,0.010712293,0.950576,0.00036978323,0.0022899173,0.00047829092],"about_ca_topic_score_codex":0.0046094246,"about_ca_topic_score_gemma":0.0008310459,"teacher_disagreement_score":0.16941139,"about_ca_system_score_codex":0.008790135,"about_ca_system_score_gemma":0.0014650741,"threshold_uncertainty_score":0.99501497},"labels":[],"label_agreement":null},{"id":"W2093539468","doi":"10.3747/co.v18i4.652","title":"cml Biology for the Clinician in 2011: Six Impossible Things to Believe before Breakfast on the Way to Cure","year":2011,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Juravinski Hospital","funders":"","keywords":"Medicine; Bioinformatics; Biology","score_opus":0.1325539787712528,"score_gpt":0.41448757690674126,"score_spread":0.28193359813548846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2093539468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93127906,0.0011242522,0.0004180942,0.049065884,0.0045578536,0.0059611304,0.00011138366,0.00009677873,0.007385557],"genre_scores_gemma":[0.98470765,0.00019689043,0.0009248047,0.010420997,0.0010302993,0.0014853227,0.00007412774,0.000063691805,0.0010961959],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99800086,0.00014323967,0.00051047286,0.0005388829,0.00013729188,0.00066923857],"domain_scores_gemma":[0.99794495,0.0008509406,0.00015109558,0.0007142041,0.00011701001,0.00022178554],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007756236,0.000283842,0.0005293407,0.0001707416,0.00015665716,0.00000826318,0.00046748013,0.00025431046,0.0005965576],"category_scores_gemma":[0.00041782507,0.00014881621,0.0001681054,0.00023744824,0.00014648189,0.000041404273,0.00020321376,0.00056727155,0.0008121053],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033170425,0.0028203274,0.106493555,0.00012075975,0.00037332892,0.00004569527,0.02693969,0.000008604779,0.0004490352,0.01796553,0.1457284,0.695738],"study_design_scores_gemma":[0.0051646177,0.009279138,0.07906,0.00021995063,0.00020725372,0.00004823559,0.00091236475,0.00018551107,0.0005110225,0.0017277704,0.9024402,0.00024397338],"about_ca_topic_score_codex":0.00033658894,"about_ca_topic_score_gemma":0.001480019,"teacher_disagreement_score":0.7567118,"about_ca_system_score_codex":0.0011274491,"about_ca_system_score_gemma":0.0004585044,"threshold_uncertainty_score":0.9999659},"labels":[],"label_agreement":null},{"id":"W2094243744","doi":"10.1038/sj.bmt.1705284","title":"A novel triple purge strategy for eliminating chronic myelogenous leukemia (CML) cells from autografts","year":2006,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute; University of British Columbia","funders":"National Cancer Institute; University of Texas MD Anderson Cancer Center","keywords":"Chronic myelogenous leukemia; Medicine; Purge; Leukemia; Blast Crisis; Immunology; Cancer research","score_opus":0.0184314675122318,"score_gpt":0.2520793104036068,"score_spread":0.23364784289137502,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094243744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95763075,0.001208658,0.035346236,0.00016645552,0.00034249396,0.0020660157,0.0011401266,0.00028132493,0.0018179439],"genre_scores_gemma":[0.9817863,0.00017592114,0.010586101,0.00008206283,0.000531756,0.00028448444,0.005080507,0.00008512718,0.0013877173],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997766,0.000034320954,0.00063970336,0.00059033657,0.00038541725,0.0005841916],"domain_scores_gemma":[0.9990223,0.00020199816,0.00021967819,0.0003227523,0.00010110042,0.00013218044],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018261399,0.00036774314,0.00049561745,0.00016972976,0.00018521775,0.000048201935,0.00010169538,0.0002442847,0.00015265554],"category_scores_gemma":[0.000013066467,0.000367636,0.00023191715,0.00022386294,0.000056269073,0.00015813041,0.000008001647,0.00019871518,0.000047383295],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009844534,0.00034385183,0.0006712901,0.0007011998,0.00016484175,0.0002100514,0.00037816257,0.0018690729,0.97221434,0.00024470143,0.0007118005,0.02150626],"study_design_scores_gemma":[0.064040124,0.0022728178,0.08618395,0.0010538321,0.0032440643,0.0007463998,0.00024327794,0.040111266,0.7958672,0.0009781303,0.0038658679,0.0013930423],"about_ca_topic_score_codex":0.004944104,"about_ca_topic_score_gemma":0.0022914852,"teacher_disagreement_score":0.17634709,"about_ca_system_score_codex":0.0020687666,"about_ca_system_score_gemma":0.0010040273,"threshold_uncertainty_score":0.9998776},"labels":[],"label_agreement":null},{"id":"W2094949617","doi":"10.1016/j.leukres.2013.07.020","title":"Pregnancies in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitor","year":2013,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Terry Fox Foundation","keywords":"Medicine; Myeloid leukemia; Abortion; Tyrosine-kinase inhibitor; Tyrosine kinase; Pregnancy; Leukemia; Myeloid; Obstetrics; Internal medicine; Cancer","score_opus":0.02018674346074954,"score_gpt":0.2786858571405371,"score_spread":0.25849911367978756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094949617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906537,0.0007278764,0.000005918721,0.00034645485,0.000040509254,0.004010222,0.000019558676,0.00017411787,0.0040216562],"genre_scores_gemma":[0.9891498,0.00011716719,0.0005964893,0.00009124843,0.0002295617,0.0011071337,0.00029522204,0.000163533,0.008249809],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9941769,0.00024360229,0.00057153596,0.001105571,0.0020796596,0.0018227027],"domain_scores_gemma":[0.9967153,0.0002577323,0.00012713298,0.001320175,0.0009770342,0.0006026002],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00042686405,0.0005894083,0.0007819001,0.0008149325,0.00025018022,0.00014157851,0.00037772744,0.0003330254,0.00085524446],"category_scores_gemma":[0.00018124383,0.00039577147,0.00008602538,0.0020679638,0.0006905717,0.0005372079,0.00022363337,0.001498059,0.0009677429],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0035213116,0.00086464453,0.9621237,0.00068217196,0.00028880354,0.0006725784,0.0004565271,0.00020768907,0.0048531094,0.00009087411,0.0068723843,0.019366222],"study_design_scores_gemma":[0.038858823,0.0066216392,0.93059826,0.0025723767,0.0000781036,0.00004752195,0.00014587671,0.00082457607,0.01746648,0.000028577855,0.002184274,0.0005734856],"about_ca_topic_score_codex":0.00814112,"about_ca_topic_score_gemma":0.0011575739,"teacher_disagreement_score":0.03533751,"about_ca_system_score_codex":0.033597402,"about_ca_system_score_gemma":0.0070321443,"threshold_uncertainty_score":0.99984944},"labels":[],"label_agreement":null},{"id":"W2095357289","doi":"10.3109/10428190903370387","title":"State-of-the-art in the management of chronic myelogenous leukemia in the era of the tyrosine kinase inhibitors: evolutionary trends in diagnosis, monitoring and treatment","year":2009,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Nilotinib; Dasatinib; Imatinib; Medicine; Chronic myelogenous leukemia; Myeloid leukemia; Tyrosine kinase; Tyrosine-kinase inhibitor; Disease; Imatinib mesylate; Intensive care medicine; Oncology; Internal medicine; Leukemia","score_opus":0.019624493807393912,"score_gpt":0.27948932661892767,"score_spread":0.2598648328115338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095357289","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3677781,0.62852085,3.9505906e-7,0.00013013722,0.00027243333,0.0026762797,0.00010860307,0.00002014864,0.00049305684],"genre_scores_gemma":[0.2873456,0.7107818,0.00008632883,0.000070505346,0.00021543268,0.0009878393,0.000111698464,0.000095471296,0.0003052932],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9924994,0.0010411238,0.002715759,0.0012577821,0.0013426252,0.0011433209],"domain_scores_gemma":[0.99514735,0.0008279535,0.0014108494,0.002365399,0.000086536755,0.00016194013],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0010182668,0.0014496826,0.0031493085,0.00073293137,0.00024410167,0.000054484837,0.0013147976,0.0006805399,0.000015149931],"category_scores_gemma":[0.000055434444,0.0007631644,0.0009617164,0.0031180852,0.0008290152,0.00018587497,0.00048219055,0.00064587855,0.000004684761],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00020540338,0.00085187313,0.006842528,0.005700338,0.00051244465,0.0005949644,0.0021346896,0.00014325422,0.000015526166,0.00010363541,0.00041161824,0.98248374],"study_design_scores_gemma":[0.046734482,0.002597073,0.58249456,0.09897529,0.006014809,0.0031004157,0.0015299137,0.00050510035,0.0009693587,0.00028908654,0.25492615,0.0018637404],"about_ca_topic_score_codex":0.0058966903,"about_ca_topic_score_gemma":0.0009696279,"teacher_disagreement_score":0.98061997,"about_ca_system_score_codex":0.054612115,"about_ca_system_score_gemma":0.008247184,"threshold_uncertainty_score":0.9998253},"labels":[],"label_agreement":null},{"id":"W2095803725","doi":"10.1111/j.1582-4934.2009.00795.x","title":"Inhibition of IGF‐IR tyrosine kinase induces apoptosis and cell cycle arrest in imatinib‐resistant chronic myeloid leukaemia cells","year":2009,"lang":"en","type":"article","venue":"Journal of Cellular and Molecular Medicine","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute","keywords":"Imatinib; Cancer research; Imatinib mesylate; Tyrosine kinase; Cell cycle; Biology; Haematopoiesis; Apoptosis; Viability assay; Cell culture; Growth factor; Cell growth; Myeloid leukemia; Immunology; Internal medicine; Receptor; Signal transduction; Medicine; Stem cell; Cell biology","score_opus":0.007377465087403668,"score_gpt":0.23826131571908274,"score_spread":0.23088385063167907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095803725","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97732204,0.019852553,0.00031316615,0.001226377,0.00013254616,0.00030621947,0.0000045992397,0.00000819164,0.0008342836],"genre_scores_gemma":[0.99621755,0.002196214,0.00096127,0.00032264736,0.00020951903,0.0000022996637,0.00002232473,0.000024778697,0.000043378655],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978474,0.000087362,0.0009483045,0.00025804123,0.00055747735,0.00030145113],"domain_scores_gemma":[0.9985826,0.00006661869,0.00057187123,0.0003072767,0.00015932755,0.00031230075],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005233027,0.00028568096,0.0008483535,0.00042515973,0.000041252515,0.000011168886,0.00009842152,0.00015835668,0.000046690515],"category_scores_gemma":[0.00010919541,0.00021957021,0.00011204908,0.00029372078,0.00019755407,0.00011509216,0.000042023887,0.0004216174,0.0000013225302],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003787441,0.00028683938,0.00015458695,0.00042954768,0.00005578089,0.000825615,0.0004977964,0.000024488723,0.994055,0.000037186677,0.00013589824,0.0031185444],"study_design_scores_gemma":[0.012288541,0.0036247585,0.0033561455,0.0022124322,0.0004245114,0.00014636634,0.00030609826,0.00013182126,0.97687304,0.00030832354,0.0001606664,0.00016728294],"about_ca_topic_score_codex":0.000082040744,"about_ca_topic_score_gemma":0.00000571648,"teacher_disagreement_score":0.018895503,"about_ca_system_score_codex":0.00039531666,"about_ca_system_score_gemma":0.00035431996,"threshold_uncertainty_score":0.89538133},"labels":[],"label_agreement":null},{"id":"W2096336184","doi":"10.1200/jco.2008.21.2514","title":"Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Children's Oncology Group Study","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":709,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital","funders":"National Cancer Institute","keywords":"Medicine; Imatinib; Lymphoblastic Leukemia; Oncology; Internal medicine; Philadelphia chromosome; Leukemia; Chromosomal translocation; Genetics; Gene; Myeloid leukemia","score_opus":0.03415208848965093,"score_gpt":0.38776667454777614,"score_spread":0.35361458605812524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2096336184","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903781,0.00019794167,0.00019308679,0.0058478047,0.0008625995,0.0014871889,0.000020443993,0.000033562672,0.000979301],"genre_scores_gemma":[0.9934244,0.00024092352,0.0032032786,0.0015301293,0.0014200538,0.000024726169,0.000017100892,0.000051401483,0.00008797319],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9923785,0.0012759609,0.004056774,0.00065569713,0.0008608755,0.00077219674],"domain_scores_gemma":[0.99217045,0.0028563195,0.0029954326,0.000713003,0.00049548165,0.00076933746],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0034062022,0.0005126811,0.003816995,0.00039815524,0.00008110122,0.000022556604,0.00064792193,0.0008566923,0.000110005596],"category_scores_gemma":[0.0023560526,0.00035670813,0.0005993894,0.0005428406,0.00035263022,0.0003122435,0.00016945666,0.0025381458,0.00002510504],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.11348025,0.065311454,0.5642493,0.000053013704,0.012133434,0.050792262,0.0028803176,0.00020290233,0.0023864752,0.00018743657,0.0021470443,0.18617614],"study_design_scores_gemma":[0.09075719,0.17574832,0.72728795,0.00019907106,0.0018179151,0.0030929893,0.00027284105,0.00020985169,0.000036577538,0.00017538326,0.00015697657,0.00024495603],"about_ca_topic_score_codex":0.00023867754,"about_ca_topic_score_gemma":0.00062487996,"teacher_disagreement_score":0.18593118,"about_ca_system_score_codex":0.0059208316,"about_ca_system_score_gemma":0.009032023,"threshold_uncertainty_score":0.9998885},"labels":[],"label_agreement":null},{"id":"W2099980739","doi":"10.3109/10428194.2014.918972","title":"Is there a role for omacetaxine in the management of chronic myelogenous leukemia in the era of the tyrosine kinase inhibitors?","year":2014,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"","keywords":"Chronic myelogenous leukemia; Tyrosine kinase; Medicine; Cancer research; Leukemia; CD135; Immunology; Internal medicine; Receptor","score_opus":0.012325001069235906,"score_gpt":0.2414652612103483,"score_spread":0.2291402601411124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099980739","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90959114,0.025623664,0.00002825404,0.050311796,0.0006892293,0.008752639,0.0004064585,0.00009194564,0.0045048906],"genre_scores_gemma":[0.88765085,0.0033515827,0.0003326795,0.102039315,0.0022371346,0.001796435,0.00056619017,0.0003366606,0.0016891675],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9910117,0.00083573756,0.0024479437,0.0017603638,0.0020795031,0.0018647993],"domain_scores_gemma":[0.9930261,0.001184275,0.0015444837,0.0038401082,0.00024361785,0.00016143928],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.001781891,0.0017263979,0.0025047685,0.00048829074,0.00039016534,0.00012563901,0.0025078596,0.0018739424,0.000083698265],"category_scores_gemma":[0.000096726,0.0009946784,0.0011854374,0.0016609404,0.0010696314,0.00017537735,0.00054363103,0.0015261141,0.000024731598],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0034539632,0.0018154023,0.009236692,0.026192656,0.0046259584,0.005639873,0.02047516,0.0005154459,0.0031190335,0.0016855488,0.6104436,0.31279668],"study_design_scores_gemma":[0.08235351,0.0026781433,0.09156585,0.012627049,0.0044703716,0.0036270618,0.0031303475,0.0065071657,0.010213827,0.0015945784,0.7787952,0.0024368877],"about_ca_topic_score_codex":0.0068867053,"about_ca_topic_score_gemma":0.0005882701,"teacher_disagreement_score":0.31035978,"about_ca_system_score_codex":0.029976364,"about_ca_system_score_gemma":0.0086953575,"threshold_uncertainty_score":0.99972653},"labels":[],"label_agreement":null},{"id":"W2100155812","doi":"10.1093/jnci/djk150","title":"Instability of BCR-ABL Gene in Primary and Cultured Chronic Myeloid Leukemia Stem Cells","year":2007,"lang":"en","type":"article","venue":"JNCI Journal of the National Cancer Institute","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":135,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Myeloid leukemia; Stem cell; Cancer research; breakpoint cluster region; Gene; ABL; Biology; Cell biology; Genetics; Tyrosine kinase; Signal transduction","score_opus":0.029732078395472386,"score_gpt":0.30161037721082684,"score_spread":0.27187829881535447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100155812","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930956,0.0036953136,0.00005952678,0.00045085404,0.0009505898,0.00032574317,0.00003944174,0.000005198565,0.0013777373],"genre_scores_gemma":[0.9969118,0.00079893565,0.0008756329,0.0003828237,0.0006396687,0.0000050899284,0.0000039616352,0.00001194387,0.00037011888],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9978702,0.00004186468,0.0007723875,0.00016773379,0.0009390375,0.00020878887],"domain_scores_gemma":[0.9985608,0.00008481518,0.00056856876,0.00014835034,0.0005230702,0.000114437986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095291325,0.00015945613,0.0004029871,0.00017447928,0.000060639595,0.000008629189,0.00019627031,0.00011808357,0.000034402074],"category_scores_gemma":[0.00008231039,0.00010561141,0.00015000302,0.0003589551,0.00021410074,0.00026104462,0.0000740595,0.00042884424,0.0000013691335],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.004269156,0.0008978833,0.1688476,0.0015232823,0.0012538539,0.00023630315,0.0021716878,0.014222012,0.7308109,0.00065613474,0.0048193564,0.07029186],"study_design_scores_gemma":[0.0130906,0.00031540668,0.64629954,0.0008892721,0.0002334892,0.0006234424,0.000059845526,0.00019597106,0.3141208,0.00023133037,0.023719653,0.0002206828],"about_ca_topic_score_codex":0.00018937943,"about_ca_topic_score_gemma":0.0005228979,"teacher_disagreement_score":0.47745192,"about_ca_system_score_codex":0.013615496,"about_ca_system_score_gemma":0.005645194,"threshold_uncertainty_score":0.9999919},"labels":[],"label_agreement":null},{"id":"W2102066474","doi":"10.1586/ehm.10.60","title":"Philadelphia chromosome-positive acute lymphoblastic leukemia in children: new and emerging treatment options","year":2010,"lang":"en","type":"review","venue":"Expert Review of Hematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Children's Hospital","funders":"","keywords":"Medicine; Dasatinib; Philadelphia chromosome; Nilotinib; Imatinib; Oncology; Chemotherapy; Internal medicine; Acute lymphocytic leukemia; Hematopoietic stem cell transplantation; Transplantation; Imatinib mesylate; Chemotherapy regimen; Regimen; Leukemia; Lymphoblastic Leukemia; Myeloid leukemia; Chromosomal translocation","score_opus":0.019400866095464,"score_gpt":0.34919228973256367,"score_spread":0.3297914236370997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102066474","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008602602,0.9951677,0.000011350113,0.00050842843,0.00022444056,0.0036459446,0.000070676404,0.00005055449,0.00023490435],"genre_scores_gemma":[0.000014905942,0.9960875,0.0015601128,0.00030062784,0.00026411822,0.0006203284,0.0008261839,0.00011416277,0.0002120475],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962329,0.00022354821,0.0017272558,0.00096533936,0.00026441095,0.00058650854],"domain_scores_gemma":[0.99746513,0.00028591865,0.0008265619,0.0010066901,0.0000649797,0.00035072627],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014681982,0.0009949276,0.006622604,0.00045279358,0.0000643508,0.000008747433,0.0002440551,0.0006764314,0.00046407065],"category_scores_gemma":[0.00014570828,0.0007145192,0.000830085,0.000509709,0.00023155929,0.00007585353,0.00015257343,0.0005487057,0.00010323699],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021427692,0.00030593047,0.000075225755,0.046912808,0.0022918277,0.00051725394,0.00017633251,9.369812e-8,0.0000070350857,0.0005017076,0.0026701756,0.9465202],"study_design_scores_gemma":[0.0030152323,0.0005124228,0.000034774734,0.2303184,0.0048961914,0.025645085,0.000007094722,0.000005462335,0.000035360517,0.00001334965,0.73499084,0.0005258151],"about_ca_topic_score_codex":0.00030462584,"about_ca_topic_score_gemma":0.000025792026,"teacher_disagreement_score":0.9459944,"about_ca_system_score_codex":0.0032453865,"about_ca_system_score_gemma":0.004266069,"threshold_uncertainty_score":0.9995306},"labels":[],"label_agreement":null},{"id":"W2102107230","doi":"10.1373/clinchem.2012.196477","title":"Establishment and Validation of Analytical Reference Panels for the Standardization of Quantitative BCR-ABL1 Measurements on the International Scale","year":2013,"lang":"en","type":"article","venue":"Clinical Chemistry","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"Department of Health and Social Care; National Institute for Health and Care Research; Novartis","keywords":"Standardization; ABL; breakpoint cluster region; Certified reference materials; Computer science; Computational biology; Reliability engineering; Medicine; Mathematics; Statistics; Biology; Engineering; Tyrosine kinase; Detection limit; Internal medicine","score_opus":0.18508437955813167,"score_gpt":0.4068521241487933,"score_spread":0.22176774459066162,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102107230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99361056,0.000041086303,0.00097360584,0.0025007173,0.00006026359,0.0004849022,0.00004740549,0.0000063900698,0.002275065],"genre_scores_gemma":[0.9987021,0.000068592584,0.0005540555,0.00010253563,0.000053213425,0.00005113248,0.00005860943,0.000006878379,0.00040285898],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988445,0.00003166782,0.0004685598,0.0001841704,0.00038482662,0.00008627076],"domain_scores_gemma":[0.99764776,0.0013755591,0.00022816943,0.00025863346,0.0004385874,0.000051275478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069636153,0.000082860955,0.00020922188,0.000009946197,0.00003435394,0.000014271112,0.00012093852,0.00007766318,0.00025637753],"category_scores_gemma":[0.0021985178,0.00004563119,0.00007412667,0.00005880507,0.00020920228,0.000041267296,0.000041627252,0.00012383943,0.0000032620314],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004350541,0.0035916953,0.78979254,0.0012558801,0.0037249099,0.0000025045463,0.0009197753,0.00038455412,0.14122683,0.0027352406,0.020466544,0.031549018],"study_design_scores_gemma":[0.007497661,0.0008452722,0.13853747,0.00061700225,0.00069262617,0.00000522564,0.0010595194,0.01067819,0.8363559,0.0011377421,0.0023882678,0.00018508182],"about_ca_topic_score_codex":0.000014706303,"about_ca_topic_score_gemma":4.3643846e-7,"teacher_disagreement_score":0.6951291,"about_ca_system_score_codex":0.00012738214,"about_ca_system_score_gemma":0.00014514674,"threshold_uncertainty_score":0.28071544},"labels":[],"label_agreement":null},{"id":"W2102333383","doi":"10.1212/wnl.82.10_supplement.p7.264","title":"Bing-Neel Syndrome: Presentation of Three Unusual Patients (P7.264)","year":2014,"lang":"en","type":"article","venue":"Neurology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke; Université de Sherbrooke","funders":"","keywords":"Presentation (obstetrics); Medicine; Pediatrics; Radiology","score_opus":0.013854217744186126,"score_gpt":0.2562869380690052,"score_spread":0.24243272032481908,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102333383","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99669003,0.000022932945,0.0000975192,0.00045122165,0.00035303898,0.00034815478,0.0000052458795,0.00004672526,0.001985112],"genre_scores_gemma":[0.9989491,0.0000062302784,0.00010500247,0.0006724756,0.0000592155,0.000017918128,0.00005995391,0.000024353501,0.00010574475],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989464,0.00007595664,0.0002561389,0.00026781106,0.00022392598,0.00022974987],"domain_scores_gemma":[0.9992322,0.00014124988,0.00012554771,0.00033774305,0.000082942024,0.00008031795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007010857,0.00012562306,0.00029200967,0.00011927031,0.000027387174,0.00000257382,0.00008578389,0.00012927747,0.00011688051],"category_scores_gemma":[0.00019179586,0.00011154311,0.000060162918,0.00012576394,0.0000889158,0.000042671494,0.00005567104,0.00016490139,0.000105943924],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006519056,0.00045047043,0.9880495,0.00007609289,0.00009593449,0.000063798034,0.000100765006,0.00004834612,0.0013414106,0.00036784826,0.0007240706,0.00802987],"study_design_scores_gemma":[0.005811017,0.0048808404,0.9847232,0.000012269908,0.00010725496,0.00013790761,0.0000012440116,0.0014036885,0.0008710768,0.00026856843,0.0017094131,0.00007348761],"about_ca_topic_score_codex":0.00013856079,"about_ca_topic_score_gemma":0.000044457796,"teacher_disagreement_score":0.007956382,"about_ca_system_score_codex":0.00005061307,"about_ca_system_score_gemma":0.000064758526,"threshold_uncertainty_score":0.45485958},"labels":[],"label_agreement":null},{"id":"W2103533222","doi":"10.1084/jem.20031637","title":"The BCR-ABL1 Kinase Bypasses Selection for the Expression of a Pre–B Cell Receptor in Pre–B Acute Lymphoblastic Leukemia Cells","year":2004,"lang":"en","type":"article","venue":"The Journal of Experimental Medicine","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Deutsche Krebshilfe; Universität zu Köln; Studienstiftung des Deutschen Volkes; Deutsche Forschungsgemeinschaft; Deutscher Akademischer Austauschdienst; Stem Cell Network","keywords":"Biology; breakpoint cluster region; B-cell receptor; Leukemia; ABL; Cancer research; Acute lymphocytic leukemia; CD135; B cell; Molecular biology; Receptor; Signal transduction; Cell biology; Antibody; Immunology; Tyrosine kinase; Genetics","score_opus":0.011875385612186646,"score_gpt":0.29277821467031306,"score_spread":0.2809028290581264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103533222","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98464566,0.011098975,0.0006621933,0.001480406,0.0007165372,0.0012352722,0.000005684319,0.000011927317,0.00014334025],"genre_scores_gemma":[0.9961545,0.001864946,0.0006162017,0.00019903018,0.00055834895,0.0000617128,0.000004215777,0.00003926011,0.00050181005],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99777055,0.00014405469,0.0008875919,0.00016782554,0.00068034953,0.00034962146],"domain_scores_gemma":[0.9974117,0.0011565004,0.0007509027,0.0003751663,0.00016461304,0.00014108644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009056202,0.00027100457,0.0005071849,0.00011724398,0.00024136413,0.000010810393,0.00038306802,0.00009455774,0.00010291914],"category_scores_gemma":[0.00019906052,0.000112004964,0.00015341608,0.00029188648,0.00036196795,0.00012168287,0.000068356494,0.00035795945,0.000004207475],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006133307,0.00037235377,0.00011266254,0.00005005978,0.00016011648,0.000011574579,0.0058020875,0.00064586394,0.98278654,0.000016728107,0.0033709882,0.00053771073],"study_design_scores_gemma":[0.015682423,0.004960679,0.0007026589,0.0011702335,0.000489638,0.00030585358,0.00362623,0.00028432137,0.9714202,0.000062132676,0.0011996665,0.00009593],"about_ca_topic_score_codex":0.00036779465,"about_ca_topic_score_gemma":0.000021931693,"teacher_disagreement_score":0.01150881,"about_ca_system_score_codex":0.00242427,"about_ca_system_score_gemma":0.0007436806,"threshold_uncertainty_score":0.6339382},"labels":[],"label_agreement":null},{"id":"W2105649880","doi":"10.1093/rheumatology/ket225","title":"Inhibition of spleen tyrosine kinase in the treatment of rheumatoid arthritis","year":2013,"lang":"en","type":"review","venue":"Lara D. Veeken","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Medicine; Syk; Adverse effect; Rheumatoid arthritis; Population; Neutropenia; Immunology; Clinical trial; Internal medicine; Pharmacology; Tyrosine kinase; Toxicity; Receptor","score_opus":0.03622209965468414,"score_gpt":0.3055090114579361,"score_spread":0.2692869118032519,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105649880","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012553075,0.983443,0.0000017070198,0.0000619943,0.000083987456,0.0027138656,0.00017971922,0.000019321738,0.0009433151],"genre_scores_gemma":[0.0017418534,0.9961889,0.00022559807,0.000021718635,0.00009872298,0.00051713747,0.0009463137,0.000053797987,0.00020599387],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977896,0.00018420408,0.0010072144,0.00035517337,0.00037728462,0.00028651181],"domain_scores_gemma":[0.99825424,0.00020370481,0.0005367025,0.0008655025,0.000066560235,0.00007329187],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016933522,0.00043531417,0.002289056,0.0002371761,0.000023032859,0.000010229248,0.00013640313,0.00029406062,0.00026055906],"category_scores_gemma":[0.00004387727,0.0002644212,0.0005389719,0.00040026387,0.00010758791,0.00005407898,0.000030117817,0.00019178214,0.00010652709],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025479854,0.0013261123,0.000121854246,0.005271979,0.00030108675,0.00019451349,0.000507141,2.6399317e-7,0.000019231522,0.00010100943,0.0006958248,0.9914355],"study_design_scores_gemma":[0.005199739,0.0013767908,0.0002178978,0.032203015,0.0004965249,0.00027822514,0.00005714834,0.0000038037092,0.00022891589,0.000035247598,0.9596792,0.00022348933],"about_ca_topic_score_codex":0.0010625613,"about_ca_topic_score_gemma":0.00010636836,"teacher_disagreement_score":0.991212,"about_ca_system_score_codex":0.00089176,"about_ca_system_score_gemma":0.00048265708,"threshold_uncertainty_score":0.9999808},"labels":[],"label_agreement":null},{"id":"W2106838577","doi":"10.1182/blood-2005-10-4179","title":"The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":140,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Cytotoxic T cell; Multiple myeloma; Antibody; Cancer research; Medicine; Immunology; Chemistry; In vitro; Biochemistry","score_opus":0.009389533767043632,"score_gpt":0.25150082652777334,"score_spread":0.2421112927607297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106838577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902226,0.0008944741,0.000013282163,0.00089541107,0.00035178463,0.0014356982,0.000050776678,0.00018523236,0.0059507485],"genre_scores_gemma":[0.9856407,0.00008005665,0.0009046894,0.0005954031,0.00085367146,0.000097234806,0.000081031234,0.00007404984,0.011673137],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977813,0.00005356136,0.0004317972,0.0005352244,0.000529448,0.0006686908],"domain_scores_gemma":[0.9985284,0.00015923515,0.00011555585,0.0008595333,0.0001156727,0.00022158434],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00020222455,0.0003302774,0.00038881117,0.00010671672,0.00028304575,0.00005809587,0.000220322,0.00016087391,0.00013768565],"category_scores_gemma":[0.000072926334,0.00023381025,0.0001573386,0.00031800364,0.000109722554,0.000071856644,0.00013204764,0.00024892308,0.0012004882],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000110126944,0.002296496,0.065849185,0.00011422035,0.00025949194,0.00042644975,0.00028816095,0.000008616473,0.8814219,0.000046823563,0.04711205,0.0020664574],"study_design_scores_gemma":[0.012050667,0.00041095377,0.0843583,0.00016231126,0.00030562366,0.00015552681,0.000059585047,0.000071023576,0.8048942,0.000032365653,0.09717296,0.000326448],"about_ca_topic_score_codex":0.00043117054,"about_ca_topic_score_gemma":0.00010524249,"teacher_disagreement_score":0.076527685,"about_ca_system_score_codex":0.00027973208,"about_ca_system_score_gemma":0.00031345282,"threshold_uncertainty_score":0.99957716},"labels":[],"label_agreement":null},{"id":"W2107268345","doi":"10.1056/nejmoa062867","title":"Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia","year":2006,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3481,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"Celgene; Pfizer; Kementerian Pendidikan Nasional; Bristol-Myers Squibb; Amgen","keywords":"Medicine; Imatinib; Internal medicine; Cytarabine; Myeloid leukemia; Adverse effect; Imatinib mesylate; Philadelphia chromosome; Alpha interferon; Gastroenterology; Oncology; Surgery; Immunology; Interferon; Chromosomal translocation","score_opus":0.01252982675583111,"score_gpt":0.2622417208740349,"score_spread":0.2497118941182038,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107268345","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99157226,0.0019315731,0.0007383477,0.0013082179,0.0011813083,0.0005473123,0.000016788837,0.000018775909,0.002685401],"genre_scores_gemma":[0.9875211,0.00029953514,0.0029920589,0.0001192751,0.0056339963,0.000005135681,0.0000875651,0.00004775343,0.0032935552],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99743736,0.000059873662,0.0011757609,0.00020549868,0.0007579116,0.00036358187],"domain_scores_gemma":[0.9975077,0.0004533822,0.0009210857,0.00028480313,0.00055904477,0.0002739689],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071913743,0.00026223686,0.0009696091,0.0002803459,0.00005628429,0.0000060959615,0.00017765597,0.00012369087,0.00035047624],"category_scores_gemma":[0.000892065,0.0001790077,0.00022774299,0.00022110283,0.00011493644,0.00012129945,0.000027604376,0.00033431954,0.000006226049],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014178188,0.00069695216,0.1994035,0.0017105441,0.0014390263,0.0002463535,0.0033657455,0.00045200554,0.02747731,0.0005131657,0.23787746,0.51263976],"study_design_scores_gemma":[0.658413,0.014072966,0.22718924,0.0041592787,0.0017496543,0.00051459944,0.0002585431,0.00042084022,0.007318108,0.0014590129,0.0840723,0.0003724457],"about_ca_topic_score_codex":0.00036253818,"about_ca_topic_score_gemma":0.00011502563,"teacher_disagreement_score":0.64423484,"about_ca_system_score_codex":0.0014516242,"about_ca_system_score_gemma":0.0013929383,"threshold_uncertainty_score":0.7299722},"labels":[],"label_agreement":null},{"id":"W2108125451","doi":"10.1186/1476-4598-9-41","title":"Expression of the leukemic prognostic marker CD7 is linked to epigenetic modifications in chronic myeloid leukemia","year":2010,"lang":"en","type":"article","venue":"Molecular Cancer","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"BC Cancer Agency; Cancer Research Society; Ohio State University","keywords":"Biology; Myeloid leukemia; Epigenetics; Cancer research; Myeloid; Leukemia; Immunology; Genetics; Gene","score_opus":0.013419328852905076,"score_gpt":0.28107168911764013,"score_spread":0.26765236026473505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108125451","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944554,0.0013324565,0.0002417001,0.0012489213,0.00025979284,0.001528314,0.000026177444,0.000030829124,0.0008763869],"genre_scores_gemma":[0.9964607,0.00010396701,0.00083390705,0.0006637558,0.00009567682,0.0006564577,0.000012690803,0.000055090764,0.0011177537],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982726,0.0000588329,0.00040150338,0.00046433343,0.0004139785,0.0003887281],"domain_scores_gemma":[0.99847335,0.000046331992,0.00013050367,0.0010745586,0.000112895155,0.00016234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011948541,0.00023521514,0.0003139288,0.00013949451,0.000060053513,0.000011114498,0.00030327786,0.0001885892,0.0005616238],"category_scores_gemma":[0.00015825244,0.00017661846,0.00015107101,0.00053179247,0.000110925546,0.000038070106,0.00013529671,0.0004779352,0.00005106481],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005618657,0.000060173887,0.018996246,0.0001000239,0.000038843806,0.000016852184,0.00036777722,0.0010710778,0.97360575,0.000025990425,0.00064522383,0.00501584],"study_design_scores_gemma":[0.00265428,0.00010018327,0.42394304,0.00065455,0.00014862725,0.000017063543,0.000021554302,0.0021960104,0.56534296,0.00009215066,0.004615433,0.0002141244],"about_ca_topic_score_codex":0.0007692458,"about_ca_topic_score_gemma":0.00048433497,"teacher_disagreement_score":0.4082628,"about_ca_system_score_codex":0.0032957522,"about_ca_system_score_gemma":0.003255893,"threshold_uncertainty_score":0.86182773},"labels":[],"label_agreement":null},{"id":"W2108351867","doi":"10.1007/s12975-014-0358-6","title":"Longitudinal Assessment of Imatinib’s Effect on the Blood–Brain Barrier After Ischemia/Reperfusion Injury with Permeability MRI","year":2014,"lang":"en","type":"article","venue":"Translational Stroke Research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Toronto Western Hospital; Hospital for Sick Children","funders":"Canada Research Chairs; Heart and Stroke Foundation of Canada","keywords":"Medicine; Imatinib; Evans Blue; Blood–brain barrier; Extravasation; Ischemia; Stroke (engine); Anesthesia; Pathology; Pharmacology; Internal medicine; Central nervous system","score_opus":0.02810291715886089,"score_gpt":0.36677775339369684,"score_spread":0.33867483623483596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108351867","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9851144,0.000054224092,0.00026846293,0.0042323964,0.000018732006,0.0011980608,0.0000885741,0.000021887461,0.009003245],"genre_scores_gemma":[0.99748325,0.000007968841,0.0011927235,0.00006388138,0.00012696491,0.00027731157,0.000053886182,0.000028026663,0.00076600316],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960572,0.0006474448,0.00032455337,0.0004664509,0.002077939,0.0004264217],"domain_scores_gemma":[0.99619776,0.0026446385,0.000056413413,0.0006288378,0.00030176752,0.00017059596],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003168574,0.00021394082,0.0003464252,0.00014509367,0.00018949842,0.000022631286,0.00016464197,0.0001129207,0.0022190956],"category_scores_gemma":[0.00027510073,0.00012062179,0.00015003292,0.00026906998,0.00042264507,0.00006973792,0.000039479335,0.0007697405,0.000028169046],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043105483,0.00072939263,0.88639206,0.00041923285,0.00038680664,0.00002286213,0.00030029856,0.00009188193,0.09852412,0.0018364605,0.00041728927,0.0065690256],"study_design_scores_gemma":[0.007604343,0.0073182923,0.8307982,0.00049547665,0.00020193846,0.00003545461,0.000036634654,0.004564737,0.14723085,0.00018380373,0.0013050361,0.00022524133],"about_ca_topic_score_codex":0.000084371735,"about_ca_topic_score_gemma":0.00002667751,"teacher_disagreement_score":0.05559389,"about_ca_system_score_codex":0.00027071263,"about_ca_system_score_gemma":0.0006339884,"threshold_uncertainty_score":0.998693},"labels":[],"label_agreement":null},{"id":"W2109883040","doi":"10.1200/jco.2003.99.170","title":"CNS and Cutaneous Involvement in Patients With Chronic Myeloid Leukemia Treated With Imatinib in Hematologic Complete Remission: Two Case Reports","year":2003,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Imatinib; Myeloid leukemia; Complete remission; Leukemia; Internal medicine; Oncology; Hematologic malignancy; Chemotherapy","score_opus":0.05894890658755725,"score_gpt":0.36419404399967265,"score_spread":0.3052451374121154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2109883040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9674194,0.0006409126,0.000004947766,0.029334093,0.00037644894,0.001413387,0.000013667181,0.000017997245,0.0007791825],"genre_scores_gemma":[0.8484768,0.0009014892,0.0073043187,0.14006333,0.001813915,0.00007524572,0.000318614,0.00022088083,0.00082540856],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9911527,0.0009973006,0.0052756825,0.0008699177,0.0009264926,0.0007779051],"domain_scores_gemma":[0.9908307,0.0019794407,0.005529716,0.00070366485,0.00047381045,0.00048263493],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0016564159,0.0007209663,0.0048239427,0.0005299716,0.00005968515,0.000020836143,0.0001495062,0.0016276768,0.00021686878],"category_scores_gemma":[0.0010547667,0.00043830727,0.000295827,0.00039058147,0.00049970543,0.00011708622,0.00009322783,0.00607158,0.000006132659],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0032055,0.0009144809,0.3448156,0.00029246235,0.0005134269,0.61551607,0.000057046607,0.000043658492,0.0000024454969,6.8154645e-7,0.030594544,0.0040440992],"study_design_scores_gemma":[0.09437128,0.0588658,0.065056965,0.0048474465,0.0019539522,0.5852222,0.000097207645,0.00014243036,0.000016619308,0.000089010595,0.1884516,0.00088549795],"about_ca_topic_score_codex":0.00056147366,"about_ca_topic_score_gemma":0.0013840852,"teacher_disagreement_score":0.27975863,"about_ca_system_score_codex":0.008970159,"about_ca_system_score_gemma":0.009483546,"threshold_uncertainty_score":0.9998069},"labels":[],"label_agreement":null},{"id":"W2110652219","doi":"10.1093/jn/137.6.1518s","title":"c-Abl Tyrosine Kinase and Inhibition by the Cancer Drug Imatinib (Gleevec/STI-571)","year":2007,"lang":"en","type":"article","venue":"Journal of Nutrition","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Proto-oncogene tyrosine-protein kinase Src; SH3 domain; ABL; Tyrosine kinase; SH2 domain; Chronic myelogenous leukemia; Imatinib; Protein kinase domain; Chemistry; Imatinib mesylate; Cancer research; Kinase; Biochemistry; Cell biology; Biology; Signal transduction; Leukemia; Genetics","score_opus":0.012630899661225282,"score_gpt":0.2880250333575215,"score_spread":0.27539413369629623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110652219","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98188895,0.009871211,0.00032639867,0.0071356576,0.00019608742,0.00028457804,0.00002143328,0.000011521879,0.00026414756],"genre_scores_gemma":[0.9945929,0.0024115623,0.0013320879,0.00062306307,0.00073363504,0.000008966197,0.000025213378,0.000016455902,0.0002561282],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989279,0.00003522808,0.0004202357,0.000107393804,0.0003337244,0.00017555318],"domain_scores_gemma":[0.9991355,0.00011316005,0.00031115563,0.00011295916,0.00019744293,0.00012978187],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052960886,0.00011421098,0.00022067534,0.000101401805,0.00008754594,0.000023787668,0.00004031748,0.00006204231,0.00009893523],"category_scores_gemma":[0.00007598233,0.000075437856,0.00007658406,0.00015080198,0.00006592326,0.00017419427,0.000014583193,0.0002681967,0.0000047072517],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028202492,0.0034077922,0.01334856,0.00081091,0.00037409193,0.0008690202,0.0012485951,0.000006814012,0.54838955,0.00017966235,0.34312505,0.08541971],"study_design_scores_gemma":[0.066692755,0.002513818,0.14000654,0.0075115855,0.0015847924,0.007881442,0.0018474826,0.0003354019,0.67896044,0.0024992933,0.089588374,0.0005780805],"about_ca_topic_score_codex":0.00009650942,"about_ca_topic_score_gemma":0.000022506734,"teacher_disagreement_score":0.25353667,"about_ca_system_score_codex":0.00065970497,"about_ca_system_score_gemma":0.00009787014,"threshold_uncertainty_score":0.30762663},"labels":[],"label_agreement":null},{"id":"W2112127173","doi":"10.1084/jem.191.6.977","title":"Blockade of the Bcr-Abl Kinase Activity Induces Apoptosis of Chronic Myelogenous Leukemia Cells by Suppressing Signal Transducer and Activator of Transcription 5–Dependent Expression of Bcl-XL","year":2000,"lang":"en","type":"article","venue":"The Journal of Experimental Medicine","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":364,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Toronto; University of Minnesota","keywords":"Chronic myelogenous leukemia; STAT protein; STAT5; breakpoint cluster region; Cancer research; ABL; K562 cells; Signal transduction; Apoptosis; Biology; Kinase; Leukemia; STAT3; Cell biology; Tyrosine kinase; Immunology; Receptor","score_opus":0.014434962574539403,"score_gpt":0.2611755670376567,"score_spread":0.2467406044631173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112127173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98676944,0.012061704,0.000032822303,0.0003010392,0.00016089198,0.00048790275,0.00003328616,0.0000044069984,0.00014848133],"genre_scores_gemma":[0.99839205,0.0012102437,0.00008206133,0.000026654305,0.0001626067,0.0000047935227,0.0000032173941,0.00002941714,0.00008896094],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997274,0.00030807566,0.0009994141,0.00018056687,0.0009905299,0.00024744606],"domain_scores_gemma":[0.99811685,0.00021464229,0.0010420695,0.00036935371,0.000109258945,0.00014784059],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000538045,0.00028611268,0.00095532055,0.00012421235,0.000082426646,0.000002617618,0.00029344816,0.00014805225,0.0009396052],"category_scores_gemma":[0.000022102391,0.00015369264,0.00019897455,0.00019685185,0.00074936595,0.00016925861,0.000033636836,0.0004161967,2.6847567e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032703977,0.0009736537,0.00010503317,0.00027453533,0.00026305992,0.0000042331194,0.00835678,0.000061130966,0.9783472,6.016877e-7,0.00016615707,0.00817724],"study_design_scores_gemma":[0.008929564,0.0034710886,0.0010177034,0.0023979933,0.0006781349,0.00014434403,0.0023755461,0.000053940064,0.9807823,0.0000066756147,0.00004236737,0.000100396726],"about_ca_topic_score_codex":0.00046936268,"about_ca_topic_score_gemma":0.0000029577125,"teacher_disagreement_score":0.01162258,"about_ca_system_score_codex":0.0006883201,"about_ca_system_score_gemma":0.00042871354,"threshold_uncertainty_score":0.99997365},"labels":[],"label_agreement":null},{"id":"W2112505356","doi":"10.1158/1078-0432.ccr-07-4393","title":"Profound Inhibition of Antigen-Specific T-Cell Effector Functions by Dasatinib","year":2008,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":138,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Dasatinib; T cell; Cytotoxic T cell; Cytokine; Degranulation; Cancer research; CD8; Biology; LYN; Tyrosine kinase; CD28; Immunology; Cell biology; Signal transduction; Antigen; Immune system; Receptor; In vitro; Biochemistry","score_opus":0.23667664232533722,"score_gpt":0.48237610064549724,"score_spread":0.24569945832016002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112505356","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98837143,0.0039124247,0.00004086284,0.00066652027,0.00030180428,0.0011348239,0.000118049385,0.000044662876,0.00540944],"genre_scores_gemma":[0.98116446,0.009832094,0.00014876356,0.00008379374,0.0005817051,0.0002296983,0.00019471554,0.00003890715,0.007725874],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969773,0.0003962924,0.0006720281,0.00052567426,0.0009499908,0.00047865935],"domain_scores_gemma":[0.9974366,0.0010735486,0.0001143893,0.00058501016,0.00047915746,0.00031133665],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0013234923,0.00014547701,0.00046134822,0.00014069438,0.00020987283,0.000009392151,0.000111641566,0.00021126424,0.00194819],"category_scores_gemma":[0.0004031811,0.00012123303,0.0001885453,0.0005853868,0.0008483984,0.00006995521,0.00009464826,0.00093121757,0.0008186478],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018661215,0.0025725267,0.32836798,0.00029011656,0.0001608693,0.00015950396,0.00019834374,0.0000022773252,0.08750619,0.000019502242,0.5645601,0.014296425],"study_design_scores_gemma":[0.024044197,0.005364644,0.37269372,0.0006223048,0.00006256541,0.000056476874,0.00016474015,0.000080842976,0.10300401,0.000053160275,0.4934885,0.00036487292],"about_ca_topic_score_codex":0.0004050564,"about_ca_topic_score_gemma":0.000026789181,"teacher_disagreement_score":0.07107165,"about_ca_system_score_codex":0.00074321614,"about_ca_system_score_gemma":0.0012957773,"threshold_uncertainty_score":0.99995935},"labels":[],"label_agreement":null},{"id":"W2113301890","doi":"10.3109/10428191003802340","title":"Human leukocyte antigen class I alleles and the risk of chronic myelogenous leukemia: a meta-analysis","year":2010,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Odds ratio; Chronic myelogenous leukemia; Human leukocyte antigen; Meta-analysis; Allele; Immunology; Medicine; Context (archaeology); Population; Leukemia; Oncology; Biology; Genetics; Internal medicine; Antigen; Environmental health; Gene","score_opus":0.03427095306676008,"score_gpt":0.2982893996736653,"score_spread":0.2640184466069052,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113301890","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.045280952,0.94628745,0.000038759652,0.00007067198,0.00031348987,0.0045710197,0.0006695741,0.00032874514,0.0024393122],"genre_scores_gemma":[0.028872263,0.96282095,0.00054942747,0.00031757576,0.00090050127,0.0012780966,0.0010742286,0.0005506678,0.0036362659],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.985693,0.0018317126,0.0045288317,0.0036100596,0.0019997195,0.0023366779],"domain_scores_gemma":[0.9866504,0.0022242425,0.004442384,0.004987055,0.00047867149,0.0012172377],"candidate_categories":["metaepi_narrow","metaepi_broad","sts","research_integrity"],"consensus_categories":["metaepi_narrow","metaepi_broad","sts"],"category_scores_codex":[0.0027209884,0.0037602796,0.018823951,0.0018318925,0.0014423041,0.00035675915,0.00174684,0.0036617797,0.00044456267],"category_scores_gemma":[0.00042535597,0.0023714988,0.010156206,0.002783267,0.0039304635,0.0003486332,0.0012765424,0.0017849371,0.00011280326],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0004709303,0.00031442547,0.00021581704,0.0112045,0.3104948,0.0007891755,0.0007839713,0.00005155898,0.00004734159,0.001355532,0.0009967148,0.67327523],"study_design_scores_gemma":[0.019788861,0.00049057684,0.0009191321,0.0010481155,0.49526763,0.0029021704,0.00010511907,0.00094722724,0.000091049034,0.00017587439,0.47664547,0.0016187782],"about_ca_topic_score_codex":0.012025677,"about_ca_topic_score_gemma":0.0021417725,"teacher_disagreement_score":0.6716564,"about_ca_system_score_codex":0.028701669,"about_ca_system_score_gemma":0.02514529,"threshold_uncertainty_score":0.99985766},"labels":[],"label_agreement":null},{"id":"W2113387041","doi":"10.5430/jhm.v2n2p25","title":"The predictive value of the Sokal and Hasford scoring systems in chronic myeloid leukaemia in the imatinib era","year":2012,"lang":"en","type":"article","venue":"Journal of Hematological Malignancies","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Imatinib mesylate; Imatinib; Myeloid leukemia; Internal medicine; Oncology; Tyrosine-kinase inhibitor; Philadelphia chromosome; Cancer; Chromosomal translocation; Gene; Biology; Genetics","score_opus":0.022797778250684915,"score_gpt":0.27544926356399385,"score_spread":0.25265148531330894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113387041","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9765445,0.021040967,0.0000235791,0.0010174343,0.00027401588,0.0005449467,0.0000028829809,0.0000056636513,0.0005460297],"genre_scores_gemma":[0.99888426,0.0006791516,0.0001132034,0.0000830426,0.000168319,0.00003082762,3.5679855e-7,0.000009645213,0.000031181826],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99771535,0.0003172681,0.0008714902,0.000118669916,0.00054819835,0.00042900624],"domain_scores_gemma":[0.99802077,0.0009723396,0.0005684735,0.0002747462,0.00008667503,0.000077016484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016450514,0.0001834483,0.00058767654,0.00007312029,0.0001250461,0.000030595787,0.00027326224,0.00012355477,0.0000066730895],"category_scores_gemma":[0.00070279103,0.00006937545,0.00014759663,0.0002647918,0.0003506126,0.00016796701,0.00010992196,0.0006339692,0.0000016925837],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00085685006,0.00063764385,0.9381062,0.00101351,0.00031175572,0.0004022148,0.007108014,0.0006295396,0.010426343,0.037990835,0.0007313028,0.001785841],"study_design_scores_gemma":[0.004271504,0.0009367993,0.9695447,0.002952967,0.00017524879,0.008478407,0.0058713355,0.0010350725,0.0047641797,0.001072027,0.0007515083,0.00014621468],"about_ca_topic_score_codex":0.000060660488,"about_ca_topic_score_gemma":0.000020589385,"teacher_disagreement_score":0.036918804,"about_ca_system_score_codex":0.00074249384,"about_ca_system_score_gemma":0.00044742314,"threshold_uncertainty_score":0.2829049},"labels":[],"label_agreement":null},{"id":"W2113528374","doi":"10.1080/14653240600735743","title":"Testing the safety of clinical-grade mature autologous myeloid DC in a phase I clinical immunotherapy trial of CML","year":2006,"lang":"en","type":"article","venue":"Cytotherapy","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; University of Saskatchewan; Mayo Clinic","keywords":"Medicine; Clinical trial; Immunotherapy; Imatinib mesylate; Internal medicine; Imatinib; Oncology; Immunology; Myeloid leukemia; Cancer","score_opus":0.07013701845711165,"score_gpt":0.40279635376309414,"score_spread":0.33265933530598246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113528374","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925757,0.0021288753,0.00010018729,0.0010528644,0.0005155728,0.0018145897,0.00004205664,0.000068284906,0.0017018866],"genre_scores_gemma":[0.99223864,0.000975222,0.0046864026,0.0005953009,0.00092667487,0.000056657504,0.000041309657,0.00007256278,0.0004072044],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9953007,0.00056553853,0.0028393872,0.00048391634,0.0004267112,0.00038375205],"domain_scores_gemma":[0.9953959,0.0023289612,0.0010388704,0.0010247204,0.00012876524,0.00008281007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002356373,0.00031219953,0.001540882,0.00012539278,0.000058800226,0.000008914714,0.00032703858,0.00045005925,0.00015607083],"category_scores_gemma":[0.0005912637,0.00020337373,0.0005686803,0.00055064826,0.0005388958,0.00005095649,0.000029768209,0.00073311414,0.000010505604],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22411497,0.015810044,0.19703494,0.00014190552,0.0010995734,0.00020424275,0.0005857809,0.00005801845,0.040185556,0.00059739803,0.0022259091,0.51794165],"study_design_scores_gemma":[0.54456896,0.008582972,0.41957578,0.00044348813,0.00017094972,0.000093914445,0.00009615559,0.0006473541,0.0050879396,0.00088895886,0.019511683,0.00033183274],"about_ca_topic_score_codex":0.00044191425,"about_ca_topic_score_gemma":0.000045547393,"teacher_disagreement_score":0.51760983,"about_ca_system_score_codex":0.00020267299,"about_ca_system_score_gemma":0.0008665365,"threshold_uncertainty_score":0.82933396},"labels":[],"label_agreement":null},{"id":"W2116438773","doi":"10.5430/jhm.v2n3p45","title":"Immunological implications of the use of tyrosine kinase inhibitors in chronic myeloid leukemia","year":2012,"lang":"en","type":"article","venue":"Journal of Hematological Malignancies","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Nilotinib; Dasatinib; Imatinib; Tyrosine kinase; Myeloid leukemia; Cancer research; Medicine; Immune system; Immunology; Tyrosine-kinase inhibitor; Leukemia; Pharmacology; Cancer; Internal medicine; Receptor","score_opus":0.0515969378243635,"score_gpt":0.28553090049707736,"score_spread":0.23393396267271385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116438773","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988783,0.009658783,0.00003855138,0.0008853422,0.0001610803,0.00030936007,0.000010084613,0.000009957045,0.00014384893],"genre_scores_gemma":[0.9976267,0.0005940669,0.0014970045,0.0001036883,0.0000888868,0.0000114641625,0.0000020956775,0.000012021824,0.0000640599],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99775904,0.00013289455,0.0012182972,0.0001318783,0.0003717027,0.00038619616],"domain_scores_gemma":[0.99789554,0.0004090675,0.0009183716,0.00040281148,0.00024904165,0.00012514289],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035841423,0.00019982636,0.0008467068,0.00015335702,0.000044974324,0.000006996972,0.00024845666,0.00021966556,0.00011239789],"category_scores_gemma":[0.0010679663,0.00010468289,0.00036584254,0.0004806048,0.00045185507,0.0002175009,0.00015439432,0.0004251177,0.0000049219166],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003666967,0.001123527,0.6051563,0.0002956044,0.00016774204,0.00006952426,0.00029558424,0.00014138271,0.38082334,0.007619597,0.0011938222,0.0027468733],"study_design_scores_gemma":[0.002334199,0.00070962054,0.8204328,0.00090216566,0.00015075636,0.0017599046,0.00011706843,0.000015312755,0.17089859,0.00030957878,0.0022557224,0.00011432299],"about_ca_topic_score_codex":0.000036031473,"about_ca_topic_score_gemma":0.000006631915,"teacher_disagreement_score":0.21527646,"about_ca_system_score_codex":0.0013591263,"about_ca_system_score_gemma":0.00070287305,"threshold_uncertainty_score":0.42688444},"labels":[],"label_agreement":null},{"id":"W2117111164","doi":"10.1016/j.leukres.2014.01.003","title":"Standardizing dysgranulopoiesis in MDS and AML: Refining diagnostics and laying the foundation for novel morphological-genetic correlations","year":2014,"lang":"en","type":"letter","venue":"Leukemia Research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Medical Research Council; European Hematology Association","keywords":"Myeloid leukemia; Imatinib mesylate; Medicine; Mutation; Oncology; Internal medicine; Tyrosine-kinase inhibitor; Tyrosine kinase; Point mutation; Drug resistance; Imatinib; Protein kinase domain; Cancer research; Genetics; Biology; Cancer; Gene","score_opus":0.11842634867562067,"score_gpt":0.3782195400815864,"score_spread":0.25979319140596574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117111164","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.46485943,0.005323936,0.008979703,0.5102309,0.00045919837,0.0059445235,0.0002867226,0.00018168219,0.003733891],"genre_scores_gemma":[0.7197979,0.011840756,0.041637246,0.19661377,0.008001773,0.005184528,0.0040116766,0.00073470554,0.012177641],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99664354,0.00030025793,0.0005281401,0.0007734327,0.00090842356,0.0008461748],"domain_scores_gemma":[0.9907203,0.008076111,0.00014800618,0.0006186747,0.00032060812,0.00011632264],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0018460194,0.00034096232,0.00060441054,0.0004700062,0.00059894414,0.00019459253,0.00020906617,0.0007905968,0.000039764145],"category_scores_gemma":[0.0037986885,0.00025172447,0.00008289144,0.000445278,0.0005726286,0.00006926472,0.0002494418,0.0028821854,0.000016052642],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007905099,0.00014634029,0.10802877,0.0035296439,0.00065286097,0.0018098742,0.0024778824,0.00039781176,0.0013478628,0.0006036593,0.81260896,0.06760581],"study_design_scores_gemma":[0.012689275,0.0010476087,0.059141,0.0022100878,0.0004893939,0.00084581703,0.0005249801,0.011467508,0.00006252232,0.0011341204,0.90971154,0.0006761386],"about_ca_topic_score_codex":0.0008397266,"about_ca_topic_score_gemma":0.00010817325,"teacher_disagreement_score":0.31361714,"about_ca_system_score_codex":0.0036816904,"about_ca_system_score_gemma":0.0011565646,"threshold_uncertainty_score":0.9999935},"labels":[],"label_agreement":null},{"id":"W2117311687","doi":"10.1124/jpet.106.116640","title":"STI-571 (Imatinib Mesylate) Enhances the Apoptotic Efficacy of Pyrrolo-1,5-Benzoxazepine-6, a Novel Microtubule-Targeting Agent, in Both STI-571-Sensitive and -Resistant Bcr-Abl-Positive Human Chronic Myeloid Leukemia Cells","year":2007,"lang":"en","type":"article","venue":"Journal of Pharmacology and Experimental Therapeutics","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"","keywords":"Myeloid leukemia; K562 cells; Imatinib mesylate; Apoptosis; Cancer research; Propidium iodide; Nocodazole; Imatinib; breakpoint cluster region; Chemistry; Pharmacology; Medicine; Cell; Programmed cell death; Internal medicine; Receptor; Biochemistry; Cytoskeleton","score_opus":0.021614376830901286,"score_gpt":0.33765783738025623,"score_spread":0.31604346054935495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117311687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867383,0.011506944,0.00011481471,0.00026208215,0.00040321893,0.0007459976,0.000019171577,0.000012748617,0.00019668939],"genre_scores_gemma":[0.99640346,0.0013834732,0.00084208144,0.0008797623,0.00034994734,0.000008021741,0.000010030352,0.000043590022,0.00007962903],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973799,0.00020219466,0.0011068743,0.00033780045,0.00034462783,0.00062857865],"domain_scores_gemma":[0.9980891,0.00058035215,0.00085067685,0.00013724604,0.0001460154,0.00019661464],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010736277,0.00041066788,0.0008185678,0.00023840902,0.0002341609,0.000023085915,0.00017672383,0.00020194883,0.0001068511],"category_scores_gemma":[0.000017982797,0.00030079772,0.00016730138,0.00020961983,0.00065922365,0.00014246228,0.000110666384,0.0007407265,0.0000025433287],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00337093,0.00084526814,0.00019020331,0.00009369547,0.0010810513,0.00023806994,0.0050396416,0.000068731766,0.9881019,0.000038171227,0.000072707895,0.0008596472],"study_design_scores_gemma":[0.016014125,0.0025270171,0.011749232,0.00028694439,0.0006390064,0.0003556328,0.0022285036,0.0003260789,0.9652125,0.000013968804,0.00040837112,0.00023858299],"about_ca_topic_score_codex":0.00009648089,"about_ca_topic_score_gemma":0.00001696856,"teacher_disagreement_score":0.022889344,"about_ca_system_score_codex":0.0018373945,"about_ca_system_score_gemma":0.00051494985,"threshold_uncertainty_score":0.9999444},"labels":[],"label_agreement":null},{"id":"W2117496910","doi":"10.1517/13543776.18.9.975","title":"Structural biology in the battle against BCR-Abl","year":2008,"lang":"en","type":"article","venue":"Expert Opinion on Therapeutic Patents","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Vertex Pharmaceuticals; Bristol-Myers Squibb; Boehringer Ingelheim","keywords":"Imatinib; Chronic myelogenous leukemia; Tyrosine kinase; Drug resistance; ABL; Tyrosine-kinase inhibitor; Drug; Cancer research; Pharmacology; Medicine; Leukemia; Biology; Cancer; Immunology; Myeloid leukemia; Internal medicine; Receptor; Genetics","score_opus":0.10270415001056933,"score_gpt":0.34708296736244654,"score_spread":0.24437881735187722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117496910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877893,0.005492812,0.000017565788,0.0020089748,0.0017243513,0.0005714195,0.000009784949,0.000071042115,0.0023147797],"genre_scores_gemma":[0.9910434,0.0031704248,0.00008320613,0.0050452542,0.000281603,0.00008023951,0.00014244937,0.000028095097,0.00012535125],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985106,0.00017692991,0.00028423057,0.00035291864,0.0002844507,0.00039087795],"domain_scores_gemma":[0.99911374,0.00018775855,0.000072727744,0.0005187786,0.000028466733,0.000078520156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000112148315,0.00024181497,0.00029298387,0.000114361836,0.0001355406,0.000007944217,0.00022332538,0.00013611202,0.00018896893],"category_scores_gemma":[0.000041052786,0.00014422569,0.00010525935,0.00019560447,0.00013059087,0.00004879684,0.000029176183,0.00025668534,0.00020430941],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027236848,0.0026785864,0.475282,0.000061830935,0.0010462083,0.00069583085,0.02863349,0.000097896154,0.030939689,0.002113552,0.010173589,0.44555363],"study_design_scores_gemma":[0.02385741,0.0023422623,0.7893287,0.00031176914,0.000016994802,0.000742137,0.0010914505,0.002141274,0.006179887,0.00047256876,0.1727409,0.00077463605],"about_ca_topic_score_codex":0.00012669765,"about_ca_topic_score_gemma":0.0000023484747,"teacher_disagreement_score":0.444779,"about_ca_system_score_codex":0.00039383597,"about_ca_system_score_gemma":0.00012410812,"threshold_uncertainty_score":0.5881353},"labels":[],"label_agreement":null},{"id":"W2118057314","doi":"10.3109/10428194.2012.682314","title":"Sudden blast crisis in chronic myeloid leukemia treated with tyrosine kinase inhibitors","year":2012,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Blast Crisis; Imatinib; Imatinib mesylate; Myeloid leukemia; Internal medicine; Immunology; Oncology","score_opus":0.010599954824801078,"score_gpt":0.2298835276421774,"score_spread":0.21928357281737632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118057314","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94205624,0.022017464,0.00001997032,0.021261819,0.0011607115,0.004675736,0.0005642977,0.0013200336,0.0069237263],"genre_scores_gemma":[0.8069159,0.0064427895,0.00094876613,0.13791366,0.016192783,0.0019403945,0.00827335,0.0022265892,0.019145804],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98388207,0.0006039556,0.003079038,0.004410985,0.0028550972,0.005168844],"domain_scores_gemma":[0.9916305,0.00071538886,0.0015751094,0.0038750526,0.00049986533,0.0017040855],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.00075584045,0.0044725663,0.0051741106,0.002479519,0.0006580533,0.00046278702,0.0012330563,0.005788288,0.00081716035],"category_scores_gemma":[0.00015734494,0.0038732036,0.0010782316,0.002744004,0.0013319446,0.0010669333,0.0007695221,0.0027345617,0.0008512378],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0033103775,0.0005666911,0.018601494,0.004391848,0.0026619001,0.029755,0.0013207057,0.00013101497,0.0028577652,0.000053087275,0.8650594,0.07129077],"study_design_scores_gemma":[0.08901251,0.003115962,0.047141545,0.007044984,0.005081193,0.012676706,0.00060862006,0.0016570652,0.014314119,0.00006391201,0.81295085,0.006332512],"about_ca_topic_score_codex":0.02286553,"about_ca_topic_score_gemma":0.0012538851,"teacher_disagreement_score":0.15329991,"about_ca_system_score_codex":0.186537,"about_ca_system_score_gemma":0.033237085,"threshold_uncertainty_score":0.9999267},"labels":[],"label_agreement":null},{"id":"W2119043550","doi":"10.1016/j.bbmt.2008.04.012","title":"Allogeneic Hematopoietic Cell Transplantation for Adult Philadelphia-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors","year":2008,"lang":"en","type":"review","venue":"Biology of Blood and Marrow Transplantation","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Medicine; Imatinib; Tyrosine kinase; Transplantation; Internal medicine; Chemotherapy; Lymphoblastic Leukemia; Philadelphia chromosome; Imatinib mesylate; Oncology; Tyrosine-kinase inhibitor; Leukemia; Hematopoietic stem cell transplantation; Immunology; Myeloid leukemia; Receptor; Chromosomal translocation","score_opus":0.014058393880175556,"score_gpt":0.2724557867622116,"score_spread":0.25839739288203606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119043550","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.088719584,0.90633965,0.00026016062,0.00008842846,0.00012301082,0.002659629,0.001740419,0.000018341825,0.000050782488],"genre_scores_gemma":[0.19159648,0.8033482,0.00042282257,0.0000506056,0.00006164764,0.000227153,0.004254244,0.000031713855,0.0000071610352],"study_design_codex":"systematic_review","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979648,0.00019483696,0.0009527833,0.0004522548,0.00015894482,0.00027639806],"domain_scores_gemma":[0.99851054,0.0005935317,0.0004989402,0.00021040876,0.00012472176,0.000061862476],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013789287,0.00043992815,0.0014274155,0.00024003274,0.000060463826,0.0000037942107,0.00012999309,0.00051238644,0.0000046440746],"category_scores_gemma":[0.000016594646,0.00030685088,0.00035672777,0.00024110034,0.00025503474,0.000049672606,0.000005574763,0.00024918542,0.0000012275112],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0074482607,0.0032831454,0.0021622137,0.43520603,0.007049048,0.0020572674,0.019183582,0.00003487044,0.08973783,0.001196102,0.00030023901,0.4323414],"study_design_scores_gemma":[0.15520956,0.025671536,0.007446763,0.21596265,0.24199943,0.052955065,0.0010370793,0.00013243005,0.28146327,0.0006978775,0.012111004,0.005313337],"about_ca_topic_score_codex":0.00013415022,"about_ca_topic_score_gemma":0.00005116947,"teacher_disagreement_score":0.42702806,"about_ca_system_score_codex":0.00015340207,"about_ca_system_score_gemma":0.0007540999,"threshold_uncertainty_score":0.99993837},"labels":[],"label_agreement":null},{"id":"W2119584141","doi":"10.1016/j.jtbi.2005.03.033","title":"A mathematical model of hematopoiesis—I. Periodic chronic myelogenous leukemia","year":2005,"lang":"en","type":"article","venue":"Journal of Theoretical Biology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":276,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Natural Sciences and Engineering Research Council of Canada; Mitacs","keywords":"Haematopoiesis; Chronic myelogenous leukemia; Stem cell; Leukemia; Biology; Hematopoietic stem cell; Immunology; Platelet; Cell biology; Cancer research","score_opus":0.01444154634903463,"score_gpt":0.28196083830422836,"score_spread":0.26751929195519375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119584141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.980377,0.001830465,0.008235896,0.0027776265,0.000077701625,0.00022769127,0.000012475747,0.000019658119,0.0064414754],"genre_scores_gemma":[0.98359287,0.00017981013,0.015408445,0.00026291594,0.00038020674,0.0000041387875,0.0000037732718,0.000024933031,0.0001428964],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9980897,0.00009634882,0.0009808603,0.00018069743,0.00026203986,0.00039036715],"domain_scores_gemma":[0.9985706,0.00023716163,0.00038236793,0.0003491352,0.00019983214,0.00026089535],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005237653,0.00021384646,0.00095482817,0.00016564602,0.000037700487,0.000005854923,0.00024432124,0.00028069934,0.0017176986],"category_scores_gemma":[0.00047649245,0.00014008196,0.0003910157,0.00010661844,0.0011028314,0.00004756057,0.0000826154,0.00043319262,0.00009108865],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012219565,0.00077641173,0.0005695333,0.00034188118,0.00072768965,0.00012179512,0.0007794001,0.00064304686,0.13841446,0.8437656,0.0006448254,0.01199339],"study_design_scores_gemma":[0.0268359,0.0140072135,0.0005537898,0.001522305,0.0029673728,0.021306343,0.0004418992,0.16849174,0.1845499,0.57526463,0.0031089163,0.0009499915],"about_ca_topic_score_codex":0.0000010639849,"about_ca_topic_score_gemma":7.0248666e-7,"teacher_disagreement_score":0.26850098,"about_ca_system_score_codex":0.0014885764,"about_ca_system_score_gemma":0.0014273467,"threshold_uncertainty_score":0.99919486},"labels":[],"label_agreement":null},{"id":"W2120824302","doi":"10.1016/j.sbi.2009.10.001","title":"SH2 domains: modulators of nonreceptor tyrosine kinase activity","year":2009,"lang":"en","type":"review","venue":"Current Opinion in Structural Biology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":119,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Wellcome Trust","keywords":"SH2 domain; Proto-oncogene tyrosine-protein kinase Src; Tyrosine kinase; HAMP domain; SH3 domain; Protein kinase domain; Cell biology; Biochemistry; Biology; Kinase; Chemistry; Signal transduction; Binding domain; Binding site","score_opus":0.07965534402543507,"score_gpt":0.4179016530071306,"score_spread":0.33824630898169555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120824302","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007065151,0.98471594,0.000008269751,0.000027466695,0.006287651,0.0014780498,0.0003190556,0.00004596054,0.00005243676],"genre_scores_gemma":[0.0038623335,0.992747,0.00025530686,0.0000051357874,0.0008488289,0.00007047228,0.0021509961,0.0000403694,0.000019576191],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99719316,0.00030660318,0.0009901789,0.0007925559,0.00019841663,0.00051910506],"domain_scores_gemma":[0.9982002,0.00017013033,0.0007062601,0.000678565,0.00007199513,0.00017287092],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014351998,0.0007018204,0.002981366,0.00046107394,0.000038236016,0.000006550255,0.0002725546,0.0006605249,0.00023501024],"category_scores_gemma":[0.00014845928,0.0004946829,0.00059799064,0.00050589483,0.0002518044,0.000059219026,0.00013631613,0.00081144564,0.000030867825],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006745061,0.00009572847,0.00045794473,0.011957937,0.0001212593,0.0000023030125,0.00002124458,4.2323774e-7,0.000024503237,0.00028102018,0.000242583,0.9867276],"study_design_scores_gemma":[0.0030340026,0.0006412208,0.0026158206,0.020969829,0.00037578234,0.0001406358,0.0000036532765,0.000022990815,0.000042683376,0.00021086083,0.97139907,0.0005434274],"about_ca_topic_score_codex":0.00005074519,"about_ca_topic_score_gemma":0.0000023263958,"teacher_disagreement_score":0.9861842,"about_ca_system_score_codex":0.0014573903,"about_ca_system_score_gemma":0.00070974923,"threshold_uncertainty_score":0.9997505},"labels":[],"label_agreement":null},{"id":"W2121419898","doi":"10.1074/jbc.m400590200","title":"Role of the p38 Mitogen-activated Protein Kinase Pathway in the Generation of the Effects of Imatinib Mesylate (STI571) in BCR-ABL-expressing Cells","year":2004,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"National Cancer Institute; National Institutes of Health; Canadian Institutes of Health Research; U.S. Department of Veterans Affairs; U.S. Department of Defense","keywords":"Imatinib mesylate; Mitogen-activated protein kinase; ABL; Cancer research; Protein kinase A; p38 mitogen-activated protein kinases; breakpoint cluster region; Kinase; Imatinib; Medicine; Biology; Cell biology; Internal medicine; Tyrosine kinase; Receptor","score_opus":0.017110617749577887,"score_gpt":0.24414091325272708,"score_spread":0.22703029550314918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121419898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983758,0.00081849366,0.0000038199646,0.00019053348,0.000050626575,0.000413614,0.000006359544,0.0000022380088,0.0001385441],"genre_scores_gemma":[0.99959904,0.00003263227,0.00022499911,0.00003345131,0.000070048896,0.000010026984,0.0000027223211,0.000006567782,0.000020537413],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99859,0.00016742997,0.0006611737,0.000121366436,0.00030443133,0.0001556084],"domain_scores_gemma":[0.9986278,0.0001571742,0.0008079385,0.0002808798,0.00008995383,0.000036244106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038770298,0.0001420154,0.00039419666,0.000022913071,0.00002795525,0.0000047740086,0.00027614378,0.00018007791,0.000019807718],"category_scores_gemma":[0.0006763375,0.00005844207,0.00019187092,0.00023817307,0.00016229662,0.000032720698,0.00006215598,0.0004356294,2.1817468e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019306828,0.00041684462,0.0024909154,0.00020792917,0.000035332654,0.000021121918,0.00039514035,0.0001813646,0.99532855,0.000002716656,0.0000067404785,0.00072027807],"study_design_scores_gemma":[0.003103377,0.00021998663,0.014478166,0.0011456772,0.000027382293,0.000045956112,0.00014710297,0.000038887043,0.9805707,0.00014821933,0.000023475044,0.00005110604],"about_ca_topic_score_codex":0.000046210916,"about_ca_topic_score_gemma":0.0000025019235,"teacher_disagreement_score":0.014757884,"about_ca_system_score_codex":0.00027257792,"about_ca_system_score_gemma":0.0003009519,"threshold_uncertainty_score":0.23831984},"labels":[],"label_agreement":null},{"id":"W2123319057","doi":"10.1016/s0301-472x(00)00463-x","title":"Detection of IL-3 and g-csf mRNA and protein in CD34 progenitor cells and serum from cml patients","year":2000,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Progenitor cell; CD34; Messenger RNA; Progenitor; Molecular biology; Medicine; Andrology; Immunology; Biology; Stem cell; Cell biology; Gene; Genetics","score_opus":0.006179393603908441,"score_gpt":0.24051383626934814,"score_spread":0.2343344426654397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123319057","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99534816,0.0035151767,5.070235e-7,0.000030886695,0.0000469433,0.0008148234,0.000023201954,0.000017101005,0.00020323272],"genre_scores_gemma":[0.9992061,0.00004160652,0.00045606372,0.000030001138,0.000019755491,0.0000850367,0.000012771143,0.000016126223,0.0001325392],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991596,0.000040808594,0.00023833787,0.0002929011,0.000095638134,0.00017275609],"domain_scores_gemma":[0.999694,0.000025059644,0.000056278805,0.0001237266,0.000011995351,0.000088955414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00002720402,0.00014510917,0.0003272527,0.00006130476,0.000030891795,0.000005077316,0.000023237764,0.00011751865,0.00015850595],"category_scores_gemma":[0.0000066524135,0.00013284471,0.00001817251,0.000053094333,0.0001337248,0.00006638625,0.00004055988,0.00008449526,0.000009150214],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015447843,0.001441476,0.30260786,0.00024271592,0.00013949854,0.0001353368,0.0037640308,1.1794369e-7,0.65523714,0.00008987318,0.000036312384,0.03476085],"study_design_scores_gemma":[0.0061454293,0.00066768104,0.03782806,0.00009157722,0.000018656927,0.00009325717,0.00027871187,0.00006714493,0.95449024,0.000037834543,0.00018657159,0.000094803116],"about_ca_topic_score_codex":0.0003552662,"about_ca_topic_score_gemma":0.00003736355,"teacher_disagreement_score":0.29925314,"about_ca_system_score_codex":0.00012752893,"about_ca_system_score_gemma":0.000026248474,"threshold_uncertainty_score":0.54172504},"labels":[],"label_agreement":null},{"id":"W2123670570","doi":"10.3109/10428191003729741","title":"Mutations in ABL kinase domain are associated with inferior progression-free survival","year":2010,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Terry Fox Foundation","keywords":"Imatinib mesylate; ABL; Point mutation; Fusion gene; Cancer research; Imatinib; Protein kinase domain; Mutation; Myeloid leukemia; Biology; Medicine; Tyrosine kinase; Gene; Genetics; Mutant; Receptor","score_opus":0.009334364910513348,"score_gpt":0.2532084003162289,"score_spread":0.24387403540571553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123670570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913093,0.0004913733,0.000030870444,0.00046673455,0.0005298089,0.0013674728,0.00015961415,0.00046371258,0.005181113],"genre_scores_gemma":[0.99430245,0.00009820798,0.0026165263,0.0005781434,0.00033707792,0.0004542059,0.0005087283,0.0002135992,0.00089106575],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99449724,0.00027942815,0.0010699454,0.0014119989,0.0012891125,0.0014522568],"domain_scores_gemma":[0.9954939,0.0010046808,0.0005951748,0.0016834247,0.00031319336,0.0009096145],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00088512193,0.0010366692,0.0014305193,0.0006254421,0.00046933585,0.0001901744,0.0005489754,0.00091314764,0.00022071826],"category_scores_gemma":[0.0014773433,0.00086042425,0.0002441511,0.0013697582,0.00079444796,0.00046165907,0.00033530872,0.0005550879,0.000078975216],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0046152654,0.0025026721,0.82974094,0.00050545624,0.0010518238,0.011199031,0.00432017,0.00008600795,0.012788959,0.0025757619,0.00237134,0.12824255],"study_design_scores_gemma":[0.06353758,0.0005144121,0.92178017,0.0012630023,0.000382851,0.0013102693,0.0010900312,0.0014379558,0.0025264404,0.0009773483,0.0041057505,0.0010742104],"about_ca_topic_score_codex":0.0016599554,"about_ca_topic_score_gemma":0.0067720884,"teacher_disagreement_score":0.12716834,"about_ca_system_score_codex":0.012574623,"about_ca_system_score_gemma":0.00786569,"threshold_uncertainty_score":0.99938464},"labels":[],"label_agreement":null},{"id":"W2123967889","doi":"10.3324/haematol.12212","title":"Characterization of compound 584, an Abl kinase inhibitor with lasting effects","year":2008,"lang":"en","type":"article","venue":"Haematologica","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Cancer Institute; Associazione Italiana per la Ricerca sul Cancro; Centre National de la Recherche Scientifique; European Commission","keywords":"Nilotinib; Dasatinib; Tyrosine kinase; Imatinib; ABL; Chemistry; LYN; Kinase; Bosutinib; Proto-oncogene tyrosine-protein kinase Src; Tyrosine-kinase inhibitor; Pharmacology; Imatinib mesylate; IC50; Cancer research; Molecular biology; Biochemistry; Biology; In vitro; Signal transduction","score_opus":0.02235335089522569,"score_gpt":0.24931301543303974,"score_spread":0.22695966453781405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123967889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99791473,0.000049013335,0.00019450765,0.00006871864,0.000057202655,0.00048826332,0.0000049103337,0.000113455826,0.0011092161],"genre_scores_gemma":[0.9971874,0.000021364895,0.002311147,0.00010985058,0.00006009577,0.000033183558,0.00012649516,0.000019403498,0.00013110545],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990407,0.000056874407,0.00023129376,0.000250061,0.00021581186,0.00020524565],"domain_scores_gemma":[0.9992717,0.0000866719,0.00016693788,0.00028055452,0.00008090493,0.00011323894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000053751446,0.00016140635,0.00045701006,0.00006686888,0.00009598961,0.000004996516,0.00005753919,0.000090255795,0.00006260074],"category_scores_gemma":[0.000073394884,0.00010952274,0.000039835628,0.00016771462,0.0001353671,0.000096965414,0.00002625724,0.00010538231,0.000030222078],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014527576,0.0019611611,0.31969813,0.0014390319,0.00023541453,0.010473654,0.0015845979,0.000008426368,0.6595056,0.00055558764,0.00017124707,0.0029143959],"study_design_scores_gemma":[0.008380678,0.0036322647,0.44566944,0.0009851631,0.00020946265,0.008042007,0.00006691654,0.00052856153,0.53145576,0.000026041893,0.0006766614,0.0003270749],"about_ca_topic_score_codex":0.000026126092,"about_ca_topic_score_gemma":0.0000057301754,"teacher_disagreement_score":0.12804988,"about_ca_system_score_codex":0.000110849905,"about_ca_system_score_gemma":0.00012630633,"threshold_uncertainty_score":0.4466208},"labels":[],"label_agreement":null},{"id":"W2125213800","doi":"10.3324/haematol.11680","title":"Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib","year":2008,"lang":"en","type":"letter","venue":"Haematologica","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Associazione Italiana per la Ricerca sul Cancro; Jewish General Hospital; Agenzia Italiana del Farmaco, Ministero della Salute; McGill University","keywords":"Imatinib; Myeloid leukemia; Creatine kinase; Medicine; Creatine; Internal medicine; Cholesterol; Endocrinology; Cancer research","score_opus":0.012412933668236417,"score_gpt":0.23054926538786524,"score_spread":0.21813633171962882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125213800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9844185,0.0016559825,0.0000042787146,0.009544511,0.00005727776,0.0028463416,0.0000727813,0.0001348362,0.0012654945],"genre_scores_gemma":[0.9502953,0.004790874,0.0058215708,0.022290519,0.0010516543,0.002870908,0.0065342626,0.0003932365,0.005951672],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964364,0.0001392553,0.0007835896,0.0011517493,0.000571962,0.00091701135],"domain_scores_gemma":[0.9983447,0.00019904002,0.00040326468,0.00080166355,0.0001011865,0.00015014624],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00006294626,0.0009585415,0.0017890754,0.00046500188,0.00017841798,0.000046723715,0.0001506906,0.0006275347,0.00020070124],"category_scores_gemma":[0.00004563089,0.000608884,0.00009840343,0.00042986142,0.00031150336,0.0001621174,0.000079229845,0.0010372243,0.000041506963],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046746554,0.0017603483,0.9307976,0.0027437424,0.0011330931,0.039550632,0.002079435,0.00024999992,0.000047404148,0.000016884433,0.01362197,0.0033242432],"study_design_scores_gemma":[0.09007514,0.015134191,0.8397603,0.008926489,0.0009953459,0.0038185345,0.00007485716,0.0004183256,0.0019222328,0.000029737836,0.036618933,0.0022258763],"about_ca_topic_score_codex":0.0008474815,"about_ca_topic_score_gemma":0.00051347533,"teacher_disagreement_score":0.09103726,"about_ca_system_score_codex":0.006481319,"about_ca_system_score_gemma":0.0011194354,"threshold_uncertainty_score":0.99963623},"labels":[],"label_agreement":null},{"id":"W2127016965","doi":"10.1182/blood.v97.11.3581","title":"Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis","year":2001,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":217,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Breakpoint; Haploinsufficiency; Biology; Chromosomal translocation; breakpoint cluster region; Myeloid leukemia; Leukemia; Fluorescence in situ hybridization; Comparative genomic hybridization; Genetics; Cytogenetics; Gene rearrangement; Molecular biology; Chromosome; Cancer research; Gene; Phenotype","score_opus":0.018409199722548987,"score_gpt":0.26336061842172,"score_spread":0.244951418699171,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127016965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99552786,0.0013004036,0.000012167794,0.00066349376,0.000082005594,0.0012190118,0.00011420513,0.000072803545,0.0010080193],"genre_scores_gemma":[0.9957054,0.00028939883,0.0018291901,0.00074554613,0.000103348575,0.00014630145,0.00019958818,0.000046209934,0.0009349944],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983608,0.000042104217,0.00038777493,0.0004826403,0.000316389,0.0004102874],"domain_scores_gemma":[0.99897075,0.000040748666,0.00016657943,0.00042847483,0.0001590559,0.00023440328],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00006897112,0.00026327453,0.00053509924,0.00012386222,0.000083526385,0.00002003095,0.00012064752,0.00011685121,0.000109946355],"category_scores_gemma":[0.00006191656,0.00024861807,0.00008072973,0.00025961222,0.000094720366,0.00008514275,0.00009684921,0.00015288762,0.00005094111],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016787584,0.0010348499,0.5319323,0.00021610987,0.0004519444,0.00016053315,0.00027684646,0.0000010032613,0.45693272,0.000004346618,0.0071689654,0.0016525252],"study_design_scores_gemma":[0.014565106,0.0007607505,0.8374406,0.00067500013,0.000750175,0.00033637972,0.00015861061,0.0000093589215,0.14237902,0.0000104475785,0.0026398983,0.0002746305],"about_ca_topic_score_codex":0.00030384553,"about_ca_topic_score_gemma":0.00005336544,"teacher_disagreement_score":0.31455368,"about_ca_system_score_codex":0.0005617577,"about_ca_system_score_gemma":0.0002633773,"threshold_uncertainty_score":0.9999966},"labels":[],"label_agreement":null},{"id":"W2128705932","doi":"10.5430/jhm.v2n3p8","title":"Comparison of long-term outcome of early versus late chronic phase imatinib receivers","year":2012,"lang":"en","type":"article","venue":"Journal of Hematological Malignancies","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Imatinib; Medicine; Imatinib mesylate; Internal medicine; Myeloid leukemia; Retrospective cohort study; Oncology","score_opus":0.10637862806227015,"score_gpt":0.4103924199165446,"score_spread":0.30401379185427446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128705932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993169,0.005349037,0.0001083349,0.0001266477,0.00043551344,0.00022165949,0.000009708045,0.000015517917,0.00056454405],"genre_scores_gemma":[0.99815696,0.00014980903,0.0014395425,0.00001816179,0.00010456699,0.0000030033043,0.000004324251,0.00001504299,0.00010858858],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99738884,0.00008005149,0.0014357205,0.00012433522,0.0005663306,0.00040473556],"domain_scores_gemma":[0.9974078,0.00036229144,0.0014649836,0.0002576856,0.00026024005,0.00024699754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003858355,0.00022381767,0.0014404362,0.00015278105,0.00003673756,0.0000065340773,0.00019921591,0.0001707777,0.00044924897],"category_scores_gemma":[0.00039906718,0.0001475807,0.00039817943,0.00018905792,0.00026420446,0.0002101811,0.00006458612,0.00032259716,0.000023292947],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027981023,0.0018705699,0.9749191,0.00066178123,0.0004349547,0.00023972131,0.000612981,0.000010429781,0.016018799,0.0004164009,0.00017970859,0.0018374999],"study_design_scores_gemma":[0.033691566,0.014854381,0.79695433,0.0016007888,0.0013141965,0.001394921,0.00044905048,0.000051845203,0.14915244,0.00006558333,0.00014532512,0.00032555437],"about_ca_topic_score_codex":0.0000069002,"about_ca_topic_score_gemma":0.0000017602152,"teacher_disagreement_score":0.1779647,"about_ca_system_score_codex":0.00042597915,"about_ca_system_score_gemma":0.00020219058,"threshold_uncertainty_score":0.6018166},"labels":[],"label_agreement":null},{"id":"W2128816533","doi":"10.3324/haematol.2009.017178","title":"Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis","year":2010,"lang":"en","type":"article","venue":"Haematologica","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":169,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Medical Research Council; Cancer Research UK","keywords":"Mesenchymal stem cell; Myeloid leukemia; Cancer research; Imatinib; Stromal cell; Bone marrow; Progenitor cell; Leukemia; Imatinib mesylate; Stem cell; Immunology; Biology; Cell biology","score_opus":0.014258445648139571,"score_gpt":0.24676444514542967,"score_spread":0.2325059994972901,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128816533","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899568,0.0002617319,0.00030841038,0.0009106673,0.00088363775,0.0036675795,0.00007555393,0.00038888896,0.0035467157],"genre_scores_gemma":[0.98962796,0.00007127603,0.0074848747,0.0003168872,0.00062408554,0.0008882241,0.00010136811,0.0001256144,0.0007596915],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99497247,0.00026737482,0.0010099666,0.0013767325,0.0009524041,0.001421066],"domain_scores_gemma":[0.9963851,0.0005906736,0.0006140639,0.0017652971,0.00016654829,0.00047833956],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0005348166,0.00093989936,0.0015390102,0.00018876635,0.00057727634,0.00011471862,0.0007544493,0.00082780124,0.002587195],"category_scores_gemma":[0.00020934567,0.00061885564,0.00053157413,0.0005487046,0.00043214572,0.00021662883,0.00034224094,0.0021135926,0.0020240555],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042390818,0.00032510958,0.001276572,0.00016293315,0.00042233992,0.0003405571,0.0005130567,0.0000066224725,0.9863181,0.000047706857,0.002650416,0.007512689],"study_design_scores_gemma":[0.0053109587,0.0013722492,0.014873363,0.00017887614,0.00045327717,0.0006589424,0.00012803772,0.00216491,0.97225845,0.0002497108,0.001668449,0.0006827972],"about_ca_topic_score_codex":0.0015396097,"about_ca_topic_score_gemma":0.00042834392,"teacher_disagreement_score":0.014059661,"about_ca_system_score_codex":0.0017877477,"about_ca_system_score_gemma":0.0015223855,"threshold_uncertainty_score":0.9996263},"labels":[],"label_agreement":null},{"id":"W2128989133","doi":"10.1158/0008-5472.can-08-1101","title":"BCR/ABL and Other Kinases from Chronic Myeloproliferative Disorders Stimulate Single-Strand Annealing, an Unfaithful DNA Double-Strand Break Repair","year":2008,"lang":"en","type":"article","venue":"Cancer Research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":95,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; National Institutes of Health; U.S. Department of Defense","keywords":"Biology; Cancer research; Philadelphia chromosome; Imatinib mesylate; Chronic myelogenous leukemia; Genome instability; Tyrosine kinase; Progenitor cell; ABL; DNA damage; Cell biology; Stem cell; Molecular biology; Leukemia; Imatinib; Myeloid leukemia; Signal transduction; Genetics; DNA; Chromosomal translocation","score_opus":0.11099369996061127,"score_gpt":0.3906695035664544,"score_spread":0.27967580360584315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128989133","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98633003,0.009194094,0.00001758127,0.0006621886,0.00011025323,0.0014810289,0.00024812834,0.00019624509,0.0017604424],"genre_scores_gemma":[0.99428034,0.0024758535,0.00021551756,0.00015436135,0.00070961856,0.0002531409,0.00012833391,0.000112189366,0.0016706631],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963516,0.00023454997,0.00041192005,0.001049988,0.00095233676,0.0009996329],"domain_scores_gemma":[0.9980337,0.00025747146,0.00008253723,0.000760368,0.00026187944,0.0006040133],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004051227,0.00040054467,0.000597933,0.0002513863,0.0005335841,0.00006840787,0.00020733685,0.00023816015,0.0012727923],"category_scores_gemma":[0.00006754631,0.00034050478,0.00012792574,0.00046996947,0.0009844579,0.00027870256,0.00009633307,0.00071733166,0.000042562635],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021628378,0.0030125375,0.7566013,0.0014342024,0.0038068919,0.0019740213,0.023916483,0.0021090982,0.123909116,0.00017285,0.00911172,0.052323442],"study_design_scores_gemma":[0.17362194,0.015567689,0.42042154,0.0042800554,0.0010891219,0.0006709391,0.0027248752,0.012042925,0.23146294,0.0013481199,0.13345191,0.0033179228],"about_ca_topic_score_codex":0.01839856,"about_ca_topic_score_gemma":0.0062007005,"teacher_disagreement_score":0.3361797,"about_ca_system_score_codex":0.0019931325,"about_ca_system_score_gemma":0.0018358729,"threshold_uncertainty_score":0.9999047},"labels":[],"label_agreement":null},{"id":"W2129806364","doi":"10.1046/j.1365-2141.2002.03469.x","title":"Receptor tyrosine kinase mutations in myeloid neoplasms","year":2002,"lang":"en","type":"review","venue":"British Journal of Haematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Receptor tyrosine kinase; Platelet-derived growth factor receptor; Tyrosine kinase; ROR1; Biology; Proto-oncogene tyrosine-protein kinase Src; Cell biology; Cancer research; Tropomyosin receptor kinase C; GRB2; Growth factor receptor; Epidermal growth factor; SH2 domain; Signal transduction; Biochemistry; Growth factor; Receptor","score_opus":0.036678624574928306,"score_gpt":0.31797710477744523,"score_spread":0.2812984802025169,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129806364","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002460034,0.99518204,0.000013022726,0.00017305618,0.00074389915,0.00066588173,0.00006985542,0.000021846581,0.0006703943],"genre_scores_gemma":[0.0001325775,0.99615896,0.002013156,0.00007595213,0.00029921663,0.000042462954,0.00015960983,0.00009567269,0.0010223704],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99632645,0.00033809795,0.0021089783,0.0003581072,0.00036898474,0.00049937813],"domain_scores_gemma":[0.9974615,0.00038742536,0.0013284594,0.0003032144,0.00022333446,0.00029606576],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00032849205,0.00042177123,0.0043504005,0.00073008187,0.00006210868,0.00003866039,0.0002816826,0.00062035245,0.0015899776],"category_scores_gemma":[0.00073143205,0.00042210054,0.00079619925,0.000563541,0.00017703864,0.00012045619,0.00006196622,0.001454336,0.00035110873],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022329961,0.00044821616,0.000030943094,0.0066044065,0.00039536305,0.14959385,0.000041956097,9.302049e-7,6.111538e-7,0.00003266268,0.012449401,0.83037937],"study_design_scores_gemma":[0.002086137,0.00018901758,0.000014678486,0.032807074,0.0009375381,0.44846603,0.000015080279,0.0000022174634,0.0000021555297,0.000019602116,0.515297,0.00016349257],"about_ca_topic_score_codex":0.00009135814,"about_ca_topic_score_gemma":0.00010947867,"teacher_disagreement_score":0.8302159,"about_ca_system_score_codex":0.0012724828,"about_ca_system_score_gemma":0.0014001215,"threshold_uncertainty_score":0.9998231},"labels":[],"label_agreement":null},{"id":"W2130008150","doi":"10.1073/pnas.0900189106","title":"Glycogen synthase kinase 3β missplicing contributes to leukemia stem cell generation","year":2009,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":240,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; University of California, San Diego","keywords":"Biology; Progenitor cell; Cancer research; Stem cell; Wnt signaling pathway; Myeloid leukemia; Cancer stem cell; Haematopoiesis; Leukemia; Population; Immunology; Cell biology; Medicine; Signal transduction","score_opus":0.04238527604128569,"score_gpt":0.30782845760670446,"score_spread":0.2654431815654188,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130008150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870649,0.0003434051,0.000004839555,0.0074274563,0.00001986452,0.0004680584,0.000012934736,0.000018847797,0.0046397145],"genre_scores_gemma":[0.9961993,0.00002098447,0.0015327877,0.0015038396,0.00013620847,0.000011130571,6.0010746e-7,0.000004808828,0.0005903186],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980972,0.000005351141,0.000378183,0.00030464574,0.0010094377,0.0002051776],"domain_scores_gemma":[0.9992013,0.00007051305,0.00029254545,0.000015132742,0.00033368336,0.000086825225],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075026555,0.00012922859,0.00023653175,0.00020757582,0.00018187547,0.000023809736,0.00036471992,0.00009226727,0.0000128333595],"category_scores_gemma":[0.0002672562,0.000087831904,0.00008641456,0.00076850917,0.0002308919,0.00022367024,0.000058934816,0.0001357512,0.000005799985],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000051826737,0.00007327705,0.0017435721,0.000048956368,0.000018044946,6.408357e-8,0.00014697423,0.00020343771,0.9876461,0.0050811083,0.0026029448,0.0023836857],"study_design_scores_gemma":[0.00090829167,0.00019177036,0.020996554,0.00020132188,0.00005851506,0.000015180748,0.000106410625,0.0028699434,0.972379,0.0018191086,0.00037181965,0.000082045226],"about_ca_topic_score_codex":0.000012870982,"about_ca_topic_score_gemma":7.615425e-8,"teacher_disagreement_score":0.019252982,"about_ca_system_score_codex":0.0006549984,"about_ca_system_score_gemma":0.00020887888,"threshold_uncertainty_score":0.3581681},"labels":[],"label_agreement":null},{"id":"W2130091830","doi":"10.1016/j.bbamcr.2007.11.015","title":"Lyl1 interacts with CREB1 and alters expression of CREB1 target genes","year":2007,"lang":"en","type":"article","venue":"Biochimica et Biophysica Acta (BBA) - Molecular Cell Research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Hospital; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Biology; CREB1; Promoter; Transcription factor; Genetics; Cell biology; Gene; Gene expression; CREB","score_opus":0.02605542183314358,"score_gpt":0.3341708081514271,"score_spread":0.3081153863182835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130091830","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99192864,0.00071967207,0.00023898405,0.0006719208,0.000044780623,0.00095269067,0.000022310316,0.000050035,0.0053709457],"genre_scores_gemma":[0.99207973,0.00039038004,0.006449754,0.00017656348,0.00009669496,0.00003160697,0.00012219038,0.00010222472,0.0005508495],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99615586,0.00025575567,0.00045839275,0.0008414595,0.0013712882,0.00091723644],"domain_scores_gemma":[0.9975891,0.00035719996,0.00018618815,0.0009671203,0.00037687138,0.00052351115],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008045278,0.00039893083,0.000555629,0.00051225367,0.00013615373,0.000058378457,0.0003379714,0.00020156785,0.00006837136],"category_scores_gemma":[0.00011463489,0.00030862947,0.00015198697,0.00066950574,0.0005670584,0.00013710708,0.00039188896,0.0006755274,0.0000323959],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015825008,0.0006944351,0.000093515075,0.00034688142,0.0001356959,0.00037906427,0.0005880661,0.0000026436342,0.99460626,0.00003342346,0.00055647275,0.0009810228],"study_design_scores_gemma":[0.0032148086,0.0015659911,0.0028881868,0.00045642193,0.00008292424,0.00003743081,0.00031530118,0.0000970553,0.9903068,0.00005008659,0.0007121161,0.00027288642],"about_ca_topic_score_codex":0.00017619538,"about_ca_topic_score_gemma":0.0000059263925,"teacher_disagreement_score":0.00621077,"about_ca_system_score_codex":0.0003378202,"about_ca_system_score_gemma":0.0005822389,"threshold_uncertainty_score":0.9999366},"labels":[],"label_agreement":null},{"id":"W2131163045","doi":"10.3109/10428194.2014.994178","title":"Very late relapse of Philadelphia chromosome positive acute megakaryoblastic leukemia","year":2014,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Acute megakaryoblastic leukemia; Medicine; Philadelphia chromosome; Acute leukemia; Oncology; Internal medicine; Leukemia; Cancer research; Biology; Chromosomal translocation; Genetics; Gene","score_opus":0.010564894281328053,"score_gpt":0.23509868296768516,"score_spread":0.2245337886863571,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131163045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91547424,0.008375283,0.00013802461,0.05158896,0.0031567186,0.0047954535,0.0018683309,0.0014265076,0.013176486],"genre_scores_gemma":[0.6380734,0.007063272,0.0015546288,0.30780682,0.010158759,0.00077201595,0.009820809,0.0019018032,0.022848496],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9853113,0.0006522516,0.0035330886,0.0040536155,0.003013971,0.0034357584],"domain_scores_gemma":[0.98971784,0.0016987114,0.0025113537,0.003959636,0.00078993296,0.0013225222],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.00070951047,0.0038308268,0.0060632974,0.0016871258,0.0006664608,0.00026556372,0.0015581531,0.006062911,0.00052160287],"category_scores_gemma":[0.00036253975,0.0036242711,0.0019189051,0.0015137787,0.0019763594,0.0007132849,0.0010096546,0.0023796118,0.0007789498],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0036864062,0.00041929103,0.00087211345,0.005118017,0.01018757,0.027832344,0.0012984468,0.00016694311,0.009462718,0.00023091158,0.9233623,0.01736295],"study_design_scores_gemma":[0.10686447,0.006196601,0.027896022,0.013332116,0.022300692,0.035947617,0.00019110732,0.011179452,0.021010324,0.0011516676,0.7452034,0.008726547],"about_ca_topic_score_codex":0.003035135,"about_ca_topic_score_gemma":0.000037707785,"teacher_disagreement_score":0.27740082,"about_ca_system_score_codex":0.058953278,"about_ca_system_score_gemma":0.022031806,"threshold_uncertainty_score":0.99999905},"labels":[],"label_agreement":null},{"id":"W2131790261","doi":"10.1080/10428190310001593184","title":"Isolated Central Nervous System Relapse in Lymphoid Blast Crisis Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia in Patients on Imatinib Therapy","year":2003,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Imatinib; Medicine; Myeloid leukemia; Cytarabine; Imatinib mesylate; Methotrexate; Philadelphia chromosome; Bone marrow; Leukemia; Internal medicine; Oncology; Immunology; Chromosomal translocation; Biology","score_opus":0.0067067921439944445,"score_gpt":0.21897548995774901,"score_spread":0.21226869781375457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131790261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98670745,0.0040626004,0.000057670728,0.00009326208,0.001077841,0.0034076856,0.00017270798,0.00063812523,0.0037826505],"genre_scores_gemma":[0.99063694,0.004700057,0.0004978502,0.0013492827,0.0003563155,0.0005960768,0.00044549795,0.00055265916,0.00086534244],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98647624,0.0008762614,0.0032119213,0.0036299152,0.001853227,0.0039524427],"domain_scores_gemma":[0.9937932,0.00073175196,0.0010644747,0.0023282259,0.00031734127,0.0017650074],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.000940047,0.0027918906,0.0034266075,0.0018394055,0.00066402735,0.00037793373,0.00080903294,0.0018907719,0.00015433133],"category_scores_gemma":[0.00032705424,0.0026370548,0.0006181145,0.0024738444,0.00070258416,0.0009226039,0.00037505725,0.0008105039,0.00025441442],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.036002558,0.0040004496,0.5033583,0.005111409,0.0049238093,0.015092731,0.012314695,0.006703029,0.009860052,0.0051419586,0.008808275,0.3886827],"study_design_scores_gemma":[0.21866436,0.0061047394,0.6935863,0.0046276017,0.0010459501,0.0061728065,0.002066043,0.049608547,0.0075760405,0.0002174692,0.006048843,0.004281321],"about_ca_topic_score_codex":0.006910103,"about_ca_topic_score_gemma":0.0005759718,"teacher_disagreement_score":0.38440138,"about_ca_system_score_codex":0.19524068,"about_ca_system_score_gemma":0.021522652,"threshold_uncertainty_score":0.999703},"labels":[],"label_agreement":null},{"id":"W2132017565","doi":"10.1182/blood-2004-10-4003","title":"Differential regulation of the p70 S6 kinase pathway by interferon α (IFNα) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"National Cancer Institute; Turun Yliopistollinen Keskussairaala","keywords":"Imatinib mesylate; Chronic myelogenous leukemia; Cancer research; Leukemia; Medicine; Interferon; Imatinib; Immunology","score_opus":0.007127805237723367,"score_gpt":0.21799944094801627,"score_spread":0.2108716357102929,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132017565","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99707186,0.0013988784,0.000023795994,0.00019405542,0.00009348027,0.00064518227,0.00003813322,0.000032386415,0.00050223176],"genre_scores_gemma":[0.9984592,0.0001445023,0.00020686473,0.000057166802,0.00013412825,0.000027001364,0.00004880366,0.000033771186,0.00088855467],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99856067,0.00007652435,0.0004490143,0.0003299054,0.00026661443,0.00031727797],"domain_scores_gemma":[0.9991575,0.00005530675,0.00018775031,0.00047435102,0.000035078196,0.000090024936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009963066,0.00023394635,0.0003732497,0.000079385514,0.000054744854,0.000012852845,0.00013017522,0.00014924986,0.00023653399],"category_scores_gemma":[0.000026845475,0.00016982394,0.000089681904,0.00014722972,0.00011389676,0.000086268374,0.0001108951,0.00023418764,0.000018963443],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016463698,0.00050470576,0.002688787,0.00018552008,0.00011994819,0.000013679052,0.0007097641,0.00005906633,0.97296745,0.000038602353,0.0002372298,0.02231062],"study_design_scores_gemma":[0.014939932,0.00064577145,0.061568692,0.00041406014,0.00030382202,0.00006689233,0.000036536963,0.002101612,0.91873795,0.000040804585,0.0009443246,0.00019958154],"about_ca_topic_score_codex":0.0002182631,"about_ca_topic_score_gemma":0.00019497196,"teacher_disagreement_score":0.058879904,"about_ca_system_score_codex":0.0013057287,"about_ca_system_score_gemma":0.00046592925,"threshold_uncertainty_score":0.69252187},"labels":[],"label_agreement":null},{"id":"W2134294523","doi":"10.1093/intimm/dxl143","title":"Impaired V(D)J recombination and increased apoptosis among B cell precursors in the bone marrow of c-Abl-deficient mice","year":2007,"lang":"en","type":"article","venue":"International Immunology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research; York University; McGill University","funders":"","keywords":"Lymphopoiesis; Apoptosis; Bone marrow; Immunoglobulin D; B cell; ABL; Biology; Molecular biology; Immunology; Cancer research; Haematopoiesis; Chemistry; Cell biology; Antibody; Signal transduction; Stem cell; Genetics; Tyrosine kinase","score_opus":0.00910002259141609,"score_gpt":0.2525717768587563,"score_spread":0.24347175426734022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134294523","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99361634,0.0004887958,0.0000261107,0.00083733676,0.00025573152,0.00034607027,0.000008031825,0.000015823716,0.0044057667],"genre_scores_gemma":[0.9990285,0.000111024274,0.00025468814,0.000120279714,0.000023329163,0.000024992274,0.00008437363,0.000010364581,0.00034244466],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99896514,0.00007392932,0.00036420854,0.00019606506,0.00021946109,0.000181186],"domain_scores_gemma":[0.99920934,0.00029163092,0.00017708368,0.00017901378,0.00011689812,0.000026002812],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054739777,0.00011131742,0.00018942259,0.0002760949,0.00002541756,0.000007694505,0.00014275419,0.00011007474,0.00008773362],"category_scores_gemma":[0.00018392982,0.000087828936,0.000051434417,0.00015929276,0.00014422914,0.00007017829,0.00005119676,0.00017650999,0.000009710009],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002694778,0.0032889585,0.5387759,0.0001133622,0.0005938577,0.00013413369,0.0066592274,0.000025347123,0.4230846,0.001949655,0.00075671164,0.02192349],"study_design_scores_gemma":[0.0057669342,0.00038346177,0.9058502,0.00009154532,0.00006011806,0.00013269272,0.0009825475,0.0003985619,0.08549786,0.00018489026,0.0005553523,0.000095873795],"about_ca_topic_score_codex":0.0016343939,"about_ca_topic_score_gemma":0.00014732043,"teacher_disagreement_score":0.36707425,"about_ca_system_score_codex":0.00046511603,"about_ca_system_score_gemma":0.00006762229,"threshold_uncertainty_score":0.358156},"labels":[],"label_agreement":null},{"id":"W2134318552","doi":"10.1158/1078-0432.ccr-07-4575","title":"Phase II, Open-Label Study Evaluating the Activity of Imatinib in Treating Life-Threatening Malignancies Known to Be Associated with Imatinib-Sensitive Tyrosine Kinases","year":2008,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":216,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Imatinib; Medicine; Systemic mastocytosis; Tyrosine kinase; Dermatofibrosarcoma protuberans; Imatinib mesylate; Tyrosine-kinase inhibitor; PDGFRA; Malignancy; Cancer research; Internal medicine; GiST; Oncology; Pathology; Cancer; Disease; Receptor; Stromal cell","score_opus":0.5138175632808544,"score_gpt":0.5818905854513831,"score_spread":0.06807302217052869,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134318552","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922057,0.00028741808,0.000007451571,0.0019778155,0.000056622936,0.004601985,0.00008603269,0.00003916118,0.000737841],"genre_scores_gemma":[0.9966508,0.00011518911,0.00079310994,0.00025869775,0.00014302172,0.0009394023,0.00002487949,0.000061941464,0.0010129373],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9933931,0.002047641,0.0011421292,0.0008681349,0.0016910972,0.0008578906],"domain_scores_gemma":[0.99076605,0.0063457056,0.0004350927,0.0007908248,0.0012945867,0.0003677572],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.007996725,0.00032322475,0.001268242,0.00022815065,0.00072060106,0.000050303413,0.00047293273,0.00014267399,0.0001408374],"category_scores_gemma":[0.017566962,0.00020801117,0.0000903316,0.001744391,0.00072045304,0.00020407,0.0008616828,0.0012010115,0.000008475177],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053040277,0.0913493,0.5923132,0.0002895213,0.002617165,0.0018549185,0.03446246,0.00031553637,0.039984036,0.00003261233,0.0025870192,0.18115398],"study_design_scores_gemma":[0.20630708,0.14837486,0.59541,0.0056219245,0.00067447935,0.00006237694,0.009467573,0.011650859,0.021582853,0.000027284905,0.00005504267,0.00076567876],"about_ca_topic_score_codex":0.007015721,"about_ca_topic_score_gemma":0.0027632536,"teacher_disagreement_score":0.1803883,"about_ca_system_score_codex":0.0013993805,"about_ca_system_score_gemma":0.0037285092,"threshold_uncertainty_score":0.99959666},"labels":[],"label_agreement":null},{"id":"W2136559095","doi":"10.3109/10428194.2013.866662","title":"Pregnancy outcomes in patients with chronic myeloid leukemia treated with imatinib mesylate: short report from a developing country","year":2013,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital","funders":"","keywords":"Medicine; Myeloid leukemia; Imatinib mesylate; Pregnancy; Adverse effect; Imatinib; Fetus; Pediatrics; Obstetrics; Internal medicine","score_opus":0.007434360182514351,"score_gpt":0.22280724291478163,"score_spread":0.2153728827322673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136559095","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98988307,0.0020488224,0.00009114887,0.00010655581,0.00020790155,0.0039987867,0.00012656148,0.0006012122,0.0029359336],"genre_scores_gemma":[0.9890267,0.0004502813,0.004225766,0.0005781698,0.00017939943,0.0009306405,0.0021148731,0.0004057276,0.0020883998],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9911731,0.00017867559,0.0020785418,0.0025850195,0.0018061313,0.0021785668],"domain_scores_gemma":[0.9951704,0.000405322,0.0007652141,0.0021719176,0.0005538332,0.00093332643],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00025246342,0.0019796444,0.0026963057,0.00064805546,0.00041544033,0.0002808559,0.000592326,0.0009457371,0.000325537],"category_scores_gemma":[0.0001522664,0.0014555764,0.00026315998,0.0013803215,0.00063137227,0.0012111356,0.00033225457,0.00046201254,0.00019093383],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0011829394,0.0003957157,0.8909118,0.00038256907,0.0013174863,0.0030017898,0.0005521273,0.00006929304,0.00030358127,0.000053947926,0.00044964268,0.10137906],"study_design_scores_gemma":[0.054468356,0.0011653205,0.9320367,0.0036869524,0.00073466246,0.001000991,0.00022217768,0.0016583235,0.0021304812,0.00007384308,0.0010687937,0.0017534273],"about_ca_topic_score_codex":0.02360348,"about_ca_topic_score_gemma":0.0015771419,"teacher_disagreement_score":0.09962563,"about_ca_system_score_codex":0.06256108,"about_ca_system_score_gemma":0.016315453,"threshold_uncertainty_score":0.99929464},"labels":[],"label_agreement":null},{"id":"W2136713872","doi":"10.2174/187153010790827993","title":"Imatinib Mesylate (Gleevec©): Targeted Therapy Against Cancer with Immune Properties","year":2010,"lang":"en","type":"review","venue":"Endocrine Metabolic & Immune Disorders - Drug Targets","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institut National Du Cancer; Ligue Contre le Cancer; Institute of Cancer Research; Institut National de la Santé et de la Recherche Médicale","keywords":"Imatinib mesylate; Imatinib; Medicine; Targeted therapy; Tyrosine kinase; Tyrosine-kinase inhibitor; Cancer research; Immune system; Cancer; Pharmacology; Immunology; Internal medicine; Receptor; Myeloid leukemia","score_opus":0.020495547895603705,"score_gpt":0.2982617519964285,"score_spread":0.2777662041008248,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136713872","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0034427303,0.9838071,0.0000104192995,0.0006033688,0.0016350197,0.00753352,0.00025764044,0.0006575045,0.0020527355],"genre_scores_gemma":[0.0024051387,0.9766512,0.0010345243,0.0002119225,0.00061110227,0.0047512846,0.0022741274,0.00090501,0.011155711],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99099123,0.0005839277,0.0027369172,0.0019856538,0.0013680701,0.0023342157],"domain_scores_gemma":[0.9942965,0.00016749077,0.0017836062,0.002869302,0.0003796341,0.000503487],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00051412656,0.0030090134,0.008368964,0.00089267833,0.00053746934,0.00014732376,0.0012783237,0.000490673,0.0014662206],"category_scores_gemma":[0.00022076255,0.0019402271,0.0022240323,0.0013921433,0.00064433564,0.0004133834,0.0004446172,0.0032388088,0.00040100142],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042993584,0.0011266887,0.00008595345,0.004999518,0.005687476,0.00018634392,0.00087947585,0.000009534672,0.000648713,0.00003495902,0.00047472332,0.9854367],"study_design_scores_gemma":[0.010734001,0.00021711762,0.0002963351,0.0076450943,0.0036157116,0.00021673541,0.00014586045,0.000028709772,0.002775684,0.000015096669,0.97237134,0.0019383117],"about_ca_topic_score_codex":0.0028084933,"about_ca_topic_score_gemma":0.0002715344,"teacher_disagreement_score":0.9834984,"about_ca_system_score_codex":0.0006409202,"about_ca_system_score_gemma":0.003507847,"threshold_uncertainty_score":0.9994466},"labels":[],"label_agreement":null},{"id":"W2137508909","doi":"10.3109/10428194.2014.882507","title":"Molecular relapse after allogeneic hematopoietic cell transplant for chronic myeloid leukemia: some long-term survivors appear to tolerate even lack of major molecular response","year":2014,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Myeloid leukemia; Hematopoietic cell; Medicine; Immunology; Haematopoiesis; Myeloid; Hematopoietic stem cell transplantation; Leukemia; Transplantation; Oncology; Cancer research; Stem cell; Internal medicine; Biology; Genetics","score_opus":0.012048295225232536,"score_gpt":0.24854209005624414,"score_spread":0.2364937948310116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137508909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9588499,0.015878119,0.0010603569,0.015303109,0.000937238,0.0062365513,0.0009733322,0.0004516791,0.00030971123],"genre_scores_gemma":[0.83310187,0.0015230941,0.0012974984,0.14693771,0.0022950557,0.0029949415,0.0030130057,0.0015296382,0.007307182],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.98529905,0.0010732124,0.00333609,0.0042138286,0.002387178,0.0036906598],"domain_scores_gemma":[0.99110466,0.0011087285,0.0014444109,0.004211405,0.00058095047,0.0015498701],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0012957259,0.003582597,0.005095137,0.0015622656,0.00039442375,0.0002335564,0.0016289487,0.0047364323,0.00022374988],"category_scores_gemma":[0.00020131146,0.0035191227,0.0021610425,0.0010449314,0.0009884764,0.00036439908,0.00057660183,0.0013560605,0.00038438148],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0768908,0.0019647419,0.00625229,0.07377707,0.013340417,0.122553006,0.009571512,0.0025879005,0.46287987,0.0003577374,0.20016283,0.029661825],"study_design_scores_gemma":[0.15411815,0.012115624,0.023641668,0.018301986,0.017053971,0.016520634,0.00025627037,0.0024921454,0.4700716,0.00063479156,0.2715344,0.013258738],"about_ca_topic_score_codex":0.0011581238,"about_ca_topic_score_gemma":0.000106567546,"teacher_disagreement_score":0.13163461,"about_ca_system_score_codex":0.04155174,"about_ca_system_score_gemma":0.019044671,"threshold_uncertainty_score":0.99768966},"labels":[],"label_agreement":null},{"id":"W2138253305","doi":"10.1007/s00277-009-0822-7","title":"Response to Imatinib mesylate in chronic myeloid leukemia patients with variant BCR-ABL fusion transcripts","year":2009,"lang":"en","type":"article","venue":"Annals of Hematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Vedecká Grantová Agentúra MŠVVaŠ SR a SAV; Terry Fox Foundation; Imperial College London","keywords":"Imatinib mesylate; Myeloid leukemia; Internal medicine; Medicine; Imatinib; Gastroenterology; Philadelphia chromosome; ABL; Leukemia; Immunology; Biology; Chromosomal translocation; Tyrosine kinase; Receptor","score_opus":0.022921049663615894,"score_gpt":0.30024516466819084,"score_spread":0.27732411500457493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138253305","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909186,0.000640968,0.00007421992,0.0062556523,0.000067960216,0.0009824532,0.000020068184,0.00005359979,0.0009865201],"genre_scores_gemma":[0.9963071,0.00009357129,0.0011267093,0.0021588085,0.00002141373,0.00003511024,0.00005306707,0.00003194753,0.00017231931],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9975646,0.00019347377,0.0006998499,0.00050210237,0.00037993983,0.0006600475],"domain_scores_gemma":[0.9986289,0.0001577562,0.00019363347,0.00061514805,0.0001603716,0.00024418547],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037122658,0.0003201451,0.00092646555,0.00041946155,0.00004780869,0.0000065754593,0.0001793325,0.00021392344,0.00015824691],"category_scores_gemma":[0.00020239053,0.0002534152,0.00011185081,0.0004761983,0.000082994775,0.000104514234,0.00003369223,0.00024807785,0.00006646703],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22404857,0.00982149,0.15639019,0.002373009,0.0018516312,0.012543773,0.016977804,0.0015454995,0.40075397,0.008862383,0.023130149,0.14170153],"study_design_scores_gemma":[0.028204715,0.015281942,0.8214286,0.0018560927,0.00015925143,0.0007326748,0.00009970792,0.0003945932,0.12485101,0.00059220946,0.0057316003,0.00066759397],"about_ca_topic_score_codex":0.00014520864,"about_ca_topic_score_gemma":0.00007857559,"teacher_disagreement_score":0.6650384,"about_ca_system_score_codex":0.00053480326,"about_ca_system_score_gemma":0.0011430536,"threshold_uncertainty_score":0.99999183},"labels":[],"label_agreement":null},{"id":"W2139097707","doi":"10.1016/j.bpj.2011.11.364","title":"Crystallization of the Abl Kinase Domain with Combi-Inhibitors, ZRF1 and ZRF2","year":2012,"lang":"en","type":"article","venue":"Biophysical Journal","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Dasatinib; ABL; Imatinib; Chronic myelogenous leukemia; Protein kinase domain; Chemistry; Cancer research; Kinase; Nilotinib; Tyrosine kinase; Pharmacology; Mutant; Biology; Leukemia; Biochemistry; Gene; Myeloid leukemia; Signal transduction; Genetics","score_opus":0.00912151887376705,"score_gpt":0.23619148836419834,"score_spread":0.2270699694904313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139097707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985415,0.000121047065,0.00028139623,0.0004576041,0.00012877713,0.00014093851,0.00000415039,0.000008760322,0.00031585773],"genre_scores_gemma":[0.99837667,0.000026031246,0.00084052247,0.00008802618,0.0005772762,0.0000020164903,0.0000034499926,0.00001463817,0.000071357135],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.999177,0.000056098866,0.00017209226,0.00008339413,0.00031363207,0.00019779657],"domain_scores_gemma":[0.9994097,0.00004126986,0.00013453448,0.00015918263,0.00006115239,0.00019420186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010670702,0.00010864625,0.0001877173,0.000029148174,0.00008886161,0.0000136438075,0.0000526688,0.000044646684,0.000037220714],"category_scores_gemma":[0.000028162638,0.00005683301,0.00006781139,0.0001295261,0.00014073293,0.000098411874,0.000035857516,0.00019320656,0.0000049039545],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005899882,0.0014293478,0.100900605,0.00010923677,0.0002660241,0.0000529542,0.0013128138,0.000005997264,0.88570666,0.003201674,0.0015898636,0.0048348224],"study_design_scores_gemma":[0.015715675,0.0013789699,0.67424196,0.0010975158,0.0007206252,0.0026013206,0.0006025758,0.00015436884,0.29628786,0.00069471344,0.0061170734,0.00038731573],"about_ca_topic_score_codex":0.000013006783,"about_ca_topic_score_gemma":0.0000015804002,"teacher_disagreement_score":0.5894188,"about_ca_system_score_codex":0.00018335535,"about_ca_system_score_gemma":0.00010493624,"threshold_uncertainty_score":0.2317583},"labels":[],"label_agreement":null},{"id":"W2139097830","doi":"10.1586/14737140.3.3.295","title":"Advances in targeted therapy for chronic myeloid leukemia","year":2003,"lang":"en","type":"review","venue":"Expert Review of Anticancer Therapy","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Myeloid leukemia; Medicine; Imatinib mesylate; Imatinib; Leukemia; Targeted therapy; Immunology; Myeloid; Cancer research; Oncology; Internal medicine; Cancer","score_opus":0.03901782163630336,"score_gpt":0.4007243942037427,"score_spread":0.3617065725674393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139097830","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000040231307,0.988935,0.000046494984,0.00014449049,0.0005846922,0.009189886,0.000059141927,0.000055328954,0.0009809209],"genre_scores_gemma":[0.0000019048507,0.9916111,0.0015732342,0.001801995,0.0006493537,0.003412038,0.0003763535,0.00023145572,0.00034254824],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952779,0.00031230293,0.001977667,0.001043753,0.0005987161,0.00078967813],"domain_scores_gemma":[0.9968863,0.0003625352,0.0010277798,0.0013439648,0.00019817347,0.00018122717],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00063453807,0.0011035723,0.0063356603,0.00029468836,0.00005906292,0.000012719678,0.000487389,0.00041549664,0.0012344877],"category_scores_gemma":[0.000099955505,0.0007443342,0.0017525038,0.0009097541,0.00021178574,0.00016562668,0.000028833963,0.00050167216,0.00003455324],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00010771331,0.00021113231,0.0000058209207,0.094652355,0.00039127833,0.000014289609,0.00004787586,1.3287621e-7,0.000015309115,0.00004869855,0.0024894762,0.9020159],"study_design_scores_gemma":[0.004407742,0.00085723784,0.0000039381684,0.19903837,0.00020576228,0.00004949606,0.000004797924,0.0000022301142,0.000119679455,0.000017760642,0.7948044,0.00048856717],"about_ca_topic_score_codex":0.000045631074,"about_ca_topic_score_gemma":0.000008908829,"teacher_disagreement_score":0.90152735,"about_ca_system_score_codex":0.0046040434,"about_ca_system_score_gemma":0.0063001174,"threshold_uncertainty_score":0.9996785},"labels":[],"label_agreement":null},{"id":"W2139683904","doi":"10.1084/jem.20042170","title":"A mutation in the <i>Icsbp1</i> gene causes susceptibility to infection and a chronic myeloid leukemia–like syndrome in BXH-2 mice","year":2005,"lang":"en","type":"article","venue":"The Journal of Experimental Medicine","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Biotechnology Research Institute; McGill University","funders":"Canadian Institutes of Health Research","keywords":"Biology; IRF8; Myeloid leukemia; Leukemia; Cancer research; Immunology; Genetics; Gene; Transcription factor","score_opus":0.01855111297510638,"score_gpt":0.30531917920216245,"score_spread":0.2867680662270561,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139683904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9846446,0.008942072,0.000027356855,0.0052655814,0.00018098015,0.00075809157,0.0000013678803,0.000009608368,0.00017036812],"genre_scores_gemma":[0.9965617,0.0007667894,0.00019764304,0.0019382056,0.00043345938,0.00002297844,0.0000052282585,0.00001981189,0.000054179778],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99797636,0.00024999265,0.00072375854,0.00018910435,0.00057643594,0.00028437242],"domain_scores_gemma":[0.99900085,0.00026420472,0.0002439126,0.0002888806,0.0000613801,0.00014079013],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015272577,0.00022082614,0.0004572291,0.00027503187,0.00007553934,0.000010649971,0.00016544554,0.00007465955,0.00009679189],"category_scores_gemma":[0.00014756485,0.00012013805,0.00005376112,0.00044485417,0.00019014854,0.00018557833,0.000052429546,0.00046380443,0.000011643234],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025443037,0.001140152,0.024090232,0.00013014537,0.00020336227,0.0011276088,0.048729714,0.000858294,0.9116137,0.000039385704,0.0015746685,0.007948405],"study_design_scores_gemma":[0.04561055,0.021064514,0.6034718,0.0031471301,0.0006691295,0.05285931,0.018433724,0.0009059027,0.25025338,0.0001530826,0.0028793078,0.0005521475],"about_ca_topic_score_codex":0.0013630055,"about_ca_topic_score_gemma":0.0014136938,"teacher_disagreement_score":0.6613603,"about_ca_system_score_codex":0.0041089556,"about_ca_system_score_gemma":0.00033318525,"threshold_uncertainty_score":0.9997141},"labels":[],"label_agreement":null},{"id":"W2140060467","doi":"10.1093/annonc/mdp452","title":"Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy","year":2009,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Vascular endothelial growth factor; Vascular endothelial growth factor A; Medicine; Angiogenesis; Genotype; Haplotype; Kinase insert domain receptor; Imatinib; Imatinib mesylate; Myeloid leukemia; Internal medicine; Cancer research; Immunology; Oncology; Biology; VEGF receptors; Genetics; Gene","score_opus":0.12275547772386922,"score_gpt":0.41081870463318776,"score_spread":0.2880632269093185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140060467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9866888,0.0026548062,0.000008399209,0.008286779,0.0003034874,0.00077391096,0.000050003422,0.00002984617,0.0012039834],"genre_scores_gemma":[0.9818388,0.013502621,0.0011373104,0.002927693,0.0002571867,0.000031867647,0.000016651857,0.000027444403,0.00026039762],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9977059,0.00029478015,0.00089821406,0.00040723712,0.00033142805,0.00036243544],"domain_scores_gemma":[0.99738026,0.0013787857,0.00041870144,0.0005590601,0.00011057988,0.00015264185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005160765,0.00029166823,0.0011267316,0.0000955843,0.00006625688,0.000004802847,0.00016233478,0.0002485001,0.00013097234],"category_scores_gemma":[0.0005493183,0.00017811338,0.00058574294,0.0001227086,0.00019638953,0.000049307822,0.000021776004,0.00021980554,0.000021754731],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004107599,0.0076914188,0.11881523,0.000059521182,0.0032196182,0.0002188463,0.0022261962,0.0000026506402,0.07878656,0.0012988556,0.0015284382,0.78204507],"study_design_scores_gemma":[0.04587253,0.09311214,0.45956743,0.00032804447,0.0005612629,0.00007397835,0.00018486522,0.00006233861,0.31171408,0.0011938158,0.086738035,0.000591473],"about_ca_topic_score_codex":0.000089277746,"about_ca_topic_score_gemma":0.0000046589757,"teacher_disagreement_score":0.7814536,"about_ca_system_score_codex":0.00021744554,"about_ca_system_score_gemma":0.00033259534,"threshold_uncertainty_score":0.7263253},"labels":[],"label_agreement":null},{"id":"W2140351909","doi":"10.1016/j.ccr.2014.07.006","title":"BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia","year":2014,"lang":"en","type":"article","venue":"Cancer Cell","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":366,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; National Institutes of Health; National Heart, Lung, and Blood Institute; Huntsman Cancer Institute; University of Utah; American Society of Hematology; Leukemia and Lymphoma Society; Office of Science; Imperial College London; Howard Hughes Medical Institute","keywords":"Ponatinib; Cancer research; Protein kinase domain; Leukemia; ABL; Mutation; Biology; Philadelphia chromosome; breakpoint cluster region; Drug resistance; Kinase; Myeloid leukemia; Genetics; Tyrosine kinase; Dasatinib; Chromosomal translocation; Imatinib; Signal transduction; Gene; Mutant","score_opus":0.022433062477253903,"score_gpt":0.3231792071203803,"score_spread":0.3007461446431264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140351909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9368464,0.00080282515,0.00060508976,0.0016462475,0.0004571094,0.00094607787,0.00021341258,0.000087484266,0.05839538],"genre_scores_gemma":[0.98972803,0.000112814116,0.0042498023,0.0024702905,0.00033008633,0.0002654514,0.0003614837,0.000060345963,0.002421702],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975567,0.00023831644,0.000703197,0.0006500217,0.00034249644,0.00050928793],"domain_scores_gemma":[0.99789315,0.0007558391,0.00017720704,0.00053507806,0.00021906762,0.00041963087],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00038343325,0.0003010957,0.0006225429,0.00013131501,0.00017415767,0.000042772357,0.00017635504,0.00017939629,0.00063607603],"category_scores_gemma":[0.0001378492,0.00031020344,0.00014605075,0.00038036614,0.00019502785,0.00013177143,0.000073468924,0.00044696312,0.0002248122],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015579831,0.01690965,0.32392302,0.0033008878,0.003293684,0.008009635,0.08898454,0.00598992,0.21500745,0.059905432,0.20632556,0.052770376],"study_design_scores_gemma":[0.11201172,0.0033426443,0.6082677,0.0075209653,0.0015711223,0.00017798058,0.0051441556,0.0042985724,0.05610014,0.005646344,0.19255675,0.0033618668],"about_ca_topic_score_codex":0.00088878203,"about_ca_topic_score_gemma":0.0030740653,"teacher_disagreement_score":0.2843447,"about_ca_system_score_codex":0.0045335693,"about_ca_system_score_gemma":0.0012772981,"threshold_uncertainty_score":0.99993503},"labels":[],"label_agreement":null},{"id":"W2141229953","doi":"10.1186/1471-2407-11-528","title":"Tyrosine kinase chromosomal translocations mediate distinct and overlapping gene regulation events","year":2011,"lang":"en","type":"article","venue":"BMC Cancer","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Ontario Institute for Cancer Research","funders":"Canadian Institutes of Health Research","keywords":"Chromosomal translocation; Gene; Surgical oncology; Genetics; Tyrosine kinase; Biology; Cancer research; Medicine; Signal transduction; Computational biology; Oncology","score_opus":0.04409955949134258,"score_gpt":0.28093717840568155,"score_spread":0.23683761891433897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141229953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995474,0.0019664129,0.00084623246,0.000117255106,0.00019108831,0.0004170579,0.000046201785,0.00006164699,0.0008801015],"genre_scores_gemma":[0.996234,0.00021039078,0.001939853,0.000064560445,0.00025173894,0.00012751865,0.000092584116,0.000025857702,0.001053472],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99914545,0.000021122098,0.00019686208,0.00026228584,0.00017825456,0.00019601181],"domain_scores_gemma":[0.9994863,0.000022487693,0.0000707014,0.00023464931,0.000051008563,0.00013482606],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000059361057,0.00013948944,0.0001884063,0.000055650893,0.00007693142,0.000005014228,0.00003966557,0.000064601976,0.0008361899],"category_scores_gemma":[0.000027556478,0.00012506051,0.00004799945,0.00013215003,0.00005293583,0.000089034496,0.000017732518,0.000070999864,0.000021885795],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070903107,0.00047725352,0.91426396,0.0004892575,0.00029659783,0.00004421012,0.0028433492,0.00004208703,0.055459406,0.000262581,0.0005921177,0.024520159],"study_design_scores_gemma":[0.0034198982,0.00008019717,0.98497,0.00018610436,0.00022803195,0.000033702265,0.000018125844,0.0008744275,0.009409911,0.00009778204,0.00055545295,0.00012637602],"about_ca_topic_score_codex":0.0008493888,"about_ca_topic_score_gemma":0.0008086441,"teacher_disagreement_score":0.07070604,"about_ca_system_score_codex":0.00048274576,"about_ca_system_score_gemma":0.0003183748,"threshold_uncertainty_score":0.91556925},"labels":[],"label_agreement":null},{"id":"W2141553494","doi":"10.1016/s0165-4608(00)00227-2","title":"A Case of Near-Triploidy in Chronic Myelogenous Leukemia","year":2000,"lang":"en","type":"letter","venue":"Cancer Genetics and Cytogenetics","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Biology; Isochromosome; Chronic myelogenous leukemia; Karyotype; Cytogenetics; Leukemia; Ploidy; Bone marrow; Blast Crisis; Genetics; Immunology; Chromosome; Cancer research","score_opus":0.027539003601365013,"score_gpt":0.2878668016249412,"score_spread":0.2603277980235762,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141553494","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8769285,0.110792264,0.000006691828,0.009486059,0.00027278916,0.0012866509,0.000498028,0.00003333866,0.0006956807],"genre_scores_gemma":[0.59574085,0.27186424,0.002843006,0.115189336,0.006162804,0.00053002936,0.00082963955,0.00065249455,0.0061876164],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970669,0.0000713648,0.00083458616,0.00082939275,0.00040041876,0.00079730025],"domain_scores_gemma":[0.99836236,0.000070551745,0.00028047353,0.00096356106,0.00012689148,0.00019617098],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00008623895,0.0006543395,0.0011441968,0.0002472927,0.0000841296,0.000036658163,0.00020499506,0.0012186831,0.00048082237],"category_scores_gemma":[0.00001071548,0.0006508806,0.00019830964,0.00035058983,0.00040869252,0.000013878642,0.00012354122,0.001263812,0.000015744965],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00053325586,0.00030943085,0.027331963,0.008387693,0.0023559553,0.12618043,0.0026585173,0.0067919823,0.004747005,0.0000051702364,0.248062,0.5726366],"study_design_scores_gemma":[0.007891362,0.0016644658,0.0023452167,0.001074123,0.0017346916,0.010765135,0.000036853995,0.0024094011,0.0071673174,0.000086042484,0.96374816,0.0010772555],"about_ca_topic_score_codex":0.0014712594,"about_ca_topic_score_gemma":0.0008130421,"teacher_disagreement_score":0.71568614,"about_ca_system_score_codex":0.003896382,"about_ca_system_score_gemma":0.006101985,"threshold_uncertainty_score":0.99992746},"labels":[],"label_agreement":null},{"id":"W2142243033","doi":"10.5539/ijb.v6n4p139","title":"Molecular Screening for E255K and F359V Mutations in Non-Responders Iraqi Chronic Myeloid Leukemia Patients to Imatinib Mesylate Therapy","year":2014,"lang":"en","type":"article","venue":"International Journal of Biology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Nilotinib; Dasatinib; Myeloid leukemia; Medicine; Imatinib mesylate; Internal medicine; Tyrosine-kinase inhibitor; Tyrosine kinase; Oncology; Hematology; Imatinib; Cancer","score_opus":0.0168534540543242,"score_gpt":0.32176733375048827,"score_spread":0.30491387969616407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142243033","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98201954,0.00021699775,0.01519658,0.001669427,0.00033333228,0.0003688845,0.000018298442,0.000006525918,0.00017041802],"genre_scores_gemma":[0.9923849,0.00008988851,0.006219383,0.0009351687,0.00022619459,0.000022633501,0.00006275686,0.000019816322,0.00003926288],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99883944,0.00006426324,0.00050138443,0.00018514013,0.00020191018,0.0002078373],"domain_scores_gemma":[0.9988926,0.00023761857,0.00027177835,0.00010242758,0.00037629495,0.00011929156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003237767,0.00014370191,0.00030553015,0.00043419996,0.000028533832,0.000017050801,0.00018132238,0.00009476824,0.000034894838],"category_scores_gemma":[0.00036535424,0.000118189586,0.000106447726,0.000090866495,0.000059498976,0.00008173966,0.0000428816,0.00016784303,0.0000057574516],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005022491,0.00036420263,0.11546311,0.000042052103,0.0014736905,0.00011448081,0.0014033043,0.0030670268,0.1555339,0.0010150617,0.00048052083,0.71602017],"study_design_scores_gemma":[0.090383925,0.0140890535,0.79562944,0.0010468861,0.00021059538,0.00065150013,0.00025971787,0.019847283,0.04460535,0.004644191,0.027910914,0.0007211132],"about_ca_topic_score_codex":0.000051158735,"about_ca_topic_score_gemma":0.000020555313,"teacher_disagreement_score":0.71529907,"about_ca_system_score_codex":0.00090816733,"about_ca_system_score_gemma":0.00029150848,"threshold_uncertainty_score":0.48196316},"labels":[],"label_agreement":null},{"id":"W2142900411","doi":"10.1038/sj.leu.2403068","title":"Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia","year":2003,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":115,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Imatinib; Medicine; Myeloid leukemia; Internal medicine; Transplantation; Imatinib mesylate; Gastroenterology; Donor lymphocyte infusion; Leukemia; Stem cell; Philadelphia chromosome; Chronic leukemia; Immunology; Oncology; Hematopoietic stem cell transplantation; Acute leukemia; Chromosomal translocation; Biology","score_opus":0.009752043447362892,"score_gpt":0.24524773393457255,"score_spread":0.23549569048720967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142900411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943626,0.0004355518,0.0004100622,0.00013955936,0.00028368566,0.0029009269,0.000119095355,0.00009263363,0.0012558997],"genre_scores_gemma":[0.9887816,0.000099131365,0.0028298472,0.0009234635,0.000082196086,0.0010198611,0.00017964176,0.00012922581,0.005955074],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967321,0.00026541442,0.0007955184,0.00083494006,0.0005023265,0.0008696761],"domain_scores_gemma":[0.9982593,0.00031696158,0.00016379292,0.0007463384,0.000136991,0.00037662374],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00061866624,0.00049469445,0.00064503966,0.00039128208,0.00009303315,0.00003319809,0.00018219562,0.0003440376,0.00018647597],"category_scores_gemma":[0.00011242313,0.00047870568,0.0002178986,0.00049652735,0.000050675295,0.00018147103,0.000029061779,0.00034563983,0.00030699666],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15506051,0.0021726554,0.5944456,0.0070765116,0.000839276,0.002040546,0.025915194,0.0087613035,0.09899689,0.00043713048,0.020588024,0.08366636],"study_design_scores_gemma":[0.06274805,0.004429155,0.7936508,0.0012139136,0.00046730615,0.00008535909,0.00020714635,0.0005812921,0.09915913,0.00008564165,0.036163595,0.0012086178],"about_ca_topic_score_codex":0.000082804894,"about_ca_topic_score_gemma":0.000140525,"teacher_disagreement_score":0.19920519,"about_ca_system_score_codex":0.019116174,"about_ca_system_score_gemma":0.003088538,"threshold_uncertainty_score":0.99976647},"labels":[],"label_agreement":null},{"id":"W2143119706","doi":"10.4049/jimmunol.1201538","title":"Abelson Tyrosine Kinase Controls Phagosomal Acidification Required for Killing of <i>Mycobacterium tuberculosis</i> in Human Macrophages","year":2012,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":111,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"National Institute of Allergy and Infectious Diseases; European Commission","keywords":"Mycobacterium tuberculosis; Microbiology; Tyrosine kinase; Chemistry; Phagosome; Tuberculosis; Tyrosine; Medicine; Biology; Phagocytosis; Pathology; Biochemistry; Signal transduction","score_opus":0.020927050698575693,"score_gpt":0.29246821969920467,"score_spread":0.27154116900062897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143119706","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98126066,0.016609192,0.00023096679,0.0010689673,0.00034100655,0.00041257846,0.000009835978,0.0000075322087,0.000059276612],"genre_scores_gemma":[0.99776995,0.0012537928,0.0004801182,0.00009157577,0.00027104514,0.00001327383,0.000015165686,0.000022889471,0.00008217847],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99849457,0.00017032177,0.0007705206,0.00007965229,0.00014715928,0.00033776325],"domain_scores_gemma":[0.99850345,0.0002649569,0.00068406906,0.00029088516,0.00020217265,0.000054464635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087401684,0.00014777844,0.0005551208,0.0001611242,0.000060196813,0.0000042944453,0.00016652243,0.0001224234,0.00004193184],"category_scores_gemma":[0.00016395761,0.00009813765,0.00013810697,0.00012381567,0.0001407597,0.00016979281,0.000031060124,0.00025190372,0.0000041149174],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020099394,0.00041819955,0.00608482,0.0000617462,0.00034100426,0.0000074858553,0.0008037763,0.000007554584,0.9871975,0.00015229071,0.00007106993,0.0028445993],"study_design_scores_gemma":[0.015670573,0.001871789,0.10202013,0.0003263601,0.0007286045,0.0009356699,0.00038379407,0.000042259795,0.87680846,0.00013531848,0.0009592611,0.00011777084],"about_ca_topic_score_codex":0.00004865808,"about_ca_topic_score_gemma":0.000003871073,"teacher_disagreement_score":0.11038905,"about_ca_system_score_codex":0.00042258156,"about_ca_system_score_gemma":0.00011138711,"threshold_uncertainty_score":0.40019372},"labels":[],"label_agreement":null},{"id":"W2146959803","doi":"10.1016/j.jmoldx.2013.04.007","title":"BCR-ABL1 RT-qPCR for Monitoring the Molecular Response to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia","year":2013,"lang":"en","type":"review","venue":"Journal of Molecular Diagnostics","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"Novartis Pharmaceuticals Corporation; Ariad Pharmaceuticals; Bristol-Myers Squibb","keywords":"Dasatinib; Nilotinib; Bosutinib; Myeloid leukemia; Tyrosine kinase; Imatinib; Tyrosine-kinase inhibitor; Cancer research; Imatinib mesylate; Ponatinib; Bruton's tyrosine kinase; ABL; Medicine; Fusion gene; Biology; Internal medicine; Genetics; Cancer; Gene","score_opus":0.029669658819623877,"score_gpt":0.3327350379289139,"score_spread":0.30306537910929005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146959803","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016108785,0.9766638,0.0009509498,0.0006002432,0.0012079884,0.004356784,0.000053246957,0.000025368348,0.00003282702],"genre_scores_gemma":[0.0020562354,0.9905547,0.004582544,0.00024598202,0.0014532839,0.00055791234,0.000042301894,0.00032268706,0.00018434413],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.994231,0.0006255485,0.0023629782,0.0006254572,0.0011769334,0.0009781001],"domain_scores_gemma":[0.99319243,0.0028105841,0.0014798676,0.0012137601,0.0006370655,0.0006663032],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00165334,0.0010260463,0.0029735814,0.0010111376,0.000112168236,0.00012965003,0.0008253372,0.0006995768,0.000031163767],"category_scores_gemma":[0.008043668,0.00071622,0.0015201512,0.0010144813,0.000121355915,0.00012054184,0.00028180995,0.0017315358,0.00009061545],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0007726218,0.00043964168,0.000093330884,0.010779148,0.0017340368,0.011524804,0.00021496828,0.0012242239,0.007167623,0.00006527236,0.0075183283,0.958466],"study_design_scores_gemma":[0.0052674147,0.0026304591,0.00011030967,0.057707336,0.004637973,0.0013939696,0.00005165434,0.000036062647,0.008815175,0.000055526307,0.9185387,0.00075545796],"about_ca_topic_score_codex":0.00004981158,"about_ca_topic_score_gemma":0.0000047233025,"teacher_disagreement_score":0.95771056,"about_ca_system_score_codex":0.015076977,"about_ca_system_score_gemma":0.008496372,"threshold_uncertainty_score":0.9995289},"labels":[],"label_agreement":null},{"id":"W2147426382","doi":"10.3324/haematol.2009.016220","title":"Impact of genomic risk factors on outcome after hematopoietic stem cell transplantation for patients with chronic myeloid leukemia","year":2010,"lang":"en","type":"article","venue":"Haematologica","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Genetics","funders":"Medical Research Council; National Research Foundation; Amgen; European Commission; Les Laboratories Pierre Fabre; Gilead Sciences; F. Hoffmann-La Roche","keywords":"Transplantation; Oncology; Hematopoietic stem cell transplantation; Internal medicine; Immunology; Myeloid leukemia; Medicine; Biology","score_opus":0.012753935256534158,"score_gpt":0.25878793689998686,"score_spread":0.2460340016434527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147426382","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997456,0.000055079414,0.00010115355,0.000010496363,0.0001193484,0.0016636136,0.00030621293,0.00007396481,0.00021413011],"genre_scores_gemma":[0.9988086,0.000031610685,0.00058860553,0.000018029255,0.000029655668,0.00016894069,0.00019355264,0.00005259713,0.00010836323],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982992,0.000039012106,0.00050275837,0.0004429695,0.00028920922,0.0004268421],"domain_scores_gemma":[0.99858254,0.00023883155,0.00037155312,0.0005331575,0.00009937386,0.00017456998],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008735115,0.00038219788,0.0007459603,0.00013163153,0.00007790187,0.0000118277185,0.00013392033,0.00023919078,0.00035298732],"category_scores_gemma":[0.00001784639,0.00022666062,0.00031821345,0.00010005011,0.00010891733,0.00006650677,0.000016715361,0.00034128685,0.00006855065],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022160385,0.0004389821,0.9937727,0.00064327236,0.00017002087,0.00004477776,0.00051474356,0.000062922896,0.0014972946,0.000023423232,0.00003037421,0.00058548513],"study_design_scores_gemma":[0.008132937,0.004129516,0.9781493,0.00008005353,0.0005002111,0.000053868476,0.000026102347,0.000071436356,0.008563642,0.000023509752,0.000027959617,0.00024148775],"about_ca_topic_score_codex":0.00012991265,"about_ca_topic_score_gemma":0.000058363952,"teacher_disagreement_score":0.015623389,"about_ca_system_score_codex":0.0010161134,"about_ca_system_score_gemma":0.0004036892,"threshold_uncertainty_score":0.9242952},"labels":[],"label_agreement":null},{"id":"W2147709971","doi":"","title":"Hepoxilin analogs, PBT-3 and PBT-4, cause apoptosis of Gleevec-resistant K562 cells in vitro.","year":2007,"lang":"en","type":"article","venue":"PubMed","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Apoptosis; K562 cells; In vitro; Chemistry; Leukemia; Pharmacology; Cancer research; Tyrosine kinase; Medicine; Receptor; Immunology; Biochemistry","score_opus":0.01860820712347635,"score_gpt":0.24216430410604572,"score_spread":0.22355609698256937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147709971","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949098,0.00087314495,0.000034945457,0.00023016619,0.00013820853,0.0010633224,0.00003227988,0.00003982159,0.0026782835],"genre_scores_gemma":[0.9978895,0.00019261392,0.0005205969,0.00017034117,0.00007772965,0.000175834,0.000025889864,0.000031692536,0.000915809],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99802214,0.00004308821,0.0005577149,0.00038515843,0.00034552053,0.0006463822],"domain_scores_gemma":[0.99887925,0.00017463023,0.0001485825,0.00042804037,0.000056304078,0.00031321254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065908756,0.00022143795,0.00051573815,0.00030270594,0.00004329291,0.000008288144,0.000093689174,0.00015136991,0.000025646063],"category_scores_gemma":[0.00014741211,0.00019599329,0.00008507841,0.00039720137,0.00011933391,0.00006848016,0.000090700116,0.00020432429,0.0000069546077],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010881603,0.0031102833,0.2319475,0.0013690453,0.0014651257,0.001631525,0.0030076094,0.000014462303,0.36996174,0.00037571538,0.0021231798,0.37411222],"study_design_scores_gemma":[0.006208583,0.00010509773,0.52707356,0.00004848944,0.00023382992,0.000029243041,0.00014601095,0.000029113711,0.4641457,0.00006354986,0.0017187917,0.00019802534],"about_ca_topic_score_codex":0.0008895949,"about_ca_topic_score_gemma":0.00038033765,"teacher_disagreement_score":0.3739142,"about_ca_system_score_codex":0.00082910404,"about_ca_system_score_gemma":0.00011489238,"threshold_uncertainty_score":0.79923743},"labels":[],"label_agreement":null},{"id":"W2147935465","doi":"10.3747/co.21.1834","title":"Evidence-Based Guidelines for the Use of Tyrosine Kinase Inhibitors in Adults with Philadelphia Chromosome–Positive or Bcr-Abl–Positive Acute Lymphoblastic Leukemia: A Canadian Consensus","year":2014,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Sherritt (Canada); Hôpital Maisonneuve-Rosemont; St. Michael's Hospital; McMaster University; Dalhousie University; University Health Network; University of British Columbia; University of Calgary","funders":"","keywords":"Medicine; Philadelphia chromosome; Tyrosine kinase; Oncology; Lymphoblastic Leukemia; Internal medicine; Transplantation; Randomized controlled trial; Hematopoietic stem cell transplantation; Leukemia; Chromosomal translocation","score_opus":0.15967670680618268,"score_gpt":0.37508245595796025,"score_spread":0.21540574915177757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147935465","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96293235,0.0047115088,0.0010006363,0.023939114,0.0012562333,0.0052551418,0.0007944214,0.000063186395,0.00004740584],"genre_scores_gemma":[0.9942765,0.0007972708,0.0020113343,0.0015224597,0.00046865665,0.0005544205,0.00024754633,0.00006175981,0.00006001211],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9972788,0.00022827512,0.0008181015,0.00063259073,0.00033123093,0.0007110038],"domain_scores_gemma":[0.9933232,0.004070769,0.00041204176,0.00052865304,0.0012613921,0.000403944],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003571155,0.0004422598,0.00088583905,0.00038546202,0.0001435357,0.000018490988,0.00019533954,0.00026513825,0.000057268695],"category_scores_gemma":[0.0030106683,0.00027149482,0.00015140008,0.00056746823,0.0005830122,0.00010499411,0.000053115247,0.0003371947,0.000011648573],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.15827003,0.005849011,0.07932663,0.0053718975,0.004377643,0.006346425,0.0076588676,0.017651504,0.0073039187,0.000776303,0.1938011,0.5132667],"study_design_scores_gemma":[0.21028534,0.060530875,0.111713305,0.076240405,0.011296306,0.0034008774,0.0014906991,0.35691485,0.037817966,0.00007638835,0.1272295,0.0030034892],"about_ca_topic_score_codex":0.024111753,"about_ca_topic_score_gemma":0.0992931,"teacher_disagreement_score":0.5102632,"about_ca_system_score_codex":0.007491172,"about_ca_system_score_gemma":0.010666223,"threshold_uncertainty_score":0.9999737},"labels":[],"label_agreement":null},{"id":"W2148153235","doi":"10.1080/1042819031000139774","title":"Rescue of Interferon Induced Bone Marrow Aplasia in a Patient with Chronic Myeloid Leukemia by Allogeneic Bone Marrow Transplant","year":2003,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Markham Stouffville Hospital; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Bone marrow; Aplasia; Prednisone; Bone Marrow Aplasia; Complication; Hypoplasia; Myeloid leukemia; Immunology; Chronic myelogenous leukemia; Philadelphia chromosome; Leukemia; Gastroenterology; Internal medicine; Chromosomal translocation; Biology","score_opus":0.008472961117209849,"score_gpt":0.2164746803923874,"score_spread":0.20800171927517755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148153235","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864699,0.0066305455,0.000034852044,0.00011419461,0.00048149296,0.0022283792,0.00018903273,0.00023206376,0.0036195081],"genre_scores_gemma":[0.99452376,0.0013734224,0.0007412968,0.00057275733,0.00012632179,0.00040667527,0.0003056291,0.00034494698,0.00160517],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99115247,0.000490068,0.0023105282,0.0022950044,0.0015706423,0.0021812983],"domain_scores_gemma":[0.9957089,0.00022167657,0.00081305194,0.0019606194,0.00022926235,0.0010664774],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0005423418,0.0017717071,0.0026635677,0.000857316,0.00028254732,0.00008567267,0.000533736,0.0012948017,0.00023147986],"category_scores_gemma":[0.00014523171,0.0015676576,0.0005481426,0.001561598,0.00062968594,0.00046457793,0.00022861383,0.00060068356,0.000052757096],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.012342863,0.0020007654,0.090153076,0.0029432443,0.0015983128,0.006559725,0.0038549202,0.0005267822,0.7697647,0.00065970904,0.003918357,0.105677515],"study_design_scores_gemma":[0.14253344,0.009138641,0.10022433,0.007965948,0.0016694335,0.025659718,0.00085101865,0.0030009162,0.68834615,0.00017460017,0.016453328,0.003982516],"about_ca_topic_score_codex":0.0053389263,"about_ca_topic_score_gemma":0.0025428953,"teacher_disagreement_score":0.13019057,"about_ca_system_score_codex":0.054524813,"about_ca_system_score_gemma":0.016647888,"threshold_uncertainty_score":0.99950284},"labels":[],"label_agreement":null},{"id":"W2148274830","doi":"10.1177/1078155213520261","title":"Medication adherence among adults prescribed imatinib, dasatinib, or nilotinib for the treatment of chronic myeloid leukemia","year":2014,"lang":"en","type":"article","venue":"Journal of Oncology Pharmacy Practice","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; Foothills Medical Centre","funders":"","keywords":"Nilotinib; Medicine; Dasatinib; Myeloid leukemia; Imatinib; Chronic myeloid leukaemia; Tyrosine-kinase inhibitor; Internal medicine; Imatinib mesylate; Pharmacology; Oncology; Cancer","score_opus":0.05700371716467508,"score_gpt":0.4052629115430166,"score_spread":0.3482591943783415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148274830","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96808505,0.004382363,0.0034006883,0.013000132,0.00267134,0.0040533934,0.000034082055,0.000056285473,0.0043166424],"genre_scores_gemma":[0.9765835,0.009183759,0.010328174,0.00073373405,0.001961832,0.00024228307,0.000023446166,0.000054515793,0.0008887997],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99669963,0.0005289456,0.0014531707,0.00030419911,0.00060951593,0.00040451658],"domain_scores_gemma":[0.98579276,0.009110712,0.0033915127,0.00048916007,0.00093578757,0.0002801002],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018550693,0.0003155009,0.00089063664,0.00015053949,0.00016022015,0.00001852024,0.00036610683,0.00015038792,0.00048480826],"category_scores_gemma":[0.0044204737,0.00018041545,0.00031055816,0.0002253215,0.00030658286,0.00057161605,0.000036098307,0.00048696084,0.000021735832],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041248456,0.0054095713,0.0041009667,0.0004929429,0.003327652,0.00019406067,0.0050212853,0.00022453385,0.007722313,0.000075119686,0.013285342,0.91889775],"study_design_scores_gemma":[0.08563846,0.040770587,0.007585769,0.00050961325,0.0060252016,0.002793932,0.0011548912,0.022388704,0.023756547,0.000028261335,0.8091004,0.00024762648],"about_ca_topic_score_codex":0.00027576103,"about_ca_topic_score_gemma":0.000075991855,"teacher_disagreement_score":0.91865015,"about_ca_system_score_codex":0.0041301297,"about_ca_system_score_gemma":0.0053668674,"threshold_uncertainty_score":0.99969286},"labels":[],"label_agreement":null},{"id":"W2148743957","doi":"10.1182/blood-2006-01-0092","title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","year":2006,"lang":"en","type":"review","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1202,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Fogarty International Center; European Commission","keywords":"Imatinib mesylate; Tyrosine kinase; Philadelphia chromosome; Fluorescence in situ hybridization; Imatinib; ABL; Myeloid leukemia; Cancer research; Medicine; breakpoint cluster region; Tyrosine-kinase inhibitor; Internal medicine; Oncology; Biology; Bioinformatics; Gene; Genetics; Cancer; Chromosomal translocation; Chromosome; Receptor","score_opus":0.18646272106561537,"score_gpt":0.40711279167258724,"score_spread":0.22065007060697187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148743957","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006484784,0.97651565,0.002977403,0.00029839738,0.0002436066,0.011749417,0.0016628228,0.000062390165,0.000005520863],"genre_scores_gemma":[0.0002407219,0.79220414,0.19940999,0.000025723051,0.00038630283,0.006220387,0.0013166316,0.00014288763,0.000053222775],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968474,0.00026242094,0.001114802,0.001066397,0.00014928212,0.0005596822],"domain_scores_gemma":[0.9958232,0.0027204845,0.0005932058,0.00035464225,0.00022067592,0.00028778028],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00078794314,0.00069645076,0.00201441,0.00061262125,0.0005675764,0.00009080307,0.000068615045,0.00019991168,6.384407e-7],"category_scores_gemma":[0.0009810688,0.0005527577,0.00024530033,0.00040599954,0.00006236872,0.0001419425,0.00004653415,0.00019511238,2.0129114e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003283917,0.00042396947,0.00008576111,0.03606408,0.00040493632,0.0000066745165,0.00059461617,1.9558131e-7,0.00013457169,0.000010181006,0.00008868429,0.9618579],"study_design_scores_gemma":[0.033128865,0.0038120477,0.000050913808,0.1654183,0.025121974,0.00015842571,0.00020058334,0.000006959165,0.0018097215,0.00006515926,0.76936907,0.0008580156],"about_ca_topic_score_codex":0.00003513545,"about_ca_topic_score_gemma":0.000019375524,"teacher_disagreement_score":0.9609999,"about_ca_system_score_codex":0.000677965,"about_ca_system_score_gemma":0.00029346475,"threshold_uncertainty_score":0.9996924},"labels":[],"label_agreement":null},{"id":"W2149731431","doi":"10.1016/j.bbmt.2010.09.003","title":"Controversies in the Treatment of CML in Children and Adolescents: TKIs versus BMT?","year":2010,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Children's Hospital","funders":"","keywords":"Medicine; Pediatrics; Psychiatry; Intensive care medicine","score_opus":0.007154115530296296,"score_gpt":0.24738442899413576,"score_spread":0.24023031346383947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149731431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99857026,0.00077304844,0.0000013630442,0.00015674139,0.00004273569,0.0003310926,0.000060166305,0.0000026494222,0.000061961815],"genre_scores_gemma":[0.99561733,0.0041387416,0.00008281438,0.000024640893,0.000017330623,0.000009689911,0.000103404636,0.0000027894205,0.0000032546736],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995936,0.000032962333,0.00014172893,0.00011223681,0.00003659202,0.00008284226],"domain_scores_gemma":[0.99972546,0.00013234773,0.00004475874,0.00007059017,0.000009282322,0.00001758589],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000058965146,0.00007406227,0.0001819251,0.00006757886,0.000010836711,0.0000011786886,0.000022646662,0.00007924238,0.000004713918],"category_scores_gemma":[0.000011433521,0.000048997037,0.000021452497,0.000041189713,0.00012051731,0.000017176591,0.0000014617995,0.000051832743,1.8620214e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014140692,0.00047643966,0.90171105,0.000069887916,0.00010066973,0.000008601349,0.0014997433,1.8331625e-7,0.08960153,0.00013444664,0.000002073257,0.004981329],"study_design_scores_gemma":[0.028733129,0.0015595453,0.9506245,0.000068929585,0.00038088497,0.000067093904,0.00012068575,0.0000040971177,0.018337011,0.000029399629,0.000030315907,0.000044370412],"about_ca_topic_score_codex":0.00063633546,"about_ca_topic_score_gemma":0.001056443,"teacher_disagreement_score":0.07126452,"about_ca_system_score_codex":0.000011683176,"about_ca_system_score_gemma":0.000028646704,"threshold_uncertainty_score":0.19980413},"labels":[],"label_agreement":null},{"id":"W2150604072","doi":"10.1002/ajh.23728","title":"Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24‐month follow‐up","year":2014,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":117,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"National Cancer Institute; Ariad Pharmaceuticals; Teva Pharmaceutical Industries; Pfizer; Bristol-Myers Squibb","keywords":"Bosutinib; Medicine; Internal medicine; Imatinib; Dasatinib; Nilotinib; Nausea; Adverse effect; Gastroenterology; Myeloid leukemia; Oncology; Rash; Tyrosine-kinase inhibitor; Cancer","score_opus":0.010508573516696769,"score_gpt":0.2926125195130662,"score_spread":0.28210394599636945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150604072","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98874474,0.0076712603,0.00047973622,0.0015658502,0.00039474078,0.00050387724,0.000009873636,0.00003184207,0.0005981077],"genre_scores_gemma":[0.9941012,0.0012711374,0.0029358834,0.0005138184,0.00038657078,0.00003864191,0.000010108422,0.000069290494,0.0006733194],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963194,0.0003326331,0.001559387,0.0005358709,0.00043001783,0.0008226843],"domain_scores_gemma":[0.99691474,0.0007503263,0.0011516603,0.00060577824,0.0001613155,0.00041619458],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00063420384,0.00047217414,0.0020068611,0.00038474865,0.00008580281,0.000021507993,0.0002787989,0.0001625356,0.00033874912],"category_scores_gemma":[0.00052713364,0.000361619,0.00021193399,0.0005368192,0.0008703522,0.00017776623,0.00008903295,0.0008053468,0.000033682223],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18792024,0.0029934228,0.055880774,0.0036773062,0.0031947247,0.015427278,0.010398862,0.00023347118,0.017889246,0.0014489847,0.013667528,0.68726814],"study_design_scores_gemma":[0.5152993,0.06958779,0.11118466,0.014887832,0.0025557159,0.047402874,0.0028350656,0.0058385762,0.015098103,0.0006743896,0.21125987,0.0033758332],"about_ca_topic_score_codex":0.0000670819,"about_ca_topic_score_gemma":0.00063168,"teacher_disagreement_score":0.6838923,"about_ca_system_score_codex":0.0038839302,"about_ca_system_score_gemma":0.0031229255,"threshold_uncertainty_score":0.99994},"labels":[],"label_agreement":null},{"id":"W2151701983","doi":"10.1158/1535-7163.mct-09-0962","title":"SKI-606 (Bosutinib) Blocks Prostate Cancer Invasion, Growth, and Metastasis <i>In vitro</i> and <i>In vivo</i> through Regulation of Genes Involved in Cancer Growth and Skeletal Metastasis","year":2010,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Canadian Institutes of Health Research","keywords":"Bosutinib; Cancer; Metastasis; Cancer research; Prostate cancer; Matrigel; Bone metastasis; Cancer cell; Medicine; Biology; Pathology; Internal medicine; Angiogenesis","score_opus":0.020053318019657988,"score_gpt":0.28311392525580115,"score_spread":0.26306060723614316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151701983","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9548047,0.041975986,0.000026714559,0.0016640495,0.00014311551,0.0010977968,0.00019000935,0.000022188919,0.00007542975],"genre_scores_gemma":[0.96421725,0.03218697,0.0018271239,0.0011874748,0.000049233393,0.00039707072,0.000026927373,0.00007784969,0.000030078823],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975034,0.00014438013,0.00067025755,0.00073768175,0.0004201403,0.0005241115],"domain_scores_gemma":[0.99902964,0.00008842342,0.0002623673,0.00036100004,0.00012356053,0.00013498619],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00026661315,0.00046080456,0.0008462255,0.0002825145,0.00005783378,0.000035331144,0.0001118171,0.0002356497,0.000046165893],"category_scores_gemma":[0.000027009852,0.00041842856,0.000083579165,0.00065810466,0.00034785527,0.00020220682,0.000113022405,0.00045700622,1.7380052e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060805766,0.00019228652,0.15603872,0.00045628834,0.00037352197,0.00005876426,0.0014939873,0.000042057443,0.8219601,0.000087142405,0.000009346357,0.018679725],"study_design_scores_gemma":[0.009359869,0.00014065391,0.030478928,0.0003556073,0.0007262586,0.000027005493,0.00020290246,0.00052942935,0.9560104,0.0006738735,0.0010678103,0.00042724193],"about_ca_topic_score_codex":0.012864472,"about_ca_topic_score_gemma":0.010318725,"teacher_disagreement_score":0.13405031,"about_ca_system_score_codex":0.00029568496,"about_ca_system_score_gemma":0.00050087756,"threshold_uncertainty_score":0.9998267},"labels":[],"label_agreement":null},{"id":"W2151724015","doi":"10.1016/j.cell.2011.08.046","title":"Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis","year":2011,"lang":"en","type":"article","venue":"Cell","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":152,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"Basic Energy Sciences; Canadian Institutes of Health Research; National Cancer Institute; National Institutes of Health; Austrian Science Fund; National Center for Research Resources; National Institute of General Medical Sciences; Österreichischen Akademie der Wissenschaften; University of Chicago; European Molecular Biology Organization; U.S. Department of Energy","keywords":"Biology; Interface (matter); Cell biology; ABL; Cancer research; Kinase; Tyrosine kinase; Signal transduction; Genetics; Computational biology; Biochemistry","score_opus":0.02668374775510418,"score_gpt":0.24977937413982373,"score_spread":0.22309562638471955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151724015","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96867836,0.0021269917,0.00007448506,0.00017042193,0.00016310705,0.000400313,0.0000026685175,0.000052861054,0.028330782],"genre_scores_gemma":[0.99421746,0.00011526924,0.0008040576,0.00026128662,0.00008775017,0.00003082633,0.000009008471,0.00003474844,0.0044396217],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988899,0.000057773846,0.00026470967,0.0002871466,0.00016026806,0.00034015515],"domain_scores_gemma":[0.99932885,0.00006295391,0.00007317259,0.00040341483,0.00003471579,0.00009686431],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022537376,0.00017628654,0.00021829852,0.0000727511,0.000054957723,0.0000087211465,0.0001479188,0.000086275104,0.00078124576],"category_scores_gemma":[0.000068202135,0.00012074543,0.00006804967,0.00020614223,0.00006438494,0.000055496315,0.00010541964,0.00022093693,0.00058335654],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015121903,0.0031932988,0.2495826,0.0010270725,0.00033561542,0.0021000642,0.040503673,0.0002624761,0.6280935,0.0001795474,0.04008104,0.033128947],"study_design_scores_gemma":[0.004848591,0.00024582827,0.016560277,0.00019846429,0.000116089046,0.00004508209,0.0012531622,0.0009382892,0.96530056,0.00006890079,0.010168117,0.00025661505],"about_ca_topic_score_codex":0.0005967612,"about_ca_topic_score_gemma":0.00004407002,"teacher_disagreement_score":0.3372071,"about_ca_system_score_codex":0.00061991386,"about_ca_system_score_gemma":0.00020639124,"threshold_uncertainty_score":0.8554093},"labels":[],"label_agreement":null},{"id":"W2152713204","doi":"10.1158/0008-5472.can-06-1199","title":"<i>In vitro</i> and <i>In vivo</i> Activity of SKI-606, a Novel Src-Abl Inhibitor, against Imatinib-Resistant Bcr-Abl+ Neoplastic Cells","year":2006,"lang":"en","type":"article","venue":"Cancer Research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":371,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Imatinib; Chronic myelogenous leukemia; ABL; Cancer research; Imatinib mesylate; In vivo; Leukemia; Biology; breakpoint cluster region; Pharmacology; Receptor; Immunology; Tyrosine kinase; Genetics","score_opus":0.02715129866584341,"score_gpt":0.33191717612750676,"score_spread":0.30476587746166334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152713204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99245864,0.0013944455,0.000016273334,0.00055679237,0.00015503442,0.0010753793,0.00022329437,0.000023027647,0.004097114],"genre_scores_gemma":[0.9963371,0.0004123765,0.00035818384,0.00010705501,0.00024344532,0.00024736286,0.000013113379,0.000058296275,0.002223073],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99670047,0.00016243377,0.00052276294,0.0006714004,0.0009914949,0.00095145445],"domain_scores_gemma":[0.99832946,0.0006167807,0.00012104048,0.00052394706,0.00018912414,0.00021963444],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00080344774,0.00028820598,0.0006810852,0.0005020916,0.000082568695,0.0000384256,0.00017529452,0.00018688677,0.00014240363],"category_scores_gemma":[0.00014397164,0.00026551858,0.00008533669,0.0009940566,0.0003711502,0.00017608429,0.00018308153,0.00077241386,0.000017917213],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002560541,0.00081011665,0.0018452841,0.0006495215,0.000034521174,0.00024202261,0.00018305516,0.00012264958,0.9893593,0.000027158516,0.0030588862,0.0011069303],"study_design_scores_gemma":[0.010387181,0.00024179672,0.0050624595,0.0007959876,0.00002847448,0.000012741739,0.00008274164,0.00074449804,0.97777104,0.000051325504,0.004600184,0.00022158811],"about_ca_topic_score_codex":0.00994586,"about_ca_topic_score_gemma":0.0023801406,"teacher_disagreement_score":0.011588291,"about_ca_system_score_codex":0.0025573403,"about_ca_system_score_gemma":0.0015700947,"threshold_uncertainty_score":0.9999797},"labels":[],"label_agreement":null},{"id":"W2153132143","doi":"10.1002/jcph.526","title":"Evaluation of the effect of food and gastric pH on the single‐dose pharmacokinetics of cabozantinib in healthy adult subjects","year":2015,"lang":"en","type":"article","venue":"The Journal of Clinical Pharmacology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Celerion (Canada)","funders":"Exelixis","keywords":"Cabozantinib; Pharmacokinetics; Esomeprazole; Bioavailability; Tyrosine-kinase inhibitor; Medicine; Pharmacology; Medullary thyroid cancer; Gastroenterology; Concomitant; Drug interaction; Internal medicine; Drug; Cancer; Thyroid cancer","score_opus":0.12958508742111535,"score_gpt":0.44994349247232857,"score_spread":0.3203584050512132,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2153132143","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927823,0.0013056459,0.0000029066666,0.0036995185,0.00095624034,0.0009373694,0.000006363934,0.0000020622622,0.00030758357],"genre_scores_gemma":[0.9981553,0.0006596905,0.00002180136,0.0008031139,0.0003342797,0.0000051362595,5.205317e-7,0.000013321198,0.0000068644745],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9926406,0.004597454,0.0015228837,0.00011295263,0.0009303235,0.0001957864],"domain_scores_gemma":[0.9911876,0.0058616903,0.001787333,0.00023300195,0.00079619803,0.00013422815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013254119,0.00014628851,0.0007922614,0.00010782339,0.00002381279,0.0000014328974,0.00027452526,0.00010479026,0.000049548267],"category_scores_gemma":[0.0048287525,0.000063993924,0.00018248019,0.00032020695,0.00043335633,0.000030641273,0.00007916867,0.0007574206,0.0000012175868],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20509219,0.010684793,0.2760863,0.0012001282,0.0061124195,0.000075083524,0.004697,0.007036682,0.2835727,0.00010064611,0.021989629,0.18335244],"study_design_scores_gemma":[0.19954167,0.09735869,0.19928692,0.0009034323,0.01236779,0.000586804,0.00038071748,0.0073851733,0.48104262,0.00055747695,0.00039039797,0.00019830235],"about_ca_topic_score_codex":0.00002214836,"about_ca_topic_score_gemma":0.000011571219,"teacher_disagreement_score":0.19746992,"about_ca_system_score_codex":0.00018730522,"about_ca_system_score_gemma":0.0010543743,"threshold_uncertainty_score":0.57808167},"labels":[],"label_agreement":null},{"id":"W2153869156","doi":"10.1002/cbic.201300253","title":"Allosteric Lariat Peptide Inhibitors of Abl Kinase","year":2013,"lang":"en","type":"article","venue":"ChemBioChem","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Allosteric regulation; Kinase; ABL; Biochemistry; Enzyme; Chemistry; Allosteric enzyme; Proto-oncogene tyrosine-protein kinase Src; Peptide; Protein kinase A; Tyrosine kinase; Receptor","score_opus":0.011417130815525426,"score_gpt":0.23851850135210564,"score_spread":0.22710137053658022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2153869156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9808773,0.00047926774,0.0000037837717,0.00052879844,0.00011648438,0.00043841466,0.0000041216235,0.000061823324,0.017490013],"genre_scores_gemma":[0.9914304,0.00003118487,0.001170942,0.00025849673,0.00017146615,0.000053786905,0.00005581026,0.000032409054,0.0067955223],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99892455,0.000010783092,0.0002943896,0.00026610342,0.00023165549,0.00027251142],"domain_scores_gemma":[0.99907774,0.000034466844,0.000109392575,0.00048748267,0.00011022804,0.00018070028],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000061141465,0.00018199168,0.00032354952,0.00006262914,0.000023400224,0.000010224182,0.00009456132,0.00012539158,0.0012145337],"category_scores_gemma":[0.00009439079,0.00015623074,0.00012990505,0.00017594207,0.00008222919,0.00007360444,0.0000822795,0.00012903639,0.0005905604],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000526697,0.00040169558,0.011382687,0.00032770503,0.00017983046,0.000041380856,0.00036796174,6.1304905e-7,0.95034575,0.000033160963,0.031386275,0.0054802466],"study_design_scores_gemma":[0.0025799992,0.00015175388,0.012381912,0.00014494373,0.000088158784,0.000040899842,0.000118732816,0.000048698086,0.981345,0.000041829593,0.002927826,0.00013023439],"about_ca_topic_score_codex":0.0002475149,"about_ca_topic_score_gemma":0.0000022774038,"teacher_disagreement_score":0.030999238,"about_ca_system_score_codex":0.00033438334,"about_ca_system_score_gemma":0.00016564279,"threshold_uncertainty_score":0.9996985},"labels":[],"label_agreement":null},{"id":"W2154297950","doi":"10.1158/1078-0432.ccr-08-3291","title":"Abnormalities in Glucose Uptake and Metabolism in Imatinib-Resistant Human BCR-ABL–Positive Cells","year":2009,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":120,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute; Novartis Pharma","keywords":"Imatinib; Oxidative phosphorylation; Glycolysis; K562 cells; Citric acid cycle; Glucose uptake; Biology; Imatinib mesylate; Biochemistry; Chemistry; Metabolism; Internal medicine; Endocrinology; Cancer research; Cell; Myeloid leukemia; Medicine; Insulin","score_opus":0.1295846495074042,"score_gpt":0.4863216507226815,"score_spread":0.3567370012152773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154297950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845013,0.0069637066,5.9489844e-7,0.0019774723,0.00009487621,0.0009160765,0.000043221706,0.000024850795,0.0054778764],"genre_scores_gemma":[0.99326646,0.0037280153,0.00022967134,0.00052887807,0.0002976016,0.0001174108,0.000021662163,0.000025164367,0.0017851117],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99621433,0.00059397856,0.0009873105,0.0006347727,0.00074716826,0.0008224134],"domain_scores_gemma":[0.9980457,0.00086316984,0.00008483353,0.00046872348,0.00019018499,0.00034738003],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00325445,0.00021154214,0.00075650844,0.0003597665,0.000107191074,0.000048798353,0.0001955592,0.00022734984,0.0004074332],"category_scores_gemma":[0.0005152705,0.00017956569,0.000108612396,0.00056830776,0.00047192027,0.00013199127,0.00013009126,0.001390499,0.000040993775],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023237085,0.011902682,0.26719406,0.0015429076,0.0008741133,0.010344246,0.015191514,0.00006458723,0.11414656,0.016788302,0.016819065,0.5218949],"study_design_scores_gemma":[0.011797212,0.0009758359,0.9715288,0.0006292156,0.000042079173,0.000008442533,0.0005299744,0.00009499938,0.0075564496,0.0016025505,0.0050314344,0.00020298579],"about_ca_topic_score_codex":0.004497627,"about_ca_topic_score_gemma":0.0024357263,"teacher_disagreement_score":0.70433474,"about_ca_system_score_codex":0.0010216602,"about_ca_system_score_gemma":0.0009057825,"threshold_uncertainty_score":0.7322476},"labels":[],"label_agreement":null},{"id":"W2157501125","doi":"10.1182/blood-2011-10-385658","title":"Rac2-MRC-cIII–generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":187,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; Medical Research Council; Imperial Experimental Cancer Medicine Centre; University of Pennsylvania; China Scholarship Council; Cancer Institute, University of Pittsburgh; Cancer Research UK; Peking University; National Institutes of Health; Warszawski Uniwersytet Medyczny; National Cancer Institute; Uniwersytet Warszawski; Cancer Research Institute; Temple University","keywords":"Genome instability; Myeloid leukemia; Biology; Cancer research; Stem cell; Progenitor cell; Mitochondrial ROS; Haematopoiesis; Mitochondrion; Molecular biology; DNA damage; Cell biology; Genetics","score_opus":0.020180924643032,"score_gpt":0.2512487543760032,"score_spread":0.23106782973297119,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157501125","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923305,0.00498409,0.0000032622559,0.00003008668,0.00022173113,0.001779487,0.000049462364,0.000119143486,0.00048224427],"genre_scores_gemma":[0.99796826,0.00035738733,0.00033152528,0.000070690956,0.00047892347,0.00018536282,0.000052050953,0.00007416528,0.0004816606],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975671,0.00015901354,0.0005372715,0.0005914255,0.0002968929,0.00084829977],"domain_scores_gemma":[0.99864924,0.00009501921,0.00015569694,0.00059689605,0.000077789904,0.00042537693],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003675204,0.0004103158,0.0005878372,0.00016427125,0.000093517076,0.000027104314,0.00011557756,0.00026842565,0.00008983522],"category_scores_gemma":[0.000033022137,0.00037061799,0.000094620606,0.0003244573,0.00015562656,0.00023017665,0.00014287887,0.00042196887,0.00011870089],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026047725,0.0015214698,0.5374551,0.00048836553,0.00060222857,0.00019256346,0.002087902,0.000028830087,0.45157048,0.000033745233,0.00008243782,0.0056764153],"study_design_scores_gemma":[0.018214494,0.00046440435,0.36043984,0.0001719473,0.0006695533,0.0002386659,0.00022946336,0.00017746005,0.61774856,0.0000038457197,0.0012082288,0.00043353514],"about_ca_topic_score_codex":0.00038876632,"about_ca_topic_score_gemma":0.00021184172,"teacher_disagreement_score":0.17701527,"about_ca_system_score_codex":0.0054737525,"about_ca_system_score_gemma":0.0020596955,"threshold_uncertainty_score":0.9998746},"labels":[],"label_agreement":null},{"id":"W2159853882","doi":"10.2353/jmoldx.2007.060134","title":"Inter-Laboratory Comparison of Chronic Myeloid Leukemia Minimal Residual Disease Monitoring","year":2007,"lang":"en","type":"article","venue":"Journal of Molecular Diagnostics","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Association for Molecular Pathology","keywords":"Myeloid leukemia; Real-time polymerase chain reaction; Minimal residual disease; Medicine; Reverse transcription polymerase chain reaction; Reverse transcriptase; Serial dilution; Polymerase chain reaction; Leukemia; Immunology; Biology; Messenger RNA; Pathology; Genetics","score_opus":0.016298827060329577,"score_gpt":0.31325245066068896,"score_spread":0.2969536236003594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159853882","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97686374,0.0187001,0.003156258,0.0001753054,0.00069569517,0.00022399872,0.000018819115,0.000016474376,0.00014957991],"genre_scores_gemma":[0.99394387,0.0008952252,0.0040312833,0.00006563089,0.0009693981,0.000002404939,0.0000096802205,0.00005345813,0.0000290426],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972352,0.00007222348,0.001194472,0.00020376193,0.0008786208,0.00041573192],"domain_scores_gemma":[0.99701947,0.00055466965,0.00082565955,0.0004151845,0.0006099173,0.0005751066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056258653,0.0002662395,0.0006891364,0.0003177393,0.00004462637,0.000017280354,0.0002343696,0.0001475687,0.000036841346],"category_scores_gemma":[0.0019731673,0.0002435815,0.00025215864,0.00028837618,0.00014361419,0.000102426275,0.00008753618,0.0006034088,0.0000124916],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002292461,0.0020261863,0.7675305,0.00076958846,0.0012279368,0.01442589,0.0007756399,0.0010158977,0.17728524,0.00011587742,0.0056382124,0.02689656],"study_design_scores_gemma":[0.00820271,0.0031753595,0.2951017,0.0026370524,0.001701902,0.00022438077,0.00047442678,0.00019356378,0.6839249,0.00005333299,0.0039646844,0.00034596902],"about_ca_topic_score_codex":0.000010776017,"about_ca_topic_score_gemma":0.0000040299715,"teacher_disagreement_score":0.50663966,"about_ca_system_score_codex":0.002688161,"about_ca_system_score_gemma":0.0024392519,"threshold_uncertainty_score":0.9932965},"labels":[],"label_agreement":null},{"id":"W2159854606","doi":"10.1016/j.exphem.2014.07.037","title":"Oncogenic transcription factors, from hematopoietic stem cells to thymocyte reprogramming","year":2014,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Haematopoiesis; Biology; Progenitor cell; Stem cell; Cell biology; Reprogramming; Bone marrow; Hematopoietic stem cell; Leukemia; Transcription factor; Immunology; Cancer research; Cell; Genetics; Gene","score_opus":0.023569566390263846,"score_gpt":0.2874429135613065,"score_spread":0.26387334717104266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159854606","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935341,0.0030337619,0.0006451481,0.0001992128,0.00061552745,0.00076949364,0.000010069059,0.0002372857,0.0009554],"genre_scores_gemma":[0.99654156,0.000008034743,0.0020180186,0.00041084678,0.000118480835,0.00012984099,0.00007873298,0.00006158534,0.0006328758],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99794537,0.00009677394,0.0004644618,0.0007043384,0.00028527738,0.00050377846],"domain_scores_gemma":[0.99875164,0.00010207069,0.000094801384,0.000666,0.000026252046,0.00035922907],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00009100625,0.00033849184,0.0007026235,0.000106279185,0.00010031771,0.000020324587,0.0001501353,0.00020620965,0.00086951326],"category_scores_gemma":[0.000009127537,0.00030222526,0.00021132799,0.00014469674,0.00007778509,0.00007352164,0.000068293106,0.00017763594,0.0010618998],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043472476,0.00090622314,0.0058168103,0.00008229182,0.00024512078,0.00015430713,0.0061539398,0.0000028340337,0.97880465,0.0036973313,0.0010292011,0.002672547],"study_design_scores_gemma":[0.0030886035,0.0006883808,0.0003071924,0.00010358544,0.00008279318,0.00025133256,0.0018659551,0.000075540374,0.9857887,0.000046265777,0.0074584447,0.0002431824],"about_ca_topic_score_codex":0.0002878731,"about_ca_topic_score_gemma":0.000011872139,"teacher_disagreement_score":0.006984055,"about_ca_system_score_codex":0.00072759634,"about_ca_system_score_gemma":0.000075642194,"threshold_uncertainty_score":0.99994296},"labels":[],"label_agreement":null},{"id":"W2161794113","doi":"10.3109/10428194.2011.652108","title":"Long-term follow-up of patients with chronic myeloid leukemia in chronic phase developing sudden blast phase on imatinib therapy","year":2011,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Imatinib; Cumulative incidence; Internal medicine; Imatinib mesylate; Myeloid leukemia; Incidence (geometry); Oncology; Dasatinib; Tyrosine-kinase inhibitor; Nilotinib; Pediatrics; Transplantation; Cancer","score_opus":0.023020625815163804,"score_gpt":0.2731842722756763,"score_spread":0.25016364646051253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2161794113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99084747,0.002706527,0.00016164672,0.00003069617,0.0004873364,0.0030029411,0.0001694249,0.00031300454,0.0022809315],"genre_scores_gemma":[0.9936508,0.0021265186,0.0009171057,0.00047906136,0.0004061679,0.00046953378,0.00085546443,0.00037336536,0.00072198303],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99179965,0.00026151954,0.0021422992,0.0021335022,0.0015227767,0.0021402508],"domain_scores_gemma":[0.9953154,0.00034236026,0.0011345209,0.0019389188,0.0004163497,0.00085246016],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0005041737,0.001821299,0.0024272804,0.0010904795,0.00037618668,0.00009827647,0.00082006044,0.0008637375,0.0005694962],"category_scores_gemma":[0.00011455101,0.0015293488,0.00048459118,0.0014295485,0.0008432934,0.00071935065,0.00029703722,0.000463209,0.0001403173],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.037108786,0.0036692098,0.15947089,0.002115438,0.0023141424,0.002199744,0.0062339576,0.0000847394,0.009326064,0.0006232269,0.0006999016,0.7761539],"study_design_scores_gemma":[0.3696922,0.012126514,0.5399015,0.0035437911,0.0005675406,0.0004308356,0.0001919354,0.001945642,0.06800396,0.00008309959,0.0014903952,0.0020225903],"about_ca_topic_score_codex":0.0024472089,"about_ca_topic_score_gemma":0.00084162736,"teacher_disagreement_score":0.7741313,"about_ca_system_score_codex":0.08581747,"about_ca_system_score_gemma":0.029661715,"threshold_uncertainty_score":0.9994532},"labels":[],"label_agreement":null},{"id":"W2162340188","doi":"10.1158/1078-0432.ccr-09-0145","title":"Clinical Relevance of a Pharmacogenetic Approach Using Multiple Candidate Genes to Predict Response and Resistance to Imatinib Therapy in Chronic Myeloid Leukemia","year":2009,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":186,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Myeloid leukemia; Imatinib; Pharmacogenetics; Medicine; Clinical significance; Oncology; Gene; Bioinformatics; Immunology; Internal medicine; Biology; Genetics; Genotype","score_opus":0.1807922541795707,"score_gpt":0.5079772695143526,"score_spread":0.32718501533478195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162340188","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.982362,0.012635368,0.0001651431,0.0016370015,0.00013380409,0.0028000341,0.00006482929,0.000037691847,0.00016413697],"genre_scores_gemma":[0.9729668,0.015133887,0.009576217,0.00084685517,0.00056972477,0.0002583863,0.000009882847,0.000057857178,0.00058040343],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99296486,0.0019858908,0.0017408414,0.0012658281,0.0010511175,0.0009914507],"domain_scores_gemma":[0.9941334,0.0033659833,0.00019516284,0.0009960899,0.00042614352,0.000883203],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.009065558,0.00031597062,0.0011104095,0.00039633195,0.00012453254,0.000030318546,0.00044303,0.0002864939,0.00006634821],"category_scores_gemma":[0.0043269354,0.00027448358,0.0001841553,0.0012992217,0.0005025854,0.000086320826,0.0002248429,0.0011701384,0.000014909701],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.098993756,0.0011246625,0.3228037,0.00041969033,0.00026650482,0.00023695578,0.00074450107,0.0013455747,0.09314897,0.00000937251,0.0035847719,0.47732157],"study_design_scores_gemma":[0.03337395,0.008379229,0.9013364,0.0020116777,0.000093119925,0.000027697113,0.00012540877,0.01597733,0.014691279,0.00009825843,0.023313085,0.00057259493],"about_ca_topic_score_codex":0.0006046504,"about_ca_topic_score_gemma":0.00051505445,"teacher_disagreement_score":0.5785327,"about_ca_system_score_codex":0.0036762913,"about_ca_system_score_gemma":0.0063860537,"threshold_uncertainty_score":0.99997073},"labels":[],"label_agreement":null},{"id":"W2162367938","doi":"10.1111/j.1749-6632.2003.tb03226.x","title":"New Models to Investigate Mechanisms of Disease Genesis from Primitive <i>BCR‐ABL</i><sup>+</sup> Hematopoietic Cells","year":2003,"lang":"en","type":"article","venue":"Annals of the New York Academy of Sciences","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Autocrine signalling; Haematopoiesis; CD34; Biology; Progenitor cell; Myeloid leukemia; Stem cell; Immunology; Cancer research; Bone marrow; Myeloid; Leukemia; Cell biology; Cell culture; Genetics","score_opus":0.08277322032977018,"score_gpt":0.30422184395522506,"score_spread":0.22144862362545487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162367938","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9804563,0.0032370784,0.0014257369,0.012759055,0.0000834817,0.0008812607,0.00008281911,0.000027486967,0.0010468046],"genre_scores_gemma":[0.9760585,0.00030034612,0.01866815,0.0037102888,0.00005828778,0.0000092256205,0.0000014539494,0.00002117113,0.0011725771],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99708134,0.00013300114,0.00064968114,0.00054684683,0.0011357323,0.00045338675],"domain_scores_gemma":[0.9981503,0.00023696356,0.0004485462,0.00033712754,0.000073577045,0.00075348985],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005641852,0.00028121102,0.0006469844,0.00016523917,0.00011116023,0.000013439085,0.00081089255,0.00013814673,0.00013689544],"category_scores_gemma":[0.00021595933,0.00019278479,0.00028395583,0.00093643006,0.00054853014,0.0001984269,0.00016824785,0.00016853267,0.000018193425],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011493708,0.001026004,0.0039044379,0.00079070433,0.001220215,0.000010596233,0.018974483,0.1257313,0.6083978,0.09766795,0.13304172,0.008085454],"study_design_scores_gemma":[0.0008876762,0.00021994201,0.0009273247,0.000727316,0.00022509567,0.0000026769496,0.0004899362,0.00097356585,0.8749587,0.1199617,0.00046229977,0.00016379685],"about_ca_topic_score_codex":0.0011640883,"about_ca_topic_score_gemma":0.0000025312108,"teacher_disagreement_score":0.2665609,"about_ca_system_score_codex":0.0000581656,"about_ca_system_score_gemma":0.0014299535,"threshold_uncertainty_score":0.78615355},"labels":[],"label_agreement":null},{"id":"W2163615334","doi":"10.18632/oncotarget.1931","title":"The anti-apoptotic form of tyrosine kinase Lyn that is generated by proteolysis is degraded by the N-end rule pathway","year":2014,"lang":"en","type":"article","venue":"Oncotarget","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"Cure Brain Cancer Foundation","keywords":"LYN; Imatinib; Tyrosine kinase; Dasatinib; Cancer research; Apoptosis; Proteolysis; Tyrosine; Chemistry; Ubiquitin; Cell biology; Biology; Signal transduction; Biochemistry; Myeloid leukemia; Enzyme","score_opus":0.0136222741899958,"score_gpt":0.2430411807059642,"score_spread":0.2294189065159684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163615334","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854804,0.0037794258,0.00012491146,0.0077044046,0.00016201327,0.0010598445,0.0002644561,0.00006355103,0.0013609529],"genre_scores_gemma":[0.98589814,0.00047313835,0.00044405888,0.0018239412,0.00013361573,0.0001336785,0.00033563902,0.00006613679,0.010691632],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99780285,0.00012713704,0.0004406033,0.00043280143,0.00064662454,0.00054995867],"domain_scores_gemma":[0.9981594,0.0001867576,0.00029822573,0.0010467481,0.0001308641,0.00017797982],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045108283,0.00035644745,0.0005455436,0.00003956409,0.00033279098,0.00004939194,0.00033617252,0.00016234165,0.00056224223],"category_scores_gemma":[0.00012281041,0.00018850395,0.00022002298,0.0003499854,0.00026208383,0.0000923895,0.00008688456,0.00028328836,0.0001159239],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025649669,0.00084238517,0.037514873,0.00016368141,0.0009619833,0.000017113618,0.0016751161,0.0000030323736,0.402227,0.000119885895,0.53966564,0.016552769],"study_design_scores_gemma":[0.004308096,0.00039268658,0.0045045805,0.000085523076,0.0003476881,0.00002524987,0.00011579231,0.0015560967,0.8397155,0.00019518042,0.14851896,0.00023465801],"about_ca_topic_score_codex":0.0005774127,"about_ca_topic_score_gemma":0.000023569684,"teacher_disagreement_score":0.4374885,"about_ca_system_score_codex":0.0004370533,"about_ca_system_score_gemma":0.0002606567,"threshold_uncertainty_score":0.7686968},"labels":[],"label_agreement":null},{"id":"W2165746197","doi":"10.3324/haematol.2009.020636","title":"Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia","year":2010,"lang":"en","type":"article","venue":"Haematologica","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":116,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute","funders":"National Health and Medical Research Council; Medical Research Council; Fondation de France","keywords":"Myeloid leukemia; Imatinib mesylate; Imatinib; microRNA; Medicine; Leukemia; TaqMan; Cancer research; Oncology; Real-time polymerase chain reaction; Internal medicine; Biology; Gene; Genetics","score_opus":0.008674175181232518,"score_gpt":0.2498548977066989,"score_spread":0.24118072252546638,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165746197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951954,0.000069660586,0.000011613877,0.0009378324,0.00016682569,0.0014324593,0.000017126578,0.00015797341,0.0020111066],"genre_scores_gemma":[0.99143815,0.0000083014,0.0069442363,0.00053869374,0.00004730157,0.00015574902,0.000048320264,0.00005105479,0.0007681968],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977083,0.00010645016,0.00047759825,0.00062648195,0.00039978503,0.00068136706],"domain_scores_gemma":[0.99834985,0.00019532644,0.00014954766,0.00086294446,0.000117949996,0.0003244049],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003416444,0.00037127352,0.00071771466,0.0002644234,0.00009045773,0.000026387352,0.00024294999,0.00025388176,0.0007917587],"category_scores_gemma":[0.00042992097,0.00025786672,0.00008678312,0.00046425185,0.0001337478,0.00009188577,0.00013044722,0.0006155786,0.0008982752],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03095866,0.0013234337,0.8375561,0.00036725786,0.00029398006,0.0027984874,0.0013718508,0.000052072322,0.10350693,0.00032136403,0.0043701218,0.01707971],"study_design_scores_gemma":[0.0141538875,0.0021778303,0.95371497,0.0002992223,0.000072367206,0.00026974172,0.000027529666,0.00004901888,0.020884324,0.000049519243,0.007898018,0.00040354714],"about_ca_topic_score_codex":0.00010738225,"about_ca_topic_score_gemma":0.00026391196,"teacher_disagreement_score":0.11615886,"about_ca_system_score_codex":0.0015013445,"about_ca_system_score_gemma":0.000942663,"threshold_uncertainty_score":0.99998736},"labels":[],"label_agreement":null},{"id":"W2168871518","doi":"10.1158/1078-0432.ccr-10-1638","title":"The<i>IFNG</i>(IFN-γ) Genotype Predicts Cytogenetic and Molecular Response to Imatinib Therapy in Chronic Myeloid Leukemia","year":2010,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Imatinib; Myeloid leukemia; Genotype; Cancer research; Immunology; Medicine; Angiogenesis; Biology; Myeloid; Oncology; Genetics; Gene","score_opus":0.09263302505358723,"score_gpt":0.4697962569955494,"score_spread":0.37716323194196216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168871518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9828937,0.006654759,0.00000674565,0.0073549445,0.0003347483,0.002009202,0.00001575306,0.000046088997,0.00068405695],"genre_scores_gemma":[0.9880174,0.007810692,0.000372519,0.0008492237,0.0005932447,0.0006747558,0.0000068105314,0.00007451858,0.0016008723],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99533147,0.0008980686,0.00078803784,0.0008582493,0.001055936,0.0010682191],"domain_scores_gemma":[0.99464464,0.0029390785,0.00008229908,0.0012527012,0.0003505893,0.0007307183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0064407657,0.00026300657,0.00050563464,0.00022538625,0.00026094,0.000088215216,0.00049074,0.00034136354,0.0003266317],"category_scores_gemma":[0.0032701795,0.00018639496,0.0001262871,0.0007626212,0.0008687109,0.000052520732,0.00035475718,0.0022424322,0.00016128633],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028414533,0.00032322409,0.06344751,0.00011639115,0.0002990178,0.0006834977,0.00063338905,0.00006012676,0.44113904,0.00014550307,0.006641415,0.45809633],"study_design_scores_gemma":[0.02248304,0.0077411295,0.7211117,0.00042895574,0.000055029293,0.00007946932,0.000106228974,0.0010717091,0.03583499,0.00066744233,0.20994447,0.0004757927],"about_ca_topic_score_codex":0.0009184168,"about_ca_topic_score_gemma":0.002089754,"teacher_disagreement_score":0.65766424,"about_ca_system_score_codex":0.0023639963,"about_ca_system_score_gemma":0.008045397,"threshold_uncertainty_score":0.9975781},"labels":[],"label_agreement":null},{"id":"W2168891695","doi":"10.1177/0192623311419524","title":"A Multifaceted Evaluation of Imatinib-induced Cardiotoxicity in the Rat","year":2011,"lang":"en","type":"article","venue":"Toxicologic Pathology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Apotex (Canada)","funders":"","keywords":"Cardiotoxicity; Medicine; Internal medicine; Vacuolization; Endocrinology; Myocyte; Myofibril; Apoptosis; Necrosis; Toxicity; Lactate dehydrogenase; Heart failure; Endoplasmic reticulum; Cardiac myocyte; Pharmacology; Biology; Cell biology; Biochemistry","score_opus":0.18235060530840486,"score_gpt":0.35865073194195274,"score_spread":0.17630012663354788,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168891695","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98769903,0.00017859098,0.000018662928,0.00011191148,0.00015088965,0.0014446375,0.000004473946,0.000033452478,0.010358375],"genre_scores_gemma":[0.99803764,0.000016514658,0.0012571127,0.00034120475,0.00002779694,0.0002689733,0.000014221374,0.000009054257,0.000027500126],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99776626,0.0009573087,0.0003722636,0.00028008854,0.00034852425,0.00027552914],"domain_scores_gemma":[0.9990087,0.00015465298,0.00016446554,0.00051093934,0.00012087848,0.000040340583],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021643783,0.00015125221,0.00043173155,0.00011876859,0.00003255921,0.0000018534009,0.00016299653,0.00023465042,0.00050391234],"category_scores_gemma":[0.0008150442,0.00009564773,0.00009700879,0.00021192199,0.00012873208,0.000033770943,0.000046618356,0.00025064187,0.00006111772],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00075084757,0.0031818545,0.18876731,0.00011705759,0.00017821856,0.0012575405,0.022255946,0.000042097094,0.7427064,0.00042339307,0.00027209055,0.040047195],"study_design_scores_gemma":[0.008289905,0.0017485144,0.8884652,0.000032485055,0.00034719936,0.0006333222,0.0008011601,0.001423701,0.09752607,0.00058313954,0.000020744274,0.00012852486],"about_ca_topic_score_codex":0.0000652022,"about_ca_topic_score_gemma":0.0000530747,"teacher_disagreement_score":0.6996979,"about_ca_system_score_codex":0.00043429222,"about_ca_system_score_gemma":0.00027401396,"threshold_uncertainty_score":0.55174863},"labels":[],"label_agreement":null},{"id":"W2169154753","doi":"10.1016/j.bbmt.2014.12.010","title":"Comparison of Outcomes of Allogeneic Transplantation for Chronic Myeloid Leukemia with Cyclophosphamide in Combination with Intravenous Busulfan, Oral Busulfan, or Total Body Irradiation","year":2014,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; Office of Naval Research; National Heart, Lung, and Blood Institute; Seattle Genetics; CellGenix; Genentech; Health Resources and Services Administration; Swedish Orphan Biovitrum; Miltenyi Biotec; Kiadis Pharma; Therakos; Sigma-Tau Pharmaceuticals; Medical College of Wisconsin; Blue Cross and Blue Shield Association; Teva Pharmaceutical Industries; WellPoint; Celgene; Otsuka America Pharmaceutical; Amgen; Ariad Pharmaceuticals; GlaxoSmithKline; Terumo BCT; Leukemia and Lymphoma Society; Be The Match Foundation; U.S. Department of Health and Human Services; National Marrow Donor Program","keywords":"Busulfan; Medicine; Myeloid leukemia; Total body irradiation; Cyclophosphamide; Transplantation; Internal medicine; Oncology; Chemotherapy","score_opus":0.011415827986296265,"score_gpt":0.27157074419431315,"score_spread":0.2601549162080169,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169154753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99223435,0.00025319925,0.006182359,0.000069795286,0.000047135083,0.0010251685,0.00012417536,0.00001967088,0.000044143635],"genre_scores_gemma":[0.99477744,0.00053006964,0.0032358216,0.0000149707985,0.000017637072,0.000074933116,0.00130406,0.00002272282,0.000022362237],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985998,0.0001128132,0.0006313685,0.0002770647,0.00016064124,0.0002182733],"domain_scores_gemma":[0.9989586,0.00029277967,0.00041769465,0.0001441593,0.00013204044,0.00005471571],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026680293,0.0002270324,0.00075299083,0.00021406694,0.000046535682,0.0000030230703,0.000059065034,0.00019197099,0.000008742628],"category_scores_gemma":[0.000022864202,0.00016405228,0.000053105035,0.00016801392,0.00019566715,0.00009554352,0.000002908839,0.00012266838,2.7080335e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0089713065,0.0007172673,0.60883206,0.0030793007,0.00048713904,0.00000796957,0.0022970764,0.0006095488,0.36132175,0.00046609828,0.0000015055297,0.013208981],"study_design_scores_gemma":[0.02152892,0.009653775,0.76507866,0.00034674257,0.0012480803,0.000115619674,0.00012619754,0.000604014,0.201071,0.00006721654,0.00000497579,0.00015482193],"about_ca_topic_score_codex":0.0004827689,"about_ca_topic_score_gemma":0.0013950346,"teacher_disagreement_score":0.16025074,"about_ca_system_score_codex":0.00012350276,"about_ca_system_score_gemma":0.00034188599,"threshold_uncertainty_score":0.6689858},"labels":[],"label_agreement":null},{"id":"W2169508471","doi":"10.1200/jco.2002.06.077","title":"Long-Term Medical Outcomes and Quality-of-Life Assessment of Patients With Chronic Myeloid Leukemia Followed at Least 10 Years After Allogeneic Bone Marrow Transplantation","year":2002,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":148,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Quality of life (healthcare); Population; Myeloid leukemia; Transplantation; Internal medicine; Bone marrow; Leukemia; Surgery","score_opus":0.06492735229229302,"score_gpt":0.40848794997173904,"score_spread":0.343560597679446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169508471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971133,0.0009924077,0.00006530927,0.0008575366,0.00036664927,0.00032902215,0.000021750328,0.000006686886,0.00024735028],"genre_scores_gemma":[0.9954217,0.002171516,0.001220511,0.0004886701,0.00020407718,0.000009041594,0.00002630661,0.000027077176,0.0004310685],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99460316,0.00051166094,0.003108356,0.00027475492,0.0012190001,0.0002830894],"domain_scores_gemma":[0.99501777,0.0015877457,0.0022503515,0.00026331792,0.00029367744,0.0005871609],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017303654,0.00022640449,0.0021789612,0.00015399311,0.000025317086,0.0000040032414,0.00014906665,0.0004968145,0.002368749],"category_scores_gemma":[0.00093026867,0.00015464473,0.00043595265,0.0001122201,0.00043948548,0.00010808307,0.000057003323,0.00064549927,0.000010548572],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058128773,0.0015270069,0.96314913,0.00029483897,0.001021642,0.0006035955,0.00009181684,0.0000075511166,0.000083186475,0.0000059612516,0.00015025586,0.02725215],"study_design_scores_gemma":[0.042975575,0.008572742,0.9466373,0.00029993212,0.00078596803,0.00011658009,0.000007800917,0.00005050783,0.00002306355,0.0000028615968,0.00040481915,0.00012285884],"about_ca_topic_score_codex":0.000027549922,"about_ca_topic_score_gemma":0.00046591513,"teacher_disagreement_score":0.0371627,"about_ca_system_score_codex":0.0014208455,"about_ca_system_score_gemma":0.0028206457,"threshold_uncertainty_score":0.9985432},"labels":[],"label_agreement":null},{"id":"W2170126309","doi":"10.1111/ejh.12597","title":"Gender and <i><scp>BCR</scp>‐<scp>ABL</scp></i> transcript type are correlated with molecular response to imatinib treatment in patients with chronic myeloid leukemia","year":2015,"lang":"en","type":"article","venue":"European Journal Of Haematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Population Health Research Institute; London Health Sciences Centre; Juravinski Hospital; McMaster University; Hamilton Health Sciences; Western University; Hamilton Regional Laboratory Medicine Program","funders":"","keywords":"Imatinib; Myeloid leukemia; Medicine; Internal medicine; Regimen; Oncology; Gastroenterology","score_opus":0.017623420847440594,"score_gpt":0.23667557265969524,"score_spread":0.21905215181225465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2170126309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939227,0.002479525,0.00025710656,0.0001689781,0.00021143559,0.00082609174,0.000013011109,0.000042481148,0.0020786666],"genre_scores_gemma":[0.99655056,0.00007910151,0.0021417106,0.0004376658,0.00005630558,0.000009118205,0.00002512168,0.00014490505,0.00055550446],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99636704,0.0010189547,0.0008667148,0.00049129524,0.0005736871,0.0006822999],"domain_scores_gemma":[0.9972732,0.00031676202,0.000626806,0.00050036673,0.0005021207,0.0007807321],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00073060644,0.0005279195,0.0011887535,0.00049754354,0.00006432215,0.000034906283,0.00022413828,0.00011516987,0.000012227775],"category_scores_gemma":[0.00065281213,0.00035956962,0.00009706216,0.00053853565,0.0001834661,0.00015733698,0.000057146357,0.00053821364,0.00010821084],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027574336,0.003260381,0.67861325,0.00062377297,0.004610364,0.21720576,0.030287566,0.0057916697,0.0091903545,0.000098362194,0.019299086,0.0034451059],"study_design_scores_gemma":[0.1572796,0.06709495,0.6680668,0.002636728,0.0021612435,0.0452412,0.004524912,0.00028450158,0.009095421,0.000032900527,0.043105718,0.00047603922],"about_ca_topic_score_codex":0.000019489671,"about_ca_topic_score_gemma":0.000023484516,"teacher_disagreement_score":0.17196457,"about_ca_system_score_codex":0.0020531989,"about_ca_system_score_gemma":0.0018854719,"threshold_uncertainty_score":0.9998856},"labels":[],"label_agreement":null},{"id":"W2170797477","doi":"10.1016/s1097-2765(00)00138-6","title":"Cytoskeletal Protein PSTPIP1 Directs the PEST-Type Protein Tyrosine Phosphatase to the c-Abl Kinase to Mediate Abl Dephosphorylation","year":2000,"lang":"en","type":"article","venue":"Molecular Cell","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":124,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Cancer Institute","keywords":"Biology; Protein tyrosine phosphatase; Dephosphorylation; ABL; Phosphorylation; Phosphatase; Cell biology; Tyrosine phosphorylation; PEST analysis; Tyrosine kinase; Tyrosine; Biochemistry; Signal transduction; Botany","score_opus":0.006673850473986136,"score_gpt":0.23052373433268936,"score_spread":0.22384988385870322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2170797477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97908807,0.0027190552,0.00028767902,0.0062815933,0.00012417167,0.006410943,0.00003712488,0.00013401532,0.0049173725],"genre_scores_gemma":[0.9816072,0.00003220375,0.0020667135,0.002803402,0.0001786704,0.000824893,0.0001788907,0.00010353503,0.01220448],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974128,0.00017331787,0.00038431748,0.00063854,0.0007380936,0.0006529528],"domain_scores_gemma":[0.9980783,0.00004041671,0.000091555,0.0012529385,0.00012396809,0.00041280963],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00037973488,0.00041487726,0.000344413,0.00007843669,0.00024096845,0.00007178096,0.00037241893,0.00013135088,0.001094907],"category_scores_gemma":[0.00020692969,0.00026071796,0.00015330393,0.0008129811,0.000069295864,0.00006779374,0.00008975092,0.0003500645,0.00275758],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021558881,0.0011020777,0.00036999967,0.00026762483,0.00022609434,0.0022526076,0.0018170814,0.0017924878,0.84754354,0.00025019166,0.011027283,0.13119514],"study_design_scores_gemma":[0.002478923,0.0008432724,0.0011952455,0.00017500887,0.00017951783,0.000025540701,0.00003753046,0.00033167007,0.85255605,0.000047275742,0.14179249,0.00033744855],"about_ca_topic_score_codex":0.00065692025,"about_ca_topic_score_gemma":0.00008936169,"teacher_disagreement_score":0.13085769,"about_ca_system_score_codex":0.0005489306,"about_ca_system_score_gemma":0.00037493792,"threshold_uncertainty_score":0.9999845},"labels":[],"label_agreement":null},{"id":"W2171034095","doi":"10.1182/blood-2003-03-0860","title":"Inhibition of acute lymphoblastic and myeloid leukemias by a novel kinase inhibitor","year":2003,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Cancer Institute","keywords":"Tyrosine kinase; Myeloid leukemia; Cancer research; Tyrosine-kinase inhibitor; Leukemia; Kinase; Cell growth; Pharmacology; CD135; Myeloid; Medicine; Biology; Cancer; Immunology; Internal medicine; Cell biology; Receptor; Biochemistry","score_opus":0.00928502401975881,"score_gpt":0.2302247136542342,"score_spread":0.22093968963447538,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171034095","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962096,0.0008010256,0.00012663854,0.00005536915,0.000055103348,0.00034943875,0.00009159973,0.00004668086,0.0022645413],"genre_scores_gemma":[0.9972443,0.0001452355,0.0016756034,0.00014279103,0.000054729255,0.000029880724,0.00006952294,0.0000328263,0.00060513907],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99885947,0.000023150997,0.00029862736,0.00031124274,0.00025125485,0.00025628402],"domain_scores_gemma":[0.99932283,0.00005874546,0.000110058754,0.00026810088,0.00006379748,0.00017647404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000093510214,0.00020019767,0.0003306322,0.00008917745,0.000044721786,0.0000097049615,0.00002951433,0.0001271403,0.00007214538],"category_scores_gemma":[0.00011201637,0.00018025479,0.000069282505,0.00018290494,0.00010157726,0.00007413224,0.000029140345,0.00010631179,0.000021305317],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013163916,0.0018414975,0.005803878,0.00020643836,0.0005018201,0.00015643089,0.00027597154,9.376243e-7,0.9889049,0.00030459408,0.0012269462,0.0006449348],"study_design_scores_gemma":[0.03430386,0.00082409626,0.0029692969,0.00033865977,0.0014163954,0.0009370653,0.00007821592,0.0000378182,0.95717824,0.00006616677,0.0016226204,0.00022756678],"about_ca_topic_score_codex":0.00004852139,"about_ca_topic_score_gemma":0.00000339404,"teacher_disagreement_score":0.03417222,"about_ca_system_score_codex":0.00029135685,"about_ca_system_score_gemma":0.00038740452,"threshold_uncertainty_score":0.7350577},"labels":[],"label_agreement":null},{"id":"W2171358244","doi":"10.1093/jnci/djt006","title":"Targeting Primitive Chronic Myeloid Leukemia Cells by Effective Inhibition of a New AHI-1–BCR-ABL–JAK2 Complex","year":2013,"lang":"en","type":"article","venue":"JNCI Journal of the National Cancer Institute","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Terry Fox Research Institute; BC Cancer Agency","funders":"Canadian Institutes of Health Research; Cancer Research UK","keywords":"Progenitor cell; Myeloid leukemia; Imatinib mesylate; Haematopoiesis; Cancer research; Stem cell; Myeloid; breakpoint cluster region; Leukemia; Imatinib; Immunology; K562 cells; Medicine; Biology; Internal medicine; Cell biology; Receptor","score_opus":0.026096586699527226,"score_gpt":0.2993805024314876,"score_spread":0.27328391573196037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171358244","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913841,0.0017699599,0.00035316806,0.0019173807,0.0012751651,0.0011942371,0.00010171194,0.000016313812,0.0019879884],"genre_scores_gemma":[0.9948608,0.0003211813,0.0010830552,0.0008593237,0.0016991419,0.000046371897,0.00003858254,0.000027110242,0.0010644118],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99748826,0.00008402017,0.0007403254,0.00021005135,0.0012037274,0.00027359658],"domain_scores_gemma":[0.997382,0.0001428701,0.0010501597,0.00013283012,0.0011060125,0.00018612237],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003278398,0.00024189826,0.00048858626,0.00016188619,0.00014065734,0.000025821175,0.00021142674,0.0001257901,0.0005561276],"category_scores_gemma":[0.00029482605,0.0001683787,0.00028051971,0.0003500156,0.00020896766,0.00055089314,0.000081482234,0.00052532664,0.000027256223],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003396474,0.00017385196,0.0016113874,0.00019343202,0.0007736955,0.000012957786,0.0005275875,0.006764157,0.7491833,0.00014676635,0.23079646,0.009476737],"study_design_scores_gemma":[0.024421621,0.0013259735,0.073734656,0.0029565247,0.0008669981,0.00046144542,0.00017553598,0.0038699592,0.7949221,0.0014027593,0.09527272,0.000589699],"about_ca_topic_score_codex":0.0010550495,"about_ca_topic_score_gemma":0.0000484718,"teacher_disagreement_score":0.13552374,"about_ca_system_score_codex":0.011912649,"about_ca_system_score_gemma":0.0056077274,"threshold_uncertainty_score":0.9947868},"labels":[],"label_agreement":null},{"id":"W2171652090","doi":"10.1021/jm101506n","title":"Crystal Structures of ABL-Related Gene (ABL2) in Complex with Imatinib, Tozasertib (VX-680), and a Type I Inhibitor of the Triazole Carbothioamide Class","year":2011,"lang":"en","type":"article","venue":"Journal of Medicinal Chemistry","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Wellcome Trust","keywords":"Imatinib; Chemistry; ABL; Cocrystal; Cancer research; Stereochemistry; Biochemistry; Receptor; Tyrosine kinase; Biology; Molecule; Hydrogen bond","score_opus":0.021782110185343845,"score_gpt":0.24769941998930195,"score_spread":0.2259173098039581,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171652090","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99666613,0.0012313507,0.0000025383063,0.00019349695,0.000075203934,0.00016236279,0.00000856652,0.0000042228785,0.001656134],"genre_scores_gemma":[0.99886626,0.00006728409,0.00077200664,0.00005474671,0.0001266832,0.0000011562109,0.000005321613,0.000018995104,0.00008755893],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99816495,0.000042477262,0.00085728767,0.00014256299,0.0006008951,0.00019183701],"domain_scores_gemma":[0.99840844,0.000078015895,0.00084958936,0.00026288716,0.0002454455,0.00015564034],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032298625,0.00018814243,0.000669574,0.00006687052,0.000021852386,0.0000027098488,0.00016199643,0.00014573125,0.00028120508],"category_scores_gemma":[0.0002522075,0.00010761621,0.000092989496,0.00024043971,0.00031982697,0.00004879349,0.000044797795,0.00052221975,1.8366357e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039160936,0.00027442913,0.05434215,0.0006826553,0.00040995446,0.00031525333,0.0020066926,0.000024218809,0.93712443,0.000006769974,0.0003878174,0.0005095144],"study_design_scores_gemma":[0.01825733,0.0012747904,0.1884492,0.0015615666,0.0006230443,0.0036670896,0.0016393389,0.000195755,0.784,0.000108666405,0.00008110652,0.00014212217],"about_ca_topic_score_codex":0.0001477737,"about_ca_topic_score_gemma":0.000014610308,"teacher_disagreement_score":0.15312445,"about_ca_system_score_codex":0.00025163754,"about_ca_system_score_gemma":0.00073474506,"threshold_uncertainty_score":0.43884617},"labels":[],"label_agreement":null},{"id":"W2171861255","doi":"10.3747/co.22.2719","title":"Dasatinib for a Child with Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia and Persistently Elevated Minimal Residual Disease during Imatinib Therapy","year":2015,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Chung Shan Medical University; Division of Materials Research; Chung Shan Medical University Hospital; China Medical University; China Medical University Hospital","keywords":"Dasatinib; Medicine; Imatinib; Minimal residual disease; Internal medicine; Chemotherapy; Philadelphia chromosome; Oncology; Hematopoietic stem cell transplantation; Acute lymphocytic leukemia; Transplantation; Leukemia; Lymphoblastic Leukemia; Chromosomal translocation; Myeloid leukemia","score_opus":0.06408072297100284,"score_gpt":0.3471809783394812,"score_spread":0.2831002553684784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171861255","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99138534,0.0036065925,0.00004226645,0.0020345035,0.00030898929,0.0019408115,0.00027166746,0.000113047085,0.00029676314],"genre_scores_gemma":[0.9967938,0.00051059545,0.00069497264,0.00015552175,0.00054674404,0.0004777037,0.0006300767,0.00007234525,0.00011824966],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9978417,0.00010235641,0.000409279,0.0006964523,0.0003491129,0.0006010584],"domain_scores_gemma":[0.998204,0.00019549402,0.00024405733,0.00035292466,0.00027113667,0.00073240796],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014920035,0.00041907572,0.0006796637,0.00016212596,0.00019175051,0.00002700786,0.00012777987,0.00014434668,0.000044454628],"category_scores_gemma":[0.00016060023,0.00032394868,0.00011407049,0.00019419307,0.0003229257,0.00012996023,0.000086448315,0.00026792233,0.000017186056],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.418242,0.020382533,0.30181155,0.0057007913,0.021605479,0.010673858,0.049156934,0.00040463472,0.031039188,0.0010678972,0.027744634,0.112170495],"study_design_scores_gemma":[0.35749748,0.03768528,0.5369997,0.003312827,0.007482713,0.0076931533,0.003631609,0.008911562,0.009238684,0.00019845227,0.024921512,0.002427039],"about_ca_topic_score_codex":0.000012051976,"about_ca_topic_score_gemma":0.000007637367,"teacher_disagreement_score":0.23518814,"about_ca_system_score_codex":0.0032136512,"about_ca_system_score_gemma":0.0024699229,"threshold_uncertainty_score":0.99992126},"labels":[],"label_agreement":null},{"id":"W2172033645","doi":"10.1155/2008/146871","title":"Stem Cell Biomarkers in Chronic Myeloid Leukemia","year":2008,"lang":"en","type":"review","venue":"Disease Markers","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute; Michael Smith Health Research BC; Stem Cell Network; Terry Fox Foundation; Cancer Research Society","keywords":"Stem cell; Imatinib mesylate; Myeloid leukemia; Haematopoiesis; Cancer research; Imatinib; Biology; Myeloid; Leukemia; Immunology; Cancer stem cell; Cell biology","score_opus":0.027325360265054815,"score_gpt":0.29491951713384407,"score_spread":0.26759415686878923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2172033645","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00040490416,0.9857971,0.0000016784816,0.000026773012,0.00037643226,0.003394326,0.00024325217,0.00019726765,0.009558248],"genre_scores_gemma":[0.00020629357,0.9919686,0.00005941993,0.00009017491,0.0003123696,0.0007246967,0.0015571626,0.0003015312,0.0047797556],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9949095,0.00036430234,0.0012945844,0.0014777733,0.0007947156,0.0011590776],"domain_scores_gemma":[0.99621284,0.00029570493,0.00050692423,0.0017004736,0.000052906093,0.0012311729],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00020943457,0.0013031623,0.002974389,0.0008933839,0.00010970781,0.00003606219,0.00047865452,0.0005874648,0.0006160354],"category_scores_gemma":[0.000038791728,0.0011353029,0.0016991674,0.0011262528,0.00025490075,0.00011743432,0.0002129191,0.0008872528,0.0011118716],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00037816947,0.00019899265,0.00032743908,0.04273271,0.0011938332,0.0057220655,0.000029391063,0.00000469884,5.877493e-7,0.0000033763463,0.016650766,0.932758],"study_design_scores_gemma":[0.0044202507,0.00013560767,0.00070845993,0.024509873,0.002774436,0.00019650934,0.000027344813,0.00012303285,9.160878e-7,0.000002158933,0.9662056,0.0008958203],"about_ca_topic_score_codex":0.00018263493,"about_ca_topic_score_gemma":0.000021600574,"teacher_disagreement_score":0.9495548,"about_ca_system_score_codex":0.03603787,"about_ca_system_score_gemma":0.02325928,"threshold_uncertainty_score":0.999972},"labels":[],"label_agreement":null},{"id":"W2184596480","doi":"10.1007/s00216-015-9204-2","title":"Initial diagnosis of chronic myelogenous leukemia based on quantification of M-BCR status using droplet digital PCR","year":2015,"lang":"en","type":"article","venue":"Analytical and Bioanalytical Chemistry","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Natural Sciences and Engineering Research Council of Canada; University of British Columbia; Genome British Columbia; Canada's Michael Smith Genome Sciences Centre","funders":"Canadian Institutes of Health Research; Natural Sciences and Engineering Research Council of Canada; Canada Research Chairs","keywords":"breakpoint cluster region; Chronic myelogenous leukemia; Chromosomal translocation; ABL; Philadelphia chromosome; Biology; Molecular biology; Derivative chromosome; Breakpoint; Fusion gene; Fluorescence in situ hybridization; Chromosome 22; Leukemia; Cancer research; Chromosome; Gene; Tyrosine kinase; Genetics","score_opus":0.0515856623414415,"score_gpt":0.3088899069658027,"score_spread":0.2573042446243612,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2184596480","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99436253,0.00028745882,0.00036807422,0.00027756643,0.0000265396,0.00017983354,0.00015847739,0.000027973965,0.0043115434],"genre_scores_gemma":[0.99916494,0.000046270077,0.00020874015,0.00006294923,0.00015082344,0.00000624586,0.00018853875,0.000023326964,0.00014815485],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9978575,0.000021242773,0.0006335515,0.0004566838,0.00061475683,0.00041622654],"domain_scores_gemma":[0.9982551,0.00027016157,0.00017112627,0.00045844933,0.0002487156,0.00059644564],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015856946,0.00027004845,0.0006778908,0.000089988076,0.000033585093,0.000024369463,0.00010316745,0.00024342249,0.0002537798],"category_scores_gemma":[0.00068892486,0.00021701015,0.00020966394,0.00038629083,0.00063474564,0.0000658023,0.00006552902,0.00024544462,0.000013188105],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010297868,0.015984459,0.7690084,0.009223961,0.0049927663,0.0015242943,0.00042432718,0.0046033026,0.09782983,0.0024836923,0.002908059,0.080719054],"study_design_scores_gemma":[0.010426904,0.0022195051,0.0069773076,0.00075934076,0.002441929,0.00012992539,0.00025442248,0.66823703,0.30627745,0.0002835349,0.0013200524,0.00067257596],"about_ca_topic_score_codex":0.00015816907,"about_ca_topic_score_gemma":0.0000030534252,"teacher_disagreement_score":0.7620311,"about_ca_system_score_codex":0.0011905899,"about_ca_system_score_gemma":0.0016527193,"threshold_uncertainty_score":0.8849417},"labels":[],"label_agreement":null},{"id":"W218989274","doi":"10.1182/blood.v124.21.5544.5544","title":"Bosutinib As Second-Line Therapy in Patients (Pts) with Chronic Phase Chronic Myeloid Leukemia (CP CML) Resistant or Intolerant to Prior Imatinib: 60-Month Update of a Phase 1/2 Study","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Bosutinib; Medicine; Internal medicine; Gastroenterology; Imatinib; Dasatinib; Imatinib mesylate; Discontinuation; Nilotinib; Myeloid leukemia","score_opus":0.0146167909784973,"score_gpt":0.29754422788039475,"score_spread":0.2829274369018975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W218989274","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99253905,0.0006399107,0.000033641933,0.00013731734,0.000114412745,0.0057862317,0.00013588934,0.00013458407,0.00047894684],"genre_scores_gemma":[0.99712366,0.000106875756,0.00075895555,0.00032463082,0.0002766335,0.000514712,0.00022999081,0.00016629377,0.00049826107],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99511766,0.00026806718,0.001449799,0.0011530103,0.0010097007,0.0010017406],"domain_scores_gemma":[0.9968505,0.0001653203,0.0005875269,0.0016103458,0.00028393773,0.0005023993],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00068506395,0.000780926,0.0015378138,0.0004587254,0.00013338779,0.000042891632,0.0004560396,0.00019026228,0.0012694099],"category_scores_gemma":[0.00021941979,0.0005515756,0.00016633308,0.00087950286,0.00014278613,0.00019360575,0.0001518195,0.00052148674,0.00012977011],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16755971,0.18744609,0.050366715,0.002602298,0.006414821,0.0030524398,0.016420074,0.00025332716,0.103024594,0.00009521399,0.0011119243,0.4616528],"study_design_scores_gemma":[0.64983773,0.21133815,0.037548877,0.0017049571,0.0010665647,0.000087814085,0.00040849642,0.00091533386,0.089063905,0.000019573721,0.006904041,0.0011045603],"about_ca_topic_score_codex":0.0006099228,"about_ca_topic_score_gemma":0.0033272656,"teacher_disagreement_score":0.48227802,"about_ca_system_score_codex":0.0031330958,"about_ca_system_score_gemma":0.0036984587,"threshold_uncertainty_score":0.9996936},"labels":[],"label_agreement":null},{"id":"W2202712680","doi":"10.1038/bcj.2015.104","title":"Prediction of response and survival in patients with chronic-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate: logistic regression and landmark analyses","year":2015,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Teva Pharmaceutical Industries","keywords":"Logistic regression; Myeloid leukemia; Medicine; Oncology; Internal medicine; Hematology; Immunology","score_opus":0.040615305099031156,"score_gpt":0.31720429007754664,"score_spread":0.2765889849785155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2202712680","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9778693,0.015665563,0.0000119632205,0.0049164696,0.00013922282,0.0008659828,0.00044372134,0.000034339555,0.000053483647],"genre_scores_gemma":[0.98970175,0.0046935063,0.00019832389,0.001473879,0.0018885611,0.00009059377,0.00079215027,0.00017490397,0.0009863536],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962507,0.0004859999,0.0007838373,0.00069589174,0.0011524312,0.0006311494],"domain_scores_gemma":[0.99752814,0.00018150298,0.00095132453,0.0004900786,0.00052580266,0.00032316122],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005924633,0.0007066341,0.0014401197,0.00067503564,0.0001231497,0.000055279655,0.00014594586,0.0005862304,0.00010466876],"category_scores_gemma":[0.0001203737,0.00043056585,0.000082289414,0.00046501844,0.00030775485,0.00019290624,0.00006421864,0.0020239064,8.631327e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.06712931,0.0010364614,0.8435975,0.0025872802,0.005682287,0.008633093,0.00040468396,0.00033497074,0.002050674,3.2567493e-7,0.055857144,0.012686286],"study_design_scores_gemma":[0.25329444,0.034152504,0.6630497,0.016142294,0.010369854,0.0030970804,0.000060513976,0.0005768914,0.002443837,0.000008165645,0.015779568,0.0010251382],"about_ca_topic_score_codex":0.0009493298,"about_ca_topic_score_gemma":0.00050448783,"teacher_disagreement_score":0.18616514,"about_ca_system_score_codex":0.006006126,"about_ca_system_score_gemma":0.005657709,"threshold_uncertainty_score":0.9999793},"labels":[],"label_agreement":null},{"id":"W2204612493","doi":"10.1155/2000/297045","title":"Hydroxyurea‐Induced Hypersensitivity Pneumonitis: A Case Report and Literature Review","year":2000,"lang":"en","type":"review","venue":"Canadian Respiratory Journal","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Medicine; Hypersensitivity pneumonitis; Dermatology; Hypersensitivity reaction; Internal medicine; Lung","score_opus":0.04769711963134342,"score_gpt":0.3262656509466949,"score_spread":0.2785685313153515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2204612493","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00063623174,0.99227464,1.0836614e-7,0.00022601827,0.0003201339,0.0014449487,0.00020854779,0.00003600972,0.0048533515],"genre_scores_gemma":[0.00005413284,0.99448645,0.000036072848,0.002997598,0.0011278176,0.00005773525,0.00013082851,0.00015501122,0.00095435546],"study_design_codex":"case_report","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959663,0.0005684293,0.0013503187,0.0008009271,0.00043766142,0.00087636476],"domain_scores_gemma":[0.9947316,0.00010280602,0.0006966685,0.0010196203,0.00023732657,0.0032119988],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00092995196,0.0008848173,0.0030464802,0.000896431,0.00045220525,0.00019041923,0.00014956138,0.0008133465,0.0003572371],"category_scores_gemma":[0.00039512932,0.00071587245,0.0008273774,0.0006711151,0.00010745237,0.00017567509,0.000031557174,0.0028794804,0.000110237655],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000002542356,0.000011281936,0.000004305266,0.011187676,0.00024211821,0.5326498,0.000017968323,5.9329364e-9,1.8888078e-7,0.0000011973846,0.0030731752,0.45280975],"study_design_scores_gemma":[0.00031866282,0.00008088973,0.0000042329684,0.103468195,0.0017295775,0.44562554,0.000004510589,1.313337e-7,1.0197803e-7,0.0000014758123,0.4485211,0.00024556083],"about_ca_topic_score_codex":0.002072298,"about_ca_topic_score_gemma":0.008466806,"teacher_disagreement_score":0.45256418,"about_ca_system_score_codex":0.00450504,"about_ca_system_score_gemma":0.016713964,"threshold_uncertainty_score":0.99952924},"labels":[],"label_agreement":null},{"id":"W2220816567","doi":"10.3109/10428194.2015.1091929","title":"Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysis","year":2015,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":92,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; McMaster University","funders":"","keywords":"Nilotinib; Bosutinib; Dasatinib; Medicine; Ponatinib; Imatinib; Internal medicine; Tyrosine kinase; Myeloid leukemia; Tyrosine-kinase inhibitor; Imatinib mesylate; Incidence (geometry); Oncology; Cancer","score_opus":0.024971778580207896,"score_gpt":0.26893631047231953,"score_spread":0.24396453189211165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2220816567","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.18396448,0.8066948,0.000013657011,0.000031869695,0.0002760717,0.00693035,0.00090811274,0.00048125346,0.0006994304],"genre_scores_gemma":[0.09396694,0.87043667,0.0012190081,0.00048307847,0.0018366101,0.005496725,0.018033117,0.0019041881,0.0066236816],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9846769,0.00096134096,0.0037555634,0.004538249,0.0031026902,0.0029652766],"domain_scores_gemma":[0.99042344,0.00044084725,0.0025441477,0.0037886158,0.0007683996,0.0020345752],"candidate_categories":["metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0009377371,0.004730899,0.016262958,0.0031765879,0.00044541105,0.0002705017,0.0010979214,0.0024659368,0.00045644687],"category_scores_gemma":[0.000118869815,0.003177645,0.003557829,0.00617502,0.0007984769,0.000806957,0.00059047516,0.0009075677,0.0002896315],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.009219454,0.002554103,0.012221639,0.01851291,0.30717462,0.0046886657,0.0005279018,0.00016287749,0.000009263734,0.00005470829,0.0023994371,0.6424744],"study_design_scores_gemma":[0.09894878,0.0041763294,0.014824317,0.0077162446,0.56769645,0.0012681712,0.00005980675,0.0002653416,0.000059209477,0.000017475375,0.3005133,0.004454611],"about_ca_topic_score_codex":0.0070366706,"about_ca_topic_score_gemma":0.0016462435,"teacher_disagreement_score":0.6380198,"about_ca_system_score_codex":0.12374479,"about_ca_system_score_gemma":0.039710417,"threshold_uncertainty_score":0.99957556},"labels":[],"label_agreement":null},{"id":"W2234278652","doi":"10.1185/03007995.2016.1140030","title":"Treatment patterns, overall survival, healthcare resource use and costs in elderly Medicare beneficiaries with chronic myeloid leukemia using second-generation tyrosine kinase inhibitors as second-line therapy","year":2016,"lang":"en","type":"article","venue":"Current Medical Research and Opinion","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Nilotinib; Medicine; Dasatinib; Hazard ratio; Internal medicine; Myeloid leukemia; Imatinib; Medicare Advantage; Medicare Part D; Emergency medicine; Health care; Medical prescription; Confidence interval; Pharmacology; Prescription drug","score_opus":0.11388979774079895,"score_gpt":0.3880523490510253,"score_spread":0.2741625513102264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2234278652","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9633861,0.030416213,0.000038653427,0.0044797026,0.00030551045,0.0011964379,0.00012422715,0.000039533174,0.000013631476],"genre_scores_gemma":[0.94962424,0.04829278,0.000027776432,0.000094861454,0.0010993702,0.000113009715,0.0005707132,0.000050884108,0.00012636752],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9955936,0.00047491302,0.00054923125,0.0008556472,0.0016536406,0.00087296806],"domain_scores_gemma":[0.9973548,0.00072217366,0.00011478272,0.00044095883,0.00026193354,0.001105357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008528278,0.00039583474,0.0005855384,0.00036350606,0.00026092984,0.00009957548,0.00011786619,0.0003087725,0.00047833714],"category_scores_gemma":[0.0005562542,0.00023573345,0.00005332437,0.00028325303,0.00041905823,0.00029044182,0.00012773093,0.0006610479,0.0000063896337],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019515168,0.000504595,0.11727227,0.0005502699,0.000119165095,0.00024948703,0.00055177335,0.0000012464377,0.003392319,0.00024734088,0.00075037,0.8744096],"study_design_scores_gemma":[0.1683556,0.07375668,0.349882,0.04308194,0.0001325314,0.001191066,0.0012873006,0.006733107,0.041039377,0.0002843175,0.31180713,0.0024489346],"about_ca_topic_score_codex":0.0028488645,"about_ca_topic_score_gemma":0.0116227055,"teacher_disagreement_score":0.8719607,"about_ca_system_score_codex":0.0050597587,"about_ca_system_score_gemma":0.003620271,"threshold_uncertainty_score":0.9987596},"labels":[],"label_agreement":null},{"id":"W2238642694","doi":"10.7490/f1000research.160.1","title":"Comprehensive evaluation of time-to-response parameter as a predictor of long-term outcomes following imatinib therapy in chronic phase chronic myeloid leukemia","year":2010,"lang":"en","type":"article","venue":"","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Imatinib; Oncology; Guideline; Internal medicine; Hazard ratio; Myeloid leukemia; Surrogate endpoint; Dasatinib; Nilotinib; Pathology; Confidence interval","score_opus":0.039736380617321924,"score_gpt":0.3698571429039926,"score_spread":0.33012076228667064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2238642694","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949777,0.0006390838,0.000042111787,0.00017497852,0.00022047243,0.0034260699,0.000030045057,0.0000738139,0.0004157359],"genre_scores_gemma":[0.9975569,0.000033963508,0.0007925846,0.00016107636,0.000076379525,0.0002719876,0.00010031846,0.000068596186,0.00093818235],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9963065,0.00033817822,0.0010302021,0.0005702227,0.0012359637,0.0005189483],"domain_scores_gemma":[0.99706954,0.0009383131,0.0003433825,0.0010386491,0.00037540233,0.00023471215],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011412814,0.00044047117,0.001102156,0.0004892166,0.000040582123,0.000014837409,0.00026187135,0.00025454504,0.0055378107],"category_scores_gemma":[0.0007661124,0.0003499729,0.0004039332,0.0004375619,0.00014784322,0.00017805789,0.0000912095,0.0004049265,0.0002932158],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0033790262,0.00079949066,0.06748565,0.00019825113,0.00089789496,0.0000680461,0.00084711687,0.00030901327,0.8578424,0.0000044454205,0.000106933636,0.068061724],"study_design_scores_gemma":[0.07939042,0.006075584,0.67517847,0.00058833254,0.00059041637,0.00004952957,0.000048495614,0.015818376,0.2216831,0.000037291175,0.00013307585,0.00040689035],"about_ca_topic_score_codex":0.0003034107,"about_ca_topic_score_gemma":0.0001503133,"teacher_disagreement_score":0.6361593,"about_ca_system_score_codex":0.004737967,"about_ca_system_score_gemma":0.0060709896,"threshold_uncertainty_score":0.9998952},"labels":[],"label_agreement":null},{"id":"W2247323713","doi":"10.1182/blood.v108.11.2176.2176","title":"In Vitro and In Vivo Activity of SKI-606, a Novel Abl/Src Inhibitor, Against Imatinib Resistant BCR-ABL+ Neoplastic Cells.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Dasatinib; Imatinib; Imatinib mesylate; Cancer research; Nilotinib; ABL; Biology; Kinase; Tyrosine kinase; Signal transduction; Cell biology; Myeloid leukemia","score_opus":0.0072796213297371135,"score_gpt":0.22424800803318024,"score_spread":0.21696838670344312,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2247323713","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99625176,0.00035539243,0.000011941876,0.00010337779,0.00008474211,0.00050892925,0.000092832786,0.000027009024,0.0025640307],"genre_scores_gemma":[0.99784833,0.000040297564,0.0014433739,0.000057365945,0.00010737159,0.000035020876,0.000014816268,0.000033943947,0.0004194718],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99840885,0.000041856936,0.0004576778,0.0003973464,0.00030801844,0.00038625108],"domain_scores_gemma":[0.9991545,0.00021148151,0.00016411356,0.00033667593,0.000037194048,0.00009601314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017844138,0.0002483378,0.00055675866,0.00024440614,0.00002776759,0.000013992282,0.00006917697,0.00014850024,0.00003119438],"category_scores_gemma":[0.00009615578,0.00023224414,0.000064622844,0.00034965068,0.00008953895,0.00010628604,0.00006963639,0.00025129443,0.0000067333035],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00081937114,0.00304363,0.006712309,0.00031690794,0.00004390432,0.00030988696,0.00020232682,0.000024463796,0.9881004,0.00001213564,0.00016783178,0.0002468311],"study_design_scores_gemma":[0.025354125,0.00022867262,0.040075388,0.00045558802,0.00013760239,0.000043956934,0.000049027545,0.00046472822,0.932606,0.00003496972,0.0003413659,0.0002085706],"about_ca_topic_score_codex":0.0018047568,"about_ca_topic_score_gemma":0.00093820156,"teacher_disagreement_score":0.055494398,"about_ca_system_score_codex":0.0004006791,"about_ca_system_score_gemma":0.00034408504,"threshold_uncertainty_score":0.94706416},"labels":[],"label_agreement":null},{"id":"W2254345040","doi":"10.1016/j.ccell.2015.12.013","title":"Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia","year":2016,"lang":"en","type":"article","venue":"Cancer Cell","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":144,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto; University Health Network","funders":"National Institute of General Medical Sciences; Stand Up To Cancer; ECOG-ACRIN Cancer Research Group; National Cancer Institute; American College of Radiology Imaging Network; Incyte; St. Jude Children's Research Hospital; St. Baldrick's Foundation; American Lebanese Syrian Associated Charities; Alex's Lemonade Stand Foundation for Childhood Cancer; Leukemia and Lymphoma Society; Amgen","keywords":"Erythropoietin receptor; Erythropoietin; Cancer research; Biology; Receptor; Genetics","score_opus":0.01385799236396094,"score_gpt":0.2714577631762065,"score_spread":0.25759977081224555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2254345040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.982362,0.0014096401,0.00006099019,0.0007215873,0.0005249963,0.00047646405,0.0000388898,0.00008290944,0.014322551],"genre_scores_gemma":[0.9754127,0.0023817413,0.00094815996,0.00040756777,0.00027600495,0.00019573474,0.000021766178,0.00006258906,0.020293714],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99845743,0.000038173697,0.00032586663,0.0004449205,0.00027001888,0.00046360865],"domain_scores_gemma":[0.99916905,0.00008711263,0.00011527698,0.00040865745,0.000052292133,0.00016760339],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000114199756,0.00022285446,0.00032543583,0.000067581954,0.000043051907,0.000009358045,0.00012070307,0.0001224179,0.0047085923],"category_scores_gemma":[0.000047824567,0.00015472702,0.00007982919,0.0001836429,0.00007333908,0.00011047645,0.000060164537,0.00010677165,0.0006940876],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011143305,0.00038746966,0.1552376,0.0004262263,0.00040286523,0.00028398723,0.0014938771,0.000016564456,0.62369215,0.00003358282,0.047655426,0.1692559],"study_design_scores_gemma":[0.10148993,0.0016258123,0.13122751,0.006983277,0.0011909044,0.00010905615,0.0010451365,0.0005261606,0.5595129,0.00016498746,0.19424063,0.0018836544],"about_ca_topic_score_codex":0.0009255339,"about_ca_topic_score_gemma":0.00021002901,"teacher_disagreement_score":0.16737224,"about_ca_system_score_codex":0.011169146,"about_ca_system_score_gemma":0.0010153629,"threshold_uncertainty_score":0.9962012},"labels":[],"label_agreement":null},{"id":"W2255952682","doi":"10.1182/blood.v122.21.511.511","title":"A Novel TWIST2-ID2 Axis That Modulates The Growth and Imatinib Sensitivity Of CML CD34+ Cells","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Haematopoiesis; Cancer research; Gene knockdown; Biology; CD34; Bone marrow; Imatinib mesylate; K562 cells; Molecular biology; Small hairpin RNA; Myeloid leukemia; Stem cell; Cell biology; Leukemia; Cell culture; Immunology; Imatinib; Genetics","score_opus":0.014382656658104212,"score_gpt":0.22512345701597689,"score_spread":0.21074080035787268,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2255952682","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968574,0.00030758773,0.000113949674,0.00059407525,0.000045296274,0.00058004627,0.000033720786,0.000036254354,0.0014316512],"genre_scores_gemma":[0.9976137,0.000058193105,0.0017508935,0.00016741751,0.000062813284,0.000025104799,0.000011852743,0.000021811964,0.0002881872],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991272,0.000045449313,0.00017896314,0.00023038416,0.00019535974,0.00022266318],"domain_scores_gemma":[0.9990766,0.0002866998,0.00010356819,0.0003746787,0.000065231085,0.00009324541],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015925617,0.00017107898,0.0003081566,0.00003730794,0.000049882907,0.000016812694,0.00005356891,0.00007370812,0.00007922772],"category_scores_gemma":[0.00009004044,0.00010464181,0.00007547641,0.00008910151,0.00013962397,0.000073312105,0.000078001496,0.00012606446,0.000042037347],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030909654,0.0011844056,0.03539035,0.00030971598,0.0004979067,0.000034851688,0.0016336743,0.0000025039787,0.9577389,0.000118947726,0.00048454286,0.0025733346],"study_design_scores_gemma":[0.008413542,0.00023132705,0.17500167,0.00016116607,0.00044108616,0.00040566575,0.0002894227,0.0016848912,0.81290126,0.00020980604,0.00008169262,0.00017848412],"about_ca_topic_score_codex":0.0020110863,"about_ca_topic_score_gemma":0.000027285492,"teacher_disagreement_score":0.1448376,"about_ca_system_score_codex":0.00003920468,"about_ca_system_score_gemma":0.00007800417,"threshold_uncertainty_score":0.42671692},"labels":[],"label_agreement":null},{"id":"W2264721079","doi":"10.1016/j.exphem.2015.12.002","title":"Inhibition of isoprenylcysteine carboxylmethyltransferase augments BCR-ABL1 tyrosine kinase inhibition-induced apoptosis in chronic myeloid leukemia","year":2015,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Ministry of Health, British Columbia; National Medical Research Council; National Research Foundation Singapore; Agency for Science, Technology and Research; National Research Foundation; Medical Research Council; Duke-NUS Medical School","keywords":"Myeloid leukemia; Tyrosine kinase; Cancer research; Apoptosis; Tyrosine-kinase inhibitor; CD135; breakpoint cluster region; Chemistry; Medicine; Biology; Cell biology; Signal transduction; Internal medicine; Receptor; Biochemistry; Cancer","score_opus":0.029033336690261948,"score_gpt":0.3005564925957576,"score_spread":0.2715231559054957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2264721079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989271,0.006717561,0.00003705567,0.00024011133,0.0003628541,0.0012323194,0.000034334687,0.00011347782,0.0019913195],"genre_scores_gemma":[0.9979441,0.00005285374,0.00059720327,0.00019538753,0.00013740482,0.00035249654,0.00046834175,0.000079501864,0.00017268596],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99681073,0.0001801883,0.0010496272,0.0007257778,0.0005519839,0.0006816613],"domain_scores_gemma":[0.9985307,0.0000743213,0.00022852639,0.0006234821,0.00012809424,0.0004148631],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024904305,0.0005064592,0.0011217536,0.0004896206,0.000059415685,0.00001136624,0.0001102334,0.00038738098,0.0003183461],"category_scores_gemma":[0.00007321593,0.000506117,0.00019260032,0.0005763171,0.00022729636,0.00023283693,0.00012261544,0.00036737198,0.00012105638],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011096095,0.001337324,0.0039566653,0.0003168453,0.00015053524,0.00046800703,0.0017687381,0.000036664853,0.9877041,0.00213639,0.0005926332,0.00042246745],"study_design_scores_gemma":[0.022654997,0.0022620447,0.00046874853,0.0006168232,0.00008628929,0.00043656648,0.0010641569,0.00028178448,0.97161,0.00008087799,0.00009018599,0.00034750177],"about_ca_topic_score_codex":0.0018358097,"about_ca_topic_score_gemma":0.0001302368,"teacher_disagreement_score":0.021545388,"about_ca_system_score_codex":0.008213064,"about_ca_system_score_gemma":0.0013214418,"threshold_uncertainty_score":0.99973905},"labels":[],"label_agreement":null},{"id":"W2264743073","doi":"10.1182/blood.v122.21.94.94","title":"Achievement and Maintenance Of Deeper Molecular Response By Switching To Nilotinib In Patients (pts) With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) With Residual Disease On Long-Term Imatinib: ENESTcmr 36-Month Follow-Up","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Princess Margaret Cancer Centre; University of Toronto; McMaster University","funders":"","keywords":"Nilotinib; Imatinib; Medicine; Discontinuation; Internal medicine; Imatinib mesylate; Oncology; Gastroenterology; Minimal residual disease; Myeloid leukemia; Leukemia","score_opus":0.006340590874513017,"score_gpt":0.24290564261922312,"score_spread":0.2365650517447101,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2264743073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952281,0.000758311,0.000068125926,0.00040264605,0.000033486565,0.0033537652,0.00005556843,0.000047209887,0.00005278267],"genre_scores_gemma":[0.9979684,0.000055614255,0.0005585172,0.00034508624,0.000035054723,0.0005728338,0.00014346813,0.00011907227,0.00020197124],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996485,0.00021230862,0.0007206668,0.00092888885,0.0007938303,0.00085929193],"domain_scores_gemma":[0.99803907,0.00014093998,0.00027623805,0.00089644926,0.00012141665,0.00052590255],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003458566,0.0005846357,0.00076390436,0.00036059273,0.00006619337,0.000038441995,0.00022764201,0.000105884894,0.000057410092],"category_scores_gemma":[0.00016973192,0.00044460778,0.00006630206,0.00044338845,0.00011022917,0.000211772,0.00012913697,0.00039304767,0.000024235387],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06317778,0.008046124,0.8255865,0.0011610358,0.00069056597,0.002107715,0.0016683884,0.00072150666,0.08347894,0.00003770269,0.0003014615,0.013022278],"study_design_scores_gemma":[0.14276022,0.016549757,0.8098846,0.004116098,0.00037905254,0.000025078472,0.000074372896,0.00016519931,0.025387798,0.000011743548,0.00004415242,0.0006019355],"about_ca_topic_score_codex":0.00080703944,"about_ca_topic_score_gemma":0.0010977222,"teacher_disagreement_score":0.07958244,"about_ca_system_score_codex":0.0046494897,"about_ca_system_score_gemma":0.0020880976,"threshold_uncertainty_score":0.99980056},"labels":[],"label_agreement":null},{"id":"W2265688788","doi":"10.1188/13.cjon.e13-e20","title":"Treating Chronic Myeloid Leukemia","year":2013,"lang":"en","type":"review","venue":"Clinical journal of oncology nursing","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada","funders":"","keywords":"Medicine; Nilotinib; Bosutinib; Dasatinib; Ponatinib; Imatinib; Myeloid leukemia; Oncology; Internal medicine; Intensive care medicine","score_opus":0.1462556582893292,"score_gpt":0.49390369508211474,"score_spread":0.34764803679278555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2265688788","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00046024736,0.98673,0.00006586334,0.00035863166,0.0035459693,0.0009942825,0.0000050523977,0.000039439336,0.007800543],"genre_scores_gemma":[0.000048344154,0.98544794,0.00568611,0.00018568007,0.0071875034,0.0000215584,0.000034246346,0.0001457706,0.0012428381],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.991924,0.0010716907,0.0051344377,0.00058400375,0.0005304414,0.0007554151],"domain_scores_gemma":[0.98966664,0.003375403,0.0050397865,0.0006750847,0.00041940855,0.0008236975],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0019104785,0.0007391321,0.007619387,0.00048716262,0.00012710918,0.0000377942,0.00052348344,0.0019942566,0.00057649554],"category_scores_gemma":[0.0014789244,0.0005117453,0.0030709712,0.0003795255,0.00073251995,0.00017060564,0.000082006016,0.0042348043,0.00048322778],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0000864445,0.0006217872,0.00006659043,0.002958791,0.0014546867,0.0014106957,0.000051852432,0.0000010644765,0.0000012613335,0.000013033535,0.012841431,0.98049235],"study_design_scores_gemma":[0.0054773795,0.0061183125,0.0000725009,0.08100539,0.0104076695,0.01584987,0.000044113964,0.000024004657,0.0000013658376,0.000059389673,0.8806289,0.00031112385],"about_ca_topic_score_codex":0.000005943505,"about_ca_topic_score_gemma":0.0000013699236,"teacher_disagreement_score":0.9801812,"about_ca_system_score_codex":0.029460609,"about_ca_system_score_gemma":0.032493297,"threshold_uncertainty_score":0.9997334},"labels":[],"label_agreement":null},{"id":"W2268106067","doi":"10.1182/blood.v124.21.4816.4816","title":"Design, Optimization, and Pre-Clinical Evaluation of Direct, Mechanism-Based STAT3 Inhibitors for Treating Myeloid Disorders","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; York University","funders":"","keywords":"Myeloid leukemia; Cancer research; Chemistry; Myeloid; Biology; Molecular biology","score_opus":0.028509852793576748,"score_gpt":0.31641545287120076,"score_spread":0.287905600077624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2268106067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7786148,0.00026641742,0.21787372,0.00019273492,0.0001043516,0.00241695,0.0000133717895,0.000070582326,0.00044702704],"genre_scores_gemma":[0.9328225,0.00004397716,0.06661372,0.000047446178,0.00009562809,0.00019733212,0.00008702993,0.000032893673,0.000059445425],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9984927,0.00023972288,0.00044119026,0.00031042067,0.0003432114,0.00017275168],"domain_scores_gemma":[0.99859387,0.00066641025,0.00021521586,0.00024036977,0.00018757724,0.00009653822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014904073,0.00014824158,0.00032991348,0.00007809212,0.00006389418,0.0000091091415,0.00004028111,0.00010357601,0.000042866137],"category_scores_gemma":[0.0012136098,0.00012967645,0.000076540775,0.000107460866,0.00005326864,0.000048636277,0.000014727852,0.00005954115,0.0000010486738],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004141727,0.017330393,0.20724392,0.0027859488,0.0040470255,0.0000061309083,0.0036541775,0.30649787,0.020193264,0.00060423143,0.0013466262,0.43214867],"study_design_scores_gemma":[0.044690676,0.0029412315,0.0041962755,0.00025881972,0.0029502036,0.0000042283496,0.00004965251,0.86554474,0.07828334,0.0007858079,0.00007569771,0.00021935163],"about_ca_topic_score_codex":0.000041367184,"about_ca_topic_score_gemma":0.00001975323,"teacher_disagreement_score":0.55904686,"about_ca_system_score_codex":0.00009278152,"about_ca_system_score_gemma":0.00039001263,"threshold_uncertainty_score":0.52880526},"labels":[],"label_agreement":null},{"id":"W2270614059","doi":"10.1200/jco.2009.27.15_suppl.7071","title":"Does pre-imatinib (IM) fluorescence in situ hybridization (FISH) predict myelosuppression and outcomes in chronic myeloid leukemia (CML)?","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Internal medicine; Gastroenterology; Myeloid leukemia","score_opus":0.036350333947076326,"score_gpt":0.3984694869978367,"score_spread":0.36211915305076037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2270614059","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990562,0.00034880085,0.000050540748,0.0067171566,0.00069670356,0.0005363381,0.000004675004,0.000020868592,0.0010629094],"genre_scores_gemma":[0.99218786,0.0026947842,0.002924054,0.0012016941,0.00065960275,0.0000074251648,0.000011163975,0.000020795474,0.0002926108],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948491,0.00052657264,0.0032406445,0.00040377578,0.0005441529,0.0004357877],"domain_scores_gemma":[0.9959486,0.0016603357,0.0015139455,0.0003190733,0.00017281644,0.00038519694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024020122,0.0002775964,0.0019670934,0.00033919583,0.00004125734,0.000017449998,0.00023106023,0.00055691565,0.00007602955],"category_scores_gemma":[0.004507721,0.00016191347,0.00025874702,0.0002554368,0.00021779818,0.00036248265,0.000083206105,0.0014701048,0.0000072021703],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035049007,0.0016131079,0.6561566,0.000114764814,0.00014002062,0.0016408595,0.00041924807,0.00023416441,0.0060260203,0.000036129903,0.0009988234,0.32911536],"study_design_scores_gemma":[0.02207988,0.0077759973,0.96315336,0.0008102916,0.00015322276,0.0002629406,0.00006512548,0.0015287773,0.0012861154,0.000418945,0.0023086958,0.0001566755],"about_ca_topic_score_codex":0.000054357362,"about_ca_topic_score_gemma":0.0004027368,"teacher_disagreement_score":0.32895866,"about_ca_system_score_codex":0.00360704,"about_ca_system_score_gemma":0.0046912176,"threshold_uncertainty_score":0.9432284},"labels":[],"label_agreement":null},{"id":"W2280073170","doi":"10.1159/000442882","title":"Immunohistochemical Analysis of PDGFR-α, PDGFR-β and c-Abl in Retinoblastoma: Potential Therapeutic Targets","year":2016,"lang":"en","type":"article","venue":"Ophthalmic Research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Platelet-derived growth factor receptor; Retinoblastoma; Imatinib mesylate; Immunohistochemistry; Pathology; ABL; Imatinib; Immunostaining; Growth factor receptor; Cancer research; Biology; Medicine; Receptor; Growth factor; Tyrosine kinase; Internal medicine","score_opus":0.04210719882127129,"score_gpt":0.3810383182305747,"score_spread":0.3389311194093034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2280073170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916435,0.0032864672,0.00003176265,0.00070602336,0.000039358227,0.00046030397,0.000020739097,0.000017077366,0.0037947576],"genre_scores_gemma":[0.9959758,0.00048428503,0.0003048763,0.0000144556325,0.000046682613,0.000051822655,0.000026264599,0.000029674684,0.0030661207],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99718326,0.00026085516,0.00046363054,0.0005553313,0.00089731184,0.00063960446],"domain_scores_gemma":[0.99836665,0.00043473454,0.00008106523,0.00069941254,0.00023031527,0.00018779421],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010374073,0.00018851487,0.0006276019,0.0010359477,0.00006391397,0.000013214609,0.00021843081,0.0001903514,0.0013468378],"category_scores_gemma":[0.0003001822,0.00012873288,0.00017431052,0.0013419556,0.0005573028,0.000079644524,0.00019777383,0.00038477802,0.000055791592],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014807801,0.0005416514,0.083116986,0.00011399588,0.001413694,0.0006296829,0.00038292253,0.0000032941841,0.8963981,0.00014951732,0.00036044468,0.015408901],"study_design_scores_gemma":[0.016952628,0.0019920033,0.86472386,0.00068945414,0.001338036,0.00081866345,0.00050158036,0.002343159,0.1077251,0.0013181827,0.0010368021,0.0005605519],"about_ca_topic_score_codex":0.00040586077,"about_ca_topic_score_gemma":0.000010755548,"teacher_disagreement_score":0.78867304,"about_ca_system_score_codex":0.0010359111,"about_ca_system_score_gemma":0.00040198036,"threshold_uncertainty_score":0.9995661},"labels":[],"label_agreement":null},{"id":"W2281554724","doi":"10.1200/jco.2007.25.18_suppl.17503","title":"Pleural effusions in patients treated with dasatinib: Results from two institutions, risk factors and management","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Dasatinib; Discontinuation; Internal medicine; Dosing; Imatinib; Incidence (geometry); Oncology; Drug; Gastroenterology; Pharmacology","score_opus":0.09354951623553806,"score_gpt":0.43307475504671666,"score_spread":0.3395252388111786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2281554724","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956642,0.000065805434,0.000031988235,0.00035705895,0.00030701904,0.00034968008,0.00003649209,0.000010444402,0.003177331],"genre_scores_gemma":[0.99430424,0.00071654614,0.0043992028,0.00022368523,0.00021448311,0.0000012007481,0.000049739934,0.000011798119,0.000079100646],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99685305,0.00023398043,0.0020839747,0.00024246519,0.0003436072,0.00024292462],"domain_scores_gemma":[0.9957576,0.002177496,0.001332948,0.00020858929,0.00014993556,0.00037343378],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015554694,0.00016584479,0.0009535575,0.0002115119,0.00005512126,0.000005928401,0.000091914364,0.00020525068,0.000028362803],"category_scores_gemma":[0.0018241191,0.00009835093,0.00013669116,0.00019201297,0.00019882232,0.00009302721,0.00006014597,0.0007897016,0.000006999543],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010870316,0.001403608,0.93802613,0.000005106924,0.00042609582,0.00095347496,0.00015211958,0.000023975796,0.000001970257,0.000020609217,0.00023616911,0.04788045],"study_design_scores_gemma":[0.0668162,0.0067312187,0.91875136,0.00016703243,0.0005294895,0.000024311139,0.00013092837,0.000031178202,0.000017322238,0.000024416062,0.0066969907,0.000079574274],"about_ca_topic_score_codex":0.0010112075,"about_ca_topic_score_gemma":0.0013956806,"teacher_disagreement_score":0.05594589,"about_ca_system_score_codex":0.00071519,"about_ca_system_score_gemma":0.00057162414,"threshold_uncertainty_score":0.40106344},"labels":[],"label_agreement":null},{"id":"W2281659047","doi":"10.71781/27034","title":"Identification de facteurs nucléaires modifiant l'activité des cellules souches hématopoïétiques","year":2012,"lang":"fr","type":"dissertation","venue":"Papyrus : Institutional Repository (Université de Montréal)","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Medical Research Council; National Cancer Institute; National Institutes of Health; Leukemia and Lymphoma Society; Canadian Institutes of Health Research; Terry Fox Foundation","keywords":"Biology; Molecular biology","score_opus":0.010515142932709599,"score_gpt":0.20610321008449184,"score_spread":0.19558806715178223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2281659047","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.897841,0.08638859,0.000677741,0.00015725929,0.001794856,0.0008172128,0.00015597472,0.00025955398,0.011907864],"genre_scores_gemma":[0.93473846,0.004156916,0.0008178443,0.00004935869,0.0006638722,0.00009320985,0.0012532144,0.00011016384,0.05811696],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9955859,0.0003686595,0.0008025329,0.0009792773,0.000999855,0.0012637781],"domain_scores_gemma":[0.9967085,0.00029731213,0.000851098,0.0007838167,0.0004255192,0.00093371293],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.00040632056,0.00093187,0.00084333436,0.00052264304,0.0069090957,0.00011849705,0.00050132076,0.0010348572,0.00024773978],"category_scores_gemma":[0.00020106998,0.0010538183,0.0006214055,0.00037930202,0.0007816077,0.0009536026,0.00016332543,0.00080861023,0.00046024722],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002180853,0.0019199568,0.23173817,0.0024874078,0.0026182595,0.004265048,0.15350164,0.0018149129,0.5535319,0.016626101,0.0005784129,0.028737353],"study_design_scores_gemma":[0.0026542982,0.0001930231,0.5609026,0.0019480399,0.0028097765,0.0024711485,0.06100458,0.0032280504,0.35543475,0.00066035416,0.0076002255,0.0010931687],"about_ca_topic_score_codex":0.090179786,"about_ca_topic_score_gemma":0.011330102,"teacher_disagreement_score":0.32916442,"about_ca_system_score_codex":0.043379128,"about_ca_system_score_gemma":0.0052906526,"threshold_uncertainty_score":0.9991912},"labels":[],"label_agreement":null},{"id":"W2283642020","doi":"10.1016/j.clml.2016.02.002","title":"Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH Study","year":2016,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Université de Montréal; University of Toronto; Princess Margaret Cancer Centre","funders":"National Cancer Institute; University of Texas MD Anderson Cancer Center; Novartis Pharmaceuticals Corporation","keywords":"Nilotinib; Medicine; Imatinib; Adverse effect; Chronic myeloid leukaemia; Oncology; Internal medicine; Myeloid leukemia","score_opus":0.03791484173415468,"score_gpt":0.3841168110887788,"score_spread":0.34620196935462416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2283642020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929412,0.00005938748,0.000006425091,0.00048608784,0.0002934816,0.005724811,0.000037107853,0.0000919072,0.00035958417],"genre_scores_gemma":[0.9983939,0.000016602575,0.0001141198,0.0002729784,0.00021296676,0.00035243575,0.000030250587,0.00013008929,0.00047664344],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99259603,0.0011883251,0.0023549744,0.0012102947,0.0016062804,0.0010440892],"domain_scores_gemma":[0.992478,0.0034291823,0.00096100685,0.0023202824,0.00035713086,0.00045437654],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00283037,0.0007499234,0.0013698862,0.00023250397,0.00021719896,0.000012177582,0.0008608428,0.00031992575,0.0002800785],"category_scores_gemma":[0.0029385255,0.00031506555,0.000606739,0.0011982648,0.0003558049,0.00015920593,0.00035379888,0.00055221707,0.0005088351],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056915926,0.003419686,0.7887046,0.00003367527,0.0009642623,0.000051368097,0.0008407273,0.00044581303,0.0002531641,0.000013300281,0.00021620146,0.1993656],"study_design_scores_gemma":[0.05129638,0.022448663,0.9231609,0.0012603031,0.00036931096,0.000020209945,0.0001680058,0.00068315753,0.00014945073,0.00006723768,0.000017789154,0.00035860986],"about_ca_topic_score_codex":0.00071976404,"about_ca_topic_score_gemma":0.00012422018,"teacher_disagreement_score":0.19900699,"about_ca_system_score_codex":0.010030925,"about_ca_system_score_gemma":0.004682755,"threshold_uncertainty_score":0.99993014},"labels":[],"label_agreement":null},{"id":"W2285786982","doi":"10.1182/blood.v122.21.3961.3961","title":"A Phase I Study Of Nilotinib As a c-Kit Inhibitor Combined With Re-Induction Chemotherapy For Relapsed and Refractory c-Kit Positive Acute Myeloid Leukemia","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Alberta","funders":"","keywords":"Cytarabine; Medicine; Nilotinib; Etoposide; Mitoxantrone; Internal medicine; Gastroenterology; Myeloid leukemia; Refractory (planetary science); Chemotherapy; Phases of clinical research; Pharmacology; Imatinib","score_opus":0.012373781639105902,"score_gpt":0.27684445000487296,"score_spread":0.26447066836576705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2285786982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99375945,0.00012197139,0.000013383741,0.00043183495,0.000081657934,0.004997598,0.000027842534,0.00009238626,0.0004738593],"genre_scores_gemma":[0.9960459,0.000052571704,0.0011745706,0.00020163995,0.0001751164,0.00055306643,0.00008992449,0.000083321094,0.0016239302],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982615,0.000058865495,0.00043862118,0.00054823613,0.00036246187,0.0003303021],"domain_scores_gemma":[0.9986002,0.000110511144,0.00031183587,0.00049323414,0.00027900672,0.00020520436],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013814824,0.0003383512,0.0006663111,0.00015261483,0.00010689205,0.000024857494,0.000084682535,0.00016164171,0.000100657664],"category_scores_gemma":[0.000061690655,0.00026326394,0.00008013676,0.00022078987,0.000103339065,0.00021235502,0.000033170312,0.00023915229,0.000017223017],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.048960097,0.08232764,0.01553103,0.0007053468,0.014941642,0.00048178132,0.031543,0.0000025370714,0.7619193,0.00008415636,0.0057956493,0.037707806],"study_design_scores_gemma":[0.49430004,0.1516777,0.026379433,0.0006185355,0.004216865,0.00047039802,0.0051588253,0.00010527006,0.31573358,0.00012215291,0.00056506344,0.00065212365],"about_ca_topic_score_codex":0.0005378389,"about_ca_topic_score_gemma":0.000033308817,"teacher_disagreement_score":0.4461857,"about_ca_system_score_codex":0.00046246639,"about_ca_system_score_gemma":0.00048531976,"threshold_uncertainty_score":0.99998194},"labels":[],"label_agreement":null},{"id":"W2287760468","doi":"10.71781/11724","title":"Spéciation chimique et immunotoxicologie du béryllium : effets thérapeutiques des agents complexants NTA, NTP et tiron","year":2008,"lang":"fr","type":"dissertation","venue":"Papyrus : Institutional Repository (Université de Montréal)","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Natural Sciences and Engineering Research Council of Canada; Institut de Recherche Robert-Sauvé en Santé et en Sécurité du Travail","keywords":"Tiron; Chemistry","score_opus":0.017747350557804582,"score_gpt":0.23789713141085742,"score_spread":0.22014978085305284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2287760468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92351836,0.029842835,0.00026312598,0.0006219452,0.0026579127,0.0016842424,0.00022752551,0.00031720445,0.04086684],"genre_scores_gemma":[0.93436646,0.026247045,0.0015642557,0.00063950993,0.0004467299,0.00012134739,0.0051592933,0.00012380375,0.031331528],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945669,0.00085061847,0.0009633446,0.0012444359,0.0012536029,0.0011210658],"domain_scores_gemma":[0.9965224,0.0004971687,0.0009930376,0.0007907019,0.00057544344,0.0006211924],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.00050317094,0.0011609215,0.0011546286,0.00058082584,0.0067761103,0.000089470945,0.00061251444,0.0012527672,0.00026628506],"category_scores_gemma":[0.00028479792,0.0013039433,0.0006866746,0.00048043503,0.0007329852,0.00080509775,0.00031865595,0.0012333491,0.00037360095],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.01137694,0.0075456337,0.4997252,0.0032233647,0.008149607,0.038823627,0.20519312,0.008828474,0.15643552,0.025047429,0.0057087224,0.029942377],"study_design_scores_gemma":[0.0084367655,0.0008446913,0.91557044,0.0023923388,0.0015215367,0.0038519772,0.010158242,0.0029176748,0.031348053,0.00027531033,0.021493401,0.001189576],"about_ca_topic_score_codex":0.06015641,"about_ca_topic_score_gemma":0.0182306,"teacher_disagreement_score":0.41584525,"about_ca_system_score_codex":0.044654083,"about_ca_system_score_gemma":0.008135837,"threshold_uncertainty_score":0.99968415},"labels":[],"label_agreement":null},{"id":"W2294086343","doi":"10.1007/s40266-016-0351-8","title":"Management of Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Accelerated or Blastic Phase","year":2016,"lang":"en","type":"review","venue":"Drugs & Aging","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Myeloid leukemia; Internal medicine; Pharmacotherapy; Dasatinib; Chronic myeloid leukaemia; Oncology; Transplantation; Intensive care medicine; Pediatrics; Imatinib","score_opus":0.02752429383985643,"score_gpt":0.32371042544477835,"score_spread":0.2961861316049219,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2294086343","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.019514445,0.972384,0.000053328236,0.000048175247,0.00020575,0.005600647,0.000096752345,0.00009208154,0.0020048197],"genre_scores_gemma":[0.013791226,0.9833906,0.00017803795,0.00006366692,0.00018861511,0.0006705862,0.00056971767,0.00015310202,0.0009944229],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963944,0.00021827151,0.0010562951,0.000776474,0.0008172701,0.0007373097],"domain_scores_gemma":[0.9974039,0.0005567787,0.00070039346,0.0010972562,0.00010034299,0.00014129342],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032320342,0.00079504214,0.001970911,0.000403419,0.000083773724,0.000043894106,0.0005652345,0.00020497353,0.00033490057],"category_scores_gemma":[0.00003802064,0.00038006157,0.00028933617,0.000980469,0.00012611564,0.00013312914,0.00013598603,0.0005598264,0.00013147393],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015755737,0.0003792513,0.000059425933,0.01666777,0.0008595598,0.00091079273,0.00055291114,0.0000038361522,3.32644e-7,0.000016825143,0.00031783734,0.9800739],"study_design_scores_gemma":[0.050175488,0.0019754923,0.00054384425,0.19769964,0.005342982,0.00006633019,0.00020581178,0.000042647305,0.000007633891,0.000006768733,0.74307436,0.0008590058],"about_ca_topic_score_codex":0.00016990809,"about_ca_topic_score_gemma":0.00004377007,"teacher_disagreement_score":0.9792149,"about_ca_system_score_codex":0.007101865,"about_ca_system_score_gemma":0.0027361794,"threshold_uncertainty_score":0.9998651},"labels":[],"label_agreement":null},{"id":"W2294106478","doi":"10.1016/j.bbmt.2016.02.015","title":"Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis","year":2016,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Cancer Institute","keywords":"Medicine; Myeloid leukemia; Internal medicine; Univariate analysis; Transplantation; Hematopoietic stem cell transplantation; Young adult; Multivariate analysis; Cohort; Oncology; Leukemia","score_opus":0.003868413697807001,"score_gpt":0.21166669706566074,"score_spread":0.20779828336785375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2294106478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997307,0.0012940789,0.00051301136,0.00006209612,0.000015193311,0.0005476636,0.00018901243,0.00001579667,0.00005617196],"genre_scores_gemma":[0.9876161,0.011452897,0.00040256145,0.000011874735,0.000010485287,0.00003355197,0.00042791766,0.000012410294,0.00003219056],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99887884,0.000059455073,0.0003959535,0.00035663726,0.00011697706,0.00019215731],"domain_scores_gemma":[0.99948657,0.0000888389,0.00017061738,0.00014923191,0.000040153656,0.000064616164],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012777667,0.00019329628,0.00057992415,0.00028368298,0.000023877323,0.0000020277068,0.000045629517,0.0001647531,0.00002502737],"category_scores_gemma":[0.000004097477,0.00012412124,0.00007148842,0.00018886218,0.00019773512,0.00006578843,0.000004440211,0.000066327615,7.277708e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006696946,0.00009367207,0.8802952,0.00046312631,0.0010930958,0.000017824219,0.00051713985,0.0000062295585,0.115731604,0.000025337124,3.586828e-7,0.0010867086],"study_design_scores_gemma":[0.012626668,0.0006897442,0.9006416,0.00023394352,0.004801055,0.00026880464,0.000020913601,0.000008525062,0.08056944,0.00001698564,3.055836e-7,0.00012200464],"about_ca_topic_score_codex":0.0008499615,"about_ca_topic_score_gemma":0.0012849678,"teacher_disagreement_score":0.035162166,"about_ca_system_score_codex":0.0000697344,"about_ca_system_score_gemma":0.00014495368,"threshold_uncertainty_score":0.50615174},"labels":[],"label_agreement":null},{"id":"W2294720344","doi":"10.1038/leu.2016.37","title":"Estimating deep molecular responses in chronic myelogenous leukemia: a Bayesian approach","year":2016,"lang":"en","type":"letter","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Chronic myelogenous leukemia; Leukemia; Bayesian probability; Medicine; Oncology; Immunology; Artificial intelligence; Computer science","score_opus":0.015615159401913435,"score_gpt":0.2642797321289984,"score_spread":0.24866457272708498,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2294720344","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21016593,0.04248937,0.079042114,0.4931774,0.005593198,0.024029687,0.0008786694,0.0046885875,0.13993502],"genre_scores_gemma":[0.11510026,0.00059585756,0.10986553,0.6862206,0.03275783,0.0033761438,0.0049907006,0.0025024135,0.04459069],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9922207,0.00049580634,0.001414185,0.0021525605,0.0013559109,0.002360867],"domain_scores_gemma":[0.99577606,0.0005586084,0.0006205735,0.0025496825,0.0001481294,0.00034693768],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.00058257475,0.0015137921,0.0021403593,0.0010580141,0.00018133293,0.000094198534,0.0008433352,0.0031375368,0.00043268295],"category_scores_gemma":[0.00049144065,0.0012703262,0.0006337617,0.0007139443,0.00037473536,0.00017364608,0.00034980272,0.0049445615,0.00058997615],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0015061535,0.00021352706,0.0016016919,0.009848858,0.002792061,0.12444949,0.0017323851,0.0037300182,0.016862376,0.00010958991,0.72095734,0.11619648],"study_design_scores_gemma":[0.048392802,0.0027156097,0.0021927035,0.0127117615,0.0033108164,0.014332769,0.00012679872,0.09750362,0.0053718556,0.0016153991,0.80493855,0.0067873034],"about_ca_topic_score_codex":0.00092387013,"about_ca_topic_score_gemma":0.000062531384,"teacher_disagreement_score":0.19304316,"about_ca_system_score_codex":0.09023551,"about_ca_system_score_gemma":0.016789887,"threshold_uncertainty_score":0.9997611},"labels":[],"label_agreement":null},{"id":"W2296398034","doi":"10.1002/ajh.24360","title":"Long‐term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome‐positive leukemias treated with bosutinib","year":2016,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":95,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Bosutinib; Medicine; Internal medicine; Imatinib; Tyrosine-kinase inhibitor; Nilotinib; Myeloid leukemia; Cardiology; Oncology; Cancer","score_opus":0.00965328692726936,"score_gpt":0.2594641061946532,"score_spread":0.24981081926738385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2296398034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99867123,0.0004446498,0.00004680104,0.00029979498,0.000021891512,0.0004352951,0.000012063782,0.0000057091133,0.000062561885],"genre_scores_gemma":[0.99947774,0.00011616144,0.00029869447,0.00003960376,0.000022513843,0.000009483535,0.000009091437,0.00002292871,0.000003773781],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981839,0.000269637,0.0004861752,0.00022437291,0.0005867948,0.00024911357],"domain_scores_gemma":[0.9981347,0.0001566911,0.00074177835,0.00023450605,0.0005857763,0.00014655192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000350773,0.0002006093,0.0010186486,0.0002393339,0.000021754071,0.000003061577,0.00006876329,0.00005972783,0.00004675169],"category_scores_gemma":[0.00008724594,0.00010872901,0.000081147875,0.00027351177,0.000540871,0.00011768955,0.000021158947,0.00014548772,0.0000015987767],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017036066,0.00031725658,0.9798031,0.000027806891,0.00085049594,0.0000719488,0.00027106615,0.00000518973,0.00060089055,0.00000855616,0.000012566078,0.016327536],"study_design_scores_gemma":[0.015673324,0.0065649743,0.9671029,0.00081974274,0.00091670797,0.0005345615,0.000108634624,0.000008933333,0.0081374515,0.000007505283,0.000003871631,0.00012140986],"about_ca_topic_score_codex":0.00006946043,"about_ca_topic_score_gemma":0.000020036436,"teacher_disagreement_score":0.016206125,"about_ca_system_score_codex":0.0008378127,"about_ca_system_score_gemma":0.0006409183,"threshold_uncertainty_score":0.44338402},"labels":[],"label_agreement":null},{"id":"W2299152083","doi":"10.1200/jco.2013.31.15_suppl.7053","title":"Switching patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with residual disease on long-term imatinib (IM) to nilotinib (NIL): ENESTcmr 24-mo follow-up.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McMaster University","funders":"","keywords":"Medicine; Nilotinib; Internal medicine; Myeloid leukemia; Imatinib; Gastroenterology","score_opus":0.05615508806723663,"score_gpt":0.39863005748680974,"score_spread":0.3424749694195731,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2299152083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928742,0.00043291086,0.00012310645,0.0026967027,0.0009954441,0.0021667131,0.00001593785,0.00005107357,0.0006439348],"genre_scores_gemma":[0.9924714,0.00030309244,0.0015972254,0.0024624981,0.0021341117,0.00013635124,0.00005085231,0.00014274042,0.0007017034],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9919317,0.0006901225,0.0038219308,0.0009279295,0.0014621683,0.0011661511],"domain_scores_gemma":[0.99169916,0.0020713948,0.0026100953,0.000830459,0.00072592514,0.002062978],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0017738004,0.0007363591,0.002881543,0.0005474246,0.00014667002,0.000063156855,0.00059548754,0.00047730329,0.0005515318],"category_scores_gemma":[0.0022387127,0.00048019856,0.00047747063,0.0005390239,0.000313392,0.00052586984,0.00017854829,0.002541883,0.00035766524],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.057362985,0.007940176,0.54669434,0.0004320894,0.0013491346,0.0065489644,0.0004468309,0.0013766488,0.0007303003,0.000038020768,0.0043264837,0.37275404],"study_design_scores_gemma":[0.14482859,0.10029146,0.7466665,0.0027943368,0.00095349865,0.00031538814,0.000055320932,0.0004100854,0.00026030044,0.000055537606,0.0027970104,0.000572019],"about_ca_topic_score_codex":0.00027740348,"about_ca_topic_score_gemma":0.0014431854,"teacher_disagreement_score":0.372182,"about_ca_system_score_codex":0.016010385,"about_ca_system_score_gemma":0.02214479,"threshold_uncertainty_score":0.999765},"labels":[],"label_agreement":null},{"id":"W2301273092","doi":"10.1182/blood.v122.21.5501.5501","title":"A Comparison Of Long-Term Outcomes Of Donor Lymphocyte Infusions and Tyrosine Kinase Inhibitors In CML Patients Relapsed After Allogeneic Hemopoietic Stem Cell Transplantation","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Nilotinib; Dasatinib; Internal medicine; Transplantation; Donor lymphocyte infusion; Imatinib; Cumulative incidence; Tyrosine-kinase inhibitor; Graft-versus-host disease; Gastroenterology; Hematopoietic stem cell transplantation; Stem cell; Oncology; Myeloid leukemia; Surgery; Cancer","score_opus":0.012373655439929127,"score_gpt":0.255595072388396,"score_spread":0.24322141694846688,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2301273092","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99783725,0.0010731273,0.0000028872355,0.000033679687,0.000056974106,0.0008805969,0.000031897405,0.000014415797,0.00006919791],"genre_scores_gemma":[0.99924695,0.0001903571,0.00024375276,0.00003077362,0.000009683593,0.00007999821,0.00007637042,0.000021789036,0.000100319325],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987205,0.00004445736,0.0005812328,0.00022748676,0.00023374113,0.00019255134],"domain_scores_gemma":[0.99930435,0.0000745797,0.00019495506,0.0002464726,0.00007529031,0.000104355764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000047842397,0.00018466814,0.00050602155,0.00016863448,0.000017825432,0.0000055301693,0.000052921714,0.00011199592,0.00006555204],"category_scores_gemma":[0.000009210623,0.00015169135,0.00007287979,0.0001499724,0.00006796019,0.000075877324,0.000031181444,0.00008227811,0.00000952811],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019177531,0.0023257704,0.9795518,0.00060463586,0.000065313056,0.000029232922,0.0014169213,0.000004286965,0.013054456,4.7965256e-7,0.000008890364,0.0027464598],"study_design_scores_gemma":[0.020015098,0.00045032473,0.8476058,0.00033694756,0.00036919158,0.0000058187393,0.00005478395,0.000021431366,0.1310402,0.0000015982679,0.0000011739564,0.00009757739],"about_ca_topic_score_codex":0.00030652125,"about_ca_topic_score_gemma":0.00013484004,"teacher_disagreement_score":0.13194592,"about_ca_system_score_codex":0.00014310153,"about_ca_system_score_gemma":0.000106398016,"threshold_uncertainty_score":0.6185794},"labels":[],"label_agreement":null},{"id":"W2304073669","doi":"10.1182/blood.v122.21.513.513","title":"Disruption Of Ikaros In Patients’ Chronic Phase CML Cells Induces The Features Of Accelerated Phase Disease","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Immunology; CD34; Biology; Cancer research; Myeloid; Myeloid leukemia; CD38; Stromal cell; Stem cell; Cell biology","score_opus":0.017056089418271032,"score_gpt":0.289482142458701,"score_spread":0.27242605304043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2304073669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973481,0.0008666895,0.0000013576981,0.00014808714,0.000068826506,0.0012766274,0.000078296915,0.000019403475,0.00019256346],"genre_scores_gemma":[0.99931294,0.00011370684,0.000032554617,0.00004257943,0.00006965078,0.00009637073,0.00018380591,0.000020817626,0.00012757456],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99879676,0.000061463994,0.00038110098,0.00022387717,0.00030429024,0.00023250717],"domain_scores_gemma":[0.9990454,0.000058646187,0.00020821308,0.00043539036,0.00012331406,0.00012903845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007194967,0.00017454491,0.00031107222,0.00010454564,0.000030789688,0.000010895261,0.00013193057,0.00007441604,0.00038160916],"category_scores_gemma":[0.00007079295,0.000113221024,0.00009015746,0.00026988515,0.000103246246,0.00012356324,0.000044183118,0.00016553492,0.000023653201],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020498794,0.061148003,0.14184786,0.0010872579,0.00082416437,0.000077594545,0.0020981205,0.000032379376,0.7094143,0.000069005284,0.0021370603,0.07921437],"study_design_scores_gemma":[0.08054813,0.002169721,0.40974367,0.00034313626,0.00059906393,0.0000029317366,0.00009567153,0.00011417836,0.506085,0.000038307193,0.00009296798,0.00016726064],"about_ca_topic_score_codex":0.00034676248,"about_ca_topic_score_gemma":0.000017909939,"teacher_disagreement_score":0.2678958,"about_ca_system_score_codex":0.00019146131,"about_ca_system_score_gemma":0.00032799965,"threshold_uncertainty_score":0.46170196},"labels":[],"label_agreement":null},{"id":"W2305151049","doi":"10.1182/blood.v118.21.3766.3766","title":"Imatinib Long-Term Effects Study: Global Independent Assessment of Imatinib in Chronic Myeloid Leukemia: Results At 8 Years,","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Imatinib; Cumulative incidence; Internal medicine; Incidence (geometry); Population; Standardized mortality ratio; Imatinib mesylate; Myeloid leukemia; Adverse effect; Mortality rate; Rate ratio; Cohort; Confidence interval","score_opus":0.02203925635593625,"score_gpt":0.3071219850640448,"score_spread":0.2850827287081086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2305151049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900011,0.0005146448,0.00000902321,0.000018555347,0.00018735962,0.0023667957,0.00006668051,0.00008811829,0.0067477454],"genre_scores_gemma":[0.9981808,0.00007616579,0.0010434729,0.000038012484,0.00011356798,0.00017794242,0.00010618747,0.000046419376,0.00021740524],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99674207,0.00018342487,0.00094919355,0.00070274435,0.00081801944,0.0006045618],"domain_scores_gemma":[0.998144,0.00011964888,0.0004118905,0.0010360443,0.000062308885,0.00022616373],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005111578,0.00039301228,0.0008419442,0.0001553599,0.00004735546,0.000012799641,0.00029650013,0.00022583717,0.000198755],"category_scores_gemma":[0.00010839732,0.00036257395,0.00016665073,0.00038594735,0.000095677155,0.00010836644,0.00036431124,0.0003761927,0.00009658315],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005180012,0.0050596935,0.98211473,0.000628003,0.0007326026,0.0027128006,0.0014652645,0.000008217461,0.002777492,0.000056731216,0.000107648724,0.003818806],"study_design_scores_gemma":[0.051475987,0.003016027,0.9358755,0.0005817385,0.00062229397,0.00019270649,0.00006866335,0.000048649195,0.007832102,0.000029783525,0.000009682683,0.00024687583],"about_ca_topic_score_codex":0.00095935434,"about_ca_topic_score_gemma":0.0013533946,"teacher_disagreement_score":0.050957985,"about_ca_system_score_codex":0.0070528723,"about_ca_system_score_gemma":0.001822434,"threshold_uncertainty_score":0.99988264},"labels":[],"label_agreement":null},{"id":"W2307668285","doi":"10.1186/s12967-016-0837-5","title":"Single nucleotide polymorphisms in apoptosis pathway are associated with response to imatinib therapy in chronic myeloid leukemia","year":2016,"lang":"en","type":"article","venue":"Journal of Translational Medicine","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Imatinib; Apoptosis; Genotype; Single-nucleotide polymorphism; Myeloid leukemia; Fas ligand; Fas receptor; Medicine; Cancer research; Immunology; Oncology; Biology; Programmed cell death; Gene; Genetics","score_opus":0.02610373860163125,"score_gpt":0.2707129881274358,"score_spread":0.24460924952580457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2307668285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9645036,0.0010550924,0.00023381399,0.033338483,0.00015125735,0.00047731484,0.00001959255,0.0000175085,0.00020333542],"genre_scores_gemma":[0.99764556,0.00016640095,0.0007741336,0.00067782786,0.0003871942,0.000015960935,0.000009692955,0.000048285874,0.00027492028],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99701726,0.00023618637,0.0010587819,0.0002637313,0.0010262114,0.0003978064],"domain_scores_gemma":[0.99765676,0.0010586833,0.0005142621,0.00022167197,0.00025930622,0.0002892881],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012913615,0.0002841554,0.00081357226,0.00084844104,0.00003472505,0.000006663991,0.0001612929,0.00013509291,0.00043537377],"category_scores_gemma":[0.0006608262,0.00016028967,0.00011015788,0.0007330915,0.00013722258,0.00021053059,0.000008484574,0.00034631786,0.000012179065],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022440903,0.0006365636,0.124034494,0.000031556872,0.00036463252,0.00075593585,0.0021912423,0.00033440586,0.79403836,0.000022697466,0.00050436583,0.054644864],"study_design_scores_gemma":[0.053096533,0.0077105025,0.9029889,0.009319674,0.0000844,0.00025507892,0.00013963618,0.00006438447,0.02401342,0.0001680069,0.0019062605,0.0002532088],"about_ca_topic_score_codex":0.0000655464,"about_ca_topic_score_gemma":0.0002817034,"teacher_disagreement_score":0.7789544,"about_ca_system_score_codex":0.0054945843,"about_ca_system_score_gemma":0.0020147362,"threshold_uncertainty_score":0.99832314},"labels":[],"label_agreement":null},{"id":"W2312433151","doi":"10.1038/sj.leu.2401870","title":"Autoantibodies to Abl and Bcr proteins","year":2000,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"ABL; Immunoprecipitation; breakpoint cluster region; Biology; Autoantibody; Philadelphia chromosome; Leukemia; Immune system; Fusion protein; Immunology; Cancer research; Antibody; Cell biology; Tyrosine kinase; Receptor; Chromosomal translocation; Genetics; Signal transduction; Gene","score_opus":0.011829536000266101,"score_gpt":0.2645045572600215,"score_spread":0.2526750212597554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2312433151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9562007,0.00043874834,0.000014281523,0.0010644731,0.000045231038,0.0006916676,0.000007948972,0.00015974141,0.04137717],"genre_scores_gemma":[0.9551295,0.00015484603,0.0049098576,0.0014897446,0.00018909675,0.000076420634,0.000018068376,0.00003442744,0.037998043],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9989391,0.000016169697,0.00017986068,0.00033400516,0.00020525014,0.00032558863],"domain_scores_gemma":[0.9993138,0.000026237212,0.00002188797,0.00036292168,0.00002597949,0.00024920073],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000068255285,0.00017928728,0.00026991352,0.000069714624,0.000080703954,0.000023061204,0.000065101056,0.00008912926,0.0018301709],"category_scores_gemma":[0.00004126509,0.00014911442,0.000048070717,0.00015022817,0.00005631005,0.00006297845,0.000035943827,0.00015107382,0.0011895115],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011918037,0.00031180392,0.060036503,0.00064531446,0.0005394472,0.0012404247,0.004646557,0.00013040048,0.025913334,0.00088188867,0.042818163,0.8616444],"study_design_scores_gemma":[0.010455536,0.001330597,0.4869264,0.00072896795,0.00026755227,0.0008605612,0.00013851233,0.0009848112,0.02008743,0.0004263482,0.47710028,0.00069299294],"about_ca_topic_score_codex":0.00059479097,"about_ca_topic_score_gemma":0.00003999059,"teacher_disagreement_score":0.86095136,"about_ca_system_score_codex":0.0011214125,"about_ca_system_score_gemma":0.00037994515,"threshold_uncertainty_score":0.9995882},"labels":[],"label_agreement":null},{"id":"W2313398017","doi":"10.1158/1538-7445.am2013-3454","title":"Abstract 3454: Bcl-xL anti-apoptotic network is dispensable for emergence and maintenance of CML but required for disease progression, and represents an alternative target for halting survival of blast crisis CML progenitors.","year":2013,"lang":"en","type":"article","venue":"Cancer Research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Bcl-xL; Progenitor cell; Cancer research; Chronic myelogenous leukemia; Biology; Bone marrow; Stem cell; Haematopoiesis; Stromal cell; Leukemia; Immunology; Apoptosis; Programmed cell death; Cell biology; Genetics","score_opus":0.08764253185837266,"score_gpt":0.4240263148210392,"score_spread":0.3363837829626665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2313398017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98883295,0.0021330612,0.00048030866,0.00079753756,0.00020478437,0.0068591796,0.0006529295,0.000017614395,0.000021657517],"genre_scores_gemma":[0.9903538,0.0007182715,0.00460983,0.000019215295,0.00046653656,0.0032373078,0.00009842111,0.00006759781,0.0004290216],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99709916,0.0000797873,0.00056831026,0.000769268,0.0006035408,0.00087994285],"domain_scores_gemma":[0.9967248,0.00048538257,0.00029744324,0.0005138411,0.0015102898,0.00046823852],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095746055,0.00023847351,0.0006073455,0.000112630965,0.000246436,0.000039470437,0.00021782948,0.00009237734,0.00010358264],"category_scores_gemma":[0.0007906078,0.00019188372,0.00011762852,0.00024297007,0.0003866023,0.00028909452,0.00015295595,0.00016457467,0.0000011106937],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015484187,0.0021527738,0.72242475,0.019675065,0.002041794,0.000039049366,0.003590562,0.00047836345,0.11099234,0.00037234867,0.07174884,0.050999954],"study_design_scores_gemma":[0.050718635,0.008897665,0.36508873,0.0109572755,0.0010592456,0.00002088288,0.0073336987,0.11215629,0.42330065,0.014051495,0.0046355263,0.0017798857],"about_ca_topic_score_codex":0.0011160829,"about_ca_topic_score_gemma":0.000046789242,"teacher_disagreement_score":0.35733598,"about_ca_system_score_codex":0.00025254017,"about_ca_system_score_gemma":0.0005652736,"threshold_uncertainty_score":0.7824791},"labels":[],"label_agreement":null},{"id":"W2313445985","doi":"10.1182/blood-2015-06-653006","title":"Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Institutes of Health; National Cancer Institute; Princess Margaret Hospital Foundation","keywords":"Myeloid; Cancer research; Signal transduction; Transformation (genetics); Biology; Immunology; Cell biology; Genetics; Gene","score_opus":0.01176830110819154,"score_gpt":0.22468968606838985,"score_spread":0.2129213849601983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2313445985","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994834,0.0015476727,0.001958011,0.00047204865,0.000052800096,0.0006291524,0.0002727051,0.000072958865,0.00016063434],"genre_scores_gemma":[0.9983098,0.00036635023,0.0006598375,0.000070124406,0.00015957472,0.00009666183,0.000087812645,0.000034851266,0.00021497364],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989339,0.0000223934,0.00026190365,0.00032113589,0.00017668496,0.00028398604],"domain_scores_gemma":[0.9993159,0.00014466172,0.00009957361,0.00022073029,0.000054747532,0.00016436804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012671105,0.00020287486,0.00029405399,0.000056190347,0.0001313346,0.000024518185,0.00005647013,0.00010627734,0.00004040275],"category_scores_gemma":[0.00009089767,0.00014202285,0.00006760493,0.00005787492,0.00007035257,0.00013838209,0.000026236215,0.000034805886,0.0000069468783],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047976946,0.00052185514,0.039638452,0.0007018666,0.00042899596,0.000035650733,0.00084213883,3.2348285e-7,0.9018423,0.00010221916,0.00066219264,0.054744236],"study_design_scores_gemma":[0.05028615,0.00069399195,0.02053995,0.00062697654,0.001462894,0.0005391915,0.00023617983,0.00016934486,0.92116004,0.00034078068,0.0034808046,0.00046369966],"about_ca_topic_score_codex":0.000039820185,"about_ca_topic_score_gemma":0.000016028327,"teacher_disagreement_score":0.054280534,"about_ca_system_score_codex":0.00017734867,"about_ca_system_score_gemma":0.00013829154,"threshold_uncertainty_score":0.5791524},"labels":[],"label_agreement":null},{"id":"W2313668596","doi":"10.1038/sj.leu.2401855","title":"Increase in mutant frequencies in mice expressing the BCR-ABL activated tyrosine kinase","year":2000,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; Montreal Clinical Research Institute; Royal Victoria Regional Health Centre","funders":"Medical Research Council","keywords":"Chromosomal translocation; Tyrosine kinase; Biology; ABL; Cancer research; breakpoint cluster region; Philadelphia chromosome; Mutant; Receptor tyrosine kinase; Phenotype; Molecular biology; Kinase; Mutagenesis; Cell biology; Genetics; Signal transduction; Gene","score_opus":0.015066016234404117,"score_gpt":0.25597965106315246,"score_spread":0.24091363482874834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2313668596","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888718,0.0009395176,0.000001962372,0.0006144011,0.000055710992,0.0005605643,0.0000121996745,0.000086309534,0.008857542],"genre_scores_gemma":[0.996378,0.00018918615,0.00038890057,0.00087782746,0.000117311916,0.000080061654,0.000050403825,0.00004445072,0.0018738726],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980884,0.00014498505,0.00045339932,0.0004338721,0.000323461,0.00055587146],"domain_scores_gemma":[0.9989626,0.00021099059,0.00008206426,0.00056866,0.000031533356,0.00014415594],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00027478414,0.0002934708,0.00041158425,0.000171762,0.000087065484,0.00003731675,0.00020932118,0.00017395802,0.0011314079],"category_scores_gemma":[0.00019850992,0.00020966052,0.00007656359,0.0006736136,0.00014795175,0.00019554995,0.00004955424,0.0005840541,0.00015985635],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015321634,0.0004952799,0.027521903,0.00014772866,0.00008650576,0.0037371537,0.0035135308,0.00080523477,0.90674627,0.00007111679,0.0012910342,0.054052066],"study_design_scores_gemma":[0.03224449,0.00039162324,0.28686345,0.0031403552,0.00022688424,0.000873008,0.0012688434,0.006676813,0.64949095,0.0005089571,0.017318917,0.0009957091],"about_ca_topic_score_codex":0.013768489,"about_ca_topic_score_gemma":0.00084019534,"teacher_disagreement_score":0.25934157,"about_ca_system_score_codex":0.0055380035,"about_ca_system_score_gemma":0.001052729,"threshold_uncertainty_score":0.99978167},"labels":[],"label_agreement":null},{"id":"W2314330969","doi":"10.1038/sj.leu.2401752","title":"Autonomous multi-lineage differentiation in vitro of primitive CD34+ cells from patients with chronic myeloid leukemia","year":2000,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"BC Cancer Agency; University of British Columbia","keywords":"Clonogenic assay; CD34; Biology; Autocrine signalling; Myeloid; Progenitor cell; Immunology; Interleukin 3; Population; Haematopoiesis; Cancer research; Myeloid leukemia; Megakaryocyte; Stem cell; Cell biology; In vitro; Cell culture; Antigen; Medicine; Interleukin 21; Biochemistry; Genetics","score_opus":0.008677923137142322,"score_gpt":0.2237158773523174,"score_spread":0.21503795421517508,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2314330969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966658,0.00027002342,0.00014299569,0.000020944277,0.000129244,0.0012907684,0.00024377047,0.00011125001,0.001125206],"genre_scores_gemma":[0.9929818,0.0001134555,0.00331915,0.0001298432,0.00015700019,0.00008936621,0.0014026911,0.00009296009,0.001713721],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9972019,0.00009503034,0.00076809846,0.00075764424,0.000563465,0.0006138219],"domain_scores_gemma":[0.99846274,0.00014344828,0.00030854007,0.0007492272,0.000122057405,0.00021399691],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0000888106,0.0004972286,0.00085398706,0.00021323375,0.00006397744,0.000020442385,0.0002190745,0.00030532238,0.0011687893],"category_scores_gemma":[0.000029097431,0.000420244,0.00016195682,0.00036986975,0.00015217751,0.00021145657,0.000057621495,0.0005167842,0.00022273313],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011700042,0.0037190828,0.27439278,0.00079095794,0.0016723183,0.00047977516,0.005254965,0.0056861183,0.42090914,0.000022204686,0.0006006819,0.27477196],"study_design_scores_gemma":[0.027954934,0.000540493,0.6383034,0.00039311187,0.00027158146,0.0000041468156,0.00003277032,0.010563782,0.3210155,0.000006068871,0.0005297904,0.00038440776],"about_ca_topic_score_codex":0.003416052,"about_ca_topic_score_gemma":0.00047257377,"teacher_disagreement_score":0.36391065,"about_ca_system_score_codex":0.01567392,"about_ca_system_score_gemma":0.0022631492,"threshold_uncertainty_score":0.99982494},"labels":[],"label_agreement":null},{"id":"W2315538824","doi":"10.1016/s0959-8049(12)71627-1","title":"1009 Targeting Chronic Myeloid Leukemia Stem/progenitor Cells by Effective Inhibition of a Novel AHI-1-BCR-ABL-JAK2 Interaction Complex","year":2012,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute","funders":"","keywords":"Myeloid leukemia; Progenitor cell; Cancer research; breakpoint cluster region; Stem cell; Medicine; Chemistry; Cell biology; Internal medicine; Biology; Receptor","score_opus":0.022557032013183032,"score_gpt":0.2887791172738332,"score_spread":0.26622208526065017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2315538824","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871705,0.0077592707,0.0010871803,0.00013087253,0.0011931364,0.0005027545,0.000036381785,0.000025789128,0.002094095],"genre_scores_gemma":[0.995496,0.00043222256,0.00097065506,0.00014655614,0.002322642,0.000009677676,0.000024750954,0.00008612001,0.00051139016],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976214,0.00030857508,0.00089118065,0.00020560912,0.00054865424,0.00042458327],"domain_scores_gemma":[0.99779785,0.00011295934,0.0012136818,0.00020614968,0.00037019246,0.00029914372],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008850861,0.00028568783,0.000556543,0.00017345772,0.00007872163,0.000020914818,0.0001224653,0.000054159416,0.00045734996],"category_scores_gemma":[0.000057317375,0.00023803132,0.0002600914,0.00020856997,0.00009060898,0.00043496015,0.00006377657,0.00054380693,0.000052839878],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00068454706,0.0003372838,0.0026764409,0.00024597946,0.00049554504,0.000054482756,0.00086665334,0.0001949019,0.9298293,0.0000035824896,0.01557903,0.04903223],"study_design_scores_gemma":[0.016558073,0.00209256,0.015842149,0.002124456,0.0008030669,0.0004723397,0.00052546686,0.00077705435,0.857002,0.000001022131,0.10341771,0.00038410144],"about_ca_topic_score_codex":0.000063047206,"about_ca_topic_score_gemma":0.0000038825206,"teacher_disagreement_score":0.08783868,"about_ca_system_score_codex":0.0052640066,"about_ca_system_score_gemma":0.000503968,"threshold_uncertainty_score":0.9985546},"labels":[],"label_agreement":null},{"id":"W2316643661","doi":"10.1097/00043426-200203000-00011","title":"Allogeneic Bone Marrow Transplantation in Children With Chronic Myelogenous Leukemia","year":2002,"lang":"en","type":"article","venue":"Journal of Pediatric Hematology/Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; SickKids Foundation; Hospital for Sick Children","funders":"","keywords":"Medicine; Bone marrow transplantation; Chronic myelogenous leukemia; Leukemia; Bone marrow; Oncology; Immunology","score_opus":0.014722889428658905,"score_gpt":0.26286545769425423,"score_spread":0.24814256826559533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2316643661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98167646,0.015203365,0.00014015716,0.0011300616,0.00024972917,0.0005701565,0.0000076026054,0.000031205785,0.0009912546],"genre_scores_gemma":[0.98308045,0.012577829,0.002820651,0.00027613834,0.0009781502,0.00002595048,0.000021182866,0.00004898578,0.00017065972],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.9970883,0.00023995362,0.0012338278,0.0003547062,0.00041714762,0.00066605356],"domain_scores_gemma":[0.9980604,0.0002481222,0.00091590214,0.00028920182,0.00017302079,0.00031332928],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005048688,0.0003419831,0.0013009203,0.0008364986,0.00006806489,0.000008187895,0.0002162463,0.0005577346,0.00051431975],"category_scores_gemma":[0.00008775336,0.00026415056,0.00020220883,0.00061514636,0.00014273867,0.00015260982,0.0000256905,0.00093230215,0.00011302355],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011048693,0.0012365001,0.95764303,0.0002669676,0.000709312,0.016277919,0.0011235793,0.0003038735,0.001325864,0.00006886217,0.0037602428,0.016178973],"study_design_scores_gemma":[0.06830498,0.018733408,0.42286566,0.00019306129,0.0048374,0.47686127,0.00018871746,0.00046512618,0.0021942137,0.00014321,0.0043741125,0.00083883957],"about_ca_topic_score_codex":0.00006663562,"about_ca_topic_score_gemma":0.00023967242,"teacher_disagreement_score":0.53477734,"about_ca_system_score_codex":0.00539372,"about_ca_system_score_gemma":0.002712276,"threshold_uncertainty_score":0.99998105},"labels":[],"label_agreement":null},{"id":"W2317071210","doi":"10.1016/j.exphem.2014.07.191","title":"The transcription elongation control by IKAROS and NuRD is required for normal hematopoiesis","year":2014,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Haematopoiesis; Elongation; Transcription factor; Transcription (linguistics); Biology; Cell biology; Genetics; Stem cell; Gene","score_opus":0.010001754531850083,"score_gpt":0.2783644340615301,"score_spread":0.26836267952968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2317071210","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9713005,0.0136270635,0.00436605,0.006706723,0.0004165898,0.0019973821,0.000040163668,0.00012077507,0.001424787],"genre_scores_gemma":[0.99709713,0.000031242063,0.0004905582,0.0010245175,0.00006534556,0.0004316696,0.000061482664,0.000025629128,0.0007724306],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989351,0.000055611155,0.0002916615,0.00028042134,0.00013676882,0.00030045098],"domain_scores_gemma":[0.99934983,0.00019751326,0.00008982923,0.00022978889,0.0000329849,0.000100025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014240063,0.00017275632,0.00033827833,0.000029834844,0.00025895183,0.000019262132,0.00006207955,0.00012677952,0.00008065014],"category_scores_gemma":[0.000036321646,0.00012794528,0.00008676,0.000041007755,0.00018054649,0.00008762831,0.000012603024,0.000067776884,0.000023425202],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049568624,0.0010594038,0.006526933,0.0003967238,0.0007197225,0.000017498576,0.0066857613,6.823836e-7,0.77284735,0.102019034,0.09557718,0.009192844],"study_design_scores_gemma":[0.0132327145,0.00086530397,0.00033129248,0.0000405475,0.00009794068,0.00048433006,0.0008041642,0.0020238673,0.96143967,0.00035238336,0.020166658,0.00016112012],"about_ca_topic_score_codex":0.00002549814,"about_ca_topic_score_gemma":0.000005843618,"teacher_disagreement_score":0.18859233,"about_ca_system_score_codex":0.00020250205,"about_ca_system_score_gemma":0.000036329868,"threshold_uncertainty_score":0.52174574},"labels":[],"label_agreement":null},{"id":"W2318261983","doi":"10.1240/sav_gbm_2004_h_000834","title":"The BCR-ABL1 kinase bypasses selection for the expression of a pre-B cell receptor in pre-B acute lymphoblastic leukemia cells","year":2004,"lang":"en","type":"article","venue":"GBM Annual Fall meeting M�nster 2004","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Deutsche Krebshilfe; Universität zu Köln; Studienstiftung des Deutschen Volkes; Deutsche Forschungsgemeinschaft; Deutscher Akademischer Austauschdienst; Stem Cell Network","keywords":"Cancer research; Lymphoblastic Leukemia; Medicine; Selection (genetic algorithm); breakpoint cluster region; Leukemia; Receptor; Immunology; Internal medicine; Computer science","score_opus":0.007466478549094536,"score_gpt":0.24966455773472326,"score_spread":0.24219807918562872,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2318261983","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940009,0.0012342909,0.0012029024,0.00036643283,0.0004985562,0.0020269784,0.000084777,0.00008701902,0.00049810443],"genre_scores_gemma":[0.9929081,0.00033227247,0.002697264,0.0001791068,0.000291518,0.00033024108,0.000037329835,0.00007698457,0.003147144],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997523,0.00011562744,0.00069603574,0.00052177993,0.00047994524,0.0006635782],"domain_scores_gemma":[0.99795556,0.00079505733,0.00035655353,0.0005335271,0.00022554152,0.0001337683],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000537519,0.0003732493,0.00043139985,0.00011609198,0.00030227407,0.000047274945,0.0003192911,0.00022061469,0.000017949404],"category_scores_gemma":[0.00024062795,0.00022710202,0.00020204364,0.00035668732,0.00014333417,0.0001801475,0.000114303875,0.00029565347,0.000032745436],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009509436,0.0016058425,0.010973068,0.0013925122,0.0005822799,0.00005514028,0.02173544,0.041437868,0.88280874,0.00007170414,0.018412644,0.011415311],"study_design_scores_gemma":[0.01777941,0.0017258469,0.0056217005,0.0022502681,0.0006025013,0.000060933984,0.001632305,0.001182705,0.9570803,0.0001576181,0.011410278,0.0004961549],"about_ca_topic_score_codex":0.0018959055,"about_ca_topic_score_gemma":0.0008578039,"teacher_disagreement_score":0.07427152,"about_ca_system_score_codex":0.0024071508,"about_ca_system_score_gemma":0.0011517691,"threshold_uncertainty_score":0.9260952},"labels":[],"label_agreement":null},{"id":"W2323397864","doi":"10.1002/cmdc.201600021","title":"Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)‐Resistant CML Lines While Circumventing Pharmacokinetic Liabilities","year":2016,"lang":"en","type":"article","venue":"ChemMedChem","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Amgen (Canada); University of Toronto","funders":"National Cancer Institute; Canadian Institutes of Health Research; National Institutes of Health; Leukemia and Lymphoma Society","keywords":"Pharmacology; Chemistry; Tyrosine kinase; Tyrosine-kinase inhibitor; STAT protein; In vivo; STAT3; Kinome; Myeloid leukemia; Pharmacokinetics; Kinase; Cancer research; Medicine; Biochemistry; Biology; Signal transduction; Cancer; Internal medicine","score_opus":0.027323075401604186,"score_gpt":0.2838871783152141,"score_spread":0.2565641029136099,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2323397864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99333316,0.0018211007,0.000024402549,0.0020850247,0.00018550616,0.000610949,0.000021065187,0.00023545911,0.0016833523],"genre_scores_gemma":[0.9958988,0.00016078028,0.0006143512,0.0002422017,0.0009427359,0.00014048374,0.00008614207,0.000114471564,0.0018000263],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9967754,0.00007922355,0.0007913797,0.0008541711,0.0004873501,0.0010124675],"domain_scores_gemma":[0.99832827,0.00022698016,0.00020119417,0.00071923004,0.000150597,0.0003737429],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041681563,0.00047856168,0.0006713023,0.0002525057,0.00012087532,0.000034585293,0.00022443944,0.00019018856,0.00041059614],"category_scores_gemma":[0.000615703,0.000364206,0.00017530503,0.00048657396,0.00020183591,0.0003295824,0.00011795443,0.0003539776,0.00005078643],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035645743,0.00051857793,0.012413186,0.00039289592,0.00005719802,0.00028152997,0.0008909589,0.0000021678443,0.9477125,0.00008151272,0.00019845313,0.037094586],"study_design_scores_gemma":[0.007327973,0.00045372042,0.004482419,0.0012353561,0.00015689817,0.00009875634,0.0004099759,0.00026493467,0.98292905,0.00037266297,0.0018100389,0.00045822156],"about_ca_topic_score_codex":0.00015750711,"about_ca_topic_score_gemma":0.00004328595,"teacher_disagreement_score":0.036636364,"about_ca_system_score_codex":0.0018821165,"about_ca_system_score_gemma":0.0004303897,"threshold_uncertainty_score":0.99988097},"labels":[],"label_agreement":null},{"id":"W2325902406","doi":"10.1038/sj.onc.1203804","title":"Early events in leukemogenesis in P190Bcr-abl transgenic mice","year":2000,"lang":"en","type":"article","venue":"Oncogene","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital","funders":"National Cancer Institute; Medical Research Council; National Institutes of Health","keywords":"Biology; ABL; Cancer research; Haematopoiesis; Leukemia; Cell cycle; Carcinogenesis; Tyrosine kinase; Apoptosis; Cell biology; Immunology; Signal transduction; Cancer; Stem cell; Genetics","score_opus":0.014927976592644273,"score_gpt":0.2658516541146014,"score_spread":0.2509236775219571,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2325902406","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98963106,0.0011228003,0.000004428597,0.00030016105,0.000098148965,0.00057654496,0.0000122578995,0.000048041184,0.008206569],"genre_scores_gemma":[0.9902723,0.0007058854,0.00055396726,0.00029559637,0.00013946419,0.00007922149,0.00003978116,0.000052711293,0.007861077],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981284,0.00008697737,0.00046512194,0.00046960788,0.00032391978,0.00052595977],"domain_scores_gemma":[0.9992947,0.000049807335,0.00004260712,0.00041835205,0.00002090559,0.00017363367],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00020770125,0.00025407318,0.00046571577,0.00022808077,0.00002889663,0.0000048756897,0.00015182345,0.00017997494,0.0023749454],"category_scores_gemma":[0.000018449631,0.00024887253,0.00013931055,0.0005940869,0.0000315697,0.00007429731,0.000015321397,0.00020974613,0.00089936965],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019008751,0.0016485672,0.55842286,0.0001760305,0.0002587905,0.00085560203,0.0021077357,0.00032057555,0.07632255,0.00001686336,0.0003849207,0.35758466],"study_design_scores_gemma":[0.02452011,0.00054744305,0.93020666,0.0004272218,0.00017613782,0.00017829736,0.000053459476,0.00025487787,0.03262845,0.00009545556,0.010425748,0.0004861275],"about_ca_topic_score_codex":0.003129684,"about_ca_topic_score_gemma":0.0015296417,"teacher_disagreement_score":0.37178382,"about_ca_system_score_codex":0.0018904955,"about_ca_system_score_gemma":0.00049625896,"threshold_uncertainty_score":0.99999636},"labels":[],"label_agreement":null},{"id":"W2329477786","doi":"10.1158/1538-7445.am2012-1352","title":"Abstract 1352: Shp2 is required for CML initiation and maintenance","year":2012,"lang":"en","type":"article","venue":"Cancer Research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Dasatinib; Cancer research; Tyrosine kinase; Imatinib; Bosutinib; Stem cell; Myeloid leukemia; Bone marrow; Imatinib mesylate; Haematopoiesis; Medicine; Biology; Immunology; Signal transduction; Cell biology","score_opus":0.1621364712561549,"score_gpt":0.4530184521059848,"score_spread":0.29088198084982986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2329477786","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98591745,0.0039926535,0.00003594645,0.0034297244,0.00014939718,0.000987056,0.00006214866,0.000027924509,0.0053976714],"genre_scores_gemma":[0.9934638,0.0010343494,0.00028908622,0.00034646882,0.00057874335,0.00048292248,0.000028777253,0.000028279472,0.0037475831],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9986224,0.000025411257,0.00015057155,0.00022625792,0.00036805388,0.0006072601],"domain_scores_gemma":[0.9990271,0.00020005532,0.000036115536,0.00025378668,0.00024952105,0.00023344815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006431833,0.00009377083,0.00016377721,0.00010395797,0.00011842347,0.000019698831,0.0000632829,0.00008519339,0.0005580611],"category_scores_gemma":[0.00028448238,0.000077820674,0.000038843944,0.0001615287,0.00011919748,0.0001809306,0.00004507192,0.0002143281,0.00007481891],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003984281,0.00080160465,0.1530384,0.0031589663,0.00066593266,0.00007965185,0.010637809,0.0000025481195,0.21210572,0.0037599895,0.36476028,0.24700482],"study_design_scores_gemma":[0.017580407,0.00077073433,0.54209185,0.0012425308,0.00013759687,0.00007845602,0.0010198161,0.00023524328,0.14076196,0.0015844356,0.2940429,0.00045410648],"about_ca_topic_score_codex":0.0003103036,"about_ca_topic_score_gemma":0.000021203638,"teacher_disagreement_score":0.38905343,"about_ca_system_score_codex":0.0012674191,"about_ca_system_score_gemma":0.00046302867,"threshold_uncertainty_score":0.6110378},"labels":[],"label_agreement":null},{"id":"W2329982161","doi":"10.1016/j.jval.2014.08.2301","title":"Prioritization of Future Outcomes Research Studies in Chronic Myeloid Leukemia: Value of Information Analysis","year":2014,"lang":"en","type":"article","venue":"Value in Health","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Nilotinib; Value of information; Quality-adjusted life year; Dasatinib; Population; Time horizon; Actuarial science; Oncology; Cost effectiveness; Internal medicine; Myeloid leukemia; Imatinib; Environmental health; Economics; Risk analysis (engineering)","score_opus":0.06702508704875788,"score_gpt":0.4088890275643781,"score_spread":0.34186394051562025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2329982161","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945593,0.0028558373,0.00015240567,0.0011119159,0.00014125444,0.0008597416,0.00001160452,0.000018776012,0.00028915668],"genre_scores_gemma":[0.99467856,0.0036622297,0.0013079494,0.000090542984,0.00008426834,0.000035734545,0.000075406504,0.0000117016925,0.000053634736],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996814,0.0006030847,0.0012046272,0.0002185504,0.0007530995,0.00040661363],"domain_scores_gemma":[0.9982114,0.0005353518,0.0003785088,0.00047156023,0.00031014264,0.00009305173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033756515,0.00015057695,0.00092871644,0.0016216344,0.000048472317,0.000004632686,0.00012021422,0.00015194109,0.000013108122],"category_scores_gemma":[0.0009516054,0.00012803843,0.000110096145,0.002548089,0.00012943974,0.00019411996,0.00006686312,0.0004086595,0.000007748278],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020487707,0.00023623701,0.80853206,0.008062761,0.00070582755,0.000005790312,0.0152175445,0.12960793,0.00016831321,0.0069224467,0.00022792329,0.0301083],"study_design_scores_gemma":[0.00641277,0.0011061621,0.9037557,0.001329942,0.0001504714,0.0000048347156,0.003114046,0.08190618,0.00069061125,0.0005933283,0.00079295854,0.00014296542],"about_ca_topic_score_codex":0.011964881,"about_ca_topic_score_gemma":0.00091156375,"teacher_disagreement_score":0.09522369,"about_ca_system_score_codex":0.009748168,"about_ca_system_score_gemma":0.0027297568,"threshold_uncertainty_score":0.99461454},"labels":[],"label_agreement":null},{"id":"W2337492017","doi":"10.71781/26592","title":"Caractérisation moléculaire d’un récent modèle d’étude de la leucémie myéloïde aigüe à caryotype normal :la lignée cellulaire CG-SH","year":2013,"lang":"fr","type":"dissertation","venue":"Open MIND","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Louisiana State University","keywords":"Molecular biology; Physics; Karyotype; Biology; Genetics; Chromosome; Gene","score_opus":0.019617697863039348,"score_gpt":0.2895488065844691,"score_spread":0.2699311087214297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2337492017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89463633,0.004778016,0.00009173619,0.00025794347,0.001444292,0.0032698174,0.00013518828,0.000019741514,0.095366955],"genre_scores_gemma":[0.9349384,0.0009354482,0.004611903,0.00009895206,0.0009820025,0.00048811507,0.008720187,0.00027512226,0.04894991],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9936904,0.00086321466,0.0013196109,0.0015579241,0.0011127925,0.0014560896],"domain_scores_gemma":[0.99581933,0.0005840577,0.00094042416,0.0013875662,0.00039709941,0.0008714936],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.00105713,0.0013052428,0.0014960294,0.00031142047,0.00059783435,0.00058196735,0.0011531828,0.0019520699,0.01498833],"category_scores_gemma":[0.0003093889,0.0013486634,0.00048095526,0.00047083577,0.00029040666,0.00078735943,0.0003659159,0.0016414026,0.006351692],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0021164832,0.004788912,0.062244844,0.001932343,0.004608017,0.0057264282,0.06172378,0.0056206505,0.059727747,0.00048545087,0.007480538,0.78354484],"study_design_scores_gemma":[0.032138817,0.0021212464,0.41058135,0.009735358,0.011004949,0.0017780104,0.029049978,0.041003875,0.34445944,0.00025656822,0.1127912,0.005079193],"about_ca_topic_score_codex":0.015082908,"about_ca_topic_score_gemma":0.002390709,"teacher_disagreement_score":0.7784656,"about_ca_system_score_codex":0.006184404,"about_ca_system_score_gemma":0.0060383067,"threshold_uncertainty_score":0.9999699},"labels":[],"label_agreement":null},{"id":"W2338574807","doi":"10.1038/srep23885","title":"Tracking of Normal and Malignant Progenitor Cell Cycle Transit in a Defined Niche","year":2016,"lang":"en","type":"article","venue":"Scientific Reports","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency","funders":"National Cancer Institute; NIH Clinical Center; University of California, San Diego; National Institute of General Medical Sciences; California Institute for Regenerative Medicine","keywords":"Niche; Progenitor cell; Transit (satellite); Progenitor; Cell cycle; Computational biology; Computer science; Biology; Bioinformatics; Stem cell; Cell; Cell biology; Ecology; Genetics; Transport engineering; Public transport; Engineering","score_opus":0.013452674272329296,"score_gpt":0.2427301119817939,"score_spread":0.2292774377094646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2338574807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974519,0.0003869906,0.000035002737,0.000183058,0.00065256865,0.0004548673,0.0000040429272,0.00002460638,0.0008069513],"genre_scores_gemma":[0.99732226,0.000010803243,0.0006130276,0.000008272041,0.000026736716,0.000020707226,0.000009094892,0.000014520154,0.0019745743],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998316,0.000024101833,0.0005030003,0.00051561336,0.00035589273,0.00028539257],"domain_scores_gemma":[0.99909693,0.000036294394,0.00017685727,0.00049192563,0.00007584514,0.00012216806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064697023,0.0001207913,0.00026047335,0.00016083514,0.000047998954,0.000021225154,0.000042435415,0.00006578425,0.00010506708],"category_scores_gemma":[0.00008610673,0.00007774214,0.000069593385,0.000256944,0.00018119026,0.00011417723,0.000027630093,0.000057133002,0.000008307058],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007774433,0.00028274304,0.248963,0.00016585084,0.000022601966,0.0017821554,0.0007020059,0.0000026127937,0.73396856,0.000008027667,0.00035538277,0.013669315],"study_design_scores_gemma":[0.0031667177,0.0001532496,0.067390405,0.0004838083,0.000096284355,0.0013763602,0.000088572655,0.000051079223,0.9242799,0.0004509508,0.0022973316,0.00016528575],"about_ca_topic_score_codex":0.000059539652,"about_ca_topic_score_gemma":0.00005076286,"teacher_disagreement_score":0.19031139,"about_ca_system_score_codex":0.00017767701,"about_ca_system_score_gemma":0.00039735192,"threshold_uncertainty_score":0.31702325},"labels":[],"label_agreement":null},{"id":"W2339943063","doi":"10.1016/s1470-2045(16)00080-2","title":"Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":259,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; Princess Margaret Cancer Centre","funders":"Ariad Pharmaceuticals","keywords":"Ponatinib; Medicine; Imatinib; Internal medicine; Myeloid leukemia; Imatinib mesylate; Oncology; Clinical trial; Clinical endpoint; Nilotinib","score_opus":0.14917091176216268,"score_gpt":0.447745619994161,"score_spread":0.29857470823199833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2339943063","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94218534,0.0003561066,0.00060016796,0.025018655,0.004449434,0.008364982,0.00029887556,0.00018855339,0.018537859],"genre_scores_gemma":[0.9525493,0.0023959342,0.010473812,0.0041709384,0.015809625,0.007238053,0.00071408926,0.00017550206,0.0064727603],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975819,0.00032926377,0.0006078525,0.0005504899,0.00029365873,0.0006368104],"domain_scores_gemma":[0.99486005,0.0034514721,0.0003922049,0.00092774944,0.00017054091,0.00019800071],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013723791,0.0003038144,0.0010528781,0.00008199015,0.00017355422,0.0000479604,0.0010769905,0.00024685054,0.0010466644],"category_scores_gemma":[0.0017967954,0.0001694616,0.00012468985,0.00011752124,0.00024076545,0.000309152,0.00023431469,0.00026211972,0.00016169966],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7218275,0.0019942503,0.000034423865,0.00003246378,0.00067024946,0.00010295284,0.00026043772,0.0000023098155,0.0076348507,0.001765154,0.024573302,0.24110211],"study_design_scores_gemma":[0.7431617,0.012624355,0.000057722587,0.00006655265,0.0002864519,0.000052579922,0.000044042263,0.0003264584,0.0010049695,0.00028408665,0.24192837,0.00016273974],"about_ca_topic_score_codex":0.000109034096,"about_ca_topic_score_gemma":0.00027160294,"teacher_disagreement_score":0.24093938,"about_ca_system_score_codex":0.003405822,"about_ca_system_score_gemma":0.0020803993,"threshold_uncertainty_score":0.9998665},"labels":[],"label_agreement":null},{"id":"W2343443334","doi":"10.14740/jocmr2566w","title":"Extramedullary Involvement by Chronic Myelogeneous Leukemia in Five Patients With Unusual Clinicopathologic Features: A Review of the Effectiveness of Tyrosine Kinase Inhibitors","year":2016,"lang":"en","type":"review","venue":"Journal of Clinical Medicine Research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Tyrosine kinase; Leukemia; Pathology; Cancer research; Tyrosine-kinase inhibitor; Internal medicine; Cancer","score_opus":0.08582594506485629,"score_gpt":0.47097783417881806,"score_spread":0.38515188911396175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2343443334","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016980132,0.9769629,0.0000027564097,0.00033110974,0.00072222715,0.004735408,0.00009086609,0.0000059914923,0.00016857016],"genre_scores_gemma":[0.0037291285,0.9946055,0.000059341535,0.00012467064,0.0010207613,0.000104154715,0.00007868477,0.00009849131,0.00017929685],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.97730345,0.010009987,0.007068605,0.0007884068,0.0040160646,0.00081347575],"domain_scores_gemma":[0.9708054,0.019490017,0.005127524,0.0014295988,0.0025682163,0.00057926646],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.029409567,0.0007390059,0.008686766,0.0007935196,0.00006392043,0.0000060287553,0.001177067,0.00093032635,0.00012605752],"category_scores_gemma":[0.028888483,0.00030830808,0.0014917301,0.0018746684,0.0024319312,0.00008435622,0.00047470725,0.0048806244,0.000008424006],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0026412914,0.0015575454,0.009582379,0.22877216,0.0009846336,0.00056764495,0.00003068509,6.854615e-7,0.000014778234,0.0000096328595,0.0079022795,0.7479363],"study_design_scores_gemma":[0.016694413,0.019099602,0.0087971175,0.8341837,0.002006061,0.00028809468,0.000023191542,5.212357e-7,0.000072219096,0.0000381099,0.11854949,0.0002474873],"about_ca_topic_score_codex":0.00009134912,"about_ca_topic_score_gemma":0.000015570586,"teacher_disagreement_score":0.7476888,"about_ca_system_score_codex":0.006389449,"about_ca_system_score_gemma":0.01806136,"threshold_uncertainty_score":0.9999369},"labels":[],"label_agreement":null},{"id":"W2345491145","doi":"10.1182/blood.v124.21.4542.4542","title":"Efficacy and Safety of Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTxtnd Interim Analysis","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Nilotinib; Internal medicine; Interim analysis; Adverse effect; Clinical endpoint; Anemia; Myeloid leukemia; Clinical trial; Imatinib","score_opus":0.009825242666280267,"score_gpt":0.26291835273030134,"score_spread":0.2530931100640211,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2345491145","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967517,0.0009030422,0.000131542,0.00005620564,0.000047194015,0.0015197317,0.000030401652,0.0000605864,0.0004995754],"genre_scores_gemma":[0.99752647,0.00048737664,0.0012030887,0.00005902516,0.000108162785,0.000112316084,0.0003347033,0.000073430776,0.000095423646],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99664384,0.00022923444,0.0010577682,0.0008726955,0.0005037712,0.00069269806],"domain_scores_gemma":[0.997896,0.00039974155,0.00041241868,0.00090597355,0.00010264291,0.00028319983],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00042403955,0.0005324515,0.0015306157,0.000782218,0.00005239022,0.00002353867,0.00023404826,0.00023080787,0.00021434684],"category_scores_gemma":[0.00024703526,0.00044579429,0.00018423518,0.0013619527,0.00028728135,0.00015853407,0.000135668,0.00042146476,0.000016214603],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024256743,0.016825775,0.80602914,0.0014299371,0.0067751976,0.0005751703,0.0028090952,0.013349441,0.010237644,0.00008760197,0.00008564423,0.11753862],"study_design_scores_gemma":[0.43716052,0.00807463,0.5376116,0.0010648535,0.0032743998,0.00002117049,0.000060644816,0.0060136775,0.005778127,0.0000060436287,0.0003895651,0.00054479804],"about_ca_topic_score_codex":0.0018394793,"about_ca_topic_score_gemma":0.0029878991,"teacher_disagreement_score":0.41290376,"about_ca_system_score_codex":0.0042266375,"about_ca_system_score_gemma":0.0015638316,"threshold_uncertainty_score":0.9997994},"labels":[],"label_agreement":null},{"id":"W2346252846","doi":"10.1097/cad.0000000000000366","title":"Pharmacokinetics of cabozantinib tablet and capsule formulations in healthy adults","year":2016,"lang":"en","type":"article","venue":"Anti-Cancer Drugs","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Caprion (Canada); Celerion (Canada)","funders":"","keywords":"Bioequivalence; Cabozantinib; Cmax; Pharmacokinetics; Medicine; Dosing; Capsule; Confidence interval; Pharmacology; Medullary thyroid cancer; Urology; Cancer; Internal medicine; Thyroid cancer","score_opus":0.015577115231370895,"score_gpt":0.31329053114583844,"score_spread":0.29771341591446754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2346252846","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948489,0.0013248789,0.000027890253,0.0021329932,0.000110751986,0.0004130512,0.00009559874,0.000022338332,0.0010235684],"genre_scores_gemma":[0.9931449,0.0054084817,0.00031598884,0.00033245276,0.000086561726,0.00003698295,0.000013910814,0.000020885642,0.00063980254],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989729,0.000018153973,0.00031226446,0.0002423249,0.00017683709,0.00027751512],"domain_scores_gemma":[0.99944,0.00005724587,0.00011104428,0.0002132824,0.0000742398,0.00010419692],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008432059,0.00012945541,0.00030781716,0.000112955306,0.000029324492,0.0000031410032,0.00005033635,0.000058187157,0.00025678775],"category_scores_gemma":[0.000024549441,0.000091831505,0.0000365883,0.00019583075,0.00007600462,0.000094751034,0.00003616318,0.00007838366,0.000012723968],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022082592,0.00094949757,0.6577378,0.00117241,0.00030994712,0.00004560999,0.003924262,0.000025373718,0.10310004,0.0006753492,0.004365149,0.22548632],"study_design_scores_gemma":[0.09236228,0.0010817944,0.66457736,0.0028867943,0.0003209171,0.000042046067,0.00033477054,0.001648432,0.20382635,0.00014901336,0.032193214,0.00057704333],"about_ca_topic_score_codex":0.0015500385,"about_ca_topic_score_gemma":0.0001435207,"teacher_disagreement_score":0.22490928,"about_ca_system_score_codex":0.00021387708,"about_ca_system_score_gemma":0.00030409687,"threshold_uncertainty_score":0.374478},"labels":[],"label_agreement":null},{"id":"W2358319290","doi":"","title":"Construction of bcr-abl retroviral vector-mediated mouse chronic myeloid leukemia like model","year":2008,"lang":"en","type":"article","venue":"Di-Si Junyi Daxue xuebao","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Blood Services","funders":"","keywords":"Bone marrow; Spleen; Myeloid leukemia; Biology; Retrovirus; Virology; Fusion gene; Leukemia; breakpoint cluster region; Population; ABL; Viral vector; Haematopoiesis; Immunology; Chronic myelogenous leukemia; Cancer research; Molecular biology; Stem cell; Medicine; Receptor; Virus; Gene; Recombinant DNA; Cell biology","score_opus":0.017352685508471986,"score_gpt":0.24016947433309782,"score_spread":0.22281678882462583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2358319290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991361,0.0010718743,0.00041184618,0.00016958489,0.0005213733,0.00084231916,0.00016866736,0.00035313528,0.005100204],"genre_scores_gemma":[0.9855313,0.0011302875,0.0029729493,0.00022899531,0.00044198838,0.00007376042,0.00069062493,0.00013685315,0.00879327],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99646986,0.00008951125,0.0009158898,0.00082606723,0.00083643047,0.00086225156],"domain_scores_gemma":[0.99755925,0.00012276675,0.00042474267,0.0012114503,0.00026474232,0.0004170348],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019723338,0.00057857425,0.001029414,0.00036635052,0.00021862156,0.000020065032,0.00030467004,0.00046681304,0.0003128037],"category_scores_gemma":[0.00022360201,0.00055832125,0.00034955237,0.0006433748,0.0006573913,0.00036764715,0.00014228429,0.0006901195,0.00034008696],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004438206,0.0024200582,0.15442358,0.002611779,0.0034230172,0.0019877828,0.005448945,0.011663639,0.7333312,0.0034947188,0.05607608,0.020680966],"study_design_scores_gemma":[0.084426105,0.0065527824,0.084458426,0.0016918294,0.0024970546,0.005677173,0.00084523956,0.38474706,0.3856991,0.00053503487,0.0384201,0.004450099],"about_ca_topic_score_codex":0.000792945,"about_ca_topic_score_gemma":0.000104301005,"teacher_disagreement_score":0.37308344,"about_ca_system_score_codex":0.0054681366,"about_ca_system_score_gemma":0.0036526518,"threshold_uncertainty_score":0.99968684},"labels":[],"label_agreement":null},{"id":"W2392563048","doi":"10.1016/j.exphem.2015.06.122","title":"Comparative RNA-seq analyses identify new microRNA biomarkers and candidate target genes in patients’ drug-resistant CD34+ CML stem/progenitor cells","year":2015,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia; BC Cancer Agency","funders":"","keywords":"microRNA; CD34; Progenitor cell; Stem cell; Nilotinib; Cancer research; Biology; MiRBase; Deep sequencing; Haematopoiesis; Gene; Medicine; Immunology; Genetics; Genome; Imatinib; Myeloid leukemia","score_opus":0.05347771730664376,"score_gpt":0.3577675142742415,"score_spread":0.3042897969675978,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2392563048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96579105,0.032258797,0.0000065220806,0.00011521223,0.00043078978,0.0008110892,0.00003698,0.00004713721,0.0005024267],"genre_scores_gemma":[0.99717313,0.00003357566,0.0017865532,0.000107232554,0.000057270983,0.000061187835,0.00014023845,0.000035887795,0.0006048948],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978709,0.00015395363,0.00058322476,0.00059506844,0.0003069194,0.00048989314],"domain_scores_gemma":[0.99883014,0.000057823367,0.00020678397,0.00035123646,0.00006818092,0.00048584124],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00010064065,0.0003830605,0.0009299851,0.000249521,0.00006871093,0.00002801222,0.0001406607,0.0001369385,0.00014518094],"category_scores_gemma":[0.000008718193,0.00033631665,0.000100492616,0.0002456012,0.00021676593,0.00013261492,0.00016347265,0.00013829503,0.00012286393],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068098437,0.003027489,0.4623279,0.00024076298,0.0022116404,0.0012387461,0.015417753,0.000008884958,0.45770657,0.00024505408,0.050249133,0.00051622494],"study_design_scores_gemma":[0.012144717,0.0004501388,0.0065962807,0.000085241525,0.00009946696,0.000096932476,0.0047930623,0.00006768666,0.9743366,0.000021872924,0.0010179431,0.00029005518],"about_ca_topic_score_codex":0.0024884937,"about_ca_topic_score_gemma":0.00020784073,"teacher_disagreement_score":0.51663005,"about_ca_system_score_codex":0.0010521288,"about_ca_system_score_gemma":0.0004332688,"threshold_uncertainty_score":0.99990886},"labels":[],"label_agreement":null},{"id":"W2409099220","doi":"10.1200/jop.2016.012054","title":"Unexpected Success of Watch and Wait Strategy in a Ponatinib-Intolerant Patient With Chronic Myeloid Leukemia","year":2016,"lang":"en","type":"article","venue":"Journal of Oncology Practice","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Ponatinib; Myeloid leukemia; Oncology; Internal medicine; Intensive care medicine; Bioinformatics; Dasatinib; Imatinib","score_opus":0.01686788898137336,"score_gpt":0.31267565369987566,"score_spread":0.2958077647185023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2409099220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98669624,0.0011423358,0.00006517171,0.007845402,0.00010767109,0.0003264991,0.0000041396233,0.000008099208,0.003804454],"genre_scores_gemma":[0.9962952,0.0013121332,0.0018452633,0.00018137775,0.00012053839,0.000009548481,0.0000014919657,0.000022950044,0.00021150614],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99782944,0.00030228985,0.0008853635,0.00022312839,0.00045337796,0.00030642244],"domain_scores_gemma":[0.9961585,0.0014077866,0.0014454314,0.00021703847,0.0005840939,0.00018718289],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006352214,0.00020044831,0.00074193085,0.0002030652,0.000031313695,0.000008995601,0.00011589756,0.00019212165,0.00015571111],"category_scores_gemma":[0.00080925075,0.00011275883,0.00006504976,0.00025967043,0.00018897114,0.00054030196,0.000047544538,0.000522139,0.0000056140098],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038884822,0.0042737233,0.07371117,0.00037967967,0.0026270049,0.021455599,0.004539586,0.00039381953,0.14922345,0.00036327072,0.0016727042,0.7024752],"study_design_scores_gemma":[0.17851159,0.12728469,0.33799675,0.0052254964,0.003444599,0.12091056,0.006541716,0.00064550067,0.070961095,0.00026208934,0.14716879,0.0010471453],"about_ca_topic_score_codex":0.000346738,"about_ca_topic_score_gemma":0.00033218114,"teacher_disagreement_score":0.70142806,"about_ca_system_score_codex":0.0048483796,"about_ca_system_score_gemma":0.0053248187,"threshold_uncertainty_score":0.9989718},"labels":[],"label_agreement":null},{"id":"W2412914653","doi":"10.1038/nature18288","title":"Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells","year":2016,"lang":"en","type":"article","venue":"Nature","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":229,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Centre","funders":"Medical Research Council; Imperial Experimental Cancer Medicine Centre; Howat Foundation; Cancer Research UK; Constellation Pharmaceuticals","keywords":"Stem cell; Cancer research; Tyrosine kinase; Haematopoiesis; Imatinib mesylate; Biology; Imatinib; Bruton's tyrosine kinase; breakpoint cluster region; Myeloid leukemia; Cell biology; Signal transduction; Receptor; Genetics","score_opus":0.0071483261694447724,"score_gpt":0.24499010596907395,"score_spread":0.23784177979962917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2412914653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99394023,0.0041088853,0.000009013463,0.0006919532,0.00012269255,0.00022097689,0.000027515158,0.00004330663,0.0008354476],"genre_scores_gemma":[0.99627453,0.0002000258,0.00057280145,0.00014878347,0.0001532671,0.000005669132,0.000004728264,0.000022086233,0.0026181247],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991248,0.0000265646,0.00016465012,0.0002543775,0.00021313423,0.00021644153],"domain_scores_gemma":[0.9993866,0.00017231908,0.00008800238,0.00015139197,0.00011946481,0.00008223799],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011386345,0.00014286985,0.00025489574,0.00006705482,0.000032503547,0.0000039782053,0.00004658447,0.0005781399,0.000068528694],"category_scores_gemma":[0.000057188674,0.00008718829,0.00004827557,0.000115364746,0.00006075611,0.00006128854,0.00004102125,0.0005670736,0.000018910418],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024518545,0.00008769838,0.02431343,0.0001971485,0.00017375399,0.00007584912,0.0004015675,4.3174657e-7,0.92891663,0.00014895211,0.014128432,0.03131091],"study_design_scores_gemma":[0.004420636,0.00034936707,0.023399143,0.00038830325,0.00013868419,0.00010336868,0.00014622993,0.000025181502,0.9639847,0.00008667005,0.006807631,0.00015004668],"about_ca_topic_score_codex":0.00001287448,"about_ca_topic_score_gemma":0.000002535088,"teacher_disagreement_score":0.035068095,"about_ca_system_score_codex":0.0003419416,"about_ca_system_score_gemma":0.0001724771,"threshold_uncertainty_score":0.44591445},"labels":[],"label_agreement":null},{"id":"W2466259172","doi":"10.1007/978-1-62703-429-6_2","title":"Methods for the Expression, Purification, Preparation, and Biophysical Characterization of Constructs of the c-Myc and Max b-HLH-LZs","year":2013,"lang":"en","type":"article","venue":"Methods in molecular biology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Transcription factor; Carcinogenesis; Chemistry; Gene; DNA; Cell growth; Cell; Molecular biology; Stereochemistry; Biochemistry; Biology","score_opus":0.018929371311408524,"score_gpt":0.3951148188790282,"score_spread":0.3761854475676197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2466259172","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.46381482,0.00038128986,0.53416896,0.0005461372,0.000067329005,0.0009839277,0.0000072609423,0.000004600964,0.00002569958],"genre_scores_gemma":[0.20947734,0.00010291279,0.7899489,0.00013714047,0.000018650586,0.00023283764,0.000023173932,0.000011139041,0.000047921498],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99840546,0.0008531244,0.00034535446,0.0002321805,0.000047921418,0.00011593862],"domain_scores_gemma":[0.99859154,0.0006236866,0.00022411703,0.0003820398,0.00014861404,0.000029976525],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066249876,0.00010766551,0.0002958974,0.000052748714,0.000041078132,0.000004914104,0.00009342588,0.00012517183,0.000017132032],"category_scores_gemma":[0.0008569642,0.000060028466,0.000046862944,0.00015843735,0.0004146024,0.00002709852,0.00007285409,0.00008129696,2.2405183e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000040004197,0.000032373166,0.0037854987,0.000054646476,0.00004348917,9.16634e-8,0.00022382919,8.1486684e-7,0.95175415,0.0022483643,0.0000060679367,0.04181064],"study_design_scores_gemma":[0.0009668775,0.00012710015,0.040348396,0.000038420752,0.0000802201,0.000015908085,0.00004056533,0.0015017854,0.95176065,0.004414482,0.00065228366,0.00005328577],"about_ca_topic_score_codex":0.000032422584,"about_ca_topic_score_gemma":6.0209186e-7,"teacher_disagreement_score":0.25577995,"about_ca_system_score_codex":0.000030211042,"about_ca_system_score_gemma":0.00008479012,"threshold_uncertainty_score":0.24478899},"labels":[],"label_agreement":null},{"id":"W2468990687","doi":"10.1200/jco.2013.31.15_suppl.tps7129","title":"EPIC: A phase III randomized, open-label study of ponatinib versus imatinib in adult patients with newly diagnosed chronic myeloid leukemia in chronic phase.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ponatinib; Medicine; Imatinib; Myeloid leukemia; Internal medicine; Oncology; Imatinib mesylate; Tyrosine-kinase inhibitor; Nilotinib; Cancer","score_opus":0.07600175076412469,"score_gpt":0.44549411153852037,"score_spread":0.3694923607743957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2468990687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903865,0.00043555952,0.000023608454,0.00061221264,0.0008200656,0.0063462285,0.000010895091,0.000012391233,0.0013525637],"genre_scores_gemma":[0.9958444,0.00069560605,0.0020361484,0.00036669945,0.0004928046,0.00035246206,0.0000308128,0.00006137382,0.00011965816],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98887324,0.0017641885,0.0070663597,0.0005980247,0.0009882393,0.00070996926],"domain_scores_gemma":[0.9837865,0.008880498,0.0050837523,0.00062859425,0.0010490373,0.0005715683],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0042553195,0.0004976489,0.006000519,0.00053008815,0.000048978716,0.000029418645,0.00076288235,0.000536796,0.00083822804],"category_scores_gemma":[0.0078063873,0.00033604176,0.00035617585,0.00062872993,0.00048286226,0.0005865325,0.00026343195,0.002013589,0.000043050837],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.634416,0.072154,0.023167621,0.00012664137,0.0019844293,0.0015864167,0.0011309331,0.00026250674,0.00008629181,0.000040211948,0.000987855,0.2640571],"study_design_scores_gemma":[0.8489597,0.1227607,0.022289412,0.0006925101,0.00078588596,0.000037005608,0.00049252814,0.003327691,0.000032029642,0.00004596195,0.00033402973,0.00024256515],"about_ca_topic_score_codex":0.0025503698,"about_ca_topic_score_gemma":0.0040106815,"teacher_disagreement_score":0.26381454,"about_ca_system_score_codex":0.010542188,"about_ca_system_score_gemma":0.017626189,"threshold_uncertainty_score":0.99990916},"labels":[],"label_agreement":null},{"id":"W2469735602","doi":"10.1080/14740338.2016.1207760","title":"A safety evaluation of omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia","year":2016,"lang":"en","type":"review","venue":"Expert Opinion on Drug Safety","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Homoharringtonine; Myeloid leukemia; Adverse effect; Pharmacology; Tyrosine-kinase inhibitor; Oncology; Internal medicine; Intensive care medicine; Cancer","score_opus":0.07044490029049531,"score_gpt":0.39386546745387674,"score_spread":0.3234205671633814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2469735602","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000008739287,0.9857046,0.00020400735,0.00067425286,0.0015245968,0.009722006,0.00073280634,0.000057718906,0.0013712632],"genre_scores_gemma":[0.00015503945,0.9930672,0.0001905852,0.000034098706,0.0013998096,0.0021245275,0.0011442134,0.00015887935,0.0017256654],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99455833,0.00059098593,0.0020039068,0.00093926425,0.0013315587,0.00057595165],"domain_scores_gemma":[0.99369794,0.0021174182,0.0015172295,0.001961194,0.0005262932,0.00017994405],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015409997,0.0009857375,0.0033542465,0.00031527455,0.00018892121,0.000008448289,0.00041257785,0.00044249097,0.00086816185],"category_scores_gemma":[0.00027760037,0.00050320104,0.0018298535,0.00037397255,0.00020645966,0.00007094824,0.00006359416,0.00022119703,0.000078213845],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00078297243,0.0006131878,8.7370455e-7,0.0032989683,0.001964621,0.0000017339913,0.00043287376,0.000029194935,0.000009685721,0.00027912983,0.0020399252,0.9905468],"study_design_scores_gemma":[0.015648818,0.0020038204,0.0000323952,0.022812521,0.0012896678,0.000038954135,0.00004415938,0.00066355406,0.0003647509,0.000017276701,0.9567021,0.0003819524],"about_ca_topic_score_codex":0.00015201986,"about_ca_topic_score_gemma":0.000022073984,"teacher_disagreement_score":0.9901649,"about_ca_system_score_codex":0.022017658,"about_ca_system_score_gemma":0.006756689,"threshold_uncertainty_score":0.999742},"labels":[],"label_agreement":null},{"id":"W2471352820","doi":"10.1080/10245332.2001.11746548","title":"Current Treatment of Chronic Myeloid Leukemia","year":2001,"lang":"en","type":"article","venue":"Hematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Fondation de France; University of Toronto; University Health Network","keywords":"Myeloid leukemia; Medicine; Tyrosine-kinase inhibitor; Malignancy; Transplantation; Disease; Hematopoietic stem cell transplantation; Hematopoietic cell; Immunology; Myeloid; Tyrosine kinase; Cancer research; Targeted therapy; Haematopoiesis; Internal medicine; Stem cell; Biology; Cancer","score_opus":0.026941200772379454,"score_gpt":0.3099029128687474,"score_spread":0.28296171209636795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2471352820","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9713876,0.021606123,0.0001254106,0.0003680116,0.00036348455,0.0005324318,0.0000061228093,0.00009495517,0.0055158422],"genre_scores_gemma":[0.9924614,0.0057075974,0.00027544523,0.000036712307,0.00019493638,0.00008551138,0.0000595081,0.000030277695,0.00114862],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986547,0.000035314293,0.00039856014,0.00033469463,0.0001689855,0.00040773887],"domain_scores_gemma":[0.99903524,0.00007808948,0.00013411617,0.0005411739,0.000058935027,0.00015246109],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00003848105,0.00023138955,0.000698502,0.00013685027,0.00003751238,0.000002441966,0.000074147225,0.00012955256,0.00095907494],"category_scores_gemma":[0.000025782596,0.00018206988,0.00017658838,0.000192471,0.0001332089,0.00003206173,0.00002761543,0.00009156961,0.0003876038],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012205365,0.0051221526,0.41691107,0.001120011,0.0012614125,0.0028239433,0.0011268861,0.000043084445,0.008009352,0.015108029,0.00674107,0.54051244],"study_design_scores_gemma":[0.04048562,0.008824533,0.06460698,0.0007494425,0.0012001744,0.02038882,0.00016116821,0.0021508753,0.10792204,0.00086269947,0.7518963,0.00075130194],"about_ca_topic_score_codex":0.00010957142,"about_ca_topic_score_gemma":0.00006090267,"teacher_disagreement_score":0.7451553,"about_ca_system_score_codex":0.0031531723,"about_ca_system_score_gemma":0.0010621974,"threshold_uncertainty_score":0.99995416},"labels":[],"label_agreement":null},{"id":"W2473625996","doi":"10.1182/blood.v124.21.4517.4517","title":"Chaetocin Anti-Leukemia Activity Against Chronic Myelogenous Leukemia Stem Cells Is Potentiated By Bone Marrow Stromal Factors and Overcomes Innate Imatinib Resistance","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Chronic myelogenous leukemia; Cancer research; Imatinib mesylate; Imatinib; Stem cell; Bone marrow; Immunology; Biology; Stromal cell; Leukemia; Cell biology; Myeloid leukemia","score_opus":0.009206879605860375,"score_gpt":0.21920697518989332,"score_spread":0.21000009558403296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2473625996","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946466,0.002351764,0.000037642327,0.00016251925,0.00017543175,0.0009561273,0.0003992684,0.0002615048,0.0010091064],"genre_scores_gemma":[0.9954232,0.00074310583,0.0003161805,0.00022333508,0.00015792262,0.000040553925,0.000171699,0.0001257942,0.0027982257],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99657243,0.00017966422,0.0005886003,0.0010108924,0.0006636922,0.000984703],"domain_scores_gemma":[0.9978993,0.00017199319,0.00043359952,0.0009552214,0.00010053718,0.00043936292],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00030256578,0.0007173338,0.0011432737,0.00017565266,0.000287373,0.00007865456,0.00023131559,0.0004043933,0.000110792986],"category_scores_gemma":[0.00004073672,0.0006321272,0.00021610444,0.00031385914,0.00022190264,0.00024557393,0.00018017099,0.0005822623,0.000051743562],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027650408,0.00067361374,0.04682165,0.0009954445,0.0010983299,0.00027021588,0.0007520405,0.000013796379,0.9380484,0.000020760486,0.004244868,0.0067843497],"study_design_scores_gemma":[0.024940016,0.00088106154,0.14002794,0.0005944255,0.000987894,0.00010271063,0.00013352133,0.00088537554,0.82637775,0.00002065289,0.0040929816,0.0009556588],"about_ca_topic_score_codex":0.0003764594,"about_ca_topic_score_gemma":0.00013059887,"teacher_disagreement_score":0.11167066,"about_ca_system_score_codex":0.003135957,"about_ca_system_score_gemma":0.0010735365,"threshold_uncertainty_score":0.999613},"labels":[],"label_agreement":null},{"id":"W2480309755","doi":"10.1182/blood.v112.11.970.970","title":"Allogeneic Myeloablative Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia in the Imatinib Era.","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Chronic myelogenous leukemia; Transplantation; Imatinib; Internal medicine; Imatinib mesylate; Hematopoietic stem cell transplantation; Stem cell; Busulfan; Leukemia; Surgery; Oncology; Immunology; Myeloid leukemia","score_opus":0.020669656392199538,"score_gpt":0.25117399639886223,"score_spread":0.2305043400066627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2480309755","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928142,0.0022865355,0.00031301187,0.00017235008,0.00006374771,0.0020085473,0.000048026017,0.00006402819,0.0022295858],"genre_scores_gemma":[0.99639785,0.00077302096,0.0011587578,0.0002532197,0.00017440133,0.00048046838,0.0001730117,0.000046845715,0.0005424396],"study_design_codex":"qualitative","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99826974,0.000094818424,0.00043295766,0.00039302785,0.00033208658,0.00047735922],"domain_scores_gemma":[0.9989889,0.00030315464,0.00013131647,0.00043469283,0.000057738493,0.00008416407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022647982,0.0002760954,0.00040121345,0.00010968415,0.0001821092,0.000011428236,0.00019081104,0.00014897529,0.00004971835],"category_scores_gemma":[0.000010979551,0.0002013574,0.00016524202,0.0002601075,0.00009262798,0.0000728808,0.000013271941,0.0002492358,0.00006876651],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048280577,0.014487774,0.13405916,0.016973091,0.003936922,0.01762716,0.39148447,0.004157439,0.35266772,0.002240237,0.005098048,0.052439917],"study_design_scores_gemma":[0.1392477,0.007103059,0.27299643,0.0011161083,0.0043648514,0.017645786,0.004112729,0.002002292,0.54574,0.0006764047,0.003204753,0.0017898852],"about_ca_topic_score_codex":0.00009995111,"about_ca_topic_score_gemma":0.00010115428,"teacher_disagreement_score":0.38737175,"about_ca_system_score_codex":0.0011462488,"about_ca_system_score_gemma":0.0015132152,"threshold_uncertainty_score":0.8211116},"labels":[],"label_agreement":null},{"id":"W2484268954","doi":"10.1074/jbc.m116.741074","title":"Selective Inhibition of Human Equilibrative and Concentrative Nucleoside Transporters by BCR-ABL Kinase Inhibitors","year":2016,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Imatinib; Dasatinib; Pharmacology; Cladribine; Uridine; Chemistry; Tyrosine kinase; Cytarabine; Bosutinib; Imatinib mesylate; Cancer research; Biology; Medicine; Biochemistry; Myeloid leukemia; Internal medicine; Signal transduction","score_opus":0.016312453962795268,"score_gpt":0.2620181825413524,"score_spread":0.24570572857855713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2484268954","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979827,0.0005592702,0.00004690065,0.00046325466,0.0000209261,0.00012810809,0.00005140816,0.000010579236,0.0007368991],"genre_scores_gemma":[0.9993333,0.00022710324,0.00012813692,0.000067083594,0.00011216653,0.0000029596615,0.000015823669,0.0000085451475,0.00010485454],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998866,0.000041171646,0.0005283972,0.00019160242,0.00018719598,0.00018558658],"domain_scores_gemma":[0.9989491,0.00013314757,0.00047873036,0.00008245465,0.00016069913,0.00019584713],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001362956,0.00017143141,0.00045844156,0.00002248819,0.00003412401,0.000004757321,0.000048774433,0.00019377471,0.00021054808],"category_scores_gemma":[0.00012477595,0.0000929599,0.00013476955,0.00008419138,0.00041947747,0.000105892614,0.000016697086,0.00021753827,8.025678e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004961521,0.00022199328,0.017358342,0.000047446847,0.00014734609,0.00008351627,0.00022184668,7.572517e-8,0.97956264,0.000008346946,0.00068536063,0.0011669052],"study_design_scores_gemma":[0.0045842053,0.0013242043,0.009054275,0.0004806211,0.00007603129,0.00011582411,0.00030868826,9.433436e-7,0.9836383,0.00021723416,0.000097888245,0.00010180744],"about_ca_topic_score_codex":0.000004638491,"about_ca_topic_score_gemma":3.5156484e-7,"teacher_disagreement_score":0.008304068,"about_ca_system_score_codex":0.00035753977,"about_ca_system_score_gemma":0.00013543991,"threshold_uncertainty_score":0.37907946},"labels":[],"label_agreement":null},{"id":"W2487553529","doi":"10.1158/1538-7445.am2016-951","title":"Abstract 951: Role of the MSC-derived exosomal and endogenous JAK2-SET/PP2A-β-catenin-modulator miR-300 in leukemic stem/progenitor proliferation and survival in CML","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"CD38; Progenitor cell; Haematopoiesis; Cancer research; Stem cell; CD34; Biology; Clonogenic assay; Cell biology; Cell culture; Molecular biology; Genetics","score_opus":0.08059856188916881,"score_gpt":0.34483196839210617,"score_spread":0.26423340650293736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2487553529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99360424,0.0040103365,3.7142334e-7,0.0005749102,0.00007923277,0.0014596735,0.000049431485,0.000013782088,0.0002080295],"genre_scores_gemma":[0.998469,0.0006968464,0.000018447261,0.000013214758,0.00014765107,0.0003413751,0.0000050905974,0.000035562694,0.0002728035],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9978082,0.00019902729,0.00037430218,0.0004601321,0.0006209405,0.0005374062],"domain_scores_gemma":[0.9989827,0.00023721223,0.00007922384,0.0003826423,0.00016021258,0.0001579837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006543277,0.00018033475,0.0003585514,0.00021517943,0.000083801286,0.00002221627,0.00016176655,0.00014597617,0.00008259299],"category_scores_gemma":[0.00013008481,0.0001115602,0.000041809937,0.0003115217,0.00029763574,0.00012677729,0.00015499267,0.00036769707,0.000009782836],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052682136,0.000074202624,0.3053904,0.0001342123,0.000043388103,0.00003303615,0.0007774082,0.000002134794,0.6845122,0.000020786538,0.000017403745,0.008468039],"study_design_scores_gemma":[0.0067163883,0.0001791846,0.54837096,0.0005031985,0.000018902021,0.000044172535,0.0003794417,0.00006938361,0.4433924,0.00008270034,0.00012677947,0.0001164798],"about_ca_topic_score_codex":0.0033077186,"about_ca_topic_score_gemma":0.0021435998,"teacher_disagreement_score":0.24298058,"about_ca_system_score_codex":0.0018309844,"about_ca_system_score_gemma":0.0014389263,"threshold_uncertainty_score":0.5000303},"labels":[],"label_agreement":null},{"id":"W2492371880","doi":"","title":"Functional analysis of adapter protein c-Abl Src homology 3 domain-binding protein 2.","year":2009,"lang":"en","type":"dissertation","venue":"Library and Archives Canada (Government of Canada)","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"SH3 domain; Proto-oncogene tyrosine-protein kinase Src; Signal transducing adaptor protein; Adapter (computing); ABL; Computational biology; Homology (biology); Biology; Cell biology; Chemistry; Computer science; Genetics; Signal transduction; Tyrosine kinase; Operating system; Gene","score_opus":0.004576528421140886,"score_gpt":0.17114757403392453,"score_spread":0.16657104561278363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2492371880","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87484133,0.00039064878,0.00001578781,0.00078292796,0.00011482285,0.00081562303,0.00037987414,0.000010890653,0.12264808],"genre_scores_gemma":[0.88606113,0.000041277006,0.001753627,0.00020225141,0.00007029962,0.00006498405,0.0011541031,0.000040922358,0.11061139],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99637437,0.000071123366,0.0006110104,0.00045910227,0.0021243358,0.00036008254],"domain_scores_gemma":[0.99873453,0.000098086115,0.0005450148,0.00035135628,0.0000028797456,0.00026815562],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000016597769,0.00037723192,0.00093659404,0.0001966384,0.00011286508,0.0000093493245,0.00014974241,0.00012677515,0.00033461754],"category_scores_gemma":[0.000006719089,0.00035576985,0.00015360992,0.0002949929,0.00006747411,0.00012947491,0.000041061205,0.000307616,8.205582e-9],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019793855,0.0007725708,0.030319547,0.004711733,0.021175243,0.0020678549,0.00070397515,0.00018312372,0.8079377,0.0688489,0.002481842,0.04100368],"study_design_scores_gemma":[0.0047136946,0.0010469562,0.38594684,0.002181727,0.0041345772,0.000039306266,0.005171422,0.0006170825,0.5824652,0.0013101147,0.011319955,0.0010531541],"about_ca_topic_score_codex":0.004924288,"about_ca_topic_score_gemma":0.072378166,"teacher_disagreement_score":0.3556273,"about_ca_system_score_codex":0.00009192281,"about_ca_system_score_gemma":0.0061697476,"threshold_uncertainty_score":0.99988943},"labels":[],"label_agreement":null},{"id":"W2506959456","doi":"10.1182/blood-2016-01-695460","title":"CML with complex chromosome rearrangements and dysplastic megakaryocytes","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's Hospital of Eastern Ontario; Ottawa Hospital","funders":"","keywords":"Basophilia; Thrombocytosis; Leukocytosis; Chronic myelogenous leukemia; Philadelphia chromosome; Hemoglobin; Medicine; Platelet; Pathology; Microcytosis; Leukemia; Anemia; Immunology; Biology; Internal medicine; Chromosomal translocation; Genetics; Gene","score_opus":0.017491442550165118,"score_gpt":0.24104105997089864,"score_spread":0.22354961742073354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2506959456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994922,0.00033863654,0.00003665856,0.0004972703,0.000028818833,0.00031975392,0.000020149697,0.00008343636,0.0037533226],"genre_scores_gemma":[0.9963833,0.00011813985,0.0013837839,0.00012725704,0.00010565771,0.000030380874,0.000015579164,0.000028731702,0.0018071509],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990935,0.000015848684,0.00013214951,0.000280319,0.00022629627,0.0002519421],"domain_scores_gemma":[0.9993951,0.00008270133,0.000046991387,0.00027986304,0.00003663821,0.00015874124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000042111304,0.00015971741,0.00023752547,0.000055456876,0.00005137777,0.000010676444,0.000049843802,0.000044596407,0.00047954186],"category_scores_gemma":[0.000038924994,0.00008714876,0.000023791814,0.00007973611,0.000108399254,0.00006814073,0.000041431023,0.00004991635,0.00013716746],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008482366,0.001986445,0.6594745,0.00038493588,0.002145285,0.0015116365,0.0003507831,3.1322705e-7,0.31442648,0.0003582577,0.0027842298,0.015728936],"study_design_scores_gemma":[0.07654466,0.0032144333,0.857772,0.0012172614,0.0017110577,0.0019813268,0.000050814968,0.00002263657,0.045561153,0.00011237056,0.011343024,0.00046925698],"about_ca_topic_score_codex":0.00002686054,"about_ca_topic_score_gemma":0.000017176144,"teacher_disagreement_score":0.26886532,"about_ca_system_score_codex":0.00011453808,"about_ca_system_score_gemma":0.00009746589,"threshold_uncertainty_score":0.5250647},"labels":[],"label_agreement":null},{"id":"W2509397348","doi":"10.1016/j.exphem.2016.06.100","title":"Generation of a new de novo model of human AML from C-MYC-transduced normal human CD34+ cord blood cells transplanted into NRG-3/GM-CSF/S mice","year":2016,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute; University of British Columbia","funders":"","keywords":"Haematopoiesis; Cord blood; Biology; CD34; Myeloid leukemia; Leukemia; Cancer research; Myeloid; Progenitor cell; Cell culture; Stromal cell; Molecular biology; CD33; Xenotransplantation; Immunology; Stem cell; Transplantation; Cell biology; Medicine; Internal medicine","score_opus":0.04657367745767458,"score_gpt":0.32171538599600086,"score_spread":0.27514170853832626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2509397348","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962717,0.0010147195,0.0012311233,0.00010445073,0.000110746456,0.00048075189,0.000084462554,0.000056507226,0.0006454911],"genre_scores_gemma":[0.9940974,0.000030153878,0.0048548994,0.00009870145,0.00010715402,0.000042296513,0.0002075805,0.000048806527,0.00051298673],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99811786,0.00006754192,0.0007255672,0.00045112864,0.0002550888,0.00038282893],"domain_scores_gemma":[0.99902517,0.00005277054,0.00023098387,0.0004257103,0.000056296776,0.00020905],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000064847125,0.0003114812,0.0007688082,0.00013385792,0.0000781235,0.000004093354,0.00018915543,0.0002622043,0.0007916006],"category_scores_gemma":[0.0000060971433,0.00025801486,0.0001805077,0.00008514714,0.00020371855,0.00011106329,0.000030772844,0.00012072285,0.000018562478],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00059154315,0.0010493692,0.001850962,0.0001015434,0.0003134229,0.00008213568,0.004041716,0.0000059060567,0.99018294,0.0014036014,0.00018497578,0.00019190274],"study_design_scores_gemma":[0.014286146,0.0011504455,0.00015349894,0.00027890634,0.00028089396,0.00021313565,0.00020425832,0.00032462418,0.9827701,0.00011839567,0.00001042176,0.00020918247],"about_ca_topic_score_codex":0.001937815,"about_ca_topic_score_gemma":0.0004182821,"teacher_disagreement_score":0.013694602,"about_ca_system_score_codex":0.00033786803,"about_ca_system_score_gemma":0.00031577895,"threshold_uncertainty_score":0.9999872},"labels":[],"label_agreement":null},{"id":"W2510316350","doi":"10.1182/blood.v122.21.172.172","title":"High Content Screening Identifies Synthetic Lethality Of Retinoid Receptor Agonists In IKZF1-Mutated BCR-ABL1 positive Acute Lymphoblastic Leukemia","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Cancer research; Chronic myelogenous leukemia; Leukemia; Lymphoid leukemia; Biology; CDKN2A; Imatinib; Immunology; Myeloid leukemia; ABL; Philadelphia chromosome; Tyrosine kinase; Chromosomal translocation; Receptor; Genetics; Cancer; Gene","score_opus":0.016279198228062598,"score_gpt":0.2427733639240559,"score_spread":0.22649416569599332,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2510316350","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99708194,0.00038523876,0.0000618054,0.00043172928,0.0001966037,0.0011781215,0.000105582396,0.0001028541,0.00045615586],"genre_scores_gemma":[0.9965102,0.00010058312,0.0018448939,0.000119431956,0.00007643912,0.0001449845,0.00022081728,0.000059770555,0.0009228568],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997237,0.00019047013,0.0008410576,0.0006152918,0.0005280918,0.0005880397],"domain_scores_gemma":[0.99817526,0.00030763503,0.00035145617,0.0006204604,0.00031552542,0.00022963615],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00028255433,0.0003873965,0.00089341524,0.00021755484,0.00007889027,0.000041829746,0.00020319484,0.00022340303,0.00048499205],"category_scores_gemma":[0.00040010145,0.00034581692,0.00019073919,0.00036172583,0.00027182334,0.00018765642,0.00013686842,0.00029803385,0.0002563563],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007918841,0.0019670718,0.04672946,0.0005083532,0.0026730574,0.0007805186,0.0019323145,0.000056196102,0.9392624,0.00015574484,0.000764409,0.0043785986],"study_design_scores_gemma":[0.017303975,0.000670861,0.32223913,0.0017043025,0.0011994486,0.00032173825,0.0004925048,0.00024225871,0.6553089,0.00009160105,0.000028011595,0.00039729176],"about_ca_topic_score_codex":0.0070748944,"about_ca_topic_score_gemma":0.00007725234,"teacher_disagreement_score":0.28395352,"about_ca_system_score_codex":0.0012169941,"about_ca_system_score_gemma":0.0005217228,"threshold_uncertainty_score":0.9998994},"labels":[],"label_agreement":null},{"id":"W2510853686","doi":"10.1007/978-1-4939-4011-0_16","title":"New Mouse Models to Investigate the Efficacy of Drug Combinations in Human Chronic Myeloid Leukemia","year":2016,"lang":"en","type":"article","venue":"Methods in molecular biology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Terry Fox Research Institute; BC Cancer Agency","funders":"","keywords":"Myeloid leukemia; Drug; Medicine; Pharmacology; Cancer research","score_opus":0.03707487485085719,"score_gpt":0.37823962013151047,"score_spread":0.34116474528065327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2510853686","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.68708426,0.0005439838,0.30858386,0.0021523153,0.00007922536,0.00082423567,0.000006011957,0.000030605286,0.0006954875],"genre_scores_gemma":[0.6086448,0.000080758364,0.38860327,0.00066349853,0.000049917984,0.00012475331,0.0000206212,0.000051231327,0.0017611617],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973973,0.001006252,0.0005490703,0.00044909626,0.00012406104,0.00047422887],"domain_scores_gemma":[0.9983037,0.0005609575,0.00012214415,0.00078605185,0.000049443013,0.00017771531],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011842978,0.00022473122,0.00051900075,0.0003481845,0.00003535961,0.0000042082456,0.00033499085,0.00017221896,0.00006668164],"category_scores_gemma":[0.0006801797,0.00013899883,0.00011012973,0.0005100135,0.00022730137,0.000032791548,0.00019190066,0.0002556347,0.000012998049],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000049320217,0.000097487646,0.002110925,0.000020533043,0.000062993655,0.000022676215,0.0005413433,0.0005886804,0.95161575,0.0140293725,0.000112756665,0.030748153],"study_design_scores_gemma":[0.014340719,0.00055929314,0.006282713,0.00029264708,0.00008044818,0.000022520655,0.000044260076,0.00058817473,0.93397146,0.042214297,0.0013239589,0.000279477],"about_ca_topic_score_codex":0.0012495241,"about_ca_topic_score_gemma":0.00032139552,"teacher_disagreement_score":0.08001939,"about_ca_system_score_codex":0.0021950179,"about_ca_system_score_gemma":0.0010460918,"threshold_uncertainty_score":0.57398957},"labels":[],"label_agreement":null},{"id":"W2513033601","doi":"10.1182/blood.v122.21.2717.2717","title":"Dramatic Down-Regulation Of MNDA Expression In CP-CML Cells From The LSC Compartment","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Biology; K562 cells; Molecular biology; Myeloid; Myeloid leukemia; Immunology; Leukemia","score_opus":0.01243895763756645,"score_gpt":0.23603142204701646,"score_spread":0.22359246440945002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2513033601","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974035,0.0004747402,0.0000185134,0.00032058524,0.00006758136,0.00083522865,0.0000105007375,0.00002083603,0.00084853877],"genre_scores_gemma":[0.9979273,0.00001973031,0.0014660598,0.000088644134,0.00006846638,0.00007197732,0.00007504657,0.000012421656,0.00027037438],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9990613,0.000059659018,0.000302313,0.00016674782,0.00025646173,0.00015352658],"domain_scores_gemma":[0.9992139,0.00015973218,0.00011551547,0.000422148,0.000033072847,0.00005564027],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000073685194,0.000116518255,0.00024380228,0.000035099143,0.000027175618,0.000010519654,0.00008910111,0.00005955686,0.0010481079],"category_scores_gemma":[0.00002257178,0.000071538125,0.00005224489,0.00009424407,0.000038581522,0.00005867245,0.00004344639,0.00009196092,0.00023170127],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006029492,0.002333234,0.09850125,0.00012084916,0.00018779525,0.000012258172,0.0029957118,0.00010934708,0.8845669,0.000029889117,0.0054426193,0.005639843],"study_design_scores_gemma":[0.008771263,0.0001190385,0.5257349,0.00048395986,0.00017403465,0.0000039170804,0.00021965665,0.00083996955,0.4628763,0.0003109716,0.00038177375,0.00008423133],"about_ca_topic_score_codex":0.0010203744,"about_ca_topic_score_gemma":0.00005019142,"teacher_disagreement_score":0.42723364,"about_ca_system_score_codex":0.00013345413,"about_ca_system_score_gemma":0.000076529934,"threshold_uncertainty_score":0.99986506},"labels":[],"label_agreement":null},{"id":"W2514643390","doi":"10.1182/blood.v124.21.5539.5539","title":"Second Report of Arab Leukemia Net (ALN) Registry for Chronic Myeloid Leukemia (CML) in the Middle East &amp;North Africa Region (AFME). Epidemiology of CML and Additional Chromosomal Abnormalities (ACAs) in Egypt, Multicenter Results","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Isochromosome; Imatinib; Medicine; Imatinib mesylate; Myeloid leukemia; Philadelphia chromosome; Leukemia; Disease; Internal medicine; Oncology; Cancer research; Immunology; Biology; Chromosome; Genetics; Gene; Karyotype; Chromosomal translocation","score_opus":0.056383297708517334,"score_gpt":0.2643666379781462,"score_spread":0.20798334026962886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2514643390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99233645,0.0012594697,0.00003828455,0.0003096055,0.00010067906,0.001123283,0.0012379696,0.000027991371,0.003566245],"genre_scores_gemma":[0.9934652,0.00016235087,0.001507067,0.00014969152,0.00041219144,0.00030504304,0.002811491,0.000043221862,0.0011437673],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99608797,0.0003868263,0.0017616715,0.00074286235,0.00033854178,0.0006821338],"domain_scores_gemma":[0.9956737,0.0019147597,0.0010628846,0.0010492911,0.00015725767,0.00014209758],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013254936,0.00039668454,0.0010844745,0.0002410491,0.0000721965,0.000007229496,0.0002814988,0.00034281253,0.00015716834],"category_scores_gemma":[0.002424917,0.0003151772,0.00021702709,0.0002731058,0.000495605,0.00016020982,0.00010285822,0.0004958053,0.0000057841344],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015693964,0.0065682116,0.817328,0.014800976,0.0027986814,0.0034415056,0.032456655,0.0014074086,0.003968955,0.0056111715,0.08892392,0.007000592],"study_design_scores_gemma":[0.06997781,0.0027381375,0.83218753,0.0032172147,0.00073139515,0.0072668283,0.0015023169,0.002018665,0.0015183551,0.0008578631,0.077135965,0.0008478902],"about_ca_topic_score_codex":0.0005743574,"about_ca_topic_score_gemma":0.004221656,"teacher_disagreement_score":0.05428385,"about_ca_system_score_codex":0.0011502695,"about_ca_system_score_gemma":0.0013643629,"threshold_uncertainty_score":0.99993},"labels":[],"label_agreement":null},{"id":"W2514731023","doi":"10.1182/blood.v118.21.4438.4438","title":"Dasatinib As a Late Second Line Therapy in Chronic Myeloid Leukemia Patients: A Retrospective Study From a Tertiary Care Centre in India","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Dasatinib; Medicine; Imatinib mesylate; Imatinib; Transplantation; Internal medicine; Myeloid leukemia; Retrospective cohort study; Surgery","score_opus":0.011086752805389276,"score_gpt":0.24195531160317577,"score_spread":0.23086855879778648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2514731023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927984,0.0014666265,1.606151e-7,0.000012912222,0.00010302327,0.002578748,0.000112785485,0.000077809644,0.0028495246],"genre_scores_gemma":[0.99864155,0.00013852674,0.000121986704,0.00020767216,0.0001415045,0.00018000281,0.00026681068,0.00007470248,0.00022723805],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99752086,0.00015579347,0.000595605,0.00078826386,0.0003856496,0.0005538513],"domain_scores_gemma":[0.998806,0.000046606172,0.00018411432,0.0006922896,0.00010387392,0.000167089],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000114165196,0.0004139309,0.00064239267,0.0002819066,0.0000438213,0.000014705967,0.00020605995,0.0002187562,0.0016372618],"category_scores_gemma":[0.000075333985,0.00036387728,0.00010526399,0.00041363374,0.00006457003,0.00014830098,0.00011235419,0.00060287426,0.00013431003],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041970238,0.0035227062,0.93674845,0.00003506202,0.00036588428,0.00082754676,0.05512567,9.2699344e-7,0.0004724789,0.0000020749176,0.00001724739,0.002462234],"study_design_scores_gemma":[0.06328049,0.0026574265,0.92504585,0.00029471368,0.00013788702,0.0000054923466,0.002990604,0.000014354749,0.0051740212,0.000072760704,0.000043176206,0.00028320213],"about_ca_topic_score_codex":0.005421506,"about_ca_topic_score_gemma":0.006566473,"teacher_disagreement_score":0.06286079,"about_ca_system_score_codex":0.005070492,"about_ca_system_score_gemma":0.0012642586,"threshold_uncertainty_score":0.9998813},"labels":[],"label_agreement":null},{"id":"W2514819484","doi":"10.1182/blood.v120.21.3770.3770","title":"Pharmacologic Monitoring of Dasatinib As First Line Therapy in Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CP-CML) Identifies Patients At Higher Risk of Pleural Effusion: A Sub-Analysis of the OPTIM-Dasatinib Trial","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Dasatinib; Medicine; Cmin; Chronic myelogenous leukemia; Internal medicine; Cumulative incidence; Imatinib mesylate; Imatinib; Randomization; Gastroenterology; Clinical trial; Oncology; Surgery; Leukemia; Cohort; Cmax; Pharmacokinetics; Myeloid leukemia","score_opus":0.030395112303557268,"score_gpt":0.3138880972698649,"score_spread":0.2834929849663076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2514819484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98934233,0.0070354817,0.0000017030723,0.000034810524,0.00088455895,0.0024000478,0.00017080735,0.00003705305,0.00009320268],"genre_scores_gemma":[0.99448115,0.0040726983,0.00008546856,0.000018573603,0.00072551164,0.00023991312,0.000138886,0.00005839319,0.00017942196],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959466,0.0003958147,0.0015190165,0.0005072152,0.0009302101,0.00070114096],"domain_scores_gemma":[0.9963478,0.0007598579,0.0014977625,0.0009808854,0.00022038535,0.00019335229],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006217993,0.00049269723,0.0014946255,0.00041385935,0.00015897992,0.000010073202,0.0004503565,0.00027840366,0.0008162018],"category_scores_gemma":[0.0003366302,0.0003465648,0.000792299,0.0013885938,0.00027815986,0.00015381078,0.00026771298,0.00042060774,0.000013358632],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010530519,0.009774282,0.864251,0.00031080967,0.0073954947,0.00003280504,0.00250372,0.0010852949,0.09769271,0.000002753622,0.00005278329,0.006367802],"study_design_scores_gemma":[0.22659574,0.003940403,0.4629098,0.00022889313,0.0070239333,0.000004475246,0.000052677333,0.00019695131,0.29872176,0.0000042819506,0.00008445077,0.00023663898],"about_ca_topic_score_codex":0.0014940551,"about_ca_topic_score_gemma":0.00029198846,"teacher_disagreement_score":0.40134123,"about_ca_system_score_codex":0.0024980477,"about_ca_system_score_gemma":0.0008746098,"threshold_uncertainty_score":0.9998986},"labels":[],"label_agreement":null},{"id":"W2515880454","doi":"10.1182/blood.v122.21.4010.4010","title":"Comparative Efficacy Among Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Patients After Failure Of 2nd Generation Tyrosine Kinase Inhibitors (2G TKIs)","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Bosutinib; Nilotinib; Ponatinib; Dasatinib; Internal medicine; Oncology; Imatinib; Clinical trial; Cochrane Library; Myeloid leukemia; Meta-analysis","score_opus":0.01315385967319664,"score_gpt":0.25550061569469507,"score_spread":0.24234675602149844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2515880454","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941181,0.0023947002,0.000033024022,0.00009332752,0.00026337797,0.002494519,0.000073806994,0.000116888754,0.00041226987],"genre_scores_gemma":[0.9962074,0.000084341,0.0005353357,0.0000654404,0.0010486189,0.00041870496,0.0010504705,0.00008431332,0.0005053843],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9968744,0.00011749426,0.00089056266,0.00075057807,0.0006841597,0.0006828092],"domain_scores_gemma":[0.99788105,0.00008506812,0.00042984175,0.00083200773,0.00041014765,0.00036187214],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00010984361,0.00057992723,0.00090359716,0.00024897166,0.00012863637,0.000055620636,0.00018874854,0.0003095209,0.0014324214],"category_scores_gemma":[0.00007130063,0.00050460186,0.0002646068,0.0004321635,0.0002949949,0.00044888534,0.0001237223,0.00042942102,0.00032974523],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000873992,0.019459916,0.22262536,0.0014711997,0.0033952813,0.00027299815,0.004616003,0.00068115717,0.6894773,0.000067276545,0.030996919,0.026062554],"study_design_scores_gemma":[0.08574687,0.005244915,0.27097636,0.00095756794,0.0015083294,0.000027228023,0.00010391904,0.002700956,0.6295754,0.000011803998,0.0023178698,0.0008288042],"about_ca_topic_score_codex":0.00056523934,"about_ca_topic_score_gemma":0.0004380761,"teacher_disagreement_score":0.08487288,"about_ca_system_score_codex":0.0030489794,"about_ca_system_score_gemma":0.0011700103,"threshold_uncertainty_score":0.99974054},"labels":[],"label_agreement":null},{"id":"W2516537857","doi":"10.1002/ajh.24536","title":"Long‐term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib","year":2016,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":112,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Pfizer","keywords":"Bosutinib; Medicine; Nilotinib; Dasatinib; Internal medicine; Imatinib; Cumulative incidence; Adverse effect; Nausea; Myeloid leukemia; Gastroenterology; Oncology; Cohort","score_opus":0.014649612863998386,"score_gpt":0.3128337850963781,"score_spread":0.2981841722323797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2516537857","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98958784,0.0033233475,0.0035376048,0.0022931818,0.00023728742,0.00083193573,0.00008132976,0.000033712735,0.00007376886],"genre_scores_gemma":[0.9918969,0.0006729115,0.0061755776,0.00024122419,0.00048553938,0.00008915446,0.000013427975,0.00009001164,0.00033524923],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9965968,0.0001444603,0.0015971871,0.0004685284,0.00040591406,0.0007870748],"domain_scores_gemma":[0.9957336,0.00092651224,0.0019357632,0.0005924143,0.00037293212,0.00043877537],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00042132437,0.00047454645,0.0020690942,0.0003661497,0.00007032457,0.000012858968,0.00030288193,0.00017479349,0.0007563313],"category_scores_gemma":[0.00042841892,0.0002878034,0.00040707205,0.0002788465,0.0012418922,0.00020994374,0.00010655751,0.0003405265,0.000022002012],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043463975,0.001711409,0.09079879,0.0040569548,0.004915937,0.003927639,0.0027839206,0.000011650905,0.07453551,0.0010276206,0.0062202397,0.76654637],"study_design_scores_gemma":[0.36591187,0.16758233,0.07311727,0.014788823,0.006166178,0.14011836,0.0020226487,0.0006795864,0.2015271,0.0006519215,0.024536125,0.0028977667],"about_ca_topic_score_codex":0.000021972046,"about_ca_topic_score_gemma":0.00007846752,"teacher_disagreement_score":0.76364857,"about_ca_system_score_codex":0.0023786142,"about_ca_system_score_gemma":0.004695255,"threshold_uncertainty_score":0.9999574},"labels":[],"label_agreement":null},{"id":"W2517939523","doi":"10.1016/j.bbmt.2015.11.1048","title":"Isolated Penile Meatal Chronic GVHD in a Boy Following Allogeneic Transplant for JMML","year":2016,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre","funders":"","keywords":"Medicine; Graft-versus-host disease; Surgery; Busulfan; Urinary system; Tacrolimus; Glans penis; Immunosuppression; Hematopoietic stem cell transplantation; Gastroenterology; Transplantation; Internal medicine; Penis","score_opus":0.011489702824778045,"score_gpt":0.2585221322528517,"score_spread":0.24703242942807366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2517939523","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946309,0.0017531986,0.002279802,0.00031590727,0.00010534405,0.0005986538,0.00022123953,0.000028022423,0.00006692997],"genre_scores_gemma":[0.99748904,0.0013779976,0.00052108767,0.000029166506,0.000039527968,0.00007791157,0.00037494316,0.000015352107,0.00007500201],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99907064,0.000037682832,0.00029967687,0.00028370327,0.000060024046,0.00024828865],"domain_scores_gemma":[0.9996305,0.00012088578,0.00006433931,0.00010507788,0.000019454485,0.000059760292],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013080846,0.00015022088,0.00032857264,0.000119325705,0.000032477674,0.000002040437,0.000046612087,0.00017117686,0.00003074061],"category_scores_gemma":[0.000010008206,0.00010472185,0.00010583637,0.00006393035,0.000054627882,0.00006141099,0.0000033251642,0.000050443898,0.000002021136],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009339037,0.00011292301,0.068253025,0.00037145158,0.0002349088,0.00006993996,0.00032905932,5.1596885e-7,0.9184464,0.00011752022,0.000005320042,0.011125027],"study_design_scores_gemma":[0.09065501,0.006610563,0.12429816,0.0012359299,0.0041403887,0.00096886256,0.000087888606,0.00016434366,0.7702734,0.0005199857,0.00042160976,0.00062385865],"about_ca_topic_score_codex":0.000089557056,"about_ca_topic_score_gemma":0.00030023753,"teacher_disagreement_score":0.148173,"about_ca_system_score_codex":0.00006637257,"about_ca_system_score_gemma":0.00015219046,"threshold_uncertainty_score":0.4270433},"labels":[],"label_agreement":null},{"id":"W2518117171","doi":"10.1080/17474086.2016.1232163","title":"Ponatinib in the therapy of chronic myeloid leukemia","year":2016,"lang":"en","type":"review","venue":"Expert Review of Hematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Ponatinib; Medicine; Magic bullet; Myeloid leukemia; Targeted therapy; Disease; Oncology; Tyrosine-kinase inhibitor; Nilotinib; Internal medicine; Immunology; Bioinformatics; Imatinib; Cancer","score_opus":0.0426814344624905,"score_gpt":0.38783313961551064,"score_spread":0.3451517051530201,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2518117171","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000006537613,0.992752,0.000004550406,0.00060173025,0.00022076827,0.003373649,0.000022938213,0.0000194491,0.0029983588],"genre_scores_gemma":[0.000012283153,0.99758995,0.00019250244,0.00077583647,0.00021119467,0.0008516969,0.00011592607,0.00007580711,0.00017482699],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99545383,0.0007501973,0.002278133,0.0005645128,0.00048509912,0.00046821198],"domain_scores_gemma":[0.9956497,0.0010902393,0.0013996525,0.0016731493,0.00011416556,0.00007311632],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008614798,0.00065562624,0.0064938683,0.00026249146,0.00002366292,0.0000022980655,0.0007613556,0.00046567398,0.0013156878],"category_scores_gemma":[0.00038876696,0.00030437566,0.0012173683,0.00051967415,0.00031582642,0.000039199578,0.00010200272,0.0004809356,0.00015422],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012087367,0.00016694095,0.0000043130294,0.15194176,0.00029363064,0.000104633735,0.00008155237,2.0779563e-9,0.0000032089854,0.001001138,0.0077460837,0.8386446],"study_design_scores_gemma":[0.0011216692,0.0002630296,0.0000024131573,0.298613,0.0001602551,0.0019049937,0.000007193531,2.0779447e-7,0.00003341417,0.000017558297,0.6977192,0.00015702688],"about_ca_topic_score_codex":0.000050098017,"about_ca_topic_score_gemma":0.0000064909595,"teacher_disagreement_score":0.8384876,"about_ca_system_score_codex":0.0014887638,"about_ca_system_score_gemma":0.003991592,"threshold_uncertainty_score":0.9999408},"labels":[],"label_agreement":null},{"id":"W2519147980","doi":"10.1182/blood.v124.21.1784.1784","title":"Inhibitory Effects of Icaritin on TKI-Resistant CML Cells through Disruption of the BCR-ABL-GRB2-RAS-MAPK Signaling Pathway","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Nilotinib; Dasatinib; Cancer research; Imatinib mesylate; Tyrosine kinase; Imatinib; Myeloid leukemia; Stem cell; Population; Medicine; Progenitor cell; Tyrosine-kinase inhibitor; Biology; Cancer; Internal medicine; Cell biology; Receptor","score_opus":0.0077195876594145976,"score_gpt":0.22396764023192917,"score_spread":0.21624805257251456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2519147980","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954856,0.00051550637,0.000057843048,0.00008071424,0.00029407383,0.00067438907,0.000023808212,0.000038969032,0.0028290697],"genre_scores_gemma":[0.99887645,0.000030731073,0.00042810335,0.00013376487,0.00024606442,0.000030505918,0.000016903885,0.00003767597,0.00019977354],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99828106,0.00018033161,0.0004277409,0.0003143911,0.00052534713,0.0002711089],"domain_scores_gemma":[0.9983767,0.000506108,0.00028385012,0.000682037,0.000077807264,0.00007347089],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002354144,0.0002228466,0.00045966855,0.000051325642,0.00006770611,0.000006587727,0.00014706001,0.00014303817,0.00003269868],"category_scores_gemma":[0.00026838534,0.00015235014,0.00021088538,0.00017707872,0.00012534806,0.0000474508,0.00006893041,0.00022196624,0.000021012836],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014805737,0.0014421175,0.0020223795,0.0009683169,0.00019842687,0.000024033196,0.0005663354,0.000024681674,0.99222153,0.0008531806,0.00015637797,0.0013745663],"study_design_scores_gemma":[0.0074695405,0.000957441,0.0056064087,0.0020765488,0.0004912777,0.0000079435,0.000059973085,0.000026616368,0.9823279,0.00023427798,0.00061610603,0.00012596018],"about_ca_topic_score_codex":0.00013917203,"about_ca_topic_score_gemma":0.000013981263,"teacher_disagreement_score":0.00989362,"about_ca_system_score_codex":0.00017531568,"about_ca_system_score_gemma":0.00018372573,"threshold_uncertainty_score":0.6212659},"labels":[],"label_agreement":null},{"id":"W2519942097","doi":"","title":"Targeting cancer stem cells: Challenges and opportunities","year":2013,"lang":"en","type":"article","venue":"Journal of Bioequivalence & Bioavailability","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Dasatinib; Imatinib; Stem cell; Progenitor cell; Cancer research; Cancer stem cell; Medicine; Tyrosine kinase; Myeloid leukemia; CD34; Haematopoiesis; Chronic myelogenous leukemia; Tyrosine-kinase inhibitor; Population; Immunology; Cancer; Leukemia; Biology; Internal medicine; Cell biology; Receptor","score_opus":0.08584506014930933,"score_gpt":0.295643831768893,"score_spread":0.20979877161958366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2519942097","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.924855,0.06856049,0.0000080205555,0.005380619,0.0003134154,0.0003342692,0.000011335212,0.000025402718,0.0005114429],"genre_scores_gemma":[0.92212975,0.07592209,0.000767081,0.00020868996,0.0002739874,0.000015534368,7.833833e-7,0.000019381083,0.0006626957],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99808913,0.00011235563,0.00072417915,0.00028209426,0.0004491726,0.00034307435],"domain_scores_gemma":[0.9982099,0.00013324068,0.00048881565,0.00030821926,0.00049303094,0.00036679115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007553791,0.00023186393,0.0005426594,0.00011803342,0.000067336194,0.000032851392,0.00015053473,0.00012828481,0.00076769583],"category_scores_gemma":[0.00006602544,0.00016661322,0.00013826722,0.00006627365,0.00047619911,0.00041348656,0.00008395268,0.00031378443,0.000030993928],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033133104,0.00074701017,0.039464865,0.0019904664,0.00047847803,0.00026409124,0.0031477776,0.000005018715,0.09401731,0.0001712969,0.005229657,0.8541527],"study_design_scores_gemma":[0.025483988,0.012823892,0.40027693,0.007738246,0.0033218195,0.003621611,0.06292158,0.0020356504,0.34305447,0.002443956,0.1330746,0.0032032642],"about_ca_topic_score_codex":0.00012629364,"about_ca_topic_score_gemma":0.000005333897,"teacher_disagreement_score":0.8509494,"about_ca_system_score_codex":0.0005665708,"about_ca_system_score_gemma":0.00050787104,"threshold_uncertainty_score":0.8405731},"labels":[],"label_agreement":null},{"id":"W2522060114","doi":"10.1159/000448983","title":"Dasatinib-Induced T-Cell-Mediated Colitis: A Case Report and Review of the Literature","year":2016,"lang":"en","type":"letter","venue":"Acta Haematologica","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Covenant Health","funders":"","keywords":"Dasatinib; Discontinuation; Medicine; Colitis; Chronic myelogenous leukemia; Drug; Tyrosine-kinase inhibitor; Imatinib; Tyrosine kinase; Internal medicine; Pharmacology; Gastroenterology; Immunology; Leukemia; Cancer; Myeloid leukemia; Receptor","score_opus":0.022756465360404706,"score_gpt":0.27852410377747067,"score_spread":0.25576763841706596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2522060114","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11592205,0.047474455,2.82833e-7,0.822497,0.0005009123,0.0036298337,0.00043937407,0.00013763447,0.009398423],"genre_scores_gemma":[0.17464171,0.031500936,0.0002612681,0.7808495,0.0012791813,0.00047998814,0.0013993448,0.00014635439,0.009441708],"study_design_codex":"not_applicable","study_design_gemma":"case_report","domain_scores_codex":[0.99696046,0.00030369923,0.000967743,0.0007421882,0.0005337481,0.00049215805],"domain_scores_gemma":[0.9960656,0.0006236919,0.0011380438,0.0017755305,0.00027355735,0.00012353831],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003223491,0.0005458023,0.0016582448,0.00007089768,0.00009668398,0.000020002757,0.00026283783,0.0012294642,0.00039304103],"category_scores_gemma":[0.0016265569,0.00026370373,0.00032909086,0.00030758622,0.00020745973,0.000054492608,0.00024124287,0.0015021024,0.00002748805],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000211244,0.000030630898,0.00016644227,0.014291406,0.00015710352,0.37834132,0.00006435691,1.6076027e-10,0.00011299917,0.000003162822,0.6065835,0.00022801127],"study_design_scores_gemma":[0.0013969246,0.00016505945,0.00019551757,0.043281578,0.0006845945,0.5364879,0.000010204961,2.8261402e-7,0.00047066933,0.00003282955,0.41702825,0.00024623307],"about_ca_topic_score_codex":0.00005504058,"about_ca_topic_score_gemma":0.0000048859924,"teacher_disagreement_score":0.18955521,"about_ca_system_score_codex":0.0003012097,"about_ca_system_score_gemma":0.00072339975,"threshold_uncertainty_score":0.9999815},"labels":[],"label_agreement":null},{"id":"W2523106824","doi":"10.1016/j.clml.2016.07.094","title":"Treatment-Free Remission (TFR) Following Frontline or Second-Line Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTfreedom and ENESTop","year":2016,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Nilotinib; Imatinib; Medicine; Tyrosine-kinase inhibitor; Myeloid leukemia; Internal medicine; Tyrosine kinase; Oncology; Dasatinib","score_opus":0.025605541508677207,"score_gpt":0.3167900096385131,"score_spread":0.2911844681298359,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2523106824","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99248827,0.002563623,0.00008615478,0.00053057796,0.0006327183,0.0027831683,0.0001604976,0.0003071885,0.00044783365],"genre_scores_gemma":[0.9889298,0.0014474187,0.0013932007,0.00032076632,0.0011442361,0.00035424388,0.00039494433,0.00031442876,0.0057009235],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99067616,0.00049991097,0.003154294,0.0026396234,0.0010601075,0.00196989],"domain_scores_gemma":[0.99309564,0.0018851743,0.0008232331,0.002749956,0.0001916558,0.0012543363],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0009646756,0.001526887,0.0029557387,0.0006616233,0.00022360381,0.00007568934,0.0007745632,0.0011462129,0.0008328905],"category_scores_gemma":[0.001542125,0.00094873935,0.0005881155,0.0009952149,0.0007125224,0.0007176846,0.00051437685,0.00060269446,0.00017261984],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.013435947,0.0014845254,0.30643076,0.00021623928,0.00047130574,0.0025798047,0.00013294825,0.000024899571,0.0027168347,0.000026204088,0.00048753794,0.671993],"study_design_scores_gemma":[0.24162652,0.015691455,0.7225223,0.0027443094,0.0004715077,0.00021457917,0.000031327723,0.0010032012,0.0024262958,0.0000791479,0.012105183,0.0010841367],"about_ca_topic_score_codex":0.0011062962,"about_ca_topic_score_gemma":0.0049329815,"teacher_disagreement_score":0.67090887,"about_ca_system_score_codex":0.063873895,"about_ca_system_score_gemma":0.017683677,"threshold_uncertainty_score":0.999748},"labels":[],"label_agreement":null},{"id":"W2525124319","doi":"10.1200/jco.2012.30.15_suppl.tps4134","title":"Dasatinib combined with gemcitabine (Gem) in patients (pts) with locally advanced pancreatic adenocarcinoma (PaCa): Design of CA180-375, a placebo-controlled, randomized, double-blind phase II trial.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Dasatinib; Medicine; Internal medicine; Gemcitabine; Phases of clinical research; Cancer; Clinical endpoint; Oncology; Gastroenterology; Clinical trial; Myeloid leukemia; Imatinib","score_opus":0.08178953788669324,"score_gpt":0.4010976613704846,"score_spread":0.31930812348379134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2525124319","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860402,0.00091214874,0.0016669648,0.0007617717,0.00061620044,0.008999095,0.0000056307117,0.00001663481,0.0009813725],"genre_scores_gemma":[0.98538756,0.00026861118,0.012646757,0.00038092994,0.0005605562,0.0003084325,0.000020267362,0.00006917205,0.0003577193],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9898753,0.0021075099,0.0057699806,0.00041001316,0.0010885108,0.0007486624],"domain_scores_gemma":[0.98242444,0.009404374,0.0058571314,0.0005400196,0.00092869287,0.00084534765],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.009153599,0.00053500297,0.007976944,0.0004503294,0.00007090419,0.00001031416,0.00030608318,0.0005646883,0.0002161892],"category_scores_gemma":[0.0053538433,0.00030160058,0.00069370406,0.00043550887,0.00065627653,0.0003657524,0.00008098914,0.001402154,0.000011242732],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9231045,0.026445225,0.036638465,0.00007912293,0.0030192526,0.0003422741,0.0003718474,0.00030331747,0.000017308597,0.00005347186,0.00018379345,0.009441387],"study_design_scores_gemma":[0.81409174,0.17552026,0.0049260324,0.0005620026,0.00379355,0.00015612972,0.000121334444,0.00037018766,0.00005851751,0.000028853008,0.00014460947,0.00022681219],"about_ca_topic_score_codex":0.000046094745,"about_ca_topic_score_gemma":0.000038204522,"teacher_disagreement_score":0.14907503,"about_ca_system_score_codex":0.0010288605,"about_ca_system_score_gemma":0.0046488247,"threshold_uncertainty_score":0.9999436},"labels":[],"label_agreement":null},{"id":"W2526894720","doi":"10.1007/s12012-016-9386-7","title":"The Myocyte-Damaging Effects of the BCR-ABL1-Targeted Tyrosine Kinase Inhibitors Increase with Potency and Decrease with Specificity","year":2016,"lang":"en","type":"article","venue":"Cardiovascular Toxicology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Canadian Institutes of Health Research; Canada Research Chairs","keywords":"Nilotinib; Dasatinib; Tyrosine kinase; Ponatinib; Tyrosine-kinase inhibitor; Imatinib; Imatinib mesylate; Cardiac myocyte; Myocyte; Pharmacology; Chronic myelogenous leukemia; Chemistry; Cancer research; Biology; Leukemia; Internal medicine; Cell biology; Medicine; Signal transduction; Biochemistry; Myeloid leukemia","score_opus":0.004570088613258425,"score_gpt":0.19433149858704118,"score_spread":0.18976140997378277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2526894720","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9861977,0.010802062,0.00027563522,0.00075954624,0.00019807872,0.0013165072,0.000008610329,0.00005421202,0.00038761928],"genre_scores_gemma":[0.9982985,0.0006085635,0.0003163999,0.00018038585,0.0001666188,0.00009944051,0.000004829699,0.000053704654,0.00027152768],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977222,0.00045707932,0.0002865313,0.00052310346,0.00051381934,0.0004972787],"domain_scores_gemma":[0.99733436,0.0005981659,0.0001486838,0.0014014478,0.0001920493,0.00032526528],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005009795,0.00033764605,0.00071898254,0.00006342889,0.00026241224,0.000016108701,0.000195312,0.00014653374,0.000017367285],"category_scores_gemma":[0.00088360405,0.0001352795,0.00035433527,0.00034583663,0.00095491146,0.00007637785,0.00015830337,0.00023784257,0.0000061980636],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009423475,0.0016822573,0.30237773,0.0015252598,0.023174416,0.00885759,0.0008627612,0.00015116138,0.2314878,0.0012182804,0.0015381359,0.41770113],"study_design_scores_gemma":[0.042060606,0.003036788,0.4434081,0.0019011456,0.0062604896,0.0041845716,0.00024183856,0.00006446898,0.48239052,0.00013858035,0.01557334,0.0007395732],"about_ca_topic_score_codex":0.0002860737,"about_ca_topic_score_gemma":0.00009543212,"teacher_disagreement_score":0.41696155,"about_ca_system_score_codex":0.00048005045,"about_ca_system_score_gemma":0.0005544554,"threshold_uncertainty_score":0.5516538},"labels":[],"label_agreement":null},{"id":"W2527059769","doi":"10.1182/blood.v112.11.193.193","title":"Differentially Expressed and Novel Transcripts in Highly Purified Chronic Phase CML Stem Cells","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency","funders":"","keywords":"CD38; Stem cell; Biology; Haematopoiesis; CD34; Molecular biology; Cancer research; Immunology; Cell biology","score_opus":0.02778141772518316,"score_gpt":0.24876513662024582,"score_spread":0.22098371889506266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2527059769","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964842,0.0017222653,0.0001474239,0.00014413163,0.00012624863,0.0006639332,0.000045040957,0.00008254254,0.0005841906],"genre_scores_gemma":[0.9974672,0.00048777577,0.00027196985,0.000075621625,0.00014702156,0.000058787067,0.00003095641,0.000041794203,0.0014188396],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985218,0.000029209617,0.0003408274,0.00043786637,0.00027470806,0.0003956072],"domain_scores_gemma":[0.99928075,0.000043951317,0.00006446573,0.00038511056,0.000027543241,0.00019815007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005557792,0.00025673618,0.0004461605,0.00012893227,0.00006311355,0.000012885423,0.000097877455,0.00013944569,0.00008075623],"category_scores_gemma":[0.0000057384964,0.00022787534,0.00008251257,0.00014164395,0.000088723864,0.00007947518,0.000026811027,0.00021419064,0.000023576495],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024281458,0.004129634,0.0019391584,0.00015224455,0.00017318616,0.0006798767,0.0007890596,0.0000021279716,0.98949873,0.000037149308,0.00013545174,0.0022205885],"study_design_scores_gemma":[0.12623589,0.0010952313,0.019002646,0.0002724785,0.00041788165,0.00033231522,0.000041613202,0.00016780893,0.8502566,0.000008097316,0.0018588165,0.0003106012],"about_ca_topic_score_codex":0.0001087258,"about_ca_topic_score_gemma":0.000057495596,"teacher_disagreement_score":0.1392421,"about_ca_system_score_codex":0.00025136388,"about_ca_system_score_gemma":0.00040736364,"threshold_uncertainty_score":0.9292487},"labels":[],"label_agreement":null},{"id":"W2527307458","doi":"10.1182/blood.v122.21.5186.5186","title":"Impact Of Dedicated CML Clinic On The Outcome Of Patients With Newly Diagnosed CML: Experience Of a Single Canadian Center","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; McGill University Health Centre","funders":"","keywords":"Medicine; Imatinib mesylate; Imatinib; Internal medicine; Anagrelide; Single Center; Pediatrics; Oncology; Surgery; Myeloid leukemia","score_opus":0.022624023929361477,"score_gpt":0.27698677658597687,"score_spread":0.2543627526566154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2527307458","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980899,0.000027177088,7.372236e-7,0.00009410779,0.000031195254,0.00073954585,0.0000776146,0.000008994769,0.00093073846],"genre_scores_gemma":[0.99957633,0.0000050658414,0.00010794341,0.000118418786,0.000013491774,0.00003825056,0.000039179646,0.000020795527,0.00008054611],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987962,0.000038526076,0.00041866436,0.00017456475,0.000309051,0.0002629655],"domain_scores_gemma":[0.9986721,0.00015777937,0.00027107284,0.00051546574,0.0001721772,0.00021138579],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000057421435,0.0001503229,0.00036303492,0.0000993166,0.000022428527,0.0000035565834,0.00015117525,0.00006765581,0.0010746277],"category_scores_gemma":[0.00024282947,0.000082002894,0.00011563733,0.00019487929,0.00015051,0.000045601762,0.000021380449,0.00009812957,0.00002949739],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008964321,0.0021017385,0.99543566,0.000027636816,0.00025149452,0.000008476638,0.0009397401,0.0000011493869,0.0005889953,0.0000019704707,0.00022053963,0.00033294436],"study_design_scores_gemma":[0.010991748,0.0023488249,0.9816324,0.00018845349,0.00013241851,0.0000024671388,0.00013620334,0.000006633027,0.004465321,0.0000022747045,0.000024329634,0.0000689337],"about_ca_topic_score_codex":0.095249124,"about_ca_topic_score_gemma":0.0058052223,"teacher_disagreement_score":0.08944391,"about_ca_system_score_codex":0.00024427447,"about_ca_system_score_gemma":0.0004361816,"threshold_uncertainty_score":0.99983853},"labels":[],"label_agreement":null},{"id":"W2528188718","doi":"10.1200/jco.2016.68.2914","title":"Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":494,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Saint-François d'Assise","funders":"","keywords":"Medicine; Discontinuation; Imatinib; Myeloid leukemia; Internal medicine; Surgery; Imatinib mesylate; Minimal residual disease; Population; Gastroenterology; Leukemia","score_opus":0.048477034347511404,"score_gpt":0.38468864223977933,"score_spread":0.33621160789226795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2528188718","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99629706,0.00015093497,0.000030176392,0.00086435693,0.0012416999,0.00090259843,0.0000061892724,0.000007082322,0.00049989304],"genre_scores_gemma":[0.99805546,0.00008121226,0.00032398634,0.00020692065,0.0004324276,0.000011013439,0.0000015746077,0.00002900007,0.0008584196],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949663,0.000624708,0.002913398,0.00029853432,0.0008274415,0.0003695681],"domain_scores_gemma":[0.99403805,0.0019065551,0.0026833587,0.0005947684,0.00050643994,0.0002708057],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019618494,0.00024396673,0.0018368803,0.00015030391,0.000036925994,0.000004706883,0.0004357244,0.00032566767,0.0003249554],"category_scores_gemma":[0.002472494,0.00010636792,0.00043134298,0.00025125637,0.00036568593,0.0001438586,0.00015245628,0.0009050648,0.000022964932],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033535082,0.003006061,0.887028,0.00003240398,0.0005348623,0.00019662766,0.00017646067,0.0000062781296,0.000043413515,0.0000036016622,0.00046437432,0.10515444],"study_design_scores_gemma":[0.08819403,0.028995112,0.8810015,0.00063784193,0.00051161164,0.000052933716,0.000028353166,0.0000052041205,0.00007295146,0.000025618961,0.00037402657,0.00010083835],"about_ca_topic_score_codex":0.00008376675,"about_ca_topic_score_gemma":0.0009278092,"teacher_disagreement_score":0.1050536,"about_ca_system_score_codex":0.0036875985,"about_ca_system_score_gemma":0.008302898,"threshold_uncertainty_score":0.9973191},"labels":[],"label_agreement":null},{"id":"W2530737867","doi":"10.1182/blood.v112.11.4393.4393","title":"Pediatric Treatment Guidelines for Philadelphia Positive (Ph+) Acute Lymphoblastic Leukemia (ALL): What Are They in today’s Imatinib Era?","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Stollery Children's Hospital","funders":"","keywords":"Medicine; Imatinib; Acute lymphocytic leukemia; Transplantation; Imatinib mesylate; Philadelphia chromosome; Internal medicine; Hematopoietic cell; Pediatrics; Hematopoietic stem cell transplantation; Lymphoblastic Leukemia; Oncology; Leukemia; Haematopoiesis; Stem cell; Myeloid leukemia","score_opus":0.04565763939235168,"score_gpt":0.3121178310377678,"score_spread":0.2664601916454161,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2530737867","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897388,0.004628845,0.00003529632,0.002634953,0.0002715749,0.0020326243,0.00019805919,0.00014446833,0.00031535633],"genre_scores_gemma":[0.97903323,0.01102185,0.0055057267,0.0011092613,0.0011323967,0.00070740865,0.00045015762,0.00011775489,0.00092220225],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973451,0.000053517757,0.0007843254,0.0007087019,0.00040508373,0.00070327934],"domain_scores_gemma":[0.99821854,0.00031370245,0.00028119463,0.00058293337,0.0003323655,0.00027126397],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012322264,0.00054546184,0.00083803205,0.00028418162,0.00014334824,0.000039789975,0.00016933997,0.00023216345,0.000068092246],"category_scores_gemma":[0.00023519881,0.00043012542,0.00031792233,0.00025226333,0.000055715253,0.00025480703,0.00006173698,0.00015373922,0.0001119291],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013467236,0.043990295,0.6911168,0.0027907814,0.02418066,0.04081119,0.03803717,0.0023984953,0.022931535,0.00064395077,0.07539064,0.04424126],"study_design_scores_gemma":[0.3578862,0.014592049,0.52404195,0.003073118,0.022474915,0.013284438,0.0028236299,0.0057318793,0.04548791,0.0009291224,0.005976327,0.003698435],"about_ca_topic_score_codex":0.00039977906,"about_ca_topic_score_gemma":0.00022368276,"teacher_disagreement_score":0.34441897,"about_ca_system_score_codex":0.002856724,"about_ca_system_score_gemma":0.0014741393,"threshold_uncertainty_score":0.99981505},"labels":[],"label_agreement":null},{"id":"W2530761803","doi":"10.1182/blood.v120.21.4274.4274","title":"Patient Preferences for Stopping Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Victoria Hospital; London Health Sciences Centre; Western University","funders":"","keywords":"Nilotinib; Medicine; Dasatinib; Imatinib; Imatinib mesylate; Internal medicine; Oncology; Myeloid leukemia; Clinical trial; Family medicine","score_opus":0.02184095435986586,"score_gpt":0.2647925601303088,"score_spread":0.24295160577044292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2530761803","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895669,0.0075019524,0.00001747516,0.00008047506,0.00029008312,0.0011253274,0.000018821545,0.00007487671,0.0013240579],"genre_scores_gemma":[0.99742067,0.00012893912,0.0010652483,0.00010380178,0.00064940844,0.0003054454,0.00008378934,0.00003843306,0.00020425572],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99840176,0.000031640076,0.00037677388,0.0003015237,0.00024975283,0.00063854235],"domain_scores_gemma":[0.99920523,0.00009018317,0.00011309526,0.0003281792,0.000048393318,0.00021493067],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016364377,0.00023554312,0.0003601109,0.00014948205,0.00006222657,0.000013397891,0.0000724748,0.00013593513,0.000089483285],"category_scores_gemma":[0.00011787033,0.0002010375,0.00010451378,0.00021034924,0.00004736657,0.00016354755,0.00006023306,0.00018776178,0.00004850956],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00063515524,0.005384718,0.5916508,0.0018355051,0.00071878167,0.00013143382,0.005848852,0.000120260825,0.19658038,0.0005394144,0.0035989531,0.19295575],"study_design_scores_gemma":[0.052059736,0.004079167,0.3158329,0.0023347766,0.0010810676,0.00021012615,0.0007541258,0.0003951534,0.58450717,0.00016505734,0.037510715,0.0010699721],"about_ca_topic_score_codex":0.00019611567,"about_ca_topic_score_gemma":0.00008163993,"teacher_disagreement_score":0.3879268,"about_ca_system_score_codex":0.0025847724,"about_ca_system_score_gemma":0.000860584,"threshold_uncertainty_score":0.8198072},"labels":[],"label_agreement":null},{"id":"W2530814035","doi":"10.1182/blood-2016-04-708560","title":"Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":139,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Mutation; Myeloid leukemia; Tyrosine-kinase inhibitor; Tyrosine kinase; Cancer research; Medicine; Persistence (discontinuity); Somatic cell; Biology; Immunology; Oncology; Internal medicine; Genetics; Receptor; Cancer; Gene","score_opus":0.009926625770245863,"score_gpt":0.24813385797908094,"score_spread":0.23820723220883508,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2530814035","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967111,0.0014418066,0.0001059039,0.00036832364,0.00014138335,0.0006008726,0.000013367119,0.00006575928,0.00055152987],"genre_scores_gemma":[0.99842846,0.0002661952,0.0004725421,0.000035462526,0.00017688853,0.000044692675,0.00003997511,0.000047400183,0.0004883825],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99851763,0.00004405691,0.00046380082,0.0003060441,0.00031831086,0.00035014967],"domain_scores_gemma":[0.999193,0.00011010345,0.00015435247,0.00042376868,0.00002751359,0.00009127167],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001613141,0.00021926567,0.00042549107,0.00020146207,0.000030318944,0.000007395561,0.00009466012,0.00012268263,0.000095265066],"category_scores_gemma":[0.000089240835,0.00015494927,0.00015672685,0.00029211215,0.000054085656,0.00012843806,0.00003157371,0.00011348335,0.00004721379],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042014816,0.0018559423,0.23939982,0.00050481653,0.00077049504,0.0012681959,0.0005691718,0.00002865585,0.70850223,0.00068370864,0.00005866645,0.04593815],"study_design_scores_gemma":[0.075758696,0.0018948319,0.13818231,0.0024714912,0.0003699837,0.00017211484,0.00012473279,0.0016855876,0.7780584,0.00078108424,0.000091637936,0.00040912078],"about_ca_topic_score_codex":0.00021170432,"about_ca_topic_score_gemma":0.0004197869,"teacher_disagreement_score":0.1012175,"about_ca_system_score_codex":0.005501592,"about_ca_system_score_gemma":0.0010697094,"threshold_uncertainty_score":0.9983161},"labels":[],"label_agreement":null},{"id":"W2531107772","doi":"10.1182/blood.v110.11.35.35","title":"Comparative Transcriptome Analysis of Different Subsets of CD34+ Normal and Chronic Myeloid Leukemia Cells Identifies Novel Perturbations in the CML Stem Cell Population.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency","funders":"","keywords":"CD38; Biology; Myeloid leukemia; Stem cell; CD34; Haematopoiesis; Myelopoiesis; clone (Java method); Myeloid; Cancer research; Immunology; Population; Bone marrow; Leukemia; Molecular biology; Medicine; Cell biology; Genetics; Gene","score_opus":0.020682749448830775,"score_gpt":0.265246752713857,"score_spread":0.24456400326502623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2531107772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99735564,0.0012930062,0.00016936737,0.00003073243,0.000044921195,0.0004986184,0.000084854335,0.000011894185,0.0005109719],"genre_scores_gemma":[0.999297,0.00009406091,0.00010869652,0.000020635376,0.000031394775,0.000015641663,0.00015926223,0.000011259032,0.00026203634],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9984167,0.00005463733,0.0006257553,0.00025292535,0.00040229733,0.00024764144],"domain_scores_gemma":[0.999016,0.000256419,0.00022958625,0.00035111373,0.00007916874,0.0000677387],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002528028,0.00019896391,0.0006625193,0.0004391889,0.000055315162,0.000011476779,0.00012689496,0.00009132936,0.000051037798],"category_scores_gemma":[0.0000053694475,0.0001409115,0.0001849635,0.0007594569,0.00010797828,0.000084656436,0.00002213146,0.0001676234,0.0000018207863],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018304246,0.0026076338,0.26889923,0.00047723568,0.0022826025,0.000022885926,0.018951213,0.0005988745,0.70540684,0.00019670321,0.00003693939,0.00033675673],"study_design_scores_gemma":[0.0051893336,0.00018866244,0.80290556,0.000064963395,0.0031070998,0.000008391907,0.001380974,0.0010122951,0.18602198,0.0000056449703,0.0000112212065,0.00010386953],"about_ca_topic_score_codex":0.000584419,"about_ca_topic_score_gemma":0.002161287,"teacher_disagreement_score":0.5340063,"about_ca_system_score_codex":0.00040438943,"about_ca_system_score_gemma":0.00014032448,"threshold_uncertainty_score":0.5746204},"labels":[],"label_agreement":null},{"id":"W2531853837","doi":"10.1039/c6ib00127k","title":"Accurate prediction of the age incidence of chronic myeloid leukemia with an improved two-mutation mathematical model","year":2016,"lang":"en","type":"article","venue":"Integrative Biology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Metropolitan University","funders":"","keywords":"Myeloid leukemia; Incidence (geometry); Haematopoiesis; Chronic myelogenous leukemia; Leukemia; Mutation; Medicine; Myeloid; Body mass index; Oncology; Internal medicine; Biology; Genetics; Mathematics; Stem cell; Gene","score_opus":0.02219598395344676,"score_gpt":0.30116662652201315,"score_spread":0.2789706425685664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2531853837","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92871183,0.000056568068,0.06969987,0.00016947422,0.00005083272,0.0006033441,0.00009820054,0.000029327683,0.00058053446],"genre_scores_gemma":[0.9966362,0.000025916814,0.0027475068,0.00003776244,0.000051249077,0.00007052196,0.000030716456,0.000016091708,0.00038403028],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988694,0.00012913774,0.0003965244,0.00028062437,0.00013069157,0.00019359379],"domain_scores_gemma":[0.9987688,0.00018776211,0.0003122189,0.000425154,0.00025463282,0.00005143724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016321435,0.00018722437,0.00039039305,0.00006424105,0.000032558743,0.000002441178,0.00015993898,0.00013049904,0.00006310783],"category_scores_gemma":[0.00026041546,0.000075150856,0.00007634257,0.00014086708,0.00062102417,0.00012458352,0.000047199257,0.00014838617,0.0000063379975],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008971228,0.00018924996,0.0040174364,0.00007857821,0.00023349721,0.00000818003,0.0012588231,0.00011680524,0.97541744,0.006797551,0.000037507056,0.0109478235],"study_design_scores_gemma":[0.011937969,0.009780623,0.024261236,0.0016567914,0.00041886012,0.00026150394,0.0005343661,0.20564587,0.726664,0.018538788,0.000034418346,0.0002655835],"about_ca_topic_score_codex":0.00015071935,"about_ca_topic_score_gemma":0.0002960404,"teacher_disagreement_score":0.24875344,"about_ca_system_score_codex":0.001388691,"about_ca_system_score_gemma":0.0011788231,"threshold_uncertainty_score":0.36313787},"labels":[],"label_agreement":null},{"id":"W2532994364","doi":"10.1182/blood.v110.11.737.737","title":"Clinical Relevance of a Pharmacogenetic Approach Using Multiple Candidate Gene Polymorphisms To Predict Response and Resistance to Imatinib Mesylate Therapy in Chronic Myeloid Leukemia.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Imatinib mesylate; Single-nucleotide polymorphism; Myeloid leukemia; Pharmacogenetics; Oncology; Medicine; Population; Internal medicine; Imatinib; Biology; Genotype; Immunology; Genetics; Gene","score_opus":0.03150146730821448,"score_gpt":0.32829309079163177,"score_spread":0.2967916234834173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2532994364","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902364,0.0065667517,0.001045483,0.00011772185,0.00008301896,0.0017219537,0.00005541566,0.000049747843,0.00012351386],"genre_scores_gemma":[0.9546515,0.00094331533,0.043478932,0.00035894747,0.00018948765,0.000058037716,0.000015066487,0.00006798347,0.00023677251],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99691397,0.0002537995,0.0010148021,0.00074251654,0.00042644233,0.0006484659],"domain_scores_gemma":[0.9979948,0.0005715652,0.00021869977,0.0006596853,0.000088082576,0.000467164],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020753774,0.00032587245,0.0007366756,0.00031093505,0.00006307078,0.000011435848,0.00018915022,0.00016225863,0.000017728415],"category_scores_gemma":[0.00055832573,0.00030143984,0.00010417689,0.00063612295,0.00012514036,0.0000590021,0.00010976973,0.00028914993,0.0000068415407],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018500825,0.00079431094,0.13463895,0.00014255686,0.00032030453,0.00035804414,0.0010518975,0.00032776437,0.8285247,0.0000024560516,0.0000772566,0.01526092],"study_design_scores_gemma":[0.049410652,0.0021506562,0.44808555,0.00076434104,0.0003181535,0.00024004368,0.000060811162,0.0029423132,0.49376917,0.000012958918,0.0017189527,0.0005264182],"about_ca_topic_score_codex":0.00025872132,"about_ca_topic_score_gemma":0.00021199755,"teacher_disagreement_score":0.33475554,"about_ca_system_score_codex":0.0013442488,"about_ca_system_score_gemma":0.001418804,"threshold_uncertainty_score":0.9999438},"labels":[],"label_agreement":null},{"id":"W2535537998","doi":"10.1182/blood.v116.21.2569.2569","title":"Impact of Treatment Strategies on Clinical Outcomes In Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients In Canada","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Bristol-Myers Squibb (Canada)","funders":"","keywords":"Medicine; Imatinib; Myeloid leukemia; Internal medicine; Imatinib mesylate; Cancer","score_opus":0.022420404387260093,"score_gpt":0.34404296924215816,"score_spread":0.32162256485489804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2535537998","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99746025,0.00016585302,2.2532943e-7,0.000033588414,0.00027928562,0.0010450023,0.00012971835,0.000025520785,0.0008605454],"genre_scores_gemma":[0.99911,0.0002537645,0.000047739657,0.000028349854,0.00016285638,0.00008028806,0.00015677851,0.000048150923,0.000112073394],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972163,0.00008806485,0.0010497739,0.0005610683,0.00040675025,0.0006780785],"domain_scores_gemma":[0.99828243,0.00028310958,0.00027566077,0.0008120767,0.000062895255,0.00028380728],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016265734,0.0004598806,0.0010869373,0.00023014592,0.00003000592,0.000013434002,0.00019126937,0.00021760548,0.00032364996],"category_scores_gemma":[0.00013827135,0.00033725085,0.00031306833,0.0002717542,0.0001014353,0.00011183553,0.000044558205,0.0006183161,0.000025992105],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00032678584,0.004559024,0.9788492,0.00005328863,0.0005083081,0.00024866298,0.00008947623,0.0002134345,0.0018652527,0.000018985162,0.00005029837,0.013217287],"study_design_scores_gemma":[0.07661645,0.011743212,0.9084329,0.00014696519,0.0001982969,0.000013189634,0.00004351742,0.00019309239,0.0022354533,0.000013501354,0.00012554042,0.00023787346],"about_ca_topic_score_codex":0.8332166,"about_ca_topic_score_gemma":0.9589243,"teacher_disagreement_score":0.12570767,"about_ca_system_score_codex":0.03055676,"about_ca_system_score_gemma":0.047862813,"threshold_uncertainty_score":0.999908},"labels":[],"label_agreement":null},{"id":"W2536831387","doi":"10.1182/blood.v120.21.4433.4433","title":"Associations Between Baseline Mutation Status and Response to Treatment with Omacetaxine Mepesuccinate in Heavily Pretreated Patients with Chronic Myeloid Leukemia","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Myeloid leukemia; Tolerability; Imatinib; Phases of clinical research; Gastroenterology; Oncology; Immunology; Adverse effect; Clinical trial","score_opus":0.010706767314877245,"score_gpt":0.25315316635441687,"score_spread":0.24244639903953963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2536831387","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967413,0.00053202634,0.0000308426,0.0002452289,0.000021461585,0.0018187652,0.00038125666,0.00009073218,0.00013838883],"genre_scores_gemma":[0.9965548,0.000051986775,0.001457082,0.00005807252,0.0001033357,0.00017379985,0.0011395647,0.00006360285,0.00039777483],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99780726,0.00021856016,0.00038071044,0.00043430878,0.00042486345,0.0007342989],"domain_scores_gemma":[0.9985405,0.0002784083,0.00016525296,0.00036979842,0.0001486204,0.0004973866],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00033994936,0.00036550016,0.0005771396,0.00031070408,0.00010001782,0.00002220049,0.000045413246,0.00012054127,0.000041294403],"category_scores_gemma":[0.0001437053,0.00025906472,0.000037307665,0.00059481984,0.000040282997,0.0002136901,0.00002746037,0.00016039153,0.000030862826],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021220117,0.0012372216,0.98696214,0.000025843903,0.000520811,0.000051602703,0.0013390402,0.000034355744,0.00042921884,0.0000019960776,0.000012103117,0.0072636465],"study_design_scores_gemma":[0.043153264,0.006792128,0.94257355,0.00018897184,0.0009697762,0.000018578794,0.000042738782,0.000029207962,0.0056030364,0.0000013849277,0.00037314612,0.0002542019],"about_ca_topic_score_codex":0.0013713028,"about_ca_topic_score_gemma":0.001024853,"teacher_disagreement_score":0.044388585,"about_ca_system_score_codex":0.0065211006,"about_ca_system_score_gemma":0.0010430814,"threshold_uncertainty_score":0.9999862},"labels":[],"label_agreement":null},{"id":"W2538510330","doi":"10.1182/blood.v114.22.4286.4286","title":"Comparison of Healthcare Utilization and Costs Between Nilotinib and Dasatinib as Second Line Therapies in Chronic Myeloid Leukemia.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Nilotinib; Medicine; Dasatinib; Internal medicine; Myeloid leukemia; Medical prescription; Pharmacy; Imatinib; Pharmacology; Family medicine","score_opus":0.04967079517563694,"score_gpt":0.3562436461687651,"score_spread":0.30657285099312814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2538510330","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9791261,0.018810257,0.000005237509,0.000711063,0.000019850268,0.00062247284,0.000027031745,0.00003918793,0.000638779],"genre_scores_gemma":[0.9980273,0.0010819603,0.00031411636,0.00016444849,0.00012259217,0.000010074742,0.0001435395,0.000020005133,0.00011594669],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99866503,0.0000674532,0.00047855053,0.0003250184,0.00020721948,0.00025673944],"domain_scores_gemma":[0.99926126,0.000118206204,0.00017392612,0.0002492377,0.000059358623,0.00013800855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016396804,0.00020100988,0.00060757686,0.0001406115,0.000048756734,0.000012366231,0.00005548595,0.00015657858,0.000059135815],"category_scores_gemma":[0.000059044494,0.00018363215,0.00003076268,0.00019771219,0.000085147534,0.00007663708,0.000029708703,0.00022714915,0.000003819018],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015338155,0.00040792642,0.8346806,0.00042898205,0.00015229445,0.000021261456,0.002793639,0.000002688356,0.0074265986,0.00027921124,0.00005123006,0.15360218],"study_design_scores_gemma":[0.016459433,0.0035149462,0.93088144,0.00063300924,0.00019203896,0.0000520921,0.00043085712,0.00023201945,0.046342224,0.00018330182,0.0008855732,0.00019307126],"about_ca_topic_score_codex":0.0003300131,"about_ca_topic_score_gemma":0.0005466013,"teacher_disagreement_score":0.15340911,"about_ca_system_score_codex":0.0005883859,"about_ca_system_score_gemma":0.00057518337,"threshold_uncertainty_score":0.7488302},"labels":[],"label_agreement":null},{"id":"W2542022508","doi":"10.1182/blood.v110.11.31.31","title":"MicroRNAs Act as Decoy Molecules To Restore Granulocytic Maturation of Differentiation-Arrested BCR/ABL+ Myeloid Precursors.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Biology; microRNA; CEBPA; Chronic myelogenous leukemia; Cancer research; K562 cells; Myeloid leukemia; Imatinib mesylate; Molecular biology; ABL; Leukemia; Imatinib; Cell biology; Immunology; Genetics; Gene; Transcription factor; Signal transduction; Tyrosine kinase","score_opus":0.009725888427012245,"score_gpt":0.2688193717649545,"score_spread":0.2590934833379423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2542022508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961009,0.00068928633,0.00028541553,0.0002083137,0.00020780627,0.0008511412,0.000014962563,0.00009148663,0.0015507026],"genre_scores_gemma":[0.9958061,0.00004681174,0.0026134285,0.00012142106,0.00012533696,0.00002813587,0.00016832082,0.000045779347,0.001044692],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998356,0.00004066074,0.0004805932,0.00036554685,0.00038517232,0.0003720527],"domain_scores_gemma":[0.9988198,0.0001147217,0.00019048114,0.00050520804,0.00016102409,0.00020873956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016606005,0.0002486473,0.0003720846,0.00024516214,0.000065525564,0.000018507846,0.00013662693,0.0001604651,0.00013727466],"category_scores_gemma":[0.0002910334,0.0002224937,0.00012519916,0.0003492367,0.000042090865,0.000080641315,0.000045681565,0.00016317323,0.00016156434],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014927398,0.0021550488,0.13116649,0.0004210296,0.00078592275,0.00021586714,0.001946158,0.000014815913,0.8529828,0.00026464858,0.0009270678,0.007627391],"study_design_scores_gemma":[0.005761781,0.0004060882,0.4545752,0.0002992283,0.00044995348,0.00010403715,0.000082156526,0.000012426311,0.5377687,0.00005257624,0.0003328254,0.00015496704],"about_ca_topic_score_codex":0.0001799046,"about_ca_topic_score_gemma":0.00012272483,"teacher_disagreement_score":0.32340872,"about_ca_system_score_codex":0.00040150533,"about_ca_system_score_gemma":0.00031843528,"threshold_uncertainty_score":0.907303},"labels":[],"label_agreement":null},{"id":"W2542967618","doi":"10.1182/blood.v112.11.4008.4008","title":"Pharmacokinetic Results from a Phase 1 Study of a Multi-Targeted Tyrosine Kinase Inhibitor, ABT-869, in Patients with Refractory or Relapsed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pharmacokinetics; Internal medicine; Cohort; Pharmacodynamics; Dosing; Pharmacology; Oncology; Cmax; Tyrosine-kinase inhibitor; Gastroenterology; Cancer","score_opus":0.021109433626469908,"score_gpt":0.2692309816465821,"score_spread":0.2481215480201122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2542967618","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944753,0.00038315196,0.0000070718474,0.000016938578,0.0002266956,0.003620247,0.0010659497,0.00017339179,0.000031272706],"genre_scores_gemma":[0.9960463,0.0001448787,0.0014907329,0.000076279044,0.00009923268,0.00022526263,0.0010615453,0.00016064865,0.0006951299],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9951742,0.00022854733,0.0014866629,0.0012086662,0.0010877055,0.0008141825],"domain_scores_gemma":[0.9970011,0.00042381976,0.0006486359,0.0011721901,0.000293437,0.00046080776],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017078253,0.0007723555,0.0014414754,0.00054196717,0.00015611132,0.000014239269,0.0003175024,0.00027599555,0.00024921802],"category_scores_gemma":[0.0004868595,0.0005403145,0.00011738532,0.0011613442,0.00020564548,0.00020941114,0.00014658578,0.0006999591,0.000058203503],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27010363,0.24658722,0.24929897,0.00053314114,0.009180615,0.12414868,0.02245844,0.00031709045,0.07143871,2.6803144e-7,0.0007783164,0.0051549133],"study_design_scores_gemma":[0.5373941,0.036092717,0.40699553,0.0009155618,0.0034758348,0.00065429765,0.00033400464,0.00033547418,0.012970385,4.9373824e-7,0.00012166095,0.00070991047],"about_ca_topic_score_codex":0.001878916,"about_ca_topic_score_gemma":0.0004960936,"teacher_disagreement_score":0.26729047,"about_ca_system_score_codex":0.0013958587,"about_ca_system_score_gemma":0.0017887962,"threshold_uncertainty_score":0.99970484},"labels":[],"label_agreement":null},{"id":"W2545387711","doi":"10.1182/blood.v126.23.4029.4029","title":"Treatment-Free Remission (TFR) Eligibility in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Residual Disease on Long-Term Imatinib (IM) Who Switched to Second-Line Nilotinib (NIL)","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; McMaster University","funders":"","keywords":"Nilotinib; Medicine; Imatinib; Internal medicine; Imatinib mesylate; Myeloid leukemia; Dasatinib; Tyrosine-kinase inhibitor; Gastroenterology; Surgery; Cancer","score_opus":0.02562510594425862,"score_gpt":0.31139104084803493,"score_spread":0.28576593490377633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2545387711","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940245,0.0012870778,0.0000052703385,0.00038064647,0.0000843028,0.0034707817,0.00021827819,0.00012731687,0.00040178653],"genre_scores_gemma":[0.99689317,0.00014010492,0.0002778783,0.00016895168,0.00030954333,0.00032689792,0.00075930235,0.000120392215,0.0010037535],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99554443,0.00019268112,0.00096413714,0.0014684297,0.0008361167,0.0009941948],"domain_scores_gemma":[0.99617165,0.00015404986,0.00027326113,0.0018822893,0.00015147564,0.0013672916],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037485917,0.0008048118,0.0011163009,0.00043409632,0.00009443133,0.000052953223,0.00031779616,0.00021871168,0.00014578206],"category_scores_gemma":[0.0005150335,0.0006278796,0.00010770681,0.00057706225,0.00014956157,0.00025022382,0.00024305627,0.00046915794,0.000079594305],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0172277,0.010016881,0.94350946,0.00083426206,0.0003422974,0.001914979,0.0013833288,0.00020192255,0.0029111726,0.00001140116,0.0004937811,0.021152796],"study_design_scores_gemma":[0.25083905,0.022624489,0.7082576,0.0020085503,0.000535637,0.000060223072,0.000051025963,0.0003539012,0.014222299,0.00004966675,0.00026679257,0.0007307263],"about_ca_topic_score_codex":0.0005384514,"about_ca_topic_score_gemma":0.0048327995,"teacher_disagreement_score":0.23525184,"about_ca_system_score_codex":0.01666371,"about_ca_system_score_gemma":0.0057455623,"threshold_uncertainty_score":0.9998909},"labels":[],"label_agreement":null},{"id":"W2545704931","doi":"10.1182/blood.v122.21.4040.4040","title":"Validation of Digital-PCR Analysis through Programmed imatinib Interruption in Q-RT-PCR Negative Chronic Myeloid Leukemia Patients","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Imatinib; Medicine; Imatinib mesylate; Discontinuation; Myeloid leukemia; Minimal residual disease; Digital polymerase chain reaction; Internal medicine; Oncology; Population; Leukemia; Immunology; Gastroenterology; Polymerase chain reaction; Biology; Genetics","score_opus":0.021275528157952882,"score_gpt":0.27987430172668853,"score_spread":0.2585987735687357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2545704931","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955087,0.00011002076,0.00015687576,0.00009105858,0.000057399855,0.0016869986,0.0000350387,0.000076053024,0.0022778814],"genre_scores_gemma":[0.99680686,0.00004494825,0.0014401849,0.00003082794,0.00006863573,0.00031378097,0.0010064719,0.000036407982,0.00025189423],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977655,0.000067753084,0.00078391586,0.00047431528,0.000489819,0.00041869268],"domain_scores_gemma":[0.99855083,0.0001069928,0.00041780135,0.0005252457,0.00028594313,0.00011320385],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00010620937,0.00029836496,0.0006600493,0.00034095527,0.00003784627,0.000056613273,0.00014676049,0.0001633172,0.0004016006],"category_scores_gemma":[0.00026890106,0.00025910052,0.00025659337,0.0012106526,0.00011166506,0.0006724035,0.0000874365,0.00021860028,0.00016529245],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016124884,0.003908695,0.94495934,0.00042226742,0.003201803,0.000017171766,0.003994072,0.00020522714,0.0038190978,0.000045683744,0.00016608974,0.039099332],"study_design_scores_gemma":[0.037868794,0.0023543916,0.8370824,0.00061922555,0.0039812224,0.000014332,0.0007360483,0.0026927781,0.113091715,0.00081515894,0.00014563209,0.0005983095],"about_ca_topic_score_codex":0.001101046,"about_ca_topic_score_gemma":0.00009118044,"teacher_disagreement_score":0.109272614,"about_ca_system_score_codex":0.0018974543,"about_ca_system_score_gemma":0.0004087171,"threshold_uncertainty_score":0.9999861},"labels":[],"label_agreement":null},{"id":"W2547251167","doi":"10.1182/blood.v122.21.1474.1474","title":"Effectively Targeting Treatment-Naïve CML Stem/Progenitor Cells From Imatinib-Nonresponders With Combination Treatments Of JAK2 and ABL Inhibitors In Vitro and In Vivo","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Stem cell; Imatinib mesylate; Progenitor cell; Dasatinib; Nilotinib; Cancer research; Imatinib; Tyrosine kinase; CD34; Haematopoiesis; K562 cells; Tyrosine-kinase inhibitor; Myeloid leukemia; Medicine; Biology; Immunology; Leukemia; Internal medicine; Cell biology; Receptor; Cancer","score_opus":0.00753092431805815,"score_gpt":0.22145988514125378,"score_spread":0.21392896082319562,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2547251167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997001,0.00080381834,0.0000017552677,0.000042663538,0.000034698685,0.0018826288,0.000043730473,0.000024488118,0.00016521392],"genre_scores_gemma":[0.99777555,0.00009777506,0.0016456002,0.000012521224,0.000027683436,0.00025155614,0.000045139306,0.000036291207,0.000107849046],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99857837,0.00013503213,0.00036476887,0.00042560045,0.0002120021,0.0002842038],"domain_scores_gemma":[0.99916005,0.00031829518,0.00017267192,0.00018552161,0.000038648042,0.00012483401],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009638041,0.00029157285,0.0005479983,0.00023154041,0.00003591066,0.000021206059,0.000037289727,0.00012039895,0.000030612326],"category_scores_gemma":[0.000023440532,0.00022559981,0.000040737254,0.00018611211,0.00008200665,0.00017546838,0.000029840547,0.000098810764,0.0000075530625],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009601791,0.002422224,0.36109364,0.00009634725,0.00047167263,0.00012848242,0.0020786482,0.0000018927792,0.6241073,0.0000010814896,0.000012964977,0.008625552],"study_design_scores_gemma":[0.04285964,0.0016915954,0.13997784,0.00025418628,0.00035913143,0.00002063978,0.0008123644,0.00022213616,0.8136046,0.000027703078,0.000005883572,0.0001643126],"about_ca_topic_score_codex":0.003685149,"about_ca_topic_score_gemma":0.0001156013,"teacher_disagreement_score":0.2211158,"about_ca_system_score_codex":0.00049892813,"about_ca_system_score_gemma":0.00010970949,"threshold_uncertainty_score":0.9199693},"labels":[],"label_agreement":null},{"id":"W2547879229","doi":"10.1182/blood.v126.23.2090.2090","title":"Nilotinib Vs Dasatinib As Second-Line Therapy in Patients with Philadelphia-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP) Who Are Resistant or Intolerant to Imatinib: A Cost-Effectiveness Analysis (CEA) Based on Real-World Data","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Nilotinib; Dasatinib; Medicine; Discontinuation; Internal medicine; Imatinib; Imatinib mesylate; Oncology; Myeloid leukemia","score_opus":0.055607528918262344,"score_gpt":0.347892726618645,"score_spread":0.29228519770038264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2547879229","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901832,0.00026729412,0.00008151614,0.000490847,0.000077374534,0.006584329,0.0015338138,0.00014072297,0.0006409198],"genre_scores_gemma":[0.99300337,0.00007998175,0.00048843276,0.0006854173,0.00023709457,0.00086773484,0.0042846003,0.00018376429,0.00016962594],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9934891,0.0007474072,0.001254731,0.0020010923,0.0013517523,0.0011559374],"domain_scores_gemma":[0.9946458,0.0007251155,0.0006881263,0.0027946166,0.00042077422,0.00072559656],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001326561,0.0009861161,0.0023129035,0.0017387482,0.000120897996,0.000086121414,0.00074562494,0.00022283632,0.0003559876],"category_scores_gemma":[0.00040855503,0.0007520342,0.00019144644,0.0044428543,0.00019823981,0.00035087607,0.00025336127,0.00084148004,0.00006914697],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.3024138,0.0297099,0.5900794,0.0016246736,0.009731305,0.0052055623,0.0038390576,0.024321828,0.0035990358,0.000056535795,0.0009846904,0.028434215],"study_design_scores_gemma":[0.22819744,0.033890363,0.6986345,0.0044692256,0.0018455888,0.000013629384,0.00018543411,0.019887969,0.010940445,0.000009678677,0.0007764169,0.0011492823],"about_ca_topic_score_codex":0.0043842,"about_ca_topic_score_gemma":0.053610757,"teacher_disagreement_score":0.10855512,"about_ca_system_score_codex":0.016403696,"about_ca_system_score_gemma":0.00778442,"threshold_uncertainty_score":0.99949306},"labels":[],"label_agreement":null},{"id":"W2547945753","doi":"10.1080/10245332.2016.1232011","title":"Relationship between cigarette smoking and risk of chronic myeloid leukaemia: a meta-analysis of epidemiological studies","year":2016,"lang":"en","type":"review","venue":"Hematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Chronic myeloid leukaemia; Medicine; Meta-analysis; Epidemiology; Cigarette smoking; Oncology; Internal medicine; Myeloid leukaemia; Environmental health; Immunology","score_opus":0.2889808341790041,"score_gpt":0.4356912925544605,"score_spread":0.14671045837545638,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2547945753","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0035406242,0.9948802,0.00008970616,0.00013414427,0.000049474795,0.00082490814,0.0003178944,0.000036711517,0.00012636399],"genre_scores_gemma":[0.024006838,0.9749885,0.00028925727,0.000015003562,0.00007536976,0.00020369662,0.00017793055,0.000042916625,0.00020045045],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99460167,0.0014038159,0.0024140396,0.00083186274,0.00030478998,0.00044380466],"domain_scores_gemma":[0.97963476,0.016338205,0.0027035829,0.0010172377,0.0001692321,0.00013696658],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0016774522,0.00065693184,0.017599406,0.0008576571,0.00007378603,0.0000020896841,0.00020396676,0.0010979252,0.00023949427],"category_scores_gemma":[0.00506199,0.00035461393,0.0035685385,0.00082979153,0.0007415062,0.00003676009,0.0002539852,0.00078162935,0.00001153623],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013556341,0.000057059795,0.16970089,0.02142002,0.762189,0.00006590824,0.00006918878,7.6784886e-7,6.136532e-8,0.002633611,0.00024204292,0.043607917],"study_design_scores_gemma":[0.00076079014,0.00023433293,0.0061882366,0.0024266974,0.9627577,0.00022519458,0.000015933369,0.0000028846448,0.0000041800786,0.0005165242,0.026614899,0.00025262698],"about_ca_topic_score_codex":0.000041014067,"about_ca_topic_score_gemma":0.00002735148,"teacher_disagreement_score":0.20056872,"about_ca_system_score_codex":0.00085287547,"about_ca_system_score_gemma":0.0006115503,"threshold_uncertainty_score":0.99989057},"labels":[],"label_agreement":null},{"id":"W2548957629","doi":"10.1182/blood.v106.11.2870.2870","title":"Role of Jak3 in Chronic Myeloid Leukemia: Evidence To Identify Jak3 as a Potential Therapeutic Target.","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Myeloid leukemia; Imatinib mesylate; Cancer research; K562 cells; Imatinib; Tyrosine kinase; ABL; Biology; Nilotinib; Philadelphia chromosome; Leukemia; Immunology; Chromosomal translocation; Signal transduction; Cell biology; Genetics; Gene","score_opus":0.015271822040073057,"score_gpt":0.30017312717276945,"score_spread":0.2849013051326964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2548957629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97580504,0.020732397,0.00004489899,0.00070715783,0.000084445004,0.00093424745,0.000007784806,0.00006781893,0.0016161754],"genre_scores_gemma":[0.99599385,0.0005458821,0.0013263753,0.00045336725,0.00048235542,0.00010649829,0.000014701419,0.00005611217,0.0010208343],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99751234,0.000078458885,0.0006043939,0.0005678294,0.0006256599,0.00061132765],"domain_scores_gemma":[0.9986921,0.00008957975,0.00014422489,0.00072490604,0.00010018304,0.00024900286],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029932283,0.00031364104,0.00056516065,0.0002902794,0.000050769846,0.000022533543,0.0003037638,0.00020917598,0.0008663424],"category_scores_gemma":[0.00014753957,0.00029403594,0.00019042501,0.00049859885,0.00007458199,0.00022439938,0.00013946103,0.00036535307,0.00075073383],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005042197,0.0013270302,0.02392048,0.00028441456,0.00053226104,0.0002504949,0.0013569822,0.0011730149,0.92536724,0.00013115146,0.0002436143,0.044909097],"study_design_scores_gemma":[0.021045694,0.0021988843,0.3294579,0.0017544974,0.0010415085,0.0006841687,0.0003438989,0.0014101929,0.6339808,0.0004901754,0.006943963,0.0006482934],"about_ca_topic_score_codex":0.0008372106,"about_ca_topic_score_gemma":0.00027437747,"teacher_disagreement_score":0.30553743,"about_ca_system_score_codex":0.0027919337,"about_ca_system_score_gemma":0.0021422252,"threshold_uncertainty_score":0.9999512},"labels":[],"label_agreement":null},{"id":"W2549389531","doi":"10.1182/blood.v116.21.438.438","title":"Genetic Screen to Isolate “Lariat” Peptides for Characterizing ABL Kinase Activity and Conformation","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal University Hospital; Health Sciences Centre; Sunnybrook Health Science Centre; University of Saskatchewan","funders":"","keywords":"ABL; Mutant; Biochemistry; Mutagenesis; Saturated mutagenesis; Chemistry; Peptide; Kinase; Protein kinase domain; In vitro; Biology; Stereochemistry; Gene; Tyrosine kinase; Signal transduction","score_opus":0.012502817356456015,"score_gpt":0.2577570151845734,"score_spread":0.2452541978281174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2549389531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977963,0.000033384003,0.00033515194,0.00046464097,0.000084618776,0.00084502203,0.000036675785,0.00004867782,0.00035555137],"genre_scores_gemma":[0.98912907,0.000017649647,0.010083606,0.00027945568,0.00020236599,0.00006881818,0.000024842166,0.000018774019,0.00017544652],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99937385,0.000008331715,0.00013620495,0.00018105074,0.000095748605,0.00020483932],"domain_scores_gemma":[0.99945694,0.000045536675,0.000063009524,0.00022741617,0.00004874349,0.00015832265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000100708465,0.000120229146,0.00018263812,0.0000626247,0.000077463555,0.000023429351,0.00004091437,0.000081413134,0.00003079808],"category_scores_gemma":[0.0000949826,0.00010822936,0.000038919057,0.00005040353,0.00001971285,0.00011903663,0.000035244226,0.000119378186,0.000029705141],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001684806,0.00020745635,0.012452075,0.00011338855,0.00010324449,0.000011566023,0.00036577048,2.2155665e-7,0.96206653,0.000033254844,0.00007173415,0.024406264],"study_design_scores_gemma":[0.009053246,0.0005826384,0.8026044,0.00008118162,0.00036552464,0.00014732742,0.000023912315,0.00066486746,0.18189591,0.000030305808,0.00436688,0.0001838072],"about_ca_topic_score_codex":0.00014081072,"about_ca_topic_score_gemma":0.00007700891,"teacher_disagreement_score":0.7901523,"about_ca_system_score_codex":0.00003909783,"about_ca_system_score_gemma":0.00009010217,"threshold_uncertainty_score":0.44134653},"labels":[],"label_agreement":null},{"id":"W2549419806","doi":"10.1182/blood.v124.21.4554.4554","title":"Retrospective Analysis of Allogeneic Transplant Outcomes in Chronic Myeloid Leukemia Patients with Tyrosine Kinase Inhibitors Failure","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Toronto General Hospital; Juravinski Hospital; McMaster University; Princess Margaret Cancer Centre; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Internal medicine; Transplantation; Nilotinib; Retrospective cohort study; Myeloid leukemia; Dasatinib; Blast Crisis; Gastroenterology; Imatinib","score_opus":0.0048966949608432835,"score_gpt":0.2149515720510933,"score_spread":0.21005487709025003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2549419806","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987513,0.00016471316,0.000034828776,0.00007879252,0.0000358911,0.00054463715,0.00010180312,0.0000459276,0.00024212245],"genre_scores_gemma":[0.9988479,0.0000331275,0.0004731528,0.000050761806,0.000053077532,0.00004201775,0.00035544933,0.000040273222,0.000104216204],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979907,0.00006345333,0.0004982615,0.0005122877,0.0005357265,0.0003995218],"domain_scores_gemma":[0.99887085,0.000057853227,0.00021200514,0.00058570714,0.00012469274,0.00014886819],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014351336,0.00033018563,0.0010441465,0.0005375195,0.00003814015,0.00000837168,0.00012600931,0.00015740207,0.00012560259],"category_scores_gemma":[0.000057535333,0.00024111832,0.00024009412,0.0010229344,0.00010393649,0.000076091266,0.000028323084,0.00023641823,0.000013062748],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014192067,0.0008952545,0.9914141,0.000084076964,0.0026180001,0.000033903307,0.00026727034,0.00021202659,0.0039602504,0.000039191127,0.000012049632,0.0003219375],"study_design_scores_gemma":[0.019897347,0.0012454181,0.959966,0.00019797354,0.0052232128,0.0000043786727,0.000017887965,0.00013777203,0.013013246,0.0000064882797,0.00006859342,0.00022166366],"about_ca_topic_score_codex":0.00043132663,"about_ca_topic_score_gemma":0.0021501041,"teacher_disagreement_score":0.0314481,"about_ca_system_score_codex":0.0020662176,"about_ca_system_score_gemma":0.0004630204,"threshold_uncertainty_score":0.983252},"labels":[],"label_agreement":null},{"id":"W2550077017","doi":"10.1182/blood.v116.21.3432.3432","title":"Pharmacokinetics of Dasatinib as a First Line Therapy In Newly Diagnosed CML Patients (OPTIM dasatinib trial): Correlation with Safety and Response.","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Dasatinib; Cmin; Medicine; Cmax; Internal medicine; Pharmacokinetics; Adverse effect; Dosing; Tyrosine-kinase inhibitor; Gastroenterology; Pharmacology; Oncology; Tyrosine kinase; Cancer; Receptor","score_opus":0.012216324951888725,"score_gpt":0.27324229331482786,"score_spread":0.2610259683629391,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2550077017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967888,0.00013210415,0.000017454217,0.00030471518,0.00014516588,0.0019337297,0.00003610404,0.000034912293,0.00060699106],"genre_scores_gemma":[0.9971965,0.0005581384,0.0015672679,0.00013586832,0.00010359505,0.000069204776,0.00012353211,0.00004077824,0.00020512239],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984722,0.00010156595,0.0005166276,0.00032614567,0.000354049,0.0002294172],"domain_scores_gemma":[0.9984281,0.0006671473,0.00026656286,0.0003803604,0.000121352765,0.00013644138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003405499,0.00022911288,0.00042314813,0.00015017846,0.000050984876,0.000010611145,0.00008118647,0.00015215627,0.00019832987],"category_scores_gemma":[0.000570015,0.00017842182,0.00004698638,0.00026941596,0.00010721401,0.000072653755,0.00003194707,0.00034220572,0.000008928589],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27143046,0.007532709,0.6779488,0.0000898348,0.0003825215,0.00014534594,0.003488164,0.00008992628,0.007836778,0.000027626196,0.00009523295,0.030932622],"study_design_scores_gemma":[0.4527923,0.007599647,0.53037864,0.00017850156,0.00022851567,0.000026256257,0.00004134054,0.00039644388,0.0064760456,0.000013225893,0.0016869714,0.00018213266],"about_ca_topic_score_codex":0.00017413324,"about_ca_topic_score_gemma":0.00017306491,"teacher_disagreement_score":0.18136182,"about_ca_system_score_codex":0.00008243206,"about_ca_system_score_gemma":0.00035702254,"threshold_uncertainty_score":0.72758305},"labels":[],"label_agreement":null},{"id":"W2550403115","doi":"10.1182/blood.v110.11.467.467","title":"Interaction of a Novel Signaling Protein (AHI-1) with BCR-ABL Modulates BCR-ABL Transforming Activity and Imatinib Response of Chronic Myeloid Leukemia Progenitor Cells.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Biology; Myeloid leukemia; K562 cells; Cancer research; Progenitor cell; ABL; Gene knockdown; Imatinib mesylate; breakpoint cluster region; Leukemia; Ectopic expression; Stem cell; Fusion protein; Molecular biology; Cell culture; Signal transduction; Tyrosine kinase; Immunology; Cell biology; Imatinib; Receptor; Gene; Genetics","score_opus":0.013463994117201455,"score_gpt":0.25779876929931145,"score_spread":0.24433477518211,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2550403115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956133,0.0003908694,0.0018142303,0.000037869864,0.000047538637,0.0018608429,0.000028831006,0.000065317814,0.00014122885],"genre_scores_gemma":[0.9896794,0.000022239008,0.009854356,0.00000763987,0.000117568066,0.00007488821,0.0000120650075,0.00006273307,0.00016913604],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979883,0.000069300324,0.00058638013,0.00044963157,0.00045614375,0.00045026795],"domain_scores_gemma":[0.99860644,0.0002695779,0.00041834108,0.00038117752,0.00015479191,0.00016967568],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000764563,0.0003395413,0.0006250912,0.00025529542,0.00008037009,0.000014144448,0.000097857745,0.00018591157,0.000036246976],"category_scores_gemma":[0.00009639811,0.00028250137,0.00012103592,0.00033410714,0.00016903621,0.0002639738,0.000036407328,0.0003379492,0.0000021231665],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070620496,0.0014065166,0.0010614442,0.0010199385,0.0004371085,0.00005471714,0.0011009129,0.00006771907,0.9786198,0.000006219371,0.0000013111109,0.009162231],"study_design_scores_gemma":[0.016058378,0.002537637,0.0034974485,0.0014924097,0.0005276602,0.00027253278,0.00026868613,0.0017142349,0.9733436,0.000004264424,0.00005092261,0.00023223367],"about_ca_topic_score_codex":0.00042068455,"about_ca_topic_score_gemma":0.000075031516,"teacher_disagreement_score":0.008996328,"about_ca_system_score_codex":0.0009673332,"about_ca_system_score_gemma":0.001105346,"threshold_uncertainty_score":0.9999627},"labels":[],"label_agreement":null},{"id":"W2550517509","doi":"10.1182/blood.v112.11.4399.4399","title":"Pediatric Treatment Guidelines for Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML): What Are They in Today’s Imatinib Era?","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Stollery Children's Hospital","funders":"","keywords":"Medicine; Chronic myelogenous leukemia; Imatinib; Imatinib mesylate; Philadelphia chromosome; Internal medicine; Transplantation; Oncology; Leukemia; Pediatrics; Myeloid leukemia; Chromosomal translocation","score_opus":0.05288349843955804,"score_gpt":0.3092616858624974,"score_spread":0.2563781874229394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2550517509","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97137636,0.02224184,0.000026726795,0.0026162602,0.0002834656,0.0027846727,0.00015482242,0.00016481733,0.00035104452],"genre_scores_gemma":[0.9732212,0.018501395,0.0035238387,0.00062388956,0.0020700055,0.00079776614,0.0004177738,0.00012997354,0.0007141812],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969708,0.00006816681,0.0008741877,0.00080394634,0.00042142882,0.0008615062],"domain_scores_gemma":[0.9980541,0.00024826088,0.00032147294,0.00073333585,0.0003736066,0.000269224],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001708181,0.00060066517,0.0009386137,0.0003170835,0.0002288061,0.000039097606,0.00020087417,0.0002860679,0.000093661394],"category_scores_gemma":[0.00021658007,0.00048612276,0.00036190756,0.0003260365,0.00007273307,0.00028294144,0.00006762275,0.00024197595,0.0001188578],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068983086,0.039303597,0.6693461,0.004281321,0.010911143,0.026488619,0.03999469,0.0036617345,0.028576553,0.0005507581,0.034805726,0.13518147],"study_design_scores_gemma":[0.30083165,0.022230417,0.5611895,0.0031965133,0.0099038305,0.0117349,0.003388245,0.0033883143,0.06923633,0.00087062956,0.0099943485,0.004035385],"about_ca_topic_score_codex":0.00072332245,"about_ca_topic_score_gemma":0.00079391047,"teacher_disagreement_score":0.29393333,"about_ca_system_score_codex":0.0050421576,"about_ca_system_score_gemma":0.002868977,"threshold_uncertainty_score":0.999759},"labels":[],"label_agreement":null},{"id":"W2550804007","doi":"10.1182/blood.v124.21.4529.4529","title":"MiR-300 Acts As a Tumor Supressor in Ph+ Progenitors By Modulating the JAK2-SET/PP2A/β-Catenin Interplay","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Chronic myelogenous leukemia; Biology; Cancer research; Progenitor cell; Haematopoiesis; Stem cell; CD38; Leukemia; breakpoint cluster region; Tyrosine kinase; Protein phosphatase 2; Imatinib mesylate; Immunology; Cell biology; Imatinib; Signal transduction; CD34; Myeloid leukemia; Genetics; Phosphatase; Receptor; Phosphorylation","score_opus":0.010312455442733785,"score_gpt":0.2688393094466123,"score_spread":0.2585268540038785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2550804007","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938359,0.0004973225,0.00000804695,0.0007671376,0.00013210601,0.00088616356,0.000014109535,0.000098494456,0.0037607125],"genre_scores_gemma":[0.9977117,0.000006592901,0.00034603893,0.0004001466,0.0002588786,0.0001895299,0.000058586105,0.00006167024,0.0009668233],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980948,0.00013672162,0.00040550667,0.00044947758,0.00037475736,0.00053874886],"domain_scores_gemma":[0.9988705,0.00021485814,0.00014668326,0.00054341817,0.000047435227,0.00017711447],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031538712,0.00029217647,0.00039521127,0.00008753592,0.000087385975,0.00003935319,0.00025045345,0.0001048424,0.00016472414],"category_scores_gemma":[0.0004264483,0.00020004652,0.000113768765,0.00022281223,0.000080757156,0.000088510955,0.000118068376,0.00036663728,0.00025328906],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011549051,0.006755035,0.4112367,0.0007466885,0.002424148,0.0011841039,0.0136479465,0.000065201544,0.5308106,0.00042585787,0.01317121,0.018377593],"study_design_scores_gemma":[0.042441923,0.0016749998,0.03877395,0.0012635482,0.0015195498,0.001443393,0.0008252886,0.006224026,0.8834098,0.00033841532,0.021140413,0.0009447191],"about_ca_topic_score_codex":0.00071522064,"about_ca_topic_score_gemma":0.00009997254,"teacher_disagreement_score":0.37246278,"about_ca_system_score_codex":0.00023687824,"about_ca_system_score_gemma":0.0001908945,"threshold_uncertainty_score":0.81576604},"labels":[],"label_agreement":null},{"id":"W2551196508","doi":"10.1182/blood.v110.11.4587.4587","title":"Short-Term Cost Per Responder among New Tyrosine Kinase Inhibitors for Imatinib-Resistant CML in Chronic Phase (CML-CP) — Canada and Germany Perspectives.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Novartis (Canada)","funders":"","keywords":"Dasatinib; Nilotinib; Medicine; Imatinib; Internal medicine; Oncology; Cost effectiveness; Drug holiday; Adverse effect; Tyrosine-kinase inhibitor; Surrogate endpoint; Imatinib mesylate; Pharmacology; Immunology; Cancer","score_opus":0.014634641788989407,"score_gpt":0.29216159735608727,"score_spread":0.27752695556709783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2551196508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99193335,0.005403664,0.00005335116,0.00026181433,0.00011385124,0.0016902565,0.00008413316,0.000046064557,0.00041351045],"genre_scores_gemma":[0.99717575,0.000101048725,0.00047032972,0.00010034007,0.0005010154,0.00007278738,0.00008842405,0.00006958505,0.0014207128],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99780166,0.000029484021,0.00051589275,0.0005812755,0.0003811837,0.0006904837],"domain_scores_gemma":[0.99872994,0.00017101661,0.000105634426,0.0004308345,0.000093742856,0.00046879993],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029950065,0.0003466306,0.00047913558,0.0002105149,0.00010406037,0.000030039088,0.000095749754,0.00014191635,0.00013888627],"category_scores_gemma":[0.00012961129,0.00031884725,0.000090391266,0.0002316836,0.00012337224,0.00012107935,0.00005544422,0.00027099045,0.0000034217908],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011523049,0.0087064,0.26058078,0.0018065529,0.0019595614,0.011247281,0.0127852,0.000024019986,0.6163027,0.0005711008,0.020608258,0.053885054],"study_design_scores_gemma":[0.10819894,0.0021512562,0.76297975,0.001020694,0.0012000066,0.00033048805,0.0021180687,0.000215669,0.11200826,0.000033535212,0.008691386,0.0010519347],"about_ca_topic_score_codex":0.108264506,"about_ca_topic_score_gemma":0.5363123,"teacher_disagreement_score":0.5042945,"about_ca_system_score_codex":0.0040135747,"about_ca_system_score_gemma":0.0029438476,"threshold_uncertainty_score":0.9999264},"labels":[],"label_agreement":null},{"id":"W2551536162","doi":"10.1182/blood.v104.11.2960.2960","title":"Transplantation of Immunodeficient Mice with Chronic Myeloid Leukemia (CML) Cells from Chronic Phase Patients Reveals a Hierarchy of CD34+ Aldehyde Dehydrogenase-Positive Cells with Short- and Long-Term Repopulating Activity and Transient Responsiveness to Imatinib Mesylate in Vivo.","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Nod; Biology; Haematopoiesis; CD34; Bone marrow; CD38; Immunology; Transplantation; Severe combined immunodeficiency; Myeloid; Stem cell; Leukemia; Immunophenotyping; Cancer research; Medicine; Antigen; Internal medicine; Cell biology; Endocrinology; In vivo","score_opus":0.008369133972260287,"score_gpt":0.2499668929042245,"score_spread":0.24159775893196422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2551536162","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956919,0.0010363733,0.000423624,0.000022790307,0.00002740861,0.0022550547,0.00049672334,0.000025866451,0.00002025146],"genre_scores_gemma":[0.99758434,0.00028915465,0.001788812,0.000021385365,0.000020188401,0.000084738866,0.00014023221,0.00006204086,0.000009084271],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99740064,0.00015451865,0.0007070027,0.0007507417,0.00052290515,0.00046416995],"domain_scores_gemma":[0.99867415,0.00017882683,0.00035515736,0.00044166922,0.00015016097,0.00020002443],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022163063,0.0004332503,0.0008604273,0.00027721608,0.000082413855,0.000016972219,0.000101262776,0.00013734178,0.000012380623],"category_scores_gemma":[0.000015301539,0.00036227927,0.00007472935,0.00041227357,0.00018871437,0.0001758944,0.000035427816,0.00024736105,7.671941e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058302134,0.0016792268,0.02208134,0.0010555955,0.00040401844,0.00036953096,0.0045212274,0.0026136064,0.959037,0.0000016633851,2.965163e-7,0.0024062935],"study_design_scores_gemma":[0.032291636,0.004795763,0.182155,0.003712948,0.0008521455,0.00010590275,0.000045655954,0.00012759339,0.7756337,0.0000032523046,6.800115e-7,0.00027571752],"about_ca_topic_score_codex":0.00149602,"about_ca_topic_score_gemma":0.0013785674,"teacher_disagreement_score":0.18340327,"about_ca_system_score_codex":0.0015829178,"about_ca_system_score_gemma":0.00096941116,"threshold_uncertainty_score":0.99988294},"labels":[],"label_agreement":null},{"id":"W2551937125","doi":"10.1182/blood.v124.21.1250.1250","title":"Allogeneic Hematopoietic Stem Cell Transplantation Is an Effective Salvage Therapy for Patients with Chronic Myeloid Leukemia Failing Treatment with Tyrosine Kinase Inhibitors","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada; BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Dasatinib; Nilotinib; Internal medicine; Hematopoietic stem cell transplantation; Myeloid leukemia; Transplantation; Imatinib; Tyrosine-kinase inhibitor; Population; Oncology; Imatinib mesylate; Cancer","score_opus":0.007256990767380318,"score_gpt":0.22156768665226786,"score_spread":0.21431069588488755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2551937125","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99427485,0.00080337696,0.0005412219,0.000036487723,0.00005800691,0.003982123,0.00007477411,0.00013191771,0.00009721088],"genre_scores_gemma":[0.9966491,0.00025207744,0.0011096741,0.000110247485,0.00021289231,0.0008397591,0.00054279185,0.00012816598,0.00015530406],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980048,0.00008733114,0.00031190462,0.00071853754,0.00037988252,0.0004975762],"domain_scores_gemma":[0.9987535,0.00014155636,0.00019028981,0.0005399954,0.00013451207,0.00024015312],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00010475085,0.00051494676,0.0005638552,0.00012156645,0.00016662473,0.000034437016,0.00009227692,0.00014822738,0.00002240342],"category_scores_gemma":[0.0000023229,0.000337612,0.00012573125,0.0001849928,0.00007555484,0.00015564049,0.000007561147,0.00011832139,0.00001473512],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016250428,0.017762274,0.5900546,0.0032793712,0.0034821657,0.00027812034,0.015938543,0.00046820904,0.09733856,0.000047955196,0.00006884053,0.25503093],"study_design_scores_gemma":[0.123807214,0.050609276,0.06987702,0.0006163822,0.002085292,0.00007170667,0.00012555055,0.00023942278,0.7514186,0.000009816668,0.0005219955,0.0006177394],"about_ca_topic_score_codex":0.00012994518,"about_ca_topic_score_gemma":0.00011594435,"teacher_disagreement_score":0.65408003,"about_ca_system_score_codex":0.0015613914,"about_ca_system_score_gemma":0.00044064684,"threshold_uncertainty_score":0.9999076},"labels":[],"label_agreement":null},{"id":"W2552106802","doi":"10.1182/blood.v108.11.4143.4143","title":"Red Blood Cell Transfusion and Chemotherapy Administration: A Study of Resource Utilization at the London Regional Cancer Program (LRCP).","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Medicine; Chemotherapy; Internal medicine; Blood transfusion; Hematology; Incidence (geometry); Multiple myeloma; Cancer; Retrospective cohort study; Breast cancer","score_opus":0.021459637566489168,"score_gpt":0.2856372833222259,"score_spread":0.2641776457557367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2552106802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940341,0.0017925415,0.0000027918852,0.0011445803,0.000015640286,0.0018121286,0.000007123769,0.000052255524,0.0011388296],"genre_scores_gemma":[0.996733,0.00043406646,0.00015712387,0.000080639926,0.00012982528,0.00019063661,0.00007937412,0.000024413674,0.0021708861],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989046,0.000056018005,0.00026873944,0.0002870826,0.00033398188,0.0001495921],"domain_scores_gemma":[0.99943686,0.00003895082,0.00012112803,0.0002960825,0.00005889367,0.000048097867],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009412891,0.00014892533,0.00020438482,0.000037497877,0.00010836107,0.0000110741885,0.000054802436,0.00007663633,0.00010915149],"category_scores_gemma":[0.0000047578324,0.00010468168,0.00004805565,0.00018497556,0.00006997749,0.000027654109,0.000014809789,0.00008609682,9.272194e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004144312,0.06373357,0.8069821,0.0006367206,0.0010098704,0.00021696537,0.0058351303,0.000050651248,0.0726014,0.00004645973,0.006305189,0.038437616],"study_design_scores_gemma":[0.107803725,0.01101578,0.5593758,0.00030535212,0.0033805077,0.00044163293,0.0010713596,0.0002501711,0.28107342,0.00003502606,0.034841776,0.0004054386],"about_ca_topic_score_codex":0.0005066466,"about_ca_topic_score_gemma":0.0013245377,"teacher_disagreement_score":0.2476063,"about_ca_system_score_codex":0.000073622585,"about_ca_system_score_gemma":0.00016000695,"threshold_uncertainty_score":0.42687953},"labels":[],"label_agreement":null},{"id":"W2553044273","doi":"10.1182/blood.v126.23.1567.1567","title":"Identification and Characterization of New Microrna Biomarkers and Target Genes in Drug-Insensitive CD34+ CML Stem/Progenitor Cells Using Global Comparative RNA-Seq Analyses","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia; BC Cancer Agency","funders":"","keywords":"microRNA; CD34; Stem cell; Progenitor cell; Biology; Cancer research; Haematopoiesis; MiRBase; Gene; Genetics","score_opus":0.07088415501151525,"score_gpt":0.33085009260272763,"score_spread":0.2599659375912124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2553044273","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976708,0.0014849892,0.000116878924,0.000049321974,0.0000792692,0.00047045838,0.00007345205,0.000014839496,0.000039952614],"genre_scores_gemma":[0.997973,0.00007922089,0.0016905178,0.000015645866,0.00006518682,0.000003970175,0.00009351948,0.000009969743,0.000068917485],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99900526,0.00008050756,0.00032597655,0.0002754851,0.0001714814,0.00014132066],"domain_scores_gemma":[0.9993238,0.000021408354,0.00022799855,0.0001467674,0.00013141315,0.00014860506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012010335,0.00015330591,0.00035055022,0.000104588056,0.000027378674,0.000021306698,0.000032682314,0.000062962354,0.00000280662],"category_scores_gemma":[0.0000114679415,0.00014404926,0.000031226722,0.0002742288,0.00007726968,0.00012056438,0.000035173514,0.00004183464,0.000003057492],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015634546,0.00019780626,0.06645895,0.000054283977,0.00031819282,0.000025075668,0.0015643158,0.0000042492543,0.9305492,0.0000020140476,0.000024206372,0.000645378],"study_design_scores_gemma":[0.0055797985,0.00007109492,0.10569222,0.00011033586,0.00047130277,0.00006808903,0.0010510994,0.00091895653,0.88588655,0.000013224719,0.000024205134,0.00011312891],"about_ca_topic_score_codex":0.00094877643,"about_ca_topic_score_gemma":0.000064305874,"teacher_disagreement_score":0.044662636,"about_ca_system_score_codex":0.00024250572,"about_ca_system_score_gemma":0.00033200587,"threshold_uncertainty_score":0.5874159},"labels":[],"label_agreement":null},{"id":"W2553090920","doi":"10.1182/blood.v118.21.494.494","title":"Older Adults with Chronic Myelogenous Leukemia (CML), During the Tyrosine Kinase Inhibitor (TKI) Era, Can Be Successfully Treated with Reduced Intensity Conditioning (RIC) Hematopoietic Cell Transplant (HCT) Using Sibling or Unrelated Donors: A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Cohort; Graft-versus-host disease; Transplantation; Tyrosine-kinase inhibitor; Hematopoietic cell; Chronic myelogenous leukemia; Hematopoietic stem cell transplantation; Leukemia; Gastroenterology; Oncology; Surgery; Cancer; Stem cell; Haematopoiesis","score_opus":0.023914268884525323,"score_gpt":0.25561950522369226,"score_spread":0.23170523633916693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2553090920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963891,0.00047174952,0.0000959347,0.00013642652,0.0000675769,0.0021338335,0.0005011375,0.0001160685,0.00008819565],"genre_scores_gemma":[0.997029,0.0002435518,0.0009603872,0.000055017146,0.00021290196,0.00023866442,0.0009590875,0.00011161621,0.00018973865],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99652886,0.0001459595,0.00067235605,0.0010102506,0.00070969725,0.0009328833],"domain_scores_gemma":[0.99768686,0.00019211642,0.00027705808,0.0005843049,0.0009228201,0.0003368314],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037950373,0.00056808087,0.0008133567,0.00075625174,0.00064088334,0.00010462557,0.0002719984,0.00023805024,0.00017524099],"category_scores_gemma":[0.000045058237,0.00035724166,0.00018893284,0.001283935,0.0003792338,0.00019319543,0.000053792824,0.0007112849,0.0000016491606],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040514722,0.0063316617,0.70918435,0.003584988,0.021293562,0.008239218,0.043993536,0.0004494335,0.16617493,0.000019318437,0.000030110683,0.00018417712],"study_design_scores_gemma":[0.10202828,0.00411371,0.109694466,0.006637375,0.020753955,0.0051436233,0.0023765895,0.0029435463,0.745226,0.000004717251,0.000009166781,0.0010685195],"about_ca_topic_score_codex":0.0045889434,"about_ca_topic_score_gemma":0.0051186434,"teacher_disagreement_score":0.59948987,"about_ca_system_score_codex":0.0011510367,"about_ca_system_score_gemma":0.0010974888,"threshold_uncertainty_score":0.99988794},"labels":[],"label_agreement":null},{"id":"W2553101160","doi":"10.1182/blood.v114.22.1108.1108","title":"Late Development of Cytogenetic Abnormalities in Ph Negative Cells of Chronic Myeloid Leukemia Patients Treated with Imatinib.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Imatinib; Medicine; Internal medicine; Imatinib mesylate; Myeloid leukemia; Chronic myelogenous leukemia; Philadelphia chromosome; Confidence interval; Gastroenterology; Cytogenetics; Leukemia; Cohort; Surgery; Chromosomal translocation; Biology; Genetics","score_opus":0.009663185553796073,"score_gpt":0.2261462707512802,"score_spread":0.2164830851974841,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2553101160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967409,0.00025814728,0.000006691483,0.000010006564,0.00001569103,0.0007103508,0.000023496317,0.000027908747,0.0022068142],"genre_scores_gemma":[0.99577373,0.000061423336,0.0036798231,0.00002549229,0.000020991522,0.000029172264,0.00006941328,0.000024729838,0.0003152456],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982528,0.000045740177,0.0006717514,0.00028472327,0.0003877419,0.00035724466],"domain_scores_gemma":[0.99907225,0.000056124183,0.0003078638,0.00031703626,0.00014954041,0.0000972056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000094572366,0.00027157002,0.0005895966,0.00019283868,0.00003048885,0.0000043600126,0.00010882894,0.00009765432,0.00007939355],"category_scores_gemma":[0.000018396735,0.00021477012,0.000061116974,0.00033908244,0.000094158655,0.00006705335,0.000028927574,0.000130856,0.00001305135],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019015907,0.009097897,0.7665105,0.0015153934,0.0015453541,0.00022928754,0.016466621,0.0005284499,0.15835994,0.00004106477,0.000060500606,0.0437434],"study_design_scores_gemma":[0.01707244,0.0015821784,0.36587015,0.0005851452,0.00017949681,0.000007643328,0.000082943494,0.000056707464,0.61438876,0.000012502718,0.00001653145,0.00014551365],"about_ca_topic_score_codex":0.00017818423,"about_ca_topic_score_gemma":0.000102348735,"teacher_disagreement_score":0.45602882,"about_ca_system_score_codex":0.0010306428,"about_ca_system_score_gemma":0.0013992647,"threshold_uncertainty_score":0.87580717},"labels":[],"label_agreement":null},{"id":"W2553125824","doi":"10.1182/blood.v116.21.2290.2290","title":"Subcutaneous Omacetaxine (OM) Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients Following Multiple Tyrosine Kinase Inhibitor (TKI) Failure","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nilotinib; Dasatinib; Imatinib; Internal medicine; Myeloid leukemia; Adverse effect; Imatinib mesylate; Population; Tyrosine-kinase inhibitor; Oncology; Gastroenterology; Cancer","score_opus":0.009099521023974712,"score_gpt":0.2515323980287856,"score_spread":0.24243287700481086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2553125824","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992909,0.002820963,0.0000145314325,0.00014043508,0.000902567,0.0023127866,0.00024795666,0.00025882182,0.0003928947],"genre_scores_gemma":[0.99452996,0.00022300873,0.0015295396,0.00003691872,0.0012747818,0.00023274342,0.0009612072,0.00018807243,0.0010237666],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9958969,0.00007389245,0.0010233965,0.0010466225,0.0008452787,0.0011139599],"domain_scores_gemma":[0.9970549,0.00019249925,0.00043826262,0.0014936767,0.00021679077,0.0006039158],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013683946,0.000871396,0.0012956472,0.00031373967,0.0002268125,0.000041401658,0.00028864635,0.00047198072,0.0005754073],"category_scores_gemma":[0.0002270074,0.0007401987,0.00071556814,0.00049537525,0.00020364804,0.00020665099,0.00012170547,0.0005233974,0.00019562936],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000856694,0.016998071,0.037175354,0.0004444467,0.0016706735,0.0018402461,0.00044544155,0.000023531886,0.90396374,0.000025291602,0.00034836942,0.036208123],"study_design_scores_gemma":[0.17121282,0.020456657,0.0044886745,0.0005079781,0.0029380633,0.0006094827,0.00005109069,0.0006988014,0.77660483,0.000013443477,0.021536224,0.0008819435],"about_ca_topic_score_codex":0.00057573844,"about_ca_topic_score_gemma":0.0016368311,"teacher_disagreement_score":0.17035612,"about_ca_system_score_codex":0.0045550233,"about_ca_system_score_gemma":0.0023068136,"threshold_uncertainty_score":0.9995049},"labels":[],"label_agreement":null},{"id":"W2553377881","doi":"10.1182/blood.v118.21.1694.1694","title":"Clonal Evolution but Not Variant Chromosomal Translocations Is An Adverse Prognostic Marker for Cytogenetic Response and Survival in CML Patients Treated with Imatinib","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada","funders":"","keywords":"Internal medicine; Imatinib; Imatinib mesylate; Medicine; Chromosomal translocation; Gastroenterology; Cohort; Oncology; Biology; Genetics; Myeloid leukemia","score_opus":0.02470868249571424,"score_gpt":0.2440317924407672,"score_spread":0.21932310994505297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2553377881","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99764127,0.00004816414,0.00013035485,0.000047063568,0.00002712608,0.0016873247,0.00024944707,0.000043799533,0.00012546264],"genre_scores_gemma":[0.99470717,0.0000064761166,0.0045365854,0.000037387636,0.000029324388,0.00032870928,0.00019700866,0.00003850253,0.00011883173],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99865735,0.00012852812,0.0002900486,0.00039723868,0.00022329505,0.00030353598],"domain_scores_gemma":[0.9992189,0.00012486766,0.00007869697,0.0002828037,0.00012773603,0.00016699142],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019076391,0.00020934561,0.00026193284,0.00013123173,0.00007366454,0.0000066503017,0.000058407415,0.000104438746,0.00008969326],"category_scores_gemma":[0.00010840064,0.00017393654,0.000043663716,0.00017825406,0.000087987275,0.00010082512,0.000012457954,0.0000892114,0.0000077787545],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010529764,0.0037143948,0.9792469,0.00010097103,0.00022705275,0.00011713508,0.0016776462,0.0000015122151,0.003828946,0.000028436289,0.000004869373,0.00052238617],"study_design_scores_gemma":[0.028956965,0.0033370685,0.9606439,0.00014687156,0.0007150472,0.00011587858,0.00012050025,0.00060066575,0.0051649227,0.000013805142,0.000010192218,0.00017417289],"about_ca_topic_score_codex":0.0003549298,"about_ca_topic_score_gemma":0.0002238937,"teacher_disagreement_score":0.018602975,"about_ca_system_score_codex":0.00020805179,"about_ca_system_score_gemma":0.00045090212,"threshold_uncertainty_score":0.7092926},"labels":[],"label_agreement":null},{"id":"W2554284156","doi":"10.1182/blood.v114.22.3384.3384","title":"FluBup-ATG-TBI for High-Risk or Advanced Adult ALL in Remission: A Retrospective Review of a Mature Cohort.","year":2009,"lang":"en","type":"review","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre","funders":"","keywords":"Medicine; Fludarabine; Busulfan; Internal medicine; Transplantation; Cohort; Imatinib mesylate; Hematopoietic stem cell transplantation; Total body irradiation; Population; Gastroenterology; Surgery; Median follow-up; Acute lymphocytic leukemia; Leukemia; Cyclophosphamide; Chemotherapy; Imatinib; Lymphoblastic Leukemia; Myeloid leukemia","score_opus":0.022507297620351155,"score_gpt":0.34004128672208894,"score_spread":0.3175339891017378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2554284156","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011834536,0.98926574,0.000003316766,0.00014111084,0.00013851098,0.008985659,0.0004840337,0.00007801666,0.00078526145],"genre_scores_gemma":[0.000010765159,0.98865426,0.0060179844,0.0003704397,0.0002952691,0.0011424872,0.0011853372,0.00013135704,0.0021920844],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996054,0.00018787726,0.0015883845,0.0010437369,0.000579306,0.00054670067],"domain_scores_gemma":[0.9963665,0.00029711187,0.0013925729,0.0013363557,0.00037062322,0.0002368219],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00046929467,0.00082260935,0.0054635475,0.00022916462,0.000037177062,0.000007662473,0.00031750574,0.0007447836,0.0002546198],"category_scores_gemma":[0.002428064,0.0005395348,0.00088242796,0.0007665585,0.000049032788,0.00005924471,0.00007146487,0.00097012735,0.000026168847],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025090663,0.0012952652,0.00025048244,0.3073679,0.001657265,0.000409168,0.000038326645,4.0606523e-8,0.0000022971049,0.00006822613,0.006545144,0.682115],"study_design_scores_gemma":[0.008828592,0.0011347956,0.00036981504,0.4399664,0.013402101,0.0003775749,0.0000039845736,4.696605e-7,0.000023289258,0.00006139827,0.53545684,0.00037475378],"about_ca_topic_score_codex":0.00006754156,"about_ca_topic_score_gemma":0.000036161546,"teacher_disagreement_score":0.6817402,"about_ca_system_score_codex":0.0015137243,"about_ca_system_score_gemma":0.0018104998,"threshold_uncertainty_score":0.9997056},"labels":[],"label_agreement":null},{"id":"W2555386364","doi":"10.1182/blood.v110.11.324.324","title":"Properties of CD34+ CML Cells That Predict Clinical Response to Tyrosine Kinase Inhibitors.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"CD38; Tyrosine kinase; Cancer research; Myeloid leukemia; Imatinib; CD34; Stem cell; Progenitor cell; Haematopoiesis; Biology; Tyrosine-kinase inhibitor; Imatinib mesylate; ABL; Signal transduction; Cell biology; Genetics; Cancer","score_opus":0.03740029712751713,"score_gpt":0.2989407790691427,"score_spread":0.26154048194162555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2555386364","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966301,0.000919414,0.000020379108,0.0005132383,0.00033409795,0.0008148603,0.000018652892,0.000092874754,0.0006563945],"genre_scores_gemma":[0.9956974,0.00005801907,0.0014531604,0.00032436225,0.00041640693,0.000017875333,0.000007878504,0.000041870197,0.001983058],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99798965,0.00011148394,0.00065220526,0.00037978767,0.00047367293,0.0003932063],"domain_scores_gemma":[0.9985589,0.0001901982,0.00013801518,0.0006314765,0.00011512639,0.00036631635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013319134,0.00021159118,0.00048586444,0.00015922158,0.000040385687,0.000008943926,0.00012574553,0.00018057397,0.00007117134],"category_scores_gemma":[0.00058917253,0.0001601511,0.00017370864,0.00023553001,0.0001425933,0.00005298423,0.00010868918,0.0002221362,0.00013626942],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011430618,0.004519362,0.14649615,0.00023657171,0.0003541415,0.000702965,0.000701534,0.0000021220155,0.82562697,0.000005496357,0.004517858,0.005406187],"study_design_scores_gemma":[0.01061943,0.001984941,0.09541158,0.0005316859,0.00034987455,0.000061769104,0.00009514607,0.0000055697355,0.8852347,0.0000020571235,0.005562956,0.00014027664],"about_ca_topic_score_codex":0.00007874541,"about_ca_topic_score_gemma":0.00001596179,"teacher_disagreement_score":0.05960772,"about_ca_system_score_codex":0.00018378432,"about_ca_system_score_gemma":0.00045624783,"threshold_uncertainty_score":0.65307724},"labels":[],"label_agreement":null},{"id":"W2556062232","doi":"10.1182/blood.v118.21.2735.2735","title":"BCL2 Splice Isoform Switching Promotes Leukemia Stem Cell Survival and Sensitivity to a Novel Pan BCL2 Inhibitor","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Dasatinib; Biology; Progenitor cell; Cancer research; Myeloid leukemia; Transplantation; Leukemia; Stem cell; Immunology; Nilotinib; Molecular biology; Imatinib; Medicine; Internal medicine; Genetics","score_opus":0.027240904311153967,"score_gpt":0.23638403108706824,"score_spread":0.20914312677591426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2556062232","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924624,0.00015689609,0.00023258361,0.00008096763,0.00014370325,0.0009174953,0.000027917411,0.0001606822,0.005817356],"genre_scores_gemma":[0.9948267,0.000018946284,0.003922218,0.00014594551,0.00029183176,0.00003374419,0.000012118846,0.00006416304,0.0006843421],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99817115,0.000044088996,0.00032526325,0.0005884045,0.00034155152,0.00052953424],"domain_scores_gemma":[0.9987842,0.00012023719,0.00011359726,0.00051515346,0.00008367555,0.00038317515],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037991692,0.0003420046,0.000509193,0.00011203879,0.000120813915,0.000023059289,0.00006469823,0.00016389757,0.00003347496],"category_scores_gemma":[0.00004946664,0.00029739682,0.00009004129,0.00019474277,0.00003784845,0.00013955236,0.00019002498,0.00029940903,0.0001457959],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009360354,0.0059382725,0.096897915,0.0010541545,0.0007494125,0.0014772671,0.01727537,0.0000014075563,0.8483323,0.00018314285,0.00022645986,0.026928289],"study_design_scores_gemma":[0.030962257,0.0023857772,0.24868093,0.0006965948,0.0012623214,0.0015106791,0.0018977621,0.0003761544,0.71040136,0.0000342796,0.00085041585,0.0009414863],"about_ca_topic_score_codex":0.0015627263,"about_ca_topic_score_gemma":0.00039334383,"teacher_disagreement_score":0.15178302,"about_ca_system_score_codex":0.0004769327,"about_ca_system_score_gemma":0.00042973724,"threshold_uncertainty_score":0.9999478},"labels":[],"label_agreement":null},{"id":"W2556435626","doi":"10.1182/blood.v114.22.1369.1369","title":"Diagnostic Delays and Survival for Medicare Patients with Chronic Myeloid Leukemia in the Pre-Imatinib Era.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; Cancer Care Ontario","funders":"","keywords":"Medicine; Imatinib; Medical diagnosis; Imatinib mesylate; Epidemiology; Internal medicine; Proportional hazards model; Surveillance, Epidemiology, and End Results; Pediatrics; Cancer registry; Myeloid leukemia; Pathology","score_opus":0.007608612429487388,"score_gpt":0.2430349537698107,"score_spread":0.23542634134032334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2556435626","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955017,0.0010584,0.000056558198,0.00053335977,0.000052827963,0.0018991863,0.000040951752,0.000042060732,0.00081495836],"genre_scores_gemma":[0.99814755,0.00013066598,0.0006228901,0.0004018362,0.00019168497,0.0002089263,0.00021126925,0.000025764779,0.000059443122],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985013,0.000056649136,0.0002755711,0.0003475158,0.0004221172,0.00039686094],"domain_scores_gemma":[0.9986048,0.00072181097,0.000089617555,0.0003943242,0.00007010512,0.000119373915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002155495,0.00023258901,0.00033798788,0.000066612265,0.00008772262,0.000022344964,0.00014158864,0.00010430204,0.000028468832],"category_scores_gemma":[0.00045564005,0.00014223116,0.0000497463,0.000175055,0.00007321047,0.00007431886,0.000022918066,0.00023964277,0.0000061098594],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00087516924,0.0033390496,0.9205584,0.00066102267,0.00053886266,0.00033011072,0.0051771603,0.00007578285,0.00016245032,0.00040014,0.0014595006,0.06642235],"study_design_scores_gemma":[0.03515116,0.0031874776,0.9591263,0.00041212054,0.0005212545,0.00005921529,0.00010848766,0.00017273249,0.00024516715,0.00012083908,0.00070235424,0.00019286832],"about_ca_topic_score_codex":0.00010816509,"about_ca_topic_score_gemma":0.0002942038,"teacher_disagreement_score":0.06622948,"about_ca_system_score_codex":0.00061282364,"about_ca_system_score_gemma":0.0007228749,"threshold_uncertainty_score":0.58000183},"labels":[],"label_agreement":null},{"id":"W2556547291","doi":"10.1182/blood.v126.23.4030.4030","title":"Pulmonary Complications in Patients Treated with Tyrosine Kinase Inhibitors, a Systematic Review and Meta-Analysis","year":2015,"lang":"en","type":"review","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Bosutinib; Dasatinib; Nilotinib; Internal medicine; Ponatinib; Imatinib; Cumulative incidence; Pleural effusion; Subgroup analysis; Meta-analysis; Gastroenterology; Surgery; Myeloid leukemia; Cohort","score_opus":0.05895177354479435,"score_gpt":0.31572737349242075,"score_spread":0.2567755999476264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2556547291","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000028905113,0.99150383,4.0800157e-7,0.000049150814,0.0000038765697,0.007705966,0.00030289943,0.0000460294,0.00035890922],"genre_scores_gemma":[0.00019784449,0.99340826,0.00013188629,0.00009987315,0.000011949429,0.0025112922,0.002992196,0.00006969045,0.00057699997],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9969613,0.0003637718,0.0012767958,0.00068093365,0.0004511645,0.0002660464],"domain_scores_gemma":[0.99737597,0.000105804414,0.00076776644,0.0012642962,0.00023210021,0.00025406713],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032498362,0.000652262,0.009988843,0.0004968083,0.00003702542,0.000019898756,0.00014706714,0.00018811366,0.000051089795],"category_scores_gemma":[0.000106825086,0.00036515007,0.0009864251,0.0018415928,0.00005609795,0.000053208394,0.0000725613,0.000273618,0.000049819082],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000004175068,0.0016493598,0.00050798105,0.8437652,0.15306263,0.00014321422,0.000008382965,4.6949076e-8,1.0975028e-8,0.0000028143263,0.00008088373,0.00077529845],"study_design_scores_gemma":[0.0014732112,0.00016479215,0.000093721545,0.0918893,0.90152055,0.00021135565,0.0000015521066,8.146562e-7,1.3597577e-7,5.3402283e-7,0.004384216,0.0002597952],"about_ca_topic_score_codex":0.00010854293,"about_ca_topic_score_gemma":0.000020765941,"teacher_disagreement_score":0.7518759,"about_ca_system_score_codex":0.00053083996,"about_ca_system_score_gemma":0.00038996976,"threshold_uncertainty_score":0.9998801},"labels":[],"label_agreement":null},{"id":"W2557135000","doi":"10.1182/blood.v112.11.570.570","title":"Distinct Gab2-Mediated Signaling Pathways Are Essential for Myeloid or Lymphoid Transformation and Leukemogenesis by BCR-ABL","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Chronic myelogenous leukemia; Cancer research; Biology; Leukemia; breakpoint cluster region; Myeloid; Tyrosine kinase; Dasatinib; Myeloid leukemia; Immunology; Signal transduction; Imatinib; Cell biology; Genetics","score_opus":0.021270133654297252,"score_gpt":0.2350585023237531,"score_spread":0.21378836866945586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2557135000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957849,0.0012112149,0.000889764,0.00019207761,0.00009088329,0.00101571,0.00041463439,0.00016127164,0.0002395552],"genre_scores_gemma":[0.99645543,0.0005218877,0.0011234133,0.00014221006,0.00024129105,0.00017977464,0.00092940795,0.000059511516,0.00034708026],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984034,0.00003521265,0.00042998092,0.000392862,0.00032021292,0.00041836494],"domain_scores_gemma":[0.99900436,0.00019982475,0.00015680968,0.0003085785,0.00009995972,0.00023044093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012509512,0.000294903,0.00045502977,0.00009334737,0.00027236584,0.000020565356,0.000103955485,0.00016962801,0.00011519302],"category_scores_gemma":[0.00020345022,0.00023916751,0.00012557735,0.00018733568,0.00009104368,0.00014684939,0.000026560689,0.00008796106,0.000024092735],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004508921,0.0047303056,0.08408081,0.0026702862,0.0021242858,0.0010505341,0.0062250216,0.000020262363,0.87188154,0.000042530446,0.007939458,0.014726047],"study_design_scores_gemma":[0.09070742,0.0016853901,0.022683458,0.00053493393,0.0024545814,0.0033126187,0.0007491831,0.0020922006,0.86671793,0.00005658183,0.00800904,0.0009966313],"about_ca_topic_score_codex":0.00008621131,"about_ca_topic_score_gemma":0.000030335768,"teacher_disagreement_score":0.0861985,"about_ca_system_score_codex":0.00030906688,"about_ca_system_score_gemma":0.0004990658,"threshold_uncertainty_score":0.9752968},"labels":[],"label_agreement":null},{"id":"W2557375195","doi":"10.1182/blood.v126.23.344.344","title":"Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Final Results from ENESTxtnd Study","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Nilotinib; Medicine; Internal medicine; Adverse effect; Clinical endpoint; Imatinib mesylate; Imatinib; Phases of clinical research; Gastroenterology; Myeloid leukemia; Clinical trial; Surgery","score_opus":0.03109947596682438,"score_gpt":0.28580327226961083,"score_spread":0.25470379630278644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2557375195","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932918,0.0011619254,0.000007734905,0.00011474918,0.00021412234,0.00397869,0.0001775893,0.00016780787,0.00088556454],"genre_scores_gemma":[0.9959558,0.00012353703,0.0011872527,0.00009980043,0.00049040205,0.0004512417,0.0011094228,0.00014204014,0.0004405015],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9944927,0.00034992147,0.0013695944,0.0014701026,0.0011748436,0.0011428467],"domain_scores_gemma":[0.99691314,0.00038676528,0.00044958314,0.0014450649,0.00019654488,0.0006088887],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00063479,0.0008008708,0.001364327,0.0004790942,0.000078086516,0.00006092621,0.00043495084,0.00030945832,0.00014164667],"category_scores_gemma":[0.00055603194,0.0006799519,0.00013439835,0.00094405754,0.0001908216,0.0003161536,0.00019765334,0.0008363577,0.00020963214],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.06765252,0.06723721,0.7785246,0.00027917026,0.0022328154,0.01435288,0.014100605,0.011337699,0.0013312364,0.000009368727,0.0025396796,0.040402237],"study_design_scores_gemma":[0.7302939,0.018436434,0.244622,0.00083963,0.00077243854,0.000032276206,0.0006331584,0.0014150853,0.0014526247,0.00001528658,0.0007510695,0.0007360561],"about_ca_topic_score_codex":0.014835524,"about_ca_topic_score_gemma":0.013828321,"teacher_disagreement_score":0.6626414,"about_ca_system_score_codex":0.014550908,"about_ca_system_score_gemma":0.008787913,"threshold_uncertainty_score":0.9995652},"labels":[],"label_agreement":null},{"id":"W2557861511","doi":"10.1182/blood.v124.21.896.896","title":"A New AHI-1-DNM2-BCR-ABL Complex Regulates Endocytosis Processes in Chronic Myeloid Leukemia","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Stem cell; Progenitor cell; Cancer research; CD34; Biology; Myeloid leukemia; CD38; Cell biology","score_opus":0.018846216180627328,"score_gpt":0.2585228386021348,"score_spread":0.2396766224215075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2557861511","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98358357,0.0035020013,0.000078046534,0.00051196286,0.000089894056,0.00085017836,0.000011626489,0.00028104134,0.011091678],"genre_scores_gemma":[0.9913163,0.0004104621,0.0036542565,0.00030732548,0.0007463526,0.00009146373,0.000117530086,0.00008426734,0.0032720324],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975414,0.00006782805,0.0005406744,0.00066468917,0.00044665142,0.0007387513],"domain_scores_gemma":[0.9984514,0.00020469395,0.00016911022,0.00075096986,0.00008414107,0.00033967078],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000184802,0.00041046494,0.0007624325,0.00024223853,0.000087607536,0.000042294316,0.00024202598,0.00019425579,0.00079069246],"category_scores_gemma":[0.00032683203,0.00037005273,0.00012804482,0.0006390752,0.00008880868,0.00015100586,0.000112614674,0.00031479157,0.00032204366],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015760427,0.005126772,0.21937838,0.010434121,0.0029875136,0.0020296997,0.0058777425,0.00072213,0.43816745,0.0022085956,0.044678453,0.2668131],"study_design_scores_gemma":[0.110301144,0.003758279,0.20312375,0.0033052485,0.0020823092,0.0021996403,0.0002141833,0.0019793329,0.4815706,0.0015103593,0.18807536,0.0018797977],"about_ca_topic_score_codex":0.0010644894,"about_ca_topic_score_gemma":0.0008380969,"teacher_disagreement_score":0.2649333,"about_ca_system_score_codex":0.0023975414,"about_ca_system_score_gemma":0.0036623913,"threshold_uncertainty_score":0.9998751},"labels":[],"label_agreement":null},{"id":"W2557965693","doi":"10.1182/blood.v126.23.1596.1596","title":"Treatment Patterns and Healthcare Costs in Newly Diagnosed Patients with Chronic Myeloid Leukemia Receiving Dasatinib or Nilotinib As First-Line Therapy in the United States: A Retrospective Claims Database Analysis","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Nilotinib; Medicine; Dasatinib; Discontinuation; Internal medicine; Myeloid leukemia; Retrospective cohort study; Imatinib","score_opus":0.03002437962263441,"score_gpt":0.2961061800249184,"score_spread":0.26608180040228396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2557965693","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99534094,0.0005312189,0.00001243357,0.001009101,0.000033991862,0.002599489,0.00037153222,0.00005810581,0.000043183252],"genre_scores_gemma":[0.9905696,0.004199649,0.00016332505,0.0005652779,0.00008849226,0.00046151702,0.003836054,0.00006026931,0.00005582058],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970154,0.00034670142,0.00057922525,0.0007915148,0.0006540538,0.0006130657],"domain_scores_gemma":[0.9978508,0.00046955212,0.00026331522,0.0009029312,0.00019821251,0.00031522918],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036146858,0.0004938517,0.00081026054,0.0005896968,0.000107475986,0.000053480162,0.00018688782,0.00013602353,0.00006442138],"category_scores_gemma":[0.00020075667,0.00028477793,0.0000798359,0.0020326183,0.000089240675,0.00015838842,0.000059846672,0.00039587758,0.000008339619],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018239107,0.0022684117,0.98163384,0.000058646154,0.0009150233,0.0007753346,0.008222927,0.0001725379,0.0000027070632,0.000004864238,0.000027276308,0.004094534],"study_design_scores_gemma":[0.080983736,0.010697088,0.90400034,0.0004893543,0.00071927335,0.00003842954,0.0016026056,0.0008779405,0.00009310729,0.000011424024,0.00020402663,0.00028264665],"about_ca_topic_score_codex":0.06554815,"about_ca_topic_score_gemma":0.14224471,"teacher_disagreement_score":0.079159826,"about_ca_system_score_codex":0.006824821,"about_ca_system_score_gemma":0.001427956,"threshold_uncertainty_score":0.9999604},"labels":[],"label_agreement":null},{"id":"W2558149620","doi":"10.1182/blood.v116.21.4758.4758","title":"Dose Adjustment and Treatment Interruptions Associated with Second-Line Nilotinib or Dasatinib In Real-World Treatment of Chronic Myeloid Leukemia","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Nilotinib; Dasatinib; Medicine; Internal medicine; Myeloid leukemia; Imatinib; Tyrosine-kinase inhibitor; Adverse effect; Imatinib mesylate; Oncology; Cancer","score_opus":0.033580665530182026,"score_gpt":0.30357519657101895,"score_spread":0.2699945310408369,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2558149620","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99404246,0.00047916654,0.000001169851,0.00014904117,0.00013852293,0.0018053097,0.00016414131,0.000108864064,0.0031113322],"genre_scores_gemma":[0.9875507,0.0010883628,0.0007489721,0.00003652459,0.00024097557,0.00044894844,0.00038983137,0.00007479947,0.009420904],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977478,0.00007270009,0.00069230853,0.00064388185,0.00029691998,0.0005464198],"domain_scores_gemma":[0.998325,0.0002600561,0.00031680844,0.000719947,0.000087071974,0.00029110114],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00012036003,0.0005306466,0.0010050045,0.00035763351,0.00007262945,0.000016801949,0.00009515149,0.00018877622,0.0010580459],"category_scores_gemma":[0.000057216894,0.0003444046,0.00013250372,0.0004719192,0.00019964867,0.00009366797,0.000043054846,0.00023855445,0.000018131379],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008238311,0.07392102,0.5724604,0.000690281,0.0118271485,0.0045786356,0.0097970115,0.000102067796,0.11329882,0.0006554993,0.00026913476,0.20416167],"study_design_scores_gemma":[0.11960424,0.029959053,0.7837529,0.0007681428,0.002490468,0.0005050024,0.000258881,0.00046133174,0.05898619,0.000021694346,0.0026243546,0.0005677051],"about_ca_topic_score_codex":0.0025551866,"about_ca_topic_score_gemma":0.14458504,"teacher_disagreement_score":0.21129254,"about_ca_system_score_codex":0.00428719,"about_ca_system_score_gemma":0.00201721,"threshold_uncertainty_score":0.9999008},"labels":[],"label_agreement":null},{"id":"W2558303915","doi":"10.1038/leu.2016.336","title":"Cardiologist’s perspective to the European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia","year":2016,"lang":"en","type":"letter","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Hôpital du Saint-Sacrement; Hôpital Charles-Le Moyne; Centre Hospitalier de l’Université de Montréal; Montreal Heart Institute; Jewish General Hospital; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Chronic myeloid leukaemia; Myeloid leukaemia; Perspective (graphical); Adverse effect; Myeloid; Internal medicine; Intensive care medicine; Oncology","score_opus":0.02773850650527052,"score_gpt":0.2892765878858304,"score_spread":0.26153808138055984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2558303915","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.036326453,0.01169172,0.0017699947,0.88361317,0.0020124742,0.027123213,0.003710891,0.00019537898,0.033556685],"genre_scores_gemma":[0.6127433,0.029899983,0.008656123,0.18492186,0.017007755,0.009361745,0.0027770435,0.0011235568,0.1335086],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969036,0.0003834848,0.0008255637,0.0008607447,0.00036467245,0.00066192937],"domain_scores_gemma":[0.9969499,0.0007619582,0.00051958056,0.0015099279,0.00016972641,0.00008888615],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00065650913,0.00061232946,0.0010052457,0.0002705571,0.00014725733,0.00000563535,0.000542339,0.00031434835,0.00005073588],"category_scores_gemma":[0.00008789156,0.00033134606,0.00040145862,0.00029325523,0.00028377355,0.00005803542,0.0002599115,0.0006739191,0.000043724758],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00081542606,0.000098913646,0.0027157029,0.0017978282,0.005990619,0.00040783358,0.004093685,0.0013484132,0.000364916,0.00043733924,0.9112312,0.07069811],"study_design_scores_gemma":[0.009107799,0.0012487927,0.015518912,0.0017019559,0.0014787241,0.000067189496,0.0008216095,0.00010826036,0.00032841455,0.00018360716,0.9690278,0.0004069437],"about_ca_topic_score_codex":0.0019307169,"about_ca_topic_score_gemma":0.0004189005,"teacher_disagreement_score":0.6986913,"about_ca_system_score_codex":0.032414593,"about_ca_system_score_gemma":0.0017475646,"threshold_uncertainty_score":0.9999139},"labels":[],"label_agreement":null},{"id":"W2558380786","doi":"10.1182/blood.v116.21.3404.3404","title":"Combined Targeting of BCR-ABL and JAK2 with ABL and JAK2 Inhibitors Is Effective Against CML Patients' Leukemic Stem/Progenitor Cells.","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Progenitor cell; Stem cell; Imatinib mesylate; Cancer research; Haematopoiesis; Tyrosine kinase; ABL; Imatinib; K562 cells; Biology; Myeloid leukemia; Medicine; Immunology; Leukemia; Cell biology; Signal transduction","score_opus":0.002756804409487737,"score_gpt":0.19052913707364796,"score_spread":0.1877723326641602,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2558380786","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997222,0.000498611,0.000001476714,0.000037718983,0.00022180434,0.0014283316,0.000052669566,0.0000585122,0.0004788926],"genre_scores_gemma":[0.998309,0.00007398504,0.0010350761,0.00009357717,0.00015825835,0.000072160765,0.00005141342,0.00006203942,0.00014449227],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983505,0.000053606287,0.00036882004,0.0005077964,0.0003489831,0.00037027453],"domain_scores_gemma":[0.99879223,0.00016984681,0.0002451967,0.00036125846,0.00017928434,0.00025220908],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016787807,0.00034054203,0.00055214274,0.00011883962,0.00011152491,0.000022430344,0.000079143705,0.00019413022,0.000024086079],"category_scores_gemma":[0.00006322237,0.00026564187,0.00006607702,0.00018549962,0.00020745334,0.00010436788,0.000103172686,0.0003876521,0.000010630895],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049787597,0.0013179599,0.75368893,0.00061315956,0.0006588563,0.000063842956,0.0016720159,6.3865724e-7,0.2334095,0.000007810085,0.00041711642,0.0076522883],"study_design_scores_gemma":[0.044389103,0.002818764,0.13145113,0.0005021843,0.0009925916,0.00003976661,0.00035157197,0.000091810856,0.8184626,0.000012302197,0.00045940475,0.00042878286],"about_ca_topic_score_codex":0.000245372,"about_ca_topic_score_gemma":0.000018348881,"teacher_disagreement_score":0.6222378,"about_ca_system_score_codex":0.00014437687,"about_ca_system_score_gemma":0.00021483364,"threshold_uncertainty_score":0.99997956},"labels":[],"label_agreement":null},{"id":"W2558513717","doi":"10.1182/blood.v120.21.1662.1662","title":"Identification of a Unique Autophagy Gene Expression Signature in CD34+ CML Stem/Progenitor Cells That Correlates with Clinical Response to Imatinib Mesylate","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada; Genome British Columbia; BC Cancer Agency","funders":"","keywords":"Stem cell; Autophagy; ATG5; Imatinib mesylate; Cancer research; CD34; Progenitor cell; Nilotinib; Dasatinib; Myeloid leukemia; Biology; Tyrosine-kinase inhibitor; Haematopoiesis; Imatinib; Medicine; Tyrosine kinase; Internal medicine; Apoptosis; Cell biology; Cancer; Genetics; Receptor","score_opus":0.0215117853545327,"score_gpt":0.30171182606775976,"score_spread":0.28020004071322707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2558513717","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99751234,0.0007903751,0.00010187716,0.00010809403,0.00022153014,0.0011406102,0.000027130527,0.000058594724,0.000039465125],"genre_scores_gemma":[0.9954957,0.000050646235,0.0033482942,0.00006599117,0.00011147369,0.000103190476,0.000024735371,0.000044342032,0.0007556307],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99794275,0.00036227802,0.00064783177,0.00034805475,0.0003591699,0.00033991013],"domain_scores_gemma":[0.99839115,0.0003388271,0.00031096567,0.0006095197,0.00009457483,0.00025496178],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010943637,0.00021618992,0.00046090086,0.00016709673,0.000033492153,0.000010446799,0.00013645767,0.00027809117,0.00004957333],"category_scores_gemma":[0.00013597378,0.00016126517,0.00009321807,0.00026612455,0.000051912342,0.00013130916,0.0000694166,0.00031829448,0.00006680092],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035786375,0.0016217387,0.13698235,0.00008469758,0.00011913649,0.000070357346,0.0011154704,0.000012595716,0.8557797,0.000004446731,0.00012918477,0.0005016956],"study_design_scores_gemma":[0.0069609247,0.0005161704,0.12531844,0.00035512712,0.00023680554,0.000062771986,0.000110803965,0.000041276366,0.8661672,0.0000046611653,0.00009090682,0.00013491297],"about_ca_topic_score_codex":0.000015567448,"about_ca_topic_score_gemma":0.0000036807146,"teacher_disagreement_score":0.011663922,"about_ca_system_score_codex":0.0001748045,"about_ca_system_score_gemma":0.0002914096,"threshold_uncertainty_score":0.65762025},"labels":[],"label_agreement":null},{"id":"W2558641380","doi":"10.1182/blood.v120.21.2793.2793","title":"Baseline Predictors of Response to Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib Plus Dasatinib and/or Nilotinib.","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Nilotinib; Dasatinib; Bosutinib; Medicine; Internal medicine; Imatinib; Gastroenterology; Myeloid leukemia; Tolerability; Imatinib mesylate; Tyrosine-kinase inhibitor; Oncology; Adverse effect; Cancer","score_opus":0.0127938758954647,"score_gpt":0.2793898243812088,"score_spread":0.2665959484857441,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2558641380","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946289,0.0011923665,0.00011799837,0.00026033638,0.0002400143,0.0030795126,0.00016300341,0.00011648329,0.00020135676],"genre_scores_gemma":[0.9914609,0.00003645243,0.0059509045,0.0002817021,0.0003709143,0.00035268575,0.00009628177,0.00012589319,0.0013242721],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958278,0.00027081932,0.0011094349,0.00080005627,0.0008695428,0.0011223272],"domain_scores_gemma":[0.9971271,0.0006017371,0.000323159,0.0010168435,0.00014830954,0.00078283896],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011966623,0.00058882544,0.0011275626,0.00042890036,0.00011141192,0.000022856195,0.000273444,0.0001883412,0.00019307023],"category_scores_gemma":[0.0012917889,0.00043400095,0.0001164874,0.0011478593,0.00010666704,0.0003049139,0.00017883307,0.00036941966,0.00004008293],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19167262,0.008210438,0.7465538,0.0024358283,0.0014599797,0.00051630335,0.01193019,0.00027019455,0.02186818,0.00002769173,0.0017985638,0.013256259],"study_design_scores_gemma":[0.23460995,0.020170758,0.6889498,0.0073313615,0.0011506503,0.00006352225,0.00030934086,0.00021212923,0.035274792,0.00000198681,0.010689078,0.0012366126],"about_ca_topic_score_codex":0.00010764002,"about_ca_topic_score_gemma":0.00080805266,"teacher_disagreement_score":0.05760393,"about_ca_system_score_codex":0.0037189345,"about_ca_system_score_gemma":0.0035491972,"threshold_uncertainty_score":0.9998112},"labels":[],"label_agreement":null},{"id":"W2559100699","doi":"10.1182/blood.v118.21.4422.4422","title":"Effect of Switching to Nilotinib in Patients with Imatinib-Related Low-Grade Non-Hematologic Adverse Events","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Princess Margaret Cancer Centre","funders":"","keywords":"Nilotinib; Medicine; Imatinib; Adverse effect; Internal medicine; Imatinib mesylate; Gastroenterology; Myeloid leukemia","score_opus":0.006665188434979954,"score_gpt":0.2330796546725744,"score_spread":0.22641446623759445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559100699","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969872,0.000019015572,0.000008403109,0.000010829231,0.00006328784,0.0015496826,0.0000061425153,0.00004902197,0.0013063728],"genre_scores_gemma":[0.99839956,0.0000016408285,0.0013743063,0.00003921636,0.000007791586,0.000064067324,0.000028322082,0.000037023176,0.00004809336],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984775,0.00007958039,0.00043979098,0.00033597785,0.00032036862,0.00034675174],"domain_scores_gemma":[0.9991027,0.00008668063,0.00018702561,0.00041887196,0.0000453229,0.0001593784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021407197,0.0002565676,0.0005878495,0.0001895081,0.00002548228,0.0000011246461,0.00012747591,0.000113334594,0.000105846164],"category_scores_gemma":[0.00013689755,0.00017850426,0.00008410498,0.0003429608,0.000022439708,0.000077232005,0.00006454129,0.00019981925,0.000120534256],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009213907,0.002486093,0.9934261,0.00031826805,0.00023872011,0.000105318104,0.0011833656,0.000004932512,0.00077893696,0.0000054745187,0.000006976384,0.00052443694],"study_design_scores_gemma":[0.045988724,0.0050448836,0.8928807,0.00126404,0.00044232127,0.000029626322,0.000032633685,0.000030521926,0.054084033,0.0000134153115,0.0000015602365,0.00018756307],"about_ca_topic_score_codex":0.00016257506,"about_ca_topic_score_gemma":0.000015462912,"teacher_disagreement_score":0.100545414,"about_ca_system_score_codex":0.00014978305,"about_ca_system_score_gemma":0.00009546109,"threshold_uncertainty_score":0.7279193},"labels":[],"label_agreement":null},{"id":"W2559435609","doi":"10.1182/blood.v126.23.902.902","title":"PP2A Is Required for B Cell Survival and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Protein phosphatase 2; Biology; Cancer research; Protein kinase B; Leukemia; Protein subunit; Myeloid leukemia; Myeloid; Lymphoblast; PI3K/AKT/mTOR pathway; breakpoint cluster region; Stem cell; Phosphatase; Phosphorylation; Immunology; Signal transduction; Genetics; Cell culture; Gene","score_opus":0.03293970052511146,"score_gpt":0.2863745782250327,"score_spread":0.25343487769992123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559435609","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99393,0.0016297244,0.000108624474,0.00027504613,0.00016731273,0.00086159224,0.000039822302,0.000056057903,0.0029318656],"genre_scores_gemma":[0.9941347,0.00010335248,0.0018665636,0.00026277604,0.00012388638,0.000111708185,0.00005309609,0.000048813577,0.0032951068],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99853593,0.000044383334,0.00028726144,0.0004493246,0.00028458072,0.00039850204],"domain_scores_gemma":[0.99903816,0.00012497026,0.00008113804,0.00043615454,0.000073469055,0.0002461327],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022142915,0.0002158144,0.0004250655,0.000101077465,0.000033466622,0.00001944589,0.00009781674,0.00013544744,0.000030011237],"category_scores_gemma":[0.00009404661,0.00018673918,0.00007265777,0.00016591413,0.00005681683,0.00008139134,0.00006842075,0.00009736157,0.00003873676],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0073938863,0.007435433,0.86981875,0.001317598,0.003998831,0.0023490079,0.010776382,0.000048268066,0.075946204,0.00037430384,0.013899634,0.006641702],"study_design_scores_gemma":[0.5155476,0.008107903,0.20667143,0.00090375385,0.0068275523,0.0013046545,0.0019810349,0.013901458,0.21084405,0.007600606,0.02417938,0.00213061],"about_ca_topic_score_codex":0.00018078033,"about_ca_topic_score_gemma":0.00001766829,"teacher_disagreement_score":0.66314733,"about_ca_system_score_codex":0.0006546703,"about_ca_system_score_gemma":0.00084579596,"threshold_uncertainty_score":0.7615003},"labels":[],"label_agreement":null},{"id":"W2559633807","doi":"10.1182/blood.v108.11.4795.4795","title":"Higher Prevalence of Prior Prostate Cancer in Patients Diagnosed with Chronic Myelogenous Leukemia.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Prostate cancer; Imatinib; Internal medicine; Chronic myelogenous leukemia; Cancer; Population; Incidence (geometry); Imatinib mesylate; Pediatrics; Leukemia; Oncology; Myeloid leukemia","score_opus":0.005851050836075837,"score_gpt":0.22422903359861238,"score_spread":0.21837798276253653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559633807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99448925,0.0032317978,4.8566534e-7,0.00003673984,0.000059912632,0.0012675395,0.00007013267,0.000043038417,0.0008011279],"genre_scores_gemma":[0.9964151,0.00035588638,0.0002047884,0.000031334537,0.00010436473,0.00022730362,0.00003668817,0.00004229011,0.0025822758],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998494,0.000028657769,0.0003479317,0.00036438767,0.00037027497,0.00039470612],"domain_scores_gemma":[0.999231,0.00003929706,0.00017197416,0.0003848953,0.00010188697,0.000070961345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005693064,0.00021767418,0.00037012814,0.000096322765,0.000029297033,0.000005494435,0.00010170605,0.000089535686,0.00025132147],"category_scores_gemma":[0.00001296136,0.00016711964,0.000048342252,0.00026132065,0.00009294303,0.00006828477,0.00003542968,0.0001520647,0.00001624577],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002677638,0.0015306649,0.991995,0.00079222256,0.00010754276,0.0001480961,0.00018305062,0.00011666851,0.0012805497,0.0000089076,0.00008059187,0.0034889549],"study_design_scores_gemma":[0.029847248,0.0011901853,0.9549885,0.00072887685,0.0003603937,0.000007890031,0.0000040545,0.000010654056,0.012428817,0.0000075752882,0.00026460315,0.00016119675],"about_ca_topic_score_codex":0.0030267555,"about_ca_topic_score_gemma":0.0009749245,"teacher_disagreement_score":0.037006482,"about_ca_system_score_codex":0.0016522874,"about_ca_system_score_gemma":0.0012778245,"threshold_uncertainty_score":0.6814941},"labels":[],"label_agreement":null},{"id":"W2560046425","doi":"10.1182/blood.v114.22.3286.3286","title":"Efficacy and Safety of Nilotinib in Elderly Patients with Imatinib-Resistant or -;Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A Sub-Analysis of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Nilotinib; Medicine; Imatinib; Internal medicine; Imatinib mesylate; Myeloid leukemia; Tyrosine-kinase inhibitor; Cancer","score_opus":0.05427079988921533,"score_gpt":0.3957849007024577,"score_spread":0.34151410081324235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560046425","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942434,0.0007481588,0.0000086842465,0.00007842331,0.00005969844,0.0046824357,0.00007752381,0.00002541001,0.0000762781],"genre_scores_gemma":[0.9992914,0.00029714938,0.000078960446,0.000039242495,0.000075650605,0.000083740466,0.00007159375,0.000043771473,0.000018470113],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99231875,0.0013273326,0.0038861437,0.0009299265,0.0008623472,0.0006755296],"domain_scores_gemma":[0.99533916,0.0017972215,0.0014792896,0.0010629268,0.00012757616,0.00019384846],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0037034387,0.0005423823,0.0032146736,0.0009510327,0.00006690881,0.000037295253,0.00049228163,0.00024204557,0.000096669006],"category_scores_gemma":[0.001764632,0.0003317137,0.00039492868,0.0028960654,0.00021008159,0.0002108849,0.00015487884,0.0007660214,0.0000012051896],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030413356,0.023415172,0.8797187,0.00036493826,0.003341271,0.00022224787,0.0023787615,0.0008031233,0.0050784755,0.00001121788,0.000007200008,0.05424549],"study_design_scores_gemma":[0.19065596,0.010066664,0.790042,0.0013383651,0.0037096983,0.000005249831,0.00017888001,0.00082096126,0.0029046682,0.000005358784,0.000008051151,0.0002641779],"about_ca_topic_score_codex":0.0011799573,"about_ca_topic_score_gemma":0.011180466,"teacher_disagreement_score":0.16024262,"about_ca_system_score_codex":0.00256536,"about_ca_system_score_gemma":0.003137653,"threshold_uncertainty_score":0.9999135},"labels":[],"label_agreement":null},{"id":"W2560125532","doi":"10.1182/blood.v112.11.3237.3237","title":"A Population (Registry) Based Analysis of the Impact of Bcr-Abl Specific Tyrosine Kinase Inhibition on Survival after Diagnosis of Philadelphia Chromosome Positive Chronic Myelogenous Leukemia..","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Cancer Foundation","funders":"","keywords":"Medicine; Chronic myelogenous leukemia; Philadelphia chromosome; Population; Internal medicine; Alpha interferon; Cytarabine; Leukemia; Oncology; Immunology; Interferon; Chromosomal translocation; Biology","score_opus":0.017478972537347242,"score_gpt":0.2561987802988473,"score_spread":0.23871980776150006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560125532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99713963,0.0011247025,0.000016479877,0.00009520138,0.0000503266,0.00068876473,0.0007350722,0.000022154389,0.00012768166],"genre_scores_gemma":[0.9987694,0.0002899249,0.00008398123,0.000020952499,0.00012207188,0.0000655331,0.0005890162,0.00003886202,0.00002022701],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977819,0.00014823255,0.00070875045,0.00040837287,0.0006442887,0.0003084647],"domain_scores_gemma":[0.99793077,0.00018182085,0.0006317051,0.00091273006,0.00023234959,0.0001106161],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014379539,0.00032301713,0.0009916474,0.00045553618,0.00007044453,0.0000040940254,0.00012396678,0.00018171432,0.0004230969],"category_scores_gemma":[0.00008947837,0.00023432903,0.000862831,0.0015350154,0.00024328774,0.00006907862,0.00004555349,0.00019355935,0.0000043879036],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013164543,0.004730133,0.8960541,0.0002519408,0.00429445,0.0002335394,0.00042923773,0.0061347573,0.08610799,0.000019674286,0.00009168028,0.0003360559],"study_design_scores_gemma":[0.0063407486,0.0013471093,0.79041713,0.00042864023,0.0027704157,0.000026850059,0.000010807376,0.00040615586,0.19810444,0.000005488121,0.000002455984,0.00013976383],"about_ca_topic_score_codex":0.0031714665,"about_ca_topic_score_gemma":0.00017203853,"teacher_disagreement_score":0.11199646,"about_ca_system_score_codex":0.0021291727,"about_ca_system_score_gemma":0.00079752674,"threshold_uncertainty_score":0.95556605},"labels":[],"label_agreement":null},{"id":"W2560144914","doi":"10.1182/blood.v104.11.152.152","title":"A Novel Triple Purge Strategy for Eliminating Chronic Myelogenous Leukemia (CML) Cells from Autografts.","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute","funders":"","keywords":"Chronic myelogenous leukemia; Stem cell; Progenitor cell; CD34; Transplantation; Medicine; Immunology; Granulocyte colony-stimulating factor; Haematopoiesis; Cancer research; Imatinib mesylate; Allotransplantation; Leukemia; Autotransplantation; Imatinib; Internal medicine; Biology; Chemotherapy; Myeloid leukemia; Cell biology","score_opus":0.025405745969745114,"score_gpt":0.26564080718873034,"score_spread":0.24023506121898522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560144914","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99074745,0.0027273367,0.0022719072,0.0001779781,0.00031269516,0.0018150772,0.00033601097,0.000286058,0.0013255071],"genre_scores_gemma":[0.98013526,0.000105764666,0.0172915,0.00019063057,0.0007937787,0.00027592728,0.00034407046,0.00010805645,0.00075498334],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976391,0.000016625405,0.00052190217,0.00067712076,0.00036008636,0.0007851346],"domain_scores_gemma":[0.99864537,0.00013811086,0.0002027006,0.0006315217,0.000105866224,0.0002764513],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015646455,0.00039740346,0.0005963451,0.00012514235,0.00018293395,0.000045134733,0.00020992452,0.00026872102,0.00017624798],"category_scores_gemma":[0.00009479845,0.0003721163,0.00029289926,0.00024790948,0.000075722324,0.00009951642,0.00006519297,0.00029193127,0.000120782046],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034916124,0.00413096,0.0006683802,0.0005273131,0.001736177,0.0004982451,0.0011957244,0.0018055256,0.9446494,0.0005334952,0.00052669056,0.043378904],"study_design_scores_gemma":[0.14398898,0.0047404342,0.009462138,0.00082437176,0.0033310875,0.0005117805,0.0004247453,0.0020416887,0.8259646,0.0009996097,0.0066023003,0.00110825],"about_ca_topic_score_codex":0.002214374,"about_ca_topic_score_gemma":0.00045372677,"teacher_disagreement_score":0.14363983,"about_ca_system_score_codex":0.0030002506,"about_ca_system_score_gemma":0.0033094685,"threshold_uncertainty_score":0.9998731},"labels":[],"label_agreement":null},{"id":"W2560300269","doi":"10.1182/blood.v120.21.4450.4450","title":"Treatment Response and Predictors of Response Among Patients with Chronic Myeloid Leukemia: A Retrospective Medical Record Review","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Nilotinib; Dasatinib; Imatinib; Internal medicine; Imatinib mesylate; Myeloid leukemia; Logistic regression; Oncology; Medical record","score_opus":0.00787791313397045,"score_gpt":0.2425229670254747,"score_spread":0.23464505389150425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560300269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9833975,0.014195696,0.0000022255933,0.00029810268,0.000111597736,0.0016134788,0.000053658256,0.00007755849,0.00025017466],"genre_scores_gemma":[0.9919598,0.0066518416,0.00022288077,0.00010516394,0.00018599122,0.00019224008,0.00005007305,0.00006193929,0.0005700317],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970756,0.00046031183,0.0005515702,0.0004648265,0.0008874721,0.00056021084],"domain_scores_gemma":[0.997765,0.0004301671,0.00029754292,0.00070284074,0.00015751911,0.0006469492],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00085124926,0.0003777186,0.000890202,0.00014965028,0.0000749557,0.0000061583187,0.00010740883,0.00023049065,0.00029882384],"category_scores_gemma":[0.0012731039,0.00026516157,0.00013097505,0.00033832755,0.0003301618,0.00016772878,0.00008027904,0.0002789722,0.000020840454],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0089683,0.0015718574,0.9839603,0.0004420392,0.00079526065,0.00010461343,0.0003630153,5.69899e-8,0.00018866538,0.0000039765437,0.00026504608,0.0033369185],"study_design_scores_gemma":[0.02439085,0.008727651,0.9577638,0.003220458,0.0016646868,0.00017455943,0.000017939668,0.0000035836892,0.001502264,0.0000013726416,0.0023220265,0.00021079431],"about_ca_topic_score_codex":0.00018013953,"about_ca_topic_score_gemma":0.00005465748,"teacher_disagreement_score":0.026196437,"about_ca_system_score_codex":0.0034945165,"about_ca_system_score_gemma":0.001980566,"threshold_uncertainty_score":0.99998003},"labels":[],"label_agreement":null},{"id":"W2560387080","doi":"10.1182/blood.v118.21.1986.1986","title":"A Phase 1 Open Label, Dose Escalation Study of Nilotinib in Steroid Dependent/Refractory Chronic Graft-Versus-Host Disease","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada","funders":"","keywords":"Nilotinib; Medicine; Prednisone; Adverse effect; Refractory (planetary science); Internal medicine; Tyrosine-kinase inhibitor; Pharmacology; Dosing; Imatinib; Corticosteroid; Gastroenterology; Urology; Cancer","score_opus":0.08625308435952153,"score_gpt":0.3471174880040857,"score_spread":0.2608644036445642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560387080","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950523,0.00059649674,0.000002607823,0.000017732116,0.00014305738,0.0025487752,0.00003778844,0.000045034012,0.001556207],"genre_scores_gemma":[0.9990789,0.00004834082,0.00016331045,0.000024231238,0.000078289406,0.00018699998,0.000069937785,0.000045390185,0.00030456643],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99815685,0.00012594783,0.00051166845,0.00048349975,0.0003919872,0.00033007632],"domain_scores_gemma":[0.99862945,0.000066103756,0.00021733485,0.000749566,0.00006775203,0.00026976308],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022360524,0.0002494674,0.00045153368,0.0001838906,0.00004596441,0.000017460648,0.0003078449,0.00007967897,0.00048353808],"category_scores_gemma":[0.00010201712,0.00022758234,0.00004698619,0.0002582049,0.000048419137,0.0002783966,0.00024293199,0.00021544695,0.00006972851],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025920492,0.36633283,0.5591146,0.00051068934,0.0018690749,0.0026497624,0.009351122,0.0000047292374,0.018399794,0.00006230339,0.00012095458,0.015663683],"study_design_scores_gemma":[0.51466584,0.02217477,0.4536332,0.0003436422,0.0019181627,0.000016696775,0.0009056243,0.00012034562,0.005683508,0.000025573132,0.00013205802,0.00038055333],"about_ca_topic_score_codex":0.0010278873,"about_ca_topic_score_gemma":0.0014059657,"teacher_disagreement_score":0.4887454,"about_ca_system_score_codex":0.00054357713,"about_ca_system_score_gemma":0.0006757429,"threshold_uncertainty_score":0.92805386},"labels":[],"label_agreement":null},{"id":"W2560580245","doi":"10.1182/blood.v116.21.4471.4471","title":"Significant Discrepancy In Peripheral Blood Compared to Bone Marrow BCR-ABL Transcript Levels In Chronic Phase Chronic Myeloid Leukemia (CML)","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Izaak Walton Killam Health Centre; Dalhousie University","funders":"","keywords":"Imatinib mesylate; Imatinib; Myeloid leukemia; Medicine; Bone marrow; Philadelphia chromosome; Chronic myelogenous leukemia; Internal medicine; Leukemia; Cancer research; Chromosomal translocation; Immunology; Oncology; Biology; Genetics","score_opus":0.02024127394987327,"score_gpt":0.2851995279233199,"score_spread":0.2649582539734466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560580245","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99174607,0.002186903,0.00003661956,0.0007085636,0.00041268687,0.0025242853,0.00016070882,0.00020991535,0.002014267],"genre_scores_gemma":[0.9943186,0.00012488135,0.002150779,0.00023031932,0.00073667,0.00053071155,0.00019009253,0.00016020199,0.0015577406],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9949579,0.000140011,0.0012596244,0.0013283895,0.00072127994,0.0015927671],"domain_scores_gemma":[0.9975391,0.00009715499,0.00018932289,0.0013737443,0.00008535464,0.00071530085],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00048366492,0.00079635857,0.0013934112,0.0005417804,0.00011875284,0.00006913979,0.00046548547,0.00041103177,0.0016237486],"category_scores_gemma":[0.00013264395,0.0007647672,0.0003072556,0.0009901844,0.00020779026,0.0002568131,0.00010848211,0.0014307748,0.00017294321],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052064995,0.0045909183,0.013262205,0.00040071754,0.00032080198,0.0024665112,0.0015866129,0.0001126054,0.9695784,0.00015918285,0.00021369451,0.0067877057],"study_design_scores_gemma":[0.30890882,0.007024725,0.18569438,0.0022578244,0.0019589975,0.00156963,0.0005002184,0.0034617388,0.4678581,0.00018320986,0.017835015,0.002747359],"about_ca_topic_score_codex":0.0025095022,"about_ca_topic_score_gemma":0.016059473,"teacher_disagreement_score":0.5017203,"about_ca_system_score_codex":0.00477822,"about_ca_system_score_gemma":0.0048669153,"threshold_uncertainty_score":0.9994803},"labels":[],"label_agreement":null},{"id":"W2560761889","doi":"10.1182/blood.v126.23.5140.5140","title":"High Prevalence of Peripheral Artery Occlusive Disease (PAOD) Among Patients with Chronic Myeloid Leukemia (CML) Receiving Tyrosine Kinase Inhibitors (TKIs): A Cross-Sectional Study","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Nilotinib; Internal medicine; Dasatinib; Diabetes mellitus; Population; Imatinib; Coronary artery disease; Myeloid leukemia; Imatinib mesylate; Surgery; Gastroenterology","score_opus":0.011089586736931367,"score_gpt":0.24601862072024425,"score_spread":0.23492903398331288,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560761889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99654365,0.00063278223,0.000011999545,0.000017708637,0.00037554096,0.0020447276,0.00015651104,0.00012115595,0.000095941476],"genre_scores_gemma":[0.99803406,0.000019579425,0.00022241607,0.000033195913,0.0005212838,0.00018728008,0.00017374531,0.00008380881,0.0007246348],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965001,0.00012302605,0.00072480674,0.00083578133,0.0012600815,0.0005562137],"domain_scores_gemma":[0.9974389,0.00007150354,0.00040840424,0.0008199978,0.0005927575,0.00066844845],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00027175923,0.00047456415,0.00056337175,0.00017448832,0.00015808185,0.000057971538,0.00022159284,0.00013396714,0.00019810547],"category_scores_gemma":[0.00026665052,0.00039037748,0.00014601664,0.00039247493,0.00034159992,0.0004068161,0.00019291537,0.00035638877,0.00002538607],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014873357,0.004124073,0.991649,0.00041696144,0.00045407392,0.00031324752,0.0006579261,0.0003604206,0.00022384399,0.0000036551378,0.00010277073,0.00020670377],"study_design_scores_gemma":[0.03859685,0.0039346092,0.95459414,0.0005067436,0.0007710833,0.00002923839,0.00007668877,0.00008832528,0.0010291858,0.00001181791,0.00001722264,0.00034409488],"about_ca_topic_score_codex":0.00065521133,"about_ca_topic_score_gemma":0.00017497079,"teacher_disagreement_score":0.037109513,"about_ca_system_score_codex":0.0032835293,"about_ca_system_score_gemma":0.0024776412,"threshold_uncertainty_score":0.9998548},"labels":[],"label_agreement":null},{"id":"W2560782884","doi":"10.1182/blood.v124.21.4551.4551","title":"Comparative Efficacy Among 3rd Line Post-Imatinib Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Patients after Failure of Dasatinib or Nilotinib Tyrosine Kinase Inhibitors","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Nilotinib; Dasatinib; Medicine; Imatinib; Ponatinib; Internal medicine; Bosutinib; Imatinib mesylate; Tyrosine-kinase inhibitor; Tyrosine kinase; Oncology; Myeloid leukemia; Cancer","score_opus":0.014707307269292999,"score_gpt":0.2779437002241801,"score_spread":0.2632363929548871,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560782884","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994447,0.000960705,0.000053012,0.00017393882,0.00033076556,0.0026688443,0.00033544228,0.00025573515,0.00077458087],"genre_scores_gemma":[0.99451154,0.00005448541,0.0015590306,0.00017933123,0.0011568106,0.0002795667,0.0013598003,0.0001686249,0.00073079154],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9948835,0.0002611845,0.0016056448,0.0011264047,0.0010402532,0.0010830215],"domain_scores_gemma":[0.9959987,0.0004925239,0.00090281456,0.0013913227,0.00062816776,0.0005864818],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003419674,0.00096362294,0.0017698327,0.00037148182,0.00017791915,0.000053178166,0.00040078256,0.00044793417,0.0013292071],"category_scores_gemma":[0.0005735361,0.0007646528,0.00043298115,0.0007170243,0.00053678383,0.0003356609,0.0002678525,0.00079317,0.00029932597],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029121457,0.08432079,0.39838842,0.011843033,0.010945085,0.0013817071,0.019241856,0.0010839185,0.3182209,0.0003199684,0.017196756,0.10793608],"study_design_scores_gemma":[0.24270628,0.034054983,0.25691065,0.004609931,0.0036105367,0.00010415236,0.00029408163,0.0024850417,0.44624457,0.000020087959,0.0070890584,0.0018706132],"about_ca_topic_score_codex":0.00023317947,"about_ca_topic_score_gemma":0.0006058106,"teacher_disagreement_score":0.21358483,"about_ca_system_score_codex":0.002189509,"about_ca_system_score_gemma":0.002078014,"threshold_uncertainty_score":0.9995837},"labels":[],"label_agreement":null},{"id":"W2560941332","doi":"10.1182/blood.v114.22.2634.2634","title":"Mutational Analysis of BCR-Abl From Subjects with Relapsed Ph+ALL Treated On the COG Protocol AALL0031: a Report From the Children's Oncology Group.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"","keywords":"Imatinib; Cohort; Medicine; Internal medicine; Imatinib mesylate; Acute lymphocytic leukemia; Oncology; Clinical endpoint; Surgery; Leukemia; Lymphoblastic Leukemia; Clinical trial; Myeloid leukemia","score_opus":0.015325575877178317,"score_gpt":0.28136079700191335,"score_spread":0.26603522112473504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560941332","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97175753,0.000041869396,0.000014125454,0.0016028371,0.000015184968,0.0232672,0.00014728468,0.000067051275,0.003086911],"genre_scores_gemma":[0.9874038,0.000004022475,0.0006713434,0.0011034772,0.00015199446,0.008641682,0.0017991081,0.000026051846,0.0001985407],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978394,0.0002202692,0.0005262787,0.0005309966,0.00061179255,0.00027126473],"domain_scores_gemma":[0.9975387,0.00077013794,0.00050430826,0.0009603088,0.00012590773,0.00010066153],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025145416,0.00028382716,0.00066254626,0.000118489224,0.00010101566,0.00001723752,0.00020967363,0.00016374624,0.0004704745],"category_scores_gemma":[0.00022951797,0.00014094274,0.00023217565,0.00073557225,0.00013024855,0.000040542385,0.00002423554,0.0003134312,0.000020040892],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0082485415,0.0155044105,0.89018744,0.000018250936,0.05760282,0.0052385232,0.0032458024,0.00022609404,0.010537564,0.00037020206,0.0035590848,0.0052612773],"study_design_scores_gemma":[0.019798946,0.0023846098,0.95654833,0.00011432156,0.01279526,0.00016931619,0.00007883581,0.00015066763,0.0070081404,0.00016126022,0.00062793616,0.00016238834],"about_ca_topic_score_codex":0.0032491714,"about_ca_topic_score_gemma":0.00073475856,"teacher_disagreement_score":0.06636089,"about_ca_system_score_codex":0.00029043425,"about_ca_system_score_gemma":0.0005071158,"threshold_uncertainty_score":0.5747478},"labels":[],"label_agreement":null},{"id":"W2561214156","doi":"10.1182/blood.v118.21.4437.4437","title":"A Canadian Expanded Access Trial of Oral Nilotinb in Adult Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Novartis (Canada); St. John’s Health Sciences Centre; Jewish General Hospital; McMaster University Medical Centre; Capital District Health Authority; Health Sciences Centre; Windsor Regional Hospital; Ottawa Hospital; London Health Sciences Centre; Brampton Civic Hospital; St. Paul's Hospital; Hôpital Maisonneuve-Rosemont; University of British Columbia; McGill University; McGill University Health Centre; University of Ottawa; Victoria Hospital; Hôpital de l'Enfant-Jésus","funders":"","keywords":"Nilotinib; Medicine; Discontinuation; Internal medicine; Adverse effect; Imatinib; Rash; Imatinib mesylate; Myeloid leukemia; Phases of clinical research; Cytopenia; Surgery; Gastroenterology; Clinical trial; Bone marrow","score_opus":0.0408920691426776,"score_gpt":0.3157582836705189,"score_spread":0.27486621452784127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2561214156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949194,0.00014595351,0.0000058121377,0.00005209788,0.00015201712,0.0038935181,0.00025434137,0.00006975567,0.000507081],"genre_scores_gemma":[0.9981163,0.00011211501,0.00040178158,0.00012343048,0.00012491175,0.0004927733,0.00037648715,0.000111688816,0.00014052211],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9956765,0.00016621359,0.0014223137,0.00086842786,0.0006603771,0.0012061574],"domain_scores_gemma":[0.99760705,0.000079573045,0.00049838074,0.0008535612,0.00033102033,0.00063041487],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00026626044,0.0006591293,0.0013425018,0.0008548761,0.00008870755,0.000050605417,0.00050631334,0.00029215173,0.0018323753],"category_scores_gemma":[0.00022267911,0.00045648636,0.0001288876,0.0014613961,0.00012805795,0.00041209272,0.00009491666,0.000571361,0.00002405203],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.8440988,0.05494283,0.043758217,0.0022522535,0.0023471408,0.008966001,0.008028385,0.00006563526,0.0069419397,0.000034843077,0.0011318024,0.027432129],"study_design_scores_gemma":[0.9217945,0.026162017,0.01295455,0.0014901835,0.0007108913,0.000060485287,0.00033209246,0.00078689645,0.03488492,0.000006178693,0.00013734403,0.00067994697],"about_ca_topic_score_codex":0.26035544,"about_ca_topic_score_gemma":0.6953464,"teacher_disagreement_score":0.434991,"about_ca_system_score_codex":0.011970783,"about_ca_system_score_gemma":0.024750607,"threshold_uncertainty_score":0.9997887},"labels":[],"label_agreement":null},{"id":"W2561489460","doi":"10.1182/blood.v114.22.644.644","title":"Safety and Efficacy of Subcutaneous-Administered Omacetaxine Mepesuccinate in Imatinib-Resistant Chronic Myeloid Leukemia (CML) Patients Who Harbor the Bcr- Abl T315I Mutation–Results of An Ongoing Multicenter Phase 2/3 Study.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Imatinib; Imatinib mesylate; Dasatinib; Adverse effect; Gastroenterology; Myeloid leukemia","score_opus":0.010307821270581765,"score_gpt":0.28015971471022333,"score_spread":0.26985189343964155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2561489460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99601984,0.00051146984,0.0000040682125,0.00018771652,0.00005115497,0.002601196,0.0002004863,0.000040964267,0.00038312192],"genre_scores_gemma":[0.9988949,0.00009198495,0.00056994084,0.00006219747,0.00005916212,0.000024955354,0.00015159743,0.000042015014,0.00010326848],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9966094,0.0002488099,0.0014306267,0.0006256896,0.0006098574,0.00047560612],"domain_scores_gemma":[0.9974892,0.0003619658,0.00067452056,0.0010747123,0.00020496918,0.0001946055],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00051447784,0.00040805995,0.0008795108,0.00021685855,0.000110498804,0.000025795911,0.0003080328,0.00011638467,0.00003842968],"category_scores_gemma":[0.00057535357,0.00030228414,0.00011989336,0.0003687845,0.00013057109,0.000160257,0.00009373613,0.00029005873,0.000004292601],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22261156,0.16160479,0.06089028,0.0029205894,0.005145335,0.0072695115,0.05010684,0.0008978044,0.16790068,0.00013926582,0.0001533186,0.32036],"study_design_scores_gemma":[0.27430978,0.026460594,0.65789396,0.0009160322,0.0011503433,0.00009220728,0.0006332268,0.0029977567,0.035040144,0.0000104345,0.000104428,0.00039111153],"about_ca_topic_score_codex":0.00034759744,"about_ca_topic_score_gemma":0.00037492532,"teacher_disagreement_score":0.59700364,"about_ca_system_score_codex":0.00072713534,"about_ca_system_score_gemma":0.0005171249,"threshold_uncertainty_score":0.9999429},"labels":[],"label_agreement":null},{"id":"W2561629989","doi":"10.1182/blood.v112.11.3239.3239","title":"Safety and Efficacy of Subcutaneous (SC) Omacetaxine Mepesuccinate in Imatinib(IM)-Resistant Chronic Myeloid Leukemia (CML) Patients (pts) with the T315I Mutation – Results of An Ongoing Multicenter Phase II Study.","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Homoharringtonine; Imatinib; Internal medicine; Adverse effect; Dasatinib; Myeloid leukemia; Imatinib mesylate; Phases of clinical research; Gastroenterology; Clinical trial","score_opus":0.00963936395558686,"score_gpt":0.25648359686461075,"score_spread":0.24684423290902388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2561629989","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99686456,0.0003237437,0.0000042920265,0.0000887989,0.000030054678,0.0022841408,0.00011088762,0.00003769401,0.0002558556],"genre_scores_gemma":[0.9989293,0.00010109182,0.00053990004,0.000020412223,0.00004153781,0.000032036824,0.00017476126,0.000047987218,0.00011297121],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972949,0.00019874898,0.000943171,0.000544864,0.0006277678,0.00039055463],"domain_scores_gemma":[0.9979856,0.00024498024,0.0005706854,0.0008476871,0.00021130974,0.00013972931],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037292318,0.00034437017,0.0006886732,0.00019350214,0.00019745644,0.000008154847,0.00020933295,0.00009150658,0.000020885085],"category_scores_gemma":[0.00027915838,0.0002293178,0.00007142385,0.00038692795,0.00021699654,0.00014074973,0.00012011818,0.00026621646,0.000002416637],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31823075,0.15488973,0.105012484,0.0023270666,0.0056623956,0.013936796,0.12314855,0.0029489063,0.12712425,0.000032098993,0.00014453972,0.14654244],"study_design_scores_gemma":[0.4518016,0.062129743,0.43848786,0.0008782356,0.0013669325,0.000603765,0.0012562658,0.0025302623,0.040384043,0.0000026322155,0.00010008961,0.0004585753],"about_ca_topic_score_codex":0.0010091447,"about_ca_topic_score_gemma":0.0013873765,"teacher_disagreement_score":0.33347538,"about_ca_system_score_codex":0.0007577349,"about_ca_system_score_gemma":0.0005285939,"threshold_uncertainty_score":0.93513083},"labels":[],"label_agreement":null},{"id":"W2561643684","doi":"10.1182/blood.v108.11.2240.2240","title":"Molecular and Pharmacologic Suppression of MAPK Activity Rescues Differentiation of BCR/ABL+ Myeloid Progenitors by Releasing C/EBPa from the Inhibitory Effect of hnRNP E2.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"K562 cells; ABL; breakpoint cluster region; Progenitor cell; Chronic myelogenous leukemia; Myeloid; Biology; Molecular biology; Cancer research; Myeloid leukemia; Leukemia; Stem cell; Cell biology; Immunology; Receptor; Signal transduction; Tyrosine kinase; Genetics","score_opus":0.005215759300502526,"score_gpt":0.23902528953109806,"score_spread":0.23380953023059553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2561643684","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99580204,0.00318195,0.000013068112,0.00004738938,0.00007852967,0.00068935094,0.00007157709,0.000022414326,0.00009367331],"genre_scores_gemma":[0.9995463,0.00010610728,0.00010451458,0.0000063725565,0.00008286395,0.000024671837,0.000089496454,0.000019602576,0.00002008216],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99871385,0.00027526374,0.0002971821,0.00024078811,0.00031752212,0.00015540174],"domain_scores_gemma":[0.999028,0.00031313355,0.00030354442,0.0002601362,0.000053940705,0.00004123858],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013005034,0.0001740973,0.00041466538,0.000048690494,0.00004131507,0.0000044633416,0.00007544698,0.00012216772,0.000019800416],"category_scores_gemma":[0.00008676089,0.0001126931,0.000101156504,0.00010595808,0.00012832951,0.00005782011,0.00006782495,0.00014534462,5.7318016e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004178663,0.00063442846,0.11405302,0.00023224358,0.00021019687,0.000008096442,0.00009272294,0.0000028384386,0.88215554,0.0000014444455,0.00024365167,0.0019479662],"study_design_scores_gemma":[0.0068793935,0.00049736793,0.12254794,0.00026175848,0.00094234414,0.000005078122,0.000017143304,0.00005710324,0.8686833,0.000019467032,0.000021962167,0.000067182475],"about_ca_topic_score_codex":0.0007301566,"about_ca_topic_score_gemma":0.000005332799,"teacher_disagreement_score":0.0134722665,"about_ca_system_score_codex":0.00007551993,"about_ca_system_score_gemma":0.000066307926,"threshold_uncertainty_score":0.45954913},"labels":[],"label_agreement":null},{"id":"W2561803583","doi":"10.1182/blood.v126.23.1358.1358","title":"Broad Activity of Apto-253 in AML and Other Hematologic Malignancies Correlates with KLF4 Expression Level","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Aptose Biosciences (Canada)","funders":"","keywords":"KLF4; Medicine; Cancer research; Myeloid leukemia; Leukemia; Myeloid; In vivo; Transcription factor; Biology; Internal medicine; Gene; Biochemistry; Genetics; SOX2","score_opus":0.044699027983813346,"score_gpt":0.26992499622529653,"score_spread":0.2252259682414832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2561803583","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975939,0.00076102593,0.000028619364,0.000053017066,0.00002030515,0.00027335243,0.000010295167,0.000026950715,0.0012325767],"genre_scores_gemma":[0.9982108,0.000019021452,0.0013243936,0.000033694956,0.000013405303,0.000020051808,0.000002877617,0.000015408976,0.00036033848],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999299,0.000032429092,0.00013284244,0.0001972833,0.00017533629,0.00016311674],"domain_scores_gemma":[0.9995186,0.00005695401,0.000089823174,0.0002128901,0.00003436315,0.00008739656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009197001,0.00012939602,0.0003144311,0.000059683833,0.000013757718,0.0000041504036,0.000041661493,0.00009147277,0.00002420113],"category_scores_gemma":[0.000069522044,0.000085089254,0.000020608637,0.00009467991,0.000088479486,0.000056904904,0.000041225463,0.00010075904,0.000007909745],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004813251,0.0011706912,0.9229612,0.00015442952,0.00008162767,0.00018509496,0.00091848866,0.0000041998755,0.07304339,0.00004985433,0.0001900608,0.00075967936],"study_design_scores_gemma":[0.030039437,0.001080029,0.2764168,0.0012602342,0.00024098696,0.000781851,0.0005291722,0.00008001646,0.6889605,0.00017961088,0.00020092403,0.00023043329],"about_ca_topic_score_codex":0.00030273272,"about_ca_topic_score_gemma":0.00007422716,"teacher_disagreement_score":0.64654434,"about_ca_system_score_codex":0.00007425913,"about_ca_system_score_gemma":0.00016181677,"threshold_uncertainty_score":0.3469839},"labels":[],"label_agreement":null},{"id":"W2562057618","doi":"10.1182/blood.v104.11.3496.3496","title":"Generation and Verification of a Three-Dimensional Model of the ALK Kinase Domain: ALK - a “Supermutant” of Abl.","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Anaplastic lymphoma kinase; ABL; Protein kinase domain; Tyrosine kinase; Cancer research; Biology; Imatinib mesylate; Chemistry; Molecular biology; Imatinib; Biochemistry; Medicine; Receptor; Internal medicine","score_opus":0.0291674528069216,"score_gpt":0.24343910952395972,"score_spread":0.21427165671703813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2562057618","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984981,0.00054306217,0.0002011217,0.00021829102,0.000022893157,0.000298708,0.000039115133,0.0000063885404,0.000172355],"genre_scores_gemma":[0.99469364,0.000025851079,0.0051526735,0.000039598937,0.000029836314,0.000010611188,0.000023856484,0.000009945503,0.000013981958],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992604,0.000013982494,0.00025049562,0.00014270039,0.00025078666,0.000081607475],"domain_scores_gemma":[0.99942213,0.000017514758,0.00012547919,0.0003115764,0.00008875929,0.000034547535],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000080874735,0.00008414224,0.0001935536,0.000037890408,0.000026437232,0.0000014003035,0.000046673442,0.00006086544,0.000011165036],"category_scores_gemma":[0.000037470243,0.00005910626,0.000055652003,0.00009895458,0.0000996442,0.00003621257,0.000027372767,0.00005101007,7.2585897e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000080484366,0.00081892684,0.002817368,0.00009151736,0.00011608212,0.0000036986387,0.00048112503,0.0023197297,0.991196,0.0015968784,0.000015983236,0.00046223943],"study_design_scores_gemma":[0.01367194,0.00025966775,0.01859613,0.00020564366,0.0004633271,0.00007053042,0.000031968335,0.011227019,0.9538273,0.0015521657,0.000012315447,0.0000819905],"about_ca_topic_score_codex":0.00014421795,"about_ca_topic_score_gemma":0.00006149919,"teacher_disagreement_score":0.037368663,"about_ca_system_score_codex":0.00007050835,"about_ca_system_score_gemma":0.0003611705,"threshold_uncertainty_score":0.24102834},"labels":[],"label_agreement":null},{"id":"W2562742960","doi":"10.1016/s1525-0016(16)33761-3","title":"156. Cationic Lipopolymers for BCR-ABL siRNA Delivery and Growth Arrest in Chronic Myeloid Leukemia Tumors","year":2015,"lang":"en","type":"article","venue":"Molecular Therapy","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency; University of Alberta","funders":"","keywords":"Myeloid leukemia; K562 cells; Chemistry; Cancer research; Gene silencing; Lipofectamine; Oncogene; Molecular biology; Biology; Biochemistry; Cell; Cell cycle; Vector (molecular biology)","score_opus":0.02068729028567529,"score_gpt":0.26879484878004956,"score_spread":0.24810755849437427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2562742960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98060054,0.016301833,0.00043290804,0.0006536113,0.00015533167,0.0011862147,0.000009674486,0.0000716174,0.0005882721],"genre_scores_gemma":[0.9960518,0.0012338697,0.0008404309,0.00088195485,0.00016589544,0.00016865575,0.000117555835,0.00008268378,0.0004571561],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983036,0.00006896303,0.00033361357,0.00049564126,0.00031276667,0.00048544645],"domain_scores_gemma":[0.998993,0.00006148876,0.00010464174,0.000437619,0.00011831672,0.0002849726],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023802719,0.00030573132,0.00041091975,0.0001957177,0.00006260835,0.00003207682,0.00014131427,0.00014722816,0.000030414241],"category_scores_gemma":[0.00007408691,0.00028530817,0.00011430341,0.0002745417,0.000121654535,0.00010593663,0.000035897167,0.00020080816,0.00003212063],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0062585287,0.0012051361,0.048171725,0.00087181624,0.0021052465,0.0021182536,0.0065574953,0.0010910679,0.6607458,0.0041724094,0.0044739926,0.26222852],"study_design_scores_gemma":[0.11906873,0.006878055,0.045313634,0.001042454,0.00043509604,0.0005641485,0.000783635,0.011181253,0.78753513,0.0062536458,0.01877856,0.0021656558],"about_ca_topic_score_codex":0.0011979496,"about_ca_topic_score_gemma":0.00012850715,"teacher_disagreement_score":0.26006287,"about_ca_system_score_codex":0.0041968017,"about_ca_system_score_gemma":0.002371781,"threshold_uncertainty_score":0.9999599},"labels":[],"label_agreement":null},{"id":"W2562770396","doi":"10.1182/blood.v118.21.2736.2736","title":"Targeting Rac2 - Mitochondrial Respiratory Chain Complex III Signaling to Prevent Genomic Instability in Leukemia Stem and Progenitor Cells","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"CD38; Leukemia; Biology; Cancer research; Myeloid leukemia; Stem cell; Progenitor cell; CD34; Molecular biology; Immunology; Cell biology","score_opus":0.03771426220807529,"score_gpt":0.254789813261864,"score_spread":0.21707555105378873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2562770396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99663484,0.0005633617,0.000026627335,0.00001743723,0.00018230491,0.0021803938,0.00001646632,0.00007139159,0.00030720397],"genre_scores_gemma":[0.9929176,0.000008047042,0.0062178914,0.00015548004,0.00037534756,0.0001676385,0.000011687504,0.00004594492,0.00010033679],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99794835,0.00015607446,0.00060011505,0.0005958017,0.00024475428,0.00045489593],"domain_scores_gemma":[0.99905074,0.00007256246,0.00013423468,0.00040566095,0.000052789397,0.00028399285],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004019158,0.00026762552,0.00047538878,0.00014038342,0.00007901514,0.00001565551,0.00012914995,0.00013882185,0.00012541129],"category_scores_gemma":[0.000055683216,0.00025438663,0.00007510949,0.0001711294,0.00006141666,0.00006645122,0.00015403038,0.00025017318,0.00003588854],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005812307,0.0011700072,0.038341366,0.00022470787,0.0001500512,0.00018136077,0.0057190666,0.000022104048,0.9519151,0.000010648669,0.000119427285,0.0015649358],"study_design_scores_gemma":[0.02938904,0.0014142347,0.06278256,0.00039961055,0.0004447683,0.00005226721,0.0012874327,0.00024045829,0.9012412,0.000036352798,0.0020455911,0.00066647853],"about_ca_topic_score_codex":0.0003379319,"about_ca_topic_score_gemma":0.0000659312,"teacher_disagreement_score":0.05067389,"about_ca_system_score_codex":0.0011495389,"about_ca_system_score_gemma":0.00064241665,"threshold_uncertainty_score":0.9999908},"labels":[],"label_agreement":null},{"id":"W2563054377","doi":"10.1182/blood.v120.21.3739.3739","title":"Sabutoclax, a Novel Pan BCL2 Family Inhibitor, Sensitizes Dormant Blast Crisis Chronic Myeloid Leukemia Stem Cells to Dasatinib","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre","funders":"","keywords":"Dasatinib; Myeloid leukemia; Cancer research; Stem cell; Population; Biology; Haematopoiesis; Immunology; Myeloid; Medicine; Imatinib; Cell biology","score_opus":0.019584618279888277,"score_gpt":0.25045505481255137,"score_spread":0.2308704365326631,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2563054377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923788,0.0016894814,0.000141269,0.00031287273,0.00073726056,0.001462818,0.00012586036,0.00034547568,0.0028061734],"genre_scores_gemma":[0.9914358,0.00015751399,0.0025730955,0.0013505765,0.002249638,0.00014918469,0.00007027443,0.00015140958,0.0018625017],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.996216,0.00007225648,0.0007483554,0.00074376824,0.0008163381,0.0014032996],"domain_scores_gemma":[0.9974481,0.00014208526,0.00021070559,0.0011355937,0.00015094402,0.00091260305],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00036820344,0.00064898556,0.00085734896,0.00025729422,0.0001840864,0.000059419748,0.00022828314,0.0003186034,0.00013774143],"category_scores_gemma":[0.000032977838,0.0005747839,0.00028156894,0.0004904288,0.000084491614,0.00024794106,0.00027292734,0.00049485656,0.0019474636],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026991992,0.0020119601,0.005560158,0.0004288642,0.00096813426,0.00020514095,0.0030681563,0.000039848917,0.95994246,0.00007136676,0.018441442,0.008992532],"study_design_scores_gemma":[0.027408013,0.0017209195,0.03674812,0.0007500348,0.0017383642,0.0007958364,0.0019718679,0.00015342489,0.8846676,0.000004365729,0.042898364,0.0011431149],"about_ca_topic_score_codex":0.0005034538,"about_ca_topic_score_gemma":0.000070572874,"teacher_disagreement_score":0.0752749,"about_ca_system_score_codex":0.0034460605,"about_ca_system_score_gemma":0.0014021293,"threshold_uncertainty_score":0.9996704},"labels":[],"label_agreement":null},{"id":"W2563324741","doi":"10.1182/blood.v124.21.402.402","title":"Integrin-Linked Kinase As a Key Mediator of Stromal Cell-Enhanced Resistance of Primitive CML Cells to Tyrosine Kinase Inhibitors","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Stem cell; Integrin-linked kinase; Cancer research; CD34; Imatinib mesylate; Biology; Progenitor cell; Tyrosine kinase; CD38; Cell biology; Side population; Protein kinase B; Myeloid leukemia; Imatinib; Kinase; Signal transduction; Cancer stem cell; Protein kinase A; Cyclin-dependent kinase 2","score_opus":0.007134724326067442,"score_gpt":0.2358817679389637,"score_spread":0.22874704361289627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2563324741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99184054,0.00038883576,0.000119048236,0.00017194051,0.00022333543,0.00088654965,0.00007798869,0.000056949557,0.006234838],"genre_scores_gemma":[0.99198157,0.000042453867,0.0058176247,0.000118162025,0.00024330273,0.00006304005,0.000041386033,0.000055605506,0.001636856],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99772596,0.0000951097,0.00067441136,0.00050867326,0.00058381347,0.00041202304],"domain_scores_gemma":[0.99801,0.00022349476,0.0003628018,0.00072520174,0.00031026654,0.00036823115],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023766464,0.00032536272,0.00075734424,0.00019120383,0.000036205773,0.000007214833,0.00019678392,0.00017515721,0.00014062572],"category_scores_gemma":[0.0005122903,0.00028962985,0.00017970035,0.00037299294,0.00014006042,0.000061404746,0.00011019169,0.000248479,0.00009123997],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00081760826,0.0019482858,0.0012352412,0.0004943087,0.00014868629,0.00006864571,0.0012562254,0.0000056106524,0.99262106,0.00015969454,0.0006865017,0.000558103],"study_design_scores_gemma":[0.012480804,0.0017169913,0.0046538427,0.0007869824,0.00045077514,0.000005245224,0.00025147301,0.000009977094,0.97861445,0.00003338168,0.000784423,0.00021162894],"about_ca_topic_score_codex":0.00014984146,"about_ca_topic_score_gemma":0.00007613178,"teacher_disagreement_score":0.014006613,"about_ca_system_score_codex":0.00027242085,"about_ca_system_score_gemma":0.0005098787,"threshold_uncertainty_score":0.9999556},"labels":[],"label_agreement":null},{"id":"W2563459892","doi":"10.1182/blood.v126.23.5164.5164","title":"Compliance with Guidelines for Management of Chronic Myeloid Leukemia in Saskatchewan, Canada","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Saskatchewan; Royal University Hospital","funders":"","keywords":"Medicine; Myeloid leukemia; Clinical trial; Intensive care medicine; Oncology; Internal medicine","score_opus":0.06068286338946651,"score_gpt":0.30555610565897284,"score_spread":0.24487324226950632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2563459892","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99291086,0.0023154253,0.00023653111,0.0005899655,0.00010452531,0.0012211716,0.000038347378,0.000030527575,0.0025526222],"genre_scores_gemma":[0.97552335,0.000047242876,0.01992705,0.0002736993,0.0001321083,0.00016223996,0.00006788848,0.000036642563,0.0038297724],"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99868715,0.00001050442,0.00037008425,0.0002741624,0.00034973555,0.00030835794],"domain_scores_gemma":[0.99903977,0.000026713758,0.00011337753,0.0003949552,0.0002794487,0.0001457321],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013897325,0.00017513867,0.00036632887,0.000047155856,0.000016997785,0.0000037328937,0.000119790966,0.000045029257,0.000014828908],"category_scores_gemma":[0.000023976801,0.00014024843,0.00003569773,0.00018959484,0.000038795504,0.000033183274,0.000038864127,0.00007593623,0.0000033178521],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008373187,0.007410505,0.32571986,0.027009325,0.012114735,0.008956829,0.003972976,0.017279577,0.008470479,0.0014997567,0.3298351,0.24935769],"study_design_scores_gemma":[0.469855,0.0104998555,0.14554185,0.017909404,0.0055683698,0.0013381706,0.026287606,0.013407854,0.13252462,0.00054313964,0.17372645,0.0027976616],"about_ca_topic_score_codex":0.20927884,"about_ca_topic_score_gemma":0.73617184,"teacher_disagreement_score":0.526893,"about_ca_system_score_codex":0.003648855,"about_ca_system_score_gemma":0.007173971,"threshold_uncertainty_score":0.99845445},"labels":[],"label_agreement":null},{"id":"W2563961854","doi":"10.1182/blood.v120.21.694.694","title":"Switching to Nilotinib Is Associated with Continued Deeper Molecular Responses in CML-CP Patients with Minimal Residual Disease After ≥ 2 Years On Imatinib: Enestcmr 2-Year Follow-up Results","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Nilotinib; Imatinib; Medicine; Internal medicine; Imatinib mesylate; Myeloid leukemia; Population; Minimal residual disease; Oncology; Gastroenterology; Leukemia","score_opus":0.00883477986199611,"score_gpt":0.23853790824656565,"score_spread":0.22970312838456955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2563961854","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977198,0.00009772247,0.000002432887,0.0002685608,0.00007161308,0.0011533474,0.00025489126,0.00008594933,0.00034567752],"genre_scores_gemma":[0.99648345,0.0000022066095,0.0013801723,0.00088467234,0.000084166146,0.00016889597,0.00018329074,0.000109203276,0.00070392765],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972059,0.00019848853,0.00044026432,0.000565476,0.0008460074,0.0007438654],"domain_scores_gemma":[0.99828833,0.00022789167,0.00017596949,0.00062399893,0.00013392637,0.0005498866],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00033727154,0.00037683386,0.0004928796,0.0002458833,0.000050304276,0.000033564098,0.0001228734,0.00012587504,0.00005491035],"category_scores_gemma":[0.0010702556,0.00029606675,0.000082200386,0.00037148563,0.000041985455,0.00014513107,0.00006782388,0.00027256782,0.00010158173],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0426879,0.0027044355,0.94874364,0.000030504,0.00037609367,0.000987938,0.0033092652,0.0000031974475,0.0005156002,0.000007046916,0.00036005312,0.0002743348],"study_design_scores_gemma":[0.053798232,0.0017701058,0.93928796,0.0009625452,0.000578116,0.000007302183,0.000113651426,0.0000017053127,0.0029206907,0.0000036427157,0.00020957574,0.0003464444],"about_ca_topic_score_codex":0.000092492126,"about_ca_topic_score_gemma":0.00009447068,"teacher_disagreement_score":0.01111033,"about_ca_system_score_codex":0.00036418534,"about_ca_system_score_gemma":0.0003423805,"threshold_uncertainty_score":0.99994916},"labels":[],"label_agreement":null},{"id":"W2564282668","doi":"10.1182/blood.v116.21.1222.1222","title":"The BCR-ABL1-Regulated hnRNP A1, hnRNP E2, and hnRNP K Are Differentially Expressed Between CD34+ and CD34+/CD38- Ph+ Cells, and After Blastic Transformation of CML.","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"CD38; Chronic myelogenous leukemia; Biology; Molecular biology; Myeloid; Leukemia; breakpoint cluster region; K562 cells; Myeloid leukemia; Progenitor cell; CD34; Cancer research; Stem cell; Immunology; Cell biology; Genetics; Receptor","score_opus":0.006312495415965988,"score_gpt":0.2107061530749103,"score_spread":0.20439365765894432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2564282668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99715513,0.0010023421,0.000057820238,0.000410055,0.00012902716,0.00083222776,0.00015370574,0.00006084111,0.0001988264],"genre_scores_gemma":[0.9986375,0.00047993436,0.00021820297,0.000036690148,0.00017115212,0.000055596465,0.000074915864,0.00004623284,0.0002797583],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99826264,0.000066346736,0.00050191977,0.00041131314,0.00036359162,0.00039418906],"domain_scores_gemma":[0.9987309,0.00025192826,0.00020355775,0.0004599338,0.000102494814,0.00025118864],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016627082,0.00035278936,0.0005429525,0.000106960004,0.00017264753,0.0000735464,0.000111784226,0.00025754073,0.0000679486],"category_scores_gemma":[0.00006045398,0.00024732773,0.000076902004,0.00012516206,0.00031729482,0.00016080814,0.00007571105,0.0003569435,0.000006508977],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014800044,0.0016397136,0.21270862,0.0023162933,0.0022191165,0.00013573507,0.0065268488,0.000002745583,0.7376397,0.00012757801,0.00043982905,0.034763806],"study_design_scores_gemma":[0.023363601,0.0006625667,0.7526114,0.00053245533,0.0026678836,0.00010353368,0.0003260196,0.00037292027,0.2168197,0.00030277763,0.0017845326,0.0004526098],"about_ca_topic_score_codex":0.000073399766,"about_ca_topic_score_gemma":0.00017020965,"teacher_disagreement_score":0.53990275,"about_ca_system_score_codex":0.00003665309,"about_ca_system_score_gemma":0.00010213481,"threshold_uncertainty_score":0.9999979},"labels":[],"label_agreement":null},{"id":"W2564377031","doi":"10.1182/blood.v110.11.5178.5178","title":"Medical Costs of Adverse Events in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors: Canadian Perspective.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Novartis (Canada)","funders":"","keywords":"Nilotinib; Dasatinib; Medicine; Imatinib; Myeloid leukemia; Internal medicine; Adverse effect; Context (archaeology); Chronic myelogenous leukemia; Imatinib mesylate; Oncology; Leukemia","score_opus":0.006123493295899442,"score_gpt":0.23869893077015675,"score_spread":0.2325754374742573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2564377031","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950815,0.0004462048,0.0000027538917,0.000108513705,0.00006568501,0.0009022974,0.000036607555,0.00004424629,0.0033121842],"genre_scores_gemma":[0.9991414,0.000053914846,0.00010591855,0.00010824194,0.00016489258,0.000024814564,0.0001680932,0.000056436988,0.00017630651],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99737465,0.000050714723,0.0005225503,0.00048613286,0.0008319928,0.0007339401],"domain_scores_gemma":[0.99823046,0.00007177451,0.00015340482,0.00044090184,0.00026390696,0.0008395531],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00030058774,0.00032723037,0.0005102283,0.00052345387,0.000054116783,0.0000015454099,0.00015499123,0.00028179117,0.0002854657],"category_scores_gemma":[0.00025783925,0.00027215978,0.000093070965,0.00072770746,0.00014704294,0.00009839961,0.00004182902,0.00038075921,0.000045199453],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00048384344,0.001364839,0.99369663,0.000068565445,0.00025877715,0.0013988748,0.0003610025,0.000006857819,0.00087945163,0.00007108913,0.000075652715,0.0013344458],"study_design_scores_gemma":[0.048443917,0.0019238783,0.9226435,0.0015305524,0.00033407385,0.00012113217,0.00033403633,0.000045797256,0.024120726,0.0000067525607,0.00018398855,0.00031164198],"about_ca_topic_score_codex":0.25468963,"about_ca_topic_score_gemma":0.38969514,"teacher_disagreement_score":0.13500549,"about_ca_system_score_codex":0.018332817,"about_ca_system_score_gemma":0.0063687167,"threshold_uncertainty_score":0.99997306},"labels":[],"label_agreement":null},{"id":"W2564514339","doi":"10.1182/blood.v110.11.1093.1093","title":"Stem Cell Transplantation (SCT) Improves Survival in Acute Biphenotypic (ABL) and Acute Undifferentiated Leukemia (AUL): A Single Centre Experience.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Imatinib mesylate; Internal medicine; Transplantation; Gastroenterology; Population; Surgery; Vincristine; Chemotherapy regimen; Autologous stem-cell transplantation; Chemotherapy; Oncology; Imatinib; Myeloid leukemia; Cyclophosphamide","score_opus":0.011427683246522572,"score_gpt":0.24009789355894848,"score_spread":0.2286702103124259,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2564514339","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99754834,0.00046997925,0.00017105858,0.000042339252,0.00018170069,0.00058906054,0.000035737467,0.00010601529,0.00085576886],"genre_scores_gemma":[0.9977111,0.0003091473,0.0006365485,0.000049544742,0.00006424081,0.000015211102,0.0001725373,0.000043553704,0.0009980949],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981628,0.00004516892,0.00042608794,0.00049234944,0.000313296,0.0005602985],"domain_scores_gemma":[0.99924815,0.00008523824,0.00011581956,0.0002885998,0.00004262861,0.00021955147],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001263503,0.0003025336,0.00041355938,0.00019236616,0.00007102337,0.00003328696,0.000097589,0.00019001265,0.000053885335],"category_scores_gemma":[0.000003929088,0.0002678007,0.00007240216,0.0003134075,0.000076123964,0.00014367948,0.00003236284,0.00021921631,0.000019883975],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015305098,0.0019300652,0.2025569,0.00038885354,0.000742024,0.0025895392,0.014133924,0.000002555414,0.7643399,0.00005387374,0.000023983805,0.011707881],"study_design_scores_gemma":[0.031930104,0.00068935356,0.41618288,0.000258399,0.0018080759,0.00027293724,0.0020369533,0.00013526362,0.54611796,0.000033406457,0.00008084763,0.00045379827],"about_ca_topic_score_codex":0.00027031646,"about_ca_topic_score_gemma":0.00047432055,"teacher_disagreement_score":0.21822192,"about_ca_system_score_codex":0.0006003499,"about_ca_system_score_gemma":0.00020576578,"threshold_uncertainty_score":0.9999774},"labels":[],"label_agreement":null},{"id":"W2564696975","doi":"10.1182/blood.v110.11.4550.4550","title":"Should the Initial Starting Dose of Imatinib for Treatment of Some Patients with Chronic Myelocytic Leukemia (CML) Be Lower Than 400 mg Daily?.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; St. Boniface Hospital","funders":"","keywords":"Medicine; Imatinib mesylate; Imatinib; Fusion gene; Gastroenterology; Internal medicine; Bone marrow; breakpoint cluster region; ABL; Philadelphia chromosome; Chromosomal translocation; Myeloid leukemia; Biology","score_opus":0.033644825586234356,"score_gpt":0.3011877963220362,"score_spread":0.2675429707358018,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2564696975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99616045,0.00064396963,0.00005064241,0.0001165615,0.00012590818,0.0020544073,0.00013075717,0.00004198757,0.0006752972],"genre_scores_gemma":[0.9979748,0.000038568756,0.0010585195,0.0001065775,0.00029694836,0.00011119712,0.00015398278,0.000066777146,0.00019262133],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99778795,0.000033340773,0.0006980861,0.00036480257,0.00055034406,0.0005654906],"domain_scores_gemma":[0.9981774,0.00035638185,0.00044020242,0.0006911503,0.00019023259,0.0001446188],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002482972,0.00034279496,0.0006436102,0.000110927416,0.00010131195,0.000009416178,0.00015064434,0.00013632835,0.00005926173],"category_scores_gemma":[0.00007627754,0.00020576992,0.00021898776,0.0002000475,0.00020433907,0.00010599116,0.000041287127,0.00008741941,0.0000050956974],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036160056,0.044683635,0.6575402,0.00490111,0.015844183,0.0006583225,0.020161916,0.00044192694,0.046361566,0.0022452679,0.00087101036,0.17013083],"study_design_scores_gemma":[0.24574164,0.041948058,0.27752247,0.0013529722,0.0067617865,0.00006535145,0.0008120597,0.000650071,0.42184004,0.000231926,0.0021823838,0.0008912451],"about_ca_topic_score_codex":0.00033004314,"about_ca_topic_score_gemma":0.00025058584,"teacher_disagreement_score":0.3800177,"about_ca_system_score_codex":0.0016357284,"about_ca_system_score_gemma":0.001238603,"threshold_uncertainty_score":0.83910537},"labels":[],"label_agreement":null},{"id":"W2564745782","doi":"10.1182/blood.v108.11.752.752","title":"Chronic Myeloid Leukemia Stem Cells Possess Unique Properties That Predict Intrinsic and Acquired Resistance to Imatinib Mesylate.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Imatinib mesylate; Myeloid leukemia; Tyrosine kinase; Cancer research; CD38; Stem cell; Biology; Haematopoiesis; Side population; clone (Java method); Population; Imatinib; Leukemia; Myeloid; CD34; Chemistry; Cell biology; Immunology; Cancer stem cell; Medicine; Signal transduction; Genetics; Gene","score_opus":0.015010967907248644,"score_gpt":0.22290690074657749,"score_spread":0.20789593283932883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2564745782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98673666,0.0077342177,0.00003262387,0.0005988674,0.000116859446,0.0015727738,0.00003320245,0.00028657756,0.0028882306],"genre_scores_gemma":[0.9865415,0.00032207288,0.001055398,0.00019216162,0.00035105317,0.00018777941,0.000032039927,0.00008467313,0.011233337],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99770355,0.00008249662,0.00046643006,0.0006656011,0.00046328575,0.00061864866],"domain_scores_gemma":[0.9986896,0.0000658563,0.0001552081,0.00072171865,0.0001088574,0.0002587851],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019447441,0.0004170864,0.00058989425,0.00015253901,0.00014843288,0.00007640786,0.00019205036,0.0001912409,0.000055675308],"category_scores_gemma":[0.00001816016,0.00033907208,0.000090974936,0.0002887294,0.00014989162,0.00017735323,0.00014176288,0.0001820781,0.00007952146],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023361365,0.0019867471,0.06681726,0.005940311,0.0017881835,0.0021936314,0.002961449,0.00017483262,0.8610177,0.0011631456,0.01899682,0.034623787],"study_design_scores_gemma":[0.014135708,0.0008077936,0.04361545,0.0015343876,0.0006379805,0.00024175592,0.0001679933,0.00007213418,0.92707264,0.00009624513,0.011044973,0.00057295774],"about_ca_topic_score_codex":0.0003181869,"about_ca_topic_score_gemma":0.00036041945,"teacher_disagreement_score":0.066054925,"about_ca_system_score_codex":0.0016438665,"about_ca_system_score_gemma":0.0011402249,"threshold_uncertainty_score":0.9999061},"labels":[],"label_agreement":null},{"id":"W2565035265","doi":"10.1182/blood.v120.21.2445.2445","title":"Next-Generation STAT3 Inhibitors As Targeted Therapeutics in Chronic Myeloid Leukemia.","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Imatinib; Myeloid leukemia; Cancer research; STAT3; Tyrosine-kinase inhibitor; K562 cells; Imatinib mesylate; Medicine; Leukemia; Pharmacology; Biology; Immunology; Signal transduction; Internal medicine; Cancer; Cell biology","score_opus":0.03915596805188665,"score_gpt":0.2826460204642045,"score_spread":0.24349005241231786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2565035265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98788023,0.009007346,0.000013818414,0.00024953313,0.00034244035,0.00059854385,0.0000067646683,0.00010608723,0.0017952342],"genre_scores_gemma":[0.9957281,0.0006503862,0.00044930275,0.0004800803,0.0014872364,0.00007308329,0.0002010467,0.00006012722,0.0008706868],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982399,0.00007273643,0.00038826824,0.00029802174,0.00036056014,0.0006405364],"domain_scores_gemma":[0.9991785,0.000044056273,0.00010188663,0.00042108807,0.000039811497,0.00021465322],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002208197,0.00026661126,0.00033218093,0.00016761711,0.000066983375,0.000025916594,0.00008582976,0.00020526032,0.0003208513],"category_scores_gemma":[0.00004100804,0.00023853396,0.00009175466,0.0003288653,0.000052014508,0.00028893992,0.000043663676,0.00031595025,0.00040541365],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013412417,0.002143532,0.1233013,0.00017556804,0.0006470544,0.00015535612,0.0027350064,0.00011566791,0.847716,0.0003598838,0.0011755103,0.021341035],"study_design_scores_gemma":[0.028477322,0.0012104533,0.06250282,0.00023537276,0.00090691884,0.00032651296,0.00030184744,0.0015805595,0.8717948,0.00008109154,0.031884324,0.0006979502],"about_ca_topic_score_codex":0.0003633111,"about_ca_topic_score_gemma":0.00014229114,"teacher_disagreement_score":0.06079848,"about_ca_system_score_codex":0.0033118988,"about_ca_system_score_gemma":0.0014718309,"threshold_uncertainty_score":0.97271323},"labels":[],"label_agreement":null},{"id":"W2565606062","doi":"10.1182/blood.v110.11.734.734","title":"Efficacy of Dasatinib in Patients with Chronic-Phase Chronic Myelogenous Leukemia with Resistance or Intolerance to Imatinib: 2-Year Follow-Up Data from START-C (CA180-013).","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Dasatinib; Imatinib; Medicine; Chronic myelogenous leukemia; Internal medicine; Imatinib mesylate; Gastroenterology; Pharmacology; Oncology; Leukemia; Myeloid leukemia","score_opus":0.022522741568587655,"score_gpt":0.2861795180592287,"score_spread":0.26365677649064106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2565606062","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947235,0.00083641795,0.0003494746,0.0000611683,0.00010250881,0.002490553,0.0007335734,0.00009859472,0.0006042034],"genre_scores_gemma":[0.982512,0.000041857442,0.014848558,0.00010862519,0.00025638836,0.000059605503,0.0015655055,0.00013186302,0.0004756289],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958892,0.00006961584,0.0009551084,0.0011820707,0.0009847541,0.0009192413],"domain_scores_gemma":[0.99597055,0.00033862953,0.00042873886,0.0026497967,0.00022286945,0.00038940302],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00039133622,0.00055153295,0.001020206,0.00023736368,0.00009469888,0.000026104959,0.0006967142,0.00018425648,0.00032420352],"category_scores_gemma":[0.000284034,0.00040374472,0.0000622514,0.0009078472,0.00018359306,0.00023522628,0.00023696496,0.00043675373,0.000079692996],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18273136,0.020456836,0.7156959,0.0022586412,0.0045132507,0.0031392346,0.0073748217,0.0003466561,0.011864766,0.00008488676,0.0035015654,0.048032083],"study_design_scores_gemma":[0.35582748,0.012504582,0.60122305,0.0042041102,0.0012003379,0.000023764507,0.00019859846,0.00012008327,0.0197594,0.000009761922,0.003947354,0.0009814915],"about_ca_topic_score_codex":0.0011545612,"about_ca_topic_score_gemma":0.024678828,"teacher_disagreement_score":0.17309614,"about_ca_system_score_codex":0.0026586067,"about_ca_system_score_gemma":0.0034989128,"threshold_uncertainty_score":0.99984145},"labels":[],"label_agreement":null},{"id":"W2566359172","doi":"10.1182/blood.v126.23.52.52","title":"A New AHI-1-DNM2-BCR-ABL Complex Regulates Leukemic Properties of Primitive CML Cells through Mediation of Cellular Endocytosis and ROS-Induced Autophagy","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Cancer research; Stem cell; CD38; Tyrosine kinase; Biology; Cell biology; Signal transducing adaptor protein; CD34; Endocytosis; Imatinib mesylate; Bosutinib; Chemistry; Molecular biology; Imatinib; Signal transduction; Myeloid leukemia; Nilotinib; Cell; Biochemistry","score_opus":0.056452530433944714,"score_gpt":0.25597004461634304,"score_spread":0.19951751418239833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2566359172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950463,0.002850222,0.000049151742,0.00010914603,0.00009183567,0.0007801915,0.000021620985,0.00005888402,0.0009926594],"genre_scores_gemma":[0.9951581,0.00015631087,0.0038884468,0.00004598223,0.00013895638,0.000022774399,0.000050579245,0.00003954642,0.0004993116],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99830025,0.000078151585,0.00051681855,0.00035152028,0.00046860825,0.00028461867],"domain_scores_gemma":[0.9987993,0.00006547546,0.00033223472,0.00041221865,0.00019632679,0.00019443565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014490429,0.00025590314,0.0006668381,0.00009585779,0.000034132,0.000009982645,0.000111845926,0.00015145232,0.00004986706],"category_scores_gemma":[0.00013120942,0.00021045747,0.00009337771,0.0001932862,0.00012685741,0.0001547425,0.0000908503,0.00013051304,0.0000115500225],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018512596,0.00040913702,0.0012628215,0.00028228541,0.00035633377,0.000022401084,0.00436823,0.0000059533377,0.99173516,0.00008620033,0.0003452416,0.0009411142],"study_design_scores_gemma":[0.013716753,0.0008503723,0.0054404656,0.00029640138,0.00066509796,0.00005079714,0.00050118135,0.0001815247,0.9778253,0.00012905542,0.00018061616,0.00016243907],"about_ca_topic_score_codex":0.0012555915,"about_ca_topic_score_gemma":0.000017452503,"teacher_disagreement_score":0.01390986,"about_ca_system_score_codex":0.0003398964,"about_ca_system_score_gemma":0.0011083309,"threshold_uncertainty_score":0.85822064},"labels":[],"label_agreement":null},{"id":"W2567444712","doi":"10.1182/blood.v118.21.3750.3750","title":"The Gads Adaptor Protein Is Required to Mediate Lymphoid Disease Downstream of BCR-ABL,","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Ontario Institute for Cancer Research","funders":"","keywords":"Signal transducing adaptor protein; GRB2; Cancer research; Biology; breakpoint cluster region; Bone marrow; ABL; Signal transduction; Leukemia; Immunology; Cell biology; Tyrosine kinase; Receptor; Genetics","score_opus":0.024346671392333635,"score_gpt":0.2444021836191539,"score_spread":0.22005551222682027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2567444712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920481,0.00086453767,0.000005884902,0.00062808,0.00008981422,0.0012201783,0.0000889529,0.00006910042,0.0049853846],"genre_scores_gemma":[0.99519026,0.000091753005,0.0009756711,0.00023256,0.00015649552,0.00025873023,0.000017923612,0.00003731194,0.0030392706],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99851674,0.000042112915,0.0003396241,0.00031893048,0.000411361,0.0003712043],"domain_scores_gemma":[0.9983834,0.000045925823,0.00012262817,0.0008933418,0.00009749553,0.00045722054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015290527,0.00020390385,0.00028398103,0.000061076134,0.00008141987,0.000008618779,0.00021423463,0.00006728893,0.00028585814],"category_scores_gemma":[0.0002484377,0.00013199275,0.00013036923,0.00019706249,0.00010750922,0.000053722106,0.00009311704,0.00007466309,0.00019735974],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018525463,0.0279068,0.3815567,0.0021657466,0.00763141,0.0032449835,0.020890553,0.0000023519576,0.39794642,0.0037070343,0.037974663,0.09844789],"study_design_scores_gemma":[0.025404438,0.0019324198,0.08257722,0.0007872816,0.0017828194,0.0000903536,0.00030591476,0.000038945833,0.87481904,0.000545758,0.011220474,0.0004953481],"about_ca_topic_score_codex":0.00028496102,"about_ca_topic_score_gemma":0.000023625567,"teacher_disagreement_score":0.4768726,"about_ca_system_score_codex":0.00017887665,"about_ca_system_score_gemma":0.00067775935,"threshold_uncertainty_score":0.53825086},"labels":[],"label_agreement":null},{"id":"W2567764101","doi":"10.1182/blood.v106.11.1213.1213","title":"Tel-PDGFβR Specifically Induces Interferon-Stimulated Genes.","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Fusion gene; Imatinib mesylate; Myeloid leukemia; Cancer research; Tyrosine kinase; Biology; ABL; Fusion protein; Platelet-derived growth factor receptor; Leukemia; Chromosomal translocation; breakpoint cluster region; Molecular biology; Imatinib; Signal transduction; Immunology; Cell biology; Gene; Growth factor; Receptor; Genetics","score_opus":0.024870028848037393,"score_gpt":0.2704788076366559,"score_spread":0.24560877878861848,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2567764101","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9811525,0.0014990921,0.0000263982,0.00070344127,0.00011385091,0.0003372639,0.000007076869,0.00019177327,0.015968645],"genre_scores_gemma":[0.9930921,0.00014549236,0.0029803605,0.00037141505,0.00073647837,0.000017461309,0.000046230412,0.00004280042,0.002567659],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99867374,0.000023743545,0.00031889664,0.00036110004,0.00027454735,0.0003479874],"domain_scores_gemma":[0.9991499,0.00004627543,0.00006582309,0.00046543777,0.00006373997,0.0002088129],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000082104656,0.00021677594,0.0003124731,0.000097741795,0.000049629707,0.000021568785,0.00013419648,0.0001517649,0.0014389048],"category_scores_gemma":[0.00004520491,0.00018015715,0.00010324807,0.00016829041,0.0000569471,0.00007721419,0.000063537096,0.00023268553,0.001320144],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011225633,0.013642537,0.06600648,0.00026006755,0.0032264516,0.0020403701,0.001891366,0.00017053085,0.49124432,0.00043353386,0.012007259,0.40795454],"study_design_scores_gemma":[0.052844618,0.002457982,0.11950242,0.00051412045,0.0017395477,0.0014965335,0.00016589457,0.00077555154,0.6645388,0.00007458905,0.15489382,0.0009961558],"about_ca_topic_score_codex":0.00003120129,"about_ca_topic_score_gemma":0.000016880993,"teacher_disagreement_score":0.40695837,"about_ca_system_score_codex":0.0003098548,"about_ca_system_score_gemma":0.00021216238,"threshold_uncertainty_score":0.9994739},"labels":[],"label_agreement":null},{"id":"W2569641842","doi":"10.1182/blood.v114.22.4270.4270","title":"Non-Adherence to Imatinib in Chronic Myeloid Leukemia Patients Is Associated with a Short Term and Long Term Negative Impact On Healthcare Utilization and Costs.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Imatinib; Discontinuation; Medical prescription; Internal medicine; Imatinib mesylate; Emergency medicine; Nilotinib; Medicare Advantage; Health care; Retrospective cohort study; Emergency department; Myeloid leukemia; Pharmacology","score_opus":0.021770386798016392,"score_gpt":0.3115423220825145,"score_spread":0.2897719352844981,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2569641842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976049,0.0002435288,0.000003773309,0.00011926391,0.000015788362,0.0015973598,0.000060703733,0.000040448787,0.00031421744],"genre_scores_gemma":[0.99897003,0.00015328395,0.00008225366,0.00044329462,0.000031810618,0.000050531213,0.00018138568,0.000028062559,0.000059333513],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984289,0.000042308675,0.00029975577,0.00049216306,0.00032483798,0.00041207895],"domain_scores_gemma":[0.99916995,0.00006402175,0.00010934341,0.00026299446,0.00011026464,0.0002834106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009330193,0.00030971554,0.0004505249,0.00016221513,0.00007495509,0.00003387015,0.00006202059,0.00013755569,0.000024239243],"category_scores_gemma":[0.00008239658,0.00023732742,0.000033702774,0.0003493058,0.000047145455,0.00012314405,0.00003120771,0.0002351138,0.00000572478],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034478653,0.00045327478,0.9438685,0.00006122097,0.0001116164,0.000083171195,0.0015641513,0.0000027545434,0.0005480758,0.000001401291,0.00004428584,0.052916724],"study_design_scores_gemma":[0.012876466,0.008866106,0.97158265,0.0019006042,0.00012218425,0.000026020209,0.000038781614,0.0001345822,0.0042407545,0.000005393087,8.983128e-7,0.00020557527],"about_ca_topic_score_codex":0.00037414432,"about_ca_topic_score_gemma":0.0007039177,"teacher_disagreement_score":0.052711148,"about_ca_system_score_codex":0.0041152756,"about_ca_system_score_gemma":0.00075202837,"threshold_uncertainty_score":0.99970776},"labels":[],"label_agreement":null},{"id":"W2570921152","doi":"10.1182/blood.v114.22.861.861","title":"Safety and Efficacy of Subcutaneous-Administered Omacetaxine Mepesuccinate in Chronic Myeloid Leukemia (CML) Patients Who Are Resistant or Intolerant to Two or More Tyrosine Kinase Inhibitors – Results of A Multicenter Phase 2/3 Study.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Dasatinib; Adverse effect; Gastroenterology; Dosing; Regimen; Clinical trial; Myeloid leukemia; Imatinib","score_opus":0.015939251782126147,"score_gpt":0.30403649885043266,"score_spread":0.28809724706830653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2570921152","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994837,0.00052982033,0.0000019708518,0.00034130178,0.00007219705,0.0036639906,0.00040936115,0.000047516252,0.00009688464],"genre_scores_gemma":[0.998508,0.00015129028,0.00043489542,0.00012136183,0.000091616625,0.000035600242,0.00012278336,0.000057784968,0.00047671946],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9958426,0.00016569822,0.0017768007,0.0008970419,0.0007056727,0.0006122202],"domain_scores_gemma":[0.9974609,0.00023693015,0.00066462473,0.0009631917,0.00027958362,0.00039479267],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036044087,0.0005611001,0.0014868431,0.0004446426,0.00007226518,0.000018649202,0.00022370729,0.00014832059,0.00004767784],"category_scores_gemma":[0.000791481,0.0004039376,0.00013223685,0.000777867,0.000113516915,0.00010057732,0.00014926789,0.00030905285,0.0000045443235],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7025066,0.05802778,0.035926186,0.001743775,0.0012702387,0.013775848,0.014973963,0.00015509746,0.090102136,0.0000055931564,0.0003634818,0.08114933],"study_design_scores_gemma":[0.4770002,0.059984583,0.36476627,0.0052175666,0.0011634893,0.00015059534,0.000894677,0.00042436924,0.089321874,0.0000014475796,0.00044380876,0.0006311288],"about_ca_topic_score_codex":0.00058873557,"about_ca_topic_score_gemma":0.0019849078,"teacher_disagreement_score":0.32884008,"about_ca_system_score_codex":0.0017102546,"about_ca_system_score_gemma":0.0008544034,"threshold_uncertainty_score":0.9998413},"labels":[],"label_agreement":null},{"id":"W2571213554","doi":"10.1182/blood.v120.21.3776.3776","title":"High Risk of Error in Categorizing Treatment Response in Individual CML Patients by Standard Cytogenetic Analysis or PCR Assay with High CV: A Bayesian Analysis","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Imatinib; Nilotinib; Oncology; Dasatinib; Internal medicine; Medicine; Imatinib mesylate; Statistics; Myeloid leukemia; Mathematics","score_opus":0.018499044465678856,"score_gpt":0.27368544468186706,"score_spread":0.2551864002161882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2571213554","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99769264,0.00047372302,0.00014387064,0.00005717324,0.000025416113,0.00072527764,0.0008339058,0.000027594484,0.000020417137],"genre_scores_gemma":[0.99560416,0.0001016138,0.003155808,0.000020696234,0.000028362594,0.00013908463,0.00075508485,0.000044243796,0.00015092397],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99654716,0.0006790254,0.0007635171,0.0005473895,0.00079641154,0.00066648034],"domain_scores_gemma":[0.99808353,0.0003686403,0.00042021996,0.0007413043,0.00009254633,0.00029375037],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008515739,0.0004190982,0.00138688,0.0015759267,0.000053639003,0.000017403,0.00014448773,0.00018150108,0.00025370123],"category_scores_gemma":[0.00021077562,0.00028961178,0.00026351857,0.0039179157,0.00007478023,0.00011042433,0.000052785388,0.0001959705,0.0000061555797],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064981184,0.0043588597,0.9697309,0.000023040322,0.01566105,0.00010574395,0.0018339407,0.00040470352,0.00020924787,0.0000019015245,0.000012209711,0.00116025],"study_design_scores_gemma":[0.029111946,0.003466923,0.916874,0.000057245412,0.039917465,0.0000050656413,0.00027600976,0.00008096109,0.0099202655,0.0000034598568,0.000028171333,0.00025849213],"about_ca_topic_score_codex":0.009456734,"about_ca_topic_score_gemma":0.00770719,"teacher_disagreement_score":0.05285694,"about_ca_system_score_codex":0.0016238112,"about_ca_system_score_gemma":0.00051471614,"threshold_uncertainty_score":0.9999556},"labels":[],"label_agreement":null},{"id":"W2571522394","doi":"10.1182/blood.v112.11.3201.3201","title":"Identification of AHI-1 Involvement in Mediating Cellular Resistance to Imatinib Mesylate in Chronic Myeloid Leukemia Cells","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute; BC Cancer Agency","funders":"","keywords":"Imatinib mesylate; Cancer research; Myeloid leukemia; Tyrosine kinase; Biology; Progenitor cell; K562 cells; Haematopoiesis; Imatinib; Stem cell; breakpoint cluster region; Myeloid; Protein kinase B; Leukemia; Signal transduction; Immunology; Cell biology; Receptor","score_opus":0.01551737333334093,"score_gpt":0.24862020094174092,"score_spread":0.23310282760839998,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2571522394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99658626,0.0014602091,0.00004123614,0.00011333082,0.000089013876,0.0009649682,0.000015141242,0.000035177753,0.00069466693],"genre_scores_gemma":[0.9969271,0.0003588451,0.0013596126,0.000064713146,0.0000951845,0.00013318127,0.000051875588,0.00003631769,0.0009731954],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99756557,0.00007222711,0.0010069829,0.0004559443,0.0004904312,0.00040882474],"domain_scores_gemma":[0.99885774,0.00008475266,0.00028280565,0.000580637,0.000065761655,0.00012829059],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046758942,0.00021720995,0.0004771542,0.00033062522,0.00004281869,0.0000060679204,0.00017290897,0.000114813294,0.00005577109],"category_scores_gemma":[0.00013006572,0.00022371372,0.00007534235,0.00065291376,0.000060203303,0.00009153441,0.00007034935,0.00022178584,0.00007332262],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000077358374,0.0004486876,0.023503289,0.00042965566,0.000055014687,0.00026253465,0.0031592792,0.0003567149,0.97120726,0.000034266304,0.00012950061,0.00033643178],"study_design_scores_gemma":[0.008631895,0.00015697234,0.04395971,0.00047761988,0.00006807078,0.000008227515,0.00015036805,0.00040020794,0.9456864,0.000040131006,0.00023911454,0.00018127663],"about_ca_topic_score_codex":0.00034513,"about_ca_topic_score_gemma":0.0007308871,"teacher_disagreement_score":0.025520863,"about_ca_system_score_codex":0.00301718,"about_ca_system_score_gemma":0.0011375973,"threshold_uncertainty_score":0.9122781},"labels":[],"label_agreement":null},{"id":"W2572661861","doi":"10.1182/blood.v118.21.966.966","title":"Molecular and Structural Characterization of the SH3 Domain of AHI-1 in Regulation of Cellular Resistance of BCR-ABL+ Chronic Myeloid Leukemia Cells to Tyrosine Kinase Inhibitors","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Dasatinib; Tyrosine kinase; Cancer research; Nilotinib; Imatinib mesylate; Myeloid leukemia; K562 cells; Stem cell; SH3 domain; Biology; Progenitor cell; Philadelphia chromosome; Imatinib; ABL; breakpoint cluster region; Leukemia; Cell biology; Signal transduction; Immunology; Receptor; Genetics; Gene; Chromosomal translocation","score_opus":0.006730726741856921,"score_gpt":0.2000704274830921,"score_spread":0.19333970074123516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2572661861","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985574,0.0004381348,0.00005967957,0.000026351561,0.000058029218,0.0006685507,0.000044137523,0.0000055158084,0.00014218391],"genre_scores_gemma":[0.99885684,0.000025356365,0.000939958,0.000009669103,0.000026030817,0.000008859014,0.000034029395,0.000021224312,0.00007803907],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985243,0.000081336315,0.0006837576,0.00023162697,0.00032239067,0.00015656702],"domain_scores_gemma":[0.9987889,0.00002103952,0.00051388436,0.0005088509,0.00011373816,0.000053590098],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018087158,0.00015693514,0.00044204417,0.00013958392,0.000015676998,0.0000017209886,0.00011113417,0.000105413594,0.00004112791],"category_scores_gemma":[0.000042826065,0.00012379458,0.00007909794,0.00038809224,0.00014366624,0.00006054465,0.00006766362,0.000084451036,4.4797264e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020942796,0.00013048183,0.015836107,0.0005540146,0.000053057778,0.0000060604134,0.0009470234,0.000018077324,0.9818112,0.00019917339,0.0000035975618,0.00023173795],"study_design_scores_gemma":[0.003202245,0.0002151737,0.2388978,0.0005332869,0.00011255591,0.0000025603927,0.000031024334,0.000040546827,0.7568,0.00009122009,0.000009172095,0.00006443922],"about_ca_topic_score_codex":0.00018724105,"about_ca_topic_score_gemma":0.000063557534,"teacher_disagreement_score":0.22501127,"about_ca_system_score_codex":0.0002673655,"about_ca_system_score_gemma":0.00029960708,"threshold_uncertainty_score":0.50481963},"labels":[],"label_agreement":null},{"id":"W2573896831","doi":"10.1182/blood.v114.22.510.510","title":"Comparative in Vitro Cellular Data Alone Is Insufficient to Predict Clinical Responses and Guide Choice of BCR-ABL Inhibitor to Treat Imatinib-Resistant Chronic Myeloid Leukemia.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Nilotinib; Imatinib; Dasatinib; Bosutinib; Cmax; Imatinib mesylate; Medicine; Pharmacology; In vivo; Tyrosine-kinase inhibitor; Oncology; Cancer research; Myeloid leukemia; Pharmacokinetics; Internal medicine; Biology; Cancer; Genetics","score_opus":0.05735597344942199,"score_gpt":0.3607660134032223,"score_spread":0.3034100399538003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2573896831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992526,0.0028099448,0.00003675625,0.0012737341,0.00008394734,0.0017039707,0.00066438154,0.00006486456,0.0008364335],"genre_scores_gemma":[0.99096924,0.00017875456,0.006536613,0.0008114979,0.00035038477,0.000044156037,0.00025205547,0.000034768214,0.00082253333],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9960481,0.00024420186,0.0013936093,0.0010952608,0.00062715914,0.00059165945],"domain_scores_gemma":[0.99633497,0.0006118381,0.00024761038,0.0021215992,0.00013548136,0.00054847664],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008156109,0.00042368635,0.001321411,0.0003459545,0.000072817056,0.00002852424,0.00053958024,0.00019658674,0.00005274508],"category_scores_gemma":[0.0012045292,0.00036995986,0.00010582594,0.0006283424,0.00014413033,0.0001298638,0.00049806153,0.0003485404,0.000057629884],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007942347,0.005733499,0.0100887595,0.0003001994,0.00036556536,0.0004905077,0.0026649965,0.00004034179,0.9476292,0.000011933169,0.017143048,0.0075895754],"study_design_scores_gemma":[0.033358924,0.008889747,0.14087227,0.0011397871,0.00088892493,0.00006498828,0.00029500813,0.0009027083,0.7970783,0.000011088439,0.015949754,0.00054852315],"about_ca_topic_score_codex":0.00057466293,"about_ca_topic_score_gemma":0.00017076195,"teacher_disagreement_score":0.15055095,"about_ca_system_score_codex":0.0011732138,"about_ca_system_score_gemma":0.0017197464,"threshold_uncertainty_score":0.99987525},"labels":[],"label_agreement":null},{"id":"W2573996312","doi":"10.1182/blood.v110.11.3328.3328","title":"Cost-Effectiveness Analysis in Canada of Dasatinib Versus Imatinib for the Treatment of Chronic Myelogenous Leukemia in Patients with Imatinib Resistance.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; Bristol-Myers Squibb (Canada)","funders":"","keywords":"Dasatinib; Medicine; Chronic myelogenous leukemia; Imatinib; Internal medicine; Cost effectiveness; Oncology; Imatinib mesylate; Leukemia; Myeloid leukemia","score_opus":0.020920169824421454,"score_gpt":0.27869984494827155,"score_spread":0.2577796751238501,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2573996312","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952064,0.0009184413,0.000106673964,0.0000120098875,0.00006628799,0.0032472732,0.00018157509,0.0000075488906,0.0002537941],"genre_scores_gemma":[0.99855405,0.00006994559,0.0007854616,0.000006631227,0.000026382488,0.00032118458,0.00018218097,0.000028269083,0.000025873867],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99805665,0.00006822386,0.00066195324,0.0003378191,0.00042884864,0.00044653376],"domain_scores_gemma":[0.9973749,0.0014387888,0.00035568397,0.0005912312,0.00015879599,0.00008063042],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033358234,0.00026066636,0.0008558935,0.00024547035,0.000041627307,0.000003304979,0.00013012782,0.000072192684,0.000029347264],"category_scores_gemma":[0.0000897401,0.00017282803,0.00014196493,0.0009865861,0.00008332274,0.000034926783,0.000015138844,0.00009060442,4.591411e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009557332,0.0022549618,0.96958244,0.00040189188,0.003321923,0.000055399792,0.0008789209,0.0018458042,0.00016626366,0.00002268293,0.0000061854166,0.011906176],"study_design_scores_gemma":[0.07390082,0.0026194023,0.90752524,0.00020504178,0.002398286,0.0000010533357,0.00030053174,0.00030064746,0.012500189,0.0000036437618,0.00010001311,0.00014513376],"about_ca_topic_score_codex":0.37776738,"about_ca_topic_score_gemma":0.92910755,"teacher_disagreement_score":0.55134016,"about_ca_system_score_codex":0.0119833555,"about_ca_system_score_gemma":0.004595087,"threshold_uncertainty_score":0.9918095},"labels":[],"label_agreement":null},{"id":"W2574969036","doi":"10.1182/blood.v110.11.2930.2930","title":"Synergistic Activity of the Novel Src/Abl Inhibitor Bosutinib in Combination with Imatinib.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Bosutinib; Imatinib; Imatinib mesylate; ABL; Dasatinib; Pharmacology; Cancer research; Myeloid leukemia; Chemistry; Nilotinib; Tyrosine kinase; Medicine; Receptor; Biochemistry","score_opus":0.013128247588446251,"score_gpt":0.2557750856804566,"score_spread":0.24264683809201035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2574969036","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99488914,0.00003480801,0.00022867961,0.00016275434,0.000070982176,0.0004639839,0.0000073751744,0.00002164932,0.004120615],"genre_scores_gemma":[0.9987589,0.0000021575156,0.00086982816,0.000039314615,0.00004759103,0.000011124269,0.000006376324,0.000016369659,0.00024830556],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9990947,0.00002013581,0.00021178502,0.00016911293,0.00030229328,0.00020194624],"domain_scores_gemma":[0.9992902,0.00013759114,0.00014428058,0.00031968887,0.00005782719,0.00005038723],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025512188,0.00011578983,0.00021647516,0.00007109249,0.00003093436,0.000003978729,0.000070490234,0.00006871966,0.000021000587],"category_scores_gemma":[0.00017216719,0.00007423983,0.000043097756,0.00030297608,0.00007932017,0.00004427469,0.000035342375,0.00016287538,0.0000048193106],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009487321,0.014241641,0.38338464,0.00049266877,0.00034499672,0.00013538968,0.0011093363,0.000022753153,0.5904325,0.0015972899,0.00008927841,0.0072007594],"study_design_scores_gemma":[0.018420957,0.00038379416,0.59787214,0.00033662678,0.00018758059,0.000047828085,0.000053035506,0.00010413736,0.38241374,0.000025905434,0.0000695591,0.00008467746],"about_ca_topic_score_codex":0.00022044152,"about_ca_topic_score_gemma":0.0002223864,"teacher_disagreement_score":0.2144875,"about_ca_system_score_codex":0.00023140616,"about_ca_system_score_gemma":0.00024400496,"threshold_uncertainty_score":0.30274123},"labels":[],"label_agreement":null},{"id":"W2575287594","doi":"10.1182/blood.v104.11.2941.2941","title":"G-CSF as a Potent Mitogen Augments the Elimination of CML Stem Cells by Imatinib Mesylate In Vitro.","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Imatinib mesylate; Granulocyte colony-stimulating factor; CD34; Haematopoiesis; Medicine; Molecular biology; Myeloid leukemia; Immunology; Internal medicine; Stem cell; Biology; Imatinib; Chemotherapy","score_opus":0.009398610449783523,"score_gpt":0.24161201657698037,"score_spread":0.23221340612719685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2575287594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964562,0.00071199733,0.000015300338,0.0007479569,0.00010864812,0.0007222293,0.000036074503,0.000025101823,0.0011764999],"genre_scores_gemma":[0.99818647,0.00009111132,0.0003509581,0.00016254003,0.00003482338,0.000051308194,0.00004703374,0.000022937224,0.0010528449],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987693,0.00004335031,0.00034497055,0.0002229203,0.00038146024,0.00023799257],"domain_scores_gemma":[0.9993374,0.000042193496,0.00014887408,0.00034634492,0.00005492707,0.00007031212],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015962838,0.00015468101,0.0002577246,0.000068799585,0.000033956545,0.000008785372,0.000118417454,0.00007904428,0.00003699093],"category_scores_gemma":[0.000021872986,0.0001094408,0.00008391141,0.0001710176,0.00004030435,0.0000521692,0.00004498229,0.00012761485,0.00010088208],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034285552,0.002577607,0.0011335213,0.00016684753,0.00042759132,0.00012390196,0.0023512864,0.000049118153,0.978675,0.00006487535,0.0004044033,0.013682999],"study_design_scores_gemma":[0.016173841,0.00028500668,0.002516367,0.00014707183,0.00028756686,0.00004882752,0.00024107439,0.000039275757,0.9797446,0.0000977708,0.00032707292,0.00009150624],"about_ca_topic_score_codex":0.00032548822,"about_ca_topic_score_gemma":0.000009898001,"teacher_disagreement_score":0.015830986,"about_ca_system_score_codex":0.00041724357,"about_ca_system_score_gemma":0.00022569233,"threshold_uncertainty_score":0.44628662},"labels":[],"label_agreement":null},{"id":"W2575394572","doi":"10.1182/blood.v120.21.3782.3782","title":"Change in Chronic Low-Grade Nonhematologic Adverse Events (AEs) and Quality of Life (QoL) in Adult Patients (pts) with Philadelphia Chromosome–Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Switched From Imatinib (IM) to Nilotinib (NIL)","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Adverse effect; Internal medicine; Common Terminology Criteria for Adverse Events; Quality of life (healthcare)","score_opus":0.03111188851208853,"score_gpt":0.3032667500792633,"score_spread":0.2721548615671748,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2575394572","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98971474,0.0043172003,0.000010586729,0.00028409966,0.0001596986,0.0049602757,0.00037278023,0.00009425843,0.000086332206],"genre_scores_gemma":[0.9962221,0.0005699836,0.00045372066,0.0003100118,0.00046366543,0.0010585384,0.0007580972,0.00014797552,0.000015930316],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9933206,0.00044712203,0.0020297167,0.0013756979,0.0010456692,0.0017812308],"domain_scores_gemma":[0.9966265,0.00037240091,0.00088126474,0.0011218855,0.000164124,0.0008338006],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006094917,0.0010425802,0.0022554982,0.00075967255,0.00008761475,0.000013534048,0.00043458617,0.00056344137,0.00021124019],"category_scores_gemma":[0.0004071998,0.0009371851,0.0002072538,0.0013910595,0.00026022916,0.00068057555,0.00034520015,0.000963363,0.00011561498],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030909926,0.010339167,0.94233,0.0021326288,0.00067946163,0.00023206744,0.009183436,0.00010428777,0.029446885,0.000048425332,0.000024664363,0.002388009],"study_design_scores_gemma":[0.16267061,0.004473047,0.7967863,0.0051481887,0.00042706664,0.000040474322,0.0007113354,0.0007888139,0.027793309,0.000020841675,0.000026738518,0.001113266],"about_ca_topic_score_codex":0.008835172,"about_ca_topic_score_gemma":0.011757273,"teacher_disagreement_score":0.15957962,"about_ca_system_score_codex":0.014805823,"about_ca_system_score_gemma":0.003244465,"threshold_uncertainty_score":0.9993079},"labels":[],"label_agreement":null},{"id":"W2576736597","doi":"10.1182/blood.v114.22.2073.2073","title":"Lack of Inhibition of AKT Predicts Clinical Resistance to Therapy with Imatinib + Reinduction Chemotherapy in Relapsed/Refractory c-Kit+ Acute Myeloid Leukemia.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cytarabine; Internal medicine; Imatinib; Myeloid leukemia; Imatinib mesylate; Gastroenterology; Etoposide; Mitoxantrone; Chemotherapy","score_opus":0.0315470808838495,"score_gpt":0.31778597889663485,"score_spread":0.28623889801278535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2576736597","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954463,0.00049256615,0.000028943889,0.00096893567,0.00006048187,0.0009901717,0.00001688197,0.00005678643,0.0019389327],"genre_scores_gemma":[0.9925566,0.00104179,0.0049069854,0.0005933542,0.00017034427,0.000029603245,0.000045378216,0.000037385387,0.0006185721],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99780655,0.00009866367,0.0008929866,0.00044864404,0.00047334327,0.0002798224],"domain_scores_gemma":[0.998572,0.00008962946,0.0004197641,0.00061628607,0.0001598958,0.00014242053],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042422308,0.0002433333,0.0007171026,0.00019354722,0.00002535367,0.0000050458143,0.00009812673,0.00023787202,0.000043882443],"category_scores_gemma":[0.00009035034,0.00019696061,0.000119283824,0.00049636705,0.00011097992,0.00010487015,0.0000125725555,0.00033662547,0.000008818899],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041013233,0.019287186,0.13310415,0.00057752203,0.0020510058,0.00057152426,0.0052650925,0.00007626149,0.7084796,0.00040559343,0.0059208605,0.083248],"study_design_scores_gemma":[0.06531156,0.009755633,0.44829187,0.0016894686,0.0002866559,0.00007119033,0.00010970546,0.000014408039,0.47252885,0.00023607783,0.0014046256,0.00029995112],"about_ca_topic_score_codex":0.000049052764,"about_ca_topic_score_gemma":0.000052944517,"teacher_disagreement_score":0.31518772,"about_ca_system_score_codex":0.00041516675,"about_ca_system_score_gemma":0.00063257135,"threshold_uncertainty_score":0.80318207},"labels":[],"label_agreement":null},{"id":"W2576905928","doi":"10.1016/j.leukres.2017.01.005","title":"Current approach to the treatment of chronic myeloid leukaemia","year":2017,"lang":"en","type":"review","venue":"Leukemia Research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Bosutinib; Nilotinib; Dasatinib; Medicine; Ponatinib; Hematologist; Imatinib; Intensive care medicine; Imatinib mesylate; Chronic myeloid leukaemia; Oncology; Myeloid leukemia; Immunology; Internal medicine; Disease","score_opus":0.31006381007860545,"score_gpt":0.4895030462241493,"score_spread":0.17943923614554386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2576905928","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008228351,0.97484845,0.000017891587,0.00011677427,0.00050469243,0.0087014735,0.00015845735,0.00006831779,0.015501654],"genre_scores_gemma":[0.00009183008,0.9798663,0.00021202743,0.000008686356,0.0024987548,0.0036431458,0.0006028092,0.00022038705,0.012856021],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9922735,0.00080406124,0.0013003543,0.0015758852,0.0023138758,0.0017322951],"domain_scores_gemma":[0.9919732,0.000800959,0.00054545305,0.0054827924,0.00047309676,0.0007244522],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016379405,0.0010530262,0.0039951988,0.0009668755,0.0006612171,0.00014396447,0.0019218464,0.00068848365,0.00015258067],"category_scores_gemma":[0.00043556144,0.0005875024,0.0015372359,0.0010793629,0.0006772351,0.00007932051,0.0005459889,0.0020122465,0.0019656864],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00007333628,0.0009233738,0.0000084994335,0.020352293,0.00083875976,0.00007051055,0.000305281,0.0000059941303,0.0000011338011,0.0001682239,0.011377404,0.9658752],"study_design_scores_gemma":[0.0025488543,0.0020485667,0.00003126239,0.014731954,0.0013612406,0.00023686618,0.000027301125,0.000100448655,0.000021847092,0.000013041462,0.97848034,0.00039829698],"about_ca_topic_score_codex":0.0008714272,"about_ca_topic_score_gemma":0.00008285061,"teacher_disagreement_score":0.96710294,"about_ca_system_score_codex":0.057639662,"about_ca_system_score_gemma":0.027922524,"threshold_uncertainty_score":0.99965763},"labels":[],"label_agreement":null},{"id":"W2577122677","doi":"10.1182/blood.v110.11.775.775","title":"Missplicing of Glycogen Synthase Kinase 3β: A Potential Mechanism of Blast Crisis Chronic Myeloid Leukemia Stem Cell Generation.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Cancer research; Biology; Stem cell; Myeloid leukemia; Progenitor cell; Immunology; Cell biology","score_opus":0.012448884815565359,"score_gpt":0.23715488911954571,"score_spread":0.22470600430398036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2577122677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99247825,0.0018067,0.0037185194,0.000048216076,0.00017608392,0.0006449983,0.00005732143,0.000062625804,0.001007303],"genre_scores_gemma":[0.9958546,0.00013670715,0.002608587,0.000066756875,0.0005112516,0.000018052953,0.00006771312,0.000067017405,0.000669272],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975512,0.000049054815,0.0008163945,0.00048658173,0.00059073494,0.0005060278],"domain_scores_gemma":[0.99835014,0.00006353261,0.00039398458,0.0007262394,0.00020411333,0.00026197892],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00038100698,0.00032334338,0.00062438374,0.0002551515,0.00008322802,0.000010301017,0.00017727248,0.00022327495,0.00023091379],"category_scores_gemma":[0.000024054783,0.00030874606,0.00026486412,0.00031304735,0.000066667555,0.000080832775,0.00009144629,0.00020849363,0.000038963542],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018277088,0.00096111913,0.00020918847,0.0005232722,0.00038765874,0.00048304608,0.00038256994,0.00012937142,0.99379617,0.00016542803,0.00029594701,0.0024834522],"study_design_scores_gemma":[0.011763766,0.0009407647,0.00031573843,0.00019239372,0.0013526848,0.00021913109,0.00037581837,0.0011620262,0.98332316,0.000017078066,0.0001179659,0.00021949154],"about_ca_topic_score_codex":0.00052174344,"about_ca_topic_score_gemma":0.00006624239,"teacher_disagreement_score":0.011580995,"about_ca_system_score_codex":0.0010398943,"about_ca_system_score_gemma":0.001116206,"threshold_uncertainty_score":0.99993646},"labels":[],"label_agreement":null},{"id":"W2577361732","doi":"10.1182/blood.v112.11.189.189","title":"Activation of PP2A by FTY720 Inhibits Survival and Self-Renewal of the Ph(+) Chronic Myelogenous Leukemia (CML) CD34+/CD38− Stem Cell through the Simultaneous Suppression of BCR/ABL and BCR/ABL– independent Signals","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"CD38; Dasatinib; Progenitor cell; Cancer research; Chronic myelogenous leukemia; Stem cell; Biology; Clonogenic assay; Haematopoiesis; CD34; Imatinib; Imatinib mesylate; Leukemia; Immunology; Myeloid leukemia; Cell biology; Cell; Biochemistry","score_opus":0.01192342116242778,"score_gpt":0.222397065891162,"score_spread":0.21047364472873423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2577361732","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933321,0.0041834465,0.000018520219,0.00010815997,0.000095954296,0.0011729131,0.00009558231,0.000032731987,0.000960619],"genre_scores_gemma":[0.99744964,0.0017340386,0.000106716965,0.000034948407,0.00009795787,0.000020356187,0.000033217446,0.000051532064,0.00047158933],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972941,0.00025074623,0.0007336872,0.00047847306,0.0008447942,0.0003981811],"domain_scores_gemma":[0.9976375,0.00070866966,0.00066146144,0.0006859075,0.00019697609,0.00010947049],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025916932,0.0003768934,0.0007359432,0.0000637156,0.00019079859,0.000009632523,0.00025041917,0.0002884415,0.000047764468],"category_scores_gemma":[0.00008009777,0.0002351395,0.00013852668,0.0002906132,0.0003490714,0.00012395982,0.00025079102,0.0003515284,0.0000025615623],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004752175,0.0021753267,0.017065622,0.0010864455,0.0007992848,0.000053077638,0.008477198,0.00078881154,0.9670556,0.000029146024,0.00028480226,0.0017094727],"study_design_scores_gemma":[0.011873039,0.0010759337,0.004024615,0.00042013245,0.0006789893,0.00024110421,0.00059242087,0.00035709454,0.98018396,0.000038342085,0.00030360624,0.00021073749],"about_ca_topic_score_codex":0.0011311244,"about_ca_topic_score_gemma":0.000060100734,"teacher_disagreement_score":0.01312839,"about_ca_system_score_codex":0.00048194762,"about_ca_system_score_gemma":0.0010439899,"threshold_uncertainty_score":0.95887107},"labels":[],"label_agreement":null},{"id":"W2578080654","doi":"10.1182/blood.v114.22.855.855","title":"Suppression of RISC-Independent Decoy and RISC-Mediated mRNA Base-Pairing Activities of MicroRNA-328 Is Required for Differentiation-Arrest and Enhanced Survival of Blast Crisis CML Progenitors.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Biology; CEBPA; Molecular biology; Gene silencing; Myeloid leukemia; microRNA; Progenitor cell; Ectopic expression; Cell biology; Cancer research; breakpoint cluster region; Stem cell; Transcription factor; Genetics; Gene","score_opus":0.013029467973255963,"score_gpt":0.25933981210786206,"score_spread":0.2463103441346061,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2578080654","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99793124,0.00071102905,0.0001170285,0.000112008776,0.00011188368,0.000723399,0.00021617267,0.00002367947,0.000053576023],"genre_scores_gemma":[0.99859923,0.00018621198,0.00093672395,0.000012373547,0.00007113737,0.000027601327,0.00007845,0.000024657718,0.00006362934],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99852246,0.00005458765,0.0005184674,0.00033210433,0.00033484655,0.00023754704],"domain_scores_gemma":[0.9988017,0.00023933622,0.00040197122,0.00030063814,0.0001422597,0.00011407747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001523523,0.00022048321,0.00062201574,0.00014987007,0.000052082654,0.000009137057,0.000075335694,0.00014298758,0.000041381074],"category_scores_gemma":[0.00014675848,0.00018824784,0.0001100914,0.00010698307,0.000085735504,0.00010993787,0.000050846054,0.000093507064,7.1090335e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005707257,0.0011526482,0.061036196,0.0006065514,0.0004255649,0.00000437817,0.0012380574,9.162095e-7,0.9337534,0.0000035048258,0.00018218567,0.0010259006],"study_design_scores_gemma":[0.010914089,0.00071634795,0.12471298,0.0003737794,0.0006134854,0.000007856446,0.00052150176,0.00007976055,0.8618945,0.000036105834,0.000009901088,0.000119685355],"about_ca_topic_score_codex":0.000085704356,"about_ca_topic_score_gemma":0.000036851383,"teacher_disagreement_score":0.07185886,"about_ca_system_score_codex":0.00006587293,"about_ca_system_score_gemma":0.00014117594,"threshold_uncertainty_score":0.7676524},"labels":[],"label_agreement":null},{"id":"W2578506856","doi":"10.1182/blood.v104.11.4696.4696","title":"Philadelphia-Negative Clonal Hematopoiesis Following Imatinib Therapy in Patients with Chronic Myeloid Leukemia (CML).","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada; BC Cancer Agency; Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Imatinib; Medicine; Internal medicine; Imatinib mesylate; Myeloid leukemia; Cytarabine; Gastroenterology; Transplantation; Median follow-up; Surgery; Oncology; Immunology; Chemotherapy","score_opus":0.009918820047680492,"score_gpt":0.23906104265185985,"score_spread":0.22914222260417935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2578506856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964539,0.00060496497,0.000023383278,0.00041896055,0.00009762182,0.0012771284,0.000019600015,0.00012630936,0.0009781475],"genre_scores_gemma":[0.9964971,0.00006979361,0.0025825487,0.00025857828,0.00016459975,0.00015841515,0.000106175656,0.00008673924,0.0000760328],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99755776,0.000043071246,0.00047388388,0.0005857784,0.00070735795,0.0006321418],"domain_scores_gemma":[0.99891907,0.00009378679,0.0001697746,0.00053763145,0.000085199244,0.0001945394],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013065092,0.00043338936,0.00064108986,0.00020267958,0.000112377966,0.000027047694,0.000173766,0.00016896859,0.00015603505],"category_scores_gemma":[0.00006891534,0.0003364347,0.00019574293,0.00050138094,0.00010004869,0.00022368714,0.00005498736,0.00037736338,0.00009509139],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023709766,0.008587631,0.9693802,0.00037264975,0.0034933866,0.0012710878,0.004607186,0.00059594074,0.0035671187,0.0003582231,0.00018000316,0.005215599],"study_design_scores_gemma":[0.18221544,0.0039826646,0.77128625,0.0013705908,0.00045187812,0.000086669424,0.0001467313,0.000025253068,0.03902153,0.0005228444,0.0001861616,0.0007039766],"about_ca_topic_score_codex":0.0004264752,"about_ca_topic_score_gemma":0.00016948069,"teacher_disagreement_score":0.19809394,"about_ca_system_score_codex":0.0031987026,"about_ca_system_score_gemma":0.001818657,"threshold_uncertainty_score":0.99990875},"labels":[],"label_agreement":null},{"id":"W2578525969","doi":"10.1182/blood.v124.21.4519.4519","title":"Synthetic Anti-IL3 Receptor Antibodies As Therapeutics to Block Innate Imatinib Resistance in Chronic Myelogenous Leukemia","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Chronic myelogenous leukemia; Imatinib mesylate; Biology; Antibody; Cancer research; Immunology; Imatinib; Leukemia; Myeloid leukemia","score_opus":0.013783822288686602,"score_gpt":0.2682412677283323,"score_spread":0.2544574454396457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2578525969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98551244,0.003001009,0.000015938953,0.00091762305,0.00016735768,0.000865361,0.000018137831,0.00016168795,0.0093404595],"genre_scores_gemma":[0.99274886,0.00069076,0.003037218,0.0007964004,0.000268587,0.00007658968,0.000028049559,0.00008915314,0.002264392],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99750245,0.00012826973,0.00054498,0.00065323885,0.00043065628,0.00074041024],"domain_scores_gemma":[0.99841666,0.00017859602,0.00014767017,0.0009429141,0.00010276035,0.0002113975],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003569852,0.00039288055,0.0007107754,0.00023784404,0.000116309755,0.000035002566,0.00026766147,0.00019955459,0.00013596677],"category_scores_gemma":[0.00022857441,0.00035140026,0.000118423566,0.0004565463,0.00011472608,0.00006276616,0.000102961065,0.00034225636,0.0009036745],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001250575,0.0038134754,0.08004779,0.0024172019,0.0023270873,0.0009911649,0.01060131,0.00038103873,0.86187845,0.0027502272,0.0026210765,0.03092062],"study_design_scores_gemma":[0.05012642,0.0044785426,0.13763216,0.005545872,0.0020817749,0.00072353194,0.00043414024,0.0006540442,0.6115583,0.0012153359,0.18309806,0.0024517819],"about_ca_topic_score_codex":0.00017758281,"about_ca_topic_score_gemma":0.0003787172,"teacher_disagreement_score":0.2503201,"about_ca_system_score_codex":0.0019092748,"about_ca_system_score_gemma":0.0011093059,"threshold_uncertainty_score":0.9998938},"labels":[],"label_agreement":null},{"id":"W2578791119","doi":"10.1182/blood.v110.11.1019.1019","title":"Cbl-b Deficiency Enhances Motility and Impairs Leukemogenesis by Bcr-Abl.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Bone marrow; Ubiquitin ligase; Biology; Haematopoiesis; Cancer research; Philadelphia chromosome; breakpoint cluster region; Chronic myelogenous leukemia; Myeloid; ABL; Immunology; Leukemia; Ubiquitin; Tyrosine kinase; Signal transduction; Stem cell; Cell biology; Chromosomal translocation; Receptor; Genetics","score_opus":0.009114481552950941,"score_gpt":0.2540121762098526,"score_spread":0.24489769465690167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2578791119","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870954,0.0063220765,0.00012947254,0.00009151529,0.00007327136,0.0003179501,0.000017642913,0.000102473365,0.005850188],"genre_scores_gemma":[0.9974708,0.00023961527,0.001069949,0.00013546212,0.000085541855,0.0000108934355,0.000020403564,0.000021433596,0.0009458821],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985763,0.00002119535,0.0002756388,0.00040546313,0.00028719197,0.0004342277],"domain_scores_gemma":[0.9991946,0.000100014695,0.000069077454,0.00035499348,0.000046752943,0.00023452811],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003371197,0.00019629614,0.00028262532,0.00006632059,0.00009876464,0.000013641291,0.000080432736,0.00011164854,0.00013968417],"category_scores_gemma":[0.00010102793,0.00016463488,0.000071317736,0.00019230423,0.00011543952,0.000049000948,0.00004790192,0.00011230492,0.000051465147],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019426314,0.0031901645,0.7920104,0.00035942806,0.00032638505,0.00031653643,0.0006917268,7.7202935e-7,0.14878346,0.000049722014,0.0019730825,0.052104037],"study_design_scores_gemma":[0.010523206,0.0007587151,0.49009112,0.000083025414,0.00065005315,0.0003983522,0.00032653293,0.000033049448,0.49384788,0.00007881734,0.002925432,0.0002838277],"about_ca_topic_score_codex":0.00028660425,"about_ca_topic_score_gemma":0.000059681333,"teacher_disagreement_score":0.3450644,"about_ca_system_score_codex":0.00023914607,"about_ca_system_score_gemma":0.00019032726,"threshold_uncertainty_score":0.67136157},"labels":[],"label_agreement":null},{"id":"W2579961262","doi":"10.1182/blood.v120.21.910.910","title":"Combined JAK/STAT5A and BCR-ABL Inhibition Impairs Blast Crisis Chronic Myeloid Leukemia Stem Cell Self-Renewal","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"CD38; Cancer research; Dasatinib; Stem cell; Myeloid leukemia; STAT5; Haematopoiesis; Biology; Tyrosine kinase; Imatinib mesylate; Janus kinase; Myeloid; Immunology; Imatinib; CD34; Signal transduction; Cytokine; Cell biology","score_opus":0.008321276368305514,"score_gpt":0.22148471468510003,"score_spread":0.21316343831679452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2579961262","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99128395,0.0034837753,0.000017049304,0.00020214074,0.00023103958,0.0007892716,0.000037688045,0.00034731906,0.003607764],"genre_scores_gemma":[0.9965926,0.00059371593,0.00072290265,0.00021252838,0.0006203602,0.00009052164,0.00013934096,0.00009296097,0.00093510665],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99756736,0.00008999182,0.00047649592,0.00051207136,0.0004507757,0.0009033357],"domain_scores_gemma":[0.99845266,0.00009367152,0.0001913629,0.0005831612,0.00008108889,0.0005980356],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002652228,0.0004493778,0.00055845495,0.00017504446,0.00017296782,0.0000427939,0.000090766924,0.0002640003,0.00020288893],"category_scores_gemma":[0.000013106144,0.00041045892,0.00015337422,0.00027746035,0.000078799705,0.00028623283,0.00013720347,0.00034152792,0.00026401653],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020836098,0.02440022,0.5733128,0.007934362,0.0061396984,0.0015466996,0.02349464,0.000052727857,0.2904315,0.0009114337,0.05084218,0.018850092],"study_design_scores_gemma":[0.13400593,0.0072330213,0.10117587,0.00091522536,0.0073230164,0.0018613002,0.0037162479,0.0004905434,0.73039794,0.00016183368,0.010520401,0.0021986726],"about_ca_topic_score_codex":0.00025806035,"about_ca_topic_score_gemma":0.00003717473,"teacher_disagreement_score":0.47213697,"about_ca_system_score_codex":0.0022467866,"about_ca_system_score_gemma":0.0008365175,"threshold_uncertainty_score":0.9998347},"labels":[],"label_agreement":null},{"id":"W2580021056","doi":"10.18553/jmcp.2017.23.2.214","title":"Health Care Resource Utilization and Costs in Patients with Chronic Myeloid Leukemia with Better Adherence to Tyrosine Kinase Inhibitors and Increased Molecular Monitoring Frequency","year":2017,"lang":"en","type":"article","venue":"Journal of Managed Care & Specialty Pharmacy","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Myeloid leukemia; Emergency medicine; Health care; Internal medicine; Incidence (geometry); Intensive care medicine","score_opus":0.015540074172635065,"score_gpt":0.29812006386282514,"score_spread":0.28257998969019005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2580021056","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922601,0.0057825646,0.000018517228,0.0004957094,0.00013645981,0.0009651676,0.000016873893,0.00001315942,0.0003114481],"genre_scores_gemma":[0.9974913,0.00042637874,0.0011430314,0.00028373947,0.0005516615,0.000012952419,0.000027081584,0.00005347557,0.000010381687],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979321,0.00011925151,0.0005030512,0.00038060898,0.000678413,0.00038660198],"domain_scores_gemma":[0.9980801,0.000030533352,0.00064595614,0.00040926266,0.0003556983,0.000478487],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020050921,0.00032033076,0.00057120615,0.00030427426,0.0002824303,0.00012339292,0.00019243931,0.00005424128,0.00001272621],"category_scores_gemma":[0.00008470159,0.00025441084,0.00004771599,0.00018753165,0.00010960681,0.00032659326,0.00010598735,0.00050954847,0.0000014618348],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001617108,0.000064664564,0.8027114,0.00037671128,0.0000985774,0.000648396,0.0016028694,0.00002052002,0.00052824296,0.0000030865226,0.0001346529,0.19219373],"study_design_scores_gemma":[0.026702212,0.002775777,0.9584089,0.0032722019,0.00024142054,0.00006446695,0.00074733567,0.000008359331,0.005956022,0.0000025330567,0.0015330435,0.000287725],"about_ca_topic_score_codex":0.0016640745,"about_ca_topic_score_gemma":0.00094229745,"teacher_disagreement_score":0.191906,"about_ca_system_score_codex":0.0059755044,"about_ca_system_score_gemma":0.001010855,"threshold_uncertainty_score":0.9999908},"labels":[],"label_agreement":null},{"id":"W2581094758","doi":"10.1182/blood.v106.11.438.438","title":"Leukemic Stem Cells of Chronic Phase CML Patients Possess Uniquely Elevated BCR-ABL Kinase Activity and Acquire Spontaneous BCR-ABL Kinase Domain Mutations at a High Frequency.","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute; BC Cancer Agency","funders":"","keywords":"CD38; Tyrosine kinase; Imatinib mesylate; Biology; Cancer research; Stem cell; ABL; Molecular biology; breakpoint cluster region; Haematopoiesis; Progenitor cell; CD117; CD34; Imatinib; Myeloid leukemia; Cell biology; Signal transduction; Genetics; Gene","score_opus":0.00918812710597172,"score_gpt":0.24648312898287658,"score_spread":0.23729500187690486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2581094758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99576974,0.0011338801,0.000030734747,0.00011077463,0.00014669939,0.0016440646,0.0006661211,0.00018342223,0.00031457696],"genre_scores_gemma":[0.9967377,0.00022422621,0.0014132708,0.00009541174,0.00013524338,0.000111018526,0.00043834193,0.00010737295,0.00073738425],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9967826,0.00022440359,0.0007381799,0.0008472178,0.0006278343,0.00077978225],"domain_scores_gemma":[0.9974923,0.000345341,0.00048727464,0.0009340753,0.00026379872,0.00047716772],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020563377,0.0006030541,0.00086953375,0.00027588164,0.00025097287,0.000032483735,0.00022589375,0.0003290086,0.00043892817],"category_scores_gemma":[0.00007341397,0.00057693943,0.00017899655,0.00047700302,0.00029122175,0.00029938787,0.00015184205,0.00035582908,0.00007152956],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014968191,0.012718741,0.0056315297,0.0007825443,0.0008718564,0.0051559038,0.001317971,0.00006646721,0.9526075,0.00015737185,0.00021056528,0.018982725],"study_design_scores_gemma":[0.0818979,0.0035505365,0.015127804,0.00081187824,0.0019152599,0.0017535108,0.00014363111,0.00039306443,0.8929737,0.00015355874,0.0004161873,0.0008629393],"about_ca_topic_score_codex":0.0012584934,"about_ca_topic_score_gemma":0.0013688446,"teacher_disagreement_score":0.08040108,"about_ca_system_score_codex":0.0041217827,"about_ca_system_score_gemma":0.0015036919,"threshold_uncertainty_score":0.9997012},"labels":[],"label_agreement":null},{"id":"W2581312672","doi":"10.1182/blood.v114.22.3295.3295","title":"Nilotinib Responses and Tolerability Confirmed in North American Patients with Chronic Myeloid Leukemia (CML) From ENACT (Expanding Nilotinib Access in Clinical Trials).","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Nilotinib; Medicine; Tolerability; Imatinib; Internal medicine; Adverse effect; Imatinib mesylate; Myeloid leukemia","score_opus":0.0551837068716041,"score_gpt":0.3749707380968654,"score_spread":0.31978703122526125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2581312672","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99686986,0.00041435476,0.000004268755,0.00025555928,0.00010499365,0.001978748,0.00010417647,0.0000916261,0.00017642685],"genre_scores_gemma":[0.9982514,0.00029106624,0.0003836661,0.00040620478,0.00027276683,0.0000716345,0.00024271029,0.000044989,0.000035561232],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946057,0.0011847664,0.0019009889,0.0010917027,0.0005220617,0.00069473847],"domain_scores_gemma":[0.9956234,0.0024449439,0.000687599,0.00076888286,0.000091377195,0.00038381634],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017551652,0.00048410505,0.0020172962,0.00030882767,0.0000741185,0.000075154785,0.0002688353,0.00017325554,0.00008226661],"category_scores_gemma":[0.0029901615,0.00037885993,0.00015699945,0.0007737529,0.00032177047,0.0002621326,0.000102283906,0.0007824879,0.000010792254],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0062453807,0.00216835,0.9434132,0.000035620596,0.00016270897,0.00015707083,0.0003758071,0.000007776434,0.00013242291,0.0000018014974,0.000022445905,0.047277436],"study_design_scores_gemma":[0.057041764,0.0034592603,0.9374341,0.00030611863,0.0002985003,0.00000963402,0.00005191416,0.00006682242,0.00083328586,0.000016918098,0.00013839288,0.00034334],"about_ca_topic_score_codex":0.0031457965,"about_ca_topic_score_gemma":0.010803981,"teacher_disagreement_score":0.050796382,"about_ca_system_score_codex":0.0016131724,"about_ca_system_score_gemma":0.0018574566,"threshold_uncertainty_score":0.9998663},"labels":[],"label_agreement":null},{"id":"W2581343726","doi":"10.1182/blood.v116.21.204.204","title":"Stromal Cell-Derived Secreted Factors Contribute to the Innate Imatinib Resistance of Leukemia Stem Cells In a Genetically Defined Murine Model of Chronic Myeloid Leukemia Blast Crisis","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Royal University Hospital; University of Saskatchewan","funders":"","keywords":"Myeloid leukemia; Cancer research; Dasatinib; Biology; Stem cell; Imatinib; Bone marrow; Leukemia; Haematopoiesis; Immunology; CD117; Nilotinib; Imatinib mesylate; CD34; Cell biology","score_opus":0.011018198858723547,"score_gpt":0.22677607630232796,"score_spread":0.21575787744360442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2581343726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965854,0.00032746373,0.00056136976,0.00017335458,0.00011819999,0.0014172854,0.00048019714,0.000052157964,0.00028456113],"genre_scores_gemma":[0.9947172,0.00009273124,0.004350126,0.00007676768,0.00008515158,0.0000938442,0.00006635326,0.00007849229,0.00043935303],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99679524,0.00009971375,0.0011080584,0.0006269418,0.0006625404,0.0007075255],"domain_scores_gemma":[0.99752444,0.00022685486,0.00044924827,0.0011853303,0.00031275104,0.00030135468],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034201174,0.00047411287,0.00096514024,0.00022105104,0.0000677516,0.000017376511,0.00048391664,0.00028992895,0.000081517064],"category_scores_gemma":[0.00011892774,0.00036240063,0.0002226575,0.00052196835,0.00017053727,0.000056736986,0.00021877632,0.0006260222,0.000016781698],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005677632,0.00041560392,0.0017597567,0.00039057125,0.0002203248,0.000031390886,0.00087881496,0.0030273348,0.99226356,0.0000746864,0.00024545589,0.00012471303],"study_design_scores_gemma":[0.016936438,0.0007405849,0.014383751,0.0002547691,0.0004556489,0.000010751522,0.00021532037,0.012541485,0.9540291,0.000025814423,0.000097193995,0.00030918806],"about_ca_topic_score_codex":0.00042340934,"about_ca_topic_score_gemma":0.0016459334,"teacher_disagreement_score":0.03823453,"about_ca_system_score_codex":0.001169442,"about_ca_system_score_gemma":0.0026791994,"threshold_uncertainty_score":0.9998828},"labels":[],"label_agreement":null},{"id":"W2581583940","doi":"10.1182/blood.v126.23.53.53","title":"Role of the MSC-Derived Exosomal and Endogenous JAK2-SET/PP2A-Beta Catenin-Modulator Mir-300 in Leukemic Stem/Progenitor Proliferation and Survival in CML","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"CD38; Progenitor cell; Ectopic expression; Cancer research; Biology; Stem cell; Haematopoiesis; CD34; Imatinib mesylate; Cell biology; Cell culture; Molecular biology; Imatinib; Myeloid leukemia; Genetics","score_opus":0.03148552727015677,"score_gpt":0.23968508549445475,"score_spread":0.20819955822429798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2581583940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995162,0.0032497349,4.0426147e-7,0.00011454535,0.00008148707,0.0011028731,0.000022617294,0.000023120445,0.00024318436],"genre_scores_gemma":[0.99949217,0.000045109504,0.00012523543,0.000024361223,0.00010499254,0.00007927275,0.000019449679,0.000030815205,0.00007860789],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985225,0.00013035064,0.0003880516,0.0003509683,0.00031361598,0.00029450544],"domain_scores_gemma":[0.9992767,0.000052382315,0.00011960785,0.0003302736,0.00006977541,0.00015123373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024587353,0.00021236241,0.00042058868,0.00010532269,0.000036687517,0.000016168433,0.00009862399,0.000140276,0.0000053365693],"category_scores_gemma":[0.000058373153,0.00016025426,0.000042140913,0.00018826345,0.00009228727,0.00008989,0.00010404733,0.00019261871,0.0000043781065],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021823081,0.00040748998,0.68970877,0.0000867444,0.00010186934,0.000052329447,0.0025455668,0.000006187599,0.30625153,0.000025655085,0.0000061440633,0.0005895026],"study_design_scores_gemma":[0.028643059,0.00051811093,0.5059486,0.00019454154,0.00032038195,0.00058622786,0.0010814124,0.00050655927,0.46183008,0.00007701401,0.000054984503,0.00023901965],"about_ca_topic_score_codex":0.0010779785,"about_ca_topic_score_gemma":0.00093822414,"teacher_disagreement_score":0.18376014,"about_ca_system_score_codex":0.0003417349,"about_ca_system_score_gemma":0.00066275906,"threshold_uncertainty_score":0.6534979},"labels":[],"label_agreement":null},{"id":"W2581610696","doi":"10.1182/blood.v116.21.4181.4181","title":"The WD40-Repeats of Ahi-1 Oncogene Critical for Protein Interaction Between Ahi-1 and BCR-ABL Modulates Imatinib-Induced Apoptosis In BCR-ABL-Transduced Cells","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Cancer research; Fusion protein; Biology; SH3 domain; Progenitor cell; ABL; breakpoint cluster region; Tyrosine kinase; Philadelphia chromosome; Myeloid leukemia; Stem cell; K562 cells; Haematopoiesis; Leukemia; Cell biology; Signal transduction; Immunology; Receptor; Chromosomal translocation; Genetics; Recombinant DNA","score_opus":0.020925623757325637,"score_gpt":0.3038845966690858,"score_spread":0.28295897291176014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2581610696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962507,0.00013108765,0.000047155583,0.00097552966,0.00021851844,0.0019580731,0.000055971297,0.000051140854,0.00031186105],"genre_scores_gemma":[0.9950543,0.000032582182,0.0040485584,0.00003742156,0.00023492433,0.00034438592,0.000043712378,0.000055306537,0.00014878671],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980246,0.00008093928,0.0006564928,0.00046498782,0.00030106844,0.0004719414],"domain_scores_gemma":[0.99833363,0.0006645095,0.00015757863,0.00053398433,0.00012360064,0.00018668456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043898655,0.00029275837,0.0005591396,0.00013128197,0.00013384395,0.000039058235,0.00015531368,0.00026304025,0.000054834047],"category_scores_gemma":[0.00047825178,0.00022168692,0.00014596416,0.00015786267,0.00014129003,0.00014591611,0.000053635213,0.00044448057,0.000010428595],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021835201,0.00067336764,0.005743234,0.00032082354,0.00022112556,0.000006464765,0.00044115703,6.9538635e-7,0.9817232,0.00008409291,0.00003310375,0.010534402],"study_design_scores_gemma":[0.0084617,0.00076147635,0.0074811243,0.00031333076,0.00047818563,0.000026668557,0.00014136973,0.00026041616,0.9813138,0.000301912,0.0002624956,0.00019747904],"about_ca_topic_score_codex":0.00029221666,"about_ca_topic_score_gemma":0.00014009407,"teacher_disagreement_score":0.010336923,"about_ca_system_score_codex":0.00011427682,"about_ca_system_score_gemma":0.00020410406,"threshold_uncertainty_score":0.90401304},"labels":[],"label_agreement":null},{"id":"W2583651793","doi":"10.1182/blood.v108.11.2140.2140","title":"Imatinib in Children with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CP CML): AAML0123 COG Study.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Medicine; Imatinib; Imatinib mesylate; Chronic myelogenous leukemia; Internal medicine; Gastroenterology; Absolute neutrophil count; Phases of clinical research; Leukemia; Chemotherapy; Surgery; Neutropenia; Myeloid leukemia","score_opus":0.008364758774985158,"score_gpt":0.25655507079033585,"score_spread":0.2481903120153507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2583651793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98767835,0.006164267,0.000023789831,0.00008004335,0.000070614,0.003940448,0.000059033835,0.00027916624,0.0017042755],"genre_scores_gemma":[0.9965621,0.00014308252,0.0005367914,0.0000863604,0.0009174898,0.0004957072,0.0004555093,0.00014978362,0.0006531535],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963397,0.00012088222,0.00077142176,0.00096644973,0.0006988808,0.0011026791],"domain_scores_gemma":[0.99814975,0.00011342528,0.00026941064,0.0011279299,0.00008334323,0.0002561458],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024488123,0.00065368816,0.00094140886,0.0003095546,0.00016229339,0.000052713563,0.00031822236,0.0002169368,0.00038292707],"category_scores_gemma":[0.000046210364,0.0005449396,0.00015371833,0.00071142666,0.00016910858,0.00016260752,0.00010738496,0.0005816724,0.00027516828],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006304145,0.024305006,0.93336666,0.00022052719,0.0024452333,0.004452663,0.0008260944,0.0008266283,0.007473755,0.000048984028,0.00097007875,0.02443398],"study_design_scores_gemma":[0.23768668,0.009681951,0.73800266,0.00039500152,0.0025913198,0.0013887874,0.00013765905,0.00026151186,0.008573147,0.000026804399,0.0004942707,0.00076022674],"about_ca_topic_score_codex":0.0065322346,"about_ca_topic_score_gemma":0.005570598,"teacher_disagreement_score":0.23705627,"about_ca_system_score_codex":0.004176517,"about_ca_system_score_gemma":0.0037630387,"threshold_uncertainty_score":0.9997002},"labels":[],"label_agreement":null},{"id":"W2584084443","doi":"10.1182/blood.v108.11.288.288","title":"FTY720, a New and Alternative Strategy for Treating Blast Crisis CML and Ph1 ALL Patients.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Cancer research; Chronic myelogenous leukemia; Progenitor cell; Myeloid; Philadelphia chromosome; Dasatinib; Immunology; Imatinib; Megakaryocytopoiesis; Leukemia; CD34; Medicine; Myeloid leukemia; Biology; Stem cell; Megakaryocyte; Chromosomal translocation; Cell biology","score_opus":0.01786129546141479,"score_gpt":0.27060594563445467,"score_spread":0.2527446501730399,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2584084443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961082,0.0007086293,0.00005869246,0.00019080359,0.000025757865,0.0005633556,0.00004611949,0.000035651276,0.0022628126],"genre_scores_gemma":[0.9961127,0.00005663981,0.0021909494,0.00013005284,0.00024216781,0.000032305452,0.000104608574,0.000027240718,0.001103305],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99913824,0.000012330745,0.00018833314,0.00029929154,0.00012959367,0.0002322318],"domain_scores_gemma":[0.9995412,0.00007504436,0.000078702666,0.00013088771,0.000047566133,0.00012657729],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000037434762,0.00016641489,0.00023752164,0.000052315634,0.00005105266,0.000027506354,0.00003036078,0.000058626003,0.000024601994],"category_scores_gemma":[0.000032987453,0.00013985774,0.000042483985,0.00004868539,0.000028562888,0.00006783273,0.000027060642,0.000063173014,0.0000036923375],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012544452,0.0070215194,0.81370676,0.00089778507,0.0032152347,0.000284895,0.0047080354,0.000062509556,0.006284804,0.0015998875,0.029594887,0.13136923],"study_design_scores_gemma":[0.3186259,0.01218975,0.55362034,0.0008342202,0.0074203582,0.0004388125,0.0017387423,0.0028054183,0.07890112,0.006819351,0.0149935745,0.0016124463],"about_ca_topic_score_codex":0.0019774132,"about_ca_topic_score_gemma":0.00016580668,"teacher_disagreement_score":0.31737146,"about_ca_system_score_codex":0.00008994289,"about_ca_system_score_gemma":0.00009472521,"threshold_uncertainty_score":0.57032335},"labels":[],"label_agreement":null},{"id":"W2584781338","doi":"10.1182/blood.v114.22.4285.4285","title":"Lower Healthcare Resource Utilization Associated with Managing Nilotinib Related Adverse Events in Chronic Myeloid Leukemia (CML) Patients – Evidence From a Clinical Practice Setting Study.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Nilotinib; Dasatinib; Medicine; Adverse effect; Imatinib; Internal medicine; Clinical trial; Myeloid leukemia; Oncology","score_opus":0.036676422257919485,"score_gpt":0.3391300849218322,"score_spread":0.3024536626639127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2584781338","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949207,0.0008799301,0.000008916253,0.0009746785,0.0001329729,0.0024153155,0.000013791495,0.00021989578,0.00043383212],"genre_scores_gemma":[0.99771434,0.0001909454,0.0005884474,0.0007235471,0.0001315227,0.000042464253,0.00035628112,0.000069736234,0.00018272112],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99490625,0.0009721276,0.0013309924,0.0010580886,0.0010491962,0.000683337],"domain_scores_gemma":[0.99671555,0.001013563,0.00087463163,0.00079633313,0.00031421302,0.00028569796],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014085107,0.00042502856,0.0007185702,0.00019931527,0.00016665862,0.000013922299,0.00023121104,0.00031474937,0.000042553595],"category_scores_gemma":[0.00425282,0.0003872224,0.00012662212,0.00090724026,0.00004907501,0.0004977072,0.00009940747,0.0010009421,0.000053838976],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013854362,0.0049997983,0.9816959,0.000043648317,0.0005602789,0.00077729,0.001781532,0.00016573606,0.00003404123,0.0000021721792,0.00008617274,0.008467983],"study_design_scores_gemma":[0.035666835,0.005411138,0.95150423,0.0041176747,0.001085733,0.000022157492,0.0007812897,0.0008880136,0.00004030455,0.000022607572,0.00013215996,0.0003278561],"about_ca_topic_score_codex":0.00090064004,"about_ca_topic_score_gemma":0.0006053715,"teacher_disagreement_score":0.0342814,"about_ca_system_score_codex":0.005013775,"about_ca_system_score_gemma":0.0016688876,"threshold_uncertainty_score":0.99985796},"labels":[],"label_agreement":null},{"id":"W2585952718","doi":"10.1182/blood.v120.21.3785.3785","title":"Bosutinib As Therapy for Chronic Phase Chronic Myeloid Leukemia Following Failure with Imatinib Plus Dasatinib and/or Nilotinib: 24-Month Minimum Follow-up Update","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Nilotinib; Bosutinib; Dasatinib; Medicine; Internal medicine; Imatinib; Gastroenterology; Discontinuation; Myeloid leukemia; Interquartile range; Surgery","score_opus":0.021190996040951808,"score_gpt":0.29488857032200017,"score_spread":0.27369757428104835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2585952718","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98052055,0.011502481,0.0002047626,0.000676424,0.0007203642,0.0046493327,0.00013718614,0.00043790136,0.0011510034],"genre_scores_gemma":[0.98395604,0.00085585064,0.006781692,0.000641112,0.0019767284,0.001202672,0.0006731631,0.000346461,0.0035662649],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9949625,0.00012403513,0.00095866766,0.0011564823,0.0008235746,0.0019746996],"domain_scores_gemma":[0.9967546,0.00042069168,0.00050113705,0.0013046501,0.00014301226,0.000875936],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006666086,0.0010585597,0.0014735062,0.00024825192,0.0004786918,0.00011712217,0.00037714973,0.00043337134,0.000676978],"category_scores_gemma":[0.00024835658,0.0007732069,0.00050167955,0.00048489685,0.00022253198,0.0006169407,0.00014656105,0.0005934983,0.00020053376],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08235971,0.027452609,0.07616587,0.010003482,0.04538696,0.0032694212,0.035095904,0.000111007204,0.28813407,0.0028719448,0.060103532,0.3690455],"study_design_scores_gemma":[0.6541456,0.029200595,0.0036620137,0.0023446192,0.0065712323,0.0026383859,0.00165474,0.0014680276,0.115092315,0.00010581859,0.18021592,0.0029007306],"about_ca_topic_score_codex":0.00012996246,"about_ca_topic_score_gemma":0.00025606347,"teacher_disagreement_score":0.5717859,"about_ca_system_score_codex":0.0026395472,"about_ca_system_score_gemma":0.005245726,"threshold_uncertainty_score":0.9994719},"labels":[],"label_agreement":null},{"id":"W2586559902","doi":"10.1182/blood.v120.21.3753.3753","title":"Blast Phase Chronic Myeloid Leukemia: A Pooled Analysis of Subcutaneous Omacetaxine Mepesuccinate in Treatment-Resistant Patients","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Neutropenia; Tolerability; Myeloid leukemia; Leukemia; Gastroenterology; Adverse effect; Oncology; Pharmacology; Immunology; Chemotherapy","score_opus":0.011099158388696065,"score_gpt":0.26919389661000453,"score_spread":0.25809473822130846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586559902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99418694,0.0031818545,0.0000057576613,0.00003812416,0.000085856365,0.0008934428,0.00020652535,0.00006727669,0.0013342288],"genre_scores_gemma":[0.9979545,0.00031198244,0.00019677858,0.00003380972,0.000118939155,0.000090579095,0.0005461802,0.00005540212,0.0006918619],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99722755,0.00010720269,0.00080840575,0.00049229735,0.00050584,0.0008587057],"domain_scores_gemma":[0.9982748,0.00012520936,0.00033130674,0.0007873983,0.00011717151,0.00036411834],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017837078,0.00045942157,0.0012681534,0.0008433479,0.00005656412,0.000010781629,0.0001445811,0.00019998659,0.0005644474],"category_scores_gemma":[0.00008896897,0.0003753589,0.00045267693,0.0015365409,0.000080755766,0.0001337121,0.000057382604,0.00019310547,0.00006055203],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052948873,0.05279175,0.740345,0.00045209753,0.03612486,0.0019786442,0.0029841247,0.00024748346,0.12338772,0.00008360817,0.00009172924,0.036218088],"study_design_scores_gemma":[0.21840285,0.01521405,0.5246174,0.00040087922,0.07329734,0.00024696626,0.00021427337,0.0020521833,0.16287753,0.000009489169,0.001623321,0.0010437727],"about_ca_topic_score_codex":0.00095750205,"about_ca_topic_score_gemma":0.00090109324,"teacher_disagreement_score":0.21572767,"about_ca_system_score_codex":0.0043603354,"about_ca_system_score_gemma":0.00067059847,"threshold_uncertainty_score":0.9998698},"labels":[],"label_agreement":null},{"id":"W2586955463","doi":"10.1182/blood.v112.11.3233.3233","title":"Nilotinib in Elderly Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) with Imatinib Resistance or Intolerance: Efficacy and Safety Analysis","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Nilotinib; Medicine; Discontinuation; Internal medicine; Imatinib; Adverse effect; Myeloid leukemia; Gastroenterology","score_opus":0.01335522527399351,"score_gpt":0.27032661347821196,"score_spread":0.25697138820421844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586955463","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99439096,0.0028888725,0.0000366061,0.00009185922,0.000034911893,0.0014341963,0.00005587866,0.000085946296,0.000980761],"genre_scores_gemma":[0.99553776,0.0017663654,0.0011443929,0.00007075357,0.00012465662,0.00014232966,0.0002791733,0.00006813374,0.0008664373],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966103,0.00012122637,0.00093256484,0.0009466142,0.00059569685,0.00079361035],"domain_scores_gemma":[0.99833107,0.00020301901,0.00028777815,0.0008069322,0.00010468906,0.00026648986],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002256648,0.00051317416,0.0011624293,0.0005909338,0.00014454164,0.000021975737,0.00019879382,0.00020567824,0.00025534135],"category_scores_gemma":[0.0001399773,0.00040440852,0.00011830484,0.0021226702,0.00025833008,0.00021535577,0.000070802205,0.0005505453,0.000026121726],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02130035,0.012069905,0.9017467,0.0017389517,0.0038137035,0.005299678,0.0057477816,0.0014503077,0.0030375211,0.000044114287,0.00040439318,0.043346576],"study_design_scores_gemma":[0.20668635,0.004653038,0.78047353,0.0012658207,0.0014594345,0.00010561721,0.000063321546,0.00078175665,0.0022038852,0.0000063613056,0.001675772,0.00062513514],"about_ca_topic_score_codex":0.0006173795,"about_ca_topic_score_gemma":0.012602173,"teacher_disagreement_score":0.185386,"about_ca_system_score_codex":0.004961874,"about_ca_system_score_gemma":0.0029369406,"threshold_uncertainty_score":0.9998408},"labels":[],"label_agreement":null},{"id":"W2587441942","doi":"10.1182/blood.v126.23.4041.4041","title":"Predictors of Response Duration and Survival with Second-Line Bosutinib Therapy in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML) Resistant or Intolerant to Prior Imatinib","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Bosutinib; Internal medicine; Imatinib; Cumulative incidence; Proportional hazards model; Gastroenterology; Discontinuation; Tyrosine-kinase inhibitor; Retrospective cohort study; Myeloid leukemia; Oncology; Nilotinib; Cohort; Cancer","score_opus":0.019198493718807292,"score_gpt":0.2742516609083612,"score_spread":0.2550531671895539,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587441942","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996385,0.00058086176,0.000027352944,0.00016402926,0.00008131916,0.0024565263,0.000109561515,0.00007043433,0.00012493103],"genre_scores_gemma":[0.9979511,0.00008146178,0.0009847506,0.00006165046,0.00014802245,0.0001647404,0.00013941336,0.00008165028,0.00038722806],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9970248,0.00023148923,0.0008452949,0.0006314346,0.0007558054,0.00051117776],"domain_scores_gemma":[0.9980822,0.00017403172,0.0003723445,0.00066166796,0.00029630895,0.00041342937],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00075973704,0.00043472293,0.0007750952,0.00029600394,0.00006363143,0.000027094531,0.00014706189,0.00014825696,0.00012269641],"category_scores_gemma":[0.0002546344,0.0002813038,0.00004589671,0.00057114667,0.00016116498,0.00018750354,0.0000609125,0.00027264652,0.000008502388],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5152499,0.010496376,0.3517187,0.0011742932,0.0020383417,0.000900398,0.011848204,0.00023835636,0.08197888,0.00002532722,0.00039438356,0.023936827],"study_design_scores_gemma":[0.36514646,0.11896569,0.41768822,0.0018087814,0.0005010405,0.00014913436,0.00044542592,0.0004560023,0.091797404,0.0000050496824,0.0023248082,0.0007119637],"about_ca_topic_score_codex":0.00025333214,"about_ca_topic_score_gemma":0.0028991944,"teacher_disagreement_score":0.15010345,"about_ca_system_score_codex":0.0027235989,"about_ca_system_score_gemma":0.005647148,"threshold_uncertainty_score":0.9999899},"labels":[],"label_agreement":null},{"id":"W2587669739","doi":"10.1182/blood.v110.11.5177.5177","title":"Cost of Myelosuppression with the Second Generation Tyrosine Kinase Inhibitors (TKIs) in Imatinib Resistant/Intolerant Chronic Myelogenous Leukemia (CML): An Economic Analysis Using Global Literature.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Nilotinib; Medicine; Dasatinib; Neutropenia; Chronic myelogenous leukemia; Imatinib; Internal medicine; Anemia; Leukemia; Myeloid leukemia; Chemotherapy","score_opus":0.01814481978442503,"score_gpt":0.2816822068926222,"score_spread":0.2635373871081972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587669739","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952289,0.003010724,0.00023531486,0.000052498443,0.000083219886,0.00084756094,0.0001784368,0.0000339388,0.00032940728],"genre_scores_gemma":[0.9966619,0.000047638747,0.0022205347,0.0000676361,0.0004304608,0.00002099084,0.00045089703,0.000035462006,0.00006445027],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977819,0.00011807422,0.00071648264,0.0005605516,0.0003325844,0.0004904506],"domain_scores_gemma":[0.99850553,0.000059399634,0.0003791104,0.00076451985,0.00011014119,0.00018131074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055000186,0.0003493621,0.000640374,0.0003073332,0.00014375344,0.000058891244,0.00016799086,0.00021104893,0.00016151095],"category_scores_gemma":[0.000018684304,0.00024048702,0.00016293375,0.0009658816,0.00013720634,0.00022241325,0.000053723274,0.0002663508,0.0000047527765],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030268107,0.0020206985,0.1232597,0.0005805655,0.0030742323,0.00133841,0.004035581,0.02056617,0.8320244,0.00016912466,0.0001772418,0.009727092],"study_design_scores_gemma":[0.03867926,0.0027882217,0.2927467,0.001302607,0.006459321,0.0006924206,0.0007390992,0.05024993,0.6047393,0.000025713456,0.0005893265,0.0009881187],"about_ca_topic_score_codex":0.0007635553,"about_ca_topic_score_gemma":0.019081526,"teacher_disagreement_score":0.22728509,"about_ca_system_score_codex":0.003854885,"about_ca_system_score_gemma":0.0011618261,"threshold_uncertainty_score":0.9999691},"labels":[],"label_agreement":null},{"id":"W2588130165","doi":"10.1182/blood.v118.21.5006.5006","title":"Pharmacokinetics of Dasatinib in a Patient with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia During Treatment with Anti-Tuberculosis Therapy","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; London Health Sciences Centre","funders":"","keywords":"Dasatinib; Medicine; Imatinib; Internal medicine; Concomitant; Cmax; Imatinib mesylate; Gastroenterology; Isoniazid; Tyrosine-kinase inhibitor; Myeloid leukemia; Pharmacology; Tuberculosis; Oncology; Pharmacokinetics; Pathology; Cancer","score_opus":0.015005173936140545,"score_gpt":0.23890642743556095,"score_spread":0.22390125349942042,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588130165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99708813,0.00052585406,0.0000042647885,0.000048227368,0.000024197265,0.0011877712,0.00007104183,0.00005367512,0.0009968635],"genre_scores_gemma":[0.99718875,0.0011505766,0.0012317783,0.000057015426,0.000046121313,0.0001712997,0.000048305086,0.00007257567,0.00003360609],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982892,0.00004457717,0.00039249624,0.00047074893,0.00037346155,0.0004295153],"domain_scores_gemma":[0.99904054,0.00004820881,0.00021186868,0.00043019457,0.00009987383,0.0001692943],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000030878324,0.00041310972,0.0006262592,0.00019749367,0.000046264857,0.0000066630423,0.000091058646,0.00008887411,0.00015138826],"category_scores_gemma":[0.0000046394043,0.000268998,0.00008754717,0.00038066908,0.00013276766,0.00008567879,0.000031013,0.0001186197,0.000009254668],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015023245,0.023612035,0.4843574,0.00041634214,0.016441446,0.018111972,0.027244847,0.0002486949,0.40753925,0.000027686336,0.000012078684,0.0069650305],"study_design_scores_gemma":[0.057165794,0.01150372,0.22459608,0.00062158564,0.0016560076,0.0017555263,0.00015535223,0.000082346916,0.7021398,0.0000030157207,0.000016011227,0.0003047495],"about_ca_topic_score_codex":0.0005632783,"about_ca_topic_score_gemma":0.000037055524,"teacher_disagreement_score":0.29460058,"about_ca_system_score_codex":0.0011842386,"about_ca_system_score_gemma":0.00058431964,"threshold_uncertainty_score":0.9999762},"labels":[],"label_agreement":null},{"id":"W2588130364","doi":"10.1182/blood-2016-12-757302","title":"Stopping second-generation TKIs in CML","year":2017,"lang":"en","type":"letter","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Nilotinib; Medicine; Dasatinib; Discontinuation; Imatinib; Tyrosine-kinase inhibitor; Bosutinib; Internal medicine; Oncology; Imatinib mesylate; Myeloid leukemia; Observational study; Cancer","score_opus":0.037087056406952534,"score_gpt":0.2793085231867801,"score_spread":0.2422214667798276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588130364","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5843452,0.0033543669,0.0000071341165,0.36857048,0.0015096334,0.001743389,0.0001282828,0.0001745402,0.040166974],"genre_scores_gemma":[0.16326296,0.0002841384,0.0014032209,0.6361787,0.036603853,0.0003996631,0.006386797,0.00033660544,0.1551441],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99851066,0.000044727185,0.0002967802,0.00048033556,0.00030267844,0.00036484323],"domain_scores_gemma":[0.9988045,0.000035577665,0.00019934023,0.0008663266,0.000041102438,0.00005312856],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00010881876,0.0002920239,0.0005148282,0.00019859627,0.000075341515,0.000047601858,0.00016643741,0.000739135,0.00077736145],"category_scores_gemma":[0.000084572355,0.00027602992,0.00012549147,0.000047675057,0.000037138238,0.00007266406,0.000053691307,0.0012061329,0.00025413634],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000069166513,0.0001667123,0.0022368971,0.00034637153,0.00029034875,0.0062912484,0.00012641451,5.4933975e-7,0.0018371175,0.0000025498584,0.9871352,0.0015596951],"study_design_scores_gemma":[0.010112848,0.00015803875,0.004561935,0.0005995044,0.00056607043,0.00055286,0.0000044503,0.000044294502,0.0029824253,0.000013917121,0.9800474,0.0003562285],"about_ca_topic_score_codex":0.00017078136,"about_ca_topic_score_gemma":0.0002829931,"teacher_disagreement_score":0.42108226,"about_ca_system_score_codex":0.000581943,"about_ca_system_score_gemma":0.00056635117,"threshold_uncertainty_score":0.9999692},"labels":[],"label_agreement":null},{"id":"W2588455970","doi":"10.1182/blood.v112.11.4258.4258","title":"Retrospective Study of Trough Imatinib Plasma Levels Conducted as Part of the Follow-up of Patients with Chronic Myeloid Leukemia in a Canadian Cohort","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Imatinib; Myeloid leukemia; Medicine; Trough level; Internal medicine; Cohort; Gastroenterology; Oncology","score_opus":0.016316615937859352,"score_gpt":0.23718431651633629,"score_spread":0.22086770057847693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588455970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955319,0.000062473366,1.0621771e-7,0.000015857056,0.0000950546,0.0024439,0.00018192716,0.000012428702,0.0016563509],"genre_scores_gemma":[0.99941266,0.000011915825,0.0000535317,0.00001628208,0.00002631407,0.00008395901,0.00003841176,0.000036486843,0.000320446],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99778765,0.00009877253,0.00066016265,0.00036406153,0.0006790427,0.0004102977],"domain_scores_gemma":[0.9983239,0.000046109522,0.00043032208,0.00072249246,0.00031654842,0.00016060607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014066267,0.0002526637,0.00080734654,0.00017274424,0.00006371542,0.000002047512,0.00020770455,0.00011522183,0.00015146156],"category_scores_gemma":[0.00023401584,0.0001762512,0.000096858384,0.0006477494,0.00022280558,0.00007081801,0.000050566585,0.0002579115,0.000004238559],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002961425,0.0013183403,0.99306226,0.00006893822,0.0008323338,0.000051187344,0.003542713,0.000020001662,0.00068573956,0.000016704735,0.000051637373,0.00005400237],"study_design_scores_gemma":[0.047388185,0.0029286363,0.93439347,0.0002700133,0.00053840247,0.000030347543,0.00034578712,0.000018608738,0.01391465,0.0000064924766,0.00003443571,0.00013100424],"about_ca_topic_score_codex":0.21616203,"about_ca_topic_score_gemma":0.2576638,"teacher_disagreement_score":0.058668822,"about_ca_system_score_codex":0.003213599,"about_ca_system_score_gemma":0.006751577,"threshold_uncertainty_score":0.9988792},"labels":[],"label_agreement":null},{"id":"W2588916936","doi":"10.1182/blood.v128.22.792.792","title":"Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase According to Reasons for Switching from Imatinib to Nilotinib: Subgroup Analysis from ENESTop","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Nilotinib; Medicine; Internal medicine; Imatinib; Clinical endpoint; Imatinib mesylate; Interim analysis; Myeloid leukemia; Gastroenterology; Surgery; Clinical trial","score_opus":0.013697153198881004,"score_gpt":0.27771215606763033,"score_spread":0.26401500286874935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588916936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99428684,0.0003407128,0.0014242509,0.00043594211,0.00008419799,0.0026830717,0.0005465722,0.000120153694,0.000078255114],"genre_scores_gemma":[0.9897877,0.000044220847,0.00809131,0.000089056855,0.0003511773,0.0006529444,0.00069968525,0.0001180396,0.0001658627],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996341,0.000096013595,0.0008080365,0.0013106739,0.00051932543,0.0009249653],"domain_scores_gemma":[0.9969414,0.00057704095,0.00025902042,0.001594848,0.00007719714,0.0005505163],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018923018,0.0006166217,0.0012273906,0.0007888737,0.00010923775,0.0000431194,0.0004042483,0.00021708097,0.00013988487],"category_scores_gemma":[0.0004718918,0.00041970494,0.00025318775,0.0012580347,0.00002556682,0.0002469532,0.00017559185,0.00017818197,0.000055520017],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034352122,0.001878539,0.8338159,0.000043002696,0.0015944048,0.0001244777,0.0008897659,0.00015251833,0.07774485,0.0000058032692,0.000068216126,0.08024736],"study_design_scores_gemma":[0.23063548,0.008409856,0.70310634,0.00283978,0.0043402705,0.0000055260693,0.00017047791,0.0008938563,0.04774235,0.000087586566,0.00079551764,0.00097295275],"about_ca_topic_score_codex":0.0120508,"about_ca_topic_score_gemma":0.011880946,"teacher_disagreement_score":0.22720027,"about_ca_system_score_codex":0.017695079,"about_ca_system_score_gemma":0.0019091977,"threshold_uncertainty_score":0.9998255},"labels":[],"label_agreement":null},{"id":"W2589983700","doi":"10.1182/blood.v128.22.1891.1891","title":"Patient-Reported Quality of Life before and after Stopping Treatment in the ENESTop Trial of Treatment-Free Remission for Patients with Chronic Myeloid Leukemia in Chronic Phase","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nilotinib; Internal medicine; Imatinib mesylate; Adverse effect; Imatinib; Gastroenterology; Myeloid leukemia","score_opus":0.02172127991890915,"score_gpt":0.29370315122618446,"score_spread":0.2719818713072753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589983700","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99453354,0.0007358378,0.000007685512,0.00011110595,0.00004677347,0.00437236,0.000135729,0.000016805454,0.000040161212],"genre_scores_gemma":[0.9983763,0.00020577588,0.00017925419,0.000016086502,0.00010116274,0.00092401926,0.00008881505,0.00003553016,0.00007304664],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99756074,0.00015487296,0.001017369,0.0004972043,0.00037212804,0.00039769136],"domain_scores_gemma":[0.99796265,0.0003128918,0.0005557603,0.00094111654,0.00009603945,0.00013152251],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025237008,0.0003573593,0.00084643223,0.0001820878,0.00003762354,0.0000059750146,0.00011174359,0.00015278338,0.000026496413],"category_scores_gemma":[0.00030377347,0.00017500625,0.00015500064,0.00021594492,0.00012081657,0.00010619666,0.000042982745,0.00006953555,5.796697e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0986811,0.0122588165,0.73920083,0.0006172835,0.0010270874,0.000084092986,0.0034011612,0.000007748538,0.008977642,0.00003031463,0.000012906072,0.13570105],"study_design_scores_gemma":[0.6769295,0.04930573,0.2652155,0.00094791956,0.00063583173,0.000011239702,0.0000990638,0.00003251607,0.0063265515,0.00004766195,0.00024134101,0.0002071687],"about_ca_topic_score_codex":0.0012832019,"about_ca_topic_score_gemma":0.0027441778,"teacher_disagreement_score":0.5782484,"about_ca_system_score_codex":0.006255622,"about_ca_system_score_gemma":0.0032859244,"threshold_uncertainty_score":0.9975592},"labels":[],"label_agreement":null},{"id":"W2591297419","doi":"10.1182/blood.v120.21.69.69","title":"Assessment of Early Molecular Response As a Predictor of Long-Term Clinical Outcomes in the Phase 3 BELA Study","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Bosutinib; Discontinuation; Medicine; Internal medicine; Gastroenterology; Population; Clinical endpoint; Imatinib; Imatinib mesylate; Myeloid leukemia; Clinical trial; Dasatinib","score_opus":0.040900576643565646,"score_gpt":0.423422908470745,"score_spread":0.3825223318271793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591297419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99793833,0.00022092948,0.0000092429755,0.00009074075,0.00007743956,0.0013598016,0.000017740369,0.0000135804075,0.0002722131],"genre_scores_gemma":[0.9994378,0.000010234076,0.00022579062,0.00008025594,0.00004613201,0.00007491079,0.000008151715,0.000018226221,0.00009847995],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99772614,0.00061700295,0.0006661489,0.00019152887,0.00055715174,0.00024199918],"domain_scores_gemma":[0.998301,0.00062187464,0.0002025588,0.00071132777,0.000050983337,0.000112247646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017075913,0.00014961534,0.0005313588,0.00009714938,0.0000149979805,0.0000042294964,0.00017572133,0.000083802646,0.00006574928],"category_scores_gemma":[0.00048121726,0.00009498466,0.00017351616,0.00015876528,0.00008315606,0.000051843977,0.00006848416,0.0002295373,0.000008231744],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008892609,0.036553003,0.9578428,0.00003448832,0.0007013747,0.00039997767,0.0013833604,1.3814353e-7,0.0018300094,0.00002043534,0.000006074398,0.000339048],"study_design_scores_gemma":[0.039046243,0.0065959464,0.95156157,0.00006858019,0.00096997106,0.000040664258,0.00023048355,0.0000017770147,0.0014126445,0.000003327883,0.0000057665634,0.00006302731],"about_ca_topic_score_codex":0.00008901759,"about_ca_topic_score_gemma":0.000008977515,"teacher_disagreement_score":0.038156983,"about_ca_system_score_codex":0.000087312255,"about_ca_system_score_gemma":0.00041378193,"threshold_uncertainty_score":0.3873362},"labels":[],"label_agreement":null},{"id":"W2591377132","doi":"10.1200/jco.2014.32.15_suppl.7025","title":"Effect of continued imatinib (IM) in pts with detectable BCR-ABL after ≥ 2 years on study on deep molecular responses (MR): 36-month update from ENESTcmr.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Vancouver General Hospital; Ontario Institute for Cancer Research; McMaster University","funders":"","keywords":"Medicine; Imatinib; Nilotinib; Imatinib mesylate; Internal medicine; Gastroenterology; Nuclear medicine; Myeloid leukemia","score_opus":0.02489342773528545,"score_gpt":0.4009312724431337,"score_spread":0.37603784470784823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591377132","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976027,0.00017264816,0.000045185134,0.0004116899,0.0003448211,0.0007049218,0.000005152712,0.000010192025,0.00070268527],"genre_scores_gemma":[0.9972842,0.000036094443,0.001395969,0.0008964596,0.00024156412,0.000030432066,0.0000031846812,0.00004078195,0.00007136438],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9936526,0.003039765,0.002006119,0.0003533217,0.00062173087,0.0003264712],"domain_scores_gemma":[0.9876789,0.009891676,0.0014773788,0.00050810375,0.00015691212,0.0002870445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0048171314,0.0002697886,0.0023830119,0.00024497404,0.00001785496,0.000009013904,0.0002150901,0.00034213896,0.00012478654],"category_scores_gemma":[0.006712542,0.00017458964,0.00032220825,0.00017560166,0.00016719509,0.000064169784,0.000054254084,0.0010441949,0.000048150683],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3115728,0.00811303,0.4953722,0.00006211632,0.00143944,0.011606657,0.00041643967,0.00019929766,0.0023225304,0.000009183861,0.00020636243,0.16867995],"study_design_scores_gemma":[0.06393733,0.16378056,0.76292694,0.00065731636,0.0008321846,0.00008748461,0.000084087354,0.00016113442,0.0055748625,0.000049294697,0.0017490687,0.00015974017],"about_ca_topic_score_codex":0.00010783189,"about_ca_topic_score_gemma":0.00024001545,"teacher_disagreement_score":0.26755473,"about_ca_system_score_codex":0.00048520314,"about_ca_system_score_gemma":0.0007599493,"threshold_uncertainty_score":0.80360246},"labels":[],"label_agreement":null},{"id":"W2591449905","doi":"10.1182/blood.v124.21.3133.3133","title":"Identification of New microRNA Biomarkers and Candidate Target Genes in Primitive CML Cells Using Global Comparative RNA analyses","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"CD34; Imatinib mesylate; microRNA; Progenitor cell; Biology; Stem cell; Haematopoiesis; Cancer research; MiRBase; Molecular biology; Immunology; Imatinib; Gene; Genetics; Myeloid leukemia","score_opus":0.04231022861407496,"score_gpt":0.33850139428500786,"score_spread":0.2961911656709329,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591449905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99749744,0.0014103984,0.0003869813,0.000030479536,0.00004322208,0.00028382207,0.000035862526,0.000010956619,0.00030081847],"genre_scores_gemma":[0.9960972,0.0000637796,0.003696994,0.000020721489,0.000037414222,0.0000027741085,0.00003321551,0.000007104723,0.000040774954],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991025,0.000062483356,0.00030696503,0.00024085387,0.00013370355,0.0001535122],"domain_scores_gemma":[0.999451,0.00003577169,0.0001896846,0.00017990898,0.000051630894,0.00009204753],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000108933855,0.00012967072,0.00033192226,0.000084742416,0.000026271167,0.0000114988,0.000049243645,0.000053788597,0.000014131884],"category_scores_gemma":[0.000024183168,0.00011650547,0.00004311499,0.0002317581,0.000076688644,0.000057568428,0.00002924756,0.000043121563,0.0000048002435],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000092738985,0.00022691462,0.0791674,0.00005356042,0.00039850755,0.000010667629,0.00051465956,0.00004553662,0.918562,0.000008610165,0.00006461295,0.0008547692],"study_design_scores_gemma":[0.0056002117,0.00010551684,0.14856689,0.000097000375,0.0004791257,0.000023501703,0.00021594192,0.0016246227,0.8431138,0.0000404605,0.000041113806,0.000091812944],"about_ca_topic_score_codex":0.002189833,"about_ca_topic_score_gemma":0.00017875215,"teacher_disagreement_score":0.075448215,"about_ca_system_score_codex":0.00021814056,"about_ca_system_score_gemma":0.00024081531,"threshold_uncertainty_score":0.4750955},"labels":[],"label_agreement":null},{"id":"W2591596051","doi":"10.1182/blood.v120.21.1339.1339","title":"Targeting Treatment-Naive CML Stem/Progenitor Cells From Imatinib-Nonresponders with JAK2 (BMS-911543)/ABL Inhibitor Combination Therapy","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Cancer research; Imatinib; Imatinib mesylate; Stem cell; Progenitor cell; Tyrosine kinase; Tyrosine-kinase inhibitor; Haematopoiesis; breakpoint cluster region; Medicine; Myeloid leukemia; Immunology; Biology; Internal medicine; Cell biology; Receptor; Cancer","score_opus":0.021509866091431473,"score_gpt":0.25519863139554966,"score_spread":0.2336887653041182,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591596051","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99364424,0.00317372,0.000042610456,0.00016663565,0.00038658775,0.0014992915,0.00007487336,0.00019044674,0.0008215725],"genre_scores_gemma":[0.99252564,0.00025562558,0.0040560425,0.00014635875,0.0009032803,0.0002150084,0.00035337772,0.00010980413,0.0014348836],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977682,0.00016132697,0.00041149225,0.00047463088,0.0005153484,0.000668998],"domain_scores_gemma":[0.99851245,0.00026375474,0.00026312287,0.0005206012,0.00009468229,0.00034536648],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001716436,0.0004671149,0.0005440287,0.00013239091,0.00016769317,0.000043147462,0.00011542595,0.00018971856,0.00032369304],"category_scores_gemma":[0.000025138621,0.00033925896,0.00014798668,0.00023734722,0.00007876208,0.0002914982,0.000032523978,0.00018801473,0.00032029938],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036651138,0.018556967,0.34902322,0.00012730899,0.005391456,0.00035316808,0.012320742,0.000010167291,0.58081394,0.000079776684,0.0021229559,0.027535187],"study_design_scores_gemma":[0.055598512,0.0029254206,0.016337704,0.00020773613,0.0011352128,0.000070396185,0.0015159316,0.00009715854,0.91616756,0.0000194751,0.005377549,0.00054732716],"about_ca_topic_score_codex":0.00035104287,"about_ca_topic_score_gemma":0.0000085330985,"teacher_disagreement_score":0.33535364,"about_ca_system_score_codex":0.0007691567,"about_ca_system_score_gemma":0.00030195783,"threshold_uncertainty_score":0.99990594},"labels":[],"label_agreement":null},{"id":"W2591685873","doi":"10.1182/blood.v126.23.5165.5165","title":"Disruption of the Peripheral Lymphoid Niche Contributes to Lymphopenia in CML Patients Undergoing Imatinib Treatments","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Imatinib mesylate; Imatinib; Medicine; Immunology; Myeloid; Myeloid leukemia; Chronic myelogenous leukemia; Bone marrow; CD34; CD8; Haematopoiesis; Progenitor cell; Tyrosine-kinase inhibitor; Stem cell; Internal medicine; Cancer research; Leukemia; Immune system; Biology; Cancer","score_opus":0.01682470344825451,"score_gpt":0.26586622001207955,"score_spread":0.24904151656382503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591685873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99660295,0.00028273687,0.000009469292,0.00027138178,0.00017035157,0.0010037766,0.00002823941,0.000024464427,0.0016066219],"genre_scores_gemma":[0.9985022,0.000016725631,0.00043060485,0.00024049038,0.000033432352,0.00008027133,0.00004980421,0.000025052817,0.0006214517],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986638,0.000078885714,0.00037181308,0.00025721808,0.00034440614,0.00028390557],"domain_scores_gemma":[0.9991325,0.00006987268,0.00012534457,0.00041658917,0.00011389278,0.00014178449],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012981516,0.00018657059,0.00034726874,0.00007777699,0.00003956955,0.000013566525,0.00013428021,0.00008256697,0.000024729941],"category_scores_gemma":[0.00038585387,0.00012647049,0.00009164583,0.00032787418,0.000040149454,0.00007445323,0.000107333646,0.000058767582,0.000034846664],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023525453,0.0017200406,0.99387693,0.000034124678,0.00018996811,0.000011171051,0.0007788947,0.000021470454,0.0012384893,0.000030719722,0.00020421937,0.0016587359],"study_design_scores_gemma":[0.06653765,0.00075785397,0.9155456,0.00041375778,0.0004114854,0.000032696513,0.00025330138,0.00010074979,0.015411743,0.0001108389,0.00028042475,0.00014390134],"about_ca_topic_score_codex":0.00032833978,"about_ca_topic_score_gemma":0.00020243194,"teacher_disagreement_score":0.078331314,"about_ca_system_score_codex":0.0017060231,"about_ca_system_score_gemma":0.0006861549,"threshold_uncertainty_score":0.5157317},"labels":[],"label_agreement":null},{"id":"W2592114706","doi":"10.1182/blood.v110.11.4545.4545","title":"BCR-ABL Induces Autocrine IGF-1 Signaling.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Autocrine signalling; Cancer research; Imatinib mesylate; breakpoint cluster region; Chronic myelogenous leukemia; Biology; Signal transduction; Tyrosine kinase; Imatinib; Cell biology; Leukemia; Immunology; Cell culture; Receptor; Myeloid leukemia; Genetics","score_opus":0.019275800723235655,"score_gpt":0.2817426360693515,"score_spread":0.26246683534611587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592114706","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9750848,0.0007420658,0.000049176513,0.00026561518,0.0001319096,0.0003003438,0.000003982597,0.00017955959,0.02324255],"genre_scores_gemma":[0.99290603,0.000022057611,0.0026473461,0.0003890969,0.00047879442,0.000011846433,0.000029638817,0.000032617038,0.0034825448],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987446,0.000013250317,0.00026584772,0.00027436606,0.00029864995,0.00040329574],"domain_scores_gemma":[0.99923015,0.00008937085,0.00006691484,0.0003507823,0.000056865767,0.00020591514],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023045881,0.00017037374,0.00025492685,0.00010839874,0.000058830075,0.00001189929,0.000089770896,0.00009910726,0.00059661514],"category_scores_gemma":[0.00010684701,0.00014334674,0.000088190594,0.000204883,0.000043939304,0.00004982389,0.000043712054,0.00020192719,0.0003529528],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007455301,0.00995717,0.19280139,0.0005528097,0.0027227546,0.008962065,0.0021522169,0.000010163374,0.69463086,0.0013559877,0.0072882227,0.078820854],"study_design_scores_gemma":[0.022336267,0.0010223829,0.09900997,0.00024902134,0.0009894425,0.00095785444,0.00019947428,0.000018814402,0.8509249,0.00019946543,0.023694951,0.0003974284],"about_ca_topic_score_codex":0.00012123243,"about_ca_topic_score_gemma":0.000021245938,"teacher_disagreement_score":0.15629409,"about_ca_system_score_codex":0.00021013079,"about_ca_system_score_gemma":0.0002625954,"threshold_uncertainty_score":0.6532517},"labels":[],"label_agreement":null},{"id":"W2592137822","doi":"10.1182/blood.v128.22.1895.1895","title":"Treatment-Free Remission (TFR) in Patients with Chronic Phase Chronic Myeloid Leukemia (CML-CP) and in Stable Deep Molecular Response (DMR) to Dasatinib - the Dasfree Study","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Dasatinib; Discontinuation; Medicine; Internal medicine; Clinical endpoint; Oncology; Imatinib; Drug holiday; Surrogate endpoint; Myeloid leukemia; Clinical trial; Immunology","score_opus":0.009186561493443199,"score_gpt":0.2607091870981696,"score_spread":0.2515226256047264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592137822","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936483,0.0012193492,0.000032799097,0.0006375612,0.00004498944,0.0041411547,0.00004819579,0.00006818577,0.0001594661],"genre_scores_gemma":[0.9981524,0.000106691485,0.00026647517,0.00008056777,0.00007499843,0.0004714208,0.0000326514,0.0000929795,0.0007218695],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966261,0.0003890935,0.0005926202,0.0009353165,0.00063847034,0.00081839156],"domain_scores_gemma":[0.99721867,0.00032460858,0.00016143268,0.0018748065,0.00007747164,0.00034303693],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00047295762,0.0005347406,0.0006630682,0.00032992932,0.000120136676,0.00003607915,0.00036056415,0.0001482957,0.00012990269],"category_scores_gemma":[0.0004502691,0.00028929635,0.000066179186,0.0006093504,0.00011801743,0.00017641265,0.000266703,0.00023922652,0.00003700562],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025978979,0.013712959,0.81736845,0.00011634581,0.0007798865,0.0020440046,0.0029986762,0.00008486717,0.07153326,0.0000115904,0.00015926566,0.065211706],"study_design_scores_gemma":[0.30132738,0.02756014,0.6428453,0.00088416296,0.0006016538,0.00006404721,0.000260648,0.0000816982,0.024246814,0.000025724048,0.0015527101,0.00054974825],"about_ca_topic_score_codex":0.000714788,"about_ca_topic_score_gemma":0.0025951865,"teacher_disagreement_score":0.2753484,"about_ca_system_score_codex":0.0074554896,"about_ca_system_score_gemma":0.0018933987,"threshold_uncertainty_score":0.9999559},"labels":[],"label_agreement":null},{"id":"W2592143294","doi":"10.1182/blood.v108.11.388.388","title":"Deregulated Expression of a Novel Oncogene, Ahi-1, in Murine Hematopoietic Cells Confers a Proliferative Advantage In Vitro and Leukemogenic Activity In Vivo and Enhances the Effects of BCR-ABL.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Haematopoiesis; Cancer research; Biology; Myeloid; breakpoint cluster region; CD34; Myeloid leukemia; K562 cells; Leukemia; Stem cell; Immunology; Cell biology; Receptor","score_opus":0.0052313813399006235,"score_gpt":0.232767478647267,"score_spread":0.22753609730736638,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592143294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971143,0.001396639,0.000012615155,0.000030486462,0.000017125187,0.0012607473,0.000013777694,0.00000814008,0.00014618672],"genre_scores_gemma":[0.9992708,0.00018533797,0.00036541995,0.000012290468,0.0000109671255,0.00008016773,0.000004415879,0.000015821564,0.000054756078],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988647,0.00009757528,0.00033525823,0.00029364918,0.00018607632,0.00022273361],"domain_scores_gemma":[0.99924296,0.00032013137,0.0001619172,0.00020742894,0.000024212073,0.00004337039],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015234992,0.00019352202,0.0005372773,0.00016325808,0.000017026645,0.0000046425685,0.000054385706,0.00010279081,0.0000060693073],"category_scores_gemma":[0.000055486347,0.00013813587,0.000036401714,0.00023859122,0.0001468303,0.00007291604,0.000063807085,0.00016407369,1.6277116e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060542853,0.001864507,0.013551508,0.0008354453,0.00003496602,0.00007191219,0.00088033814,0.000009027304,0.9818814,0.0000068875715,0.0000024902413,0.0002560835],"study_design_scores_gemma":[0.023406787,0.00031116445,0.036201112,0.0009583333,0.000084458385,0.000043382995,0.00014779961,0.00026868997,0.9384549,0.000022699598,0.0000026314558,0.000098030345],"about_ca_topic_score_codex":0.00079762767,"about_ca_topic_score_gemma":0.00062201265,"teacher_disagreement_score":0.043426495,"about_ca_system_score_codex":0.00013979395,"about_ca_system_score_gemma":0.00022120883,"threshold_uncertainty_score":0.5633018},"labels":[],"label_agreement":null},{"id":"W2592269524","doi":"10.1182/blood.v112.11.4217.4217","title":"Direct Interaction of Ahi-1 with BCR-ABL Modulates BCR-ABL Transforming Activity and Imatinib Response in a BCR-ABL Inducible Cell Line Model","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Cancer research; Progenitor cell; Biology; ABL; Imatinib mesylate; Chronic myelogenous leukemia; K562 cells; breakpoint cluster region; Stem cell; Tyrosine kinase; Haematopoiesis; Myeloid leukemia; Imatinib; Leukemia; Cell biology; Immunology; Signal transduction; Receptor","score_opus":0.024331189195292816,"score_gpt":0.26476059003146923,"score_spread":0.24042940083617642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592269524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99608445,0.0004603899,0.00026270337,0.00018279467,0.00004029341,0.0008563028,0.000036676487,0.00008475299,0.0019916154],"genre_scores_gemma":[0.9940718,0.0003824256,0.0043731993,0.000041858017,0.000048019527,0.00007847842,0.00002511253,0.00006640531,0.0009127067],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979524,0.00014664674,0.00048841763,0.0005836933,0.0003812241,0.0004475971],"domain_scores_gemma":[0.9986807,0.00031159382,0.00022341791,0.00051619153,0.00008805517,0.00018000185],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004418417,0.00037497285,0.00074882957,0.000367355,0.00010298202,0.000013826526,0.00009820343,0.0002071701,0.00004086995],"category_scores_gemma":[0.00013283345,0.00031531378,0.000100134384,0.00043337094,0.0001283426,0.00041418677,0.00004520117,0.00044411296,0.000006534443],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018243471,0.0068376423,0.022724314,0.00085524353,0.00050807965,0.0005939395,0.00943079,0.004839576,0.9303169,0.0000053914705,0.00006451809,0.005580137],"study_design_scores_gemma":[0.023103893,0.002144836,0.015396226,0.0008109759,0.00045062025,0.00058618205,0.00026093778,0.04153187,0.9152272,0.00002578204,0.00007537024,0.00038615207],"about_ca_topic_score_codex":0.0010269079,"about_ca_topic_score_gemma":0.00018353928,"teacher_disagreement_score":0.03669229,"about_ca_system_score_codex":0.00036810446,"about_ca_system_score_gemma":0.0006264681,"threshold_uncertainty_score":0.9999299},"labels":[],"label_agreement":null},{"id":"W2592540907","doi":"10.21577/0100-4042.20170027","title":"Sínteses e propriedades de fármacos inibidores da tirosina quinase BCR-ABL, utilizados no tratamento da Leucemia Mieloide Crônica","year":2017,"lang":"pt","type":"article","venue":"Química Nova","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec en Outaouais","funders":"","keywords":"Myeloid leukemia; Tyrosine kinase; Imatinib; Philadelphia chromosome; Cancer research; Medicine; Chromosomal translocation; ABL; Biology; Internal medicine; Genetics; Receptor","score_opus":0.08286090140897212,"score_gpt":0.3674617877413903,"score_spread":0.2846008863324182,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592540907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96074563,0.0051535633,0.00008416302,0.0034958823,0.0026921537,0.003113669,0.00054707436,0.00037293255,0.023794921],"genre_scores_gemma":[0.96152127,0.0009998482,0.0013364097,0.0012783916,0.0017286924,0.00021750959,0.00032883824,0.00030662204,0.03228243],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99193716,0.0003283322,0.0016335049,0.0020712623,0.0014310604,0.0025986927],"domain_scores_gemma":[0.991462,0.0004704935,0.0012819003,0.004936011,0.00048487243,0.0013647436],"candidate_categories":["metaepi_narrow","sts","scholarly_communication","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0009257327,0.00154425,0.0018520742,0.00034437262,0.0013413237,0.0011015603,0.002284306,0.0009939633,0.0049437713],"category_scores_gemma":[0.0027841865,0.0014285145,0.0006353862,0.00035401923,0.0015978736,0.00086076534,0.0010064461,0.001664394,0.0051233326],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01035092,0.008857924,0.24842304,0.0056171636,0.0047639734,0.00739251,0.007925186,0.000024188186,0.31917727,0.0014519325,0.30585703,0.08015886],"study_design_scores_gemma":[0.07666164,0.010337443,0.26313165,0.015686762,0.008531781,0.0018935058,0.0035501353,0.009287207,0.28960395,0.00040409612,0.313627,0.007284846],"about_ca_topic_score_codex":0.0061024143,"about_ca_topic_score_gemma":0.00066311203,"teacher_disagreement_score":0.07287402,"about_ca_system_score_codex":0.004624937,"about_ca_system_score_gemma":0.0047861417,"threshold_uncertainty_score":0.9999588},"labels":[],"label_agreement":null},{"id":"W2592691487","doi":"10.1182/blood.v104.11.2573.2573","title":"Forced Overexpression of Ahi-1 Confers a Proliferative Advantage on Primitive Murine Hematopoietic Cells and Enhances the Effects of BCR-ABL.","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Biology; Haematopoiesis; Cancer research; Bone marrow; CD34; Transduction (biophysics); breakpoint cluster region; Stem cell; Myeloid; Molecular biology; Virology; Immunology; Cell biology; Gene; Genetics","score_opus":0.005244031291528187,"score_gpt":0.24380019077078874,"score_spread":0.23855615947926057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592691487","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962907,0.00041251583,0.000022915205,0.000069352034,0.000037646696,0.0013720524,0.000015114958,0.00001735496,0.0017623699],"genre_scores_gemma":[0.9990733,0.00020836211,0.0003250378,0.000080489124,0.000030097719,0.00006736341,0.000007974714,0.000017184257,0.00019017296],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99905413,0.000046708818,0.0002344139,0.00022939565,0.0002625341,0.0001727956],"domain_scores_gemma":[0.99912035,0.00030521932,0.00018421437,0.00026536317,0.000055809847,0.00006905074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000065968015,0.0001762834,0.0003867568,0.000048379134,0.000041568932,0.0000041555186,0.000062176594,0.000066305896,0.00001864989],"category_scores_gemma":[0.000116990996,0.00010581973,0.00006865942,0.00007686972,0.00016843055,0.00004505406,0.000045565175,0.00012318093,0.000003355818],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037933845,0.0010455672,0.00051603804,0.0010889113,0.0002531235,0.00003890903,0.0029158269,0.000005545819,0.99283373,0.0007313864,0.00001638902,0.00017524564],"study_design_scores_gemma":[0.01558051,0.0024046986,0.002632285,0.0024221314,0.00029929122,0.00003305498,0.00038637358,0.0000054794546,0.9759778,0.00016015074,0.00001531319,0.00008295682],"about_ca_topic_score_codex":0.000031225503,"about_ca_topic_score_gemma":0.0000028241634,"teacher_disagreement_score":0.016855964,"about_ca_system_score_codex":0.00007511748,"about_ca_system_score_gemma":0.00018517666,"threshold_uncertainty_score":0.43152034},"labels":[],"label_agreement":null},{"id":"W2592765878","doi":"10.1159/000458164","title":"Isodicentric Philadelphia Chromosome: A Rare Chromosomal Aberration in Imatinib-Resistant Chronic Myelogenous Leukemia Patients - Case Report with Review of the Literature","year":2016,"lang":"en","type":"review","venue":"Cytogenetic and Genome Research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Chronic myelogenous leukemia; Biology; Imatinib; Philadelphia chromosome; Genetics; Chromosome; Cancer research; Leukemia; Chromosome aberration; Imatinib mesylate; Cytogenetics; Chromosomal translocation; Gene; Myeloid leukemia","score_opus":0.04250548512086243,"score_gpt":0.3513765399475626,"score_spread":0.3088710548267002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592765878","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009309514,0.9824803,0.000001065433,0.00019202389,0.000074393094,0.0071729356,0.0004232979,0.000019092171,0.00032736978],"genre_scores_gemma":[0.0063290093,0.99093455,0.0000724352,0.00003183797,0.000303115,0.0007209766,0.00079727167,0.0001324004,0.0006784324],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9935761,0.000895826,0.0017161142,0.001231352,0.0015268374,0.0010537823],"domain_scores_gemma":[0.99531704,0.00030582026,0.0008429089,0.0023856082,0.00078375125,0.00036484795],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001227098,0.0007701014,0.0025276577,0.0006392009,0.00029392084,0.000054586282,0.0005861217,0.00056687783,0.0002967755],"category_scores_gemma":[0.00055096217,0.00040887215,0.00041615276,0.0025075537,0.000588961,0.00007937842,0.0005990615,0.0012730659,0.000038097012],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00023458427,0.00053176,0.0004250215,0.55421466,0.0009969269,0.059609555,0.0005888183,9.983974e-7,0.00012380905,0.000013381065,0.0006042707,0.38265622],"study_design_scores_gemma":[0.0051782783,0.0019329286,0.0012702432,0.5439486,0.0014674618,0.076820426,0.00003254513,0.000002783405,0.00003437406,0.000015938525,0.36859322,0.0007032524],"about_ca_topic_score_codex":0.00008486973,"about_ca_topic_score_gemma":0.00006363038,"teacher_disagreement_score":0.38195297,"about_ca_system_score_codex":0.006246472,"about_ca_system_score_gemma":0.009665417,"threshold_uncertainty_score":0.9998363},"labels":[],"label_agreement":null},{"id":"W2592892140","doi":"10.1182/blood.v116.21.lba-6.lba-6","title":"A Randomized Phase II Trial of Dasatinib 100 Mg Vs Imatinib 400 Mg In Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): The S0325 Intergroup Trial","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Dasatinib; Internal medicine; Clinical endpoint; Imatinib; Imatinib mesylate; Randomized controlled trial; Gastroenterology; Nilotinib; Myeloid leukemia; Surgery","score_opus":0.018861270659581344,"score_gpt":0.32013891735561084,"score_spread":0.3012776466960295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592892140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98347425,0.0011103468,0.00002846445,0.0005559653,0.0014297938,0.011933537,0.00009574399,0.00012513614,0.0012467597],"genre_scores_gemma":[0.99288803,0.0005435379,0.00037729056,0.000156105,0.0025981318,0.0025382526,0.00030702286,0.00012994393,0.0004616699],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9932855,0.0008369422,0.0027612587,0.0010321763,0.0009296178,0.0011545464],"domain_scores_gemma":[0.9945042,0.0022706126,0.0010283865,0.0017506168,0.0001181283,0.00032805657],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0030398073,0.0008375531,0.0029011993,0.0006061143,0.00016599536,0.00005810443,0.0007606432,0.00058644515,0.0014944223],"category_scores_gemma":[0.0031430803,0.0006028276,0.00087047135,0.00093973393,0.00067407585,0.0002653637,0.0003061941,0.0018485485,0.000056440178],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9193755,0.011997088,0.000034357065,0.00022611122,0.00068269635,0.00038756756,0.002418818,0.000021433547,0.046751082,0.00014688532,0.00036927537,0.017589185],"study_design_scores_gemma":[0.95956725,0.015696995,0.000050418043,0.00066131237,0.0011957745,0.0000815226,0.00012042259,0.003292745,0.017177537,0.00013194754,0.0015471355,0.0004769125],"about_ca_topic_score_codex":0.0024399136,"about_ca_topic_score_gemma":0.0047821775,"teacher_disagreement_score":0.040191777,"about_ca_system_score_codex":0.003512717,"about_ca_system_score_gemma":0.008119891,"threshold_uncertainty_score":0.9996423},"labels":[],"label_agreement":null},{"id":"W2593332867","doi":"10.1007/s11899-017-0372-3","title":"New Treatment Strategies for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia","year":2017,"lang":"en","type":"review","venue":"Current Hematologic Malignancy Reports","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Ponatinib; Medicine; Blinatumomab; Internal medicine; Oncology; Philadelphia chromosome; Dasatinib; Imatinib; Hematology; Chemotherapy; Lymphoblastic Leukemia; Leukemia; Chromosomal translocation; Myeloid leukemia","score_opus":0.11414245544969435,"score_gpt":0.400997813282527,"score_spread":0.2868553578328326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2593332867","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000046859896,0.98517436,0.00070717215,0.000062779065,0.002989222,0.008735799,0.00033865412,0.00037895856,0.001566196],"genre_scores_gemma":[0.00039610462,0.98826295,0.0008854234,0.000013896367,0.0009830605,0.0029185163,0.0035950493,0.000235043,0.0027099822],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99275595,0.00011351465,0.0026864891,0.0023961656,0.00067080633,0.0013770527],"domain_scores_gemma":[0.9917719,0.0003655818,0.0038594163,0.0029706894,0.00025173678,0.00078071054],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00022750211,0.0021507114,0.007478959,0.00041096375,0.00045848664,0.00025041963,0.00047015707,0.0010391243,0.00034368795],"category_scores_gemma":[0.00024338136,0.0014946263,0.0027372881,0.00026090935,0.00023372142,0.00027899104,0.00021964846,0.00048230548,0.00017611188],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00009151702,0.0005977214,0.00005195085,0.038805474,0.004338653,0.017737553,0.00011027114,0.0000011383696,0.000002505739,0.0010619449,0.010926391,0.9262749],"study_design_scores_gemma":[0.0027685573,0.0010418291,0.000010190192,0.060844567,0.017137319,0.04282511,0.00001569456,0.000009195249,0.000049735005,0.0012664119,0.8728881,0.0011433322],"about_ca_topic_score_codex":0.00007199289,"about_ca_topic_score_gemma":0.000009898168,"teacher_disagreement_score":0.92513156,"about_ca_system_score_codex":0.008420918,"about_ca_system_score_gemma":0.022784244,"threshold_uncertainty_score":0.99912333},"labels":[],"label_agreement":null},{"id":"W2593660667","doi":"10.1182/blood.v128.22.2778.2778","title":"Use of Tyrosine Kinase Inhibitors Post-Allogeneic Stem Cell Transplant in Patients with Philadelphia or BCR-ABL Positive Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis","year":2016,"lang":"en","type":"review","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; University of Alberta","funders":"","keywords":"Medicine; Internal medicine; Transplantation; Oncology; Systematic review; Philadelphia chromosome; Meta-analysis; Hematopoietic stem cell transplantation; Pediatrics; MEDLINE","score_opus":0.031879298493492594,"score_gpt":0.2647455008461922,"score_spread":0.2328662023526996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2593660667","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0021990198,0.9853979,0.0000064784094,0.000041167717,0.000021045864,0.008391654,0.0039016737,0.00003318637,0.000007872551],"genre_scores_gemma":[0.005421769,0.9918563,0.00014392822,0.0001501956,0.000018468947,0.0008399974,0.0009453904,0.00014865205,0.0004752956],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99448454,0.0006348807,0.002423674,0.0010978224,0.0008009883,0.0005580789],"domain_scores_gemma":[0.9955783,0.00071319885,0.0017639407,0.0012689404,0.0003457715,0.00032983455],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032343421,0.0012628871,0.01380683,0.0008598942,0.000048062535,0.000028650597,0.00025635274,0.00044249737,0.00011181341],"category_scores_gemma":[0.000061010407,0.0006020991,0.0019514174,0.0014569235,0.00012938645,0.00015856995,0.00008975837,0.00032980565,0.000024005965],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018028727,0.0010985576,0.0001033976,0.75365704,0.24366833,0.000759228,0.0000800371,4.5721052e-7,0.0000032078485,0.0000012125257,0.000012819221,0.0004354446],"study_design_scores_gemma":[0.0048051486,0.0009877264,0.000067004956,0.20272599,0.79053706,0.00023850823,0.0000038372127,6.0542993e-7,0.000037930295,9.5064465e-8,0.00013070545,0.00046538663],"about_ca_topic_score_codex":0.00010901313,"about_ca_topic_score_gemma":0.000056664856,"teacher_disagreement_score":0.55093104,"about_ca_system_score_codex":0.0013250523,"about_ca_system_score_gemma":0.0015803612,"threshold_uncertainty_score":0.999643},"labels":[],"label_agreement":null},{"id":"W2593776441","doi":"10.1182/blood.v110.11.472.472","title":"Efficacy and Safety of Dasatinib in Patients with Chronic Myeloid Leukemia in Blast Phase Whose Disease Is Resistant or Intolerant to Imatinib: 2-Year Follow-Up Data from the START Program.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Dasatinib; Imatinib; Medicine; Internal medicine; Imatinib mesylate; Transplantation; Gastroenterology; Myeloid leukemia; Oncology","score_opus":0.022644311821729567,"score_gpt":0.2975425443278579,"score_spread":0.2748982325061284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2593776441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99460524,0.00040977955,0.000015065559,0.00025008403,0.00004371497,0.0035110821,0.001049112,0.00004145574,0.00007446735],"genre_scores_gemma":[0.99584967,0.000060576378,0.0025798278,0.0002087013,0.000082103186,0.000070978436,0.0010322413,0.000055314467,0.000060596874],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972719,0.00007844716,0.000778515,0.00073234417,0.0006107299,0.00052806217],"domain_scores_gemma":[0.997505,0.00035221718,0.00019867356,0.0015094641,0.000079605576,0.0003550187],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000471079,0.0003346606,0.0005727719,0.00013835978,0.000062857056,0.000027298463,0.00036824725,0.000085416556,0.00013264205],"category_scores_gemma":[0.00039407253,0.00020802396,0.00004086166,0.00056914345,0.00014685301,0.0001423938,0.00029551832,0.00029414037,0.00001372683],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13726075,0.010843802,0.7766137,0.00047526314,0.000815194,0.00064606784,0.006231333,0.000013741987,0.0010682208,0.000013603359,0.001121915,0.06489639],"study_design_scores_gemma":[0.15553501,0.0030647547,0.8357704,0.0016550542,0.00048537552,0.0000022210736,0.00025678874,0.00018038925,0.00077850337,0.000005102177,0.0020133208,0.0002530589],"about_ca_topic_score_codex":0.001282933,"about_ca_topic_score_gemma":0.005620255,"teacher_disagreement_score":0.06464333,"about_ca_system_score_codex":0.0009784978,"about_ca_system_score_gemma":0.0015762472,"threshold_uncertainty_score":0.84829706},"labels":[],"label_agreement":null},{"id":"W2594032372","doi":"10.1182/blood.v126.23.1568.1568","title":"Whole Exome Sequencing Reveals That DNMT3A and ASXL1 Mutation Are Involved in the Development of Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia Patients without ABL1 Tyrosine Kinase Domain Mutation","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Ponatinib; Dasatinib; Nilotinib; Tyrosine-kinase inhibitor; Medicine; Myeloid leukemia; Mutation; Imatinib; Imatinib mesylate; Exome sequencing; Tyrosine kinase; Resistance mutation; Cancer research; Internal medicine; Biology; Genetics; Cancer; Reverse transcriptase; Gene; Receptor","score_opus":0.02896320036997661,"score_gpt":0.26013344898843765,"score_spread":0.23117024861846105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594032372","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99561256,0.0025337224,0.00004028758,0.0001585402,0.00007695614,0.0013571131,0.000039040082,0.000037626025,0.00014415395],"genre_scores_gemma":[0.9925545,0.00003306512,0.0064420486,0.00010808324,0.000090741516,0.00018699463,0.00043855803,0.00004773106,0.000098274184],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971666,0.00023103645,0.00085173215,0.0005409785,0.00076446956,0.00044523043],"domain_scores_gemma":[0.99852914,0.00013639823,0.00049970625,0.00045441304,0.00021397341,0.00016637213],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009859515,0.00035474263,0.0005785706,0.0003215409,0.00008645638,0.000036451198,0.0001497749,0.0001774653,0.0000065207373],"category_scores_gemma":[0.0004000167,0.00028890415,0.000047353795,0.00062838977,0.00012080904,0.00029321684,0.00007376392,0.00029620188,0.000012241655],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015426513,0.0019042055,0.85312206,0.0019397598,0.00019017879,0.0011351766,0.05104309,0.00018243608,0.085390516,0.00009570479,0.00036695923,0.003087295],"study_design_scores_gemma":[0.044433363,0.00045626797,0.8665272,0.0037664971,0.00019084895,0.000037525977,0.005582309,0.0001255741,0.0776588,0.0005172525,0.00023773032,0.00046665495],"about_ca_topic_score_codex":0.00020705874,"about_ca_topic_score_gemma":0.004718685,"teacher_disagreement_score":0.04546078,"about_ca_system_score_codex":0.005730825,"about_ca_system_score_gemma":0.0018594688,"threshold_uncertainty_score":0.9999563},"labels":[],"label_agreement":null},{"id":"W2594040066","doi":"10.1182/blood.v106.11.1208.1208","title":"RIZ1 Tumor Suppressor Regulates IGF-1 Autocrine Loop To Control Cell Proliferation, Apoptosis, and Differentiation in Chronic Myeloid Leukemia Blast Crisis Cell Lines.","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Biology; Cancer research; Myeloid leukemia; K562 cells; Tumor suppressor gene; Cell growth; Leukemia; Immunology; Genetics; Cancer; Carcinogenesis","score_opus":0.006151422821804697,"score_gpt":0.2258149700100713,"score_spread":0.2196635471882666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594040066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944928,0.0012907671,0.00012837705,0.001656664,0.00007884261,0.001900922,0.000048478494,0.0001399289,0.00026318472],"genre_scores_gemma":[0.995324,0.00011784064,0.00097311154,0.00061066827,0.0006791412,0.00035652771,0.00016152857,0.00007582591,0.0017013451],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975006,0.00008015519,0.0006876055,0.0007160775,0.00040101475,0.0006145773],"domain_scores_gemma":[0.998698,0.000089068104,0.0001837353,0.0005557401,0.00014589756,0.00032758905],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015871823,0.00043572029,0.0006367134,0.0003097493,0.000106636726,0.00007292535,0.00014430245,0.00015339282,0.00023677121],"category_scores_gemma":[0.00007874087,0.00039553287,0.00010022685,0.00031886675,0.000044044675,0.00020495246,0.000083973355,0.00029810198,0.00013336449],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008666551,0.0037537625,0.04503623,0.0012344006,0.00034990968,0.0000782377,0.0015945514,0.0019137769,0.935018,0.000029815328,0.007909013,0.0022156253],"study_design_scores_gemma":[0.03789236,0.0007768397,0.051651146,0.00018898773,0.00067403744,0.00005596878,0.00007468375,0.008323112,0.8989917,0.000015620433,0.000937976,0.0004175603],"about_ca_topic_score_codex":0.00020969649,"about_ca_topic_score_gemma":0.00031302753,"teacher_disagreement_score":0.037025705,"about_ca_system_score_codex":0.0017900662,"about_ca_system_score_gemma":0.0007756536,"threshold_uncertainty_score":0.9998497},"labels":[],"label_agreement":null},{"id":"W2594219762","doi":"10.1182/blood.v112.11.3232.3232","title":"Preliminary Clinical Activity in a Phase I Trial of the BCR-ABL/IGF- 1R/Aurora Kinase Inhibitor XL228 in Patients with Ph++ Leukemias with Either Failure to Multiple TKI Therapies or with T315I Mutation","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Dasatinib; Medicine; Nilotinib; Dosing; Adverse effect; Internal medicine; Pharmacology; Imatinib mesylate; Imatinib; Gastroenterology; Myeloid leukemia","score_opus":0.024536031285848286,"score_gpt":0.2890415884862166,"score_spread":0.2645055572003683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594219762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99552196,0.000036237467,0.00001622606,0.0002523708,0.00006007232,0.0039777816,0.000044056374,0.000039786948,0.000051520015],"genre_scores_gemma":[0.9975423,0.000009020968,0.0016389054,0.000121405006,0.00012467553,0.0003014181,0.000034821158,0.00007007862,0.00015734465],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975124,0.00026975246,0.0005656453,0.0005809222,0.0006833306,0.00038795185],"domain_scores_gemma":[0.9982931,0.00035319582,0.00033994144,0.00070738286,0.00014648343,0.00015991084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002604687,0.00037262714,0.0007308856,0.00017540398,0.000075579715,0.000010719586,0.0001643165,0.00017992171,0.00003273104],"category_scores_gemma":[0.00030906408,0.00019135403,0.00008671544,0.0007577102,0.00024407275,0.0001961618,0.00006235119,0.00046538218,0.0000061669452],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3499812,0.020508373,0.6203965,0.000089746354,0.0003578728,0.00065492396,0.0033764818,0.00007708864,0.00037821065,9.3556037e-7,0.00009908966,0.0040795766],"study_design_scores_gemma":[0.48831573,0.03326655,0.4686427,0.0007752804,0.0003118091,0.00007400492,0.0003462838,0.00007010248,0.0078013227,0.0000015298004,0.0001274148,0.0002672669],"about_ca_topic_score_codex":0.0005013959,"about_ca_topic_score_gemma":0.0022532248,"teacher_disagreement_score":0.1517538,"about_ca_system_score_codex":0.00044969298,"about_ca_system_score_gemma":0.0014757508,"threshold_uncertainty_score":0.7803191},"labels":[],"label_agreement":null},{"id":"W2594833014","doi":"10.1182/blood.v112.11.1110.1110","title":"Clinical Relevance of Vascular Endothelial Growth Factor (VEGFA) and VEGF Receptor (VEGFR2) Gene Single Nucleotide Polymorphism on the Treatment Outcomes Following Imatinib Mesylate Therapy.","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Haplotype; Genotype; Imatinib mesylate; Vascular endothelial growth factor A; Vascular endothelial growth factor; Angiogenesis; Biology; Internal medicine; Single-nucleotide polymorphism; Immunology; Myeloid leukemia; Cancer research; Oncology; Medicine; VEGF receptors; Genetics; Imatinib; Gene","score_opus":0.04238334477860886,"score_gpt":0.2849597639319657,"score_spread":0.24257641915335684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594833014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99471825,0.0027909938,0.000004251804,0.0005947356,0.0003478521,0.00094034715,0.000066654204,0.000089904424,0.00044701813],"genre_scores_gemma":[0.99047714,0.006488383,0.0016554503,0.00035985326,0.00024861717,0.00005934282,0.000019813267,0.0000796651,0.0006117475],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976587,0.00018708542,0.00068748597,0.0005435214,0.00051782746,0.00040535445],"domain_scores_gemma":[0.9977545,0.0010020586,0.0002590326,0.0007406965,0.00005602088,0.00018765083],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021171705,0.0004132024,0.0009038744,0.00007895797,0.00018299356,0.000012630022,0.00015982651,0.0001528818,0.000116778094],"category_scores_gemma":[0.00037151866,0.00024720785,0.0006483015,0.00013274161,0.00020807657,0.00006953111,0.000039316565,0.00021293879,0.000053484007],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053159293,0.009919893,0.83112305,0.000054053962,0.006000911,0.00044684016,0.0025572504,8.3374414e-7,0.13025466,0.00008499538,0.00014272223,0.018883185],"study_design_scores_gemma":[0.054291654,0.0074990625,0.46486035,0.00031444267,0.0011209039,0.00010865954,0.00008823244,0.000019809915,0.4653925,0.00008464189,0.005648989,0.0005707464],"about_ca_topic_score_codex":0.00015160309,"about_ca_topic_score_gemma":0.0000049526852,"teacher_disagreement_score":0.3662627,"about_ca_system_score_codex":0.00022432076,"about_ca_system_score_gemma":0.00020431902,"threshold_uncertainty_score":0.99999803},"labels":[],"label_agreement":null},{"id":"W2594964815","doi":"10.1182/blood.v116.21.3509.3509","title":"Significant Improvement In Day 100 and 1-Year Overall Survival In Patients Who Underwent Myeloablative Allogeneic Hematopoietic Cell Transplant In the US or Canada Between 1994 and 2005","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Transplantation; Internal medicine; Hematopoietic stem cell transplantation; Population; Hematopoietic cell; Statistical significance; Disease; Surgery; Pediatrics; Demography; Haematopoiesis; Stem cell","score_opus":0.008981173167389412,"score_gpt":0.21691360767267126,"score_spread":0.20793243450528184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594964815","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99815285,0.000093424,8.742277e-7,0.00022422266,0.000057934132,0.0010708898,0.0000956036,0.0000054509637,0.0002987357],"genre_scores_gemma":[0.9994027,0.00012293992,0.000047829337,0.00015381038,0.00003665626,0.000048067508,0.000067940135,0.000020461837,0.0000996102],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99835014,0.00009712019,0.00038531603,0.00037685162,0.00036488034,0.0004256782],"domain_scores_gemma":[0.9993094,0.00020467707,0.00007636051,0.0002591001,0.000012098934,0.00013836366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033753912,0.00023265477,0.000402242,0.00009761395,0.000033072036,0.000016354388,0.00010703678,0.00010221866,0.00003949667],"category_scores_gemma":[0.000018208004,0.00015604295,0.000022116285,0.00012453405,0.000056490495,0.000041775555,0.000038640017,0.00037338756,9.473601e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010509309,0.00062083226,0.99548936,0.00009535641,0.0000523514,0.00019692413,0.001878711,0.0000035203232,0.0011776129,0.000014349245,0.000032565844,0.00033334538],"study_design_scores_gemma":[0.017808937,0.00043045334,0.9775257,0.00012103277,0.00011777281,0.0000061965084,0.00027735435,0.000015569382,0.0032991741,0.00002462437,0.00019556217,0.00017763516],"about_ca_topic_score_codex":0.18201566,"about_ca_topic_score_gemma":0.6603116,"teacher_disagreement_score":0.47829592,"about_ca_system_score_codex":0.0003458142,"about_ca_system_score_gemma":0.0006862448,"threshold_uncertainty_score":0.8234314},"labels":[],"label_agreement":null},{"id":"W2596296337","doi":"10.1200/jco.2013.31.15_suppl.7073","title":"Omacetaxine mepesuccinate in chronic phase chronic myeloid leukemia (CML-CP): A post hoc analysis of myelosuppression.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Neutropenia; Internal medicine; Adverse effect; Pancytopenia; Febrile neutropenia; Anemia; Sepsis; Dosing; Gastroenterology; Toxicity; Bone marrow","score_opus":0.05854109868732343,"score_gpt":0.4407336791632391,"score_spread":0.38219258047591564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2596296337","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862449,0.006488103,0.00006496362,0.0040864204,0.0006710224,0.00069372903,0.00002345057,0.000020332724,0.0017070565],"genre_scores_gemma":[0.99073887,0.0047860914,0.0017446367,0.00076790224,0.0011230864,0.00002830709,0.00004596058,0.00004769692,0.0007174519],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99122936,0.0008313275,0.0057675582,0.0005468159,0.0008830829,0.0007418765],"domain_scores_gemma":[0.99073815,0.0025221594,0.0040627993,0.0007792833,0.0010738613,0.00082374056],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0031676705,0.00043432467,0.004715107,0.0013340587,0.000051876235,0.000016149414,0.00053683674,0.0008891321,0.0049631856],"category_scores_gemma":[0.0029159284,0.00030915882,0.0017875631,0.0014682851,0.00042981052,0.00037800233,0.00018476098,0.0020271528,0.00013119738],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.012717309,0.007977208,0.03244743,0.00042218808,0.015765985,0.0037722352,0.00046123168,0.0024773625,0.048185334,0.00010057261,0.007985611,0.8676875],"study_design_scores_gemma":[0.15338936,0.09466783,0.6607495,0.001152549,0.0140916705,0.00089820597,0.00027740764,0.02462621,0.0042953487,0.00023147109,0.044943415,0.0006770529],"about_ca_topic_score_codex":0.0005697232,"about_ca_topic_score_gemma":0.00088059856,"teacher_disagreement_score":0.8670105,"about_ca_system_score_codex":0.009672709,"about_ca_system_score_gemma":0.016394248,"threshold_uncertainty_score":0.99993604},"labels":[],"label_agreement":null},{"id":"W2597539313","doi":"10.1200/jco.2013.31.15_suppl.7088","title":"Predictive factors associated with achievement of major cytogenetic response (MCyR) to omacetaxine mepesuccinate among patients with chronic phase chronic myeloid leukemia (CML-CP).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Logistic regression; Internal medicine; Blast Crisis; Myeloid leukemia; Oncology; Gastroenterology","score_opus":0.04249160936299737,"score_gpt":0.36757103020577675,"score_spread":0.3250794208427794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597539313","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99543536,0.00029202164,0.00022140986,0.0011459643,0.00040525227,0.002188622,0.00006496693,0.00003241348,0.00021400492],"genre_scores_gemma":[0.9977443,0.000096119045,0.0007016213,0.00033038273,0.00036991527,0.000065440196,0.00005359196,0.00008935948,0.0005492473],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9927294,0.0011811332,0.003340352,0.0005929044,0.0013397764,0.00081640715],"domain_scores_gemma":[0.98982066,0.0026925406,0.003990083,0.0006156608,0.0016841614,0.0011968771],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024254606,0.0005627474,0.0028663303,0.0004305988,0.000098084434,0.000018758896,0.00043036605,0.0006029903,0.00083245506],"category_scores_gemma":[0.0034434376,0.0003450945,0.0004878631,0.0005663296,0.00053376803,0.00029482326,0.00014808319,0.0014283065,0.000035593286],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.06164357,0.009806373,0.8858603,0.0001257495,0.0074146134,0.0005598396,0.00049360545,0.0011198239,0.0040159733,0.000004130298,0.0020275847,0.02692839],"study_design_scores_gemma":[0.07637214,0.14982645,0.7671674,0.00073476153,0.0015595827,0.000027871496,0.00008752642,0.00023117833,0.0027638355,0.000009554634,0.00096520304,0.00025450496],"about_ca_topic_score_codex":0.0002171422,"about_ca_topic_score_gemma":0.00052968855,"teacher_disagreement_score":0.14002007,"about_ca_system_score_codex":0.010548516,"about_ca_system_score_gemma":0.012954816,"threshold_uncertainty_score":0.9999001},"labels":[],"label_agreement":null},{"id":"W2598103319","doi":"10.1200/jco.2012.30.15_suppl.6604","title":"Pooled safety analysis of omacetaxine mepesuccinate in patients with chronic myeloid leukemia (CML) resistant to tyrosine-kinase inhibitors (TKIs).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Neutropenia; Adverse effect; Tolerability; Rash; Gastroenterology; Nausea; Febrile neutropenia; Anemia; Surgery; Toxicity","score_opus":0.03072465755673829,"score_gpt":0.36816574566352855,"score_spread":0.33744108810679024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598103319","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954198,0.0009413876,0.000061842824,0.0014653549,0.00061560137,0.0005516146,0.000030393825,0.000011220805,0.0009027919],"genre_scores_gemma":[0.99555516,0.000254574,0.0026188775,0.0006255727,0.00064367516,0.0000074473965,0.00003478725,0.00003893901,0.00022096452],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9931316,0.0006154016,0.0042972076,0.00035640705,0.0009269328,0.0006724773],"domain_scores_gemma":[0.993711,0.0013214895,0.0027230044,0.0005484253,0.0007401366,0.0009559645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040236833,0.00034023993,0.003439299,0.0010369188,0.000043278214,0.000006449217,0.0002643991,0.00048522043,0.00037793157],"category_scores_gemma":[0.0026501205,0.0002290864,0.0007811404,0.0017103996,0.00019558484,0.00023432223,0.000118847995,0.0011120035,0.00002197136],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027930927,0.003937957,0.9086611,0.00007771452,0.004751306,0.00029018187,0.0002163345,0.00071413873,0.00060741196,0.00003927348,0.0008362324,0.05193739],"study_design_scores_gemma":[0.03159613,0.016431231,0.9327131,0.0003209033,0.005510978,0.000019704354,0.000047056194,0.00011814375,0.0005983704,0.0000059204485,0.012442283,0.00019620241],"about_ca_topic_score_codex":0.00022679736,"about_ca_topic_score_gemma":0.00082465674,"teacher_disagreement_score":0.051741187,"about_ca_system_score_codex":0.0067407396,"about_ca_system_score_gemma":0.0044154106,"threshold_uncertainty_score":0.9970722},"labels":[],"label_agreement":null},{"id":"W2599582945","doi":"10.1200/jco.2013.31.15_suppl.7099","title":"Evolution of bosutinib (BOS) toxicity in patients (pts) with Ph+ leukemia after resistance/intolerance to prior therapy.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Bosutinib; Internal medicine; Dasatinib; Discontinuation; Rash; Nilotinib; Gastroenterology; Cohort; Neutropenia; Adverse effect; Imatinib; Mucositis; Toxicity; Incidence (geometry); Febrile neutropenia; Myeloid leukemia","score_opus":0.0351583267820405,"score_gpt":0.3684158386602952,"score_spread":0.3332575118782547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599582945","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950859,0.00043824347,0.000058105135,0.0016590912,0.0003895064,0.00074913603,0.0000043683494,0.000006802087,0.001608865],"genre_scores_gemma":[0.99342716,0.00015298203,0.004262303,0.0013007756,0.00034706848,0.000030153058,0.0000016916148,0.000021935248,0.0004559281],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961158,0.00031767462,0.0023984527,0.00027330237,0.0005663889,0.0003283979],"domain_scores_gemma":[0.9963738,0.0006797502,0.0014797351,0.00033283673,0.00076729065,0.0003666373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012240174,0.00019442565,0.0015134029,0.00018199031,0.00002060607,0.0000055944342,0.00018910089,0.0003510359,0.0004099344],"category_scores_gemma":[0.0012756678,0.00012732817,0.00026062975,0.00028247942,0.00015570872,0.00018597725,0.000035251913,0.00076351385,0.00004727216],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025936315,0.0029878018,0.89864755,0.00004810519,0.00023648648,0.00013477441,0.0002625988,0.000042816333,0.00031571367,0.000016542388,0.0028492627,0.06852201],"study_design_scores_gemma":[0.027898205,0.014623857,0.946714,0.00044343897,0.00008262515,0.000019753576,0.000046734982,0.000025662179,0.00032999882,0.00011406917,0.009592321,0.00010934855],"about_ca_topic_score_codex":0.00016091838,"about_ca_topic_score_gemma":0.00048654678,"teacher_disagreement_score":0.06841266,"about_ca_system_score_codex":0.003239883,"about_ca_system_score_gemma":0.003330017,"threshold_uncertainty_score":0.84721816},"labels":[],"label_agreement":null},{"id":"W2600488379","doi":"10.1200/jco.2012.30.15_suppl.6596","title":"Omacetaxine mepesuccinate in chronic-phase chronic myeloid leukemia (CML) in patients resistant, intolerant, or both to two or more tyrosine-kinase inhibitors (TKIs).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nilotinib; Dasatinib; Internal medicine; Adverse effect; Imatinib; Gastroenterology; Myeloid leukemia; Imatinib mesylate; Bosutinib; Tyrosine kinase","score_opus":0.07203863384198393,"score_gpt":0.4499658444050667,"score_spread":0.37792721056308276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600488379","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99055636,0.0025182557,0.000023676617,0.0028823037,0.0020344,0.0012958057,0.000024950346,0.000030185478,0.00063405716],"genre_scores_gemma":[0.9903655,0.0010970144,0.0020945116,0.001967947,0.0034245562,0.000045390054,0.000025974035,0.000099547375,0.0008795678],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99036556,0.00089451723,0.0057140025,0.0006340393,0.0009926726,0.0013992046],"domain_scores_gemma":[0.99318224,0.0018821143,0.0022851757,0.0007018743,0.00040471816,0.0015438555],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0048407535,0.0006166505,0.0034072173,0.0009134155,0.00007639928,0.00002303932,0.0004910404,0.00079621136,0.0008805993],"category_scores_gemma":[0.0057654036,0.00040935507,0.0005608901,0.0011651975,0.0002851481,0.0005403681,0.00025922834,0.0025372875,0.0001083946],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.13637267,0.01765013,0.29776022,0.00054017646,0.00082269276,0.010197333,0.0013522219,0.0005349762,0.0036086522,0.00005704085,0.015972283,0.5151316],"study_design_scores_gemma":[0.21575865,0.06627998,0.5799628,0.0021757723,0.00059929525,0.00047859465,0.00020862908,0.00058738963,0.0019242539,0.000022245782,0.13132228,0.00068010995],"about_ca_topic_score_codex":0.0005010654,"about_ca_topic_score_gemma":0.004639606,"teacher_disagreement_score":0.5144515,"about_ca_system_score_codex":0.025459193,"about_ca_system_score_gemma":0.017275045,"threshold_uncertainty_score":0.99983585},"labels":[],"label_agreement":null},{"id":"W2600737182","doi":"10.1182/blood.v120.21.137.137","title":"Continuous Dose Dasatinib Is Safe and Feasible in Combination with Intensive Chemotherapy in Pediatric Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Children's Oncology Group (COG) Trial AALL0622","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital","funders":"","keywords":"Dasatinib; Medicine; Cohort; Internal medicine; Imatinib; Acute lymphocytic leukemia; Chemotherapy; Oncology; Clinical endpoint; Surgery; Clinical trial; Leukemia; Lymphoblastic Leukemia; Myeloid leukemia","score_opus":0.012422455077250191,"score_gpt":0.26943409156285975,"score_spread":0.25701163648560954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600737182","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941127,0.0011024633,0.0000089977575,0.0010889141,0.00015566725,0.0030078976,0.000041333977,0.000055256216,0.00042681413],"genre_scores_gemma":[0.9960344,0.0010229968,0.00048615414,0.0013702147,0.00047027052,0.00022287831,0.00025624994,0.000072697156,0.00006414456],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99761856,0.00015109075,0.000572207,0.0005797864,0.00036521774,0.00071313913],"domain_scores_gemma":[0.99866813,0.00027219934,0.00031807338,0.00032782144,0.0001426469,0.00027111958],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00028091727,0.00043671502,0.00091130164,0.0004342889,0.000054313463,0.000023524994,0.00012411643,0.00034262481,0.000083541934],"category_scores_gemma":[0.00011564118,0.00037603072,0.00008130427,0.0005278198,0.00013919674,0.0002711181,0.00007571081,0.00042710442,0.000027551378],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.070337616,0.014563751,0.88711303,0.00018129227,0.0026603458,0.0012544749,0.0124882255,0.0000054703128,0.004397991,0.00023453699,0.0007160513,0.0060472027],"study_design_scores_gemma":[0.36118135,0.006763049,0.62779313,0.00013618807,0.0012577993,0.00095546717,0.00017977225,0.000051767565,0.0012538458,0.000038240796,0.000049088263,0.0003403042],"about_ca_topic_score_codex":0.0004838596,"about_ca_topic_score_gemma":0.00012557645,"teacher_disagreement_score":0.29084373,"about_ca_system_score_codex":0.0019100093,"about_ca_system_score_gemma":0.0007222967,"threshold_uncertainty_score":0.99986917},"labels":[],"label_agreement":null},{"id":"W2601029316","doi":"10.1200/jco.2012.30.15_suppl.6605","title":"Analysis of imatinib (IM)-related, low-grade (LG), non-hematologic (heme) adverse events (AEs) in patients (pts) with chronic myeloid leukemia (CML) switched to nilotinib (NIL): ENRICH study update.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Adverse effect; Gastroenterology; Rash; Nilotinib; Hypokalemia; Imatinib mesylate; Imatinib; Myeloid leukemia","score_opus":0.036510584720778234,"score_gpt":0.38490619678427845,"score_spread":0.3483956120635002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601029316","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961378,0.00024988962,0.00006102209,0.0004927192,0.00089177204,0.0016855791,0.000013395984,0.000023158487,0.00044467257],"genre_scores_gemma":[0.9965053,0.00015484866,0.0022270558,0.0005019082,0.000316159,0.0000440527,0.000046580015,0.00006571553,0.00013834613],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9897723,0.0009509973,0.006257549,0.0006413564,0.0013598995,0.0010178563],"domain_scores_gemma":[0.9908964,0.0016979938,0.004721628,0.0008740443,0.00068793754,0.0011219853],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004440096,0.0005876724,0.005125156,0.0010343853,0.00006985932,0.000005488553,0.0006177555,0.00077598705,0.0005311834],"category_scores_gemma":[0.002390188,0.0004098755,0.0010454362,0.0022231184,0.00022227893,0.0003625234,0.00026618008,0.0018606677,0.00020206264],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059188833,0.017918162,0.95882326,0.000093508446,0.006971572,0.0003840254,0.001148267,0.0008973242,0.000079955425,0.000008344607,0.000342555,0.0074141333],"study_design_scores_gemma":[0.0538022,0.023539815,0.91335106,0.0003149036,0.0066980147,0.00010124707,0.00081140717,0.000473317,0.00012221359,0.000015209674,0.00043783954,0.00033277157],"about_ca_topic_score_codex":0.0001733441,"about_ca_topic_score_gemma":0.00043954208,"teacher_disagreement_score":0.047883313,"about_ca_system_score_codex":0.0052391533,"about_ca_system_score_gemma":0.00410832,"threshold_uncertainty_score":0.9998353},"labels":[],"label_agreement":null},{"id":"W2605150999","doi":"10.1038/bcj.2017.29","title":"Imatinib mesylate inhibits STAT5 phosphorylation in response to IL-7 and promotes T cell lymphopenia in chronic myelogenous leukemia patients","year":2017,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"STAT5; Chronic myelogenous leukemia; T-cell receptor; CD8; T cell; Immunology; Leukemia; Imatinib mesylate; Cancer research; Medicine; Signal transduction; Biology; Imatinib; Internal medicine; Receptor; Immune system; Cell biology","score_opus":0.012434273716650008,"score_gpt":0.280681376245871,"score_spread":0.26824710252922096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605150999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99553263,0.0024781441,0.0000031460315,0.00050634687,0.00019314178,0.0009593759,0.000038248927,0.000015133542,0.0002738116],"genre_scores_gemma":[0.9974581,0.0011066918,0.0005693931,0.00013610613,0.00015810055,0.0000803089,0.000009123101,0.00004922279,0.00043298033],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99783945,0.00013581419,0.0006088817,0.00040707568,0.00043097336,0.00057779386],"domain_scores_gemma":[0.99859697,0.000067450695,0.0004244234,0.0004386024,0.00013769015,0.00033485968],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007070697,0.00028699508,0.00047794392,0.00030083783,0.00028002574,0.00014516203,0.00020807452,0.00013868924,0.00012235764],"category_scores_gemma":[0.00028188803,0.00025760644,0.000058561272,0.00015943234,0.00006711516,0.00030691343,0.0001398098,0.00044390568,0.000023890409],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006984315,0.00070427667,0.7963655,0.0002637386,0.00017675779,0.0010903941,0.0063029137,0.00041953142,0.086695865,0.0000024281885,0.00032224043,0.100672014],"study_design_scores_gemma":[0.0352616,0.0014202577,0.90349495,0.0012092111,0.00014034682,0.00021327668,0.00006509748,0.00033989543,0.0567042,0.000052593354,0.0007927004,0.00030585943],"about_ca_topic_score_codex":0.0015283967,"about_ca_topic_score_gemma":0.0016379082,"teacher_disagreement_score":0.10712944,"about_ca_system_score_codex":0.0070931558,"about_ca_system_score_gemma":0.0038883612,"threshold_uncertainty_score":0.9999876},"labels":[],"label_agreement":null},{"id":"W2605372253","doi":"10.1038/leu.2017.108","title":"A novel AHI-1–BCR-ABL–DNM2 complex regulates leukemic properties of primitive CML cells through enhanced cellular endocytosis and ROS-mediated autophagy","year":2017,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada; University of British Columbia; BC Cancer Agency","funders":"BC Cancer Agency; Canadian Institutes of Health Research; Deutsche Krebshilfe; University of British Columbia","keywords":"Ponatinib; Autophagy; Cancer research; Stem cell; Biology; Cell biology; Endocytosis; Myeloid leukemia; Tyrosine kinase; Dasatinib; Progenitor cell; Imatinib mesylate; Immunology; Signal transduction; Cell; Apoptosis; Imatinib; Biochemistry","score_opus":0.0414186278086687,"score_gpt":0.2650314953372631,"score_spread":0.2236128675285944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605372253","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909414,0.0014796681,0.00028250404,0.00019718734,0.00024967804,0.001355202,0.00010154238,0.00018191802,0.005210919],"genre_scores_gemma":[0.9913783,0.0005179704,0.0038104542,0.0002840463,0.0002045417,0.00011633365,0.00013437738,0.00011178546,0.0034422083],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99677974,0.00006796983,0.000813519,0.00092318194,0.0006143795,0.00080119225],"domain_scores_gemma":[0.99699026,0.00015555893,0.0007602839,0.0015687405,0.00025107892,0.0002741002],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001974395,0.0006373546,0.0012570334,0.00013428158,0.00044749855,0.000099830904,0.0004776886,0.00036287447,0.00018217361],"category_scores_gemma":[0.00032176322,0.00053365907,0.00023509597,0.00015249274,0.0010159912,0.0004394355,0.00038740205,0.00045235347,0.00008155308],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048197623,0.00019860899,0.00044990345,0.00052120193,0.00043713968,0.00007082918,0.0021064396,0.000027926762,0.99364704,0.00013017838,0.0005324247,0.0013963185],"study_design_scores_gemma":[0.011639485,0.00045136147,0.023085356,0.000857856,0.0004203339,0.000088399625,0.00031259694,0.0019905202,0.9593126,0.00006619038,0.0013100073,0.00046528052],"about_ca_topic_score_codex":0.0026152867,"about_ca_topic_score_gemma":0.00006434417,"teacher_disagreement_score":0.03433444,"about_ca_system_score_codex":0.0028388384,"about_ca_system_score_gemma":0.0014673067,"threshold_uncertainty_score":0.9997115},"labels":[],"label_agreement":null},{"id":"W2607663437","doi":"10.1182/blood.v128.22.4241.4241","title":"Combined Targeting of STAT3 and STAT5: A Novel Approach to Overcome Drug Resistance in Ph+ Cml","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Ponatinib; Dasatinib; Nilotinib; Bosutinib; Imatinib; Cancer research; Imatinib mesylate; Tyrosine kinase; Myeloid leukemia; Medicine; Pharmacology; Internal medicine","score_opus":0.012290476567410358,"score_gpt":0.2382235188245373,"score_spread":0.22593304225712693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2607663437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951901,0.00048815584,0.00027041914,0.0004901747,0.000023661374,0.00049008813,0.000046992933,0.000026932961,0.0029735111],"genre_scores_gemma":[0.98021364,0.00004323456,0.01714933,0.00008275096,0.000026371066,0.000035224602,0.0000113549595,0.00002364143,0.0024144466],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988818,0.000024702118,0.00029743448,0.0003015976,0.00022678997,0.00026766883],"domain_scores_gemma":[0.9993542,0.00012036573,0.00008090399,0.00027128772,0.00004427351,0.00012895747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020886485,0.00013873813,0.00033753106,0.000101978825,0.000019425948,0.000004861119,0.00006886278,0.00004264522,0.00001834468],"category_scores_gemma":[0.00015094229,0.00009836038,0.00003124757,0.00018145468,0.000048434336,0.000057659323,0.000062991,0.00007499254,0.0000064350247],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026521012,0.010471242,0.48199257,0.001723045,0.00063962955,0.0001705422,0.010771662,0.0000036467063,0.48078975,0.0032729225,0.0048589115,0.0026539653],"study_design_scores_gemma":[0.18422556,0.0010203102,0.6720882,0.0031428342,0.00057011395,0.000053939966,0.0010431889,0.00010148397,0.12920815,0.00097499526,0.006593549,0.0009776826],"about_ca_topic_score_codex":0.00016475427,"about_ca_topic_score_gemma":0.00006885358,"teacher_disagreement_score":0.3515816,"about_ca_system_score_codex":0.00019428734,"about_ca_system_score_gemma":0.00015129919,"threshold_uncertainty_score":0.40110198},"labels":[],"label_agreement":null},{"id":"W2608393446","doi":"10.1182/blood.v128.22.1921.1921","title":"Efficacy and Safety Following Bosutinib Dose Reduction in Patients with Philadelphia Chromosome‒Positive Chronic Myeloid Leukemia","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Nilotinib; Bosutinib; Medicine; Dasatinib; Internal medicine; Gastroenterology; Myeloid leukemia; Philadelphia chromosome; Imatinib; Surgery; Chromosomal translocation; Biology","score_opus":0.006967615130548236,"score_gpt":0.2284353939009106,"score_spread":0.22146777877036236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2608393446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99681264,0.0005792514,0.000009825355,0.0005420567,0.00015469138,0.0012169634,0.000024428564,0.000091978036,0.00056816585],"genre_scores_gemma":[0.9988527,0.00016487406,0.00024178503,0.000038123257,0.0003054155,0.000049250793,0.00008333618,0.000059392092,0.00020510351],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99803835,0.000059378486,0.00038107487,0.00062543544,0.0003914735,0.00050426286],"domain_scores_gemma":[0.9990815,0.000093134,0.0001321315,0.00042965935,0.00005788637,0.00020568326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013428366,0.00032674376,0.0004768623,0.0001662677,0.000105950996,0.000016295415,0.000082764636,0.00015871153,0.000076861426],"category_scores_gemma":[0.000071182694,0.00021631476,0.0000790278,0.0002926974,0.00012256688,0.00024095057,0.0000701207,0.00021034671,0.000043950553],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012145148,0.0068617705,0.7931884,0.00041337195,0.003533655,0.0007450018,0.0023616373,0.000026126472,0.08163438,0.00016205467,0.0004204473,0.098508045],"study_design_scores_gemma":[0.11314707,0.0020853418,0.87263924,0.0015745418,0.00055584277,0.00010997727,0.000027428816,0.0000053629915,0.0091852425,0.000013684905,0.00033557435,0.0003207075],"about_ca_topic_score_codex":0.00006726964,"about_ca_topic_score_gemma":0.000020756253,"teacher_disagreement_score":0.101001926,"about_ca_system_score_codex":0.002564388,"about_ca_system_score_gemma":0.0006864278,"threshold_uncertainty_score":0.882106},"labels":[],"label_agreement":null},{"id":"W2613372458","doi":"10.1182/blood.v128.22.3079.3079","title":"Adherence to Chronic Myeloid Leukemia Monitoring and Treatment Guidelines in Canadian Registries","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; Saskatchewan Cancer Agency; Université de Montréal; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Hôpital Maisonneuve-Rosemont; McMaster University","funders":"","keywords":"Medicine; Imatinib mesylate; Disease registry; Imatinib; Family medicine; Myeloid leukemia; Dasatinib; Cancer registry; Clinical trial; Cancer; Internal medicine; Disease","score_opus":0.038302530915274885,"score_gpt":0.3065045354085133,"score_spread":0.2682020044932384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2613372458","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935007,0.0025663443,0.0000028758416,0.0019070324,0.00011710503,0.00049346604,0.000023011513,0.000045817065,0.001343645],"genre_scores_gemma":[0.99123925,0.001465468,0.00093562447,0.00006330189,0.0004199028,0.000128342,0.00000473356,0.000026690444,0.0057166927],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985949,0.000016858998,0.00029343317,0.00039231716,0.0001669634,0.0005355317],"domain_scores_gemma":[0.9988917,0.000054600536,0.000042865973,0.0003991822,0.000067797606,0.0005438144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010191796,0.00021807732,0.00030057004,0.00018079007,0.000056342033,0.000019092795,0.00008508161,0.00009368612,0.00006508248],"category_scores_gemma":[0.00022046386,0.00014574558,0.000039690985,0.00017456,0.00004743366,0.000069285394,0.000034499917,0.000055501972,0.00009488469],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000070326336,0.00009377369,0.7414263,0.0000416483,0.00015509671,0.0006351427,0.00031315343,0.0000037270256,0.020380607,0.000058806614,0.00060410216,0.23621735],"study_design_scores_gemma":[0.038460407,0.0050087287,0.6028092,0.0033680517,0.00045722738,0.0005751018,0.00019512489,0.000021037951,0.20235968,0.00007295858,0.14589003,0.00078247534],"about_ca_topic_score_codex":0.31786582,"about_ca_topic_score_gemma":0.3307095,"teacher_disagreement_score":0.23543487,"about_ca_system_score_codex":0.006824077,"about_ca_system_score_gemma":0.0033656915,"threshold_uncertainty_score":0.99698853},"labels":[],"label_agreement":null},{"id":"W2619606660","doi":"","title":"Real-time quantitative PCR for rapid detection of translocations, amplifications, polymorphisms, and viral/bacterial load in blood or formalin-fixed paraffin embedded tissues","year":2007,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval","funders":"","keywords":"Biology; Genotyping; Real-time polymerase chain reaction; TaqMan; Amplicon; Molecular biology; Chronic myelogenous leukemia; Leukemia; Concordance; Polymerase chain reaction; Genotype; Virology; Gene; Immunology; Genetics","score_opus":0.16673668296149532,"score_gpt":0.49122057125903,"score_spread":0.3244838882975347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2619606660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99423546,0.0018660849,0.0005199843,0.00087414915,0.0001309964,0.002108439,0.00010092324,0.000038124086,0.00012585537],"genre_scores_gemma":[0.9861011,0.0060580005,0.0060651805,0.000032350046,0.00029922786,0.00047734287,0.00010121064,0.00003986487,0.0008257442],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9969984,0.0003102097,0.0011309624,0.0005106876,0.0005337897,0.0005159075],"domain_scores_gemma":[0.99576116,0.0028350446,0.00018461258,0.0004161462,0.0005702868,0.00023273798],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004288127,0.00016764544,0.0005797779,0.00029331216,0.00012336587,0.000020365937,0.00014555755,0.00025695626,0.0002523454],"category_scores_gemma":[0.0018501575,0.00014013409,0.000110412126,0.00053946784,0.00046104737,0.00012856192,0.000038694707,0.00039757584,0.000018233384],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054834824,0.0028872269,0.010705462,0.0007215387,0.0006310463,0.00005379426,0.0026070639,0.000004819357,0.7388935,0.0011242288,0.0008387601,0.18669774],"study_design_scores_gemma":[0.06279516,0.015085344,0.21482144,0.0011343936,0.00068143976,0.000050882154,0.0015140128,0.0013085085,0.69309074,0.0009539748,0.007891968,0.0006721245],"about_ca_topic_score_codex":0.0027857178,"about_ca_topic_score_gemma":0.0028962295,"teacher_disagreement_score":0.20411597,"about_ca_system_score_codex":0.00056599604,"about_ca_system_score_gemma":0.001690625,"threshold_uncertainty_score":0.57145023},"labels":[],"label_agreement":null},{"id":"W2621933252","doi":"10.1016/j.exphem.2017.05.007","title":"Whole-genome analysis reveals unexpected dynamics of mutant subclone development in a patient with JAK2-V617F-positive chronic myeloid leukemia","year":2017,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Myeloid leukemia; Biology; Induced pluripotent stem cell; Cancer research; Philadelphia chromosome; Haematopoiesis; Mutation; clone (Java method); Mutant; Stem cell; Myeloid; Leukemia; Genetics; Gene; Embryonic stem cell; Chromosomal translocation","score_opus":0.010313885165983295,"score_gpt":0.2724285352739896,"score_spread":0.2621146501080063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2621933252","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940226,0.0027822072,0.00011445307,0.00017857856,0.00007554826,0.0010656579,0.00006316247,0.00004617937,0.0016515886],"genre_scores_gemma":[0.99623114,0.000022420867,0.00243231,0.000051408595,0.00002358261,0.0002537019,0.00068941974,0.000053695385,0.00024233006],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971263,0.00008925303,0.0009089964,0.00075634295,0.00045523487,0.0006638966],"domain_scores_gemma":[0.9978158,0.000064805114,0.0006852225,0.0010956449,0.000117699536,0.0002208554],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000119938464,0.00046677326,0.0014805081,0.0004908755,0.00022373373,0.000023027882,0.00031090304,0.00023085611,0.00023261402],"category_scores_gemma":[0.000036306352,0.0003990752,0.00018348328,0.00043439097,0.00043015552,0.00013169483,0.0002674897,0.00027477447,0.000044790908],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071046026,0.006115306,0.33176157,0.00077288406,0.013436217,0.015776353,0.024875194,0.0004268416,0.58492273,0.0108338455,0.00006365304,0.0039108205],"study_design_scores_gemma":[0.012796496,0.0023283437,0.15885597,0.00055032293,0.00064360583,0.001606589,0.0024291596,0.0014726163,0.8185077,0.000023061968,0.00012850782,0.00065767055],"about_ca_topic_score_codex":0.00074629503,"about_ca_topic_score_gemma":0.0016248653,"teacher_disagreement_score":0.23358494,"about_ca_system_score_codex":0.009685948,"about_ca_system_score_gemma":0.0011556367,"threshold_uncertainty_score":0.9998461},"labels":[],"label_agreement":null},{"id":"W2624005914","doi":"10.3324/haematol.2016.163436","title":"Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia","year":2017,"lang":"en","type":"article","venue":"Haematologica","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Cancer Institute; Austrian Science Fund","keywords":"Cancer research; Myeloid leukemia; Tyrosine kinase; K562 cells; Haematopoiesis; Chemistry; Biology; Stem cell; Leukemia; Pharmacology; Signal transduction; Cell biology; Immunology","score_opus":0.027134315873230307,"score_gpt":0.2831470672737546,"score_spread":0.2560127514005243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2624005914","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860904,0.0011221771,0.00022407352,0.00061437185,0.00005492098,0.0009747165,0.00002882416,0.000055363907,0.010835154],"genre_scores_gemma":[0.9774661,0.00015410694,0.020738406,0.00011266178,0.000026919653,0.000094454124,0.00003105679,0.000028802102,0.0013474835],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980185,0.00004610713,0.0005427785,0.00057270925,0.00031814544,0.00050177815],"domain_scores_gemma":[0.9983841,0.00013452093,0.00034587644,0.0008625742,0.00007252545,0.00020040186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038304116,0.00027877907,0.00090866286,0.00013384531,0.00018501004,0.000037606915,0.00030062394,0.00012751241,0.00003722185],"category_scores_gemma":[0.0005299693,0.00022782302,0.000072502815,0.00013545556,0.00024420503,0.00012943405,0.00027771154,0.00027454627,0.000015674648],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014385597,0.005667004,0.6744941,0.018551806,0.0015023234,0.0036518143,0.027268803,0.000499922,0.13478796,0.07722605,0.035291757,0.006672909],"study_design_scores_gemma":[0.033695817,0.00090844935,0.9336041,0.0022631001,0.00021849854,0.00023613572,0.0009996637,0.0025786224,0.015871914,0.001721111,0.0068521732,0.001050407],"about_ca_topic_score_codex":0.0006197622,"about_ca_topic_score_gemma":0.0003047807,"teacher_disagreement_score":0.25911003,"about_ca_system_score_codex":0.001562103,"about_ca_system_score_gemma":0.00060953014,"threshold_uncertainty_score":0.92903537},"labels":[],"label_agreement":null},{"id":"W2624315412","doi":"10.1182/blood.v128.22.3976.3976","title":"Outcomes of Adult Philadelphia Positive Acute Lymphoblastic Leukemia Patients Treated with Pediatric Multi-Agent Chemotherapy and Imatinib and the Impact of Residual Disease Monitoring on Survival","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Imatinib; Minimal residual disease; Imatinib mesylate; Chemotherapy; Oncology; Surgery; Leukemia; Myeloid leukemia","score_opus":0.010022237313677169,"score_gpt":0.26519829035814707,"score_spread":0.2551760530444699,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2624315412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987443,0.00013188402,0.0000052062255,0.00011948558,0.00002182193,0.00068199716,0.00025706683,0.000019306877,0.000018936385],"genre_scores_gemma":[0.99919873,0.00048530192,0.00012796662,0.0000118626085,0.000057014688,0.000025740996,0.000015577312,0.000033225526,0.000044563425],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988365,0.000066447756,0.00029134296,0.00027044435,0.00032104945,0.00021417384],"domain_scores_gemma":[0.998773,0.00037780925,0.00023543622,0.00028365466,0.0001557432,0.00017436461],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006129689,0.00026069436,0.00049673027,0.00009098888,0.00004540773,0.000006676788,0.00006202616,0.000052483905,0.000007061542],"category_scores_gemma":[0.00012937609,0.00011266708,0.000091324466,0.00011409681,0.00017789715,0.0000556556,0.000033475146,0.000058438698,0.0000012892194],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005311016,0.000808308,0.9911013,0.000053424174,0.0012509704,0.000023796414,0.00038615227,0.0000023482262,0.0005410251,0.0000043365353,0.000005132407,0.00051216036],"study_design_scores_gemma":[0.08212421,0.001323976,0.90839756,0.0002242316,0.001423057,0.0000071067766,0.000025196428,0.00003249371,0.006332452,0.0000033232448,4.2505242e-8,0.00010638205],"about_ca_topic_score_codex":0.00031105513,"about_ca_topic_score_gemma":0.0000025601091,"teacher_disagreement_score":0.08270381,"about_ca_system_score_codex":0.00029508278,"about_ca_system_score_gemma":0.0002533323,"threshold_uncertainty_score":0.45944303},"labels":[],"label_agreement":null},{"id":"W2625541339","doi":"10.1016/j.leukres.2017.06.009","title":"Exome sequencing reveals DNMT3A and ASXL1 variants associate with progression of chronic myeloid leukemia after tyrosine kinase inhibitor therapy","year":2017,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"Ministry of Education, Science and Technology; National Research Foundation of Korea; Ministry of Education","keywords":"Myeloid leukemia; Tyrosine-kinase inhibitor; Exome sequencing; Tyrosine kinase; Cancer research; Exome; CD135; Medicine; Mutation; Biology; Receptor; Genetics; Internal medicine; Gene; Cancer","score_opus":0.054807777901119875,"score_gpt":0.36418839409618997,"score_spread":0.30938061619507007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2625541339","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904232,0.004257726,0.000010986169,0.0006306408,0.00012183706,0.001903613,0.000044110104,0.000079809055,0.0025280833],"genre_scores_gemma":[0.9909784,0.0018054481,0.0011164156,0.00007773585,0.00062069757,0.00037498632,0.00004182144,0.00013141692,0.004853072],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99468184,0.00035903932,0.0006468543,0.0010296555,0.0019365438,0.0013460951],"domain_scores_gemma":[0.996028,0.0003108218,0.00046550838,0.0019486091,0.0007111307,0.0005359056],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0022407058,0.0004981908,0.00094423816,0.0004017085,0.0007516364,0.00023511724,0.0005156218,0.000449164,0.00027226834],"category_scores_gemma":[0.0006658356,0.00036114786,0.000132682,0.00039730564,0.0010397481,0.0005143644,0.000514573,0.001308083,0.00008202128],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.011443733,0.0006532623,0.22850575,0.0024478796,0.0011908525,0.005602951,0.002454499,0.000022057024,0.57639897,0.00021510622,0.0029553548,0.16810957],"study_design_scores_gemma":[0.040881086,0.007919514,0.69652873,0.0088875,0.00021983344,0.00054626644,0.00029361225,0.0016955226,0.23865621,0.0004581187,0.0029404592,0.0009731663],"about_ca_topic_score_codex":0.0014476022,"about_ca_topic_score_gemma":0.00015788528,"teacher_disagreement_score":0.46802297,"about_ca_system_score_codex":0.01842767,"about_ca_system_score_gemma":0.0076399148,"threshold_uncertainty_score":0.99988407},"labels":[],"label_agreement":null},{"id":"W2627091086","doi":"10.1016/j.clml.2017.06.001","title":"Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias","year":2017,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Pfizer","keywords":"Bosutinib; Renal function; Medicine; Imatinib; Internal medicine; Oncology; Gastroenterology; Dasatinib","score_opus":0.018810396390509344,"score_gpt":0.2963083973831734,"score_spread":0.27749800099266403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2627091086","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935518,0.00015574535,0.000014028297,0.00030218036,0.00055660796,0.0021122107,0.000049482405,0.00010004692,0.0031579032],"genre_scores_gemma":[0.99767494,0.00013317344,0.00025146757,0.00039141282,0.0005052081,0.00017023775,0.0002255418,0.00011642677,0.00053157826],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99538773,0.00024962806,0.0014113928,0.001274115,0.0008680825,0.00080903945],"domain_scores_gemma":[0.9951534,0.0010561575,0.0011151625,0.0018911541,0.00025896466,0.0005251154],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036306411,0.00076521403,0.0016943212,0.00026316085,0.00031631486,0.00005885326,0.00042216005,0.00061607227,0.000082687395],"category_scores_gemma":[0.0008042673,0.00056852493,0.0005073663,0.0002324369,0.0007473077,0.00028947653,0.00016116964,0.00039687692,0.00020654777],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023677295,0.004874914,0.552016,0.00023153576,0.001373822,0.0010001682,0.0001825742,0.000032291577,0.00044578942,0.00019593246,0.0006289273,0.41534072],"study_design_scores_gemma":[0.06624033,0.016611164,0.9056219,0.001484183,0.00074673793,0.000024737526,0.000012268571,0.00012069756,0.007810016,0.000071213915,0.00081443385,0.0004423524],"about_ca_topic_score_codex":0.00042188592,"about_ca_topic_score_gemma":0.000067671805,"teacher_disagreement_score":0.41489837,"about_ca_system_score_codex":0.009056215,"about_ca_system_score_gemma":0.0024825528,"threshold_uncertainty_score":0.99967664},"labels":[],"label_agreement":null},{"id":"W266794678","doi":"10.1182/blood.v122.21.514.514","title":"Whole Genome Sequencing Of Chronic Myeloid Leukemia (CML)-Derived Induced Pluripotent Stem Cells (iPSC) Reveals Faithful Genocopying Of Highly Mutated Primary Leukemic Cells","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Induced pluripotent stem cell; Biology; Cancer research; Myeloid leukemia; KLF4; SOX2; Stem cell; Myeloid; Progenitor cell; Genetics; Gene; Embryonic stem cell","score_opus":0.01788640998757009,"score_gpt":0.2193060988833037,"score_spread":0.2014196888957336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W266794678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931931,0.0023247614,0.00005189422,0.00006078137,0.00022649838,0.0029647222,0.00011075838,0.00020003454,0.00086743163],"genre_scores_gemma":[0.99476135,0.0003370269,0.0025326805,0.00016028364,0.00026134934,0.00018543313,0.00017335628,0.00018270452,0.0014058029],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99494743,0.00020516771,0.0017937156,0.001004501,0.0009448884,0.0011042819],"domain_scores_gemma":[0.9962934,0.00019132737,0.0011425257,0.0014307024,0.00047758574,0.00046440784],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037473039,0.00075281214,0.001700899,0.0004361236,0.00012897336,0.000036783505,0.0005332629,0.00047457393,0.0003137413],"category_scores_gemma":[0.000028002785,0.0007023028,0.00041509792,0.0006515126,0.0002219175,0.00031457425,0.00030200105,0.00065256224,0.00037079875],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008763568,0.00042481298,0.00038150308,0.0017487395,0.0008830492,0.00019966766,0.0011821726,0.00063478074,0.9923645,0.0000039254196,0.00010039208,0.001988818],"study_design_scores_gemma":[0.014230703,0.001212936,0.007941246,0.0009905508,0.0009964891,0.00019710243,0.0005239782,0.0004886709,0.9727323,0.000026322916,0.000102284925,0.00055741833],"about_ca_topic_score_codex":0.0016507654,"about_ca_topic_score_gemma":0.000017917302,"teacher_disagreement_score":0.019632205,"about_ca_system_score_codex":0.008339165,"about_ca_system_score_gemma":0.004509395,"threshold_uncertainty_score":0.99954283},"labels":[],"label_agreement":null},{"id":"W2682865355","doi":"10.1097/mcp.0000000000000412","title":"Pulmonary arterial hypertension induced by tyrosine kinase inhibitors","year":2017,"lang":"en","type":"review","venue":"Current Opinion in Pulmonary Medicine","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Agence Nationale de Sécurité du Médicament et des Produits de Santé","keywords":"Medicine; Dasatinib; Discontinuation; Bosutinib; Ponatinib; Tyrosine kinase; Internal medicine; Imatinib; Pulmonary hypertension; Tyrosine-kinase inhibitor; Pharmacology; Cardiology; Cancer; Myeloid leukemia","score_opus":0.18294528100987542,"score_gpt":0.4086893511833855,"score_spread":0.2257440701735101,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2682865355","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015825589,0.96640944,0.0000020811806,0.0005210097,0.027631132,0.00342332,0.00017765924,0.00016323922,0.0015138398],"genre_scores_gemma":[0.0008006151,0.976588,0.000016638094,0.00003947488,0.009537592,0.0005639064,0.011673359,0.00024917032,0.0005312099],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9929935,0.00036912283,0.002465091,0.0018412806,0.0012710667,0.0010599442],"domain_scores_gemma":[0.9950966,0.0003064067,0.0013853672,0.0022656498,0.00017070223,0.0007752747],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00069933425,0.0016263325,0.0052811797,0.0010834808,0.0002550771,0.000036940794,0.0007083152,0.0010510169,0.0004201657],"category_scores_gemma":[0.00063189986,0.0011998747,0.0006745284,0.0006621359,0.00046488474,0.00026439194,0.00041368662,0.0021125048,0.00029888438],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021213132,0.0013824867,0.0000679393,0.02900651,0.00012958072,0.0006700983,0.000027122345,4.292005e-8,0.00013649535,0.000011042547,0.028213803,0.94014275],"study_design_scores_gemma":[0.0035518392,0.00046819603,0.00019761064,0.16634443,0.0008618925,0.002101707,0.000018561257,0.000044979894,0.000003476407,0.00001957688,0.8256514,0.0007363348],"about_ca_topic_score_codex":0.00018743433,"about_ca_topic_score_gemma":0.000001025494,"teacher_disagreement_score":0.9394064,"about_ca_system_score_codex":0.0022100795,"about_ca_system_score_gemma":0.00144135,"threshold_uncertainty_score":0.9996484},"labels":[],"label_agreement":null},{"id":"W2729618901","doi":"10.1002/jcb.26257","title":"Pathological role of a point mutation (T315I) in BCR‐ABL1 protein—A computational insight","year":2017,"lang":"en","type":"article","venue":"Journal of Cellular Biochemistry","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":114,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Point mutation; Mutation; Mutant; Myeloid leukemia; Biology; Tyrosine kinase; Flexibility (engineering); Threonine; Genetics; Cancer research; Serine; Phosphorylation; Computational biology; Cell biology; Signal transduction; Gene","score_opus":0.01034753035492276,"score_gpt":0.2572099942122778,"score_spread":0.24686246385735505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2729618901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965203,0.0010011606,0.00025796043,0.0003990425,0.000038703376,0.00016400155,0.0000051264683,0.000004567086,0.001609134],"genre_scores_gemma":[0.99567,0.00001538878,0.003940092,0.000023545523,0.00014182419,0.000004244962,0.00002352625,0.0000114420545,0.00016990678],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99871004,0.000028583421,0.0005652756,0.00014605855,0.00040616075,0.00014387647],"domain_scores_gemma":[0.99851954,0.00002949185,0.00082906074,0.0002792281,0.00023086047,0.000111834794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029183083,0.00013034,0.00034980488,0.00006166687,0.00005015097,0.00002037022,0.00017463168,0.000157134,0.0000976494],"category_scores_gemma":[0.00037533158,0.00010495963,0.00015291579,0.00004767393,0.00012104618,0.00008565217,0.00005191043,0.00030010554,0.000005051939],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031827646,0.00045968243,0.0074819904,0.00015163627,0.00007039524,0.0013549981,0.0001865697,0.000092885726,0.98815644,0.000025203999,0.000042814932,0.0016591169],"study_design_scores_gemma":[0.004489138,0.00032121764,0.017174372,0.0004690916,0.00006248567,0.0008534085,0.0001391723,0.0006292632,0.97449905,0.0011970461,0.00007088949,0.00009484918],"about_ca_topic_score_codex":0.000011971382,"about_ca_topic_score_gemma":6.345221e-7,"teacher_disagreement_score":0.013657363,"about_ca_system_score_codex":0.00034385902,"about_ca_system_score_gemma":0.00048577576,"threshold_uncertainty_score":0.42801297},"labels":[],"label_agreement":null},{"id":"W2730057868","doi":"10.1038/leu.2017.250","title":"SHP2 is required for BCR-ABL1-induced hematologic neoplasia","year":2017,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Cancer Institute","keywords":"Cancer research; Philadelphia chromosome; Tyrosine kinase; ABL; Biology; MAPK/ERK pathway; Myeloid leukemia; breakpoint cluster region; Leukemia; Kinase; Signal transduction; Immunology; Cell biology; Genetics; Chromosomal translocation; Receptor","score_opus":0.052665312393913935,"score_gpt":0.3294850386991547,"score_spread":0.27681972630524077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2730057868","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9736609,0.00020413796,0.00011815197,0.0027831055,0.00058697973,0.0012458327,0.00003413991,0.00020881952,0.021157926],"genre_scores_gemma":[0.98252565,0.000041012456,0.0031872706,0.0013715205,0.00041336266,0.00021838998,0.00006275061,0.000070376926,0.012109656],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979531,0.000020356265,0.00040181933,0.00064393226,0.00032287958,0.0006578855],"domain_scores_gemma":[0.997308,0.00012962498,0.00032345628,0.0018406827,0.00011948073,0.0002787677],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018275605,0.00035226488,0.0006695497,0.00008430155,0.0005337311,0.00010003636,0.0004363854,0.0003502643,0.00036929525],"category_scores_gemma":[0.00056908693,0.00029670968,0.0002835253,0.000065874105,0.00012146772,0.00021303326,0.00014490994,0.0002536934,0.00059623865],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048480756,0.0011028898,0.10881579,0.0031382288,0.003168083,0.00340192,0.004453273,0.000011749471,0.22737403,0.009772815,0.46019465,0.1737185],"study_design_scores_gemma":[0.07957001,0.003639384,0.17426315,0.0016611442,0.0020897521,0.0027993342,0.00053253776,0.007976805,0.5402911,0.0085876705,0.17622371,0.002365426],"about_ca_topic_score_codex":0.00036277276,"about_ca_topic_score_gemma":0.000048715385,"teacher_disagreement_score":0.31291705,"about_ca_system_score_codex":0.0026232612,"about_ca_system_score_gemma":0.0012048038,"threshold_uncertainty_score":0.9999485},"labels":[],"label_agreement":null},{"id":"W2735666722","doi":"10.1016/j.clml.2017.07.006","title":"Cardiovascular Events After Exposure to Nilotinib in Chronic Myeloid Leukemia: Long-term Follow-up","year":2017,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital; University of Toronto; University Health Network","funders":"","keywords":"Nilotinib; Myeloid leukemia; Medicine; Chronic myeloid leukaemia; Term (time); Internal medicine; Oncology; Imatinib","score_opus":0.033579433887023086,"score_gpt":0.32650502168535495,"score_spread":0.2929255877983319,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2735666722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98568875,0.0046410584,0.000087699635,0.00057172496,0.0030869795,0.0027669896,0.00006306816,0.00031390198,0.0027798363],"genre_scores_gemma":[0.9861891,0.0010690262,0.0006655857,0.001246492,0.0028284886,0.0008041496,0.00015090097,0.00031996757,0.006726291],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9899355,0.0004908736,0.0028020802,0.0028169453,0.0017561818,0.002198406],"domain_scores_gemma":[0.9898584,0.00048761396,0.00071866176,0.006831367,0.00034618116,0.0017578148],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.002206696,0.0013425593,0.0032180608,0.00045382045,0.0005603188,0.00023125995,0.00180664,0.0014936705,0.00056732295],"category_scores_gemma":[0.0023993275,0.0012647257,0.0026796262,0.0004880237,0.0006174929,0.0006335622,0.0013435931,0.0011638138,0.0032619545],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0024898376,0.0002794803,0.5237573,0.00030296456,0.001453439,0.0050446126,0.00017648558,0.00006101605,0.00024698203,0.000020340824,0.0010830782,0.46508446],"study_design_scores_gemma":[0.03658669,0.0017977927,0.9467103,0.0016856536,0.0009788942,0.00049746956,0.00002512841,0.0001143333,0.0007796427,0.00007949765,0.009614227,0.0011303723],"about_ca_topic_score_codex":0.0009221312,"about_ca_topic_score_gemma":0.0010561257,"teacher_disagreement_score":0.4639541,"about_ca_system_score_codex":0.02891776,"about_ca_system_score_gemma":0.00993309,"threshold_uncertainty_score":0.9999325},"labels":[],"label_agreement":null},{"id":"W2735850899","doi":"10.1111/bjh.14829","title":"Nilotinib dose‐optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from <scp>ENEST</scp>xtnd","year":2017,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Novartis Pharmaceuticals Corporation","keywords":"Nilotinib; Medicine; Adverse effect; Rash; Internal medicine; Clinical endpoint; Nausea; Clinical trial; Oncology; Myeloid leukemia; Imatinib","score_opus":0.02974140965789916,"score_gpt":0.31044792188506387,"score_spread":0.2807065122271647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2735850899","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9832616,0.0133633865,0.0002763187,0.00075556536,0.00066702615,0.00061638496,0.000097162396,0.000030391457,0.0009321892],"genre_scores_gemma":[0.98885787,0.007086261,0.0024983077,0.0001307092,0.000773505,0.000029988054,0.00021099678,0.00007369236,0.00033868276],"study_design_codex":"case_report","study_design_gemma":"observational","domain_scores_codex":[0.9957653,0.00027940382,0.0019464564,0.00062219746,0.00052686373,0.0008597723],"domain_scores_gemma":[0.9961553,0.0007982704,0.0017476263,0.0007447267,0.00023417595,0.00031985602],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007758042,0.00039441616,0.0016307946,0.00046069326,0.00021573853,0.00015083585,0.000655604,0.00050090405,0.00018706567],"category_scores_gemma":[0.0037876097,0.00044778248,0.00024685508,0.00023417229,0.00034799858,0.0005821934,0.0001562617,0.0012069012,0.000050594568],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029526518,0.0037268656,0.05773425,0.00064523355,0.0008750662,0.7187152,0.0014762017,0.027881268,0.0042029177,0.000099147015,0.021885596,0.15980563],"study_design_scores_gemma":[0.3479252,0.004734063,0.39001825,0.012717501,0.00064728723,0.20817864,0.0003612739,0.019629193,0.005452146,0.0005675941,0.009139381,0.00062948413],"about_ca_topic_score_codex":0.0040251743,"about_ca_topic_score_gemma":0.009828035,"teacher_disagreement_score":0.51053655,"about_ca_system_score_codex":0.0038732702,"about_ca_system_score_gemma":0.0037502213,"threshold_uncertainty_score":0.9999507},"labels":[],"label_agreement":null},{"id":"W2741643140","doi":"10.1183/13993003.00217-2017","title":"Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study","year":2017,"lang":"en","type":"article","venue":"European Respiratory Journal","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":129,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Lloyd's Tercentenary Research Foundation; Agence Nationale de Sécurité du Médicament et des Produits de Santé; Canadian Thoracic Society; European Respiratory Society","keywords":"Medicine; Dasatinib; Discontinuation; Pulmonary hypertension; Internal medicine; Cardiology; Hemodynamics; Vascular resistance; Population; Surgery; Imatinib","score_opus":0.08942395129371418,"score_gpt":0.33511614154807806,"score_spread":0.2456921902543639,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2741643140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996393,0.00006807161,0.0000079042975,0.00015452695,0.00078386586,0.00048424175,0.0000057584352,0.000039261955,0.0020633268],"genre_scores_gemma":[0.998378,0.0000018145113,0.00010955745,0.0004139271,0.00083385856,0.00000363351,0.000007953795,0.000071108,0.00018018034],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975128,0.0004508212,0.000785086,0.00032694754,0.0006350453,0.00028929417],"domain_scores_gemma":[0.9973641,0.00006910812,0.00085967255,0.0012076685,0.00020265453,0.00029677487],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008051558,0.00027873777,0.00059015106,0.00018272389,0.00057726545,0.00011848582,0.00039031188,0.000053041298,0.0003138501],"category_scores_gemma":[0.00048473018,0.00021094758,0.00023411587,0.00005048385,0.000054335294,0.00018774923,0.00011249126,0.00040977585,0.00009126135],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041410732,0.001001514,0.9720211,0.000023724479,0.0002205363,0.007220334,0.00008009626,0.000003765355,0.008622017,0.0000010490484,0.00009480915,0.010296934],"study_design_scores_gemma":[0.009720211,0.0010352557,0.9877478,0.00018846987,0.00024409068,0.0003402466,0.000042857933,0.000015615165,0.00038665376,0.0000019756378,0.00010531351,0.00017151315],"about_ca_topic_score_codex":0.000018398363,"about_ca_topic_score_gemma":0.000011301673,"teacher_disagreement_score":0.015726684,"about_ca_system_score_codex":0.00027240216,"about_ca_system_score_gemma":0.00037202422,"threshold_uncertainty_score":0.86021924},"labels":[],"label_agreement":null},{"id":"W2744041560","doi":"10.1038/leu.2017.247","title":"Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results","year":2017,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital; University Health Network; University of Toronto; McMaster University","funders":"Novartis Pharmaceuticals Corporation","keywords":"Nilotinib; Imatinib; Medicine; Randomized controlled trial; Oncology; Internal medicine; Myeloid leukemia","score_opus":0.023929054748583402,"score_gpt":0.2993948302622677,"score_spread":0.2754657755136843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2744041560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98432195,0.000034809313,0.00006625393,0.0032433898,0.0005055827,0.0066621494,0.00004351813,0.00009814368,0.00502419],"genre_scores_gemma":[0.9915544,0.0000059019067,0.0019958185,0.0015900255,0.00023599685,0.0006622886,0.0001343166,0.00008832889,0.0037329206],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9954953,0.00047539824,0.0011670903,0.0010216467,0.0009576887,0.00088288344],"domain_scores_gemma":[0.9959071,0.00079048536,0.0004542744,0.0019611965,0.000273409,0.0006135244],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014817879,0.00056654925,0.001585956,0.0004848762,0.00027583094,0.0001298935,0.00054942095,0.0002737744,0.00007299647],"category_scores_gemma":[0.016299736,0.00047874954,0.0005296237,0.00023534232,0.000116230316,0.000117096475,0.0003540186,0.00043209936,0.00035785398],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9886918,0.00053051114,0.0008107961,0.000057431265,0.0002299116,0.0009496617,0.0014008643,0.00034155272,0.0005514435,0.00007715589,0.00070950313,0.0056493427],"study_design_scores_gemma":[0.9683108,0.004534452,0.020912142,0.00048849836,0.00029036234,0.000020061987,0.00019540169,0.00065347017,0.0034849811,0.00006739501,0.0005672913,0.00047515077],"about_ca_topic_score_codex":0.000976035,"about_ca_topic_score_gemma":0.000109096785,"teacher_disagreement_score":0.020381033,"about_ca_system_score_codex":0.005884054,"about_ca_system_score_gemma":0.0014521088,"threshold_uncertainty_score":0.9997664},"labels":[],"label_agreement":null},{"id":"W2744179443","doi":"10.2147/vhrm.s108874","title":"Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance","year":2017,"lang":"en","type":"review","venue":"Vascular Health and Risk Management","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital; University of Toronto; University Health Network","funders":"Princess Margaret Hospital Foundation","keywords":"Medicine; Myeloid leukemia; Tyrosine kinase; Tyrosine-kinase inhibitor; Immunology; Internal medicine; Cancer; Receptor","score_opus":0.02911039164264766,"score_gpt":0.30605158630237966,"score_spread":0.276941194659732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2744179443","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011227077,0.9920658,0.00010809535,0.000009723375,0.00026784602,0.0056197313,0.00009984337,0.00006074222,0.00064549904],"genre_scores_gemma":[0.00079422945,0.9973278,0.00044021467,0.000014861534,0.0002930345,0.00050662505,0.00026612045,0.00012967776,0.00022741198],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99394405,0.00097267923,0.0015090766,0.0015252485,0.001063904,0.0009850506],"domain_scores_gemma":[0.9958651,0.00009906368,0.0008527348,0.0025892348,0.00009370404,0.0005001563],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0028947683,0.0010461262,0.0060780435,0.0007349105,0.00034804686,0.00012338636,0.00031936044,0.00046973594,0.000010787683],"category_scores_gemma":[0.00008577898,0.00085542974,0.002387756,0.00040603036,0.0004115652,0.00023556597,0.0004959842,0.000844361,0.000008589593],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025926693,0.000074105184,0.00024863335,0.10279886,0.013248365,0.00027454906,0.00018881445,0.00012788898,2.8119864e-8,0.000106400825,0.00011254369,0.8827939],"study_design_scores_gemma":[0.0052185673,0.00050354155,0.001013457,0.026524192,0.005097064,0.000085528234,0.0005943705,0.00003809457,0.0000013526778,0.00004371743,0.9602509,0.0006292208],"about_ca_topic_score_codex":0.0064482754,"about_ca_topic_score_gemma":0.0004330031,"teacher_disagreement_score":0.9601383,"about_ca_system_score_codex":0.003668841,"about_ca_system_score_gemma":0.0037431042,"threshold_uncertainty_score":0.99938965},"labels":[],"label_agreement":null},{"id":"W2749902584","doi":"10.1182/blood.v128.22.1922.1922","title":"Treatment-Free Remission Accomplished By Dasatinib (TRAD): Preliminary Results of the Pan-Canadian Tyrosine Kinase Inhibitor Discontinuation Trial","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; London Health Sciences Centre; University of Alberta; McGill University Health Centre; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Hôpital de l'Enfant-Jésus; Université de Montréal; Hôpital Maisonneuve-Rosemont; Princess Margaret Cancer Centre; University of Calgary; University of British Columbia; University Health Network; CancerCare Manitoba; Ottawa Hospital; Dalhousie University; University of Toronto","funders":"","keywords":"Discontinuation; Dasatinib; Medicine; Internal medicine; Imatinib; Tyrosine-kinase inhibitor; Imatinib mesylate; Myeloid leukemia; Cancer","score_opus":0.017443082424518697,"score_gpt":0.25378755329799185,"score_spread":0.23634447087347316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2749902584","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98856044,0.00034275776,0.0000027309204,0.005723736,0.0002916654,0.0017787005,0.0006306584,0.00004373863,0.002625602],"genre_scores_gemma":[0.99329495,0.00006623923,0.00024567093,0.000049879633,0.00040197273,0.00008953979,0.00020062592,0.000035914443,0.005615205],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982251,0.00010559346,0.00054986426,0.0004181046,0.00035906344,0.0003422538],"domain_scores_gemma":[0.9979461,0.00020169797,0.00027589552,0.0012482038,0.00007475888,0.00025335414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015029244,0.00025333525,0.00037164136,0.000084136474,0.000111311885,0.000014854102,0.00023578014,0.00016396208,0.00007972981],"category_scores_gemma":[0.0009785504,0.00012814335,0.00017441939,0.00018553731,0.00010291273,0.00011983139,0.000072433584,0.00008807879,0.000019210307],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11065282,0.011949463,0.021762691,0.00011392071,0.0009935988,0.00019795746,0.001477781,5.165089e-7,0.57106996,0.00009260372,0.099342205,0.18234648],"study_design_scores_gemma":[0.48370728,0.007377547,0.0370277,0.0008304027,0.0009381226,0.000055422686,0.00006063308,0.000010456555,0.45793435,0.00007191529,0.01173139,0.00025477048],"about_ca_topic_score_codex":0.008370373,"about_ca_topic_score_gemma":0.0023659326,"teacher_disagreement_score":0.37305447,"about_ca_system_score_codex":0.0007225208,"about_ca_system_score_gemma":0.0008245472,"threshold_uncertainty_score":0.99823296},"labels":[],"label_agreement":null},{"id":"W2750259239","doi":"10.1016/j.exphem.2017.06.136","title":"Targeting ILK impairs TKI-resistance of quiescent leukemic stem cells in vitro and in vivo","year":2017,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia Hospital","funders":"","keywords":"Dasatinib; Integrin-linked kinase; CD34; Stem cell; Cancer research; Myeloid leukemia; Stromal cell; CD38; Biology; Nilotinib; Bone marrow; Tyrosine kinase; Haematopoiesis; Progenitor cell; Immunology; Kinase; Imatinib; Cell biology; Signal transduction; Protein kinase A","score_opus":0.014281683401347613,"score_gpt":0.28889942956028875,"score_spread":0.27461774615894113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2750259239","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98797596,0.009726875,0.0000021763526,0.00010644848,0.00016326873,0.0004465508,0.0000097527745,0.000017344606,0.0015516428],"genre_scores_gemma":[0.9987196,0.000082749626,0.00061008264,0.00004354389,0.000020440715,0.00005141539,0.0000041131884,0.000023300516,0.00044476838],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99862874,0.000048684873,0.00045425966,0.00036041037,0.00014373499,0.00036415583],"domain_scores_gemma":[0.99919295,0.000058765752,0.00022364876,0.00042081584,0.0000132096975,0.000090582136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012158346,0.00019793242,0.0006286451,0.00011567234,0.00006548121,0.000009065501,0.00014178216,0.0001267037,0.00007417857],"category_scores_gemma":[0.000016710594,0.00018981648,0.00005069852,0.000046939476,0.0002456539,0.00009001368,0.00015383174,0.00015615625,0.000009345472],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012134138,0.00045819822,0.050860707,0.00026783464,0.000035510704,0.00053539703,0.001710244,0.0000024139454,0.9437769,0.0006390143,0.000376366,0.00012402171],"study_design_scores_gemma":[0.006072528,0.00009334857,0.0024304893,0.00026223925,0.000009479409,0.00010186171,0.0021265848,0.00016689883,0.9884418,0.000016700327,0.00014927315,0.00012875782],"about_ca_topic_score_codex":0.0003826068,"about_ca_topic_score_gemma":0.00009555424,"teacher_disagreement_score":0.04843022,"about_ca_system_score_codex":0.0009392873,"about_ca_system_score_gemma":0.0001367039,"threshold_uncertainty_score":0.77404916},"labels":[],"label_agreement":null},{"id":"W2752250321","doi":"10.1016/j.clml.2017.07.115","title":"ENESTfreedom and ENESTop Update: Durable Treatment-Free Remission (TFR) at 96 Weeks after Nilotinib Treatment Cessation in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)","year":2017,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Nilotinib; Myeloid leukemia; Medicine; Internal medicine; Oncology; Blast Crisis; Imatinib","score_opus":0.021696032878341164,"score_gpt":0.3103709124858914,"score_spread":0.2886748796075502,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2752250321","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99204934,0.002349534,0.000008413965,0.00060619885,0.00049727893,0.0030777622,0.00015873158,0.0001913729,0.0010613431],"genre_scores_gemma":[0.9896654,0.0031708318,0.00051899947,0.00019367327,0.00080380344,0.0008116011,0.00092581846,0.00024710002,0.0036628065],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99192035,0.00041181577,0.0023944904,0.0025580437,0.000973175,0.0017421093],"domain_scores_gemma":[0.9926654,0.00056626555,0.0012315097,0.004241789,0.00020960778,0.0010854399],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.000689731,0.001509609,0.0024307305,0.000492811,0.000642764,0.00022187261,0.00081622595,0.0011180143,0.00046508465],"category_scores_gemma":[0.0005926778,0.001168563,0.0004555621,0.00041133715,0.0010458735,0.0008988887,0.0006290765,0.00049307465,0.00025075037],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.010158884,0.0015153701,0.59835577,0.00016246302,0.00032073093,0.0013167211,0.00018534737,0.000067087145,0.0004717913,0.000023893674,0.00026342622,0.38715854],"study_design_scores_gemma":[0.15426391,0.010108728,0.81921566,0.001198379,0.00054278085,0.00013511296,0.000022845272,0.0014537548,0.00258025,0.00007487669,0.00949054,0.00091316464],"about_ca_topic_score_codex":0.0048931786,"about_ca_topic_score_gemma":0.0088002,"teacher_disagreement_score":0.38624537,"about_ca_system_score_codex":0.10944497,"about_ca_system_score_gemma":0.010569037,"threshold_uncertainty_score":0.9997653},"labels":[],"label_agreement":null},{"id":"W2761499066","doi":"10.1093/annonc/mdx362.027","title":"Effects of neratinib (N) on health-related quality of life (HRQoL) in early-stage HER2+ breast cancer (BC): longitudinal analyses from the phase III ExteNET trial","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Neratinib; Medicine; Breast cancer; Quality of life (healthcare); Oncology; Stage (stratigraphy); Health related quality of life; Internal medicine; Gerontology; Cancer; Gynecology; Trastuzumab; Disease; Nursing","score_opus":0.22954304827326835,"score_gpt":0.5096455933815812,"score_spread":0.2801025451083129,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761499066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98888797,0.0019360721,0.0000034419563,0.0070189224,0.00030760327,0.00111535,0.0003469047,0.000009825248,0.00037390966],"genre_scores_gemma":[0.997656,0.0012651546,0.000045278186,0.00056855567,0.00020239297,0.00006639376,0.000054328106,0.000017841305,0.00012407616],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9968887,0.0007256961,0.0013233473,0.00036236426,0.00036292867,0.0003369478],"domain_scores_gemma":[0.99537313,0.0014826364,0.0019602065,0.00081670465,0.0001978979,0.00016942593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010170696,0.0002248181,0.0016935491,0.00010377832,0.000096982476,0.000007120806,0.00030157645,0.0002282122,0.00026067795],"category_scores_gemma":[0.0010109342,0.00015515694,0.00025184144,0.00013130659,0.00041430083,0.0000792069,0.000085132655,0.00032075215,0.000004411058],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.50082237,0.021034963,0.2647671,0.0010827737,0.006505191,0.00041374005,0.0052816775,0.00028542234,0.012127448,0.00048489944,0.013621506,0.17357288],"study_design_scores_gemma":[0.16579853,0.009005282,0.8150625,0.00041186687,0.00020428014,0.000003195112,0.000079284095,0.00007251173,0.008879022,0.00006762329,0.0003043269,0.00011155695],"about_ca_topic_score_codex":0.2749864,"about_ca_topic_score_gemma":0.014459964,"teacher_disagreement_score":0.5502954,"about_ca_system_score_codex":0.00023593547,"about_ca_system_score_gemma":0.0018565761,"threshold_uncertainty_score":0.8068999},"labels":[],"label_agreement":null},{"id":"W2761656877","doi":"10.1038/cddis.2017.458","title":"BCR–ABL1-induced downregulation of WASP in chronic myeloid leukemia involves epigenetic modification and contributes to malignancy","year":2017,"lang":"en","type":"article","venue":"Cell Death and Disease","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Sociedade Beneficente Israelita Brasileira Albert Einstein; Conselho Nacional de Desenvolvimento Científico e Tecnológico; Canadian Institutes of Health Research; Cancer Research Society; Coordenação de Aperfeiçoamento de Pessoal de Nível Superior; University of Toronto; Fundação de Amparo à Pesquisa do Estado de São Paulo; Natural Sciences and Engineering Research Council of Canada; Princess Margaret Cancer Foundation","keywords":"Myeloid leukemia; Cancer research; Biology; K562 cells; Carcinogenesis; breakpoint cluster region; Haematopoiesis; Tyrosine kinase; Chronic myelogenous leukemia; DNA methylation; Leukemia; Immunology; Signal transduction; Cell biology; Stem cell; Cancer; Gene expression; Genetics; Gene","score_opus":0.02783287584222453,"score_gpt":0.28518667046715124,"score_spread":0.2573537946249267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761656877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923079,0.0059532365,0.00008178879,0.00036868016,0.000035241585,0.0007819087,0.000025888854,0.000016264097,0.00042908377],"genre_scores_gemma":[0.998537,0.0006540154,0.00014167817,0.00009007673,0.000050553877,0.00007039432,0.00007449161,0.0000157482,0.0003660114],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99898946,0.00002706145,0.00026186276,0.0003532535,0.00013510474,0.00023324664],"domain_scores_gemma":[0.9987727,0.000039424474,0.0001322774,0.0005463474,0.00006105903,0.0004482314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010074131,0.00016765251,0.0002814195,0.00012386632,0.00012312017,0.000039069095,0.00008170747,0.000078128236,0.000015427318],"category_scores_gemma":[0.0001948008,0.00015202502,0.00004024372,0.000058348778,0.000069349604,0.00010534404,0.0000660853,0.00006289754,0.0000085314405],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001111839,0.0002915134,0.5681022,0.0014142777,0.000068319576,0.00009557634,0.00041706042,0.00017725986,0.39294577,0.0012057668,0.00017556324,0.03399486],"study_design_scores_gemma":[0.005093423,0.00016379655,0.9633148,0.0002991148,0.00016242026,0.0000015907503,0.000027917884,0.002969072,0.026830038,0.00090940174,0.000097409196,0.00013106997],"about_ca_topic_score_codex":0.00037440078,"about_ca_topic_score_gemma":0.000050194863,"teacher_disagreement_score":0.39521256,"about_ca_system_score_codex":0.0006771311,"about_ca_system_score_gemma":0.0008127323,"threshold_uncertainty_score":0.61994004},"labels":[],"label_agreement":null},{"id":"W2765616093","doi":"10.1016/j.bbmt.2017.10.021","title":"Anti–Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease","year":2017,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada","funders":"National Cancer Institute; University of Pittsburgh","keywords":"Nilotinib; Medicine; Internal medicine; Tyrosine-kinase inhibitor; Adverse effect; Refractory (planetary science); Discontinuation; Gastroenterology; Clinical endpoint; Oncology; Immunology; Tyrosine kinase; Clinical trial; Receptor; Cancer","score_opus":0.025505351497772718,"score_gpt":0.3001403847256764,"score_spread":0.27463503322790367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765616093","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99492913,0.0007336841,0.000118633216,0.00082421314,0.00036973075,0.0015002529,0.0014648838,0.000041869156,0.000017609285],"genre_scores_gemma":[0.9953716,0.0032802802,0.0004206768,0.000048370122,0.00011869602,0.00011724396,0.00045406792,0.000029942723,0.00015912647],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.998481,0.0001292385,0.00040697935,0.00048764417,0.00013594331,0.00035923196],"domain_scores_gemma":[0.99879444,0.00035900538,0.00022522056,0.00032311978,0.000076809636,0.0002214033],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027150026,0.0002711711,0.0005210195,0.00021045316,0.0001628736,0.000017826083,0.00015158259,0.00018613087,0.00004983162],"category_scores_gemma":[0.00028231263,0.00021840181,0.000085831685,0.000039063092,0.00020225636,0.00015564349,0.000026411322,0.00012063818,0.0000045946385],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05331522,0.00030669794,0.07428248,0.00086588156,0.0003026166,0.000097066455,0.00082363473,7.9311945e-7,0.8677717,0.000013402337,0.000021859192,0.0021986428],"study_design_scores_gemma":[0.040220253,0.005845439,0.65580297,0.00064971345,0.0005962785,0.000033705684,0.00009626078,0.00002711898,0.29605296,0.000015474307,0.000340192,0.00031960564],"about_ca_topic_score_codex":0.00016428519,"about_ca_topic_score_gemma":0.00049532735,"teacher_disagreement_score":0.5815205,"about_ca_system_score_codex":0.00013212701,"about_ca_system_score_gemma":0.00040608455,"threshold_uncertainty_score":0.8906167},"labels":[],"label_agreement":null},{"id":"W2766175045","doi":"10.1002/cncr.31082","title":"Long‐term patient‐reported outcomes from an open‐label safety and efficacy study of bosutinib in Philadelphia chromosome–positive chronic myeloid leukemia patients resistant or intolerant to prior therapy","year":2017,"lang":"en","type":"article","venue":"Cancer","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Ariad Pharmaceuticals; Pfizer","keywords":"Medicine; Cohort; Internal medicine; Bosutinib; Quality of life (healthcare); Myeloid leukemia; Cancer; Visual analogue scale; Oncology; Nilotinib; Imatinib; Physical therapy","score_opus":0.05714009683101398,"score_gpt":0.36964228302197205,"score_spread":0.31250218619095804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766175045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926196,0.00071321067,0.0000019738122,0.00041422996,0.00030626988,0.005538919,0.0002655836,0.00003445877,0.000105774925],"genre_scores_gemma":[0.9982443,0.0005524043,0.00008321176,0.00033578917,0.000100986224,0.0003285278,0.00014164028,0.00008068351,0.00013247365],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967126,0.0001284329,0.0010523589,0.0010201425,0.0005743834,0.00051208644],"domain_scores_gemma":[0.996861,0.00013344063,0.00075145153,0.0016454726,0.00024119034,0.0003674349],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018239806,0.0004956913,0.0012407413,0.00015842212,0.00031086028,0.000110520035,0.0005804287,0.00016040076,0.00038002647],"category_scores_gemma":[0.000198082,0.00036177336,0.000054642336,0.00018844914,0.00016310287,0.0003887798,0.0004844086,0.00030150972,0.0000055905566],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019210858,0.00447183,0.8151472,0.000060282724,0.00096405216,0.00040745444,0.010319591,0.00001556582,0.003842574,0.0000013376132,0.00005469136,0.14550452],"study_design_scores_gemma":[0.07163502,0.007852282,0.9162958,0.0008511252,0.0002125645,0.0000039238175,0.00024128964,0.000040407576,0.0023619775,0.000002647035,0.00014920285,0.00035371076],"about_ca_topic_score_codex":0.010373913,"about_ca_topic_score_gemma":0.0104195895,"teacher_disagreement_score":0.14515081,"about_ca_system_score_codex":0.004443926,"about_ca_system_score_gemma":0.0016628073,"threshold_uncertainty_score":0.9998834},"labels":[],"label_agreement":null},{"id":"W2766645178","doi":"10.3892/mmr.2017.7952","title":"Off‑target effect of imatinib and nilotinib on human vitamin D3 metabolism","year":2017,"lang":"en","type":"article","venue":"Molecular Medicine Reports","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Shriners Hospitals for Children - Canada","funders":"Novartis Pharma","keywords":"HaCaT; Calcitriol; Nilotinib; Imatinib; Vitamin D and neurology; Bone remodeling; Internal medicine; Endocrinology; Medicine; Pharmacology; Chemistry; In vitro; Biochemistry; Myeloid leukemia","score_opus":0.014870646104461815,"score_gpt":0.32744168930778034,"score_spread":0.3125710432033185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766645178","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97740704,0.0020379107,0.00003532124,0.0010590219,0.00033077126,0.00091540226,0.0000033959789,0.000054883825,0.01815625],"genre_scores_gemma":[0.9981741,0.00006304352,0.00038160806,0.00023572854,0.00020838964,0.00004696867,0.00006787828,0.000060626797,0.0007616656],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974643,0.000105059335,0.0007277322,0.0005866778,0.00077358243,0.0003426537],"domain_scores_gemma":[0.99687815,0.00010031777,0.0008192969,0.0018093897,0.00010000368,0.00029282045],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00093603146,0.00037467055,0.0011713038,0.00018013881,0.00019269332,0.000014729103,0.0001267685,0.00014357652,0.00017283167],"category_scores_gemma":[0.0017162653,0.00026129332,0.00015200392,0.000068747795,0.00043190323,0.000060723734,0.000115205825,0.00026544384,0.0000066018797],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005757153,0.00043025272,0.09569311,0.0013292274,0.0011955963,0.031509284,0.0006317864,0.000006483269,0.8371723,0.00049737794,0.0034021523,0.027556656],"study_design_scores_gemma":[0.01236659,0.0037686832,0.32117984,0.0016855695,0.0014600755,0.0031210664,0.00002689622,0.00005658291,0.6495207,0.00037900676,0.0060936185,0.0003414132],"about_ca_topic_score_codex":0.0002812172,"about_ca_topic_score_gemma":0.0000031516968,"teacher_disagreement_score":0.22548671,"about_ca_system_score_codex":0.00012268337,"about_ca_system_score_gemma":0.00011725664,"threshold_uncertainty_score":0.9999839},"labels":[],"label_agreement":null},{"id":"W2780749295","doi":"","title":"Hoge dosis imatinib versus hoge dosis imatinib in combinatie met intermediaire dosis cytarabine bij patienten met nieuw gediagnosticeerde chronische myeloïde leukemie","year":2014,"lang":"nl","type":"article","venue":"Data Archiving and Networked Services (DANS)","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Medicine; Imatinib; Cytarabine; Cancer research; Internal medicine; Leukemia","score_opus":0.021647884748163558,"score_gpt":0.27343491020381766,"score_spread":0.2517870254556541,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2780749295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97831535,0.006393941,0.00040721797,0.0009808948,0.0026250856,0.0023677442,0.004861665,0.00036851538,0.0036795686],"genre_scores_gemma":[0.9595078,0.011193076,0.004519075,0.0007958828,0.0015518827,0.00040397226,0.021366023,0.00034650133,0.00031578288],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9882392,0.0016698439,0.0026106637,0.003114712,0.0016135474,0.002751992],"domain_scores_gemma":[0.98434144,0.00834296,0.0014009975,0.004474383,0.00018714892,0.0012530616],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0027128325,0.0020446463,0.0028624013,0.00080981065,0.00089625915,0.00047030102,0.0034395216,0.00061794213,0.0004566245],"category_scores_gemma":[0.0011844946,0.0018545669,0.00038112665,0.0014465676,0.0008115135,0.0013451688,0.0040471423,0.0020069145,0.0004966709],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011461302,0.0066558626,0.5383276,0.021206867,0.010302961,0.0010867679,0.0486446,0.002968318,0.0035215116,0.0005450068,0.022481538,0.3327977],"study_design_scores_gemma":[0.06574155,0.0064463583,0.2398983,0.02364172,0.0077618635,0.00014183366,0.008268915,0.6242962,0.00092358177,0.00022973966,0.018819503,0.0038304452],"about_ca_topic_score_codex":0.011259654,"about_ca_topic_score_gemma":0.0099291615,"teacher_disagreement_score":0.6213279,"about_ca_system_score_codex":0.0016764606,"about_ca_system_score_gemma":0.00065452047,"threshold_uncertainty_score":0.99922955},"labels":[],"label_agreement":null},{"id":"W2786168520","doi":"10.1200/jco.2014.32.15_suppl.tps7119","title":"An open-label, phase 1b, dose-escalation study (CA180-373) of dasatinib plus nivolumab, an investigational anti-programmed cell death 1 (PD-1) antibody, in patients (pts) with previously treated chronic myeloid leukemia (CML).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Dasatinib; Nivolumab; Nilotinib; Tolerability; Internal medicine; Oncology; Myeloid leukemia; Pharmacology; Imatinib; Immunotherapy; Cancer; Adverse effect","score_opus":0.10616471924736708,"score_gpt":0.4579118950979487,"score_spread":0.35174717585058163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2786168520","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995936,0.00007683047,0.00017863508,0.00017919326,0.00034155516,0.002725609,0.000014931162,0.000033654076,0.0005136185],"genre_scores_gemma":[0.99178725,0.00010301796,0.0066157617,0.0003040889,0.0006313263,0.000041071788,0.00036164408,0.00008258476,0.00007322347],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99087733,0.0021291133,0.0044531375,0.0007824194,0.0011096917,0.000648322],"domain_scores_gemma":[0.9916781,0.0011208409,0.004270312,0.0008315155,0.001065878,0.0010333502],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0045578475,0.00050613814,0.0030819871,0.00041357518,0.00011293914,0.00005490449,0.0007777045,0.00063426996,0.000111520116],"category_scores_gemma":[0.0015135397,0.0003782126,0.00017523041,0.00058581174,0.00044508823,0.0008343483,0.00015517075,0.001388155,0.000013909299],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.015762549,0.06836507,0.819881,0.00011190401,0.00045120428,0.00025874024,0.00051782577,0.0003747086,0.0013741859,0.000028107865,0.00011872014,0.092755966],"study_design_scores_gemma":[0.22245762,0.2004978,0.56723434,0.00028022059,0.00076303544,0.00005510736,0.000111075475,0.007709216,0.00023757461,0.00004695096,0.0003594063,0.00024763128],"about_ca_topic_score_codex":0.0008814656,"about_ca_topic_score_gemma":0.0010785753,"teacher_disagreement_score":0.25264665,"about_ca_system_score_codex":0.0039729048,"about_ca_system_score_gemma":0.010695327,"threshold_uncertainty_score":0.99986696},"labels":[],"label_agreement":null},{"id":"W2787506206","doi":"10.1126/scitranslmed.aan8735","title":"PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL <sup>+</sup> human leukemia","year":2018,"lang":"en","type":"article","venue":"Science Translational Medicine","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; Leukemia & Lymphoma Society of Canada; University of British Columbia; BC Cancer Agency","funders":"Canadian Institutes of Health Research; Canadian Cancer Society","keywords":"Cancer research; Leukemia; Tyrosine kinase; Protein phosphatase 2; ABL; Chemistry; Philadelphia chromosome; Cancer; Biology; Phosphorylation; Immunology; Biochemistry; Phosphatase; Signal transduction; Chromosomal translocation; Genetics; Gene","score_opus":0.02681835111812607,"score_gpt":0.3130971335826155,"score_spread":0.2862787824644894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2787506206","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98399997,0.00042509433,0.00021096373,0.010779381,0.00047225837,0.0010889695,0.000042074586,0.00010598253,0.002875334],"genre_scores_gemma":[0.9946144,0.000036890116,0.0010561105,0.0017010758,0.0014913571,0.00007233191,0.00005675347,0.000038758626,0.0009323059],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99573666,0.0000665925,0.00076805253,0.00094410183,0.0017135169,0.0007710633],"domain_scores_gemma":[0.9982056,0.00012633747,0.00012748367,0.00046035895,0.00049695186,0.0005832859],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010847368,0.00038307885,0.0005591483,0.0009230199,0.00039302875,0.0000296317,0.00019592531,0.00012016821,0.00086841657],"category_scores_gemma":[0.00007875735,0.00031488005,0.00007425824,0.0024179462,0.0020603226,0.0004025204,0.000044605364,0.00033492962,0.00016069286],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004948153,0.0002539086,0.015130756,0.00020350963,0.000046811587,0.00024241646,0.009850864,0.0028792175,0.9407726,0.0011507614,0.0048049935,0.024169361],"study_design_scores_gemma":[0.02968843,0.003562802,0.13140528,0.007890716,0.0003788851,0.00024670357,0.0022849478,0.021221051,0.79205173,0.0013141653,0.008592567,0.0013626935],"about_ca_topic_score_codex":0.0019528471,"about_ca_topic_score_gemma":0.00071491813,"teacher_disagreement_score":0.14872083,"about_ca_system_score_codex":0.0024690647,"about_ca_system_score_gemma":0.0018567608,"threshold_uncertainty_score":0.9999303},"labels":[],"label_agreement":null},{"id":"W2791438625","doi":"10.1007/s11864-018-0532-2","title":"When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia","year":2018,"lang":"en","type":"review","venue":"Current Treatment Options in Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Nilotinib; Chronic myelogenous leukemia; Dasatinib; Oncology; Internal medicine; Tyrosine-kinase inhibitor; Imatinib mesylate; Myeloid leukemia; Clinical trial; Clinical endpoint; Intensive care medicine; Imatinib; Leukemia; Cancer","score_opus":0.10711034678265129,"score_gpt":0.4213271519235706,"score_spread":0.3142168051409193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791438625","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006220334,0.9816106,0.00010920693,0.00036155494,0.002972287,0.013343309,0.00069175457,0.00008228483,0.00020699644],"genre_scores_gemma":[0.00007194663,0.9779155,0.001542186,0.000017951921,0.002085069,0.014385913,0.0016257705,0.00014912804,0.0022065225],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955264,0.0002780403,0.0016992025,0.0012454888,0.00032054403,0.0009303471],"domain_scores_gemma":[0.99569637,0.0013925856,0.00069477776,0.0016666526,0.0002077091,0.00034190042],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002631742,0.001208549,0.003751057,0.0008649413,0.0002209198,0.000023442337,0.0003738789,0.00064108503,0.00026023178],"category_scores_gemma":[0.000111796944,0.0007258233,0.0015098801,0.0007386094,0.00039679385,0.00005918293,0.0001030074,0.0002861624,0.00029981454],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00020401888,0.006122129,0.000031290758,0.0027612343,0.001340722,0.000041965326,0.0006709014,0.000027052325,0.0000025999914,0.00016567626,0.004301387,0.984331],"study_design_scores_gemma":[0.009627361,0.022039616,0.00003083446,0.006626068,0.007338537,0.00011810985,0.000054315802,0.00008272471,0.00003875759,0.000026483398,0.9535869,0.00043032496],"about_ca_topic_score_codex":0.00024243855,"about_ca_topic_score_gemma":0.0006048897,"teacher_disagreement_score":0.9839007,"about_ca_system_score_codex":0.07760677,"about_ca_system_score_gemma":0.008900765,"threshold_uncertainty_score":0.9995193},"labels":[],"label_agreement":null},{"id":"W2794097777","doi":"10.1016/j.bbmt.2017.12.219","title":"Multiinstitution Retrospective Review of Long Term Outcomes in Pediatric Chronic Myeloid Leukemia","year":2018,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; BC Children's Hospital","funders":"","keywords":"Medicine; Myeloid leukemia; Imatinib; Internal medicine; Retrospective cohort study; Imatinib mesylate; Tyrosine-kinase inhibitor; Nilotinib; Pediatrics; Cancer","score_opus":0.013670330654531541,"score_gpt":0.28436876196296795,"score_spread":0.2706984313084364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794097777","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848971,0.013932586,0.000092012175,0.00007672514,0.00009620656,0.0004756048,0.000043204396,0.00001526323,0.00037134287],"genre_scores_gemma":[0.90215814,0.097240664,0.0002601933,0.000043172346,0.00008085464,0.000016038439,0.0001692938,0.000006369504,0.000025242822],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99910694,0.000047365134,0.00038663807,0.00022629295,0.000087321765,0.00014541647],"domain_scores_gemma":[0.9995385,0.000043303306,0.00017140564,0.0001296326,0.00007840594,0.000038785543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016187495,0.00012849463,0.0004376542,0.00014321414,0.000024488307,9.458932e-7,0.000042506817,0.00012420329,0.00003674056],"category_scores_gemma":[0.000037241956,0.000104433515,0.00006118115,0.00014909662,0.00020174243,0.000058649137,0.0000069268276,0.000089720095,0.0000028904922],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013216234,0.000103114646,0.934941,0.0066493303,0.000093264374,0.00001896118,0.0001599248,1.4984829e-7,0.054241307,0.000096412405,0.000004222216,0.0035601764],"study_design_scores_gemma":[0.0052422383,0.0009445521,0.94505805,0.0019628813,0.0008597057,0.000082722145,0.0000038443673,0.0000054904453,0.045728344,0.000022403838,0.000005134308,0.00008465886],"about_ca_topic_score_codex":0.00014076765,"about_ca_topic_score_gemma":0.00025748496,"teacher_disagreement_score":0.08330808,"about_ca_system_score_codex":0.00018663553,"about_ca_system_score_gemma":0.00030177372,"threshold_uncertainty_score":0.42586753},"labels":[],"label_agreement":null},{"id":"W2794414754","doi":"10.14740/jmc.v9i3.2993","title":"Leukostasis-Related Fatal Cardiopulmonary Arrest as Initial Chronic Myeloid Leukemia Presentation","year":2018,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Leukostasis; Medicine; Myeloproliferative neoplasm; Myeloid leukemia; Complication; Internal medicine; Leukemia; Bone marrow","score_opus":0.026963885417679877,"score_gpt":0.33747968058962036,"score_spread":0.3105157951719405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794414754","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877395,0.0035889654,0.000065958986,0.002672262,0.0019079318,0.00028040604,0.000015549598,0.000047482044,0.0036819472],"genre_scores_gemma":[0.99190736,0.00090170075,0.0001574203,0.0005019293,0.005995406,0.0000068878085,0.000058923644,0.000045801477,0.00042455475],"study_design_codex":"design_other","study_design_gemma":"case_report","domain_scores_codex":[0.9954182,0.00018156032,0.0010649645,0.00028386424,0.0025926617,0.00045876298],"domain_scores_gemma":[0.9974803,0.0004105276,0.00049936364,0.00033624473,0.0003921493,0.00088145054],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00076590327,0.00028547694,0.00069255347,0.00026792663,0.00014396095,0.000034604807,0.0003007061,0.00039519172,0.0039909096],"category_scores_gemma":[0.0023841986,0.00021763443,0.00036537257,0.00032418946,0.0005481371,0.0002933187,0.000115826384,0.00094813074,0.00035605626],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009610929,0.0018674273,0.020772802,0.0009572411,0.0052837115,0.270547,0.0026734627,0.00009106881,0.0071658897,0.0005044965,0.15761076,0.52291524],"study_design_scores_gemma":[0.08266142,0.039293937,0.093212485,0.00895703,0.005433255,0.52074546,0.0036347834,0.004029519,0.08770739,0.0010617578,0.15146229,0.0018006617],"about_ca_topic_score_codex":0.00044858182,"about_ca_topic_score_gemma":0.000057165522,"teacher_disagreement_score":0.5211145,"about_ca_system_score_codex":0.002980317,"about_ca_system_score_gemma":0.0071697007,"threshold_uncertainty_score":0.99845874},"labels":[],"label_agreement":null},{"id":"W2800868099","doi":"10.1093/rheumatology/key075.457","title":"233 Durability, maintenance and effects of dose reduction following prolonged treatment with baricitinib","year":2018,"lang":"en","type":"article","venue":"Lara D. Veeken","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Durability; Reduction (mathematics); Composite material","score_opus":0.011062954209153037,"score_gpt":0.2620213913069669,"score_spread":0.25095843709781385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2800868099","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965213,0.0004347663,0.000031989257,0.00036047044,0.00015390589,0.0011928546,0.000003838424,0.000063512045,0.0012373584],"genre_scores_gemma":[0.99718046,0.0000620705,0.0015824252,0.000049655926,0.00016449341,0.00010809477,0.000016293507,0.000026729598,0.00080976903],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99888843,0.0000508773,0.0002032317,0.00037523432,0.00020963897,0.00027258805],"domain_scores_gemma":[0.99924123,0.00007232887,0.00009387404,0.0004068629,0.00007310269,0.00011261487],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011044941,0.00019710613,0.00039651847,0.00005916409,0.0000715431,0.000009801447,0.000044563807,0.000083307095,0.000018182223],"category_scores_gemma":[0.00006722278,0.00013402004,0.000077188204,0.00016415212,0.00018163011,0.0000813783,0.000029315364,0.00008040243,0.000012348501],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010462087,0.004261091,0.5110951,0.0028658754,0.0043564932,0.0016807995,0.013566191,0.000004172396,0.28826025,0.0004012466,0.0010411637,0.16200551],"study_design_scores_gemma":[0.058207072,0.029757317,0.6266197,0.002401149,0.0024001822,0.001235945,0.00044085464,0.00041617572,0.27397877,0.00042123406,0.0034776763,0.00064391457],"about_ca_topic_score_codex":0.000257478,"about_ca_topic_score_gemma":0.000050571485,"teacher_disagreement_score":0.16136159,"about_ca_system_score_codex":0.0005449403,"about_ca_system_score_gemma":0.00017336129,"threshold_uncertainty_score":0.5465179},"labels":[],"label_agreement":null},{"id":"W2801721440","doi":"10.1007/s11899-018-0449-7","title":"Tyrosine Kinase Inhibitors in the Treatment of Chronic-Phase CML: Strategies for Frontline Decision-making","year":2018,"lang":"en","type":"review","venue":"Current Hematologic Malignancy Reports","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Bosutinib; Nilotinib; Dasatinib; Medicine; Imatinib; Oncology; Disease; Tyrosine kinase; Imatinib mesylate; Tyrosine-kinase inhibitor; Internal medicine; Myeloid leukemia; Toxicity; Pharmacology; Intensive care medicine; Cancer","score_opus":0.07998761122677826,"score_gpt":0.4216340902875697,"score_spread":0.34164647906079143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2801721440","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002819352,0.9866053,0.00043774865,0.000020870875,0.0018538086,0.00787125,0.00012470057,0.00008386893,0.00018310599],"genre_scores_gemma":[0.008243018,0.9866268,0.00096058846,0.000008559495,0.00076100667,0.0025010381,0.0007533219,0.000102468555,0.000043183576],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9936889,0.0001823548,0.003346301,0.0013365756,0.00064827874,0.0007975989],"domain_scores_gemma":[0.99415034,0.0009516115,0.0025891063,0.0019410608,0.00022579783,0.00014207877],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000618639,0.0011499883,0.0044214507,0.00046221638,0.00012530551,0.0000555824,0.00030915294,0.00054048223,0.000148856],"category_scores_gemma":[0.0004287186,0.0006400202,0.0014936818,0.00063643954,0.0002663317,0.00011045753,0.000079029196,0.00030537543,0.000017380245],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011406206,0.005416133,0.0001622694,0.031107808,0.00030981976,0.004231449,0.0002627292,0.0000011879365,0.0000011542693,0.0002844291,0.0034589726,0.95465],"study_design_scores_gemma":[0.0038631484,0.0033111852,0.0000065536965,0.10404025,0.0029110294,0.0047438936,0.00009474147,0.00003770668,0.000041920255,0.0014244418,0.8789709,0.00055422296],"about_ca_topic_score_codex":0.000025682819,"about_ca_topic_score_gemma":0.00005534336,"teacher_disagreement_score":0.9540958,"about_ca_system_score_codex":0.002312282,"about_ca_system_score_gemma":0.0033084787,"threshold_uncertainty_score":0.9996051},"labels":[],"label_agreement":null},{"id":"W2802234447","doi":"10.1111/bjh.15226","title":"Abstracts","year":2018,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Tyrosine-kinase inhibitor; Tyrosine kinase; Imatinib; Molecular biomarkers","score_opus":0.015911102005050557,"score_gpt":0.2857256306784795,"score_spread":0.2698145286734289,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802234447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872907,0.0019018439,0.000081774786,0.00064803474,0.00046900037,0.000074084695,0.0000019018543,0.000013545176,0.009519151],"genre_scores_gemma":[0.9957182,0.00022483004,0.002638056,0.00046185392,0.00047067396,8.938376e-7,0.0000018517828,0.000014900473,0.00046875633],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9989874,0.000033122487,0.00048359265,0.000098094984,0.00018400894,0.0002137795],"domain_scores_gemma":[0.9990899,0.000052211628,0.00028091605,0.000114075745,0.00030215108,0.00016074406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019885904,0.00007584749,0.00044000664,0.00008606662,0.000048981863,0.000013905422,0.000090219226,0.00009792458,0.00078056304],"category_scores_gemma":[0.00023599163,0.0000767423,0.00011078384,0.00007605315,0.0001842843,0.00007576024,0.0000213003,0.0002373545,0.00021321891],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006894999,0.00093343464,0.013703212,0.00019474364,0.0009039337,0.6518944,0.00035876074,0.000001776269,0.002788009,0.00040054083,0.15010229,0.17802943],"study_design_scores_gemma":[0.0033197284,0.00067108555,0.028419888,0.00037734784,0.000117505966,0.93984663,0.000043247805,0.000007540755,0.0047514513,0.00037320814,0.022007827,0.00006452198],"about_ca_topic_score_codex":0.000058386868,"about_ca_topic_score_gemma":0.000052681477,"teacher_disagreement_score":0.28795227,"about_ca_system_score_codex":0.00013586869,"about_ca_system_score_gemma":0.00034492492,"threshold_uncertainty_score":0.8546618},"labels":[],"label_agreement":null},{"id":"W2804630302","doi":"10.6000/1929-2279.2018.07.02.3","title":"Pharmacotherapeutic Options for Philadelphia Chromosome-Positive CML","year":2018,"lang":"en","type":"article","venue":"Journal of cancer research updates","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Imatinib; Nilotinib; Dasatinib; Tyrosine kinase; Medicine; Philadelphia chromosome; Cancer research; Bosutinib; Myeloid leukemia; Tyrosine-kinase inhibitor; Oncology; Pharmacology; Internal medicine; Biology; Genetics; Cancer; Chromosomal translocation; Receptor","score_opus":0.10213934092164889,"score_gpt":0.4858416534499229,"score_spread":0.383702312528274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2804630302","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91551214,0.027795449,0.0004790015,0.051585782,0.0009173647,0.0018176888,0.00020092168,0.000038615042,0.0016530473],"genre_scores_gemma":[0.98791707,0.005408023,0.0013381661,0.000604918,0.0034630583,0.00008998283,0.000012789364,0.000046460245,0.0011195448],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998013,0.00010628058,0.00039579245,0.00018950546,0.00078951946,0.0005058657],"domain_scores_gemma":[0.99709886,0.0002779719,0.00018192465,0.00020105319,0.0019420603,0.0002981138],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00086821866,0.0001390836,0.00034090359,0.0003812155,0.00022341302,0.0000457133,0.00022151181,0.000071824696,0.0018766884],"category_scores_gemma":[0.00012667853,0.000103196704,0.00017909601,0.00040407502,0.00037221436,0.00021918361,0.000043386044,0.00047999728,0.000060231436],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010146983,0.0014620533,0.005938578,0.00040231989,0.0052146874,0.00030633184,0.0017887171,0.000040467363,0.70315963,0.0009798665,0.21360663,0.056953765],"study_design_scores_gemma":[0.017832324,0.0066032712,0.0065124133,0.0011338053,0.0006706375,0.000571194,0.00033567776,0.0008352487,0.58782154,0.0016903351,0.37573364,0.00025992788],"about_ca_topic_score_codex":0.00007078731,"about_ca_topic_score_gemma":0.00003365013,"teacher_disagreement_score":0.16212702,"about_ca_system_score_codex":0.0015447728,"about_ca_system_score_gemma":0.0016823432,"threshold_uncertainty_score":0.9990357},"labels":[],"label_agreement":null},{"id":"W2804873419","doi":"10.1177/1203475418775663","title":"Recurrent and Fixed Neutrophilic Dermatosis Associated With Dasatinib","year":2018,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Dasatinib; Neutrophilic dermatosis; Dermatology; Pathology; Internal medicine; Tyrosine kinase; Receptor; Disease; Pyoderma gangrenosum","score_opus":0.02919084915791108,"score_gpt":0.2728350980259927,"score_spread":0.24364424886808161,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2804873419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99103403,0.0030413924,0.000010095382,0.0049111876,0.00024467902,0.000121373116,0.0000021163087,0.000016388898,0.0006187614],"genre_scores_gemma":[0.99523145,0.002619639,0.00010779963,0.0011859154,0.00065570895,0.0000014620749,0.0000072334474,0.000022821429,0.00016797346],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.99847347,0.00007485708,0.0005832248,0.00016222506,0.00045658567,0.00024964617],"domain_scores_gemma":[0.99779665,0.00092263747,0.00045890542,0.00014541009,0.000333118,0.0003432848],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039173136,0.0001933177,0.00081478397,0.00025975294,0.000088290966,0.0000114223,0.000038003025,0.000086260836,0.00013879294],"category_scores_gemma":[0.00081958785,0.00011505218,0.000069120826,0.00020195213,0.00036193285,0.000068713874,0.000017531504,0.0002624878,0.000002296957],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006548013,0.0009340684,0.6617196,0.0005642665,0.0033592198,0.02469035,0.0060683195,0.0000012601762,0.0062686973,0.00004149847,0.14123031,0.1485744],"study_design_scores_gemma":[0.03233614,0.03343689,0.369986,0.024357019,0.0070751286,0.4516815,0.0031187923,0.0008710438,0.0034639589,0.00048095666,0.071822524,0.0013700747],"about_ca_topic_score_codex":0.000017475983,"about_ca_topic_score_gemma":0.000015561052,"teacher_disagreement_score":0.42699113,"about_ca_system_score_codex":0.00016399682,"about_ca_system_score_gemma":0.00033747475,"threshold_uncertainty_score":0.46916917},"labels":[],"label_agreement":null},{"id":"W2804990894","doi":"10.3324/haematol.2017.171249","title":"Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study","year":2018,"lang":"en","type":"article","venue":"Haematologica","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Pfizer","keywords":"Bosutinib; Medicine; Cumulative incidence; Internal medicine; Nausea; Myeloid leukemia; Adverse effect; Imatinib; Gastroenterology; Rash; Mucositis; Oncology; Dasatinib; Surgery; Toxicity; Cohort","score_opus":0.03689671586753953,"score_gpt":0.344653472804586,"score_spread":0.3077567569370465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2804990894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933725,0.0012529835,0.000095789714,0.00018648009,0.00012659177,0.0033085644,0.00063561817,0.00008640571,0.00093504426],"genre_scores_gemma":[0.99662673,0.00012988976,0.0010624526,0.00005154603,0.00031870944,0.00011320621,0.00021041179,0.000047992304,0.0014390526],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9966335,0.00011569953,0.0013379293,0.000868134,0.00040739987,0.0006373165],"domain_scores_gemma":[0.99742067,0.0004010431,0.0007024599,0.00095509656,0.00028271665,0.00023801514],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005630155,0.00047411348,0.0015691668,0.00019756936,0.0002557736,0.000012448707,0.0002511628,0.0002583883,0.0012943208],"category_scores_gemma":[0.00056603237,0.00036967473,0.00026378356,0.00033149714,0.0007021684,0.00009815677,0.0002495567,0.00027958682,0.00002209384],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45885292,0.07794955,0.005193154,0.0102974195,0.008958185,0.0027564324,0.036366634,0.00007065897,0.17421351,0.0032311794,0.028929153,0.19318122],"study_design_scores_gemma":[0.6422958,0.23128974,0.016158912,0.0013270455,0.0019316555,0.001132631,0.001215888,0.0042241774,0.05491415,0.00009265947,0.044496305,0.00092108635],"about_ca_topic_score_codex":0.0000987876,"about_ca_topic_score_gemma":0.0002376446,"teacher_disagreement_score":0.19226013,"about_ca_system_score_codex":0.0011969372,"about_ca_system_score_gemma":0.0017422138,"threshold_uncertainty_score":0.99987555},"labels":[],"label_agreement":null},{"id":"W2808263699","doi":"10.1016/j.jmb.2018.06.016","title":"The Emerging Potential for Network Analysis to Inform Precision Cancer Medicine","year":2018,"lang":"en","type":"review","venue":"Journal of Molecular Biology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Institute for Advanced Research","funders":"National Cancer Institute; National Institutes of Health; U.S. National Library of Medicine; National Institute of General Medical Sciences; Canadian Institute for Advanced Research","keywords":"Precision medicine; Chronic myelogenous leukemia; Systems biology; Imatinib; Cancer Medicine; Computational biology; Cancer; Medicine; Bioinformatics; Biology; Leukemia; Cancer research; Genetics","score_opus":0.03017837297007626,"score_gpt":0.4133700470679093,"score_spread":0.38319167409783306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808263699","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009485141,0.97823817,0.018206207,0.0011409719,0.0013159864,0.0008907721,0.000015829239,0.0000059482163,0.00009127563],"genre_scores_gemma":[0.000048655045,0.9940563,0.0022899432,0.0003300741,0.0027631563,0.000066646826,0.00007963372,0.000039843766,0.00032575976],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99740064,0.00016404098,0.0014069594,0.00027024548,0.00031202883,0.00044609798],"domain_scores_gemma":[0.9970139,0.00032695933,0.0014116364,0.0004696199,0.00054364995,0.00023418684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012350578,0.00034905452,0.0023842256,0.0004781467,0.00016308435,0.000012804858,0.00039817338,0.0003559281,0.00011569398],"category_scores_gemma":[0.00060780515,0.00016910097,0.001452716,0.0010048513,0.00011953811,0.000018892899,0.00011252647,0.00037918132,0.000009549022],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000236243,0.000019138663,0.000012324056,0.0005469614,0.01251875,0.00006962323,0.000027029164,0.0001056176,0.000018320014,0.000051645977,0.010523164,0.9758712],"study_design_scores_gemma":[0.001115662,0.0014158443,0.000012262057,0.0038785425,0.024561187,0.00030502572,0.0000070358665,0.000047134497,0.0000054933084,0.00012936995,0.96839017,0.0001322903],"about_ca_topic_score_codex":0.000025107232,"about_ca_topic_score_gemma":0.000026806121,"teacher_disagreement_score":0.9757389,"about_ca_system_score_codex":0.00079467276,"about_ca_system_score_gemma":0.00094586326,"threshold_uncertainty_score":0.6895737},"labels":[],"label_agreement":null},{"id":"W2808391935","doi":"10.1016/s2352-3026(18)30051-6","title":"Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies","year":2018,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":133,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency; University of Toronto; Princess Margaret Cancer Centre","funders":"National Cancer Institute; Research England; U.S. Food and Drug Administration; Aalborg Universitetshospital; Astellas Pharma; Eisai; Aalborg Universitet; Genentech; Celgene; Gilead Sciences; National Institutes of Health; Laura and John Arnold Foundation; Pfizer","keywords":"Medicine; Adverse effect; Intensive care medicine; Context (archaeology); Clinical trial; Multiple myeloma; Cancer; Population; Hematology; Disease; Transplantation; Internal medicine; Oncology","score_opus":0.16852219324577863,"score_gpt":0.42282099634139564,"score_spread":0.25429880309561703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808391935","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.058020327,0.9371599,0.000053122847,0.0011894613,0.00028602305,0.0020509928,0.000019790492,0.00005319881,0.0011672068],"genre_scores_gemma":[0.026697075,0.9708965,0.001513278,0.0002063625,0.0001908155,0.00025221668,0.0000624507,0.000060006383,0.00012131692],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953092,0.00068018923,0.0024466184,0.00058603496,0.0003521642,0.0006258141],"domain_scores_gemma":[0.9946544,0.0007724823,0.0032211242,0.001210948,0.000069797694,0.000071216135],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019816284,0.0005025891,0.006043126,0.0001402292,0.00013135026,0.0000041246212,0.0004308834,0.00044405274,0.00004111211],"category_scores_gemma":[0.0006248928,0.0002362351,0.00036327288,0.0002722048,0.000651083,0.000041757332,0.00041810042,0.0008156793,0.000018314711],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006136363,0.0022094585,0.28678215,0.2834639,0.006783833,0.025262618,0.00539502,0.000020646812,0.000023504304,0.043758202,0.0070544844,0.33863255],"study_design_scores_gemma":[0.017209368,0.0014322564,0.037238114,0.1476223,0.017118966,0.30290806,0.0015266046,0.0010011243,0.00007572479,0.05654297,0.41457486,0.0027496496],"about_ca_topic_score_codex":0.000063366104,"about_ca_topic_score_gemma":0.00005291597,"teacher_disagreement_score":0.40752035,"about_ca_system_score_codex":0.00039781688,"about_ca_system_score_gemma":0.00074394414,"threshold_uncertainty_score":0.96333873},"labels":[],"label_agreement":null},{"id":"W2809072903","doi":"10.1016/j.ejpb.2018.06.018","title":"siRNA/lipopolymer nanoparticles to arrest growth of chronic myeloid leukemia cells in vitro and in vivo","year":2018,"lang":"en","type":"article","venue":"European Journal of Pharmaceutics and Biopharmaceutics","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency; University of Alberta","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Health Canada; Alberta Innovates; Women and Children's Health Research Institute","keywords":"Gene silencing; K562 cells; In vivo; ABL; Myeloid leukemia; Cancer research; In vitro; Genetic enhancement; RNA interference; Leukemia; Gene delivery; Small interfering RNA; Chemistry; Fusion gene; Biology; Immunology; Cell culture; Cell biology; Gene; Transfection; Biochemistry; RNA; Signal transduction; Genetics","score_opus":0.0281030590593791,"score_gpt":0.3042099216364296,"score_spread":0.2761068625770505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2809072903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99371165,0.0042568697,0.000017887252,0.0006810381,0.00053300476,0.00032179357,0.00002858397,0.000010437426,0.00043875707],"genre_scores_gemma":[0.99211204,0.0052614077,0.0010401839,0.0008960258,0.0005361984,0.0000012613932,0.000001261423,0.000055417175,0.0000961942],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99756235,0.00025446556,0.0010151291,0.0002955013,0.00037674946,0.00049580855],"domain_scores_gemma":[0.99859524,0.00009924019,0.0003670733,0.0001844273,0.00020284706,0.00055116136],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010704015,0.0003098899,0.0005722485,0.00049650477,0.000054616565,0.00003315803,0.0002006561,0.00005506369,0.00007166352],"category_scores_gemma":[0.00006340925,0.00026562845,0.00008322524,0.00051528076,0.00034951264,0.00013025213,0.0001854254,0.00051623635,0.000014042043],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001708724,0.0002642825,0.005035145,0.00022999108,0.000110697765,0.000847439,0.0007882947,0.000019090416,0.97566056,0.000007082695,0.00022541228,0.0151032815],"study_design_scores_gemma":[0.010137898,0.0008432192,0.003975284,0.00038200498,0.00024252955,0.00033328953,0.00012281502,0.00207565,0.9698718,0.0000075042353,0.011780354,0.00022765451],"about_ca_topic_score_codex":0.000022776356,"about_ca_topic_score_gemma":0.000012668036,"teacher_disagreement_score":0.014875627,"about_ca_system_score_codex":0.00058724254,"about_ca_system_score_gemma":0.00037827034,"threshold_uncertainty_score":0.9999796},"labels":[],"label_agreement":null},{"id":"W2809367512","doi":"10.1038/s41375-018-0179-9","title":"Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial","year":2018,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":123,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Shriners Hospitals for Children - Canada","funders":"Deutsche Forschungsgemeinschaft","keywords":"Medicine; Imatinib; Internal medicine; Myeloid leukemia; Cohort; Imatinib mesylate; Transplantation; Prospective cohort study; Surgery; Gastroenterology","score_opus":0.014608484347654034,"score_gpt":0.2794650063076702,"score_spread":0.26485652196001613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2809367512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936951,0.0008712532,0.000059831353,0.00015831314,0.00022160073,0.0034291563,0.00042998142,0.00018010865,0.00095465407],"genre_scores_gemma":[0.9932564,0.00036132286,0.0011703827,0.00022976611,0.0021796715,0.00020972751,0.0012601501,0.00010494093,0.0012276404],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9961822,0.00011386574,0.0009866583,0.0012933473,0.0005518411,0.00087211153],"domain_scores_gemma":[0.9978683,0.00009180604,0.00036480147,0.0011261688,0.00009269607,0.00045620865],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022315628,0.00072363246,0.0011411638,0.00025203958,0.00016055883,0.000057922407,0.00020999578,0.0003725169,0.0003113318],"category_scores_gemma":[0.00010140787,0.00054240436,0.00014072441,0.00031231635,0.00037874066,0.00020373549,0.00011406182,0.0004852094,0.00027866327],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7369467,0.0046563004,0.062743604,0.00017011842,0.0024322376,0.0013532693,0.0063310075,0.00011339908,0.006278677,0.000018953508,0.00505186,0.17390385],"study_design_scores_gemma":[0.89345884,0.015059911,0.075344086,0.0014678846,0.0007439331,0.00022395556,0.00008431609,0.0032953592,0.008412215,0.00003629172,0.001215137,0.00065807113],"about_ca_topic_score_codex":0.01636795,"about_ca_topic_score_gemma":0.0038934092,"teacher_disagreement_score":0.17324577,"about_ca_system_score_codex":0.01736987,"about_ca_system_score_gemma":0.003916286,"threshold_uncertainty_score":0.99970275},"labels":[],"label_agreement":null},{"id":"W2809992610","doi":"10.1016/j.bcp.2018.07.001","title":"Multitargeted kinase inhibitors imatinib, sorafenib and sunitinib perturb energy metabolism and cause cytotoxicity to cultured C2C12 skeletal muscle derived myotubes","year":2018,"lang":"en","type":"article","venue":"Biochemical Pharmacology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Alberta Innovates - Health Solutions; Alberta Cancer Foundation","keywords":"Sunitinib; Sorafenib; Imatinib; Skeletal muscle; Chemistry; Pharmacology; Myogenesis; Endocrinology; Internal medicine; Cancer research; Biology; Medicine; Cancer","score_opus":0.016427276422795976,"score_gpt":0.2955629378759653,"score_spread":0.27913566145316937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2809992610","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946096,0.0026055446,0.000033249085,0.0013581915,0.00039338815,0.0006025343,0.000091412025,0.00014395858,0.00016212517],"genre_scores_gemma":[0.9919871,0.00024877375,0.002636469,0.0035208757,0.0011154718,0.00011779558,0.00013810105,0.000051026745,0.00018439392],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979112,0.00012376563,0.0004102141,0.0007221901,0.00022041918,0.0006122108],"domain_scores_gemma":[0.9985654,0.00014790226,0.0000962633,0.00023217748,0.00020284094,0.0007554353],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000111220776,0.00041723554,0.00061081385,0.0001474319,0.00016774068,0.000021922018,0.00011895999,0.00032092718,0.0004318883],"category_scores_gemma":[0.00024921744,0.00035416728,0.000094557945,0.00024214266,0.00063683995,0.000091450114,0.00027268336,0.00026476715,0.000033522487],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003785405,0.0003227205,0.00013091858,0.000045791592,0.00026897388,0.00010064474,0.0006113052,1.68212e-7,0.9603414,0.000027776885,0.03653418,0.0012375684],"study_design_scores_gemma":[0.008184585,0.0003930092,0.0053109885,0.000034020803,0.00050442014,0.00012700012,0.000102736776,0.0003609339,0.9688416,0.000027133628,0.015753103,0.00036045024],"about_ca_topic_score_codex":0.00024838303,"about_ca_topic_score_gemma":0.000010840537,"teacher_disagreement_score":0.020781074,"about_ca_system_score_codex":0.0002438211,"about_ca_system_score_gemma":0.0001490574,"threshold_uncertainty_score":0.99989104},"labels":[],"label_agreement":null},{"id":"W2810407144","doi":"10.1080/23723556.2018.1465882","title":"DDR1 inhibition as a new therapeutic strategy for colorectal cancer","year":2018,"lang":"en","type":"article","venue":"Molecular & Cellular Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Australian Research Council; Fondation de France; Ligue Contre le Cancer; CNIB","keywords":"Nilotinib; Colorectal cancer; Medicine; Tyrosine kinase; Cancer research; Receptor tyrosine kinase; DDR1; Oncology; Cancer; Receptor; Internal medicine; Pharmacology","score_opus":0.03072248631703369,"score_gpt":0.3434663599972563,"score_spread":0.3127438736802226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2810407144","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9727365,0.0023703973,0.011971031,0.0026005132,0.0004172852,0.0015413035,0.000012173633,0.00010299712,0.008247832],"genre_scores_gemma":[0.9916092,0.000063284366,0.0015626571,0.0030571735,0.00063787785,0.00027261057,0.00014875348,0.00006998443,0.0025784725],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984131,0.00008735633,0.00029451572,0.00048573423,0.00021685348,0.00050243],"domain_scores_gemma":[0.9990392,0.000057631172,0.00012529227,0.00028812085,0.00017019681,0.0003195705],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00013593565,0.0002545266,0.00043566796,0.0001056266,0.00009925775,0.000016570788,0.00008869552,0.00033218434,0.0011945087],"category_scores_gemma":[0.00006642215,0.00023649825,0.00018984632,0.00019047191,0.0001854641,0.000041498173,0.000042453383,0.00019063185,0.00030047982],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00088644505,0.00027323078,0.00019326771,0.000039895243,0.0003508138,0.00052578526,0.00028691938,0.000009738369,0.9518359,0.0010042865,0.0023592054,0.04223456],"study_design_scores_gemma":[0.008324434,0.0064487415,0.00027564698,0.000049730323,0.0005043113,0.00023184149,0.00006836442,0.0004156049,0.89861983,0.0022826702,0.08256407,0.0002147461],"about_ca_topic_score_codex":0.00070169277,"about_ca_topic_score_gemma":0.0002459713,"teacher_disagreement_score":0.08020487,"about_ca_system_score_codex":0.0015311654,"about_ca_system_score_gemma":0.0037520921,"threshold_uncertainty_score":0.99971855},"labels":[],"label_agreement":null},{"id":"W2886320425","doi":"10.3324/haematol.2018.188987","title":"Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia","year":2018,"lang":"en","type":"article","venue":"Haematologica","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":95,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McGill University Health Centre","funders":"National Cancer Institute; Bristol-Myers Squibb","keywords":"Dasatinib; Medicine; Internal medicine; Imatinib; Pleural effusion; Myeloid leukemia; Oncology; Philadelphia chromosome; Population; Gastroenterology; Chromosomal translocation","score_opus":0.02326542935298994,"score_gpt":0.2916060793368093,"score_spread":0.2683406499838194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2886320425","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99774724,0.00016898896,0.00002144031,0.00009679937,0.00011883964,0.0014560423,0.000062110055,0.00004692597,0.00028163177],"genre_scores_gemma":[0.99824876,0.00034037657,0.0010648862,0.00009588029,0.000031788066,0.00006155731,0.0000967194,0.000025025383,0.000034998],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983354,0.00009828777,0.0005185353,0.00043628342,0.00026545284,0.0003460342],"domain_scores_gemma":[0.9985346,0.00052484137,0.00035670417,0.00031530324,0.00016086116,0.0001076635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020185017,0.00027945585,0.00078684126,0.00015971359,0.00012230714,0.000009875234,0.000116815456,0.0002015224,0.0001055124],"category_scores_gemma":[0.00062102923,0.00018702289,0.0001069388,0.00021332769,0.00025087298,0.00010393252,0.00009084346,0.00018309585,0.000006620289],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006940494,0.00022206588,0.99456596,0.000054439566,0.00010286617,0.000011839227,0.0010913772,8.3353694e-7,0.00030595434,0.000034388086,0.0001871092,0.002729103],"study_design_scores_gemma":[0.009301106,0.0023279488,0.9799579,0.00025559674,0.000065160464,0.00001658925,0.000115832016,0.00019907739,0.0073728897,0.00014620475,0.00007384059,0.00016788983],"about_ca_topic_score_codex":0.00041975867,"about_ca_topic_score_gemma":0.00009146169,"teacher_disagreement_score":0.01460811,"about_ca_system_score_codex":0.00047267423,"about_ca_system_score_gemma":0.00015234541,"threshold_uncertainty_score":0.7626572},"labels":[],"label_agreement":null},{"id":"W2888908066","doi":"10.1007/s12325-018-0772-3","title":"Burden of Infections Among Chronic Myeloid Leukemia Patients Receiving Dasatinib or Nilotinib: A Real-World Retrospective Healthcare Claims Study in the United States","year":2018,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Novartis Pharmaceuticals Corporation","keywords":"Nilotinib; Dasatinib; Medicine; Myeloid leukemia; Internal medicine; Cohort; Retrospective cohort study; Oncology; Imatinib","score_opus":0.023342761391455184,"score_gpt":0.34780418259492707,"score_spread":0.3244614212034719,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888908066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949258,0.0006154714,0.0000067499936,0.00021652093,0.00026442893,0.0027653421,0.000020735988,0.00007273891,0.0011122319],"genre_scores_gemma":[0.99008846,0.008670428,0.00011533318,0.0001855525,0.0002738163,0.0003340575,0.00009571587,0.000055138928,0.00018148459],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971637,0.00046866134,0.0007817282,0.0005454564,0.00052866933,0.0005117912],"domain_scores_gemma":[0.99797595,0.0005098546,0.00039823403,0.0007402174,0.00029578037,0.00007998912],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005876816,0.0003331781,0.00061268674,0.0005802528,0.00016177435,0.000018525345,0.00028885968,0.00009432067,0.00012389233],"category_scores_gemma":[0.00016525039,0.00022087575,0.00007234103,0.002538955,0.00035416058,0.00030974872,0.00005561101,0.00055733026,0.000008417314],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008619446,0.0008198004,0.96035385,0.000057722005,0.000094621566,0.000020670295,0.020371992,0.00031849745,0.000030664796,0.000047212696,0.000035255136,0.01698774],"study_design_scores_gemma":[0.012115049,0.008882513,0.97050637,0.0005412444,0.000028570108,0.000004160051,0.0047079013,0.00044589204,0.00021293142,0.00046451215,0.0018816136,0.00020926933],"about_ca_topic_score_codex":0.020460216,"about_ca_topic_score_gemma":0.11157649,"teacher_disagreement_score":0.09111627,"about_ca_system_score_codex":0.004620247,"about_ca_system_score_gemma":0.0006619082,"threshold_uncertainty_score":0.9992008},"labels":[],"label_agreement":null},{"id":"W2888974667","doi":"10.1016/j.clml.2018.07.090","title":"Treatment-Free Remission (TFR) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) and Stable Deep Molecular Response (DMR) Discontinuing Dasatinib (DASFREE)","year":2018,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Dasatinib; Discontinuation; Myeloid leukemia; Medicine; Tyrosine-kinase inhibitor; Tyrosine kinase; Internal medicine; Imatinib; Oncology; Cancer research; Receptor; Cancer","score_opus":0.015153637621143239,"score_gpt":0.3076260359295255,"score_spread":0.29247239830838223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888974667","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920392,0.0022271913,0.0003105087,0.0004389958,0.0004458857,0.0028290567,0.00011424789,0.0003584562,0.0012364369],"genre_scores_gemma":[0.99188775,0.0004393129,0.0031763136,0.00039063554,0.0010345089,0.00024075099,0.00045141848,0.00033530506,0.0020439979],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9904348,0.0009216921,0.0025989332,0.0026739435,0.0012722524,0.0020983554],"domain_scores_gemma":[0.9922892,0.001315886,0.0009275242,0.003576182,0.00043335865,0.0014578721],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0013580965,0.0014797451,0.0023651393,0.0005313274,0.0004535748,0.0001789756,0.000836734,0.0010396324,0.00042603203],"category_scores_gemma":[0.0021918458,0.001181625,0.00049348146,0.0010620244,0.0015900731,0.00063655083,0.00073810655,0.00073808775,0.00023547979],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.037414685,0.0019627393,0.19635108,0.00025213143,0.0008437108,0.0021620716,0.00068081764,0.000043074087,0.007523962,0.00008813546,0.00081885303,0.7518587],"study_design_scores_gemma":[0.13303211,0.022707168,0.81514716,0.0015345896,0.0007265562,0.00024099513,0.000108922395,0.004284085,0.007265294,0.00011853309,0.013567574,0.0012670063],"about_ca_topic_score_codex":0.00084949285,"about_ca_topic_score_gemma":0.000826541,"teacher_disagreement_score":0.75059175,"about_ca_system_score_codex":0.03545437,"about_ca_system_score_gemma":0.0102156475,"threshold_uncertainty_score":0.9997952},"labels":[],"label_agreement":null},{"id":"W2889046911","doi":"10.1002/pbc.27431","title":"Generic formulations of imatinib for treatment of Philadelphia chromosome–positive leukemia in pediatric patients","year":2018,"lang":"en","type":"review","venue":"Pediatric Blood & Cancer","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital","funders":"","keywords":"Imatinib; Medicine; Leukemia; Philadelphia chromosome; Internal medicine; Imatinib mesylate; Oncology; Chromosomal translocation; Genetics; Gene; Myeloid leukemia","score_opus":0.04851311132027888,"score_gpt":0.34594769880448445,"score_spread":0.2974345874842056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889046911","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.033276815,0.95777917,0.000010823687,0.000011302113,0.0004460859,0.0055653383,0.0026984415,0.000034135504,0.0001778748],"genre_scores_gemma":[0.005347771,0.9862141,0.0012400055,0.000010931963,0.002668087,0.0025706852,0.0016439897,0.00016311328,0.0001412965],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99581534,0.00008810562,0.0020401182,0.0008526623,0.0005485379,0.0006552414],"domain_scores_gemma":[0.9961232,0.0004886589,0.0019424997,0.00074129895,0.00048822863,0.00021610953],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001299199,0.0008449549,0.0035287158,0.0010383825,0.00006540511,0.0000081571425,0.00024846877,0.0005548486,0.00016042053],"category_scores_gemma":[0.00011045431,0.00067814515,0.0011056279,0.0016650697,0.000079753365,0.00010431866,0.00007556421,0.00016744062,0.000016668622],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0007719362,0.011920007,0.13712925,0.26986396,0.0066361297,0.00007190375,0.0020955338,0.00007966169,0.0000041265025,0.0000805357,0.0049983272,0.5663486],"study_design_scores_gemma":[0.14911434,0.031902116,0.060172185,0.028208384,0.3836612,0.00014420523,0.000057095145,0.00046617317,0.00041723155,0.00022969919,0.33951345,0.0061139087],"about_ca_topic_score_codex":0.00044377157,"about_ca_topic_score_gemma":0.00008082099,"teacher_disagreement_score":0.5602347,"about_ca_system_score_codex":0.004676754,"about_ca_system_score_gemma":0.0066704974,"threshold_uncertainty_score":0.999567},"labels":[],"label_agreement":null},{"id":"W2889099819","doi":"10.1016/j.clml.2018.07.092","title":"ENESTop 144-Week Update: Long-Term Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After Stopping Second-Line Nilotinib","year":2018,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Nilotinib; Myeloid leukemia; Medicine; Internal medicine; Chronic myeloid leukaemia; Oncology; Imatinib","score_opus":0.026631027669511552,"score_gpt":0.3220819260204965,"score_spread":0.295450898350985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889099819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99197453,0.0020441895,0.00006937143,0.00027033355,0.0009315413,0.0033143482,0.00017138208,0.00038124592,0.000843083],"genre_scores_gemma":[0.98946565,0.00072386034,0.00085166685,0.00091734156,0.002507861,0.00054818194,0.0012667936,0.00039746126,0.0033211703],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9886367,0.0006119718,0.003710677,0.0031198703,0.0013243544,0.0025964617],"domain_scores_gemma":[0.9924955,0.0007153914,0.0010672197,0.0038858273,0.00044408237,0.0013919756],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0010771935,0.0018211871,0.0029562227,0.00089041743,0.00029170536,0.00013252934,0.0011488895,0.0014014274,0.00270427],"category_scores_gemma":[0.00066558825,0.0015068125,0.00069599407,0.0015770597,0.0013084355,0.00079568586,0.0006987599,0.001115431,0.0010120724],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.015877964,0.003092332,0.47803256,0.00041168946,0.0005024495,0.0028086095,0.00028636455,0.00003695488,0.0008082152,0.000019872034,0.00066427496,0.4974587],"study_design_scores_gemma":[0.13163997,0.017754527,0.83416456,0.0025611727,0.00045510486,0.00019396155,0.000019982936,0.0010966555,0.0033081982,0.00004293628,0.0074799093,0.001282997],"about_ca_topic_score_codex":0.0006559013,"about_ca_topic_score_gemma":0.005624861,"teacher_disagreement_score":0.4961757,"about_ca_system_score_codex":0.08730309,"about_ca_system_score_gemma":0.019375678,"threshold_uncertainty_score":0.999895},"labels":[],"label_agreement":null},{"id":"W2889267835","doi":"10.14740/jh421w","title":"Chronic Myeloid Leukemia With P190 BCR-ABL Translocation and Persistent Moderate Monocytosis: A Case Report.","year":2018,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Monocytosis; Medicine; Dasatinib; Myeloid leukemia; Imatinib; Imatinib mesylate; Nilotinib; breakpoint cluster region; Chronic myelomonocytic leukemia; Leukemia; Philadelphia chromosome; Chromosomal translocation; Immunology; Bone marrow; Cancer research; Oncology; Internal medicine; Myelodysplastic syndromes; Biology; Receptor","score_opus":0.019692693981968167,"score_gpt":0.2750585456881901,"score_spread":0.25536585170622195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889267835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884683,0.006956256,0.0017374774,0.0017451217,0.0001334264,0.00027392755,0.0000016271712,0.000021209,0.0006626462],"genre_scores_gemma":[0.9958622,0.0003424975,0.0029549147,0.00015290789,0.00035096673,0.000011117585,0.0000039150464,0.00003067014,0.00029083877],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9983975,0.00006545348,0.00070357317,0.00026945505,0.00025003808,0.00031392984],"domain_scores_gemma":[0.99843574,0.00006209375,0.00056191895,0.00031388836,0.00038086137,0.00024547812],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029933816,0.00021957413,0.0007030723,0.0001997909,0.00012792618,0.000019521454,0.00006606792,0.00015716704,0.00009011851],"category_scores_gemma":[0.00006240602,0.0001551299,0.0001395056,0.00014023148,0.0002598386,0.00015669927,0.00001971683,0.0003119951,0.000012208906],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009798,0.0008067492,0.012890448,0.001557828,0.0067553585,0.8888732,0.011687404,0.00059911195,0.014655376,0.00082855416,0.004162814,0.047385134],"study_design_scores_gemma":[0.0075357445,0.0034491671,0.00047814986,0.00044495662,0.00073046127,0.96408075,0.0007402637,0.0033798807,0.0182125,0.00006937622,0.00073176395,0.00014696561],"about_ca_topic_score_codex":0.000096105,"about_ca_topic_score_gemma":0.0001616492,"teacher_disagreement_score":0.07520755,"about_ca_system_score_codex":0.0014735432,"about_ca_system_score_gemma":0.001728205,"threshold_uncertainty_score":0.63260144},"labels":[],"label_agreement":null},{"id":"W2889341292","doi":"10.14740/jh410w","title":"Cytokine Syntheses by T-Cell Subsets From Chronic Myeloid Leukemia Patients: Relationship Between Pre-Treatment Levels and Response to Imatinib Therapy","year":2018,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Cytokine; Immunology; Myeloid leukemia; Imatinib; CD8; Tumor necrosis factor alpha; T cell; Interferon; Immune system","score_opus":0.03453732425901716,"score_gpt":0.3089148284496339,"score_spread":0.27437750419061674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889341292","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99404395,0.0031340006,0.00016522135,0.0015779223,0.00016510361,0.00057451177,0.00016487793,0.000026408014,0.00014801936],"genre_scores_gemma":[0.99675304,0.00015369183,0.002105396,0.00020974898,0.00032844534,0.000019589217,0.000035068828,0.000048168975,0.00034686486],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976934,0.00032419612,0.000894998,0.00033589685,0.00035738215,0.00039411764],"domain_scores_gemma":[0.9959865,0.0023743089,0.00059180026,0.00041450522,0.00027175972,0.00036111346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036438552,0.00032886502,0.00092912425,0.00026054666,0.00014019238,0.000022997889,0.00016151572,0.0002356321,0.0002556546],"category_scores_gemma":[0.0008765977,0.00023846234,0.00013497123,0.00017686668,0.0001770919,0.0001496404,0.000052006806,0.0002608432,0.00010362615],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047185724,0.0005199376,0.9625883,0.00004624416,0.0005527948,0.00012706999,0.0019109021,0.0000016722565,0.015629528,0.000019069417,0.0049373554,0.008948537],"study_design_scores_gemma":[0.016179286,0.0112453485,0.8326246,0.0005003539,0.00038934004,0.0005569789,0.00010966621,0.00001571172,0.12326955,0.00024337186,0.014572667,0.00029310535],"about_ca_topic_score_codex":0.00011279672,"about_ca_topic_score_gemma":0.00002678944,"teacher_disagreement_score":0.1299637,"about_ca_system_score_codex":0.003278794,"about_ca_system_score_gemma":0.0011283348,"threshold_uncertainty_score":0.97242117},"labels":[],"label_agreement":null},{"id":"W2890730652","doi":"10.1016/j.leukres.2018.08.021","title":"Canadian chronic myeloid leukemia outcomes post-transplant in the tyrosine kinase inhibitor era","year":2018,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; University of Toronto; Ottawa Hospital; University Health Network; Université Laval; University of Ottawa; Vancouver General Hospital; Princess Margaret Cancer Centre; University of Calgary; Alberta Health Services; BC Cancer Agency; McMaster University","funders":"","keywords":"Medicine; Internal medicine; Myeloid leukemia; Transplantation; Gastroenterology; Tyrosine-kinase inhibitor; Population; Oncology; Cancer","score_opus":0.03327361829229448,"score_gpt":0.3345510187944684,"score_spread":0.30127740050217394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890730652","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97150207,0.00095750584,0.000003508072,0.011583379,0.00033012702,0.0018858281,0.000119577875,0.00008653534,0.013531462],"genre_scores_gemma":[0.99008685,0.00027425488,0.00018083306,0.0021233335,0.0013371471,0.0002871832,0.00026511386,0.00009951533,0.0053457934],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99376017,0.0005188348,0.00065774075,0.000927335,0.0018368722,0.002299036],"domain_scores_gemma":[0.9962357,0.0006427803,0.000069334375,0.001644407,0.00058211904,0.0008256012],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0022733114,0.0004929256,0.00064060243,0.0011326079,0.00063944637,0.00015632174,0.0009096492,0.0004365677,0.0011718925],"category_scores_gemma":[0.0005314685,0.00033836125,0.00020929278,0.0016849734,0.0007485354,0.00021645382,0.00014734258,0.0023449548,0.0022097535],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.004289383,0.0012226229,0.6204537,0.0018065439,0.0011907625,0.025878694,0.025857069,0.00009333378,0.09178857,0.006363954,0.13876522,0.08229013],"study_design_scores_gemma":[0.021798348,0.0043995995,0.82553715,0.0013515741,0.00018623633,0.0011158959,0.0016985709,0.0016530938,0.023043197,0.00034842998,0.11778947,0.0010784193],"about_ca_topic_score_codex":0.44594324,"about_ca_topic_score_gemma":0.5875566,"teacher_disagreement_score":0.20508344,"about_ca_system_score_codex":0.054228526,"about_ca_system_score_gemma":0.029065477,"threshold_uncertainty_score":0.99995667},"labels":[],"label_agreement":null},{"id":"W2891752553","doi":"10.1038/s41375-018-0247-1","title":"Cardiovascular events in chronic myeloid leukemia clinical trials. Is it time to reassess and report the events according to cardiology guidelines?","year":2018,"lang":"en","type":"review","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Myeloid leukemia; Clinical trial; Adverse effect; Internal medicine; Intensive care medicine; Cancer; Oncology","score_opus":0.2008790955792837,"score_gpt":0.4662470239497821,"score_spread":0.2653679283704984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891752553","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004264758,0.9810921,0.00019565178,0.00087527797,0.0017848309,0.009849315,0.00011022978,0.00014507074,0.0016827856],"genre_scores_gemma":[0.00028068095,0.97679114,0.0009349369,0.0019009829,0.0076343534,0.0015475989,0.0005181774,0.00037301384,0.010019084],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98300415,0.0036451556,0.0070136,0.0032366326,0.001504419,0.0015960514],"domain_scores_gemma":[0.98977286,0.0020967042,0.0016138903,0.0048885173,0.0005489781,0.0010790491],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.021014642,0.0017200513,0.012461051,0.00076186884,0.00023932905,0.000055846947,0.00125547,0.001987941,0.00026119736],"category_scores_gemma":[0.013497202,0.0011709036,0.004502034,0.0015166973,0.00019551402,0.00014901192,0.0014281864,0.0020699697,0.003748928],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00025540724,0.000041781568,0.0011398819,0.004584539,0.008794546,0.0025498974,0.00010294594,0.000095981195,0.0000031916243,0.000002345925,0.124885015,0.8575445],"study_design_scores_gemma":[0.004358084,0.00051117013,0.0007830921,0.020934682,0.008373742,0.0051715006,0.00003668419,0.000094133546,0.0000028153759,0.000017222648,0.95875007,0.00096682424],"about_ca_topic_score_codex":0.0011220626,"about_ca_topic_score_gemma":0.000060099814,"teacher_disagreement_score":0.85657763,"about_ca_system_score_codex":0.034550376,"about_ca_system_score_gemma":0.020131668,"threshold_uncertainty_score":0.9995546},"labels":[],"label_agreement":null},{"id":"W2891881749","doi":"10.1200/jco.2018.36.15_suppl.10065","title":"Pregnancies during and following trastuzumab (T) and/or lapatinib (L) in patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Fleurimont","funders":"","keywords":"Medicine; Pregnancy; Trastuzumab; Breast cancer; Lapatinib; Internal medicine; Gestation; Cancer; Gynecology; Obstetrics","score_opus":0.06382796730366658,"score_gpt":0.3910603095119024,"score_spread":0.3272323422082358,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891881749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956613,0.0012613069,0.000020238269,0.001980643,0.0003443954,0.0005489895,0.00006967583,0.0000087143935,0.00010473831],"genre_scores_gemma":[0.9959044,0.0012891764,0.0006772239,0.0006876183,0.0012168535,0.000020927864,0.000010067894,0.000029282162,0.00016445543],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99542385,0.0010503778,0.0021879352,0.00046026488,0.000496429,0.00038112103],"domain_scores_gemma":[0.9929643,0.004384146,0.0016672469,0.00025078477,0.0003194562,0.00041403386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023161413,0.0003029057,0.0026317595,0.0001888218,0.00014613812,0.0000444819,0.00014416111,0.00035232565,0.00006527243],"category_scores_gemma":[0.0019286774,0.00016118634,0.00034935618,0.00039072632,0.00049770065,0.00017342858,0.00011345304,0.0008268904,0.000002552171],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011339277,0.0007501123,0.87950355,0.000019627076,0.0038545532,0.00033570614,0.0018260152,0.0000037107022,0.000027214875,0.0000014453581,0.0000924864,0.102246284],"study_design_scores_gemma":[0.037999373,0.0090724025,0.946357,0.0007815918,0.0045704544,0.00011305146,0.0004409103,0.000058299884,0.000033844633,0.000023983917,0.00039160324,0.00015744753],"about_ca_topic_score_codex":0.0026634408,"about_ca_topic_score_gemma":0.008267661,"teacher_disagreement_score":0.10208884,"about_ca_system_score_codex":0.0006791602,"about_ca_system_score_gemma":0.0014355894,"threshold_uncertainty_score":0.6572988},"labels":[],"label_agreement":null},{"id":"W2892510970","doi":"10.1016/j.bbmt.2018.09.029","title":"Practice Patterns of Physician Treatment for Pediatric Chronic Myelogenous Leukemia","year":2018,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital","funders":"Novartis","keywords":"Medicine; Chronic myelogenous leukemia; Sibling; Pediatrics; Bone marrow transplantation; Disease; Clinical trial; Leukemia; Bone marrow; Intensive care medicine; Family medicine; Internal medicine","score_opus":0.015460808152838878,"score_gpt":0.2847188708109921,"score_spread":0.2692580626581532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892510970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99639565,0.001502487,0.0007587583,0.00010015106,0.00009141582,0.000588404,0.00025105916,0.000017139553,0.0002949647],"genre_scores_gemma":[0.9921154,0.005623915,0.001369211,0.000058988688,0.00035664087,0.000044879365,0.00036689092,0.00001281612,0.000051269813],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992652,0.000036977013,0.00025449073,0.00021635683,0.000057733127,0.0001692677],"domain_scores_gemma":[0.999358,0.00017114807,0.00018610759,0.00013091398,0.00010745748,0.000046385034],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007662452,0.00013370246,0.00029900853,0.00008115024,0.000044777033,0.0000015403812,0.00003434752,0.00011365305,0.00001176381],"category_scores_gemma":[0.000013990131,0.00010811218,0.00007277333,0.000058493995,0.00009064489,0.00004695625,0.0000036147837,0.000034179535,0.0000018972094],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028382337,0.0009461039,0.07997319,0.002212091,0.0012852609,0.00002722719,0.0026054056,0.0000026933196,0.84982014,0.0006412488,0.000025180963,0.05962325],"study_design_scores_gemma":[0.028935703,0.02475697,0.04407309,0.00018774573,0.009973319,0.0003378537,0.00021672415,0.00007076077,0.88961774,0.00016359768,0.0013935664,0.00027290912],"about_ca_topic_score_codex":0.00029558942,"about_ca_topic_score_gemma":0.00010284201,"teacher_disagreement_score":0.059350338,"about_ca_system_score_codex":0.0001245668,"about_ca_system_score_gemma":0.0003459095,"threshold_uncertainty_score":0.44086868},"labels":[],"label_agreement":null},{"id":"W2895187195","doi":"10.21693/1933-088x-17.2.69","title":"Tyrosine Kinase Inhibitor–Induced Pulmonary Arterial Hypertension","year":2018,"lang":"en","type":"article","venue":"Advances in Pulmonary Hypertension","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Bosutinib; Medicine; Dasatinib; Ponatinib; Imatinib; Tyrosine-kinase inhibitor; Pulmonary hypertension; Tyrosine kinase; Imatinib mesylate; Nilotinib; Internal medicine; Cardiology; Myeloid leukemia; Pharmacology; Receptor","score_opus":0.021333767465348565,"score_gpt":0.2715717155937096,"score_spread":0.25023794812836103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2895187195","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9834215,0.0061015366,0.000017277569,0.00084503135,0.0024920907,0.0008529058,0.000012066358,0.0002334048,0.006024178],"genre_scores_gemma":[0.99248093,0.0018908201,0.0014163515,0.0013627937,0.0020302054,0.00006309352,0.00019203944,0.00010778877,0.00045597772],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9965778,0.00010786467,0.00072946586,0.0011159346,0.0006547908,0.0008141311],"domain_scores_gemma":[0.99805206,0.00013292531,0.00017468868,0.0010058314,0.00030477275,0.0003297035],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022226635,0.0005605708,0.0008531158,0.00037347904,0.00023448393,0.000021197404,0.00020247963,0.00033804495,0.00024283228],"category_scores_gemma":[0.00021253708,0.0004692213,0.00017667885,0.0006923601,0.00029710418,0.00076999667,0.0002149636,0.00044296158,0.0004704142],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036133071,0.0021201787,0.01153239,0.0001331763,0.00003654561,0.01388482,0.00006858307,0.000008679241,0.8012519,0.000039270777,0.0008858395,0.16642533],"study_design_scores_gemma":[0.030570857,0.0079343105,0.37604377,0.0064300764,0.0008925819,0.044837054,0.00094856374,0.03581238,0.2804428,0.0023281176,0.21002577,0.003733723],"about_ca_topic_score_codex":0.00011057966,"about_ca_topic_score_gemma":0.000040245053,"teacher_disagreement_score":0.52080905,"about_ca_system_score_codex":0.00065574015,"about_ca_system_score_gemma":0.00023150584,"threshold_uncertainty_score":0.99977595},"labels":[],"label_agreement":null},{"id":"W2899001777","doi":"10.1186/s13104-018-3890-8","title":"Incidence of chronic myeloid leukemia in Calgary, Alberta, Canada","year":2018,"lang":"en","type":"article","venue":"BMC Research Notes","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services; University of Calgary","funders":"Canadian Institutes of Health Research","keywords":"Incidence (geometry); Myeloid leukemia; Medicine; Gerontology; Immunology","score_opus":0.06340959391161845,"score_gpt":0.36532510824960324,"score_spread":0.3019155143379848,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899001777","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907439,0.00077296584,0.000034763263,0.00034779255,0.00011498526,0.0006784646,0.0000062628906,0.000013632053,0.007287269],"genre_scores_gemma":[0.99576914,0.000112682486,0.0006667743,0.00006157302,0.00034822588,0.00006443366,0.000020904718,0.000031998974,0.0029242916],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996808,0.00021432588,0.00042909634,0.00045843143,0.0012440359,0.00084612693],"domain_scores_gemma":[0.99656415,0.0019006846,0.00007089665,0.00077136187,0.00041762835,0.0002752751],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085460616,0.00018174015,0.00040405916,0.0002957051,0.00009716055,0.000012609073,0.00032687845,0.00012442001,0.00084392517],"category_scores_gemma":[0.0036030114,0.00015697513,0.00005744424,0.0008295821,0.00053838984,0.000091978734,0.00023417122,0.00050790975,0.00015081918],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0009350402,0.00024366894,0.9381482,0.0010092551,0.00012257346,0.00043266264,0.00082855,0.00006627167,0.024275696,0.00062176667,0.010987755,0.02232859],"study_design_scores_gemma":[0.006854192,0.002017952,0.79642963,0.0013009952,0.000035943103,0.000117669726,0.00017917504,0.012490311,0.16857523,0.0002807943,0.011362285,0.00035584348],"about_ca_topic_score_codex":0.9789041,"about_ca_topic_score_gemma":0.99334157,"teacher_disagreement_score":0.14429954,"about_ca_system_score_codex":0.014691937,"about_ca_system_score_gemma":0.034791235,"threshold_uncertainty_score":0.9890905},"labels":[],"label_agreement":null},{"id":"W2900357627","doi":"10.1002/ajh.25342","title":"Treatment‐free remission with first‐ and second‐generation tyrosine kinase inhibitors","year":2018,"lang":"en","type":"review","venue":"American Journal of Hematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":147,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Bristol-Myers Squibb","keywords":"Nilotinib; Dasatinib; Discontinuation; Medicine; Imatinib; Bosutinib; Clinical trial; Tyrosine-kinase inhibitor; Tyrosine kinase; Myeloid leukemia; Oncology; Intensive care medicine; Imatinib mesylate; Internal medicine; Cancer","score_opus":0.027303292112272524,"score_gpt":0.3110332930561482,"score_spread":0.2837300009438757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900357627","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01116729,0.9876006,0.000020546382,0.00035736003,0.00020427685,0.00044423036,0.000016433594,0.000015670628,0.00017356926],"genre_scores_gemma":[0.0014804283,0.99406356,0.0031789944,0.000056582143,0.00067136344,0.000020810441,0.000053820233,0.00007544324,0.00039902137],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99800044,0.0001592285,0.0009351337,0.00036744075,0.00023715069,0.0003006331],"domain_scores_gemma":[0.99695283,0.00023677936,0.0017823653,0.00052813033,0.00017108669,0.00032883376],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000121865385,0.00049772725,0.0030877935,0.00036359136,0.00008773272,0.000016301674,0.00013655346,0.0001880618,0.00014994245],"category_scores_gemma":[0.00014469161,0.00028501378,0.00030502473,0.00029135798,0.0005015931,0.00007415404,0.000050702798,0.00030593327,0.000015489339],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035771108,0.00038266435,0.0006053905,0.004629202,0.001810539,0.0032254334,0.00020724924,1.526617e-7,0.000013005943,0.00004015044,0.013691047,0.97503746],"study_design_scores_gemma":[0.0035431716,0.0104820235,0.000015489422,0.010964943,0.0030722737,0.084644414,0.000052409738,0.000003859804,0.00015008799,0.000006246868,0.88681567,0.00024942902],"about_ca_topic_score_codex":0.00003684507,"about_ca_topic_score_gemma":0.00008943804,"teacher_disagreement_score":0.974788,"about_ca_system_score_codex":0.0009696087,"about_ca_system_score_gemma":0.0015602405,"threshold_uncertainty_score":0.9999602},"labels":[],"label_agreement":null},{"id":"W2900398518","doi":"10.1016/j.jcjo.2018.07.008","title":"Optic neuropathy in extramedullary, blast crisis of chronic myeloid leukemia","year":2018,"lang":"en","type":"letter","venue":"Canadian Journal of Ophthalmology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Pathology; Optic neuropathy; Myeloid leukemia; Optic nerve; Bone marrow; Ophthalmology; Internal medicine","score_opus":0.021380699585252034,"score_gpt":0.26609266326015013,"score_spread":0.2447119636748981,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900398518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90544987,0.0062546562,0.0000047158796,0.07582189,0.0029595285,0.0005844104,0.00012249759,0.000007063876,0.008795377],"genre_scores_gemma":[0.9689527,0.00010494975,0.0005802765,0.02039627,0.0067174314,0.0000150745245,0.00013288099,0.0002278132,0.0028725693],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99587345,0.0003252096,0.0015803361,0.00053561764,0.00048621444,0.0011991423],"domain_scores_gemma":[0.9964553,0.00022908233,0.001150389,0.00085867365,0.00050926197,0.00079729425],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00044176274,0.0006112338,0.0018742622,0.001989614,0.000060814684,0.000023843371,0.0007271066,0.0014784451,0.004666476],"category_scores_gemma":[0.00040392714,0.0005822844,0.0004996186,0.0005110779,0.0006447124,0.00010350216,0.000049285776,0.0034522442,0.00010999008],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00009795414,0.00004275146,0.0058246395,0.00053581403,0.00038320152,0.5662768,0.0002166928,0.000033514432,0.000102281316,0.0000038654694,0.42620766,0.00027483454],"study_design_scores_gemma":[0.0048889504,0.0060078427,0.011990267,0.0015903673,0.00070823135,0.8707592,0.00009046335,0.00006622334,0.00033763907,0.00013262905,0.10287504,0.00055314304],"about_ca_topic_score_codex":0.009725206,"about_ca_topic_score_gemma":0.000637069,"teacher_disagreement_score":0.3233326,"about_ca_system_score_codex":0.009801548,"about_ca_system_score_gemma":0.02914484,"threshold_uncertainty_score":0.99981785},"labels":[],"label_agreement":null},{"id":"W2901631194","doi":"10.1002/cncr.31835","title":"Molecular monitoring of therapeutic milestones and clinical outcomes in patients with chronic myeloid leukemia","year":2018,"lang":"en","type":"article","venue":"Cancer","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Jeunesse de Quebec; McGill University Health Centre; Université de Montréal; Hôpital Maisonneuve-Rosemont; McGill University; Université du Québec; Jewish General Hospital","funders":"Réseau de cancérologie Rossy","keywords":"Medicine; Internal medicine; Cohort; Odds ratio; Myeloid leukemia; Confidence interval; Nilotinib; Cohort study; Oncology; Pediatrics; Imatinib","score_opus":0.021163750502852997,"score_gpt":0.3301684813763505,"score_spread":0.3090047308734975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901631194","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973493,0.001855598,0.00000847396,0.000063009655,0.00022049897,0.00036533308,0.0000051395973,0.000017066643,0.00011553129],"genre_scores_gemma":[0.99905956,0.00031493462,0.00022177231,0.00008391266,0.00014490497,0.000032067226,0.0000036254614,0.000027310056,0.00011191182],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989947,0.000028132807,0.00028465327,0.00026561745,0.00021036284,0.00021654571],"domain_scores_gemma":[0.9993903,0.000051303068,0.000097626944,0.00028085877,0.000095135285,0.000084756124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007276804,0.00015158491,0.00039077297,0.000064512,0.00002156774,0.000004169099,0.000060620965,0.000087776854,0.000050495943],"category_scores_gemma":[0.000022764134,0.00010772584,0.000050116952,0.00012206059,0.0002430981,0.000047270856,0.000032540956,0.00014131216,0.0000060336956],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023764705,0.000090063484,0.9744976,0.000052027164,0.00021448554,0.000008529732,0.00009531793,0.000005350281,0.0002645685,0.0000072681482,0.0000069079983,0.024520226],"study_design_scores_gemma":[0.007927738,0.0009312463,0.9865946,0.00031399966,0.00014739104,0.0000013790686,0.000016778287,0.00003576302,0.003748549,0.000009055045,0.00017229741,0.00010118537],"about_ca_topic_score_codex":0.00031940782,"about_ca_topic_score_gemma":0.000092471346,"teacher_disagreement_score":0.02441904,"about_ca_system_score_codex":0.0012525119,"about_ca_system_score_gemma":0.0006017649,"threshold_uncertainty_score":0.43929324},"labels":[],"label_agreement":null},{"id":"W2904063612","doi":"10.1182/blood-2018-99-117464","title":"Glycemic Control in Patients Treated with Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: A Systematic Review","year":2018,"lang":"en","type":"review","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster Children's Hospital; Juravinski Cancer Centre; Impact; McMaster University; Hamilton Health Sciences","funders":"","keywords":"Medicine; Nilotinib; Dasatinib; Bosutinib; Ponatinib; Population; Internal medicine; Randomized controlled trial; Glycemic; Oncology; Myeloid leukemia; Imatinib; Insulin","score_opus":0.014493104895645306,"score_gpt":0.2698555046363557,"score_spread":0.2553623997407104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2904063612","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00056166045,0.97054285,0.0000045388297,0.000016546155,0.00011475424,0.028217198,0.00030604517,0.00013661268,0.0000998234],"genre_scores_gemma":[0.0005262519,0.98878527,0.00008975818,0.00018753752,0.0004254138,0.007406792,0.0018393134,0.00029947227,0.00044022003],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9946714,0.0002946651,0.0022759766,0.0011838668,0.00064797106,0.00092610816],"domain_scores_gemma":[0.99596006,0.00035965236,0.0014555685,0.0015570433,0.0003424177,0.00032526988],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00043306482,0.0012703302,0.007818745,0.00044494416,0.00008425526,0.000032398828,0.0003619867,0.00065535214,0.000045530596],"category_scores_gemma":[0.0005254537,0.0008452781,0.000938944,0.0009198461,0.00013686522,0.00009765778,0.00006610247,0.0005951909,0.000220421],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024591776,0.0009293159,0.00013279144,0.98807627,0.0019419477,0.00014295502,0.000011397126,6.143106e-8,5.0672395e-7,0.0000024291,0.0006823563,0.007834057],"study_design_scores_gemma":[0.04308783,0.004606506,0.0000130955605,0.86626375,0.050721027,0.00026994277,0.0000016877945,0.0000057531806,0.0000079199135,6.640679e-7,0.034353543,0.0006682719],"about_ca_topic_score_codex":0.00007168125,"about_ca_topic_score_gemma":0.000046937803,"teacher_disagreement_score":0.12181251,"about_ca_system_score_codex":0.007982725,"about_ca_system_score_gemma":0.0039635273,"threshold_uncertainty_score":0.9993998},"labels":[],"label_agreement":null},{"id":"W2904280057","doi":"10.1182/blood-2018-99-116563","title":"Updated 18-Month Results from Dasfree: A Study Evaluating Dasatinib Discontinuation in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Deep Molecular Response (DMR)","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Dasatinib; Discontinuation; Medicine; Internal medicine; Clinical endpoint; Imatinib; Imatinib mesylate; Myeloid leukemia; Oncology; Randomized controlled trial","score_opus":0.019105447816516262,"score_gpt":0.3126539785206752,"score_spread":0.293548530704159,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2904280057","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99505913,0.0006705516,0.00002545031,0.000071715986,0.0000686622,0.0036435442,0.000107632135,0.000090601665,0.0002627196],"genre_scores_gemma":[0.99741274,0.000022531014,0.00088316563,0.000057473913,0.00018855852,0.00024213389,0.000998808,0.000096111675,0.00009845053],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952744,0.0007372284,0.0010888889,0.0012646711,0.0009024789,0.0007322824],"domain_scores_gemma":[0.9977157,0.00027893897,0.00043970335,0.0011206628,0.00021517914,0.00022979788],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013035594,0.0005403096,0.00076525984,0.0004162339,0.00012500476,0.000064871805,0.0002246192,0.00020228155,0.00013314236],"category_scores_gemma":[0.000941999,0.00046999,0.000057638114,0.0008153724,0.00020034703,0.0002876258,0.00017883768,0.00048663074,0.00003808488],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.123478025,0.024390059,0.5606612,0.00017957854,0.0023408504,0.002921414,0.02803684,0.00083509437,0.14905371,0.0000092259625,0.00019548326,0.10789855],"study_design_scores_gemma":[0.31014183,0.029905697,0.63697803,0.0008503837,0.0007600821,0.000016233269,0.0005196823,0.011102704,0.00912572,0.000017581247,0.000055536315,0.000526488],"about_ca_topic_score_codex":0.0033281466,"about_ca_topic_score_gemma":0.011621829,"teacher_disagreement_score":0.18666382,"about_ca_system_score_codex":0.00649577,"about_ca_system_score_gemma":0.0027135527,"threshold_uncertainty_score":0.9997752},"labels":[],"label_agreement":null},{"id":"W2904444738","doi":"10.1038/s41375-018-0321-8","title":"HMGCLL1 is a predictive biomarker for deep molecular response to imatinib therapy in chronic myeloid leukemia","year":2018,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Princess Margaret Cancer Foundation","keywords":"Myeloid leukemia; Imatinib; Biomarker; Tyrosine-kinase inhibitor; Cancer research; Tyrosine kinase; Imatinib mesylate; Medicine; Haematopoiesis; Myeloid; Oncology; Biology; Stem cell; Internal medicine; Cancer; Genetics; Receptor","score_opus":0.01940578935515964,"score_gpt":0.3067759477697558,"score_spread":0.2873701584145962,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2904444738","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868954,0.0010753524,0.00411205,0.0013087683,0.00028113366,0.003716241,0.00009219737,0.00021532376,0.002303549],"genre_scores_gemma":[0.9847549,0.000113919436,0.006599694,0.004272216,0.00046835945,0.0011723097,0.00008635025,0.00017540499,0.0023568238],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99626726,0.00019194478,0.0007320417,0.0011067115,0.00059067074,0.0011113685],"domain_scores_gemma":[0.99743104,0.00038094807,0.00018200952,0.0012409486,0.00030660466,0.00045844575],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007574766,0.00059843686,0.00077140843,0.00054407155,0.00015357613,0.000049023023,0.00038010697,0.00040709117,0.00061425276],"category_scores_gemma":[0.00047201657,0.00054324087,0.00030745554,0.00095121923,0.000249268,0.0001650437,0.0001414856,0.00035700048,0.0005570075],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.06618299,0.00034058306,0.006624488,0.00033272407,0.0013054366,0.00064521795,0.010647773,0.00029424054,0.76712257,0.00010976904,0.024206188,0.12218804],"study_design_scores_gemma":[0.07820289,0.017647937,0.21146064,0.0015522985,0.00041421416,0.00037011263,0.0005807599,0.05996357,0.49716407,0.0008011283,0.12997296,0.0018694345],"about_ca_topic_score_codex":0.00034366397,"about_ca_topic_score_gemma":0.00011259221,"teacher_disagreement_score":0.2699585,"about_ca_system_score_codex":0.0279196,"about_ca_system_score_gemma":0.0058219293,"threshold_uncertainty_score":0.99981415},"labels":[],"label_agreement":null},{"id":"W2904733418","doi":"10.1016/j.msard.2018.10.093","title":"Pregnancy Outcomes During the Clinical Development of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety","year":2018,"lang":"en","type":"article","venue":"Multiple Sclerosis and Related Disorders","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Cladribine; Medicine; Multiple sclerosis; Pregnancy; Clinical trial; Pediatrics; Internal medicine; Immunology","score_opus":0.05563929869226659,"score_gpt":0.2898989886019169,"score_spread":0.2342596899096503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2904733418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997939,0.00077855197,0.000052059087,0.00015496273,0.00012348632,0.00076493947,0.00004111276,0.00004726644,0.00009860943],"genre_scores_gemma":[0.9963889,0.001592951,0.0016723945,0.000025276513,0.000008029621,0.000028744511,0.00012865916,0.00003367677,0.0001213686],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969257,0.000200585,0.0016076143,0.000556297,0.0003370557,0.00037273052],"domain_scores_gemma":[0.9983076,0.00032843978,0.00043237075,0.00061803573,0.00015672694,0.00015683637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051778974,0.000313478,0.001031956,0.0004221644,0.00020352691,0.000011060185,0.00019062149,0.00029365087,0.00013899597],"category_scores_gemma":[0.0004368797,0.00019965522,0.00031588273,0.0014227469,0.00059741,0.00011330404,0.000120657845,0.00034926095,0.00000521508],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048695222,0.0011120847,0.9393899,0.000060425104,0.0025438939,0.0000011395155,0.0032852963,0.00019515467,0.0036673723,0.000004386408,0.0000039470624,0.049249448],"study_design_scores_gemma":[0.013397769,0.000266921,0.9726499,0.0009972219,0.0008918554,6.097021e-7,0.0014220806,0.008524906,0.0015946794,0.000003511083,0.00005720441,0.00019334503],"about_ca_topic_score_codex":0.0009933807,"about_ca_topic_score_gemma":0.0065758955,"teacher_disagreement_score":0.0490561,"about_ca_system_score_codex":0.00022235529,"about_ca_system_score_gemma":0.00020849591,"threshold_uncertainty_score":0.81417036},"labels":[],"label_agreement":null},{"id":"W2904943167","doi":"10.1182/blood-2018-99-117309","title":"Inhibiting the Core Autophagy Enzyme ATG4B with Novel Drugs Sensitizes Resistant Leukemic Stem/Progenitor Cells to Standard Targeted Therapy","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia; Simon Fraser University; Leukemia & Lymphoma Society of Canada; Terry Fox Research Institute; University of British Columbia","funders":"","keywords":"Stem cell; Progenitor cell; Cancer research; Myeloid leukemia; CD34; Imatinib mesylate; Haematopoiesis; Autophagy; Leukemia; K562 cells; Myeloid; Bone marrow; Medicine; Imatinib; Biology; Immunology; Cell biology; Biochemistry","score_opus":0.019366957654133217,"score_gpt":0.2521375220791523,"score_spread":0.2327705644250191,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2904943167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99553084,0.0010831477,0.00008301528,0.00048664492,0.00018254979,0.0014400494,0.00017780224,0.00022652242,0.000789414],"genre_scores_gemma":[0.9935758,0.000057097524,0.0024383205,0.0010416468,0.0009004268,0.00007507174,0.000029927813,0.0001046377,0.0017770354],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975807,0.00005677481,0.00041156184,0.00059257733,0.000722065,0.00063629996],"domain_scores_gemma":[0.9982734,0.0001608448,0.0001795487,0.0007612731,0.00035439234,0.00027055474],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033167592,0.00039730727,0.0005019039,0.000101837395,0.0003178246,0.000055255165,0.00018658876,0.00012926184,0.000109736284],"category_scores_gemma":[0.000035474397,0.00024156102,0.000114495786,0.00042688783,0.00021261157,0.00006243563,0.00008800396,0.000270872,0.0001030361],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026827676,0.00035524124,0.0007119798,0.000053791584,0.00065334147,0.00023349034,0.0038316161,0.0000034814334,0.98728377,0.00006490472,0.0025353003,0.0015902928],"study_design_scores_gemma":[0.01785477,0.0024770068,0.001620818,0.00033865203,0.00031735064,0.00023325584,0.0011088867,0.000051472718,0.96907085,0.00000956819,0.006612855,0.00030450607],"about_ca_topic_score_codex":0.0002284821,"about_ca_topic_score_gemma":0.00006551726,"teacher_disagreement_score":0.018212935,"about_ca_system_score_codex":0.000684439,"about_ca_system_score_gemma":0.0010584333,"threshold_uncertainty_score":0.98505723},"labels":[],"label_agreement":null},{"id":"W2905418023","doi":"10.1182/blood-2018-99-111294","title":"The Predictive Value of Intracellular Imatinib Levels in Chronic Myeloid Leukemia","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University; Princess Margaret Cancer Centre; University Health Network; Dalhousie University; University of Alberta; Université de Montréal; University of Ottawa; University of Calgary; Windsor Regional Hospital; Juravinski Cancer Centre; McMaster University","funders":"","keywords":"Imatinib; Medicine; Intracellular; Myeloid leukemia; Imatinib mesylate; Internal medicine; Gastroenterology; Pharmacology; Oncology; Immunology; Biology; Genetics","score_opus":0.014179183226821108,"score_gpt":0.2640143196536612,"score_spread":0.24983513642684008,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905418023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99034303,0.002116609,0.00009611989,0.00016956736,0.00014089358,0.0007000124,0.00002242108,0.000048208633,0.0063631097],"genre_scores_gemma":[0.99781895,0.00015722305,0.0006975991,0.00004501894,0.00046037527,0.000057452242,0.000012798111,0.00003350036,0.00071708654],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983638,0.00008011384,0.00046744614,0.00030827982,0.0003621018,0.00041829227],"domain_scores_gemma":[0.9987869,0.00019931493,0.00016850937,0.0006287754,0.00011764764,0.00009885204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037659833,0.00019886861,0.0003625303,0.000082974504,0.00009673371,0.000011225183,0.00020499504,0.00013335438,0.00015132311],"category_scores_gemma":[0.00022888176,0.00013856069,0.000094175775,0.0002914897,0.0003784672,0.000066632056,0.000090885536,0.00026646763,0.00010597441],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018743939,0.003711791,0.11958862,0.0013172047,0.0043031136,0.00083248684,0.012019026,0.00031273867,0.7680401,0.009578231,0.0031170782,0.07530519],"study_design_scores_gemma":[0.024259668,0.0030892221,0.22361003,0.00074309343,0.00062221906,0.00020960963,0.0003235202,0.005663967,0.7364379,0.00083317264,0.0039185174,0.00028908096],"about_ca_topic_score_codex":0.00022281108,"about_ca_topic_score_gemma":0.00010675132,"teacher_disagreement_score":0.1040214,"about_ca_system_score_codex":0.0016756393,"about_ca_system_score_gemma":0.0019502341,"threshold_uncertainty_score":0.5650341},"labels":[],"label_agreement":null},{"id":"W2905465042","doi":"10.1182/blood-2018-99-114656","title":"Second Attempt of TKI Discontinuation with Dasatinib for Treatment-Free Remission after Failing First Attempt with Imatinib: Treatment-Free Remission Accomplished By Dasatinib (TRAD) Trial","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hamilton Health Sciences; McGill University Health Centre; Alberta Hospital Edmonton; London Health Sciences Centre; Juravinski Cancer Centre; Hôpital de l'Enfant-Jésus; Princess Margaret Cancer Centre; University of Calgary; Université de Montréal; Leukemia & Lymphoma Society of Canada; Université Laval; Queen Elizabeth II Health Sciences Centre; Hôpital Maisonneuve-Rosemont; Health Sciences Centre; CancerCare Manitoba; University of Alberta Hospital; Ottawa Hospital; University Health Network","funders":"","keywords":"Discontinuation; Medicine; Dasatinib; Internal medicine; Imatinib; Imatinib mesylate; Oncology","score_opus":0.01882563202833285,"score_gpt":0.27185925639656455,"score_spread":0.2530336243682317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905465042","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896239,0.0003584655,0.00022195496,0.00073919713,0.00015936935,0.0056600235,0.0007118026,0.00018967023,0.002335591],"genre_scores_gemma":[0.9716677,0.000052804673,0.019633198,0.000077534794,0.0009118431,0.0013308164,0.0013152087,0.00021426391,0.0047966223],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99594355,0.00009605992,0.0011411262,0.0012820328,0.00075220043,0.0007850104],"domain_scores_gemma":[0.9952801,0.0005264887,0.00088519626,0.0025565985,0.00032643453,0.00042519756],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029425448,0.00090526306,0.0014175356,0.00020358255,0.00034394494,0.00007939493,0.00043098006,0.00033546783,0.0007825187],"category_scores_gemma":[0.00036551786,0.00057428615,0.00031344112,0.00035527823,0.0002978754,0.00039537955,0.00012114642,0.00015135233,0.000017067714],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4912011,0.038929492,0.23770718,0.002550853,0.011388104,0.00044236126,0.019766636,0.000013891844,0.11834792,0.000078337296,0.030744176,0.04882993],"study_design_scores_gemma":[0.6383502,0.050610363,0.008328629,0.002616112,0.004383578,0.00021140906,0.00075848587,0.0003048273,0.28261504,0.0001428046,0.010605067,0.0010735028],"about_ca_topic_score_codex":0.00032005468,"about_ca_topic_score_gemma":0.001062317,"teacher_disagreement_score":0.22937855,"about_ca_system_score_codex":0.00088834716,"about_ca_system_score_gemma":0.0007525459,"threshold_uncertainty_score":0.99967086},"labels":[],"label_agreement":null},{"id":"W2906819145","doi":"10.1182/blood-2018-99-112982","title":"Imatinib Suspension and Validation (ISAV) Study: Final Results at 79 Months","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Discontinuation; Imatinib; Medicine; Internal medicine; Imatinib mesylate; Oncology; Surgery; Myeloid leukemia; Minimal residual disease; Gastroenterology; Leukemia","score_opus":0.034307350655045366,"score_gpt":0.2990021715276285,"score_spread":0.2646948208725831,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2906819145","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99216765,0.00011275258,0.0000018394537,0.00025527674,0.00008982381,0.00068918767,0.000012371,0.0000669597,0.006604128],"genre_scores_gemma":[0.99683684,0.000022788914,0.0007617431,0.00006062586,0.00026984696,0.000017591537,0.00007450981,0.000018760004,0.0019373201],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99891096,0.00004627654,0.0002489593,0.00033625806,0.0002640426,0.00019352729],"domain_scores_gemma":[0.99926656,0.000070039,0.000089001216,0.0003815681,0.00008711123,0.00010570162],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019697762,0.00013762011,0.00020772839,0.000055351007,0.00012606209,0.000015475343,0.00004288859,0.00006295549,0.00013498047],"category_scores_gemma":[0.00019514385,0.00011263125,0.000029628809,0.00009688197,0.0000638864,0.00004852065,0.00009546195,0.00007521539,0.00023140381],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061190818,0.008326925,0.8706944,0.00021551552,0.001133319,0.0012201746,0.013808097,0.0000024293777,0.06018673,0.000119794975,0.015999286,0.022174276],"study_design_scores_gemma":[0.07952241,0.0062453565,0.7752038,0.00023527107,0.0012034146,0.0004987805,0.0004966824,0.00024447712,0.13375333,0.000121908655,0.0021640114,0.00031054948],"about_ca_topic_score_codex":0.00015741517,"about_ca_topic_score_gemma":0.0001326217,"teacher_disagreement_score":0.09549056,"about_ca_system_score_codex":0.00016896124,"about_ca_system_score_gemma":0.00008570644,"threshold_uncertainty_score":0.4592969},"labels":[],"label_agreement":null},{"id":"W2906937980","doi":"10.1016/j.cjca.2018.12.025","title":"Reversible Cabozantinib-Induced Cardiomyopathy","year":2018,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Population Health Research Institute; McMaster University; Hamilton Health Sciences","funders":"","keywords":"Cabozantinib; Medicine; Tyrosine-kinase inhibitor; Cardiomyopathy; Renal cell carcinoma; Tyrosine kinase; Internal medicine; Cancer research; Oncology; Heart failure; Cancer; Receptor","score_opus":0.024828421939104228,"score_gpt":0.2651467499347344,"score_spread":0.2403183279956302,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2906937980","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9070503,0.0006890657,0.00028468977,0.0010756311,0.0021177705,0.00015578573,0.000013551066,0.000009886276,0.088603325],"genre_scores_gemma":[0.9944561,0.00003403331,0.00038567194,0.0003881718,0.004134101,0.0000014884508,0.0000046589785,0.000022422264,0.0005733171],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.998792,0.00009807479,0.0003458672,0.00016163602,0.0001460893,0.00045633398],"domain_scores_gemma":[0.9981141,0.00004234973,0.00015411356,0.00032735878,0.0004985028,0.00086359243],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003727952,0.0001452129,0.0006545613,0.0003884529,0.00010372392,0.000011069869,0.00015638776,0.00017640473,0.00014197372],"category_scores_gemma":[0.0002925026,0.00012592883,0.00029602382,0.00021602995,0.00021597002,0.00006661339,0.000012359001,0.00029793882,0.00015457135],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00067685655,0.000016192673,0.5422445,0.00009184542,0.0038091328,0.01486531,0.0013999352,0.00007395385,0.013772553,0.00075995026,0.38275573,0.03953406],"study_design_scores_gemma":[0.0046985014,0.0024991215,0.093811,0.00012329192,0.000535466,0.015242739,0.00023115346,0.000006884949,0.0033887103,0.00012686079,0.87913483,0.00020142863],"about_ca_topic_score_codex":0.0016196244,"about_ca_topic_score_gemma":0.0010636884,"teacher_disagreement_score":0.4963791,"about_ca_system_score_codex":0.0008142016,"about_ca_system_score_gemma":0.005518232,"threshold_uncertainty_score":0.9789106},"labels":[],"label_agreement":null},{"id":"W2908337540","doi":"10.1182/blood-2018-99-119974","title":"Comparison of the Transcriptomic Signature of Pediatric Vs. Adult CML and Normal Bone Marrow Stem Cells","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Medicine; Bone marrow; Stem cell; CD34; Imatinib; Imatinib mesylate; Pediatric cancer; Myeloid leukemia; Hematopoietic stem cell transplantation; Myeloid; Transplantation; Immunology; Internal medicine; Oncology; Cancer; Biology","score_opus":0.01135950920785769,"score_gpt":0.2461413045899703,"score_spread":0.2347817953821126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908337540","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955225,0.0031630804,0.0000040588156,0.00014193117,0.00016034665,0.00036644554,0.000037232767,0.000016563794,0.00058785005],"genre_scores_gemma":[0.99888545,0.00011348431,0.00023318597,0.00008466666,0.00022716439,0.000005053861,0.000003812005,0.000017750554,0.00042940883],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990163,0.000037584814,0.00032034144,0.00018322608,0.00026188316,0.00018065596],"domain_scores_gemma":[0.9992613,0.000051834068,0.0001716228,0.00033047664,0.00011361539,0.00007111819],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007348731,0.00013770201,0.00038720036,0.000057164194,0.000038294133,0.0000032247278,0.00010206794,0.00012877659,0.00006483772],"category_scores_gemma":[0.000013078822,0.00009291104,0.00009290608,0.0001810964,0.00012997001,0.000031033633,0.00003317579,0.00017930727,0.0000075110706],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00073117705,0.0025859678,0.71516865,0.0013375299,0.0004867155,0.00002022408,0.0059046387,0.0000028170846,0.26442835,0.00008758457,0.006689736,0.0025566171],"study_design_scores_gemma":[0.0121594425,0.0010139527,0.08465852,0.00011356163,0.001593947,0.00003660264,0.00020675799,0.00011738754,0.8996135,0.0000064935366,0.00036353464,0.000116301766],"about_ca_topic_score_codex":0.000058267633,"about_ca_topic_score_gemma":0.00003799048,"teacher_disagreement_score":0.6351852,"about_ca_system_score_codex":0.000041653664,"about_ca_system_score_gemma":0.00015739801,"threshold_uncertainty_score":0.3788802},"labels":[],"label_agreement":null},{"id":"W2908902338","doi":"10.3324/haematol.2018.211235","title":"Persistence with generic imatinib for chronic myeloid leukemia: a matched cohort study","year":2019,"lang":"en","type":"letter","venue":"Haematologica","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; McGill University; Jewish General Hospital","funders":"","keywords":"Imatinib; Persistence (discontinuity); Myeloid leukemia; Medicine; Cohort; Chronic myeloid leukaemia; Oncology; Internal medicine; Cohort study; Leukemia","score_opus":0.039788586859992175,"score_gpt":0.27108964129736374,"score_spread":0.23130105443737156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908902338","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7547837,0.00378706,0.0005168826,0.18572077,0.0011922732,0.04219423,0.00033302006,0.0012765471,0.010195553],"genre_scores_gemma":[0.40172058,0.00061170245,0.019403895,0.48047787,0.0062376587,0.019147472,0.006184789,0.0011376926,0.06507836],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99480176,0.0001624035,0.0008616113,0.0018583867,0.0010444759,0.0012713857],"domain_scores_gemma":[0.9962011,0.00051908335,0.0007285132,0.0021039394,0.0003021325,0.00014521886],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0003193543,0.0011411514,0.0030484805,0.00024742758,0.00021216516,0.000072791685,0.00060562027,0.0013354464,0.0006967537],"category_scores_gemma":[0.00014440446,0.0007699041,0.0005170607,0.00035941345,0.00025558926,0.000089023306,0.00018683705,0.001864973,0.0007367447],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00066371815,0.00047147457,0.047243,0.004554394,0.003348245,0.0093994895,0.00046114385,0.000027164933,0.00008916423,0.0000073381884,0.9332115,0.000523379],"study_design_scores_gemma":[0.049947783,0.0300438,0.055997305,0.003707687,0.01651414,0.022665674,0.0015996426,0.0018390798,0.00072046154,0.00007916612,0.8121696,0.004715651],"about_ca_topic_score_codex":0.000118995755,"about_ca_topic_score_gemma":0.00003638765,"teacher_disagreement_score":0.3530631,"about_ca_system_score_codex":0.0056310077,"about_ca_system_score_gemma":0.003065775,"threshold_uncertainty_score":0.999961},"labels":[],"label_agreement":null},{"id":"W2910542347","doi":"10.1182/blood-2018-99-110543","title":"Efficacy and Safety Following Dose Reduction of Bosutinib or Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia: Analysis of the Phase 3 BFORE Trial","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Bosutinib; Medicine; Imatinib; Adverse effect; Internal medicine; Tyrosine-kinase inhibitor; Population; Tolerability; Oncology; Myeloid leukemia; Pharmacology; Nilotinib; Cancer","score_opus":0.012736563623910518,"score_gpt":0.2805123147050226,"score_spread":0.26777575108111207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2910542347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99773455,0.00012085393,0.000006286004,0.000037272137,0.00015891464,0.0017262524,0.000039797254,0.000018967896,0.00015708563],"genre_scores_gemma":[0.9991326,0.000030577296,0.00041896926,0.000013109867,0.00018258553,0.000035944184,0.00009277354,0.000024693434,0.00006874435],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99817926,0.00009379958,0.0006591331,0.000359373,0.000439939,0.00026848723],"domain_scores_gemma":[0.9986645,0.00015624902,0.00040159703,0.00058993715,0.000101316466,0.00008641283],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024894124,0.00021799724,0.0007404549,0.00025281252,0.00007710057,0.000007471353,0.000121220306,0.00012214882,0.0000907411],"category_scores_gemma":[0.0003180596,0.00012961698,0.0001944665,0.0012844272,0.0002128153,0.00009173885,0.00006519674,0.00016876188,0.0000013978071],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35218617,0.022880351,0.5120849,0.0006295759,0.020414503,0.000085546686,0.008450009,0.00027894584,0.013167986,0.000039745253,0.00019521512,0.06958703],"study_design_scores_gemma":[0.5652855,0.0064410353,0.4131348,0.00043071475,0.007284446,0.0000055482337,0.00011186492,0.0001955385,0.0069183386,0.0000025880986,0.000050826122,0.0001387931],"about_ca_topic_score_codex":0.000275756,"about_ca_topic_score_gemma":0.00025052085,"teacher_disagreement_score":0.21309932,"about_ca_system_score_codex":0.00058418995,"about_ca_system_score_gemma":0.0009243766,"threshold_uncertainty_score":0.52856266},"labels":[],"label_agreement":null},{"id":"W2913290054","doi":"10.1182/blood-2018-99-110798","title":"Bosutinib or Imatinib in Older Vs Younger Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Phase 3 BFORE Trial","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Bosutinib; Medicine; Imatinib; Internal medicine; Population; Adverse effect; Myeloid leukemia; Imatinib mesylate; Surgery; Oncology; Gastroenterology; Nilotinib","score_opus":0.015334596920880966,"score_gpt":0.28505220632130956,"score_spread":0.2697176094004286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913290054","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99399495,0.00015697024,0.0000054938696,0.00024433833,0.0002161693,0.003693642,0.00003800051,0.00006193894,0.0015885148],"genre_scores_gemma":[0.9967349,0.000037437705,0.00042409767,0.0007049151,0.0008971271,0.0005070249,0.00021853475,0.00006830576,0.00040766317],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99721545,0.00015281465,0.00064509927,0.0005840061,0.00067239645,0.00073025626],"domain_scores_gemma":[0.9984279,0.0002705947,0.00021071837,0.0008417944,0.00010306066,0.00014587611],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037810652,0.00040482444,0.0006013568,0.00020496812,0.0000976494,0.000043586548,0.0003093074,0.00019896802,0.00081035536],"category_scores_gemma":[0.00030274122,0.00022988756,0.000099200755,0.0006864824,0.00021310557,0.00021025592,0.00006462748,0.0004463079,0.0001548935],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2896604,0.04987022,0.55684257,0.00083956274,0.0014686368,0.005419876,0.025997078,0.000025829011,0.0008654268,0.0001561987,0.013894077,0.054960154],"study_design_scores_gemma":[0.7916632,0.012916327,0.18935838,0.0006023846,0.00042099183,0.00006612856,0.0002570028,0.00014576515,0.0010867782,0.000014317225,0.0031102786,0.0003584264],"about_ca_topic_score_codex":0.00056837866,"about_ca_topic_score_gemma":0.0017729118,"teacher_disagreement_score":0.50200284,"about_ca_system_score_codex":0.0017781766,"about_ca_system_score_gemma":0.0023273549,"threshold_uncertainty_score":0.9374543},"labels":[],"label_agreement":null},{"id":"W2921202997","doi":"10.1210/js.2018-00268","title":"The Bone Phenotype and Pain Response to Pamidronate in Tyrosine Kinase Inhibitor–Treated Chronic Myelogenous Leukemia","year":2019,"lang":"en","type":"article","venue":"Journal of the Endocrine Society","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Shriners Hospitals for Children - Canada; Children's Hospital of Eastern Ontario","funders":"","keywords":"Medicine; Bone pain; Bone mineral; Chronic myelogenous leukemia; Bone resorption; Dasatinib; Tibia; Imatinib; Internal medicine; Osteoporosis; Surgery; Leukemia; Myeloid leukemia","score_opus":0.006701879450432016,"score_gpt":0.24283155478938986,"score_spread":0.23612967533895785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921202997","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836967,0.005049324,0.0000067778137,0.010152569,0.00033475528,0.00065248064,0.000006055327,0.00001662844,0.00008470059],"genre_scores_gemma":[0.99365574,0.0008903419,0.00032515806,0.0009995827,0.00032803122,0.000009494642,0.0000020381567,0.00004138683,0.0037482106],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.997803,0.00038643766,0.0006015416,0.00022711788,0.0004894129,0.0004925211],"domain_scores_gemma":[0.99818987,0.0006125066,0.0003171152,0.0005327193,0.00015753428,0.00019027275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018355083,0.0002508484,0.0004758226,0.000064115455,0.00016886785,0.00003706829,0.00024310143,0.000074585005,0.00004409868],"category_scores_gemma":[0.0005629005,0.00013622,0.0003300453,0.00042978564,0.00012014397,0.00008622593,0.00020461215,0.000687314,0.000024135981],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018099422,0.0007515062,0.17775603,0.0004970111,0.0016169853,0.001498293,0.0057589025,0.0018799073,0.68098766,0.00010779764,0.04593753,0.06510894],"study_design_scores_gemma":[0.05800123,0.008668229,0.6613749,0.0027669508,0.00084350415,0.005028108,0.0026893106,0.0038094816,0.060853004,0.00039372,0.19460084,0.0009706796],"about_ca_topic_score_codex":0.00015814301,"about_ca_topic_score_gemma":0.00008018187,"teacher_disagreement_score":0.62013465,"about_ca_system_score_codex":0.0047111255,"about_ca_system_score_gemma":0.0011597761,"threshold_uncertainty_score":0.9991096},"labels":[],"label_agreement":null},{"id":"W2921446080","doi":"10.1042/bst028a333","title":"Characterization of Two New DNA Activators of the DNA-Dependent Protein Kinase","year":2000,"lang":"en","type":"article","venue":"Biochemical Society Transactions","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Icon; Citation; Library science; Web site; Information retrieval; Computer science; World Wide Web; The Internet","score_opus":0.01055007738369582,"score_gpt":0.24158061680009385,"score_spread":0.23103053941639803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921446080","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99682015,0.00003345732,0.0013003176,0.0009014336,0.000044417728,0.00061134226,0.00006406644,0.000036237496,0.00018856766],"genre_scores_gemma":[0.99589056,0.000051878298,0.0006165198,0.000085350315,0.00006886462,0.000032901196,0.000040024606,0.00001950863,0.0031944213],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99901575,0.000021114713,0.00028646685,0.00020351211,0.0003043893,0.00016879158],"domain_scores_gemma":[0.99940026,0.000017976814,0.00009381733,0.00032714164,0.00004356529,0.00011726819],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000044393826,0.00013903364,0.00022361365,0.000012262404,0.00006351005,0.0000038734042,0.00010178777,0.0001373299,0.0016941065],"category_scores_gemma":[0.000007873737,0.000103602026,0.00038648027,0.00027343648,0.00012702138,0.000056376946,0.000005188954,0.00018762822,0.000008558518],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007026746,0.00038054338,0.0001401891,0.00007144763,0.00015404275,3.4332342e-7,0.00035929948,0.000003680505,0.9936677,0.0000072822827,0.0001002909,0.0050448636],"study_design_scores_gemma":[0.002364211,0.000054864682,0.0030574414,0.00013243992,0.00019212595,0.0000078601615,0.0000411699,0.00005864798,0.9931552,0.00001979696,0.0008354202,0.00008081764],"about_ca_topic_score_codex":0.00019410765,"about_ca_topic_score_gemma":0.000002979154,"teacher_disagreement_score":0.0049640457,"about_ca_system_score_codex":0.00033511937,"about_ca_system_score_gemma":0.00035286343,"threshold_uncertainty_score":0.99921846},"labels":[],"label_agreement":null},{"id":"W2945758629","doi":"10.1016/j.drudis.2019.05.007","title":"Current outlook on drug resistance in chronic myeloid leukemia (CML) and potential therapeutic options","year":2019,"lang":"en","type":"review","venue":"Drug Discovery Today","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency; University of Alberta","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Alberta Innovates; Women and Children's Health Research Institute; Leukemia and Lymphoma Society of Canada","keywords":"Myeloid leukemia; Medicine; Drug; Drug resistance; Drug discovery; Pharmacology; Immunology; Bioinformatics; Biology; Genetics","score_opus":0.028393766034187154,"score_gpt":0.3182430373525468,"score_spread":0.28984927131835964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2945758629","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001389678,0.9921653,0.000012866738,0.00020376683,0.0011697514,0.0029897306,0.00025770886,0.00008530067,0.0017258993],"genre_scores_gemma":[0.0020120912,0.963233,0.00003913167,0.000101840626,0.00060746656,0.000386185,0.0009449108,0.00018807402,0.032487307],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99551326,0.00036443016,0.0010953787,0.0014441843,0.00072145945,0.0008612588],"domain_scores_gemma":[0.9974502,0.00031038994,0.000504338,0.0014604073,0.00004338467,0.00023131435],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00038043005,0.0010948074,0.0027272617,0.00054333603,0.00012845967,0.00014821903,0.00039532038,0.0003352399,0.0001316584],"category_scores_gemma":[0.000040566163,0.0008541981,0.0007629003,0.000471647,0.00019429039,0.0003273757,0.00022051952,0.0015408238,0.0005576905],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0002628208,0.0005829479,0.000074232434,0.047752436,0.00095851155,0.00032715418,0.0004714908,0.00007377508,0.000009526404,0.0022886072,0.009921654,0.93727684],"study_design_scores_gemma":[0.0033630705,0.000089452,0.00025187532,0.041947473,0.0020637289,0.000053480973,0.000029948405,0.00003271136,0.000006452257,0.00013075958,0.9512816,0.00074942654],"about_ca_topic_score_codex":0.000096171316,"about_ca_topic_score_gemma":0.0003121114,"teacher_disagreement_score":0.94135994,"about_ca_system_score_codex":0.01430803,"about_ca_system_score_gemma":0.006295533,"threshold_uncertainty_score":0.9993909},"labels":[],"label_agreement":null},{"id":"W2947126667","doi":"10.1136/annrheumdis-2019-eular.2325","title":"THU0117 PHARMACOKINETICS AND SHORT-TERM SAFETY OF FILGOTINIB, A SELECTIVE JANUS KINASE 1 INHIBITOR, IN SUBJECTS WITH MODERATE HEPATIC IMPAIRMENT","year":2019,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Japan Society for the Promotion of Science; Pfizer Japan; AbbVie Canada; Astellas Foundation for Research on Metabolic Disorders; Chugai Pharmaceutical; Mitsubishi Tanabe Pharma Corporation; Bristol-Myers Squibb; AstraZeneca; Teijin Pharma; Pfizer; Japan Blood Products Organization; Ono Pharmaceutical","keywords":"Medicine; Pharmacokinetics; Janus kinase inhibitor; Term (time); Pharmacology; Internal medicine; Janus kinase","score_opus":0.018262813676154774,"score_gpt":0.28580252139100093,"score_spread":0.26753970771484614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947126667","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99652517,0.0012853992,0.000004417444,0.00027186272,0.000048400794,0.0014448644,0.00009013372,0.000015701742,0.00031407748],"genre_scores_gemma":[0.998845,0.00074336916,0.00008234861,0.00011057665,0.000010269451,0.000043862463,0.000020496369,0.00002631624,0.00011780861],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99845725,0.000113514034,0.00048044298,0.0002601001,0.00040752967,0.00028116285],"domain_scores_gemma":[0.9988315,0.00022119924,0.00022891852,0.00044073042,0.00013311928,0.0001445286],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000144722,0.0002389017,0.000614733,0.000105202824,0.00003153561,0.000009432403,0.000120919394,0.00004124034,0.0000698583],"category_scores_gemma":[0.00010379276,0.0001495649,0.0001162875,0.00024713526,0.00013488285,0.0000886325,0.00009688183,0.00010955912,0.0000037273403],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063600494,0.0030140313,0.9662539,0.0041807448,0.0011917796,0.000051314626,0.002859857,0.001137412,0.0013647722,0.00005326257,0.00047010288,0.013062794],"study_design_scores_gemma":[0.00815471,0.0014829037,0.9363997,0.0054570897,0.0005152764,0.00003501785,0.00024966314,0.008043173,0.03917464,0.00024887887,0.00000653341,0.0002324436],"about_ca_topic_score_codex":0.00017401976,"about_ca_topic_score_gemma":0.00003187973,"teacher_disagreement_score":0.037809864,"about_ca_system_score_codex":0.00011541082,"about_ca_system_score_gemma":0.00044446715,"threshold_uncertainty_score":0.609908},"labels":[],"label_agreement":null},{"id":"W2949176444","doi":"10.3892/ol.2019.10518","title":"Imatinib mesylate and nilotinib decrease synthesis of bone matrix in�vitro","year":2019,"lang":"en","type":"article","venue":"Oncology Letters","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Montreal Children's Hospital","funders":"Technische Universität Dresden","keywords":"RANKL; Osteoprotegerin; Bone remodeling; Osteoblast; Imatinib mesylate; Nilotinib; Cancer research; Osteocalcin; Internal medicine; Medicine; Chemistry; Endocrinology; Myeloid leukemia; Activator (genetics); Imatinib; Alkaline phosphatase; Receptor; In vitro; Biochemistry","score_opus":0.009162864746320094,"score_gpt":0.283428120952737,"score_spread":0.2742652562064169,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949176444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891637,0.000265425,0.0000039158667,0.0070454506,0.00010920751,0.00048901915,0.000011215157,0.000027533377,0.0028845218],"genre_scores_gemma":[0.9928103,0.00006149873,0.0046648174,0.0020442475,0.00003837614,0.00004105098,0.000014632755,0.000025015343,0.0003000536],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99881196,0.0000933544,0.0003728777,0.00028797856,0.00014493558,0.00028890674],"domain_scores_gemma":[0.99886054,0.00049900706,0.00016630895,0.00030871463,0.000020304518,0.0001451544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026695326,0.0001600207,0.0006605546,0.00018992796,0.000015586702,0.0000031594557,0.00005703798,0.00012859637,0.00034126514],"category_scores_gemma":[0.00024122605,0.00014122637,0.000074512354,0.00012309247,0.00012819949,0.000050502284,0.00005405768,0.00018115928,0.00011553448],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022682925,0.00050151517,0.10622099,0.00042573627,0.00026261524,0.0009963614,0.0005108079,0.000009940358,0.86505866,0.00007426085,0.0019054498,0.021765353],"study_design_scores_gemma":[0.064002246,0.002657228,0.4291045,0.0013110696,0.001840949,0.0031420854,0.0008512845,0.0017864086,0.46755055,0.00015597416,0.02637269,0.0012250051],"about_ca_topic_score_codex":0.00021153873,"about_ca_topic_score_gemma":0.000012712,"teacher_disagreement_score":0.3975081,"about_ca_system_score_codex":0.0005441266,"about_ca_system_score_gemma":0.00025951027,"threshold_uncertainty_score":0.5759044},"labels":[],"label_agreement":null},{"id":"W2949279564","doi":"10.1097/01.hs9.0000561604.66251.2e","title":"S831 CPI‐0610, A BROMODOMAIN AND EXTRATERMINAL DOMAIN (BET) INHIBITOR, REDUCES PRO‐INFLAMMATORY CYTOKINES, BONE MARROW FIBROSIS AND THE NUMBER OF TRANSFUSIONS IN MYELOFIBROSIS PATIENTS","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Myelofibrosis; Myeloproliferative neoplasm; Ruxolitinib; Bone marrow; Anemia; Internal medicine; Cancer research","score_opus":0.0057436719220246395,"score_gpt":0.22666235977413904,"score_spread":0.2209186878521144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949279564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940589,0.0011449317,0.0000020441485,0.00037795486,0.00008665022,0.0016733714,0.00003513505,0.000032986696,0.0025880313],"genre_scores_gemma":[0.99640596,0.00026675622,0.0016640733,0.000058468548,0.000061741026,0.00013708281,0.00002992883,0.000050798502,0.001325172],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978751,0.00015990288,0.00061452657,0.000517987,0.00044056363,0.0003919145],"domain_scores_gemma":[0.99893665,0.00019982764,0.00018501013,0.0004412843,0.000071353505,0.00016589307],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030019463,0.0003413877,0.0007146267,0.00006380912,0.00008645154,0.000027022414,0.00009492421,0.00021346664,0.00056893186],"category_scores_gemma":[0.000042964046,0.00023710227,0.00012080289,0.00025329666,0.0003708327,0.00017410691,0.00009178545,0.00026384552,0.000026569041],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042401673,0.00058912655,0.8706703,0.0015940279,0.00019002918,0.00009515046,0.0046028555,0.0000020310977,0.107264176,0.00058520195,0.0009035854,0.009263345],"study_design_scores_gemma":[0.068672456,0.00089340145,0.8905321,0.0038026716,0.00044610695,0.00055427005,0.002458025,0.00018477296,0.028235834,0.0014084477,0.002026658,0.00078530796],"about_ca_topic_score_codex":0.00028256187,"about_ca_topic_score_gemma":0.00014277341,"teacher_disagreement_score":0.07902834,"about_ca_system_score_codex":0.00022937068,"about_ca_system_score_gemma":0.00023659214,"threshold_uncertainty_score":0.966875},"labels":[],"label_agreement":null},{"id":"W2949456808","doi":"10.1097/01.hs9.0000566328.51622.ab","title":"PB1958 SUDDEN ONSET HEARING AND VISUAL LOSS: AN UNUSUAL PRESENTATION OF CHRONIC PHASE CHRONIC MYELOID LEUKEMIA","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Hearing loss; Sensorineural hearing loss; Tinnitus; Vertigo; Chronic myelogenous leukemia; Pediatrics; Audiology; Surgery; Leukemia; Internal medicine","score_opus":0.01761472004695952,"score_gpt":0.3226365060866205,"score_spread":0.30502178603966096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949456808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99401593,0.002876875,0.00007171827,0.0000821399,0.0001649566,0.0010283915,0.000025262014,0.00010510507,0.0016296197],"genre_scores_gemma":[0.9959463,0.0002668086,0.00030450904,0.000052973563,0.00037116124,0.000037798123,0.00025807152,0.00007372625,0.002688663],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99786395,0.00007743591,0.00048437927,0.0006017213,0.0004709778,0.00050156016],"domain_scores_gemma":[0.9988121,0.00010091184,0.0002015166,0.0005150175,0.000093599,0.00027690225],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00017721928,0.00032451432,0.00059229136,0.00009385812,0.000071284936,0.00002862364,0.00011084377,0.00020659858,0.0018053561],"category_scores_gemma":[0.00003801988,0.00030957587,0.00010819813,0.00024601258,0.00015588805,0.00034240392,0.0001072058,0.00029956794,0.00019274635],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00426147,0.0040528825,0.27774712,0.008449307,0.0017806242,0.0008401483,0.0037848656,0.0007846051,0.39964992,0.0006699131,0.00356929,0.29440984],"study_design_scores_gemma":[0.1426731,0.03268188,0.19933096,0.0041132285,0.0016877488,0.0028635017,0.0037731943,0.112478055,0.4877296,0.00027832435,0.010072928,0.002317471],"about_ca_topic_score_codex":0.0006799405,"about_ca_topic_score_gemma":0.0003014803,"teacher_disagreement_score":0.29209235,"about_ca_system_score_codex":0.002749033,"about_ca_system_score_gemma":0.0019523137,"threshold_uncertainty_score":0.9999356},"labels":[],"label_agreement":null},{"id":"W2949541642","doi":"10.1101/157966","title":"SHP2 Is Required for BCR-ABL1-Induced Hematologic Neoplasms","year":2017,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Institutes of Health; Princess Margaret Cancer Foundation","keywords":"Cancer research; Philadelphia chromosome; Tyrosine kinase; Myeloid leukemia; ABL; breakpoint cluster region; Biology; Leukemia; MAPK/ERK pathway; Myeloid; Kinase; Signal transduction; Immunology; Cell biology; Genetics; Receptor; Chromosomal translocation","score_opus":0.040930169570335594,"score_gpt":0.2825276387440098,"score_spread":0.24159746917367422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949541642","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98785734,0.0016690483,0.00042968025,0.0017083026,0.002601939,0.0041631493,0.00059155835,0.00085929205,0.0001196648],"genre_scores_gemma":[0.98513025,0.00034810687,0.010846528,0.0007640112,0.0010139791,0.0013841153,0.000003957732,0.0003448216,0.0001642537],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99481165,0.00008735818,0.0009939002,0.0021275142,0.0007115985,0.0012679634],"domain_scores_gemma":[0.99255043,0.0001890276,0.0011566477,0.0045902827,0.00081664923,0.0006969823],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0006491177,0.0012069824,0.001948969,0.00037452354,0.00047638392,0.00029516142,0.0010040379,0.0016258851,0.00018860851],"category_scores_gemma":[0.0011259229,0.0011754511,0.000667819,0.00023466915,0.00020768454,0.00020497409,0.00076794944,0.0011074103,0.00038410097],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008081511,0.0010489457,0.013206544,0.0053215423,0.0027147469,0.0011441655,0.000067723944,0.0000074012873,0.9601652,0.0009396477,0.014545255,0.000030702457],"study_design_scores_gemma":[0.0110663045,0.0006995821,0.042635538,0.00333359,0.0020252613,9.806224e-7,0.0000071503982,0.0010813876,0.91670597,0.00003142654,0.020253755,0.0021590504],"about_ca_topic_score_codex":0.00016286729,"about_ca_topic_score_gemma":0.0000052226783,"teacher_disagreement_score":0.0434592,"about_ca_system_score_codex":0.0023804612,"about_ca_system_score_gemma":0.0037088254,"threshold_uncertainty_score":0.9996702},"labels":[],"label_agreement":null},{"id":"W2950165149","doi":"10.1097/01.hs9.0000566236.65976.7d","title":"PB1935 REAL LIFE EXPERIENCE IN CML PATIENTS IN CANARY ISLAND","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Utilities Corporation","funders":"","keywords":"Medicine; Imatinib; Internal medicine; Cumulative incidence; Myeloid leukemia; Incidence (geometry); Dasatinib; Gastroenterology; Cohort","score_opus":0.013506230120531003,"score_gpt":0.2677709842224399,"score_spread":0.2542647541019089,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950165149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96782666,0.00020549414,6.1444115e-7,0.000093973234,0.00014862466,0.0005370488,0.0000060090533,0.000024442066,0.031157117],"genre_scores_gemma":[0.9958448,0.000094360155,0.00011152597,0.0002827313,0.00004237166,0.000047506124,0.000041549283,0.000023540206,0.0035116517],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987731,0.000028373239,0.0002784695,0.00032890795,0.00025699515,0.00033415403],"domain_scores_gemma":[0.9993757,0.00004139937,0.000051984403,0.00036301924,0.000025847683,0.00014203542],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000052623014,0.00015511457,0.0003081323,0.000054479453,0.000013231038,0.0000058985506,0.000082207145,0.0001074778,0.002098243],"category_scores_gemma":[0.00006134595,0.00013711509,0.000037533468,0.00023843124,0.000026355443,0.00009124079,0.000049939074,0.00018458047,0.00032989442],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014562998,0.0002375468,0.9950233,0.0000718946,0.000010515271,0.0001448401,0.0018866006,0.000012235241,0.00011697992,0.000023178129,0.0013250922,0.0010021504],"study_design_scores_gemma":[0.009148682,0.00025072592,0.98635256,0.0003268611,0.0000091679085,0.000010147798,0.0010179151,0.00035398177,0.00032877014,0.000015181037,0.0020182522,0.00016773587],"about_ca_topic_score_codex":0.011411833,"about_ca_topic_score_gemma":0.012814908,"teacher_disagreement_score":0.028018089,"about_ca_system_score_codex":0.0009169813,"about_ca_system_score_gemma":0.0004085505,"threshold_uncertainty_score":0.998814},"labels":[],"label_agreement":null},{"id":"W2950424869","doi":"10.1002/pbc.27827","title":"Management of chronic myeloid leukemia in children and adolescents: Recommendations from the Children's Oncology Group CML Working Group","year":2019,"lang":"en","type":"review","venue":"Pediatric Blood & Cancer","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's Hospital of Eastern Ontario; BC Children's Hospital; Centre Hospitalier Universitaire Sainte-Justine; Hamilton Health Sciences; McMaster Children's Hospital","funders":"National Cancer Institute; National Institutes of Health","keywords":"Medicine; Myeloid leukemia; Disease; Leukemia; Pediatrics; Internal medicine; Oncology","score_opus":0.022160527744497716,"score_gpt":0.3067136168058835,"score_spread":0.28455308906138577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950424869","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011573764,0.98266995,0.000006020462,0.000110898385,0.00063916144,0.0043263733,0.0004154954,0.000052649484,0.00020567185],"genre_scores_gemma":[0.0057866443,0.98838794,0.0003304055,0.000122367,0.0025681295,0.0007226612,0.0018191439,0.00013915326,0.00012353508],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961217,0.00029711754,0.001287606,0.0011423484,0.0004576673,0.00069355464],"domain_scores_gemma":[0.9973972,0.00029901526,0.0010669847,0.0010341462,0.00003584262,0.0001668364],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037060326,0.0007774594,0.0023779604,0.00036246225,0.000103636936,0.000029941471,0.00055659283,0.0005605778,0.00029007555],"category_scores_gemma":[0.000019175186,0.0005760781,0.00044468974,0.001004711,0.00010633059,0.00008656269,0.0004960633,0.0012753975,0.000048910115],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000031048916,0.00038601668,0.09850524,0.006146417,0.0022361104,0.000024460442,0.00006261313,0.0000026551581,9.817454e-8,0.0000265584,0.0009960823,0.8915827],"study_design_scores_gemma":[0.022947049,0.0008331969,0.35416365,0.0651643,0.06827488,0.00026399936,0.000052644995,0.000014811643,6.238681e-7,0.000028438635,0.4868178,0.0014386256],"about_ca_topic_score_codex":0.0037407351,"about_ca_topic_score_gemma":0.0005579395,"teacher_disagreement_score":0.89014405,"about_ca_system_score_codex":0.0062000137,"about_ca_system_score_gemma":0.0019564582,"threshold_uncertainty_score":0.9996691},"labels":[],"label_agreement":null},{"id":"W2950655888","doi":"10.1038/s41375-019-0512-y","title":"Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia","year":2019,"lang":"en","type":"review","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":149,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute; National Institute for Health and Care Research; Howard Hughes Medical Institute","keywords":"Myeloid leukemia; Disease; Medicine; Drug resistance; Cancer; Bioinformatics; Intensive care medicine; Oncology; Internal medicine; Biology; Genetics","score_opus":0.05262389046321067,"score_gpt":0.3617774958511126,"score_spread":0.30915360538790193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950655888","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00088867615,0.98429143,0.001363216,0.00012652572,0.0007751115,0.010299636,0.00015751006,0.00016023875,0.0019376632],"genre_scores_gemma":[0.0006414769,0.9870182,0.003526612,0.00028748377,0.0011362546,0.0026400378,0.002623463,0.00031543017,0.0018110342],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9950126,0.00040246014,0.0015952218,0.001303146,0.0006447648,0.0010418036],"domain_scores_gemma":[0.9949392,0.0016397726,0.0011862805,0.0019001133,0.00013372833,0.00020091102],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012169243,0.0010555625,0.0029504215,0.00043682937,0.00025045255,0.00013475903,0.00068236794,0.0008967265,0.00027913452],"category_scores_gemma":[0.00028352605,0.0007228065,0.0012883822,0.00060241664,0.00014326724,0.00013141677,0.00017252559,0.00210843,0.0006750755],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00007772046,0.000056099925,0.00027112948,0.023185553,0.00061828987,0.00003613306,0.00004432581,0.0007755064,0.000013547032,0.00015421287,0.0011037296,0.97366375],"study_design_scores_gemma":[0.0073389052,0.0004160585,0.0004967458,0.012553832,0.00404287,0.000054347256,0.000021634092,0.0075505013,0.0000070908413,0.000060496648,0.96678746,0.00067006744],"about_ca_topic_score_codex":0.00060133764,"about_ca_topic_score_gemma":0.00015358298,"teacher_disagreement_score":0.9729937,"about_ca_system_score_codex":0.12828366,"about_ca_system_score_gemma":0.04988622,"threshold_uncertainty_score":0.9995223},"labels":[],"label_agreement":null},{"id":"W2950895705","doi":"10.1097/01.hs9.0000559856.05874.69","title":"PF411 ENESTOP 192‐WK RESULTS: DURABILITY AND IMPACT ON QUALITY OF LIFE OF TREATMENT‐FREE REMISSION (TFR) FOLLOWING SECOND‐LINE (2L) NILOTINIB (NIL) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA (CML)","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Nilotinib; Internal medicine; Gastroenterology; Imatinib mesylate; Surgery; Myeloid leukemia; Imatinib","score_opus":0.018766925244077012,"score_gpt":0.2870449102057383,"score_spread":0.2682779849616613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950895705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944503,0.0007880774,0.0000026735847,0.00009154116,0.000112306974,0.0018405057,0.0002346119,0.000057462414,0.0024225398],"genre_scores_gemma":[0.9973477,0.00009596095,0.00038977037,0.000045691646,0.00006928312,0.00003551834,0.00027094717,0.00007321791,0.0016718996],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961252,0.00024189356,0.0014200892,0.00094767363,0.00068856747,0.0005765404],"domain_scores_gemma":[0.99638635,0.00056179904,0.0007491121,0.0017594226,0.00016330683,0.00038001832],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00059740443,0.00061302504,0.0016436265,0.00012632465,0.00005409405,0.00001134651,0.00020614442,0.0003155936,0.00058808026],"category_scores_gemma":[0.0007003965,0.00041840374,0.00033063808,0.0004287875,0.00013813414,0.00019663,0.000115590396,0.00033856713,0.00002076909],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012975692,0.0014001274,0.96845824,0.0012924195,0.00048950966,0.00002341887,0.0007646322,0.00029061592,0.0066626305,0.00001988854,0.00019714491,0.007425671],"study_design_scores_gemma":[0.07560471,0.014283875,0.89184326,0.0019205387,0.00020698398,0.000010214236,0.0002904111,0.00025998263,0.014678538,0.000036644695,0.00041881672,0.00044605072],"about_ca_topic_score_codex":0.0040202183,"about_ca_topic_score_gemma":0.0014589488,"teacher_disagreement_score":0.076615006,"about_ca_system_score_codex":0.007962736,"about_ca_system_score_gemma":0.002661047,"threshold_uncertainty_score":0.9998268},"labels":[],"label_agreement":null},{"id":"W2951038309","doi":"10.1016/s2352-3026(19)30112-7","title":"The true value of second-generation TKIs as first-line therapy in chronic myeloid leukaemia","year":2019,"lang":"en","type":"letter","venue":"The Lancet Haematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Life expectancy; Imatinib; Myeloid leukemia; Population; Chronic myeloid leukaemia; Myeloid; Oncology; Internal medicine; Immunology","score_opus":0.04028012513636689,"score_gpt":0.30244136964268353,"score_spread":0.2621612445063166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951038309","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4538424,0.010050687,0.000009606929,0.5300012,0.0011099703,0.002030157,0.000061796825,0.00006685714,0.0028273228],"genre_scores_gemma":[0.48602527,0.019114574,0.00012846428,0.46105638,0.013971846,0.00071321527,0.0016172702,0.00029661163,0.017076345],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965749,0.00051751686,0.00091057376,0.0006337199,0.00046414524,0.00089915335],"domain_scores_gemma":[0.9958783,0.0012636062,0.0006379882,0.002074221,0.000106724474,0.00003917803],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00065882906,0.00056845095,0.002291528,0.0001652342,0.00015503044,0.000025722027,0.0008002711,0.0011232065,0.000708436],"category_scores_gemma":[0.0001727682,0.00031589545,0.000280398,0.00026732718,0.0004143443,0.000053450767,0.00013438262,0.0023139226,0.00045019208],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049678766,0.0000632538,0.0013319113,0.0010227977,0.0006728305,0.000952914,0.00054985326,0.0001797032,0.0010938103,0.0014641046,0.9892356,0.0029364834],"study_design_scores_gemma":[0.010680248,0.0010935419,0.0018553656,0.00045953057,0.00023313261,0.0026021842,0.000022471431,0.0012071162,0.0049100933,0.00095663447,0.97557116,0.00040855224],"about_ca_topic_score_codex":0.00043208545,"about_ca_topic_score_gemma":0.0016209817,"teacher_disagreement_score":0.06894481,"about_ca_system_score_codex":0.0017240086,"about_ca_system_score_gemma":0.0017893638,"threshold_uncertainty_score":0.9999878},"labels":[],"label_agreement":null},{"id":"W2951051106","doi":"10.1097/01.hs9.0000559844.15284.b3","title":"PF408 DASFREE 2‐YEAR UPDATE: DASATINIB DISCONTINUATION IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML‐CP) AND DEEP MOLECULAR RESPONSE (DMR)","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Dasatinib; Discontinuation; Medicine; Internal medicine; Clinical endpoint; Oncology; Myeloid leukemia; Imatinib; Gastroenterology; Clinical trial","score_opus":0.005851570532110407,"score_gpt":0.24902571653131772,"score_spread":0.2431741459992073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951051106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942794,0.002048526,0.00006783259,0.00018656979,0.000081982456,0.002197171,0.00002120783,0.000071480725,0.0010458637],"genre_scores_gemma":[0.9973669,0.00016028307,0.00081140915,0.00013779356,0.00007142683,0.00014270938,0.00032570603,0.00010947618,0.000874272],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99691963,0.00021697184,0.0006324979,0.00089906005,0.00060079986,0.0007310296],"domain_scores_gemma":[0.9983943,0.0001189456,0.00023156246,0.0009442504,0.00008570366,0.00022525141],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00039987318,0.0004867145,0.0007114866,0.00020454092,0.000049063445,0.00004240977,0.00018276733,0.00025877057,0.0010558772],"category_scores_gemma":[0.00013083822,0.0004234954,0.00007804822,0.00056450587,0.00012566011,0.00033477994,0.00013070146,0.00052714336,0.0002895137],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029650146,0.0024167565,0.80508864,0.001431083,0.0005340925,0.0014929479,0.0027805502,0.0023824451,0.052113824,0.000539662,0.0006821154,0.10088773],"study_design_scores_gemma":[0.23892553,0.01297415,0.70310783,0.0034645463,0.0003466915,0.00011140299,0.000758032,0.012538692,0.019776266,0.00012270462,0.0062557855,0.0016183333],"about_ca_topic_score_codex":0.00037868955,"about_ca_topic_score_gemma":0.0019014947,"teacher_disagreement_score":0.2092754,"about_ca_system_score_codex":0.011084444,"about_ca_system_score_gemma":0.0022578642,"threshold_uncertainty_score":0.9998573},"labels":[],"label_agreement":null},{"id":"W2952334241","doi":"10.1089/scd.2018.0196","title":"<i>BCR-Abl</i> Silencing by siRNA: A Potent Approach to Sensitize Chronic Myeloid Leukemia Cells to Tyrosine Kinase Inhibitor Therapy","year":2018,"lang":"en","type":"article","venue":"Stem Cells and Development","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"K562 cells; Myeloid leukemia; Biology; Cancer research; Tyrosine kinase; Gene silencing; Imatinib; Small interfering RNA; ABL; Chronic myelogenous leukemia; Jurkat cells; Leukemia; Tyrosine-kinase inhibitor; Pharmacology; Immunology; Transfection; Cell culture; Cell biology; Cancer; Signal transduction; Immune system; T cell; Gene; Biochemistry","score_opus":0.0156116221053003,"score_gpt":0.226286041159996,"score_spread":0.21067441905469572,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952334241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898428,0.002060995,0.0017006198,0.00031412786,0.0006110063,0.0022252584,0.00003910964,0.0001552409,0.0030508554],"genre_scores_gemma":[0.9659053,0.0004993074,0.021223081,0.0033440453,0.0007295437,0.0002045661,0.00006424827,0.000121301615,0.007908626],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9965626,0.0000594397,0.0006675436,0.001085888,0.0006784823,0.00094602635],"domain_scores_gemma":[0.9981331,0.000051693914,0.0001293113,0.00057153834,0.00020592228,0.0009084162],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036172927,0.00061257026,0.0007088703,0.00018643835,0.000326248,0.00009102598,0.00016051462,0.0001974537,0.00007151787],"category_scores_gemma":[0.0000058315954,0.0005056558,0.00008675499,0.00040307938,0.00009145702,0.000081051825,0.00024975985,0.00023489127,0.0006026892],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004958485,0.000357134,0.00017352068,0.00026822247,0.00022803326,0.0000905234,0.004734293,0.000056970777,0.8449054,0.0000062738213,0.046563677,0.10212014],"study_design_scores_gemma":[0.0044634915,0.00096879166,0.00051640935,0.00033972997,0.000039646464,0.00006357307,0.00048372525,0.00015303986,0.84574014,0.000001321384,0.1466841,0.00054603803],"about_ca_topic_score_codex":0.00018072328,"about_ca_topic_score_gemma":0.000024104209,"teacher_disagreement_score":0.1015741,"about_ca_system_score_codex":0.004451379,"about_ca_system_score_gemma":0.0017500634,"threshold_uncertainty_score":0.9997395},"labels":[],"label_agreement":null},{"id":"W2953435662","doi":"10.1182/blood.2019001014","title":"Yet do much less...so much less!","year":2019,"lang":"en","type":"letter","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Discontinuation; Myeloid leukemia; Medicine; Tyrosine kinase; Polymerase chain reaction; Oncology; Internal medicine; Immunology; Intensive care medicine; Cancer research; Biology; Genetics; Receptor; Gene","score_opus":0.02532328184483203,"score_gpt":0.2614187806101923,"score_spread":0.23609549876536026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953435662","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.40101534,0.009847767,0.000011292674,0.4953594,0.0035414319,0.0035662672,0.00061212626,0.0006930644,0.08535332],"genre_scores_gemma":[0.05116451,0.00087877805,0.0011537662,0.7385037,0.017355446,0.00032512288,0.0058886046,0.00071961567,0.18401048],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961685,0.00010600115,0.00058685645,0.0011391095,0.0010231443,0.0009763952],"domain_scores_gemma":[0.99712443,0.00027281523,0.0003112122,0.0019940345,0.00014571974,0.00015180284],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.0001600955,0.0008056448,0.0013220174,0.0002912336,0.00010635328,0.00009552732,0.00046908003,0.0017101566,0.0011926091],"category_scores_gemma":[0.0001144251,0.0006956071,0.0004454138,0.0002358431,0.00014257505,0.00007441529,0.00020440071,0.0026381994,0.003622294],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030728963,0.000465123,0.0037345388,0.0009862148,0.001217271,0.004663532,0.00018769316,2.3516402e-7,0.00021828403,0.000018898285,0.98591745,0.002560011],"study_design_scores_gemma":[0.01425222,0.00036125793,0.0008407516,0.0010265482,0.0024016295,0.0009997013,0.00008030581,0.000004714046,0.0017319114,0.00008623095,0.977539,0.0006757244],"about_ca_topic_score_codex":0.00044435728,"about_ca_topic_score_gemma":0.000023739369,"teacher_disagreement_score":0.34985083,"about_ca_system_score_codex":0.00082822173,"about_ca_system_score_gemma":0.0016316294,"threshold_uncertainty_score":0.99972045},"labels":[],"label_agreement":null},{"id":"W2953589658","doi":"10.1007/s40258-019-00489-0","title":"Cost Effectiveness of the Third-Generation Tyrosine Kinase Inhibitor (TKI) Ponatinib, vs. Second-Generation TKIs or Stem Cell Transplant, as Third-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia","year":2019,"lang":"en","type":"article","venue":"Applied Health Economics and Health Policy","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Incyte; Ariad Pharmaceuticals","keywords":"Ponatinib; Medicine; Myeloid leukemia; Dasatinib; Tyrosine-kinase inhibitor; Tyrosine kinase; Health economics; Stem cell; Quality of Life Research; Internal medicine; Imatinib; Cancer research; Oncology; Public health; Cancer; Biology; Receptor; Pathology","score_opus":0.06399726909779262,"score_gpt":0.35767961196601733,"score_spread":0.2936823428682247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953589658","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97616637,0.0027497995,0.00010464083,0.006479754,0.0005099939,0.012296783,0.0011584831,0.000056333978,0.00047782838],"genre_scores_gemma":[0.97825974,0.011647779,0.00026909052,0.0043613575,0.0019255826,0.0011890158,0.0013576966,0.00010946201,0.0008802518],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99656147,0.00016202667,0.00133318,0.00086547737,0.00016498203,0.0009128562],"domain_scores_gemma":[0.99748635,0.00025676383,0.0009167374,0.00071123266,0.000081902355,0.0005470214],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010495362,0.0005549421,0.0013501681,0.0002357744,0.00050979515,0.000041408544,0.00014959472,0.00028839387,0.00006285273],"category_scores_gemma":[0.000006585999,0.00041812094,0.00019286525,0.00021893476,0.00009481184,0.00011259566,0.000046787758,0.00028000723,0.00003280632],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.026008531,0.006651496,0.001953473,0.06793061,0.0018084395,0.00001496085,0.017065713,0.017332112,0.14766124,0.1541635,0.010808777,0.54860115],"study_design_scores_gemma":[0.22980152,0.057694837,0.007377323,0.0020823998,0.0005268834,0.00023401153,0.00041632255,0.088942915,0.42425653,0.00035633406,0.18640181,0.0019090849],"about_ca_topic_score_codex":0.004029855,"about_ca_topic_score_gemma":0.007773013,"teacher_disagreement_score":0.5466921,"about_ca_system_score_codex":0.019162057,"about_ca_system_score_gemma":0.024288414,"threshold_uncertainty_score":0.9998271},"labels":[],"label_agreement":null},{"id":"W2954158294","doi":"10.14740/jh519","title":"Large Vessel Vasculitis as a Possible Mechanism of Vascular Side Effects of Ponatinib: A Case Report","year":2019,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Ponatinib; Vasculitis; Arteriosclerosis; Mechanism (biology); Cardiology; Internal medicine; Pathology; Disease; Receptor","score_opus":0.006972108121307305,"score_gpt":0.2719501417185509,"score_spread":0.2649780335972436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954158294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99424076,0.0026356175,0.00046430738,0.0001967227,0.00042601913,0.0004459168,0.000004023392,0.000010508796,0.0015761022],"genre_scores_gemma":[0.9971683,0.00013199111,0.0021715034,0.00009679734,0.000050773837,0.000005715239,0.0000045453994,0.000030508885,0.00033983742],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9977481,0.0001235449,0.0011246162,0.00020480374,0.0004944801,0.00030449798],"domain_scores_gemma":[0.99723315,0.00038508337,0.0012715163,0.0005214158,0.00041749654,0.00017131088],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006284458,0.0001892142,0.0013724482,0.00029655884,0.000023331208,0.0000030637245,0.00011809199,0.00020772725,0.00022725115],"category_scores_gemma":[0.0008124671,0.00014854736,0.00049299194,0.00018842678,0.000049358026,0.00008937743,0.0000649835,0.00030280027,0.00003239956],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00073359575,0.0023841776,0.018575361,0.0060543343,0.0051869815,0.9007185,0.0021313878,0.000012963338,0.03477819,0.027798403,0.0008375194,0.00078855985],"study_design_scores_gemma":[0.013667831,0.0021685697,0.0014279865,0.0009879264,0.0008767739,0.8083471,0.00039703905,0.00008918617,0.16922846,0.0022224262,0.0004674274,0.00011924149],"about_ca_topic_score_codex":0.00013861251,"about_ca_topic_score_gemma":0.000009979333,"teacher_disagreement_score":0.13445029,"about_ca_system_score_codex":0.00019863422,"about_ca_system_score_gemma":0.0008935701,"threshold_uncertainty_score":0.60575855},"labels":[],"label_agreement":null},{"id":"W2955461406","doi":"10.1161/hyp.70.suppl_1.p431","title":"Abstract P431: Renal Artery Stenosis Caused by a Bcr-Abl Tyrosine Kinase Inhibitor: Blood Pressure Response to Revascularization","year":2017,"lang":"en","type":"article","venue":"Hypertension","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Public Health","funders":"","keywords":"Medicine; Internal medicine; Renovascular hypertension; Renal artery stenosis; Cardiology; Ponatinib; Angioplasty; Right Renal Artery; Candesartan; Renal artery; Blood pressure; Nilotinib; Angiotensin II; Kidney; Imatinib","score_opus":0.021529337969565902,"score_gpt":0.25339648480799143,"score_spread":0.23186714683842552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955461406","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99398077,0.0013519073,0.000031915402,0.002847551,0.00028854934,0.0010043987,0.00006830637,0.00013895857,0.0002876744],"genre_scores_gemma":[0.9948813,0.00013034583,0.0005655127,0.0009503074,0.0002902177,0.000057614463,0.00018912466,0.00007776729,0.0028578113],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99775505,0.00009960038,0.00040504234,0.0006850892,0.0006205581,0.00043467025],"domain_scores_gemma":[0.9973498,0.0000996998,0.00021544896,0.0016787783,0.0002677726,0.00038848535],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00042540152,0.0003400434,0.000540171,0.00015025759,0.0004447888,0.000116838135,0.00018972669,0.00027274893,0.00013212289],"category_scores_gemma":[0.000998183,0.00028544973,0.00016529152,0.000114901646,0.00007336754,0.00023961115,0.000141113,0.00026790064,0.00021393182],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020967661,0.00066872,0.0031699848,0.00009968696,0.00038723706,0.000845154,0.00013252243,0.000013377548,0.9512903,0.0000017717492,0.039058737,0.0022357285],"study_design_scores_gemma":[0.020654,0.0014444849,0.52640575,0.0018844887,0.0034059393,0.00039769014,0.000044173405,0.00045611305,0.38582674,0.000010445677,0.058823206,0.000646962],"about_ca_topic_score_codex":0.00026473778,"about_ca_topic_score_gemma":0.000019401581,"teacher_disagreement_score":0.5654636,"about_ca_system_score_codex":0.00019314743,"about_ca_system_score_gemma":0.00024332303,"threshold_uncertainty_score":0.99995977},"labels":[],"label_agreement":null},{"id":"W2955579951","doi":"10.1371/journal.pone.0218968","title":"Evidence that 6q25.1 variant rs6931104 confers susceptibility to chronic myeloid leukemia through RMND1 regulation","year":2019,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Expression quantitative trait loci; Biology; Single-nucleotide polymorphism; Myeloid leukemia; Genetics; Allele; Gene; Chromatin immunoprecipitation; Gene expression; Cancer research; Genotype; Promoter","score_opus":0.08763807307651054,"score_gpt":0.28250233117841833,"score_spread":0.19486425810190777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955579951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867342,0.0008200843,0.0003667377,0.003170352,0.00019501512,0.0030209578,0.000019104169,0.00026604944,0.0054074754],"genre_scores_gemma":[0.9855216,0.00040490873,0.004646024,0.0010938356,0.0003758785,0.000119250086,0.000091680944,0.00007591166,0.0076709106],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99639654,0.0001242135,0.000508663,0.001022924,0.0012433103,0.00070437306],"domain_scores_gemma":[0.997179,0.00030996866,0.0002456814,0.0016924022,0.0002481365,0.0003248239],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000480436,0.00041255326,0.0008157373,0.00011392833,0.00010573481,0.000054791948,0.0003006154,0.0002551,0.004743536],"category_scores_gemma":[0.00048428567,0.00037941194,0.00016207392,0.00037941034,0.00010699674,0.0004825099,0.00018715736,0.00040792898,0.004683598],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021936507,0.0027983598,0.18360236,0.0032171821,0.0021438585,0.00019465468,0.0029316884,0.0003798682,0.78968465,0.0017160735,0.00382302,0.007314656],"study_design_scores_gemma":[0.014913784,0.005470083,0.50895983,0.01231761,0.0022566966,0.00013297735,0.00038077845,0.0056642387,0.4437013,0.0011323674,0.0035625752,0.0015077939],"about_ca_topic_score_codex":0.000647517,"about_ca_topic_score_gemma":0.00019004387,"teacher_disagreement_score":0.34598333,"about_ca_system_score_codex":0.010047333,"about_ca_system_score_gemma":0.0019170601,"threshold_uncertainty_score":0.9998658},"labels":[],"label_agreement":null},{"id":"W2956011050","doi":"10.1200/jco.2012.30.15_suppl.9088","title":"Risk of rash with nilotinib: A systematic review of the literature and meta-analysis.","year":2012,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Nilotinib; Medicine; Rash; Incidence (geometry); Internal medicine; Relative risk; GiST; Confidence interval; Meta-analysis; Adverse effect; Odds ratio; Imatinib; Myeloid leukemia","score_opus":0.22331938847786797,"score_gpt":0.4993376894450839,"score_spread":0.2760183009672159,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2956011050","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000044030166,0.9972361,0.000005409467,0.0003858108,0.00017703201,0.0018203207,0.00006350776,0.000002407574,0.00026542987],"genre_scores_gemma":[0.00023383289,0.9975138,0.0009784895,0.00049558154,0.000229555,0.000029408333,0.0000088794495,0.000031481173,0.0004790055],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98482156,0.005489128,0.008438831,0.00025630734,0.00078382844,0.00021034146],"domain_scores_gemma":[0.964862,0.0074776243,0.025510058,0.00097261334,0.00086961675,0.0003080791],"candidate_categories":["metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.011938114,0.0004345315,0.03365839,0.00024265205,0.000021776874,0.0000051121456,0.00041991394,0.0007611873,0.00018606198],"category_scores_gemma":[0.008349805,0.00015092595,0.010450626,0.0009078087,0.0003187669,0.000059096696,0.0001157809,0.0021617908,0.000004043482],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006676466,0.0005019581,0.00019552888,0.65139353,0.33826065,0.000066887216,0.00003502573,1.2171371e-7,6.9460473e-9,0.000010418797,0.00021212328,0.0092569655],"study_design_scores_gemma":[0.0011603682,0.0014588161,0.00012912786,0.20994894,0.718979,0.001223998,0.000004680492,2.598048e-7,7.846635e-8,0.000007543805,0.06701246,0.000074750016],"about_ca_topic_score_codex":0.0000070410533,"about_ca_topic_score_gemma":0.000011989827,"teacher_disagreement_score":0.4414446,"about_ca_system_score_codex":0.00026885525,"about_ca_system_score_gemma":0.0037168742,"threshold_uncertainty_score":0.99961},"labels":[],"label_agreement":null},{"id":"W2957103174","doi":"10.1200/jco.2019.37.15_suppl.7005","title":"ENESTop 192-week results: Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib (NIL).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Nilotinib; Imatinib; Gastroenterology; Imatinib mesylate; Surgery; Myeloid leukemia","score_opus":0.05632872461739119,"score_gpt":0.39284762659985123,"score_spread":0.33651890198246004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2957103174","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923472,0.0016318465,0.000015474528,0.0014414438,0.0011291124,0.0014036953,0.000047633406,0.000030295027,0.0019533413],"genre_scores_gemma":[0.99154806,0.0013599638,0.0012890383,0.0007557022,0.001496589,0.000046594927,0.00009467833,0.000098050754,0.0033113468],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9911952,0.00078466476,0.005224904,0.0009256226,0.0008668909,0.0010027123],"domain_scores_gemma":[0.99260354,0.0020555889,0.0029592747,0.0012050383,0.0004038792,0.00077268254],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0027203048,0.0006527633,0.0033430967,0.00064313354,0.00004975343,0.000022310123,0.0005256218,0.000975456,0.0009981225],"category_scores_gemma":[0.0021087169,0.00045321515,0.0005838717,0.00056318083,0.00026693355,0.00043656543,0.00019849076,0.0022081297,0.00014865765],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.13961133,0.016073396,0.40967444,0.00044858048,0.0011632595,0.0074417386,0.00082120334,0.0013921377,0.001544276,0.000013838517,0.0020665005,0.4197493],"study_design_scores_gemma":[0.35901672,0.15701027,0.3739283,0.0024367156,0.0005157919,0.0004190928,0.00009694705,0.0009623485,0.0006210442,0.00004785328,0.10442854,0.00051638455],"about_ca_topic_score_codex":0.00034914393,"about_ca_topic_score_gemma":0.0035038644,"teacher_disagreement_score":0.4192329,"about_ca_system_score_codex":0.03914784,"about_ca_system_score_gemma":0.021868274,"threshold_uncertainty_score":0.9999151},"labels":[],"label_agreement":null},{"id":"W2960549986","doi":"10.1158/1078-0432.ccr-18-3373","title":"Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients","year":2019,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":110,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Imatinib; Medicine; Discontinuation; Chronic myelogenous leukemia; Internal medicine; Imatinib mesylate; Oncology; Tyrosine-kinase inhibitor; Cancer; Leukemia","score_opus":0.2040924732734839,"score_gpt":0.5438174705927702,"score_spread":0.3397249973192863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2960549986","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99301577,0.002167758,0.00008718601,0.0007533508,0.00015982687,0.0034308126,0.0003396726,0.000010045575,0.000035578774],"genre_scores_gemma":[0.99828625,0.0003220047,0.000069319394,0.00003275005,0.0001488388,0.00093538966,0.00015861748,0.000023549797,0.000023293438],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99621135,0.00058419234,0.00073735614,0.0005911769,0.0014813028,0.0003945999],"domain_scores_gemma":[0.9957408,0.001870105,0.00013423814,0.00037576258,0.0015922564,0.00028686976],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0031435022,0.00015028988,0.0004055223,0.00016875233,0.000053780896,0.00001682444,0.000093739785,0.00013935508,0.00026691303],"category_scores_gemma":[0.013771113,0.00012901914,0.00008937601,0.0002446537,0.00030417205,0.0001566872,0.00010027704,0.00045988403,0.00000637206],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010642371,0.0018545688,0.9568453,0.0016503817,0.00014690781,0.000020047351,0.00046712538,0.00024032196,0.00030715394,0.00004453916,0.00020192233,0.02757938],"study_design_scores_gemma":[0.031458605,0.005021862,0.902926,0.0025420007,0.00041507094,3.8746887e-7,0.00014730787,0.0551908,0.0011657237,0.0008678175,0.00008533413,0.00017904378],"about_ca_topic_score_codex":0.00009217254,"about_ca_topic_score_gemma":0.0001704846,"teacher_disagreement_score":0.05495048,"about_ca_system_score_codex":0.0022645257,"about_ca_system_score_gemma":0.0024106044,"threshold_uncertainty_score":0.99453634},"labels":[],"label_agreement":null},{"id":"W2962651472","doi":"10.1126/scitranslmed.aav0819","title":"Response to Comment on “PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL <sup>+</sup> human leukemia”","year":2019,"lang":"en","type":"letter","venue":"Science Translational Medicine","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; Leukemia & Lymphoma Society of Canada; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Cancer research; Tyrosine kinase; ABL; Leukemia; K562 cells; Philadelphia chromosome; Chemistry; Medicine; Biology; Immunology; Signal transduction; Chromosomal translocation; Cell biology; Gene; Biochemistry","score_opus":0.030421785252750806,"score_gpt":0.3080085273706561,"score_spread":0.2775867421179053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2962651472","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.28614658,0.00020490434,0.00005319616,0.7088486,0.0007874755,0.0029343672,0.00025761256,0.0000887509,0.000678545],"genre_scores_gemma":[0.3575501,0.000028320499,0.00058949564,0.6337557,0.0028893605,0.00029206084,0.00050811225,0.000121838115,0.004264981],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9914091,0.00034179186,0.0012957326,0.0018487059,0.0038375456,0.001267082],"domain_scores_gemma":[0.99667925,0.0009048354,0.0002690874,0.0010828404,0.00047230747,0.00059167086],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0023669638,0.0009117638,0.0013303234,0.0025996063,0.00033280923,0.000056835837,0.00042751647,0.0004996147,0.00070990284],"category_scores_gemma":[0.00017942836,0.0007631041,0.00017420898,0.0021156848,0.0009212308,0.0002456681,0.00009088153,0.0017885548,0.0004136192],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023971156,0.00018873016,0.0005331544,0.00044492458,0.000069077316,0.0012637116,0.005210382,0.008858909,0.10971136,0.000058639926,0.86784214,0.0034218566],"study_design_scores_gemma":[0.024233498,0.0056777718,0.006236714,0.022618549,0.00044207097,0.00014886241,0.0006222318,0.002005213,0.071854435,0.00020216763,0.86407423,0.0018842694],"about_ca_topic_score_codex":0.0020826405,"about_ca_topic_score_gemma":0.00013404393,"teacher_disagreement_score":0.07509286,"about_ca_system_score_codex":0.009178328,"about_ca_system_score_gemma":0.003528254,"threshold_uncertainty_score":0.999482},"labels":[],"label_agreement":null},{"id":"W2964967733","doi":"10.1182/blood.v130.suppl_1.1622.1622","title":"Interim Results of the Canadian Tyrosine Kinase Inhibitor Discontinuation Trial for 2nd Attempt of Treatment Free Remission: Treatment Free Remission Accomplished By Dasatinib (TRAD)","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; London Health Sciences Centre; CancerCare Manitoba; University Health Network; Ottawa Hospital; University of Alberta Hospital; Alberta Hospital Edmonton; McGill University Health Centre; Hôpital de l'Enfant-Jésus; Juravinski Hospital; Hôpital Maisonneuve-Rosemont; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; University of Calgary; BC Cancer Agency","funders":"","keywords":"Discontinuation; Medicine; Dasatinib; Internal medicine; Interim analysis; Imatinib mesylate; Tyrosine-kinase inhibitor; Imatinib; Oncology; Gastroenterology; Clinical trial; Cancer; Myeloid leukemia","score_opus":0.04639728352886525,"score_gpt":0.3133246904818379,"score_spread":0.2669274069529727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2964967733","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98722637,0.00033640058,0.0000035355558,0.0042251986,0.0005109322,0.0036125574,0.0016839406,0.000025753661,0.002375286],"genre_scores_gemma":[0.9939672,0.000057173096,0.0007794541,0.000029286115,0.00050812424,0.00022906398,0.0005586104,0.000048652862,0.0038224338],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99770296,0.00008432375,0.0008794814,0.0005676456,0.000379252,0.00038633475],"domain_scores_gemma":[0.9954976,0.00016592687,0.0009020731,0.0029097674,0.00017033872,0.00035429126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025870552,0.0003890105,0.0007596296,0.00009560054,0.00043418654,0.00005291736,0.00052736513,0.00023535741,0.000056663805],"category_scores_gemma":[0.0015506836,0.00023795666,0.0003588684,0.0000852709,0.0001787529,0.00012531197,0.00013002873,0.00010529974,0.000001738039],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12849677,0.025395073,0.038628824,0.0006736688,0.004147796,0.00015696637,0.006608758,0.000009248214,0.53799266,0.00014530146,0.15093721,0.10680774],"study_design_scores_gemma":[0.38115984,0.007913667,0.01387022,0.0010540962,0.0012894945,0.000018314357,0.000100861536,0.00006130723,0.5790332,0.00008409634,0.015173394,0.00024149822],"about_ca_topic_score_codex":0.09853432,"about_ca_topic_score_gemma":0.07523204,"teacher_disagreement_score":0.25266308,"about_ca_system_score_codex":0.002007772,"about_ca_system_score_gemma":0.0016301351,"threshold_uncertainty_score":0.9703591},"labels":[],"label_agreement":null},{"id":"W2966084920","doi":"10.1182/blood.v130.suppl_1.2880.2880","title":"Dasatinib Induced Reversible Nephrotic Range Proteinuria Occurs More Frequently Compared to Other Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Dasatinib; Medicine; Proteinuria; Ponatinib; Bosutinib; Nilotinib; Nephrotic syndrome; Internal medicine; Discontinuation; Gastroenterology; Myeloid leukemia; Imatinib; Kidney","score_opus":0.03632181369499163,"score_gpt":0.3000526370663322,"score_spread":0.2637308233713406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2966084920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918812,0.001103047,0.0000020577381,0.0011677335,0.00015902388,0.0042324304,0.00005832027,0.000047501988,0.0013486954],"genre_scores_gemma":[0.99775445,0.00006356233,0.00048771477,0.00024215833,0.0004253386,0.0005241055,0.000040573992,0.00005915192,0.00040292484],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99777925,0.00010689941,0.00054269284,0.00052957167,0.00050755235,0.00053400616],"domain_scores_gemma":[0.99747795,0.00007518866,0.00035392764,0.0018178764,0.00008150492,0.00019356233],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023396587,0.00041537292,0.00074364274,0.00018555121,0.00020505782,0.000055465785,0.0004546154,0.00017485603,0.00014370376],"category_scores_gemma":[0.000129544,0.0002898549,0.00019643441,0.00025742344,0.00016361164,0.00013214267,0.0000627947,0.0002052062,0.00008304235],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022835974,0.018029267,0.540565,0.0010643458,0.001899578,0.0021399227,0.025436278,0.00010741208,0.37780973,0.00017122501,0.0034638199,0.0270298],"study_design_scores_gemma":[0.092756934,0.0076101953,0.4470388,0.0021555934,0.0015084733,0.00015324731,0.0010041624,0.00015771484,0.4364606,0.000053774842,0.010320542,0.0007799432],"about_ca_topic_score_codex":0.005631565,"about_ca_topic_score_gemma":0.0011704095,"teacher_disagreement_score":0.09352622,"about_ca_system_score_codex":0.002438295,"about_ca_system_score_gemma":0.0010080506,"threshold_uncertainty_score":0.99995536},"labels":[],"label_agreement":null},{"id":"W2966662961","doi":"10.1200/jco.2012.30.15_suppl.6513","title":"Subcutaneous omacetaxine mepesuccinate in patients with chronic phase (CP) or accelerated phase (AP) chronic myeloid leukemia (CML) resistant/intolerant to two or three approved tyrosine-kinase inhibitors (TKIs).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Dasatinib; Nilotinib; Internal medicine; Adverse effect; Gastroenterology; Imatinib; Neutropenia; Myeloid leukemia; Imatinib mesylate; Pharmacology; Chemotherapy","score_opus":0.07884208343562826,"score_gpt":0.4232277760321592,"score_spread":0.34438569259653096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2966662961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99180657,0.0016055191,0.00017212874,0.001770209,0.001789774,0.0023423391,0.00005740808,0.00006845231,0.000387587],"genre_scores_gemma":[0.9918825,0.00033811948,0.002607846,0.0011023219,0.003162901,0.00006793567,0.00007623064,0.0001595016,0.0006026684],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99003965,0.0007536983,0.005367717,0.00084823364,0.0012977354,0.0016929617],"domain_scores_gemma":[0.9911127,0.0018074521,0.0030896617,0.00092185807,0.0010046903,0.0020636152],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0032687099,0.0008809371,0.003975546,0.00068732863,0.00015841919,0.00004990937,0.0005982782,0.0008125251,0.0013719974],"category_scores_gemma":[0.0030308226,0.00053116184,0.00057329267,0.0012809894,0.00038180067,0.0005975313,0.00021289931,0.0025931774,0.00012001634],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.4270932,0.030667445,0.038777515,0.0003975083,0.0019848805,0.015596102,0.0004733061,0.00033207267,0.009036599,0.000023097,0.004570654,0.4710476],"study_design_scores_gemma":[0.5236711,0.30428287,0.08987735,0.0019528024,0.002502469,0.0025785137,0.00012052571,0.0017369139,0.006200239,0.00002203235,0.06574042,0.001314748],"about_ca_topic_score_codex":0.0003480326,"about_ca_topic_score_gemma":0.0055712354,"teacher_disagreement_score":0.46973288,"about_ca_system_score_codex":0.015668465,"about_ca_system_score_gemma":0.015713943,"threshold_uncertainty_score":0.999714},"labels":[],"label_agreement":null},{"id":"W2967006695","doi":"10.1016/j.jconrel.2019.08.018","title":"siRNA-mediated BCR-ABL silencing in primary chronic myeloid leukemia cells using lipopolymers","year":2019,"lang":"en","type":"article","venue":"Journal of Controlled Release","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency; University of Alberta","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Alberta Innovates - Health Solutions","keywords":"K562 cells; Gene silencing; Myeloid leukemia; Cancer research; Chemistry; Imatinib; ABL; Tyrosine kinase; Small interfering RNA; Chronic myelogenous leukemia; Imatinib mesylate; Oncogene; Leukemia; Molecular biology; Cell culture; Biology; Transfection; Cell; Immunology; Cell cycle; Signal transduction; Biochemistry","score_opus":0.007689649926938244,"score_gpt":0.23640339581405642,"score_spread":0.22871374588711818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2967006695","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856138,0.009845977,0.00007747836,0.0002535826,0.0010483634,0.0011891581,0.0000059462436,0.000029096478,0.0019365464],"genre_scores_gemma":[0.9949212,0.001227105,0.00070940884,0.00060268375,0.0007329686,0.00000851087,0.000009805529,0.000079159596,0.001709123],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9961456,0.00022463969,0.0016383837,0.00035090017,0.0009314474,0.00070899614],"domain_scores_gemma":[0.9968884,0.0006061204,0.0012623967,0.00047356985,0.00026933785,0.0005001723],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008386545,0.00043076702,0.0019390882,0.00072816794,0.000062963314,0.000032779608,0.00023071805,0.0002917304,0.000683623],"category_scores_gemma":[0.00037618872,0.00033463305,0.0006432463,0.00047993948,0.00007866919,0.00034470102,0.000060206712,0.0011164994,0.00016299388],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.013600768,0.00045811143,0.006885102,0.00040960172,0.0010458411,0.0027449077,0.00034491107,0.008503993,0.95818883,0.000008374106,0.0005609206,0.0072486424],"study_design_scores_gemma":[0.70874166,0.0066102836,0.0173808,0.0075169997,0.0037649751,0.0040578586,0.0011059912,0.1256622,0.118525766,0.000055014105,0.004907151,0.0016713022],"about_ca_topic_score_codex":0.00020298368,"about_ca_topic_score_gemma":0.000013946217,"teacher_disagreement_score":0.839663,"about_ca_system_score_codex":0.012295331,"about_ca_system_score_gemma":0.008147045,"threshold_uncertainty_score":0.9999106},"labels":[],"label_agreement":null},{"id":"W2968512648","doi":"10.1016/j.cjca.2019.08.002","title":"Dasatinib-Induced Pulmonary Arterial Hypertension","year":2019,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Alberta Health Services; Libin Cardiovascular Institute of Alberta; University of Calgary; University of Manitoba","funders":"United Therapeutics Corporation; Novartis; European Respiratory Society; Bayer","keywords":"Medicine; Dasatinib; Cardiology; Internal medicine; Pulmonary hypertension; Imatinib","score_opus":0.022816525666446704,"score_gpt":0.2387745330549281,"score_spread":0.2159580073884814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2968512648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9753858,0.0002542987,0.000016316304,0.00085832016,0.0022075095,0.00016519839,0.0000065294626,0.0000051661664,0.021100868],"genre_scores_gemma":[0.9973653,0.000019206336,0.00011373459,0.00039241993,0.0017589827,0.0000012722465,0.000011940608,0.00001959214,0.00031757154],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990276,0.00007715956,0.00031349578,0.00013975648,0.0001220442,0.00031994475],"domain_scores_gemma":[0.9987977,0.0000529794,0.00013106331,0.00026090472,0.00017384763,0.0005834993],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018173657,0.00012333841,0.0005857743,0.00022770416,0.000036537673,0.000007563404,0.00010128327,0.00016865313,0.00022058286],"category_scores_gemma":[0.000113919086,0.00010012471,0.000202094,0.00008100293,0.000048796453,0.00005668873,0.000008531916,0.00027727598,0.00019354107],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014665568,0.000026866663,0.5727187,0.00011826989,0.001988139,0.026091805,0.00039905994,0.00040208368,0.27761853,0.0002939188,0.061519127,0.057357002],"study_design_scores_gemma":[0.008827725,0.0018955979,0.6404328,0.0002211041,0.0004359676,0.052308653,0.00024639827,0.00008208319,0.0016479511,0.00018536318,0.2934237,0.00029266972],"about_ca_topic_score_codex":0.00048287888,"about_ca_topic_score_gemma":0.0001429304,"teacher_disagreement_score":0.27597058,"about_ca_system_score_codex":0.00063753984,"about_ca_system_score_gemma":0.003013655,"threshold_uncertainty_score":0.53460944},"labels":[],"label_agreement":null},{"id":"W2969113056","doi":"10.1182/blood.v130.suppl_1.315.315","title":"Persistence with Generic Imatinib for Chronic Myeloid Leukemia: A Matched Cohort Study","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Université de Montréal; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Hôpital Maisonneuve-Rosemont; Jewish General Hospital","funders":"","keywords":"Medicine; Internal medicine; Discontinuation; Hazard ratio; Imatinib; Imatinib mesylate; Myeloid leukemia; Cohort; Proportional hazards model; Confidence interval; Oncology; Surgery","score_opus":0.02978029303048314,"score_gpt":0.2783285087066372,"score_spread":0.2485482156761541,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2969113056","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992416,0.00040107805,0.00008520696,0.00020559649,0.00009680036,0.0034643572,0.000019216151,0.00011137454,0.0032003266],"genre_scores_gemma":[0.99171996,0.00004972035,0.00399767,0.00006890314,0.00035075826,0.00095321017,0.000037458456,0.00006873745,0.0027535742],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981819,0.000023092342,0.00028145855,0.0006167346,0.00040813244,0.0004887323],"domain_scores_gemma":[0.9977863,0.00005329755,0.0002713333,0.0015609275,0.00013707517,0.00019109955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023272817,0.00030840107,0.00059563975,0.000058370948,0.00047133886,0.0000852843,0.00034416877,0.000101838945,0.000095628006],"category_scores_gemma":[0.00011871932,0.00023320857,0.00013611752,0.000070567934,0.00014460104,0.00013508511,0.000102822196,0.00018207703,0.000068980895],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004226351,0.0021579727,0.9846674,0.00036901963,0.0022594903,0.00044552895,0.0009029393,0.000014216576,0.0054803346,0.000016470829,0.00040974846,0.0028541978],"study_design_scores_gemma":[0.04766252,0.0048956973,0.9337609,0.00022896608,0.003631355,0.0004964256,0.00063509797,0.00046917857,0.0071647107,0.000013786596,0.00062970084,0.00041169787],"about_ca_topic_score_codex":0.0002538516,"about_ca_topic_score_gemma":0.0002227067,"teacher_disagreement_score":0.05090658,"about_ca_system_score_codex":0.0012438069,"about_ca_system_score_gemma":0.0014011443,"threshold_uncertainty_score":0.95099694},"labels":[],"label_agreement":null},{"id":"W2970066205","doi":"10.1016/j.clml.2019.07.245","title":"Assessing the Clinical Significance of Major (MMR) and Deep (DMR) Molecular Responses for Overall (OS), Progression-Free (PFS) and Event-Free (EFS) Survival in Patients with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs)","year":2019,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Precision Nanosystems (Canada)","funders":"","keywords":"Myeloid leukemia; Overall survival; Medicine; Internal medicine; Oncology; Clinical significance; Event (particle physics); Progression-free survival","score_opus":0.017227433463172674,"score_gpt":0.32058193472298846,"score_spread":0.3033545012598158,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970066205","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99164623,0.0020308783,0.00010059018,0.00050550024,0.00030915625,0.005010569,0.0001188143,0.00011927835,0.00015899638],"genre_scores_gemma":[0.9941899,0.00029988878,0.0038360397,0.00033566199,0.00032546764,0.00033286514,0.0001958488,0.00021788703,0.00026643643],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99197114,0.0010038238,0.002664964,0.001944127,0.001267468,0.0011484995],"domain_scores_gemma":[0.9907229,0.004098806,0.0013470871,0.0026400187,0.00052904635,0.00066216255],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024722824,0.0010025244,0.0022714543,0.00027220754,0.00023497222,0.00015625065,0.00078307354,0.000788174,0.000041928837],"category_scores_gemma":[0.0027355917,0.00064613833,0.00039421045,0.000688185,0.001623056,0.0005302957,0.0006384275,0.0007796876,0.000010751746],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016815213,0.0008793186,0.841584,0.0005367975,0.0005898317,0.00025259666,0.000081668666,0.000038688882,0.0010107447,0.00013758994,0.0002295565,0.13784397],"study_design_scores_gemma":[0.075351365,0.00802167,0.9086467,0.002135605,0.00070488313,0.00006209401,0.00010337503,0.001579766,0.0019819883,0.00016716174,0.00053788157,0.0007074765],"about_ca_topic_score_codex":0.00032879054,"about_ca_topic_score_gemma":0.000266798,"teacher_disagreement_score":0.13713649,"about_ca_system_score_codex":0.0035890783,"about_ca_system_score_gemma":0.005446781,"threshold_uncertainty_score":0.999599},"labels":[],"label_agreement":null},{"id":"W2972598562","doi":"10.1136/bmjopen-2019-030092","title":"Evaluating the endometabolic and bone health effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukaemia: a systematic review protocol","year":2019,"lang":"en","type":"review","venue":"BMJ Open","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster Children's Hospital; St. Joseph’s Healthcare Hamilton; Impact; Juravinski Cancer Centre; McMaster University","funders":"","keywords":"Medicine; Chronic myeloid leukaemia; Tyrosine kinase; Protocol (science); Tyrosine-kinase inhibitor; Cancer research; Internal medicine; Pathology; Alternative medicine; Cancer","score_opus":0.13915938529651403,"score_gpt":0.5087787125207488,"score_spread":0.36961932722423474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972598562","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000057074467,0.53339434,2.3405123e-7,0.000083458304,0.000056135326,0.46634305,0.000010262587,0.0000115772755,0.00009523521],"genre_scores_gemma":[0.0000019646745,0.5445215,0.00009987408,0.000184119,0.00009648078,0.45450786,0.000047303078,0.0000733934,0.00046746884],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99164844,0.0025890714,0.003383842,0.0008444209,0.00092389394,0.00061031675],"domain_scores_gemma":[0.9927147,0.0013400175,0.0034683526,0.00216975,0.00010780409,0.00019935465],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0071207425,0.0008163317,0.010272845,0.00029008326,0.00008493532,0.00006271795,0.0006641536,0.00026978116,0.000044080116],"category_scores_gemma":[0.00314088,0.000451588,0.00051132677,0.0010280401,0.00010275981,0.00013346017,0.0009334097,0.0007090014,0.000085712316],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00003835136,0.00009865019,0.0000051092325,0.82282937,0.00024789575,0.000049500475,0.00005968251,2.803912e-7,0.0000027405865,0.000014777232,0.00034302208,0.17631061],"study_design_scores_gemma":[0.0073373043,0.0016231743,0.000010968207,0.94623923,0.0045240903,0.0006087378,0.000007953718,0.000027255475,0.000008242582,0.0000031113088,0.039280813,0.00032912544],"about_ca_topic_score_codex":0.000541854,"about_ca_topic_score_gemma":0.000081830665,"teacher_disagreement_score":0.17598148,"about_ca_system_score_codex":0.004472285,"about_ca_system_score_gemma":0.013327741,"threshold_uncertainty_score":0.9997936},"labels":[],"label_agreement":null},{"id":"W2972660309","doi":"10.1159/000502472","title":"Tyrosine Kinase Inhibitors in the Clinical Setting: A Conundrum of Choices","year":2019,"lang":"en","type":"letter","venue":"Acta Haematologica","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Tyrosine kinase; Medicine; Internal medicine; Receptor","score_opus":0.04779974702121283,"score_gpt":0.33578279874975947,"score_spread":0.28798305172854666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972660309","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.32749078,0.0015767147,5.5126446e-7,0.6603141,0.0007635877,0.0022253701,0.00006531091,0.00007875797,0.007484821],"genre_scores_gemma":[0.56512654,0.0003250678,0.00030468544,0.4300869,0.0015282825,0.00011604807,0.0005968875,0.00006834577,0.0018472637],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99599725,0.0005683287,0.0013736687,0.0007599051,0.0006869407,0.00061393215],"domain_scores_gemma":[0.9947067,0.0028239249,0.0008930216,0.0014243345,0.00009613897,0.000055887882],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0008395318,0.0005190282,0.0018715787,0.00020453778,0.000046141296,0.000026392672,0.00062618055,0.0015911559,0.00027460337],"category_scores_gemma":[0.0012531207,0.00029737843,0.00048817942,0.00031546166,0.00039663434,0.000061726714,0.00019411804,0.0028920108,0.00019647198],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012292806,0.00033281874,0.04668078,0.00088785484,0.00019895355,0.004472518,0.0001393083,1.5997632e-7,0.000038529008,0.00001935007,0.9462928,0.00081399374],"study_design_scores_gemma":[0.0044165812,0.0009392401,0.01528467,0.0013763179,0.0004798043,0.0011910279,0.00010547306,0.00001649321,0.0002801265,0.00007018288,0.9754907,0.00034941727],"about_ca_topic_score_codex":0.0001621222,"about_ca_topic_score_gemma":0.000022345366,"teacher_disagreement_score":0.23763572,"about_ca_system_score_codex":0.00024259808,"about_ca_system_score_gemma":0.00061368285,"threshold_uncertainty_score":0.99994785},"labels":[],"label_agreement":null},{"id":"W2979304829","doi":"10.1182/blood.v114.22.40.40","title":"GNF-2, An Allosteric BCR-ABL Inhibitor, Identifies a Novel Myristoylation-Mediated Mechanism Regulating the Ability of BCR-ABL to Activate HCK and IGF-1 Signaling.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Allosteric regulation; Kinase; Myristoylation; Dasatinib; Biology; Autophosphorylation; Cell biology; ABL; Imatinib mesylate; Proto-oncogene tyrosine-protein kinase Src; Protein kinase domain; Nilotinib; Signal transduction; Cancer research; Phosphorylation; Tyrosine kinase; Chemistry; Protein kinase A; Imatinib; Biochemistry; Mutant; Receptor","score_opus":0.01710268104111163,"score_gpt":0.26105384173302265,"score_spread":0.24395116069191103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979304829","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974316,0.00019043394,0.00021453625,0.0007093895,0.000101293386,0.0009397661,0.000029829216,0.000098548844,0.00028465065],"genre_scores_gemma":[0.9960273,0.000013076612,0.0032108813,0.00030553437,0.00017889364,0.000029240722,0.000054833323,0.000032205044,0.00014806166],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99798363,0.000091905364,0.0005676269,0.00052314915,0.00048046082,0.00035323884],"domain_scores_gemma":[0.9984091,0.00026114014,0.0002672156,0.00067453284,0.00017382787,0.00021418097],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000491288,0.0002849172,0.00046660626,0.0001245862,0.00016869116,0.00004557094,0.00015324319,0.00015105665,0.000062575265],"category_scores_gemma":[0.00048036358,0.00021798295,0.00009193517,0.00037699036,0.00008550759,0.00020442353,0.00008569373,0.00021844472,0.000011421249],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023878287,0.0009254428,0.0014962462,0.00008890074,0.00014942941,0.000012827277,0.002216314,0.000023928256,0.9922875,0.000091582995,0.00003562812,0.0024333815],"study_design_scores_gemma":[0.012722327,0.0019488579,0.20175299,0.0005611922,0.0008050548,0.00013756231,0.00087357947,0.0011798737,0.7775646,0.0018389532,0.00014003272,0.000475017],"about_ca_topic_score_codex":0.00025036721,"about_ca_topic_score_gemma":0.00003968601,"teacher_disagreement_score":0.21472298,"about_ca_system_score_codex":0.00021377408,"about_ca_system_score_gemma":0.00021469442,"threshold_uncertainty_score":0.8889087},"labels":[],"label_agreement":null},{"id":"W2979370887","doi":"10.1182/blood.v110.11.2965.2965","title":"HyperCKemia in CML Patients on Imatinib Mesylate.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; myalgia; Imatinib mesylate; Muscle cramp; Internal medicine; Gastroenterology; Creatine kinase; Adverse effect; Rhabdomyolysis; Imatinib; Chronic myelogenous leukemia; Surgery; Leukemia; Myeloid leukemia","score_opus":0.011314892418957528,"score_gpt":0.2648738234964562,"score_spread":0.2535589310774987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979370887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9648599,0.000087602464,0.0000022335887,0.000070651215,0.00010550834,0.00037326606,0.0000053076515,0.00005517012,0.034440387],"genre_scores_gemma":[0.99807674,0.00001672821,0.0007294777,0.0003765714,0.00009308396,0.000011435052,0.000052146923,0.000027000026,0.0006167901],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99882704,0.0000150928445,0.00027853122,0.00024769662,0.00028948692,0.00034215083],"domain_scores_gemma":[0.9993933,0.000078131234,0.00005145642,0.00031483083,0.00003497243,0.00012730478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016919403,0.00015071139,0.00023108743,0.00014015917,0.00002510356,0.000005348153,0.0000651144,0.00010412992,0.00017904311],"category_scores_gemma":[0.00012717556,0.00012654657,0.00005685594,0.00018572314,0.000023216635,0.00003565196,0.00002642123,0.0001951687,0.00042582912],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028598096,0.003685655,0.97407484,0.00005660115,0.00009621463,0.00047149375,0.0004118596,0.0000016751317,0.0013580694,0.000107276035,0.0005909686,0.018859383],"study_design_scores_gemma":[0.02379648,0.0006853927,0.9507772,0.00018541176,0.00010156185,0.000030449293,0.000038382885,0.000011476164,0.022305006,0.000052776384,0.0018677711,0.00014812761],"about_ca_topic_score_codex":0.00009541544,"about_ca_topic_score_gemma":0.000048869857,"teacher_disagreement_score":0.0338236,"about_ca_system_score_codex":0.00042100626,"about_ca_system_score_gemma":0.00010222682,"threshold_uncertainty_score":0.5473314},"labels":[],"label_agreement":null},{"id":"W2979388195","doi":"10.1182/blood.v108.11.1932.1932","title":"BCR-ABL Activates IGF-1 Expression and Signaling in Chronic Myelogenous Leukemia Blast Crisis Cell Lines.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Autocrine signalling; Cancer research; Biology; Philadelphia chromosome; Chronic myelogenous leukemia; Imatinib mesylate; breakpoint cluster region; ABL; Signal transduction; Imatinib; Myeloid leukemia; Cell biology; Cell culture; Leukemia; Immunology; Receptor; Genetics; Chromosomal translocation; Tyrosine kinase","score_opus":0.008307562850966019,"score_gpt":0.22633433926904356,"score_spread":0.21802677641807755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979388195","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99220294,0.005624114,0.000024756026,0.0000880852,0.000052548712,0.00043958693,0.000010295626,0.000100129095,0.0014575431],"genre_scores_gemma":[0.99714077,0.00028192328,0.0012680894,0.00007688918,0.00047678367,0.000049833616,0.000063164225,0.00005873762,0.0005838301],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982734,0.000046747966,0.00039091645,0.0005171004,0.0002683514,0.00050349574],"domain_scores_gemma":[0.9992047,0.00011812043,0.00012253388,0.00037558543,0.00004504648,0.00013398887],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000122043435,0.0003059415,0.00043515651,0.00018094096,0.00009678373,0.000029654935,0.000099012555,0.0002120621,0.00013882863],"category_scores_gemma":[0.000028909883,0.0002652861,0.00008073496,0.00023415354,0.000054958877,0.00010663558,0.0000901751,0.00030640065,0.000045127206],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009043457,0.0006150756,0.017868267,0.0002635581,0.000046656485,0.00036365038,0.00026507667,0.00023579045,0.9786531,0.0000039814777,0.0006601529,0.00093429524],"study_design_scores_gemma":[0.014437509,0.0003697267,0.011431054,0.00040478038,0.00024412324,0.00013210907,0.00018397292,0.0002430443,0.97143406,0.00007402389,0.00076652004,0.00027910652],"about_ca_topic_score_codex":0.0014537226,"about_ca_topic_score_gemma":0.0001575005,"teacher_disagreement_score":0.014347075,"about_ca_system_score_codex":0.0014916128,"about_ca_system_score_gemma":0.00077605114,"threshold_uncertainty_score":0.9999799},"labels":[],"label_agreement":null},{"id":"W2979452863","doi":"10.1182/blood.v118.21.3761.3761","title":"Subcutaneous Omacetaxine in Chronic or Accelerated Chronic Myeloid Leukemia Resistant to Two or More Tyrosine-Kinase Inhibitors Including Imatinib,","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Imatinib; Myeloid leukemia; Internal medicine; Dasatinib; Leukemia; Chronic myelogenous leukemia; Imatinib mesylate; Tyrosine-kinase inhibitor; Tyrosine kinase; Pharmacology; Gastroenterology; Cancer","score_opus":0.058431577757724666,"score_gpt":0.3155030366773857,"score_spread":0.25707145891966104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979452863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926847,0.002227789,0.000010895987,0.00024935594,0.00024716638,0.0021391534,0.000055748562,0.00036067306,0.0020245085],"genre_scores_gemma":[0.9922728,0.00029951637,0.0026932496,0.00029193764,0.000701541,0.0003199495,0.00011699347,0.00019746044,0.0031065545],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99553645,0.00012041254,0.0011745556,0.0011179788,0.0006914115,0.0013591688],"domain_scores_gemma":[0.9975767,0.00015782427,0.0002952903,0.0011728628,0.0001787243,0.00061855675],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00037225557,0.00076940784,0.0010924862,0.0005923157,0.00020925599,0.00005729315,0.00043150468,0.00029865906,0.0021095688],"category_scores_gemma":[0.00041106963,0.0005768671,0.00017829236,0.0016833711,0.00015192488,0.0002174944,0.0003818036,0.00067583274,0.00035320153],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0189874,0.0038268678,0.010758078,0.002109217,0.0012988439,0.05975584,0.0070347185,0.0002682705,0.86711085,0.000109632725,0.0029058484,0.025834443],"study_design_scores_gemma":[0.08598137,0.01432224,0.022595547,0.004928795,0.0014354978,0.0051887697,0.00072363426,0.0015860734,0.8564631,0.000037812613,0.004693341,0.0020438428],"about_ca_topic_score_codex":0.002471061,"about_ca_topic_score_gemma":0.006865784,"teacher_disagreement_score":0.06699397,"about_ca_system_score_codex":0.011969164,"about_ca_system_score_gemma":0.0065132715,"threshold_uncertainty_score":0.9996683},"labels":[],"label_agreement":null},{"id":"W2979483347","doi":"10.1182/blood.v106.11.1992.1992","title":"ReSETting PP2A Tumor Suppressor Activity Overcomes BCR/ABL Leukemogenic Potential in Blast Crisis CML.","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Protein phosphatase 2; Cancer research; Progenitor cell; Chronic myelogenous leukemia; Biology; Imatinib mesylate; Myeloid leukemia; Cell biology; Stem cell; Phosphatase; Leukemia; Immunology; Imatinib; Phosphorylation","score_opus":0.01090257695061078,"score_gpt":0.2600076689796081,"score_spread":0.2491050920289973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979483347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99529314,0.0005217833,0.000013574358,0.0016602702,0.00012697054,0.00056127616,0.000036353056,0.0001352388,0.0016513809],"genre_scores_gemma":[0.9964937,0.000046735764,0.0013494226,0.00035335266,0.00062827585,0.00006200561,0.000027381579,0.000063833344,0.00097531255],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976368,0.000112066155,0.00040379836,0.0006068301,0.0005256961,0.000714799],"domain_scores_gemma":[0.9987992,0.00010859262,0.00013960988,0.00067326025,0.00005525121,0.00022408302],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025815118,0.00032321352,0.00054302986,0.00023029139,0.00010242001,0.00003968778,0.00019246653,0.00014548715,0.0006182312],"category_scores_gemma":[0.00019375022,0.00030545495,0.00021328707,0.00030977966,0.00005787602,0.00026714194,0.00016546309,0.00046985655,0.0002573052],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025123225,0.017617323,0.24869448,0.0008400171,0.0026180746,0.007298623,0.0029808774,0.0005428948,0.670363,0.000071060924,0.021153824,0.025307473],"study_design_scores_gemma":[0.052559726,0.00070725795,0.4370411,0.00041688533,0.0013367134,0.0012797528,0.0005066226,0.0019420377,0.49707812,0.00005447116,0.006236881,0.0008404263],"about_ca_topic_score_codex":0.0008254119,"about_ca_topic_score_gemma":0.00037231334,"teacher_disagreement_score":0.18834662,"about_ca_system_score_codex":0.0009594324,"about_ca_system_score_gemma":0.00046055592,"threshold_uncertainty_score":0.99993974},"labels":[],"label_agreement":null},{"id":"W2979513542","doi":"10.1182/blood.v118.21.1693.1693","title":"Combination Targeted Therapy to Impair Self-Renewal Capacity of Human Blast Crisis Leukemia Stem Cells","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Dasatinib; Progenitor cell; Bone marrow; Medicine; CD34; Population; Stem cell; Haematopoiesis; Immunology; Cancer research; Internal medicine; Myeloid leukemia; Biology; Imatinib","score_opus":0.030206154551618406,"score_gpt":0.24691443842859162,"score_spread":0.21670828387697322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979513542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966153,0.00009971049,0.000011732681,0.00003403186,0.000104574945,0.0007057905,0.00002506581,0.00016369826,0.00224012],"genre_scores_gemma":[0.99797875,0.000028780316,0.0014132494,0.00014176121,0.00006449727,0.000043735086,0.000021182648,0.000040090526,0.0002679521],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99860275,0.00006572838,0.0003711212,0.0003276598,0.00033100703,0.0003017236],"domain_scores_gemma":[0.9989404,0.000026014686,0.00015269678,0.0005109814,0.0001613249,0.00020859162],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015553593,0.00022913754,0.00040294472,0.0001517519,0.00006916303,0.0000069720536,0.0001471587,0.00013875781,0.00029074817],"category_scores_gemma":[0.000006541299,0.00020054769,0.00013347872,0.00024052008,0.00003558428,0.00006208303,0.000041080526,0.00013794602,0.00007399576],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038853803,0.009117086,0.08434871,0.00027513102,0.0019098483,0.00009949247,0.021258729,0.000003670953,0.8773706,0.0003728022,0.0036022451,0.0012531424],"study_design_scores_gemma":[0.0127731515,0.0021451162,0.042142056,0.000055249886,0.00029184076,0.000019413357,0.0002957083,0.000011952005,0.94186413,0.000096034666,0.00012848628,0.00017684793],"about_ca_topic_score_codex":0.0014307122,"about_ca_topic_score_gemma":0.000062646344,"teacher_disagreement_score":0.06449354,"about_ca_system_score_codex":0.00059067213,"about_ca_system_score_gemma":0.00026471002,"threshold_uncertainty_score":0.8178097},"labels":[],"label_agreement":null},{"id":"W2979619193","doi":"10.1182/blood.v122.21.4009.4009","title":"ENESTxtnd: Impact Of Nilotinib Dose Re-Escalation In Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP)","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Nilotinib; Medicine; Tolerability; Adverse effect; Internal medicine; Clinical endpoint; Clinical trial; Interim analysis; Imatinib; Oncology; Myeloid leukemia","score_opus":0.011478519877969141,"score_gpt":0.275172306118641,"score_spread":0.26369378624067186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979619193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958804,0.0007055686,0.0000067001574,0.000053603486,0.000055479883,0.0025529116,0.000028102826,0.00006735625,0.00064987334],"genre_scores_gemma":[0.9984326,0.00019085378,0.00029341012,0.000036816746,0.00016620621,0.00029715121,0.00035520483,0.00008779828,0.00014000542],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99703795,0.00011592196,0.0008647477,0.0006375342,0.00057012925,0.0007737042],"domain_scores_gemma":[0.9982535,0.00015904204,0.0003719092,0.00079404074,0.00014731975,0.00027415194],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019416187,0.00048589078,0.0008239873,0.0004653691,0.000039747785,0.00002482238,0.00019999394,0.0002498755,0.0008125711],"category_scores_gemma":[0.00013361381,0.0003846901,0.00017403142,0.000771578,0.00014972576,0.00038873585,0.000070922375,0.00042164157,0.00014246098],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010232744,0.006002946,0.94193816,0.0003719393,0.00042968366,0.00021227989,0.0008402486,0.0021290656,0.015037075,0.000009805639,0.00034979082,0.03165574],"study_design_scores_gemma":[0.1434639,0.00826276,0.8385464,0.0008634747,0.00022319228,0.000018274266,0.000044033393,0.0016281423,0.0065554813,0.000017483373,0.000044204524,0.00033268315],"about_ca_topic_score_codex":0.012536617,"about_ca_topic_score_gemma":0.0030257225,"teacher_disagreement_score":0.14244062,"about_ca_system_score_codex":0.013023279,"about_ca_system_score_gemma":0.004257669,"threshold_uncertainty_score":0.9998605},"labels":[],"label_agreement":null},{"id":"W2979628842","doi":"10.1182/blood.v114.22.3392.3392","title":"Optimizing Patient Selection for Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Transplantation; Internal medicine; Stem cell; Hematopoietic stem cell transplantation; Busulfan; Imatinib mesylate; Myeloid leukemia; Imatinib; Oncology; Univariate analysis; Bone marrow; Cyclophosphamide; Surgery; Gastroenterology; Chemotherapy; Multivariate analysis","score_opus":0.012599521397272951,"score_gpt":0.24140445001694935,"score_spread":0.2288049286196764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979628842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956769,0.0013157565,0.00075463566,0.00007808608,0.00006103759,0.0011065956,0.000010680492,0.00008625123,0.000910085],"genre_scores_gemma":[0.99485534,0.00042373897,0.0039460273,0.00014960955,0.00013058595,0.000111792295,0.00011886229,0.000026078265,0.00023797298],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987762,0.000027821981,0.0003194719,0.0003379147,0.00018338776,0.00035522957],"domain_scores_gemma":[0.9995786,0.000040880048,0.000089168214,0.000159944,0.000044191554,0.00008724967],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008733074,0.0001868869,0.00026326376,0.0001459301,0.00006073266,0.000012440919,0.000051319716,0.00013031124,0.00002080067],"category_scores_gemma":[0.0000041341546,0.00018110483,0.00009649298,0.00020243207,0.000010770631,0.00008271291,0.0000044783715,0.00014098537,0.000014273874],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012190093,0.0022412306,0.010378236,0.0010489946,0.00024337979,0.00021643532,0.0044263727,0.012037443,0.81324196,0.00008803199,0.0002391447,0.15461978],"study_design_scores_gemma":[0.033475157,0.004608311,0.02023995,0.0003668735,0.00074375386,0.00028256417,0.00014044005,0.0046167215,0.93414944,0.000044572265,0.00095063436,0.00038157112],"about_ca_topic_score_codex":0.000055770477,"about_ca_topic_score_gemma":0.00009556936,"teacher_disagreement_score":0.15423821,"about_ca_system_score_codex":0.0024651515,"about_ca_system_score_gemma":0.0007333068,"threshold_uncertainty_score":0.7385241},"labels":[],"label_agreement":null},{"id":"W2979637103","doi":"10.1182/blood.v114.22.1110.1110","title":"Comprehensive Evaluation of Time-to-Response Parameter as a Predictor of Long-Term Outcomes Following Imatinib Therapy in Chronic Phase Chronic Myeloid Leukemia.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Imatinib; Oncology; Internal medicine; Hazard ratio; Surrogate endpoint; Guideline; Nilotinib; Myeloid leukemia; Dasatinib; Proportional hazards model; Imatinib mesylate; Confidence interval; Pathology","score_opus":0.037978300145872015,"score_gpt":0.35547855773314907,"score_spread":0.31750025758727707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979637103","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99326617,0.0034123417,0.000015517462,0.00016396154,0.00006940308,0.0027986765,0.000032906057,0.00006013655,0.0001808891],"genre_scores_gemma":[0.99878865,0.00008754285,0.00036292482,0.0001789712,0.00007083235,0.00013899727,0.000093796625,0.00004521161,0.0002330679],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9966674,0.00037281634,0.0008937018,0.000501733,0.0010874339,0.0004769207],"domain_scores_gemma":[0.99793214,0.0004996138,0.00033271738,0.00080661924,0.00024880588,0.00018010555],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00075717,0.00039041459,0.0010578784,0.00040673386,0.000036158013,0.000011896628,0.00021505146,0.00018232435,0.0007254524],"category_scores_gemma":[0.00048659302,0.00033575614,0.00036563163,0.00043950952,0.00007257085,0.00013331637,0.00004428727,0.00022432618,0.00012466416],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004768404,0.004738786,0.06696575,0.00028256158,0.0019436595,0.00029104573,0.0017863468,0.0007602204,0.8072497,0.0000028967993,0.00007183993,0.11113875],"study_design_scores_gemma":[0.11816403,0.011212702,0.6812946,0.0010432651,0.0011766091,0.000058084774,0.000027686512,0.0025181624,0.1841048,0.000041417607,0.00003590216,0.00032269204],"about_ca_topic_score_codex":0.00006773777,"about_ca_topic_score_gemma":0.000012441376,"teacher_disagreement_score":0.6231449,"about_ca_system_score_codex":0.0034566522,"about_ca_system_score_gemma":0.0039722878,"threshold_uncertainty_score":0.99990946},"labels":[],"label_agreement":null},{"id":"W2979656437","doi":"10.1182/blood.v108.11.1377.1377","title":"ENMD-981693 Is an Orally-Active Kinase Inhibitor with Activity towards Human Hematologic Cancers In Vitro and In Vivo.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Kinase; Aurora inhibitor; Tyrosine kinase; Cancer research; Ponatinib; Chronic myelogenous leukemia; Pharmacology; Dasatinib; Biology; Imatinib; Leukemia; Apoptosis; Cell cycle; Cell biology; Immunology; Biochemistry; Myeloid leukemia; Signal transduction","score_opus":0.015070919677906807,"score_gpt":0.2672596203174913,"score_spread":0.2521887006395845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979656437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99700284,0.00018239036,0.0000016126085,0.00017611907,0.00002077923,0.00056683965,0.000037512964,0.000047427406,0.0019644995],"genre_scores_gemma":[0.99900496,0.000021451127,0.0004922545,0.000103795486,0.00007533472,0.00009377038,0.000022661849,0.000027798269,0.00015795777],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99870884,0.000053223604,0.00019369963,0.00046941088,0.00022036191,0.00035445997],"domain_scores_gemma":[0.9994575,0.000022971499,0.000085201114,0.0002884671,0.000030858675,0.00011502076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000080111,0.00024441752,0.00046434946,0.00016107644,0.000046349,0.000015892887,0.00006061723,0.00012967088,0.00007768887],"category_scores_gemma":[0.000013852898,0.00019897924,0.00003197301,0.00025176912,0.00010522318,0.00016845929,0.000039105395,0.00024223859,0.0000025560119],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00369085,0.006250698,0.2693642,0.0003076903,0.00022272747,0.004649604,0.0020868499,0.00001749447,0.70716196,0.00004184632,0.00020125472,0.0060048467],"study_design_scores_gemma":[0.018959649,0.0007304828,0.1640555,0.00017279455,0.00009607748,0.00016737556,0.00020789,0.00004894134,0.81513333,0.00007725613,0.000111349116,0.00023935536],"about_ca_topic_score_codex":0.017394478,"about_ca_topic_score_gemma":0.008874507,"teacher_disagreement_score":0.10797139,"about_ca_system_score_codex":0.0010505085,"about_ca_system_score_gemma":0.00045590225,"threshold_uncertainty_score":0.9891488},"labels":[],"label_agreement":null},{"id":"W2979656709","doi":"10.1182/blood.v120.21.2770.2770","title":"Longterm Serial Transplantability of BCR-ABL+ Chronic Phase CML Cells Is Predicted by a 6-Week LTC-IC Assay.","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"CD34; Haematopoiesis; CD38; Molecular biology; Biology; Flow cytometry; Stem cell; Imatinib mesylate; Bone marrow; Stromal cell; Immunology; Cancer research; Imatinib; Myeloid leukemia; Cell biology","score_opus":0.01377356161243415,"score_gpt":0.26515686154616774,"score_spread":0.2513832999337336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979656709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936457,0.001866351,0.00008468681,0.000091629496,0.0003934861,0.0009833265,0.0017352392,0.00012126925,0.0010782777],"genre_scores_gemma":[0.9975678,0.00022276485,0.00027841338,0.000088472625,0.0006103293,0.000063711544,0.0005691174,0.00005439115,0.00054500275],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99766284,0.000117361444,0.0005855719,0.00043350653,0.00049388956,0.00070680986],"domain_scores_gemma":[0.9984978,0.00011977481,0.00018577519,0.00074407633,0.000069457325,0.000383134],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00033668656,0.00034670264,0.00065190584,0.000077518474,0.000057389087,0.000010281407,0.0001737796,0.00025814513,0.0020663736],"category_scores_gemma":[0.000039195613,0.00030672978,0.00021885552,0.00019922043,0.00015439153,0.00017458503,0.000037858634,0.0002747048,0.00007697878],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015707497,0.03278675,0.04323414,0.0018089818,0.0016058211,0.00010115155,0.0031027207,7.080433e-7,0.90269387,0.000007968655,0.008936925,0.0041502034],"study_design_scores_gemma":[0.05205797,0.0024246247,0.0067814155,0.00027659148,0.002069782,0.00016978326,0.000043400138,0.00007008614,0.93244123,0.0000060778307,0.0033702827,0.00028877385],"about_ca_topic_score_codex":0.00025837292,"about_ca_topic_score_gemma":0.000022656675,"teacher_disagreement_score":0.05048722,"about_ca_system_score_codex":0.0005269377,"about_ca_system_score_gemma":0.0006002026,"threshold_uncertainty_score":0.9999385},"labels":[],"label_agreement":null},{"id":"W2979695032","doi":"10.1182/blood.v120.21.2787.2787","title":"Long-Term Follow-up of Ongoing Patients in 2 Studies of Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia.","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Internal medicine; Myeloid leukemia; Adverse effect; Phases of clinical research; Oncology; Gastroenterology; Clinical trial","score_opus":0.02828955524897615,"score_gpt":0.30231408564641565,"score_spread":0.2740245303974395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979695032","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893735,0.008747651,0.000010630483,0.000029390438,0.00029602204,0.0011729227,0.00003717875,0.000026392281,0.0003062959],"genre_scores_gemma":[0.9978955,0.0006665836,0.00051396096,0.00002183336,0.00016844089,0.00011761955,0.000076992575,0.000044400305,0.0004946859],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981374,0.000040945546,0.00067010376,0.00027277175,0.00033373295,0.0005450306],"domain_scores_gemma":[0.99870217,0.00019666948,0.00033411596,0.0004268971,0.00022012145,0.00012004395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031600602,0.00026050807,0.00086140045,0.00021107847,0.0000365069,0.0000025480078,0.00012449047,0.0001185382,0.00003985007],"category_scores_gemma":[0.00035555777,0.00022038056,0.00020102269,0.00024709036,0.00008842062,0.00014181346,0.00009858613,0.00013433248,0.000008842504],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030158594,0.0016489034,0.9775381,0.0021438617,0.0010302999,0.000010130851,0.0014691553,0.000004498933,0.008594689,0.000039979048,0.000101554986,0.0071172486],"study_design_scores_gemma":[0.05412709,0.0013452717,0.7645836,0.0010832297,0.0009701553,0.000015058649,0.000107621294,0.000017002907,0.17745127,0.000016717884,0.00008414431,0.00019886876],"about_ca_topic_score_codex":0.00009407729,"about_ca_topic_score_gemma":0.00021067305,"teacher_disagreement_score":0.21295452,"about_ca_system_score_codex":0.001257852,"about_ca_system_score_gemma":0.00040704914,"threshold_uncertainty_score":0.8986858},"labels":[],"label_agreement":null},{"id":"W2979699646","doi":"10.1182/blood.v116.21.515.515","title":"BCR-ABL1 Kinase Activity but Not Its Expression Is Dispensable for Ph+ Quiescent Stem Cell Survival Which Depends on the PP2A-Controlled Jak2 Activation and Is Sensitive to FTY720 Treatment","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"CD38; Progenitor cell; Stem cell; Chronic myelogenous leukemia; CD34; Haematopoiesis; Tyrosine kinase; Cancer research; Biology; Imatinib mesylate; Cell biology; Chemistry; Leukemia; Immunology; Imatinib; Myeloid leukemia; Signal transduction","score_opus":0.024861234722222018,"score_gpt":0.2680445943309308,"score_spread":0.2431833596087088,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979699646","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99086374,0.000018491288,0.000067830726,0.0034939626,0.000253406,0.0037620906,0.00018252281,0.000058934125,0.0012990208],"genre_scores_gemma":[0.9932319,0.000040377563,0.00019119063,0.0006255979,0.00028107167,0.0005014453,0.000034158424,0.000058643873,0.0050356467],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979559,0.00012146683,0.0002780461,0.0007011807,0.0004618965,0.00048149808],"domain_scores_gemma":[0.99784774,0.00079677324,0.00019256507,0.0006661497,0.00021426548,0.00028252596],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002854029,0.00043665429,0.0006744285,0.00009129788,0.0003010989,0.00006150596,0.000093087096,0.00020659354,0.000113339345],"category_scores_gemma":[0.00014176713,0.00027329166,0.00016869047,0.0001551625,0.000029768908,0.00012850905,0.00007258732,0.00026919087,0.000055079046],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006709545,0.0026121363,0.0007161777,0.00007368037,0.00036580957,0.000023848328,0.0015735034,0.0000033574472,0.9825145,0.0000370033,0.0004635462,0.0049069133],"study_design_scores_gemma":[0.03873297,0.0015201229,0.005322426,0.00014657786,0.00059083133,0.000013452211,0.00035246872,0.0005332271,0.95174336,0.0000035647706,0.0008032029,0.00023777985],"about_ca_topic_score_codex":0.00028806448,"about_ca_topic_score_gemma":0.00021290418,"teacher_disagreement_score":0.032023422,"about_ca_system_score_codex":0.0004648951,"about_ca_system_score_gemma":0.00028299793,"threshold_uncertainty_score":0.9999719},"labels":[],"label_agreement":null},{"id":"W2979720787","doi":"10.1182/blood.v128.22.1907.1907","title":"Failure to Achieve Early Molecular Milestone within 3 Months Is Associated with Higher Risk of Relapse and Worse Survival after Allogeneic Hematopoietic Stem Cell Transplant for Chronic Myeloid Leukemia Patients, Especially after Tyrosine Kinase Inhibitor Failure","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; Juravinski Hospital; McMaster University; Université Laval; Princess Margaret Cancer Centre; Ottawa Hospital; University of Calgary; University of Ottawa; University of Toronto","funders":"","keywords":"Medicine; Transplantation; Internal medicine; Myeloid leukemia; Milestone; Hematopoietic stem cell transplantation; Oncology; Refractory (planetary science); Disease","score_opus":0.004515056254231405,"score_gpt":0.19101327670544416,"score_spread":0.18649822045121275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979720787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99420637,0.0013165185,0.00013359835,0.0004451715,0.00012754537,0.0022866267,0.0013846462,0.00007581272,0.000023728262],"genre_scores_gemma":[0.9962602,0.00007635605,0.0014361986,0.00014622063,0.00016036344,0.00056791905,0.00008833861,0.00017110551,0.0010932581],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968025,0.00015020487,0.0007243097,0.00091283204,0.00070445996,0.0007056853],"domain_scores_gemma":[0.99797964,0.00015930031,0.00037949716,0.0007182613,0.00029808117,0.00046523788],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022835012,0.0006588506,0.00096262567,0.00018624823,0.000075351236,0.000030828396,0.00016876735,0.00040705712,0.00011790017],"category_scores_gemma":[0.000030136494,0.0004467506,0.00023286614,0.0003080905,0.00016941754,0.00014507805,0.000077023105,0.00027838463,0.00002211047],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024399979,0.0056176144,0.69062835,0.0017485656,0.0049225893,0.0020067182,0.011091298,0.000034513807,0.25693527,0.00005398339,0.00085945876,0.001701644],"study_design_scores_gemma":[0.11525088,0.0150220385,0.45048788,0.005851437,0.00852174,0.00006724018,0.00016242305,0.00000720499,0.40142563,0.000062047984,0.0012800884,0.00186141],"about_ca_topic_score_codex":0.0000989472,"about_ca_topic_score_gemma":0.0008537309,"teacher_disagreement_score":0.2401405,"about_ca_system_score_codex":0.00096009485,"about_ca_system_score_gemma":0.0006384951,"threshold_uncertainty_score":0.9997984},"labels":[],"label_agreement":null},{"id":"W2979737440","doi":"10.1182/blood.v126.23.2775.2775","title":"Imatinib Suspension and Validation (ISAV) Study: Results at 24 Months","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Imatinib; Discontinuation; Medicine; Imatinib mesylate; Internal medicine; Oncology; Minimal residual disease; Myeloid leukemia; Digital polymerase chain reaction; Surgery; Gastroenterology; Leukemia; Polymerase chain reaction; Biology","score_opus":0.0445280892108227,"score_gpt":0.2954789681220792,"score_spread":0.2509508789112565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979737440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914208,0.00030451623,0.0000010129464,0.00033677914,0.00011951448,0.0007581139,0.000010486496,0.00007636987,0.0069724033],"genre_scores_gemma":[0.9962021,0.000024100671,0.0006578744,0.000047440204,0.00011644813,0.000020781448,0.00010315493,0.000019757137,0.0028083283],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989204,0.000053756976,0.00024047411,0.00029507032,0.00032314882,0.00016715578],"domain_scores_gemma":[0.9992154,0.000060104638,0.000081975035,0.000369202,0.00008266128,0.00019063876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026967836,0.00013012603,0.00021780473,0.00005210706,0.000053265587,0.000014991839,0.000037916016,0.00006046428,0.000025787678],"category_scores_gemma":[0.00031103578,0.00010515926,0.000025547415,0.00008997407,0.0000258945,0.00006649823,0.000095176794,0.00007971015,0.00014564309],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003813276,0.008941598,0.9068672,0.0001571698,0.0009051949,0.0015761758,0.017561048,0.000020234796,0.014818782,0.000065395034,0.036290623,0.008983292],"study_design_scores_gemma":[0.29905978,0.009419537,0.5361055,0.0004448391,0.0032940297,0.0012793265,0.00430412,0.0006706365,0.13475223,0.00036405347,0.009497347,0.0008086265],"about_ca_topic_score_codex":0.00019479515,"about_ca_topic_score_gemma":0.00007682788,"teacher_disagreement_score":0.37076172,"about_ca_system_score_codex":0.00026056473,"about_ca_system_score_gemma":0.00013177609,"threshold_uncertainty_score":0.42882705},"labels":[],"label_agreement":null},{"id":"W2979776691","doi":"10.1182/blood.v122.21.854.854","title":"BP5-087, a Novel STAT3 Inhibitor, Combines With BCR-ABL1 Inhibition To Overcome Kinase-Independent Resistance In Chronic Myeloid Leukemia","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Imatinib; Myeloid leukemia; Cancer research; Tyrosine-kinase inhibitor; Imatinib mesylate; Tyrosine kinase; Leukemia; breakpoint cluster region; Chemistry; Biology; Signal transduction; Immunology; Cell biology; Biochemistry; Genetics; Receptor; Cancer","score_opus":0.010732773050989158,"score_gpt":0.2340605270182843,"score_spread":0.22332775396729515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979776691","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99292713,0.0009775186,0.00009561092,0.00084276305,0.00012302656,0.0022901066,0.00004745403,0.00017611025,0.0025202741],"genre_scores_gemma":[0.9923052,0.00008305101,0.0028774291,0.0005450513,0.00030432062,0.0006194703,0.0001317649,0.00010602167,0.0030276896],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99672604,0.000052742344,0.00064249703,0.00086505135,0.00083948305,0.000874185],"domain_scores_gemma":[0.99823046,0.00009102517,0.0001860833,0.00085238396,0.00020273699,0.0004373015],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020125923,0.00051586557,0.0007082606,0.00036971885,0.00011172172,0.000076738004,0.00016795893,0.00022411389,0.00033312227],"category_scores_gemma":[0.00008557143,0.00044278076,0.00010398168,0.00074377743,0.000104068386,0.00035549141,0.00013915985,0.0004963603,0.0004950661],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028839738,0.008990999,0.12847073,0.0025046798,0.0011514967,0.00305233,0.0040172366,0.00038393695,0.8307233,0.0019146223,0.012360988,0.0035457362],"study_design_scores_gemma":[0.12346637,0.0046441564,0.6490157,0.005835432,0.0006870195,0.00055356923,0.0004957265,0.00021574955,0.20541829,0.00065248704,0.007228705,0.0017867888],"about_ca_topic_score_codex":0.0022794248,"about_ca_topic_score_gemma":0.0046703503,"teacher_disagreement_score":0.625305,"about_ca_system_score_codex":0.006062513,"about_ca_system_score_gemma":0.0018154052,"threshold_uncertainty_score":0.9998024},"labels":[],"label_agreement":null},{"id":"W2979809231","doi":"10.1182/blood.v124.21.519.519","title":"Epic: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML)","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Ponatinib; Medicine; Imatinib; Internal medicine; Imatinib mesylate; Myeloid leukemia; Clinical endpoint; Nilotinib; Oncology; Randomized controlled trial","score_opus":0.012773701566025007,"score_gpt":0.2755707507136372,"score_spread":0.26279704914761215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979809231","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946512,0.00027362024,0.00005670717,0.000058738224,0.00008654508,0.0036792895,0.00007659066,0.00007945392,0.0010378853],"genre_scores_gemma":[0.9972504,0.00003620174,0.0012725818,0.0000647716,0.00026839433,0.00040297332,0.0005164294,0.00010093868,0.00008732965],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99625117,0.0002094237,0.0010923492,0.00077393226,0.00085619034,0.00081691967],"domain_scores_gemma":[0.99771124,0.00034270994,0.0005578778,0.00095082266,0.00015371686,0.00028361648],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00039152656,0.00057193474,0.0013747598,0.00045281646,0.00005442689,0.000021785198,0.0002841825,0.00019788425,0.0002673196],"category_scores_gemma":[0.000230476,0.00044062166,0.00012470942,0.0007798557,0.00022372922,0.00020091291,0.00007001464,0.0005142928,0.000030185516],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45892137,0.10451161,0.28762537,0.0032842949,0.0028954253,0.0018502071,0.0048971167,0.0031925007,0.010154321,0.00030662402,0.00057298836,0.12178817],"study_design_scores_gemma":[0.92559373,0.031367354,0.031718384,0.0014399404,0.0005004991,0.0000240501,0.000050695748,0.0026939476,0.00571754,0.000016368382,0.00040735296,0.0004701055],"about_ca_topic_score_codex":0.000807854,"about_ca_topic_score_gemma":0.0017939102,"teacher_disagreement_score":0.4666724,"about_ca_system_score_codex":0.0045844344,"about_ca_system_score_gemma":0.004158864,"threshold_uncertainty_score":0.99980456},"labels":[],"label_agreement":null},{"id":"W2979819506","doi":"10.1182/blood.v128.22.1884.1884","title":"Impact of Long-Term Tyrosine Kinase Inhibitor Exposure on Spermatogenesis in Juvenile Rats","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Shriners Hospitals for Children - Canada","funders":"","keywords":"Spermatogenesis; Dasatinib; Internal medicine; Endocrinology; Tyrosine-kinase inhibitor; Imatinib; Biology; Tyrosine kinase; Medicine; Andrology; Receptor; Cancer; Myeloid leukemia","score_opus":0.015866259245845768,"score_gpt":0.2786456389294777,"score_spread":0.2627793796836319,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979819506","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983257,0.0006362684,0.0000017823229,0.00011802779,0.000069969414,0.00036891238,0.000058910315,0.000034558678,0.00038587718],"genre_scores_gemma":[0.99906677,0.00009960981,0.000062008825,0.000031753436,0.00016352949,0.000024189316,0.000022528031,0.000034736553,0.00049486797],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988233,0.000037081616,0.0003380838,0.00027020086,0.00024412265,0.00028721255],"domain_scores_gemma":[0.99914396,0.00007001736,0.0001028019,0.00048893935,0.000048326,0.00014597068],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007678963,0.00020366226,0.00040611497,0.00016131953,0.00001609995,0.000004559324,0.00007876238,0.00011016036,0.0004858858],"category_scores_gemma":[0.000079287565,0.00012375027,0.00017212617,0.00017968079,0.000049039387,0.000060921015,0.000035534635,0.000073328796,0.00012668215],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027377473,0.0018354598,0.731457,0.00006159163,0.0001217626,0.0005615567,0.00006717057,6.577197e-7,0.25988507,0.0000036485796,0.0002060542,0.0055262526],"study_design_scores_gemma":[0.012058099,0.0009676731,0.59711736,0.0005227822,0.00009890745,0.00008032894,0.0000025926136,4.824884e-7,0.38905522,0.0000023390828,0.000009374133,0.000084845604],"about_ca_topic_score_codex":0.000073699564,"about_ca_topic_score_gemma":0.000033504788,"teacher_disagreement_score":0.13433965,"about_ca_system_score_codex":0.00045155842,"about_ca_system_score_gemma":0.00033351438,"threshold_uncertainty_score":0.53201085},"labels":[],"label_agreement":null},{"id":"W2979943258","doi":"10.1182/blood.v120.21.31.31","title":"STAT3 Inhibition Synergizes with BCR-ABL1 Inhibition to Overcome Kinase-Independent TKI Resistance in Chronic Myeloid Leukemia (CML)","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Imatinib mesylate; Imatinib; Cancer research; Dasatinib; K562 cells; Myeloid leukemia; Progenitor cell; Medicine; Leukemia; Biology; Immunology; Stem cell; Cell biology","score_opus":0.011499081624645462,"score_gpt":0.245605280269978,"score_spread":0.23410619864533252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979943258","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98985684,0.0026556156,0.000078826306,0.00038922214,0.00012611871,0.0012608544,0.000050253926,0.00017301989,0.0054092244],"genre_scores_gemma":[0.9945974,0.00019858535,0.0018735126,0.00035276826,0.00052767125,0.00030095156,0.0002152097,0.000096439224,0.0018375092],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99688184,0.0001006005,0.0005563157,0.0006402734,0.00081328064,0.0010076994],"domain_scores_gemma":[0.99845254,0.00008497498,0.00018146877,0.0006928212,0.00010220048,0.00048600053],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00038222846,0.00045275228,0.0005676825,0.0003724416,0.00011339401,0.00003848432,0.000090140995,0.00022503735,0.00025184447],"category_scores_gemma":[0.00007604871,0.0004007012,0.00010129605,0.0006711725,0.00008030679,0.00046954496,0.00009726833,0.00045501272,0.0003236339],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008081956,0.012023219,0.30522618,0.004374092,0.0017023394,0.0068213907,0.011104284,0.00072454946,0.6223992,0.009714748,0.010441028,0.007387038],"study_design_scores_gemma":[0.060433336,0.0027711992,0.4928855,0.0053469017,0.0009928633,0.00065285363,0.00067812746,0.000033667948,0.4233882,0.0004703029,0.010797653,0.0015493921],"about_ca_topic_score_codex":0.0005834904,"about_ca_topic_score_gemma":0.0027755725,"teacher_disagreement_score":0.19901098,"about_ca_system_score_codex":0.008451445,"about_ca_system_score_gemma":0.0012340196,"threshold_uncertainty_score":0.9998445},"labels":[],"label_agreement":null},{"id":"W2979954166","doi":"10.1182/blood.v114.22.37.37","title":"The Bcr-Abl SH2-Kinase Domain Interface Is Critical for Leukemogenesis and An Additional Therapeutic Target in CML.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"","keywords":"SH2 domain; Tyrosine kinase; Cancer research; ABL; Protein kinase domain; Autophosphorylation; Philadelphia chromosome; Biology; Cell biology; Proto-oncogene tyrosine-protein kinase Src; Kinase; Signal transduction; Chemistry; Protein kinase A; Biochemistry; Mutant","score_opus":0.017092326915973316,"score_gpt":0.3116450184784985,"score_spread":0.29455269156252517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979954166","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873317,0.004174758,0.00028200756,0.0062728566,0.000060185852,0.00068251864,0.0005382091,0.00005105262,0.00060670945],"genre_scores_gemma":[0.99260145,0.00007649555,0.0053175115,0.0013373143,0.00020987226,0.00010885431,0.00013661964,0.00002185655,0.00019002208],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9988861,0.000055948927,0.0002197803,0.00031352774,0.00018797233,0.0003366443],"domain_scores_gemma":[0.99895006,0.0005399917,0.000029437644,0.00028870365,0.000052856525,0.00013893911],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001779089,0.00016931964,0.00021709465,0.00005404345,0.000137816,0.000033906614,0.000093802235,0.00009135175,0.0005445287],"category_scores_gemma":[0.00015367623,0.00012172093,0.00006416674,0.00009441522,0.00011268707,0.00007946978,0.000019184357,0.00012130681,0.000014449665],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014706099,0.047181815,0.0655114,0.0012009257,0.0039820494,0.0026005222,0.017076567,0.000044451026,0.16556437,0.08558356,0.14317693,0.45337132],"study_design_scores_gemma":[0.104331605,0.011603152,0.4649957,0.0010842651,0.0020840124,0.0017472329,0.0041757775,0.0035762386,0.13317701,0.12625813,0.14505401,0.001912846],"about_ca_topic_score_codex":0.00001686795,"about_ca_topic_score_gemma":0.00003068986,"teacher_disagreement_score":0.45145845,"about_ca_system_score_codex":0.00018639059,"about_ca_system_score_gemma":0.00021135603,"threshold_uncertainty_score":0.5962208},"labels":[],"label_agreement":null},{"id":"W2979965900","doi":"10.1182/blood.v126.23.2778.2778","title":"Comparative Effectiveness of Generic Imatinib and Brand-Name Imatinib for the Treatment of Chronic Myeloid Leukemia","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Notre-Dame; McGill University Health Centre; Hôpital du Sacré-Cœur de Montréal; Hôpital Maisonneuve-Rosemont; Hôpital de l'Enfant-Jésus; Jewish General Hospital","funders":"","keywords":"Imatinib; Hazard ratio; Medicine; Internal medicine; Oncology; Cumulative incidence; Proportional hazards model; Confidence interval; Odds ratio; Poisson regression; Myeloid leukemia; Imatinib mesylate; Cohort; Population","score_opus":0.04255657440685568,"score_gpt":0.3102607268209065,"score_spread":0.2677041524140508,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979965900","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98367584,0.013038157,0.00032304358,0.00003485956,0.00008543537,0.0022003807,0.00008200176,0.000024447392,0.00053582597],"genre_scores_gemma":[0.9971911,0.0004877918,0.0016081666,0.00000872161,0.00011645596,0.00038440147,0.00005981714,0.000025486423,0.000118116885],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988033,0.00010572495,0.0003588538,0.00026850775,0.0002274872,0.00023609982],"domain_scores_gemma":[0.99820733,0.00086391537,0.00022850647,0.0004083351,0.00017051592,0.00012138074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002659224,0.00024145187,0.0008453653,0.00005695554,0.00005223653,0.000007090003,0.000087052926,0.00007731726,0.000017349648],"category_scores_gemma":[0.000056720382,0.00014783259,0.00014763886,0.00013743121,0.00021440123,0.000047098303,0.000026534417,0.000055239336,0.000005491719],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029617105,0.038338725,0.14658312,0.017888347,0.03458203,0.00018503878,0.060543302,0.0041517946,0.48456022,0.0029091372,0.0017637209,0.17887744],"study_design_scores_gemma":[0.119982615,0.01777364,0.08210279,0.00068424543,0.0041087843,0.00022988456,0.00074599264,0.007711342,0.76382923,0.00028893555,0.0021820797,0.00036048456],"about_ca_topic_score_codex":0.00020195633,"about_ca_topic_score_gemma":0.0000219247,"teacher_disagreement_score":0.27926898,"about_ca_system_score_codex":0.0008244363,"about_ca_system_score_gemma":0.0009834096,"threshold_uncertainty_score":0.60284376},"labels":[],"label_agreement":null},{"id":"W2979970416","doi":"10.1182/blood.v104.11.711.711","title":"Leukemic Stem Cells of Chronic Phase CML Patients Consistently Display Very High BCR-ABL Transcript Levels and Reduced Responsiveness to Imatinib Mesylate in Addition to Generating a Rare Subset That Produce Imatinib Mesylate-Resistant Differentiated Progeny.","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"CD38; Imatinib mesylate; CD34; Haematopoiesis; Cancer research; Stem cell; Imatinib; Myeloid leukemia; Biology; Immunology; Medicine; Cell biology","score_opus":0.022833019468571577,"score_gpt":0.26156553584485576,"score_spread":0.23873251637628418,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979970416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99254286,0.0006129765,0.000053906293,0.00017480784,0.00023152062,0.0045209257,0.0017484342,0.000096375436,0.00001818445],"genre_scores_gemma":[0.99672014,0.00003093079,0.0015656777,0.00010108352,0.000072433,0.0005296956,0.0007553729,0.0001092347,0.000115431896],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99599326,0.00027499523,0.0011668896,0.0010739437,0.000707667,0.0007832363],"domain_scores_gemma":[0.9979814,0.0001274259,0.00041277372,0.00075664785,0.00029928284,0.00042241532],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034707141,0.00063076324,0.0011331345,0.00043060334,0.00015269018,0.00005923677,0.00020703899,0.00021076437,0.00007216336],"category_scores_gemma":[0.00014308178,0.00057084655,0.00016135917,0.0006512804,0.000095181254,0.00022355426,0.00010113143,0.00029432826,0.000017985247],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003064028,0.0031786375,0.0015173575,0.0010296978,0.00044318056,0.0002279163,0.0026775713,0.00025432542,0.9847227,0.00002080363,0.00004979809,0.002814001],"study_design_scores_gemma":[0.049070325,0.0029254497,0.040400416,0.0029003373,0.00067993114,0.000053968815,0.00019352554,0.00016055722,0.9030368,0.000019811352,0.00003067061,0.00052823016],"about_ca_topic_score_codex":0.00025512482,"about_ca_topic_score_gemma":0.00018802762,"teacher_disagreement_score":0.08168591,"about_ca_system_score_codex":0.0017072314,"about_ca_system_score_gemma":0.0012493798,"threshold_uncertainty_score":0.9996743},"labels":[],"label_agreement":null},{"id":"W2980009311","doi":"10.1182/blood.v128.22.3072.3072","title":"Timely Molecular Monitoring and Achievement of Major Molecular Response in Chronic Myeloid Leukemia","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Notre-Dame; McGill University Health Centre; Hôpital du Sacré-Cœur de Montréal; Hôpital Maisonneuve-Rosemont; Hôpital de l'Enfant-Jésus; Jewish General Hospital","funders":"","keywords":"Medicine; Internal medicine; Odds ratio; Confidence interval; Nilotinib; Myeloid leukemia; Cohort; Generalized estimating equation; Oncology; Pediatrics; Imatinib","score_opus":0.009334774563588175,"score_gpt":0.2540622047700731,"score_spread":0.2447274302064849,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980009311","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951815,0.0034973319,0.00008483091,0.0004227798,0.00004120909,0.0004723445,0.0000091625825,0.000037466692,0.00025338662],"genre_scores_gemma":[0.9980151,0.00020769557,0.0012416436,0.000029958532,0.00005005513,0.000053968226,0.0000031781228,0.000042682554,0.0003557025],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99843866,0.00010177109,0.00036726266,0.00038638295,0.00033603175,0.00036989542],"domain_scores_gemma":[0.9990922,0.00010711338,0.000102020145,0.000502941,0.00004480119,0.00015092226],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031307872,0.00022234183,0.00038527645,0.00019444933,0.0000218534,0.000006561498,0.00010516684,0.00011859256,0.000043743337],"category_scores_gemma":[0.00014149847,0.00016848702,0.0000798082,0.0001816178,0.000086734406,0.0000602793,0.000108334905,0.00012561906,0.000028046314],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007554809,0.00021522655,0.022006191,0.00009936262,0.00020628341,0.0007334504,0.00009061076,0.0000060391158,0.9724345,0.00006203266,0.0000056395825,0.0033851708],"study_design_scores_gemma":[0.01825001,0.00095961895,0.10557645,0.00073057227,0.00023045744,0.00008028581,0.000021032205,0.000010186683,0.87372845,0.000060054157,0.00019388781,0.00015899695],"about_ca_topic_score_codex":0.000086901535,"about_ca_topic_score_gemma":0.0000033692108,"teacher_disagreement_score":0.09870606,"about_ca_system_score_codex":0.0016668625,"about_ca_system_score_gemma":0.0008280675,"threshold_uncertainty_score":0.68707013},"labels":[],"label_agreement":null},{"id":"W2980012151","doi":"10.1182/blood-2018-99-114589","title":"Patients' Perspectives on the Definition of Cure in Chronic Myeloid Leukemia: A US Based Survey","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Respondent; Family medicine; Myeloid leukemia; Disease; Internal medicine","score_opus":0.023972809184352604,"score_gpt":0.2560843325740426,"score_spread":0.23211152338969002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980012151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99354917,0.00024126067,0.000005828971,0.0001418355,0.00005361699,0.00053449906,0.000058221092,0.000027269023,0.0053883176],"genre_scores_gemma":[0.9992706,0.00006385937,0.00016536028,0.00016071502,0.0001300749,0.000044909226,0.000096856704,0.000025605303,0.00004199208],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99870336,0.00017073145,0.0002521789,0.00030151967,0.0003181443,0.00025407103],"domain_scores_gemma":[0.9988518,0.00030543402,0.0001198381,0.00047238695,0.00019516419,0.00005540334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030333226,0.00017234278,0.00026279772,0.0001222964,0.000056543722,0.000006851366,0.00010900057,0.00011226365,0.00032155847],"category_scores_gemma":[0.00041976833,0.00011843076,0.000079126025,0.00034222967,0.00018670125,0.000036687125,0.000027840671,0.00023076477,0.0000966891],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000977806,0.004386345,0.98472065,0.00016153834,0.00033643012,0.000039402756,0.0023877933,0.00001253803,0.0034376364,0.0014274928,0.001089727,0.0010226225],"study_design_scores_gemma":[0.014642245,0.0024893172,0.96541995,0.0003129994,0.00012694461,0.000004801407,0.00018763014,0.00012471875,0.016342413,0.000075947595,0.00014596769,0.00012707172],"about_ca_topic_score_codex":0.0009052046,"about_ca_topic_score_gemma":0.00083727145,"teacher_disagreement_score":0.019300723,"about_ca_system_score_codex":0.0017287943,"about_ca_system_score_gemma":0.001107838,"threshold_uncertainty_score":0.48294663},"labels":[],"label_agreement":null},{"id":"W2980110969","doi":"10.1182/blood.v118.21.4518.4518","title":"Very Late Relapse of a Philadelphia Positive Acute Megakaryocytic Leukemia Post Allogenic Bone Marrow Transplant","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Cytarabine; Bone marrow; Leukemia; Internal medicine; Acute leukemia; Minimal residual disease; Cyclophosphamide; Induction chemotherapy; Chemotherapy; Acute megakaryoblastic leukemia; Oncology","score_opus":0.014640710586387969,"score_gpt":0.2255738572674379,"score_spread":0.21093314668104993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980110969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933905,0.0012149083,0.000007687344,0.00022940568,0.000120788616,0.0006081188,0.00025117156,0.00010134986,0.0040760734],"genre_scores_gemma":[0.996685,0.00048235,0.0011185507,0.00030857004,0.00007463798,0.000035352798,0.00022933389,0.000067075845,0.0009990947],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981111,0.00005793882,0.00052215526,0.00045863233,0.0003671643,0.00048300286],"domain_scores_gemma":[0.9987625,0.00006689069,0.00018676417,0.0006062944,0.00012258752,0.00025494958],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013699075,0.0003436308,0.0006543681,0.00017801813,0.00005759472,0.000005490775,0.00016862278,0.00023007377,0.0003042926],"category_scores_gemma":[0.000027835993,0.00029885457,0.0003093137,0.0002265151,0.0001457639,0.00011944082,0.000051875275,0.00031762826,0.00014343549],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055545564,0.0033236765,0.018657062,0.00045832852,0.008714172,0.013666716,0.009419965,0.000003491567,0.9389235,0.0002987975,0.00052958773,0.00045018166],"study_design_scores_gemma":[0.055220254,0.0049881237,0.22390364,0.0013558544,0.01666448,0.008182532,0.00018025827,0.00013110047,0.6880987,0.00023116429,0.00015457133,0.0008892641],"about_ca_topic_score_codex":0.0005578703,"about_ca_topic_score_gemma":0.000046209963,"teacher_disagreement_score":0.25082472,"about_ca_system_score_codex":0.00052381615,"about_ca_system_score_gemma":0.0008522378,"threshold_uncertainty_score":0.99994636},"labels":[],"label_agreement":null},{"id":"W2980124547","doi":"10.1182/blood.v116.21.2266.2266","title":"Allogeneic Stem Cell Transplantation for Blast Crisis (BC) Chronic Myelogenous Leukemia (CML) In the Tyrosine Kinase Inhibitors (TKIs) Era. Analysis of Pre-Transplant Variables on Transplant Outcome. On Behalf of the Societe Francaise De Greffe De Moelle Et De Therapie Cellulaire and the French Group of CML","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Dasatinib; Medicine; Imatinib; Transplantation; Internal medicine; Imatinib mesylate; Chronic myelogenous leukemia; Chemotherapy; Surgery; Chemotherapy regimen; Hematopoietic stem cell transplantation; Oncology; Gastroenterology; Myeloid leukemia; Leukemia","score_opus":0.008025564271183915,"score_gpt":0.23945587822861347,"score_spread":0.23143031395742955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980124547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99540323,0.0012084732,0.00059459085,0.00040139232,0.00006436505,0.001495718,0.00075173867,0.000016870648,0.00006360162],"genre_scores_gemma":[0.9976548,0.0011279322,0.00046924036,0.00028211178,0.000058071462,0.00019395814,0.0001485058,0.0000433285,0.000022066732],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975476,0.000401235,0.0007546168,0.000391363,0.0004544276,0.00045076004],"domain_scores_gemma":[0.99779564,0.0010215949,0.00037670488,0.00066294905,0.00005923141,0.0000838903],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013212466,0.00036314945,0.0007779823,0.0001884028,0.0001446555,0.00001374697,0.00037242184,0.00028869652,0.000018703871],"category_scores_gemma":[0.0000147906185,0.00019993208,0.0005202802,0.00049047376,0.00027190105,0.00004126745,0.000013697155,0.0005078576,3.1564883e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033320258,0.0032950048,0.19250627,0.0027731047,0.0037977647,0.00007688584,0.056376062,0.0077720527,0.72802,0.0006232413,0.000048525457,0.001379064],"study_design_scores_gemma":[0.025162,0.0014629705,0.32459798,0.0005491524,0.014050105,0.00007430286,0.00048307335,0.003630415,0.62959105,0.00009927183,0.00002512043,0.00027455774],"about_ca_topic_score_codex":0.004621349,"about_ca_topic_score_gemma":0.005169372,"teacher_disagreement_score":0.13209172,"about_ca_system_score_codex":0.00032256966,"about_ca_system_score_gemma":0.0007550126,"threshold_uncertainty_score":0.8152994},"labels":[],"label_agreement":null},{"id":"W2980161915","doi":"10.1182/blood.v118.21.2743.2743","title":"Targeting the CML Stem/Progenitor Cell with JAK2 (BMS-911543)/ABL Inhibitor Combination Therapy","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Progenitor cell; Stem cell; Cancer research; Imatinib mesylate; Haematopoiesis; Biology; Tyrosine kinase; Imatinib; Medicine; Immunology; Myeloid leukemia; Cell biology; Signal transduction","score_opus":0.021412703126364174,"score_gpt":0.2213805887140572,"score_spread":0.19996788558769302,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980161915","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990608,0.0014887002,0.000021975971,0.00016638392,0.0001717375,0.0010108075,0.0000057910884,0.000118453965,0.006408154],"genre_scores_gemma":[0.9960267,0.00012239197,0.0012031131,0.00019900348,0.00031713172,0.00012026646,0.000028097775,0.000056938854,0.0019263745],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986901,0.00006957606,0.0002454268,0.00030819274,0.00036201792,0.00032466959],"domain_scores_gemma":[0.99911255,0.000059940896,0.00014781383,0.0004477698,0.00012206241,0.00010985692],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019338199,0.0002286062,0.00023875778,0.000053668296,0.0001547088,0.00002061718,0.00014675457,0.00009691994,0.00021717712],"category_scores_gemma":[0.000013782907,0.00013224593,0.000074406315,0.00018818282,0.00007268434,0.00008909167,0.000036430753,0.00021789136,0.00014476976],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033130394,0.025866425,0.6723466,0.00066493906,0.0033817843,0.0011460384,0.025086394,0.000006373825,0.22832368,0.001054098,0.008835777,0.029974837],"study_design_scores_gemma":[0.03918314,0.0030167073,0.026282988,0.00018070861,0.00067813316,0.00018774193,0.0011033076,0.00008474308,0.92279047,0.00007300793,0.005989494,0.0004295312],"about_ca_topic_score_codex":0.000117974465,"about_ca_topic_score_gemma":0.000006045968,"teacher_disagreement_score":0.6944668,"about_ca_system_score_codex":0.00014524828,"about_ca_system_score_gemma":0.00023800302,"threshold_uncertainty_score":0.5392833},"labels":[],"label_agreement":null},{"id":"W2980189821","doi":"10.1182/blood.v120.21.2777.2777","title":"BCR/ABL Transcript At 3 Months Predicts Long-Term Outcomes Following Second Generation Tyrosine Kinase Inhibitor Therapy in the Patients with CML in Chronic Phase Who Failed Imatinib.","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Imatinib; Medicine; Dasatinib; Internal medicine; Tyrosine-kinase inhibitor; Myeloid leukemia; Imatinib mesylate; Tyrosine kinase; Gastroenterology; Oncology; Cancer; Receptor","score_opus":0.02163640729661542,"score_gpt":0.2752854487210246,"score_spread":0.2536490414244092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980189821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99393743,0.0031051962,0.000008748266,0.00013169949,0.00021558563,0.0023456488,0.000050839713,0.000045469187,0.00015935922],"genre_scores_gemma":[0.99809057,0.00005619443,0.00012075924,0.00029085306,0.00027986636,0.00035754216,0.0004951701,0.00006050774,0.0002485549],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978042,0.0001460563,0.0005147626,0.00038169057,0.0005397415,0.0006134949],"domain_scores_gemma":[0.9990686,0.000073742776,0.00013510117,0.00053265865,0.000038726426,0.0001511449],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029658093,0.00037779263,0.0005329475,0.00016526217,0.00010139595,0.000035960722,0.00014112529,0.00014099659,0.00022290982],"category_scores_gemma":[0.00003761935,0.00023687277,0.00013888955,0.00028510558,0.000046553454,0.0004209154,0.000024726509,0.00026139154,0.00001772083],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027973513,0.004193106,0.9738986,0.000083422055,0.0002352015,0.000109217995,0.0037380632,0.00000514688,0.0146204885,0.0000027792582,0.000102111095,0.0027321535],"study_design_scores_gemma":[0.09370101,0.0014250637,0.87751025,0.0002754311,0.00023959951,0.000008910538,0.000047004643,0.00008849096,0.026366398,8.891539e-7,0.000105185914,0.00023174567],"about_ca_topic_score_codex":0.000075334116,"about_ca_topic_score_gemma":0.0013175498,"teacher_disagreement_score":0.0963883,"about_ca_system_score_codex":0.0010752117,"about_ca_system_score_gemma":0.00023938024,"threshold_uncertainty_score":0.9659391},"labels":[],"label_agreement":null},{"id":"W2980250364","doi":"10.1182/blood.v114.22.2178.2178","title":"IFN-γ (interferon-gamma) Genotype Predict Cytogenetic and Molecular Response to Imatinib Therapy in Chronic Myeloid Leukemia.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Imatinib; Cancer research; Myeloid leukemia; Imatinib mesylate; Medicine; Interferon; Pharmacology; Immunology; Biology","score_opus":0.012863517730166836,"score_gpt":0.2668555399682042,"score_spread":0.25399202223803735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980250364","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901241,0.006759659,0.000051327243,0.0009786191,0.00004592961,0.0012024393,0.000011806591,0.00010256267,0.0007235686],"genre_scores_gemma":[0.9959564,0.00072115747,0.0016081842,0.0010570914,0.00012573293,0.00007215281,0.000019955176,0.00005148243,0.00038782874],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99796253,0.0001399541,0.00041035516,0.0005853269,0.00034535388,0.0005564588],"domain_scores_gemma":[0.9988151,0.000082413804,0.00007100119,0.0006720193,0.000050927025,0.0003085488],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032132634,0.00033795822,0.00047907443,0.00021326929,0.000047938087,0.000029781722,0.00016803524,0.00016560078,0.0001186554],"category_scores_gemma":[0.00012399128,0.00030688502,0.00008671016,0.00032904977,0.000054676657,0.00005455007,0.000059593258,0.00025662518,0.00009629503],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047648665,0.00055582396,0.0049718064,0.000054991742,0.00020801031,0.0010252845,0.0009715797,0.00010638563,0.94828665,0.000018109506,0.00024179643,0.03879469],"study_design_scores_gemma":[0.046668753,0.018096954,0.44716167,0.00064308726,0.00028870718,0.00071524846,0.00007059551,0.00046471806,0.4815157,0.00016958445,0.0035580741,0.00064688467],"about_ca_topic_score_codex":0.00007253175,"about_ca_topic_score_gemma":0.000035155917,"teacher_disagreement_score":0.46677095,"about_ca_system_score_codex":0.0015838968,"about_ca_system_score_gemma":0.0011861012,"threshold_uncertainty_score":0.9999383},"labels":[],"label_agreement":null},{"id":"W2980266028","doi":"10.1182/blood.v128.22.2909.2909","title":"Potential Targeting Ph+ Acute Lymphoblastic Leukemia Stem and Progenitor Cells By Modulating the CIP2A-SET-SETBP1 -Mediated Suppression of PP2A Activity","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Progenitor cell; Cancer research; Protein phosphatase 2; Haematopoiesis; Stem cell; Leukemia; Myeloid leukemia; Biology; Immunology; Medicine; Cell biology; Phosphatase","score_opus":0.007683294762602238,"score_gpt":0.2254734273308391,"score_spread":0.21779013256823687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980266028","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99805725,0.0004050926,0.00019434757,0.00014396902,0.00020128443,0.00066676957,0.00019798585,0.000076950004,0.000056333472],"genre_scores_gemma":[0.9987664,0.000105737636,0.00032532672,0.00002202598,0.00020085783,0.0000427413,0.00003663348,0.000048431528,0.00045183947],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982089,0.00012024687,0.0003659023,0.00043026468,0.00044611946,0.00042861424],"domain_scores_gemma":[0.9987185,0.00033269936,0.00029842235,0.0003899379,0.000084377825,0.00017608554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020530973,0.00027641203,0.00040904302,0.00005322318,0.00014732395,0.000018529598,0.00013745484,0.00016844847,0.0000577951],"category_scores_gemma":[0.000104620354,0.00015175862,0.000102163474,0.00013279848,0.000142267,0.0001321767,0.00016188227,0.00014874896,0.00002011781],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022884499,0.00023731144,0.008355051,0.00010512643,0.00040642457,0.00005501843,0.00017843406,0.000004398945,0.9847988,9.1542256e-7,0.0007368442,0.0048928633],"study_design_scores_gemma":[0.012722731,0.00033189944,0.006585114,0.00035857773,0.00090245454,0.00010354845,0.000081760314,0.001751169,0.97680795,0.000006077776,0.0001566146,0.00019208489],"about_ca_topic_score_codex":0.00007584045,"about_ca_topic_score_gemma":0.0000015564902,"teacher_disagreement_score":0.012493885,"about_ca_system_score_codex":0.00039287377,"about_ca_system_score_gemma":0.0003491071,"threshold_uncertainty_score":0.6188537},"labels":[],"label_agreement":null},{"id":"W2980283917","doi":"10.1182/blood.v114.22.38.38","title":"A Novel AHI-1-BCR-ABL-JAK2 Interaction Complex Mediates Cellular Resistance to Tyrosine Kinase Inhibitors in CML .","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia Hospital","funders":"","keywords":"Cancer research; Tyrosine kinase; Imatinib mesylate; Biology; Stem cell; Myeloid leukemia; Protein kinase B; Imatinib; Signal transduction; Cell biology","score_opus":0.020534149640663465,"score_gpt":0.27000577000732534,"score_spread":0.24947162036666187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980283917","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926366,0.0009127154,0.00008087378,0.0025211421,0.0001898491,0.0006851573,0.000019153802,0.00010974538,0.0028447425],"genre_scores_gemma":[0.9929412,0.000039603587,0.004463382,0.0008746608,0.0003657833,0.00003753782,0.00013131439,0.00003168466,0.0011148597],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99831563,0.000030169049,0.00044382573,0.00045380293,0.00034940493,0.00040716553],"domain_scores_gemma":[0.9990735,0.00006889389,0.00010677898,0.00044572027,0.000066962646,0.00023811468],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014713116,0.00025896693,0.00040471606,0.00025061332,0.000052321666,0.000024834013,0.00011197914,0.00011384422,0.00014240724],"category_scores_gemma":[0.00019580137,0.0002455056,0.00008582526,0.0005004514,0.00003415533,0.00011843239,0.000039664705,0.00024737132,0.00011983783],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005254279,0.0037628128,0.008888537,0.0000987521,0.000083102634,0.000569385,0.00076627627,0.000018330265,0.9761735,0.00009418895,0.0053003374,0.0037193072],"study_design_scores_gemma":[0.030967284,0.0013396677,0.12845819,0.0015009727,0.0004016744,0.00014307928,0.0003038954,0.00029737357,0.8029773,0.00013940614,0.03281054,0.0006606294],"about_ca_topic_score_codex":0.0001870841,"about_ca_topic_score_gemma":0.0004060689,"teacher_disagreement_score":0.17319624,"about_ca_system_score_codex":0.00066184276,"about_ca_system_score_gemma":0.00015534947,"threshold_uncertainty_score":0.9999997},"labels":[],"label_agreement":null},{"id":"W2980302906","doi":"10.1182/blood.v114.22.2606.2606","title":"Secondary Chromosomal Abnormalities Appear to Be Less Prognostic for Children with Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with Intensified Imatinib and Chemotherapy: Results of the Children's Oncology Group (COG) Study AALL0031.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"","keywords":"Medicine; Internal medicine; Etoposide; Chemotherapy; Imatinib; Chemotherapy regimen; Philadelphia chromosome; Acute lymphocytic leukemia; Ifosfamide; Imatinib mesylate; Cohort; Oncology; Gastroenterology; Leukemia; Chromosomal translocation; Lymphoblastic Leukemia; Biology; Myeloid leukemia","score_opus":0.012310091314362148,"score_gpt":0.24852121687732937,"score_spread":0.23621112556296722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980302906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98867273,0.00017748383,0.00001525908,0.0017646959,0.000027640563,0.008209755,0.0007691097,0.00012874803,0.0002345943],"genre_scores_gemma":[0.9964199,0.000027510836,0.0009767984,0.0013507674,0.0001582233,0.00033775778,0.00052905193,0.00009882618,0.0001011282],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970619,0.00013825229,0.0006962322,0.000908345,0.0004992846,0.00069597905],"domain_scores_gemma":[0.9980171,0.00022835255,0.00044201192,0.00074112776,0.00028771948,0.00028374066],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019835298,0.00066300604,0.0011341699,0.0001807757,0.00020538659,0.000043112606,0.00030335883,0.00020967766,0.000014399378],"category_scores_gemma":[0.000087798515,0.0004133979,0.00013071732,0.00043826725,0.000345167,0.00015702622,0.00009876573,0.00034171165,0.0000020520263],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12433292,0.04291607,0.6269185,0.0008057548,0.07665499,0.0018576352,0.061314695,0.00019049793,0.039540894,0.00036140817,0.0016461763,0.023460489],"study_design_scores_gemma":[0.083462924,0.0361457,0.8573056,0.0005700265,0.0057002963,0.00309798,0.0010134614,0.000040221203,0.012167996,0.000009531409,0.000016812852,0.0004694694],"about_ca_topic_score_codex":0.00045072194,"about_ca_topic_score_gemma":0.00026704327,"teacher_disagreement_score":0.2303871,"about_ca_system_score_codex":0.0005758113,"about_ca_system_score_gemma":0.000982053,"threshold_uncertainty_score":0.9998318},"labels":[],"label_agreement":null},{"id":"W2980391958","doi":"10.1182/blood.v122.21.2743.2743","title":"Final Analysis Of The Efficacy and Tolerability Of Subcutaneous Omacetaxine Mepesuccinate, ≥24 Months After First Dose, In Patients With Chronic Phase (CP) Or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML)","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Tolerability; Discontinuation; Internal medicine; Adverse effect; Cohort; Nilotinib; Dasatinib; Neutropenia; Oncology; Imatinib; Surgery; Myeloid leukemia; Chemotherapy","score_opus":0.013854395526400921,"score_gpt":0.2597159242319458,"score_spread":0.24586152870554487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980391958","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99575204,0.0011340735,0.000003866137,0.00010373126,0.00004927662,0.0026626165,0.00017553703,0.00003730093,0.00008158219],"genre_scores_gemma":[0.9990639,0.00010424624,0.00011637621,0.00003319247,0.000046077537,0.00020685438,0.00015334619,0.000048372698,0.00022759846],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969337,0.00012636544,0.0010058647,0.00073255925,0.0006100873,0.0005914309],"domain_scores_gemma":[0.9976019,0.00022235392,0.0004735024,0.0011628029,0.00032030573,0.0002191276],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001693764,0.0005001148,0.0013243542,0.00036644773,0.000085451655,0.000026479676,0.0002773592,0.00020445995,0.0016471593],"category_scores_gemma":[0.00014744476,0.00030237617,0.00021374453,0.0018095883,0.00031550846,0.0001882481,0.00014356949,0.00038418698,0.000008223256],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02153714,0.026563462,0.9082229,0.001498274,0.0068044676,0.00045193496,0.001292183,0.0010883993,0.0095892465,0.0000027846877,0.00011294998,0.022836268],"study_design_scores_gemma":[0.12731154,0.007987753,0.84260195,0.00039923567,0.0049063913,0.00004597224,0.000021734382,0.003354539,0.012979603,0.00000240509,0.00006359318,0.00032525812],"about_ca_topic_score_codex":0.0017164329,"about_ca_topic_score_gemma":0.0050933743,"teacher_disagreement_score":0.105774395,"about_ca_system_score_codex":0.0018049759,"about_ca_system_score_gemma":0.001227811,"threshold_uncertainty_score":0.99994284},"labels":[],"label_agreement":null},{"id":"W2980451885","doi":"10.1182/blood.v122.21.2723.2723","title":"Bosutinib As Therapy For Chronic Phase Chronic Myeloid Leukemia Following Resistance Or Intolerance To Imatinib: 48-Month Update","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Bosutinib; Medicine; Nilotinib; Internal medicine; Imatinib; Dasatinib; Gastroenterology; Imatinib mesylate; Myeloid leukemia; Tyrosine-kinase inhibitor; Cancer","score_opus":0.01628572101885572,"score_gpt":0.30704614556833904,"score_spread":0.2907604245494833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980451885","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9788104,0.0095962705,0.00043392018,0.0020266098,0.00047824153,0.0056545855,0.000060693073,0.0003702695,0.0025689634],"genre_scores_gemma":[0.97051257,0.0008416316,0.010050264,0.0019053142,0.0012496546,0.002997859,0.0002006383,0.00021952628,0.012022558],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99631876,0.00006485386,0.00081332546,0.0010229534,0.0005755311,0.0012045657],"domain_scores_gemma":[0.9975806,0.00019082698,0.00025871865,0.0012742829,0.00016133337,0.0005342528],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00030796,0.0006327583,0.0009466191,0.0001713797,0.0002946207,0.00011137052,0.00044270686,0.00023243275,0.0013224384],"category_scores_gemma":[0.00026368498,0.0005061285,0.00041835537,0.00050419895,0.000081857455,0.0003364827,0.000091330745,0.0003364483,0.0013918156],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012009377,0.008436296,0.002362467,0.0029217089,0.0068776584,0.0014807484,0.0044430736,0.00012835494,0.4195716,0.0009471205,0.13390955,0.40691203],"study_design_scores_gemma":[0.251319,0.01097061,0.0036769162,0.0027866901,0.0012835036,0.00025563766,0.00024698733,0.0013700837,0.29680985,0.0006891982,0.42856982,0.0020217034],"about_ca_topic_score_codex":0.00024308193,"about_ca_topic_score_gemma":0.0003642703,"teacher_disagreement_score":0.40489033,"about_ca_system_score_codex":0.0034922077,"about_ca_system_score_gemma":0.003621812,"threshold_uncertainty_score":0.99973905},"labels":[],"label_agreement":null},{"id":"W2980964338","doi":"10.1182/blood-2018-99-110135","title":"Early Prediction of Stable MR4.5 By Achievement of 2.8 Log Reduction in BCR-ABL1 qPCR Levels at 6 Months in Patients with Chronic Myeloid Leukemia Treated with Frontline Imatinib","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Discontinuation; Imatinib; Medicine; Imatinib mesylate; Internal medicine; Oncology; Population; Univariate analysis; Tyrosine-kinase inhibitor; Myeloid leukemia; Multivariate analysis; Cancer; Environmental health","score_opus":0.009069011810929513,"score_gpt":0.21465828633521317,"score_spread":0.20558927452428366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980964338","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972984,0.00027592617,0.000028098406,0.000032296433,0.00004605179,0.0015843968,0.0002817807,0.00004481277,0.00040823343],"genre_scores_gemma":[0.99769557,0.00003515643,0.0008408224,0.00000800205,0.000071426744,0.000100925354,0.00047552132,0.000056899713,0.0007156971],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99766016,0.000074092815,0.0007352087,0.00050608075,0.0005821034,0.00044237578],"domain_scores_gemma":[0.99867177,0.000025581887,0.00043044702,0.0005352644,0.00022647694,0.000110447916],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019387227,0.00032242035,0.00064718345,0.00026163078,0.000044817272,0.000006042121,0.000106528016,0.00016772689,0.00013039571],"category_scores_gemma":[0.000025303803,0.0002494648,0.00004594529,0.0005179145,0.00020644107,0.00021044524,0.000052947344,0.00020609982,0.000009761873],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035287498,0.004222858,0.9497953,0.00022656075,0.00040157716,0.000011087832,0.0008241783,0.00009157336,0.039376527,0.000002445077,0.00026048912,0.0012586755],"study_design_scores_gemma":[0.05579645,0.01149589,0.76454335,0.00082999223,0.00033654468,0.00000977566,0.000061812316,0.00023229001,0.16646092,0.0000035311812,0.00006310672,0.0001663145],"about_ca_topic_score_codex":0.0050968276,"about_ca_topic_score_gemma":0.0012304893,"teacher_disagreement_score":0.1852519,"about_ca_system_score_codex":0.003280193,"about_ca_system_score_gemma":0.0006170871,"threshold_uncertainty_score":0.99999577},"labels":[],"label_agreement":null},{"id":"W2981061287","doi":"10.1182/blood-2018-99-116981","title":"Inactivation of Stage-Specific B-Cell Commitment Genes Generates Distinct Molecular Subtypes of BCR-ABL1 Lymphoblastic Leukemia","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Princess Margaret Cancer Centre; University Health Network; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Biology; Imatinib mesylate; Cancer research; Myeloid leukemia; Dasatinib; Leukemia; Immunology; Imatinib","score_opus":0.014884738564380445,"score_gpt":0.24219055843686338,"score_spread":0.22730581987248294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981061287","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99430394,0.00233141,0.0004310407,0.000020260772,0.00009906444,0.00041136917,0.00003935108,0.000036413487,0.002327155],"genre_scores_gemma":[0.9966634,0.00016977527,0.002347564,0.000025755333,0.00014739473,0.000024823124,0.000093272334,0.000038428785,0.00048958557],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99860334,0.000054403175,0.00043771986,0.00030826102,0.00035336515,0.00024288803],"domain_scores_gemma":[0.99875,0.00008701818,0.00027896455,0.00054007955,0.00024834715,0.0000955954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011038382,0.00022019564,0.0004341784,0.00012039479,0.000050408853,0.000007685019,0.00012074368,0.000100255376,0.00023614414],"category_scores_gemma":[0.000047784688,0.00018997584,0.000102130594,0.00024130274,0.00019265887,0.0000483672,0.00006401046,0.00007023419,0.000038303642],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002505637,0.0014515226,0.036556467,0.0003202872,0.000303422,0.000050077877,0.00022534296,0.000038491857,0.9584558,0.00023070305,0.00021255932,0.0019047777],"study_design_scores_gemma":[0.0077430317,0.0010700002,0.020095194,0.00012752994,0.00032928342,0.000017249447,0.00007058124,0.0002347276,0.96877426,0.00003129821,0.0013683189,0.00013851139],"about_ca_topic_score_codex":0.0002037818,"about_ca_topic_score_gemma":0.0000135121345,"teacher_disagreement_score":0.016461274,"about_ca_system_score_codex":0.00056234584,"about_ca_system_score_gemma":0.0004698222,"threshold_uncertainty_score":0.774699},"labels":[],"label_agreement":null},{"id":"W2981513517","doi":"10.1016/j.bbmt.2019.10.017","title":"Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study","year":2019,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"National Cancer Institute","keywords":"Medicine; Chronic myelogenous leukemia; Dasatinib; Nilotinib; Imatinib; Internal medicine; Transplantation; Maintenance therapy; Leukemia; Imatinib mesylate; Hematopoietic stem cell transplantation; Tyrosine-kinase inhibitor; Graft-versus-host disease; Oncology; Myeloid leukemia; Chemotherapy; Cancer","score_opus":0.0181249317964496,"score_gpt":0.28316357766975087,"score_spread":0.2650386458733013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981513517","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99176705,0.0022429659,0.0005861248,0.00016214927,0.00050212507,0.0037915932,0.00083741156,0.00003850063,0.000072067334],"genre_scores_gemma":[0.9939437,0.0030648776,0.0007194463,0.00003920365,0.00016208342,0.00041624805,0.0014090791,0.00004685033,0.00019853664],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99778897,0.00012899275,0.00061354984,0.0007018402,0.00025641365,0.0005102255],"domain_scores_gemma":[0.9988728,0.0003734157,0.00016261867,0.00021265954,0.00024947297,0.00012903837],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006496422,0.00031519678,0.00057115895,0.00028874393,0.00015068681,0.000019221101,0.00012990687,0.00026433938,0.000012354423],"category_scores_gemma":[0.000013827463,0.0002784809,0.00017662415,0.00012658794,0.00013474753,0.000118191376,0.000012543468,0.00020305587,0.0000019565737],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034885267,0.0009902968,0.16648532,0.0041583953,0.00095909456,0.00011569798,0.0050646784,0.000013127716,0.81563747,0.00012758128,0.000025355432,0.002934481],"study_design_scores_gemma":[0.13796572,0.018977705,0.043443643,0.0024663203,0.008027728,0.0012250923,0.0022749654,0.00031649243,0.7834769,0.00028858808,0.0005316359,0.0010051891],"about_ca_topic_score_codex":0.000105051,"about_ca_topic_score_gemma":0.00019426843,"teacher_disagreement_score":0.1344772,"about_ca_system_score_codex":0.00016067215,"about_ca_system_score_gemma":0.00029055445,"threshold_uncertainty_score":0.99996674},"labels":[],"label_agreement":null},{"id":"W2981763967","doi":"10.1080/10428194.2019.1675879","title":"Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study","year":2019,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":150,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"Bristol-Myers Squibb","keywords":"Dasatinib; Discontinuation; Medicine; Myeloid leukemia; Internal medicine; Imatinib; Tyrosine-kinase inhibitor; Adverse effect; Tyrosine kinase; Oncology; Gastroenterology; Cancer; Receptor","score_opus":0.005489341495418336,"score_gpt":0.237756561886154,"score_spread":0.23226722039073566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981763967","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886814,0.003611557,0.00007097985,0.00020418363,0.00027230312,0.0059250197,0.000064382875,0.00022044253,0.00094977586],"genre_scores_gemma":[0.9959876,0.0002713385,0.00027251727,0.00046863142,0.00021948872,0.00055528875,0.0003368316,0.00026303937,0.0016252449],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99247026,0.00068780925,0.0014137125,0.0021316565,0.0015894821,0.0017070612],"domain_scores_gemma":[0.9954694,0.0006597249,0.0006488294,0.002334487,0.0002657352,0.000621806],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0012396532,0.0013648468,0.0016398,0.00056770426,0.0004887492,0.00031174612,0.0006338631,0.0005489395,0.0002009546],"category_scores_gemma":[0.00023297676,0.0010014595,0.00020979025,0.0011872357,0.00057460583,0.00078975526,0.0005378468,0.00048088736,0.00012287006],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.028162407,0.0030944948,0.65694654,0.0007544224,0.0017065163,0.001338179,0.0069860374,0.0012462144,0.008746474,0.0004095305,0.0005692219,0.29003996],"study_design_scores_gemma":[0.15715867,0.008724243,0.8130581,0.0006995277,0.000684537,0.00027096728,0.0012849207,0.010900307,0.002171424,0.00005100688,0.0038053708,0.0011909519],"about_ca_topic_score_codex":0.0029697795,"about_ca_topic_score_gemma":0.0013027863,"teacher_disagreement_score":0.288849,"about_ca_system_score_codex":0.04769249,"about_ca_system_score_gemma":0.011627966,"threshold_uncertainty_score":0.99991024},"labels":[],"label_agreement":null},{"id":"W2981815608","doi":"10.1038/s41571-019-0287-0","title":"Imatinib and the long tail of targeted drug development","year":2019,"lang":"en","type":"review","venue":"Nature Reviews Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University","funders":"Canadian Institutes of Health Research","keywords":"Imatinib; Medicine; Drug; Drug development; Imatinib mesylate; Anticancer drug; Targeted therapy; Cancer; Pharmacology; Intensive care medicine; Internal medicine","score_opus":0.12461724817597737,"score_gpt":0.48656931244882984,"score_spread":0.3619520642728525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981815608","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000019185121,0.9882828,0.0000042983734,0.00054307317,0.0011782575,0.0069747106,0.000014280501,0.000026506801,0.0029568993],"genre_scores_gemma":[0.0000071948316,0.98966014,0.004737434,0.0012414833,0.0004919267,0.00038255422,0.00028383077,0.000070409886,0.0031250087],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9904787,0.0028774962,0.0049205315,0.00088748446,0.00040484717,0.00043092127],"domain_scores_gemma":[0.9873564,0.0075202263,0.003470275,0.0012162641,0.00017732823,0.00025950043],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0072648046,0.00071782904,0.012687852,0.00013116925,0.000059378737,0.000008626169,0.0004899692,0.0025883145,0.00028447816],"category_scores_gemma":[0.0062346943,0.00033500718,0.0018965605,0.00039975086,0.00064816786,0.00003345837,0.00038089967,0.004606585,0.00051987066],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014236501,0.00026905313,0.00006935351,0.039530434,0.0009481597,0.00004553934,0.00004571157,6.7002657e-9,1.30366935e-8,0.00013601854,0.008975205,0.94983816],"study_design_scores_gemma":[0.0062415185,0.00027475812,0.00016083503,0.0258558,0.0065213013,0.00025068343,0.0000038420058,0.0000016658123,2.760873e-7,0.000012080047,0.9604292,0.0002480332],"about_ca_topic_score_codex":0.000006626045,"about_ca_topic_score_gemma":0.0000230939,"teacher_disagreement_score":0.951454,"about_ca_system_score_codex":0.00097631675,"about_ca_system_score_gemma":0.0057811826,"threshold_uncertainty_score":0.9999102},"labels":[],"label_agreement":null},{"id":"W2981978294","doi":"10.1016/j.jtho.2019.08.839","title":"P1.01-124 Health-Related Quality of Life (HRQoL) Data in a Phase 3 Study of First-Line Brigatinib vs Crizotinib in NSCLC (ALTA-1L)","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Ottawa Mental Health Centre","funders":"","keywords":"Medicine; Crizotinib; Quality of life (healthcare); Oncology; Internal medicine; Nursing; Lung cancer","score_opus":0.10817143177756502,"score_gpt":0.48927874484780903,"score_spread":0.38110731307024404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981978294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99201584,0.0014497654,0.000013292465,0.0040076245,0.0005595006,0.0014994226,0.000081464634,0.000011597052,0.0003614989],"genre_scores_gemma":[0.998017,0.00021512737,0.0010561405,0.000315245,0.00012948885,0.000008426734,0.00006552226,0.000037415906,0.00015562466],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99224764,0.0014670426,0.0045514135,0.00046521652,0.000781927,0.00048678447],"domain_scores_gemma":[0.99298996,0.0012219716,0.003963465,0.0011751319,0.00029285878,0.00035664506],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0062674624,0.000299118,0.003045039,0.00067104684,0.000029465727,0.0000055966607,0.0006411456,0.00030810985,0.00047038644],"category_scores_gemma":[0.0024082088,0.0002495582,0.00014715607,0.00079993653,0.00012725683,0.0002542611,0.0002909721,0.0011592448,0.000017817461],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.066526346,0.05703552,0.7553988,0.0025995327,0.0015952638,0.0013313422,0.010843954,0.0005021362,0.0027850517,0.00002595339,0.0018897328,0.099466376],"study_design_scores_gemma":[0.18940127,0.09059685,0.6939731,0.0039917426,0.0009323822,0.0011026543,0.011070776,0.003521241,0.0007849863,0.00025078407,0.0037498097,0.0006243658],"about_ca_topic_score_codex":0.003664803,"about_ca_topic_score_gemma":0.004825827,"teacher_disagreement_score":0.122874916,"about_ca_system_score_codex":0.0017535861,"about_ca_system_score_gemma":0.0038914003,"threshold_uncertainty_score":0.99999565},"labels":[],"label_agreement":null},{"id":"W2982074944","doi":"10.1182/blood.v112.11.1095.1095","title":"Dasatinib-Associated Major Molecular Responses Are Rapidly Achieved in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Following Resistance, Suboptimal Response, or Intolerance on Imatinib.","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Dasatinib; Nilotinib; Imatinib; Medicine; Internal medicine; Imatinib mesylate; Myeloid leukemia; Oncology; Pharmacology; Immunology","score_opus":0.012918723189271996,"score_gpt":0.26444529648828324,"score_spread":0.25152657329901124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982074944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954056,0.0013335941,0.00000941371,0.00019540059,0.00009868548,0.0022984517,0.000115078976,0.00019923829,0.00034453862],"genre_scores_gemma":[0.99606884,0.000089559784,0.0010479013,0.0002643828,0.00008038775,0.00038686703,0.000248612,0.00018611115,0.001627341],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99440324,0.00076689693,0.0011703356,0.0012378627,0.0011391116,0.0012825541],"domain_scores_gemma":[0.99714696,0.0006612351,0.0005686311,0.0011722599,0.00014705266,0.0003038287],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007798459,0.00081199064,0.0013611364,0.0007169962,0.00023369453,0.00003565419,0.0003744427,0.00039108357,0.00011006027],"category_scores_gemma":[0.0014226381,0.0006892739,0.00024902806,0.001674413,0.00021043081,0.00027378942,0.000095003066,0.0009677013,0.000054669494],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.280107,0.013023488,0.6193823,0.0007033153,0.002093143,0.030625248,0.0027192237,0.0015364354,0.047796864,0.000026763073,0.0006590695,0.001327139],"study_design_scores_gemma":[0.19604427,0.007352641,0.7760158,0.0037864463,0.00032061647,0.00004747297,0.000064008425,0.00023432336,0.015083104,0.0000066869575,0.0002635051,0.00078108907],"about_ca_topic_score_codex":0.00016665347,"about_ca_topic_score_gemma":0.002042275,"teacher_disagreement_score":0.15663353,"about_ca_system_score_codex":0.013766481,"about_ca_system_score_gemma":0.0068937005,"threshold_uncertainty_score":0.9995558},"labels":[],"label_agreement":null},{"id":"W2982369322","doi":"10.1159/000500229","title":"Safety-Related Postmarketing Modifications of Drugs for Hematological Malignancies","year":2019,"lang":"en","type":"article","venue":"Acta Haematologica","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Postmarketing surveillance; Drug; Adverse effect; Off-label use; Clinical trial; Food and drug administration; Pharmacovigilance; Drug approval; Pharmacology; Intensive care medicine; Internal medicine","score_opus":0.018820497167384247,"score_gpt":0.2734930318153418,"score_spread":0.2546725346479575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982369322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97248876,0.00041455383,0.000072366616,0.0024429613,0.0001089671,0.0016368874,0.000038878934,0.00015543238,0.022641217],"genre_scores_gemma":[0.99253166,0.00008411664,0.004932381,0.00016563672,0.000010994134,0.00009151906,0.0001165269,0.000024374212,0.0020427806],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99821305,0.00006757089,0.000671671,0.0004257591,0.00023691171,0.0003850301],"domain_scores_gemma":[0.9979242,0.00088014203,0.0003207065,0.0005910396,0.00017843615,0.00010546644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003223942,0.0002259809,0.00082992134,0.0000976976,0.000091394555,0.000008171644,0.00019283638,0.00026548267,0.0007429172],"category_scores_gemma":[0.0006534544,0.00016342699,0.0002500324,0.00023633325,0.00013434252,0.000068313,0.00008034137,0.00016089497,0.00014172248],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011891674,0.0063312817,0.28104228,0.008229675,0.004186877,0.00049103046,0.0060374336,0.00012396976,0.23611033,0.4074541,0.023959061,0.014142278],"study_design_scores_gemma":[0.09811421,0.01160367,0.45276174,0.007401192,0.004708193,0.01541841,0.013110225,0.022369524,0.24634999,0.024750002,0.09853877,0.00487408],"about_ca_topic_score_codex":0.000013036095,"about_ca_topic_score_gemma":0.0000011481479,"teacher_disagreement_score":0.3827041,"about_ca_system_score_codex":0.00016397356,"about_ca_system_score_gemma":0.00023067696,"threshold_uncertainty_score":0.81344223},"labels":[],"label_agreement":null},{"id":"W2983137419","doi":"10.1182/blood-2019-129825","title":"Interim Analysis of a Prospective Multicentre Study Using Next Generation Sequencing for Kinase Domain Mutational Analysis in CML Patients on First or Subsequent TKI Therapy","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Medicine; Ponatinib; Prospective cohort study; Internal medicine; Interim analysis; Oncology; Dasatinib; Clinical trial; Myeloid leukemia; Imatinib","score_opus":0.06965957962405488,"score_gpt":0.3214276455862354,"score_spread":0.2517680659621805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2983137419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99695116,0.000046161447,0.00013527951,0.00001266571,0.000046408673,0.002710697,0.000064489206,0.000013931838,0.000019194651],"genre_scores_gemma":[0.99742615,0.000006948744,0.001850404,0.000034537556,0.000039414983,0.00013709557,0.00046033945,0.000021484055,0.000023636445],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99833083,0.00008371801,0.0005014693,0.00047406377,0.00039355172,0.00021639082],"domain_scores_gemma":[0.9989424,0.00016503422,0.00026260843,0.00033872834,0.00022958781,0.00006164564],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018991414,0.00020670748,0.000641896,0.00084618997,0.000060001228,0.000020546484,0.00006949938,0.000064585576,0.00017227794],"category_scores_gemma":[0.00010139819,0.0001614352,0.00026397165,0.0015771898,0.000019558744,0.00010262028,0.00002063904,0.000083204555,0.0000030669871],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011955448,0.0054976717,0.9567241,0.00003279506,0.009815436,0.000036017733,0.008754991,0.011651945,0.006009212,0.000008903994,7.167813e-7,0.00027265458],"study_design_scores_gemma":[0.03678799,0.002026015,0.8364057,0.00008609551,0.0097668385,0.0000014818629,0.0029445922,0.10245362,0.009318038,0.000007285552,0.0000018443328,0.00020052219],"about_ca_topic_score_codex":0.0011825033,"about_ca_topic_score_gemma":0.006011472,"teacher_disagreement_score":0.120318435,"about_ca_system_score_codex":0.0017701105,"about_ca_system_score_gemma":0.00022839064,"threshold_uncertainty_score":0.6583136},"labels":[],"label_agreement":null},{"id":"W2983575857","doi":"10.1182/blood-2019-131454","title":"BCR-ABL1 qPCR-Based Doubling Time within the First 6 Months after Imatinib Discontinuation Is a Predictive of Successful TKI Treatment-Free Remission","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; McGill University Health Centre; London Health Sciences Centre; Juravinski Cancer Centre; Hôpital de l'Enfant-Jésus; Dalhousie University; Princess Margaret Cancer Centre; Vancouver General Hospital; University of Calgary; BC Cancer Agency; Alberta Health Services; Alberta Hospital Edmonton; University of British Columbia; Université de Montréal; Hôpital Maisonneuve-Rosemont; CancerCare Manitoba; University of Alberta Hospital; University Health Network; Ottawa Hospital; Western University; University of Toronto","funders":"","keywords":"Discontinuation; Medicine; Internal medicine; Imatinib; Imatinib mesylate; Oncology","score_opus":0.008339008115263034,"score_gpt":0.23771599707618798,"score_spread":0.22937698896092495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2983575857","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925255,0.00048894103,0.000023420975,0.001366149,0.00009199671,0.0017481815,0.00012604921,0.00007811656,0.003551604],"genre_scores_gemma":[0.9959716,0.000016209571,0.00086249376,0.00017191768,0.00011881816,0.00020411536,0.000108574444,0.000047315396,0.0024989345],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99826634,0.000055319582,0.0004761348,0.00043666246,0.0004893172,0.00027624948],"domain_scores_gemma":[0.99806494,0.0002038894,0.00034799613,0.0011507589,0.00012487124,0.000107545944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020351188,0.00029740582,0.00046845266,0.000103399085,0.00008073732,0.000028882247,0.0002123323,0.00014246214,0.00074507657],"category_scores_gemma":[0.00013329356,0.00017938997,0.00019282979,0.00022967969,0.00007770658,0.00016118471,0.00007488001,0.00014659179,0.00013729848],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056649544,0.0064613824,0.95551115,0.0005240152,0.0020884627,0.00012847404,0.010934242,0.0003711478,0.013653952,0.000038465478,0.0017438601,0.002879868],"study_design_scores_gemma":[0.1613338,0.010060493,0.20428862,0.005141561,0.006740257,0.00011002311,0.0013532193,0.066430256,0.54069537,0.00038376206,0.00239988,0.001062744],"about_ca_topic_score_codex":0.00053868233,"about_ca_topic_score_gemma":0.00008532415,"teacher_disagreement_score":0.75122255,"about_ca_system_score_codex":0.00038817618,"about_ca_system_score_gemma":0.00042615482,"threshold_uncertainty_score":0.81580657},"labels":[],"label_agreement":null},{"id":"W2984671704","doi":"10.1200/jco.2009.27.15_suppl.7027","title":"Subcutaneous omacetaxine mepesuccinate in chronic myeloid leukemia (CML) patients resistant or intolerant to two or more tyrosine kinase inhibitors (TKIs): Data from an ongoing phase II trial","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Gastroenterology; Regimen; Phases of clinical research; Clinical trial","score_opus":0.1223123378830397,"score_gpt":0.4804999839927469,"score_spread":0.3581876461097072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2984671704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903055,0.0005224082,0.000031951167,0.0053931023,0.0018443431,0.001532944,0.00016121997,0.000041939773,0.00016661244],"genre_scores_gemma":[0.98684937,0.00052490144,0.003931527,0.0033750425,0.004612056,0.000012186759,0.00028848933,0.00006775493,0.00033865636],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99022704,0.00089706486,0.0058632204,0.0010299196,0.001122271,0.00086047215],"domain_scores_gemma":[0.99199486,0.0020578464,0.00258526,0.0014441656,0.0005016942,0.0014162041],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0034783506,0.000581573,0.0034773555,0.00048723022,0.00014964466,0.000040843533,0.0009920541,0.00066897715,0.0009910151],"category_scores_gemma":[0.008325221,0.00037820172,0.0003959731,0.0006344304,0.00018620184,0.00049659895,0.00038881565,0.0020914027,0.0000470885],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.55924004,0.014235483,0.0007025861,0.00003259164,0.0003862515,0.024005627,0.00041925535,0.00015389943,0.0029337264,0.0000044621656,0.0044082557,0.3934778],"study_design_scores_gemma":[0.5813718,0.3556069,0.016001403,0.0011459826,0.0011157125,0.00059991656,0.0001504178,0.003106364,0.00084740657,0.000065049964,0.039442692,0.00054636376],"about_ca_topic_score_codex":0.000738582,"about_ca_topic_score_gemma":0.0041550207,"teacher_disagreement_score":0.39293143,"about_ca_system_score_codex":0.008788622,"about_ca_system_score_gemma":0.014660254,"threshold_uncertainty_score":0.9999222},"labels":[],"label_agreement":null},{"id":"W2985196709","doi":"10.1182/blood.v106.11.1532.1532","title":"Characterization of Gene Expression Associated with Cyclophosphamide Resistance in Chronic Myeloid Leukemia (CML).","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Biology; Fluorescence in situ hybridization; Molecular biology; Myeloid leukemia; Chromosomal translocation; Leukemia; Cancer research; Gene; Genetics; Chromosome","score_opus":0.008037697384282326,"score_gpt":0.22493923227944498,"score_spread":0.21690153489516265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2985196709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972972,0.00068701344,0.000043711494,0.00008385528,0.000027249545,0.00046971094,0.00002614557,0.00006805352,0.0012970403],"genre_scores_gemma":[0.99596256,0.00016898697,0.0014925421,0.000062402876,0.00013853714,0.000054345517,0.00031387727,0.00004325804,0.00176347],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985776,0.00006877788,0.00040318645,0.00029513016,0.00034395533,0.00031135915],"domain_scores_gemma":[0.9991274,0.00005169514,0.0002621158,0.00039059084,0.000079333826,0.00008890388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016506821,0.00020128067,0.00038970975,0.000111715024,0.000048903617,0.0000067727688,0.00009570902,0.0001465339,0.000079492536],"category_scores_gemma":[0.00009026993,0.00017024495,0.00005006174,0.00034910298,0.000053907883,0.00013665503,0.000023952236,0.00024510635,0.000016303728],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002577407,0.00059175404,0.03144392,0.0000981187,0.0000966915,0.00006429101,0.00041073348,0.000035588982,0.9663565,0.00000874805,0.000025683863,0.00061024266],"study_design_scores_gemma":[0.010557393,0.00020749313,0.3320315,0.00088514993,0.00010969444,0.000011962598,0.000010706856,0.0000308767,0.6557379,0.0000049724413,0.0002933007,0.000119067554],"about_ca_topic_score_codex":0.000056218192,"about_ca_topic_score_gemma":0.000577318,"teacher_disagreement_score":0.3106186,"about_ca_system_score_codex":0.0027918743,"about_ca_system_score_gemma":0.0009582029,"threshold_uncertainty_score":0.7300654},"labels":[],"label_agreement":null},{"id":"W2985424883","doi":"10.1182/blood-2019-124934","title":"Initial Characterization and Toxicology of an Nmt Inhibitor in Development for Hematologic Malignancies","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Myristoylation; Dasatinib; Kinase; LYN; Cancer research; Proto-oncogene tyrosine-protein kinase Src; Ibrutinib; Apoptosis; Chemistry; Biology; Cell growth; Leukemia; Pharmacology; Chronic lymphocytic leukemia; Myeloid leukemia; Biochemistry; Immunology; Phosphorylation","score_opus":0.017481372173402985,"score_gpt":0.2693090047003008,"score_spread":0.25182763252689777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2985424883","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99908656,0.00004197985,0.000019902498,0.000048805552,0.000058648006,0.00063743786,0.000007994492,0.000013537791,0.00008511066],"genre_scores_gemma":[0.9974895,0.00000721393,0.0020932013,0.00007418929,0.000029399876,0.000064560416,0.00012675664,0.000008489446,0.00010666306],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9994522,0.000014090739,0.00019992057,0.00014974813,0.00006182621,0.00012225016],"domain_scores_gemma":[0.9997473,0.000031102398,0.00006512289,0.000093146686,0.000029631221,0.00003371806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007175638,0.000073429386,0.0002262439,0.00006873207,0.000011065836,0.000002718022,0.000024216133,0.00008015825,0.000030780586],"category_scores_gemma":[0.00003371486,0.0000635139,0.000013724889,0.00004975357,0.000020709598,0.000048613063,0.00002081671,0.000032555858,0.000005030852],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023601294,0.0011314559,0.20807227,0.0004825825,0.000059212714,0.000032627264,0.0010052313,2.8768747e-7,0.7852207,0.00021736992,0.000003073503,0.0035391648],"study_design_scores_gemma":[0.01076556,0.00083747285,0.3449694,0.00012898014,0.000043535423,0.00010383126,0.000079029865,0.000032350683,0.64258826,0.000021136206,0.00035211706,0.00007831935],"about_ca_topic_score_codex":0.000004322218,"about_ca_topic_score_gemma":0.000015793099,"teacher_disagreement_score":0.14263244,"about_ca_system_score_codex":0.00006134505,"about_ca_system_score_gemma":0.00022137549,"threshold_uncertainty_score":0.25900218},"labels":[],"label_agreement":null},{"id":"W2985546444","doi":"10.1182/blood-2019-127826","title":"Inhibition of the MiR-185-PAK6-Mediated Survival and Metabolic Pathways Selectively Targets Drug-Resistant CML Stem/Progenitor Cells","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; BC Cancer Agency; Terry Fox Research Institute","funders":"","keywords":"Cancer research; Stem cell; Biology; Myeloid leukemia; CD34; Progenitor cell; microRNA; Transcriptome; Tyrosine kinase; Gene expression profiling; Signal transduction; Gene expression; Cell biology; Gene; Genetics","score_opus":0.010034371061484203,"score_gpt":0.20809709615340616,"score_spread":0.19806272509192197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2985546444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947592,0.0025574889,0.0000014650866,0.000079551515,0.00026965013,0.0011113925,0.00016259341,0.00005325075,0.0010054155],"genre_scores_gemma":[0.9988578,0.00011169408,0.00012939177,0.00004651913,0.00010952108,0.00003743641,0.000039061128,0.00004047687,0.0006281013],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99838823,0.0001335177,0.00034014805,0.00036577095,0.00044515962,0.00032717295],"domain_scores_gemma":[0.9989856,0.00012951034,0.00020223463,0.00040555888,0.00014602592,0.000131104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002230577,0.00023555984,0.00048340717,0.0000780963,0.00006546351,0.0000122743495,0.000089006615,0.00011209463,0.00007011185],"category_scores_gemma":[0.000042964086,0.00016266124,0.00012750509,0.00030571118,0.00007688528,0.000065641376,0.00008509337,0.00019344952,0.000070701746],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018909854,0.0007789944,0.03777781,0.00020833628,0.00046190716,0.000025058815,0.00081279746,0.000001028364,0.9592588,0.00011654398,0.0001367519,0.0002328872],"study_design_scores_gemma":[0.010530326,0.00021133218,0.10800892,0.00013107335,0.0005858709,0.000022684017,0.00030201263,0.000029444773,0.8791876,0.000028881443,0.0008022656,0.00015959516],"about_ca_topic_score_codex":0.0001774216,"about_ca_topic_score_gemma":0.000053017116,"teacher_disagreement_score":0.08007119,"about_ca_system_score_codex":0.00012153757,"about_ca_system_score_gemma":0.00040401713,"threshold_uncertainty_score":0.66331327},"labels":[],"label_agreement":null},{"id":"W2988190468","doi":"10.1182/blood-2019-127839","title":"NUP98-HOXA9-Initiates Molecular and Biologic Features of Disease Progression in a Humanized Model of CML","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Clonogenic assay; Myeloid leukemia; Haematopoiesis; Cancer research; Myeloid; Stem cell; Biology; CD34; Progenitor cell; Immunology; Leukemia; clone (Java method); Cell culture; Cell biology; Gene","score_opus":0.013251522429729034,"score_gpt":0.27452625005757514,"score_spread":0.2612747276278461,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2988190468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99544203,0.0034198167,0.0000034548218,0.00005631327,0.000010874031,0.00056222355,0.000021507174,0.000017030037,0.00046673953],"genre_scores_gemma":[0.9985502,0.00009912932,0.0011565265,0.000038090817,0.000006935594,0.000021669002,0.000037497808,0.000012693954,0.00007728013],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9993124,0.00002906755,0.00018744596,0.00019750072,0.00013980934,0.00013379859],"domain_scores_gemma":[0.9995333,0.000030785806,0.0000910296,0.00023934558,0.000035333152,0.00007021669],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000063228625,0.00010769699,0.0003036452,0.0000838169,0.000007668316,0.0000023520722,0.00005089988,0.000066297966,0.000023101831],"category_scores_gemma":[0.000058366208,0.000080240956,0.000052162886,0.000077958364,0.00005625292,0.000026504285,0.000052995427,0.000077018885,0.000002668986],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013022155,0.0029603643,0.4725977,0.0012602474,0.00024816487,0.00012672054,0.00048223237,0.00005955725,0.5174897,0.00077877246,0.000026596836,0.0026677775],"study_design_scores_gemma":[0.058873236,0.0022446522,0.49467352,0.0025969748,0.0010162866,0.00003125496,0.00015384688,0.004050446,0.43304187,0.0029172373,0.000013252653,0.00038741922],"about_ca_topic_score_codex":0.00001867266,"about_ca_topic_score_gemma":0.0000024264525,"teacher_disagreement_score":0.08444778,"about_ca_system_score_codex":0.000030191813,"about_ca_system_score_gemma":0.00013897727,"threshold_uncertainty_score":0.3272131},"labels":[],"label_agreement":null},{"id":"W2988207531","doi":"10.1182/blood-2019-128283","title":"The Canadian Tyrosine Kinase Inhibitor Discontinuation Trial with Imatinib Discontinuation As a First Attempt and with Dasatinib Discontinuation As a Second Attempt of Treatment-Free Remission: Results of 4 Years of Follow-up","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; McGill University Health Centre; London Health Sciences Centre; University of Toronto; Western University; Juravinski Cancer Centre; Hôpital de l'Enfant-Jésus; Princess Margaret Cancer Centre; Vancouver General Hospital; University of Calgary; BC Cancer Agency; Alberta Health Services; Alberta Hospital Edmonton; University of British Columbia; Université de Montréal; Hôpital Maisonneuve-Rosemont; CancerCare Manitoba; University of Alberta Hospital; University Health Network; Ottawa Hospital; Dalhousie University","funders":"","keywords":"Discontinuation; Medicine; Dasatinib; Internal medicine; Imatinib; Oncology","score_opus":0.010774978578036299,"score_gpt":0.2412208297980505,"score_spread":0.2304458512200142,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2988207531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936111,0.0002167153,0.0000022995491,0.00077068276,0.00011355068,0.0031043766,0.00026224655,0.000018176195,0.0019008416],"genre_scores_gemma":[0.99451697,0.00003937492,0.0004655845,0.00001540819,0.000117759744,0.000120575656,0.00040426725,0.000048169666,0.0042718975],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99758345,0.0000946948,0.00089531287,0.0005039554,0.00059739035,0.00032518955],"domain_scores_gemma":[0.99709857,0.00038855852,0.0010127854,0.0010226055,0.00026270878,0.0002147762],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045272766,0.0003227955,0.00073025835,0.00018023505,0.00012818557,0.000038978094,0.00016134263,0.00014842938,0.00007277688],"category_scores_gemma":[0.0005737786,0.00020342259,0.00011610011,0.00032902858,0.00023158197,0.00022955023,0.000048507456,0.00013443868,0.0000065813774],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34085247,0.0110368375,0.4539816,0.0014242952,0.0071023973,0.00027916723,0.04836717,0.00006319789,0.07091013,0.0015181642,0.0025878963,0.061876677],"study_design_scores_gemma":[0.6641453,0.04291554,0.15271065,0.0042521404,0.002716694,0.00013168053,0.002840362,0.00020097001,0.12736225,0.00012569342,0.0019127389,0.00068601116],"about_ca_topic_score_codex":0.041721903,"about_ca_topic_score_gemma":0.25349808,"teacher_disagreement_score":0.32329282,"about_ca_system_score_codex":0.00038622695,"about_ca_system_score_gemma":0.0016215981,"threshold_uncertainty_score":0.96465933},"labels":[],"label_agreement":null},{"id":"W2988244627","doi":"10.1182/blood-2019-131599","title":"Comprehensive Analysis of Hematological Parameter Changes after TKI Discontinuation for Treatment-Free Remission Attempt","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; McGill University Health Centre; London Health Sciences Centre; Juravinski Cancer Centre; Hôpital de l'Enfant-Jésus; Dalhousie University; Princess Margaret Cancer Centre; Vancouver General Hospital; University of Calgary; BC Cancer Agency; Alberta Health Services; Alberta Hospital Edmonton; University of British Columbia; Université de Montréal; Hôpital Maisonneuve-Rosemont; CancerCare Manitoba; University of Alberta Hospital; University Health Network; Ottawa Hospital; Western University; University of Toronto","funders":"","keywords":"Discontinuation; Medicine; Leukopenia; Adverse effect; Internal medicine; Dasatinib; Gastroenterology; Imatinib; Immunology; Chemotherapy","score_opus":0.028937070154508786,"score_gpt":0.29384906614162654,"score_spread":0.26491199598711773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2988244627","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99746513,0.00060566637,0.00004169236,0.00044920112,0.00004334152,0.0010340583,0.00008465489,0.00003156614,0.00024466735],"genre_scores_gemma":[0.9956377,0.000056123892,0.00248028,0.00009892367,0.000041277624,0.00019590212,0.0002907132,0.000016384558,0.0011827077],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989904,0.00003303023,0.0002465838,0.0003403699,0.00018706123,0.00020256621],"domain_scores_gemma":[0.9987618,0.00028208917,0.0001415431,0.0006425655,0.00009285685,0.00007919234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000043727712,0.0001790523,0.0007185348,0.0001690589,0.000018883085,0.0000067981,0.000071799484,0.00011883349,0.00031623358],"category_scores_gemma":[0.00008009912,0.00011886623,0.0002946961,0.00023445164,0.0000338305,0.000034224162,0.000041090094,0.00003356484,0.000018612593],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014924922,0.0034130272,0.94884175,0.00033272145,0.009273244,0.00006282627,0.0007728733,0.000011102775,0.029086914,0.00006560818,0.00029546756,0.0063519534],"study_design_scores_gemma":[0.05116908,0.006239133,0.7423397,0.00042188098,0.030433407,0.00006601238,0.0003716061,0.0022202006,0.16142699,0.00020557053,0.004615841,0.0004905904],"about_ca_topic_score_codex":0.000044279313,"about_ca_topic_score_gemma":0.000045379693,"teacher_disagreement_score":0.20650208,"about_ca_system_score_codex":0.00013355193,"about_ca_system_score_gemma":0.000047566584,"threshold_uncertainty_score":0.4847224},"labels":[],"label_agreement":null},{"id":"W2988746454","doi":"10.1182/blood-2019-129545","title":"Myeloproliferative Neoplasm (MPN) Patient Online Questionnaire: Assessing Patients' Disease Knowledge in a Rare Hematologic Malignancy in the Modern Digital Information Era","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Population; Social media; The Internet; Disease; Family medicine; Internal medicine; World Wide Web; Computer science; Environmental health","score_opus":0.007325194631079829,"score_gpt":0.24303595928560537,"score_spread":0.23571076465452553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2988746454","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962864,0.00045457482,0.000025346782,0.00024313724,0.000095458476,0.0014469858,0.00006585751,0.000050484126,0.0013317624],"genre_scores_gemma":[0.9985614,0.000016156318,0.00014779335,0.00028655233,0.000029301884,0.00013903377,0.0007607357,0.000015950136,0.00004310956],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99848825,0.00009230586,0.0005185144,0.0002576721,0.00033233975,0.00031093552],"domain_scores_gemma":[0.99917173,0.000086800355,0.00016003521,0.00035833407,0.00011941776,0.00010366949],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000084332256,0.00024126886,0.00031685625,0.00018037634,0.000047216017,0.00009671819,0.000114262606,0.00009645013,0.000015871325],"category_scores_gemma":[0.00023518149,0.00016650528,0.000072627234,0.0003404326,0.000032389726,0.0009677961,0.000070825416,0.00029477917,0.0001241079],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012548022,0.0042553507,0.967525,0.00026611311,0.00003604204,0.00010835793,0.006848082,0.00006592925,0.0000074855675,0.00011825868,0.00003432475,0.020609582],"study_design_scores_gemma":[0.01413686,0.00037203214,0.9783474,0.0015322494,0.00008254173,0.000055822817,0.0007961618,0.0037338706,0.00008549666,0.00047894672,0.00012674743,0.00025185812],"about_ca_topic_score_codex":0.000027951666,"about_ca_topic_score_gemma":0.0000478027,"teacher_disagreement_score":0.020357724,"about_ca_system_score_codex":0.0004557618,"about_ca_system_score_gemma":0.00056930166,"threshold_uncertainty_score":0.6789889},"labels":[],"label_agreement":null},{"id":"W2988926823","doi":"10.1182/blood-2019-125941","title":"Patient Age and Donor HLA Matching Can Stratify Allogeneic Hematopoietic Cell Transplantation (HCT) Patients into Prognostic Groups: A Collaborative Study","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Transplantation; Population; Internal medicine; Hematopoietic cell; Cohort; Hematopoietic stem cell transplantation; Retrospective cohort study; Propensity score matching; Surgery; Haematopoiesis; Stem cell","score_opus":0.005541743676965089,"score_gpt":0.2276902146287002,"score_spread":0.22214847095173512,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2988926823","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99492264,0.00026345905,0.0000062840595,0.00003591904,0.000107690495,0.0040034195,0.000046401685,0.000058698857,0.00055551],"genre_scores_gemma":[0.99858844,0.000050050345,0.0006719942,0.0000686887,0.000026458305,0.00021738846,0.00023003232,0.000041679064,0.00010529175],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998305,0.000112430724,0.0003916098,0.0004975602,0.00040184736,0.00029155612],"domain_scores_gemma":[0.99918175,0.000090674956,0.00015472034,0.00029677714,0.000105627274,0.00017045155],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000081305865,0.00029210138,0.0004046223,0.00009795662,0.00009241551,0.00004591658,0.000065227665,0.0000904203,0.0000471054],"category_scores_gemma":[0.000018139717,0.0002482759,0.000045419034,0.00021679787,0.000035400393,0.00009023044,0.000035184177,0.00017040098,0.000046394685],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022504877,0.0056071407,0.9404742,0.00080757344,0.00034566195,0.0006539624,0.047018915,0.000010515067,0.003968073,0.000020149431,0.000016013028,0.00085271563],"study_design_scores_gemma":[0.03575616,0.008169928,0.93116766,0.0004605901,0.0018129727,0.00007797839,0.012985041,0.000013639058,0.008902992,0.00014674167,0.0000229931,0.00048328502],"about_ca_topic_score_codex":0.00033794774,"about_ca_topic_score_gemma":0.0004933783,"teacher_disagreement_score":0.03553111,"about_ca_system_score_codex":0.00022556164,"about_ca_system_score_gemma":0.00025529906,"threshold_uncertainty_score":0.99999696},"labels":[],"label_agreement":null},{"id":"W2990706354","doi":"10.1182/blood-2019-125226","title":"Increased Tumour Burden over a 36 Month Period in Chronic Myeloid Leukemia Patients Following Imatinib Discontinuation: Role of Digital PCR","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Imatinib; Discontinuation; Medicine; Myeloid leukemia; Imatinib mesylate; Internal medicine; Digital polymerase chain reaction; Oncology; Gastroenterology; Polymerase chain reaction; Biology","score_opus":0.005623635596803564,"score_gpt":0.22542339872005393,"score_spread":0.21979976312325036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990706354","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99203557,0.00063832186,0.0000012470842,0.00003397743,0.00008753165,0.0011393201,0.00005866223,0.00005436192,0.00595101],"genre_scores_gemma":[0.99858105,0.000009961516,0.00015211492,0.000018093422,0.00015020111,0.00006521354,0.00034257508,0.000056932928,0.0006238843],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978691,0.000039121227,0.00060218386,0.0004585488,0.0005899538,0.00044113645],"domain_scores_gemma":[0.9989541,0.00007085924,0.00023594109,0.00052736065,0.000065312284,0.00014639366],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012318855,0.0003057797,0.0006463932,0.00017332683,0.000034803463,0.000042011165,0.00017090503,0.00013398443,0.00028342355],"category_scores_gemma":[0.00015540485,0.00027653357,0.00025132188,0.00027877605,0.00003798445,0.0003792861,0.000119384866,0.00022137242,0.00014441],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029709746,0.0010427431,0.96128684,0.00016203595,0.00037488906,0.00008323079,0.001596431,0.000044493445,0.031110644,0.000022477287,0.000039194452,0.0039399336],"study_design_scores_gemma":[0.061158966,0.0014523709,0.9176667,0.0010361903,0.00048182192,0.000025862313,0.0006414186,0.0019643109,0.014693581,0.00006137183,0.00036723237,0.00045017328],"about_ca_topic_score_codex":0.0007676001,"about_ca_topic_score_gemma":0.00007205163,"teacher_disagreement_score":0.060861867,"about_ca_system_score_codex":0.0017709044,"about_ca_system_score_gemma":0.0011772644,"threshold_uncertainty_score":0.9999687},"labels":[],"label_agreement":null},{"id":"W2991655819","doi":"10.1016/j.leukres.2019.106285","title":"The predictive value of intracellular imatinib levels in newly diagnosed chronic myeloid leukemia","year":2019,"lang":"en","type":"letter","venue":"Leukemia Research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; University Health Network; Dalhousie University; Windsor Regional Hospital; Université de Montréal; Ottawa Hospital; Alberta Health Services; McMaster University","funders":"Novartis Pharmaceuticals Canada; Princess Margaret Cancer Foundation","keywords":"Imatinib; Myeloid leukemia; Medicine; Predictive value; Value (mathematics); Internal medicine; Oncology; Leukemia; Cancer research; Statistics; Mathematics","score_opus":0.04394516131639886,"score_gpt":0.33581562774929136,"score_spread":0.2918704664328925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2991655819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5636449,0.029698964,0.0001641746,0.34344688,0.002890379,0.024131378,0.0011533173,0.00045636646,0.034413658],"genre_scores_gemma":[0.6715921,0.019689655,0.0019881001,0.10156922,0.029800842,0.006819266,0.005450592,0.0025419223,0.16054831],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9865328,0.001867377,0.0019472955,0.0018619745,0.004681004,0.0031095527],"domain_scores_gemma":[0.9860572,0.008530118,0.0004974964,0.003693635,0.0009369583,0.00028454533],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.004124639,0.001099593,0.002112015,0.0012502184,0.0003814382,0.00015578364,0.0019879998,0.0027223283,0.0005518518],"category_scores_gemma":[0.0026410525,0.0008223193,0.0006251132,0.0018462989,0.0015723954,0.00023318833,0.00095541886,0.014199078,0.0010970151],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00086094067,0.00015249458,0.0019275188,0.003778301,0.0011667566,0.0060813692,0.0011473532,0.0009797318,0.0050038323,0.00021277566,0.9666646,0.012024304],"study_design_scores_gemma":[0.031560678,0.0039398223,0.018045101,0.0072338753,0.00050593266,0.0003839271,0.0005511923,0.022454424,0.01818047,0.00093613117,0.8947745,0.0014339694],"about_ca_topic_score_codex":0.0050980602,"about_ca_topic_score_gemma":0.00027328008,"teacher_disagreement_score":0.24187768,"about_ca_system_score_codex":0.07086175,"about_ca_system_score_gemma":0.03863958,"threshold_uncertainty_score":0.99968076},"labels":[],"label_agreement":null},{"id":"W2993113471","doi":"10.1182/blood.v110.11.1950.1950","title":"No Significance of Derivative Chromosome 9 Deletion on the Clearance Kinetics of BCR/ABL Fusion Transcripts, Cytogenetic or Molecular Response, Loss of Response or Treatment Failure to Imatinib Mesylate Therapy for Chronic Myeloid Leukemia.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Imatinib mesylate; Internal medicine; Medicine; Imatinib; Myeloid leukemia; breakpoint cluster region; Oncology; Philadelphia chromosome; Gastroenterology; Immunology; Chromosomal translocation; Biology; Genetics; Gene; Receptor","score_opus":0.025823373421198916,"score_gpt":0.2909204147503886,"score_spread":0.2650970413291897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2993113471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99232846,0.0009618928,0.001437814,0.0006560357,0.000058230755,0.0042776535,0.00020590369,0.000032736018,0.000041283693],"genre_scores_gemma":[0.9922988,0.00065028155,0.0057667918,0.00018128542,0.000071699185,0.00030733668,0.000028039993,0.00008736543,0.00060838996],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99706596,0.00037000334,0.00094029756,0.00052858464,0.0005911694,0.0005039821],"domain_scores_gemma":[0.99660486,0.0014091372,0.0004868196,0.00091501157,0.00043106164,0.0001530956],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00083577726,0.00044104145,0.00085753185,0.00021972893,0.00006804217,0.000006908885,0.00027041213,0.00020427933,0.00014046983],"category_scores_gemma":[0.00060580997,0.00026972577,0.0002731056,0.00064624276,0.0002450517,0.000037818645,0.000026373977,0.00014438026,0.000009349127],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14782515,0.0013580767,0.00012224086,0.00025109312,0.0004613709,0.00008380859,0.00136042,0.00024865175,0.8445511,0.000028766248,0.00003742227,0.003671911],"study_design_scores_gemma":[0.020742688,0.03446048,0.01436753,0.0007768887,0.00032505108,0.00004610309,0.00016583258,0.00007322312,0.92585504,0.00001487443,0.00295065,0.00022166116],"about_ca_topic_score_codex":0.00006715763,"about_ca_topic_score_gemma":0.000078043675,"teacher_disagreement_score":0.12708245,"about_ca_system_score_codex":0.0012600956,"about_ca_system_score_gemma":0.0013860499,"threshold_uncertainty_score":0.9999755},"labels":[],"label_agreement":null},{"id":"W2994442551","doi":"10.1182/blood.v112.11.1078.1078","title":"A Novel Strategy for Expanding Primitive Leukemic Cells from Chronic Phase CML Patients by Forced Overexpression of a NUP98-HOXA10 Homeodomain Fusion Gene.","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute","funders":"","keywords":"Bone marrow; Haematopoiesis; CD34; Stem cell; Biology; Homeobox; Fusion gene; Leukemia; Immunology; Cancer research; Molecular biology; Gene; Cell biology; Gene expression; Genetics","score_opus":0.024252556526667905,"score_gpt":0.28433722553601887,"score_spread":0.26008466900935096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2994442551","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935273,0.0008746529,0.0018569359,0.000007674053,0.00010156901,0.0018942808,0.0014455982,0.00006556496,0.00022645775],"genre_scores_gemma":[0.9941224,0.00030713342,0.0030092725,0.000044946002,0.00019552812,0.0001622408,0.0016724452,0.000078619385,0.00040744757],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99780667,0.000036398655,0.0005693194,0.00060603,0.00047394665,0.00050764775],"domain_scores_gemma":[0.99858254,0.00020526854,0.00038342035,0.00047582985,0.00012857535,0.00022438577],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00007603146,0.00036737492,0.00063568534,0.00011860309,0.0001563891,0.0000094904235,0.00015445727,0.00023844441,0.00014204816],"category_scores_gemma":[0.000053879485,0.00032411018,0.00022717143,0.00015153838,0.00009626191,0.0001453417,0.00008925093,0.00018243512,0.000012831445],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007482819,0.0038220657,0.0014618802,0.0001351901,0.00027585423,0.000014940576,0.0005467596,0.000012325928,0.9898342,0.0000035885682,0.0011757248,0.001969215],"study_design_scores_gemma":[0.10467151,0.0028108924,0.0030341009,0.0007050403,0.00041179731,0.000023569068,0.000086655484,0.00064361363,0.8871299,0.000020944351,0.00018974599,0.00027223598],"about_ca_topic_score_codex":0.00032010674,"about_ca_topic_score_gemma":0.000006868289,"teacher_disagreement_score":0.10392323,"about_ca_system_score_codex":0.0011173581,"about_ca_system_score_gemma":0.0007818043,"threshold_uncertainty_score":0.9999211},"labels":[],"label_agreement":null},{"id":"W2994649246","doi":"10.1200/jco.2012.30.15_suppl.6512","title":"BELA trial update: Bosutinib (BOS) versus imatinib (IM) in patients (pts) with newly diagnosed chronic phase chronic myeloid leukemia (CP CML) after 30 months of follow-up.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Discontinuation; Bosutinib; Cumulative incidence; Imatinib; Adverse effect; Gastroenterology; Myeloid leukemia; Imatinib mesylate; Cohort; Dasatinib","score_opus":0.055493534638035254,"score_gpt":0.40123744529537675,"score_spread":0.3457439106573415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2994649246","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98903626,0.002593526,0.000035346435,0.00056556956,0.0050700475,0.0016438562,0.000042498654,0.000023219873,0.000989675],"genre_scores_gemma":[0.9923958,0.0011874324,0.0015893106,0.00042747514,0.0039772703,0.00009160837,0.00006366449,0.00009507838,0.00017234843],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9908894,0.0008933719,0.0052969023,0.0005317873,0.0012253409,0.0011632101],"domain_scores_gemma":[0.9901587,0.00328807,0.004150386,0.0007707096,0.00056193717,0.0010702441],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0034214738,0.00058943813,0.003623244,0.00037967257,0.00006661611,0.000015888376,0.00047189646,0.0010114203,0.0018980382],"category_scores_gemma":[0.003949798,0.0004268372,0.0009882826,0.00044770987,0.00056699436,0.0005460547,0.00018169082,0.002175112,0.00015189889],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.60468924,0.01592872,0.1382242,0.00021194675,0.002267261,0.0011985388,0.0005363901,0.00008789648,0.000089434536,0.000035180576,0.005203524,0.23152766],"study_design_scores_gemma":[0.735822,0.10135441,0.12654717,0.0005621282,0.0016622904,0.00007380624,0.000097046555,0.00013515216,0.00023644461,0.000017396525,0.03312331,0.00036880188],"about_ca_topic_score_codex":0.00016487933,"about_ca_topic_score_gemma":0.00051123044,"teacher_disagreement_score":0.23115885,"about_ca_system_score_codex":0.009474489,"about_ca_system_score_gemma":0.014059614,"threshold_uncertainty_score":0.9998183},"labels":[],"label_agreement":null},{"id":"W2996390597","doi":"10.14740/wjon1246","title":"Hypercalcemia in T-Cell/Histiocyte-Rich Large B-Cell Lymphoma: An Unusual Presentation of a Rare Disease and Literature Review","year":2019,"lang":"en","type":"article","venue":"World Journal of Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Presentation (obstetrics); Histiocyte; Disease; Lymphoma; Rare disease; Pathology; Dermatology; Radiology","score_opus":0.011585655827893332,"score_gpt":0.31006923395192476,"score_spread":0.2984835781240314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2996390597","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9033016,0.0919504,0.0000045832176,0.0008196975,0.00018810267,0.00046656927,0.000016240685,0.00000485966,0.003247934],"genre_scores_gemma":[0.9800621,0.015997931,0.0006434686,0.0007171544,0.00013927922,0.0000071685854,0.00004701771,0.000018652634,0.0023672013],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998497,0.00022287997,0.00062457944,0.00018914061,0.00025481614,0.00021156263],"domain_scores_gemma":[0.99871695,0.00014535067,0.00046254357,0.0002192228,0.00020262845,0.00025332105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038558454,0.00015227267,0.0006791587,0.00032009263,0.000018517652,0.000007059586,0.00009965746,0.000090468246,0.00014900608],"category_scores_gemma":[0.00009496056,0.00011995776,0.00009715936,0.00040307248,0.00004124689,0.00017315552,0.000040662344,0.00027345162,0.000009983764],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0143282935,0.024800474,0.76276547,0.025040774,0.0005172001,0.02003642,0.0049080607,0.000062607694,0.017064989,0.0004914413,0.029116059,0.10086822],"study_design_scores_gemma":[0.21870984,0.01234299,0.5613311,0.027058061,0.0033709437,0.005954164,0.0008684692,0.0009352053,0.0029452117,0.00031704473,0.16533141,0.00083558436],"about_ca_topic_score_codex":0.000008542368,"about_ca_topic_score_gemma":0.00003899417,"teacher_disagreement_score":0.20438154,"about_ca_system_score_codex":0.00096146436,"about_ca_system_score_gemma":0.0011094277,"threshold_uncertainty_score":0.48917356},"labels":[],"label_agreement":null},{"id":"W2999942872","doi":"10.1182/blood-2019-128712","title":"The AHI-1-BCR-ABL-DNM2 Complex Mediates Mitochondrial Dynamics in Drug-Resistant BCR-ABL+ Cells","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute; Kinexus Bioinformatics Corporation (Canada); University of British Columbia","funders":"","keywords":"Tyrosine kinase; Protein kinase domain; SH3 domain; Biology; ABL; Ponatinib; Cancer research; Philadelphia chromosome; Cell biology; Kinase; Chemistry; Signal transduction; Nilotinib; Mutant; Biochemistry; Chromosomal translocation","score_opus":0.008218869422463049,"score_gpt":0.232257251863164,"score_spread":0.22403838244070096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999942872","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9806164,0.00089763175,0.0000032472865,0.0009332087,0.0010184963,0.0014127818,0.000085094805,0.00010352822,0.014929602],"genre_scores_gemma":[0.9868657,0.00033458293,0.00096682645,0.00024844444,0.0005240946,0.00008379963,0.00025933687,0.00008350001,0.010633745],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99740344,0.00011750202,0.00059076934,0.0005479691,0.0006133536,0.0007269674],"domain_scores_gemma":[0.99800605,0.0005570102,0.00018546656,0.0009608032,0.00007827395,0.00021242292],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00024622862,0.00036530333,0.00058734824,0.00012017874,0.00013134487,0.000059768037,0.00036250465,0.0001729851,0.0003955007],"category_scores_gemma":[0.00011783123,0.00025863462,0.00017808942,0.0003177596,0.00014133261,0.00007914813,0.00014363401,0.00041638123,0.0007980102],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064899297,0.014287518,0.24991882,0.0018030355,0.004257888,0.002904005,0.0065211053,0.00022318326,0.6212749,0.010994436,0.06974303,0.011582147],"study_design_scores_gemma":[0.28204918,0.0041184006,0.16244222,0.0025037182,0.004340408,0.0005358178,0.010015242,0.023311527,0.20164795,0.0024568222,0.30238524,0.004193459],"about_ca_topic_score_codex":0.0009491081,"about_ca_topic_score_gemma":0.003384128,"teacher_disagreement_score":0.41962695,"about_ca_system_score_codex":0.001120306,"about_ca_system_score_gemma":0.0005008401,"threshold_uncertainty_score":0.9999866},"labels":[],"label_agreement":null},{"id":"W3000218098","doi":"10.1007/s11302-019-09686-x","title":"Imatinib mesylate affects extracellular ATP catabolism and expression of NTPDases in a chronic myeloid leukemia cell line","year":2020,"lang":"en","type":"article","venue":"Purinergic Signalling","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Pró-Reitoria de Pesquisa, Universidade Federal do Rio Grande do Sul; Fonds de Recherche du Québec - Santé; Universidade Federal do Rio Grande do Sul; Coordenação de Aperfeiçoamento de Pessoal de Nível Superior; Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul; Conselho Nacional de Desenvolvimento Científico e Tecnológico; Natural Sciences and Engineering Research Council of Canada; Ministério da Ciência, Tecnologia e Inovação","keywords":"Imatinib mesylate; Myeloid leukemia; Imatinib; Cancer research; Extracellular; Adenosine; Dasatinib; Chemistry; Pharmacology; Biology; Biochemistry","score_opus":0.018775843163327956,"score_gpt":0.24959984580757782,"score_spread":0.23082400264424988,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3000218098","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96808666,0.029955208,0.0004153592,0.00032001207,0.00005372034,0.0006567192,0.000013125871,0.000091635404,0.00040757592],"genre_scores_gemma":[0.9954316,0.0015560687,0.0020465546,0.00011146507,0.0003489602,0.00005134711,0.000073808944,0.0000674855,0.00031272855],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978786,0.0000730587,0.00057960494,0.00059545145,0.00039813324,0.00047516497],"domain_scores_gemma":[0.9988494,0.00020026957,0.00026275328,0.00030220195,0.000054041215,0.00033136364],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020000058,0.00036779256,0.00074350473,0.00016144603,0.000052531956,0.00001742497,0.00015159915,0.0001622647,0.0002317096],"category_scores_gemma":[0.000105465064,0.0003244537,0.000120138524,0.0003539029,0.000083412706,0.00013259854,0.00015167335,0.0003941122,0.00002274112],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003137296,0.000119084594,0.0017404881,0.0014564873,0.000037325146,0.00046004003,0.001635347,0.007746835,0.9839103,0.000029079103,0.00011423552,0.002437006],"study_design_scores_gemma":[0.0095806755,0.0006181085,0.0015376539,0.0011460542,0.00015804023,0.000044076514,0.00014725834,0.045753345,0.93927276,0.000031378928,0.0013748629,0.00033577022],"about_ca_topic_score_codex":0.00016148691,"about_ca_topic_score_gemma":0.000007151894,"teacher_disagreement_score":0.04463757,"about_ca_system_score_codex":0.00067061733,"about_ca_system_score_gemma":0.00061244896,"threshold_uncertainty_score":0.9999207},"labels":[],"label_agreement":null},{"id":"W3000609526","doi":"10.18433/jpps30559","title":"Effects of Trough Concentration and Solute Carrier Polymorphisms on Imatinib Efficacy in Chinese Patients with Chronic Myeloid Leukemia","year":2020,"lang":"en","type":"article","venue":"Journal of Pharmacy & Pharmaceutical Sciences","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Xiangya Hospital, Central South University; Chinese Medical Association; Central South University","keywords":"Imatinib; Medicine; Myeloid leukemia; Internal medicine; Genotyping; Gastroenterology; Genotype; Genetics; Gene; Biology","score_opus":0.0247441676122409,"score_gpt":0.33426666679809197,"score_spread":0.30952249918585106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3000609526","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951444,0.0017813598,0.00002855479,0.002024352,0.00016820768,0.00065255706,0.00000774795,0.000012545835,0.00018023788],"genre_scores_gemma":[0.997777,0.00054388336,0.0003435973,0.0010385095,0.00026653492,0.000005435294,0.0000027273163,0.000016132519,0.0000061695264],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99750674,0.00013658898,0.0006618139,0.0003135393,0.00096821215,0.00041312393],"domain_scores_gemma":[0.99842733,0.00042100166,0.00041020277,0.000077620025,0.00012063002,0.0005432302],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002845145,0.00026424293,0.0005705183,0.00009378057,0.00008518878,0.000030155326,0.00020937972,0.000042753094,0.00013296164],"category_scores_gemma":[0.0002742459,0.00016519606,0.00010581678,0.0006366263,0.00048942456,0.00042969742,0.00005161058,0.00049225555,0.0000042283623],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070769675,0.0013879592,0.67311543,0.00068489637,0.00032205065,0.0005182064,0.0018856406,0.00084096775,0.211352,0.00005984753,0.00017920618,0.10257679],"study_design_scores_gemma":[0.07868747,0.0060888673,0.6861422,0.0007640313,0.0006137708,0.0001373356,0.000032542186,0.019126223,0.2062375,0.000015111747,0.0017954926,0.00035944872],"about_ca_topic_score_codex":0.000031136948,"about_ca_topic_score_gemma":0.0000017822501,"teacher_disagreement_score":0.10221734,"about_ca_system_score_codex":0.00070881005,"about_ca_system_score_gemma":0.0010550788,"threshold_uncertainty_score":0.67364997},"labels":[],"label_agreement":null},{"id":"W3001673888","doi":"10.1111/bjh.16338","title":"Experience with ponatinib in paediatric patients with leukaemia","year":2020,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; BC Children's Hospital","funders":"","keywords":"Ponatinib; Medicine; Chronic myeloid leukaemia; Pediatrics; Cohort; Lymphoblastic Leukemia; Internal medicine; Disease; Leukemia; Myeloid leukemia; Dasatinib","score_opus":0.010286206791769429,"score_gpt":0.23234594625693816,"score_spread":0.22205973946516874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3001673888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99740255,0.0011681878,0.00007747728,0.0006760113,0.000054590153,0.00023058195,0.0000046991563,0.000012807728,0.00037311472],"genre_scores_gemma":[0.9967929,0.0001232799,0.0022489056,0.00070716575,0.000071581184,0.000007792277,0.00000742311,0.000023881512,0.000017065444],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99860233,0.00006041152,0.0004911422,0.00019902203,0.00037638855,0.00027071653],"domain_scores_gemma":[0.9990505,0.0000735121,0.0003241339,0.00009891181,0.00021217355,0.00024079894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007596076,0.00013683704,0.00063628814,0.000108949804,0.000030494992,0.000014816168,0.00013094483,0.00008122767,0.00015283824],"category_scores_gemma":[0.0002207304,0.00011206927,0.000052786007,0.00034427748,0.00011260356,0.00015219301,0.000030503103,0.0004127534,0.000011111655],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001367891,0.0003530037,0.88398165,0.00010283981,0.000103988095,0.10339217,0.0010303026,0.000029588515,0.000016572574,0.000020717882,0.0010966983,0.008504594],"study_design_scores_gemma":[0.039292723,0.0047644135,0.69943666,0.001086843,0.00022472607,0.25214216,0.00078819395,0.000081629696,0.00046298525,0.000026110169,0.0013609107,0.00033261755],"about_ca_topic_score_codex":0.00005181069,"about_ca_topic_score_gemma":0.00006331193,"teacher_disagreement_score":0.18454495,"about_ca_system_score_codex":0.00020896102,"about_ca_system_score_gemma":0.00048747327,"threshold_uncertainty_score":0.4570052},"labels":[],"label_agreement":null},{"id":"W3006423751","doi":"10.1016/j.blre.2020.100671","title":"Unraveling survivin expression in chronic myeloid leukemia: Molecular interactions and clinical implications","year":2020,"lang":"en","type":"review","venue":"Blood Reviews","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Ministério da Saúde; Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro; Conselho Nacional de Desenvolvimento Científico e Tecnológico; CNIB","keywords":"Survivin; Cancer research; Myeloid leukemia; Inhibitor of apoptosis; Biology; XIAP; Tyrosine kinase; Apoptosis; Leukemia; Myeloid; Medicine; Immunology; Signal transduction; Cell biology; Programmed cell death; Caspase; Genetics","score_opus":0.0902583960252066,"score_gpt":0.4137724889208068,"score_spread":0.3235140928956002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006423751","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000059110916,0.99422634,0.00011898327,0.00022294847,0.00021200473,0.0043057157,0.000040010786,0.00007465713,0.00074020814],"genre_scores_gemma":[0.000025336938,0.9952584,0.0022623488,0.00017025163,0.000545963,0.0009068493,0.00044121488,0.00012803625,0.0002616321],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99453396,0.0008679806,0.0026746206,0.0012372627,0.00022378299,0.00046239505],"domain_scores_gemma":[0.9968396,0.0005011644,0.0009280389,0.0012415549,0.000053800024,0.00043587264],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008320684,0.0007626204,0.004550039,0.0002701311,0.00008517109,0.000040670817,0.00030305912,0.0005352824,0.00014383261],"category_scores_gemma":[0.00090387603,0.0005750867,0.001131991,0.0007262018,0.000099245204,0.00009023345,0.0003257086,0.0018493991,0.00040429205],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000044860017,0.00016677065,0.000073743366,0.016841114,0.00029297604,0.00011338189,0.000021796008,2.134317e-7,0.00006509788,0.000029040739,0.00054583035,0.98184556],"study_design_scores_gemma":[0.0015450817,0.00016294618,0.00006414576,0.061392885,0.0047619245,0.0005847112,0.0000040503724,0.00001366134,0.000014459302,0.000008922595,0.93107086,0.00037633858],"about_ca_topic_score_codex":0.000049049842,"about_ca_topic_score_gemma":0.00008330953,"teacher_disagreement_score":0.9814692,"about_ca_system_score_codex":0.0027310387,"about_ca_system_score_gemma":0.0034375095,"threshold_uncertainty_score":0.99967},"labels":[],"label_agreement":null},{"id":"W3006487497","doi":"10.1182/blood.2019003928","title":"CML in megakaryocytic transformation and extramedullary infiltration","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Infiltration (HVAC); Medicine; Physics","score_opus":0.018079431160512777,"score_gpt":0.244336848639094,"score_spread":0.22625741747858122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006487497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99408233,0.0005304177,0.000082399085,0.0019873467,0.0000141338605,0.00032455957,0.0000026962814,0.000042328847,0.0029337632],"genre_scores_gemma":[0.9986265,0.00016342694,0.00048547873,0.0005883858,0.000054504242,0.000014658384,0.000041490868,0.000008450253,0.00001711258],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99949104,0.000014467302,0.0001595085,0.00012138014,0.000110998546,0.000102607126],"domain_scores_gemma":[0.99978864,0.000019394476,0.000021283195,0.00006965039,0.000010404162,0.00009061141],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000041282685,0.00007436072,0.00012783984,0.000038726244,0.000015276204,0.000008586256,0.00001927697,0.000053692915,0.00003548812],"category_scores_gemma":[0.00003763941,0.000068353955,0.0000198236,0.0001203988,0.000016038539,0.00011370712,0.000005330622,0.000099718585,0.000020714422],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016037561,0.0035954933,0.5680142,0.0036634663,0.00079761626,0.00165185,0.058400325,0.0001403453,0.22309342,0.0034325428,0.00096353836,0.13464345],"study_design_scores_gemma":[0.09919999,0.003057699,0.7156179,0.00062256615,0.0012540432,0.0012397261,0.0015170242,0.016956333,0.15351674,0.0005240418,0.0057623265,0.0007316112],"about_ca_topic_score_codex":0.000026918484,"about_ca_topic_score_gemma":0.000014235956,"teacher_disagreement_score":0.1476037,"about_ca_system_score_codex":0.00006562782,"about_ca_system_score_gemma":0.0001090069,"threshold_uncertainty_score":0.27873933},"labels":[],"label_agreement":null},{"id":"W3008063389","doi":"10.1007/s11899-020-00560-x","title":"Mechanisms of Cardiovascular Toxicity of BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia","year":2020,"lang":"en","type":"review","venue":"Current Hematologic Malignancy Reports","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Princess Margaret Cancer Centre; McMaster University; University of Toronto; University Health Network","funders":"","keywords":"Chronic myelogenous leukemia; Medicine; Tyrosine kinase; Hematology; Dasatinib; Toxicity; Internal medicine; Tyrosine-kinase inhibitor; breakpoint cluster region; Imatinib; Leukemia; Cancer research; Pharmacology; Oncology; Receptor; Myeloid leukemia; Cancer","score_opus":0.04617367194453772,"score_gpt":0.3129403496724175,"score_spread":0.2667666777278798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008063389","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016329131,0.9920624,0.00022043163,0.000010131457,0.001147104,0.0044115814,0.00008409366,0.00012661242,0.0003047424],"genre_scores_gemma":[0.02502425,0.9732759,0.00038474752,0.000006175726,0.00016005932,0.0004662594,0.00050740666,0.00013930385,0.000035886853],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9912453,0.00036444564,0.004487057,0.0017546249,0.0012509676,0.00089759595],"domain_scores_gemma":[0.99357647,0.00015555574,0.0032657695,0.002387289,0.0002424963,0.000372404],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0008624703,0.0013160935,0.009900083,0.00060833216,0.00005434729,0.000011308701,0.00038274063,0.00094390236,0.0001687342],"category_scores_gemma":[0.0006374392,0.0010524144,0.0032593284,0.0014306218,0.00025831143,0.00008007404,0.00044155747,0.0010305982,0.000026901776],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000038307546,0.0008339057,0.00024440125,0.21513627,0.0025933401,0.026049487,0.00010169481,0.000031627245,0.00020978764,0.00056063005,0.0003913304,0.7538092],"study_design_scores_gemma":[0.0034673577,0.001323264,0.00003840426,0.19613938,0.013740008,0.021054063,0.000033238706,0.000035665096,0.015416181,0.0011186915,0.74586385,0.0017699125],"about_ca_topic_score_codex":0.00014145768,"about_ca_topic_score_gemma":0.000009934328,"teacher_disagreement_score":0.7520393,"about_ca_system_score_codex":0.006269491,"about_ca_system_score_gemma":0.008346957,"threshold_uncertainty_score":0.99995905},"labels":[],"label_agreement":null},{"id":"W3009209752","doi":"10.1007/s12012-020-09565-7","title":"Mechanisms of the Cardiac Myocyte-Damaging Effects of Dasatinib","year":2020,"lang":"en","type":"article","venue":"Cardiovascular Toxicology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Canadian Institutes of Health Research; Canada Research Chairs","keywords":"Dasatinib; Dexrazoxane; Myocyte; Doxorubicin; Cardiac myocyte; Pharmacology; Tyrosine kinase; Tyrosine-kinase inhibitor; Chronic myelogenous leukemia; Medicine; Chemistry; Cancer research; Internal medicine; Anthracycline; Leukemia; Chemotherapy; Receptor; Cancer","score_opus":0.01290230171705532,"score_gpt":0.23000711632022505,"score_spread":0.21710481460316974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009209752","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9838254,0.008081158,0.0030032457,0.0007432755,0.00089677534,0.0014784083,0.000013162459,0.0000600424,0.0018985292],"genre_scores_gemma":[0.9982124,0.000112634625,0.0008920327,0.0005378099,0.00011048952,0.000044149387,0.000007142113,0.000033583412,0.00004973614],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99834305,0.00032399633,0.00031656952,0.00032999006,0.000426942,0.00025943218],"domain_scores_gemma":[0.9985692,0.00019202167,0.00012463144,0.0008855691,0.000099103,0.00012948974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026677654,0.00018351966,0.0010604102,0.00004595514,0.00003879968,0.000002310957,0.00020798984,0.00016247884,0.000033830645],"category_scores_gemma":[0.00063323823,0.00013475561,0.001454998,0.00031274106,0.000170064,0.000025348063,0.00018815185,0.00022480564,0.000014343461],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025656543,0.00033108259,0.007834704,0.0031374076,0.01890991,0.00039791426,0.0019565017,0.0007177288,0.9290036,0.00345122,0.0013076828,0.032695714],"study_design_scores_gemma":[0.0057302914,0.00065044867,0.044345833,0.00016805476,0.0033941097,0.00007457267,0.00011694037,0.00019405053,0.9392451,0.00015518659,0.005761087,0.00016433514],"about_ca_topic_score_codex":0.000024857967,"about_ca_topic_score_gemma":5.0581104e-7,"teacher_disagreement_score":0.03651113,"about_ca_system_score_codex":0.00020264792,"about_ca_system_score_gemma":0.00032490664,"threshold_uncertainty_score":0.54951745},"labels":[],"label_agreement":null},{"id":"W3009751715","doi":"10.1038/s41375-020-0776-2","title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","year":2020,"lang":"en","type":"review","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1510,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Daiichi Sankyo Europe; Scheme for Promotion of Academic and Research Collaboration; Sun Pharma; Servier; Astellas Pharma; Incyte; Italfarmaco; Seagen; Agios Pharmaceuticals; Astex Pharmaceuticals; Celgene; Daiichi-Sankyo; National Institute for Health and Care Research; Teva Pharmaceutical Industries; Gilead Sciences; Ariad Pharmaceuticals; Amgen; Pfizer; Ascentage Pharma","keywords":"Medicine; Dasatinib; Nilotinib; Bosutinib; Discontinuation; Imatinib; Myeloid leukemia; Tyrosine-kinase inhibitor; Internal medicine; Oncology; Intensive care medicine","score_opus":0.04811984751068918,"score_gpt":0.33357866587836627,"score_spread":0.28545881836767706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009751715","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000014894673,0.9722241,0.0003072627,0.00066314294,0.0008841562,0.0056043793,0.00096210616,0.00085800583,0.01848196],"genre_scores_gemma":[0.000025437408,0.9618719,0.006488719,0.0006299658,0.0056349984,0.0012201493,0.011744171,0.00087033527,0.011514305],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9923265,0.00054164993,0.0025321257,0.002343633,0.0006770897,0.0015790084],"domain_scores_gemma":[0.9943925,0.0009825489,0.001452723,0.0019352057,0.00019490127,0.0010421125],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.00061638164,0.002006306,0.005048637,0.00042069238,0.0005140917,0.00019213418,0.0009845461,0.00095016917,0.0009842302],"category_scores_gemma":[0.00064773,0.0017929254,0.0023623533,0.0012130017,0.00019806591,0.00023838997,0.00046245198,0.0021838872,0.00317014],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000055071327,0.000044431617,0.0000026382668,0.020052614,0.0012898317,0.00054611254,0.00014476097,0.000008845145,0.000012386382,0.00008992318,0.10927632,0.86847705],"study_design_scores_gemma":[0.0055919685,0.0007023793,0.0000059359268,0.021948995,0.006536294,0.0013239552,0.00004505554,0.00042393405,0.000023577464,0.00002112533,0.96206456,0.001312216],"about_ca_topic_score_codex":0.00017342604,"about_ca_topic_score_gemma":0.00004545317,"teacher_disagreement_score":0.86716485,"about_ca_system_score_codex":0.065407835,"about_ca_system_score_gemma":0.022333974,"threshold_uncertainty_score":0.999929},"labels":[],"label_agreement":null},{"id":"W3011063776","doi":"10.1111/jch.13843","title":"Renovascular hypertension from the BCR‐ABL tyrosine kinase inhibitor ponatinib","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Hypertension","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Ponatinib; Renovascular hypertension; Tyrosine-kinase inhibitor; Tyrosine kinase; Imatinib; Internal medicine; Pharmacology; Dasatinib; Blood pressure; Receptor; Myeloid leukemia","score_opus":0.11396696851798846,"score_gpt":0.3399499468106748,"score_spread":0.22598297829268635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011063776","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9454503,0.0045349603,0.000098510835,0.048115015,0.0012877324,0.0003213969,0.000011821443,0.000039248924,0.0001410105],"genre_scores_gemma":[0.96229523,0.0017170779,0.004225178,0.026440872,0.0051567038,0.0000016998013,0.00002969445,0.000057021804,0.00007652204],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9956957,0.000351035,0.0020862282,0.0004313613,0.0011248082,0.00031085825],"domain_scores_gemma":[0.9952134,0.0017693053,0.00087219,0.000597988,0.00085793895,0.00068921165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012397926,0.000304271,0.0014550653,0.000054140564,0.00012812257,0.00003097225,0.00028806235,0.000330688,0.0002878749],"category_scores_gemma":[0.008242074,0.00016338033,0.0009917215,0.00031513514,0.00017457997,0.00015966236,0.00016363378,0.001314039,0.00018304166],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018682303,0.004786989,0.06944197,0.00015496461,0.0032779488,0.024054667,0.000575228,0.00009204807,0.15602876,0.000065638436,0.41218725,0.31065223],"study_design_scores_gemma":[0.07701411,0.011268387,0.46474698,0.0032138762,0.0059308647,0.005262529,0.000623219,0.010166782,0.014398683,0.00043084985,0.40606156,0.0008821439],"about_ca_topic_score_codex":0.00006856197,"about_ca_topic_score_gemma":0.0000034526556,"teacher_disagreement_score":0.395305,"about_ca_system_score_codex":0.00013137699,"about_ca_system_score_gemma":0.0006257362,"threshold_uncertainty_score":0.98671275},"labels":[],"label_agreement":null},{"id":"W3011685940","doi":"10.1200/jco.2012.30.15_suppl.tps6634","title":"Dasatinib plus SMO antagonist versus dasatinib alone for treating patients (pts) with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP): Design of CA180-363, a phase II, open-label randomized trial.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bristol-Myers Squibb (Canada)","funders":"","keywords":"Dasatinib; Medicine; Smoothened; Internal medicine; Tolerability; Imatinib; Clinical endpoint; Imatinib mesylate; Oncology; Phases of clinical research; Nilotinib; Myeloid leukemia; Pharmacology; Clinical trial; Hedgehog signaling pathway; Adverse effect; Signal transduction; Biology","score_opus":0.13809043613215347,"score_gpt":0.45719034527125646,"score_spread":0.319099909139103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011685940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.979924,0.0022815296,0.0019704944,0.0010202602,0.0021375874,0.011825821,0.00019113428,0.00003414331,0.0006150321],"genre_scores_gemma":[0.9784247,0.0018008508,0.014581443,0.00042285418,0.003360688,0.00077653717,0.00032780893,0.0001623186,0.00014276875],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9863399,0.002563981,0.0076750102,0.0008700939,0.0011180084,0.0014329957],"domain_scores_gemma":[0.9670663,0.021445386,0.0084948,0.0007879562,0.0010467452,0.0011588127],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.009629631,0.00092154846,0.008394119,0.0005158562,0.0002975097,0.000051680803,0.00084711134,0.0010131792,0.00033526114],"category_scores_gemma":[0.012803319,0.0006730417,0.0009225454,0.00069065025,0.0011360357,0.00088394905,0.0003147093,0.0018988516,0.000012647553],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.8998641,0.026097674,0.00028960823,0.00018693233,0.0033435328,0.00049628783,0.00097607344,0.00041758327,0.0015030893,0.00004553807,0.0013463408,0.06543328],"study_design_scores_gemma":[0.78418314,0.2021071,0.00026155467,0.001046821,0.0032623238,0.00012428325,0.00015653654,0.005224956,0.0015920313,0.0000284973,0.001544458,0.00046826506],"about_ca_topic_score_codex":0.00046943207,"about_ca_topic_score_gemma":0.0002624302,"teacher_disagreement_score":0.17600943,"about_ca_system_score_codex":0.01992083,"about_ca_system_score_gemma":0.03280935,"threshold_uncertainty_score":0.9995721},"labels":[],"label_agreement":null},{"id":"W3014512348","doi":"10.1101/2020.04.03.024620","title":"RIPK2 dictates insulin responses to tyrosine kinase inhibitors in obese mice","year":2020,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Internal medicine; Endocrinology; Gefitinib; Insulin; Medicine; Tyrosine kinase; Glucose uptake; Insulin resistance; Cancer; Receptor; Epidermal growth factor receptor","score_opus":0.019176634866069044,"score_gpt":0.2530344929977491,"score_spread":0.23385785813168006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3014512348","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98671097,0.005056598,0.00005506058,0.003724648,0.0010173363,0.0023757638,0.00043547034,0.0006022909,0.000021873762],"genre_scores_gemma":[0.9888253,0.0006485188,0.00737756,0.0014001816,0.0008701568,0.00055071746,0.0000031126253,0.00028983734,0.000034566798],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9950213,0.000266696,0.0011175162,0.0018782828,0.0007618215,0.000954391],"domain_scores_gemma":[0.99617904,0.0002190139,0.00038858107,0.001738454,0.00042187673,0.0010530528],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000583316,0.0010289806,0.0013903064,0.00088278635,0.000104014405,0.00014689476,0.0005633847,0.0007657852,0.00009942417],"category_scores_gemma":[0.0021949136,0.0010772109,0.00026315518,0.0015797201,0.00014568993,0.00013904642,0.0010455925,0.0015927979,0.00057803764],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018477113,0.00089617615,0.07781779,0.0014372857,0.00035021344,0.003299441,0.0001294428,0.00005373999,0.9112838,0.00006917991,0.0027927132,0.00002249543],"study_design_scores_gemma":[0.005768054,0.00051119406,0.41329837,0.004072781,0.00037848926,1.8956561e-7,0.000013783548,0.00033315638,0.56111753,0.000002718656,0.013227597,0.0012761266],"about_ca_topic_score_codex":0.00056569953,"about_ca_topic_score_gemma":0.00002658091,"teacher_disagreement_score":0.3501663,"about_ca_system_score_codex":0.0032860446,"about_ca_system_score_gemma":0.0030157457,"threshold_uncertainty_score":0.9991678},"labels":[],"label_agreement":null},{"id":"W3015526907","doi":"10.1182/blood.2019003636","title":"The miR-185/PAK6 axis predicts therapy response and regulates survival of drug-resistant leukemic stem cells in CML","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada; Canada's Michael Smith Genome Sciences Centre; University of British Columbia; Terry Fox Research Institute","funders":"Canadian Institutes of Health Research","keywords":"Cancer research; Stem cell; Myeloid leukemia; Biology; Targeted therapy; Cancer stem cell; Progenitor cell; microRNA; Leukemia; Drug resistance; Transcriptome; Cancer; Immunology; Cell biology; Gene expression","score_opus":0.018334693448379697,"score_gpt":0.23717166788424407,"score_spread":0.21883697443586436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3015526907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905417,0.0068205753,7.2243176e-7,0.001670397,0.00006878211,0.0006435556,0.000041319476,0.00004768191,0.00016524589],"genre_scores_gemma":[0.99743265,0.0013134073,0.00006217987,0.00012542114,0.00006898867,0.000025514966,0.0000061425285,0.000034902874,0.00093080103],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983038,0.00026953043,0.00041535575,0.00034712945,0.00035240623,0.0003118046],"domain_scores_gemma":[0.9985259,0.00069112884,0.00013051085,0.00043087793,0.000051106515,0.00017044539],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052980403,0.00020802184,0.00040848917,0.000055636658,0.000064836095,0.000017158003,0.00015379758,0.00008964969,0.000020883224],"category_scores_gemma":[0.00009150947,0.0001407886,0.000077025674,0.00025175427,0.0001589043,0.000041820716,0.000068639834,0.00018892792,0.0000097683605],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020703774,0.0008144266,0.044256337,0.00028909202,0.0006837155,0.00039744412,0.008381274,0.0000147351375,0.9176722,0.00005865591,0.0014184975,0.0053098467],"study_design_scores_gemma":[0.039622385,0.0018033066,0.22737633,0.00037956124,0.00025135095,0.000038961065,0.0017597595,0.0003029576,0.7213146,0.000051266245,0.006818329,0.00028120118],"about_ca_topic_score_codex":0.00017092055,"about_ca_topic_score_gemma":0.0000703026,"teacher_disagreement_score":0.19635761,"about_ca_system_score_codex":0.00017232489,"about_ca_system_score_gemma":0.0004701174,"threshold_uncertainty_score":0.57411927},"labels":[],"label_agreement":null},{"id":"W3016305930","doi":"10.1182/blood.v130.suppl_1.98.98","title":"CA180-372: An International Collaborative Phase 2 Trial of Dasatinib and Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital","funders":"","keywords":"Dasatinib; Medicine; Internal medicine; Imatinib; Oncology; Minimal residual disease; Chemotherapy; Philadelphia chromosome; Imatinib mesylate; Acute lymphocytic leukemia; Clinical trial; Hematopoietic stem cell transplantation; Chemotherapy regimen; Leukemia; Transplantation; Lymphoblastic Leukemia; Chromosomal translocation; Myeloid leukemia; Biology","score_opus":0.010661051771750417,"score_gpt":0.2896659076061985,"score_spread":0.27900485583444806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016305930","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970706,0.000056401394,0.0000058565956,0.00026611803,0.00016204204,0.0016144942,0.00042310698,0.000024223928,0.00037715444],"genre_scores_gemma":[0.99791026,0.00039141817,0.0006074735,0.00012238105,0.00037334286,0.00010447558,0.00041406634,0.000045115856,0.00003144273],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982585,0.00005799343,0.0004230872,0.0004928653,0.0004848253,0.00028276924],"domain_scores_gemma":[0.9983561,0.00013509704,0.00051681726,0.0005285351,0.00026348128,0.00019996616],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00010573464,0.00030430013,0.0005485637,0.00019275432,0.00009566252,0.00005649248,0.00024279553,0.00013894186,0.00005931449],"category_scores_gemma":[0.00018779379,0.0002513853,0.00004977289,0.0001574552,0.0001683871,0.00040044487,0.00006494934,0.00015550356,0.000003938946],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1393547,0.024192078,0.81494033,0.00014274253,0.00359858,0.0013831638,0.0064245537,0.000019494464,0.0027569034,0.00008511134,0.00018869594,0.006913632],"study_design_scores_gemma":[0.5337425,0.0065580118,0.45613843,0.0001101673,0.00075480534,0.000017338196,0.000049809558,0.00013759118,0.0022357968,0.000013441557,0.000031735457,0.00021036353],"about_ca_topic_score_codex":0.00020181632,"about_ca_topic_score_gemma":0.000102952756,"teacher_disagreement_score":0.39438778,"about_ca_system_score_codex":0.00059365167,"about_ca_system_score_gemma":0.0010286596,"threshold_uncertainty_score":0.99999386},"labels":[],"label_agreement":null},{"id":"W3017596149","doi":"10.1111/cas.14430","title":"Budget impact analysis of treatment‐free remission in nilotinib‐treated Japanese chronic myeloid leukemia patients","year":2020,"lang":"en","type":"article","venue":"Cancer Science","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Novartis Japan","keywords":"Nilotinib; Medicine; Myeloid leukemia; Tyrosine-kinase inhibitor; Internal medicine; Population; Imatinib; Cancer","score_opus":0.022382525836239366,"score_gpt":0.3183473209959485,"score_spread":0.29596479515970914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3017596149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970718,0.0007821228,0.0000032313144,0.00026027954,0.00007632635,0.0005620222,0.00012287809,0.000055817294,0.0010655051],"genre_scores_gemma":[0.9989348,0.00038405863,0.00009020987,0.00014413541,0.00006648817,0.000048432856,0.000085644024,0.000021923102,0.00022432895],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973787,0.00004091103,0.00050829904,0.0008220333,0.00065654743,0.0005934776],"domain_scores_gemma":[0.9980878,0.00005976412,0.00025418398,0.0008180435,0.00022414546,0.00055602554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015938954,0.00032060363,0.0008045469,0.0005711103,0.00008957157,0.00002283984,0.0004841419,0.00009496901,0.00055225135],"category_scores_gemma":[0.00033838936,0.00023261055,0.00025741415,0.0061901608,0.0003881262,0.00027036064,0.00014592818,0.00014936831,0.000017519082],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043977285,0.00021561119,0.92912245,0.000069632646,0.00051692326,0.000035983277,0.0025584968,0.0035368414,0.048776377,0.0000027460137,0.00028550648,0.0144396825],"study_design_scores_gemma":[0.009101263,0.00250315,0.9172471,0.00019564139,0.0011743535,0.0000029962728,0.000103612125,0.032740563,0.036399994,0.0000031846682,0.00025559746,0.0002725132],"about_ca_topic_score_codex":0.0075458353,"about_ca_topic_score_gemma":0.00050168106,"teacher_disagreement_score":0.029203722,"about_ca_system_score_codex":0.019319806,"about_ca_system_score_gemma":0.0053324793,"threshold_uncertainty_score":0.999063},"labels":[],"label_agreement":null},{"id":"W3020162492","doi":"10.1093/rheumatology/keaa111.214","title":"P219 Long-term safety of filgotinib in patients with PsA: week 52 safety data from a Phase 2 open-label extension study","year":2020,"lang":"en","type":"article","venue":"Lara D. Veeken","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Interim analysis; Internal medicine; Placebo; Adverse effect; Open label; Clinical trial; Surgery","score_opus":0.07578834547100038,"score_gpt":0.33916573967664815,"score_spread":0.26337739420564776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3020162492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935502,0.00024147626,0.00010717403,0.0004821334,0.00009393301,0.0033518514,0.0018220327,0.000052777163,0.00029841127],"genre_scores_gemma":[0.9908398,0.00003875016,0.0013998565,0.0005376484,0.0000976239,0.000030507754,0.006878571,0.00006700897,0.00011022557],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969605,0.00017151817,0.0007689968,0.0010454458,0.00066769705,0.00038583355],"domain_scores_gemma":[0.9973084,0.00016614245,0.0002927236,0.0018126603,0.0001282194,0.00029189794],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00027389053,0.00035933452,0.0009651255,0.00007435371,0.000069791786,0.00002980095,0.00083070685,0.000113404996,0.00059928076],"category_scores_gemma":[0.0002482719,0.00028687913,0.000034867586,0.00044192045,0.00007165946,0.00037701894,0.0011154808,0.00036675658,0.000092736154],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021958813,0.01871202,0.94207096,0.000097854696,0.0005930361,0.0006891876,0.0014044566,0.000009352353,0.00030096827,0.0000021759286,0.0014886297,0.012672563],"study_design_scores_gemma":[0.14325146,0.0060079605,0.84805036,0.00045602306,0.00047809965,0.0000040254668,0.00014481446,0.00072607695,0.00013921055,0.0000030460358,0.00047734796,0.00026156133],"about_ca_topic_score_codex":0.0009237723,"about_ca_topic_score_gemma":0.0004515764,"teacher_disagreement_score":0.12129266,"about_ca_system_score_codex":0.0004000722,"about_ca_system_score_gemma":0.0004117985,"threshold_uncertainty_score":0.99995834},"labels":[],"label_agreement":null},{"id":"W3024994706","doi":"10.1016/j.stem.2020.04.005","title":"Integrin-Linked Kinase Mediates Therapeutic Resistance of Quiescent CML Stem Cells to Tyrosine Kinase Inhibitors","year":2020,"lang":"en","type":"article","venue":"Cell stem cell","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada; BC Cancer Agency; Terry Fox Research Institute; University of British Columbia","funders":"National Research Council Canada; Canadian Institutes of Health Research; Cancer Research Society; Mitacs; Canadian Cancer Society; Leukemia and Lymphoma Society of Canada; Bristol-Myers Squibb","keywords":"Biology; Tyrosine kinase; Integrin; Cancer research; Cell biology; Stem cell; Kinase; Integrin-linked kinase; Signal transduction; Protein kinase A; Cell; Biochemistry; Cyclin-dependent kinase 2","score_opus":0.02266429170467633,"score_gpt":0.23975685809892516,"score_spread":0.21709256639424884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3024994706","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9799731,0.010764179,0.00013663003,0.0016937163,0.0006689981,0.00181431,0.00007498608,0.00018957072,0.004684508],"genre_scores_gemma":[0.9878607,0.00040875806,0.0004898846,0.001194923,0.00031403254,0.000057883957,0.00003546965,0.000114070055,0.009524305],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9968558,0.0001282095,0.00088121474,0.0008144096,0.00068580563,0.00063457555],"domain_scores_gemma":[0.99767756,0.00020009138,0.0003404392,0.0008119067,0.00018782321,0.00078214775],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020387075,0.0005337483,0.0008919871,0.00013998541,0.00008265478,0.000028685898,0.00034691385,0.000218882,0.00024354924],"category_scores_gemma":[0.00001083858,0.0004554972,0.000263341,0.000629762,0.000115535964,0.00007488209,0.00018284525,0.00041629543,0.0006117771],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013921328,0.0009784936,0.002287876,0.0029497384,0.00012165275,0.00038803622,0.004625818,0.000087363755,0.9673211,0.000031600364,0.013242138,0.0065740785],"study_design_scores_gemma":[0.0049759373,0.00084930134,0.00037027473,0.000444804,0.00027532195,0.00000237981,0.0013364478,0.0001618055,0.9538476,0.000005151646,0.037358362,0.00037263107],"about_ca_topic_score_codex":0.00006949104,"about_ca_topic_score_gemma":0.000028280567,"teacher_disagreement_score":0.024116224,"about_ca_system_score_codex":0.000875671,"about_ca_system_score_gemma":0.00045413148,"threshold_uncertainty_score":0.99978966},"labels":[],"label_agreement":null},{"id":"W3025859301","doi":"10.18433/jpps30868","title":"Importance of Therapeutic Drug Monitoring to Detect Drug Interaction between Pazopanib and Warfarin: A Case Report","year":2020,"lang":"en","type":"article","venue":"Journal of Pharmacy & Pharmaceutical Sciences","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Pazopanib; Medicine; Warfarin; Renal cell carcinoma; Pharmacology; Internal medicine; Prothrombin time; Pharmacokinetics; Urology; Gastroenterology; Atrial fibrillation","score_opus":0.12775687869491484,"score_gpt":0.4384109801599421,"score_spread":0.31065410146502725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3025859301","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98908734,0.002149664,0.00013066953,0.0077820877,0.00033882904,0.0003132111,0.000003846032,0.000021377193,0.0001729554],"genre_scores_gemma":[0.99632174,0.00035918574,0.0018401437,0.0006922619,0.0007426766,0.0000042394386,4.225342e-7,0.000015156274,0.000024200628],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975146,0.00010718948,0.00093110086,0.0003398795,0.0007649619,0.0003422584],"domain_scores_gemma":[0.9980413,0.0003261625,0.0005065894,0.0001134694,0.00018218077,0.00083034043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011333227,0.00020827427,0.000514072,0.00014824515,0.00013150758,0.000045644247,0.00020865686,0.000021839938,0.000121439385],"category_scores_gemma":[0.00025793602,0.00015278612,0.00015265588,0.0005729339,0.00021169834,0.00042586197,0.00010994566,0.0005268354,0.0000058474207],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00078583835,0.00012145246,0.7178927,0.0002060311,0.0003427116,0.023054086,0.0020086658,0.00006658127,0.07671177,0.000004613843,0.00027889406,0.17852667],"study_design_scores_gemma":[0.009191976,0.0010866568,0.03763051,0.00047495292,0.0019270426,0.08377259,0.0019206294,0.00406548,0.83416927,0.00008217138,0.025198601,0.0004800973],"about_ca_topic_score_codex":0.00007974259,"about_ca_topic_score_gemma":0.000003121922,"teacher_disagreement_score":0.7574575,"about_ca_system_score_codex":0.00028235122,"about_ca_system_score_gemma":0.00038597066,"threshold_uncertainty_score":0.6230437},"labels":[],"label_agreement":null},{"id":"W3029545901","doi":"10.1200/jco.2020.38.15_suppl.7502","title":"Interim analysis (IA) of OPTIC: A dose-ranging study of three ponatinib (PON) starting doses.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Clinical endpoint; Ponatinib; Interim analysis; Population; Cohort; Gastroenterology; Randomized controlled trial; Dasatinib; Imatinib","score_opus":0.23149264534880898,"score_gpt":0.4974280322814075,"score_spread":0.2659353869325985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029545901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99497986,0.00024224739,0.0005923235,0.002595629,0.00028132094,0.00039905874,0.0000036173085,0.000008473615,0.0008974641],"genre_scores_gemma":[0.99186957,0.000043245404,0.007062138,0.00051011646,0.0004669502,0.000004041143,0.0000022465679,0.000019580832,0.000022110265],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99387115,0.0004762836,0.004475725,0.0002611027,0.0006680961,0.000247653],"domain_scores_gemma":[0.9918553,0.0026891215,0.004164015,0.0002924822,0.0005952638,0.0004037982],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003048858,0.00018089531,0.00321661,0.00030117054,0.00002539084,0.0000047946596,0.00028612465,0.00022985076,0.0003823602],"category_scores_gemma":[0.00684565,0.00013284001,0.0010255262,0.0007479845,0.00016158009,0.00009789306,0.00015736956,0.00090726145,0.000006464924],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014743906,0.011210151,0.84845144,0.00022208,0.020075187,0.0025443342,0.004140597,0.0013969429,0.0033523412,0.00003347132,0.00030672317,0.093522854],"study_design_scores_gemma":[0.050966706,0.08582002,0.8318751,0.0002965364,0.016619468,0.00014518091,0.0050205393,0.0074823885,0.00069197564,0.000097245145,0.0007657069,0.00021917607],"about_ca_topic_score_codex":0.000098449724,"about_ca_topic_score_gemma":0.00012966634,"teacher_disagreement_score":0.09330368,"about_ca_system_score_codex":0.0003119987,"about_ca_system_score_gemma":0.0015721457,"threshold_uncertainty_score":0.81953764},"labels":[],"label_agreement":null},{"id":"W3033636562","doi":"10.1182/blood.2019004371","title":"Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation","year":2020,"lang":"en","type":"letter","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Imatinib; Discontinuation; Medicine; Myeloid leukemia; Internal medicine; Imatinib mesylate; Oncology","score_opus":0.006081803957819466,"score_gpt":0.20998298433039336,"score_spread":0.2039011803725739,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033636562","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9793728,0.0005650704,0.000003807021,0.016204793,0.000093953044,0.002611574,0.000331825,0.000086325206,0.000729824],"genre_scores_gemma":[0.94276184,0.00002276424,0.0008901898,0.048663735,0.0023288669,0.00064241415,0.003976366,0.00025199377,0.0004618156],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996605,0.0001256216,0.00086333277,0.0008145323,0.0009990102,0.0005925399],"domain_scores_gemma":[0.99812734,0.000115179275,0.00060097664,0.0008503666,0.0001608279,0.00014532376],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00008456552,0.0006599984,0.0012761962,0.00029763026,0.000029026829,0.000024631072,0.00024959072,0.0004130701,0.00037739318],"category_scores_gemma":[0.00013189664,0.000531471,0.00020465752,0.00036530916,0.00013434915,0.00013582296,0.000116041076,0.0013490843,0.00009282931],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006968468,0.0028623892,0.80810463,0.007409914,0.0039274697,0.011761429,0.0021493472,0.000029989576,0.0006615895,0.0000025892125,0.15145704,0.0046651335],"study_design_scores_gemma":[0.12150173,0.005950025,0.81458694,0.007849821,0.0050359434,0.000075254844,0.000046378726,0.00026096223,0.0032450208,0.00002744592,0.039761495,0.001659001],"about_ca_topic_score_codex":0.0013618936,"about_ca_topic_score_gemma":0.00014615845,"teacher_disagreement_score":0.11453326,"about_ca_system_score_codex":0.0022862132,"about_ca_system_score_gemma":0.0021665173,"threshold_uncertainty_score":0.99971366},"labels":[],"label_agreement":null},{"id":"W3034273622","doi":"10.1002/elps.202000118","title":"Quantification of imatinib and related compounds using capillary electrophoresis‐tandem mass spectrometry with field‐amplified sample stacking","year":2020,"lang":"en","type":"article","venue":"Electrophoresis","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Chromatography; Repeatability; Capillary electrophoresis; Analyte; Chemistry; Reproducibility; Sample preparation; Mass spectrometry; Electrospray; Capillary electrophoresis–mass spectrometry; Analytical Chemistry (journal); Detection limit; Tandem mass spectrometry; Liquid chromatography–mass spectrometry; Stacking; Electrospray ionization","score_opus":0.023518463943198606,"score_gpt":0.26383752921994785,"score_spread":0.24031906527674923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034273622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858126,0.003294175,0.008652755,0.00094720966,0.00002975125,0.00057618757,0.000013939035,0.00010642737,0.0005669539],"genre_scores_gemma":[0.9789684,0.0009859733,0.019537989,0.00021977622,0.000076775555,0.000011651886,0.00009428189,0.00006979262,0.000035351088],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977799,0.00009376292,0.0005455922,0.00058124406,0.0004800673,0.00051943015],"domain_scores_gemma":[0.9985547,0.00033932267,0.00031708632,0.00041222892,0.00014666455,0.00022997899],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001504448,0.00032483885,0.0006848701,0.00020816784,0.0001482506,0.000035219753,0.00012794299,0.0001723362,0.00019920703],"category_scores_gemma":[0.0002799267,0.00028164522,0.00010471107,0.0009905254,0.00010372498,0.000086391476,0.000036802365,0.0003921924,0.0000054144352],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001474038,0.00008990607,0.023371669,0.0002010684,0.00055678963,0.000078882054,0.00035359056,0.000024184403,0.972553,0.00040535541,0.00036824425,0.0005232864],"study_design_scores_gemma":[0.0061299657,0.004239148,0.03264724,0.00025351346,0.0009579794,0.00034477536,0.00027828588,0.0072248876,0.9463685,0.0006592742,0.00033526134,0.00056112383],"about_ca_topic_score_codex":0.00033866812,"about_ca_topic_score_gemma":0.000014891065,"teacher_disagreement_score":0.026184442,"about_ca_system_score_codex":0.0005348947,"about_ca_system_score_gemma":0.000445657,"threshold_uncertainty_score":0.9999636},"labels":[],"label_agreement":null},{"id":"W3034872713","doi":"10.1183/13993003.00279-2020","title":"Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors","year":2020,"lang":"en","type":"review","venue":"European Respiratory Journal","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Libin Cardiovascular Institute of Alberta; University of Calgary","funders":"","keywords":"Dasatinib; Medicine; Bosutinib; Imatinib; Chronic myelogenous leukemia; Tyrosine kinase; Ponatinib; Imatinib mesylate; Pulmonary hypertension; Cancer research; Interstitial lung disease; Pharmacology; Immunology; Internal medicine; Lung; Leukemia; Myeloid leukemia; Receptor","score_opus":0.07577194581163411,"score_gpt":0.3343112660655918,"score_spread":0.2585393202539577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034872713","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000054353855,0.97329247,0.000023346782,0.000094000985,0.00034080658,0.00070960785,0.00008734338,0.00007204463,0.025326047],"genre_scores_gemma":[0.00015130492,0.9963763,0.0004113362,0.0003796055,0.00187903,0.00001277752,0.00009202021,0.00024285456,0.0004548082],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99577934,0.00094708236,0.0017784811,0.0005241043,0.00059010845,0.00038089388],"domain_scores_gemma":[0.9966601,0.0001281863,0.00145375,0.0008494226,0.00022373727,0.0006847926],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00064844475,0.0006041194,0.0019780032,0.00042056612,0.00019042125,0.00004800382,0.00048544203,0.00015037178,0.00031250805],"category_scores_gemma":[0.0002812754,0.00047186838,0.0010151194,0.00058705435,0.00018252066,0.00009039499,0.00022928888,0.0016003933,0.0010495373],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027116957,0.0002754847,0.000062404084,0.005574346,0.0004487514,0.0060982024,0.00004286601,6.3621997e-7,0.000067611414,0.000022057513,0.009690528,0.97769],"study_design_scores_gemma":[0.0009803001,0.00036566186,0.00025914944,0.01958902,0.0015462139,0.005462492,0.000014248589,0.000001729532,0.000015428841,0.0000030885699,0.9714664,0.00029621573],"about_ca_topic_score_codex":0.0000018418815,"about_ca_topic_score_gemma":2.0121703e-7,"teacher_disagreement_score":0.9773938,"about_ca_system_score_codex":0.0010226865,"about_ca_system_score_gemma":0.0022120776,"threshold_uncertainty_score":0.9997733},"labels":[],"label_agreement":null},{"id":"W3038100380","doi":"10.1002/pbc.28491","title":"Outcomes of children with chronic myeloid leukemia: A population‐based cohort study","year":2020,"lang":"en","type":"article","venue":"Pediatric Blood & Cancer","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University; Kingston General Hospital; McMaster University; Ontario Clinical Oncology Group; University of Ottawa; Hospital for Sick Children","funders":"","keywords":"Medicine; Myeloid leukemia; Cohort; Pediatrics; Hematopoietic stem cell transplantation; Retrospective cohort study; Imatinib; Population; Internal medicine; Dasatinib; Disease; Medical record; Cancer registry; Cancer","score_opus":0.012254203957653347,"score_gpt":0.263892561448974,"score_spread":0.25163835749132063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3038100380","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99443346,0.0022451787,0.000017206874,0.0005180746,0.00007927074,0.0023519949,0.00007187108,0.00014106964,0.00014189513],"genre_scores_gemma":[0.9974404,0.0002681665,0.00031234845,0.0004356021,0.00090037886,0.00033386066,0.00010694419,0.00006995372,0.00013235143],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977106,0.000047398808,0.0004986568,0.00060171966,0.0007639707,0.00037765794],"domain_scores_gemma":[0.9987365,0.00006355793,0.0003065871,0.0005005613,0.00011828442,0.0002744879],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000100291574,0.00034766292,0.00083767367,0.00014001245,0.00006853181,0.0000113029,0.00017522214,0.00010442457,0.00054014224],"category_scores_gemma":[0.00006129177,0.00026266722,0.00014406606,0.0007737005,0.000034351837,0.000081190345,0.000057334408,0.00030519877,0.00002562068],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016611465,0.0005058274,0.99639624,0.00018215209,0.0012421064,0.000029841609,0.0001568671,0.00058188615,0.000020361904,0.0000018124573,0.00028882243,0.00042798548],"study_design_scores_gemma":[0.015860155,0.0015399448,0.975855,0.000025179705,0.0060500083,0.000010263943,0.000017708198,0.00015361066,0.000225073,9.043604e-7,0.000023433417,0.00023875407],"about_ca_topic_score_codex":0.005716261,"about_ca_topic_score_gemma":0.0005321369,"teacher_disagreement_score":0.020541258,"about_ca_system_score_codex":0.001094928,"about_ca_system_score_gemma":0.0023675351,"threshold_uncertainty_score":0.99998254},"labels":[],"label_agreement":null},{"id":"W3038581931","doi":"10.14740/jmc3510","title":"Therapeutic Challenges in Chronic Myeloid Leukemia: A Case-Based Discussion","year":2020,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Myeloid leukemia; Myeloproliferative neoplasm; Chromosomal translocation; Tyrosine kinase; Refractory (planetary science); Philadelphia chromosome; breakpoint cluster region; Cancer research; Tyrosine-kinase inhibitor; Myeloid; Oncology; Internal medicine; Myelofibrosis; Gene; Bone marrow; Genetics; Receptor; Cancer; Biology","score_opus":0.08051606826457529,"score_gpt":0.3299708531466709,"score_spread":0.2494547848820956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3038581931","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.797753,0.044598605,0.0002098911,0.15651216,0.0002669987,0.00033501827,0.0000054902653,0.000041024527,0.00027784135],"genre_scores_gemma":[0.99178827,0.004509682,0.00018297718,0.0023200123,0.0011315021,0.0000070827796,0.0000036847694,0.000032144628,0.000024644889],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9970341,0.00016972917,0.00075523223,0.00024273369,0.0014562098,0.00034203674],"domain_scores_gemma":[0.9981434,0.00044811933,0.00028224828,0.00020370704,0.000084372645,0.0008381557],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00064284494,0.00022812442,0.00068068644,0.0001691004,0.000042095136,0.0000133010035,0.0001978103,0.00027128906,0.0010804269],"category_scores_gemma":[0.001198562,0.00012488815,0.00024317829,0.00024747697,0.00012157139,0.00009917154,0.000052343043,0.0010351882,0.000028343851],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017772027,0.0005911014,0.0029098534,0.0010477555,0.00030396917,0.53637964,0.0013431117,0.00017165422,0.0014143373,0.00008266774,0.0029453225,0.45103338],"study_design_scores_gemma":[0.12122932,0.033604696,0.018868448,0.012876554,0.0021515905,0.58001953,0.0093173,0.043761138,0.011358979,0.00026943022,0.1651036,0.001439415],"about_ca_topic_score_codex":0.00006125017,"about_ca_topic_score_gemma":0.00014890851,"teacher_disagreement_score":0.449594,"about_ca_system_score_codex":0.0026833923,"about_ca_system_score_gemma":0.0053596827,"threshold_uncertainty_score":0.99983275},"labels":[],"label_agreement":null},{"id":"W3043346807","doi":"10.1212/wnl.94.15_supplement.804","title":"Design of a Phase 2b Dose-finding Trial to Evaluate Safety and Efficacy of the CNS-penetrant BTK Inhibitor SAR442168 in Patients with Relapsing Forms of Multiple Sclerosis (804)","year":2020,"lang":"en","type":"article","venue":"Neurology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital; University of British Columbia","funders":"","keywords":"Penetrant (biochemical); Medicine; Multiple sclerosis; Bruton's tyrosine kinase; Pharmacology; Dermatology; Oncology; Internal medicine; Immunology; Chemistry; Receptor","score_opus":0.05628610320701249,"score_gpt":0.2833231516528835,"score_spread":0.22703704844587103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3043346807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969143,0.000037119287,0.00014611143,0.00049066,0.00010689717,0.0022578798,0.000018952913,0.000009537683,0.0000185166],"genre_scores_gemma":[0.9992101,0.000016922186,0.00039568203,0.00029819857,0.00002924833,0.000015907099,0.0000073659494,0.00002517219,0.0000013934592],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99832183,0.00021081038,0.00058932684,0.00032733413,0.0003159875,0.00023469598],"domain_scores_gemma":[0.99884814,0.00042205112,0.00028534592,0.0002768817,0.00006606404,0.00010151137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022712519,0.00016669335,0.0005866166,0.00010857018,0.000031838288,0.0000021571161,0.000107406566,0.00010290743,0.00001925712],"category_scores_gemma":[0.0005736721,0.000107635264,0.000061399056,0.0003468633,0.000122867,0.00004100514,0.00008692598,0.00021435364,9.1618847e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6631887,0.0018307059,0.21212763,0.0001863574,0.00018857185,0.00001738308,0.003080822,0.002149921,0.103910014,0.0000069287803,0.00002298502,0.013290011],"study_design_scores_gemma":[0.47270083,0.032704547,0.45735267,0.0003029149,0.00030751355,0.00000614914,0.000016847102,0.0035378318,0.03291201,0.0000049746877,0.000025425657,0.00012828641],"about_ca_topic_score_codex":0.000086476306,"about_ca_topic_score_gemma":0.000024302544,"teacher_disagreement_score":0.24522506,"about_ca_system_score_codex":0.00008150979,"about_ca_system_score_gemma":0.00019685407,"threshold_uncertainty_score":0.43892387},"labels":[],"label_agreement":null},{"id":"W3043868002","doi":"10.14740/jmc3511","title":"Transformation of Chronic Myeloid Leukemia to Acute Biphenotypic Leukemia","year":2020,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"JFK Medical Center Foundation","keywords":"Medicine; Myeloid leukemia; Myeloid; Context (archaeology); Blast Crisis; Leukemia; Bone marrow; Immunology","score_opus":0.026566103253131582,"score_gpt":0.30086835260341016,"score_spread":0.2743022493502786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3043868002","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9762626,0.0017673329,0.002522098,0.018172322,0.00030467368,0.00033340347,0.000021099153,0.00002964779,0.00058681256],"genre_scores_gemma":[0.9941396,0.0010598452,0.000807318,0.0027028066,0.0011697235,0.0000049405517,0.000014672547,0.000029477415,0.00007160002],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963316,0.000068794136,0.0011360096,0.00018051511,0.0019647353,0.00031836677],"domain_scores_gemma":[0.9977466,0.00023004042,0.00039894506,0.00019824076,0.00023922701,0.0011869641],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004785484,0.00022208349,0.0007920909,0.00019020583,0.000042538024,0.000012558297,0.00031009762,0.00022905551,0.0015074868],"category_scores_gemma":[0.0011521663,0.00016364038,0.00030837752,0.00043692437,0.00010583331,0.00018888318,0.0000528362,0.0006543202,0.0000775345],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012957268,0.0011180728,0.003785925,0.0041914596,0.004687062,0.02799462,0.013759411,0.0015534478,0.07032404,0.0011260419,0.12805857,0.7304441],"study_design_scores_gemma":[0.116674535,0.07243874,0.037373118,0.012425115,0.009676936,0.07130558,0.0043216655,0.026310138,0.30552423,0.0002993853,0.3415399,0.0021106524],"about_ca_topic_score_codex":0.00007134078,"about_ca_topic_score_gemma":0.000018118177,"teacher_disagreement_score":0.7283334,"about_ca_system_score_codex":0.003001074,"about_ca_system_score_gemma":0.0062985383,"threshold_uncertainty_score":0.99940526},"labels":[],"label_agreement":null},{"id":"W3046965403","doi":"","title":"The combi-targeting concept: an optimized single-molecule dual-targeting model for the treatment of Chronic Myelogenous Leukemia","year":2007,"lang":"en","type":"article","venue":"Cancer Research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Health Canada","funders":"","keywords":"Imatinib; Chronic myelogenous leukemia; Cancer research; Apoptosis; breakpoint cluster region; Imatinib mesylate; ABL; Tyrosine kinase; DNA damage; Leukemia; Biology; Chemistry; Cell biology; Immunology; Signal transduction; DNA; Receptor; Biochemistry","score_opus":0.09225582972052165,"score_gpt":0.40192676211249106,"score_spread":0.3096709323919694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3046965403","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93053347,0.05447185,0.007152367,0.0013985309,0.00034462922,0.0050683115,0.000085050255,0.000094864685,0.00085094717],"genre_scores_gemma":[0.9896169,0.0042150375,0.0018807078,0.00006596138,0.0007968308,0.00076238584,0.00009642347,0.000099795216,0.0024659648],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99645287,0.00018178295,0.00060710596,0.0005362088,0.0008670719,0.0013549866],"domain_scores_gemma":[0.9960086,0.0020430246,0.00018356195,0.0008265922,0.0006675125,0.00027075698],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022167207,0.00029098373,0.00048069295,0.00010925763,0.0010987775,0.00006017586,0.00035693153,0.00015259064,0.000081077305],"category_scores_gemma":[0.00033113052,0.00016671368,0.00023086455,0.00038714334,0.0007073478,0.0000739336,0.000084390536,0.00037724528,0.000007271389],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009412571,0.0025368193,0.0005264969,0.0004449788,0.0022804746,0.00021667466,0.021510186,0.085333034,0.57863003,0.0009327614,0.008495683,0.2896803],"study_design_scores_gemma":[0.024467327,0.0071229218,0.00018373349,0.00024797648,0.00041124324,0.000033910044,0.0038306625,0.47953963,0.46301323,0.0001984976,0.02052932,0.00042155935],"about_ca_topic_score_codex":0.0013103852,"about_ca_topic_score_gemma":0.00046796538,"teacher_disagreement_score":0.39420658,"about_ca_system_score_codex":0.011077913,"about_ca_system_score_gemma":0.0033859257,"threshold_uncertainty_score":0.9927184},"labels":[],"label_agreement":null},{"id":"W3047237087","doi":"10.1182/blood.v130.suppl_1.2516.2516","title":"Loss of Ahi-1 Impairs the Self-Renewal Activity of Normal and BCR-ABL+ Stem Cells in Vitro and in Vivo","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Stem cell; Biology; Haematopoiesis; Cancer research; Progenitor cell; Embryonic stem cell; Chronic myelogenous leukemia; ABL; Myeloid; Cell biology; Imatinib mesylate; Leukemia; Tyrosine kinase; Myeloid leukemia; Immunology; Molecular biology; Imatinib; Signal transduction; Genetics","score_opus":0.010177606323744108,"score_gpt":0.24117322254109022,"score_spread":0.2309956162173461,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047237087","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984918,0.00023849861,3.2890782e-7,0.00009653691,0.000028889983,0.0003089515,0.000027747312,0.000006829365,0.00080037693],"genre_scores_gemma":[0.99959123,0.0001515451,0.000103913546,0.000009101217,0.000025431134,0.000008895936,6.401504e-7,0.000009794158,0.000099457364],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99928707,0.000041599513,0.00018178641,0.00016967893,0.00014405996,0.00017580531],"domain_scores_gemma":[0.9992713,0.00009299119,0.00015768514,0.00040479616,0.000017457496,0.00005582613],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020945827,0.00011330791,0.00032162043,0.000056202796,0.000039005256,0.000008866836,0.000094929645,0.00007594616,0.000009989695],"category_scores_gemma":[0.00001837706,0.00008036928,0.00003197145,0.000044801352,0.00013839816,0.00008197066,0.000110566216,0.00012168814,5.6701384e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005781418,0.0011780951,0.6215103,0.00032833283,0.00016185209,0.00011497331,0.0012393439,0.0000016836259,0.37207878,0.000006153782,0.000014599077,0.002787741],"study_design_scores_gemma":[0.010639908,0.00018362748,0.22293785,0.000095663185,0.00013156205,0.00004498327,0.00009001014,0.00009773805,0.76568425,0.0000092318005,0.000024208957,0.000060984978],"about_ca_topic_score_codex":0.0016440524,"about_ca_topic_score_gemma":0.0006368231,"teacher_disagreement_score":0.39857247,"about_ca_system_score_codex":0.00007134294,"about_ca_system_score_gemma":0.00016223738,"threshold_uncertainty_score":0.3277364},"labels":[],"label_agreement":null},{"id":"W3048391772","doi":"10.1016/j.exphem.2020.08.004","title":"Feeder-free and serum-free in vitro assay for measuring the effect of drugs on acute and chronic myeloid leukemia stem/progenitor cells","year":2020,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute; BC Cancer Agency; Stemcell Technologies","funders":"","keywords":"Myeloid leukemia; Progenitor cell; In vitro; Stem cell; Progenitor; Cancer research; Pharmacology; Medicine; Immunology; Biology; Cell biology; Biochemistry","score_opus":0.013293357465867888,"score_gpt":0.265568906250678,"score_spread":0.2522755487848101,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3048391772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98535335,0.011273587,0.000011005017,0.0010325497,0.0001541287,0.0018323787,0.0000521178,0.00004553269,0.00024534843],"genre_scores_gemma":[0.9988222,0.0000489131,0.00034347695,0.00022833317,0.00010994753,0.00032203138,0.000013473935,0.0000511778,0.00006043504],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982998,0.00015283946,0.00038761168,0.0005121955,0.00024067759,0.00040687466],"domain_scores_gemma":[0.99863476,0.00050884055,0.00013604964,0.00052810775,0.00001790023,0.00017436294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002307454,0.00033121515,0.0008017229,0.000074060976,0.00009121872,0.000013107917,0.00024957137,0.0001679892,0.000021235133],"category_scores_gemma":[0.000060176833,0.00023690735,0.00011131485,0.00011316159,0.00020931108,0.00005901047,0.00031349942,0.0002308455,0.0000081003],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060031503,0.00014641683,0.004010378,0.0012042512,0.00062556623,0.00016577635,0.003328826,0.000004458629,0.97870445,0.00056030985,0.001215884,0.004030545],"study_design_scores_gemma":[0.018459938,0.00280087,0.00022845533,0.00013126002,0.00014111021,0.00024674344,0.0005594653,0.0007098716,0.9763783,0.00001562506,0.00016466802,0.0001636647],"about_ca_topic_score_codex":0.000035117682,"about_ca_topic_score_gemma":0.000008722415,"teacher_disagreement_score":0.01346886,"about_ca_system_score_codex":0.00090898393,"about_ca_system_score_gemma":0.00017374157,"threshold_uncertainty_score":0.9660801},"labels":[],"label_agreement":null},{"id":"W3091343940","doi":"10.1007/s12185-020-03014-5","title":"Chronic myeloid leukemia in solid organ transplant patients: a case series","year":2020,"lang":"en","type":"article","venue":"International Journal of Hematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Myeloid leukemia; Hematology; Solid organ; Medicine; Internal medicine; Series (stratigraphy); Oncology; Leukemia; Organ transplantation; Intensive care medicine; Transplantation; Biology","score_opus":0.013460645434833274,"score_gpt":0.2785525493361462,"score_spread":0.26509190390131293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3091343940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905557,0.00063370337,0.00019492429,0.007637032,0.00048987573,0.00014640062,0.000021058726,0.000015630378,0.00030565643],"genre_scores_gemma":[0.99797755,0.00021765057,0.00046571397,0.0008300557,0.0004130388,0.000004205552,0.000025311976,0.000021120157,0.000045354896],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99846244,0.00004796189,0.0007435192,0.00016925999,0.00036424748,0.00021258688],"domain_scores_gemma":[0.9990087,0.00007172299,0.00030791337,0.00009330502,0.00033761695,0.00018073084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008651908,0.00016058257,0.0004896107,0.00020494394,0.000019889272,0.000012661135,0.00020326907,0.00010662244,0.00041838936],"category_scores_gemma":[0.00017859926,0.000133972,0.00013083105,0.00011630142,0.00007162503,0.0001942486,0.000040121406,0.0003740361,0.00004833116],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060275,0.0007194633,0.47442746,0.00042612496,0.0024898886,0.47511774,0.008301756,0.0005594232,0.0072685676,0.0026118588,0.003405594,0.01864462],"study_design_scores_gemma":[0.045648478,0.005306191,0.01804187,0.0013824829,0.00039514704,0.8706622,0.000823734,0.0014270643,0.04117803,0.00045894115,0.014163685,0.00051213807],"about_ca_topic_score_codex":0.000042752115,"about_ca_topic_score_gemma":0.00011271318,"teacher_disagreement_score":0.45638558,"about_ca_system_score_codex":0.0021689353,"about_ca_system_score_gemma":0.0012651187,"threshold_uncertainty_score":0.567169},"labels":[],"label_agreement":null},{"id":"W3092516330","doi":"10.6004/jnccn.2020.7627","title":"Treatment Outcomes in Chronic Myeloid Leukemia: Does One Size Fit All?","year":2020,"lang":"en","type":"review","venue":"Journal of the National Comprehensive Cancer Network","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Discontinuation; Adverse effect; Myeloid leukemia; Intensive care medicine; Population; Disease; Quality of life (healthcare); Oncology; Internal medicine","score_opus":0.10120312174648217,"score_gpt":0.38201367040170936,"score_spread":0.2808105486552272,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092516330","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002621423,0.9927841,0.0000012735841,0.003383661,0.0017097103,0.0014778794,0.00012327422,0.000018432787,0.00023956924],"genre_scores_gemma":[0.00049149216,0.9901199,0.00034473377,0.0014737841,0.0057550785,0.00014437789,0.000024751314,0.00009811953,0.0015477905],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955392,0.000347572,0.001715401,0.00045841088,0.0014200006,0.0005194298],"domain_scores_gemma":[0.9947121,0.0018629039,0.0020832277,0.0003368839,0.00074498606,0.0002598904],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014405578,0.0007888862,0.0039400635,0.00018459333,0.000108534194,0.00003920205,0.00056596147,0.00039731906,0.00032808978],"category_scores_gemma":[0.00029392983,0.00038883323,0.0018961173,0.00069700123,0.00011762178,0.00010206306,0.00019093431,0.0014319187,0.000035210942],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0008760481,0.0008326334,0.0017461355,0.012045973,0.030544516,0.0010800441,0.00034607816,0.018842135,0.000021657199,0.00020302199,0.041999478,0.89146227],"study_design_scores_gemma":[0.004668143,0.0004852758,0.0018641578,0.014866605,0.003591719,0.000443865,0.000009138509,0.000088802175,0.000003419254,0.00018036195,0.9734804,0.0003181176],"about_ca_topic_score_codex":0.000076081415,"about_ca_topic_score_gemma":0.00009350607,"teacher_disagreement_score":0.93148094,"about_ca_system_score_codex":0.055257227,"about_ca_system_score_gemma":0.014530042,"threshold_uncertainty_score":0.99985635},"labels":[],"label_agreement":null},{"id":"W3094840453","doi":"10.1182/blood-2020-136162","title":"BCR-ABL1 Transcript Doubling Time after Imatinib Discontinuation for Treatment-Free Remission in Chronic Myeloid Leukemia in Chronic Phase: Predictor for Treatment-Free Remission Failure","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; McGill University Health Centre; London Health Sciences Centre; Juravinski Cancer Centre; Hôpital de l'Enfant-Jésus; Université de Montréal; Hôpital Maisonneuve-Rosemont; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; Vancouver General Hospital; University of Calgary; BC Cancer Agency; Alberta Health Services; CancerCare Manitoba; University of Alberta Hospital; Ottawa Hospital; University Health Network; University of Toronto; Alberta Hospital Edmonton; University of British Columbia","funders":"","keywords":"Discontinuation; Medicine; Imatinib; Myeloid leukemia; Internal medicine; Imatinib mesylate; Immunology; Oncology","score_opus":0.024197562769817122,"score_gpt":0.28793813815254676,"score_spread":0.26374057538272966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094840453","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97939783,0.0056823315,0.0006321093,0.0037618442,0.00013911174,0.0088020405,0.0010218594,0.00030412007,0.00025875395],"genre_scores_gemma":[0.9758181,0.0007729883,0.0095119085,0.00016361538,0.0018917096,0.0050788126,0.0033415665,0.0003070461,0.0031142847],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9954431,0.00011519878,0.0012994171,0.0014411184,0.0005187211,0.0011824134],"domain_scores_gemma":[0.99726385,0.00030251165,0.00036259394,0.0014028946,0.00011166138,0.0005564896],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00028770603,0.0009271902,0.0014397594,0.00035649995,0.00015825397,0.00008043015,0.00047465853,0.0005423723,0.0004024776],"category_scores_gemma":[0.00049722154,0.0007552072,0.0005649651,0.00056698767,0.00008516677,0.0004889049,0.000097408025,0.00022643147,0.000033191744],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014489931,0.0046777604,0.0040990403,0.0020870692,0.0011965232,0.00035990347,0.00591925,0.00044531934,0.90429634,0.00003631295,0.004471569,0.057920977],"study_design_scores_gemma":[0.54839283,0.029517813,0.0023299537,0.0040000034,0.0033654906,0.00009935651,0.00033690353,0.05946276,0.30310404,0.00032128833,0.047607336,0.0014622026],"about_ca_topic_score_codex":0.0002974675,"about_ca_topic_score_gemma":0.0009115162,"teacher_disagreement_score":0.6011923,"about_ca_system_score_codex":0.018631259,"about_ca_system_score_gemma":0.0045105396,"threshold_uncertainty_score":0.9994899},"labels":[],"label_agreement":null},{"id":"W3094845574","doi":"10.1182/blood-2020-133922","title":"Efficacy and Safety of Ponatinib (PON) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Who Failed One or More Second-Generation (2G) Tyrosine Kinase Inhibitors (TKIs): Analyses Based on PACE and Optic","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Ponatinib; Internal medicine; Clinical trial; Population; Interim analysis; Oncology; Myeloid leukemia; Dasatinib; Imatinib","score_opus":0.02353885709393887,"score_gpt":0.2795732222064298,"score_spread":0.2560343651124909,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094845574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963354,0.0011095281,0.000030296513,0.00049451785,0.00002942017,0.0017259795,0.00014178846,0.0000566182,0.00007647667],"genre_scores_gemma":[0.997584,0.0001031062,0.0009859073,0.00025117947,0.00023065173,0.00005912671,0.00064288185,0.00007286323,0.00007031009],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99745286,0.00010960919,0.0006744344,0.000780665,0.00056593417,0.0004165277],"domain_scores_gemma":[0.9985425,0.00018401313,0.00031446153,0.00046670286,0.00013119278,0.00036115342],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014385908,0.00047147987,0.0008794057,0.00025245335,0.000095777716,0.000033738554,0.0000951314,0.00018186256,0.00026193893],"category_scores_gemma":[0.00024212775,0.00036577974,0.00006845248,0.0006271378,0.00018418446,0.00017596628,0.000070876515,0.00033848957,0.0000051607285],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0851528,0.027180567,0.2632849,0.008827837,0.0046373485,0.001848213,0.005693563,0.011540046,0.5298675,0.000121365825,0.0010391597,0.06080671],"study_design_scores_gemma":[0.3284364,0.027310628,0.41174218,0.0023773143,0.0018480282,0.000020404354,0.000103723774,0.026706679,0.2003787,0.0000011182592,0.00023372719,0.0008410835],"about_ca_topic_score_codex":0.000104588704,"about_ca_topic_score_gemma":0.00033006226,"teacher_disagreement_score":0.32948878,"about_ca_system_score_codex":0.0012717571,"about_ca_system_score_gemma":0.0014503461,"threshold_uncertainty_score":0.9998794},"labels":[],"label_agreement":null},{"id":"W3094944282","doi":"10.1182/blood-2020-142270","title":"Comparison of the Transcriptomic Signatures in Pediatric and Adult CML","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"CD34; Myeloid; Bone marrow; Transcriptome; Biology; Leukemia; Gene; Medicine; Immunology; Gene expression; Genetics; Stem cell","score_opus":0.017352543797186645,"score_gpt":0.2692044365278447,"score_spread":0.25185189273065806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094944282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99448776,0.0031190827,0.0000013964262,0.0014740927,0.000025340374,0.00024356393,0.0000054927773,0.000013868492,0.0006294085],"genre_scores_gemma":[0.99925333,0.00011755328,0.00010281378,0.00040323345,0.00007583827,0.00000513765,0.0000024769627,0.000008553242,0.000031090323],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99946004,0.00002166533,0.00016330875,0.00013162446,0.00012649415,0.00009687708],"domain_scores_gemma":[0.9997359,0.000037579794,0.000042793454,0.00011338029,0.000016227712,0.00005415672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000022777323,0.000074326235,0.0002063825,0.000025333342,0.00001282204,0.0000023704602,0.00005935335,0.00005569829,0.000026793035],"category_scores_gemma":[0.000076925586,0.000049408052,0.000041506773,0.000163206,0.000025720003,0.000014821527,0.000017387523,0.00016458197,0.0000026044424],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006844919,0.0003808705,0.98931205,0.0002167045,0.00003807378,0.000010957184,0.0019747321,0.000009693714,0.006694099,0.000037924878,0.0009277565,0.00032868568],"study_design_scores_gemma":[0.014752211,0.00035743054,0.937162,0.000054502078,0.00060135935,0.000007833277,0.00020388888,0.00055687124,0.045933757,0.000018503488,0.00026269804,0.00008894268],"about_ca_topic_score_codex":0.000042053503,"about_ca_topic_score_gemma":0.00004433112,"teacher_disagreement_score":0.05215005,"about_ca_system_score_codex":0.000024422687,"about_ca_system_score_gemma":0.00008793203,"threshold_uncertainty_score":0.2014802},"labels":[],"label_agreement":null},{"id":"W3095006759","doi":"10.1182/blood-2020-135883","title":"Outcome By Mutation Status and Line of Treatment in Optic, a Dose-Ranging Study of 3 Starting Doses of Ponatinib in Patients with CP-CML","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Ponatinib; Medicine; Maximum tolerated dose; Internal medicine; Oncology; Dasatinib; Adverse effect; Imatinib; Myeloid leukemia","score_opus":0.01917147793811123,"score_gpt":0.272747336042538,"score_spread":0.25357585810442673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095006759","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99865466,0.00016806292,0.0000016236299,0.000031360407,0.000005839505,0.0010519354,0.000041361345,0.000008035774,0.000037138354],"genre_scores_gemma":[0.9991687,0.00000851061,0.0007151495,0.000011751759,0.000005153041,0.000023134624,0.000045630484,0.00001548749,0.000006461552],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988273,0.000041877676,0.000549556,0.00019504355,0.0002279741,0.0001582809],"domain_scores_gemma":[0.99942875,0.00009096136,0.00023650772,0.00012245867,0.000058307283,0.00006303101],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000071247785,0.00013176061,0.00047886552,0.000118399665,0.000008231103,0.0000020428931,0.000027442884,0.000030069023,0.000009151569],"category_scores_gemma":[0.0001095505,0.000100894795,0.000021658769,0.0002554538,0.000025882378,0.00004767619,0.000023079183,0.000060137023,2.3694224e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007004376,0.0050982265,0.98005396,0.00019436043,0.00018206329,0.000028825172,0.010448092,0.00014220699,0.0015630265,0.0000015210464,3.7885752e-7,0.001586874],"study_design_scores_gemma":[0.07992568,0.012024402,0.8936558,0.00018761783,0.0003334563,8.9010354e-7,0.0032550278,0.00031630823,0.010214447,0.000001863574,0.0000011166679,0.0000834051],"about_ca_topic_score_codex":0.0012781727,"about_ca_topic_score_gemma":0.00019594555,"teacher_disagreement_score":0.0863982,"about_ca_system_score_codex":0.00016642603,"about_ca_system_score_gemma":0.00011391599,"threshold_uncertainty_score":0.41143703},"labels":[],"label_agreement":null},{"id":"W3095036810","doi":"10.1002/jha2.125","title":"T‐lymphoblastic transformation of chronic myeloid leukemia","year":2020,"lang":"en","type":"article","venue":"eJHaem","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Population; Pathology; Medicine; Myeloid; Bone marrow; Complete blood count; Immunology; Gastroenterology; Molecular biology; Biology","score_opus":0.018718451764002088,"score_gpt":0.2517856187239334,"score_spread":0.23306716695993132,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095036810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98060477,0.0009406101,0.0022622962,0.0016931515,0.0001548589,0.0005713324,0.000019909612,0.00015494128,0.013598162],"genre_scores_gemma":[0.9985386,0.00011311745,0.00033332861,0.00038111804,0.0002995152,0.00001597384,0.000060052957,0.000025391844,0.00023288475],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989393,0.000019536637,0.00033531233,0.00020030398,0.00028352946,0.00022206706],"domain_scores_gemma":[0.9994294,0.000041195475,0.000086533626,0.00020837635,0.000049040667,0.00018543917],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005346846,0.00015291278,0.00032376844,0.000050755883,0.000031294443,0.0000052407454,0.00008629055,0.00008311623,0.0006338691],"category_scores_gemma":[0.000059545848,0.00013439075,0.000118802294,0.00023732903,0.00005933686,0.000101560654,0.00001965531,0.00012989771,0.0003638079],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028559922,0.0008277266,0.0058877417,0.007282769,0.0015988345,0.00055608904,0.03162439,0.0032622912,0.4517879,0.0050792303,0.01641339,0.47282365],"study_design_scores_gemma":[0.043563258,0.006912859,0.03276623,0.001135322,0.0013346423,0.00047541904,0.0010605152,0.097305045,0.7192554,0.00019604417,0.095031634,0.00096362503],"about_ca_topic_score_codex":0.000048731752,"about_ca_topic_score_gemma":0.00000844328,"teacher_disagreement_score":0.47186002,"about_ca_system_score_codex":0.0015406341,"about_ca_system_score_gemma":0.00095882604,"threshold_uncertainty_score":0.69404215},"labels":[],"label_agreement":null},{"id":"W3095325704","doi":"10.1182/blood-2020-137393","title":"Bosutinib (BOS) Versus Imatinib for Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukemia (CML): Final 5-Year Results from the Bfore Trial","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Bosutinib; Imatinib; Medicine; Myeloid leukemia; Nilotinib; Internal medicine; Imatinib mesylate; Oncology; Dasatinib","score_opus":0.060811541791056856,"score_gpt":0.31567383139095306,"score_spread":0.2548622895998962,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095325704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98075193,0.0026818432,0.0001261341,0.0052193915,0.0010862952,0.0053717266,0.0027397037,0.00035364777,0.0016693511],"genre_scores_gemma":[0.97848064,0.0005073115,0.002152726,0.0009095989,0.012321604,0.00077293714,0.0041668555,0.00018718075,0.00050114444],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9958712,0.00013671075,0.0010826564,0.0011581491,0.0007389189,0.0010123806],"domain_scores_gemma":[0.9957159,0.0019221349,0.0004756569,0.0012288411,0.00013177362,0.0005257064],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003672626,0.0006422772,0.00092978904,0.00006038123,0.00034042753,0.0000970757,0.0006134109,0.00035039533,0.0007150835],"category_scores_gemma":[0.0023349477,0.00048689984,0.0005891876,0.00040096208,0.00021476245,0.00016608709,0.0001906821,0.000702539,0.0004374175],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7048153,0.0056980737,0.0004694039,0.00076953106,0.0065603238,0.0014152183,0.006111442,0.0002944867,0.019654648,0.0005826915,0.16491799,0.088710845],"study_design_scores_gemma":[0.87799525,0.015643332,0.00047931442,0.00028942447,0.002413064,0.000021144799,0.0002711383,0.0023702763,0.012167565,0.000052871535,0.0877748,0.00052179483],"about_ca_topic_score_codex":0.0005666763,"about_ca_topic_score_gemma":0.00033010117,"teacher_disagreement_score":0.17317992,"about_ca_system_score_codex":0.002379197,"about_ca_system_score_gemma":0.005223208,"threshold_uncertainty_score":0.99975824},"labels":[],"label_agreement":null},{"id":"W3095353694","doi":"10.1080/23723556.2020.1835423","title":"Bad to the bone: B cell acute lymphoblastic leukemia cells mediate bone destruction","year":2020,"lang":"en","type":"article","venue":"Molecular & Cellular Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"Ontario Institute for Cancer Research; Hospital for Sick Children; Leukemia and Lymphoma Society of Canada","keywords":"RANKL; Activator (genetics); Effector; Cancer research; Medicine; Receptor; RANK Ligand; Immunology; Internal medicine","score_opus":0.009757562973587909,"score_gpt":0.24493000860983422,"score_spread":0.2351724456362463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095353694","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9720183,0.001367424,0.013500502,0.008045578,0.0008005266,0.0014107683,0.000024908302,0.00018736387,0.0026446162],"genre_scores_gemma":[0.9828652,0.00016040479,0.005364054,0.009819721,0.0005011399,0.00014209255,0.000146795,0.00012175477,0.000878844],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9969357,0.0002654637,0.0006101486,0.000844352,0.00056928396,0.000775053],"domain_scores_gemma":[0.99801064,0.00011748039,0.00022346513,0.0007797829,0.00012068715,0.0007479668],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00024429522,0.00046357096,0.00078176655,0.00013280334,0.00016013558,0.000032025746,0.00031702622,0.000377986,0.00039697092],"category_scores_gemma":[0.00011970483,0.00037197466,0.00030025683,0.0005881335,0.00014922855,0.00005442059,0.00027561194,0.0005132566,0.0024344036],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004930415,0.00013963238,0.00013566767,0.00007380677,0.0002505229,0.007917677,0.00074875227,0.0007741429,0.978245,0.000039522434,0.007019445,0.0041627903],"study_design_scores_gemma":[0.006714159,0.0021433851,0.00025327023,0.000032532847,0.0012322508,0.00061492267,0.00016350647,0.0023611593,0.8767755,0.000031503965,0.109300666,0.00037717004],"about_ca_topic_score_codex":0.00013738817,"about_ca_topic_score_gemma":0.000023130742,"teacher_disagreement_score":0.10228122,"about_ca_system_score_codex":0.00302798,"about_ca_system_score_gemma":0.001623894,"threshold_uncertainty_score":0.9998732},"labels":[],"label_agreement":null},{"id":"W3095409250","doi":"10.1182/blood-2020-136250","title":"ENESTop 5-Year Update: Durability of Treatment-Free Remission Following Second-Line Nilotinib and Exploratory Analysis of Molecular Response Regain after Nilotinib Re-Initiation in Patients with Chronic Myeloid Leukemia","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Nilotinib; Medicine; Internal medicine; Myeloid leukemia; Interim analysis; Imatinib mesylate; Imatinib; Neutropenia; Surgery; Gastroenterology; Clinical trial; Toxicity","score_opus":0.011738637734572068,"score_gpt":0.23703720142662135,"score_spread":0.2252985636920493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095409250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980379,0.00064241345,0.000018243125,0.00020516191,0.00002062669,0.0008474653,0.00012913324,0.000042485808,0.0000566161],"genre_scores_gemma":[0.99846363,0.000048549125,0.00092375674,0.00010703079,0.000025707039,0.00006854642,0.00029243997,0.00004877569,0.000021550773],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99746114,0.00034397346,0.0007845144,0.0006644816,0.0004453753,0.0003005431],"domain_scores_gemma":[0.99818015,0.0001741498,0.00036080132,0.0009143908,0.00013795588,0.00023253573],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000399889,0.00034194672,0.0010050817,0.00035679148,0.00003237458,0.000008880496,0.0001339933,0.00016707864,0.0001718057],"category_scores_gemma":[0.0005502025,0.0002842418,0.00022972941,0.0010816432,0.00008970795,0.0001730284,0.00010149766,0.00016829578,0.0000027830233],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013754546,0.001077223,0.9389762,0.00032433422,0.0020817842,0.00019174686,0.0015792218,0.00015455016,0.04123639,0.000003838394,0.0000123413965,0.0006078109],"study_design_scores_gemma":[0.045973673,0.005621088,0.80208033,0.00037436318,0.004544286,0.0000024719936,0.00019330763,0.00027838,0.14056489,0.000012185502,0.00006120272,0.00029378815],"about_ca_topic_score_codex":0.00006378883,"about_ca_topic_score_gemma":0.00015891546,"teacher_disagreement_score":0.13689585,"about_ca_system_score_codex":0.00126794,"about_ca_system_score_gemma":0.001060953,"threshold_uncertainty_score":0.99996096},"labels":[],"label_agreement":null},{"id":"W3096123657","doi":"10.1182/blood-2020-140459","title":"Inhibition of PAK6-Mediated Survival and Cell Cycle Controls Selectively Targets Therapy-Resistant CML Stem/Progenitor Cells","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute","funders":"","keywords":"Stem cell; Progenitor cell; Cancer research; CD34; Myeloid leukemia; Biology; Medicine; Immunology; Cell biology","score_opus":0.013684772930984907,"score_gpt":0.2212394822924047,"score_spread":0.2075547093614198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096123657","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950526,0.002787826,0.000017317163,0.00023779423,0.000055253793,0.00087352685,0.00014150584,0.00007537333,0.000758849],"genre_scores_gemma":[0.9989663,0.00027138565,0.00023256666,0.00017147708,0.00015817386,0.000035696485,0.000053809297,0.0000384158,0.00007220157],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986782,0.000087921544,0.00032452558,0.0003415013,0.00030539825,0.00026241652],"domain_scores_gemma":[0.9991942,0.00013328444,0.00016114925,0.00016171818,0.00012087668,0.00022875692],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000105251085,0.00020900485,0.0004663368,0.000045191122,0.000045538047,0.000011592037,0.000048509333,0.00011248712,0.00007382585],"category_scores_gemma":[0.000033267308,0.00017690257,0.00008638138,0.00018806971,0.00005858203,0.0000533076,0.000030375979,0.00014808906,0.000029607116],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00077127473,0.0008648514,0.008704944,0.00016327937,0.0003101948,0.00009598214,0.0006884326,0.0000014928657,0.9879267,0.00000700797,0.000120575365,0.0003452271],"study_design_scores_gemma":[0.028785033,0.0014582269,0.01157552,0.00004993909,0.00027812354,0.000007342284,0.0002224659,0.00010429241,0.95694584,0.000010519263,0.0004034748,0.00015924276],"about_ca_topic_score_codex":0.00007508068,"about_ca_topic_score_gemma":0.000007321632,"teacher_disagreement_score":0.030980919,"about_ca_system_score_codex":0.00008395091,"about_ca_system_score_gemma":0.00023942046,"threshold_uncertainty_score":0.72138774},"labels":[],"label_agreement":null},{"id":"W3096705707","doi":"10.1182/blood-2020-141910","title":"Nonclinical Efficacy and Toxicity and Selection of a Safe Clinical Starting Dose for an NMT Inhibitor in Development for Hematological Malignancies","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Dasatinib; Cancer research; LYN; Medicine; Pharmacology; Apoptosis; Myristoylation; Toxicity; Leukemia; Ibrutinib; Lymphoma; Myeloid leukemia; Proto-oncogene tyrosine-protein kinase Src; Biology; Internal medicine; Chronic lymphocytic leukemia; Receptor; Phosphorylation","score_opus":0.09150383230867733,"score_gpt":0.36303785247179987,"score_spread":0.27153402016312256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096705707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997877,0.00014347227,0.00023860422,0.0004739489,0.000021452892,0.0011881076,0.00000896404,0.000028368338,0.000020056028],"genre_scores_gemma":[0.9657177,0.00002359153,0.03371117,0.00029523816,0.00013455268,0.000081859915,0.000015014421,0.00001299239,0.000007891284],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99854994,0.00004932865,0.0007106532,0.00037508633,0.000108475106,0.00020651563],"domain_scores_gemma":[0.99889106,0.00065170636,0.00013599233,0.0000671119,0.00006112045,0.00019301803],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048093003,0.00012814968,0.0005188028,0.000029976372,0.000046960373,0.000007989317,0.00003343953,0.00015518475,0.000004043659],"category_scores_gemma":[0.0015990445,0.000104987,0.000053792293,0.00008250111,0.00007796287,0.000045665394,0.000046722227,0.00012105356,5.7495123e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007478124,0.008407635,0.88870597,0.0016658818,0.00037854313,0.000035669516,0.0024688789,0.0000028418406,0.062836185,0.00027531703,0.00023656873,0.027508417],"study_design_scores_gemma":[0.12600112,0.016899442,0.6305911,0.00062365935,0.00061893306,0.000102420396,0.00035590716,0.002968475,0.22004767,0.00015947246,0.0011866011,0.00044518075],"about_ca_topic_score_codex":0.0000052345,"about_ca_topic_score_gemma":0.00003395203,"teacher_disagreement_score":0.2581148,"about_ca_system_score_codex":0.00004368224,"about_ca_system_score_gemma":0.0003105754,"threshold_uncertainty_score":0.42812455},"labels":[],"label_agreement":null},{"id":"W3096722156","doi":"10.1016/j.htct.2020.10.454","title":"POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE AFTER 1 PRIOR LINE OF THERAPY IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBANALYSIS OF OPTIMMISM BY AGE, PRIOR TRANSPLANT, AND HIGH-RISK CYTOGENETICS","year":2020,"lang":"en","type":"article","venue":"Hematology Transfusion and Cell Therapy","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Fleurimont; Centre Hospitalier Universitaire de Sherbrooke; Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Pomalidomide; Bortezomib; Medicine; Oncology; Multiple myeloma; Internal medicine; Dexamethasone; Refractory (planetary science); Lenalidomide; Cytogenetics; Biology; Chromosome","score_opus":0.018030600615336935,"score_gpt":0.2509549417080469,"score_spread":0.23292434109270996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096722156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97577685,0.022183528,0.00041471788,0.00051330304,0.000029859371,0.00093136483,0.00010053204,0.000030369318,0.000019499505],"genre_scores_gemma":[0.8373377,0.15966035,0.0023828251,0.0003865834,0.000015051477,0.000047101184,0.000047380643,0.000046672256,0.000076377175],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978088,0.00024374337,0.0008334961,0.00057382137,0.00023960837,0.00030052094],"domain_scores_gemma":[0.99875945,0.0003904373,0.00024530134,0.00033229863,0.000055351735,0.00021714617],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021177392,0.00036819972,0.0013185426,0.00016761295,0.000049986622,0.000005391048,0.00010387589,0.00037529954,0.00034718122],"category_scores_gemma":[0.000023742823,0.00027194165,0.00016194119,0.00032955012,0.00026181535,0.0000361197,0.000012792194,0.00033907592,0.0000012186125],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.048710003,0.0021422477,0.3260586,0.0006130798,0.0007778542,0.0006587696,0.008366149,0.000016282438,0.54696655,0.000006155213,0.00006660285,0.06561768],"study_design_scores_gemma":[0.09005807,0.006095936,0.082537904,0.00024083754,0.0005896614,0.00016452558,0.0003930798,0.0013824359,0.81683767,0.000017531562,0.0012057291,0.00047663107],"about_ca_topic_score_codex":0.00036835516,"about_ca_topic_score_gemma":0.00023632732,"teacher_disagreement_score":0.2698711,"about_ca_system_score_codex":0.000037082737,"about_ca_system_score_gemma":0.00013475996,"threshold_uncertainty_score":0.9999733},"labels":[],"label_agreement":null},{"id":"W3097162507","doi":"10.1182/blood-2020-140234","title":"Retro-Prospective Observational Study on the Risk of Progression in Chronic Phase-Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation (TFR-PRO)","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Discontinuation; Medicine; Observational study; Myeloid leukemia; Tyrosine-kinase inhibitor; Internal medicine; Tyrosine kinase; Oncology; Bosutinib; Imatinib; Dasatinib; Immunology; Cancer","score_opus":0.04972576376106308,"score_gpt":0.3249673287236165,"score_spread":0.2752415649625534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097162507","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99154955,0.00061668514,0.000040915475,0.0005514811,0.0001018276,0.0068005533,0.00016790892,0.00006315891,0.00010794338],"genre_scores_gemma":[0.9975101,0.0000511009,0.00027632786,0.00008737602,0.00053758366,0.0010465423,0.00037047037,0.000059267277,0.00006125857],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973606,0.00014283249,0.0007144918,0.0006574683,0.0007304993,0.00039409776],"domain_scores_gemma":[0.998354,0.00028156315,0.00048977474,0.0004738522,0.00027379286,0.00012702007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037031312,0.00034245488,0.0005375828,0.00010936513,0.0001497135,0.000024422088,0.00018703235,0.00012910795,0.00005533884],"category_scores_gemma":[0.00092299236,0.00023530831,0.00016434431,0.00055672956,0.00009086086,0.00016275786,0.000093770206,0.00039835664,0.000019574445],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025851538,0.009503332,0.95198786,0.00025759474,0.00054293487,0.000020334182,0.0024146186,0.0001328684,0.024907472,0.00020740519,0.00066010584,0.006780338],"study_design_scores_gemma":[0.089504264,0.02472178,0.7342126,0.0007513629,0.0007765017,0.0000015142992,0.0003779517,0.0031020371,0.1459809,0.000110893096,0.00016152867,0.00029871313],"about_ca_topic_score_codex":0.00009233826,"about_ca_topic_score_gemma":0.000097030825,"teacher_disagreement_score":0.21777529,"about_ca_system_score_codex":0.0032219784,"about_ca_system_score_gemma":0.0014402915,"threshold_uncertainty_score":0.95955944},"labels":[],"label_agreement":null},{"id":"W3097213049","doi":"10.1182/blood-2020-136163","title":"Optimal Duration of Imatinib Treatment / Deep Molecular Response for Treatment-Free Remission after Imatinib Discontinuation from a Canadian Tyrosine Kinase Inhibitor Discontinuation Trial","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; McGill University Health Centre; Queen Elizabeth II Health Sciences Centre; London Health Sciences Centre; Juravinski Cancer Centre; Hôpital de l'Enfant-Jésus; Université de Montréal; Hôpital Maisonneuve-Rosemont; Princess Margaret Cancer Centre; University of Calgary; Vancouver General Hospital; Alberta Hospital Edmonton; University of British Columbia; CancerCare Manitoba; University of Alberta Hospital; Ottawa Hospital; University Health Network; University of Toronto; BC Cancer Agency; Alberta Health Services","funders":"","keywords":"Discontinuation; Imatinib; Medicine; Tyrosine-kinase inhibitor; Tyrosine kinase; Imatinib mesylate; Dasatinib; Internal medicine; Oncology; Drug holiday; Immunology; Cancer; Receptor; Human immunodeficiency virus (HIV)","score_opus":0.016663848680172025,"score_gpt":0.2648742075237999,"score_spread":0.2482103588436279,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097213049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894956,0.0005110422,0.0009431073,0.003631089,0.00012199845,0.00427278,0.0008860673,0.00006501521,0.00007329818],"genre_scores_gemma":[0.97745645,0.000027295831,0.018296545,0.00011594823,0.0004760904,0.0011260022,0.002247976,0.000070379305,0.00018328322],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99763334,0.00018361254,0.00083877187,0.0006073143,0.00035291395,0.00038407877],"domain_scores_gemma":[0.9981143,0.00022205152,0.00037947434,0.0006477212,0.00015520379,0.00048125858],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017253088,0.00041326374,0.00068249163,0.00015723544,0.00009655473,0.000048475536,0.00010981051,0.00019457516,0.00016258552],"category_scores_gemma":[0.00105931,0.00033370274,0.00031934312,0.0002107772,0.00005109657,0.00020326342,0.00003112692,0.000061854706,0.000015494703],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32509276,0.00712762,0.004865032,0.00012692092,0.0016209211,0.0005332416,0.010787515,0.00012231937,0.61868906,0.000046337824,0.0003396488,0.03064862],"study_design_scores_gemma":[0.33460245,0.018479982,0.007188037,0.00032879531,0.002870016,0.000013749942,0.00039804645,0.00618101,0.62846434,0.00004122476,0.0009896127,0.00044273006],"about_ca_topic_score_codex":0.007493359,"about_ca_topic_score_gemma":0.0053492924,"teacher_disagreement_score":0.03020589,"about_ca_system_score_codex":0.0012213798,"about_ca_system_score_gemma":0.0011133925,"threshold_uncertainty_score":0.9999115},"labels":[],"label_agreement":null},{"id":"W3098051819","doi":"10.7759/cureus.11009","title":"Precursor Lymphoblastic Lymphoma in the Extramedullary Tissue: A Rare Manifestation of Chronic Myeloid Leukemia in Blast Crisis","year":2020,"lang":"en","type":"article","venue":"Cureus","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Pathology; Bone marrow; Lymphoblastic lymphoma; Immunology","score_opus":0.01862745617590096,"score_gpt":0.26895243683841025,"score_spread":0.2503249806625093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3098051819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916507,0.0039757267,0.00009884945,0.0013924538,0.00011547129,0.0010610094,0.00002896229,0.000050342245,0.0016265105],"genre_scores_gemma":[0.9980429,0.00050350494,0.00027421082,0.0006391737,0.0002060183,0.000119630895,0.00009103916,0.000042303334,0.00008123666],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99802095,0.0001355914,0.00055669487,0.00043718997,0.00045115687,0.0003984341],"domain_scores_gemma":[0.99899006,0.00020596228,0.00016314095,0.00045333605,0.00005421301,0.00013325912],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017731199,0.00027106554,0.0004546051,0.00011065918,0.000031548458,0.00001727961,0.00028363083,0.00016921102,0.0002835607],"category_scores_gemma":[0.0002694026,0.00021481655,0.000084834275,0.00064083736,0.00008207627,0.00013991815,0.000062846586,0.00018498063,0.000103981576],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009367803,0.008306682,0.11122391,0.014639509,0.0017668256,0.020869408,0.20275997,0.010637388,0.08215415,0.003564361,0.086422816,0.4482872],"study_design_scores_gemma":[0.08289887,0.010747061,0.73415405,0.003979411,0.0013788663,0.0023704444,0.022604859,0.05855154,0.049026724,0.0010165733,0.031261753,0.0020098865],"about_ca_topic_score_codex":0.0007330522,"about_ca_topic_score_gemma":0.0006630466,"teacher_disagreement_score":0.6229301,"about_ca_system_score_codex":0.004779417,"about_ca_system_score_gemma":0.0018177974,"threshold_uncertainty_score":0.9990411},"labels":[],"label_agreement":null},{"id":"W3098816157","doi":"10.30968/rbfhss.2020.114.0510","title":"Use of tyrosine kinase inhibitor by patients with chronic myeloid leukemia at a public hematology institution in the state of Amazonas, Brazil","year":2020,"lang":"en","type":"article","venue":"Revista Brasileira de Farmácia Hospitalar e Serviços de Saúde","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Air (Canada)","funders":"","keywords":"Medicine; Dasatinib; Nilotinib; Internal medicine; Observational study; Imatinib; Hematology; Tyrosine-kinase inhibitor; Myeloid leukemia; Test (biology); Socioeconomic status; Family medicine; Population","score_opus":0.01506005681046235,"score_gpt":0.24062805483687344,"score_spread":0.2255679980264111,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3098816157","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99429536,0.002532153,0.00011986255,0.0006936996,0.000039389586,0.0018806162,0.0003154966,0.0000671376,0.0000562925],"genre_scores_gemma":[0.99674934,0.0002752096,0.00045347365,0.001550815,0.00006510128,0.000100420606,0.0006813831,0.000084507206,0.00003976742],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99653065,0.00030389577,0.0009937732,0.0006588938,0.0007281286,0.0007846693],"domain_scores_gemma":[0.9976151,0.00018300473,0.00061622227,0.000849563,0.0003863611,0.00034977295],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00033040647,0.0005118829,0.0010413205,0.00018716404,0.00009604283,0.000059488113,0.0004421469,0.00023085043,0.00007220171],"category_scores_gemma":[0.0005211127,0.00039203902,0.00020411499,0.00114867,0.0003472378,0.00039428798,0.00021593578,0.0005362916,0.000024410321],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00080848404,0.00072253833,0.9833173,0.0018913941,0.000237162,0.00016799114,0.0011627836,0.000106789324,0.0076152757,0.00036037472,0.0015985019,0.0020114],"study_design_scores_gemma":[0.010098879,0.002600762,0.96614,0.0010595166,0.00030381785,0.0000973621,0.00008308405,0.001036145,0.014143684,0.0000073223614,0.0039555477,0.00047391944],"about_ca_topic_score_codex":0.00054946926,"about_ca_topic_score_gemma":0.00027217015,"teacher_disagreement_score":0.017177345,"about_ca_system_score_codex":0.0040666373,"about_ca_system_score_gemma":0.0019906296,"threshold_uncertainty_score":0.99985313},"labels":[],"label_agreement":null},{"id":"W3099980423","doi":"10.1182/blood-2020-143816","title":"Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Bosutinib; Medicine; Open label; Myeloid leukemia; Internal medicine; Phases of clinical research; Oncology; Adverse effect; Clinical trial; Imatinib; Nilotinib","score_opus":0.02238647833757712,"score_gpt":0.28372661809334515,"score_spread":0.26134013975576803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3099980423","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868635,0.0012003033,0.0000019644242,0.00023957156,0.00005469781,0.010916351,0.0005450238,0.00009556004,0.00008300769],"genre_scores_gemma":[0.9973628,0.00038960623,0.00026219303,0.000103349834,0.00016951197,0.00042845734,0.0010748191,0.0001751851,0.00003410702],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99329627,0.0003792522,0.0021483088,0.002044822,0.0009850009,0.0011463613],"domain_scores_gemma":[0.9967332,0.00040432636,0.00083636324,0.0011732389,0.00019261145,0.000660282],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004387968,0.0010498957,0.0020777984,0.0005031164,0.0001250415,0.00009337699,0.000506466,0.00030823844,0.000057837675],"category_scores_gemma":[0.00041406773,0.00086021266,0.00006672027,0.0018067531,0.00022885614,0.0004961139,0.00046581458,0.00092695485,0.000013984529],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3437257,0.175163,0.4184027,0.001504242,0.0020114705,0.0057859756,0.022716798,0.0008439578,0.012401751,0.0000023783261,0.00032458338,0.01711744],"study_design_scores_gemma":[0.8190449,0.083676904,0.071897216,0.00509887,0.0010754097,0.000015973736,0.0005578357,0.0027203818,0.014690274,4.3806534e-7,0.00042064273,0.0008011854],"about_ca_topic_score_codex":0.011720628,"about_ca_topic_score_gemma":0.022245025,"teacher_disagreement_score":0.47531915,"about_ca_system_score_codex":0.006540463,"about_ca_system_score_gemma":0.0028447395,"threshold_uncertainty_score":0.9993849},"labels":[],"label_agreement":null},{"id":"W3102608389","doi":"10.1182/blood.v130.suppl_1.4236.4236","title":"Serially Transplantable Patient-Derived Xenograft Model of Chronic Myelomonocytic Leukemia (CMML)","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Chronic myelomonocytic leukemia; Medicine; Leukemia; Cancer research; Immunology; Bone marrow; Myelodysplastic syndromes","score_opus":0.02241161785346447,"score_gpt":0.2548835494229029,"score_spread":0.23247193156943846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3102608389","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900994,0.0005947226,0.0001563011,0.00008401082,0.00014846362,0.00064106047,0.00008821679,0.00008159409,0.008106289],"genre_scores_gemma":[0.9967054,0.00043653426,0.0018439593,0.00004309525,0.00014999711,0.000050953022,0.00006845697,0.00005740552,0.00064420555],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982883,0.000023887538,0.00044596582,0.00040713375,0.00034911506,0.00048560297],"domain_scores_gemma":[0.9980717,0.000028105276,0.00032089738,0.0012856603,0.00008719707,0.0002064858],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00009252619,0.00029041767,0.0005845795,0.0000820315,0.0002323503,0.000037485755,0.0003218245,0.000179822,0.00014557788],"category_scores_gemma":[0.000051247385,0.00026148802,0.0001969662,0.00005195934,0.00016945401,0.0001964667,0.000086598106,0.00019809589,0.000059823633],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007137962,0.0014981715,0.005922821,0.00095475756,0.0012026462,0.00030911443,0.0012592304,0.0012129191,0.97347736,0.00016355442,0.00023523951,0.013050413],"study_design_scores_gemma":[0.03431411,0.0016413073,0.005157251,0.0007157683,0.0019156887,0.0002366836,0.000050856106,0.015203974,0.9397477,0.00018956845,0.00038749448,0.00043959616],"about_ca_topic_score_codex":0.00045891822,"about_ca_topic_score_gemma":0.00015112074,"teacher_disagreement_score":0.033729635,"about_ca_system_score_codex":0.0008130576,"about_ca_system_score_gemma":0.0020940998,"threshold_uncertainty_score":0.9999837},"labels":[],"label_agreement":null},{"id":"W3106155982","doi":"10.1002/mds.28389","title":"Long‐Term Safety and Clinical Effects of Nilotinib in Parkinson's Disease","year":2020,"lang":"en","type":"article","venue":"Movement Disorders","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Nilotinib; Tolerability; Adverse effect; Medicine; Internal medicine; Placebo; Parkinson's disease; Quality of life (healthcare); Clinical trial; Disease","score_opus":0.013553161896174499,"score_gpt":0.2873205877209793,"score_spread":0.2737674258248048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3106155982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991945,0.0012237884,0.00009314031,0.005217244,0.00008528352,0.0010013876,0.000010300109,0.000031082185,0.0003927461],"genre_scores_gemma":[0.9928635,0.0021573901,0.00008427699,0.0046862946,0.000041859923,0.000022536478,0.000035982288,0.000021144911,0.00008704306],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987421,0.000062260144,0.00041056678,0.00034749453,0.00022111037,0.00021643625],"domain_scores_gemma":[0.9992092,0.0001500224,0.000090858906,0.0002179907,0.0000118566095,0.0003200196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000107334396,0.00015917435,0.0003772381,0.000043888747,0.000019329198,0.000004781966,0.0000646886,0.00005197955,0.0000793929],"category_scores_gemma":[0.00023462817,0.00014228853,0.000104254825,0.000133056,0.000101248894,0.000040778687,0.000082621096,0.00014004896,0.000009876799],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001135517,0.0005818284,0.97199136,0.0005884245,0.00011448003,0.000086656364,0.00018276951,0.0000052464966,0.00007038922,0.000038963637,0.00033840034,0.02486595],"study_design_scores_gemma":[0.012535247,0.0006537163,0.9846629,0.00018689502,0.00014687539,7.594948e-8,0.000034236164,0.0003518929,0.00009928346,0.00014455248,0.0010741403,0.00011021631],"about_ca_topic_score_codex":0.00006888442,"about_ca_topic_score_gemma":0.000091849586,"teacher_disagreement_score":0.024755735,"about_ca_system_score_codex":0.00014223042,"about_ca_system_score_gemma":0.00012784009,"threshold_uncertainty_score":0.5802358},"labels":[],"label_agreement":null},{"id":"W311177223","doi":"10.1371/journal.pone.0124960","title":"Abl Kinases Regulate HGF/Met Signaling Required for Epithelial Cell Scattering, Tubulogenesis and Motility","year":2015,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"National Cancer Institute; Canadian Institutes of Health Research; National Institutes of Health; U.S. Department of Defense","keywords":"Hepatocyte growth factor; Receptor tyrosine kinase; RHOA; ABL; Cell biology; Kinase; Cancer research; Tyrosine kinase; Biology; Hepatocyte Growth Factor Receptor; Receptor Protein-Tyrosine Kinases; Proto-oncogene tyrosine-protein kinase Src; Signal transduction; Receptor; C-Met; Biochemistry","score_opus":0.08990283362504954,"score_gpt":0.2675006078183309,"score_spread":0.17759777419328138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W311177223","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99700826,0.0011344213,0.000055231612,0.00032642862,0.00005610239,0.00087550277,0.000098246186,0.000106120286,0.00033966062],"genre_scores_gemma":[0.9827384,0.000041862022,0.014826398,0.00013204355,0.0002945413,0.00009625882,0.000088504064,0.00004952163,0.0017324868],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99849343,0.00004912722,0.00029841004,0.00042410463,0.00038777056,0.00034716658],"domain_scores_gemma":[0.9987826,0.00010062402,0.000103408,0.0004289488,0.00022040351,0.00036404957],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038562852,0.00021335352,0.0004888076,0.00007741825,0.000061760205,0.000021747463,0.000081802384,0.000106945234,0.00005037953],"category_scores_gemma":[0.00030263828,0.00019600816,0.0000670088,0.00009882745,0.00009303903,0.00008629645,0.00007636497,0.00007626312,0.00003756689],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012223682,0.0022697363,0.031864807,0.001133227,0.00066726416,0.00006941333,0.00073440594,0.000018816727,0.95891213,0.000008294917,0.0006851458,0.0024144058],"study_design_scores_gemma":[0.011130451,0.001429911,0.0062193526,0.00045702906,0.001429881,0.000022412813,0.00013621488,0.0012035306,0.97682947,0.0004889475,0.0004024218,0.0002503932],"about_ca_topic_score_codex":0.0001470061,"about_ca_topic_score_gemma":0.000009345765,"teacher_disagreement_score":0.025645453,"about_ca_system_score_codex":0.00054780865,"about_ca_system_score_gemma":0.00029859247,"threshold_uncertainty_score":0.7992981},"labels":[],"label_agreement":null},{"id":"W3112054388","doi":"10.1182/blood.v130.suppl_1.898.898","title":"Response to Front-Line Imatinib Treatment in Children and Adolescents with CML - Data from a Large Pediatric Cohort","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Shriners Hospitals for Children - Canada","funders":"","keywords":"Medicine; Imatinib; Internal medicine; Neutropenia; Adverse effect; Imatinib mesylate; Transplantation; Cohort; Gastroenterology; Myeloid leukemia; Surgery; Toxicity","score_opus":0.017945412882390877,"score_gpt":0.2875594664409274,"score_spread":0.2696140535585365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3112054388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99635684,0.0006242847,0.000011397026,0.00034496665,0.00003164169,0.0014564847,0.0010299857,0.000038738846,0.000105628096],"genre_scores_gemma":[0.99678904,0.00020290754,0.0016872126,0.00011634789,0.00022089516,0.00006191635,0.0005985192,0.00003786785,0.0002852808],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984179,0.00006484764,0.00023786869,0.0006650889,0.00026370236,0.00035060494],"domain_scores_gemma":[0.9975199,0.00003792049,0.00012508668,0.0020378996,0.00002369408,0.0002554909],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024369558,0.00025193,0.00043409792,0.00010935019,0.00012425106,0.00005177423,0.00029962388,0.00008234197,0.000069406626],"category_scores_gemma":[0.00021380492,0.00018581879,0.000025520618,0.000054371143,0.00003120063,0.00013173698,0.00030469062,0.00011557926,0.000109466564],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021789833,0.0019913581,0.9942684,0.000013425774,0.00024816155,0.00027219826,0.00018345329,3.2667683e-7,0.00010511564,3.0127555e-7,0.00024346702,0.0004948092],"study_design_scores_gemma":[0.041302685,0.0008244314,0.9559667,0.00020250074,0.000996415,0.00007028585,0.000016256252,0.00005522005,0.00026065533,0.0000027265396,0.00013753935,0.00016454596],"about_ca_topic_score_codex":0.002947004,"about_ca_topic_score_gemma":0.0010758789,"teacher_disagreement_score":0.039123703,"about_ca_system_score_codex":0.00024413555,"about_ca_system_score_gemma":0.00034278812,"threshold_uncertainty_score":0.75774705},"labels":[],"label_agreement":null},{"id":"W3118832452","doi":"10.1136/heartjnl-2020-318251","title":"Tyrosine kinase inhibitors in chronic myeloid leukaemia and emergent cardiovascular disease","year":2021,"lang":"en","type":"article","venue":"Heart","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa; Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Mace; Internal medicine; Hazard ratio; Population; Incidence (geometry); Cumulative incidence; Cohort; Retrospective cohort study; Surgery; Confidence interval; Myocardial infarction; Percutaneous coronary intervention","score_opus":0.016806394767940745,"score_gpt":0.2595096306681998,"score_spread":0.24270323590025908,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3118832452","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9265626,0.07099473,0.0000067229917,0.0014360086,0.00020585429,0.0003585832,0.000010589773,0.000049379745,0.0003755304],"genre_scores_gemma":[0.9952599,0.0024245642,0.0002398776,0.00032000244,0.00036067778,0.000060325194,0.00008621198,0.00003809615,0.0012103501],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984268,0.000071830436,0.00026555872,0.00050037017,0.00036664898,0.00036877673],"domain_scores_gemma":[0.9988351,0.000023421699,0.000020981475,0.0006552534,0.00005668426,0.00040858221],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016078775,0.00019911493,0.00041860997,0.00008810281,0.0000542342,0.000015451564,0.00003089957,0.00008278575,0.00033554097],"category_scores_gemma":[0.00011901583,0.00019156188,0.00023090621,0.00029822957,0.00006234144,0.00006699093,0.00009102564,0.00021632729,0.000101420315],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00066508236,0.0014135712,0.76513386,0.0027058262,0.00197374,0.020989873,0.00074103277,0.0016337057,0.08069446,0.00030691703,0.030401021,0.093340926],"study_design_scores_gemma":[0.011400353,0.00023197554,0.5427525,0.0009002318,0.0006836382,0.00046654922,0.00010262952,0.0011028948,0.029349038,0.000054825174,0.4124834,0.00047198933],"about_ca_topic_score_codex":0.00030276706,"about_ca_topic_score_gemma":0.000080221034,"teacher_disagreement_score":0.38208237,"about_ca_system_score_codex":0.0016931093,"about_ca_system_score_gemma":0.0012705785,"threshold_uncertainty_score":0.7811667},"labels":[],"label_agreement":null},{"id":"W3120347152","doi":"10.1016/j.rmra.2020.11.406","title":"Effet du nintédanib sur le déclin de la CVF chez des patients atteints de PID fibrosantes progressives : données de l’étude INBUILD","year":2021,"lang":"fr","type":"article","venue":"Revue des Maladies Respiratoires Actualités","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; St. Joseph’s Healthcare Hamilton","funders":"","keywords":"Gynecology; Medicine; Philosophy","score_opus":0.030911929258180544,"score_gpt":0.2810996737196978,"score_spread":0.25018774446151726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120347152","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8834349,0.11147236,0.00024423236,0.0013664997,0.00045318223,0.00090416713,0.00029275377,0.00025128812,0.0015806083],"genre_scores_gemma":[0.94801664,0.026906552,0.010824491,0.0009568228,0.0018851022,0.0003665954,0.00025144898,0.00034218444,0.010450175],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99099404,0.0027010653,0.0014560822,0.0013915033,0.0006547476,0.0028025494],"domain_scores_gemma":[0.99317783,0.0031150696,0.0006203626,0.0013360088,0.0006670521,0.0010836968],"candidate_categories":["metaresearch","metaepi_narrow","sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015966078,0.0012206625,0.0016421494,0.0002996054,0.000878685,0.0004598825,0.0007426417,0.0010209194,0.0010785059],"category_scores_gemma":[0.008922234,0.0012635699,0.0006986807,0.0008496354,0.0028688253,0.0006386502,0.00075538893,0.0011571323,0.00015541309],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008206177,0.0035079175,0.682103,0.009965476,0.0017820254,0.0047188783,0.024351744,0.00030506225,0.01431917,0.0009438141,0.0020173932,0.25516495],"study_design_scores_gemma":[0.01470691,0.002417811,0.65181845,0.03247259,0.0015595262,0.0029627753,0.004248068,0.0019877625,0.1788108,0.0020952108,0.10487249,0.0020476147],"about_ca_topic_score_codex":0.0014119883,"about_ca_topic_score_gemma":0.0011345632,"teacher_disagreement_score":0.25311732,"about_ca_system_score_codex":0.00579923,"about_ca_system_score_gemma":0.0036971436,"threshold_uncertainty_score":0.9998448},"labels":[],"label_agreement":null},{"id":"W3120669570","doi":"10.3390/cancers13020184","title":"Protein Tyrosine Kinases: Their Roles and Their Targeting in Leukemia","year":2021,"lang":"en","type":"review","venue":"Cancers","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":95,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan","funders":"","keywords":"Receptor tyrosine kinase; Cancer research; Tyrosine kinase; Biology; Platelet-derived growth factor receptor; Receptor Protein-Tyrosine Kinases; Protein tyrosine phosphatase; ROR1; Cell biology; Kinase; Signal transduction; Receptor; Growth factor; Biochemistry","score_opus":0.03050771481807006,"score_gpt":0.3031622415284536,"score_spread":0.27265452671038354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120669570","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0025786543,0.9946895,0.0000034424384,0.000031717416,0.00012967672,0.0017414248,0.000087949426,0.000054591943,0.00068301614],"genre_scores_gemma":[0.0006406852,0.99683744,0.00016661867,0.00007795449,0.00033668318,0.00063227036,0.00047134297,0.00010931477,0.00072769145],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979641,0.0001347288,0.00057390425,0.00070803124,0.00015511192,0.00046416116],"domain_scores_gemma":[0.99888694,0.00012590214,0.00026434808,0.00049823086,0.00005099024,0.00017357686],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002120065,0.0006150986,0.002260147,0.00018089492,0.000056221845,0.000032949672,0.00014162801,0.0003433116,0.00014088363],"category_scores_gemma":[0.00015836232,0.00041532176,0.00030902823,0.0004350705,0.0001127998,0.000055375804,0.00012446493,0.000644083,0.0000126908235],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000016489119,0.0000152058155,0.000028017295,0.015405758,0.0003184258,0.00024533694,0.0003478114,0.0000069325256,0.000026974149,0.00002464458,0.0013016455,0.98226273],"study_design_scores_gemma":[0.0013602393,0.00008222005,0.000006018587,0.06873905,0.00029599317,0.00011040504,0.00039937894,0.00005942566,0.00013593875,0.000008374765,0.9284527,0.00035030275],"about_ca_topic_score_codex":0.0005224804,"about_ca_topic_score_gemma":0.00013366678,"teacher_disagreement_score":0.98191243,"about_ca_system_score_codex":0.020610364,"about_ca_system_score_gemma":0.010093273,"threshold_uncertainty_score":0.9998299},"labels":[],"label_agreement":null},{"id":"W3128681620","doi":"10.1038/s41392-020-00410-5","title":"Inhibition of cystathionine β-synthase promotes apoptosis and reduces cell proliferation in chronic myeloid leukemia","year":2021,"lang":"en","type":"article","venue":"Signal Transduction and Targeted Therapy","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia Hospital; University of British Columbia","funders":"Chongqing Medical University","keywords":"Cystathionine beta synthase; Myeloid leukemia; Apoptosis; K562 cells; Cancer research; Cell growth; Leukemia; Bone marrow; Chronic myelogenous leukemia; Biology; Myeloid; Chemistry; Molecular biology; Immunology; Biochemistry; Enzyme","score_opus":0.015846425551478107,"score_gpt":0.24925571331278457,"score_spread":0.23340928776130646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3128681620","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99262184,0.005721964,0.0001921576,0.00064677896,0.0000621053,0.0005551219,0.000017004546,0.00003844005,0.00014461456],"genre_scores_gemma":[0.99268955,0.0060075945,0.00069155573,0.00006420746,0.00011469039,0.000057436046,0.0001898217,0.00002256594,0.00016255229],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987993,0.00010175263,0.00034968977,0.00036049864,0.00020116114,0.00018759136],"domain_scores_gemma":[0.9995597,0.000030958447,0.000089859794,0.00011704029,0.00010982967,0.00009258373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001563524,0.00018662309,0.0003123124,0.00016548595,0.0000698298,0.000018814904,0.000017112356,0.00012772743,0.0004278795],"category_scores_gemma":[0.000010546623,0.00016834855,0.000057433015,0.00032206622,0.000099412515,0.0001717609,0.00000544935,0.00019134152,0.000001543914],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004907323,0.00024468324,0.0005549446,0.00020241125,0.000061292434,0.000015795791,0.0015048217,0.000038936298,0.9754901,0.000028840983,0.000014729274,0.021352721],"study_design_scores_gemma":[0.007686269,0.0008083283,0.0024621533,0.00020275993,0.000046548943,0.00007780414,0.0003507791,0.0006044744,0.9872781,0.00018363618,0.0001611808,0.00013793535],"about_ca_topic_score_codex":0.00006237951,"about_ca_topic_score_gemma":0.000015307634,"teacher_disagreement_score":0.021214785,"about_ca_system_score_codex":0.0004165989,"about_ca_system_score_gemma":0.0006451341,"threshold_uncertainty_score":0.68650544},"labels":[],"label_agreement":null},{"id":"W3133799417","doi":"10.1080/10428194.2021.1889536","title":"The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study","year":2021,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Dasatinib; Myeloid leukemia; Medicine; Nivolumab; Nilotinib; Oncology; Internal medicine; Leukemia; Immunotherapy; Cancer; Imatinib","score_opus":0.011044376472123788,"score_gpt":0.24454907450342167,"score_spread":0.2335046980312979,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3133799417","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98256505,0.00537205,0.000009651316,0.0026313984,0.00039095228,0.0067845667,0.0011632353,0.00025119205,0.0008319186],"genre_scores_gemma":[0.96963185,0.00340488,0.00024684737,0.0067999256,0.0017187371,0.0004908359,0.014233888,0.0005694901,0.00290354],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9874582,0.0010438131,0.0036029052,0.0034748365,0.0023383007,0.0020818892],"domain_scores_gemma":[0.9905841,0.002719428,0.0021967413,0.00329187,0.0005986927,0.00060918875],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0008653371,0.002373576,0.003901492,0.0006887115,0.0007593598,0.00033338094,0.00082296197,0.0023472456,0.00006202679],"category_scores_gemma":[0.00064747175,0.0017876673,0.00048231802,0.001492619,0.0010692735,0.00044325,0.00063744345,0.0015591867,0.000024886878],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.119640015,0.008575644,0.09055955,0.002803934,0.010968024,0.012014721,0.015187759,0.0004255697,0.00025825892,0.000022257573,0.07212713,0.6674171],"study_design_scores_gemma":[0.47149014,0.00710686,0.46355885,0.003705134,0.003279295,0.000303531,0.0006178853,0.003069235,0.00026841465,0.00001698104,0.044719927,0.0018637239],"about_ca_topic_score_codex":0.015981292,"about_ca_topic_score_gemma":0.0020291514,"teacher_disagreement_score":0.6655534,"about_ca_system_score_codex":0.0708144,"about_ca_system_score_gemma":0.022177381,"threshold_uncertainty_score":0.9989479},"labels":[],"label_agreement":null},{"id":"W3137145556","doi":"10.1101/2021.03.21.436331","title":"The Central Importance of Hub Proteins in a Disease-Gene Network Model: A New Paradigm of Chronic Myeloid Leukemia Disease Study","year":2021,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; Royal University Hospital","funders":"","keywords":"Computational biology; Myeloid leukemia; Biology; Gene regulatory network; Gene; Disease; Context (archaeology); Systems biology; DECIPHER; Genetics; Bioinformatics; Medicine; Cancer research; Gene expression","score_opus":0.0155204588073861,"score_gpt":0.23887032127664565,"score_spread":0.22334986246925956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3137145556","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9710472,0.02200537,0.00045294134,0.0002648664,0.00043292093,0.005424694,0.00023903835,0.00013055088,0.0000023879056],"genre_scores_gemma":[0.99518424,0.001590826,0.0013835643,0.000060205268,0.00067300297,0.00088046305,0.0000056768654,0.00020232976,0.000019708761],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99443007,0.00026274673,0.0015630228,0.0014860987,0.0010434061,0.0012146858],"domain_scores_gemma":[0.99388677,0.000112381145,0.0010792797,0.0034760812,0.00030323523,0.0011422797],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000618498,0.0008817786,0.0014986517,0.00018322277,0.00013614206,0.00008172357,0.00076192594,0.00032339714,0.000039066985],"category_scores_gemma":[0.00040571706,0.0007731544,0.0004596428,0.0009509652,0.0002501657,0.00013020942,0.0007223468,0.0010081747,0.0000036658344],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0025165544,0.0033402944,0.8919303,0.003473887,0.0020791185,0.0023827727,0.00021106238,0.060285818,0.033053473,0.00041430345,0.0002940261,0.00001843835],"study_design_scores_gemma":[0.0066325166,0.00029898106,0.9614011,0.0031552266,0.001350179,6.124154e-8,0.000015169699,0.019552287,0.0066260863,0.00001888045,0.00016657628,0.0007829496],"about_ca_topic_score_codex":0.00055784587,"about_ca_topic_score_gemma":0.00025200035,"teacher_disagreement_score":0.06947083,"about_ca_system_score_codex":0.005834617,"about_ca_system_score_gemma":0.03164893,"threshold_uncertainty_score":0.99947196},"labels":[],"label_agreement":null},{"id":"W3143794578","doi":"10.18433/jpps31425","title":"Sigmoid Sinus Thrombosis Followed by Splenic Infarction Due to Imatinib Therapy in a Patient with Gastrointestinal Stromal Tumor; Hematological Side Effects of Imatinib","year":2021,"lang":"en","type":"article","venue":"Journal of Pharmacy & Pharmaceutical Sciences","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Imatinib; Imatinib mesylate; Thrombosis; Surgery; Abdominal pain; Internal medicine","score_opus":0.03667319825763152,"score_gpt":0.3612388805803254,"score_spread":0.3245656823226939,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3143794578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99530685,0.0011929101,0.00024495146,0.002098658,0.00018180648,0.0006302411,0.000009129284,0.000020181315,0.00031527807],"genre_scores_gemma":[0.9863077,0.00015092107,0.01230254,0.0011065019,0.00007725548,0.000025370393,0.0000032376727,0.000018525627,0.000007973664],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9962233,0.00033246836,0.001056519,0.00042647278,0.0013253388,0.00063595467],"domain_scores_gemma":[0.9976183,0.00078519934,0.0005258999,0.00015746505,0.00032988202,0.0005832143],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006411298,0.00033085796,0.0008913964,0.00023157318,0.000105225896,0.000050421448,0.0002723872,0.00003316702,0.00038986636],"category_scores_gemma":[0.0005887594,0.0002176338,0.0002344565,0.0010825011,0.00037159544,0.00033441954,0.00009758084,0.00059188745,0.000008975421],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025494539,0.0027916909,0.0910797,0.00025420653,0.00019114019,0.0073772143,0.00050424895,0.00019747156,0.87471086,0.000027085554,0.0005560694,0.01976086],"study_design_scores_gemma":[0.02163082,0.008851191,0.023506606,0.0015556347,0.00034052253,0.034033414,0.00044356013,0.0033044785,0.90467453,0.00004724612,0.0012663716,0.0003456114],"about_ca_topic_score_codex":0.00004956161,"about_ca_topic_score_gemma":0.0000065928048,"teacher_disagreement_score":0.06757309,"about_ca_system_score_codex":0.00046260643,"about_ca_system_score_gemma":0.0010730745,"threshold_uncertainty_score":0.8874849},"labels":[],"label_agreement":null},{"id":"W3150954884","doi":"10.1007/s12185-021-03126-6","title":"Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia","year":2021,"lang":"en","type":"review","venue":"International Journal of Hematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Imatinib; Myeloid leukemia; Medicine; Druggability; Tyrosine kinase; Tyrosine-kinase inhibitor; Dasatinib; Homoharringtonine; Oncology; Hematology; Pharmacology; Adverse effect; Chronic myelogenous leukemia; Cancer research; Leukemia; Cancer; Internal medicine; Biology; Receptor","score_opus":0.022313506583901303,"score_gpt":0.3286523114547571,"score_spread":0.3063388048708558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3150954884","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0020480582,0.9933978,0.000017308215,0.00091916125,0.0026795487,0.00039882842,0.00003682075,0.0000069022385,0.0004956242],"genre_scores_gemma":[0.007472715,0.9904797,0.00037996325,0.000094837655,0.00097519986,0.000015972459,0.00006768042,0.00006195551,0.00045193892],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960862,0.00026851374,0.002159115,0.00031697497,0.0008328345,0.000336365],"domain_scores_gemma":[0.9965567,0.0003352526,0.0021549817,0.00044885685,0.00038640268,0.0001177854],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003915443,0.0004240459,0.0027915682,0.00068110076,0.000023766273,0.000016548172,0.0007951184,0.0004243743,0.0006118923],"category_scores_gemma":[0.00049968273,0.0002764102,0.001194901,0.00042185513,0.0001976804,0.000088185465,0.00029326288,0.0012360798,0.000027038435],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0006339344,0.0024838983,0.008059278,0.030048965,0.015315544,0.041814104,0.0005728248,0.00029250473,0.000418158,0.014243038,0.028696263,0.8574215],"study_design_scores_gemma":[0.0039921487,0.00031441922,0.00015556844,0.053351775,0.00093840127,0.037816815,0.000030014698,0.000023920822,0.0020843332,0.0002722747,0.9007618,0.00025851937],"about_ca_topic_score_codex":0.00007359604,"about_ca_topic_score_gemma":0.000060979793,"teacher_disagreement_score":0.87206554,"about_ca_system_score_codex":0.009000348,"about_ca_system_score_gemma":0.010567767,"threshold_uncertainty_score":0.9999688},"labels":[],"label_agreement":null},{"id":"W3155637160","doi":"10.1111/bjh.17447","title":"Optimal duration of imatinib treatment/deep molecular response for treatment‐free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial","year":2021,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Toronto General Hospital; University of Alberta; London Health Sciences Centre; Hôpital de l'Enfant-Jésus; Université de Montréal; Hôpital Maisonneuve-Rosemont; Queen Elizabeth II Health Sciences Centre; McGill University Health Centre; University of Ottawa; Princess Margaret Cancer Centre; Vancouver General Hospital; University of Calgary; BC Cancer Agency; Alberta Health Services; CancerCare Manitoba; University Health Network; Ottawa Hospital; Dalhousie University; Western University; University of Toronto; University of British Columbia","funders":"","keywords":"Discontinuation; Imatinib; Medicine; Internal medicine; Tyrosine-kinase inhibitor; Imatinib mesylate; Gastroenterology; Cancer","score_opus":0.013217752408859433,"score_gpt":0.27940593252199886,"score_spread":0.26618818011313944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3155637160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99034095,0.0037750048,0.0014939439,0.0021227961,0.00042622763,0.0013118518,0.0004642868,0.000014500327,0.000050439015],"genre_scores_gemma":[0.9779558,0.00024728777,0.020108795,0.00006903418,0.00031062952,0.000170118,0.00078212493,0.000052858923,0.00030334023],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9969823,0.0004539479,0.001465605,0.00037945193,0.0003381168,0.00038061087],"domain_scores_gemma":[0.99726325,0.00040820046,0.00096151576,0.00040992143,0.0006152984,0.0003418402],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037148787,0.00029842125,0.0012039919,0.00026366874,0.000106549116,0.00006788363,0.00010748328,0.00025923178,0.00028738764],"category_scores_gemma":[0.002117758,0.0002835775,0.000467382,0.00019064323,0.0000960316,0.00029087358,0.000026653654,0.0001176116,0.0000042971997],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38897467,0.009002653,0.0045018583,0.0002804591,0.0036275894,0.13609323,0.0051926523,0.00019576776,0.2661242,0.00016518547,0.002739008,0.18310276],"study_design_scores_gemma":[0.40676433,0.01871253,0.012854302,0.003327511,0.0038238645,0.04718472,0.0013842721,0.00255603,0.49930102,0.0005329976,0.0028146186,0.0007438119],"about_ca_topic_score_codex":0.0060105724,"about_ca_topic_score_gemma":0.01809353,"teacher_disagreement_score":0.23317681,"about_ca_system_score_codex":0.0015357779,"about_ca_system_score_gemma":0.0023364706,"threshold_uncertainty_score":0.9999616},"labels":[],"label_agreement":null},{"id":"W3155962936","doi":"10.1111/bjh.17444","title":"How much imatinib is enough?","year":2021,"lang":"en","type":"letter","venue":"British Journal of Haematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Imatinib; Discontinuation; Dasatinib; Medicine; Tyrosine kinase; Hematology; Tyrosine-kinase inhibitor; Internal medicine; Oncology; Imatinib mesylate; Myeloid leukemia; Cancer","score_opus":0.023454219672114904,"score_gpt":0.26698682004997143,"score_spread":0.2435326003778565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3155962936","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.048898052,0.038103513,0.000077648234,0.9087967,0.0017313578,0.00034251282,0.00010971872,0.000032907963,0.0019075515],"genre_scores_gemma":[0.01178727,0.00794927,0.00928282,0.9301463,0.010119207,0.000027133685,0.00060045056,0.00028664048,0.029800937],"study_design_codex":"not_applicable","study_design_gemma":"case_report","domain_scores_codex":[0.9967274,0.0002636497,0.0010501584,0.00044969353,0.0008278913,0.0006812182],"domain_scores_gemma":[0.997032,0.0002602882,0.0012484835,0.00048930116,0.00077262014,0.00019733007],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00022694937,0.00042062337,0.0025528485,0.0002857729,0.000088616514,0.0001659311,0.0003561696,0.0015396981,0.0018838975],"category_scores_gemma":[0.00056274293,0.00045135443,0.0007861175,0.00019036094,0.00020305418,0.00014408167,0.000111055175,0.0044118166,0.00006894397],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001711277,0.00006629793,0.000053898777,0.00050348166,0.00066884526,0.4428977,0.000054250988,2.3522817e-8,0.000021175063,0.00000497634,0.551577,0.0041352618],"study_design_scores_gemma":[0.0023691838,0.00017403335,0.000041267504,0.0017388491,0.00052937184,0.5169383,0.000065304,0.0000018489586,0.00045786452,0.00012496828,0.4773953,0.00016369538],"about_ca_topic_score_codex":0.00007191483,"about_ca_topic_score_gemma":0.000016155638,"teacher_disagreement_score":0.074181676,"about_ca_system_score_codex":0.0006360683,"about_ca_system_score_gemma":0.0018035866,"threshold_uncertainty_score":0.9997938},"labels":[],"label_agreement":null},{"id":"W3160346821","doi":"10.1038/s41375-021-01260-y","title":"Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update","year":2021,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Novartis Pharmaceuticals Corporation","keywords":"Nilotinib; Medicine; Myeloid leukemia; Internal medicine; Adverse effect; Tyrosine-kinase inhibitor; Imatinib; Surgery; Cancer","score_opus":0.009310910288651317,"score_gpt":0.24042484876914275,"score_spread":0.23111393848049144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3160346821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99443144,0.0015932439,0.000019189909,0.00027536732,0.00029207312,0.0011101385,0.00011684896,0.00020406512,0.001957648],"genre_scores_gemma":[0.9836689,0.00040753087,0.0012422139,0.0005743094,0.00045968077,0.0002209785,0.00153702,0.00019963428,0.0116896955],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99582267,0.00013687584,0.00082361157,0.0013430074,0.0007752233,0.0010985974],"domain_scores_gemma":[0.99659806,0.00009528576,0.0002564456,0.002269156,0.00024169586,0.00053932855],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00014105883,0.0008242473,0.0010612858,0.00027985574,0.00011758557,0.00006775834,0.0003376862,0.00043821862,0.004161248],"category_scores_gemma":[0.00010917576,0.0006567221,0.00025110485,0.00071149797,0.00014980856,0.00032108164,0.00028545997,0.0006155435,0.00049826066],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0032376123,0.0006824705,0.9706334,0.00038147316,0.00038866245,0.003281314,0.00025766258,0.00007959972,0.0012993634,0.000021930084,0.0009837836,0.018752737],"study_design_scores_gemma":[0.0498705,0.0018880775,0.92088467,0.0010795115,0.0003824569,0.0001811013,0.00002316636,0.00009089278,0.01926709,0.000034504927,0.005613945,0.00068407814],"about_ca_topic_score_codex":0.00021894832,"about_ca_topic_score_gemma":0.0020540478,"teacher_disagreement_score":0.049748715,"about_ca_system_score_codex":0.02762262,"about_ca_system_score_gemma":0.0064981193,"threshold_uncertainty_score":0.99958843},"labels":[],"label_agreement":null},{"id":"W3160467278","doi":"","title":"Development of a simple method for the simultaneous determination of imatinib, norimatinib, dasatinib and nilotinib in human plasma by hplc photodiode array detector.","year":2011,"lang":"en","type":"preprint","venue":"HAL (Le Centre pour la Communication Scientifique Directe)","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre d'expertise et de recherche en infrastructures urbaines","funders":"","keywords":"Nilotinib; Dasatinib; Imatinib; Photodiode; Simple (philosophy); Detector; Human plasma; Computer science; Materials science; Chromatography; Optoelectronics; Chemistry; Medicine; Cancer research; Telecommunications","score_opus":0.02552967546408848,"score_gpt":0.29260146845512586,"score_spread":0.2670717929910374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3160467278","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.78038406,0.0006062558,0.21213928,0.0002859427,0.00007714566,0.0028129949,0.00023621063,0.0000709435,0.0033871862],"genre_scores_gemma":[0.60069937,0.00009124547,0.39779735,0.000016985914,0.000007841266,0.00031640916,0.00051544904,0.000046728834,0.00050863606],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9959216,0.0013331333,0.0012852777,0.0006846651,0.00043389818,0.00034139166],"domain_scores_gemma":[0.9910722,0.004949194,0.0012934572,0.0014340323,0.0011245857,0.00012654896],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0043041473,0.00040463102,0.0008247595,0.0002188355,0.00020644144,0.00004414247,0.0005988586,0.0003047069,0.0000797736],"category_scores_gemma":[0.0026421284,0.00035116967,0.00017605942,0.0002289717,0.00023824943,0.000055896653,0.0004735322,0.00045340537,0.0000016069067],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033133128,0.00203271,0.0033499612,0.0032774652,0.00046496035,0.000005778415,0.07391229,0.0000453202,0.30335155,0.001466495,0.00014714793,0.611615],"study_design_scores_gemma":[0.0038904848,0.0000064494234,0.0017479415,0.0020175208,0.00022350097,0.000016148724,0.00037151753,0.040902775,0.9479237,0.0006658679,0.0018967827,0.00033731892],"about_ca_topic_score_codex":0.0016982475,"about_ca_topic_score_gemma":0.0023343507,"teacher_disagreement_score":0.64457214,"about_ca_system_score_codex":0.00036332742,"about_ca_system_score_gemma":0.0006649234,"threshold_uncertainty_score":0.999894},"labels":[],"label_agreement":null},{"id":"W3161448988","doi":"10.3389/fonc.2021.672287","title":"Clinical Relevance of ABCB1, ABCG2, and ABCC2 Gene Polymorphisms in Chronic Myeloid Leukemia Patients Treated With Nilotinib","year":2021,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Nilotinib; Abcg2; Single-nucleotide polymorphism; Dasatinib; Multidrug resistance-associated protein 2; Pharmacogenetics; Genotype; Myeloid leukemia; Internal medicine; ATP-binding cassette transporter; Medicine; Tyrosine-kinase inhibitor; Pharmacology; Genetics; Oncology; Imatinib; Biology; Transporter; Gene; Cancer","score_opus":0.01558706461041151,"score_gpt":0.2976799333228173,"score_spread":0.2820928687124058,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3161448988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918286,0.004890047,0.000107778505,0.0002732932,0.0005013494,0.00064611447,0.000023946113,0.000031766493,0.0016971142],"genre_scores_gemma":[0.9746529,0.003959238,0.019473892,0.00034230563,0.00014030129,0.000070687696,0.00017875528,0.000058895803,0.0011230469],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971157,0.00030048875,0.0010048132,0.0007524379,0.0002714057,0.00055516616],"domain_scores_gemma":[0.9985328,0.0002694016,0.00032568478,0.00053001766,0.00013923105,0.00020290735],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034578296,0.0003060253,0.0013178186,0.00027502995,0.000031094733,0.000005127924,0.00013408427,0.00045881732,0.00007509755],"category_scores_gemma":[0.00032684588,0.00027238904,0.00009272145,0.00057965255,0.00046074745,0.00008682849,0.00010498782,0.00058268994,0.000008263152],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015126022,0.00069239474,0.9333663,0.00006708726,0.00019632273,0.0010719869,0.00019963118,0.00003868354,0.0007257574,0.000012608294,0.001653767,0.060462873],"study_design_scores_gemma":[0.036939375,0.004061169,0.9448255,0.00036370064,0.00018875772,0.00014663395,0.00010242899,0.00067979033,0.0038347251,0.000064477696,0.0085284235,0.0002650328],"about_ca_topic_score_codex":0.0003157103,"about_ca_topic_score_gemma":0.0006968303,"teacher_disagreement_score":0.06019784,"about_ca_system_score_codex":0.007168677,"about_ca_system_score_gemma":0.0038695228,"threshold_uncertainty_score":0.9999728},"labels":[],"label_agreement":null},{"id":"W3161505483","doi":"10.5737/23688076312165174","title":"Shared-care model for complex chronic haematological malignancies","year":2021,"lang":"en","type":"article","venue":"Canadian Oncology Nursing Journal","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Shared care; Chronic care; Health care; Family medicine; Quality of life (healthcare); Disease; Nursing; Chronic disease; Intensive care medicine; Primary care; Internal medicine","score_opus":0.07443591828888714,"score_gpt":0.35430533515612045,"score_spread":0.2798694168672333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3161505483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5693745,0.099260435,0.05936831,0.18141548,0.006631278,0.0037338657,0.0011378853,0.0003601897,0.078718066],"genre_scores_gemma":[0.964687,0.00016920122,0.029697053,0.0028204676,0.0006993895,0.00003690973,0.00029957388,0.000048478425,0.0015419434],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982839,0.00006814692,0.00036682925,0.00032145035,0.0001683605,0.00079128856],"domain_scores_gemma":[0.9979949,0.000089508714,0.0001249921,0.00025340499,0.0004827379,0.0010544667],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012782481,0.0002070335,0.0005640294,0.00018754281,0.00050973153,0.000055031152,0.00013970652,0.00032640505,0.0007720124],"category_scores_gemma":[0.00021322837,0.00019430691,0.00022863844,0.00013970192,0.00021636067,0.000079735015,0.000013179341,0.00047985907,0.00003643845],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0005921939,0.0007078475,0.006733995,0.00051081175,0.0009291628,0.030325852,0.00848004,0.00241287,0.009294168,0.006412418,0.62023914,0.31336153],"study_design_scores_gemma":[0.039673008,0.004980478,0.028600829,0.007136794,0.0025147048,0.19520865,0.00939406,0.34573907,0.0023643384,0.008747257,0.35410014,0.0015406553],"about_ca_topic_score_codex":0.00016082854,"about_ca_topic_score_gemma":0.0130146835,"teacher_disagreement_score":0.3953125,"about_ca_system_score_codex":0.03290115,"about_ca_system_score_gemma":0.03665383,"threshold_uncertainty_score":0.97081137},"labels":[],"label_agreement":null},{"id":"W3163987935","doi":"10.1136/annrheumdis-2021-eular.884","title":"POS1038 THE EFFECT OF FILGOTINIB ON ENTHESITIS: 100-WEEK DATA FROM AN OPEN-LABEL EXTENSION STUDY IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS","year":2021,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"Galápagos; Gilead Sciences","keywords":"Medicine; Enthesitis; Psoriatic arthritis; Internal medicine; Placebo; Surgery; Arthritis; Pathology","score_opus":0.07128501438015125,"score_gpt":0.3573001817615732,"score_spread":0.28601516738142196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3163987935","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99537057,0.00084675156,7.853544e-7,0.0004133171,0.00009319078,0.002314624,0.00089819956,0.000011940805,0.000050645653],"genre_scores_gemma":[0.9989344,0.00013710394,0.000038703038,0.00020133983,0.000014739033,0.000072111194,0.00053690356,0.000031389947,0.000033312732],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9972661,0.00084833405,0.00047944742,0.0004687143,0.0007150036,0.00022237317],"domain_scores_gemma":[0.99574953,0.001218045,0.00038344914,0.0023840433,0.00015247933,0.00011243428],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002952546,0.0002466748,0.00075069064,0.000051829393,0.00008204371,0.00003326694,0.0007800023,0.00003630898,0.00016844716],"category_scores_gemma":[0.0015968805,0.00012711038,0.00005485467,0.00027493763,0.00010552618,0.00025660114,0.00054285163,0.00012918445,0.000012100562],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013672731,0.04506883,0.44931254,0.00049760286,0.0032410896,0.00016815064,0.003116618,0.000091640664,0.000036367164,0.000014503081,0.0031645698,0.48161536],"study_design_scores_gemma":[0.018680554,0.0067653954,0.9667416,0.0047497326,0.0006262861,0.0000024244769,0.00070720917,0.00026738763,0.0012261348,0.00010696942,0.0000040065543,0.0001222652],"about_ca_topic_score_codex":0.0012226236,"about_ca_topic_score_gemma":0.00027091114,"teacher_disagreement_score":0.5174291,"about_ca_system_score_codex":0.00007263385,"about_ca_system_score_gemma":0.00032472634,"threshold_uncertainty_score":0.5183411},"labels":[],"label_agreement":null},{"id":"W3167228241","doi":"10.1182/blood.v130.suppl_1.2870.2870","title":"Imatinib Suspension and Validation Study: Results from the Isav Study at 62 Months","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Discontinuation; Imatinib; Medicine; Internal medicine; Imatinib mesylate; Oncology; Myeloid leukemia; Minimal residual disease; Surgery; Gastroenterology; Leukemia","score_opus":0.03645360255583744,"score_gpt":0.3078223878722005,"score_spread":0.27136878531636305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167228241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949507,0.00014323606,2.1713213e-7,0.0007076295,0.00011524742,0.0018228646,0.000039753868,0.00004169086,0.0021786238],"genre_scores_gemma":[0.99857557,0.000026604577,0.00009382592,0.000044216016,0.00019461534,0.000037008005,0.00006901573,0.000019914862,0.00093921047],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987381,0.000098495926,0.00026430783,0.00039649545,0.00034162775,0.00016094868],"domain_scores_gemma":[0.99810284,0.00023429263,0.00020750875,0.0013261648,0.000052208135,0.0000770059],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035277437,0.00015542837,0.000250512,0.000019265492,0.0005211895,0.00007962302,0.0001574045,0.000047774512,0.000051168638],"category_scores_gemma":[0.0005926664,0.00009750965,0.0000341534,0.000027920165,0.000053008887,0.00009019768,0.00027331864,0.00011760506,0.000081945866],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005390883,0.0030279479,0.9836334,0.000005410094,0.00043553772,0.00023617642,0.0075235213,5.95308e-7,0.0013066608,0.0000026568512,0.0010665063,0.0022225298],"study_design_scores_gemma":[0.038195495,0.00091081613,0.9544331,0.00005464279,0.00093076896,0.000017444367,0.0017343073,0.000036278216,0.0034156472,0.000029060173,0.00015077545,0.00009168155],"about_ca_topic_score_codex":0.0031948483,"about_ca_topic_score_gemma":0.0014878929,"teacher_disagreement_score":0.037656404,"about_ca_system_score_codex":0.00012113152,"about_ca_system_score_gemma":0.000062465195,"threshold_uncertainty_score":0.48296762},"labels":[],"label_agreement":null},{"id":"W3168603500","doi":"10.1200/jco.2021.39.15_suppl.7000","title":"OPTIC primary analysis: A dose-optimization study of 3 starting doses of ponatinib (PON).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Ponatinib; Clinical endpoint; Internal medicine; Regimen; Adverse effect; Gastroenterology; Dasatinib; Randomized controlled trial; Myeloid leukemia; Imatinib","score_opus":0.11285544431389544,"score_gpt":0.46048573744329807,"score_spread":0.34763029312940263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168603500","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958384,0.0005762774,0.00041879312,0.0007241628,0.00030551723,0.00022242207,0.000003374629,0.0000057617985,0.001905264],"genre_scores_gemma":[0.9721675,0.00025583038,0.026835937,0.0003037245,0.00025325554,0.000002607796,0.000010397413,0.000013808623,0.00015693682],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9940759,0.00079518446,0.0040916232,0.00021763178,0.0006431017,0.00017656614],"domain_scores_gemma":[0.99117297,0.0029959495,0.004025102,0.00032697624,0.0012722417,0.00020674939],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002854856,0.00013535944,0.0025181933,0.00029139413,0.000023687104,0.000004164086,0.00013677534,0.0002340572,0.0003970717],"category_scores_gemma":[0.00661989,0.00010257721,0.00068536,0.00075043534,0.00011153343,0.0000955777,0.00008886929,0.0005626397,0.0000020300886],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009844232,0.039554436,0.79901564,0.00031076433,0.02369278,0.0043564388,0.0018730912,0.05503899,0.0018686133,0.00004686214,0.00044043866,0.06395773],"study_design_scores_gemma":[0.054190166,0.038425982,0.8727036,0.00030913405,0.020526228,0.0003353422,0.0039979955,0.008107849,0.0006573084,0.00007656085,0.00048872037,0.00018109364],"about_ca_topic_score_codex":0.000034190612,"about_ca_topic_score_gemma":0.000054717493,"teacher_disagreement_score":0.07368799,"about_ca_system_score_codex":0.00042527966,"about_ca_system_score_gemma":0.004374439,"threshold_uncertainty_score":0.7925105},"labels":[],"label_agreement":null},{"id":"W3169098949","doi":"10.1007/s11864-021-00856-x","title":"Current Management of Chronic Neutrophilic Leukemia","year":2021,"lang":"en","type":"review","venue":"Current Treatment Options in Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Ruxolitinib; Dasatinib; Oncology; Clinical trial; Internal medicine; Myelofibrosis; Imatinib; Immunology; Bone marrow; Myeloid leukemia","score_opus":0.1147755261590812,"score_gpt":0.4451971280526817,"score_spread":0.3304216018936005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169098949","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00023644239,0.9911831,0.000019166286,0.00003770538,0.0026022983,0.0040756497,0.00016847052,0.00008175965,0.0015953779],"genre_scores_gemma":[0.000060468035,0.9918405,0.00060650846,0.000003065665,0.00047220278,0.0032676305,0.0031111143,0.00011260329,0.000525903],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99516577,0.00044350687,0.0018504778,0.0013110893,0.00040283176,0.0008263235],"domain_scores_gemma":[0.9970804,0.00026625986,0.00073432724,0.001531974,0.00011449108,0.000272537],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019281801,0.0010742765,0.0046687145,0.0009377673,0.000082147235,0.000015187203,0.00033004882,0.0005257659,0.0005109507],"category_scores_gemma":[0.00001850347,0.0008720777,0.001469396,0.0012288219,0.00023760878,0.00006216067,0.00030166897,0.0008488496,0.00030649398],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000021230724,0.005697889,0.000037614995,0.022417767,0.001591663,0.00064880215,0.00004787362,0.000025224956,2.3984978e-7,0.0017301809,0.00045133324,0.96733016],"study_design_scores_gemma":[0.0060913945,0.0015704622,0.00009717492,0.045437943,0.008049278,0.00039711973,0.0000266192,0.0000338718,0.0000012548574,0.00001980089,0.9378497,0.00042536436],"about_ca_topic_score_codex":0.000026862668,"about_ca_topic_score_gemma":0.000041498985,"teacher_disagreement_score":0.9669048,"about_ca_system_score_codex":0.064061314,"about_ca_system_score_gemma":0.008949362,"threshold_uncertainty_score":0.999373},"labels":[],"label_agreement":null},{"id":"W3169554845","doi":"10.3389/fonc.2021.665273","title":"RUNX2 Phosphorylation by Tyrosine Kinase ABL Promotes Breast Cancer Invasion","year":2021,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Ryobi Teien Memory Foundation; Japan Society for the Promotion of Science; Princess Takamatsu Cancer Research Fund; Okinaka Memorial Institute for Medical Research; Uehara Memorial Foundation","keywords":"RUNX2; Cancer research; Transcription factor; Tyrosine kinase; Tyrosine phosphorylation; Phosphorylation; Proto-oncogene tyrosine-protein kinase Src; Biology; ABL; Promoter; Cell biology; Signal transduction; Gene expression; Gene; Genetics","score_opus":0.012098431216210471,"score_gpt":0.2841114313522879,"score_spread":0.27201300013607743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169554845","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9625074,0.018290488,0.0011797504,0.010491311,0.002657656,0.0008543077,0.00013288268,0.000099033874,0.0037871513],"genre_scores_gemma":[0.95697784,0.0041395156,0.022555163,0.0025712978,0.00044216425,0.00031530444,0.00084932434,0.00008404708,0.012065311],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986295,0.00009842937,0.00030578565,0.0004252623,0.00018795827,0.0003530457],"domain_scores_gemma":[0.99931026,0.000045994875,0.000103548475,0.0002939974,0.00010897827,0.00013724146],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013810846,0.00018033011,0.00047963037,0.000107589636,0.000052854048,0.000009121206,0.00007309698,0.00026783426,0.00070560985],"category_scores_gemma":[0.00009729932,0.00017129812,0.000063327076,0.00036027457,0.00009307843,0.000083745756,0.000060364437,0.0002780066,0.000026218939],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006731465,0.0011371046,0.48983648,0.00010837108,0.00014855803,0.0009277144,0.00042004167,0.00002216073,0.021439234,0.00002671987,0.24187319,0.24338728],"study_design_scores_gemma":[0.035766292,0.0014305079,0.42722666,0.0008745562,0.0006171995,0.0012899513,0.0010225665,0.0048172995,0.12567322,0.00081112265,0.39962304,0.0008475942],"about_ca_topic_score_codex":0.00051163253,"about_ca_topic_score_gemma":0.00025086544,"teacher_disagreement_score":0.24253969,"about_ca_system_score_codex":0.004238814,"about_ca_system_score_gemma":0.0014042489,"threshold_uncertainty_score":0.9995837},"labels":[],"label_agreement":null},{"id":"W3172717443","doi":"10.1200/jco.2021.39.15_suppl.7037","title":"The effect of body mass index on efficacy and safety of bosutinib or imatinib in patients with newly diagnosed chronic myeloid leukemia.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Internal medicine; Discontinuation; Imatinib; Bosutinib; Myeloid leukemia; Body mass index; Gastroenterology; Imatinib mesylate; Cumulative incidence; Dasatinib; Surgery; Cohort","score_opus":0.02403921838685768,"score_gpt":0.37050232835505315,"score_spread":0.34646310996819546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172717443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969443,0.00047348355,0.000015010167,0.0008135929,0.00038812502,0.00062444597,0.000007849055,0.0000045565503,0.0007286097],"genre_scores_gemma":[0.9976138,0.0012317679,0.00054885,0.00017958577,0.0002586034,0.000007318611,0.0000078383055,0.000026442598,0.00012579678],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99484843,0.0010631724,0.002859584,0.00027144141,0.0006299793,0.00032738136],"domain_scores_gemma":[0.97927225,0.01731554,0.0023862817,0.00040329248,0.00036115167,0.00026147437],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0027770498,0.00023906623,0.0021869915,0.000112803944,0.00004567129,0.0000065741483,0.0001932966,0.00038085366,0.000093084906],"category_scores_gemma":[0.009640202,0.000118925826,0.0002756331,0.00028880642,0.00043475846,0.000067883135,0.000080680955,0.0011831515,0.000003575514],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0751636,0.001389093,0.7541687,0.00017655258,0.0007824492,0.00082222384,0.000060483806,0.00020077784,0.0001113244,0.00002089017,0.0003076522,0.16679627],"study_design_scores_gemma":[0.11655149,0.06541593,0.81289977,0.00083294115,0.00038903183,0.00007163987,0.000035046505,0.00012425709,0.0007405714,0.000013260591,0.0028395117,0.00008655083],"about_ca_topic_score_codex":0.000027595199,"about_ca_topic_score_gemma":0.00011380481,"teacher_disagreement_score":0.16670972,"about_ca_system_score_codex":0.0014043342,"about_ca_system_score_gemma":0.0064067673,"threshold_uncertainty_score":0.999226},"labels":[],"label_agreement":null},{"id":"W3174565213","doi":"10.1111/bjh.17654","title":"Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients","year":2021,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Bristol-Myers Squibb","keywords":"Dasatinib; Medicine; Cumulative incidence; Clinical endpoint; Internal medicine; Incidence (geometry); Pleural effusion; Adverse effect; Tyrosine-kinase inhibitor; Gastroenterology; Oncology; Myeloid leukemia; Randomized controlled trial; Imatinib; Cohort; Cancer","score_opus":0.019886682977544506,"score_gpt":0.29675663241679906,"score_spread":0.2768699494392546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3174565213","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99289805,0.0052734255,0.000014547032,0.00059570075,0.000677989,0.00027071912,0.0000051042307,0.000019323275,0.0002451362],"genre_scores_gemma":[0.9973313,0.0009376135,0.001102487,0.0001792142,0.00023904102,0.000013507386,0.000049946502,0.00003783586,0.0001090613],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99766135,0.00033212465,0.00085225725,0.00030344506,0.00046684165,0.00038396474],"domain_scores_gemma":[0.99854666,0.00029800294,0.0004652417,0.00020862874,0.00032645886,0.00015501073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003328731,0.00021666888,0.0007434476,0.00023618684,0.00009714887,0.000047106027,0.00014054427,0.0001634099,0.00020132979],"category_scores_gemma":[0.00036364864,0.00022451156,0.00017259203,0.00027093972,0.0000809493,0.00017082832,0.0000410054,0.0006298909,0.00001592197],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026298056,0.0032673248,0.53959376,0.0008360216,0.0005606874,0.10899235,0.0012589133,0.0061095254,0.033575308,0.00004414811,0.001777715,0.3013544],"study_design_scores_gemma":[0.039728962,0.0016492819,0.7281352,0.0075699557,0.0003232085,0.047068883,0.0005298656,0.0038052946,0.17012385,0.00017224686,0.00038968038,0.0005035608],"about_ca_topic_score_codex":0.00009045871,"about_ca_topic_score_gemma":0.00005774944,"teacher_disagreement_score":0.30085087,"about_ca_system_score_codex":0.0018323312,"about_ca_system_score_gemma":0.0014587578,"threshold_uncertainty_score":0.9155316},"labels":[],"label_agreement":null},{"id":"W3175545552","doi":"10.1136/heartjnl-2021-319415","title":"Response to ‘Adverse cardiac outcomes in patients with chronic myeloid leukaemia treated with tyrosine kinase inhibitors’","year":2021,"lang":"en","type":"letter","venue":"Heart","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Population Health Research Institute","funders":"","keywords":"Medicine; Chronic myeloid leukaemia; Tyrosine kinase; Adverse effect; Internal medicine; Myeloid; Myeloid leukaemia; Tyrosine-kinase inhibitor; Oncology; Cancer","score_opus":0.010022655548260215,"score_gpt":0.23933795628203902,"score_spread":0.22931530073377882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3175545552","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8845273,0.00032306285,7.241388e-7,0.11175015,0.00027287955,0.0025542353,0.0002370487,0.00014457402,0.00018997144],"genre_scores_gemma":[0.48092633,0.00006882885,0.002091489,0.44512475,0.0033142194,0.0015733809,0.009758916,0.0011618991,0.055980187],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99524623,0.0004008968,0.0006472303,0.0013187941,0.0012709686,0.0011158908],"domain_scores_gemma":[0.99725276,0.00026769124,0.00017897041,0.0016352872,0.000302154,0.00036315198],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023944738,0.0009994751,0.0019546682,0.00065665465,0.00009187322,0.000040810584,0.00015169072,0.00080943067,0.00031433383],"category_scores_gemma":[0.00015706217,0.0007274606,0.00028919854,0.00093980995,0.00013820949,0.0001222015,0.00012656195,0.001792047,0.00037700604],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004158998,0.0002765082,0.652485,0.00019873268,0.0004402208,0.004033735,0.000115448194,0.000015263431,0.00024065933,1.5755158e-7,0.33780554,0.00022970464],"study_design_scores_gemma":[0.013138925,0.0028019259,0.5738126,0.0019704497,0.00041014512,0.000040308307,0.000017058444,0.0000011892242,0.0010609687,1.4754023e-7,0.40611938,0.00062687736],"about_ca_topic_score_codex":0.0009818914,"about_ca_topic_score_gemma":0.00021749853,"teacher_disagreement_score":0.40360102,"about_ca_system_score_codex":0.008715216,"about_ca_system_score_gemma":0.0030087978,"threshold_uncertainty_score":0.9995176},"labels":[],"label_agreement":null},{"id":"W3176579594","doi":"10.1101/2021.06.28.449968","title":"Mutation in Abl kinase with altered drug binding kinetics indicates a novel mechanism of imatinib resistance","year":2021,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institutes of Health; Cycle for Survival; Genome Canada; Genentech; Bayer","keywords":"Imatinib; Protein kinase domain; ABL; Mutation; Drug resistance; Cancer research; Imatinib mesylate; Mutant; Wild type; Myeloid leukemia; Kinase; Biology; Pharmacology; Chemistry; Genetics; Tyrosine kinase; Signal transduction; Gene","score_opus":0.013704159493292322,"score_gpt":0.23197223384211546,"score_spread":0.21826807434882314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3176579594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99521714,0.00093723094,0.0016064183,0.00019753503,0.0003077114,0.0013448832,0.00022569571,0.00014202597,0.000021337635],"genre_scores_gemma":[0.9445606,0.00014804465,0.054658152,0.000063184896,0.00012122733,0.0002657156,0.000007156906,0.00015532445,0.000020613563],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9967068,0.000099997844,0.0009078463,0.0010620807,0.00068483746,0.00053847866],"domain_scores_gemma":[0.99697953,0.00011737103,0.0009439513,0.001220797,0.00050049135,0.00023787153],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00043653254,0.0006084271,0.0010541503,0.00059585716,0.000055694298,0.00008054856,0.0002984306,0.0004019026,0.000060875303],"category_scores_gemma":[0.00031609088,0.00060814456,0.00012956123,0.00092982844,0.00012783793,0.00011921945,0.00027006256,0.0008004316,0.000009219548],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002543623,0.00084744534,0.0053658853,0.002675944,0.00038788258,0.0006876964,0.00016294402,0.000081203914,0.98908895,0.0004138668,0.000031892258,0.0000019538847],"study_design_scores_gemma":[0.005779721,0.00014295634,0.053004634,0.0069609396,0.00043313575,2.5808774e-7,0.000049084367,0.0005451194,0.9324079,0.0000023947662,0.000062829175,0.00061100465],"about_ca_topic_score_codex":0.00017300845,"about_ca_topic_score_gemma":0.00007222207,"teacher_disagreement_score":0.056681,"about_ca_system_score_codex":0.0017166809,"about_ca_system_score_gemma":0.001889734,"threshold_uncertainty_score":0.999637},"labels":[],"label_agreement":null},{"id":"W3183822763","doi":"10.1016/j.bbiosy.2021.100021","title":"Polymeric siRNA delivery targeting integrin-β1 could reduce interactions of leukemic cells with bone marrow microenvironment","year":2021,"lang":"en","type":"article","venue":"Biomaterials and Biosystems","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research; Natural Sciences and Engineering Research Council of Canada; Alex's Lemonade Stand Foundation for Childhood Cancer","keywords":"K562 cells; Integrin; Cancer research; Bone marrow; Stromal cell; Cell biology; Small interfering RNA; Fibronectin; Chemistry; Cell; Cell culture; Extracellular matrix; Biology; Immunology; Transfection; Biochemistry","score_opus":0.012587849236193266,"score_gpt":0.2340241406410625,"score_spread":0.22143629140486923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3183822763","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937151,0.0047419323,0.00000981781,0.0001846898,0.0006559816,0.0003692846,0.0001238208,0.00003850623,0.00016087764],"genre_scores_gemma":[0.99719656,0.0008093951,0.00075352524,0.000054992022,0.00021364806,0.000023648498,0.00013267946,0.000033007425,0.0007825543],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985063,0.00008869626,0.0005461522,0.00038878722,0.00020673744,0.00026329196],"domain_scores_gemma":[0.99916905,0.00004075839,0.0002928402,0.00030438902,0.00006138778,0.00013155339],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013542759,0.00024341754,0.00057297735,0.00008075014,0.00006865064,0.000038906826,0.000051842555,0.00008007787,0.00024260508],"category_scores_gemma":[0.000010356032,0.0001776569,0.00007552181,0.00013363246,0.000097536635,0.00006907002,0.00007952455,0.000048459482,0.00002556659],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025524592,0.00016348744,0.0014223864,0.00052948244,0.00022644766,0.00018578111,0.00016090125,6.243635e-7,0.9956925,0.0000024361354,0.0006359578,0.0007247853],"study_design_scores_gemma":[0.001908682,0.00022911836,0.0014431865,0.00093685475,0.00020084128,0.000997733,0.00086526433,0.00003083497,0.98980993,5.0983164e-7,0.003405566,0.00017145606],"about_ca_topic_score_codex":0.0009668491,"about_ca_topic_score_gemma":0.000025889267,"teacher_disagreement_score":0.0058825114,"about_ca_system_score_codex":0.00042223642,"about_ca_system_score_gemma":0.00019159164,"threshold_uncertainty_score":0.7244638},"labels":[],"label_agreement":null},{"id":"W3185045240","doi":"10.1007/s41669-021-00286-3","title":"Economic Model to Evaluate the Cost-Effectiveness of Second-Line Nilotinib Versus Dasatinib for the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (CML-CP) in Italy","year":2021,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Nilotinib; Dasatinib; Medicine; Imatinib; Internal medicine; Tyrosine-kinase inhibitor; Myeloid leukemia; Tyrosine kinase; Cost effectiveness; Oncology; Cancer","score_opus":0.10076930907736435,"score_gpt":0.41178376477177653,"score_spread":0.31101445569441216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3185045240","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9814152,0.001732076,0.00014221168,0.0019820784,0.00065426604,0.010771688,0.0015844058,0.000017034465,0.0017010272],"genre_scores_gemma":[0.9935394,0.0015407862,0.00036867894,0.0003497599,0.0002716962,0.0029925103,0.00043477415,0.00009978498,0.00040263956],"study_design_codex":"simulation_or_modeling","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99724174,0.00024119826,0.0010065761,0.00081567233,0.00014469157,0.0005501422],"domain_scores_gemma":[0.9959984,0.0022808185,0.00036672223,0.0009783122,0.00018214252,0.00019364181],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010590932,0.0004915077,0.0012230914,0.00012506178,0.00014435132,0.000060828595,0.0007236337,0.00011553948,0.0007566608],"category_scores_gemma":[0.000067672234,0.000359601,0.0003746422,0.00018147001,0.00017236244,0.00026132428,0.0003341264,0.00021045194,0.00006308185],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04082122,0.0025813072,0.0014477588,0.00095569436,0.009364856,0.000059177102,0.0046579787,0.73930055,0.14951113,0.00203258,0.0018449377,0.047422834],"study_design_scores_gemma":[0.079187155,0.0033172008,0.004730876,0.0003011567,0.0016619648,0.000040975967,0.00036948983,0.25309905,0.6500848,0.00027763454,0.006405055,0.0005246444],"about_ca_topic_score_codex":0.00074424996,"about_ca_topic_score_gemma":0.001843146,"teacher_disagreement_score":0.5005737,"about_ca_system_score_codex":0.011738013,"about_ca_system_score_gemma":0.0052185073,"threshold_uncertainty_score":0.9998856},"labels":[],"label_agreement":null},{"id":"W3185598664","doi":"10.1016/j.leukres.2021.106674","title":"Clinical outcome of chronic myeloid leukemia patients who switch from first-line therapy with a second generation tyrosine kinase inhibitor to an alternative TKI","year":2021,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; Alberta Children's Hospital","funders":"Alberta Health Services","keywords":"Medicine; Tyrosine-kinase inhibitor; Myeloid leukemia; Internal medicine; Tyrosine kinase; Nilotinib; Oncology; First line; Dasatinib; Cancer; Imatinib; Receptor","score_opus":0.10737315984632013,"score_gpt":0.40013615825058946,"score_spread":0.29276299840426934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3185598664","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99518585,0.0008655479,0.00018433777,0.0006227174,0.00036741188,0.0018277577,0.0002796413,0.00006304417,0.0006036774],"genre_scores_gemma":[0.98892236,0.0006957546,0.0022588957,0.00059220195,0.0023281602,0.00024423611,0.0014098906,0.00014402266,0.0034044522],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.993415,0.00065414177,0.001354505,0.0015000018,0.0020769534,0.0009993932],"domain_scores_gemma":[0.99450666,0.00064272055,0.0002784869,0.001718788,0.0020029256,0.00085040694],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011863598,0.0005174638,0.0011837196,0.0003838461,0.0002675202,0.000100902966,0.00045334874,0.00040628677,0.0015391844],"category_scores_gemma":[0.000713217,0.00041541338,0.0002292042,0.0011539276,0.00032744298,0.00033596376,0.00035143827,0.0014067403,0.00018403935],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.009298584,0.004974024,0.7539639,0.00055008644,0.0017020755,0.0017491849,0.003177714,0.0012350774,0.07800254,0.0002089051,0.011126344,0.13401157],"study_design_scores_gemma":[0.06525271,0.019688858,0.4587885,0.0012376864,0.00018802927,0.000046164205,0.0002899306,0.015932573,0.4165491,0.00018834347,0.020820266,0.0010178566],"about_ca_topic_score_codex":0.0029083136,"about_ca_topic_score_gemma":0.0068140742,"teacher_disagreement_score":0.33854654,"about_ca_system_score_codex":0.012936516,"about_ca_system_score_gemma":0.006728684,"threshold_uncertainty_score":0.99982977},"labels":[],"label_agreement":null},{"id":"W3186885234","doi":"10.3389/fonc.2021.729192","title":"Corrigendum: RUNX2 Phosphorylation by Tyrosine Kinase ABL Promotes Breast Cancer Invasion","year":2021,"lang":"en","type":"erratum","venue":"Frontiers in Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Phosphorylation; Cancer research; ABL; Tyrosine kinase; Breast cancer; Proto-oncogene tyrosine-protein kinase Src; Cancer; Tyrosine phosphorylation; Tyrosine; Medicine; Signal transduction; Biology; Internal medicine; Cell biology; Biochemistry","score_opus":0.0169661501126741,"score_gpt":0.28529278807451164,"score_spread":0.26832663796183753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3186885234","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018826557,0.3898266,0.0015239395,0.017173534,0.4830828,0.008617441,0.003991131,0.00061421306,0.0763438],"genre_scores_gemma":[0.0037411575,0.04821099,0.008573552,0.0024002,0.0049254624,0.0011760027,0.024113355,0.00041722247,0.90644205],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965134,0.00023097293,0.00078664947,0.0011359906,0.0005245711,0.0008084053],"domain_scores_gemma":[0.99814963,0.000048481637,0.00051000237,0.00074379414,0.0002474119,0.00030069498],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00026489998,0.0006666663,0.0017731462,0.00040999075,0.000107538835,0.000026825066,0.00026600962,0.002036807,0.0017676308],"category_scores_gemma":[0.00016735378,0.00064591796,0.00022019894,0.00061783864,0.00023005283,0.000105361105,0.00017060003,0.0019024529,0.000044469685],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00049415283,0.00078420545,0.021200735,0.00038394262,0.0003122442,0.0011237395,0.0002560633,0.00000236081,0.00039098496,0.000003239641,0.90164423,0.073404096],"study_design_scores_gemma":[0.006908982,0.0006294813,0.010377949,0.0015610243,0.00061954843,0.00035492243,0.00021762303,0.0006984128,0.0007837126,0.00006301059,0.97722715,0.0005581962],"about_ca_topic_score_codex":0.0023681952,"about_ca_topic_score_gemma":0.0010083239,"teacher_disagreement_score":0.8300983,"about_ca_system_score_codex":0.015879711,"about_ca_system_score_gemma":0.007239785,"threshold_uncertainty_score":0.9995992},"labels":[],"label_agreement":null},{"id":"W3194203975","doi":"10.1182/blood.2021012082","title":"Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":193,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Takeda Oncology; National Cancer Institute; National Institute for Health and Care Research","keywords":"Ponatinib; Medicine; Internal medicine; Clinical endpoint; Adverse effect; Myeloid leukemia; Cohort; Confidence interval; Oncology; Nilotinib; Clinical trial; Imatinib","score_opus":0.08930478020376911,"score_gpt":0.43065048697855457,"score_spread":0.3413457067747855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3194203975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97830427,0.0065289303,0.000043310414,0.00037435803,0.0008433384,0.010176218,0.00004474366,0.00015453431,0.0035302716],"genre_scores_gemma":[0.99080956,0.000917343,0.0011478591,0.00035323016,0.00224001,0.0014984659,0.00031305,0.00014205376,0.0025784576],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9926581,0.0013696576,0.0025039874,0.0015429683,0.00085904414,0.0010662914],"domain_scores_gemma":[0.9957597,0.001479406,0.0005168704,0.0015439003,0.0002040813,0.00049599004],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0038229222,0.00067379395,0.0030290056,0.00029588086,0.00019339022,0.00017040677,0.00060832023,0.0004147318,0.0010981567],"category_scores_gemma":[0.0024653906,0.0005961304,0.0004942097,0.00093887857,0.00024377958,0.00030271223,0.00065834075,0.0013026907,0.00022609142],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.7782721,0.12105625,0.0008118137,0.0002831655,0.0041626752,0.01800925,0.0011290073,0.000019670231,0.0044355495,0.00016412108,0.00077726424,0.07087912],"study_design_scores_gemma":[0.97734797,0.012127294,0.00014359172,0.00046868052,0.0026870312,0.00035630897,0.00029937012,0.0019731214,0.002153189,0.000042451396,0.001889998,0.00051099586],"about_ca_topic_score_codex":0.00041177744,"about_ca_topic_score_gemma":0.00070400554,"teacher_disagreement_score":0.19907585,"about_ca_system_score_codex":0.004784893,"about_ca_system_score_gemma":0.015262726,"threshold_uncertainty_score":0.999815},"labels":[],"label_agreement":null},{"id":"W3195243079","doi":"10.1182/blood.2020009984","title":"A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":336,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute; National Institute for Health and Care Research; Novartis Pharmaceuticals Corporation","keywords":"Bosutinib; Medicine; Open label; Randomized controlled trial; Internal medicine; Oncology; Imatinib; Nilotinib; Myeloid leukemia","score_opus":0.0352400247850263,"score_gpt":0.35368915112360194,"score_spread":0.31844912633857564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3195243079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936412,0.0009515165,0.000002708528,0.0003723119,0.00012298411,0.0042719906,0.000048521008,0.000037943086,0.00055084313],"genre_scores_gemma":[0.99451005,0.00008954946,0.0015604715,0.00031243273,0.000103818995,0.0009514364,0.00004950981,0.000054610024,0.0023681272],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99717647,0.00033763854,0.0009255653,0.00062851823,0.00052858144,0.00040324972],"domain_scores_gemma":[0.9982042,0.00036647051,0.00022024426,0.00084530277,0.00017221709,0.00019156504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060709345,0.00032035584,0.0015973708,0.00016944692,0.00004064462,0.000042842366,0.00021210745,0.00013114256,0.0008554183],"category_scores_gemma":[0.0009251711,0.00023711014,0.00010863395,0.00058659585,0.000100340745,0.00012724541,0.00036234237,0.00026840667,0.000026569684],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.621223,0.29007292,0.022740208,0.00068492297,0.003478668,0.022246154,0.022068692,0.0000014016757,0.008388957,0.000014358341,0.0009599354,0.0081208],"study_design_scores_gemma":[0.97198117,0.0041614855,0.0018293583,0.00056975055,0.0016104162,0.00018038023,0.0019209269,0.000051984684,0.01696981,0.000009289644,0.0004890031,0.00022644427],"about_ca_topic_score_codex":0.00035019108,"about_ca_topic_score_gemma":0.0005977339,"teacher_disagreement_score":0.35075817,"about_ca_system_score_codex":0.00023626586,"about_ca_system_score_gemma":0.001501084,"threshold_uncertainty_score":0.96690714},"labels":[],"label_agreement":null},{"id":"W3195599002","doi":"10.1016/j.leukres.2021.106690","title":"Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome‒positive leukemias","year":2021,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Pfizer","keywords":"Bosutinib; Medicine; Oncology; Reduction (mathematics); Internal medicine; Imatinib; Dasatinib","score_opus":0.030280875152699713,"score_gpt":0.33020283225029673,"score_spread":0.299921957097597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3195599002","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99263775,0.00069749565,0.000005563599,0.0012846612,0.00015627366,0.0014423659,0.000018820714,0.0000695104,0.003687554],"genre_scores_gemma":[0.99704397,0.00023174567,0.00061046204,0.00008250803,0.00025567747,0.00008464663,0.00040811067,0.00008049366,0.0012024082],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99560046,0.00039422582,0.0004980687,0.0010355542,0.0014557029,0.0010159697],"domain_scores_gemma":[0.9979258,0.00039795414,0.00007858313,0.0007565068,0.00043777603,0.0004033455],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00078583864,0.00034154704,0.00060412794,0.00043171184,0.00031678067,0.0000809812,0.00014889466,0.00028062618,0.00016577906],"category_scores_gemma":[0.00050163205,0.00029727435,0.00010188381,0.0015526257,0.00028698388,0.00028449655,0.00027485596,0.0013784388,0.00007723317],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.059267204,0.007903131,0.72599787,0.0017855063,0.0041142763,0.01446446,0.014433373,0.0007873764,0.042226452,0.0014565208,0.009444245,0.11811961],"study_design_scores_gemma":[0.06474379,0.0015177875,0.921023,0.0015396015,0.00014673709,0.00027148813,0.00065973523,0.00024828746,0.0076472345,0.00007763365,0.0016892083,0.00043551667],"about_ca_topic_score_codex":0.0004511278,"about_ca_topic_score_gemma":0.00006764072,"teacher_disagreement_score":0.19502515,"about_ca_system_score_codex":0.011399845,"about_ca_system_score_gemma":0.003970958,"threshold_uncertainty_score":0.99994797},"labels":[],"label_agreement":null},{"id":"W3197361064","doi":"10.1111/bjh.17807","title":"<i>BCR–ABL1</i> transcript doubling time as a predictor for treatment‐free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phase","year":2021,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Toronto General Hospital; University of Alberta; London Health Sciences Centre; Hôpital de l'Enfant-Jésus; Queen Elizabeth II Health Sciences Centre; Dalhousie University; Université de Montréal; Hôpital Maisonneuve-Rosemont; Princess Margaret Cancer Centre; Vancouver General Hospital; University of Calgary; BC Cancer Agency; Alberta Health Services; McGill University Health Centre; University of Ottawa; Calgary Laboratory Services; CancerCare Manitoba; Ottawa Hospital; University Health Network; Western University; University of Toronto; University of British Columbia","funders":"Bristol-Myers Squibb Canada; Princess Margaret Cancer Foundation; Novartis","keywords":"Discontinuation; Imatinib; Chronic myeloid leukaemia; Internal medicine; Medicine; Doubling time; Imatinib mesylate; Gastroenterology; breakpoint cluster region; Oncology; Immunology; Myeloid leukemia; Biology; Cell; Genetics; Receptor","score_opus":0.013792805251477757,"score_gpt":0.2961651463502976,"score_spread":0.28237234109881987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197361064","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9717005,0.024519106,0.0002816589,0.0018780269,0.00023046331,0.0010642388,0.00009963477,0.000030189785,0.00019617668],"genre_scores_gemma":[0.99319226,0.0020329123,0.0025990321,0.00014870042,0.00046957756,0.0002115883,0.000247382,0.00008268721,0.0010158547],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9966066,0.00022546703,0.0015382997,0.00052557775,0.0003905159,0.00071354245],"domain_scores_gemma":[0.9983206,0.00022878946,0.00051655096,0.00040135917,0.0002621428,0.0002705748],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00043534877,0.00036683795,0.0015277792,0.0003672359,0.00007308625,0.000070225455,0.00021724317,0.00038315458,0.00082594366],"category_scores_gemma":[0.00050404435,0.00037276495,0.0004147504,0.00038885762,0.00011046482,0.00044600692,0.00004794743,0.00047468737,0.000021401896],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013574895,0.0074695013,0.008333931,0.002952104,0.001909086,0.39733383,0.0038909144,0.00052277173,0.35199916,0.00018211153,0.013633519,0.19819817],"study_design_scores_gemma":[0.3296621,0.012152625,0.005342887,0.021044683,0.0017427804,0.47917572,0.00072117016,0.0073461914,0.11260811,0.0015597844,0.027452009,0.0011919113],"about_ca_topic_score_codex":0.00021496006,"about_ca_topic_score_gemma":0.0030505601,"teacher_disagreement_score":0.31608722,"about_ca_system_score_codex":0.0063186055,"about_ca_system_score_gemma":0.005188233,"threshold_uncertainty_score":0.99987245},"labels":[],"label_agreement":null},{"id":"W3199767937","doi":"10.1200/jco.21.02072","title":"Sotorasib: Is Maximum Tolerated Dose Really the Issue at Hand?","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Medical physics; Nuclear medicine","score_opus":0.10949717507999111,"score_gpt":0.4568581657929333,"score_spread":0.3473609907129422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3199767937","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89021784,0.0018504604,0.000023091088,0.09089657,0.0023571667,0.00021042237,0.0000060549887,0.00001266939,0.014425753],"genre_scores_gemma":[0.910898,0.0032986137,0.0033022496,0.04429852,0.0048682694,0.000007781307,0.000015984084,0.00005240381,0.0332582],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99613345,0.00058272644,0.0022216511,0.00025378878,0.0004994299,0.00030897776],"domain_scores_gemma":[0.994738,0.0021870008,0.0013238264,0.00046186603,0.00084397994,0.00044535223],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019980373,0.00017533245,0.0014374218,0.000049910625,0.00011611035,0.000021497568,0.00021147887,0.00049499306,0.0040922356],"category_scores_gemma":[0.0037019548,0.000100156685,0.0006232306,0.00020869223,0.0003045145,0.000069943824,0.0001472273,0.0011757012,0.00042062718],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009398449,0.004174938,0.07482755,0.00006757747,0.002759092,0.02300049,0.0008686448,0.000015558167,0.0032439374,0.00006649605,0.6122132,0.2693641],"study_design_scores_gemma":[0.017917778,0.0054109646,0.1229786,0.000106409236,0.00075186463,0.004339577,0.000144979,0.00008031601,0.0023222035,0.00033230733,0.8455119,0.000103100036],"about_ca_topic_score_codex":0.000032973538,"about_ca_topic_score_gemma":0.0001152707,"teacher_disagreement_score":0.269261,"about_ca_system_score_codex":0.0010768225,"about_ca_system_score_gemma":0.0067755478,"threshold_uncertainty_score":0.9988551},"labels":[],"label_agreement":null},{"id":"W3200539468","doi":"10.1200/jco.21.01371","title":"Dose Optimization of Sotorasib: Is the US Food and Drug Administration Sending a Message?","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Food and drug administration; Drug; Drug administration; Administration (probate law); Pharmacology","score_opus":0.08411590816840064,"score_gpt":0.43765098846508205,"score_spread":0.3535350802966814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3200539468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9804514,0.00076033775,0.00048503611,0.016157664,0.0004901548,0.00015065429,0.000004154598,0.0000040554096,0.0014965242],"genre_scores_gemma":[0.988592,0.0011738283,0.008280167,0.0012143236,0.00043581842,0.0000017850052,0.000003861384,0.000009739758,0.00028842574],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977342,0.00035891743,0.0013984139,0.00013184859,0.00026659752,0.00011004995],"domain_scores_gemma":[0.9964304,0.0016169179,0.001275466,0.00016715196,0.00035798698,0.00015210279],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015172949,0.000085995445,0.000725775,0.000043669446,0.000038145743,0.000008964775,0.000063838306,0.00018444064,0.00018782052],"category_scores_gemma":[0.002464168,0.000054092496,0.00022356046,0.000117230484,0.00013363575,0.000082885745,0.000040359988,0.0004507596,0.0000016781582],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01447992,0.010849968,0.5290346,0.0006024287,0.0069009117,0.0058302386,0.003749604,0.0023615768,0.0018177278,0.0015770262,0.025701104,0.3970949],"study_design_scores_gemma":[0.10743284,0.06161378,0.6688775,0.0015147905,0.007577559,0.015212919,0.0037016193,0.014617153,0.026755812,0.0018414651,0.09026464,0.00058994826],"about_ca_topic_score_codex":0.000004951934,"about_ca_topic_score_gemma":0.000028385015,"teacher_disagreement_score":0.39650494,"about_ca_system_score_codex":0.00019753003,"about_ca_system_score_gemma":0.0030869877,"threshold_uncertainty_score":0.5476183},"labels":[],"label_agreement":null},{"id":"W3201791129","doi":"10.3324/haematol.2021.279317","title":"Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkers","year":2021,"lang":"en","type":"review","venue":"Haematologica","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Medical Research Council; Medical Research Council","keywords":"Myeloid leukemia; Epigenetics; Bioinformatics; Clinical trial; Gene expression profiling; Medicine; Computational biology; Profiling (computer programming); DNA microarray; Oncology; Biology; Gene; Cancer research; Gene expression; Genetics; Computer science","score_opus":0.0483749563130761,"score_gpt":0.34039579600795566,"score_spread":0.2920208396948796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201791129","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.019898837,0.9765599,0.00040677274,0.00002555536,0.00020684948,0.0022942147,0.00010459563,0.00014707986,0.00035620973],"genre_scores_gemma":[0.01215385,0.9684518,0.017630937,0.000035452427,0.000092988645,0.00060145115,0.00082600384,0.00014698364,0.00006055139],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99425673,0.00095947145,0.0016369058,0.0016563664,0.0005561975,0.000934332],"domain_scores_gemma":[0.99615985,0.0011664777,0.0009951488,0.0011760958,0.00009062227,0.00041183343],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003756697,0.0012686205,0.004758114,0.000570669,0.00018475592,0.00009444756,0.00037655554,0.0010968448,0.00051839266],"category_scores_gemma":[0.0006415029,0.00087642245,0.0007818268,0.00078568613,0.0002695647,0.00004665856,0.00031434267,0.0013809765,0.000031160176],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000029138697,0.00023628696,0.015255911,0.03044403,0.0010264126,0.004674248,0.00016416122,0.00003321387,0.00013175399,0.000018190516,0.00018410495,0.94780254],"study_design_scores_gemma":[0.021774694,0.0035621782,0.030354876,0.34541693,0.019364929,0.007408683,0.001160013,0.0046120565,0.0045155664,0.00022191147,0.5538632,0.007744931],"about_ca_topic_score_codex":0.00033713103,"about_ca_topic_score_gemma":0.00008745215,"teacher_disagreement_score":0.94005764,"about_ca_system_score_codex":0.007870851,"about_ca_system_score_gemma":0.0080254115,"threshold_uncertainty_score":0.99936867},"labels":[],"label_agreement":null},{"id":"W3208778166","doi":"10.1038/s41598-021-00950-y","title":"Targeting eIF4F translation complex sensitizes B-ALL cells to tyrosine kinase inhibition","year":2021,"lang":"en","type":"article","venue":"Scientific Reports","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Chao Family Comprehensive Cancer Center; National Center for Advancing Translational Sciences; National Institute of Allergy and Infectious Diseases; University of California, Irvine; National Cancer Institute; Yale University; National Institutes of Health; McGill University; Melanoma Research Alliance; American Society of Hematology","keywords":"Dasatinib; mTORC1; PI3K/AKT/mTOR pathway; Tyrosine kinase; Cancer research; mTORC2; Kinase; Biology; Cell biology; Leukemia; Signal transduction; Immunology","score_opus":0.035271546854730135,"score_gpt":0.2842784130597115,"score_spread":0.2490068662049814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3208778166","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911402,0.00030901874,0.0008620556,0.0016709429,0.003028927,0.0006192447,0.000011586551,0.00014617002,0.0022118692],"genre_scores_gemma":[0.9807332,0.0000070630645,0.0131133385,0.00040255944,0.00018158638,0.000015765983,0.0016039783,0.000029284667,0.00391318],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974844,0.000056604382,0.00057303667,0.0008676701,0.0006445478,0.00037374534],"domain_scores_gemma":[0.9984962,0.000036457084,0.00016310773,0.00068489177,0.00034740014,0.00027194826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006457686,0.00018224712,0.000290403,0.00016001498,0.00021262489,0.0001461971,0.00002524117,0.0000772298,0.00064321177],"category_scores_gemma":[0.00015407978,0.00017681724,0.00012143053,0.000629398,0.00008486316,0.00012091312,0.000044496755,0.00011761243,0.00016565321],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024166196,0.00014842364,0.00052359357,0.000068654605,0.000029466435,0.006187858,0.0004960925,0.00023796098,0.95644325,0.0000065299555,0.032446206,0.0033877988],"study_design_scores_gemma":[0.0010260004,0.00006053787,0.0015746015,0.00019990651,0.00013003362,0.0013460438,0.00016874573,0.0012529447,0.9167748,0.00029180403,0.07695305,0.0002215052],"about_ca_topic_score_codex":0.00004454842,"about_ca_topic_score_gemma":0.000030948806,"teacher_disagreement_score":0.044506848,"about_ca_system_score_codex":0.00044350052,"about_ca_system_score_gemma":0.00045139328,"threshold_uncertainty_score":0.7210398},"labels":[],"label_agreement":null},{"id":"W3208779542","doi":"10.1038/s41375-021-01451-7","title":"p21-Activated kinases as promising therapeutic targets in hematological malignancies","year":2021,"lang":"en","type":"review","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute; University of British Columbia","funders":"Leukemia and Lymphoma Society of Canada","keywords":"PAK1; Biology; CDC42; Kinase; Haematopoiesis; Stem cell; Cancer research; RAC1; Signal transduction; Cell biology","score_opus":0.0629476624436725,"score_gpt":0.3517173697215428,"score_spread":0.2887697072778703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3208779542","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0028150917,0.9922468,0.0000050671006,0.000051888983,0.00022817243,0.0017911945,0.00001618339,0.0001852249,0.0026603856],"genre_scores_gemma":[0.0013540142,0.99441,0.00037963045,0.00026412608,0.00017143358,0.0004150483,0.00069271954,0.00014725603,0.0021658193],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962914,0.00032787357,0.0010361931,0.0010430557,0.00049755175,0.00080395077],"domain_scores_gemma":[0.9979758,0.0004258955,0.00040351227,0.00088568934,0.00008562275,0.00022342805],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00021244505,0.00089115126,0.003921449,0.00031306804,0.0000820837,0.00005963971,0.000269529,0.00092885125,0.0010270617],"category_scores_gemma":[0.00041695585,0.00065337133,0.0007255432,0.00086144026,0.00013478634,0.000087398534,0.00017803868,0.0011176622,0.00037479235],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0000705957,0.0004241742,0.0001313398,0.025743525,0.0010608255,0.012721712,0.0002245779,0.0000019432237,0.00016398793,0.00044858476,0.0010718548,0.9579369],"study_design_scores_gemma":[0.0021548183,0.00020150725,0.00006445477,0.055340316,0.0013760892,0.0038767084,0.000078210534,0.000006724442,0.00081954524,0.00009002142,0.93532646,0.0006651224],"about_ca_topic_score_codex":0.00017435323,"about_ca_topic_score_gemma":0.000016368207,"teacher_disagreement_score":0.95727175,"about_ca_system_score_codex":0.008887413,"about_ca_system_score_gemma":0.0066132825,"threshold_uncertainty_score":0.99988616},"labels":[],"label_agreement":null},{"id":"W3209426648","doi":"10.3390/cancers13215543","title":"Statins Enhance the Molecular Response in Chronic Myeloid Leukemia when Combined with Tyrosine Kinase Inhibitors","year":2021,"lang":"en","type":"article","venue":"Cancers","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Ontario Institute for Cancer Research; University of Toronto","funders":"Samsung; Ministry of Science and ICT, South Korea; National Research Foundation of Korea; National Research Foundation","keywords":"Imatinib; Statin; Medicine; Myeloid leukemia; Rosuvastatin; Nilotinib; Pharmacology; Tyrosine-kinase inhibitor; Combination therapy; Cancer research; Tyrosine kinase; Immunology; Internal medicine; Cancer","score_opus":0.009205311423751533,"score_gpt":0.26084676791171874,"score_spread":0.2516414564879672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3209426648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903691,0.0052308757,0.00009560178,0.0026072003,0.00015640113,0.00063572626,0.000020167996,0.00005996236,0.00082497037],"genre_scores_gemma":[0.9948725,0.00028999953,0.00056545815,0.0011759584,0.00010094608,0.00019035242,0.00006462967,0.00006094162,0.0026791939],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99808264,0.00019028982,0.0003146614,0.00050776807,0.000412983,0.00049163966],"domain_scores_gemma":[0.99864584,0.00017095833,0.00011461565,0.0007739089,0.00012601932,0.00016864389],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002488086,0.00027843064,0.00038012062,0.00008699879,0.00008412021,0.000027755683,0.00014060375,0.00009423459,0.00029731853],"category_scores_gemma":[0.00019366031,0.00020038392,0.00007915793,0.0005637059,0.00021720587,0.000080090336,0.00006603725,0.00040273575,0.000038395214],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.030426288,0.0002018107,0.005650961,0.0006210032,0.0008481821,0.014734008,0.0069152107,0.021785991,0.8862009,0.0006519476,0.013425115,0.01853857],"study_design_scores_gemma":[0.022010216,0.0032282446,0.016788539,0.0014621259,0.0002848758,0.00020279667,0.0012366367,0.0023373011,0.9213864,0.000111334644,0.030336814,0.00061471196],"about_ca_topic_score_codex":0.0010331827,"about_ca_topic_score_gemma":0.0014984346,"teacher_disagreement_score":0.035185494,"about_ca_system_score_codex":0.034529068,"about_ca_system_score_gemma":0.018282665,"threshold_uncertainty_score":0.98728275},"labels":[],"label_agreement":null},{"id":"W3211783573","doi":"10.1182/blood-2021-148636","title":"Association between Bariatric Surgery and Outcomes in Patients with Chronic Myeloid Leukemia Treated with Oral Tyrosine Kinase Inhibitors","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Myeloid leukemia; Tyrosine kinase; Internal medicine; Surgery; Tyrosine-kinase inhibitor; Gastroenterology; Cancer","score_opus":0.00798914801371739,"score_gpt":0.21606377838258492,"score_spread":0.20807463036886753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211783573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99857724,0.00048803358,0.0000015669993,0.00020051058,0.000039267565,0.0004730249,0.000042558186,0.00007092913,0.00010684799],"genre_scores_gemma":[0.9981795,0.000067591616,0.00021968236,0.000050823586,0.00011593011,0.000034050434,0.0005718988,0.00005176046,0.0007087672],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981273,0.00009037169,0.00037660342,0.00046681316,0.0004981221,0.0004408268],"domain_scores_gemma":[0.9988944,0.00025420298,0.00020463398,0.00030871952,0.00016634208,0.0001717342],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016310568,0.00030330964,0.00074098917,0.00021866526,0.000063948886,0.00003445129,0.000038218815,0.00017880117,0.00004910209],"category_scores_gemma":[0.00017171583,0.00022210357,0.00006603556,0.00071639783,0.000034774257,0.00014737625,0.00004372409,0.0002492924,0.000012055876],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001313823,0.00060618564,0.99603164,0.000083665065,0.0007230453,0.00022689301,0.000044473785,0.0000033347271,0.000067377405,0.0000011704813,0.000113827344,0.0019669964],"study_design_scores_gemma":[0.026487688,0.0005741683,0.96612686,0.00023319104,0.001311115,0.000011598955,0.0000122299425,0.0000047925814,0.0049102237,0.0000020108903,0.00009277961,0.00023332967],"about_ca_topic_score_codex":0.00057636993,"about_ca_topic_score_gemma":0.00056012935,"teacher_disagreement_score":0.029904775,"about_ca_system_score_codex":0.0029910966,"about_ca_system_score_gemma":0.0013165197,"threshold_uncertainty_score":0.90571207},"labels":[],"label_agreement":null},{"id":"W3212299214","doi":"10.1182/blood-2021-152561","title":"Efficacy and Safety Results from Ascembl, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, Vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase after ≥2 Prior Tyrosine Kinase Inhibitors: Update after 48 Weeks","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Bosutinib; Medicine; Discontinuation; Tolerability; Internal medicine; Adverse effect; Nilotinib; Imatinib mesylate; Imatinib; Myeloid leukemia; Gastroenterology; Oncology","score_opus":0.01260281943940314,"score_gpt":0.278387262362273,"score_spread":0.26578444292286985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212299214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895521,0.0031034108,0.0000014454563,0.00020403096,0.00019813055,0.0060438327,0.00081429514,0.000046607933,0.000036169757],"genre_scores_gemma":[0.9970999,0.0003673098,0.00043064696,0.00013114688,0.00021705909,0.0006983834,0.00083724235,0.00014165309,0.0000766608],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9936332,0.00037937125,0.0021180466,0.0018905995,0.0008960123,0.0010827739],"domain_scores_gemma":[0.996997,0.00029920213,0.00054668036,0.0015094643,0.00022614108,0.00042149663],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00050521747,0.00087833195,0.0016692756,0.00051973766,0.00008526721,0.00011376297,0.00035393573,0.00033499912,0.00018424504],"category_scores_gemma":[0.00034124494,0.00079251424,0.00007948272,0.0011436492,0.00017935739,0.00054102065,0.00078330643,0.00089138804,0.00002906156],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3248995,0.22714126,0.38879144,0.0012340539,0.0014562069,0.014767596,0.011696191,0.000117181495,0.0068560415,0.0000015572351,0.0002587915,0.02278017],"study_design_scores_gemma":[0.66073096,0.012438544,0.30941263,0.004730678,0.00062606676,0.0000137755005,0.00025200236,0.00056359416,0.009830209,0.0000014393844,0.00076894683,0.00063119107],"about_ca_topic_score_codex":0.0027236952,"about_ca_topic_score_gemma":0.024042826,"teacher_disagreement_score":0.33583143,"about_ca_system_score_codex":0.0062250723,"about_ca_system_score_gemma":0.0033504802,"threshold_uncertainty_score":0.9994526},"labels":[],"label_agreement":null},{"id":"W3212419124","doi":"10.1182/blood-2021-152614","title":"Low-Dose Dasatinib 50 Mg/Day Versus Standard-Dose Dasatinib 100 Mg/Day As Frontline Therapy in Chronic Myeloid Leukemia in Chronic Phase: A Propensity Score Analysis","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Dasatinib; Medicine; Myeloid leukemia; Internal medicine; Propensity score matching; Oncology; Imatinib","score_opus":0.03958019677847365,"score_gpt":0.3183442552377831,"score_spread":0.27876405845930946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212419124","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9809473,0.0135915475,0.000054731747,0.00035164566,0.00037751574,0.0024809144,0.00024646628,0.00021711712,0.0017327315],"genre_scores_gemma":[0.99042314,0.004177336,0.0005324682,0.0002709914,0.00078159914,0.000362684,0.0017170366,0.00018652219,0.0015481914],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9924968,0.0007313104,0.0016545695,0.0020236166,0.001480091,0.0016136413],"domain_scores_gemma":[0.9956957,0.00047114975,0.00054048485,0.002358243,0.00036675425,0.00056763],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013868627,0.0010853088,0.0024528932,0.0009163261,0.00021301824,0.00013246734,0.00055545924,0.00057969615,0.0033228216],"category_scores_gemma":[0.00072795857,0.0010004281,0.0006846245,0.0033749866,0.00030269177,0.00037656302,0.00033598937,0.0014427822,0.00025088992],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.04437463,0.020455161,0.20349136,0.0021572374,0.027888516,0.03368692,0.011193569,0.00673567,0.41444063,0.0002625971,0.0019163908,0.2333973],"study_design_scores_gemma":[0.5480171,0.013637776,0.21899696,0.0023466547,0.0059492197,0.0002910846,0.00055292615,0.0066326708,0.19080476,0.00009419834,0.0102333445,0.002443309],"about_ca_topic_score_codex":0.0026325919,"about_ca_topic_score_gemma":0.018210668,"teacher_disagreement_score":0.5036425,"about_ca_system_score_codex":0.024265252,"about_ca_system_score_gemma":0.023773832,"threshold_uncertainty_score":0.9997044},"labels":[],"label_agreement":null},{"id":"W3212525057","doi":"10.1182/blood-2021-154380","title":"Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Following the Discontinuation of Tyrosine Kinase Inhibitors","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Discontinuation; Medicine; Internal medicine; Univariate analysis; Myeloid leukemia; Imatinib mesylate; Imatinib; Multivariate analysis; Oncology","score_opus":0.007465383064755747,"score_gpt":0.22651198705685585,"score_spread":0.2190466039921001,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212525057","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99681765,0.0015304419,0.000004275159,0.00027524916,0.00009693115,0.00064364745,0.000016725015,0.000028887878,0.0005862074],"genre_scores_gemma":[0.99847054,0.00007137338,0.00031993302,0.000022311524,0.00010890179,0.00004726972,0.00025697847,0.000035144727,0.000667566],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99853235,0.00006690489,0.00036480476,0.00034591515,0.00041351654,0.0002765334],"domain_scores_gemma":[0.99878144,0.00007466264,0.00015124278,0.0008006533,0.0001070249,0.00008494849],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008316912,0.00022572782,0.0003779233,0.00007750011,0.000066335306,0.0000139215645,0.000102980164,0.00009067192,0.000041104566],"category_scores_gemma":[0.00021636275,0.00013500561,0.00010996798,0.000532474,0.00004852422,0.00010809579,0.000074936215,0.00013331475,0.000005388372],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032600338,0.0022167624,0.9610939,0.00007643441,0.0004069076,0.0002933057,0.0006269923,0.000028513738,0.018011833,0.000023848776,0.00012652222,0.016768953],"study_design_scores_gemma":[0.06872897,0.0021487228,0.6443975,0.0011084472,0.00096960855,0.000024591092,0.00015751494,0.00006285527,0.28168634,0.000019733772,0.0004799083,0.00021582107],"about_ca_topic_score_codex":0.00032296032,"about_ca_topic_score_gemma":0.00037294909,"teacher_disagreement_score":0.31669644,"about_ca_system_score_codex":0.0017409355,"about_ca_system_score_gemma":0.0014395223,"threshold_uncertainty_score":0.55053693},"labels":[],"label_agreement":null},{"id":"W3212904758","doi":"10.1182/blood-2021-148701","title":"Gene Expression Analysis of CML Patients across the Age Spectrum","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Myeloid; Biology; CD34; Young adult; White blood cell; Medicine; Oncology; Immunology; Internal medicine; Genetics; Stem cell","score_opus":0.012250775473735123,"score_gpt":0.27023088864152833,"score_spread":0.25798011316779323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212904758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998253,0.00044632624,0.00001385871,0.00012332188,0.000056701716,0.00013394603,0.000068771675,0.000017687164,0.00088641664],"genre_scores_gemma":[0.99812937,0.000068055466,0.00044394165,0.00012381507,0.00006522921,0.000009711432,0.00028622767,0.000012166671,0.0008614616],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99903595,0.000040542287,0.0002101998,0.00021940985,0.0002957113,0.00019816188],"domain_scores_gemma":[0.99915326,0.00005022023,0.0000855047,0.00059788127,0.0000608901,0.000052271185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006916771,0.00010056867,0.0003014139,0.000041700958,0.000060159182,0.000009345937,0.00008117627,0.000053790332,0.00030089854],"category_scores_gemma":[0.000076226235,0.000064358064,0.00019929527,0.00054881215,0.000041556923,0.00002238239,0.000098970195,0.0000878637,0.000016463628],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006400212,0.0027319088,0.91384304,0.000048658232,0.0039414163,0.0004595955,0.0015827864,0.000023754425,0.075300224,0.000009106998,0.0005142515,0.0014812631],"study_design_scores_gemma":[0.00409051,0.000074465344,0.47003272,0.00003221524,0.0024749262,0.0000069535495,0.00007968707,0.000019545287,0.52272666,0.000010511728,0.00039975197,0.0000520418],"about_ca_topic_score_codex":0.000056109708,"about_ca_topic_score_gemma":0.00007313738,"teacher_disagreement_score":0.44742644,"about_ca_system_score_codex":0.00008471623,"about_ca_system_score_gemma":0.00009621225,"threshold_uncertainty_score":0.3294628},"labels":[],"label_agreement":null},{"id":"W3212999994","doi":"10.1182/blood-2021-147601","title":"Health-Related Quality of Life (HRQoL) during Treatment with Enasidenib (ENA) Plus Azacitidine (AZA) in Patients with Newly Diagnosed Mutant <i>IDH2</i> (m <i>IDH2</i>) Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy (IC)","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Azacitidine; IDH2; Myeloid leukemia; Medicine; Quality of life (healthcare); Internal medicine; Myeloid; Oncology; Mutant; Biology; IDH1; DNA methylation; Genetics; Gene","score_opus":0.017589774981762136,"score_gpt":0.2627484715674916,"score_spread":0.24515869658572945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212999994","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99253255,0.0012233686,0.00005031536,0.0017137324,0.00011286836,0.0036703437,0.00043761084,0.00014969453,0.00010952009],"genre_scores_gemma":[0.992325,0.0010472342,0.0028114333,0.0014204482,0.00008518704,0.00053026504,0.0010578784,0.00019268408,0.0005298369],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99506426,0.00018724438,0.0015916419,0.0012306178,0.000823764,0.0011024899],"domain_scores_gemma":[0.996089,0.00037181386,0.0009414815,0.0011416951,0.0009375776,0.00051847607],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002702006,0.00084050605,0.0024072863,0.0002695445,0.00016958019,0.000036217898,0.00020059453,0.00028171227,0.000054964923],"category_scores_gemma":[0.0002391547,0.0006422826,0.0003242562,0.00085546396,0.00019083952,0.00020266933,0.00008048422,0.00038015953,0.00001205438],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07774817,0.017501736,0.7110838,0.003365871,0.019615835,0.0032582604,0.014199721,0.00072245253,0.1432888,0.00011494533,0.0005329642,0.008567429],"study_design_scores_gemma":[0.3082778,0.008194574,0.21178497,0.0015226976,0.0011158211,0.00022231282,0.0008463975,0.00004776836,0.46693417,0.000017400029,0.00023452318,0.0008015811],"about_ca_topic_score_codex":0.002909468,"about_ca_topic_score_gemma":0.0014616757,"teacher_disagreement_score":0.49929884,"about_ca_system_score_codex":0.0040562544,"about_ca_system_score_gemma":0.005276866,"threshold_uncertainty_score":0.999767},"labels":[],"label_agreement":null},{"id":"W3213586012","doi":"10.1182/blood-2021-149588","title":"A Real-World Canadian Experience of Asciminib Use in Chronic Myeloid Leukemia (CML) Patients Who Failed Multiple Lines of Tyrosine Kinase Inhibitor (TKI) Therapy","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; Juravinski Cancer Centre; McGill University; University of Calgary; Brampton Civic Hospital; Alberta Health Services; Hôpital Maisonneuve-Rosemont; Western University; Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Bosutinib; Dasatinib; Medicine; Nilotinib; Discontinuation; Internal medicine; Imatinib mesylate; Imatinib; Adverse effect; Oncology; Myeloid leukemia","score_opus":0.023282543078454003,"score_gpt":0.26629955650069187,"score_spread":0.24301701342223786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213586012","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99746895,0.0010106053,6.202337e-7,0.000072206945,0.000145667,0.00074781984,0.0001436984,0.000026839416,0.00038360228],"genre_scores_gemma":[0.99698305,0.0008085738,0.0006921765,0.0000964109,0.00013904709,0.00009948781,0.0002391878,0.000056117304,0.0008859502],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99763,0.00008788569,0.0007623886,0.0005428351,0.00043977678,0.0005371401],"domain_scores_gemma":[0.9980785,0.0001709789,0.0002447534,0.00081017567,0.00036025,0.00033528736],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00010237241,0.00032077997,0.0007472622,0.00039083976,0.000051213105,0.000016935528,0.00016802299,0.00016198494,0.0002235641],"category_scores_gemma":[0.00042772735,0.00029812404,0.0001532861,0.00089759013,0.00014951099,0.00018560763,0.00007243466,0.00022099988,0.00000841522],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002455627,0.00118137,0.92219275,0.000180096,0.0001656443,0.0003048524,0.0019004683,0.000029002167,0.07125847,0.000021280734,0.00020903215,0.0023114684],"study_design_scores_gemma":[0.021114457,0.0004395871,0.55399126,0.0006908343,0.00008239263,0.000006683582,0.00015513132,0.00017529512,0.42208508,0.0000034531506,0.0010579668,0.00019786322],"about_ca_topic_score_codex":0.21415728,"about_ca_topic_score_gemma":0.46329272,"teacher_disagreement_score":0.3682015,"about_ca_system_score_codex":0.0022962273,"about_ca_system_score_gemma":0.0050714016,"threshold_uncertainty_score":0.9999471},"labels":[],"label_agreement":null},{"id":"W3214034632","doi":"10.1182/blood-2021-152693","title":"Trial in Progress: Phase 1b Bridging Study of the Pharmacokinetics (PK), Safety, and Efficacy of Orally Administered Olverembatinib (HQP1351) in Patients with Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph⁺ ALL)","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Adverse effect; Ponatinib; Dasatinib; Oncology; Myeloid leukemia; Imatinib; Pharmacology","score_opus":0.01288316360663517,"score_gpt":0.28068947466523486,"score_spread":0.2678063110585997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214034632","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947075,0.0012134241,0.0000017291082,0.00010480686,0.00010729409,0.0036510408,0.00013156224,0.000024735538,0.000057908153],"genre_scores_gemma":[0.9990277,0.00036479114,0.000124522,0.000052541178,0.00011065705,0.00007984712,0.00013966556,0.000071768336,0.000028479562],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.996522,0.0002967737,0.0011350842,0.0007861291,0.0007508629,0.0005091193],"domain_scores_gemma":[0.9980105,0.0002930171,0.0006378327,0.00065008266,0.00021468864,0.00019386265],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022782397,0.0004944193,0.0011119964,0.00022324872,0.00007017965,0.000027036194,0.00021440256,0.00016730577,0.000029741113],"category_scores_gemma":[0.0001638061,0.000379278,0.00009142032,0.0006585798,0.0003309076,0.00014981524,0.00032189878,0.00044601999,8.6525756e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28707618,0.11645685,0.46896473,0.0026165822,0.010526235,0.0037060298,0.018139593,0.0003876415,0.037884872,0.000015647776,0.00008556782,0.054140072],"study_design_scores_gemma":[0.64269227,0.014330365,0.32212785,0.0016087821,0.0023408781,0.00010400044,0.0002560837,0.00038810706,0.015773732,0.000001962704,0.000034638924,0.00034133263],"about_ca_topic_score_codex":0.00011127169,"about_ca_topic_score_gemma":0.00025044917,"teacher_disagreement_score":0.3556161,"about_ca_system_score_codex":0.0019500642,"about_ca_system_score_gemma":0.0029722557,"threshold_uncertainty_score":0.9998659},"labels":[],"label_agreement":null},{"id":"W3214248259","doi":"10.1182/blood-2021-145995","title":"Post Hoc Analysis of Responses to Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) By Baseline <i>BCR-ABL1</i> Level and Baseline Mutation Status in the Optic Trial","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ponatinib; Medicine; Myeloid leukemia; Internal medicine; Imatinib; Oncology; Dasatinib","score_opus":0.01470383091207388,"score_gpt":0.28042550153440937,"score_spread":0.2657216706223355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214248259","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939403,0.002199507,0.00009248322,0.0004930868,0.000046539815,0.001619447,0.0015433674,0.000022126549,0.000043159245],"genre_scores_gemma":[0.9941649,0.00021651461,0.0013457756,0.00040250452,0.000096202144,0.00014817282,0.0033785286,0.000045080993,0.00020231759],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.996463,0.00057903497,0.0009057984,0.0007026752,0.0007882829,0.00056118716],"domain_scores_gemma":[0.9975599,0.000917552,0.00026454692,0.00071147847,0.00033753767,0.00020898409],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010169412,0.00036940174,0.000871084,0.0006489627,0.000064728905,0.000034671742,0.00015059876,0.00014514868,0.00017001595],"category_scores_gemma":[0.0012648074,0.00027819705,0.00012795164,0.0022514134,0.00009295981,0.00013767305,0.00007621727,0.00032597018,0.0000059170065],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4470614,0.051195752,0.26982033,0.0016436991,0.012338166,0.0055136816,0.011068048,0.0064690285,0.063127495,0.00010968908,0.0017048827,0.12994781],"study_design_scores_gemma":[0.69414866,0.022538524,0.25361365,0.00067710597,0.007139294,0.00007699467,0.00080143544,0.004785492,0.014411731,0.000005476985,0.0010616302,0.0007400067],"about_ca_topic_score_codex":0.0010437908,"about_ca_topic_score_gemma":0.0043925117,"teacher_disagreement_score":0.24708727,"about_ca_system_score_codex":0.0018721864,"about_ca_system_score_gemma":0.0034670897,"threshold_uncertainty_score":0.99996704},"labels":[],"label_agreement":null},{"id":"W3214297432","doi":"10.1182/blood-2021-154494","title":"DNA Mediated Blood Coagulation: Extracellular DNA Accelerates Fibrinogen Polymerization By Thrombin Independent of Contact Pathway","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Extracellular; DNA; Chemistry; Coagulation; Thrombin; Biochemistry; Activator (genetics); Fibrinogen; Biophysics; Cell biology; Molecular biology; Biology; Platelet; Immunology; Medicine; Receptor","score_opus":0.014508326899427527,"score_gpt":0.23522403920320462,"score_spread":0.2207157123037771,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214297432","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99004805,0.007743182,0.00004520518,0.00019500982,0.0001124708,0.00047285526,0.00015344906,0.00009367374,0.0011361317],"genre_scores_gemma":[0.99581414,0.00026729616,0.00018794803,0.000072787356,0.00010998476,0.000028528102,0.002406952,0.00005243749,0.0010599346],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99796695,0.00010034996,0.0005744071,0.00046253705,0.00056845776,0.0003273276],"domain_scores_gemma":[0.99872315,0.00011305,0.00026223256,0.0005191204,0.00019411521,0.00018835436],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00011371566,0.0002731153,0.0005395165,0.00007913043,0.00006911284,0.0000280705,0.00010750366,0.00022770888,0.0013520684],"category_scores_gemma":[0.0001322425,0.00026603416,0.00013606907,0.0003640735,0.000047019545,0.0001327707,0.000068952155,0.00015788557,0.000044279746],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000045955105,0.0018585111,0.038835563,0.0001065433,0.00075716776,0.00032039583,0.00023038185,0.0000020981922,0.9572578,0.00012268423,0.00012378293,0.00033913268],"study_design_scores_gemma":[0.013471562,0.00036284994,0.030644411,0.00014495278,0.0007625314,0.00029768105,0.00010767303,0.000059217295,0.9536008,0.000022489938,0.0003213817,0.00020440895],"about_ca_topic_score_codex":0.000096574135,"about_ca_topic_score_gemma":0.000016325217,"teacher_disagreement_score":0.013425607,"about_ca_system_score_codex":0.00011641641,"about_ca_system_score_gemma":0.00072274066,"threshold_uncertainty_score":0.9999792},"labels":[],"label_agreement":null},{"id":"W3214381809","doi":"10.1182/blood-2021-149185","title":"Identification of a Highly Deregulated eIF4F Translation Initiation Complex in Drug-Resistant BCR-ABL + Cells By a Phospho-Proteomic Antibody Microarray","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute; Kinexus Bioinformatics Corporation (Canada); University of British Columbia","funders":"","keywords":"Biology; Phosphorylation; Antibody microarray; Microarray analysis techniques; Cancer research; Myeloid leukemia; ABL; Imatinib mesylate; breakpoint cluster region; Tyrosine kinase; Progenitor cell; Imatinib; Stem cell; Antibody; Cell biology; Molecular biology; Signal transduction; Immunology; Gene expression; Genetics; Receptor; Gene","score_opus":0.01393623118559776,"score_gpt":0.2615298038477432,"score_spread":0.24759357266214546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214381809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968292,0.0013300237,0.00018525735,0.0003783194,0.00006254989,0.00078128214,0.00012679007,0.00004907362,0.0002574651],"genre_scores_gemma":[0.9962229,0.00016607552,0.0014676386,0.000051274044,0.000026971229,0.00003635727,0.0016954945,0.000034042434,0.00029923455],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99818665,0.00011771281,0.0007359444,0.00040778602,0.00030951988,0.00024238742],"domain_scores_gemma":[0.9990272,0.000057539415,0.00027501525,0.0004063483,0.00016161283,0.000072319795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002038664,0.00019180884,0.00039093907,0.0001420064,0.000045765537,0.000021330581,0.000078796256,0.00012762233,0.000144835],"category_scores_gemma":[0.000037044218,0.00020422401,0.00009910936,0.00051792606,0.000052142415,0.00010952428,0.000015165957,0.00013509204,0.000031103318],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017168911,0.0013406031,0.0033557834,0.00024226,0.00013421608,0.00005257006,0.00071389414,0.00001221353,0.9932834,0.000017372999,0.00024836443,0.00042763175],"study_design_scores_gemma":[0.011617441,0.000070984526,0.051003035,0.00022620545,0.0003174316,0.00002433401,0.00011264947,0.0004632112,0.93575597,0.000039835995,0.00021945235,0.00014947458],"about_ca_topic_score_codex":0.00043328674,"about_ca_topic_score_gemma":0.000120964745,"teacher_disagreement_score":0.057527456,"about_ca_system_score_codex":0.00029174294,"about_ca_system_score_gemma":0.00038695868,"threshold_uncertainty_score":0.8328013},"labels":[],"label_agreement":null},{"id":"W3214599575","doi":"10.1182/blood-2021-150496","title":"Risk of Progression in Chronic Phase - Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation (TFR-PRO study): Preliminary Results","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Quebec - Clinical Research Organization in Cancer; Jewish General Hospital","funders":"","keywords":"Discontinuation; Medicine; Internal medicine; Imatinib mesylate; Drug holiday; Myeloid leukemia; Tyrosine-kinase inhibitor; Oncology; Clinical trial; Imatinib; Immunology; Cancer; Human immunodeficiency virus (HIV)","score_opus":0.015651943631827047,"score_gpt":0.3103818157024025,"score_spread":0.29472987207057544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214599575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99002296,0.0042596096,0.00002667071,0.000093764866,0.00022247272,0.0047850725,0.00035129528,0.000076558405,0.00016157329],"genre_scores_gemma":[0.9951296,0.00038944613,0.0009703269,0.0000132348205,0.0004632369,0.0007720584,0.0016877169,0.000080944184,0.0004934372],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99644464,0.00019260842,0.0011770064,0.00092286925,0.00065642997,0.00060643797],"domain_scores_gemma":[0.9976775,0.00020562513,0.00061977585,0.0009169027,0.0003933255,0.00018684645],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004927879,0.0004201803,0.00076240115,0.00024696588,0.00012722822,0.00002814982,0.0001587452,0.00021833688,0.000035151617],"category_scores_gemma":[0.0008897789,0.00036776662,0.00020814479,0.00061132613,0.00008904889,0.00023242076,0.00018327031,0.00035022033,0.000015354597],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03595399,0.12158148,0.32088682,0.0038075254,0.0024193926,0.001309901,0.0063416595,0.0005238413,0.20061754,0.00003749658,0.0034733273,0.30304703],"study_design_scores_gemma":[0.26634464,0.039206002,0.12892385,0.002636062,0.0018986162,0.000024896666,0.00033143553,0.0018499915,0.5574154,0.000035400426,0.0008239072,0.00050976645],"about_ca_topic_score_codex":0.00021410009,"about_ca_topic_score_gemma":0.0004135175,"teacher_disagreement_score":0.3567979,"about_ca_system_score_codex":0.0035343524,"about_ca_system_score_gemma":0.00316442,"threshold_uncertainty_score":0.99987745},"labels":[],"label_agreement":null},{"id":"W3215439278","doi":"10.1182/blood-2021-147739","title":"<i>Patient and Physician Perspectives of Unmet Needs in CML - Designing the CML SUN Survey</i>","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Family medicine; Referral; Quality of life (healthcare); Qualitative research; Inclusion (mineral); Nursing; Psychology","score_opus":0.01520937901663872,"score_gpt":0.24867288394776552,"score_spread":0.2334635049311268,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3215439278","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99289364,0.004381392,0.000009660088,0.0001938175,0.000028464889,0.00020792017,0.00001373541,0.000011847664,0.0022595248],"genre_scores_gemma":[0.9990991,0.00017126993,0.00036592188,0.00014919283,0.000038291273,0.000012236451,0.000018048413,0.000015703807,0.00013026051],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99913746,0.00015522605,0.00017261185,0.00018444798,0.00017871223,0.00017152536],"domain_scores_gemma":[0.99932134,0.00022367999,0.0000637807,0.00026840714,0.00007711843,0.000045699027],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001787143,0.000112171234,0.00025377862,0.000060697548,0.000036260386,0.000009088554,0.000041300405,0.00004097984,0.00002159746],"category_scores_gemma":[0.00015639239,0.000082386396,0.000045804376,0.00040066516,0.00007895401,0.00003612697,0.00005573119,0.00013024449,0.00000321841],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021725913,0.0043350304,0.84248036,0.00019704213,0.00094465615,0.0004114243,0.048202086,0.000024080013,0.09035891,0.0005855607,0.00038210762,0.011861489],"study_design_scores_gemma":[0.010907775,0.0005892778,0.6858428,0.00035058215,0.00041497525,0.000114873794,0.026462227,0.00005660841,0.27467826,0.000109177796,0.00026318736,0.00021025224],"about_ca_topic_score_codex":0.00046421424,"about_ca_topic_score_gemma":0.00019668996,"teacher_disagreement_score":0.18431935,"about_ca_system_score_codex":0.0001039717,"about_ca_system_score_gemma":0.00024367301,"threshold_uncertainty_score":0.33596197},"labels":[],"label_agreement":null},{"id":"W3215790083","doi":"","title":"The Effects of Hemin at Varying Concentrations on the Differentiation in Chronic Myeloid Leukemia (CML) Cell Line K562","year":2021,"lang":"en","type":"article","venue":"Student Research Proceedings","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"MacEwan University","funders":"","keywords":"Hemin; Benzidine; K562 cells; Myeloid leukemia; Hemoglobin; Globin; Cell culture; Myeloid; Chemistry; Molecular biology; Cellular differentiation; Cell division; Cell growth; Fetal hemoglobin; Biology; Cell; Cell biology; Immunology; Biochemistry; Fetus; Enzyme; Genetics; Heme; Gene","score_opus":0.04455461974150395,"score_gpt":0.36330707156846337,"score_spread":0.31875245182695944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3215790083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98598355,0.002048089,0.0000023309128,0.0018308646,0.00010667143,0.0018005971,0.0000030235854,0.000026790529,0.0081980815],"genre_scores_gemma":[0.98937,0.0028053515,0.000016516413,0.000071607996,0.00021637419,0.00044091602,0.000027566524,0.000030248357,0.007021437],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99675006,0.000106021354,0.0004272722,0.00045610784,0.0015573171,0.00070321927],"domain_scores_gemma":[0.99697256,0.0018605556,0.00013005512,0.00035328994,0.00055353984,0.00013000777],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009723377,0.00020680494,0.00029712205,0.000121560086,0.000527165,0.00009230906,0.00033566312,0.00010625004,0.000106034866],"category_scores_gemma":[0.001366629,0.00012392046,0.000106053325,0.0007896972,0.00024225916,0.00008137268,0.00041808444,0.00082304375,0.000051794064],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034527294,0.00073526363,0.04585707,0.0013518081,0.0002503652,0.000098326855,0.005653898,0.000019404819,0.9336849,0.0035465746,0.005816633,0.0026404806],"study_design_scores_gemma":[0.005937039,0.0011130552,0.07336447,0.0012179079,0.000077226716,0.000015688096,0.0015066336,0.00092239026,0.9132842,0.00021577821,0.0021933613,0.0001522755],"about_ca_topic_score_codex":0.0000941653,"about_ca_topic_score_gemma":0.00012774073,"teacher_disagreement_score":0.027507398,"about_ca_system_score_codex":0.008259345,"about_ca_system_score_gemma":0.0013961198,"threshold_uncertainty_score":0.9955478},"labels":[],"label_agreement":null},{"id":"W3215933821","doi":"10.1182/blood-2021-154497","title":"The Prognostic Implication of Adult Comorbidity Evaluation 27 Score in CML Patients on Tyrosine-Kinase Inhibitors","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Dasatinib; Medicine; Nilotinib; Internal medicine; Imatinib mesylate; Imatinib; Population; Oncology; Philadelphia chromosome; Ponatinib; Tyrosine-kinase inhibitor; Cancer; Myeloid leukemia","score_opus":0.02204189603364523,"score_gpt":0.2844263008851013,"score_spread":0.2623844048514561,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3215933821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99750274,0.00035446786,8.671161e-7,0.00034923287,0.00015564707,0.0009782205,0.000015844988,0.000015768253,0.0006272143],"genre_scores_gemma":[0.99925315,0.0000926448,0.000060103208,0.000059632213,0.00006415289,0.00011129276,0.0002930541,0.000014295856,0.000051645293],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987096,0.00010608633,0.00030549447,0.00023500514,0.00048241921,0.00016135826],"domain_scores_gemma":[0.9987433,0.00015824933,0.00013611869,0.0004122668,0.0004977695,0.0000522754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018562422,0.000110736866,0.00016050212,0.000048598424,0.00005021327,0.000009516745,0.000055495584,0.00006580032,0.00002284578],"category_scores_gemma":[0.0013523687,0.00008174165,0.000051743682,0.00028013985,0.00004069924,0.000036432702,0.000032816275,0.00012360692,0.000023354272],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007970454,0.0025313413,0.9782675,0.00007006731,0.000050734772,0.000013413062,0.00015131194,0.0000075963226,0.0036260833,0.00011688857,0.0002976075,0.014787731],"study_design_scores_gemma":[0.009319784,0.00035893338,0.8687322,0.0003560884,0.0002365583,0.0000071942845,0.000043940912,0.00014728817,0.1205448,0.0001063137,0.00008185717,0.0000650351],"about_ca_topic_score_codex":0.0001117778,"about_ca_topic_score_gemma":0.00019555862,"teacher_disagreement_score":0.11691871,"about_ca_system_score_codex":0.00034721076,"about_ca_system_score_gemma":0.0004523088,"threshold_uncertainty_score":0.33333278},"labels":[],"label_agreement":null},{"id":"W3217194789","doi":"10.1182/blood-2021-151761","title":"Real-Life Use of Nilotinib for Chronic Phase CML Demonstrates Similar Efficacy and Rate of Cardiovascular Events As Enestnd","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; Hôpital Maisonneuve-Rosemont; Quebec - Clinical Research Organization in Cancer; Centre Hospitalier de l’Université de Montréal; McGill University","funders":"","keywords":"Nilotinib; Medicine; Internal medicine; Imatinib; Myeloid leukemia; Dasatinib; Imatinib mesylate","score_opus":0.036006044511524796,"score_gpt":0.3029920284002244,"score_spread":0.2669859838886996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217194789","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98999417,0.008737479,0.00007901984,0.0000821676,0.00005762009,0.0008275586,0.0001001342,0.000027193864,0.000094679366],"genre_scores_gemma":[0.9946493,0.003255864,0.0015345712,0.00003684808,0.00010837873,0.000042783486,0.00014347598,0.000043196353,0.00018559105],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985403,0.0000983504,0.00045085006,0.00039730564,0.00023622387,0.0002769853],"domain_scores_gemma":[0.9984767,0.000332929,0.00015700232,0.0006251229,0.0002124702,0.00019576798],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023426043,0.00021717034,0.0007712617,0.000067027424,0.00004284881,0.000007834534,0.000063013395,0.000119753655,0.0000517459],"category_scores_gemma":[0.0006619669,0.00020087068,0.00032277266,0.00017713965,0.000091443486,0.00007482986,0.00005241215,0.00008970487,0.000003818832],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040593287,0.025654284,0.08248744,0.008991557,0.051299673,0.0021228555,0.0011811416,0.0010161663,0.78276986,0.00090052944,0.00083344866,0.03868374],"study_design_scores_gemma":[0.10934125,0.0026719626,0.025020016,0.0008323562,0.008962063,0.0003158927,0.0000819245,0.0003569798,0.84754443,0.00007949049,0.004479684,0.00031396846],"about_ca_topic_score_codex":0.00019743135,"about_ca_topic_score_gemma":0.000011303937,"teacher_disagreement_score":0.10528192,"about_ca_system_score_codex":0.00010015363,"about_ca_system_score_gemma":0.0013879205,"threshold_uncertainty_score":0.81912684},"labels":[],"label_agreement":null},{"id":"W3217205918","doi":"10.1182/blood-2021-146175","title":"Dose Modification Dynamics of Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) from the PACE and Optic Trials","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ponatinib; Medicine; Adverse effect; Internal medicine; Dosing; Clinical trial; Myeloid leukemia; Oncology; Nilotinib; Imatinib","score_opus":0.021214651857451392,"score_gpt":0.28550244644087175,"score_spread":0.26428779458342033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217205918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936086,0.00423495,0.000051839586,0.0004566958,0.00006445618,0.0011258338,0.00023867044,0.000027694954,0.0001912794],"genre_scores_gemma":[0.99706924,0.0003870424,0.0009762937,0.00004541368,0.00013723715,0.000075981436,0.0011279236,0.000041156756,0.00013969225],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99793035,0.00021952941,0.0006459122,0.00047612854,0.00043079036,0.00029730034],"domain_scores_gemma":[0.9980949,0.00052942964,0.00035886816,0.00074471516,0.00016151648,0.00011054328],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038353197,0.00025993394,0.0006975614,0.000070045615,0.00006112456,0.000025288702,0.0001265044,0.0001449172,0.0001231279],"category_scores_gemma":[0.00048785695,0.00017673125,0.00008732459,0.00033324028,0.00012535306,0.00009755734,0.00007725008,0.00026427483,0.000008554975],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008549371,0.021322478,0.69917023,0.0017803984,0.006775113,0.0009702626,0.0064131287,0.001235897,0.045956463,0.003169282,0.00062105164,0.2040363],"study_design_scores_gemma":[0.22520937,0.0032548723,0.7347982,0.0013952769,0.0025814709,0.000061572464,0.00044142312,0.0091050435,0.022147529,0.00020242849,0.0002811998,0.0005216312],"about_ca_topic_score_codex":0.00059815275,"about_ca_topic_score_gemma":0.00092014193,"teacher_disagreement_score":0.21666,"about_ca_system_score_codex":0.002174883,"about_ca_system_score_gemma":0.0023083643,"threshold_uncertainty_score":0.7206891},"labels":[],"label_agreement":null},{"id":"W379374868","doi":"10.1182/blood.v124.21.5527.5527","title":"Impact of Transition to Generic Imatinib in the Molecular Response Among Patients with Chronic Myeloid Leukemia","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University; London Health Sciences Centre","funders":"","keywords":"Imatinib; Imatinib mesylate; Medicine; Myeloid leukemia; Internal medicine; Tyrosine-kinase inhibitor; Oncology; Pharmacology; Cancer","score_opus":0.00601177962925511,"score_gpt":0.23820856781201355,"score_spread":0.23219678818275843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W379374868","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984533,0.00007429722,0.00019800485,0.00008685465,0.000013092858,0.0008890083,0.000015486752,0.00002175528,0.0002481653],"genre_scores_gemma":[0.99914604,0.000004145035,0.0004997054,0.00013669276,0.00003593569,0.00007534239,0.000056767385,0.000030638505,0.000014699335],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985991,0.0002194009,0.00026475536,0.0002491849,0.00038177395,0.000285762],"domain_scores_gemma":[0.9991202,0.00009599912,0.00009142729,0.0005226984,0.00006737331,0.00010231654],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032325642,0.00019042668,0.00030605902,0.00014534297,0.000028675106,0.000009166881,0.00012778351,0.00007133664,0.000042692158],"category_scores_gemma":[0.00009579922,0.000116021605,0.000107525055,0.0004022693,0.000054606717,0.0000556379,0.000015426765,0.00014255293,0.000016339583],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008561622,0.0039728717,0.8399544,0.0003227087,0.0009240067,0.00026251512,0.0076945927,0.00612623,0.121891126,0.000038802125,0.00024928994,0.010001866],"study_design_scores_gemma":[0.014895415,0.004282795,0.9715575,0.00018974663,0.00023026094,0.00002253912,0.000023310253,0.00032137148,0.008319244,0.0000067315923,0.000027641108,0.0001234446],"about_ca_topic_score_codex":0.00039927624,"about_ca_topic_score_gemma":0.00006059075,"teacher_disagreement_score":0.13160314,"about_ca_system_score_codex":0.0009239522,"about_ca_system_score_gemma":0.0005510549,"threshold_uncertainty_score":0.47312236},"labels":[],"label_agreement":null},{"id":"W4200014938","doi":"10.1111/nep.14014","title":"Impact of imatinib treatment on renal function in chronic myeloid leukaemia patients","year":2021,"lang":"en","type":"review","venue":"Nephrology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Sun Pharma; Masarykova Univerzita","keywords":"Medicine; Imatinib; Renal function; Internal medicine; Kidney disease; Imatinib mesylate; Meta-analysis; Tyrosine-kinase inhibitor; Oncology; Myeloid leukemia; Cancer","score_opus":0.03881292250995252,"score_gpt":0.3532272788162848,"score_spread":0.3144143563063323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200014938","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04293037,0.95365334,0.0000021078604,0.00001232773,0.0002449545,0.0019040062,0.00012285737,0.000039709554,0.0010903568],"genre_scores_gemma":[0.002273662,0.99327284,0.00005641946,0.00006386828,0.0003595273,0.0003766627,0.0030414816,0.00010182583,0.00045370034],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99678534,0.00035334803,0.0011240283,0.0008059156,0.00031476753,0.00061657536],"domain_scores_gemma":[0.9978678,0.00028690157,0.0006492677,0.000930701,0.000101203266,0.0001640856],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00011658752,0.00076971704,0.0035997094,0.0005651533,0.000033407257,0.000006948286,0.00013488192,0.00085698767,0.0012721418],"category_scores_gemma":[0.00007787753,0.00054016913,0.0012408264,0.00049874716,0.000102065576,0.00004191796,0.00006969956,0.00058474625,0.00024402168],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00035822202,0.0010845322,0.00095206464,0.0024736328,0.0019494239,0.000176712,0.000045193912,0.000025836158,0.000014253519,0.000025065336,0.001082505,0.9918126],"study_design_scores_gemma":[0.014339531,0.023486838,0.010377036,0.010825612,0.004039298,0.00020687077,0.0000030228855,0.000027374435,0.000012194965,0.000011290869,0.9362127,0.00045818972],"about_ca_topic_score_codex":0.00043907363,"about_ca_topic_score_gemma":0.00013490605,"teacher_disagreement_score":0.99135435,"about_ca_system_score_codex":0.021395642,"about_ca_system_score_gemma":0.0063557494,"threshold_uncertainty_score":0.99970496},"labels":[],"label_agreement":null},{"id":"W4200080912","doi":"10.53350/pjmhs2115113047","title":"Chronic Myeloid Leukemia: Clinico-Hematological Profile from Southern Pakistan","year":2021,"lang":"en","type":"article","venue":"","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Defence Medical Centre","funders":"","keywords":"Medicine; Internal medicine; Myeloid leukemia; Hematology; Chronic leukemia; Myeloid; Leukemia; Gastroenterology; Acute leukemia","score_opus":0.025773457585286784,"score_gpt":0.3080875331823373,"score_spread":0.2823140755970505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200080912","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93228483,0.003431454,0.0002749656,0.0012132331,0.00028945546,0.00053838897,0.00013045242,0.0004277293,0.061409473],"genre_scores_gemma":[0.94996214,0.00016396522,0.0056992164,0.0010061883,0.00078749214,0.00008144145,0.00072547694,0.00006751024,0.041506547],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974489,0.000093329116,0.0006213559,0.0008263939,0.00044821334,0.0005617661],"domain_scores_gemma":[0.9981858,0.0002648945,0.00012334864,0.00095924636,0.00014021932,0.00032650656],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0001273478,0.00034183677,0.00072399445,0.000044803837,0.00010033416,0.000040217565,0.00015411318,0.0003676502,0.028847571],"category_scores_gemma":[0.0001686026,0.00025894676,0.0002918645,0.00024920353,0.00013038426,0.00005896551,0.00017231463,0.00050937966,0.0049934015],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022067497,0.004715519,0.3648764,0.0015974772,0.006072179,0.034863144,0.004540649,0.000062429644,0.21297728,0.011724624,0.09117002,0.26519352],"study_design_scores_gemma":[0.07432285,0.003155784,0.1088611,0.0016284089,0.002291304,0.004009605,0.009938164,0.0045052464,0.49595195,0.0050421716,0.28701743,0.0032759798],"about_ca_topic_score_codex":0.00044215348,"about_ca_topic_score_gemma":0.0003227824,"teacher_disagreement_score":0.28297466,"about_ca_system_score_codex":0.0026754779,"about_ca_system_score_gemma":0.003044242,"threshold_uncertainty_score":0.9999863},"labels":[],"label_agreement":null},{"id":"W4200510398","doi":"10.1182/blood.2021013480","title":"Atypical CML with mutated SRSF2, ASXL1, CSF3R, and MPL","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surrey Memorial Hospital; University of British Columbia","funders":"","keywords":"Medicine; Cancer research; Genetics; Biology","score_opus":0.009673645310568203,"score_gpt":0.23843839772295145,"score_spread":0.22876475241238325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200510398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920482,0.0012625019,0.000022212387,0.00074340444,0.000034538112,0.00017221701,0.000007452066,0.00007670673,0.0056327623],"genre_scores_gemma":[0.99349797,0.00009575125,0.0032979953,0.00039398152,0.000101839585,0.000015442925,0.000069264075,0.00002630288,0.002501439],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991363,0.000024814923,0.00013266993,0.0002951893,0.00018969877,0.00022129716],"domain_scores_gemma":[0.9993994,0.000044432174,0.000030218094,0.0002877824,0.000067317014,0.00017085235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000038282426,0.0001337249,0.00023902536,0.000029314431,0.000043929227,0.000015874124,0.000030210296,0.00007653675,0.0003587002],"category_scores_gemma":[0.00006299134,0.0001007959,0.000033364995,0.00015735798,0.00006201838,0.00003314978,0.000042045267,0.00014539741,0.00007226995],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021644637,0.008267051,0.86531425,0.00073162816,0.00435422,0.037002925,0.0016563055,0.0000056221047,0.04967089,0.0013523186,0.006350416,0.023129899],"study_design_scores_gemma":[0.08261637,0.0020518168,0.68410397,0.00066721364,0.0030914373,0.014782812,0.00043207797,0.00016053776,0.18200696,0.00022597337,0.029227292,0.00063355855],"about_ca_topic_score_codex":0.000028006762,"about_ca_topic_score_gemma":0.000046528265,"teacher_disagreement_score":0.1812103,"about_ca_system_score_codex":0.000057776317,"about_ca_system_score_gemma":0.0003596517,"threshold_uncertainty_score":0.41103375},"labels":[],"label_agreement":null},{"id":"W4210611834","doi":"10.3410/f.1002209.201474","title":"Faculty Opinions recommendation of Requirement for Ras guanine nucleotide releasing protein 3 in coupling phospholipase C-gamma2 to Ras in B cell receptor signaling.","year":2004,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Uehara Memorial Foundation","keywords":"Guanine nucleotide exchange factor; Phospholipase C; Gq alpha subunit; Cell biology; Signal transduction; Receptor; Biology; G protein; Chemistry; Biochemistry","score_opus":0.03584786830958069,"score_gpt":0.3541042029164237,"score_spread":0.318256334606843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210611834","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014054298,0.0011009938,0.00006134695,0.12021754,0.00048752467,0.007993229,0.8699475,0.00003634781,0.000014974038],"genre_scores_gemma":[0.00014414576,0.00028450153,0.007242488,0.0027270173,0.0002690316,0.0014269344,0.9871239,0.00006999837,0.00071199995],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9936914,0.00022761802,0.0028570313,0.0010787143,0.0015008068,0.00064443366],"domain_scores_gemma":[0.9929168,0.0001909789,0.0016820413,0.0014945576,0.0032644258,0.00045119488],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018918057,0.00073815417,0.0016306584,0.0008032268,0.00014353082,0.00007822335,0.00095790747,0.000757315,0.00041099402],"category_scores_gemma":[0.00869643,0.0005465874,0.000597824,0.0027753657,0.0001759132,0.00026712398,0.00035965513,0.0012181911,0.000046700632],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022786592,0.0013570257,0.00001961382,0.01625761,0.00010627715,0.0000020454759,0.00025046177,0.0000075714624,0.00022138482,0.000056223835,0.9803518,0.0011421255],"study_design_scores_gemma":[0.005817397,0.00048254876,0.00039264042,0.05860791,0.00020649674,0.00001429858,0.000069939524,0.000042577532,0.0011338233,0.00001321647,0.9328061,0.00041310454],"about_ca_topic_score_codex":0.00041891678,"about_ca_topic_score_gemma":0.000035716184,"teacher_disagreement_score":0.11749052,"about_ca_system_score_codex":0.0024480366,"about_ca_system_score_gemma":0.002248057,"threshold_uncertainty_score":0.9996986},"labels":[],"label_agreement":null},{"id":"W4210768949","doi":"10.1007/s00277-021-04741-3","title":"Successful treatment of imatinib-induced periorbital edema with a sodium-glucose cotransporter-2 inhibitor","year":2022,"lang":"en","type":"letter","venue":"Annals of Hematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Imatinib; Medicine; Hematology; Edema; Cotransporter; Internal medicine; Pharmacology; Sodium; Chemistry","score_opus":0.04498074340292752,"score_gpt":0.3127137283626949,"score_spread":0.2677329849597674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210768949","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87257636,0.0024967836,0.0000024173416,0.12158577,0.00026615866,0.0014004369,0.00041717332,0.00006977432,0.0011851212],"genre_scores_gemma":[0.94427097,0.00071862194,0.00047771688,0.049465064,0.0007051614,0.0005931637,0.002797514,0.00022424165,0.0007475755],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9962601,0.0001553343,0.001260578,0.0008167712,0.0007643772,0.00074283755],"domain_scores_gemma":[0.99714446,0.00026947184,0.0010848079,0.0011458772,0.00020657897,0.00014881615],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000079230354,0.0007746456,0.002960183,0.0004573314,0.00007833162,0.000007466695,0.0002742999,0.0007995682,0.0018389184],"category_scores_gemma":[0.000026325037,0.00059645623,0.00061741733,0.00024037846,0.00034788594,0.00007352611,0.00006020809,0.0007281161,0.000027901435],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015189282,0.0127475895,0.1145979,0.024984598,0.022053577,0.10303284,0.007965365,0.0000053441527,0.01893435,0.0004949235,0.67396,0.006034236],"study_design_scores_gemma":[0.029318497,0.046364404,0.0033918745,0.0022886905,0.0039553875,0.01392892,0.00069014035,0.000026831734,0.64776343,0.00010713013,0.2504263,0.0017384097],"about_ca_topic_score_codex":0.00054168154,"about_ca_topic_score_gemma":0.000055570123,"teacher_disagreement_score":0.62882906,"about_ca_system_score_codex":0.00024318771,"about_ca_system_score_gemma":0.0012650362,"threshold_uncertainty_score":0.9996487},"labels":[],"label_agreement":null},{"id":"W4210927728","doi":"10.1007/978-3-642-16483-5_2209","title":"Flow Cytometry","year":2011,"lang":"en","type":"book-chapter","venue":"","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal University Hospital; University of Saskatchewan","funders":"","keywords":"Flow (mathematics); Computer science; Mechanics; Physics","score_opus":0.03544455741695187,"score_gpt":0.2599059440475375,"score_spread":0.2244613866305856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210927728","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000032721884,0.0010048163,0.00011774327,0.00007655765,0.00025115674,0.00037719347,0.000022498376,0.00018900954,0.9979283],"genre_scores_gemma":[0.0016533041,0.0004929073,0.003017169,0.0005509096,0.0004004043,0.000007934053,0.00017945484,0.00011346514,0.99358445],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99882865,0.0000025734817,0.00025393677,0.00038825194,0.00030339626,0.00022317035],"domain_scores_gemma":[0.9989066,0.000027249822,0.00008460248,0.0007118265,0.00006537677,0.00020430874],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000046279147,0.00035356672,0.00054248894,0.00022718242,0.000023819282,0.000005727999,0.00009182859,0.00047719138,0.066101626],"category_scores_gemma":[0.0000149024445,0.000274914,0.0002462769,0.000020377416,0.00006329629,0.000023597157,0.00007232681,0.0003807462,0.010775601],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005658159,0.0003282997,0.00068011764,0.0009325527,0.0048137475,0.004798341,0.00026626943,4.294081e-7,0.00012964722,0.20727666,0.38136157,0.39884657],"study_design_scores_gemma":[0.0024089457,0.00033576664,0.0002467717,0.00040716885,0.00071078935,0.00039047695,0.0000021148674,0.000023279908,0.00027622885,0.0048922813,0.9899389,0.00036723836],"about_ca_topic_score_codex":0.000037709702,"about_ca_topic_score_gemma":0.0000097941465,"teacher_disagreement_score":0.6085774,"about_ca_system_score_codex":0.00085509237,"about_ca_system_score_gemma":0.0003968139,"threshold_uncertainty_score":0.9999703},"labels":[],"label_agreement":null},{"id":"W4214752487","doi":"10.1016/s2152-2650(21)01456-7","title":"Poster: MPN-356: Transfusion Independence is Associated with Improved Overall Survival in Myelofibrosis Patients Receiving Momelotinib","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sierra Wireless (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Myelofibrosis; Medicine; Independence (probability theory); Internal medicine; Oncology; Statistics","score_opus":0.022652808920628105,"score_gpt":0.28902741310178715,"score_spread":0.26637460418115905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214752487","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99284935,0.00025772507,0.000023149392,0.0006330121,0.0008184409,0.0011230153,0.000110319175,0.00025212578,0.003932867],"genre_scores_gemma":[0.99346876,0.0005434907,0.0006181322,0.0019905844,0.00025565806,0.00008655013,0.0006189613,0.0001864216,0.0022314398],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99234164,0.00068531645,0.0022109528,0.0019680965,0.0014741167,0.0013198814],"domain_scores_gemma":[0.9948905,0.001533962,0.00062665896,0.001379909,0.00080623094,0.0007627214],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011800734,0.0008527955,0.0019527043,0.00024173866,0.00021187522,0.000115077106,0.00044559556,0.0011937645,0.00052846014],"category_scores_gemma":[0.0024793716,0.0007631235,0.00060100644,0.0011596623,0.00030643572,0.0004375177,0.00032073059,0.0009922256,0.00015557668],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002359454,0.0016675817,0.79531217,0.00011327798,0.00052876107,0.0011617193,0.0005387781,0.0000047227268,0.0019470784,0.000013523762,0.00041235995,0.19594057],"study_design_scores_gemma":[0.03718366,0.0016776555,0.95273185,0.0014909431,0.00034575307,0.00011622945,0.000098639626,0.000660267,0.0043320428,0.000068210524,0.0005371064,0.00075761875],"about_ca_topic_score_codex":0.00079597614,"about_ca_topic_score_gemma":0.0012608048,"teacher_disagreement_score":0.19518295,"about_ca_system_score_codex":0.0071831625,"about_ca_system_score_gemma":0.0053526885,"threshold_uncertainty_score":0.999482},"labels":[],"label_agreement":null},{"id":"W4220676413","doi":"10.2174/2772432817666220315144253","title":"Prevalence of Anemia among Chronic Myeloid Leukemia Patients Treatedwith Imatinib: A Evidence-based Meta-analysis","year":2022,"lang":"en","type":"review","venue":"Current Reviews in Clinical and Experimental Pharmacology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Imatinib; Medicine; Myeloid leukemia; Anemia; Internal medicine; Meta-analysis; Leukemia; Oncology","score_opus":0.3101556714185251,"score_gpt":0.5030926407337178,"score_spread":0.19293696931519272,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220676413","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006377471,0.9865872,0.000001979582,0.00001523983,0.0007634368,0.0059843077,0.00017782564,0.000036611105,0.0000558928],"genre_scores_gemma":[0.002377175,0.992115,0.00013467566,0.00010922141,0.00021302309,0.0042758672,0.0005247257,0.000072119394,0.00017817625],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98855823,0.003148668,0.005206853,0.0017938544,0.00062768994,0.0006647104],"domain_scores_gemma":[0.993708,0.0020991063,0.0027187432,0.0009388835,0.000068904126,0.0004663769],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018937434,0.0011632227,0.0115605835,0.00063812075,0.000098472985,0.000015351037,0.0006158059,0.00044078808,0.012471049],"category_scores_gemma":[0.0003997621,0.0007864225,0.0060221553,0.0013948609,0.0008710864,0.00016921209,0.0005468954,0.0017880516,0.00005461176],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034506054,0.0040228968,0.014760754,0.12288768,0.036643364,0.000093444876,0.000091628564,0.000011113661,0.000003869348,0.0000027401395,0.0019719594,0.81916547],"study_design_scores_gemma":[0.005332939,0.0018358153,0.0006312051,0.00892434,0.48368183,0.000017137607,0.000006003752,0.00014568966,0.000053907996,0.0000014559156,0.49866655,0.0007031231],"about_ca_topic_score_codex":0.00007954951,"about_ca_topic_score_gemma":0.00000513844,"teacher_disagreement_score":0.8184624,"about_ca_system_score_codex":0.0031835628,"about_ca_system_score_gemma":0.001884337,"threshold_uncertainty_score":0.9994587},"labels":[],"label_agreement":null},{"id":"W4226156891","doi":"10.3390/cancers13246263","title":"Comparison of the Transcriptomic Signatures in Pediatric and Adult CML","year":2021,"lang":"en","type":"article","venue":"Cancers","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"National Institutes of Health; U.S. Department of Veterans Affairs","keywords":"CD34; Transcriptome; Medicine; Downregulation and upregulation; Hematology; Immunology; Cancer research; Biology; Stem cell; Gene; Gene expression; Cell biology; Genetics","score_opus":0.01582570088843122,"score_gpt":0.2944113162082035,"score_spread":0.2785856153197723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226156891","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878401,0.009993539,0.0000023166242,0.00042710055,0.00014034884,0.00013427477,0.0000061529513,0.000006410029,0.0014497557],"genre_scores_gemma":[0.9986314,0.00063120585,0.000053606494,0.00028285096,0.000051540388,0.000008077042,0.0000036225663,0.00000709348,0.00033058083],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995076,0.000020834623,0.00013136293,0.00012926833,0.00010908266,0.0001018674],"domain_scores_gemma":[0.9997066,0.00003582777,0.000037122765,0.00015091432,0.00003424065,0.0000352884],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000023122495,0.00006320345,0.00018307164,0.000028530498,0.0000147829505,0.000002278783,0.000037765436,0.000049943228,0.00006812244],"category_scores_gemma":[0.000051611652,0.000045293218,0.000039394792,0.00019194046,0.000039902545,0.000014765797,0.000011324952,0.00014175379,8.3229185e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001138154,0.000048753423,0.98032874,0.00033438773,0.000051394694,0.000028431949,0.0024053613,0.00083582883,0.00603558,0.000113062415,0.0070961984,0.0026084199],"study_design_scores_gemma":[0.00875672,0.00013484278,0.9250233,0.00022268134,0.00035050418,0.000015149933,0.0012438638,0.0026329122,0.05880402,0.000054892902,0.0026127119,0.00014839611],"about_ca_topic_score_codex":0.0002679546,"about_ca_topic_score_gemma":0.00079993694,"teacher_disagreement_score":0.055305462,"about_ca_system_score_codex":0.0009778701,"about_ca_system_score_gemma":0.0009744134,"threshold_uncertainty_score":0.25570962},"labels":[],"label_agreement":null},{"id":"W4229060960","doi":"10.1016/j.blre.2022.100968","title":"Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option","year":2022,"lang":"en","type":"review","venue":"Blood Reviews","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Myeloid leukemia; Concomitant; Adverse effect; Intensive care medicine; Tyrosine kinase; Oncology; Internal medicine; Disease","score_opus":0.07664484915171133,"score_gpt":0.36463835381373755,"score_spread":0.2879935046620262,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229060960","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007013034,0.9738518,0.000012090542,0.00028643117,0.0004998732,0.024652544,0.00042324906,0.00007122498,0.00013268141],"genre_scores_gemma":[6.8633574e-7,0.982856,0.0018574164,0.00087851647,0.00081048714,0.005999871,0.005276534,0.00029061994,0.0020299028],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9910328,0.00090502197,0.004355351,0.0019590587,0.00083373336,0.0009140675],"domain_scores_gemma":[0.99254096,0.00030841198,0.0021729341,0.004184954,0.00013341555,0.00065935566],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0018007064,0.0016361432,0.00864916,0.00063759205,0.00015854748,0.000055372017,0.00094665424,0.00058268016,0.0025493437],"category_scores_gemma":[0.0007995756,0.0011995444,0.0024955051,0.001108073,0.00008506287,0.00045366964,0.0004851906,0.0006944352,0.000129131],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009830519,0.0005367448,0.000011254288,0.27652535,0.000285118,0.000086700944,0.00009522771,2.74443e-7,0.00003190908,0.000004460792,0.003113698,0.719211],"study_design_scores_gemma":[0.004290928,0.0020623924,0.000009665772,0.3736549,0.0072575063,0.00016593318,0.0000061978767,0.0000016854403,0.00014975239,0.0000023485377,0.611863,0.00053568935],"about_ca_topic_score_codex":0.00015401078,"about_ca_topic_score_gemma":0.00010434608,"teacher_disagreement_score":0.71867526,"about_ca_system_score_codex":0.020347925,"about_ca_system_score_gemma":0.00548613,"threshold_uncertainty_score":0.9996386},"labels":[],"label_agreement":null},{"id":"W4232110292","doi":"10.3410/f.13293959.14653062","title":"Faculty Opinions recommendation of Rho kinase regulates the survival and transformation of cells bearing oncogenic forms of KIT, FLT3, and BCR-ABL.","year":2011,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Metropolitan University","funders":"","keywords":"Transformation (genetics); Bearing (navigation); Cancer research; ABL; Kinase; Cell biology; Chemistry; Biology; Computer science; Genetics; Gene; Tyrosine kinase; Signal transduction; Artificial intelligence","score_opus":0.0335301785181776,"score_gpt":0.3266211443350005,"score_spread":0.2930909658168229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4232110292","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022174047,0.002595733,0.000013331769,0.028747423,0.00031075638,0.002026411,0.9659934,0.000015779797,0.00007539777],"genre_scores_gemma":[0.00082038663,0.0025797666,0.00041366142,0.0003107882,0.00007959804,0.000096550444,0.9954593,0.000023804689,0.00021612336],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962149,0.0002769918,0.0017701903,0.00044862676,0.0010202139,0.00026903496],"domain_scores_gemma":[0.9943166,0.00021083617,0.0016886853,0.0011247474,0.002440915,0.00021826691],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014109617,0.00044582444,0.0011871926,0.000299751,0.0001405492,0.000032291053,0.0005794672,0.000543996,0.00015190754],"category_scores_gemma":[0.0014768253,0.0002455058,0.00042475964,0.0009822485,0.000578933,0.0003093203,0.00026637802,0.00065595174,0.0000037897146],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000074350835,0.00039182452,0.000029431712,0.017328365,0.00040058445,2.1505818e-7,0.00066418987,8.125494e-8,0.000079879144,0.00028476407,0.9732898,0.0074565024],"study_design_scores_gemma":[0.0020998425,0.00034552635,0.005409425,0.011699919,0.00075175025,0.00005557309,0.00012036133,0.000019950297,0.0013042546,0.000039703977,0.97795063,0.00020308571],"about_ca_topic_score_codex":0.00020698649,"about_ca_topic_score_gemma":0.000014845695,"teacher_disagreement_score":0.029465893,"about_ca_system_score_codex":0.00014959811,"about_ca_system_score_gemma":0.0005355118,"threshold_uncertainty_score":0.9999997},"labels":[],"label_agreement":null},{"id":"W4232777221","doi":"10.3747/co.v18i2.897","title":"E-Manuscript Article Summaries","year":2011,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Data science; Information retrieval; Computer science","score_opus":0.1897963577858121,"score_gpt":0.3832508126657494,"score_spread":0.1934544548799373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4232777221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9239196,0.0020676241,0.000086601685,0.00039879535,0.0015234087,0.00032656264,0.000006344235,0.00013487723,0.07153618],"genre_scores_gemma":[0.9967762,0.00018139767,0.001137639,0.00022735247,0.00023606258,0.000057424153,0.00003079119,0.000018278093,0.0013348365],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99907947,0.000043691856,0.00021224428,0.00023022082,0.000119650154,0.00031474986],"domain_scores_gemma":[0.9993706,0.000039988605,0.00005914685,0.00029198176,0.00006645799,0.00017182413],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00009763629,0.00012448257,0.0002674591,0.000062915686,0.00004849254,0.0000041031553,0.00007677476,0.00008898698,0.0024363578],"category_scores_gemma":[0.000097330805,0.00010325439,0.00007506014,0.00010460733,0.00014583764,0.000058292997,0.000062320796,0.0002028534,0.0011852988],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00074250315,0.003511096,0.43419752,0.00014879266,0.0002246285,0.00044115732,0.0045163496,2.1035473e-7,0.0014914249,0.0050458782,0.07215145,0.477529],"study_design_scores_gemma":[0.0055223433,0.0011703656,0.18576811,0.000056403293,0.00025579912,0.00020269061,0.00027024111,0.00012399637,0.006938363,0.0010812029,0.79844177,0.00016873099],"about_ca_topic_score_codex":0.000050379396,"about_ca_topic_score_gemma":0.00003928819,"teacher_disagreement_score":0.7262903,"about_ca_system_score_codex":0.0006874452,"about_ca_system_score_gemma":0.00035097846,"threshold_uncertainty_score":0.9995924},"labels":[],"label_agreement":null},{"id":"W4233076394","doi":"10.1016/j.exphem.2018.06.080","title":"Targeting the Process of C-MYC Stabilization in Chronic Myelogenous Leukemia","year":2018,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Chronic myelogenous leukemia; Myeloid leukemia; Cancer research; Oncogene; K562 cells; Leukemia; Tyrosine kinase; Medicine; Myeloid; Chromosomal translocation; Cancer; Immunology; Biology; Cell cycle; Internal medicine; Receptor; Gene","score_opus":0.014564940289407422,"score_gpt":0.3170537806899096,"score_spread":0.30248884040050217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4233076394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98875475,0.008050626,0.00005002071,0.000099736375,0.0001505563,0.00065922795,0.00000213019,0.00003891662,0.0021940556],"genre_scores_gemma":[0.99928284,0.000022040991,0.00022743063,0.00010008072,0.00012859527,0.00010018777,0.000029929759,0.000026099608,0.0000828058],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987371,0.000062670166,0.0004081601,0.00028338586,0.00018238758,0.00032632772],"domain_scores_gemma":[0.99938476,0.000061779734,0.00013956502,0.00029576707,0.00006759647,0.000050516872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001303932,0.00016046014,0.00035892575,0.00008237187,0.00007768321,0.0000036175538,0.00013155979,0.000115143564,0.00055420917],"category_scores_gemma":[0.000056161403,0.00011602296,0.000047842022,0.00025254628,0.0003844182,0.000056441582,0.00006363708,0.00012788553,0.00006362841],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017118431,0.0018495286,0.13490401,0.0011723978,0.00037277894,0.0003468092,0.045951556,0.000278421,0.78237367,0.026734168,0.0016161336,0.0026886736],"study_design_scores_gemma":[0.0028892658,0.0008475362,0.0012615656,0.000110321176,0.00002001196,0.00034241678,0.002810993,0.0020984586,0.9891625,0.000088872795,0.00025978283,0.00010824331],"about_ca_topic_score_codex":0.00016789239,"about_ca_topic_score_gemma":0.000062314524,"teacher_disagreement_score":0.20678885,"about_ca_system_score_codex":0.0021832064,"about_ca_system_score_gemma":0.0008151312,"threshold_uncertainty_score":0.60682017},"labels":[],"label_agreement":null},{"id":"W4233315542","doi":"10.1016/j.jval.2020.10.007","title":"Cost-Effectiveness of First-Line Tyrosine Kinase Inhibitor Therapy Initiation Strategies for Chronic Myeloid Leukemia","year":2020,"lang":"en","type":"article","venue":"Value in Health","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada; Genentech; University of North Carolina at Chapel Hill; Agency for Healthcare Research and Quality; Cecil G. Sheps Center for Health Services Research, University of North Carolina, Chapel Hill; National Institutes of Health; Arnold Ventures; Leukemia and Lymphoma Society; American Foundation for Pharmaceutical Education; GlaxoSmithKline; Pfizer; Commonwealth Fund","keywords":"Myeloid leukemia; Tyrosine-kinase inhibitor; Tyrosine kinase; Medicine; Cancer research; Oncology; Pharmacology; Internal medicine; Receptor; Cancer","score_opus":0.10672761659228684,"score_gpt":0.3530499165824488,"score_spread":0.24632229999016192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4233315542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836706,0.0058360402,0.0024363194,0.0025022742,0.00021160342,0.005056632,0.00010702707,0.00008697325,0.00009251278],"genre_scores_gemma":[0.9954153,0.0021545154,0.000753567,0.00048381268,0.00043912715,0.00043000132,0.00026360477,0.000051726947,0.000008379863],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99802494,0.00022556756,0.00065342244,0.0004120692,0.0002721702,0.00041181184],"domain_scores_gemma":[0.9985476,0.00056545757,0.0002668452,0.00027490297,0.00013100491,0.00021416429],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000634584,0.0002440433,0.00066154526,0.00012858016,0.000072181196,0.000013518789,0.00009476959,0.00013254936,0.00003762165],"category_scores_gemma":[0.00021289714,0.00022130032,0.00011327817,0.0004321649,0.00006658212,0.00015134539,0.000026385975,0.00023124758,0.00000808349],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04535718,0.0052218135,0.112431504,0.10606311,0.0011698992,0.00031837198,0.02246134,0.35982338,0.11119703,0.015392374,0.0031573977,0.21740659],"study_design_scores_gemma":[0.18859407,0.05112244,0.16673803,0.014397249,0.00023271238,0.00008813595,0.0016917543,0.2830597,0.2624295,0.0041871453,0.025845826,0.0016134422],"about_ca_topic_score_codex":0.0019499969,"about_ca_topic_score_gemma":0.00009800403,"teacher_disagreement_score":0.21579315,"about_ca_system_score_codex":0.0046771574,"about_ca_system_score_gemma":0.0047867196,"threshold_uncertainty_score":0.9991437},"labels":[],"label_agreement":null},{"id":"W4233331803","doi":"10.4081/oncol.2008.67","title":"The role of Lyn kinase in the development of imatinib resistance in chronic myelogenous leukemia","year":2011,"lang":"en","type":"article","venue":"Oncology Reviews","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Medicine; Chronic myelogenous leukemia; Imatinib; Imatinib mesylate; LYN; Nilotinib; Tyrosine kinase; Tolerability; Tyrosine-kinase inhibitor; Pharmacology; Leukemia; Cancer research; Internal medicine; Myeloid leukemia; Adverse effect; Receptor; Cancer","score_opus":0.051505346163130294,"score_gpt":0.3226476964549519,"score_spread":0.2711423502918216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4233331803","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7527068,0.1752181,0.0000068948802,0.00018565326,0.00007829994,0.0023583525,0.0000028053028,0.000008722271,0.069434345],"genre_scores_gemma":[0.96786934,0.018412879,0.012192521,0.00018834049,0.000049430233,0.00070316374,0.000013713065,0.000023401924,0.0005472044],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977252,0.00043333773,0.0011469699,0.0002176786,0.00016511985,0.00031168247],"domain_scores_gemma":[0.99852586,0.0002734388,0.0004905131,0.000628938,0.000043056603,0.00003818308],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020559253,0.0001672688,0.00076363777,0.00007086937,0.00005454704,0.0000015873637,0.00034515627,0.00012148209,0.00009034944],"category_scores_gemma":[0.00024745168,0.000089236004,0.000095976604,0.00032611404,0.0002009943,0.000026246944,0.00006196747,0.00026770192,0.000049406546],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00078629825,0.0009995154,0.032433905,0.0012605932,0.00014699696,0.0001636664,0.044370018,0.000001526529,0.010952832,0.00242187,0.0011351901,0.90532756],"study_design_scores_gemma":[0.0045035584,0.00068752206,0.11644789,0.0013472823,0.00012822411,0.00004989694,0.0011393656,0.00001822601,0.009140472,0.00077399146,0.8655925,0.00017108317],"about_ca_topic_score_codex":0.0001510937,"about_ca_topic_score_gemma":0.01192294,"teacher_disagreement_score":0.9051565,"about_ca_system_score_codex":0.0036507018,"about_ca_system_score_gemma":0.0032994533,"threshold_uncertainty_score":0.9546458},"labels":[],"label_agreement":null},{"id":"W4233476122","doi":"10.1182/blood.v112.11.4223.4223","title":"Genetic Variants in the Candidate Genes of the Apoptosis Pathway and Susceptibility to Chronic Myeloid Leukemia","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Biology; Myeloid leukemia; Cancer research; Single-nucleotide polymorphism; Imatinib mesylate; Immunology; Leukemia; Haplotype; Genetics; Allele; Imatinib; Gene; Genotype","score_opus":0.013840683967377908,"score_gpt":0.23330502280869672,"score_spread":0.2194643388413188,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4233476122","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99658585,0.0015019114,0.0000066808598,0.0003496461,0.00006344171,0.0008653382,0.00002358255,0.000015092017,0.00058845023],"genre_scores_gemma":[0.9985668,0.00046849134,0.00035164002,0.000259902,0.000111412555,0.00005948435,0.0000045170036,0.000018325618,0.00015944519],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985729,0.00012511028,0.00031378362,0.00033820193,0.00034203436,0.00030795808],"domain_scores_gemma":[0.99888194,0.00008595968,0.000079273814,0.00082229165,0.000039903207,0.00009062855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022717712,0.00018030545,0.00031010163,0.00005740542,0.0001072525,0.000007765678,0.00024818844,0.00008360154,0.000054211137],"category_scores_gemma":[0.00008897742,0.00010207633,0.00007682385,0.0003374547,0.00015445995,0.00002930893,0.00012266905,0.00016637998,0.000013262397],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000100482386,0.0006874643,0.8922403,0.00021360803,0.00019686585,0.00009747063,0.003866147,0.000056279743,0.09276591,0.00003238835,0.0002784611,0.009464633],"study_design_scores_gemma":[0.0048572137,0.00034243887,0.9316441,0.00009554929,0.00015726787,0.00025654782,0.000099814075,0.00003994031,0.06181996,0.000025405952,0.000551787,0.00011000613],"about_ca_topic_score_codex":0.0015563346,"about_ca_topic_score_gemma":0.0012228288,"teacher_disagreement_score":0.039403785,"about_ca_system_score_codex":0.00051146187,"about_ca_system_score_gemma":0.0010665482,"threshold_uncertainty_score":0.4162552},"labels":[],"label_agreement":null},{"id":"W4236828037","doi":"10.3410/f.726082355.793515567","title":"Faculty Opinions recommendation of Kinase Inhibitor Profiling Reveals Unexpected Opportunities to Inhibit Disease-Associated Mutant Kinases.","year":2016,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Kinase; Profiling (computer programming); Mutant; Computational biology; Chemistry; Cell biology; Biology; Biochemistry; Computer science; Gene","score_opus":0.0541460450060235,"score_gpt":0.3541463516860888,"score_spread":0.30000030668006533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4236828037","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000037686368,0.0009746702,0.00000600311,0.20830171,0.0007780976,0.0036324079,0.78613347,0.00009246137,0.00004348727],"genre_scores_gemma":[0.00010888533,0.0005601488,0.0003402584,0.006194545,0.0004875117,0.00081069506,0.98863584,0.000074256764,0.002787886],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99249566,0.0006756852,0.00266476,0.001095331,0.0023973803,0.000671197],"domain_scores_gemma":[0.98548317,0.00028149813,0.0023069882,0.0022193608,0.008550821,0.0011581464],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013766431,0.0009150319,0.0018315518,0.00076670427,0.00027624975,0.000104692605,0.0010678913,0.0008436267,0.00072141347],"category_scores_gemma":[0.021243455,0.0005636316,0.0009431579,0.0021157851,0.00036229787,0.00034534704,0.0006865747,0.0010390896,0.00007320976],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011208547,0.0010555731,0.000037311594,0.009860541,0.00042762398,0.000008840724,0.00009595786,3.3263095e-8,0.000047072535,0.00009727941,0.98601294,0.002244766],"study_design_scores_gemma":[0.00254859,0.00035329675,0.0018734124,0.059057962,0.0007885878,0.00004263854,0.000052712545,0.000002827732,0.00025641083,0.00001807485,0.93451464,0.000490851],"about_ca_topic_score_codex":0.00006845579,"about_ca_topic_score_gemma":0.000008190672,"teacher_disagreement_score":0.20250234,"about_ca_system_score_codex":0.0015113876,"about_ca_system_score_gemma":0.0030906722,"threshold_uncertainty_score":0.99968153},"labels":[],"label_agreement":null},{"id":"W4238562456","doi":"10.21203/rs.3.rs-63583/v3","title":"Analysis of the Gap in PCR Monitoring Availability for Patients with Chronic Myeloid Leukemia in 60 Low- and Middle-Income Countries","year":2021,"lang":"en","type":"preprint","venue":"Research Square","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Max Bell Foundation","funders":"University of Washington; Incyte; Amgen","keywords":"GeneXpert MTB/RIF; Medicine; Business; Tuberculosis","score_opus":0.04245811355364231,"score_gpt":0.3451072824243636,"score_spread":0.3026491688707213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4238562456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928721,0.0028781854,0.0000038010876,0.00012784521,0.00010531514,0.0036782005,0.00023924008,0.000016231681,0.00007908931],"genre_scores_gemma":[0.9975286,0.0009548658,0.00017887399,0.0000046582722,0.00008928434,0.0007296413,0.00027097398,0.000048443722,0.000194633],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995345,0.0004650743,0.0007678643,0.0010293609,0.0015894428,0.00080327893],"domain_scores_gemma":[0.9959824,0.001005099,0.00023332369,0.0015533055,0.0010540074,0.0001718682],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015986391,0.00037604012,0.0012355291,0.0010126648,0.00011468681,0.00007528377,0.00037552198,0.00040207966,0.00009314092],"category_scores_gemma":[0.001125702,0.00026857143,0.00026939568,0.0019588463,0.00045145364,0.00009628048,0.0010086499,0.0015111244,0.0000018941813],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00067141035,0.00023774881,0.98355937,0.011634339,0.00080415735,0.000041559953,0.001121509,0.0014691374,0.000019497396,0.0000053701656,0.0000030858505,0.0004328018],"study_design_scores_gemma":[0.005235457,0.00039565726,0.97592753,0.014220098,0.0004087064,9.794753e-7,0.00042592976,0.0023902697,0.0007393207,0.000029349607,0.000027673805,0.00019902305],"about_ca_topic_score_codex":0.004590861,"about_ca_topic_score_gemma":0.0070725153,"teacher_disagreement_score":0.01231392,"about_ca_system_score_codex":0.019122917,"about_ca_system_score_gemma":0.0068089967,"threshold_uncertainty_score":0.99997663},"labels":[],"label_agreement":null},{"id":"W4240317535","doi":"10.3410/f.737946788.793583304","title":"Faculty Opinions recommendation of Integrin-Linked Kinase Mediates Therapeutic Resistance of Quiescent CML Stem Cells to Tyrosine Kinase Inhibitors.","year":2021,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Stem cell; Tyrosine kinase; Integrin-linked kinase; Cancer research; Population; Biology; Myeloid leukemia; Medicine; Kinase; Cell biology; Signal transduction; Protein kinase A","score_opus":0.034603989741227185,"score_gpt":0.3405131079862931,"score_spread":0.3059091182450659,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4240317535","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000015190806,0.0076285983,0.000019128287,0.13603784,0.0013127271,0.002608611,0.85231394,0.000039212202,0.000024749934],"genre_scores_gemma":[0.000098690245,0.0017318398,0.0010152819,0.0038431964,0.000380141,0.00035151414,0.9906155,0.000057366928,0.001906476],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9929201,0.0006135214,0.0027520063,0.00101899,0.0021875193,0.00050784403],"domain_scores_gemma":[0.98714083,0.00030084755,0.0021694223,0.0024999285,0.0073049213,0.00058407465],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012876145,0.00081479724,0.0020074337,0.0005481098,0.00015007527,0.00007453998,0.0012043316,0.0008563013,0.00048357673],"category_scores_gemma":[0.003428905,0.0005357101,0.00092209585,0.003080716,0.00041795746,0.00020424642,0.00061750645,0.0012958389,0.000046825262],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010900818,0.0012711788,0.000012150612,0.019536337,0.0004236911,0.000002988333,0.00023621065,1.6982483e-7,0.00018228748,0.00007032064,0.9741369,0.004018767],"study_design_scores_gemma":[0.0021330141,0.00031525848,0.0007851579,0.04346411,0.00068010687,0.000023959574,0.00010185895,0.000003965368,0.0029768257,0.000006032185,0.9491346,0.00037512355],"about_ca_topic_score_codex":0.00010518767,"about_ca_topic_score_gemma":0.000032786527,"teacher_disagreement_score":0.13830155,"about_ca_system_score_codex":0.0008877925,"about_ca_system_score_gemma":0.001968612,"threshold_uncertainty_score":0.9997094},"labels":[],"label_agreement":null},{"id":"W4243597295","doi":"10.3410/f.4106956.3885054","title":"Faculty Opinions recommendation of Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate.","year":2010,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Imatinib mesylate; Chronic myelogenous leukemia; Histone deacetylase; Imatinib; Medicine; Leukemia; Cancer research; Mesylate; Pharmacology; Histone; Chemistry; Immunology; Biology; Genetics; DNA","score_opus":0.01185811671037626,"score_gpt":0.3122807084977688,"score_spread":0.3004225917873925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4243597295","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00026889713,0.0033480478,0.00002130977,0.02330059,0.0006661392,0.004945905,0.9673893,0.000038158327,0.000021681533],"genre_scores_gemma":[0.00056971016,0.0006249163,0.0005861095,0.0004923006,0.0001522004,0.00051979366,0.99669224,0.000057134526,0.00030561315],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99394286,0.00059517985,0.0023765438,0.0008538196,0.0017374307,0.00049416913],"domain_scores_gemma":[0.9909502,0.00028576117,0.0030990427,0.0013646721,0.0039801723,0.00032012377],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016250085,0.00075370073,0.0017959084,0.0005607538,0.00015668341,0.00004058359,0.00081923977,0.0010283693,0.00019276231],"category_scores_gemma":[0.0017780863,0.0004956614,0.0005057918,0.0020542804,0.0005497856,0.00027550894,0.00032361495,0.001928536,0.000018951043],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010394268,0.0011494816,0.000021166908,0.017983628,0.00029042302,0.0000014708555,0.0003013707,8.057954e-7,0.00036302643,0.000018972712,0.97232014,0.0074455985],"study_design_scores_gemma":[0.0052984906,0.0009760594,0.0007198631,0.02418581,0.0004838157,0.00005114411,0.00005755648,0.000034083154,0.0057078204,0.0000028907034,0.9621013,0.0003811984],"about_ca_topic_score_codex":0.00052469707,"about_ca_topic_score_gemma":0.000053791493,"teacher_disagreement_score":0.029302951,"about_ca_system_score_codex":0.0030796546,"about_ca_system_score_gemma":0.0025442636,"threshold_uncertainty_score":0.9997495},"labels":[],"label_agreement":null},{"id":"W4244260865","doi":"10.21203/rs.3.rs-63583/v2","title":"Analysis of the Gap in PCR Monitoring Availability for Patients with Chronic Myeloid Leukemia in 60 Low- and Middle-Income Countries","year":2020,"lang":"en","type":"preprint","venue":"Research Square","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Max Bell Foundation","funders":"","keywords":"GeneXpert MTB/RIF; Medicine; Business; Tuberculosis","score_opus":0.05207438773216867,"score_gpt":0.3491617457100352,"score_spread":0.29708735797786656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4244260865","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99302983,0.0015433616,0.0000046287128,0.00033900663,0.00008554868,0.004506084,0.00037705936,0.000022641896,0.00009181483],"genre_scores_gemma":[0.998017,0.00062463846,0.00015805865,0.00000760537,0.000114574126,0.0007062313,0.00020416125,0.000051966374,0.000115746225],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954927,0.00038859565,0.0007660232,0.0010313841,0.001560394,0.0007608846],"domain_scores_gemma":[0.99660367,0.0009458984,0.0002455403,0.0012798536,0.00071154063,0.00021348195],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012747442,0.00038508253,0.0012315081,0.00089348404,0.000106928754,0.000052848332,0.00043276485,0.00036598946,0.00006146598],"category_scores_gemma":[0.0011899642,0.0002707728,0.00024962894,0.0018979453,0.00046106044,0.0000802926,0.0010046784,0.0016055732,0.000004412961],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011640838,0.00016370184,0.98290896,0.012451046,0.00074365205,0.000029314586,0.0010710035,0.0010639539,0.000019449139,0.000011394611,0.0000074518875,0.0003659875],"study_design_scores_gemma":[0.0056523373,0.00061222183,0.9787094,0.009598145,0.0004156848,5.5916195e-7,0.00020108296,0.0039428533,0.00051273924,0.00009689773,0.00005682846,0.00020124212],"about_ca_topic_score_codex":0.0033154988,"about_ca_topic_score_gemma":0.003017081,"teacher_disagreement_score":0.011428882,"about_ca_system_score_codex":0.016731823,"about_ca_system_score_gemma":0.0053029405,"threshold_uncertainty_score":0.9999744},"labels":[],"label_agreement":null},{"id":"W4245956319","doi":"10.3410/f.1088103.541091","title":"Faculty Opinions recommendation of A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor gamma deficiency.","year":2007,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer; Université de Montréal","funders":"","keywords":"Retinoic acid; Medicine; Chemistry; Internal medicine; Cancer research; Endocrinology; Biochemistry; Gene","score_opus":0.027679563553970075,"score_gpt":0.3339182175130239,"score_spread":0.30623865395905386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4245956319","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000058116275,0.0023405026,0.000020010111,0.10497404,0.00077304424,0.003469152,0.88824743,0.000058765323,0.000058944832],"genre_scores_gemma":[0.0000796131,0.00084698916,0.0008556798,0.0045886966,0.00020811772,0.00044049713,0.9909516,0.000069197675,0.0019595828],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99233156,0.0005576504,0.0026086327,0.0012678596,0.0024789725,0.0007552964],"domain_scores_gemma":[0.9913155,0.00018275988,0.002441407,0.0022678988,0.003150819,0.0006416421],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016690338,0.0009999295,0.001874296,0.00056158146,0.00030504624,0.00008821791,0.0013356643,0.001325486,0.0015185446],"category_scores_gemma":[0.005179734,0.0006759759,0.0008777264,0.002405626,0.00054054445,0.00030461446,0.0005157447,0.00186958,0.00022951548],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005901857,0.001111038,0.000019291987,0.007382584,0.000387045,0.00000339987,0.0001883367,2.4296556e-8,0.00018605193,0.000015668897,0.9891412,0.0015063343],"study_design_scores_gemma":[0.0028371688,0.00068166666,0.0019351417,0.014906976,0.00063467084,0.00028273885,0.00005395342,0.0000027914996,0.00090399315,0.000003223077,0.9772472,0.0005105134],"about_ca_topic_score_codex":0.00008366945,"about_ca_topic_score_gemma":0.000006570103,"teacher_disagreement_score":0.1027042,"about_ca_system_score_codex":0.0014675386,"about_ca_system_score_gemma":0.0014811514,"threshold_uncertainty_score":0.99997103},"labels":[],"label_agreement":null},{"id":"W4248243317","doi":"10.3410/f.13357244.14726605","title":"Faculty Opinions recommendation of Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis.","year":2011,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Interface (matter); Cancer research; ABL; Chemistry; Cell biology; Tyrosine kinase; Biology; Signal transduction; Biochemistry","score_opus":0.039938296341327444,"score_gpt":0.3532397042770382,"score_spread":0.31330140793571076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4248243317","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000015735282,0.0044179317,0.000013914445,0.13201497,0.0008049108,0.002592809,0.8599848,0.00004086204,0.00011405887],"genre_scores_gemma":[0.00011219849,0.0011108706,0.00068213977,0.0038244678,0.00031567874,0.00041655698,0.9922702,0.00005385127,0.0012140436],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99367756,0.00075284566,0.0024896995,0.00093602383,0.0015687847,0.0005750696],"domain_scores_gemma":[0.991396,0.00026587368,0.002016814,0.0021599783,0.003809054,0.00035228694],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0022620012,0.00078157155,0.0014999729,0.00051219075,0.00022775971,0.00007749391,0.001608301,0.0008974977,0.00089840434],"category_scores_gemma":[0.009452161,0.00044094067,0.0007734103,0.0026410283,0.0004943611,0.00031126454,0.00081881747,0.001777195,0.00010968774],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005559937,0.00070005894,0.00004187757,0.0078189615,0.00024680415,0.0000015526157,0.00033240853,2.2739289e-7,0.000009463207,0.000054978067,0.9878123,0.0029257818],"study_design_scores_gemma":[0.0020984365,0.0002118317,0.0020174887,0.02164382,0.0004173425,0.00008708645,0.00008619247,0.000013707677,0.00023951996,0.000013762959,0.9728204,0.00035040127],"about_ca_topic_score_codex":0.00042136456,"about_ca_topic_score_gemma":0.000038472226,"teacher_disagreement_score":0.13228539,"about_ca_system_score_codex":0.0008843803,"about_ca_system_score_gemma":0.0016850092,"threshold_uncertainty_score":0.99980426},"labels":[],"label_agreement":null},{"id":"W4249840476","doi":"10.3410/f.733947391.793554355","title":"Faculty Opinions recommendation of Targeting quiescent leukemic stem cells using second generation autophagy inhibitors.","year":2018,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Beatson Institute for Cancer Research; Medical Research Council; Kay Kendall Leukaemia Fund; Leuka; Cancer Research UK; Howat Foundation; AstraZeneca","keywords":"Autophagy; Stem cell; Haematopoiesis; Cancer research; Myeloid; Tyrosine-kinase inhibitor; Biology; Myeloid leukemia; Cancer cell; Tyrosine kinase; Cancer stem cell; K562 cells; Leukemia; Immunology; Medicine; Cancer; Cell biology; Internal medicine; Apoptosis; Signal transduction","score_opus":0.046570536525860594,"score_gpt":0.3492153685899758,"score_spread":0.30264483206411524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249840476","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008085,0.001977408,0.0000298588,0.024154672,0.00259509,0.0025711816,0.9685068,0.0000595212,0.000024575633],"genre_scores_gemma":[0.000047491994,0.00030184604,0.0016032393,0.002571118,0.0015684427,0.00015163339,0.9922016,0.00006197781,0.0014926462],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.993401,0.0005523127,0.0026333788,0.0010215443,0.0018464876,0.0005452805],"domain_scores_gemma":[0.9893195,0.000112037575,0.0027036064,0.0017231437,0.0057105226,0.00043118262],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015323282,0.00079641625,0.0014987176,0.0005000996,0.00034102285,0.00012276118,0.00090794906,0.0010655217,0.001136827],"category_scores_gemma":[0.0017819639,0.0005483792,0.000823246,0.001762517,0.00041570852,0.00039404558,0.00053029985,0.0012240844,0.000066657136],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002360758,0.0004529859,0.000005311453,0.011032562,0.000316655,0.0000010122707,0.00014789487,4.5250107e-7,0.0004231351,0.000013298475,0.98634505,0.0012380478],"study_design_scores_gemma":[0.0019006105,0.00025497394,0.00017330269,0.015686631,0.00059296296,0.00009467672,0.000031734628,0.00018081853,0.0031212678,0.0000022858528,0.97755355,0.000407198],"about_ca_topic_score_codex":0.000113530485,"about_ca_topic_score_gemma":0.000010697751,"teacher_disagreement_score":0.023694763,"about_ca_system_score_codex":0.0017019281,"about_ca_system_score_gemma":0.0024514415,"threshold_uncertainty_score":0.99977624},"labels":[],"label_agreement":null},{"id":"W4250574615","doi":"10.3410/f.6954956.7148054","title":"Faculty Opinions recommendation of c-Abl phosphorylation of Mdm2 facilitates Mdm2-Mdmx complex formation.","year":2010,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"MDMX; Mdm2; Phosphorylation; Chemistry; Computational biology; Computer science; Cancer research; Biology; Biochemistry; Gene","score_opus":0.043977158474524665,"score_gpt":0.3586279737759091,"score_spread":0.31465081530138445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250574615","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000009790936,0.0012045765,0.00006244824,0.091178305,0.00068355096,0.002691377,0.9039689,0.000050689505,0.0001504184],"genre_scores_gemma":[0.00008587222,0.0005773766,0.0024385138,0.0018043108,0.00021989585,0.0002768166,0.9936509,0.000038996088,0.0009072882],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9935071,0.00037985216,0.0028674556,0.0007218072,0.0020816692,0.0004421268],"domain_scores_gemma":[0.98602325,0.0002904402,0.0029883853,0.002110822,0.008203456,0.00038365586],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014099414,0.0007166848,0.0017022096,0.00057158334,0.00022355637,0.0000642622,0.0011551806,0.0010917259,0.001816752],"category_scores_gemma":[0.007081322,0.0004802031,0.0009372424,0.002077909,0.0005897412,0.0005188443,0.00041767888,0.0014713267,0.00009259453],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005435746,0.00071230304,0.000019236222,0.015828459,0.00031004212,3.4677132e-7,0.00024556363,2.5716363e-7,0.00004101481,0.00011890514,0.9788241,0.0038454153],"study_design_scores_gemma":[0.002401128,0.00031107487,0.003954631,0.011690794,0.00058223895,0.00008355585,0.00006260226,0.00006839921,0.00023915867,0.000027435395,0.98023415,0.0003448077],"about_ca_topic_score_codex":0.00023199589,"about_ca_topic_score_gemma":0.00002180675,"teacher_disagreement_score":0.08968209,"about_ca_system_score_codex":0.00050530507,"about_ca_system_score_gemma":0.0012114466,"threshold_uncertainty_score":0.999765},"labels":[],"label_agreement":null},{"id":"W4252527038","doi":"10.3410/f.718326593.793493199","title":"Faculty Opinions recommendation of Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells.","year":2014,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Myeloid leukemia; Stem cell; Cancer research; Myeloid cells; Cell biology; Leukemia; Signal transduction; Growth factor; Receptor; Myeloid; Biology; Medicine; Internal medicine; Immunology","score_opus":0.021260882691403592,"score_gpt":0.3115231951246543,"score_spread":0.29026231243325074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4252527038","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005034498,0.0011906244,0.000009061657,0.014723079,0.00037799263,0.0020719864,0.98106605,0.000028095308,0.00002967113],"genre_scores_gemma":[0.0019072498,0.0014648479,0.0006256725,0.00067954,0.00016205195,0.00015676585,0.9947507,0.00004831197,0.00020488398],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9939471,0.00054534874,0.0027779816,0.0008368569,0.0014353124,0.00045740968],"domain_scores_gemma":[0.9909157,0.00030807577,0.0030855713,0.0012632891,0.004068211,0.0003591461],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010449624,0.0006979529,0.002135781,0.0006741674,0.00010326192,0.00003534193,0.0010140879,0.00088760024,0.00022337682],"category_scores_gemma":[0.002304725,0.00047664356,0.0005590179,0.0018269445,0.0005311955,0.00026107772,0.00042808498,0.0011654292,0.0000104707715],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008329789,0.00044801255,0.00013024757,0.017444493,0.0004642803,5.38365e-7,0.0003745146,7.977743e-8,0.0020578287,0.00011445431,0.9779224,0.00095988496],"study_design_scores_gemma":[0.004080725,0.0005838216,0.0031230117,0.029355995,0.0004587096,0.000031296495,0.0000962146,0.000018168448,0.005534301,0.000022739905,0.95629233,0.00040265825],"about_ca_topic_score_codex":0.0003580535,"about_ca_topic_score_gemma":0.000011440312,"teacher_disagreement_score":0.02163001,"about_ca_system_score_codex":0.0006150719,"about_ca_system_score_gemma":0.0010589124,"threshold_uncertainty_score":0.9997685},"labels":[],"label_agreement":null},{"id":"W4252692801","doi":"10.3410/f.1057897.509834","title":"Faculty Opinions recommendation of Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.","year":2007,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Ottawa Regional Cancer Foundation","funders":"","keywords":"Imatinib; Myeloid leukemia; Medicine; Oncology; Internal medicine; Leukemia; Chronic myeloid leukaemia; Cancer research","score_opus":0.028938000857086397,"score_gpt":0.34969959075284907,"score_spread":0.32076158989576264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4252692801","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00002107429,0.0011427591,0.000058766123,0.026326247,0.0014380773,0.0045264494,0.9663381,0.00004401828,0.00010448662],"genre_scores_gemma":[0.000042648615,0.000676946,0.0024033973,0.0013436499,0.00044512455,0.0004343128,0.99260336,0.000067149274,0.0019833823],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99321467,0.00029461656,0.0029330675,0.0009163528,0.0020329168,0.0006083539],"domain_scores_gemma":[0.9846581,0.00044307025,0.0032684812,0.0020179332,0.009205273,0.00040714344],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001773861,0.0007703647,0.0019272296,0.0006238193,0.00020807474,0.000049186805,0.0012740004,0.0010944061,0.00057537854],"category_scores_gemma":[0.012927835,0.00052959623,0.001284685,0.0020395962,0.0004126457,0.00031111416,0.0004704445,0.0011224728,0.000037229576],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015080783,0.0005962649,0.00004651812,0.02546721,0.0004945985,2.313927e-7,0.00016205033,2.0676852e-7,0.000004758473,0.000056754172,0.96647894,0.0065416344],"study_design_scores_gemma":[0.007992942,0.0006862992,0.0056620315,0.025861057,0.00079494744,0.00001613042,0.00003611317,0.000021097025,0.00010041638,0.000012700202,0.9584404,0.00037585868],"about_ca_topic_score_codex":0.00011596557,"about_ca_topic_score_gemma":0.0000204015,"teacher_disagreement_score":0.026265267,"about_ca_system_score_codex":0.0018887902,"about_ca_system_score_gemma":0.002984573,"threshold_uncertainty_score":0.99971557},"labels":[],"label_agreement":null},{"id":"W4255030439","doi":"10.1038/s41408-020-00374-3","title":"Correction: Imatinib mesylate inhibits STAT5 phosphorylation in response to IL-7 and promotes T cell lymphopenia in chronic myelogenous leukemia patients","year":2020,"lang":"en","type":"erratum","venue":"Blood Cancer Journal","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Cancer Research Society","keywords":"Imatinib mesylate; Chronic myelogenous leukemia; Leukemia; Medicine; Imatinib; STAT5; Cancer research; Immunology; Pharmacology; Oncology; Internal medicine; Receptor","score_opus":0.009923411100285665,"score_gpt":0.25646876323930656,"score_spread":0.2465453521390209,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4255030439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.964833,0.018703133,0.000005678388,0.00090062217,0.011465851,0.0023196759,0.00015675194,0.000056531313,0.0015587219],"genre_scores_gemma":[0.88908124,0.027782643,0.0009126854,0.0014218639,0.005424296,0.00070918154,0.0007833082,0.0005680307,0.073316775],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9958056,0.00035120823,0.0012533814,0.0008727428,0.0008851655,0.0008318982],"domain_scores_gemma":[0.99788254,0.00013598478,0.00073288806,0.00036889972,0.00027315484,0.000606498],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0006135091,0.0007121898,0.001208266,0.0007199612,0.0001687013,0.00012767238,0.00022770785,0.00063058763,0.00032396376],"category_scores_gemma":[0.00038652372,0.00068464846,0.0001468844,0.0008687926,0.00006405092,0.0002063232,0.00017669165,0.002467821,0.000048831986],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0216216,0.0016295055,0.06443198,0.0024578911,0.0010699044,0.005192247,0.01593244,0.0012949065,0.010349991,7.2629825e-7,0.75863856,0.11738027],"study_design_scores_gemma":[0.13220404,0.01611116,0.4432266,0.027420247,0.0026168607,0.0030071407,0.0005823471,0.0047198124,0.024280196,0.000074702584,0.34228894,0.00346792],"about_ca_topic_score_codex":0.0012533912,"about_ca_topic_score_gemma":0.0019580608,"teacher_disagreement_score":0.4163496,"about_ca_system_score_codex":0.02105527,"about_ca_system_score_gemma":0.017591218,"threshold_uncertainty_score":0.9998335},"labels":[],"label_agreement":null},{"id":"W4255857164","doi":"10.18433/jpps.v19i2.26074","title":"Microdialysis-directed Intra-tumor Pharmacokinetic Modeling of Methotrexate in Mice and Humans","year":2016,"lang":"en","type":"article","venue":"Journal of Pharmacy & Pharmaceutical Sciences","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Western New England University","keywords":"Pharmacokinetics; Microdialysis; Methotrexate; Chemistry; Interstitial fluid; Pharmacology; Pathology; Internal medicine; Medicine; Extracellular; Biochemistry","score_opus":0.07328186096131162,"score_gpt":0.40196600128558635,"score_spread":0.32868414032427473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4255857164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907164,0.0051500555,0.00029711315,0.0027498133,0.00024489374,0.00025731654,0.000007566297,0.000021007752,0.0005558175],"genre_scores_gemma":[0.9917456,0.0037486234,0.0037459766,0.00048354335,0.00021020691,0.000004386865,3.7868787e-7,0.000016246295,0.000045076056],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970999,0.00026428516,0.0010727589,0.00034962778,0.00071580766,0.00049764797],"domain_scores_gemma":[0.9983714,0.00045306748,0.00040240207,0.000101721635,0.00023725649,0.00043411265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001776986,0.00024660226,0.0006710362,0.00051748235,0.00007520445,0.000023733788,0.00031265942,0.000035459645,0.000590105],"category_scores_gemma":[0.00029820262,0.00014861244,0.00017939422,0.00075995584,0.00055406726,0.00040046175,0.00008669946,0.00035989337,0.000007643508],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00091080467,0.00039550842,0.022130562,0.0001098961,0.00018201645,0.00025684622,0.00028399905,0.00025749623,0.91227144,0.000022549488,0.0001095957,0.063069314],"study_design_scores_gemma":[0.0344262,0.00060581736,0.0031219998,0.0009718749,0.0015865734,0.0013330161,0.00017379897,0.15984395,0.78838474,0.00029511814,0.008821922,0.00043500285],"about_ca_topic_score_codex":0.00006811124,"about_ca_topic_score_gemma":0.0000062235467,"teacher_disagreement_score":0.15958646,"about_ca_system_score_codex":0.00032146843,"about_ca_system_score_gemma":0.00050332316,"threshold_uncertainty_score":0.6461236},"labels":[],"label_agreement":null},{"id":"W4256191981","doi":"10.1182/blood.v116.21.3437.3437","title":"Comparison of Adherence Between Nilotinib and Dasatinib as Second-Line Therapies In Chronic Myeloid Leukemia.","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Nilotinib; Dasatinib; Medicine; Myeloid leukemia; Imatinib; Internal medicine; Tyrosine-kinase inhibitor; Medical prescription; Imatinib mesylate; Tyrosine kinase; Oncology; Pharmacology; Cancer","score_opus":0.03324211498638943,"score_gpt":0.3303353564827807,"score_spread":0.29709324149639127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4256191981","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99431217,0.0019275679,0.0000027223691,0.000106867636,0.00008147939,0.00053399184,0.000028041546,0.000051396626,0.0029557373],"genre_scores_gemma":[0.99789846,0.00009828892,0.0009718572,0.000045946796,0.0002589808,0.000034497967,0.00005956375,0.0000340013,0.00059839175],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998428,0.000041831776,0.0005559739,0.00037710444,0.00026563104,0.00033148305],"domain_scores_gemma":[0.9988796,0.00022714646,0.00021206327,0.0004745767,0.000058116613,0.00014851388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022250313,0.0002447589,0.00072334043,0.00013216725,0.000041844578,0.00001298179,0.0001485853,0.00020602532,0.0008402066],"category_scores_gemma":[0.00011816581,0.00021277656,0.00006500384,0.00019962444,0.00020248673,0.000080510064,0.000079285805,0.000589132,0.000047876994],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007886101,0.00043111123,0.82818997,0.0002672571,0.00023361553,0.000025444913,0.0015497312,0.0000016000929,0.15205453,0.00012911117,0.0000709354,0.016967801],"study_design_scores_gemma":[0.019337073,0.002321548,0.66421235,0.00029329504,0.00030343977,0.000073205614,0.0002839315,0.00010503754,0.31032455,0.00022818206,0.0022456578,0.00027173734],"about_ca_topic_score_codex":0.0004236777,"about_ca_topic_score_gemma":0.0011509792,"teacher_disagreement_score":0.16397767,"about_ca_system_score_codex":0.00023583036,"about_ca_system_score_gemma":0.0010329012,"threshold_uncertainty_score":0.9199673},"labels":[],"label_agreement":null},{"id":"W4256585378","doi":"10.21203/rs.3.rs-63583/v1","title":"Analysis of the Gap in PCR Monitoring Availability for Patients with Chronic Myeloid Leukemia in 60 Low- and Middle-Income Countries","year":2020,"lang":"en","type":"preprint","venue":"Research Square","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Max Bell Foundation","funders":"University of Washington; Incyte; Amgen","keywords":"GeneXpert MTB/RIF; Medicine; Business","score_opus":0.05207438773216867,"score_gpt":0.3491617457100352,"score_spread":0.29708735797786656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4256585378","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99302983,0.0015433616,0.0000046287128,0.00033900663,0.00008554868,0.004506084,0.00037705936,0.000022641896,0.00009181483],"genre_scores_gemma":[0.998017,0.00062463846,0.00015805865,0.00000760537,0.000114574126,0.0007062313,0.00020416125,0.000051966374,0.000115746225],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954927,0.00038859565,0.0007660232,0.0010313841,0.001560394,0.0007608846],"domain_scores_gemma":[0.99660367,0.0009458984,0.0002455403,0.0012798536,0.00071154063,0.00021348195],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012747442,0.00038508253,0.0012315081,0.00089348404,0.000106928754,0.000052848332,0.00043276485,0.00036598946,0.00006146598],"category_scores_gemma":[0.0011899642,0.0002707728,0.00024962894,0.0018979453,0.00046106044,0.0000802926,0.0010046784,0.0016055732,0.000004412961],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011640838,0.00016370184,0.98290896,0.012451046,0.00074365205,0.000029314586,0.0010710035,0.0010639539,0.000019449139,0.000011394611,0.0000074518875,0.0003659875],"study_design_scores_gemma":[0.0056523373,0.00061222183,0.9787094,0.009598145,0.0004156848,5.5916195e-7,0.00020108296,0.0039428533,0.00051273924,0.00009689773,0.00005682846,0.00020124212],"about_ca_topic_score_codex":0.0033154988,"about_ca_topic_score_gemma":0.003017081,"teacher_disagreement_score":0.011428882,"about_ca_system_score_codex":0.016731823,"about_ca_system_score_gemma":0.0053029405,"threshold_uncertainty_score":0.9999744},"labels":[],"label_agreement":null},{"id":"W4281285399","doi":"10.1002/ajh.26618","title":"Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia","year":2022,"lang":"en","type":"letter","venue":"American Journal of Hematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Associazione Italiana per la Ricerca sul Cancro","keywords":"Medicine; Myeloid leukemia; Population; Cancer registry; Cancer; Internal medicine; Oncology; Incidence (geometry); Leukemia; Tyrosine-kinase inhibitor; Clinical trial","score_opus":0.02980958234156228,"score_gpt":0.2920588869648335,"score_spread":0.26224930462327123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281285399","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93513006,0.007995277,0.0007076167,0.053785615,0.0012394241,0.0009882506,0.00009687847,0.0000139605945,0.000042893138],"genre_scores_gemma":[0.8751089,0.004539518,0.0077993055,0.09040473,0.0195283,0.00017263091,0.001456321,0.00041298987,0.000577313],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968865,0.0002205068,0.0015552307,0.0003890897,0.0004650382,0.00048365857],"domain_scores_gemma":[0.9964317,0.00030551146,0.0024740123,0.00038834018,0.00031306795,0.000087381464],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00038137217,0.00041795635,0.001950777,0.00080819614,0.00009105204,0.000011150321,0.00021962202,0.00035518548,0.00076394295],"category_scores_gemma":[0.000116138304,0.00038192933,0.00040813198,0.00043204005,0.0003316901,0.000098013916,0.00005276344,0.0014872246,0.0000017810013],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008600892,0.0022109367,0.0051812776,0.0031395964,0.0038957186,0.014298604,0.0022444597,0.0040085055,0.080328904,0.00017568331,0.8057396,0.07017587],"study_design_scores_gemma":[0.031170715,0.027187372,0.00075767684,0.0015420637,0.0008075629,0.021190189,0.0002155923,0.0039091352,0.04259261,0.00015507298,0.86947095,0.0010010595],"about_ca_topic_score_codex":0.00017578657,"about_ca_topic_score_gemma":0.00025651578,"teacher_disagreement_score":0.06917481,"about_ca_system_score_codex":0.006864468,"about_ca_system_score_gemma":0.0044682384,"threshold_uncertainty_score":0.99986327},"labels":[],"label_agreement":null},{"id":"W4281951662","doi":"10.1038/s41375-022-01589-y","title":"Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial","year":2022,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":141,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Scheme for Promotion of Academic and Research Collaboration; Sun Pharma; National Cancer Institute; Incyte; Jazz Pharmaceuticals; Ariad Pharmaceuticals; Celgene; Gilead Sciences; Pfizer; Daiichi Sankyo Europe; Bristol-Myers Squibb","keywords":"Bosutinib; Imatinib; Medicine; Internal medicine; Cumulative incidence; Adverse effect; Myeloid leukemia; Oncology; Surgery; Nilotinib; Transplantation","score_opus":0.050703384527734714,"score_gpt":0.32363280685004,"score_spread":0.27292942232230527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281951662","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9750615,0.0036644738,0.00017722476,0.0028628996,0.0040651364,0.0069751744,0.0038911924,0.00043920462,0.002863189],"genre_scores_gemma":[0.9710548,0.00032428472,0.0012751197,0.0011600886,0.008460777,0.0040765954,0.008414598,0.00025049128,0.0049832747],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99410355,0.0003042071,0.0014262472,0.0014539117,0.0012769217,0.0014351731],"domain_scores_gemma":[0.9931678,0.0034832857,0.0007295901,0.002082503,0.00013626099,0.00040054863],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009784207,0.0007991508,0.0010896646,0.00015279459,0.001274556,0.00010834362,0.0009930155,0.0003318333,0.0019149997],"category_scores_gemma":[0.0014217161,0.0006470094,0.0007854441,0.00065010675,0.0002965645,0.00020474233,0.00052567193,0.0015921311,0.00022099519],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.50246024,0.0011912286,0.00009373777,0.00023564899,0.002034507,0.0010377744,0.0030198735,0.0046327156,0.0038987654,0.00056360953,0.32626835,0.15456356],"study_design_scores_gemma":[0.65186363,0.012226047,0.00040649422,0.00014822333,0.0010181335,0.000073731986,0.0005314487,0.013510841,0.0017208938,0.00017882315,0.31771442,0.0006072824],"about_ca_topic_score_codex":0.0025593303,"about_ca_topic_score_gemma":0.00073586614,"teacher_disagreement_score":0.15395628,"about_ca_system_score_codex":0.047629822,"about_ca_system_score_gemma":0.017423917,"threshold_uncertainty_score":0.99959815},"labels":[],"label_agreement":null},{"id":"W4283328999","doi":"10.1097/01.hs9.0000843512.62237.dc","title":"S155: EFFICACY AND SAFETY RESULTS FROM ASCEMBL, A PHASE 3 STUDY OF ASCIMINIB VS BOSUTINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE AFTER ≥2 PRIOR TYROSINE KINASE INHIBITORS: WK 96 UPDATE","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Bosutinib; Discontinuation; Tolerability; Internal medicine; Adverse effect; Imatinib; Myeloid leukemia; Nilotinib; Gastroenterology","score_opus":0.010204334073727377,"score_gpt":0.2673810174070419,"score_spread":0.2571766833333145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283328999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917406,0.0024528063,0.0000035276323,0.00014655992,0.00016709376,0.0044891555,0.00079935224,0.000076535376,0.00012439305],"genre_scores_gemma":[0.9974115,0.000106343374,0.00023404078,0.00010128231,0.00020850885,0.0005080762,0.0010954988,0.00012661159,0.00020815743],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99481815,0.00032313753,0.0015497335,0.0013866551,0.0010651797,0.0008571567],"domain_scores_gemma":[0.9975198,0.00023299675,0.0005574384,0.001256175,0.00010552464,0.0003280454],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00047196727,0.0006852962,0.0012810112,0.00029008198,0.00015983936,0.000029603012,0.00026356458,0.00017150183,0.0014029779],"category_scores_gemma":[0.00014980361,0.0006139732,0.00010341642,0.0010415104,0.00017692248,0.00024741556,0.00046654016,0.0009309865,0.00002436377],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45501977,0.07333038,0.27867305,0.0014049885,0.0017191237,0.007328571,0.02295156,0.0037840013,0.004954127,0.000013807291,0.0031338169,0.14768678],"study_design_scores_gemma":[0.6287124,0.03445343,0.3225434,0.0016134065,0.00050628756,0.000028104549,0.0012870212,0.001621094,0.0029668543,0.0000065186637,0.0053729275,0.0008885365],"about_ca_topic_score_codex":0.002193982,"about_ca_topic_score_gemma":0.0028495628,"teacher_disagreement_score":0.17369263,"about_ca_system_score_codex":0.012501303,"about_ca_system_score_gemma":0.002972149,"threshold_uncertainty_score":0.99963117},"labels":[],"label_agreement":null},{"id":"W4283703366","doi":"10.1002/ajh.26645","title":"Real‐life incidence of thrombotic events in leukemia patients treated with ponatinib","year":2022,"lang":"en","type":"letter","venue":"American Journal of Hematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ponatinib; Medicine; Incidence (geometry); Leukemia; Internal medicine; Oncology; Myeloid leukemia; Dasatinib","score_opus":0.011279186742634548,"score_gpt":0.2667247574138395,"score_spread":0.25544557067120494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283703366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97876036,0.00020281933,0.0000051894554,0.019957198,0.00015567214,0.000461234,0.000027228449,0.000013515525,0.00041675684],"genre_scores_gemma":[0.9623379,0.000304546,0.0007743802,0.035924062,0.00017247054,0.000028885981,0.0001809566,0.00011051696,0.00016628261],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99592084,0.0004804408,0.0015613926,0.00041097397,0.001073989,0.0005523684],"domain_scores_gemma":[0.9949455,0.00057756744,0.0033958259,0.00054286246,0.0003638211,0.00017439517],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00025507167,0.00047152303,0.0028219891,0.0008429204,0.000038477327,0.0000026766793,0.0004407309,0.0002634594,0.0005498665],"category_scores_gemma":[0.00031198218,0.00036094693,0.00025882293,0.0007526135,0.0004936745,0.000087030596,0.000109812936,0.0023342893,0.000009390203],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019452954,0.00047675375,0.9348206,0.00038871632,0.0012937367,0.008835478,0.00045066324,0.000041097228,0.000022523416,0.000012546919,0.050840173,0.00087242934],"study_design_scores_gemma":[0.04242426,0.051733576,0.8471582,0.005715951,0.0035982004,0.031312186,0.0014333961,0.0000882391,0.00051062065,0.00013658023,0.014323464,0.0015653543],"about_ca_topic_score_codex":0.0015298965,"about_ca_topic_score_gemma":0.000035791978,"teacher_disagreement_score":0.08766241,"about_ca_system_score_codex":0.0031082353,"about_ca_system_score_gemma":0.0035116097,"threshold_uncertainty_score":0.99996734},"labels":[],"label_agreement":null},{"id":"W4284666225","doi":"10.21203/rs.3.rs-1809838/v1","title":"High Sensitivity C-Reactive Protein and Circulating Biomarkers of Endothelial Dysfunction in Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitors","year":2022,"lang":"en","type":"preprint","venue":"Research Square","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Toronto General Hospital; McMaster University; University of Toronto","funders":"","keywords":"Medicine; Nilotinib; Ponatinib; Internal medicine; Myeloid leukemia; Tyrosine kinase; Pathogenesis; C-reactive protein; Chronic myelogenous leukemia; Endothelial dysfunction; Oncology; Immunology; Gastroenterology; Leukemia; Inflammation; Imatinib; Receptor","score_opus":0.01946452706433444,"score_gpt":0.2942270745688978,"score_spread":0.27476254750456336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4284666225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99303997,0.000368162,0.000017365403,0.00012875006,0.00016244066,0.005639362,0.00037873824,0.00006556333,0.00019967754],"genre_scores_gemma":[0.9975032,0.00004714901,0.00042896508,0.0000050883014,0.00022596982,0.0006043004,0.00095681835,0.00011540871,0.00011310375],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9941185,0.0011292212,0.00064473785,0.0012142794,0.0020616276,0.00083160267],"domain_scores_gemma":[0.9973816,0.00050205534,0.0004192993,0.0008630331,0.0005845164,0.0002494492],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0020236007,0.0004997937,0.00091099483,0.0010703271,0.00024498158,0.000048684393,0.00012200432,0.00037158196,0.00016176466],"category_scores_gemma":[0.001007471,0.00045669088,0.00013241314,0.00090156955,0.0003771535,0.0001615329,0.0010658997,0.0025448373,0.000004239201],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0075935866,0.0011920498,0.8803322,0.008267394,0.0009332827,0.0007580941,0.0013460565,0.0018989118,0.060282417,0.000037496306,0.000070639035,0.037287902],"study_design_scores_gemma":[0.015474989,0.002862523,0.94496596,0.008700522,0.00012503457,0.000022117027,0.0005313946,0.0013392888,0.025358217,0.00006543916,0.00006470967,0.00048982835],"about_ca_topic_score_codex":0.015240556,"about_ca_topic_score_gemma":0.00086173776,"teacher_disagreement_score":0.064633764,"about_ca_system_score_codex":0.021085614,"about_ca_system_score_gemma":0.0041250316,"threshold_uncertainty_score":0.99978846},"labels":[],"label_agreement":null},{"id":"W4284961880","doi":"10.1016/j.lana.2022.100317","title":"CostPlus and implications for generic imatinib","year":2022,"lang":"en","type":"article","venue":"The Lancet Regional Health - Americas","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Arnold Ventures","keywords":"Imatinib; Business; Computer science; Medicine; Cancer research","score_opus":0.145602861942313,"score_gpt":0.4066263761315584,"score_spread":0.2610235141892454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4284961880","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.32499146,0.009784408,0.0010509844,0.6592624,0.0001682803,0.0027856885,0.00036337794,0.00017020926,0.0014231632],"genre_scores_gemma":[0.8816537,0.0032031636,0.012800975,0.095762305,0.0008304432,0.0029257268,0.00059295556,0.00006643117,0.0021643045],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989847,0.0000791287,0.00020231167,0.0002301863,0.00016190248,0.0003417833],"domain_scores_gemma":[0.99898463,0.00027317472,0.00016648187,0.00040816245,0.000032924218,0.00013462052],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026994495,0.0001055424,0.0003390426,0.00003593126,0.00057681475,0.000006602595,0.00012285424,0.000013832225,0.000055152675],"category_scores_gemma":[0.000027276012,0.000076276796,0.00005590588,0.0002178158,0.00012668845,0.000017534343,0.000080239945,0.00017888541,0.000008128885],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001213973,0.00037867186,0.014711152,0.00037140067,0.00022503598,0.000008122453,0.0021842765,0.00014326595,0.00030292914,0.016898654,0.7484667,0.21509585],"study_design_scores_gemma":[0.00398398,0.0008806188,0.15094106,0.000022851882,0.000056022625,0.0010572132,0.00038716043,0.0011775247,0.0000036679996,0.0018159731,0.8395491,0.00012482559],"about_ca_topic_score_codex":0.00026307278,"about_ca_topic_score_gemma":0.000008916882,"teacher_disagreement_score":0.5635001,"about_ca_system_score_codex":0.0007386123,"about_ca_system_score_gemma":0.00064329855,"threshold_uncertainty_score":0.44364512},"labels":[],"label_agreement":null},{"id":"W4285274693","doi":"10.1016/bs.mcb.2022.04.002","title":"Multiple gene knockdown strategies for investigating the properties of human leukemia stem cells and exploring new therapies","year":2022,"lang":"en","type":"article","venue":"Methods in cell biology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Terry Fox Research Institute; University of British Columbia","funders":"Natural Sciences and Engineering Research Council of Canada; Leukemia and Lymphoma Society of Canada; Canadian Cancer Society; Canadian Institutes of Health Research; Mitacs; Alex's Lemonade Stand Foundation for Childhood Cancer","keywords":"Leukemia; Myeloid leukemia; Cancer research; Stem cell; Tyrosine kinase; Medicine; Progenitor cell; Biology; Immunology; Internal medicine; Cell biology; Receptor","score_opus":0.20030388549713876,"score_gpt":0.3671873083821892,"score_spread":0.16688342288505045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285274693","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99206996,0.0054388177,0.0012066796,0.000109928704,0.00017329658,0.0007801848,0.000009446242,0.000027891369,0.00018377439],"genre_scores_gemma":[0.8906948,0.00013109008,0.10803228,0.00010159861,0.00007359867,0.00045210545,0.000008423665,0.000025310399,0.00048077793],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99849546,0.0004898414,0.0003740085,0.00030338418,0.00007337038,0.00026391709],"domain_scores_gemma":[0.9988642,0.0006189483,0.00015991218,0.0002827611,0.000025703528,0.00004851184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094776653,0.00016745958,0.0003999788,0.00009358139,0.00019747262,0.000010065586,0.0001534191,0.000063700296,0.000026311818],"category_scores_gemma":[0.000045322326,0.000110445784,0.00006164661,0.00013420366,0.00021817118,0.000044919427,0.00019017159,0.00024774278,3.1592904e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006898509,0.000028997098,0.007989885,0.00015173717,0.000054685454,0.0000015107753,0.007567784,0.00026448842,0.9552203,0.00022608218,0.000019308405,0.02840623],"study_design_scores_gemma":[0.0027743692,0.0007117159,0.00066330255,0.000039457846,0.00005290819,0.000008959695,0.011858059,0.0012632704,0.97813565,0.0021499798,0.0022178702,0.00012447398],"about_ca_topic_score_codex":0.0009499417,"about_ca_topic_score_gemma":0.00004810987,"teacher_disagreement_score":0.106825605,"about_ca_system_score_codex":0.0003618461,"about_ca_system_score_gemma":0.0004200576,"threshold_uncertainty_score":0.45038486},"labels":[],"label_agreement":null},{"id":"W4289793368","doi":"10.3324/haematol.2022.280740","title":"Onset of blast crisis in chronic myeloid leukemia patients in treatment-free remission","year":2022,"lang":"en","type":"letter","venue":"Haematologica","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Centre Léon Bérard; Pfizer; Incyte; Amgen","keywords":"Blast Crisis; Myeloid leukemia; Medicine; Complete remission; Internal medicine; Oncology; Chemotherapy","score_opus":0.02280471330544193,"score_gpt":0.269305235348068,"score_spread":0.24650052204262607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4289793368","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9250871,0.0017606192,7.860548e-7,0.065346286,0.00037154753,0.0027890415,0.00054821017,0.00014149294,0.0039549344],"genre_scores_gemma":[0.85725796,0.0058541032,0.0011990516,0.110741735,0.0008865125,0.0024182417,0.013730048,0.00049496663,0.0074173673],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951605,0.0003988092,0.001366621,0.0012114177,0.0009055128,0.0009571434],"domain_scores_gemma":[0.9967776,0.00037321734,0.000668582,0.0019767645,0.000073193565,0.00013066341],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00019586128,0.0008378651,0.0023500484,0.0009046876,0.00007703151,0.000012716959,0.00064876064,0.0012682213,0.0035598108],"category_scores_gemma":[0.00035620466,0.00066732056,0.0004157216,0.00074921746,0.00014712785,0.000072795636,0.00049305917,0.001988398,0.00008815548],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000796407,0.00078647153,0.063509695,0.001260466,0.00024255263,0.016166093,0.00041287963,0.000033617784,0.00003685163,0.000005136972,0.91481084,0.0019390129],"study_design_scores_gemma":[0.052206054,0.010816782,0.0802477,0.0036405341,0.0009339776,0.0016132506,0.00038260137,0.00021779117,0.002563684,0.00050707086,0.84507203,0.001798529],"about_ca_topic_score_codex":0.0035746756,"about_ca_topic_score_gemma":0.00067641627,"teacher_disagreement_score":0.0697388,"about_ca_system_score_codex":0.025260715,"about_ca_system_score_gemma":0.002589571,"threshold_uncertainty_score":0.9995778},"labels":[],"label_agreement":null},{"id":"W4289793462","doi":"10.36469/jheor.2022.36975","title":"Chronic Myeloid Leukemia: Part I—Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States","year":2022,"lang":"en","type":"article","venue":"Journal of health economics and outcomes research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Novartis Pharmaceuticals Corporation; International Business Machines Corporation","keywords":"Medicine; Health care; Pharmacy; Myeloid leukemia; Population; Emergency medicine; Incidence (geometry); Internal medicine; Family medicine; Environmental health","score_opus":0.1146702665762677,"score_gpt":0.41339451824372464,"score_spread":0.298724251667457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4289793462","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96661973,0.0064232396,1.865863e-7,0.02605957,0.00005033634,0.0007507573,0.000067247856,0.0000027791,0.000026142296],"genre_scores_gemma":[0.84808093,0.15054427,0.0000085732445,0.0009670823,0.000049351464,0.000035370274,0.00012593613,0.000019207228,0.0001692475],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969601,0.0010305515,0.0010660748,0.00020043706,0.0002999428,0.00044286903],"domain_scores_gemma":[0.99816054,0.0008944173,0.00046602878,0.00021093934,0.00012519563,0.00014284838],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036366268,0.00015231615,0.0006921632,0.0008887911,0.00019977993,0.000027677275,0.00013683406,0.000053318614,0.00003832866],"category_scores_gemma":[0.000067122855,0.00010154384,0.0000627414,0.00044490388,0.00007449388,0.00005713696,0.00007439964,0.000613098,3.0005356e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003333157,0.00023286733,0.95944744,0.00012293058,0.000110548404,0.000043646378,0.0037578405,0.00052272587,0.0000010897614,0.000052836232,0.00028375347,0.035091028],"study_design_scores_gemma":[0.009748063,0.0035557377,0.9447602,0.00018277713,0.000009656345,0.000048303405,0.0044900216,0.0016600331,0.000021753984,0.000084177445,0.035360556,0.00007873184],"about_ca_topic_score_codex":0.013661479,"about_ca_topic_score_gemma":0.017546002,"teacher_disagreement_score":0.14412104,"about_ca_system_score_codex":0.009539508,"about_ca_system_score_gemma":0.002247727,"threshold_uncertainty_score":0.9942627},"labels":[],"label_agreement":null},{"id":"W4289815058","doi":"10.36469/001c.36976","title":"Chronic Myeloid Leukemia: Part II—Cost of Care Among Patients in Advanced Phases or Later Lines of Therapy in Chronic Phase in the United States from a Commercial Perspective","year":2022,"lang":"en","type":"article","venue":"Journal of health economics and outcomes research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Novartis Pharmaceuticals Corporation","keywords":"Myeloid leukemia; Perspective (graphical); Medicine; Phase (matter); Intensive care medicine; Internal medicine; Chemistry; Computer science; Artificial intelligence","score_opus":0.06831243107343316,"score_gpt":0.4248905147898626,"score_spread":0.35657808371642946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4289815058","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98960835,0.00672073,2.3435898e-7,0.002183273,0.000090484544,0.0011779894,0.00020192086,0.0000014193149,0.000015606514],"genre_scores_gemma":[0.9687122,0.030762076,0.000025463612,0.00022082285,0.000071888004,0.00005766567,0.00011149954,0.000019343583,0.000019026327],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99726385,0.00054214627,0.0012140711,0.00021618094,0.00032966374,0.00043409516],"domain_scores_gemma":[0.9980947,0.00077907555,0.0005546161,0.00023302887,0.00023875956,0.00009981304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014690598,0.00016199876,0.0008840545,0.00089833135,0.00013682329,0.000011552888,0.00024480492,0.00005839369,0.00012320583],"category_scores_gemma":[0.00013267646,0.00010817654,0.000095185234,0.00046144886,0.00015850154,0.0001258217,0.00013099732,0.0009579439,2.0370327e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005856697,0.0012799811,0.90302205,0.00021755203,0.00015854514,0.000077001554,0.032066837,0.0059318054,0.000021812311,0.000018515344,0.00013127718,0.051217906],"study_design_scores_gemma":[0.06716881,0.01638739,0.8771243,0.0004603475,0.000016333548,0.000011373777,0.031200934,0.0020558673,0.0002480733,0.00011287402,0.005071442,0.00014224582],"about_ca_topic_score_codex":0.013898149,"about_ca_topic_score_gemma":0.021644657,"teacher_disagreement_score":0.061312117,"about_ca_system_score_codex":0.012563649,"about_ca_system_score_gemma":0.0046648593,"threshold_uncertainty_score":0.9962078},"labels":[],"label_agreement":null},{"id":"W4289856100","doi":"10.36469/001c.36975","title":"Chronic Myeloid Leukemia: Part I—Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States","year":2022,"lang":"en","type":"article","venue":"Journal of health economics and outcomes research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Novartis Pharmaceuticals Corporation; International Business Machines Corporation","keywords":"Medicine; Health care; Myeloid leukemia; Pharmacy; Population; Incidence (geometry); Emergency medicine; Internal medicine; Family medicine; Environmental health","score_opus":0.1146702665762677,"score_gpt":0.41339451824372464,"score_spread":0.298724251667457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4289856100","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96661973,0.0064232396,1.865863e-7,0.02605957,0.00005033634,0.0007507573,0.000067247856,0.0000027791,0.000026142296],"genre_scores_gemma":[0.84808093,0.15054427,0.0000085732445,0.0009670823,0.000049351464,0.000035370274,0.00012593613,0.000019207228,0.0001692475],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969601,0.0010305515,0.0010660748,0.00020043706,0.0002999428,0.00044286903],"domain_scores_gemma":[0.99816054,0.0008944173,0.00046602878,0.00021093934,0.00012519563,0.00014284838],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036366268,0.00015231615,0.0006921632,0.0008887911,0.00019977993,0.000027677275,0.00013683406,0.000053318614,0.00003832866],"category_scores_gemma":[0.000067122855,0.00010154384,0.0000627414,0.00044490388,0.00007449388,0.00005713696,0.00007439964,0.000613098,3.0005356e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003333157,0.00023286733,0.95944744,0.00012293058,0.000110548404,0.000043646378,0.0037578405,0.00052272587,0.0000010897614,0.000052836232,0.00028375347,0.035091028],"study_design_scores_gemma":[0.009748063,0.0035557377,0.9447602,0.00018277713,0.000009656345,0.000048303405,0.0044900216,0.0016600331,0.000021753984,0.000084177445,0.035360556,0.00007873184],"about_ca_topic_score_codex":0.013661479,"about_ca_topic_score_gemma":0.017546002,"teacher_disagreement_score":0.14412104,"about_ca_system_score_codex":0.009539508,"about_ca_system_score_gemma":0.002247727,"threshold_uncertainty_score":0.9942627},"labels":[],"label_agreement":null},{"id":"W4289856656","doi":"10.36469/jheor.2022.36976","title":"Chronic Myeloid Leukemia: Part II—Cost of Care Among Patients in Advanced Phases or Later Lines of Therapy in Chronic Phase in the United States from a Commercial Perspective","year":2022,"lang":"en","type":"article","venue":"Journal of health economics and outcomes research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Discontinuation; Dasatinib; Nilotinib; Internal medicine; Myeloid leukemia; Imatinib; Bosutinib; Pediatrics","score_opus":0.06831243107343316,"score_gpt":0.4248905147898626,"score_spread":0.35657808371642946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4289856656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98960835,0.00672073,2.3435898e-7,0.002183273,0.000090484544,0.0011779894,0.00020192086,0.0000014193149,0.000015606514],"genre_scores_gemma":[0.9687122,0.030762076,0.000025463612,0.00022082285,0.000071888004,0.00005766567,0.00011149954,0.000019343583,0.000019026327],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99726385,0.00054214627,0.0012140711,0.00021618094,0.00032966374,0.00043409516],"domain_scores_gemma":[0.9980947,0.00077907555,0.0005546161,0.00023302887,0.00023875956,0.00009981304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014690598,0.00016199876,0.0008840545,0.00089833135,0.00013682329,0.000011552888,0.00024480492,0.00005839369,0.00012320583],"category_scores_gemma":[0.00013267646,0.00010817654,0.000095185234,0.00046144886,0.00015850154,0.0001258217,0.00013099732,0.0009579439,2.0370327e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005856697,0.0012799811,0.90302205,0.00021755203,0.00015854514,0.000077001554,0.032066837,0.0059318054,0.000021812311,0.000018515344,0.00013127718,0.051217906],"study_design_scores_gemma":[0.06716881,0.01638739,0.8771243,0.0004603475,0.000016333548,0.000011373777,0.031200934,0.0020558673,0.0002480733,0.00011287402,0.005071442,0.00014224582],"about_ca_topic_score_codex":0.013898149,"about_ca_topic_score_gemma":0.021644657,"teacher_disagreement_score":0.061312117,"about_ca_system_score_codex":0.012563649,"about_ca_system_score_gemma":0.0046648593,"threshold_uncertainty_score":0.9962078},"labels":[],"label_agreement":null},{"id":"W4290034027","doi":"10.1002/sim.9547","title":"Use of copula to model within‐study association in bivariate meta‐analysis of binomial data at the aggregate level: A Bayesian approach and application to surrogate endpoint evaluation","year":2022,"lang":"en","type":"review","venue":"Statistics in Medicine","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Medical Research Council; Medical Research Council Canada; University of Leicester","keywords":"Bivariate analysis; Copula (linguistics); Statistics; Beta-binomial distribution; Econometrics; Random effects model; Continuity correction; Surrogate endpoint; Binomial distribution; Bayesian probability; Computer science; Meta-analysis; Mathematics; Negative binomial distribution; Medicine; Internal medicine; Poisson distribution","score_opus":0.3400497914709901,"score_gpt":0.44790679767266445,"score_spread":0.10785700620167432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4290034027","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0024480275,0.81178963,0.12699585,0.0005957882,0.00029092346,0.031312123,0.026368404,0.000038158214,0.00016109513],"genre_scores_gemma":[0.014858722,0.885783,0.055104684,0.00023716604,0.00010943585,0.004080218,0.03896767,0.00018908482,0.0006699761],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99372536,0.0011711939,0.001959684,0.0009292956,0.0019438168,0.00027063294],"domain_scores_gemma":[0.9947256,0.0017033267,0.0015404444,0.0016287756,0.00026766528,0.0001341913],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.008825699,0.00042251337,0.0038522508,0.0013212254,0.000057362107,0.000009715062,0.00037840553,0.00014661565,0.0001334809],"category_scores_gemma":[0.004706685,0.00028578134,0.00013928952,0.0025851675,0.00007333513,0.000054018838,0.0005518876,0.00044431517,0.0000015970955],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016499831,0.00313858,0.0038118456,0.016935807,0.19592868,0.00009317787,0.025707945,0.107948765,0.000020195348,0.0013882263,0.0031866836,0.6401901],"study_design_scores_gemma":[0.0034493832,0.00053103303,0.0014186653,0.000790813,0.44134036,0.00000712927,0.00038982322,0.54447716,0.0000010726777,0.00012266301,0.0071471552,0.00032472756],"about_ca_topic_score_codex":0.0062331874,"about_ca_topic_score_gemma":0.009967044,"teacher_disagreement_score":0.6398654,"about_ca_system_score_codex":0.0041725044,"about_ca_system_score_gemma":0.0009673203,"threshold_uncertainty_score":0.9999594},"labels":[],"label_agreement":null},{"id":"W4290841268","doi":"10.1002/ajh.26686","title":"Ponatinib after failure of <scp>second‐generation</scp> tyrosine kinase inhibitor in resistant <scp>chronic‐phase</scp> chronic myeloid leukemia","year":2022,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; National Institute for Health and Care Research","keywords":"Ponatinib; Myeloid leukemia; Medicine; Tyrosine kinase; Dasatinib; Cancer research; Internal medicine; Receptor; Imatinib","score_opus":0.009934436151821244,"score_gpt":0.2624419304253864,"score_spread":0.2525074942735651,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4290841268","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98713213,0.010571712,0.00007810386,0.00067345065,0.00046324395,0.0005398309,0.00013164515,0.000030400028,0.00037947475],"genre_scores_gemma":[0.99564356,0.0002641899,0.0018814923,0.0005121823,0.0005812801,0.00013236288,0.00009829644,0.00010309348,0.00078354817],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99501395,0.00053044,0.0020356085,0.00059316016,0.00091524346,0.0009115805],"domain_scores_gemma":[0.9957336,0.0008116453,0.00200696,0.00069827883,0.00035091175,0.0003986108],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00072964776,0.00052694563,0.0019599444,0.00094830047,0.00015794834,0.000021900581,0.00044524347,0.00016067034,0.000848938],"category_scores_gemma":[0.0007157759,0.0004910292,0.00042765753,0.0011163346,0.00065553404,0.0002097169,0.00025118137,0.0013068866,0.000032340766],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0022558093,0.005691116,0.052487146,0.002011173,0.003298271,0.02866984,0.008920158,0.0021817973,0.71849865,0.0024435262,0.14849515,0.025047353],"study_design_scores_gemma":[0.08796166,0.05878712,0.024048897,0.0019895977,0.0016985033,0.046446476,0.01572466,0.0024861305,0.3629584,0.00037223607,0.39686292,0.00066336984],"about_ca_topic_score_codex":0.00014828095,"about_ca_topic_score_gemma":0.00061200594,"teacher_disagreement_score":0.35554025,"about_ca_system_score_codex":0.0066724913,"about_ca_system_score_gemma":0.006509891,"threshold_uncertainty_score":0.99975413},"labels":[],"label_agreement":null},{"id":"W4292749472","doi":"10.1038/s41375-022-01680-4","title":"Identification of key microRNAs as predictive biomarkers of Nilotinib response in chronic myeloid leukemia: a sub-analysis of the ENESTxtnd clinical trial","year":2022,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada; Canada's Michael Smith Genome Sciences Centre; Terry Fox Research Institute; University of British Columbia","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research","keywords":"Nilotinib; Medicine; Oncology; Myeloid leukemia; Internal medicine; Hazard ratio; microRNA; Proportional hazards model; Leukemia; Myeloid; Immunology; Imatinib; Biology; Confidence interval","score_opus":0.0264201446789562,"score_gpt":0.3250337087642593,"score_spread":0.2986135640853031,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292749472","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99635684,0.0006969619,0.000022142613,0.00024755756,0.0004317132,0.0017485232,0.00025076524,0.00002525949,0.00022024222],"genre_scores_gemma":[0.9987575,0.0001381656,0.00005096094,0.00006458233,0.00008255373,0.00019040545,0.000111891444,0.000042087362,0.00056189665],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9936472,0.0015908891,0.0026218158,0.0006921828,0.0010723037,0.00037559003],"domain_scores_gemma":[0.9949555,0.001372526,0.0018490587,0.0014888741,0.00021479519,0.00011926691],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0038915724,0.00029846735,0.0013695984,0.00084186177,0.00009797551,0.0000067739434,0.00059174624,0.00025752073,0.00026533927],"category_scores_gemma":[0.0018660888,0.00025146574,0.0010291899,0.0031292466,0.0007002612,0.00007933021,0.00036429003,0.0006711916,0.0000075439516],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.35789195,0.0012579432,0.06853584,0.0003142566,0.009332376,0.0000754858,0.002514095,0.009911245,0.5458786,0.00012069482,0.0010739329,0.0030935605],"study_design_scores_gemma":[0.10794452,0.0065914793,0.65845615,0.0002313561,0.008432885,0.00005198659,0.001218303,0.010421875,0.20529424,0.00009679761,0.00091496116,0.00034545627],"about_ca_topic_score_codex":0.0020772151,"about_ca_topic_score_gemma":0.00030071274,"teacher_disagreement_score":0.5899203,"about_ca_system_score_codex":0.013962675,"about_ca_system_score_gemma":0.0115685975,"threshold_uncertainty_score":0.99999374},"labels":[],"label_agreement":null},{"id":"W4293295743","doi":"","title":"Odomzo<sup>®</sup> (Sonidegib).","year":2019,"lang":"en","type":"article","venue":"PubMed","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mediprobe Research (Canada); University of Toronto","funders":"","keywords":"Medicine","score_opus":0.01773698035926516,"score_gpt":0.2308318077217572,"score_spread":0.21309482736249205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293295743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91669893,0.00039607607,0.000004759528,0.001145318,0.00022256427,0.0017368913,0.0000056629574,0.00016951236,0.07962031],"genre_scores_gemma":[0.94672173,0.000044053184,0.00017878588,0.0008391155,0.00026247735,0.00074759644,0.000034355482,0.000041943356,0.051129967],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984218,0.000028851586,0.0002277395,0.00037698794,0.00034641984,0.00059824006],"domain_scores_gemma":[0.9988909,0.000079250145,0.00005833195,0.00063892076,0.000046198973,0.0002864348],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0002013661,0.00019168743,0.00034369022,0.000096714764,0.00003278832,0.000020733578,0.00012219443,0.00011248843,0.00093529077],"category_scores_gemma":[0.00011841957,0.00015843108,0.00013246245,0.00018369187,0.000039744362,0.00009997648,0.000065532964,0.00019999656,0.0025229244],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006928186,0.0006981168,0.48869005,0.00038996252,0.00086422346,0.00039247173,0.00077634753,0.00016879388,0.00016173866,0.0011961762,0.038165897,0.46780342],"study_design_scores_gemma":[0.012007318,0.00014045635,0.7915475,0.000047347745,0.00027603842,0.00024830198,0.00015300099,0.0006751245,0.0018651973,0.00019340671,0.19249615,0.00035017912],"about_ca_topic_score_codex":0.00008078025,"about_ca_topic_score_gemma":0.0000030166082,"teacher_disagreement_score":0.46745324,"about_ca_system_score_codex":0.00084444165,"about_ca_system_score_gemma":0.00014679025,"threshold_uncertainty_score":0.999978},"labels":[],"label_agreement":null},{"id":"W4296468325","doi":"10.1016/s2152-2650(22)01359-3","title":"CML-047 Post Hoc Analysis of Responses to Ponatinib in Patients With Chronic-Phase Chronic Myeloid Leukemia (CP-CML) by Baseline BCR::ABL1 Level and Baseline Mutation Status in the OPTIC Trial","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Ponatinib; Internal medicine; Cohort; Population; Myeloid leukemia; Imatinib; Dasatinib","score_opus":0.02755615042185004,"score_gpt":0.3304778041480667,"score_spread":0.30292165372621666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296468325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99065304,0.0014548175,0.000112936534,0.00079704274,0.00028251857,0.0039171795,0.002624106,0.00007914286,0.00007920782],"genre_scores_gemma":[0.99071425,0.00024140619,0.001104601,0.0014529221,0.0002959686,0.00070361426,0.0049782246,0.00013574409,0.00037328052],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9887602,0.0026764881,0.003416785,0.0018159829,0.0019889972,0.0013415775],"domain_scores_gemma":[0.9908353,0.005308927,0.0010667496,0.0016918044,0.0004409079,0.0006562932],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0054624714,0.0008843149,0.002352984,0.0015215927,0.0003138096,0.00007290732,0.00071272044,0.00039528028,0.00060553296],"category_scores_gemma":[0.004146055,0.00070778845,0.0005292984,0.004302427,0.0005074793,0.00029141147,0.00046356797,0.0009794813,0.000026674059],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.35284412,0.0064949095,0.08512642,0.00028976824,0.002594844,0.0014145167,0.001760196,0.005298384,0.0007912503,0.00008039931,0.0025492331,0.540756],"study_design_scores_gemma":[0.22924545,0.024751673,0.7229617,0.00021827573,0.0019391511,0.0000575195,0.0005079742,0.015784957,0.00013229228,0.000012587662,0.003695096,0.0006933132],"about_ca_topic_score_codex":0.0025398077,"about_ca_topic_score_gemma":0.002024011,"teacher_disagreement_score":0.63783526,"about_ca_system_score_codex":0.021523278,"about_ca_system_score_gemma":0.012040549,"threshold_uncertainty_score":0.99953735},"labels":[],"label_agreement":null},{"id":"W4296468436","doi":"10.1016/s2152-2650(22)01379-9","title":"CML-395 Efficacy and Safety Results From ASCEMBL, a Phase III Study of Asciminib vs. Bosutinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After ≥2 Prior Tyrosine Kinase Inhibitors (TKIs): Week 96 Update","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Bosutinib; Medicine; Discontinuation; Adverse effect; Internal medicine; Imatinib; Oncology; Gastroenterology; Myeloid leukemia; Nilotinib","score_opus":0.017877768513283668,"score_gpt":0.30418020024713993,"score_spread":0.2863024317338563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296468436","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885666,0.0019533301,0.00000604397,0.00026936253,0.0006979915,0.0068431688,0.0013164325,0.00020532364,0.0001417902],"genre_scores_gemma":[0.99448144,0.00041874815,0.00029349746,0.00047958546,0.0006641229,0.0008381442,0.0023003211,0.00030055983,0.00022355355],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98526984,0.0013506499,0.0059237853,0.0034194824,0.0021329806,0.0019032825],"domain_scores_gemma":[0.9920948,0.0018118167,0.00189553,0.0028205458,0.00029001862,0.0010872813],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0022978657,0.0015667516,0.003655596,0.0009663722,0.0004168505,0.000089910725,0.00091033336,0.00067763746,0.0005866649],"category_scores_gemma":[0.00098932,0.0014381054,0.00047469084,0.0021850828,0.0009519666,0.0005283379,0.0014412923,0.0019059727,0.00007290538],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.31053472,0.031100482,0.121261485,0.00032741722,0.0012690374,0.005105431,0.0032187765,0.00087453786,0.0005995738,0.0000115802795,0.0013101147,0.5243869],"study_design_scores_gemma":[0.37426057,0.028251387,0.5882556,0.000859006,0.0006469178,0.000040363328,0.00031334005,0.0018785113,0.00047063568,0.000010987644,0.004112571,0.0009001227],"about_ca_topic_score_codex":0.004058436,"about_ca_topic_score_gemma":0.002156829,"teacher_disagreement_score":0.52348673,"about_ca_system_score_codex":0.039953392,"about_ca_system_score_gemma":0.013567683,"threshold_uncertainty_score":0.99970806},"labels":[],"label_agreement":null},{"id":"W4296528992","doi":"10.1016/s2152-2650(22)01358-1","title":"CML-046 Dose Modification Dynamics of Ponatinib in Patients With Chronic-Phase Chronic Myeloid Leukemia From the PACE and OPTIC Trials","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ponatinib; Medicine; Adverse effect; Internal medicine; Myeloid leukemia; Dosing; Oncology; Dasatinib; Imatinib","score_opus":0.03763956775805979,"score_gpt":0.3360157777617022,"score_spread":0.29837621000364245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296528992","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916668,0.0027298264,0.00007583554,0.000877489,0.0004571451,0.0030592917,0.00071877637,0.0001102393,0.00030460145],"genre_scores_gemma":[0.9948243,0.0004265463,0.00086662004,0.00036218172,0.00047732287,0.00046619624,0.0021208543,0.00014205073,0.00031393507],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9918762,0.0014560083,0.0030317863,0.0014288293,0.001355666,0.0008515221],"domain_scores_gemma":[0.9915258,0.004275165,0.001651255,0.0018739321,0.00024586113,0.0004279395],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0030600836,0.0007246173,0.002208508,0.00023757982,0.00037463047,0.000058960173,0.0007189575,0.00041330027,0.00048038876],"category_scores_gemma":[0.001927977,0.000532756,0.00045984695,0.00091245194,0.00079866836,0.00023845729,0.00058759877,0.0009523417,0.000036546913],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.013356484,0.002362439,0.18503489,0.00022872844,0.0012335024,0.0002686835,0.00075220334,0.0012134367,0.00035636002,0.0010433478,0.0015258479,0.79262406],"study_design_scores_gemma":[0.076605715,0.004969195,0.88539016,0.00034103935,0.00075502397,0.000051873343,0.00027970097,0.028764013,0.00014143607,0.00025449914,0.0019225288,0.00052480365],"about_ca_topic_score_codex":0.0016860326,"about_ca_topic_score_gemma":0.0004532585,"teacher_disagreement_score":0.7920993,"about_ca_system_score_codex":0.028479364,"about_ca_system_score_gemma":0.009866438,"threshold_uncertainty_score":0.9997124},"labels":[],"label_agreement":null},{"id":"W4296964702","doi":"10.1016/s2152-2650(22)00886-2","title":"Poster: CML-046 Dose Modification Dynamics of Ponatinib in Patients With Chronic-Phase Chronic Myeloid Leukemia From the PACE and OPTIC Trials","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myeloid leukemia; Ponatinib; Medicine; Pace; Oncology; Internal medicine; Nilotinib; Physics","score_opus":0.03591066286180756,"score_gpt":0.3327238929423084,"score_spread":0.29681323008050087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296964702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913371,0.002650906,0.00004160848,0.0010431518,0.00047135877,0.0031876967,0.0008307838,0.00010954675,0.0003278452],"genre_scores_gemma":[0.9949704,0.00036753147,0.0005587378,0.00044219225,0.00045152864,0.0004189549,0.002346455,0.00014642833,0.00029779342],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9917557,0.0014971066,0.003091669,0.0014465428,0.0013452193,0.00086374296],"domain_scores_gemma":[0.99164945,0.004073179,0.0016807537,0.001905862,0.0002569887,0.00043376873],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0028923166,0.0007453743,0.0022219983,0.0002466985,0.00036660407,0.0000650894,0.0007355632,0.00041981498,0.00043755633],"category_scores_gemma":[0.00166846,0.0005488377,0.0004692517,0.0008591934,0.00076195906,0.0002551321,0.0006421273,0.0009378688,0.000037558795],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.01571271,0.0023539215,0.23618363,0.0002435137,0.0012675282,0.0003026925,0.0008767376,0.0006567408,0.0004126737,0.0006464875,0.0012045136,0.7401388],"study_design_scores_gemma":[0.077041805,0.0057766098,0.8974603,0.00037010259,0.00076807005,0.000069080954,0.0002428446,0.015959864,0.00016831806,0.00018798311,0.0014189146,0.0005361048],"about_ca_topic_score_codex":0.0016702884,"about_ca_topic_score_gemma":0.000468451,"teacher_disagreement_score":0.73960274,"about_ca_system_score_codex":0.027161205,"about_ca_system_score_gemma":0.009171084,"threshold_uncertainty_score":0.9996963},"labels":[],"label_agreement":null},{"id":"W4298393597","doi":"10.13005/bbra/3021","title":"Overview of Molecular Quantification of the BCR-ABL Oncogene in CML Patients","year":2022,"lang":"en","type":"article","venue":"Biosciences Biotechnology Research Asia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Alberta","keywords":"breakpoint cluster region; Chromosomal translocation; ABL; Philadelphia chromosome; Myeloid leukemia; Cancer research; Oncogene; Biology; Chromosome; Gene; Genetics; Tyrosine kinase; Cell cycle; Receptor","score_opus":0.09080257346165299,"score_gpt":0.3875534603854035,"score_spread":0.2967508869237505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298393597","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99285066,0.0017864757,0.000005346251,0.00405742,0.000096124146,0.00077418226,0.000028322673,0.00001650955,0.00038494534],"genre_scores_gemma":[0.9992168,0.000338569,0.00021052512,0.000028480961,0.00000334615,0.0000709433,0.000009344515,0.00000718962,0.00011480385],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975157,0.00030952945,0.00034405632,0.00037350025,0.0010954625,0.00036178986],"domain_scores_gemma":[0.998839,0.00006918276,0.00015581437,0.0007538312,0.00014011427,0.00004203787],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012802724,0.00008754757,0.00023616232,0.00049551605,0.00015191364,0.0000037657915,0.00077289273,0.0001295977,0.00009272677],"category_scores_gemma":[0.00066615874,0.00006228077,0.00007057137,0.0034777285,0.0012633933,0.00003470602,0.0006603782,0.00047953703,0.0000061119167],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009047236,0.0009861422,0.10747712,0.0001022998,0.000026269188,0.000014632405,0.00012925966,0.000015302516,0.867103,0.004746304,0.00022227227,0.019086918],"study_design_scores_gemma":[0.0014011076,0.0011754789,0.13359159,0.00008639316,0.000013063427,0.0000143499365,0.0006654757,0.0002731386,0.8593173,0.00051156676,0.0028797693,0.00007075954],"about_ca_topic_score_codex":0.00034521142,"about_ca_topic_score_gemma":0.000046969708,"teacher_disagreement_score":0.026114471,"about_ca_system_score_codex":0.0006191182,"about_ca_system_score_gemma":0.00081820047,"threshold_uncertainty_score":0.46550253},"labels":[],"label_agreement":null},{"id":"W4300097719","doi":"10.17615/hjy2-gb88","title":"An Unbiased Evaluation of CK2 Inhibitors by Chemoproteomics: Characterization of Inhibitor Effects on CK2 and Identification of Novel Inhibitor Targets","year":2021,"lang":"en","type":"article","venue":"UNC Libraries","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Schulich School of Medicine and Dentistry","keywords":"Identification (biology); Computational biology; Pharmacology; Chemistry; Biology; Botany","score_opus":0.015767202327973153,"score_gpt":0.2586908315484393,"score_spread":0.24292362922046615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4300097719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99758804,0.000420883,0.00030541455,0.00018615871,0.00025054716,0.0009904932,0.00016338528,0.000040593695,0.000054515716],"genre_scores_gemma":[0.99569094,0.00002006648,0.0020790577,0.000055805758,0.00019044125,0.000055735607,0.0017834341,0.000035730704,0.00008878418],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979678,0.00012762359,0.0006998579,0.00037587035,0.00067924004,0.00014963708],"domain_scores_gemma":[0.99831,0.00012265654,0.0005718414,0.00044082617,0.0004621943,0.00009247323],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037262723,0.00020431587,0.00046792024,0.0001654838,0.000042627653,0.0000225557,0.000059423997,0.00017494452,0.000041932002],"category_scores_gemma":[0.00056589954,0.00019673991,0.00008140799,0.00033295024,0.00018508876,0.0005282366,0.000042176267,0.00010464737,0.0000016336478],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003044934,0.0008091727,0.007119973,0.00078407023,0.00011528069,0.0000016048658,0.0009887819,0.000008029117,0.9860125,0.00068644056,0.00021695325,0.0029526963],"study_design_scores_gemma":[0.0055724396,0.00048493978,0.031463765,0.0005320244,0.0002870951,0.0000035834735,0.00014656517,0.0019885523,0.9590991,0.00025811302,0.000039441977,0.00012438523],"about_ca_topic_score_codex":0.000018022989,"about_ca_topic_score_gemma":0.0000020829837,"teacher_disagreement_score":0.026913406,"about_ca_system_score_codex":0.00018092169,"about_ca_system_score_gemma":0.0006639406,"threshold_uncertainty_score":0.8022821},"labels":[],"label_agreement":null},{"id":"W4301963221","doi":"","title":"ISEH 2002. 31st Annual Meeting of the International Society for Experimental Hematology. Montreal, Canada, July 5-9, 2002. Abstracts.","year":2002,"lang":"en","type":"other","venue":"PubMed","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Library science; Hematology; Medicine; Internal medicine; Medical physics; Family medicine; Computer science","score_opus":0.01555919228021708,"score_gpt":0.23296574554212646,"score_spread":0.21740655326190939,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4301963221","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002765417,0.013487388,0.0000021286835,0.0012988502,0.001835992,0.0037594938,0.0025688543,0.000097291995,0.9741846],"genre_scores_gemma":[0.03068802,0.00015043152,0.00042446906,0.0006287765,0.00075528736,0.0018178157,0.00014695544,0.0002933671,0.96509486],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980022,0.000015554195,0.00047027113,0.000425908,0.0005692667,0.00051683426],"domain_scores_gemma":[0.99866194,0.000094640476,0.00054833613,0.0004513675,0.00008390582,0.00015980781],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00013470635,0.000348586,0.00056379964,0.00006399784,0.00005763718,0.0000108875265,0.0003526343,0.00031382692,0.0011101448],"category_scores_gemma":[0.0001282078,0.00026362002,0.00038902136,0.000081775506,0.00012481093,0.000031746167,0.00010294508,0.00024527853,0.000015899297],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000039975304,0.00021410512,0.00031938395,0.00012778411,0.00085901824,0.000018138508,0.00012748469,0.000004745337,0.000008415976,0.000007663825,0.99551654,0.002756765],"study_design_scores_gemma":[0.0044967458,0.000024500125,0.009201051,0.00021726196,0.00032931872,0.000091035006,0.0002467674,0.000053073032,0.0025527019,0.0000019781237,0.98253006,0.00025553862],"about_ca_topic_score_codex":0.1878278,"about_ca_topic_score_gemma":0.119876795,"teacher_disagreement_score":0.067951,"about_ca_system_score_codex":0.0018085137,"about_ca_system_score_gemma":0.0007004702,"threshold_uncertainty_score":0.9999816},"labels":[],"label_agreement":null},{"id":"W4303986419","doi":"10.1111/bjh.18486","title":"Dasatinib plus <scp>Peg‐Interferon</scp> alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: Results of a multicenter phase 2 study (<scp>DASA‐PegIFN</scp> study)","year":2022,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada; Merck KGaA","keywords":"Dasatinib; Medicine; Internal medicine; Neutropenia; Gastroenterology; Clinical endpoint; Adverse effect; Pegylated interferon; PEG ratio; Phases of clinical research; Immunology; Imatinib; Myeloid leukemia; Toxicity; Virus; Clinical trial","score_opus":0.02136001394846421,"score_gpt":0.3168797094254256,"score_spread":0.2955196954769614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4303986419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98469704,0.0089366445,0.00007887174,0.00021373878,0.0013378534,0.004080316,0.00021487525,0.00007287352,0.0003677862],"genre_scores_gemma":[0.9973153,0.00075397245,0.00016264251,0.00013709281,0.0003185798,0.0003788175,0.00020085358,0.00014652568,0.0005862561],"study_design_codex":"case_report","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9905971,0.001697479,0.0038142416,0.0010420127,0.0015824976,0.0012666512],"domain_scores_gemma":[0.99292403,0.0023367454,0.002755871,0.0008902608,0.0006021818,0.0004908864],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.002332291,0.00071468326,0.0029532455,0.0011794178,0.00034003673,0.00008549172,0.0009582025,0.0002874861,0.00020852688],"category_scores_gemma":[0.0033824379,0.00081693666,0.0005012407,0.001005605,0.0003368346,0.0004914904,0.00059331075,0.002347235,0.000028971723],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009224632,0.1708561,0.051217135,0.0016908604,0.0069799274,0.5901578,0.037723806,0.0019742984,0.006952646,0.00005615807,0.058262717,0.0649039],"study_design_scores_gemma":[0.7055778,0.11051385,0.028175388,0.0020743825,0.0022393754,0.09894437,0.038077876,0.0038700663,0.0037656515,0.000064101005,0.006336928,0.00036019686],"about_ca_topic_score_codex":0.0014787388,"about_ca_topic_score_gemma":0.0026086557,"teacher_disagreement_score":0.6963532,"about_ca_system_score_codex":0.0073662866,"about_ca_system_score_gemma":0.0034316194,"threshold_uncertainty_score":0.9999544},"labels":[],"label_agreement":null},{"id":"W4307262090","doi":"10.35754/0234-5730-2022-67-3-351-366","title":"Observation in a treatment-free remission in chronic myeloid leukemia patients with a stable deep molecular response in the Russian portion of the international multicenter population based study EUTOS PBS","year":2022,"lang":"en","type":"article","venue":"Russian journal of hematology and transfusiology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Defence Medical Centre","funders":"","keywords":"Medicine; Discontinuation; Imatinib; Myeloid leukemia; Internal medicine; Population; Blast Crisis; Cumulative incidence; Pediatrics; Cohort","score_opus":0.009863291487952976,"score_gpt":0.24606522476453355,"score_spread":0.23620193327658057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307262090","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99574107,0.00021515526,0.000044060507,0.0029094915,0.00009015175,0.00096673355,0.0000076224687,0.0000030499461,0.000022656286],"genre_scores_gemma":[0.99953246,0.000022825285,0.00018029007,0.00014492864,0.0000090264375,0.000059692895,0.00003257411,0.000012333626,0.0000058397636],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975605,0.0009920929,0.0007311759,0.00021758716,0.00029737013,0.00020127429],"domain_scores_gemma":[0.9990947,0.00018367403,0.0003811243,0.00027759,0.000025362318,0.000037524816],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070218305,0.00015997185,0.00044137664,0.00037963607,0.0000764353,0.0000043577634,0.00021678269,0.00009296327,0.00006857689],"category_scores_gemma":[0.0000889384,0.000092035676,0.0000723768,0.00032794382,0.00005089291,0.000086103326,0.000031646887,0.00041455365,1.4195135e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014025906,0.001162063,0.9782507,0.000027955508,0.00008002203,0.0003967151,0.0020902418,0.0021681015,0.0011123029,0.00015952386,0.0000010235866,0.0005254775],"study_design_scores_gemma":[0.02697972,0.0032591303,0.9665767,0.00014876851,0.00009363385,0.00022984638,0.00065025274,0.0014581352,0.0003705706,0.0001442936,0.000020409712,0.0000685287],"about_ca_topic_score_codex":0.00038470433,"about_ca_topic_score_gemma":0.0015636494,"teacher_disagreement_score":0.012953815,"about_ca_system_score_codex":0.0018954357,"about_ca_system_score_gemma":0.0006723055,"threshold_uncertainty_score":0.49564984},"labels":[],"label_agreement":null},{"id":"W4307336634","doi":"10.1111/bcp.15576","title":"Incidence of heart failure following exposure to a protein kinase inhibitor, a French population‐based study","year":2022,"lang":"en","type":"article","venue":"British Journal of Clinical Pharmacology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"The Quebec Population Health Research Network","funders":"Ligue Contre le Cancer; Fondation ARC pour la Recherche sur le Cancer","keywords":"Medicine; Hazard ratio; Internal medicine; Dasatinib; Pazopanib; Confidence interval; Everolimus; Incidence (geometry); Ruxolitinib; Population; Pharmacovigilance; Oncology; Adverse effect; Sunitinib; Tyrosine kinase; Cancer","score_opus":0.034569141751634044,"score_gpt":0.39225925084474617,"score_spread":0.3576901090931121,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307336634","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942207,0.00053570746,0.0000274434,0.0024014506,0.0013035855,0.0014600437,0.00002007792,0.00001773765,0.000013273739],"genre_scores_gemma":[0.99355066,0.000003534806,0.0036726454,0.0018188976,0.00070073263,0.00010356299,0.000008458286,0.000027927717,0.0001135789],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953873,0.0011039403,0.0020337543,0.00031828514,0.0008640976,0.00029262813],"domain_scores_gemma":[0.9979181,0.0004878773,0.00073952123,0.00018305797,0.0002683836,0.00040302167],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002454609,0.00015798036,0.0010966015,0.00021340784,0.0001494431,0.0000132949335,0.00026432434,0.00009588397,0.0011705079],"category_scores_gemma":[0.0013622816,0.00017727153,0.0005287393,0.00044295556,0.00003923371,0.00010713489,0.0001949507,0.0011936473,0.000005906004],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018309135,0.007611066,0.9191843,0.00007817882,0.00073201524,0.011122189,0.00019015842,0.0012371789,0.014131403,7.914391e-7,0.035166133,0.00871566],"study_design_scores_gemma":[0.042047936,0.021342015,0.92395675,0.00051884056,0.0009744211,0.0020572094,0.00037732124,0.000098814024,0.0016269664,0.0000429637,0.0066946372,0.00026210386],"about_ca_topic_score_codex":0.0004306663,"about_ca_topic_score_gemma":0.00012633848,"teacher_disagreement_score":0.040217023,"about_ca_system_score_codex":0.00047606186,"about_ca_system_score_gemma":0.0012754475,"threshold_uncertainty_score":0.99974257},"labels":[],"label_agreement":null},{"id":"W4307947801","doi":"10.3390/curroncol29110645","title":"Long-Term Molecular Remission after Treatment with Imatinib in a Chronic Myeloid Leukemia Patient with Extreme Thrombocytosis Harboring Rare e14a3 (b3a3) BCR::ABL1 Transcript: A Case Report","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Thrombocytosis; Imatinib; Myeloid leukemia; Medicine; Fusion gene; Chromosomal translocation; breakpoint cluster region; Fusion transcript; Philadelphia chromosome; ABL; Cancer research; Internal medicine; Gene; Genetics; Biology; Tyrosine kinase; Platelet; Receptor","score_opus":0.058334616732060536,"score_gpt":0.33381619121881023,"score_spread":0.2754815744867497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307947801","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987434,0.008248055,0.00017007413,0.00029620397,0.00041655506,0.0026471294,0.000060956176,0.00013879576,0.0005881804],"genre_scores_gemma":[0.99444246,0.0003324496,0.00068146567,0.00009163758,0.00012570088,0.0035912336,0.00038644086,0.0001271047,0.00022149144],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99581796,0.00031100915,0.0009138535,0.0012762048,0.00073544955,0.00094550394],"domain_scores_gemma":[0.9978903,0.00008075059,0.00044090248,0.0010560191,0.000116035844,0.0004160225],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00022554971,0.0007041623,0.0011644495,0.00036888666,0.00023619128,0.000024782417,0.00015132445,0.00016402268,0.0011445844],"category_scores_gemma":[0.000022604392,0.00053087046,0.00022154351,0.0006001595,0.00016667445,0.00014163302,0.00015659696,0.0007948047,0.000013882411],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005381064,0.0032016034,0.096047774,0.0006096947,0.0006375893,0.7456388,0.005374129,0.000499843,0.008557502,0.000007645191,0.00013546708,0.13390891],"study_design_scores_gemma":[0.10394782,0.0733959,0.057393223,0.0043745423,0.0046566897,0.65964264,0.0030958452,0.0030154414,0.025060914,0.000024105406,0.0624972,0.0028956486],"about_ca_topic_score_codex":0.00040907846,"about_ca_topic_score_gemma":0.0009171524,"teacher_disagreement_score":0.13101326,"about_ca_system_score_codex":0.039216716,"about_ca_system_score_gemma":0.00545092,"threshold_uncertainty_score":0.9997685},"labels":[],"label_agreement":null},{"id":"W4310107771","doi":"10.1182/blood-2022-167581","title":"Risk Factor Analysis for Second Treatment-Free Remission Failure from the Canadian TKI Discontinuation (TRAD) Trial in CML Patients: Treatment-Free Remission Accomplished By Dasatinib","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; McGill University; London Health Sciences Centre; University of Manitoba; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Hôpital de l'Enfant-Jésus; Hôpital Maisonneuve-Rosemont; Nova Scotia Health Authority; Princess Margaret Cancer Centre; University of Calgary; Alberta Health Services; University of Alberta Hospital; Ottawa Hospital; University Health Network; University of Toronto; Alberta Hospital Edmonton; University of British Columbia","funders":"","keywords":"Discontinuation; Dasatinib; Medicine; Internal medicine; Complete remission; Oncology; Surgery; Imatinib; Chemotherapy; Myeloid leukemia","score_opus":0.018545649203503014,"score_gpt":0.2556965387667733,"score_spread":0.23715088956327027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310107771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9770531,0.00041312756,0.000009385846,0.0016122843,0.00021685589,0.0042283377,0.015956568,0.00006511507,0.00044524754],"genre_scores_gemma":[0.98301506,0.0000471462,0.00070223503,0.00012557537,0.00028615555,0.0011392278,0.012772768,0.000073736584,0.0018380969],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9966314,0.00038288298,0.00077940285,0.0009465643,0.00062239746,0.00063737994],"domain_scores_gemma":[0.99636734,0.000640154,0.00049159856,0.0019759096,0.00008531911,0.00043969176],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00023832597,0.00053137913,0.00088734756,0.000281384,0.0008085721,0.00009737305,0.0005660993,0.0002176927,0.002587562],"category_scores_gemma":[0.0008430225,0.00036240387,0.000536859,0.00074373255,0.00004783638,0.00017620756,0.00014326922,0.00031552024,0.0000063534176],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010781464,0.0072605517,0.92065996,0.000016996239,0.00587008,0.00005534256,0.0045356294,0.000039805076,0.0014352499,0.000008459301,0.022456395,0.026880085],"study_design_scores_gemma":[0.5631223,0.007364798,0.3506524,0.00007955132,0.010218379,0.0000060859293,0.0013249941,0.00060169125,0.005060306,0.0003846477,0.06042886,0.00075600337],"about_ca_topic_score_codex":0.19377638,"about_ca_topic_score_gemma":0.51211095,"teacher_disagreement_score":0.57000756,"about_ca_system_score_codex":0.005541607,"about_ca_system_score_gemma":0.0011714513,"threshold_uncertainty_score":0.9998828},"labels":[],"label_agreement":null},{"id":"W4310108893","doi":"10.1182/blood-2022-168534","title":"Identification of Key microRNAs As Predictive Biomarkers of Nilotinib Response in Chronic Myeloid Leukemia: A Sub-Analysis of the Enestxtnd Clinical Trial","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Occupational Cancer Research Centre; Canada's Michael Smith Genome Sciences Centre; University of British Columbia; BC Cancer Agency; Terry Fox Research Institute","funders":"","keywords":"Nilotinib; Myeloid leukemia; Medicine; Oncology; microRNA; Identification (biology); Clinical trial; Internal medicine; Cancer research; Immunology; Bioinformatics; Biology; Imatinib; Genetics","score_opus":0.02463151413993247,"score_gpt":0.3176401550821788,"score_spread":0.2930086409422463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310108893","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971859,0.0007486107,0.0000058950177,0.00019071746,0.00020489728,0.0013361134,0.0002120704,0.000013891214,0.00010194524],"genre_scores_gemma":[0.999365,0.00010773776,0.000033414715,0.000022788512,0.00005238181,0.00012986701,0.000063207386,0.000023593939,0.0002020332],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99559504,0.0012104909,0.0017914643,0.0004540424,0.00072137895,0.00022757973],"domain_scores_gemma":[0.9965988,0.0009359292,0.0012467179,0.0010022243,0.00014488191,0.000071469694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029980764,0.00018027108,0.00092284696,0.0005556314,0.000058203852,0.0000035867454,0.00035391832,0.00014266264,0.00014935966],"category_scores_gemma":[0.0015410632,0.00014872877,0.00070335175,0.00204933,0.00040390436,0.000041377683,0.00022120062,0.0003446289,0.0000030328176],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20903586,0.0050262115,0.11339753,0.00018436287,0.012679373,0.000049227503,0.0015887169,0.00095077587,0.65593755,0.000043658634,0.00017731772,0.0009294305],"study_design_scores_gemma":[0.12359577,0.0056409854,0.5590546,0.00010567868,0.012384079,0.00003325174,0.0006269497,0.00093974295,0.29727867,0.00003119269,0.00015999525,0.00014906075],"about_ca_topic_score_codex":0.0007212179,"about_ca_topic_score_gemma":0.00016212606,"teacher_disagreement_score":0.4456571,"about_ca_system_score_codex":0.0017054722,"about_ca_system_score_gemma":0.0043046526,"threshold_uncertainty_score":0.76362693},"labels":[],"label_agreement":null},{"id":"W4310109065","doi":"10.1182/blood-2022-166416","title":"Single Centre, Retrospective Analysis of Treatment Outcomes and Prognostic Factors in Blastic Phase Chronic Myeloid Leukemia (CML-BP) Following Systemic Therapy","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Myeloid leukemia; Dasatinib; Imatinib mesylate; Oncology; Transplantation; Myeloid; Imatinib; Gastroenterology","score_opus":0.017898624782840496,"score_gpt":0.27159618912413536,"score_spread":0.25369756434129487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310109065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99538255,0.0028760664,0.0000057684956,0.000030653195,0.00011152896,0.0012845641,0.00012535232,0.000069055735,0.00011447613],"genre_scores_gemma":[0.99909014,0.00014767796,0.00004400114,0.000017973025,0.000027960474,0.00014551902,0.00020954225,0.000046051042,0.00027112348],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99777085,0.00014283136,0.0005743796,0.0006044304,0.0004543554,0.00045315674],"domain_scores_gemma":[0.9987999,0.0002954484,0.00025303976,0.00046707678,0.000038988703,0.00014552815],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014346265,0.0003835961,0.001240037,0.0006559733,0.00012565443,0.000016229322,0.00010936936,0.000075576565,0.0001975002],"category_scores_gemma":[0.000107603824,0.00030747097,0.0004374772,0.001186641,0.000055711993,0.000067121655,0.00007528071,0.0001939008,0.0000021990013],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012156123,0.0029881399,0.9695338,0.000055682365,0.0074568903,0.000253342,0.0019932117,0.00028469495,0.016420865,0.000009947387,0.0000032590299,0.00087857695],"study_design_scores_gemma":[0.062371094,0.0076334053,0.9015201,0.00020011657,0.012515977,0.000060132774,0.0016215685,0.0016707008,0.011910691,0.000013179526,0.0000620417,0.0004209928],"about_ca_topic_score_codex":0.0007186635,"about_ca_topic_score_gemma":0.0002988509,"teacher_disagreement_score":0.06801373,"about_ca_system_score_codex":0.009762612,"about_ca_system_score_gemma":0.00079345313,"threshold_uncertainty_score":0.9999377},"labels":[],"label_agreement":null},{"id":"W4310118179","doi":"10.1182/blood-2022-167088","title":"Targeting a Highly Deregulated eIF4F Translation Initiation Complex Sensitises IM-Resistant Cells to Tyrosine Kinase Inhibitors and Effectively Suppresses BCR-ABL1 Protein Expression","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute; Kinexus Bioinformatics Corporation (Canada); University of British Columbia","funders":"","keywords":"Biology; Imatinib mesylate; Molecular biology; Nilotinib; Tyrosine kinase; Myeloid leukemia; Cancer research; Signal transduction; Cell biology; Imatinib","score_opus":0.015438433996950824,"score_gpt":0.2403064383283562,"score_spread":0.22486800433140536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310118179","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959803,0.0007993429,0.00014203115,0.00035880948,0.00007876084,0.0022257522,0.00015203605,0.00015977639,0.000103184524],"genre_scores_gemma":[0.99501145,0.000011733055,0.0039136396,0.00010220019,0.00012047998,0.00027434842,0.00045743745,0.00005342201,0.000055299744],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998109,0.00026049555,0.0003668454,0.0004879532,0.00045627562,0.0003194676],"domain_scores_gemma":[0.9992524,0.000118327975,0.00014743797,0.0002203797,0.00008497729,0.00017651817],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020802637,0.00026081578,0.00035180105,0.00019182512,0.00042520772,0.00003634839,0.00005412198,0.00007488674,0.00013705694],"category_scores_gemma":[0.00008695043,0.0002524912,0.00006105422,0.00033519365,0.000042348882,0.00012429824,0.000098422,0.00019284553,0.0000074574073],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071242865,0.0006334159,0.00091152935,0.0002528818,0.000074801384,0.00021438039,0.00093727146,0.00024965656,0.9943922,0.0000058342393,0.00042760326,0.0011879749],"study_design_scores_gemma":[0.009763761,0.0010524036,0.014946514,0.0003696483,0.00027249035,0.000056168712,0.00026324068,0.0007099998,0.97158384,0.00002126092,0.00070023653,0.00026043883],"about_ca_topic_score_codex":0.00020997229,"about_ca_topic_score_gemma":0.000013276329,"teacher_disagreement_score":0.022808386,"about_ca_system_score_codex":0.00029893758,"about_ca_system_score_gemma":0.00012793826,"threshold_uncertainty_score":0.9999927},"labels":[],"label_agreement":null},{"id":"W4310125603","doi":"10.1182/blood-2022-168228","title":"The Prognostic Impact of <i>HMGCLL1</i> Gene Variant on Treatment Outcomes in Chronic Myeloid Leukemia (CML) Patients: Adverse Impact on the Response, Failure, and Progression with Imatinib Which Can be Abrogated By the Use of 2nd Generation Tyrosine Kinase Inhibitor (TKI) Upfront Therapy","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto; University Health Network","funders":"","keywords":"Imatinib; Myeloid leukemia; Medicine; Adverse effect; Internal medicine; Oncology; Imatinib mesylate; Immunology; Cancer research","score_opus":0.02146055768878582,"score_gpt":0.27370140194382564,"score_spread":0.25224084425503984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310125603","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99300843,0.0007172731,9.30252e-7,0.0011811532,0.000046050336,0.004288251,0.0007219288,0.000028023223,0.0000079814645],"genre_scores_gemma":[0.9979865,0.0002944857,0.00009010629,0.00011348965,0.000042019972,0.00078681344,0.00052947627,0.0000656204,0.00009148997],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99684364,0.00081639533,0.0006125243,0.00046955273,0.0007955567,0.0004623191],"domain_scores_gemma":[0.9972916,0.0009701481,0.0005397094,0.00089609827,0.0001772724,0.00012513573],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005247054,0.00051786203,0.0005748051,0.00013404462,0.00041311764,0.000041074072,0.00018755601,0.000088201734,0.000051895335],"category_scores_gemma":[0.0002818754,0.00019845626,0.00017577104,0.0005522394,0.0001805932,0.00009087182,0.00007845844,0.00035043628,6.9666885e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.048757344,0.017921086,0.6578191,0.000093879135,0.0055627194,0.00026421834,0.0064216717,0.01200963,0.233444,0.000046739242,0.003763601,0.013896016],"study_design_scores_gemma":[0.06596223,0.06935438,0.7125359,0.00048392516,0.0008896868,0.00012746232,0.00040664128,0.003422777,0.14560463,0.0000060415223,0.00069652364,0.0005097808],"about_ca_topic_score_codex":0.0024438952,"about_ca_topic_score_gemma":0.0009917106,"teacher_disagreement_score":0.08783938,"about_ca_system_score_codex":0.00456441,"about_ca_system_score_gemma":0.0022117211,"threshold_uncertainty_score":0.9992569},"labels":[],"label_agreement":null},{"id":"W4310214325","doi":"10.51731/cjht.2022.510","title":"Asciminib (Scemblix)","year":2022,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Medicine; Myeloid leukemia; Drug; Family medicine; Pharmacology; Internal medicine; Political science; Health care","score_opus":0.03483540550133837,"score_gpt":0.2954047634783444,"score_spread":0.260569357977006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310214325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7343896,0.11315837,0.00006045883,0.14806236,0.0012381269,0.0006009397,0.000055939454,0.00022265133,0.0022115351],"genre_scores_gemma":[0.99748325,0.00020639914,0.0006910439,0.0012038652,0.000012358934,0.000012851252,0.0000049670025,0.00001659163,0.0003686418],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99864304,0.0000529948,0.00046897732,0.000121605655,0.00025692035,0.00045645615],"domain_scores_gemma":[0.99910945,0.000036034427,0.0003376746,0.00029664012,0.00008120321,0.00013900886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055427745,0.00010621224,0.00037277196,0.00079573574,0.00041497295,0.000011275202,0.00028160168,0.000060530718,0.00036956364],"category_scores_gemma":[0.00031859896,0.00009377231,0.00009344611,0.00043833946,0.00012403376,0.000049682065,0.00004248226,0.00070984865,0.0000115883295],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000064695574,0.00007560908,0.015485338,0.000120683246,0.00015479987,0.003920031,0.00064155395,0.00005528476,0.000055733643,0.0011855148,0.0707494,0.9074913],"study_design_scores_gemma":[0.0020728982,0.0020814557,0.008956179,0.00010176888,0.000035731984,0.008341032,0.0069058426,0.000015446578,0.00027123705,0.0013146473,0.96978635,0.00011744279],"about_ca_topic_score_codex":0.0035170317,"about_ca_topic_score_gemma":0.0009668367,"teacher_disagreement_score":0.9073739,"about_ca_system_score_codex":0.004307551,"about_ca_system_score_gemma":0.012762776,"threshold_uncertainty_score":0.99951476},"labels":[],"label_agreement":null},{"id":"W4311527531","doi":"10.22541/au.167023553.38117448/v1","title":"NUP214::ABL1: A Ph-like fusion found in a pediatric acute myeloid leukemia patient with normal karyotype","year":2022,"lang":"en","type":"preprint","venue":"","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"","keywords":"Myeloid leukemia; Karyotype; Medicine; Pediatrics; Internal medicine; Biology; Genetics; Gene; Chromosome","score_opus":0.012209393602205194,"score_gpt":0.2520026342678344,"score_spread":0.23979324066562924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311527531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96365005,0.0014293892,0.000065479515,0.00027601284,0.0010854477,0.0030720856,0.000086962085,0.0003121655,0.030022439],"genre_scores_gemma":[0.9718231,0.002397062,0.0049559777,0.0011432285,0.0006390435,0.0013103124,0.0019148102,0.00025663732,0.015559823],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99464554,0.00015898657,0.0010206094,0.001625551,0.0015198742,0.0010294702],"domain_scores_gemma":[0.99703264,0.000133262,0.00051423674,0.0016853319,0.00020125035,0.0004332987],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002893373,0.0009961956,0.0013085435,0.00087104837,0.0001789787,0.0000669723,0.00046881652,0.000560115,0.0050976914],"category_scores_gemma":[0.000048411024,0.0008030431,0.00029527227,0.0010696574,0.00008149916,0.00014346086,0.0022361935,0.0025219896,0.00023482967],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.022750992,0.006304165,0.7890873,0.007149235,0.0049046446,0.044911098,0.01225872,0.01955467,0.00045727397,0.00027705185,0.047475617,0.04486926],"study_design_scores_gemma":[0.09828494,0.020418566,0.7485298,0.0029839205,0.013947806,0.0068241153,0.0029904493,0.013819073,0.0008647526,0.0005753952,0.08243483,0.008326375],"about_ca_topic_score_codex":0.004312323,"about_ca_topic_score_gemma":0.0011332997,"teacher_disagreement_score":0.07553395,"about_ca_system_score_codex":0.0128740715,"about_ca_system_score_gemma":0.00752822,"threshold_uncertainty_score":0.9997792},"labels":[],"label_agreement":null},{"id":"W4317877726","doi":"10.1055/a-1892-0074","title":"Impact of Tyrosine Kinase Inhibitors Applied for First-Line Chronic Myeloid Leukemia Treatment on Platelet Function in Whole Blood of Healthy Volunteers In Vitro","year":2023,"lang":"en","type":"article","venue":"Hämostaseologie","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Montreal Children's Hospital","funders":"","keywords":"Myeloid leukemia; In vitro; Platelet; Tyrosine kinase; Medicine; Pharmacology; Tyrosine-kinase inhibitor; Cancer research; Immunology; Internal medicine; Chemistry; Biochemistry; Cancer; Receptor","score_opus":0.033208601207764296,"score_gpt":0.3086053097621476,"score_spread":0.2753967085543833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317877726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99559766,0.00073169405,0.00001566614,0.0004308482,0.00015982077,0.002291009,0.00058194355,0.00010533289,0.00008599859],"genre_scores_gemma":[0.99632704,0.00052645855,0.00012997334,0.000056953773,0.00012033157,0.0004413144,0.0021954342,0.000056636516,0.00014588123],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975189,0.000046052257,0.00084726623,0.00057584816,0.0002862067,0.0007257025],"domain_scores_gemma":[0.9985369,0.00040933207,0.00026752203,0.0005707836,0.00006518276,0.00015028175],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032629186,0.00041126704,0.0009679282,0.0007150594,0.00004515604,0.0000042898587,0.00010580266,0.00023950847,0.000053194206],"category_scores_gemma":[0.00019138599,0.0003321972,0.00027227483,0.0010057712,0.00013296038,0.00005364398,0.000054710643,0.00022860593,0.000040242514],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.090633705,0.009005516,0.08718406,0.0028231496,0.001699421,0.0010893896,0.0013165546,0.08172747,0.5178583,0.00013753072,0.006723648,0.19980125],"study_design_scores_gemma":[0.099409126,0.040639423,0.13824716,0.000746685,0.00045458644,0.00003241334,0.00029092986,0.0063653616,0.711635,0.00018806197,0.0014000006,0.00059123297],"about_ca_topic_score_codex":0.002116871,"about_ca_topic_score_gemma":0.0008207709,"teacher_disagreement_score":0.19921002,"about_ca_system_score_codex":0.00847635,"about_ca_system_score_gemma":0.0017670388,"threshold_uncertainty_score":0.999913},"labels":[],"label_agreement":null},{"id":"W4318220699","doi":"10.1038/s41375-023-01822-2","title":"Management of children and adolescents with chronic myeloid leukemia in blast phase: International pediatric CML expert panel recommendations","year":2023,"lang":"en","type":"review","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital","funders":"","keywords":"Medicine; Myeloid leukemia; Clinical trial; Hematopoietic stem cell transplantation; Transplantation; Disease; Regimen; Intensive care medicine; Oncology; Internal medicine; Pediatrics; Immunology","score_opus":0.03833482069215284,"score_gpt":0.3354612498558526,"score_spread":0.29712642916369975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318220699","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007833417,0.9871995,0.000030436304,0.00007036376,0.00044872938,0.0033255774,0.00033396613,0.00017228081,0.0005857506],"genre_scores_gemma":[0.0026695486,0.9916586,0.0005328192,0.00003471246,0.00061555114,0.0004671523,0.0023799152,0.00019342445,0.0014482411],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99633974,0.00010129646,0.0012645853,0.0010330507,0.0006631698,0.0005981368],"domain_scores_gemma":[0.9981241,0.00008138093,0.0006893817,0.00080103084,0.00007292297,0.0002311389],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002391875,0.0007873055,0.0018732923,0.0009299144,0.00006827987,0.00003767533,0.0004645727,0.00040015622,0.0001560829],"category_scores_gemma":[0.000024748173,0.00065108266,0.00028972948,0.0010704783,0.00011701319,0.00013838669,0.00037403707,0.0008193081,0.0001452011],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014384571,0.00029525295,0.0015336111,0.022332327,0.0016251539,0.0004940089,0.0001398085,0.000015471753,9.583189e-7,0.00003066918,0.0026841473,0.97070473],"study_design_scores_gemma":[0.06929293,0.0018556997,0.023756841,0.28680933,0.01092862,0.0017954551,0.0002154858,0.0005022553,0.000020397427,0.000026799962,0.60182464,0.0029715772],"about_ca_topic_score_codex":0.0004281905,"about_ca_topic_score_gemma":0.00009821337,"teacher_disagreement_score":0.96773314,"about_ca_system_score_codex":0.019052323,"about_ca_system_score_gemma":0.0033558684,"threshold_uncertainty_score":0.99959403},"labels":[],"label_agreement":null},{"id":"W4318485463","doi":"10.1038/s41375-023-01829-9","title":"Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL","year":2023,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":135,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute; National Institute for Health and Care Research; Novartis Pharmaceuticals Corporation","keywords":"Bosutinib; Discontinuation; Medicine; Tolerability; Internal medicine; Adverse effect; Imatinib; Myeloid leukemia; Clinical endpoint; Oncology; Nilotinib; Gastroenterology; Randomized controlled trial","score_opus":0.02015551723185398,"score_gpt":0.2940192947944369,"score_spread":0.2738637775625829,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318485463","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908283,0.002944916,0.000013272045,0.00020021007,0.0004011803,0.0028998668,0.00015095735,0.00066970254,0.0018916468],"genre_scores_gemma":[0.9832115,0.00082275487,0.0001849991,0.00014154574,0.0009314298,0.0004922504,0.0016498535,0.00033066666,0.01223497],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9928457,0.00022491427,0.0017219881,0.0017626053,0.0013508548,0.0020939403],"domain_scores_gemma":[0.99584424,0.00029853923,0.0007450392,0.0020888753,0.00026893363,0.00075434183],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006580261,0.0012469323,0.0020646788,0.0010085695,0.00024285344,0.00006392767,0.00057704607,0.00057144533,0.0008064163],"category_scores_gemma":[0.00021281179,0.0010766084,0.00051354273,0.0028049387,0.00058752263,0.00039328614,0.00045512748,0.0010042181,0.00091154885],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.033412203,0.0023128742,0.20720719,0.008282974,0.0032174718,0.019906344,0.008046589,0.0058544623,0.55079496,0.00021519701,0.042160988,0.11858877],"study_design_scores_gemma":[0.3367937,0.019355638,0.09623286,0.012932354,0.0026297548,0.0017529024,0.000527885,0.015642049,0.4970107,0.00003814941,0.013721435,0.0033625928],"about_ca_topic_score_codex":0.0018593885,"about_ca_topic_score_gemma":0.0038301998,"teacher_disagreement_score":0.30338147,"about_ca_system_score_codex":0.056382578,"about_ca_system_score_gemma":0.010254351,"threshold_uncertainty_score":0.99986637},"labels":[],"label_agreement":null},{"id":"W4319159835","doi":"10.2147/ppa.s394332","title":"A Survey of Patient Experience in CML: American and Canadian Perspectives","year":2023,"lang":"en","type":"article","venue":"Patient Preference and Adherence","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Pfizer (Canada); McMaster University","funders":"Pfizer","keywords":"Medicine; Quality of life (healthcare); Family medicine; Patient satisfaction; Myeloid leukemia; Internal medicine; Nursing","score_opus":0.07005860869486286,"score_gpt":0.30729032947090723,"score_spread":0.23723172077604437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319159835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984113,0.0004961168,8.2788284e-7,0.000046193978,0.000028700446,0.00034348964,0.00004661918,0.000020616231,0.00060612],"genre_scores_gemma":[0.999023,0.0006950623,0.00008007238,0.00004195772,0.0000033459057,0.00007379874,0.000027724102,0.000008606816,0.000046390258],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998866,0.00006438909,0.00023259023,0.00035857514,0.00018135186,0.0002970742],"domain_scores_gemma":[0.9992923,0.000103395476,0.00009165312,0.00018942216,0.00008909491,0.00023411323],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000077438,0.00013938689,0.0002730048,0.00019889208,0.000042398264,0.000011236102,0.000057004203,0.000036574947,0.000046537054],"category_scores_gemma":[0.00023160788,0.00012024543,0.000015564194,0.0005740265,0.00024830754,0.00008023348,0.00006543391,0.00010880989,0.000010125808],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059829348,0.000074947304,0.8992614,0.000034100693,0.000014274556,0.000027339047,0.022203319,0.0000026131238,0.00027282684,0.000035244753,0.000032160573,0.077981934],"study_design_scores_gemma":[0.00057616533,0.0010283275,0.98685604,0.00019188452,0.000007728621,0.0000060905113,0.010176473,0.0003112264,0.00063507684,0.000023738541,0.00006847765,0.00011878186],"about_ca_topic_score_codex":0.30087644,"about_ca_topic_score_gemma":0.13713704,"teacher_disagreement_score":0.1637394,"about_ca_system_score_codex":0.00017830283,"about_ca_system_score_gemma":0.00035037025,"threshold_uncertainty_score":0.878608},"labels":[],"label_agreement":null},{"id":"W4319864271","doi":"10.5267/j.ccl.2023.1.002","title":"Quantification of Alectinib in spiked rabbit plasma using liquid chromatography- electro spray ionization-tandem mass spectrophotometry: An application to pharmacokinetic study","year":2023,"lang":"en","type":"article","venue":"Current Chemistry Letters","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Chemistry; Chromatography; Calibration curve; Pharmacokinetics; Bioanalysis; Analyte; Extraction (chemistry); Formic acid; Selected reaction monitoring; Mass spectrometry; High-performance liquid chromatography; Analytical Chemistry (journal); Tandem mass spectrometry; Detection limit","score_opus":0.02926466714667477,"score_gpt":0.3347024028011441,"score_spread":0.30543773565446936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319864271","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960911,0.00007274778,0.001775488,0.00026141084,0.0001319248,0.0014757678,0.000010613949,0.00015759406,0.000023305693],"genre_scores_gemma":[0.99877715,0.00004135089,0.00026686047,0.000029572935,0.00018415578,0.00019325728,0.00045148484,0.00004924951,0.00000689071],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978697,0.00005329166,0.00055496505,0.0006449888,0.0004690286,0.000408065],"domain_scores_gemma":[0.998903,0.000048351318,0.00023672868,0.000548019,0.00009059189,0.00017333588],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024685182,0.00027179858,0.00038669963,0.0004124844,0.00006398073,0.000020356852,0.00019487539,0.00006879578,0.000071794544],"category_scores_gemma":[0.00006913837,0.00029711032,0.00008485435,0.0028885156,0.000047224872,0.00008128994,0.000033692133,0.00025468826,0.000028079072],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023893939,0.0006314898,0.043030173,0.00022500202,0.000074742726,0.000016239403,0.00027219762,0.001179667,0.95350623,7.750408e-7,0.00009600835,0.00072855357],"study_design_scores_gemma":[0.0037711482,0.00009769463,0.01650664,0.00014599712,0.00017218012,0.00001575534,0.00016459939,0.0077902866,0.9709254,0.0000020100626,0.00015809674,0.00025020234],"about_ca_topic_score_codex":0.000036267244,"about_ca_topic_score_gemma":0.0000030776162,"teacher_disagreement_score":0.026523534,"about_ca_system_score_codex":0.0008235928,"about_ca_system_score_gemma":0.00015975816,"threshold_uncertainty_score":0.9999481},"labels":[],"label_agreement":null},{"id":"W4321770109","doi":"10.30574/gscbps.2023.22.2.0059","title":"Imatinib mesylate: Recent drug used in oncology","year":2023,"lang":"en","type":"article","venue":"GSC Biological and Pharmaceutical Sciences","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Imatinib; Imatinib mesylate; Medicine; Internal medicine; Oncology; Myeloid leukemia; Pharmacology","score_opus":0.20345097557871303,"score_gpt":0.44717839596379066,"score_spread":0.24372742038507764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321770109","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9760953,0.00075717806,0.0000016747223,0.015433421,0.00014557062,0.00028317602,0.0000053188305,0.00007636733,0.007202002],"genre_scores_gemma":[0.99296427,0.005190241,0.00034711894,0.0011594684,0.000064715845,0.000026542044,0.000011555662,0.0000029268613,0.00023318082],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998564,0.00013964152,0.00023596043,0.00039878028,0.00019567972,0.0004659246],"domain_scores_gemma":[0.9991455,0.00048951205,0.000030321818,0.000068769106,0.000015991955,0.00024990487],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008961838,0.000123424,0.00028178122,0.00008187118,0.00010951636,0.000015932057,0.00010997464,0.00010949129,0.0013562503],"category_scores_gemma":[0.00022174376,0.00006791699,0.00003776088,0.0007826777,0.00073369953,0.00004107563,0.00013034324,0.0002328581,0.00026436523],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033607148,0.00046065074,0.45213014,0.00004253341,0.000032672822,0.00044532184,0.00046286374,0.000009188516,0.011318139,0.0013896518,0.0016180191,0.5317548],"study_design_scores_gemma":[0.008563151,0.002013155,0.47388968,0.00011126256,0.00006154471,0.00021675613,0.0007691295,0.011064017,0.008293373,0.0063559785,0.48819822,0.00046374975],"about_ca_topic_score_codex":0.000023532888,"about_ca_topic_score_gemma":0.000010869482,"teacher_disagreement_score":0.531291,"about_ca_system_score_codex":0.0001432872,"about_ca_system_score_gemma":0.00013342635,"threshold_uncertainty_score":0.99955666},"labels":[],"label_agreement":null},{"id":"W4322766543","doi":"10.1016/j.ejps.2023.106418","title":"Pharmacokinetics and pharmacodynamics of imatinib for optimal drug repurposing from cancer to COVID-19","year":2023,"lang":"en","type":"article","venue":"European Journal of Pharmaceutical Sciences","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Innovative Medicines Initiative; European Commission; Innovative Health Initiative; European Federation of Pharmaceutical Industries and Associations","keywords":"Pharmacokinetics; Repurposing; Pharmacodynamics; Coronavirus disease 2019 (COVID-19); Drug repositioning; Pharmacology; Imatinib; Medicine; 2019-20 coronavirus outbreak; Drug; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Virology; Internal medicine; Biology","score_opus":0.10488699374840545,"score_gpt":0.44400318624229607,"score_spread":0.33911619249389063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322766543","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870056,0.0016218898,0.0021382426,0.0076869517,0.0005219293,0.00042176063,0.00011013453,0.000033890738,0.0004596084],"genre_scores_gemma":[0.9757585,0.0020718814,0.018993922,0.0024503197,0.0005186662,0.0000052117207,0.0000056946087,0.000030206109,0.00016557724],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99798924,0.00020159016,0.0006333485,0.0002758451,0.00054630236,0.00035369088],"domain_scores_gemma":[0.99805206,0.00057175435,0.0003017269,0.00009179503,0.00015048176,0.00083216705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020727627,0.00016370285,0.00035250332,0.00022566406,0.00015185997,0.000040476363,0.00028667043,0.000014688055,0.00022893031],"category_scores_gemma":[0.0005112161,0.00012367153,0.00011820825,0.0005714174,0.00035637448,0.00012701841,0.00013762308,0.00021216563,0.000010342905],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036207752,0.000519304,0.019910399,0.0008012604,0.00090154074,0.001521941,0.007216843,0.025361044,0.61355144,0.00015833294,0.03864556,0.28779155],"study_design_scores_gemma":[0.0391953,0.0030020287,0.012415166,0.0014100434,0.0029409565,0.000773604,0.0020783,0.3294998,0.200404,0.00022776572,0.40713808,0.00091493694],"about_ca_topic_score_codex":0.000023240476,"about_ca_topic_score_gemma":0.0000012582808,"teacher_disagreement_score":0.41314745,"about_ca_system_score_codex":0.0002272141,"about_ca_system_score_gemma":0.00050350605,"threshold_uncertainty_score":0.5043179},"labels":[],"label_agreement":null},{"id":"W4361952989","doi":"10.1158/1078-0432.c.6528791.v1","title":"Data from Pharmacokinetics of Nilotinib in Pediatric Patients with Philadelphia Chromosome–Positive Chronic Myeloid Leukemia or Acute Lymphoblastic Leukemia","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lab_Bell (Canada)","funders":"Novartis Pharmaceuticals Corporation","keywords":"Nilotinib; Medicine; Pharmacokinetics; Internal medicine; Gastroenterology; Adverse effect; Dasatinib; Rash; Body surface area; Myeloid leukemia; Imatinib","score_opus":0.04081441829820549,"score_gpt":0.304567071327996,"score_spread":0.2637526530297905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361952989","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9769434,0.0009773904,0.00028598573,0.0003729364,0.0012208055,0.0043415637,0.014926415,0.0004457347,0.00048577358],"genre_scores_gemma":[0.947618,0.0054845223,0.0025303208,0.00019240177,0.001548632,0.00029120827,0.0402082,0.00048491993,0.0016417884],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99188954,0.00018857096,0.0018669926,0.0029402487,0.0018292423,0.0012853966],"domain_scores_gemma":[0.99288607,0.0009007231,0.0012907999,0.003887099,0.00047630517,0.00055902667],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00031028184,0.0015583778,0.0025587974,0.0010075271,0.000085592685,0.0000660125,0.0019042139,0.0009673511,0.0013715521],"category_scores_gemma":[0.00027564736,0.0011965326,0.0002588028,0.0014162521,0.0003149494,0.00028570273,0.0042887838,0.0018694374,0.00042901264],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.039557017,0.007865184,0.72599095,0.018217973,0.03040107,0.012476163,0.002768082,0.03302537,0.0041049523,0.000034315504,0.115448505,0.010110415],"study_design_scores_gemma":[0.08032779,0.0037376406,0.8471277,0.0057840114,0.015302603,0.00006680725,0.00010423032,0.04032146,0.0036824897,0.000099444194,0.0007144168,0.00273145],"about_ca_topic_score_codex":0.0023957354,"about_ca_topic_score_gemma":0.0016375645,"teacher_disagreement_score":0.1211367,"about_ca_system_score_codex":0.019988973,"about_ca_system_score_gemma":0.020059789,"threshold_uncertainty_score":0.99971646},"labels":[],"label_agreement":null},{"id":"W4362692309","doi":"10.1097/mph.0000000000002660","title":"Effect of Imatinib Mesylate on Growth in Pediatric Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis","year":2023,"lang":"en","type":"review","venue":"Journal of Pediatric Hematology/Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Meta-analysis; Imatinib mesylate; Internal medicine; Myeloid leukemia; Imatinib; Publication bias; Random effects model; Observational study; Pediatrics","score_opus":0.05537252435930245,"score_gpt":0.39024383743714114,"score_spread":0.3348713130778387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362692309","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003987859,0.9935377,0.0000062768486,0.0002848863,0.00024744758,0.0052382187,0.000059817477,0.00004070045,0.0001861371],"genre_scores_gemma":[0.0003071292,0.99782634,0.00018789041,0.00012289252,0.0004953058,0.00064921944,0.00004849048,0.00014912548,0.00021361082],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98442334,0.00485313,0.007907956,0.00091401563,0.0010010772,0.00090049196],"domain_scores_gemma":[0.97625744,0.010866881,0.010974297,0.0009659349,0.0004465081,0.0004889173],"candidate_categories":["metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.008392371,0.0013776006,0.040401913,0.0054356526,0.00006078013,0.000015161712,0.0007325515,0.0016733161,0.00019335617],"category_scores_gemma":[0.0052551115,0.0008237548,0.0067407056,0.005429676,0.0001533588,0.00012005393,0.00026452504,0.0026970697,0.00017519109],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000076599645,0.00022222205,0.00012811378,0.89744824,0.09649461,0.0034506686,0.000047751106,0.0000028960346,3.8982463e-8,0.00003391537,0.001023999,0.0010709629],"study_design_scores_gemma":[0.0032207544,0.0057361056,0.000010058632,0.018251898,0.9640756,0.0071040117,0.000007490259,0.000007792726,0.0000016054194,0.000018845221,0.0011379516,0.00042784362],"about_ca_topic_score_codex":0.000029719278,"about_ca_topic_score_gemma":0.000022264778,"teacher_disagreement_score":0.87919635,"about_ca_system_score_codex":0.0064535737,"about_ca_system_score_gemma":0.00788943,"threshold_uncertainty_score":0.9998975},"labels":[],"label_agreement":null},{"id":"W4366822278","doi":"10.1038/s41408-023-00823-9","title":"Management of chronic myeloid leukemia in 2023 – common ground and common sense","year":2023,"lang":"en","type":"review","venue":"Blood Cancer Journal","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":172,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Bosutinib; Dasatinib; Nilotinib; Ponatinib; Medicine; Imatinib; Oncology; Imatinib mesylate; Internal medicine; Myeloid leukemia; Intensive care medicine","score_opus":0.04700418793668781,"score_gpt":0.35556062656842063,"score_spread":0.3085564386317328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366822278","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009163806,0.9879308,7.1217386e-7,0.000048996553,0.00053130346,0.0011864702,0.00009092603,0.000035901914,0.0010111209],"genre_scores_gemma":[0.00039365137,0.9957544,0.00008416923,0.000027417693,0.00067022257,0.00016631764,0.000080022815,0.00014561805,0.0026781685],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99653083,0.00021565969,0.0014734089,0.0005083174,0.00063447363,0.00063729886],"domain_scores_gemma":[0.99797964,0.00015871371,0.00093203166,0.00058015063,0.00005467773,0.000294789],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005946244,0.0006285968,0.002934435,0.000561639,0.000101146215,0.00004978041,0.00023587856,0.0003660785,0.0002021045],"category_scores_gemma":[0.000010084492,0.0005152506,0.00046241836,0.0007371962,0.00012777346,0.00008481888,0.00026097632,0.0014721231,0.000046341203],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000054833825,0.00016313023,0.00032588487,0.05667026,0.0037363733,0.008883324,0.00006771093,0.000013323831,0.0000016392981,0.00003486424,0.00082560524,0.92922306],"study_design_scores_gemma":[0.014313979,0.0007614488,0.0029564898,0.25646636,0.017706597,0.012083238,0.00014320287,0.000053778815,0.00001062533,0.00012629479,0.6945491,0.0008289149],"about_ca_topic_score_codex":0.001547206,"about_ca_topic_score_gemma":0.0011016834,"teacher_disagreement_score":0.92839414,"about_ca_system_score_codex":0.009049076,"about_ca_system_score_gemma":0.0029341893,"threshold_uncertainty_score":0.99972993},"labels":[],"label_agreement":null},{"id":"W4367303940","doi":"10.1212/wnl.0000000000202145","title":"Lack of Rebound Disease Activity in Participants with Relapsing Multiple Sclerosis Following Placebo Run-out in the Tolebrutinib Phase 2b Trial (P6-3.006)","year":2023,"lang":"en","type":"article","venue":"Neurology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; NeuroRx Research (Canada); University of Toronto; Montreal Neurological Institute and Hospital; McGill University; University of British Columbia","funders":"","keywords":"Multiple sclerosis; Placebo; Disease; Medicine; Internal medicine; Immunology; Alternative medicine; Pathology","score_opus":0.14587758114431398,"score_gpt":0.3641390942754008,"score_spread":0.21826151313108683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367303940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99587,0.000043939282,0.000005764947,0.0020166184,0.00033963833,0.0014591631,0.000016993292,0.000060483108,0.00018737935],"genre_scores_gemma":[0.99900466,0.000025613674,0.00002198501,0.0005322986,0.00009164676,0.00020077723,0.000025251784,0.000035932717,0.00006183897],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9976029,0.0005295068,0.00040865218,0.00048066536,0.00034950217,0.0006287877],"domain_scores_gemma":[0.9979676,0.0011639951,0.00014950597,0.0005626072,0.000017380484,0.0001389188],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071411557,0.00021575387,0.0005493561,0.00021995901,0.00006761992,0.000012412459,0.00015500974,0.00012875898,0.000024779732],"category_scores_gemma":[0.00088078936,0.00015697663,0.000119334276,0.00046788232,0.00013848359,0.00009207064,0.000073053525,0.00047185845,0.00003180782],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.50688094,0.0033773389,0.45510378,0.00013417043,0.00019826385,0.005077993,0.005185774,0.0004766579,0.018896822,0.00002000114,0.00038075302,0.0042675016],"study_design_scores_gemma":[0.44899842,0.006462259,0.5329738,0.00031374296,0.00046588224,0.000025049123,0.00016704675,0.008122674,0.0016709289,0.00008727162,0.0004257616,0.00028714904],"about_ca_topic_score_codex":0.0005378338,"about_ca_topic_score_gemma":0.0021144897,"teacher_disagreement_score":0.077870026,"about_ca_system_score_codex":0.00014987472,"about_ca_system_score_gemma":0.00043404527,"threshold_uncertainty_score":0.6401321},"labels":[],"label_agreement":null},{"id":"W4376102342","doi":"10.5281/zenodo.7919555","title":"Imatinib mesylate: Recent drug used in oncology","year":2023,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Imatinib mesylate; Drug; Imatinib; Medicine; Mesylate; Anticancer drug; Oncology; Medical physics; Internal medicine; Pharmacology; Chemistry","score_opus":0.058338928146033704,"score_gpt":0.3151679195635627,"score_spread":0.256828991417529,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376102342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7597907,0.00012940091,0.00006053747,0.009633434,0.00022625428,0.0013930643,0.00010566936,0.0021536215,0.22650729],"genre_scores_gemma":[0.98432475,0.0010266544,0.0003830131,0.000405767,0.000188966,2.7200048e-7,0.0043747057,0.0019799848,0.007315855],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981683,0.00029485725,0.00031370626,0.00039627455,0.0003690781,0.00045778975],"domain_scores_gemma":[0.99897873,0.000053848365,0.00008107157,0.00044492434,0.00024102165,0.0002004287],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000792441,0.0001394092,0.00024893598,0.00040953883,0.00050056225,0.000108592874,0.0003648319,0.000078408775,0.017433476],"category_scores_gemma":[0.0008005866,0.00013814843,0.00004723339,0.0012493356,0.00009920776,0.0001052516,0.00063303456,0.00033457717,0.02895277],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032730977,0.0006146487,0.00025435936,0.0001775184,0.0001329324,0.0007528836,0.0057176617,0.00008300483,0.009627907,0.0009105426,0.556096,0.42530525],"study_design_scores_gemma":[0.0034300906,0.00030075843,0.0064458847,0.00005896398,0.000020495627,0.00017716418,0.00053742196,0.00069963746,0.0009124419,0.000095917734,0.987199,0.00012223094],"about_ca_topic_score_codex":0.000037250644,"about_ca_topic_score_gemma":0.0000018859557,"teacher_disagreement_score":0.431103,"about_ca_system_score_codex":0.001429933,"about_ca_system_score_gemma":0.000029542614,"threshold_uncertainty_score":0.9834647},"labels":[],"label_agreement":null},{"id":"W4376641118","doi":"10.1007/s11899-023-00698-4","title":"A Pragmatic Approach to Managing Long-Term Adverse Effects in Chronic Myeloid Leukemia Treatment","year":2023,"lang":"en","type":"review","venue":"Current Hematologic Malignancy Reports","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Myeloid leukemia; Adverse effect; Hematology; Oncology; Internal medicine; Population; Intensive care medicine","score_opus":0.0647491682968343,"score_gpt":0.36325252237516004,"score_spread":0.29850335407832573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376641118","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017708791,0.97803414,0.00013887066,0.000015927433,0.0015503749,0.01582302,0.000021114074,0.00070479733,0.0019408959],"genre_scores_gemma":[0.00063399045,0.9847918,0.0004576086,0.000017752347,0.0003421655,0.010035128,0.0017664478,0.0003177743,0.0016373312],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99076515,0.0004023384,0.003331102,0.0028094016,0.0009269122,0.0017651189],"domain_scores_gemma":[0.99424726,0.0004228564,0.0018104546,0.0027227313,0.0000811493,0.0007155654],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00065291626,0.0020467178,0.0071390932,0.0014358878,0.0001387941,0.00005486443,0.0004041932,0.0007637815,0.00007617193],"category_scores_gemma":[0.00042422244,0.0015125223,0.0015514478,0.001958446,0.00011418839,0.00012544695,0.0004557926,0.0009526395,0.00087783934],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000022342154,0.0009978533,0.0024519481,0.32129973,0.0009946736,0.046202984,0.0002028265,0.000024985678,9.52008e-7,0.00016743931,0.0005363067,0.62709796],"study_design_scores_gemma":[0.0073373667,0.00159624,0.0019279162,0.63998306,0.013105675,0.05539084,0.000041651252,0.00018657734,0.000029535891,0.00042164742,0.27610075,0.003878731],"about_ca_topic_score_codex":0.00006327074,"about_ca_topic_score_gemma":0.00003552903,"teacher_disagreement_score":0.62321925,"about_ca_system_score_codex":0.028435381,"about_ca_system_score_gemma":0.0060831774,"threshold_uncertainty_score":0.9999001},"labels":[],"label_agreement":null},{"id":"W4377565617","doi":"10.1002/cpt.2956","title":"Response‐Based Dosing for Ponatinib: Model‐Based Analyses of the Dose‐Ranging OPTIC Study","year":2023,"lang":"en","type":"article","venue":"Clinical Pharmacology & Therapeutics","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Espace pour la vie","funders":"","keywords":"Ponatinib; Medicine; Neutropenia; Confidence interval; Internal medicine; Hazard ratio; Odds ratio; Dosing; Myeloid leukemia; Toxicity; Nilotinib; Imatinib","score_opus":0.30421762609624836,"score_gpt":0.533092272215992,"score_spread":0.22887464611974362,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377565617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98566455,0.00016233351,0.0011556597,0.009919762,0.00067004503,0.0021847312,0.00003756525,0.00016017497,0.000045154145],"genre_scores_gemma":[0.9786606,0.00002178291,0.0021219915,0.018441364,0.00015953236,0.00016935288,0.000020687627,0.00006674867,0.00033793715],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9969208,0.00082089123,0.000952528,0.00047814235,0.00035843812,0.0004692057],"domain_scores_gemma":[0.99305284,0.005679265,0.00033897214,0.0005799866,0.0002204538,0.00012846611],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020902997,0.0002680394,0.00071353774,0.00020664545,0.0001986729,0.000009395606,0.00034897053,0.00020641605,0.000059252914],"category_scores_gemma":[0.00021850971,0.00018720436,0.00049723487,0.0007278465,0.00037345692,0.000030101095,0.00009147033,0.00045287854,0.000016852811],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06490211,0.0141825685,0.08590832,0.00042189215,0.012115102,0.00027466158,0.0014641588,0.1701668,0.6286979,0.000020213045,0.009297064,0.012549258],"study_design_scores_gemma":[0.031294398,0.00246744,0.033273995,0.00007467523,0.0065939357,0.0000037378181,0.00017382983,0.8979142,0.026616536,0.000056783465,0.0013191813,0.00021128765],"about_ca_topic_score_codex":0.000005099214,"about_ca_topic_score_gemma":0.0000017761122,"teacher_disagreement_score":0.7277474,"about_ca_system_score_codex":0.00029468254,"about_ca_system_score_gemma":0.0013700463,"threshold_uncertainty_score":0.7633973},"labels":[],"label_agreement":null},{"id":"W4378640330","doi":"10.1111/bjh.18883","title":"Treatment‐free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5‐year analysis of <scp>DASFREE</scp>","year":2023,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; National Institutes of Health; Bristol-Myers Squibb","keywords":"Dasatinib; Discontinuation; Medicine; Internal medicine; Adverse effect; Drug holiday; Chronic myeloid leukaemia; Surgery; Gastroenterology; Imatinib; Immunology; Myeloid leukemia; Human immunodeficiency virus (HIV)","score_opus":0.01022971088303479,"score_gpt":0.27219947009552864,"score_spread":0.2619697592124938,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378640330","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957511,0.0032141928,0.000077640434,0.00015033399,0.000046192505,0.0005980046,0.00006306986,0.000025474721,0.00007402946],"genre_scores_gemma":[0.99817115,0.00051852915,0.00082478207,0.000029952562,0.00004318534,0.000051938292,0.00013786928,0.00006539404,0.00015722692],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964528,0.00040666902,0.001213384,0.0004950807,0.00072347565,0.0007085718],"domain_scores_gemma":[0.99771047,0.00039791805,0.0007498418,0.0006032966,0.00027635167,0.00026212464],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00046879076,0.00037328573,0.0018030539,0.0016914493,0.000045261404,0.000022065546,0.00029128752,0.00026148293,0.00014128655],"category_scores_gemma":[0.0005401161,0.00031943587,0.00027976843,0.0023695948,0.0002485731,0.00018296705,0.000085959364,0.0005193984,0.000010938551],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016366966,0.0019888033,0.72890264,0.00039016397,0.0040276055,0.22400972,0.00084999506,0.0029500325,0.0020048823,0.000013490823,0.00040335508,0.018092345],"study_design_scores_gemma":[0.094215214,0.01352221,0.8676493,0.0024960148,0.0024960465,0.01437442,0.00021612445,0.0012721644,0.0030958734,0.00003427498,0.0004127598,0.00021560534],"about_ca_topic_score_codex":0.00032469028,"about_ca_topic_score_gemma":0.0024898546,"teacher_disagreement_score":0.2096353,"about_ca_system_score_codex":0.0036391984,"about_ca_system_score_gemma":0.0022819636,"threshold_uncertainty_score":0.9999258},"labels":[],"label_agreement":null},{"id":"W4379282925","doi":"10.1200/jco.2023.41.16_suppl.e19069","title":"Stopping study in chronic myeloid leukemia: Defining a new paradigm for Ontario CML1.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Windsor; Western University; Windsor Regional Hospital","funders":"","keywords":"Medicine; Clinical endpoint; Myeloid leukemia; Internal medicine; Cohort; Quality of life (healthcare); Cancer; Incidence (geometry); Oncology; Clinical trial","score_opus":0.18085906819872577,"score_gpt":0.46733339883324565,"score_spread":0.2864743306345199,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282925","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915727,0.00062379707,0.00011136092,0.002815207,0.0015382026,0.0009530183,0.0000017988303,0.00003594414,0.00234799],"genre_scores_gemma":[0.99034077,0.00035820494,0.0024804354,0.0009350871,0.0018685003,0.00003536647,0.0000104275505,0.00004838938,0.0039228476],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950451,0.00029009875,0.0032415236,0.00038115293,0.00045264818,0.00058946386],"domain_scores_gemma":[0.99341965,0.0041258843,0.0014613312,0.0003285604,0.00013561909,0.0005289871],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004715942,0.00024088447,0.0022298805,0.00040196563,0.000059521186,0.00001440273,0.00026271894,0.00048681072,0.00016724085],"category_scores_gemma":[0.0033695155,0.00019228482,0.00061904744,0.0004238563,0.000083264706,0.00014628335,0.00010505513,0.0017766503,0.00011046895],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.007000181,0.0021090352,0.6499048,0.00009482016,0.0015177852,0.0059335744,0.0030052941,0.00095960096,0.000095901814,0.00032059688,0.01993674,0.30912167],"study_design_scores_gemma":[0.062112916,0.033781834,0.7653368,0.000338402,0.0006896164,0.00045510143,0.0005905877,0.0005885775,0.000013502357,0.00086505746,0.13503474,0.00019287893],"about_ca_topic_score_codex":0.0033803429,"about_ca_topic_score_gemma":0.03688939,"teacher_disagreement_score":0.3089288,"about_ca_system_score_codex":0.014977055,"about_ca_system_score_gemma":0.043770492,"threshold_uncertainty_score":0.9888043},"labels":[],"label_agreement":null},{"id":"W4381248768","doi":"10.1038/s41588-023-01429-4","title":"Transcriptomic classes of BCR-ABL1 lymphoblastic leukemia","year":2023,"lang":"en","type":"article","venue":"Nature Genetics","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"Canadian Institutes of Health Research; Hospital for Sick Children; Ontario Institute for Cancer Research; Princess Margaret Cancer Foundation; University Health Network; American Society of Hematology; V Foundation for Cancer Research","keywords":"Biology; Leukemia; Transcriptome; Cancer research; Tyrosine kinase; Progenitor cell; Stem cell; Immunology; Genetics; Signal transduction; Gene; Gene expression","score_opus":0.013382498910148753,"score_gpt":0.278462186968016,"score_spread":0.26507968805786725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381248768","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99200356,0.004067443,0.000036348647,0.00023073127,0.00061890564,0.00033618938,0.00004628989,0.00017173958,0.0024888057],"genre_scores_gemma":[0.9945889,0.0013199814,0.0012366526,0.00030663438,0.0002348192,0.000014445073,0.00010983147,0.000055384437,0.0021333406],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99851066,0.000024830886,0.00032018137,0.0003251206,0.0004467977,0.00037238124],"domain_scores_gemma":[0.99904037,0.000109249886,0.00008411138,0.0005029318,0.000118209515,0.00014512408],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009780944,0.00021862295,0.00038245413,0.00020936744,0.00003988216,0.000007950331,0.00016109161,0.0004863538,0.00013362717],"category_scores_gemma":[0.00011750331,0.00019163358,0.00015561849,0.00063691195,0.00009113145,0.000022776107,0.000040695537,0.00041042428,0.00019684661],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015583301,0.00077496347,0.26442063,0.0033755766,0.0023262335,0.0012944344,0.0026602752,0.0030264365,0.47539172,0.0008081864,0.16700593,0.07735731],"study_design_scores_gemma":[0.015391752,0.0012510136,0.53999406,0.0006138959,0.0012880203,0.00031814436,0.00032991043,0.009553899,0.34342235,0.00075170625,0.0864152,0.00067001645],"about_ca_topic_score_codex":0.000015173922,"about_ca_topic_score_gemma":0.000018275952,"teacher_disagreement_score":0.27557346,"about_ca_system_score_codex":0.00083841005,"about_ca_system_score_gemma":0.0010380427,"threshold_uncertainty_score":0.78145903},"labels":[],"label_agreement":null},{"id":"W4381660968","doi":"10.3390/curroncol30070444","title":"Myeloproliferative Neoplasm Driven by ETV6-ABL1 in an Adolescent with Recent History of Burkitt Leukemia","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre; Université Laval; Hospital for Sick Children","funders":"","keywords":"ETV6; Myeloproliferative neoplasm; Medicine; Fusion gene; ABL; Myeloid leukemia; Imatinib; Leukemia; Fusion transcript; Tyrosine kinase; Cancer research; Myeloid; Oncology; Internal medicine; Chromosomal translocation; Bone marrow; Biology; Gene; Myelofibrosis; Genetics","score_opus":0.08668141844908007,"score_gpt":0.3659810404932367,"score_spread":0.27929962204415665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381660968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927932,0.0017100604,0.000021815415,0.0009291555,0.0011649132,0.0010231085,0.000034851684,0.0001304357,0.002192472],"genre_scores_gemma":[0.99089754,0.0042119063,0.00036104347,0.0005016864,0.00029190295,0.00035942232,0.0009738183,0.000089672096,0.0023130374],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978675,0.00020021369,0.00050648826,0.0005532356,0.0003544991,0.00051805074],"domain_scores_gemma":[0.9987628,0.00011013145,0.00023774814,0.00043836248,0.00018867826,0.0002622809],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000220261,0.00028986236,0.00073447014,0.00029415463,0.000027342723,0.0000032783566,0.00016294158,0.00020515286,0.00020505198],"category_scores_gemma":[0.00008741178,0.00024333072,0.00006368065,0.0004394506,0.00025307017,0.000088879206,0.000084025865,0.00057297456,0.00009189089],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029774723,0.004278324,0.4405708,0.000738348,0.00028101867,0.00072284305,0.010145536,0.00029577408,0.0070455484,0.00014932177,0.24468742,0.2881076],"study_design_scores_gemma":[0.018684024,0.0040978105,0.1506035,0.0007084456,0.00021299407,0.00009899163,0.0007468437,0.0029530213,0.0016971069,0.00002684705,0.8197525,0.00041790627],"about_ca_topic_score_codex":0.00006898748,"about_ca_topic_score_gemma":0.0005016933,"teacher_disagreement_score":0.5750651,"about_ca_system_score_codex":0.020067634,"about_ca_system_score_gemma":0.0048549,"threshold_uncertainty_score":0.99227387},"labels":[],"label_agreement":null},{"id":"W4382011805","doi":"10.1002/ajh.27007","title":"Classification of accelerated phase chronic myeloid leukemia in the era of the <scp>BCR</scp>::<scp>ABL1</scp> tyrosine kinase inhibitors: A work in progress","year":2023,"lang":"en","type":"editorial","venue":"American Journal of Hematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Takeda Canada; Ascentage Pharma; British Mycological Society; Novartis","keywords":"Myeloid leukemia; Tyrosine kinase; Cancer research; Medicine; Internal medicine; Receptor","score_opus":0.017855564900483584,"score_gpt":0.30960908258422964,"score_spread":0.2917535176837461,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382011805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90955967,0.0053737448,0.000007969921,0.0006106712,0.08297219,0.0012559545,0.00008008154,0.000030208097,0.00010953821],"genre_scores_gemma":[0.937661,0.0019342992,0.00028556256,0.00007555718,0.059257187,0.00019103794,0.00022879694,0.00018767793,0.00017890644],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9929464,0.00106048,0.0028876832,0.0006125309,0.0015735204,0.00091939425],"domain_scores_gemma":[0.98614985,0.006253105,0.0054381927,0.0011311707,0.0008286471,0.00019905034],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00161946,0.0007061655,0.0028854317,0.0008473077,0.00008052172,0.0000331954,0.0012295196,0.0007743356,0.000015695556],"category_scores_gemma":[0.006827075,0.0004522725,0.0005269475,0.003700227,0.0016882465,0.00014914107,0.00019454,0.0037524558,0.000017012213],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00069429644,0.0021351678,0.018888494,0.0012488896,0.0010844397,0.0016913753,0.0053534256,0.00012846426,0.002889188,0.000059917344,0.951512,0.014314343],"study_design_scores_gemma":[0.119970225,0.032127213,0.08731573,0.05138699,0.0057285577,0.0053987973,0.03458574,0.0010681659,0.042809036,0.00038945387,0.6182408,0.0009793116],"about_ca_topic_score_codex":0.00042217082,"about_ca_topic_score_gemma":0.00018994622,"teacher_disagreement_score":0.3332712,"about_ca_system_score_codex":0.004149049,"about_ca_system_score_gemma":0.009951271,"threshold_uncertainty_score":0.9997929},"labels":[],"label_agreement":null},{"id":"W4382399274","doi":"10.3410/f.742681532.793599109","title":"Faculty Opinions recommendation of PPFIA1-targeting miR-181a mimic and saRNA overcome imatinib resistance in BCR-ABL1-independent chronic myeloid leukemia by suppressing leukemia stem cell regeneration.","year":2023,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute","funders":"","keywords":"Myeloid leukemia; Imatinib; Cancer research; Stem cell; Leukemia; Imatinib mesylate; Medicine; Biology; Immunology; Cell biology","score_opus":0.02261671966470749,"score_gpt":0.318877510601202,"score_spread":0.2962607909364945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382399274","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007894369,0.013959975,0.000019554396,0.052351635,0.0008066023,0.0026795694,0.92994463,0.000084682055,0.00007438142],"genre_scores_gemma":[0.00011218768,0.0035903065,0.0011096285,0.0012469661,0.00036656274,0.00043552322,0.9887622,0.00009683529,0.004279794],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9919363,0.00072255166,0.003029428,0.0013996934,0.002147021,0.00076496083],"domain_scores_gemma":[0.9924024,0.0003831781,0.002541038,0.0018314737,0.0023741112,0.00046781756],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020202126,0.0009655178,0.0018526199,0.000641461,0.00035854403,0.00020036087,0.0011293052,0.0011790273,0.00017983266],"category_scores_gemma":[0.0023312443,0.00072239205,0.0005655045,0.0023866666,0.0003864272,0.0005398225,0.000650738,0.0020218955,0.0000762703],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000055645447,0.000247443,0.000025780471,0.02045158,0.0001826244,0.0000036876304,0.00023658933,0.000001932055,0.00019665704,0.000024643594,0.9773077,0.0012657699],"study_design_scores_gemma":[0.0038160153,0.0001748767,0.0016549848,0.027389292,0.00036534618,0.00005076513,0.00008002493,0.00012291643,0.0005380535,0.000013918081,0.96524835,0.00054546306],"about_ca_topic_score_codex":0.00038878943,"about_ca_topic_score_gemma":0.00012094227,"teacher_disagreement_score":0.05881754,"about_ca_system_score_codex":0.0048440695,"about_ca_system_score_gemma":0.003658563,"threshold_uncertainty_score":0.99952275},"labels":[],"label_agreement":null},{"id":"W4382934820","doi":"10.1016/s2352-3026(23)00088-1","title":"Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trial","year":2023,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Medicine; Dasatinib; Internal medicine; Chemotherapy; Minimal residual disease; Clinical endpoint; Acute lymphocytic leukemia; Imatinib; Induction chemotherapy; Hematopoietic stem cell transplantation; Oncology; Chemotherapy regimen; Transplantation; Surgery; Pediatrics; Clinical trial; Leukemia; Lymphoblastic Leukemia","score_opus":0.035050732731479066,"score_gpt":0.3213202882339479,"score_spread":0.28626955550246885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382934820","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.982882,0.0004243204,0.00009826247,0.01298544,0.00035229692,0.0023638487,0.00009114051,0.00032539322,0.00047727145],"genre_scores_gemma":[0.9934078,0.0006149993,0.0005080928,0.0037870097,0.0008170437,0.00033558192,0.00025207154,0.00011173334,0.00016569959],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99662274,0.00031250864,0.00065819215,0.0007175381,0.00040444836,0.0012845523],"domain_scores_gemma":[0.99719125,0.0011817459,0.00035371064,0.00083660934,0.00021183449,0.00022484371],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037992137,0.0005321504,0.0018400013,0.00037010567,0.0001284595,0.000030931984,0.0003968504,0.00031032736,0.00017278809],"category_scores_gemma":[0.00052493985,0.00036036447,0.00016145385,0.0012783924,0.00041066305,0.00009635086,0.00013548326,0.0006031118,0.00029433265],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7091217,0.012574469,0.028119707,0.0015036253,0.0085379165,0.12716196,0.03811001,0.00068288087,0.024642477,0.001947858,0.03195296,0.01564446],"study_design_scores_gemma":[0.9318027,0.010280217,0.0071556447,0.0010272167,0.0027443352,0.022442102,0.0022497622,0.00828899,0.010615669,0.00079067494,0.0014435214,0.0011592018],"about_ca_topic_score_codex":0.00014785708,"about_ca_topic_score_gemma":0.00021097677,"teacher_disagreement_score":0.22268099,"about_ca_system_score_codex":0.0013382189,"about_ca_system_score_gemma":0.000928292,"threshold_uncertainty_score":0.99988484},"labels":[],"label_agreement":null},{"id":"W4383561168","doi":"10.14740/jh1118","title":"Treating Acquired Factor VIII Inhibitor and Tumor-Induced Hypoglycemia in a Case of Relapsed Diffuse Large B-Cell Lymphoma","year":2023,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Thromboelastometry; Lymphoma; Hypoglycemia; Biopsy; Risk factor; Internal medicine; Intensive care medicine; Pathology; Surgery; Oncology; Coagulopathy","score_opus":0.01869273737043113,"score_gpt":0.2836819648581608,"score_spread":0.26498922748772963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383561168","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985703,0.0005695876,0.0000034910097,0.00026518223,0.000185533,0.00022633836,0.000012682451,0.000023034192,0.00014385319],"genre_scores_gemma":[0.9992654,0.000062231506,0.00034906383,0.00006740424,0.00007413112,0.0000061314004,0.000004189569,0.000033314314,0.00013818909],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9981346,0.00010910725,0.00095512514,0.0002057537,0.0002095198,0.00038590076],"domain_scores_gemma":[0.9983903,0.00043182055,0.0006541519,0.00022591956,0.00010277348,0.00019502032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025759568,0.00020618203,0.000984715,0.00053839124,0.000045539426,0.000006728168,0.00007451317,0.00017552687,0.000037847545],"category_scores_gemma":[0.0004543924,0.00016407477,0.00014201175,0.00037465635,0.000057258945,0.00009923654,0.00007514448,0.00017598101,0.000013462044],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046408195,0.0073754378,0.31669348,0.0016793691,0.00062075694,0.33840376,0.008859935,0.0000020912985,0.31265545,0.0002113678,0.0016314018,0.007226121],"study_design_scores_gemma":[0.268872,0.004651794,0.0570323,0.001893881,0.000596451,0.35003683,0.0060883416,0.001840845,0.30787858,0.00019285735,0.00037029915,0.0005458453],"about_ca_topic_score_codex":0.00007876038,"about_ca_topic_score_gemma":0.00006749248,"teacher_disagreement_score":0.26423118,"about_ca_system_score_codex":0.00042367153,"about_ca_system_score_gemma":0.0004612206,"threshold_uncertainty_score":0.66907746},"labels":[],"label_agreement":null},{"id":"W4383872109","doi":"10.1080/13696998.2023.2234776","title":"Health care resource utilization in 3L + patients with chronic phase chronic myeloid leukemia receiving asciminib or bosutinib","year":2023,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Novartis Portugal","keywords":"Medicine; Bosutinib; Myeloid leukemia; Chronic care; Health care; Chronic disease; Internal medicine; Oncology; Intensive care medicine; Imatinib; Dasatinib","score_opus":0.029984387243782135,"score_gpt":0.3263907657694533,"score_spread":0.2964063785256712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383872109","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918318,0.0016463723,0.00007121636,0.005133525,0.00042112928,0.0005704732,0.00002526428,0.00004859377,0.0002516372],"genre_scores_gemma":[0.9908737,0.006049945,0.00029315983,0.0009886838,0.001151399,0.00001586435,0.00028599842,0.00009495367,0.00024628532],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99656755,0.0001305093,0.0014370484,0.00038191667,0.00081003486,0.0006729154],"domain_scores_gemma":[0.99752,0.0002875102,0.0009109137,0.00038170564,0.00013830967,0.0007615058],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012755969,0.00029897658,0.0009715086,0.0005132447,0.000107416665,0.0000343876,0.0003478915,0.0002912339,0.0005536515],"category_scores_gemma":[0.00067323784,0.00022261529,0.00014832924,0.000536149,0.00013871117,0.00021777274,0.00010782412,0.0009164658,0.00004829074],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00422347,0.0008231016,0.042948615,0.0012541534,0.0004977444,0.0009227388,0.00368923,0.0028167095,0.0000084003605,0.000050726074,0.01752467,0.92524046],"study_design_scores_gemma":[0.25987184,0.03268094,0.23992524,0.013288076,0.0005260323,0.0016781937,0.0039374293,0.047028486,0.00038889624,0.00005270824,0.39930603,0.0013161221],"about_ca_topic_score_codex":0.00009811723,"about_ca_topic_score_gemma":0.001447077,"teacher_disagreement_score":0.9239243,"about_ca_system_score_codex":0.019435382,"about_ca_system_score_gemma":0.01881802,"threshold_uncertainty_score":0.98674434},"labels":[],"label_agreement":null},{"id":"W4384120732","doi":"10.3324/haematol.2022.281944","title":"Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia: long-term analysis of a phase I/II study","year":2023,"lang":"en","type":"letter","venue":"Haematologica","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Princess Margaret Cancer Centre","funders":"Pfizer","keywords":"Bosutinib; Philadelphia chromosome; Term (time); Medicine; Tyrosine kinase; Internal medicine; Genetics; Biology; Nilotinib; Chromosomal translocation; Gene; Receptor","score_opus":0.028718520755449044,"score_gpt":0.33212614158053844,"score_spread":0.3034076208250894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384120732","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9643773,0.0011922948,0.000091858885,0.024986373,0.0003072229,0.0067707873,0.0018651611,0.0003519826,0.00005704222],"genre_scores_gemma":[0.9680761,0.00008094623,0.00038930564,0.020166345,0.0010537027,0.0034384988,0.00438633,0.0002636879,0.002145089],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9937045,0.00017580469,0.0016669654,0.0020547693,0.001191963,0.0012059784],"domain_scores_gemma":[0.995351,0.00060397206,0.0012926387,0.0018068549,0.00069482054,0.0002506966],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00033196155,0.0013244437,0.0043689883,0.0011721492,0.00032457442,0.00008209395,0.00048784248,0.0013281677,0.00058225193],"category_scores_gemma":[0.00022435919,0.000955718,0.0011607626,0.0022400995,0.0006962145,0.00015139877,0.00032568103,0.0015869549,0.00005126847],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.042267587,0.021470908,0.28019923,0.014134762,0.09770985,0.24474591,0.0076195034,0.00028504347,0.0009489715,0.000013611073,0.28450334,0.0061012777],"study_design_scores_gemma":[0.18115227,0.091797166,0.5097547,0.013251928,0.15755045,0.0033493557,0.00053912285,0.0020303782,0.01591515,0.000032872755,0.01794127,0.0066853375],"about_ca_topic_score_codex":0.00014872657,"about_ca_topic_score_gemma":0.00017525538,"teacher_disagreement_score":0.26656207,"about_ca_system_score_codex":0.0018508199,"about_ca_system_score_gemma":0.0009851503,"threshold_uncertainty_score":0.9999683},"labels":[],"label_agreement":null},{"id":"W4384134428","doi":"10.58931/cht.2023.2124","title":"Tyrosine kinase inhibitors for the frontline management of CML: an overview","year":2023,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Bosutinib; Nilotinib; Dasatinib; Medicine; Imatinib; Ponatinib; Tyrosine kinase; Myeloid leukemia; Tyrosine-kinase inhibitor; Drug holiday; Internal medicine; Oncology; Population; Pharmacology; Immunology; Cancer","score_opus":0.04892717281739035,"score_gpt":0.31947437695510056,"score_spread":0.2705472041377102,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384134428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9153032,0.03667926,0.00011668542,0.035896104,0.0020233174,0.0052937604,0.00061567576,0.0003216861,0.003750315],"genre_scores_gemma":[0.99173063,0.0010524208,0.00082017865,0.0013371716,0.00013759082,0.00033468107,0.00044228404,0.00005983047,0.004085204],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998809,0.00002863375,0.00029940112,0.00027890687,0.000122047815,0.00046200785],"domain_scores_gemma":[0.9987905,0.0001230615,0.00007343463,0.0006063573,0.00006408941,0.00034255072],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021917872,0.00016133794,0.0003735379,0.00018829321,0.000111864196,0.00000544475,0.00015820157,0.000119664124,0.0002886659],"category_scores_gemma":[0.000048761653,0.00012002265,0.00010967921,0.00034615924,0.000109368135,0.00003558775,0.000033966255,0.00009441628,0.00010599508],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046547895,0.00046332733,0.04618476,0.0051233848,0.0029587965,0.0048927246,0.0015887371,0.00012510158,0.000504375,0.16030928,0.6686727,0.10871136],"study_design_scores_gemma":[0.016971441,0.0011714442,0.09104304,0.0017043757,0.0021350472,0.0007409786,0.00222868,0.0049387687,0.01139672,0.0023889525,0.8644979,0.00078262296],"about_ca_topic_score_codex":0.011688705,"about_ca_topic_score_gemma":0.046007533,"teacher_disagreement_score":0.19582526,"about_ca_system_score_codex":0.00047577344,"about_ca_system_score_gemma":0.00047788722,"threshold_uncertainty_score":0.99489254},"labels":[],"label_agreement":null},{"id":"W4384274095","doi":"10.58931/cht.2022.1320","title":"Chronic Myeloid Leukemia: who should get a treatment-free trial and how?","year":2022,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Myeloid leukemia; Discontinuation; Chronic myelogenous leukemia; Life expectancy; Clinical trial; Oncology; Internal medicine; Quality of life (healthcare); Leukemia; Intensive care medicine; Population; Nursing","score_opus":0.02688000657122393,"score_gpt":0.2643091174620462,"score_spread":0.23742911089082228,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384274095","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9447308,0.011560834,0.0000047002472,0.031403083,0.00084011117,0.0023250927,0.00036869154,0.00014888405,0.008617792],"genre_scores_gemma":[0.9780892,0.00038501126,0.00015810333,0.0018599851,0.00051232794,0.000981931,0.00028143765,0.00009533014,0.017636642],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99753386,0.00016973134,0.0002954515,0.0007308664,0.00027816417,0.0009919291],"domain_scores_gemma":[0.99757016,0.00016590596,0.00011706394,0.0011066877,0.00003862887,0.0010015552],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00018214907,0.0004103997,0.00090684596,0.000442351,0.0005359916,0.00003095448,0.00028914097,0.00028066107,0.0021710354],"category_scores_gemma":[0.00017534895,0.0003912297,0.00017485002,0.00030213303,0.00022796918,0.00007904196,0.00016683004,0.00051308674,0.000052199066],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.01345003,0.00059360283,0.07093319,0.00061841664,0.0041117403,0.033490762,0.0037739074,0.00007386578,0.00064820366,0.024091134,0.78224194,0.06597319],"study_design_scores_gemma":[0.16416597,0.0054412866,0.0022420848,0.00006172635,0.00066418765,0.009499075,0.00052464724,0.00036340416,0.00077496486,0.00037140056,0.81525874,0.00063248],"about_ca_topic_score_codex":0.041463654,"about_ca_topic_score_gemma":0.15881547,"teacher_disagreement_score":0.15071595,"about_ca_system_score_codex":0.01784879,"about_ca_system_score_gemma":0.009664575,"threshold_uncertainty_score":0.99985397},"labels":[],"label_agreement":null},{"id":"W4385409879","doi":"10.21203/rs.3.rs-3201595/v1","title":"Lipopolymer Mediated siRNA Delivery Targeting Aberrant Oncogenes for Effective Therapy of Myeloid Leukemia","year":2023,"lang":"en","type":"preprint","venue":"Research Square","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Natural Sciences and Engineering Research Council of Canada; University of Alberta; Alberta Innovates; Alberta Innovates - Technology Futures; Canadian Institutes of Health Research; Mitacs; Alex's Lemonade Stand Foundation for Childhood Cancer","keywords":"Myeloid leukemia; Cancer research; Genetic enhancement; Leukemia; Medicine; Biology; Immunology; Gene; Genetics","score_opus":0.08408715319644998,"score_gpt":0.39745605389146216,"score_spread":0.31336890069501216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385409879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9618949,0.024618506,0.00007228625,0.0007249827,0.00067468866,0.010226117,0.0009341495,0.0003172507,0.0005371169],"genre_scores_gemma":[0.9691486,0.018379742,0.0008602815,0.000063352214,0.0012782865,0.0042544752,0.0032690794,0.00035756404,0.0023886277],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99361455,0.0006869783,0.0009087361,0.0013347329,0.0021099264,0.0013450535],"domain_scores_gemma":[0.9915601,0.0045246524,0.0003626445,0.0012507068,0.0018631647,0.00043874528],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0028038782,0.00064767455,0.001455251,0.0009940482,0.00026763085,0.00005169814,0.0005581304,0.0009069179,0.00023802268],"category_scores_gemma":[0.002588106,0.0005387762,0.0009466775,0.00079409155,0.00041239307,0.00007102382,0.0009121381,0.0018787174,0.00018125467],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024779119,0.0031036707,0.043308765,0.0391972,0.019801598,0.001828527,0.012065776,0.002893235,0.41524068,0.00016081115,0.07985348,0.35776716],"study_design_scores_gemma":[0.05044929,0.011089842,0.063414685,0.02164546,0.0009288236,0.00006492382,0.0045741214,0.021978915,0.78475827,0.0022567287,0.03618406,0.0026548903],"about_ca_topic_score_codex":0.0049742614,"about_ca_topic_score_gemma":0.00012727073,"teacher_disagreement_score":0.3695176,"about_ca_system_score_codex":0.005200071,"about_ca_system_score_gemma":0.0054706247,"threshold_uncertainty_score":0.9997064},"labels":[],"label_agreement":null},{"id":"W4385667424","doi":"10.1097/01.hs9.0000969628.70235.a8","title":"P681: MATCHING-ADJUSTED INDIRECT COMPARISON OF ASCIMINIB VERSUS OTHER TYROSINE KINASE INHIBITORS IN THIRD-OR-LATER LINE CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Bosutinib; Medicine; Dasatinib; Nilotinib; Ponatinib; Internal medicine; Oncology; Population; Myeloid leukemia; Imatinib","score_opus":0.05732872494174309,"score_gpt":0.3475958001907948,"score_spread":0.2902670752490517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385667424","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98915523,0.0047163065,0.000019118419,0.00038162703,0.0008415937,0.0013338208,0.00007901888,0.00047185118,0.0030014378],"genre_scores_gemma":[0.9918282,0.00031283524,0.000448094,0.000090407506,0.00075012574,0.00013973878,0.0003563192,0.00019447124,0.005879806],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9958542,0.00013632474,0.0012796243,0.00087305065,0.0008073415,0.0010494594],"domain_scores_gemma":[0.99773127,0.00035351512,0.00044021866,0.0010410444,0.00011256032,0.0003214081],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00041485653,0.0006712619,0.0014767796,0.00038415013,0.000112871356,0.000031018164,0.0003030099,0.0005064355,0.0026697894],"category_scores_gemma":[0.00017950228,0.00055663165,0.00028550337,0.0017047328,0.00021903723,0.00019294283,0.00023006367,0.00081078196,0.0007883055],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04454716,0.009844407,0.073318765,0.014020315,0.0045117964,0.0072453367,0.022452328,0.02026852,0.3501832,0.00043865308,0.11887057,0.33429897],"study_design_scores_gemma":[0.20017536,0.015099511,0.020914774,0.008349274,0.0014050764,0.00016289402,0.0039425227,0.034711637,0.65737647,0.00010215312,0.05540026,0.0023600464],"about_ca_topic_score_codex":0.0009713293,"about_ca_topic_score_gemma":0.0049118786,"teacher_disagreement_score":0.33193892,"about_ca_system_score_codex":0.0065567493,"about_ca_system_score_gemma":0.0025459223,"threshold_uncertainty_score":0.9999897},"labels":[],"label_agreement":null},{"id":"W4385683538","doi":"10.1080/10428194.2023.2242990","title":"High sensitivity c-reactive protein and circulating biomarkers of endothelial dysfunction in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors","year":2023,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; McMaster University; Toronto General Hospital; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Nilotinib; Medicine; Ponatinib; Chronic myelogenous leukemia; Myeloid leukemia; Internal medicine; C-reactive protein; Cancer; Oncology; Immunology; Leukemia; Imatinib; Inflammation","score_opus":0.006563382667115001,"score_gpt":0.20799284824514153,"score_spread":0.20142946557802652,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385683538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959538,0.00041506506,0.000034616212,0.00008566345,0.00032128106,0.0023444637,0.00015444188,0.00036627467,0.00032438917],"genre_scores_gemma":[0.9976154,0.00014783551,0.0006091655,0.00009503552,0.00033096827,0.00022312833,0.0004878196,0.00021132582,0.0002793468],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99436,0.00033120776,0.0012377215,0.0016325369,0.0011110452,0.0013274357],"domain_scores_gemma":[0.99705523,0.0004970675,0.00074780104,0.0008802489,0.00028981944,0.0005298242],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00082159694,0.0010622017,0.0015202841,0.0010197868,0.00036637232,0.00009180702,0.00015663411,0.0006428149,0.00002994715],"category_scores_gemma":[0.00039156046,0.00096352416,0.00020730088,0.0018662196,0.0006614309,0.00064400124,0.00031162068,0.00032248514,0.00002946757],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0076672984,0.0005392931,0.49787232,0.0019414686,0.0011894142,0.0014208427,0.001768279,0.0007387845,0.16763517,0.00019773879,0.00030126455,0.31872815],"study_design_scores_gemma":[0.0555067,0.0013742682,0.874304,0.0025381,0.00037700616,0.00034292953,0.00036867312,0.0068916385,0.05704883,0.00007475717,0.00023196104,0.0009411232],"about_ca_topic_score_codex":0.011611858,"about_ca_topic_score_gemma":0.00070672075,"teacher_disagreement_score":0.3764317,"about_ca_system_score_codex":0.032718617,"about_ca_system_score_gemma":0.0057942835,"threshold_uncertainty_score":0.9998419},"labels":[],"label_agreement":null},{"id":"W4386024385","doi":"10.1097/01.hs9.0000969552.85501.cf","title":"P662: POST HOC ANALYSIS OF PATIENT RESPONSES BY T315I MUTATION STATUS FROM THE 3-YEAR UPDATE OF THE OPTIC TRIAL: A DOSE-OPTIMIZATION STUDY OF 3 STARTING DOSES OF PONATINIB","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ponatinib; Medicine; Internal medicine; Myeloid leukemia; Oncology; Clinical endpoint; Clinical trial; Dasatinib; Imatinib","score_opus":0.01797731521387673,"score_gpt":0.2869151710919347,"score_spread":0.26893785587805796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386024385","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974923,0.0003379572,0.000016288104,0.00015436253,0.000064443666,0.0013461142,0.0004967162,0.00002339577,0.000068392925],"genre_scores_gemma":[0.9987063,0.00006804325,0.0007130255,0.000026356392,0.00001262069,0.000037230762,0.00032853885,0.00002453973,0.000083380495],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975919,0.00037055268,0.00091316,0.00024293932,0.00069970824,0.00018175243],"domain_scores_gemma":[0.9970034,0.0009628058,0.0010058709,0.0006354619,0.0003495395,0.000042917847],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034364715,0.00015608442,0.000598155,0.00011668997,0.000053923966,0.0000059217923,0.00013625948,0.00006211622,0.00038068977],"category_scores_gemma":[0.0010352202,0.00009586232,0.00019611065,0.0016536488,0.000094237206,0.00005566921,0.00009208189,0.00009581234,0.0000021697842],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1697337,0.010631147,0.30607548,0.0008719227,0.0248854,0.00007318713,0.12092917,0.29305157,0.052328967,0.00015730732,0.0029750788,0.018287057],"study_design_scores_gemma":[0.18551934,0.02033574,0.36100054,0.001390352,0.023719342,0.0000036324282,0.25799328,0.06356399,0.08550485,0.000118966535,0.00017672004,0.00067324383],"about_ca_topic_score_codex":0.0022312847,"about_ca_topic_score_gemma":0.0003682983,"teacher_disagreement_score":0.2294876,"about_ca_system_score_codex":0.00015601669,"about_ca_system_score_gemma":0.00031725966,"threshold_uncertainty_score":0.4168286},"labels":[],"label_agreement":null},{"id":"W4386052241","doi":"10.1097/01.hs9.0000969572.68411.a2","title":"P667: RISK OF PROGRESSION IN CHRONIC PHASE-CHRONIC MYELOID LEUKEMIA PATIENTS ELIGIBLE FOR TYROSINE KINASE INHIBITOR DISCONTINUATION: FINAL ANALYSIS OF THE TFR-PRO STUDY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Discontinuation; Medicine; Myeloid leukemia; Internal medicine; Observational study; Clinical endpoint; Cohort; Oncology; Pediatrics; Clinical trial","score_opus":0.028180351054470837,"score_gpt":0.33715202625971846,"score_spread":0.3089716752052476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386052241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947223,0.001069494,0.00003542969,0.000077131175,0.00015758988,0.003590537,0.00017352084,0.000054872755,0.00011910741],"genre_scores_gemma":[0.9975869,0.000118111355,0.0001837551,0.00000804324,0.00014980348,0.00048204628,0.00038327157,0.000047394184,0.001040658],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971887,0.00013898575,0.0009366291,0.00055326486,0.00072472834,0.00045773375],"domain_scores_gemma":[0.99793947,0.00020572133,0.0006463713,0.0008662943,0.00024704778,0.00009507038],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004582256,0.00031464166,0.0008836727,0.0002864021,0.00011482207,0.000012475138,0.0002253121,0.00014495614,0.00023680327],"category_scores_gemma":[0.0002997632,0.0002154928,0.00041416058,0.002784287,0.0001265521,0.0001123034,0.00016611133,0.0002517723,0.000014334414],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001417642,0.004128883,0.9174122,0.0008704857,0.002308604,0.000025428584,0.0018344697,0.0039612344,0.009409769,0.000026473672,0.002356439,0.056248374],"study_design_scores_gemma":[0.060870692,0.008210506,0.80916816,0.0017464267,0.006524878,0.0000018169038,0.0011401956,0.039627057,0.0714322,0.000054647582,0.0007856061,0.00043782927],"about_ca_topic_score_codex":0.0003781215,"about_ca_topic_score_gemma":0.0018630842,"teacher_disagreement_score":0.10824406,"about_ca_system_score_codex":0.003225323,"about_ca_system_score_gemma":0.0015227984,"threshold_uncertainty_score":0.8787541},"labels":[],"label_agreement":null},{"id":"W4386071245","doi":"10.1016/j.leukres.2023.107374","title":"Canadian real-world experience of asciminib treatment in heavily pre-treated chronic myeloid leukemia (CML) patients who failed multiple lines of tyrosine kinase inhibitor (TKI) therapy","year":2023,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Jewish General Hospital; Juravinski Cancer Centre; Hôpital Maisonneuve-Rosemont; Dr. Georges-L.-Dumont University Hospital Centre; Ottawa Hospital; Princess Margaret Cancer Centre; Kingston General Hospital; London Health Sciences Centre; Brampton Civic Hospital; Université de Sherbrooke; Queen Elizabeth II Health Sciences Centre; Centre Hospitalier de l’Université de Montréal","funders":"Princess Margaret Cancer Foundation","keywords":"Tolerability; Medicine; Myeloid leukemia; Cumulative incidence; Internal medicine; Tyrosine-kinase inhibitor; Tyrosine kinase; Adverse effect; Gastroenterology; Oncology; Cohort; Cancer; Receptor","score_opus":0.05328367278869478,"score_gpt":0.3594598913470843,"score_spread":0.3061762185583895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386071245","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99365336,0.0006030586,4.0281668e-7,0.0002920944,0.00015795794,0.003502558,0.00025322597,0.00011920905,0.0014181184],"genre_scores_gemma":[0.98661894,0.003258515,0.00011483247,0.000032971504,0.0002278383,0.000962859,0.0007606176,0.00013707997,0.007886321],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99365854,0.0004355904,0.0013063307,0.001137177,0.0016453742,0.001816984],"domain_scores_gemma":[0.99579686,0.0007772092,0.0002648877,0.0015253999,0.0008131615,0.0008224942],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007806797,0.0006209023,0.0013006215,0.0025794855,0.00022516226,0.000040488256,0.00053927384,0.0003886526,0.00029354042],"category_scores_gemma":[0.0005547531,0.0005204537,0.000267007,0.0046514454,0.0005584386,0.00023965829,0.00020389208,0.00067274645,0.00011163896],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0026337611,0.0007759371,0.92317486,0.00043345042,0.00025104877,0.0004826784,0.0053218203,0.000464265,0.039542954,0.000036773803,0.0022390399,0.02464341],"study_design_scores_gemma":[0.024041753,0.0033340196,0.70680124,0.0011447114,0.000037373244,0.0000043104988,0.0005455482,0.005149648,0.25498867,0.000021694976,0.0035376092,0.00039343062],"about_ca_topic_score_codex":0.6859839,"about_ca_topic_score_gemma":0.49023739,"teacher_disagreement_score":0.21637362,"about_ca_system_score_codex":0.05126601,"about_ca_system_score_gemma":0.014649854,"threshold_uncertainty_score":0.9997247},"labels":[],"label_agreement":null},{"id":"W4386259692","doi":"10.14206/canad.j.clin.nutr.2023.02.09","title":"BCR-ABL Independent Resistance Mechanisms to Chronic Myeloid Leukemia","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Clinical Nutrition","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Myeloid leukemia; breakpoint cluster region; Chronic myeloid leukaemia; Resistance (ecology); Cancer research; Biology; Medicine; Internal medicine; Receptor; Ecology","score_opus":0.046579876070505316,"score_gpt":0.34560749182437134,"score_spread":0.29902761575386605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386259692","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9689516,0.00182158,0.00092725764,0.020959005,0.0030014042,0.0011379371,0.000098335426,0.000081943166,0.0030209718],"genre_scores_gemma":[0.98933345,0.0007784927,0.0029605522,0.0016576876,0.001926074,0.000024951854,0.000052878804,0.000051879513,0.0032140224],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969854,0.00013378299,0.0013789507,0.0003206598,0.0005915516,0.0005896942],"domain_scores_gemma":[0.99638087,0.00028125042,0.00037379976,0.00038140354,0.00038998836,0.002192666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014669454,0.0002015673,0.0007223784,0.0005968067,0.00013229459,0.000048483584,0.00027697903,0.00030558888,0.00044872632],"category_scores_gemma":[0.0013141056,0.00019028998,0.00039469334,0.0007056909,0.00008759182,0.00014407147,0.000024080162,0.0007507381,0.0006017649],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0033755251,0.00061831373,0.011863129,0.001273314,0.001282591,0.025461962,0.00056099315,0.00028397466,0.008298289,0.005623079,0.85925037,0.08210844],"study_design_scores_gemma":[0.03504626,0.0055602887,0.1730004,0.0058947005,0.00065888255,0.001385041,0.0004803629,0.00025304873,0.004967066,0.016676001,0.7553013,0.0007766622],"about_ca_topic_score_codex":0.00059743953,"about_ca_topic_score_gemma":0.020608978,"teacher_disagreement_score":0.16113727,"about_ca_system_score_codex":0.00479231,"about_ca_system_score_gemma":0.009187715,"threshold_uncertainty_score":0.9990281},"labels":[],"label_agreement":null},{"id":"W4386269948","doi":"10.1016/s2152-2650(23)00547-5","title":"POSTER: CML-311 Matching-Adjusted Indirect Comparisons (MAICs) of Asciminib vs Other Tyrosine Kinase Inhibitors (TKIs) in Third- or Later-Line Chronic Myeloid Leukemia in Chronic Phase (CML-CP)","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Myeloid leukemia; Tyrosine kinase; Medicine; Internal medicine; Tyrosine-kinase inhibitor; Oncology; Cancer research; Cancer; Receptor","score_opus":0.06094914429382921,"score_gpt":0.36048216634178104,"score_spread":0.29953302204795185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386269948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903159,0.0021067602,0.000021410971,0.0007638835,0.0014322017,0.002923041,0.00035227824,0.0007857843,0.0012987033],"genre_scores_gemma":[0.9910634,0.0013254437,0.00048154342,0.00090747146,0.0015699863,0.00035130596,0.0009561398,0.0004502082,0.0028944775],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98654175,0.0009889193,0.0057473104,0.002552365,0.0015699099,0.002599755],"domain_scores_gemma":[0.9920211,0.0024484976,0.001559385,0.0025936184,0.00029746688,0.0010799201],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0030537741,0.0016503637,0.0043666367,0.0018876555,0.0002302879,0.00010435691,0.0012029299,0.001791983,0.00095827953],"category_scores_gemma":[0.0013742971,0.0014501292,0.0010789519,0.0045916773,0.0011407993,0.0005323614,0.00090842193,0.0018831325,0.0013354528],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.037514918,0.0074402927,0.23070817,0.0051423586,0.0026325462,0.018325066,0.0038951503,0.004929256,0.05028737,0.00029925062,0.034819357,0.6040063],"study_design_scores_gemma":[0.10946542,0.009002327,0.8026009,0.006097211,0.0007907951,0.000512127,0.00038579566,0.020224333,0.032043938,0.00018562337,0.016670316,0.002021225],"about_ca_topic_score_codex":0.003433982,"about_ca_topic_score_gemma":0.008166461,"teacher_disagreement_score":0.60198504,"about_ca_system_score_codex":0.038880095,"about_ca_system_score_gemma":0.019971848,"threshold_uncertainty_score":0.999955},"labels":[],"label_agreement":null},{"id":"W4386269975","doi":"10.1016/s2152-2650(23)00551-7","title":"POSTER: CML-415 Comparative Study Between Brand and Generic Imatinib Mesylate Using Molecular Genetic Analysis on CML Libyan Patients","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Imatinib mesylate; Medicine; Imatinib; Pharmacology; Internal medicine","score_opus":0.07137290501369091,"score_gpt":0.37564205739467377,"score_spread":0.30426915238098284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386269975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99661237,0.00024004099,0.00004509344,0.00008582832,0.00024402681,0.0018217375,0.000104741805,0.00027448716,0.00057164725],"genre_scores_gemma":[0.9974366,0.00007456368,0.0008380356,0.0004478675,0.0002941187,0.00006686111,0.0004534571,0.00011715897,0.00027136857],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9937807,0.00073101954,0.0019455624,0.0016037594,0.00103045,0.0009085248],"domain_scores_gemma":[0.9959453,0.0010459849,0.00060940586,0.0013309229,0.0002691558,0.0007992488],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007031645,0.0007698552,0.0023392292,0.0007041319,0.00029627752,0.00011990942,0.00036139687,0.00040434022,0.00007906773],"category_scores_gemma":[0.00037865344,0.0006755224,0.0006662542,0.002330476,0.00035846006,0.00014186105,0.00044164291,0.00038364276,0.00037706963],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006078582,0.0007082711,0.90995765,0.00005649859,0.004796044,0.0007404162,0.00080276857,0.00031900994,0.00017768083,0.000004323589,0.0002048097,0.08162469],"study_design_scores_gemma":[0.016366774,0.0027069885,0.96577626,0.0001226702,0.0053861267,0.00002134938,0.00017759846,0.008223342,0.0004126812,0.000047781657,0.00019220462,0.0005662339],"about_ca_topic_score_codex":0.00027356215,"about_ca_topic_score_gemma":0.000029118324,"teacher_disagreement_score":0.08105845,"about_ca_system_score_codex":0.0020088446,"about_ca_system_score_gemma":0.00085129926,"threshold_uncertainty_score":0.9995696},"labels":[],"label_agreement":null},{"id":"W4386270690","doi":"10.1016/s2152-2650(23)00568-2","title":"POSTER: CML-319 Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Patients With Treatment-Resistant Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Treated With Ponatinib From the Phase 2 OPTIC Trial","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ponatinib; Myeloid leukemia; Medicine; Internal medicine; Oncology; Cancer research; Nilotinib; Imatinib","score_opus":0.020010388771337477,"score_gpt":0.3236364272275156,"score_spread":0.30362603845617814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386270690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879241,0.0006267079,0.000013761428,0.00054846605,0.00021021455,0.0061796857,0.0039657387,0.00023855067,0.0002927897],"genre_scores_gemma":[0.9947868,0.00016390676,0.00033419288,0.00023993345,0.00025283662,0.0005597089,0.0024441592,0.00027547314,0.0009429626],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9899321,0.0014641976,0.0033032652,0.0020242282,0.0018555127,0.0014206734],"domain_scores_gemma":[0.9883065,0.005393543,0.0017912745,0.0030952897,0.0007380957,0.00067526055],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0011639994,0.0014487026,0.0034824563,0.0005935728,0.00022385585,0.000058888054,0.0009832478,0.0008018366,0.0004063383],"category_scores_gemma":[0.0016411357,0.0009169623,0.0009929449,0.0019638166,0.0015240287,0.00032583342,0.00038276406,0.0005750298,0.00013531065],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.82211506,0.0076799206,0.072956786,0.00016050387,0.007444563,0.0029525075,0.0014856478,0.0001546861,0.005449614,0.000023847913,0.0006008047,0.07897604],"study_design_scores_gemma":[0.3664872,0.06795168,0.5446205,0.001125654,0.0019804097,0.000023227201,0.0001817004,0.0011476065,0.015697418,0.000020236132,0.0001849897,0.00057936757],"about_ca_topic_score_codex":0.00224574,"about_ca_topic_score_gemma":0.00021299698,"teacher_disagreement_score":0.4716637,"about_ca_system_score_codex":0.021426003,"about_ca_system_score_gemma":0.01469309,"threshold_uncertainty_score":0.99982625},"labels":[],"label_agreement":null},{"id":"W4386270713","doi":"10.1016/s2152-2650(23)00549-9","title":"POSTER: CML-315 Assessment of Number Needed to Treat (NNT) and Cost per Response (CpR) in Patients (pts) With Relapsed/Refractory (R/R) Chronic Phase Chronic Myeloid Leukemia (CP-CML) Managed With Ponatinib (PON), Asciminib (ASC), and Bosutinib (BOS)","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Medicine; Refractory (planetary science); Myeloid leukemia; Internal medicine; Number needed to treat; Intensive care medicine; Relative risk","score_opus":0.02197721660446914,"score_gpt":0.33858092278543794,"score_spread":0.3166037061809688,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386270713","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909437,0.00041799815,0.000022456219,0.00097216544,0.0003255199,0.004602184,0.00030874886,0.00036728382,0.002039985],"genre_scores_gemma":[0.99141943,0.00080980506,0.0012074301,0.0010499605,0.00038398424,0.0006069717,0.00077047024,0.00038209878,0.0033698175],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98940426,0.0011686776,0.0029016717,0.0027405147,0.0018238743,0.00196101],"domain_scores_gemma":[0.9916066,0.0029785002,0.0010770665,0.0022217021,0.0005074715,0.0016086733],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0026813871,0.0015480458,0.0029328696,0.0009645364,0.00036421936,0.00014795174,0.0006355364,0.0009684061,0.00047171183],"category_scores_gemma":[0.0010015679,0.0012522236,0.00038911353,0.0018712489,0.0013051669,0.00061250327,0.0007250102,0.0012150559,0.0003128155],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.07854736,0.0035107306,0.4091039,0.0013925998,0.0016250587,0.0032846732,0.0017806339,0.00016288747,0.0041735177,0.00011404305,0.006830732,0.48947385],"study_design_scores_gemma":[0.11794064,0.017772524,0.8485267,0.0017938104,0.00084880774,0.0003756471,0.00048951444,0.0012099919,0.00078963913,0.000018767698,0.009038144,0.0011958076],"about_ca_topic_score_codex":0.00089899346,"about_ca_topic_score_gemma":0.0006157548,"teacher_disagreement_score":0.48827803,"about_ca_system_score_codex":0.020064985,"about_ca_system_score_gemma":0.011184758,"threshold_uncertainty_score":0.9997268},"labels":[],"label_agreement":null},{"id":"W4386270977","doi":"10.1016/s2152-2650(23)01133-3","title":"CML-311 Matching-Adjusted Indirect Comparisons (MAICs) of Asciminib vs Other Tyrosine Kinase Inhibitors (TKIs) in Third- or Later-Line Chronic Myeloid Leukemia in Chronic Phase (CML-CP)","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Myeloid leukemia; Tyrosine kinase; Medicine; Internal medicine; Tyrosine-kinase inhibitor; Oncology; Dasatinib; Cancer research; Imatinib; Cancer; Receptor","score_opus":0.06451954575063161,"score_gpt":0.3641190200027269,"score_spread":0.29959947425209527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386270977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905644,0.0021608586,0.000037204212,0.00064676773,0.0014144521,0.0028187602,0.0003056977,0.0008093206,0.0012425078],"genre_scores_gemma":[0.9904305,0.0015603947,0.0007200515,0.00076028326,0.0016859061,0.0003903062,0.00086716877,0.0004451164,0.0031403166],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9866138,0.00096061727,0.005690998,0.0025450329,0.0015876716,0.0026018524],"domain_scores_gemma":[0.9919746,0.0025541259,0.0015368595,0.0025681094,0.00028667075,0.0010796695],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0032257508,0.0016250042,0.0043794885,0.0018643894,0.00023427789,0.000095961404,0.0011869741,0.0018012311,0.0010549967],"category_scores_gemma":[0.0015806853,0.0014290657,0.0010703934,0.004949335,0.0011988336,0.0005052074,0.00083936844,0.0019269497,0.0013601182],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.032442883,0.007539482,0.17966631,0.0050083096,0.0025818797,0.017086323,0.0034286424,0.008890742,0.04608088,0.0004608136,0.044703674,0.65211004],"study_design_scores_gemma":[0.11493352,0.008241293,0.7756122,0.006125849,0.000818982,0.00041936222,0.00046266077,0.036853842,0.03047577,0.00025968786,0.023682624,0.00211423],"about_ca_topic_score_codex":0.0035014488,"about_ca_topic_score_gemma":0.00818678,"teacher_disagreement_score":0.6499958,"about_ca_system_score_codex":0.040935624,"about_ca_system_score_gemma":0.021631878,"threshold_uncertainty_score":0.9998582},"labels":[],"label_agreement":null},{"id":"W4386277964","doi":"10.1016/s2152-2650(23)01136-9","title":"CML-319 Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Patients With Treatment-Resistant Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Treated With Ponatinib From the Phase 2 OPTIC Trial","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ponatinib; Myeloid leukemia; Medicine; Oncology; Internal medicine; Immunology; Dasatinib; Cancer research; Imatinib","score_opus":0.02052534718663807,"score_gpt":0.32626226008500225,"score_spread":0.3057369128983642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386277964","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886163,0.0006338688,0.000022903023,0.0004675794,0.00020390868,0.0059967865,0.0035401708,0.00024209413,0.00027641896],"genre_scores_gemma":[0.9947267,0.0001866899,0.00048317108,0.00020031768,0.00026563735,0.0006176258,0.0022436474,0.00027050887,0.001005685],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9900255,0.0014266461,0.0032506243,0.0020110144,0.0018747686,0.0014114563],"domain_scores_gemma":[0.98812956,0.005646832,0.0017668756,0.0030683933,0.0007171884,0.00067117356],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0012129508,0.0014237936,0.0034799147,0.00057843793,0.00022719505,0.000054051787,0.00096807844,0.000799076,0.0004416485],"category_scores_gemma":[0.0018725516,0.00089911895,0.0009828153,0.0020860266,0.0015991656,0.00030804132,0.00035220833,0.000580884,0.00013488671],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.82338053,0.008267814,0.060779426,0.0001612073,0.007838845,0.0028815062,0.0013875943,0.0002762939,0.0052142353,0.00003702029,0.00078234036,0.088993214],"study_design_scores_gemma":[0.37905258,0.062885754,0.5373708,0.0010889944,0.0020190885,0.000018256833,0.00020862141,0.0019319506,0.014570408,0.00002652766,0.00024295069,0.0005840807],"about_ca_topic_score_codex":0.0022802516,"about_ca_topic_score_gemma":0.00020652774,"teacher_disagreement_score":0.47659135,"about_ca_system_score_codex":0.02237023,"about_ca_system_score_gemma":0.015786162,"threshold_uncertainty_score":0.9998512},"labels":[],"label_agreement":null},{"id":"W4386280296","doi":"10.14740/jh1150","title":"Leukostasis With Isolated Central Nervous System Involvement in Chronic Phase of Chronic Myelogenous Leukemia","year":2023,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Leukostasis; Medicine; Chronic myelogenous leukemia; Myeloid leukemia; Complication; Hematology; Leukemia; Midostaurin; Myeloproliferative neoplasm; Internal medicine; Myelofibrosis; Bone marrow","score_opus":0.022097658846281495,"score_gpt":0.289873789999405,"score_spread":0.2677761311531235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386280296","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934943,0.0048864563,0.00020597524,0.0003480825,0.00028749424,0.00054391066,0.000011603589,0.00005559594,0.00016663042],"genre_scores_gemma":[0.99880713,0.0005672924,0.00021156885,0.00003851553,0.00018046061,0.000016208387,0.000029706569,0.00005070654,0.00009842408],"study_design_codex":"case_report","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9970074,0.00012647589,0.0013296038,0.0002759494,0.00047826738,0.0007822954],"domain_scores_gemma":[0.99809337,0.00013130324,0.00090265647,0.0004051131,0.0002170044,0.00025054294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000383044,0.0003017629,0.0013596385,0.0007136943,0.0000493347,0.000007804152,0.0002242822,0.00022196402,0.00009685542],"category_scores_gemma":[0.000046190213,0.00022481887,0.0002079552,0.0008219512,0.0001480991,0.00010270471,0.00006439825,0.0005073531,0.000039829338],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.03225203,0.008657929,0.19939773,0.039777152,0.01713463,0.25529608,0.013829778,0.03912286,0.24470845,0.005457885,0.02005324,0.12431225],"study_design_scores_gemma":[0.2961581,0.09590838,0.065115936,0.021847721,0.0053930115,0.19179474,0.009729227,0.093431555,0.21090151,0.00019926335,0.007352829,0.0021677339],"about_ca_topic_score_codex":0.00026962353,"about_ca_topic_score_gemma":0.0003876137,"teacher_disagreement_score":0.26390606,"about_ca_system_score_codex":0.013600709,"about_ca_system_score_gemma":0.0063722604,"threshold_uncertainty_score":0.99926066},"labels":[],"label_agreement":null},{"id":"W4386303249","doi":"10.1002/ajh.27073","title":"Risk of progression in chronic <scp>phase‐chronic</scp> myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the <scp>TFR‐PRO</scp> study","year":2023,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont; McGill University; Jewish General Hospital","funders":"Dipartimento di Medicina e Chirurgia, Università degli Studi di Milano-Bicocca; Università degli Studi di Milano-Bicocca","keywords":"Discontinuation; Medicine; Cohort; Internal medicine; Myeloid leukemia; Prospective cohort study; Cohort study; Oncology","score_opus":0.016880785678153112,"score_gpt":0.32471810413039887,"score_spread":0.30783731845224577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386303249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964696,0.0013681657,0.00013042867,0.00011587901,0.00024626643,0.0015113007,0.000091405986,0.00002297983,0.000043950313],"genre_scores_gemma":[0.998599,0.00029876945,0.00050386967,0.000027180207,0.00015952901,0.00011250403,0.00008290038,0.000051834588,0.00016444031],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956047,0.0004413851,0.0019550254,0.0004698503,0.00085497805,0.0006740925],"domain_scores_gemma":[0.99369955,0.0013556017,0.0034472377,0.0006797017,0.0006205635,0.00019735962],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00096677704,0.000394393,0.0021336437,0.0012222936,0.00012084647,0.000013882353,0.0004362337,0.0001343649,0.000014670274],"category_scores_gemma":[0.0019134098,0.00026839811,0.00066503417,0.0034036313,0.0005678896,0.00015369983,0.00018552366,0.00052788144,0.000006340479],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030764766,0.0028880362,0.96042967,0.00025690254,0.0034681056,0.00014027009,0.0029000419,0.0015204825,0.003571359,0.000038471244,0.0024114463,0.022067565],"study_design_scores_gemma":[0.046477724,0.03293223,0.83967406,0.0015410769,0.00894291,0.00019305512,0.00818399,0.0071145995,0.053323902,0.000097959906,0.0013608478,0.00015764066],"about_ca_topic_score_codex":0.00023231626,"about_ca_topic_score_gemma":0.0003290733,"teacher_disagreement_score":0.12075561,"about_ca_system_score_codex":0.002153057,"about_ca_system_score_gemma":0.0023941244,"threshold_uncertainty_score":0.9999768},"labels":[],"label_agreement":null},{"id":"W4386332154","doi":"10.1016/s2152-2650(23)01011-x","title":"AML-197 Clinical Outcomes and Treatment Patterns in Adult Patients With FMS-Like Tyrosine Kinase 3 Internal Tandem Duplication Positive Acute Myeloid Leukemia Undergoing Allogeneic Hemopoietic Cell Transplantation in the US and Canada: CIBMTR® (Center for International Blood and Marrow Transplant Research Analysis)","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Myeloid leukemia; Medicine; Fms-Like Tyrosine Kinase 3; Tandem exon duplication; Tyrosine kinase; Leukemia; Haematopoiesis; Transplantation; Myeloid; Gene duplication; Hematopoietic stem cell transplantation; Oncology; Immunology; Cancer research; Internal medicine; Biology; Stem cell; Genetics; Gene; Mutation; Receptor","score_opus":0.02434578935180782,"score_gpt":0.3220667128557471,"score_spread":0.2977209235039393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386332154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99619025,0.00010036037,0.000060998012,0.00089276454,0.0002243801,0.0017412388,0.0007027233,0.00003420657,0.000053080545],"genre_scores_gemma":[0.99148446,0.0045426474,0.00023443317,0.0007905553,0.00014184558,0.00028657887,0.0023358413,0.000054540968,0.00012911328],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953742,0.00051669014,0.0014585175,0.0012060925,0.00075910374,0.00068537035],"domain_scores_gemma":[0.9955089,0.0030196512,0.00030003817,0.0004663072,0.00036427862,0.00034081665],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011809985,0.00048582215,0.0010002472,0.0004782278,0.00017872806,0.00009189959,0.00026435702,0.00031971905,0.00000914261],"category_scores_gemma":[0.0002752638,0.00034250205,0.00022392924,0.00056076306,0.00033502598,0.00016537693,0.00008120025,0.00041267258,0.0000028951229],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026827184,0.00057633827,0.97345805,0.00010253346,0.0014056497,0.0006818797,0.00063172675,0.000027720826,0.000032322674,0.000017191802,0.00007661883,0.020307226],"study_design_scores_gemma":[0.036229435,0.0015468815,0.95720226,0.00037146168,0.0017064412,0.00008296704,0.00021596889,0.0021316595,0.00011756948,0.000021172727,0.00007171537,0.00030249954],"about_ca_topic_score_codex":0.049989935,"about_ca_topic_score_gemma":0.37563407,"teacher_disagreement_score":0.32564414,"about_ca_system_score_codex":0.0030566265,"about_ca_system_score_gemma":0.0017602143,"threshold_uncertainty_score":0.9999027},"labels":[],"label_agreement":null},{"id":"W4386623512","doi":"10.1111/bjh.19058","title":"Final report of <scp>TKI</scp> discontinuation trial with dasatinib for the second attempt of treatment‐free remission after failing the first attempt with imatinib: Treatment‐free Remission Accomplished by Dasatinib (<scp>TRAD</scp>) study","year":2023,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Toronto General Hospital; University of Alberta; London Health Sciences Centre; Hôpital de l'Enfant-Jésus; Université de Montréal; Hôpital Maisonneuve-Rosemont; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; Vancouver General Hospital; University of Calgary; BC Cancer Agency; Alberta Health Services; McGill University Health Centre; University of Ottawa; CancerCare Manitoba; University Health Network; Ottawa Hospital; Dalhousie University; Western University; University of Toronto; University of British Columbia","funders":"Bristol-Myers Squibb Canada; Princess Margaret Cancer Foundation","keywords":"Dasatinib; Discontinuation; Medicine; Imatinib; Internal medicine; Tyrosine-kinase inhibitor; Drug holiday; Oncology; Immunology; Myeloid leukemia; Human immunodeficiency virus (HIV); Cancer","score_opus":0.03349169713017222,"score_gpt":0.2989456162039855,"score_spread":0.2654539190738133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386623512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919352,0.0015813309,0.00017658828,0.0009002399,0.0003487949,0.0044731614,0.00027315973,0.000058556445,0.000252963],"genre_scores_gemma":[0.99382025,0.00027030113,0.0015042996,0.000055740667,0.00034873423,0.0005446125,0.00021669561,0.00013341346,0.0031059526],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99473894,0.00033218155,0.0024774864,0.0007463333,0.000991067,0.00071400835],"domain_scores_gemma":[0.9895161,0.004827657,0.0033113447,0.0014477862,0.00064473326,0.00025239628],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001427992,0.00063834805,0.0021698985,0.0002643308,0.00044466543,0.000098004944,0.0006858801,0.00027719006,0.00006618341],"category_scores_gemma":[0.0029912547,0.00036282162,0.000509779,0.0005789639,0.00043421765,0.0003410706,0.00015918537,0.00046455208,0.0000030927818],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06193015,0.020255208,0.4429725,0.0027758814,0.022470517,0.08279518,0.053149696,0.00046558474,0.0066965087,0.000044127977,0.26262805,0.043816566],"study_design_scores_gemma":[0.49631372,0.06943432,0.105030484,0.007633281,0.009546848,0.2145432,0.039998688,0.00096280285,0.028572503,0.00048093434,0.026929792,0.00055342173],"about_ca_topic_score_codex":0.0004450598,"about_ca_topic_score_gemma":0.0014506916,"teacher_disagreement_score":0.43438357,"about_ca_system_score_codex":0.0006191067,"about_ca_system_score_gemma":0.0011781302,"threshold_uncertainty_score":0.9998824},"labels":[],"label_agreement":null},{"id":"W4386704631","doi":"10.1038/s41408-023-00918-3","title":"The expanding CML treatment landscape: an introspective commentary","year":2023,"lang":"en","type":"editorial","venue":"Blood Cancer Journal","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"University of Toronto","keywords":"Introspection; Medicine; MEDLINE; Intensive care medicine; Psychology; Political science; Law; Cognitive psychology","score_opus":0.015809717900934883,"score_gpt":0.3357773604501388,"score_spread":0.3199676425492039,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386704631","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0075823893,0.017998636,0.0000034980171,0.0029317923,0.96987575,0.00064737693,0.00045900757,0.00014242984,0.00035912805],"genre_scores_gemma":[0.00065804843,0.062885754,0.00007064958,0.000118116775,0.9319846,0.00028844556,0.00040020395,0.00017644599,0.003417712],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968296,0.00015838155,0.00057662063,0.00050459604,0.001170006,0.0007607869],"domain_scores_gemma":[0.997258,0.00090726995,0.0004958278,0.00059951976,0.00026479777,0.00047456968],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004308867,0.0005660059,0.0008114875,0.00016518052,0.00089262816,0.00026156797,0.0003424318,0.00044661644,0.00029866674],"category_scores_gemma":[0.00020661985,0.00034096997,0.00035811702,0.00021649041,0.00009564125,0.00012754397,0.00008785065,0.0016413152,0.000047110403],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054695696,0.0003650475,0.0016358625,0.000047830286,0.003827903,0.0009658406,0.0006094986,0.000007663012,0.00003880246,0.0000017971788,0.98039675,0.011556025],"study_design_scores_gemma":[0.017206308,0.0026232018,0.00049011415,0.0009390113,0.003516548,0.0002779863,0.0007246434,0.000021559594,0.0003520374,0.00006526798,0.97343415,0.00034917312],"about_ca_topic_score_codex":0.0009797366,"about_ca_topic_score_gemma":0.0014520262,"teacher_disagreement_score":0.044887114,"about_ca_system_score_codex":0.006251157,"about_ca_system_score_gemma":0.002763141,"threshold_uncertainty_score":0.9999042},"labels":[],"label_agreement":null},{"id":"W4386967886","doi":"10.21203/rs.3.rs-3286758/v1","title":"Somatic mutations in myeloid transcription factors and in activated signaling genes predict the risk of treatment failure and progression to advanced phase in chronic myeloid leukemia","year":2023,"lang":"en","type":"preprint","venue":"Research Square","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Princess Margaret Cancer Foundation","keywords":"Myeloid leukemia; Transcription factor; Gene; Myeloid; Cancer research; Somatic cell; Biology; Medicine; Genetics","score_opus":0.05865109726904647,"score_gpt":0.3973031659816088,"score_spread":0.3386520687125623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386967886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98948467,0.002813406,0.00002378716,0.000432225,0.000043199758,0.0068892296,0.00024510472,0.00005987633,0.000008513115],"genre_scores_gemma":[0.9922166,0.0048315567,0.00037468004,0.0000021766537,0.000050409755,0.0018616441,0.00054162944,0.00007197178,0.00004936315],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99609065,0.00079508725,0.00077591673,0.0008691846,0.00077178,0.00069740746],"domain_scores_gemma":[0.9979752,0.00089297025,0.00019047153,0.00057849335,0.00013393647,0.00022897344],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010338548,0.00045270624,0.00084083417,0.0014586406,0.00013436902,0.000051359642,0.00017441054,0.00037015174,0.000026883105],"category_scores_gemma":[0.00047433187,0.00030633132,0.00010852752,0.0010746117,0.00021195054,0.0001299126,0.00022940202,0.0012763721,0.000003824732],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021754443,0.0009847874,0.36571813,0.005718926,0.00041347992,0.00031876704,0.022051906,0.03387506,0.4872033,0.000004975022,0.000010656201,0.08152457],"study_design_scores_gemma":[0.03119412,0.0055269734,0.72468406,0.022151625,0.00027508862,0.000019585274,0.013879142,0.02888151,0.17217594,0.00052324403,0.00009910372,0.00058959384],"about_ca_topic_score_codex":0.0043904204,"about_ca_topic_score_gemma":0.011148174,"teacher_disagreement_score":0.35896593,"about_ca_system_score_codex":0.011689792,"about_ca_system_score_gemma":0.002866373,"threshold_uncertainty_score":0.9999389},"labels":[],"label_agreement":null},{"id":"W4387330115","doi":"10.1038/s41375-023-02048-y","title":"European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia","year":2023,"lang":"en","type":"review","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":103,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Institute for Health and Care Research; North Carolina Pork Council","keywords":"Medicine; Myeloid leukemia; Hematology; Myeloid; Internal medicine; Oncology; Intensive care medicine","score_opus":0.07640124886457271,"score_gpt":0.347823993219408,"score_spread":0.27142274435483527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387330115","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000039995695,0.9903854,0.00006507525,0.00031692095,0.0006419431,0.0056947493,0.0009895606,0.0002620224,0.0016043481],"genre_scores_gemma":[0.000020227879,0.9878226,0.0010315737,0.00015979732,0.00074946956,0.0030414842,0.0014048466,0.0003863925,0.0053836126],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959325,0.0002893605,0.001485592,0.0010567347,0.0004738534,0.00076195435],"domain_scores_gemma":[0.99553376,0.001503954,0.0008840617,0.0016587678,0.0001491985,0.00027023893],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009844915,0.0009211968,0.0022292123,0.0003596306,0.00031811805,0.00006609051,0.00064335606,0.0003994131,0.00015447605],"category_scores_gemma":[0.00012641867,0.0006582208,0.0007192135,0.0010250432,0.00029937483,0.00010098765,0.0005044101,0.00078767544,0.00034896703],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021708347,0.00004624629,0.000010724531,0.058656804,0.0028133271,0.00012712902,0.00007882788,0.000009159818,6.141681e-7,0.0003995097,0.065902054,0.8719339],"study_design_scores_gemma":[0.0027200927,0.0002765603,0.00011588665,0.03240478,0.008127912,0.00007530273,0.00008798885,0.00010940784,0.000009116028,0.000021495753,0.9555592,0.00049223757],"about_ca_topic_score_codex":0.00014682117,"about_ca_topic_score_gemma":0.000051488172,"teacher_disagreement_score":0.88965714,"about_ca_system_score_codex":0.01458832,"about_ca_system_score_gemma":0.004139364,"threshold_uncertainty_score":0.9995869},"labels":[],"label_agreement":null},{"id":"W4387569270","doi":"10.21203/rs.3.rs-3383063/v1","title":"In vitro evidence of synergistic efficacy with asciminib combined with reduced dose of ATP-binding pocket tyrosine kinase inhibitors according to the ABL1 kinase domain mutation profile","year":2023,"lang":"en","type":"preprint","venue":"Research Square","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Korea Drug Development Fund; National Research Foundation of Korea; National Research Foundation; Ministry of Science and ICT, South Korea; Princess Margaret Cancer Foundation","keywords":"Tyrosine kinase; In vitro; Proto-oncogene tyrosine-protein kinase Src; Kinase; Protein kinase domain; Chemistry; Pharmacology; Mutation; Receptor tyrosine kinase; Cancer research; Biology; Biochemistry; Signal transduction; Mutant; Gene","score_opus":0.0774375523625681,"score_gpt":0.3938041575697892,"score_spread":0.3163666052072211,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387569270","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899787,0.00044321624,0.000050159157,0.0025303934,0.00015441696,0.00654554,0.00017096536,0.00007333754,0.000053326177],"genre_scores_gemma":[0.9956757,0.00006276904,0.002195624,0.000017972216,0.00016498835,0.00094524916,0.00044493354,0.00014153242,0.00035122692],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9938703,0.00072689867,0.00090300373,0.0010859447,0.0025036905,0.00091012387],"domain_scores_gemma":[0.99369967,0.0029214935,0.00046714093,0.0015916197,0.0009831652,0.00033693842],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0027980823,0.0005032921,0.001104461,0.0014192609,0.00015779819,0.00006882691,0.0005671778,0.00027197308,0.000063112835],"category_scores_gemma":[0.0041450355,0.00033187153,0.00015097707,0.0031238997,0.000407333,0.00014147311,0.0008896414,0.0015510514,0.00004331542],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14800453,0.0046109967,0.018331615,0.031996045,0.001529869,0.010584132,0.029133482,0.011323132,0.7310404,0.00022727312,0.0032316109,0.009986903],"study_design_scores_gemma":[0.02276404,0.009797712,0.057240896,0.10893161,0.00053119165,0.00007360109,0.013043118,0.0011150411,0.78530127,0.00017185017,0.000039986833,0.0009897072],"about_ca_topic_score_codex":0.002011703,"about_ca_topic_score_gemma":0.00015080831,"teacher_disagreement_score":0.12524049,"about_ca_system_score_codex":0.0028514701,"about_ca_system_score_gemma":0.0029479605,"threshold_uncertainty_score":0.99991333},"labels":[],"label_agreement":null},{"id":"W4387705970","doi":"10.1038/s41375-023-02062-0","title":"Identification of multivariable microRNA and clinical biomarker panels to predict imatinib response in chronic myeloid leukemia at diagnosis","year":2023,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; Terry Fox Research Institute; University of British Columbia","funders":"Deutsche Forschungsgemeinschaft; Mitacs; Government of Canada; Canadian Institutes of Health Research; Leukemia and Lymphoma Society of Canada","keywords":"Imatinib; Medicine; Imatinib mesylate; Myeloid leukemia; Oncology; Internal medicine; Receiver operating characteristic; Proportional hazards model; Tyrosine-kinase inhibitor; Biomarker; microRNA; Hazard ratio; Bioinformatics; Cancer; Biology","score_opus":0.03580934012816729,"score_gpt":0.33614623320482173,"score_spread":0.30033689307665445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387705970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99674094,0.00035232125,0.00004151223,0.0006282327,0.0002774651,0.0014852551,0.00012786487,0.0001792971,0.00016711208],"genre_scores_gemma":[0.994486,0.0008309979,0.0005416046,0.00017704183,0.00013149822,0.00036022355,0.00014777374,0.000077825265,0.0032470669],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.996088,0.00036284418,0.0015358564,0.0008934366,0.00047493042,0.00064493215],"domain_scores_gemma":[0.99660367,0.0016079482,0.00036071078,0.0009473428,0.00011273671,0.00036761467],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0022410827,0.0003539756,0.0007962135,0.000549689,0.00009669833,0.00002623214,0.00023527312,0.00038048756,0.00018888738],"category_scores_gemma":[0.002094628,0.0003365395,0.00018057888,0.0012331671,0.00021558719,0.00014375577,0.0003713657,0.00034901738,0.0005806566],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006647537,0.00018231533,0.3828953,0.0005675057,0.00037110597,0.0003376315,0.0011721335,0.00042714304,0.57300967,0.000014522065,0.012034397,0.022340784],"study_design_scores_gemma":[0.00889752,0.00061756995,0.91163844,0.0006245618,0.00017432986,0.00005683015,0.00010030605,0.01128529,0.062665425,0.000029864146,0.0036380114,0.00027187553],"about_ca_topic_score_codex":0.0006545116,"about_ca_topic_score_gemma":0.00009819875,"teacher_disagreement_score":0.52874315,"about_ca_system_score_codex":0.0137266675,"about_ca_system_score_gemma":0.0023984245,"threshold_uncertainty_score":0.9999087},"labels":[],"label_agreement":null},{"id":"W4387748826","doi":"10.1016/j.htct.2023.09.517","title":"OUTCOMES IN PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA RECEIVING INOTUZUMAB OZOGAMICIN AND PROCEEDING TO HEMATOPOIETIC STEM CELL TRANSPLANTATION","year":2023,"lang":"en","type":"article","venue":"Hematology Transfusion and Cell Therapy","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada); McGill University Health Centre","funders":"","keywords":"Medicine; Hematopoietic stem cell transplantation; Internal medicine; Calicheamicin; Refractory (planetary science); Adverse effect; Transplantation; Salvage therapy; Gastroenterology; Surgery; Oncology; Chemotherapy; Myeloid leukemia","score_opus":0.009324414593363263,"score_gpt":0.23411395898418505,"score_spread":0.2247895443908218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387748826","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99734885,0.00023710473,0.00014702778,0.000212507,0.00007302572,0.00143302,0.000013119149,0.00011580669,0.00041953727],"genre_scores_gemma":[0.99592984,0.002765719,0.00022408563,0.0002123894,0.000007514426,0.00010813595,0.000048391128,0.000055890563,0.0006480384],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99831045,0.00005186123,0.00038519234,0.00056520244,0.00025594555,0.0004313674],"domain_scores_gemma":[0.99935794,0.00015128028,0.00007858228,0.00017704154,0.000044729128,0.00019045723],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00011802292,0.00034514247,0.00064329506,0.00034842148,0.00011318105,0.00001959902,0.00007205196,0.00017656336,0.000042324984],"category_scores_gemma":[0.0000016675233,0.00026359456,0.000049684935,0.00041691473,0.00006065557,0.000094301,0.0000145947515,0.00019229822,0.00002764871],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028618248,0.0005831903,0.95792603,0.0011152789,0.000092647635,0.00015645461,0.0157261,0.000018678578,0.01665289,0.000023254246,0.00005545271,0.00478818],"study_design_scores_gemma":[0.08098558,0.00346613,0.743636,0.0010539896,0.00043502825,0.00025591764,0.0024134524,0.00057687867,0.16615474,0.00006423163,0.00010409898,0.000853952],"about_ca_topic_score_codex":0.000042863965,"about_ca_topic_score_gemma":0.00003260371,"teacher_disagreement_score":0.21429005,"about_ca_system_score_codex":0.0002344089,"about_ca_system_score_gemma":0.00016169442,"threshold_uncertainty_score":0.99998164},"labels":[],"label_agreement":null},{"id":"W4387825202","doi":"10.1016/j.annonc.2023.09.1578","title":"78P Peroxiredoxin-1 knockout negatively affects the viability of ph+ B-cell acute lymphoblastic leukemia cells and sensitizes them to tyrosine kinase inhibitors","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"Narodowe Centrum Nauki","keywords":"Ponatinib; K562 cells; Dasatinib; Medicine; Myeloid leukemia; Propidium iodide; Cancer research; Imatinib mesylate; Viability assay; Molecular biology; Leukemia; Immunology; Biology; Apoptosis; Programmed cell death; Imatinib; Biochemistry","score_opus":0.036306211523819944,"score_gpt":0.31463759374362055,"score_spread":0.2783313822198006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387825202","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927903,0.00016378799,0.000008317526,0.0038324709,0.00022679033,0.00091642444,0.000096261996,0.000062569736,0.0019030784],"genre_scores_gemma":[0.99737185,0.000338571,0.0003620549,0.00079688494,0.0001222367,0.00004013831,0.000021347738,0.000035188077,0.00091170624],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981218,0.00019908453,0.0004628495,0.0004418996,0.00030644776,0.00046790074],"domain_scores_gemma":[0.9972781,0.0014574929,0.00027224008,0.0005034544,0.00025598574,0.0002327098],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057700265,0.00028224758,0.00082024396,0.00015246672,0.00008404756,0.000006976222,0.00014400788,0.00020503635,0.000054109612],"category_scores_gemma":[0.00035914988,0.00019771917,0.00016952585,0.0005416948,0.00047964122,0.00005454241,0.00023777947,0.00017982317,0.00010133526],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016651521,0.0007297306,0.0038488999,0.0005396119,0.00053217245,0.0004303875,0.004321206,0.00012601542,0.9245804,0.000069791764,0.029186329,0.033970285],"study_design_scores_gemma":[0.004963948,0.0041628624,0.029734356,0.00016589768,0.00032281768,0.00008420773,0.0006715853,0.00043689486,0.9550426,0.00015764305,0.0040760403,0.00018113981],"about_ca_topic_score_codex":0.00020152649,"about_ca_topic_score_gemma":0.000039235998,"teacher_disagreement_score":0.033789143,"about_ca_system_score_codex":0.00048622175,"about_ca_system_score_gemma":0.001009244,"threshold_uncertainty_score":0.8062754},"labels":[],"label_agreement":null},{"id":"W4389083699","doi":"10.1111/bjh.19214","title":"Early liver complications after allogeneic haematopoietic stem cell transplantation in patients with myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of the <scp>EBMT</scp>","year":2023,"lang":"en","type":"letter","venue":"British Journal of Haematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Myelofibrosis; Haematopoiesis; Stem cell; Medicine; Transplantation; Hematopoietic stem cell transplantation; Internal medicine; Oncology; Biology; Bone marrow","score_opus":0.015941105747327575,"score_gpt":0.21995706357661698,"score_spread":0.2040159578292894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389083699","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99327177,0.002001047,0.000007857475,0.0025319878,0.00028967374,0.0017266783,0.000113886046,0.000011717184,0.000045368863],"genre_scores_gemma":[0.99662334,0.00026804843,0.000042787393,0.0025346803,0.000105493295,0.00013298006,0.00002911963,0.00008361451,0.00017991492],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99639785,0.0005709431,0.001303321,0.0003650257,0.00092047843,0.0004423981],"domain_scores_gemma":[0.9969525,0.00045860073,0.0016383103,0.0005753014,0.00031795798,0.000057340236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000254178,0.00035151263,0.0012973528,0.00026787215,0.00009321897,0.000023997403,0.0005417739,0.00040257777,0.000011520671],"category_scores_gemma":[0.000034226196,0.00023900489,0.00036455432,0.00046933626,0.0003249627,0.00006417908,0.00008662813,0.0013355198,0.000007921471],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002173491,0.0016357002,0.9590639,0.0028647159,0.0009758811,0.016141377,0.004564522,0.00007890421,0.000095291616,0.000004655224,0.013501439,0.0008562838],"study_design_scores_gemma":[0.0057404665,0.0012491014,0.9708979,0.012123364,0.001278281,0.007368582,0.00026653806,0.0000022769127,0.0006551344,0.000013692719,0.00031139742,0.000093238516],"about_ca_topic_score_codex":0.00018286413,"about_ca_topic_score_gemma":0.0004642091,"teacher_disagreement_score":0.013190041,"about_ca_system_score_codex":0.00047796074,"about_ca_system_score_gemma":0.00060151145,"threshold_uncertainty_score":0.9746337},"labels":[],"label_agreement":null},{"id":"W4389221384","doi":"10.1182/blood-2023-178790","title":"Long-Term Results from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ponatinib; Medicine; Internal medicine; Clinical endpoint; Adverse effect; Oncology; Clinical trial; Dasatinib; Imatinib; Myeloid leukemia","score_opus":0.04659768767780648,"score_gpt":0.3128577532226517,"score_spread":0.2662600655448452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389221384","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99769694,0.000105896346,0.000005909544,0.00015792128,0.000103603925,0.0014653957,0.000071023685,0.00007409605,0.0003192231],"genre_scores_gemma":[0.9988847,0.000035310113,0.0005069356,0.000016841404,0.00013245405,0.000042357256,0.00018615478,0.000024031628,0.00017124914],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9984535,0.000105660656,0.00061973976,0.00024764793,0.00040729652,0.00016614654],"domain_scores_gemma":[0.99823725,0.0007353876,0.00034956116,0.00053798256,0.00009578665,0.00004403767],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037206867,0.00012474628,0.00034012494,0.00007787148,0.00004738508,0.000008279523,0.00012579061,0.00005268483,0.000052221207],"category_scores_gemma":[0.0009979077,0.000084452964,0.000071912844,0.00043182963,0.000038480925,0.000039607294,0.00007713901,0.00009661742,0.000011492004],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.114986576,0.045821514,0.68801826,0.0006904584,0.009763721,0.0014336539,0.08059232,0.021315712,0.021404324,0.000052483203,0.0015071074,0.01441386],"study_design_scores_gemma":[0.54706925,0.0052461238,0.42833313,0.00058066525,0.0023871895,0.000008697929,0.0037147433,0.0025110827,0.009925589,0.00002379638,0.000007424071,0.00019228987],"about_ca_topic_score_codex":0.0005219732,"about_ca_topic_score_gemma":0.000079825746,"teacher_disagreement_score":0.43208268,"about_ca_system_score_codex":0.000055499302,"about_ca_system_score_gemma":0.00017849392,"threshold_uncertainty_score":0.34438917},"labels":[],"label_agreement":null},{"id":"W4389228919","doi":"10.1182/blood-2023-185440","title":"In Vitro Evidence of Synergistically Enhanced Efficacy of Axitinib When Combined with Asciminib in T315I Mutated Chronic Myeloid Leukemia","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Nilotinib; Bosutinib; Axitinib; Dasatinib; Ponatinib; Myeloid leukemia; Cancer research; Medicine; Tyrosine-kinase inhibitor; Pharmacology; Imatinib; Tyrosine kinase; Sunitinib; Cancer; Internal medicine; Receptor","score_opus":0.019741417157586892,"score_gpt":0.2824718528705756,"score_spread":0.2627304357129887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389228919","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99752057,0.00039940714,0.000023965162,0.00025495305,0.000055768214,0.0009884925,0.000017050324,0.0000868597,0.000652926],"genre_scores_gemma":[0.9981451,0.00019660586,0.0009161244,0.00004264909,0.000047544578,0.00010297777,0.000073691306,0.00005209085,0.00042321195],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973869,0.000104038685,0.00085643854,0.000526555,0.00056869484,0.0005574285],"domain_scores_gemma":[0.9979315,0.0008665799,0.00026319438,0.0006584619,0.0001357475,0.00014451359],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00038403756,0.00029883356,0.0009582206,0.0004367447,0.000019914916,0.000006464293,0.00024530332,0.00016200948,0.00016088119],"category_scores_gemma":[0.0008821456,0.00025555145,0.00009810659,0.0012133478,0.00024225195,0.00011246308,0.000101650345,0.0003296597,0.00005813797],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071332967,0.0018274983,0.0036641916,0.0013518957,0.0003676446,0.0012708599,0.0014342334,0.00045871196,0.980155,0.00009013532,0.0000964583,0.0021500776],"study_design_scores_gemma":[0.046676055,0.0031079047,0.07514883,0.0032742082,0.00035799626,0.00004739459,0.00011356058,0.0009533089,0.8699599,0.00008040391,0.000017836388,0.00026262025],"about_ca_topic_score_codex":0.0005552943,"about_ca_topic_score_gemma":0.00024467072,"teacher_disagreement_score":0.110195115,"about_ca_system_score_codex":0.0010226999,"about_ca_system_score_gemma":0.0022497335,"threshold_uncertainty_score":0.9999897},"labels":[],"label_agreement":null},{"id":"W4389229234","doi":"10.1182/blood-2023-186773","title":"ASC4START and ASC4FIRST: Two Ongoing Phase 3 Trials Investigating Asciminib Monotherapy As First-Line Therapy Versus Tyrosine Kinase Inhibitors in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Nilotinib; Bosutinib; Medicine; Dasatinib; Discontinuation; Tolerability; Internal medicine; Adverse effect; Oncology; Myeloid leukemia; Imatinib","score_opus":0.03765564633306478,"score_gpt":0.32515279904201,"score_spread":0.2874971527089452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389229234","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887253,0.005122645,0.000006273111,0.00084985356,0.00028601944,0.004487084,0.00016375499,0.00028341566,0.00007562073],"genre_scores_gemma":[0.99286133,0.0036481877,0.00029316137,0.00025593876,0.00090648927,0.0006857888,0.001080784,0.0002290791,0.000039215167],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99433154,0.00040086644,0.0016117332,0.0014114935,0.0009398288,0.0013045443],"domain_scores_gemma":[0.99639755,0.0013995911,0.0006688134,0.0008249564,0.00015180699,0.0005573022],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011697967,0.0009907378,0.0018226425,0.0009742704,0.00026748388,0.00011154663,0.00026215307,0.0003343363,0.00017265246],"category_scores_gemma":[0.00084063876,0.0008586735,0.0002277034,0.002167125,0.0003581287,0.0005116577,0.00012834939,0.0008304204,0.00005953321],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.080082096,0.034423716,0.26769525,0.00211916,0.007874472,0.0121019455,0.02374209,0.012477314,0.17871569,0.00012696124,0.0014110011,0.3792303],"study_design_scores_gemma":[0.8380952,0.027546642,0.039332476,0.0038146677,0.00060486083,0.000036415964,0.00022423638,0.004186754,0.08407699,0.00005664667,0.00079446397,0.0012306671],"about_ca_topic_score_codex":0.0016316783,"about_ca_topic_score_gemma":0.001964052,"teacher_disagreement_score":0.75801307,"about_ca_system_score_codex":0.006946062,"about_ca_system_score_gemma":0.0036875582,"threshold_uncertainty_score":0.9993864},"labels":[],"label_agreement":null},{"id":"W4389229290","doi":"10.1182/blood-2023-185370","title":"Prospective Assessment of Co-Morbidities and Framingham Risk Score in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients and Its Impact on Clinical Outcomes Following Frontline TKI Therapy: Toronto CML Genomic Alliance in Greater Toronto Area &amp; Ontario (TCGA-GTA)","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"London Health Sciences Centre; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Comorbidity; Internal medicine; Framingham Risk Score; Family medicine; Disease","score_opus":0.03602746253166136,"score_gpt":0.3478674559423691,"score_spread":0.3118399934107078,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389229290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99340206,0.0035080852,0.000001136312,0.000024344059,0.00023212942,0.0022377768,0.00012992787,0.00007274959,0.00039178412],"genre_scores_gemma":[0.99428827,0.004258004,0.00023640216,0.000072467024,0.000098835844,0.0002464298,0.00020132173,0.00008086647,0.00051739626],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967025,0.00017787097,0.0009979563,0.0009178605,0.0005269773,0.00067682413],"domain_scores_gemma":[0.9982997,0.0004864096,0.00036131806,0.000543385,0.00006682057,0.0002423506],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00058086135,0.0005880004,0.0013669886,0.00010257611,0.00008602203,0.000040288425,0.00016933723,0.00029605572,0.00019402403],"category_scores_gemma":[0.0001863723,0.0004629582,0.0002744542,0.00011987663,0.00009521223,0.00033051366,0.00012775908,0.0005054681,0.000010078759],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000491531,0.0010057056,0.9917043,0.00006738433,0.00088845857,0.00017158058,0.0034735182,0.00005982905,0.00015654379,0.000003924989,0.00007777697,0.0018994462],"study_design_scores_gemma":[0.042698946,0.003168863,0.95230955,0.0005080252,0.00024077177,0.000004177132,0.00025804044,0.00016855264,0.00020085966,0.000024865978,0.000058583882,0.00035875107],"about_ca_topic_score_codex":0.11937733,"about_ca_topic_score_gemma":0.42720792,"teacher_disagreement_score":0.3078306,"about_ca_system_score_codex":0.0122149605,"about_ca_system_score_gemma":0.0014498648,"threshold_uncertainty_score":0.9997822},"labels":[],"label_agreement":null},{"id":"W4389229317","doi":"10.1182/blood-2023-186854","title":"Sustained Efficacy and Safety with Asciminib (ASC) after Almost 4 Years of Median Follow-up from Ascembl, a Phase 3 Study of ASC Vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs): An End of Study Treatment (EOS Tx) Update, Including Results from Switch Population","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Tolerability; Medicine; Discontinuation; Adverse effect; Internal medicine; Bosutinib; Nilotinib; Imatinib; Myeloid leukemia","score_opus":0.015366112831357356,"score_gpt":0.2878198482473606,"score_spread":0.27245373541600326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389229317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912832,0.00031379334,9.93495e-7,0.000029047593,0.00009154845,0.006982675,0.0012248761,0.00006568378,0.000008179302],"genre_scores_gemma":[0.9959039,0.000090024856,0.00018534694,0.000009489689,0.00013698517,0.00048153714,0.0030312806,0.0001394236,0.000021982114],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99438834,0.0003797357,0.0019292207,0.0013834944,0.00117885,0.00074033113],"domain_scores_gemma":[0.9969664,0.00035475392,0.0008592894,0.0012806475,0.00020577802,0.0003330848],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00053176016,0.0007563418,0.0017321714,0.0009147113,0.00007513137,0.00002741021,0.00022238026,0.00024002834,0.00007090536],"category_scores_gemma":[0.0001854528,0.0006285638,0.00010821807,0.0015189728,0.00017521712,0.00037718663,0.0002652117,0.00035612236,0.0000041769363],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12961105,0.043316305,0.75279886,0.00023692993,0.0019397173,0.0022068818,0.031124143,0.0002693736,0.0028417301,3.8520164e-7,0.000007294311,0.035647314],"study_design_scores_gemma":[0.3440332,0.038635116,0.60706943,0.0010211287,0.0013832509,0.0000037231803,0.002538099,0.00029650755,0.0046540676,0.000002412825,0.000008332178,0.00035472133],"about_ca_topic_score_codex":0.025294146,"about_ca_topic_score_gemma":0.046581913,"teacher_disagreement_score":0.21442218,"about_ca_system_score_codex":0.0047760815,"about_ca_system_score_gemma":0.0017634989,"threshold_uncertainty_score":0.99961656},"labels":[],"label_agreement":null},{"id":"W4389229334","doi":"10.1182/blood-2023-189797","title":"Final Report: Somatic Mutations and HMGCLL1 Haplotype Are Not Associated with Molecular Relapse-Free Survival in Patients with Chronic Myeloid Leukemia Who Attempt Treatment-Free Remission","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Myeloid leukemia; Oncology; Internal medicine; Imatinib mesylate; Medicine; Population; Immunology; Imatinib","score_opus":0.015673700188890225,"score_gpt":0.23853922376533915,"score_spread":0.22286552357644893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389229334","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971219,0.00020912586,0.000007322271,0.00051880523,0.000057477613,0.0012378447,0.00010076714,0.00028065182,0.00046613524],"genre_scores_gemma":[0.9957831,0.00006333274,0.00038062874,0.00004182967,0.000050582712,0.00015921246,0.0010520674,0.00012304353,0.002346229],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99713093,0.00012160155,0.00054822484,0.00075176003,0.0008404865,0.00060702127],"domain_scores_gemma":[0.99763745,0.00020482184,0.00040990624,0.0013379708,0.00014592883,0.00026392436],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002232898,0.00046566591,0.0007405628,0.00029068638,0.00016726347,0.00003624363,0.00019486771,0.00021407136,0.00004070295],"category_scores_gemma":[0.000772139,0.0003482914,0.0000820299,0.0007901589,0.00014995394,0.00014712379,0.00014057527,0.000290972,0.0000313878],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005726428,0.0012474832,0.98799545,0.00018127813,0.0010108823,0.0065866876,0.00049186556,0.00016221109,0.00065134687,0.000012282266,0.00031143398,0.0007764362],"study_design_scores_gemma":[0.058617555,0.0024944732,0.9331838,0.0015886035,0.0011005587,0.0001611421,0.000110416884,0.00030211208,0.0019406988,0.000077772194,0.000057571047,0.00036533078],"about_ca_topic_score_codex":0.00034438723,"about_ca_topic_score_gemma":0.001359286,"teacher_disagreement_score":0.05804491,"about_ca_system_score_codex":0.0026070515,"about_ca_system_score_gemma":0.0013205798,"threshold_uncertainty_score":0.9998969},"labels":[],"label_agreement":null},{"id":"W4389229454","doi":"10.1182/blood-2023-187689","title":"Retrospective Study to Evaluate Probability of MR4 Maintenance Following Frontline Nilotinib Dose De-Escalation after MR4 Achievement in the Patients with Chronic Myeloid Leukemia in Chronic Phase","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Nilotinib; Discontinuation; Imatinib; Internal medicine; Imatinib mesylate; Myeloid leukemia; Dasatinib; Tyrosine-kinase inhibitor; Hazard ratio; Cancer; Confidence interval","score_opus":0.015430110723707703,"score_gpt":0.29349225437395715,"score_spread":0.27806214365024945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389229454","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99287236,0.00012747785,0.000022292023,0.00020723403,0.0000700358,0.006526845,0.00003498888,0.00006181954,0.0000769746],"genre_scores_gemma":[0.998186,0.000012400174,0.00026605336,0.000071347684,0.00009029787,0.0011534722,0.00009103724,0.000048296806,0.00008109307],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966254,0.00031596827,0.0007244126,0.0007187636,0.00092432013,0.0006910833],"domain_scores_gemma":[0.99866325,0.00007924866,0.000186151,0.00082447357,0.00013127348,0.00011563103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001661504,0.000348687,0.00061794027,0.0002654639,0.00005783015,0.000017470851,0.0002279228,0.00008072431,0.00004051622],"category_scores_gemma":[0.00027540707,0.00023924229,0.00011984642,0.001245574,0.000058580274,0.00013239108,0.00012980278,0.00039112358,0.00003239552],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018009257,0.0064152475,0.9822545,0.0001356789,0.00027200274,0.00018936498,0.0056568966,0.0009579383,0.00067314954,0.0000047240183,0.00002671427,0.0016128364],"study_design_scores_gemma":[0.066000715,0.0075070593,0.923438,0.000551948,0.00037655566,0.0000027955496,0.00035354047,0.0009986655,0.0004895492,0.000065612374,0.0000149500875,0.00020058748],"about_ca_topic_score_codex":0.0008067692,"about_ca_topic_score_gemma":0.005045301,"teacher_disagreement_score":0.06419979,"about_ca_system_score_codex":0.013862763,"about_ca_system_score_gemma":0.0018214338,"threshold_uncertainty_score":0.9899228},"labels":[],"label_agreement":null},{"id":"W4389229545","doi":"10.1182/blood-2023-180772","title":"Incremental Healthcare Resource Utilization and Costs Associated with Non-Optimal Treatment in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Tyrosine Kinase Inhibitors (TKI) in Early Lines of Therapy in the United States (US)","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Discontinuation; Dasatinib; Bosutinib; Nilotinib; Internal medicine; Ponatinib; Cohort; Imatinib mesylate; Drug holiday; Imatinib; Oncology; Pediatrics; Myeloid leukemia; Immunology","score_opus":0.017867027619073838,"score_gpt":0.27037533789041845,"score_spread":0.2525083102713446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389229545","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957472,0.000684519,4.122196e-7,0.00013698342,0.0000077481145,0.003239325,0.000112342845,0.000056248875,0.000015239239],"genre_scores_gemma":[0.99524176,0.00079158565,0.00002184305,0.000059630875,0.00002790231,0.00034059418,0.0034184046,0.000078069104,0.000020215406],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99730057,0.00030466542,0.000636131,0.0005760795,0.0005486747,0.00063386245],"domain_scores_gemma":[0.9989299,0.00017026704,0.00028769686,0.00037824112,0.00011883926,0.00011505325],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031158942,0.0004818408,0.00069000304,0.00083808135,0.00006312296,0.000026031337,0.0001147971,0.00017236726,0.0000069149633],"category_scores_gemma":[0.000032256878,0.00029954777,0.000033043278,0.0033857578,0.00017648352,0.00014800842,0.00003336447,0.0003289221,0.0000013975407],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004823066,0.0031894683,0.9817488,0.00009759558,0.00020411743,0.00042272132,0.003733971,0.0016963705,0.00059461204,0.0000015333512,0.0000071039494,0.0034806046],"study_design_scores_gemma":[0.13936326,0.021188395,0.82601273,0.0021135847,0.000113070026,0.0000083673785,0.0006910621,0.002672221,0.0075614206,6.481081e-7,0.000022449498,0.00025277422],"about_ca_topic_score_codex":0.029505547,"about_ca_topic_score_gemma":0.047018506,"teacher_disagreement_score":0.15573609,"about_ca_system_score_codex":0.008424299,"about_ca_system_score_gemma":0.0013338096,"threshold_uncertainty_score":0.99994564},"labels":[],"label_agreement":null},{"id":"W4389229583","doi":"10.1182/blood-2023-190293","title":"Propensity Score Matching Comparing Asciminib <i>Versus</i> Ponatinib in Chronic Myeloid Leukemia Patients Who Failed Prior Tyrosine Kinase Inhibitor Therapy","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Foothills Medical Centre; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Bosutinib; Ponatinib; Internal medicine; Discontinuation; Propensity score matching; Oncology; Imatinib; Clinical endpoint; Myeloid leukemia; Adverse effect; Clinical trial; Dasatinib","score_opus":0.0456258352050269,"score_gpt":0.2734143701800048,"score_spread":0.22778853497497792,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389229583","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99551135,0.00045408006,0.0000019870417,0.00016899723,0.00042068324,0.0020519043,0.00002754396,0.00036266673,0.0010007698],"genre_scores_gemma":[0.9976948,0.00031716187,0.00019931274,0.00015701367,0.00040564363,0.00016185812,0.00040885748,0.00011430777,0.00054102583],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967351,0.00010774726,0.00068638386,0.00083246536,0.00076912093,0.00086917117],"domain_scores_gemma":[0.9984732,0.00015783687,0.0002330668,0.0007297486,0.00014187308,0.00026425594],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037465157,0.0005004253,0.0008788584,0.00035437712,0.00020435454,0.000067345914,0.0002709194,0.00021380496,0.00009194833],"category_scores_gemma":[0.00015681614,0.0004413237,0.0001730743,0.000963107,0.00010220683,0.00026262313,0.000282764,0.0005904819,0.0002959915],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028974747,0.0020916068,0.9364483,0.0005774851,0.00053818367,0.00086766377,0.0023870433,0.00022437748,0.028366746,0.00004063879,0.0017161276,0.023844348],"study_design_scores_gemma":[0.079827346,0.0010851742,0.8764224,0.001081748,0.00015165693,0.000013834648,0.00009382691,0.00042535012,0.039561126,0.000019649575,0.0008540768,0.00046382446],"about_ca_topic_score_codex":0.00055048714,"about_ca_topic_score_gemma":0.00045067922,"teacher_disagreement_score":0.07692987,"about_ca_system_score_codex":0.0031479604,"about_ca_system_score_gemma":0.0014338872,"threshold_uncertainty_score":0.99980384},"labels":[],"label_agreement":null},{"id":"W4389231475","doi":"10.1182/blood-2023-189827","title":"New Pattern of Emerging Somatic Mutations in Optimal Responders Following Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia Patients Evidenced from Mutational Kinetic Analysis Based on Pairwise Comparison","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Myeloid leukemia; Fluorescence in situ hybridization; Tyrosine-kinase inhibitor; Dasatinib; Population; Biology; Imatinib mesylate; Internal medicine; Cancer research; Medicine; Oncology; Immunology; Genetics; Imatinib; Cancer","score_opus":0.021858447190414257,"score_gpt":0.29689866038613794,"score_spread":0.2750402131957237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389231475","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980506,0.000306528,0.00043143428,0.00021557954,0.00008589483,0.00077179325,0.000042494354,0.00007550044,0.000020213216],"genre_scores_gemma":[0.9971538,0.000017281358,0.0012335296,0.000076724165,0.000057735622,0.00009847871,0.0012896855,0.000044969274,0.00002776489],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972106,0.0001804534,0.00089598686,0.0005219559,0.00078380894,0.00040714518],"domain_scores_gemma":[0.9984984,0.0006107836,0.0002565466,0.00043090348,0.000055215583,0.00014818688],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023722419,0.0003027114,0.0007247967,0.0014530624,0.00004773699,0.000020805513,0.00014601221,0.000121995414,0.00023069953],"category_scores_gemma":[0.00021674657,0.00029880527,0.0002944481,0.0024261735,0.00003569104,0.00012096556,0.00003517313,0.00025056754,0.000037266836],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035061798,0.000900649,0.80047494,0.00007933745,0.0006568897,0.00025388642,0.002165155,0.17397329,0.012062127,0.0000011945419,0.000043298387,0.009038627],"study_design_scores_gemma":[0.028175507,0.000707154,0.7796901,0.0008741898,0.0007497117,4.18957e-7,0.0003173408,0.1742286,0.015016636,0.000021862761,0.0000026294729,0.00021586835],"about_ca_topic_score_codex":0.0025287953,"about_ca_topic_score_gemma":0.00087182096,"teacher_disagreement_score":0.02782489,"about_ca_system_score_codex":0.0018833112,"about_ca_system_score_gemma":0.0013540341,"threshold_uncertainty_score":0.9999464},"labels":[],"label_agreement":null},{"id":"W4389231492","doi":"10.1182/blood-2023-187702","title":"Appropriateness of Immunosuppression and Blood Product Utilization in Acquired Hemophilia A: A Multicentre Provincial Practice Audit","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; University of Alberta","funders":"","keywords":"Medicine; Adverse effect; Internal medicine; Comorbidity; Pediatrics; Emergency medicine","score_opus":0.02152700142810902,"score_gpt":0.2854654781333211,"score_spread":0.2639384767052121,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389231492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967494,0.0009276128,0.0000026259454,0.00049352983,0.000114303315,0.0013139636,0.000015427091,0.00010134887,0.00028176085],"genre_scores_gemma":[0.9979971,0.00043727778,0.00077881315,0.000024506018,0.00012561794,0.00007253673,0.00012550688,0.00003265684,0.00040596834],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99849,0.00009539651,0.0003735479,0.00042316856,0.0003406053,0.0002773189],"domain_scores_gemma":[0.9990907,0.00011476214,0.00019839496,0.00038429,0.00013904352,0.00007285341],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000282634,0.000177221,0.0003372111,0.00017390003,0.00004825323,0.000011377047,0.000076457196,0.000108056774,0.000022245244],"category_scores_gemma":[0.0010629961,0.00015176361,0.000040637085,0.00055282115,0.000060552407,0.00018826537,0.00012246659,0.00010351627,0.00001704165],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031476624,0.013278757,0.26515484,0.0033890202,0.0009824154,0.001486884,0.00757757,0.000049184775,0.6748073,0.00012771832,0.00030014486,0.029698486],"study_design_scores_gemma":[0.059116192,0.0008543662,0.51642615,0.0013220815,0.0023861786,0.00052443455,0.0013961778,0.00160419,0.4149903,0.000090080954,0.0008616316,0.00042824046],"about_ca_topic_score_codex":0.00022714723,"about_ca_topic_score_gemma":0.000035560974,"teacher_disagreement_score":0.25981703,"about_ca_system_score_codex":0.00009729564,"about_ca_system_score_gemma":0.0004320196,"threshold_uncertainty_score":0.6188741},"labels":[],"label_agreement":null},{"id":"W4389234429","doi":"10.1182/blood-2023-174790","title":"Outcomes of Patients with Accelerated/Blast-Phase MPNs That Received Allogeneic Stem-Cell Transplant in the Current Era of Myeloid Therapies","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Cohort; Transplantation; Myeloid; Hematopoietic stem cell transplantation; Oncology; Gastroenterology; Surgery","score_opus":0.03210762976622982,"score_gpt":0.2810069876121128,"score_spread":0.24889935784588296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389234429","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974947,0.0008495719,0.0000029777275,0.00019766767,0.000074242445,0.0009772615,0.00021299963,0.000039388953,0.00015120974],"genre_scores_gemma":[0.9984263,0.0010402226,0.000037382408,0.00005068101,0.000015210436,0.00007802972,0.0002522991,0.00003095148,0.00006890678],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998414,0.00010521007,0.00039631003,0.0002676854,0.00051764207,0.00029918813],"domain_scores_gemma":[0.99904394,0.00018128724,0.00019397245,0.0004413293,0.00008008479,0.000059374754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016902664,0.00024395212,0.0005176411,0.00013911811,0.000033610744,0.00000767283,0.00020647123,0.00006165,0.000048540376],"category_scores_gemma":[0.0000073965134,0.00013518837,0.00010825615,0.00043394123,0.00008234737,0.000058169993,0.000021914822,0.00027274125,0.0000124770295],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052479777,0.005186587,0.96938205,0.0002715792,0.00047371283,0.000050909406,0.0059995432,0.000015700301,0.0018195694,0.000003734021,0.000052416457,0.016219381],"study_design_scores_gemma":[0.03416934,0.0011736336,0.9369898,0.00031636207,0.0004950171,0.000004326781,0.00046979453,0.000016257216,0.025990164,0.000008015494,0.00021816646,0.00014912544],"about_ca_topic_score_codex":0.000062703795,"about_ca_topic_score_gemma":0.000077453486,"teacher_disagreement_score":0.033644542,"about_ca_system_score_codex":0.00006342431,"about_ca_system_score_gemma":0.00023925671,"threshold_uncertainty_score":0.55128217},"labels":[],"label_agreement":null},{"id":"W4389243387","doi":"10.1182/blood-2023-180789","title":"Treatment Patterns and Modifications of Tyrosine Kinase Inhibitors (TKI) Therapy in Early Lines in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Real-World Analysis from a Large Commercial Claims Database in the United States (US)","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Bosutinib; Dasatinib; Nilotinib; Discontinuation; Internal medicine; Ponatinib; Imatinib mesylate; Oncology; Tolerability; Imatinib; Myeloid leukemia; Adverse effect","score_opus":0.022833910769530966,"score_gpt":0.2936828101174232,"score_spread":0.27084889934789225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389243387","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961346,0.0004000196,0.0000038610415,0.00023005088,0.000021071135,0.0016286931,0.0015340386,0.000037732552,0.000009973853],"genre_scores_gemma":[0.9848561,0.0030512835,0.00003037532,0.000056325705,0.00006892556,0.00038894144,0.011483742,0.000044663015,0.000019632118],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99742615,0.00025258237,0.0007844547,0.0005972896,0.00039711205,0.0005424103],"domain_scores_gemma":[0.9985154,0.0002919995,0.00022243056,0.00080093206,0.0000635582,0.00010562286],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002742829,0.00039086555,0.00076619844,0.0016660771,0.000057268626,0.00002649528,0.000183261,0.00010958765,0.00003679136],"category_scores_gemma":[0.000024045477,0.0002757205,0.00008851704,0.004768532,0.00010159079,0.00014944572,0.00006448114,0.000329182,0.0000046998184],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007588805,0.0045472346,0.987413,0.000054376596,0.00043557878,0.00019109416,0.0035408724,0.0009390591,0.00048310225,0.00001091446,0.000011947821,0.001613939],"study_design_scores_gemma":[0.07476246,0.0017262255,0.91523725,0.00037344883,0.00048276084,7.646e-7,0.00025963195,0.005075893,0.0017991487,0.000009562371,0.000060348324,0.00021249554],"about_ca_topic_score_codex":0.17855436,"about_ca_topic_score_gemma":0.35675803,"teacher_disagreement_score":0.17820367,"about_ca_system_score_codex":0.0032398885,"about_ca_system_score_gemma":0.00077143847,"threshold_uncertainty_score":0.9999695},"labels":[],"label_agreement":null},{"id":"W4389243588","doi":"10.1182/blood-2023-180252","title":"Identification of Multivariable microRNA and Clinical Biomarkers Panels to Predict Imatinib Response in Chronic Myeloid Leukemia at Diagnosis","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; University of British Columbia; BC Cancer Agency; Terry Fox Research Institute","funders":"","keywords":"Nilotinib; Medicine; Imatinib mesylate; Myeloid leukemia; Imatinib; Oncology; Internal medicine; microRNA; Immunology; Biology","score_opus":0.02666562689333428,"score_gpt":0.3199405976593267,"score_spread":0.2932749707659924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389243588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99767363,0.00035594363,0.0000084126295,0.00046838363,0.00012148639,0.0011028833,0.000099643774,0.000097213066,0.000072401715],"genre_scores_gemma":[0.9975234,0.0007385684,0.00049662666,0.000053818043,0.00008007061,0.00018463949,0.0000763429,0.000039968025,0.00080654596],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99761087,0.00023233294,0.00095019926,0.00054832327,0.0002844597,0.00037378984],"domain_scores_gemma":[0.9978391,0.0010907857,0.000217826,0.0005703121,0.00006208832,0.00021990157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015653188,0.00019739749,0.0004769132,0.00033327547,0.00005010144,0.0000129638165,0.00012932584,0.0001914596,0.00007862499],"category_scores_gemma":[0.0017050614,0.00018772882,0.00010510398,0.0007388804,0.00011850187,0.00007053947,0.0001954648,0.00015846278,0.00022774369],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002431247,0.00049170706,0.5125699,0.0002824903,0.0004510553,0.00016523724,0.00056893216,0.0000350777,0.47728044,0.0000029032444,0.0016313514,0.0040896414],"study_design_scores_gemma":[0.0125635695,0.0007162516,0.8320252,0.00040225583,0.0002869998,0.000039671224,0.00008023352,0.00095639686,0.15220751,0.000009567642,0.0005736805,0.00013868608],"about_ca_topic_score_codex":0.00025068052,"about_ca_topic_score_gemma":0.000047474885,"teacher_disagreement_score":0.32507294,"about_ca_system_score_codex":0.0016390383,"about_ca_system_score_gemma":0.0008218631,"threshold_uncertainty_score":0.7655359},"labels":[],"label_agreement":null},{"id":"W4389243998","doi":"10.1182/blood-2023-186092","title":"Concurrent BCR::-ABL1 and CBFB Rearrangement in De Novo Acute Myeloid Leukemia","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Grand River Hospital; McMaster University; Hamilton Regional Laboratory Medicine Program; Juravinski Cancer Centre","funders":"","keywords":"Fusion transcript; Cancer research; Myeloid leukemia; Fusion gene; Gene rearrangement; ABL; Biology; Bone marrow; Leukemia; Medicine; Internal medicine; Immunology; Genetics; Gene; Tyrosine kinase","score_opus":0.018651809357483503,"score_gpt":0.2835538800367045,"score_spread":0.264902070679221,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389243998","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951035,0.0008504744,0.0000066025573,0.00061442074,0.0001323522,0.0005133404,0.000024106443,0.00016531146,0.0025899215],"genre_scores_gemma":[0.9952886,0.0015767834,0.00027300883,0.0002652747,0.00014905204,0.000114345494,0.000096424745,0.000038645114,0.002197868],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985668,0.00003651559,0.00026531154,0.00037277178,0.00026212435,0.000496469],"domain_scores_gemma":[0.99934083,0.00006475749,0.00005203393,0.0003151609,0.000027233906,0.0001999697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000231722,0.00019913043,0.00033837723,0.00018646967,0.000047375735,0.000018407896,0.00008264907,0.00010724669,0.00012005493],"category_scores_gemma":[0.00006132852,0.00018128075,0.000058698442,0.00037369994,0.00005951032,0.000050666753,0.0001103576,0.0002187283,0.00024134657],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033041686,0.0019461078,0.72440356,0.00096197025,0.002508367,0.012814094,0.00593346,0.000037130885,0.13580583,0.0005895385,0.015015809,0.09965374],"study_design_scores_gemma":[0.07613973,0.0012804226,0.83785015,0.0009914852,0.0018557457,0.0016460448,0.00069333595,0.0011372488,0.04258924,0.00023408658,0.034811895,0.00077063305],"about_ca_topic_score_codex":0.00019411369,"about_ca_topic_score_gemma":0.0000970978,"teacher_disagreement_score":0.11344659,"about_ca_system_score_codex":0.00087498006,"about_ca_system_score_gemma":0.00049507857,"threshold_uncertainty_score":0.7392414},"labels":[],"label_agreement":null},{"id":"W4389246485","doi":"10.1182/blood-2023-175044","title":"Restoration of Mir-185 in Combination with BCR-ABL Downregulation By Therapeutic Delivery of siRNA with Lipid Nanoparticle Carriers Targets Drug Resistant Leukemic Stem/Progenitor Cells","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute","funders":"","keywords":"Cancer research; Progenitor cell; Dasatinib; Stem cell; Medicine; Downregulation and upregulation; Tyrosine kinase; Combination therapy; Myeloid leukemia; Philadelphia chromosome; Immunology; Pharmacology; Biology; Imatinib; Internal medicine; Cell biology; Chromosomal translocation","score_opus":0.01008391813627352,"score_gpt":0.21965202002132775,"score_spread":0.20956810188505423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389246485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982622,0.0005720159,0.000010305979,0.00011482673,0.000044044722,0.0008464092,0.000032312113,0.00005883819,0.00005901877],"genre_scores_gemma":[0.99905777,0.000051596333,0.00025047135,0.000014820123,0.000021514763,0.000059092257,0.00012996006,0.000036325542,0.0003784393],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984593,0.00010119343,0.00041532106,0.00028420455,0.0004931725,0.00024681393],"domain_scores_gemma":[0.9990427,0.00008183403,0.00027684082,0.00033742507,0.00018324792,0.0000779623],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024094858,0.0001777446,0.00033732323,0.00018972595,0.000046442357,0.0000085256115,0.00007576863,0.00007810839,0.0000113439055],"category_scores_gemma":[0.000010561815,0.00014207631,0.000040347782,0.00068848167,0.000095781674,0.00014478592,0.000017724966,0.00010000965,0.0000068554905],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001436317,0.0006542923,0.028838597,0.00023857171,0.00021147955,0.000026107196,0.0015323848,0.0002578032,0.9660191,0.000028785858,0.00020698305,0.00054959545],"study_design_scores_gemma":[0.014785221,0.0013032074,0.041967366,0.0003210359,0.000364091,0.000008596112,0.0006944109,0.0010243314,0.93928,0.000018188923,0.000082598875,0.00015099335],"about_ca_topic_score_codex":0.00044985942,"about_ca_topic_score_gemma":0.00022788525,"teacher_disagreement_score":0.026739124,"about_ca_system_score_codex":0.00046153122,"about_ca_system_score_gemma":0.00047568267,"threshold_uncertainty_score":0.5793704},"labels":[],"label_agreement":null},{"id":"W4389246762","doi":"10.1182/blood-2023-186963","title":"Safety and Efficacy of Axatilimab at 3 Different Doses in Patients with Chronic Graft-Versus-Host Disease (AGAVE-201)","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Vancouver General Hospital; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Graft-versus-host disease; Medicine; Agave; Host (biology); Disease; Surgery; Internal medicine; Biology","score_opus":0.009685638422480403,"score_gpt":0.2368443523090944,"score_spread":0.227158713886614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389246762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99817085,0.0004960514,5.4351966e-7,0.000111931906,0.00007015869,0.0008017159,0.000096252224,0.000067833564,0.00018465481],"genre_scores_gemma":[0.9988976,0.00027847476,0.000020702906,0.000013958816,0.000043317763,0.000028453751,0.0003288343,0.000036325237,0.000352342],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998591,0.000036009325,0.0002879014,0.0003700857,0.00037722228,0.00033777865],"domain_scores_gemma":[0.9990067,0.00018333997,0.00011311785,0.00043094004,0.00003921887,0.00022667814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000045359226,0.00022966161,0.00039918156,0.00014335243,0.000051405237,0.000005902169,0.000072449766,0.000056856567,0.0001124265],"category_scores_gemma":[0.00011266544,0.00016425917,0.00006063353,0.00027749734,0.00010992841,0.00004716338,0.00013980594,0.00011151482,0.00004012106],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006163743,0.0018399241,0.989589,0.00027588732,0.00027840232,0.000085882646,0.00020678336,0.0000071078903,0.00019911102,0.000016681539,0.000048853442,0.0012886485],"study_design_scores_gemma":[0.084383704,0.0011426538,0.91250056,0.00032719807,0.00046907246,0.0000015863978,0.000015307682,0.000048296588,0.0008163754,0.0000029777814,0.00015687919,0.00013536098],"about_ca_topic_score_codex":0.000060410457,"about_ca_topic_score_gemma":0.0001947993,"teacher_disagreement_score":0.07821996,"about_ca_system_score_codex":0.00058709946,"about_ca_system_score_gemma":0.00017110948,"threshold_uncertainty_score":0.6698295},"labels":[],"label_agreement":null},{"id":"W4389247110","doi":"10.1182/blood-2023-188204","title":"Retrospective, Multi-Center Analysis of Ruxolitinib Tapering after Successful Treatment of Steroid Refractory Chronic Graft Versus Host Disease","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan; Université Laval; Princess Margaret Cancer Centre; University of Toronto; University Health Network; University of Calgary","funders":"","keywords":"Medicine; Tapering; Ruxolitinib; Refractory (planetary science); Internal medicine; Graft-versus-host disease; Surgery; Transplantation; Myelofibrosis; Bone marrow","score_opus":0.023250787093055256,"score_gpt":0.296379348698426,"score_spread":0.27312856160537075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389247110","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99689907,0.0015626926,0.0000043234413,0.000045234123,0.00014467494,0.00047903176,0.0005439839,0.000093042996,0.0002279439],"genre_scores_gemma":[0.9978348,0.00077611895,0.00010579406,0.00000940338,0.00011136482,0.0001386023,0.0003604354,0.00004607975,0.0006174],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99816775,0.00004846528,0.00047166203,0.0004937883,0.00041056468,0.00040776536],"domain_scores_gemma":[0.99855155,0.000073646974,0.00020753813,0.0008070049,0.0001107998,0.0002494414],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000064377055,0.00029071228,0.0007911962,0.0005189798,0.000035992674,0.000008751382,0.00010337795,0.000085279906,0.000392187],"category_scores_gemma":[0.000063340965,0.00024621113,0.0005171075,0.00096201623,0.000114584735,0.00008259739,0.00007048302,0.00008592747,0.000044314853],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014575644,0.0050149667,0.97952205,0.00022872207,0.0075835325,0.00046001046,0.00047821278,0.000017189033,0.004727537,0.0000048688744,0.000010444946,0.00049487496],"study_design_scores_gemma":[0.036409684,0.001417103,0.946814,0.00014405005,0.008659581,0.0000025067327,0.00010470843,0.00042913874,0.0054712472,7.6273346e-7,0.00037975374,0.00016743713],"about_ca_topic_score_codex":0.00029915187,"about_ca_topic_score_gemma":0.00030497892,"teacher_disagreement_score":0.03495212,"about_ca_system_score_codex":0.0012861318,"about_ca_system_score_gemma":0.00032958033,"threshold_uncertainty_score":0.999999},"labels":[],"label_agreement":null},{"id":"W4389258981","doi":"10.1182/blood-2023-178722","title":"Real-World Evaluation of Treatment Patterns and Clinical Outcomes Among Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Asciminib in US Clinical Practice","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Discontinuation; Dasatinib; Internal medicine; Imatinib mesylate; Bosutinib; Ponatinib; Oncology; Myeloid leukemia; Clinical trial; Philadelphia chromosome; Imatinib; Chromosomal translocation; Biology","score_opus":0.05338237304737282,"score_gpt":0.3981197193294436,"score_spread":0.3447373462820708,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389258981","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959243,0.00011204575,0.0000012459303,0.00008032174,0.00007963345,0.0030873055,0.00006456348,0.00009616564,0.00055442133],"genre_scores_gemma":[0.99708694,0.0012999639,0.00021021818,0.00003857078,0.00013233181,0.00033305192,0.0005768825,0.00008456691,0.00023749955],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950671,0.00070502266,0.0016018824,0.0010046313,0.0009853933,0.0006359366],"domain_scores_gemma":[0.996667,0.0012119764,0.0006875193,0.0008442483,0.00029885632,0.000290388],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017667501,0.00051025744,0.0013288821,0.0005300131,0.00005223821,0.000022474856,0.00012965553,0.00026311397,0.000082194376],"category_scores_gemma":[0.0005566409,0.0003538621,0.00016425806,0.0009970794,0.00027854758,0.00028991114,0.000075108816,0.0004784078,0.000023598168],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015947683,0.004464846,0.97083294,0.000099786004,0.001178488,0.0003229432,0.00017020239,0.00019078272,0.000010301888,0.0000025623935,0.000016526456,0.021115845],"study_design_scores_gemma":[0.15484561,0.012525694,0.82563096,0.00065493723,0.003062275,0.000014513541,0.000069775655,0.0026988378,0.00016008342,0.0000024000162,0.00006975365,0.0002651644],"about_ca_topic_score_codex":0.014721829,"about_ca_topic_score_gemma":0.06258259,"teacher_disagreement_score":0.15325084,"about_ca_system_score_codex":0.009093276,"about_ca_system_score_gemma":0.0053041596,"threshold_uncertainty_score":0.99989134},"labels":[],"label_agreement":null},{"id":"W4389259512","doi":"10.1182/blood-2023-188135","title":"Asciminib Enhances Its Treatment Efficacy Synergistically in the Treatment of Chronic Myeloid Leukemia Harboring ABL1 Kinase Domain Mutation When Combined with a Reduced Dose of Ponatinib, Dasatinib, or Bosutinib, but Not with Nilotinib or Imatinib","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Bosutinib; Dasatinib; Ponatinib; Nilotinib; Imatinib; Medicine; Myeloid leukemia; Pharmacology; Tyrosine-kinase inhibitor; Tyrosine kinase; Imatinib mesylate; Cancer research; Internal medicine; Cancer; Receptor","score_opus":0.03312461366678398,"score_gpt":0.2947581460343663,"score_spread":0.2616335323675823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389259512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939307,0.00024220423,0.000017700379,0.00045690354,0.00009097793,0.0041422723,0.00023172525,0.00019418662,0.00069330283],"genre_scores_gemma":[0.9915807,0.00053670345,0.004883488,0.000046241024,0.00019756716,0.0012448748,0.0004219857,0.00013372421,0.0009547014],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9950764,0.00033154615,0.0014349963,0.0010184796,0.001199586,0.0009389604],"domain_scores_gemma":[0.99508774,0.002363753,0.00083207537,0.0011953298,0.00025861638,0.00026249202],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00052046805,0.00087338453,0.001606244,0.00048064886,0.00017513988,0.000047913236,0.00038403648,0.00021388382,0.00023267046],"category_scores_gemma":[0.00043872904,0.00045129165,0.00022363018,0.0014154655,0.00037682863,0.0001618109,0.00005043844,0.00023565657,0.00003895664],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19527923,0.09002048,0.0075416593,0.0051029776,0.012212818,0.026082087,0.1157628,0.0024733623,0.44397494,0.0021624034,0.00019994745,0.099187285],"study_design_scores_gemma":[0.19001919,0.09369786,0.07636495,0.0027366031,0.0034380988,0.0007136614,0.0047770096,0.0013347302,0.6254921,0.000050280978,0.00040104773,0.0009744454],"about_ca_topic_score_codex":0.0005621003,"about_ca_topic_score_gemma":0.0010302968,"teacher_disagreement_score":0.18151715,"about_ca_system_score_codex":0.0019231308,"about_ca_system_score_gemma":0.0041077808,"threshold_uncertainty_score":0.9997939},"labels":[],"label_agreement":null},{"id":"W4389334337","doi":"10.1021/acsmedchemlett.3c00479","title":"Atypical <i>N</i>-Alkyl to <i>N</i>-Noralkoxy Switch in a Dual cSRC/BCR-ABL1 Kinase Inhibitor Improves Drug Efflux and hERG Affinity","year":2023,"lang":"en","type":"article","venue":"ACS Medicinal Chemistry Letters","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Georgia Research Alliance; National Institute of General Medical Sciences; Natural Sciences and Engineering Research Council of Canada; University of Georgia","keywords":"Chemistry; Bioisostere; Alkyl; hERG; ABL; Hydroxylamine; Molecular switch; Amine gas treating; Stereochemistry; Combinatorial chemistry; Efflux; Pharmacology; Piperazine; Medicinal chemistry; Biochemistry; Biology; Tyrosine kinase; Chemical synthesis; Biophysics; Molecule; In vitro; Organic chemistry; Receptor","score_opus":0.010484956024932216,"score_gpt":0.25481016031071796,"score_spread":0.24432520428578575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389334337","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.969176,0.0002778285,0.000004065908,0.028810084,0.00028706854,0.000682,0.000024844323,0.0002679234,0.00047021135],"genre_scores_gemma":[0.9888026,0.00009004898,0.00025895578,0.008305964,0.0011792412,0.00015590769,0.00018044621,0.0000840583,0.0009427793],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9963587,0.000060652455,0.00066954584,0.0010028722,0.00088380545,0.0010244036],"domain_scores_gemma":[0.9978973,0.00035452185,0.00012791959,0.00070774,0.000069224814,0.0008432608],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00056507735,0.00056738773,0.0008107066,0.00018646225,0.0001172687,0.00004030059,0.00019499309,0.00024661838,0.0001143266],"category_scores_gemma":[0.00055213884,0.00051562994,0.00012344513,0.00097493915,0.00027819708,0.00012781244,0.0003131262,0.0009246637,0.00016969543],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00091720576,0.00021670797,0.016176395,0.00071223854,0.00010976297,0.0044967956,0.0012274386,0.000008518637,0.9211149,0.000002098915,0.052287206,0.0027307165],"study_design_scores_gemma":[0.020432057,0.0004527431,0.07112211,0.001989736,0.0004598052,0.0016200093,0.002093394,0.00018730496,0.8831407,0.00005429355,0.017179253,0.0012686097],"about_ca_topic_score_codex":0.00043846393,"about_ca_topic_score_gemma":0.000056740017,"teacher_disagreement_score":0.054945715,"about_ca_system_score_codex":0.0009638262,"about_ca_system_score_gemma":0.00038488986,"threshold_uncertainty_score":0.9997295},"labels":[],"label_agreement":null},{"id":"W4389746035","doi":"10.1177/20543581231215849","title":"Case Report of Renal Calculi in a Child Receiving Imatinib for Acute Lymphoblastic Leukemia","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Kidney Health and Disease","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Montreal Children's Hospital","funders":"","keywords":"Medicine; Imatinib; Internal medicine; Kidney stones; Gastroenterology","score_opus":0.01990607216792256,"score_gpt":0.3079237484612457,"score_spread":0.28801767629332314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389746035","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9606479,0.0017741502,0.00009306506,0.035571855,0.0003256718,0.0007477491,0.0006318152,0.000012435683,0.00019536797],"genre_scores_gemma":[0.98877335,0.00025705522,0.00060372445,0.009622422,0.00023801676,0.000023595909,0.00017993318,0.000034870103,0.0002670175],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.998372,0.00004104451,0.0007698003,0.00017927284,0.0001634538,0.00047440312],"domain_scores_gemma":[0.97671956,0.00009489027,0.00039421598,0.00019436693,0.00012619559,0.022470778],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00046118704,0.00013748324,0.00045889997,0.0005242461,0.00013608976,0.000012043168,0.00005332684,0.000052101812,0.000033454868],"category_scores_gemma":[0.016715126,0.00012228571,0.00012021985,0.00032969855,0.00007166691,0.000075807264,0.000009022789,0.00015568234,0.0000019614874],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014313794,0.000073013885,0.04990449,0.0023839248,0.00031325704,0.63358885,0.0018270873,0.00010293875,0.000025205485,0.00007767358,0.3038685,0.006403659],"study_design_scores_gemma":[0.063331254,0.0040540923,0.059679147,0.016550919,0.0020545153,0.77838814,0.002132791,0.012771648,0.00009073397,0.0011945084,0.0588026,0.00094965013],"about_ca_topic_score_codex":0.006448755,"about_ca_topic_score_gemma":0.002242019,"teacher_disagreement_score":0.2450659,"about_ca_system_score_codex":0.0019160773,"about_ca_system_score_gemma":0.13987361,"threshold_uncertainty_score":0.9915675},"labels":[],"label_agreement":null},{"id":"W4390246519","doi":"10.17305/bb.2023.9869","title":"Effects of neratinib on angiogenesis and the early stage of the embryo using chicken embryo as a model","year":2023,"lang":"en","type":"article","venue":"Biomolecules and Biomedicine","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Neratinib; Angiogenesis; Embryo; Cancer research; Vascular endothelial growth factor; Biology; Cell biology; Cancer; VEGF receptors; Breast cancer; Genetics","score_opus":0.014754998285607206,"score_gpt":0.2712896891122566,"score_spread":0.25653469082664937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390246519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963352,0.0013469136,0.00005300764,0.0012520006,0.00007721392,0.0007368035,0.00004475259,0.000021855149,0.00013222946],"genre_scores_gemma":[0.9979147,0.0004662042,0.000118410855,0.0003256748,0.00006192572,0.00001410248,0.000012799824,0.000021538552,0.0010646979],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988811,0.000060388254,0.00027553402,0.00023634845,0.0003477626,0.00019884935],"domain_scores_gemma":[0.99920726,0.00019413182,0.00014951623,0.0003134678,0.000047355854,0.0000882828],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002313532,0.00018116999,0.00040467374,0.00015629224,0.00009164824,0.000007562587,0.000092497045,0.00008034281,0.0000060290463],"category_scores_gemma":[0.00013390434,0.000083973624,0.000101554695,0.00056126685,0.00060407305,0.000018378028,0.000115307455,0.00007068212,0.0000016527716],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007167153,0.00010348384,0.0008491566,0.00052222953,0.00027416847,0.00004187347,0.0009573795,0.000011370553,0.99228877,0.0006177496,0.00016056755,0.0034565465],"study_design_scores_gemma":[0.037174847,0.0032994305,0.13582888,0.002954996,0.0017516286,0.0001461656,0.0007254934,0.06905534,0.7480271,0.0003720364,0.00027627024,0.00038782324],"about_ca_topic_score_codex":0.00090957957,"about_ca_topic_score_gemma":0.00000689802,"teacher_disagreement_score":0.24426168,"about_ca_system_score_codex":0.00004212921,"about_ca_system_score_gemma":0.00013320796,"threshold_uncertainty_score":0.3424345},"labels":[],"label_agreement":null},{"id":"W4390348169","doi":"10.1038/s41375-023-02122-5","title":"In vitro evidence of synergistic efficacy with asciminib combined with reduced dose of ATP-binding pocket tyrosine kinase inhibitors according to the ABL1 kinase domain mutation profile","year":2023,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Tyrosine kinase; In vitro; Mutation; Pharmacology; Kinase; Tyrosine-kinase inhibitor; Protein kinase domain; Cancer research; Medicine; Biology; Biochemistry; Internal medicine; Mutant; Signal transduction","score_opus":0.023020767430470195,"score_gpt":0.29210742132784256,"score_spread":0.26908665389737235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390348169","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99676985,0.00012082296,0.000040927116,0.0009238703,0.00013841412,0.0017994272,0.000028699904,0.00008870763,0.00008927227],"genre_scores_gemma":[0.9969062,0.000010864354,0.0022291557,0.00010849591,0.00009386766,0.00017508441,0.0001245547,0.000070436065,0.00028130683],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974854,0.00012606374,0.00063696987,0.0005353503,0.0007136593,0.0005025295],"domain_scores_gemma":[0.9976948,0.00086584524,0.0003717191,0.0007241203,0.00016665884,0.00017685643],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005709885,0.0003393728,0.0006639642,0.00047764165,0.00008885457,0.000021743439,0.00023531883,0.00010966775,0.00003903458],"category_scores_gemma":[0.0007895583,0.00022266935,0.00008129242,0.0026865988,0.00017099905,0.00019002293,0.000115195806,0.00030624887,0.000045935012],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023930985,0.0003880151,0.005167662,0.0009455981,0.00022656839,0.0016842631,0.0072454223,0.0034412565,0.9513072,0.00008687521,0.0012048231,0.004371352],"study_design_scores_gemma":[0.018127758,0.0027067803,0.03665418,0.0072171954,0.00037972062,0.000080579644,0.0029468618,0.0009805189,0.93041307,0.00002796691,0.000045144,0.00042023187],"about_ca_topic_score_codex":0.0005609071,"about_ca_topic_score_gemma":0.00004745386,"teacher_disagreement_score":0.03148652,"about_ca_system_score_codex":0.0022366121,"about_ca_system_score_gemma":0.0011665261,"threshold_uncertainty_score":0.90801924},"labels":[],"label_agreement":null},{"id":"W4390618444","doi":"10.1007/s40261-023-01329-9","title":"Maximizing the Value of Chronic Myeloid Leukemia Management Using Tyrosine Kinase Inhibitors in the USA: Potential Determinants and Consequences of Healthcare Resource Utilization and Costs, with Proposed Optimization Approaches","year":2024,"lang":"en","type":"review","venue":"Clinical Drug Investigation","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Myeloid leukemia; Imatinib; Health care; Tyrosine kinase; Tyrosine-kinase inhibitor; Life expectancy; Intensive care medicine; Tolerability; Pharmacology; Cancer research; Internal medicine; Cancer; Environmental health; Population; Adverse effect","score_opus":0.15196433801219633,"score_gpt":0.3743277414487546,"score_spread":0.22236340343655825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390618444","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10696957,0.8878788,0.00015227323,0.0004990223,0.00011872223,0.004305242,0.000028565717,0.0000201097,0.000027699845],"genre_scores_gemma":[0.099409334,0.89693224,0.0030138607,0.00007349889,0.00015006348,0.00008606993,0.00025456568,0.000054684977,0.00002570284],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99630666,0.0009852182,0.0014558495,0.0005873209,0.00044864957,0.00021632802],"domain_scores_gemma":[0.99807847,0.00036715926,0.0009642061,0.0004200576,0.00007380047,0.00009631704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016347559,0.0003613638,0.0010825435,0.00021490286,0.000114607996,0.000044936784,0.0001591612,0.00026594993,0.0000014638155],"category_scores_gemma":[0.0001971601,0.00019385139,0.00012589418,0.0006626612,0.0014720251,0.000098620774,0.00012801852,0.0005311622,5.0902935e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015105514,0.00015367141,0.004734286,0.06490123,0.00037626538,0.00010414162,0.00091169303,0.00210678,0.000007843468,0.00097226613,0.00004061074,0.92554015],"study_design_scores_gemma":[0.014650562,0.003950984,0.010070345,0.49319744,0.032388702,0.0018360857,0.005109219,0.42150927,0.0007512737,0.0007270194,0.013765173,0.002043929],"about_ca_topic_score_codex":0.0005104918,"about_ca_topic_score_gemma":0.00014971835,"teacher_disagreement_score":0.92349625,"about_ca_system_score_codex":0.0009775814,"about_ca_system_score_gemma":0.0015530473,"threshold_uncertainty_score":0.790503},"labels":[],"label_agreement":null},{"id":"W4390817926","doi":"10.1016/j.clml.2024.01.005","title":"A Review of the Therapeutic Role of Bosutinib in Chronic Myeloid Leukemia","year":2024,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Pfizer","keywords":"Bosutinib; Medicine; Dasatinib; Myeloid leukemia; Adverse effect; Oncology; Nilotinib; Population; Internal medicine; Tolerability; Imatinib","score_opus":0.05436446885694737,"score_gpt":0.3869147897249001,"score_spread":0.3325503208679528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390817926","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009255345,0.98849624,8.579813e-7,0.00012661485,0.0010979568,0.004717027,0.00019422518,0.00013047302,0.0043110955],"genre_scores_gemma":[0.0012543997,0.99431664,0.00010512378,0.00080531545,0.00089310127,0.00050465675,0.00023525275,0.00036775973,0.0015177489],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9867833,0.0013593326,0.0074948496,0.0019079045,0.001272765,0.0011818176],"domain_scores_gemma":[0.99039024,0.0018964498,0.0029362265,0.0040441416,0.00029078146,0.00044218323],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0026303707,0.0016599534,0.009714701,0.00050653104,0.000077598874,0.000027782286,0.0018793396,0.0019053855,0.00041055479],"category_scores_gemma":[0.0014603053,0.0010303453,0.005929258,0.0028148203,0.0012277025,0.000108976536,0.0010513285,0.0021085048,0.0006193375],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00006513031,0.0001761074,0.00010253234,0.20966235,0.001282842,0.00011064679,0.000033068613,4.963408e-7,0.000008133424,0.0002624733,0.0026299586,0.7856663],"study_design_scores_gemma":[0.0022287916,0.0004380995,0.003505859,0.36407888,0.008012272,0.0004648617,0.000011717908,0.000051985015,0.000025297097,0.00019230956,0.6204749,0.000515075],"about_ca_topic_score_codex":0.00030914956,"about_ca_topic_score_gemma":0.000059758255,"teacher_disagreement_score":0.7851512,"about_ca_system_score_codex":0.027431497,"about_ca_system_score_gemma":0.055208478,"threshold_uncertainty_score":0.9996148},"labels":[],"label_agreement":null},{"id":"W4391304166","doi":"10.1038/s41375-024-02159-0","title":"Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials","year":2024,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Ponatinib; Medicine; Internal medicine; Myeloid leukemia; Oncology; Clinical trial; Dasatinib; Imatinib","score_opus":0.02249795429420004,"score_gpt":0.30090854300413006,"score_spread":0.27841058870993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391304166","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887161,0.0072586546,0.00023612635,0.0006679055,0.00023863636,0.002026675,0.00035209648,0.00011207382,0.0003916894],"genre_scores_gemma":[0.9965314,0.00050050725,0.00068678695,0.00007495327,0.0003136053,0.00015751967,0.0012111651,0.000092823524,0.0004311871],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9968501,0.0002332155,0.0009945721,0.00077490887,0.00065561745,0.00049161614],"domain_scores_gemma":[0.9973969,0.0010510396,0.000338274,0.00092184026,0.000117711956,0.00017423021],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007442967,0.00046060293,0.0009530262,0.00020837934,0.00008803333,0.00007755552,0.0002492443,0.00027406876,0.00018036507],"category_scores_gemma":[0.0003609467,0.00029895874,0.00015456234,0.00060998544,0.0002680815,0.0002388276,0.000106728156,0.00062713405,0.00004356421],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014749311,0.0022041656,0.11406353,0.004660702,0.005457898,0.0009523606,0.010841495,0.0075794486,0.016543001,0.011488043,0.0070332657,0.8044268],"study_design_scores_gemma":[0.12554911,0.006427001,0.48686835,0.006741677,0.002911597,0.0000921443,0.0006415344,0.3587463,0.005099499,0.0010780558,0.0044094087,0.0014353218],"about_ca_topic_score_codex":0.0023488512,"about_ca_topic_score_gemma":0.0009621798,"teacher_disagreement_score":0.80299145,"about_ca_system_score_codex":0.02069566,"about_ca_system_score_gemma":0.0049100295,"threshold_uncertainty_score":0.99994624},"labels":[],"label_agreement":null},{"id":"W4391337081","doi":"10.22541/au.170665790.07809100/v1","title":"Outcome prediction of chronic myeloid leukaemia (CML) in children","year":2024,"lang":"en","type":"preprint","venue":"","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Nilotinib; Dasatinib; Medicine; Imatinib; Internal medicine; Oncology; Chronic myeloid leukaemia; Tyrosine-kinase inhibitor; Tyrosine kinase; Overall survival; Myeloid leukemia; Cancer","score_opus":0.021976897719882284,"score_gpt":0.29135409756646585,"score_spread":0.2693771998465836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391337081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9738608,0.0047717406,0.000038047478,0.00034898924,0.0009216469,0.00203271,0.00028362463,0.0003265212,0.017415926],"genre_scores_gemma":[0.9892425,0.000647742,0.0005085743,0.00006804679,0.0006153563,0.00017135828,0.00078033755,0.000099471035,0.007866645],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969094,0.000045956964,0.0011530932,0.00091270456,0.0005510225,0.00042782072],"domain_scores_gemma":[0.99842066,0.000042786072,0.00019133612,0.0011239348,0.000069307345,0.00015199289],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00028380126,0.0005126094,0.0010743144,0.000584965,0.000017375387,0.000020509215,0.00023823917,0.00072527723,0.00094736565],"category_scores_gemma":[0.00006861093,0.00043104947,0.00039152658,0.00029839046,0.000098746415,0.00003622476,0.0009960609,0.0017270303,0.00031791264],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010483891,0.00047087832,0.9783473,0.0030505173,0.0012901962,0.00010626291,0.00022040794,0.0005338604,0.00091304706,0.00041824277,0.0030558265,0.011488626],"study_design_scores_gemma":[0.008031825,0.00064030977,0.9718107,0.003545613,0.0014269638,0.00035495425,0.000038971124,0.0062442627,0.0048940256,0.0018302987,0.00066409685,0.0005179621],"about_ca_topic_score_codex":0.0022813373,"about_ca_topic_score_gemma":0.00021534979,"teacher_disagreement_score":0.015381675,"about_ca_system_score_codex":0.00739414,"about_ca_system_score_gemma":0.002388585,"threshold_uncertainty_score":0.9999659},"labels":[],"label_agreement":null},{"id":"W4391394357","doi":"10.22541/au.170667842.23436648/v1","title":"Prevalence of anemia among chronic myeloid leukemia patients treated with Imatinib: A evidence based meta-analysis.","year":2024,"lang":"en","type":"preprint","venue":"","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Imatinib; Medicine; Myeloid leukemia; Anemia; Internal medicine; Meta-analysis; Leukemia; Oncology","score_opus":0.04850958965549023,"score_gpt":0.2990632520097091,"score_spread":0.2505536623542189,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391394357","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9750553,0.016684724,0.0002702272,0.00023840084,0.00009896117,0.004088945,0.00053323415,0.0004713348,0.0025588956],"genre_scores_gemma":[0.9834485,0.00050750613,0.0037666273,0.00013225403,0.000079673984,0.0009199666,0.0006400562,0.00016124573,0.0103441635],"study_design_codex":"observational","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99312747,0.00029788513,0.0016774329,0.0022450967,0.0018958617,0.00075627037],"domain_scores_gemma":[0.99384433,0.00054580235,0.001156881,0.003187015,0.00083533314,0.0004306497],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0006133205,0.001318384,0.0040105516,0.001049873,0.000064300504,0.00008425261,0.0006838323,0.0006876023,0.005884069],"category_scores_gemma":[0.0002702454,0.0008451147,0.0029132653,0.0016104752,0.0004508808,0.00017482616,0.00085151545,0.0014933097,0.00013789044],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0011486165,0.0008691376,0.52064437,0.04447041,0.41214263,0.000510757,0.0003402163,0.016751738,0.00041563992,0.000036982103,0.0016058498,0.0010636653],"study_design_scores_gemma":[0.0031842182,0.001395008,0.19432048,0.0030946357,0.76324487,0.000010335458,0.000012571691,0.024033614,0.009832917,0.000031041473,0.000016365464,0.0008239166],"about_ca_topic_score_codex":0.003799432,"about_ca_topic_score_gemma":0.00037013055,"teacher_disagreement_score":0.35110226,"about_ca_system_score_codex":0.00777116,"about_ca_system_score_gemma":0.006778299,"threshold_uncertainty_score":0.9999567},"labels":[],"label_agreement":null},{"id":"W4391692164","doi":"10.1080/10428194.2024.2313626","title":"Stem cell allografting for chronic Myeloid leukemia in the tyrosine kinase era – forgotten but not gone","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Myeloid leukemia; Transplantation; Stem cell; Oncology; Tyrosine-kinase inhibitor; Tyrosine kinase; Internal medicine; Intensive care medicine; Cancer; Biology","score_opus":0.01426282834381978,"score_gpt":0.249594515214795,"score_spread":0.23533168687097522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391692164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9653366,0.023756612,0.00034457736,0.0010309105,0.0010267514,0.0034742223,0.00027210618,0.00071987795,0.0040382976],"genre_scores_gemma":[0.9811267,0.002716926,0.0013881905,0.0029317122,0.0017269625,0.0014607005,0.00057000713,0.00041177176,0.007667031],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99160117,0.00028775592,0.0018371808,0.0024584518,0.0013260784,0.002489352],"domain_scores_gemma":[0.995188,0.0016116175,0.00039390774,0.0019003008,0.000208804,0.00069735467],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0015083952,0.0016371917,0.0017898045,0.0008232322,0.00070386374,0.000616208,0.0009764292,0.0010331344,0.00010381077],"category_scores_gemma":[0.00009258975,0.0012757137,0.0008718945,0.0015864413,0.00056682486,0.0006690803,0.0003928863,0.00067408977,0.0002586357],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0034255981,0.00062690716,0.003599537,0.0074062534,0.0012617543,0.006624705,0.006814446,0.00067448744,0.07834474,0.003622537,0.02415165,0.86344737],"study_design_scores_gemma":[0.13837272,0.005794743,0.093233645,0.007063191,0.0046862466,0.012561281,0.0067831734,0.2005404,0.13073562,0.0010259183,0.39308396,0.006119091],"about_ca_topic_score_codex":0.0032614188,"about_ca_topic_score_gemma":0.00032477133,"teacher_disagreement_score":0.8573283,"about_ca_system_score_codex":0.061545845,"about_ca_system_score_gemma":0.018069977,"threshold_uncertainty_score":0.99963754},"labels":[],"label_agreement":null},{"id":"W4392501727","doi":"10.1182/bloodadvances.2023012127","title":"Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes","year":2024,"lang":"en","type":"article","venue":"Blood Advances","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; Occupational Cancer Research Centre; Princess Margaret Cancer Centre","funders":"Princess Margaret Cancer Foundation; Pfizer","keywords":"Myeloid leukemia; Transcription factor; Gene; Myeloid; Cancer research; Transcription (linguistics); Biology; Medicine; Genetics; Internal medicine; Immunology","score_opus":0.015642065460070187,"score_gpt":0.2757519528654116,"score_spread":0.2601098874053414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392501727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96161777,0.036520157,0.00008823634,0.000247893,0.00030175885,0.0005914109,0.00004895332,0.00030685886,0.0002769894],"genre_scores_gemma":[0.99519086,0.0032143127,0.00059080333,0.00003527858,0.00015448825,0.000093595,0.00016771466,0.000051605246,0.00050133216],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99830407,0.000045981003,0.00041042673,0.0005444743,0.00030496588,0.00039009022],"domain_scores_gemma":[0.9993225,0.00023633985,0.000061242186,0.00020487688,0.000033785607,0.00014126042],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00010654463,0.0003380369,0.0004536765,0.00031430766,0.000099762205,0.00005919769,0.000078368445,0.00012953515,0.00011169752],"category_scores_gemma":[0.000059634902,0.00026008795,0.00012009167,0.00042950857,0.00011294386,0.00055388,0.000021277652,0.00030084528,0.000014653188],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009189038,0.00023255861,0.32565907,0.0012110143,0.0006967313,0.00032200041,0.0020425988,0.0009639169,0.6143311,0.00015334011,0.000018891596,0.054276846],"study_design_scores_gemma":[0.010360276,0.0009998301,0.35905844,0.0021705457,0.0014581445,0.00023720226,0.0015543303,0.0021615485,0.60911196,0.0005871355,0.011510107,0.00079044804],"about_ca_topic_score_codex":0.00017156044,"about_ca_topic_score_gemma":0.00024336546,"teacher_disagreement_score":0.0534864,"about_ca_system_score_codex":0.001041064,"about_ca_system_score_gemma":0.0006440051,"threshold_uncertainty_score":0.99998516},"labels":[],"label_agreement":null},{"id":"W4392864509","doi":"10.3390/ijms25063307","title":"Clinical Insights into Structure, Regulation, and Targeting of ABL Kinases in Human Leukemia","year":2024,"lang":"en","type":"article","venue":"International Journal of Molecular Sciences","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute; University of British Columbia","funders":"Mitacs; Canadian Institutes of Health Research; Leukemia and Lymphoma Society of Canada","keywords":"Tyrosine kinase; Myeloid leukemia; Cancer research; Philadelphia chromosome; ABL; Leukemia; Biology; Myeloproliferative Disorders; Stem cell; Haematopoiesis; Protein kinase domain; Signal transduction; Immunology; Cell biology; Chromosomal translocation; Genetics","score_opus":0.018994966843389388,"score_gpt":0.3575047977236144,"score_spread":0.338509830880225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392864509","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934976,0.005045153,0.0002838183,0.00035327944,0.00044735198,0.000055203793,0.0000010500629,0.00000488208,0.00031167126],"genre_scores_gemma":[0.9959439,0.00016197536,0.0036249985,0.0000810445,0.0001580741,4.22563e-7,0.0000032945836,0.000005480511,0.000020810652],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9984181,0.000057919868,0.0006289788,0.00016653538,0.0006471462,0.00008132024],"domain_scores_gemma":[0.99931264,0.00013181061,0.00021117789,0.000058582835,0.00022442179,0.000061343795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049904006,0.00007925169,0.00020131662,0.0004011043,0.000028131977,0.000046775483,0.00019537024,0.00005029046,0.00004367004],"category_scores_gemma":[0.0002913139,0.00005754337,0.000083175466,0.00021227001,0.00028122708,0.0002025709,0.000053732365,0.0001744957,6.349566e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023420631,0.00025708982,0.20915556,0.00020381615,0.00084198004,0.004076088,0.0034552938,0.0033695018,0.68471986,0.019024113,0.0006607794,0.07400169],"study_design_scores_gemma":[0.009004348,0.00292088,0.5176441,0.00585493,0.00033477732,0.0023735405,0.0012904316,0.023482533,0.3385772,0.09354081,0.0044472474,0.00052917673],"about_ca_topic_score_codex":0.000078281286,"about_ca_topic_score_gemma":0.000018445362,"teacher_disagreement_score":0.34614268,"about_ca_system_score_codex":0.00030527494,"about_ca_system_score_gemma":0.0006172368,"threshold_uncertainty_score":0.23465505},"labels":[],"label_agreement":null},{"id":"W4392926748","doi":"10.1007/s00415-024-12249-9","title":"Correction to: The impact of metformin use on the outcomes of relapse‑remitting multiple sclerosis patients receiving interferon beta 1a: an exploratory prospective phase II open‑label randomized controlled trial","year":2024,"lang":"en","type":"erratum","venue":"Journal of Neurology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Multiple sclerosis; Relapsing remitting; Medicine; Open label; Metformin; Neurology; Interferon beta-1a; Randomized controlled trial; Internal medicine; Neuroradiology; Interferon beta; BETA (programming language); Oncology; Psychiatry","score_opus":0.06851057778571554,"score_gpt":0.34624358945144995,"score_spread":0.2777330116657344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392926748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9569179,0.00040137515,0.000018036977,0.0008768876,0.032716468,0.0086561255,0.000059651873,0.000016172271,0.00033737827],"genre_scores_gemma":[0.99394196,0.0004556711,0.00004494204,0.00036706205,0.0010363233,0.0003494667,0.000037277263,0.00011404961,0.0036532565],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9933438,0.002343623,0.0026860812,0.00047963316,0.00076176465,0.0003851514],"domain_scores_gemma":[0.9867942,0.0070921336,0.004333906,0.0007311883,0.0008678176,0.00018077868],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0039392742,0.0006092575,0.004806342,0.0006237394,0.00017849532,0.00006723514,0.000687561,0.00041185637,0.0000577674],"category_scores_gemma":[0.018342074,0.0002723862,0.001423359,0.0003579173,0.000203523,0.00034205674,0.0003712404,0.0029944354,0.0000042348743],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8966507,0.0033922347,0.00089454127,0.00002944213,0.0053757527,0.000043858123,0.0022320459,0.000053161093,0.00038337286,0.0000034492318,0.0890665,0.0018749794],"study_design_scores_gemma":[0.9183659,0.07275689,0.0015843764,0.0010638754,0.0034868252,0.00007243978,0.00013459407,0.0017351261,0.00024951602,0.000022689517,0.0003539305,0.00017384069],"about_ca_topic_score_codex":0.00026089017,"about_ca_topic_score_gemma":0.00013298946,"teacher_disagreement_score":0.088712566,"about_ca_system_score_codex":0.00091845344,"about_ca_system_score_gemma":0.0013488763,"threshold_uncertainty_score":0.9999728},"labels":[],"label_agreement":null},{"id":"W4393042773","doi":"10.14740/wjon1818","title":"Characterization of Asciminib-Resistant Philadelphia Chromosome-Positive Cells","year":2024,"lang":"en","type":"article","venue":"World Journal of Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Ponatinib; Medicine; Myeloid leukemia; Philadelphia chromosome; Dasatinib; Mutation; Chronic myelogenous leukemia; Cancer research; Tyrosine kinase; Leukemia; Gene; Immunology; Internal medicine; Genetics; Imatinib; Receptor; Biology; Chromosomal translocation","score_opus":0.017928197750701275,"score_gpt":0.30353618253437575,"score_spread":0.2856079847836745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393042773","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9831731,0.0016810421,0.00018382045,0.0077779815,0.0017088822,0.00028824553,0.000045292123,0.00002297508,0.005118689],"genre_scores_gemma":[0.99635273,0.0004996564,0.0006369538,0.000265884,0.00063729414,0.000003435783,0.00002266236,0.000026029033,0.0015553369],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99857086,0.000086985296,0.0007029482,0.00015294364,0.00029032896,0.00019595622],"domain_scores_gemma":[0.99889296,0.00020036331,0.0004104299,0.00014313936,0.00021360221,0.00013949159],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030378776,0.00014293146,0.00058173866,0.0004912914,0.000026304302,0.000011074921,0.00009896402,0.000095351,0.00072557543],"category_scores_gemma":[0.000033323824,0.000111306384,0.00019862328,0.00041268772,0.00010823656,0.00012111505,0.00002990058,0.00035555774,0.00004010108],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00080940267,0.00038574854,0.00017833138,0.00017005042,0.0005452903,0.0022303965,0.0006054427,0.0000054294596,0.97658366,0.0002868317,0.0022504725,0.015948933],"study_design_scores_gemma":[0.00823596,0.008523383,0.034913078,0.0025594675,0.0017854321,0.0034532591,0.00015489511,0.00027659087,0.5886289,0.0001964093,0.35099542,0.0002771922],"about_ca_topic_score_codex":0.000007788383,"about_ca_topic_score_gemma":0.000016752256,"teacher_disagreement_score":0.38795477,"about_ca_system_score_codex":0.00140324,"about_ca_system_score_gemma":0.001392081,"threshold_uncertainty_score":0.7944542},"labels":[],"label_agreement":null},{"id":"W4393259335","doi":"10.1002/ajh.27307","title":"The presence of additional cytogenetic abnormalities (<scp>ACAs</scp>) or Philadelphia chromosome variants do not adversely affect the achievement of treatment‐free remission in chronic myeloid leukemia","year":2024,"lang":"en","type":"letter","venue":"American Journal of Hematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Syndax Pharmaceuticals; Celgene","keywords":"Philadelphia chromosome; Myeloid leukemia; Affect (linguistics); Medicine; Complete remission; Chromosome; Internal medicine; Oncology; Genetics; Chromosomal translocation; Biology; Gene; Psychology; Chemotherapy","score_opus":0.02149606550150339,"score_gpt":0.2822251817310658,"score_spread":0.2607291162295624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393259335","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.65310556,0.031149864,0.00003427077,0.3037018,0.002147481,0.003923711,0.004535033,0.00007490724,0.0013273954],"genre_scores_gemma":[0.95925266,0.012904397,0.00076016504,0.018905679,0.0034229555,0.00034225668,0.0005797904,0.0002857687,0.0035463457],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9946575,0.000759655,0.0020213346,0.00055387843,0.0011456481,0.00086197513],"domain_scores_gemma":[0.9896946,0.0058973306,0.002752477,0.0012078069,0.00028200855,0.00016579445],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00062143937,0.0007292265,0.0022493878,0.00053609285,0.0001357738,0.000027407186,0.0010685392,0.00043394597,0.0005458188],"category_scores_gemma":[0.0008418813,0.0003760987,0.00067999464,0.00066323846,0.001784533,0.00010496763,0.00027740016,0.0018983128,0.000022751507],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0014248338,0.0003263729,0.0011072302,0.0017722418,0.0051025217,0.009953477,0.0015471134,0.00026144774,0.0030132483,0.00020910037,0.9710761,0.0042063524],"study_design_scores_gemma":[0.01746321,0.03273599,0.008492366,0.0145482365,0.004931865,0.06379868,0.0036834124,0.0003530676,0.018553358,0.0008075136,0.83392245,0.00070983596],"about_ca_topic_score_codex":0.00040272422,"about_ca_topic_score_gemma":0.00012556376,"teacher_disagreement_score":0.3061471,"about_ca_system_score_codex":0.0053549013,"about_ca_system_score_gemma":0.008772312,"threshold_uncertainty_score":0.9998691},"labels":[],"label_agreement":null},{"id":"W4394181086","doi":"10.6084/m9.figshare.15105232","title":"A novel fusion circular RNA F-circBA1 derived from the <i>BCR-ABL</i> fusion gene displayed an oncogenic role in chronic myeloid leukemia cells","year":2021,"lang":"en","type":"dataset","venue":"Figshare","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Fusion gene; Myeloid leukemia; Fusion; Cancer research; ABL; breakpoint cluster region; Leukemia; Gene; Biology; Virology; Cell biology; Genetics; Signal transduction; Tyrosine kinase","score_opus":0.023942173542898775,"score_gpt":0.25891592135130537,"score_spread":0.2349737478084066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394181086","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018435534,0.013124902,0.000002004105,0.000067497895,0.00036700003,0.002096154,0.96574926,0.00010881851,0.000048801376],"genre_scores_gemma":[0.0025996473,0.0014722471,0.00014247616,0.00112859,0.001878844,0.0008132238,0.99162936,0.00020259508,0.00013302914],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9941385,0.0002957044,0.0010806221,0.001981799,0.0013237944,0.0011795813],"domain_scores_gemma":[0.994525,0.00045522163,0.00067321595,0.0035600397,0.00023517615,0.0005513477],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00017771423,0.0012460446,0.0015254117,0.00023626133,0.00031712934,0.00017172689,0.0012790144,0.0014564731,0.13966186],"category_scores_gemma":[0.00056010066,0.0010190301,0.00058451924,0.0007568607,0.00004557892,0.0002241666,0.0011314454,0.0021168918,0.003201843],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00012793277,0.00032009563,0.000006049877,0.00048683502,0.0002866672,0.001249216,0.0001101831,0.00011821913,0.2727945,2.258199e-8,0.7224861,0.002014162],"study_design_scores_gemma":[0.009457133,0.00037788023,0.0023610452,0.010730526,0.00079781126,0.0002462896,0.00013743724,0.0010631504,0.04988096,0.0000032940209,0.92383873,0.0011057478],"about_ca_topic_score_codex":0.0071471115,"about_ca_topic_score_gemma":0.004773665,"teacher_disagreement_score":0.22291356,"about_ca_system_score_codex":0.0102831805,"about_ca_system_score_gemma":0.0076361373,"threshold_uncertainty_score":0.99983984},"labels":[],"label_agreement":null},{"id":"W4394926574","doi":"10.1002/jha2.895","title":"Concurrent <i>BCR‐ABL1</i> and core binding factor beta rearrangement in de novo acute myeloid leukemia: A case report and review of literature","year":2024,"lang":"en","type":"article","venue":"eJHaem","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; Hamilton Regional Laboratory Medicine Program; Grand River Hospital; McMaster University","funders":"","keywords":"Chromosomal translocation; Fusion gene; breakpoint cluster region; Myeloid leukemia; Cancer research; Biology; Core binding factor; ABL; Chromosomal rearrangement; Gene rearrangement; Breakpoint; Chromosome; Genetics; Gene; Molecular biology; Karyotype; Receptor; Transcription factor","score_opus":0.028341427139570535,"score_gpt":0.3238172146466163,"score_spread":0.29547578750704573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394926574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81906646,0.17879997,0.000008437719,0.0006180248,0.00019046769,0.0007025306,0.00015019809,0.000045249362,0.00041864184],"genre_scores_gemma":[0.9182669,0.078826636,0.00051295955,0.0004070162,0.00014161464,0.000076331075,0.00023314804,0.000046777874,0.0014885911],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9984325,0.00003794877,0.00051202247,0.0004766862,0.0002460601,0.00029474995],"domain_scores_gemma":[0.99921244,0.00009294802,0.00011189983,0.0003373773,0.00005860995,0.00018671098],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003460823,0.00025204182,0.00057648774,0.00016005053,0.00003619552,0.000034285997,0.000046692923,0.00013173567,0.0000906587],"category_scores_gemma":[0.00009247975,0.00019839409,0.000083986335,0.00037093947,0.0000793648,0.00010025115,0.000096595206,0.00041141192,0.0000058831915],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008908605,0.00014348932,0.029680198,0.037997615,0.0009797139,0.8112703,0.0058861403,3.6060496e-7,0.014641294,0.00020215265,0.009363247,0.08974638],"study_design_scores_gemma":[0.009489773,0.0009742211,0.00896112,0.15223746,0.0025090505,0.73460764,0.00043072502,0.00041385402,0.009544575,0.000046138157,0.07995654,0.0008288852],"about_ca_topic_score_codex":0.000107581574,"about_ca_topic_score_gemma":0.000048735612,"teacher_disagreement_score":0.11423985,"about_ca_system_score_codex":0.001203303,"about_ca_system_score_gemma":0.0005538926,"threshold_uncertainty_score":0.8090276},"labels":[],"label_agreement":null},{"id":"W4395076931","doi":"10.1093/rheumatology/keae163.153","title":"P112 The Impact of Filgotinib on Disease Activity Outcomes With Concomitant Pain Control in the Phase 3 FINCH Studies","year":2024,"lang":"en","type":"article","venue":"Lara D. Veeken","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Pfizer; Eli Lilly and Company","keywords":"Medicine; Concomitant; Internal medicine; Physical therapy","score_opus":0.03327114832427544,"score_gpt":0.36754763578614597,"score_spread":0.33427648746187055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395076931","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98954743,0.0021630481,0.00003609155,0.006428902,0.000061185914,0.0011723683,0.00020642013,0.000043001623,0.00034155897],"genre_scores_gemma":[0.99866855,0.00007509175,0.000010666055,0.00072681456,0.000077815865,0.00014803081,0.000016882956,0.000023282697,0.00025288164],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985015,0.00037160347,0.00021819118,0.00026387256,0.00036883898,0.00027599523],"domain_scores_gemma":[0.99662495,0.0026002072,0.000073591094,0.0005782941,0.00004004163,0.00008294184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085412717,0.00024282713,0.00049574574,0.00006640639,0.00005986415,0.000025445564,0.00015406175,0.000041206327,0.000059471968],"category_scores_gemma":[0.0005059571,0.000093607,0.00021800828,0.00023176291,0.00015843261,0.00006107679,0.000025936059,0.00031543893,0.000017252078],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026536746,0.007731602,0.8365282,0.0013054805,0.0121256905,0.006973205,0.017233793,0.00078924693,0.0018441539,0.0009719414,0.02962305,0.0583369],"study_design_scores_gemma":[0.037008386,0.0064471466,0.935449,0.0013685139,0.0013374243,0.00004955071,0.001691302,0.013784788,0.00025802667,0.00032713512,0.0019226851,0.00035602614],"about_ca_topic_score_codex":0.00032637687,"about_ca_topic_score_gemma":0.00008800869,"teacher_disagreement_score":0.09892083,"about_ca_system_score_codex":0.0005868802,"about_ca_system_score_gemma":0.000459954,"threshold_uncertainty_score":0.38171825},"labels":[],"label_agreement":null},{"id":"W4395669609","doi":"10.1186/s12885-024-12282-x","title":"Hematological, clinical, cytogenetic and molecular profiles of confirmed chronic myeloid leukemia patients at presentation at a tertiary care teaching hospital in Addis Ababa, Ethiopia: a cross-sectional study","year":2024,"lang":"en","type":"article","venue":"BMC Cancer","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Amorfix (Canada)","funders":"Addis Ababa University","keywords":"Medicine; Leukocytosis; Neutrophilia; Internal medicine; Cross-sectional study; Surgical oncology; Anemia; Pathology","score_opus":0.026054740640897005,"score_gpt":0.3649765118876522,"score_spread":0.33892177124675515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395669609","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854925,0.011424876,0.000009508062,0.000035467863,0.00037742546,0.0023845232,0.00010992686,0.000063726475,0.00010202235],"genre_scores_gemma":[0.99816245,0.00027074257,0.00015461301,0.00003989178,0.00013017478,0.0007262355,0.00017092707,0.000045147353,0.0002998101],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99740785,0.00019778968,0.0008020744,0.00077907374,0.0004913457,0.00032184538],"domain_scores_gemma":[0.9990069,0.00025924484,0.00017189587,0.00030952753,0.000118118456,0.00013426914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018662096,0.00027742138,0.00048290935,0.00013334067,0.000108881126,0.000041689196,0.00009936659,0.00023392352,0.00024112103],"category_scores_gemma":[0.00018530908,0.00023124956,0.00016603143,0.00014373304,0.00023581783,0.000096410266,0.0002456195,0.00041345257,0.000016141272],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029210153,0.00036235715,0.99316955,0.0010895671,0.00023294377,0.0001660329,0.002003134,0.00008273365,0.0007507813,0.000005136781,0.00027488588,0.0015707928],"study_design_scores_gemma":[0.007694684,0.0010862224,0.98742694,0.00056975754,0.00018196221,0.000033127846,0.0002848491,0.0005505771,0.0017426816,0.000005502718,0.00021891567,0.00020475445],"about_ca_topic_score_codex":0.0010681283,"about_ca_topic_score_gemma":0.0017299858,"teacher_disagreement_score":0.012669934,"about_ca_system_score_codex":0.0051563857,"about_ca_system_score_gemma":0.0011929163,"threshold_uncertainty_score":0.99866265},"labels":[],"label_agreement":null},{"id":"W4396568439","doi":"10.51731/cjht.2024.881","title":"Belumosudil (Rezurock)","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Environmental science","score_opus":0.026215156772497517,"score_gpt":0.30275199556516397,"score_spread":0.27653683879266644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396568439","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21260768,0.6270717,0.0002529162,0.15536375,0.0014943931,0.00040240926,0.000026659545,0.00051194336,0.002268585],"genre_scores_gemma":[0.9967264,0.0013928879,0.00084592,0.0005063783,0.000030029112,0.0000037809132,0.000002761368,0.000022015498,0.00046981528],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99878246,0.000019747162,0.000458427,0.0001374851,0.00016076607,0.0004411369],"domain_scores_gemma":[0.9993586,0.00004668015,0.00011791961,0.00023652744,0.00008896358,0.00015132365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033706275,0.00012319931,0.00035215373,0.0007560715,0.00011666654,0.00003265612,0.0001699784,0.00013289954,0.00011603718],"category_scores_gemma":[0.0002847898,0.0000951138,0.00010590077,0.00035336186,0.00014089992,0.00008491212,0.000013518306,0.00056267146,0.00008571474],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008779229,0.000012213766,0.002483685,0.000355255,0.00014069858,0.0032281275,0.00025066143,0.0000030795293,0.000043996028,0.0014063121,0.04484255,0.9472246],"study_design_scores_gemma":[0.00073613285,0.000842815,0.0046830727,0.0013477359,0.000059724844,0.005784939,0.0012062037,0.0000394857,0.00066284783,0.0025538474,0.98196775,0.00011544312],"about_ca_topic_score_codex":0.0026569578,"about_ca_topic_score_gemma":0.0016136857,"teacher_disagreement_score":0.9471092,"about_ca_system_score_codex":0.0025287624,"about_ca_system_score_gemma":0.012557245,"threshold_uncertainty_score":0.9930406},"labels":[],"label_agreement":null},{"id":"W4396811198","doi":"10.1016/j.jaad.2024.04.070","title":"Zinc supplementation for epidermal growth factor receptor inhibitors induced skin toxicity","year":2024,"lang":"en","type":"letter","venue":"Journal of the American Academy of Dermatology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Université de Montréal; University of Ottawa","funders":"","keywords":"Medicine; Toxicity; Epidermal growth factor receptor; Pharmacology; Receptor; Internal medicine","score_opus":0.02829127672661358,"score_gpt":0.3305900035680535,"score_spread":0.30229872684143994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396811198","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.37227583,0.00026789863,0.000026291678,0.6257562,0.0007661911,0.0006318497,0.00022726083,0.00001507593,0.000033378965],"genre_scores_gemma":[0.5649771,0.00046711566,0.002971003,0.4252393,0.005468314,0.00005654183,0.000117954085,0.00018249148,0.0005201579],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.996253,0.00038397583,0.0017241822,0.00035640883,0.00072727224,0.0005551708],"domain_scores_gemma":[0.9950327,0.0007552829,0.0036750603,0.00022712316,0.0001745623,0.00013522107],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0001913325,0.00048733174,0.0019428364,0.00055267685,0.00007081196,0.000015773316,0.0005699201,0.00067196676,0.00011910993],"category_scores_gemma":[0.00037394764,0.00031772733,0.0010604105,0.00040476528,0.0004532074,0.00012480447,0.00015729146,0.0032513079,0.000021627875],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034459398,0.00007632916,0.002809883,0.00077733054,0.0013892525,0.00013872414,0.00023681326,4.799789e-7,0.010664438,0.000015991976,0.9817763,0.0017698562],"study_design_scores_gemma":[0.005788132,0.0012249943,0.005136641,0.0012284061,0.0026247308,0.013239242,0.00022233423,0.000030841486,0.3231316,0.00067501765,0.6461506,0.0005475127],"about_ca_topic_score_codex":0.00005425434,"about_ca_topic_score_gemma":0.0000016404994,"teacher_disagreement_score":0.33562574,"about_ca_system_score_codex":0.0011352585,"about_ca_system_score_gemma":0.0007870746,"threshold_uncertainty_score":0.99992746},"labels":[],"label_agreement":null},{"id":"W4397008063","doi":"10.1016/j.esmoop.2024.103019","title":"10P PIK3CA mutation and response to neoadjuvant taselisib and endocrine therapy: A biomarker study of the LORELEI trial","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute on the Environment, University of Minnesota; Veracyte; Genentech; Daiichi Sankyo Europe; Gilead Sciences; Servier; Sociedad Española de Oncología Médica; European Society for Medical Oncology; Eisai; Astellas Pharma; Oncolytics Biotech; Relay Therapeutics; Seagen; MacroGenics; Teva Pharmaceutical Industries; Les Laboratories Pierre Fabre; F. Hoffmann-La Roche; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Sanofi; Breast Cancer Research Foundation; Amgen; Pfizer","keywords":"Biomarker; Neoadjuvant therapy; Oncology; Endocrine system; Mutation; Internal medicine; Medicine; Biology; Cancer; Genetics; Hormone; Breast cancer; Gene","score_opus":0.04233489190041899,"score_gpt":0.3595692542732487,"score_spread":0.3172343623728297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4397008063","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924355,0.0005413495,0.0000027534631,0.0023432565,0.00019947547,0.004088737,0.000018984392,0.000020385753,0.00034951596],"genre_scores_gemma":[0.99794257,0.00005458651,0.00009066742,0.00016524526,0.00004952928,0.00016970604,0.000008997461,0.000021616774,0.0014970572],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99888575,0.00022007272,0.00023590171,0.00030824548,0.00021632844,0.00013371592],"domain_scores_gemma":[0.9992386,0.00025757172,0.000042109124,0.0003467134,0.000032159653,0.00008280974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005164525,0.00013150949,0.00025737679,0.00009125916,0.000060903873,0.00007591844,0.00012542907,0.000030270023,0.0001310753],"category_scores_gemma":[0.00019550619,0.00007739292,0.00003147129,0.0002544536,0.000043525095,0.00008545132,0.00023816711,0.00009256009,0.000011180366],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.50602764,0.002915464,0.013547336,0.0001714323,0.002194872,0.0025013175,0.039877437,0.000008988931,0.0147846965,0.00014313539,0.016036442,0.40179124],"study_design_scores_gemma":[0.29318416,0.016063571,0.61693853,0.0006774809,0.00062374875,0.0006346383,0.004282331,0.0006706218,0.007533725,0.00017907938,0.05884064,0.0003714354],"about_ca_topic_score_codex":0.0020877544,"about_ca_topic_score_gemma":0.00027093999,"teacher_disagreement_score":0.60339123,"about_ca_system_score_codex":0.00014797677,"about_ca_system_score_gemma":0.00026617345,"threshold_uncertainty_score":0.31560743},"labels":[],"label_agreement":null},{"id":"W4399452580","doi":"10.1200/jco.2024.42.17_suppl.lba6500","title":"ASC4FIRST, a pivotal phase 3 study of asciminib (ASC) vs investigator-selected tyrosine kinase inhibitors (IS TKIs) in newly diagnosed patients (pts) with chronic myeloid leukemia (CML): Primary results.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Myeloid leukemia; Tyrosine kinase; Internal medicine; Oncology; Tyrosine-kinase inhibitor; Dasatinib; Imatinib; Cancer research; Pharmacology; Cancer; Receptor","score_opus":0.045553177307305306,"score_gpt":0.38039245244959036,"score_spread":0.33483927514228506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399452580","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99283904,0.00148208,0.00000801901,0.002053877,0.0013750201,0.0016076732,0.000060809052,0.000054652668,0.00051884877],"genre_scores_gemma":[0.9954653,0.0006921201,0.0011765363,0.0010507744,0.0011829359,0.00004640389,0.00007588406,0.00009960601,0.00021048608],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99013174,0.00092965533,0.005940531,0.00086406677,0.0014296125,0.0007044271],"domain_scores_gemma":[0.99096334,0.0037367821,0.0025804543,0.00066231313,0.0009282519,0.0011288507],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0028969354,0.0005797841,0.0032897808,0.00077862915,0.00006704239,0.000034720375,0.00041217566,0.0007402073,0.00009966651],"category_scores_gemma":[0.007692506,0.0004139291,0.0005105378,0.0016529133,0.00058607594,0.0004081416,0.0001807067,0.0027610648,0.000031833508],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.07644065,0.05611768,0.50770175,0.00095887866,0.0039966223,0.02350245,0.004480691,0.0003200828,0.0014917422,0.000014667254,0.054545492,0.27042925],"study_design_scores_gemma":[0.26399773,0.20600832,0.50474083,0.0026647965,0.0019538742,0.00038153786,0.00029782823,0.0006508759,0.001024468,0.00003853964,0.017757615,0.00048356983],"about_ca_topic_score_codex":0.00069552485,"about_ca_topic_score_gemma":0.0009031325,"teacher_disagreement_score":0.26994568,"about_ca_system_score_codex":0.007879442,"about_ca_system_score_gemma":0.028364107,"threshold_uncertainty_score":0.99983126},"labels":[],"label_agreement":null},{"id":"W4399519869","doi":"10.1200/jco.2024.42.16_suppl.6501","title":"Ponatinib (PON) in patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) and the T315I mutation (mut): 4-year results from OPTIC.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Myeloid leukemia; Ponatinib; Mutation; Cancer research; Dasatinib; Imatinib; Gene; Genetics","score_opus":0.03931583916447061,"score_gpt":0.3960597151784573,"score_spread":0.35674387601398666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399519869","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869629,0.0028031413,0.000056066845,0.006260993,0.0011375056,0.0007378818,0.000051628667,0.000027431417,0.0019624082],"genre_scores_gemma":[0.99388945,0.0013242548,0.0019162948,0.000494105,0.0018652258,0.000017373954,0.00008096604,0.000048479884,0.0003638755],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9947372,0.00067328324,0.0029592873,0.00050965877,0.0007126497,0.00040792336],"domain_scores_gemma":[0.9915708,0.006079782,0.0012880006,0.00039004043,0.0003090505,0.00036233832],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003413736,0.00030512665,0.0015967329,0.00022619507,0.00006513422,0.000048401424,0.00023737474,0.00048239392,0.00017246044],"category_scores_gemma":[0.0035756102,0.00017203229,0.0003181972,0.00032594043,0.0006025375,0.00028321522,0.00009727559,0.0019284507,0.00007142948],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.11295954,0.0033927,0.014509381,0.00024100245,0.0028570462,0.009022276,0.0017808917,0.00059121853,0.00010102571,0.0009802579,0.005873517,0.8476911],"study_design_scores_gemma":[0.56178373,0.0752695,0.26961163,0.0027526356,0.0025350791,0.001129646,0.00035383157,0.013629022,0.00018282964,0.0011436841,0.07108177,0.0005266626],"about_ca_topic_score_codex":0.00031791028,"about_ca_topic_score_gemma":0.0005364578,"teacher_disagreement_score":0.84716445,"about_ca_system_score_codex":0.0055670626,"about_ca_system_score_gemma":0.010047538,"threshold_uncertainty_score":0.99825037},"labels":[],"label_agreement":null},{"id":"W4400037535","doi":"10.1200/jco.2024.42.16_suppl.8522","title":"Repotrectinib in tyrosine kinase inhibitor (TKI)-naïve patients (pts) with advanced <i>ROS1</i> fusion-positive (<i>ROS1+)</i> NSCLC in the phase 1/2 TRIDENT-1 trial: Clinical update, treatment beyond progression and subsequent therapies.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; University of Toronto","funders":"","keywords":"Medicine; ROS1; Tyrosine-kinase inhibitor; Tyrosine kinase; Internal medicine; Clinical trial; Oncology; Cancer research; Cancer; Adenocarcinoma; Receptor","score_opus":0.056210437963042224,"score_gpt":0.45260694539413787,"score_spread":0.39639650743109567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400037535","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9816293,0.0058168094,0.000015426851,0.0069053713,0.0022617541,0.0028112135,0.00003389199,0.000027743343,0.0004984825],"genre_scores_gemma":[0.9872324,0.0077021546,0.0016923611,0.0017865264,0.0012320542,0.00013886894,0.00006132124,0.00006052253,0.00009379437],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9912823,0.0018901972,0.004686609,0.0007670767,0.0008438851,0.00052995584],"domain_scores_gemma":[0.9915227,0.005309405,0.0018803419,0.00047087955,0.0003377432,0.00047889494],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.005298555,0.00048087887,0.002444195,0.00033584767,0.00008413844,0.00006528479,0.00022378266,0.00058215443,0.000053990425],"category_scores_gemma":[0.0022126187,0.00024702563,0.0005786179,0.00063074403,0.0004923812,0.00033613772,0.00008489953,0.0018631157,0.000012190699],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1840239,0.023281276,0.04081586,0.0000458637,0.00051677425,0.008813829,0.0008115178,0.000004038224,0.00013259794,0.000056176188,0.001098805,0.74039936],"study_design_scores_gemma":[0.6646278,0.21687302,0.064704314,0.0026334776,0.001360588,0.0011325092,0.00064589735,0.00016219025,0.00078782026,0.00038001125,0.046240225,0.00045216252],"about_ca_topic_score_codex":0.000053415977,"about_ca_topic_score_gemma":0.00027874712,"teacher_disagreement_score":0.7399472,"about_ca_system_score_codex":0.0017757661,"about_ca_system_score_gemma":0.003335933,"threshold_uncertainty_score":0.9999982},"labels":[],"label_agreement":null},{"id":"W4400286794","doi":"10.4103/jdds.jdds_48_23","title":"Second-generation Tyrosine Kinase Inhibitors Nilotinib- and Dasatinib-induced Keratosis Pilaris: A Case Report and Review of the Literature","year":2024,"lang":"en","type":"article","venue":"Journal of Dermatology & Dermatologic Surgery","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Nilotinib; Medicine; Dermatology; Discontinuation; Adverse effect; Dasatinib; Rash; Tyrosine-kinase inhibitor; Tyrosine kinase; Myeloid leukemia; Imatinib; Internal medicine; Cancer","score_opus":0.026714277772967424,"score_gpt":0.2841973580837547,"score_spread":0.25748308031078726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400286794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7716911,0.2155806,0.0000040650375,0.01143482,0.0008704093,0.0003104842,0.000012492796,0.000025677498,0.00007036888],"genre_scores_gemma":[0.98286444,0.014473597,0.00020063663,0.0021832506,0.00016192444,0.000016245876,0.000025459762,0.00002785928,0.000046601683],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99684376,0.00043210277,0.0017746607,0.0003372453,0.00033024055,0.00028198172],"domain_scores_gemma":[0.9972785,0.00078667636,0.0009749169,0.00040714018,0.000359242,0.00019353493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006889606,0.0003269538,0.0013273983,0.00035828317,0.0001290756,0.00005699853,0.00007660741,0.00032649588,0.000061034632],"category_scores_gemma":[0.0012239104,0.00019900751,0.00036656004,0.000583604,0.00020318189,0.00027950472,0.000090545705,0.00070126523,0.0000016749264],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010362362,0.00025199633,0.1273032,0.016434275,0.00094035815,0.7047541,0.0007689508,2.3986516e-7,0.00896081,0.00007524139,0.13591383,0.004493345],"study_design_scores_gemma":[0.0006902645,0.000057386897,0.0030755992,0.011846195,0.00066713063,0.9509296,0.00007901026,0.000050829993,0.028663877,0.000037771766,0.0037516295,0.00015069955],"about_ca_topic_score_codex":0.0000061908618,"about_ca_topic_score_gemma":0.000008019066,"teacher_disagreement_score":0.24617547,"about_ca_system_score_codex":0.00012719847,"about_ca_system_score_gemma":0.00086285686,"threshold_uncertainty_score":0.8115291},"labels":[],"label_agreement":null},{"id":"W4400589592","doi":"10.1111/ejh.14271","title":"Prediction of sustained remission after tyrosine kinase inhibitor discontinuation with <i>BCR</i>::<i>ABL1</i> digital <scp>PCR</scp> in chronic myeloid leukemia patients","year":2024,"lang":"en","type":"article","venue":"European Journal Of Haematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Princess Margaret Cancer Foundation","keywords":"Discontinuation; Digital polymerase chain reaction; Imatinib; Myeloid leukemia; Medicine; Internal medicine; breakpoint cluster region; Tyrosine-kinase inhibitor; Cutoff; Oncology; Tyrosine kinase; Clinical endpoint; Gastroenterology; Immunology; Chemistry; Cancer; Polymerase chain reaction; Receptor; Clinical trial","score_opus":0.008593071422898032,"score_gpt":0.21905732001150868,"score_spread":0.21046424858861065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400589592","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934419,0.0028610535,0.00037308407,0.00020751827,0.00041972008,0.00044840132,0.00004066018,0.000044915378,0.0021627555],"genre_scores_gemma":[0.9980741,0.0001807246,0.00027621243,0.00004531778,0.0003351532,0.000008288959,0.000103136634,0.000086311884,0.00089076854],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973014,0.00024791172,0.0012025216,0.00035087316,0.00050230016,0.00039496706],"domain_scores_gemma":[0.99848735,0.00016992041,0.0005043741,0.00029680843,0.0003298018,0.00021173837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048768465,0.00031072195,0.000719693,0.0005203704,0.000034190263,0.000051426083,0.00014344437,0.00009123957,0.00003426959],"category_scores_gemma":[0.00042457395,0.00022119464,0.00016520893,0.00044927734,0.00016618866,0.000543228,0.00008656038,0.0005504868,0.00003250329],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008484921,0.0037430173,0.6307009,0.006196891,0.00207335,0.13688698,0.008964459,0.0008702394,0.056444336,0.00039251978,0.038313042,0.106929354],"study_design_scores_gemma":[0.09550505,0.041317653,0.57647204,0.03925229,0.002626838,0.03451615,0.0025731528,0.0040215747,0.09246389,0.0002216522,0.11012758,0.00090211636],"about_ca_topic_score_codex":0.00000617912,"about_ca_topic_score_gemma":0.0000061331502,"teacher_disagreement_score":0.10602724,"about_ca_system_score_codex":0.0018437989,"about_ca_system_score_gemma":0.0011083076,"threshold_uncertainty_score":0.90200555},"labels":[],"label_agreement":null},{"id":"W4400660929","doi":"10.2174/0113816128309071240626114308","title":"Impact of Tyrosine Kinase Inhibitors (TKIs) on Growth in Children and Adolescents with Chronic Myeloid Leukemia: A Systematic Review","year":2024,"lang":"en","type":"review","venue":"Current Pharmaceutical Design","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Dasatinib; Medicine; Nilotinib; Imatinib; Ponatinib; Internal medicine; Myeloid leukemia; Pediatrics; Oncology","score_opus":0.05879202596446013,"score_gpt":0.3913805999759993,"score_spread":0.33258857401153913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400660929","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00027338482,0.9858246,0.000025908588,0.000018343191,0.00018944549,0.013436214,0.00012638752,0.00009038718,0.000015330132],"genre_scores_gemma":[0.0076737134,0.9908099,0.000026389094,0.000039319653,0.00023629346,0.0007726082,0.00022425971,0.00019294565,0.000024529667],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9945153,0.0007575677,0.0018815924,0.0011854963,0.0008585862,0.0008014679],"domain_scores_gemma":[0.9976948,0.00021916404,0.0006019671,0.000735189,0.00011163092,0.0006372585],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.000763269,0.0013731775,0.005562062,0.00067408726,0.000038784478,0.000041683525,0.00031757524,0.00034697528,0.0000448676],"category_scores_gemma":[0.00029479925,0.00079529756,0.00091926137,0.0013013611,0.00024447124,0.000098965465,0.00016518918,0.0020516438,0.00019463156],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013389236,0.00061828276,0.00023406983,0.9110181,0.0011492304,0.00017058762,0.000011248206,0.0000010644713,0.0000017703583,0.000016231746,0.0008526931,0.085792825],"study_design_scores_gemma":[0.003893852,0.0014900243,0.00017745669,0.9640529,0.028066251,0.0008182463,4.5165078e-7,0.0000961218,0.000018729053,0.000003825072,0.0007771649,0.0006049685],"about_ca_topic_score_codex":0.000019918338,"about_ca_topic_score_gemma":4.990824e-7,"teacher_disagreement_score":0.08518786,"about_ca_system_score_codex":0.008946971,"about_ca_system_score_gemma":0.003765941,"threshold_uncertainty_score":0.9999019},"labels":[],"label_agreement":null},{"id":"W4400797335","doi":"10.1007/s00277-024-05851-4","title":"Practical considerations in the management of patients treated with bosutinib for chronic myeloid leukemia","year":2024,"lang":"en","type":"review","venue":"Annals of Hematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Pfizer","keywords":"Bosutinib; Medicine; Tolerability; Dosing; Myeloid leukemia; Adverse effect; Tyrosine-kinase inhibitor; Dasatinib; Oncology; Clinical trial; Internal medicine; Pharmacology; Intensive care medicine; Imatinib; Cancer","score_opus":0.12282163316628093,"score_gpt":0.42124725404727853,"score_spread":0.2984256208809976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400797335","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008311546,0.9921621,0.000011993113,0.0008632761,0.00006318528,0.004371588,0.00016903141,0.000023116385,0.0015045588],"genre_scores_gemma":[0.006447982,0.99056727,0.0009861115,0.00012894902,0.00003358717,0.00097524264,0.0006477169,0.000059977858,0.00015319457],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99767095,0.00015578681,0.0010810408,0.0004443467,0.00027443084,0.00037343852],"domain_scores_gemma":[0.9979057,0.00074383424,0.00053338247,0.0006200077,0.0001417011,0.000055410812],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025589546,0.00039211634,0.0021424731,0.00027047694,0.000032791337,0.00000819909,0.00010743755,0.00029775559,0.00005656253],"category_scores_gemma":[0.000095298084,0.00021763718,0.0003858819,0.0003463314,0.00020328871,0.000037235797,0.000061460785,0.000341054,0.000023640378],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00073471083,0.0036891252,0.00082713104,0.548539,0.0200647,0.004544403,0.00061245647,0.0000034314005,6.961855e-7,0.14189988,0.08560991,0.19347458],"study_design_scores_gemma":[0.0074681975,0.0042121112,0.00029368518,0.062243227,0.018137483,0.0030649465,0.00016555189,0.00003026006,0.00015231021,0.0006874699,0.90297943,0.00056531496],"about_ca_topic_score_codex":0.000027959324,"about_ca_topic_score_gemma":0.000030858228,"teacher_disagreement_score":0.8173695,"about_ca_system_score_codex":0.0002952473,"about_ca_system_score_gemma":0.0018309826,"threshold_uncertainty_score":0.8874987},"labels":[],"label_agreement":null},{"id":"W4401586147","doi":"10.1002/ajh.27455","title":"Imatinib versus newer generation <scp>TKIs</scp> for upfront therapy in chronic phase <scp>chronic myeloid leukemia</scp>: What is the rationale for paying more to get the same survival benefit?","year":2024,"lang":"en","type":"letter","venue":"American Journal of Hematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Myeloid leukemia; Imatinib; Hematology; Internal medicine; Transplantation; Imatinib mesylate; Disease; Oncology; Immunology","score_opus":0.0374721474033498,"score_gpt":0.32962715616823646,"score_spread":0.29215500876488665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401586147","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.50728077,0.0503478,0.0036449858,0.42725348,0.0050569796,0.0059377486,0.0003405079,0.00006642218,0.00007127355],"genre_scores_gemma":[0.06513273,0.030007776,0.0149131995,0.82105213,0.04905523,0.006455377,0.0038878948,0.001523682,0.007971987],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9949415,0.0003100464,0.001751913,0.00088116183,0.0008527145,0.001262683],"domain_scores_gemma":[0.9901963,0.006289499,0.0017115977,0.00096451817,0.00061929977,0.00021876906],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010794252,0.00090336654,0.0020975953,0.00055626937,0.00031863342,0.00024629995,0.0008377652,0.00052905903,0.000051667303],"category_scores_gemma":[0.0007850009,0.0005631629,0.00095114665,0.0005805858,0.00053180323,0.00033995396,0.000120796714,0.0020958635,0.00004247722],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00046126437,0.00017784728,0.0000691856,0.0005153866,0.0030391242,0.000495201,0.00851451,0.0012783364,0.0017616765,0.0003400465,0.91976947,0.06357799],"study_design_scores_gemma":[0.021343116,0.009464759,0.00005560502,0.0009247271,0.0011670465,0.0022034403,0.007166261,0.008285462,0.0035630504,0.0004909609,0.94509584,0.00023971904],"about_ca_topic_score_codex":0.00017311615,"about_ca_topic_score_gemma":0.0002766133,"teacher_disagreement_score":0.44214806,"about_ca_system_score_codex":0.0071890117,"about_ca_system_score_gemma":0.005867409,"threshold_uncertainty_score":0.9997684},"labels":[],"label_agreement":null},{"id":"W4401767800","doi":"10.1007/s12288-024-01843-6","title":"Prognostic Significance of Regulatory T-Cells and PD-1 + CD8 T-Cells in Chronic Myeloid Leukemia Patients Treated with Generic Imatinib","year":2024,"lang":"en","type":"article","venue":"Indian Journal of Hematology and Blood Transfusion","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Imatinib; Myeloid leukemia; Medicine; Hematology; CD8; Imatinib mesylate; Human genetics; Myeloid; Internal medicine; Cancer research; Immunology; Oncology; Immune system; Biology; Gene; Genetics","score_opus":0.00673797867265954,"score_gpt":0.21862031283579522,"score_spread":0.21188233416313568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401767800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914966,0.0076453174,0.000023401366,0.000090721805,0.00009096519,0.00057230826,0.000016677544,0.000014776246,0.000049237362],"genre_scores_gemma":[0.99709404,0.0022466371,0.0005115309,0.00002480985,0.000039565766,0.0000112125845,0.000008145302,0.000029752391,0.000034307075],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984136,0.00011293788,0.00066319935,0.0002899238,0.00024481805,0.00027551613],"domain_scores_gemma":[0.9991787,0.00020669714,0.00020836595,0.00014719869,0.00008833888,0.00017068359],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002480025,0.00024234624,0.00068088394,0.00038724727,0.000047341597,0.000012218764,0.00007000397,0.00020205103,0.00003687461],"category_scores_gemma":[0.000016363056,0.00017229687,0.000076473756,0.00030426693,0.0002560818,0.00012431844,0.0000122426245,0.00040702778,0.0000023553728],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025746897,0.0011877213,0.4860036,0.006012768,0.0012492886,0.011323572,0.0042939666,0.00008419037,0.47049165,0.00007149998,0.00012263503,0.016584402],"study_design_scores_gemma":[0.028222127,0.009540073,0.14200544,0.008462084,0.0019993703,0.012639443,0.0002758292,0.00029479398,0.79587233,0.00008933772,0.00014661087,0.00045253808],"about_ca_topic_score_codex":0.000039225237,"about_ca_topic_score_gemma":0.000045570083,"teacher_disagreement_score":0.34399816,"about_ca_system_score_codex":0.00026833944,"about_ca_system_score_gemma":0.0010149262,"threshold_uncertainty_score":0.70260626},"labels":[],"label_agreement":null},{"id":"W4401875014","doi":"10.1016/s2152-2650(24)00611-6","title":"Tolerability of Asciminib vs Investigator-Selected (IS) Tyrosine Kinase Inhibitors (TKIs) in the Phase 3 ASC4FIRST Study in Newly Diagnosed Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Tolerability; Myeloid leukemia; Tyrosine kinase; Internal medicine; Oncology; Adverse effect; Receptor","score_opus":0.026442817578052422,"score_gpt":0.33461210375836103,"score_spread":0.3081692861803086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401875014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884293,0.0028583072,0.00000687051,0.0006311247,0.00064268126,0.0068257935,0.00017339265,0.00024123437,0.00019128267],"genre_scores_gemma":[0.99626696,0.00033808654,0.00014204704,0.0007680355,0.00070314104,0.0009495121,0.0005265676,0.0002302247,0.00007543545],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9871134,0.0015675775,0.004841913,0.002767381,0.0019010439,0.001808682],"domain_scores_gemma":[0.9921524,0.0031870157,0.00076661137,0.0025888404,0.0003962959,0.0009088616],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.003195867,0.0014214956,0.0029629841,0.0011008842,0.00016347744,0.00015864382,0.0011228479,0.00092446216,0.00027328258],"category_scores_gemma":[0.003296661,0.0010659782,0.0005572643,0.005788758,0.0013658938,0.00068396854,0.0003724757,0.0020410563,0.0001337415],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0075344024,0.0136358235,0.7056814,0.0011329569,0.00049370114,0.0050855097,0.003941359,0.00025949834,0.00096437475,0.000039817347,0.002489507,0.25874168],"study_design_scores_gemma":[0.13642532,0.015725598,0.83350575,0.0029042417,0.0004565898,0.000053155836,0.00034281373,0.0058861743,0.0016125898,0.00007945733,0.0021211095,0.0008871836],"about_ca_topic_score_codex":0.004670236,"about_ca_topic_score_gemma":0.007903834,"teacher_disagreement_score":0.2578545,"about_ca_system_score_codex":0.0474402,"about_ca_system_score_gemma":0.034153443,"threshold_uncertainty_score":0.9998535},"labels":[],"label_agreement":null},{"id":"W4401875032","doi":"10.1016/s2152-2650(24)00613-x","title":"ASC4FIRST, a Pivotal Phase 3 Study of Asciminib (ASC) vs Investigator-Selected Tyrosine Kinase Inhibitors (IS-TKIs) in Newly Diagnosed Patients With Chronic Myeloid Leukemia (CML): Primary Results","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Myeloid leukemia; Tyrosine kinase; Internal medicine; Oncology; Tyrosine-kinase inhibitor; Cancer research; Receptor; Cancer","score_opus":0.019348148863125917,"score_gpt":0.29995262759059965,"score_spread":0.28060447872747374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401875032","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98964113,0.0020463734,0.000007674222,0.00043812997,0.0011294953,0.004955962,0.0004148445,0.0006283294,0.00073805],"genre_scores_gemma":[0.9942188,0.00031899888,0.00076470897,0.00088728004,0.000985265,0.00048056312,0.0013503578,0.00038430127,0.00060972705],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98717993,0.0007567183,0.0048551937,0.003165648,0.002274631,0.0017678927],"domain_scores_gemma":[0.9915509,0.0024171951,0.0010821737,0.0024931703,0.0007182858,0.0017382792],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.001474793,0.001589312,0.003107226,0.001042126,0.00023732691,0.00017053886,0.0008442916,0.0010881346,0.00013639561],"category_scores_gemma":[0.003325618,0.0013446934,0.00065193314,0.004043289,0.0011812162,0.0007257767,0.0005332032,0.0015761259,0.0002656636],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.030219391,0.01654534,0.4471882,0.0019341462,0.0025126075,0.009877523,0.0038120446,0.00018635699,0.0016530973,0.000039077662,0.029092057,0.45694014],"study_design_scores_gemma":[0.14580198,0.02112852,0.81901056,0.003488943,0.0010828318,0.00010933244,0.0001672658,0.0018253353,0.0020267195,0.00003422776,0.004187194,0.001137122],"about_ca_topic_score_codex":0.0023725862,"about_ca_topic_score_gemma":0.0007695158,"teacher_disagreement_score":0.45580304,"about_ca_system_score_codex":0.02267708,"about_ca_system_score_gemma":0.02635173,"threshold_uncertainty_score":0.99968547},"labels":[],"label_agreement":null},{"id":"W4401878208","doi":"10.1016/s2152-2650(24)00694-3","title":"Transfusion Intensity Over Time in Patients From the Phase 3 SIMPLIFY-1 and MOMENTUM Trials of Momelotinib","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Intensity (physics); Phase (matter); Oncology; Internal medicine; Quantum mechanics","score_opus":0.04017904735557419,"score_gpt":0.36146646303458746,"score_spread":0.32128741567901326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401878208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948804,0.0014764384,0.000015448633,0.0007456486,0.0007359422,0.0013410919,0.000366245,0.00011003493,0.00032876522],"genre_scores_gemma":[0.997206,0.0007169427,0.00013035926,0.00065619696,0.00043356683,0.00003691956,0.00038294878,0.000064775,0.00037234498],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99513537,0.0005116936,0.0024431497,0.0008902891,0.00057756493,0.0004419547],"domain_scores_gemma":[0.99398583,0.0044981698,0.00032281893,0.00076553744,0.00012299122,0.00030464318],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0022799491,0.00041716947,0.0018076517,0.00014756549,0.000069870046,0.00004873043,0.00023333577,0.00043117086,0.00064406614],"category_scores_gemma":[0.002454117,0.00027233016,0.0005677791,0.00043984145,0.0004105816,0.00015473957,0.0001849338,0.00041701132,0.00016117236],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006377344,0.0014766178,0.16812836,0.00015157601,0.00077589304,0.00025513856,0.00063453405,0.0000018187321,0.0027739587,0.00006090331,0.009942664,0.8094212],"study_design_scores_gemma":[0.032137223,0.0012763422,0.9541881,0.0008699048,0.00059956935,0.000016132284,0.000039720886,0.0028746743,0.0013779331,0.0005132169,0.0058627627,0.00024439706],"about_ca_topic_score_codex":0.00070592633,"about_ca_topic_score_gemma":0.000028440689,"teacher_disagreement_score":0.8091768,"about_ca_system_score_codex":0.0015789841,"about_ca_system_score_gemma":0.0011431873,"threshold_uncertainty_score":0.9999729},"labels":[],"label_agreement":null},{"id":"W4401878520","doi":"10.1016/s2152-2650(24)00390-2","title":"ASC4FIRST, a Pivotal Phase 3 Study of Asciminib (ASC) vs Investigator-Selected Tyrosine Kinase Inhibitors (IS-TKIs) in Newly Diagnosed Patients With Chronic Myeloid Leukemia (CML): Primary Results","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Myeloid leukemia; Tyrosine kinase; Internal medicine; Oncology; Cancer research; Receptor","score_opus":0.019348148863125917,"score_gpt":0.29995262759059965,"score_spread":0.28060447872747374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401878520","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98964113,0.0020463734,0.000007674222,0.00043812997,0.0011294953,0.004955962,0.0004148445,0.0006283294,0.00073805],"genre_scores_gemma":[0.9942188,0.00031899888,0.00076470897,0.00088728004,0.000985265,0.00048056312,0.0013503578,0.00038430127,0.00060972705],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98717993,0.0007567183,0.0048551937,0.003165648,0.002274631,0.0017678927],"domain_scores_gemma":[0.9915509,0.0024171951,0.0010821737,0.0024931703,0.0007182858,0.0017382792],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.001474793,0.001589312,0.003107226,0.001042126,0.00023732691,0.00017053886,0.0008442916,0.0010881346,0.00013639561],"category_scores_gemma":[0.003325618,0.0013446934,0.00065193314,0.004043289,0.0011812162,0.0007257767,0.0005332032,0.0015761259,0.0002656636],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.030219391,0.01654534,0.4471882,0.0019341462,0.0025126075,0.009877523,0.0038120446,0.00018635699,0.0016530973,0.000039077662,0.029092057,0.45694014],"study_design_scores_gemma":[0.14580198,0.02112852,0.81901056,0.003488943,0.0010828318,0.00010933244,0.0001672658,0.0018253353,0.0020267195,0.00003422776,0.004187194,0.001137122],"about_ca_topic_score_codex":0.0023725862,"about_ca_topic_score_gemma":0.0007695158,"teacher_disagreement_score":0.45580304,"about_ca_system_score_codex":0.02267708,"about_ca_system_score_gemma":0.02635173,"threshold_uncertainty_score":0.99968547},"labels":[],"label_agreement":null},{"id":"W4401878573","doi":"10.1016/s2152-2650(24)00353-7","title":"Transplant in Adult ALL: Who and When","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Intensive care medicine; Family medicine","score_opus":0.029164410784156235,"score_gpt":0.3274227186459994,"score_spread":0.2982583078618432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401878573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9851391,0.0036649166,0.00004023863,0.0026129992,0.0006011454,0.00062109303,0.00004145155,0.00033199083,0.006947092],"genre_scores_gemma":[0.98952824,0.0028653855,0.00097414217,0.0026744758,0.0005544493,0.00007579919,0.00010403799,0.00009969331,0.0031237663],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99644035,0.00015133842,0.001218311,0.0010856562,0.0004306029,0.0006737451],"domain_scores_gemma":[0.9977785,0.0008953844,0.00007920753,0.000635456,0.00006351881,0.0005479657],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006082676,0.00043899956,0.00095572893,0.00022570787,0.00005089122,0.0000844929,0.0001975132,0.0005307006,0.00025424434],"category_scores_gemma":[0.00031472533,0.0003648134,0.00032637804,0.00028923125,0.0003282271,0.00019159497,0.000096275246,0.00050120865,0.0004850672],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00083555194,0.00024226304,0.07516202,0.00057064154,0.00049082,0.0075437496,0.00112309,0.0000017969057,0.00026854774,0.002377148,0.010080247,0.9013041],"study_design_scores_gemma":[0.009859034,0.0006621181,0.9222207,0.002150804,0.00043944106,0.0013919085,0.000065301574,0.0067440504,0.00032376853,0.0012912657,0.054388653,0.00046294692],"about_ca_topic_score_codex":0.0004524291,"about_ca_topic_score_gemma":0.00018960216,"teacher_disagreement_score":0.9008412,"about_ca_system_score_codex":0.0024021645,"about_ca_system_score_gemma":0.0018105175,"threshold_uncertainty_score":0.9998804},"labels":[],"label_agreement":null},{"id":"W4402149322","doi":"10.1038/s41375-024-02385-6","title":"Correction: Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials","year":2024,"lang":"en","type":"erratum","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ponatinib; Myeloid leukemia; Medicine; Chronic myeloid leukaemia; Oncology; Internal medicine; Nilotinib; Imatinib","score_opus":0.020066686339406815,"score_gpt":0.29356906947169065,"score_spread":0.2735023831322838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402149322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88617724,0.053184427,0.0002284579,0.0016689195,0.03318174,0.010916146,0.0033543645,0.00046932942,0.010819386],"genre_scores_gemma":[0.81422734,0.007261035,0.00070664036,0.00027587105,0.0070649055,0.0010795654,0.04360437,0.0006272823,0.125153],"study_design_codex":"not_applicable","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99420804,0.00041936725,0.0018525445,0.0014979996,0.0012621431,0.000759912],"domain_scores_gemma":[0.9951807,0.0011546203,0.0013289894,0.0017542517,0.0003120908,0.00026932158],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00091305387,0.0011029807,0.0023830049,0.0004397482,0.00015619035,0.00012398725,0.00048071772,0.0012606229,0.0003033303],"category_scores_gemma":[0.0008003979,0.00075757864,0.00035799138,0.00092345325,0.00044549778,0.00020679318,0.0002419331,0.0029473824,0.00005879243],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.006443427,0.00097618054,0.0051088817,0.003655389,0.0040156823,0.00042933534,0.0024534333,0.0014332274,0.0002211384,0.0003986219,0.854263,0.12060166],"study_design_scores_gemma":[0.18911675,0.015159562,0.18105082,0.041000657,0.015497947,0.00032692877,0.0011665613,0.3667882,0.00077180244,0.00077911234,0.18367887,0.0046627717],"about_ca_topic_score_codex":0.0049545984,"about_ca_topic_score_gemma":0.0037458148,"teacher_disagreement_score":0.67058414,"about_ca_system_score_codex":0.052556083,"about_ca_system_score_gemma":0.016684204,"threshold_uncertainty_score":0.9994875},"labels":[],"label_agreement":null},{"id":"W4402267071","doi":"10.1158/1538-7445.pediatric24-b038","title":"Abstract B038: RT-PCR and Interphase FISH reveal high frequencies of BCR-ABL in pediatric ALL patients in South-East Asia","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Fish <Actinopterygii>; Medicine; Interphase; Biology; Cancer research; Internal medicine; Genetics; Fishery","score_opus":0.058946916149883,"score_gpt":0.37735465087090014,"score_spread":0.31840773472101713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402267071","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99359703,0.003554594,3.4864314e-7,0.00058597175,0.00014219385,0.00064003794,0.00015869648,0.000021887094,0.0012992563],"genre_scores_gemma":[0.99757576,0.0012388284,0.00004167385,0.00004177329,0.00018452932,0.00014495774,0.000057819474,0.00003408039,0.0006805763],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99788094,0.00008799765,0.00040592876,0.0004544778,0.0006435808,0.0005270793],"domain_scores_gemma":[0.9991653,0.00018740947,0.000042489373,0.00028539757,0.00014573439,0.00017367055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005956903,0.00016003587,0.000328136,0.00072930666,0.000023115834,0.000034315653,0.00014640458,0.00012491785,0.00037532908],"category_scores_gemma":[0.00026683518,0.00013866974,0.000046568704,0.00076098286,0.00015058427,0.00013174783,0.00012741308,0.0007460882,0.00003592634],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070916937,0.00050135935,0.9586133,0.002821872,0.00011022946,0.0010480337,0.008395174,0.000011743441,0.0035801309,0.00006761678,0.008632553,0.0155088315],"study_design_scores_gemma":[0.005413196,0.00045090762,0.9894583,0.001298423,0.000043224773,0.000007179236,0.00044933744,0.00006693222,0.0015248179,0.00014179063,0.0009864756,0.00015941891],"about_ca_topic_score_codex":0.0059726015,"about_ca_topic_score_gemma":0.0017794005,"teacher_disagreement_score":0.03084501,"about_ca_system_score_codex":0.0020768319,"about_ca_system_score_gemma":0.0011493491,"threshold_uncertainty_score":0.9028827},"labels":[],"label_agreement":null},{"id":"W4402432829","doi":"10.14785/lymphosign-2024-0008","title":"The outcome of haematopoietic stem cell transplantation in a patient with STAT1 gain-of-function: a case report","year":2024,"lang":"en","type":"article","venue":"LymphoSign Journal","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"","keywords":"Stem cell; Haematopoiesis; Transplantation; Gain of function; Function (biology); Outcome (game theory); Oncology; Medicine; Biology; Internal medicine; Cell biology; Genetics; Mathematics; Gene; Mutation","score_opus":0.016437007485745676,"score_gpt":0.26236479826766823,"score_spread":0.24592779078192256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402432829","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991687,0.0025022763,0.0044899653,0.0001679567,0.0002730235,0.00032494625,0.0000070768697,0.000014917259,0.00053282554],"genre_scores_gemma":[0.9990027,0.00017303001,0.00044667156,0.00002625852,0.000036750178,0.00001671589,0.0000045566767,0.000020956066,0.00027238854],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9984846,0.000060379494,0.00073129206,0.00015017517,0.000391137,0.00018240245],"domain_scores_gemma":[0.99920213,0.00016686741,0.00024534555,0.00020740408,0.000088132176,0.0000901345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038008072,0.00012975975,0.0002652205,0.00012939991,0.000063327105,0.000023723353,0.000042932068,0.00004631079,0.000037351117],"category_scores_gemma":[0.00000781174,0.00007308467,0.00009816707,0.0002462779,0.000055687782,0.000070991286,0.0000064301453,0.00017889877,0.0000038750745],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023652273,0.0003735742,0.03715079,0.0015429232,0.00045550862,0.914205,0.013397623,0.00043393148,0.0015086252,0.00022018791,0.00034109736,0.028005486],"study_design_scores_gemma":[0.005049588,0.0017228895,0.0021089283,0.001368069,0.0006069881,0.9748957,0.002436354,0.00087954954,0.010211825,0.00015383172,0.00044271426,0.00012354447],"about_ca_topic_score_codex":0.00011651223,"about_ca_topic_score_gemma":0.000044686025,"teacher_disagreement_score":0.06069069,"about_ca_system_score_codex":0.00077175384,"about_ca_system_score_gemma":0.0010033573,"threshold_uncertainty_score":0.29803064},"labels":[],"label_agreement":null},{"id":"W4402698098","doi":"10.51731/cjht.2024.985","title":"Maralixibat (Livmarli)","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business","score_opus":0.027999714835361657,"score_gpt":0.3060256705592148,"score_spread":0.27802595572385314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402698098","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21178548,0.60242665,0.0003236302,0.1793199,0.002197484,0.00048271928,0.000028673014,0.00054413034,0.002891358],"genre_scores_gemma":[0.9962006,0.0013774764,0.001128659,0.00051830924,0.00003034078,0.0000041462067,0.0000033283584,0.000022077831,0.0007150237],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99878734,0.000022711796,0.00045483778,0.00013522478,0.00015794614,0.00044195258],"domain_scores_gemma":[0.9993651,0.000051114235,0.0001138236,0.00024326536,0.00007717106,0.00014953683],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036918765,0.00012485356,0.0003550799,0.00080200017,0.00009744843,0.000034396173,0.00015405592,0.00014074567,0.00016453679],"category_scores_gemma":[0.00027423288,0.00009447259,0.00011121998,0.00037940327,0.0001516685,0.000094516356,0.000012990007,0.00053100736,0.00008609629],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011704436,0.000011895034,0.0033722993,0.00040375447,0.00014855544,0.0033584537,0.00027363742,0.00000255514,0.000034403714,0.0029174124,0.053414155,0.9360512],"study_design_scores_gemma":[0.0006949336,0.00072352414,0.0060395803,0.0015078608,0.000054293327,0.0052619493,0.0013110465,0.00004367262,0.00043694908,0.002196195,0.9816164,0.000113615875],"about_ca_topic_score_codex":0.0036043592,"about_ca_topic_score_gemma":0.00153232,"teacher_disagreement_score":0.9359376,"about_ca_system_score_codex":0.0027360509,"about_ca_system_score_gemma":0.0105159115,"threshold_uncertainty_score":0.9950935},"labels":[],"label_agreement":null},{"id":"W4402732213","doi":"10.1021/acs.jmedchem.4c01852","title":"Computationally Driven Discovery of a BCR-ABL1 Kinase Inhibitor with Activity in Multidrug-Resistant Chronic Myeloid Leukemia","year":2024,"lang":"en","type":"article","venue":"Journal of Medicinal Chemistry","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Georgia Research Alliance; Natural Sciences and Engineering Research Council of Canada; University of Georgia; U.S. Department of Energy","keywords":"Myeloid leukemia; Chemistry; Multiple drug resistance; Cancer research; Leukemia; P-glycoprotein; Kinase; Pharmacology; Biochemistry; Immunology; Medicine","score_opus":0.008940466491156342,"score_gpt":0.26227536460726514,"score_spread":0.2533348981161088,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402732213","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994437,0.0034410595,0.0002634583,0.0008964925,0.00015277811,0.00019737653,0.000025601874,0.00001914722,0.0005671094],"genre_scores_gemma":[0.997279,0.0002270961,0.0009840315,0.000036962592,0.00089667377,0.0000073007805,0.000021049,0.000040096347,0.0005078123],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974512,0.000041597792,0.0007730771,0.00030305955,0.0011152672,0.00031582263],"domain_scores_gemma":[0.99848205,0.0003131474,0.0004426444,0.00031309557,0.00021045798,0.00023861053],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040939965,0.0002960143,0.00076559914,0.00018906331,0.000029686646,0.000025890378,0.00021532724,0.00015670861,0.0000973274],"category_scores_gemma":[0.00022464844,0.00020886194,0.00021048976,0.0003923297,0.00024489482,0.0002884156,0.0000658536,0.00094487227,0.0000037855145],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0032266271,0.00045958374,0.004021447,0.0037095498,0.00060958863,0.00850413,0.000542478,0.00095542514,0.9722106,0.000010696866,0.0008009826,0.004948879],"study_design_scores_gemma":[0.02753576,0.0037088916,0.07250141,0.029794771,0.0013679536,0.0076554744,0.001065236,0.0107868,0.84312826,0.000117634634,0.0017245855,0.00061323756],"about_ca_topic_score_codex":0.00009512704,"about_ca_topic_score_gemma":0.000032076325,"teacher_disagreement_score":0.12908237,"about_ca_system_score_codex":0.005225151,"about_ca_system_score_gemma":0.0065194108,"threshold_uncertainty_score":0.9991127},"labels":[],"label_agreement":null},{"id":"W4403622146","doi":"10.58931/cht.2024.3253","title":"Management of Chronic Myeloid Leukemia that is Intolerant or Resistant to Front-Line Treatment","year":2024,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Myeloid leukemia; Front line; Medicine; Front (military); Line (geometry); Myeloid; Cancer research; Oncology; Internal medicine; History; Engineering; Mathematics","score_opus":0.026433980741656118,"score_gpt":0.28653558425074394,"score_spread":0.26010160350908784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403622146","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.877981,0.047784187,0.00036681152,0.030689761,0.0023096115,0.0051752096,0.0007794619,0.00045200402,0.03446198],"genre_scores_gemma":[0.9596074,0.0010366979,0.0013128202,0.0010780633,0.00013845849,0.00029182524,0.00011795347,0.00008877111,0.036328],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974903,0.00004406355,0.0005418456,0.00077730964,0.0002717934,0.00087472796],"domain_scores_gemma":[0.99792236,0.000088971115,0.00006722189,0.0009142865,0.000055451794,0.00095172453],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00013083294,0.00043854374,0.0008830444,0.0005821289,0.00009597761,0.000024582137,0.00020978173,0.00025129318,0.0041035707],"category_scores_gemma":[0.000016093358,0.00032896246,0.00021350478,0.0003908359,0.000120903926,0.000058732898,0.000056533987,0.0001896669,0.001010964],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0036844597,0.00091054634,0.0071061505,0.012291924,0.017071277,0.15702161,0.012249781,0.00016657048,0.0030879304,0.028497685,0.3169575,0.44095454],"study_design_scores_gemma":[0.008018951,0.0041019083,0.0043433174,0.0052003963,0.002183066,0.0026021516,0.00090079504,0.0017381274,0.04722334,0.0002911489,0.9225147,0.0008821237],"about_ca_topic_score_codex":0.041417323,"about_ca_topic_score_gemma":0.16980162,"teacher_disagreement_score":0.60555714,"about_ca_system_score_codex":0.017259305,"about_ca_system_score_gemma":0.005647902,"threshold_uncertainty_score":0.99998915},"labels":[],"label_agreement":null},{"id":"W4403638086","doi":"10.55563/clinexprheumatol/qonstg","title":"Allogeneic stem cell transplantation in difficult-to-treat rheumatoid arthritis","year":2024,"lang":"en","type":"letter","venue":"Clinical and Experimental Rheumatology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Rheumatoid arthritis; Transplantation; Stem cell; Arthritis; Surgery; Internal medicine","score_opus":0.02469345441860576,"score_gpt":0.31510840179669397,"score_spread":0.2904149473780882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403638086","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9022219,0.024493597,0.0000042628344,0.07016522,0.0011604868,0.00093280815,0.00009079098,0.00013524372,0.00079569354],"genre_scores_gemma":[0.8349454,0.04029179,0.0002912239,0.119172454,0.00034722307,0.00045420747,0.0013793478,0.0001928967,0.002925503],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99610436,0.00021955564,0.0014607009,0.0012720365,0.0002875288,0.0006557901],"domain_scores_gemma":[0.99864364,0.00044099236,0.00014857369,0.0004391962,0.000030904106,0.0002966724],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00016978086,0.0006163534,0.0017111361,0.00027728407,0.000058181085,0.000038846792,0.00016142333,0.0015129048,0.00024344053],"category_scores_gemma":[0.000019883482,0.0005218341,0.00028952473,0.00020518833,0.00033162738,0.000048618596,0.00012628063,0.001630077,0.0010324781],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012754749,0.0012343822,0.046697635,0.0026508993,0.00037089412,0.020473959,0.0024705117,0.000002173605,0.0011330884,0.000060014157,0.9084783,0.015152664],"study_design_scores_gemma":[0.066051595,0.008577552,0.013050435,0.017046196,0.0007114593,0.035131987,0.0021328202,0.00019657306,0.036972243,0.00026691073,0.8155902,0.00427205],"about_ca_topic_score_codex":0.000261558,"about_ca_topic_score_gemma":0.000040827108,"teacher_disagreement_score":0.092888124,"about_ca_system_score_codex":0.00033591606,"about_ca_system_score_gemma":0.00027200152,"threshold_uncertainty_score":0.99978334},"labels":[],"label_agreement":null},{"id":"W4404090560","doi":"10.1183/13993003.congress-2024.pa1505","title":"Short- and long-term effects of imatinib in patients hospitalised for COVID-19: A randomised trial","year":2024,"lang":"en","type":"article","venue":"","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Term (time); Coronavirus disease 2019 (COVID-19); Imatinib; Medicine; Randomized controlled trial; Internal medicine","score_opus":0.015195468315525774,"score_gpt":0.3179078102799381,"score_spread":0.3027123419644123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404090560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99084765,0.0006242443,0.00036602092,0.00015395058,0.00030484665,0.007459819,0.000017563963,0.00006258902,0.00016329384],"genre_scores_gemma":[0.99840426,0.000036971614,0.00027176202,0.00020691175,0.00006470275,0.0005629666,0.00011413798,0.000025844598,0.0003124437],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9988791,0.000039284594,0.00039027518,0.00030039114,0.00019258639,0.00019836564],"domain_scores_gemma":[0.9986574,0.0008916542,0.00003831619,0.00019027606,0.000030199939,0.00019215928],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019964884,0.00016329208,0.0004908191,0.00015158161,0.000017776267,0.000016479053,0.00004313058,0.000091331625,0.000094487856],"category_scores_gemma":[0.00090902526,0.000119491444,0.00013484119,0.00012652346,0.000050051884,0.000060411116,0.00002714368,0.00007297039,0.000003120717],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5614339,0.0029943716,0.34333786,0.022046734,0.0014362844,0.00045136714,0.0026123696,0.000003871297,0.0012722082,0.0003625428,0.0042247553,0.059823744],"study_design_scores_gemma":[0.8971102,0.0029573839,0.09593114,0.0005454799,0.00041263393,0.0000044464364,0.000010517558,0.00056253746,0.0021641715,0.0000708038,0.000079065445,0.00015160552],"about_ca_topic_score_codex":0.000025514819,"about_ca_topic_score_gemma":0.000010925608,"teacher_disagreement_score":0.3356763,"about_ca_system_score_codex":0.00045541447,"about_ca_system_score_gemma":0.0003484491,"threshold_uncertainty_score":0.48727196},"labels":[],"label_agreement":null},{"id":"W4404230831","doi":"10.1093/neuonc/noae165.0411","title":"CTNI-44. NCT03643549 PHASE IB/II TRIAL: EFFICACY, SAFETY, AND BIOLOGICAL MECHANISMS OF OBJECTIVE RESPONSES IN RECURRENT GBM PATIENTS WITH UNMETHYLATED MGMT PROMOTER TREATED WITH SEQUENTIAL BORTEZOMIB AND TEMOZOLOMIDE","year":2024,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Temozolomide; Bortezomib; Medicine; Oncology; Phases of clinical research; Internal medicine; Glioblastoma; Cancer research; Pharmacology; Clinical trial; Multiple myeloma","score_opus":0.025475230966699052,"score_gpt":0.3209164149299225,"score_spread":0.29544118396322344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404230831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99491495,0.00027629352,0.00007132549,0.00049078406,0.00022067662,0.0035409047,0.00010303076,0.00012896932,0.0002530459],"genre_scores_gemma":[0.9985914,0.00025998297,0.00055189076,0.00013086219,0.000049574828,0.00012916594,0.00017467387,0.000060366958,0.000052037187],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99686366,0.00073889305,0.00067841035,0.00096172176,0.00028790068,0.00046939967],"domain_scores_gemma":[0.9981192,0.0009854168,0.00022961202,0.00031638722,0.00012331497,0.00022611282],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00039654737,0.00044549463,0.0010967391,0.00040890055,0.00008645124,0.000019856167,0.000090301626,0.00037745893,0.00007737516],"category_scores_gemma":[0.00038325565,0.00028265468,0.00007072051,0.00053441204,0.00043970806,0.00010141218,0.00015269396,0.00057704595,0.000004928652],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.722494,0.007232577,0.0116937505,0.00020171667,0.00097431336,0.0039317994,0.0017391724,0.0000058824885,0.14454313,0.00022065704,0.000076357144,0.10688662],"study_design_scores_gemma":[0.5882612,0.29144973,0.046367414,0.0009633675,0.0017341024,0.0011271911,0.0002386583,0.0008456613,0.063557774,0.0003433364,0.0042585973,0.00085297925],"about_ca_topic_score_codex":0.00011728896,"about_ca_topic_score_gemma":0.00008681151,"teacher_disagreement_score":0.28421715,"about_ca_system_score_codex":0.0009151388,"about_ca_system_score_gemma":0.0008909261,"threshold_uncertainty_score":0.99996257},"labels":[],"label_agreement":null},{"id":"W4404435811","doi":"10.51731/cjht.2024.1026","title":"Lebrikizumab (Ebglyss)","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Psychology","score_opus":0.026680093527297718,"score_gpt":0.3047469040962092,"score_spread":0.27806681056891147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404435811","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.25012907,0.61267614,0.00026395486,0.13198856,0.0014977714,0.00041085432,0.000024952731,0.0005126464,0.0024960295],"genre_scores_gemma":[0.9969627,0.0012732848,0.0008297606,0.00040045357,0.000029863275,0.0000036462357,0.0000029965122,0.000021924898,0.00047537344],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987557,0.000021316506,0.00046866786,0.0001398398,0.00016439485,0.00045010223],"domain_scores_gemma":[0.9993463,0.000046635065,0.0001198835,0.00025168897,0.000085963045,0.00014948794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036034983,0.0001250817,0.00037108627,0.00084502134,0.00010752249,0.000041435444,0.00017375026,0.00014122293,0.0001095624],"category_scores_gemma":[0.00031693658,0.00009598792,0.000116853436,0.00041294238,0.00015511915,0.00009226927,0.000012388201,0.00057204126,0.00007222712],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000111607405,0.000010221655,0.0014556211,0.00030206368,0.00012850671,0.0030657481,0.00021938035,0.0000025363943,0.000029677782,0.0015525434,0.030650355,0.96257216],"study_design_scores_gemma":[0.00092082185,0.0008975934,0.0054435697,0.0016206962,0.000066512745,0.007861689,0.0013308343,0.000056084875,0.0007255383,0.002772404,0.9781773,0.00012696578],"about_ca_topic_score_codex":0.0036090326,"about_ca_topic_score_gemma":0.0015626901,"teacher_disagreement_score":0.9624452,"about_ca_system_score_codex":0.0031185064,"about_ca_system_score_gemma":0.013731207,"threshold_uncertainty_score":0.99186003},"labels":[],"label_agreement":null},{"id":"W4404469372","doi":"10.1101/2024.11.18.24317089","title":"What are the ethnic inequities in care outcomes related to haematological malignancies, treated with transplant/cellular-therapies, in the UK?","year":2024,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Aging","funders":"National Institute for Health and Care Research","keywords":"Ethnic group; Medicine; Intensive care medicine; Political science","score_opus":0.03781222805989873,"score_gpt":0.2953442469890798,"score_spread":0.2575320189291811,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404469372","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.942696,0.043144975,0.0000016363015,0.010385714,0.0003653754,0.0027950744,0.00007888071,0.00015066484,0.00038170538],"genre_scores_gemma":[0.9937129,0.0023501397,0.000041729607,0.0010306553,0.0000399716,0.0010523887,0.0003269201,0.00008714084,0.0013581632],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963316,0.00048754414,0.0008276512,0.00094616966,0.0007415607,0.00066551135],"domain_scores_gemma":[0.99783564,0.0004328058,0.00017419462,0.0013638269,0.00008050653,0.000113020156],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00066556304,0.0007534038,0.001371158,0.0003571973,0.00007583513,0.00014816671,0.00070278015,0.00061034184,0.00013364793],"category_scores_gemma":[0.000080711856,0.00033885075,0.00026240168,0.0008587881,0.0002329882,0.000049835875,0.0002900654,0.0022647206,0.00008027865],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038129868,0.00017822927,0.9221362,0.0012631855,0.00057818415,0.01195515,0.062060066,0.00017919387,0.00014368915,0.00024918836,0.0001493817,0.00072621944],"study_design_scores_gemma":[0.0053063272,0.0004993902,0.9223207,0.015363545,0.0010249448,0.00074431737,0.05123316,0.0000901987,0.00092261273,0.00083911075,0.000830418,0.0008252584],"about_ca_topic_score_codex":0.0010711196,"about_ca_topic_score_gemma":0.0074012536,"teacher_disagreement_score":0.051016916,"about_ca_system_score_codex":0.0011097442,"about_ca_system_score_gemma":0.000580234,"threshold_uncertainty_score":0.99990636},"labels":[],"label_agreement":null},{"id":"W4404494745","doi":"10.51731/cjht.2024.1027","title":"Alectinib (Alecensaro)","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Alectinib; Medicine; Internal medicine","score_opus":0.03220771378287877,"score_gpt":0.31660962255069,"score_spread":0.2844019087678112,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404494745","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.26576322,0.5836792,0.0002565889,0.1441869,0.0019321265,0.00048413326,0.000026635811,0.00058025355,0.00309095],"genre_scores_gemma":[0.9967491,0.0012978865,0.0009381716,0.00046533617,0.00003098207,0.0000035209891,0.0000027386977,0.000021900798,0.0004903738],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987912,0.000022400132,0.00044860694,0.00013834954,0.00015023052,0.00044919612],"domain_scores_gemma":[0.9993641,0.000058562324,0.00011726175,0.00022607704,0.00009203537,0.00014197921],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036533838,0.00012147115,0.00034812783,0.00082914974,0.000112405665,0.000035282086,0.00015267488,0.00013805181,0.0001118825],"category_scores_gemma":[0.00039992787,0.00009425228,0.00010507073,0.00047270357,0.00014555371,0.00008194067,0.000010003994,0.00060132117,0.0000613594],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011578097,0.000012918212,0.003387216,0.00033880142,0.00015130789,0.0028805495,0.00030702283,0.0000022486408,0.00006214947,0.0010874483,0.038622428,0.9531363],"study_design_scores_gemma":[0.0008315347,0.00096130715,0.0052985046,0.0015360654,0.00006031221,0.008123407,0.0012320046,0.000043754066,0.0011501784,0.0021839954,0.97845405,0.00012486144],"about_ca_topic_score_codex":0.0025557831,"about_ca_topic_score_gemma":0.0016927676,"teacher_disagreement_score":0.95301145,"about_ca_system_score_codex":0.0025048647,"about_ca_system_score_gemma":0.012573977,"threshold_uncertainty_score":0.9930238},"labels":[],"label_agreement":null},{"id":"W4404828842","doi":"10.1038/s41408-024-01192-7","title":"Molecular monitoring in CML—a modern example of an old proverb","year":2024,"lang":"en","type":"editorial","venue":"Blood Cancer Journal","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Department of Medicine, University of Toronto; University of Toronto","keywords":"Medicine; Computational biology; MEDLINE; Bioinformatics; Biology; Intensive care medicine; Biochemistry","score_opus":0.015990089796937803,"score_gpt":0.3082338323487274,"score_spread":0.29224374255178964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404828842","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.35943782,0.03067778,0.000011400337,0.000067270244,0.6086974,0.00049666036,0.00022532941,0.00004737641,0.00033892965],"genre_scores_gemma":[0.048666216,0.0052913,0.0007812538,0.000018802639,0.94319797,0.00013402195,0.0001163421,0.00025019227,0.0015438927],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.996609,0.000077709075,0.0007641738,0.00057104864,0.0014566085,0.00052148],"domain_scores_gemma":[0.9984011,0.0000934072,0.00038270015,0.0005372685,0.00027631712,0.00030921935],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00038880587,0.00044274103,0.00091549725,0.00038390173,0.000042187155,0.00007440172,0.00030327812,0.00066434866,0.00010361115],"category_scores_gemma":[0.00015256017,0.0003931351,0.0002601379,0.0002603579,0.000043899687,0.00014414877,0.000094171286,0.0025044768,0.0000056430777],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019838098,0.003453073,0.007851654,0.00848695,0.008934135,0.028897285,0.0044250223,0.0017354158,0.038683977,0.000027545113,0.8195408,0.07598035],"study_design_scores_gemma":[0.054095417,0.0047370805,0.0012335199,0.041034184,0.0129125025,0.001921801,0.0002891607,0.001245572,0.09304659,0.0020093978,0.7852286,0.0022461528],"about_ca_topic_score_codex":0.0034480593,"about_ca_topic_score_gemma":0.00016664264,"teacher_disagreement_score":0.33450055,"about_ca_system_score_codex":0.0023050716,"about_ca_system_score_gemma":0.005030642,"threshold_uncertainty_score":0.99985206},"labels":[],"label_agreement":null},{"id":"W4405034536","doi":"10.1182/blood-2024-207139","title":"Olverembatinib (HQP1351) Overcomes Resistance/Intolerance to Asciminib and Ponatinib in Patients (pts) with Heavily Pretreated Chronic-Phase Chronic Myeloid Leukemia (CP-CML): A 1.5-Year Follow-up Update with Comprehensive Exposure-Response (E-R) Analyses","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Ponatinib; Medicine; Internal medicine; Myeloid leukemia; Nilotinib; Gastroenterology; Imatinib","score_opus":0.01730730187031699,"score_gpt":0.2943689783184971,"score_spread":0.27706167644818014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405034536","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876363,0.007962503,0.000037694135,0.00042950708,0.00015646445,0.0026716848,0.0003276416,0.00032083102,0.0004573528],"genre_scores_gemma":[0.9948946,0.00035238176,0.0019326011,0.00026342098,0.00016068836,0.00037106583,0.0003381619,0.00019579292,0.0014912424],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949899,0.00027784746,0.00088808755,0.0016470911,0.0011232493,0.0010738284],"domain_scores_gemma":[0.997264,0.00042858475,0.00023401045,0.0011279775,0.0003660331,0.000579339],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00028358752,0.0009554903,0.0013511714,0.00073356787,0.00017938844,0.00018447934,0.00028722725,0.0002624543,0.00020226518],"category_scores_gemma":[0.00014683128,0.00073116197,0.00017833292,0.00171554,0.0002826772,0.0004001257,0.00014914534,0.0006443904,0.0000953252],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34845564,0.013888683,0.39212468,0.011351376,0.021000119,0.018177247,0.017277528,0.001985973,0.113618486,0.00050072215,0.009793427,0.051826138],"study_design_scores_gemma":[0.33611426,0.038564056,0.529535,0.015482294,0.0044441777,0.00045016082,0.000768521,0.0009556673,0.05478922,0.000040202052,0.016005171,0.0028512788],"about_ca_topic_score_codex":0.0003016626,"about_ca_topic_score_gemma":0.001991733,"teacher_disagreement_score":0.13741031,"about_ca_system_score_codex":0.0040426836,"about_ca_system_score_gemma":0.0034233292,"threshold_uncertainty_score":0.9997806},"labels":[],"label_agreement":null},{"id":"W4405034729","doi":"10.1182/blood-2024-205681","title":"Retrospective Study to Compare Treatment Outcomes of Asciminib Vs. Ponatinib in 99 Patients with T315I Mutated Chronic Myeloid Leukemia","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Ponatinib; Internal medicine; Discontinuation; Myeloid leukemia; Oncology; Nilotinib; Imatinib","score_opus":0.01279472955425322,"score_gpt":0.27741831078743623,"score_spread":0.264623581233183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405034729","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949419,0.0003401248,0.000002356275,0.00013387803,0.00014244622,0.0032322458,0.00017577165,0.00015542225,0.0008758829],"genre_scores_gemma":[0.9984709,0.000019370069,0.00025158006,0.000047201956,0.000058007146,0.0002580392,0.00019574694,0.00007801334,0.00062114774],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99742514,0.00007260949,0.00058393006,0.0007613903,0.00068159885,0.00047533857],"domain_scores_gemma":[0.99881464,0.000089005494,0.00010835061,0.0006254891,0.0001549138,0.00020760504],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012651952,0.00045853973,0.001053885,0.00041851203,0.000047540485,0.000027520315,0.00014785281,0.0000555237,0.00018349035],"category_scores_gemma":[0.000066978166,0.00031889632,0.0001305497,0.000840533,0.00006428448,0.00009290579,0.00007890345,0.00022826705,0.00008893122],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047703105,0.0072012376,0.98326904,0.000114746814,0.0017495117,0.0005726959,0.0046301214,0.00005676609,0.00008066117,0.000019309744,0.000085115986,0.0017437543],"study_design_scores_gemma":[0.033680603,0.010910782,0.9511214,0.00044923092,0.0009730257,0.000017765253,0.00054226187,0.00008023441,0.0018036381,0.000008123492,0.00014915798,0.0002637751],"about_ca_topic_score_codex":0.0016106096,"about_ca_topic_score_gemma":0.0026479973,"teacher_disagreement_score":0.033203572,"about_ca_system_score_codex":0.006900883,"about_ca_system_score_gemma":0.0013474865,"threshold_uncertainty_score":0.9999263},"labels":[],"label_agreement":null},{"id":"W4405034804","doi":"10.1182/blood-2024-207634","title":"5-Year Follow-up of the Phase 2 Optic Study in Patients with Chronic-Phase Chronic Myeloid Leukemia: Efficacy, Safety, and First End-of-Treatment Mutational Results","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Scheme for Promotion of Academic and Research Collaboration; Sun Pharma; Otsuka Pharmaceutical; Ascentage Pharma; Ipsen Biopharmaceuticals; Ipsen; Jazz Pharmaceuticals; Bristol-Myers Squibb; Incyte; Amgen","keywords":"Medicine; Myeloid leukemia; Phases of clinical research; Phase (matter); Oncology; Internal medicine; Clinical trial; Chemistry","score_opus":0.012090670285373627,"score_gpt":0.2761671150953434,"score_spread":0.2640764448099698,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405034804","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949023,0.0014973097,0.0000036671854,0.00012358089,0.0001552883,0.002625973,0.00036024002,0.000039365725,0.00029224306],"genre_scores_gemma":[0.9989876,0.000112791226,0.0001275052,0.000005398453,0.000098682685,0.0000851941,0.00023761268,0.000049324404,0.00029589576],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977778,0.000074591364,0.0006937357,0.00056815246,0.00054563576,0.00034007992],"domain_scores_gemma":[0.99868923,0.00030473885,0.00018513379,0.00061335816,0.000087819724,0.00011973337],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018752873,0.00033834678,0.00056905474,0.00018164127,0.0000844077,0.000017976332,0.00014105187,0.00009915959,0.0000749526],"category_scores_gemma":[0.000092293485,0.00021388155,0.00012703851,0.0004759016,0.00019021476,0.00008942093,0.000099407735,0.00021771462,0.000010618176],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.070626,0.14690638,0.5651291,0.005391636,0.020654002,0.0035016995,0.034598704,0.0036370412,0.0032177467,0.0008925233,0.00052895106,0.14491624],"study_design_scores_gemma":[0.64399856,0.044557273,0.29686883,0.00217983,0.003226706,0.000090935544,0.00026833304,0.001094579,0.0062326477,0.00001246206,0.0010758016,0.00039405987],"about_ca_topic_score_codex":0.00046923148,"about_ca_topic_score_gemma":0.0010969848,"teacher_disagreement_score":0.57337254,"about_ca_system_score_codex":0.0035425203,"about_ca_system_score_gemma":0.0031089645,"threshold_uncertainty_score":0.92635673},"labels":[],"label_agreement":null},{"id":"W4405038062","doi":"10.1182/blood-2024-200017","title":"Asciminib Shows High Efficacy and Favorable Tolerability at 80 Mg Once Daily and 40 Mg Twice Daily in Patients with Chronic Phase Chronic Myelogenous Leukemia Previously Treated with 2 or More Tyrosine Kinase Inhibitors: Primary Analysis from the ASC4OPT Study","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Tolerability; Internal medicine; Chronic myelogenous leukemia; Regimen; Bosutinib; Philadelphia chromosome; Adverse effect; Imatinib mesylate; Nilotinib; Gastroenterology; Imatinib; Leukemia; Chromosomal translocation","score_opus":0.009846299612478682,"score_gpt":0.24839092848246946,"score_spread":0.23854462886999078,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405038062","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9813982,0.013446288,0.0000068658437,0.00014197406,0.000046333935,0.0044538,0.00029214355,0.00017595195,0.000038442326],"genre_scores_gemma":[0.99726194,0.00026751525,0.00026373187,0.000104433755,0.00021503211,0.00031570208,0.0011985828,0.00011045605,0.00026259918],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99552965,0.00028276411,0.00079342606,0.0017324893,0.00084517064,0.0008164857],"domain_scores_gemma":[0.99727666,0.00055593933,0.00024035011,0.0014297885,0.00014233557,0.0003549335],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004147173,0.0008059072,0.0014126735,0.00027495954,0.00030268522,0.00018057399,0.00025837286,0.00020189266,0.0001903755],"category_scores_gemma":[0.00008678011,0.00046410688,0.00012708585,0.0017219232,0.0004126478,0.0003151462,0.00027908216,0.0006077346,0.000009576153],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010389172,0.009067333,0.95179826,0.0006409521,0.007334814,0.0017011823,0.004799767,0.00022705694,0.0018555556,0.0000010909446,0.00013128394,0.012053538],"study_design_scores_gemma":[0.10018718,0.016115988,0.86343855,0.0012114054,0.01567915,0.00006571009,0.00029790157,0.0009336465,0.00126941,0.0000018598381,0.00016609309,0.00063312904],"about_ca_topic_score_codex":0.0060510486,"about_ca_topic_score_gemma":0.010358322,"teacher_disagreement_score":0.08979801,"about_ca_system_score_codex":0.0056252144,"about_ca_system_score_gemma":0.0022971598,"threshold_uncertainty_score":0.9997811},"labels":[],"label_agreement":null},{"id":"W4405038508","doi":"10.1182/blood-2024-210449","title":"Retrospective Evaluation of <i>BCR::ABL</i> Kinase Domain Mutation Profiles and Treatment Outcomes in Patients with Chronic Myeloid Leukemia to Confirm Clinical Relevance of in Vitro Sensitivity-Based Treatment Switch: Real-World Experience","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Myeloid leukemia; Medicine; Oncology; Mutation; Protein kinase domain; Internal medicine; Cancer research; Immunology; Biology; Genetics; Gene","score_opus":0.024132269505190866,"score_gpt":0.32404373131770464,"score_spread":0.29991146181251377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405038508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99614215,0.00026239737,0.000018458792,0.000108549604,0.00008229774,0.0030789091,0.00013438087,0.000039848128,0.00013298527],"genre_scores_gemma":[0.9971867,0.00008451124,0.0019089209,0.000023258546,0.000042231353,0.000500872,0.00017366723,0.000039506867,0.000040307725],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971356,0.00030562637,0.00080416584,0.00073988014,0.00069987384,0.00031488246],"domain_scores_gemma":[0.99848425,0.0004906527,0.00022635526,0.00045383762,0.00021250635,0.00013241624],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005969151,0.0003565572,0.0009354722,0.0003999562,0.00002854875,0.000013327867,0.00004218016,0.000109515226,0.000014085704],"category_scores_gemma":[0.00021479452,0.00026372925,0.00010899938,0.00061798736,0.00015458831,0.00011287837,0.000022413533,0.0001375504,0.0000036127274],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021785614,0.003422175,0.96169287,0.00014597957,0.0003103521,0.0002394952,0.0028418228,0.00025337408,0.008981953,0.000041141044,0.0000017933788,0.019890472],"study_design_scores_gemma":[0.035114527,0.004457403,0.8431841,0.0007353632,0.00054005947,0.000005837886,0.00017035198,0.0013282243,0.114232406,0.000029978599,0.00001327693,0.00018848278],"about_ca_topic_score_codex":0.0025147714,"about_ca_topic_score_gemma":0.005348907,"teacher_disagreement_score":0.118508786,"about_ca_system_score_codex":0.00724973,"about_ca_system_score_gemma":0.0020005098,"threshold_uncertainty_score":0.99998146},"labels":[],"label_agreement":null},{"id":"W4405038834","doi":"10.1182/blood-2024-201022","title":"ASC4REAL: Efficacy and Tolerability Comparison between Ascembl Study, a Phase 3 Randomized Clinical Trial (RCT), and Consolidated Real-World (RW) Evidence with Asciminib in CML Patients Beyond 2 TKIs","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Randomized controlled trial; Tolerability; Medicine; Internal medicine; Adverse effect","score_opus":0.07919037351382231,"score_gpt":0.4299993825019653,"score_spread":0.350809008988143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405038834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98999625,0.0011942834,0.0000068176264,0.0002531166,0.0001878502,0.0078052334,0.000048883474,0.00015348887,0.00035406344],"genre_scores_gemma":[0.9985478,0.00033500692,0.0002937896,0.000047356636,0.00024430113,0.00025847394,0.0001236509,0.00004909691,0.00010054584],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9947529,0.0013578734,0.0017097623,0.0011364333,0.000602792,0.00044028249],"domain_scores_gemma":[0.99176484,0.006817157,0.00026408196,0.00062835973,0.000117510295,0.0004080524],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0031838838,0.00044262296,0.0024821449,0.00027373357,0.0000833576,0.0001103498,0.0001281145,0.00017867058,0.000054958415],"category_scores_gemma":[0.0020833951,0.00031615476,0.00014795848,0.0005453729,0.0004937162,0.00017826486,0.00014745122,0.00069673586,0.000012379804],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.318609,0.011227795,0.65198576,0.00020310697,0.0012511364,0.0002282747,0.0013869143,3.7235165e-7,0.000007863741,0.000005683709,0.00017582551,0.014918266],"study_design_scores_gemma":[0.7397391,0.007392885,0.24771607,0.00085244334,0.003534808,0.000010523271,0.00009968025,0.00022117633,0.00008041166,0.00001803313,0.00009922214,0.00023561141],"about_ca_topic_score_codex":0.0011758641,"about_ca_topic_score_gemma":0.0006976043,"teacher_disagreement_score":0.42113012,"about_ca_system_score_codex":0.00023914989,"about_ca_system_score_gemma":0.0006311928,"threshold_uncertainty_score":0.9999291},"labels":[],"label_agreement":null},{"id":"W4405039612","doi":"10.1182/blood-2024-193201","title":"Treatment with Asciminib As a Second Line after One Prior Tyrosine Kinase Inhibitor (TKI) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) - a Chart Review Study in the United States","year":2024,"lang":"en","type":"review","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Myeloid leukemia; Dasatinib; Medicine; Nilotinib; Tyrosine-kinase inhibitor; Bosutinib; Internal medicine; Imatinib; Oncology; Cancer","score_opus":0.026122440919423676,"score_gpt":0.31621558707558883,"score_spread":0.29009314615616516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405039612","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21103296,0.7696785,2.2211877e-7,0.00013973875,0.000079523765,0.018392792,0.0005163329,0.0000991095,0.00006087162],"genre_scores_gemma":[0.008686448,0.97322667,0.00006962175,0.00032351294,0.0005018797,0.009235736,0.0066257627,0.0003895756,0.00094078307],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9929057,0.00064774015,0.0020044625,0.0019203321,0.0012986789,0.0012231328],"domain_scores_gemma":[0.9963118,0.00022592122,0.0007071715,0.0021876188,0.00019431539,0.00037321096],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00056120474,0.0020112249,0.0046980204,0.0010969392,0.000100347424,0.00012396232,0.0004873263,0.00040563365,0.00067209813],"category_scores_gemma":[0.00005500761,0.0010605946,0.00047324944,0.0030417922,0.0002036436,0.00017335874,0.0002018749,0.0015292087,0.00034154908],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0041574817,0.086395375,0.002850488,0.26125658,0.012938871,0.027192943,0.004171189,0.0000049166665,0.0000028359084,0.000008328606,0.0009243358,0.60009664],"study_design_scores_gemma":[0.1015983,0.063408226,0.0009220948,0.24555434,0.035422232,0.0006220365,0.000116128256,0.000012037786,0.000017499486,0.0000018629612,0.55088395,0.0014413124],"about_ca_topic_score_codex":0.00079609937,"about_ca_topic_score_gemma":0.0046094325,"teacher_disagreement_score":0.59865534,"about_ca_system_score_codex":0.013446177,"about_ca_system_score_gemma":0.008760042,"threshold_uncertainty_score":0.99926305},"labels":[],"label_agreement":null},{"id":"W4405040029","doi":"10.1182/blood-2024-199996","title":"Presence of Leukemia-Related Basophils and Mast Cells with Atypical Immunophenotype during Induction Should Not be Interpreted As Measurable Residual Disease in Children with Acute Myeloid Leukemia with <i>RUNX1</i>::<i>RUNX1T1</i>","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Terry Fox Research Institute; University of British Columbia; University Health Network","funders":"","keywords":"Immunophenotyping; Myeloid leukemia; RUNX1; Leukemia; Immunology; Medicine; Preleukemia; Biology; Haematopoiesis; Flow cytometry; Genetics; Stem cell","score_opus":0.009527451395144439,"score_gpt":0.22748793660838887,"score_spread":0.21796048521324443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405040029","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957669,0.0015649436,0.000009213458,0.0004156874,0.00006818103,0.0015078621,0.000094503936,0.00021706842,0.00035564628],"genre_scores_gemma":[0.997791,0.00032028358,0.0006462601,0.000088516994,0.0000904835,0.00012530443,0.000129846,0.00014229227,0.0006660482],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996639,0.00011441588,0.0005823831,0.0010592667,0.00095472304,0.0006501774],"domain_scores_gemma":[0.9983965,0.00011677101,0.00017564991,0.0007780334,0.00013575747,0.00039728192],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002274276,0.0005987121,0.00073685107,0.0003419074,0.00011721513,0.00008201036,0.00021754304,0.00025300996,0.000067178604],"category_scores_gemma":[0.00005684033,0.00042054156,0.000074761454,0.0008836053,0.00044050007,0.00044705922,0.00014002476,0.0010011846,0.000015164127],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07005195,0.0021358277,0.49346778,0.0023044867,0.013889644,0.008603249,0.005267208,0.0038524077,0.39819452,0.00035521045,0.00021463857,0.0016630706],"study_design_scores_gemma":[0.03549502,0.004027314,0.62167835,0.0064604543,0.005579396,0.004125426,0.00022921557,0.0006684694,0.32055908,0.000056088287,0.000041247094,0.0010799256],"about_ca_topic_score_codex":0.0010547846,"about_ca_topic_score_gemma":0.00012262212,"teacher_disagreement_score":0.12821059,"about_ca_system_score_codex":0.0011071188,"about_ca_system_score_gemma":0.0024763083,"threshold_uncertainty_score":0.99982464},"labels":[],"label_agreement":null},{"id":"W4405040167","doi":"10.1182/blood-2024-210782","title":"Multi-Pronged Effects of Cohesin Mutations in the Myeloid Leukemia of Down Syndrome","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Myeloid leukemia; Cohesin; Cancer research; Genetics; Mutation; Leukemia; Medicine; Myeloid; Biology; Gene; Chromosome","score_opus":0.012481530175688444,"score_gpt":0.2660339515104317,"score_spread":0.25355242133474326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405040167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952763,0.0029578675,0.000026556274,0.0001438217,0.00009561992,0.000842768,0.000017001874,0.00004219631,0.0005979258],"genre_scores_gemma":[0.99813354,0.000057346864,0.0012960635,0.000034000073,0.000025578238,0.000098118726,0.00003357169,0.00002172839,0.00030005336],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99894077,0.000080214915,0.00031727948,0.00021158595,0.0002680589,0.0001820749],"domain_scores_gemma":[0.9990337,0.00047098682,0.000059450227,0.00036157138,0.000032102213,0.000042202104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019802479,0.00013773456,0.00032107483,0.00016545564,0.00002020139,0.000008034715,0.00012007045,0.00008557777,0.000040794457],"category_scores_gemma":[0.00018331961,0.00009284325,0.000108761735,0.0004406464,0.000096657175,0.00004708504,0.000025834925,0.0002007225,0.000037410784],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038703985,0.0124801565,0.110817,0.02684291,0.004947672,0.018030623,0.035017584,0.00021165384,0.7656,0.0017182961,0.001406887,0.02254013],"study_design_scores_gemma":[0.020426216,0.0012502638,0.77150744,0.0030260254,0.0022059898,0.0014216366,0.0005183311,0.0011921383,0.19780678,0.00014233463,0.00026519888,0.00023765716],"about_ca_topic_score_codex":0.00027301203,"about_ca_topic_score_gemma":0.000052802978,"teacher_disagreement_score":0.6606904,"about_ca_system_score_codex":0.0002584547,"about_ca_system_score_gemma":0.00054596126,"threshold_uncertainty_score":0.3786038},"labels":[],"label_agreement":null},{"id":"W4405040397","doi":"10.1182/blood-2024-202621","title":"Treatment Intensification Does Not Improve Outcome for Children with Myeloid Leukemia of Down Syndrome (ML-DS) Who Are MRD-Positive after Induction Therapy: A Report from the Children's Oncology Group","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Agricultural Research Institute of Ontario; Hospital for Sick Children","funders":"","keywords":"Medicine; Internal medicine; Oncology; Myeloid leukemia; Down syndrome; Leukemia; Pediatrics","score_opus":0.013940598050119029,"score_gpt":0.2664940596437294,"score_spread":0.25255346159361036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405040397","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921412,0.0011363968,0.00009961876,0.0018095463,0.0002872581,0.0034034753,0.00094416353,0.00013277415,0.000045604098],"genre_scores_gemma":[0.99530554,0.00024604725,0.00077885087,0.00024988558,0.00046834134,0.0011576107,0.001142902,0.00008195564,0.00056886283],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99781877,0.00007605248,0.0006222692,0.00083086785,0.00032074677,0.0003312702],"domain_scores_gemma":[0.99828297,0.00024713395,0.0003791731,0.0008066006,0.00017942247,0.00010467761],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017707303,0.00041693167,0.0007574991,0.00011830923,0.000096906915,0.000042218107,0.00012694813,0.00025927124,0.000039790157],"category_scores_gemma":[0.00006973646,0.00020973315,0.0002654232,0.00019907656,0.00017517341,0.0001421486,0.000040713323,0.00028601268,0.00001341358],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045270156,0.0029626875,0.87077135,0.00012669251,0.014274101,0.0014590927,0.0049599777,0.0000044214453,0.034232963,0.000090684196,0.00017304957,0.06641796],"study_design_scores_gemma":[0.01113979,0.0036628733,0.939024,0.00030773884,0.0025857396,0.0032348651,0.00026933133,0.000023621871,0.039251726,0.0000500683,0.00020424585,0.00024601657],"about_ca_topic_score_codex":0.0023455664,"about_ca_topic_score_gemma":0.00024886744,"teacher_disagreement_score":0.06825263,"about_ca_system_score_codex":0.0017780256,"about_ca_system_score_gemma":0.0005708758,"threshold_uncertainty_score":0.8552669},"labels":[],"label_agreement":null},{"id":"W4405042935","doi":"10.1182/blood-2024-203757","title":"Asciminib (ASC) Demonstrates Favorable Safety and Tolerability Compared with Each Investigator-Selected Tyrosine Kinase Inhibitor (IS TKI) in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Pivotal Phase 3 ASC4FIRST Study","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Tolerability; Medicine; Myeloid leukemia; Tyrosine-kinase inhibitor; Internal medicine; Tyrosine kinase; Nilotinib; Phases of clinical research; Oncology; Imatinib; Pharmacology; Adverse effect; Clinical trial; Cancer; Receptor","score_opus":0.01849470641750113,"score_gpt":0.2865542485673685,"score_spread":0.2680595421498674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405042935","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9847217,0.009275536,0.000007021879,0.00066964957,0.000102946775,0.004709022,0.0001365108,0.00018389798,0.00019372406],"genre_scores_gemma":[0.9980341,0.00032642463,0.00014707171,0.00016776902,0.0002694426,0.00060053606,0.00029938552,0.00010034259,0.000054920783],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9946915,0.00056126894,0.0013608455,0.0015017901,0.00077473157,0.0011098911],"domain_scores_gemma":[0.9975636,0.0006956191,0.00017895138,0.0010038705,0.000107290965,0.00045064854],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011427611,0.000826672,0.0013410675,0.0005550819,0.00017765218,0.0002001247,0.0003509501,0.00027452272,0.00012554399],"category_scores_gemma":[0.00039855557,0.0006184678,0.000109638706,0.00295143,0.0005029397,0.00042913374,0.00012759453,0.0014423628,0.000022881626],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0075525143,0.049167987,0.79894096,0.0033608673,0.0015374703,0.020905137,0.03162359,0.001017382,0.065621935,0.00008478431,0.0013631661,0.01882419],"study_design_scores_gemma":[0.48826236,0.026554747,0.3921655,0.0062463954,0.0020035685,0.0010522164,0.005980882,0.030556817,0.043361895,0.00012026349,0.0015697625,0.002125591],"about_ca_topic_score_codex":0.0060391296,"about_ca_topic_score_gemma":0.026446847,"teacher_disagreement_score":0.48070985,"about_ca_system_score_codex":0.007971295,"about_ca_system_score_gemma":0.010359843,"threshold_uncertainty_score":0.99962664},"labels":[],"label_agreement":null},{"id":"W4405045036","doi":"10.1182/blood-2024-204342","title":"Sex-Related Differences in CML Outcomes in a Real-World Prospective Registry (GQR LMC-NMP)","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal; Université Laval; Jewish General Hospital; McGill University; Centre intégré de santé et de services sociaux de Chaudière-Appalaches; Centre Intégré de Santé et de Services Sociaux des Laurentides","funders":"","keywords":"Medicine","score_opus":0.017467691490128792,"score_gpt":0.2875683838844543,"score_spread":0.27010069239432555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405045036","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9710439,0.0010375711,6.010374e-7,0.0007351989,0.00016932879,0.0007177805,0.000015178541,0.00020450368,0.026075961],"genre_scores_gemma":[0.9750648,0.00016283189,0.000119513395,0.000046525372,0.000059194404,0.00013115624,0.00002412175,0.000034985518,0.024356842],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99835587,0.00005398947,0.00041745853,0.00052187743,0.00028787612,0.00036295355],"domain_scores_gemma":[0.99925596,0.00018254694,0.000053047832,0.00039461357,0.000018558012,0.000095258874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001565707,0.0002487808,0.00057253346,0.00035365252,0.000023842522,0.000033052936,0.000113773545,0.0001386038,0.00016477349],"category_scores_gemma":[0.000104536,0.00019118747,0.00009701114,0.00072078087,0.000073848634,0.00007824115,0.000060298466,0.0005101595,0.00010992695],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000036910184,0.0009664089,0.99300814,0.00016192792,0.00031961754,0.0020587232,0.0015582686,6.886281e-7,0.00026672162,0.0006912316,0.0001191206,0.0008122712],"study_design_scores_gemma":[0.008290262,0.00020670341,0.9871193,0.0009093827,0.00021082527,0.0000758306,0.00026357875,0.00017301092,0.0013873613,0.0010474615,0.00012353764,0.0001927528],"about_ca_topic_score_codex":0.00224996,"about_ca_topic_score_gemma":0.0027806442,"teacher_disagreement_score":0.008253352,"about_ca_system_score_codex":0.00087431737,"about_ca_system_score_gemma":0.0004276837,"threshold_uncertainty_score":0.7796399},"labels":[],"label_agreement":null},{"id":"W4405047930","doi":"10.1182/blood-2024-204999","title":"Prognostic Implication of Framingham Risk Score As a Comorbidity Measure on Treatment Outcomes Following First-Line Tyrosine Kinase Inhibitor in Newly Diagnosed CML Patients","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"London Health Sciences Centre; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Comorbidity; Internal medicine; Framingham Risk Score; Tyrosine-kinase inhibitor; Oncology; Second line treatment; Tyrosine kinase; Disease; Cancer; Overall survival","score_opus":0.020487231727785323,"score_gpt":0.2813010690425929,"score_spread":0.26081383731480756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405047930","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955658,0.0014162549,0.000010554817,0.00029814485,0.00028305053,0.002029703,0.00013154837,0.00013503426,0.00012993725],"genre_scores_gemma":[0.99860567,0.00020373655,0.00018753445,0.00004640189,0.000102757884,0.00036334732,0.00031521032,0.000059531438,0.0001158032],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998002,0.000067867586,0.000530936,0.00055197557,0.00051329687,0.00033390746],"domain_scores_gemma":[0.99859846,0.00048715892,0.0001434619,0.00053501263,0.000078204255,0.00015769496],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000156071,0.0003680101,0.0006029679,0.0002455307,0.00006784043,0.00002630362,0.000089308116,0.00016086377,0.000028889148],"category_scores_gemma":[0.0009605523,0.00027247425,0.0002834234,0.00042341292,0.000037021055,0.0000870113,0.00004194334,0.00023310562,0.00007108795],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010360561,0.008086224,0.97510433,0.00020148268,0.00048348436,0.00040974427,0.0005725291,0.000021676895,0.00035977247,0.00001614825,0.00004876586,0.0145922275],"study_design_scores_gemma":[0.022384865,0.0035851516,0.95623195,0.0018187915,0.001408443,0.0000075270195,0.000024914147,0.00013898253,0.01390636,0.000063583095,0.00022096095,0.00020848648],"about_ca_topic_score_codex":0.0021021573,"about_ca_topic_score_gemma":0.0005893604,"teacher_disagreement_score":0.02228126,"about_ca_system_score_codex":0.001045085,"about_ca_system_score_gemma":0.00039763493,"threshold_uncertainty_score":0.99997276},"labels":[],"label_agreement":null},{"id":"W4405049186","doi":"10.1182/blood-2024-194223","title":"Biomarkers of Renal Health in Patients (pts) Treated with Fedratinib in the FREEDOM and FREEDOM2 Trials","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Intensive care medicine","score_opus":0.022741468250481678,"score_gpt":0.2896173974461189,"score_spread":0.26687592919563724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405049186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961425,0.0011294944,0.0000017583036,0.0005090293,0.000033427605,0.0015784323,0.000046406534,0.000021767757,0.00053715234],"genre_scores_gemma":[0.99947125,0.000060897997,0.00020078904,0.00005832372,0.000039352497,0.000054322623,0.000060438357,0.000017372957,0.00003722747],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984329,0.00031856852,0.00052964146,0.0002695025,0.0002495681,0.00019986278],"domain_scores_gemma":[0.9992483,0.00030406573,0.00010639867,0.00025862697,0.000022240967,0.00006033106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009478392,0.00015098903,0.00053653744,0.0002159118,0.000020802543,0.0000181306,0.000064666914,0.00005416836,0.000026171054],"category_scores_gemma":[0.00015916902,0.00008213481,0.000043609693,0.0005014243,0.000070744856,0.000044864995,0.00001793026,0.0001450334,0.0000027736955],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012095209,0.003903998,0.9795672,0.00023322989,0.00069848425,0.00025215183,0.0032120964,0.000003893258,0.00023132843,0.000040725612,0.0008063701,0.009840986],"study_design_scores_gemma":[0.069750175,0.006756782,0.9199171,0.0013129102,0.0004909443,0.000042590942,0.0007067863,0.00016234025,0.00048270606,0.000027997954,0.0002081548,0.0001414836],"about_ca_topic_score_codex":0.0027275472,"about_ca_topic_score_gemma":0.001319128,"teacher_disagreement_score":0.068540655,"about_ca_system_score_codex":0.00016227124,"about_ca_system_score_gemma":0.00036576577,"threshold_uncertainty_score":0.41232538},"labels":[],"label_agreement":null},{"id":"W4405049187","doi":"10.1182/blood-2024-211439","title":"Real-World Experience of Asciminib Treatment and Its Clinical Outcomes Including Cardiovascular (CV) Event-Free, Failure-Free Survival Associated with CV Comorbidity and Framingham CV Risk Score in Patients with Chronic Myeloid Leukemia","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Framingham Risk Score; Tolerability; Nilotinib; Blood pressure; Myocardial infarction; Hazard ratio; Coronary artery disease; Myeloid leukemia; Disease; Adverse effect; Imatinib; Confidence interval","score_opus":0.03312432397367527,"score_gpt":0.2997797406652448,"score_spread":0.26665541669156956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405049187","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99495757,0.002904833,0.000009242152,0.00006371576,0.00015992191,0.0014194482,0.00022273396,0.00012010289,0.00014240891],"genre_scores_gemma":[0.9974185,0.0015688875,0.0003173631,0.0000124032495,0.000099751494,0.00012754962,0.0001247377,0.000085475825,0.00024531584],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99630314,0.00031537915,0.0008221476,0.0010459357,0.00092208944,0.0005912997],"domain_scores_gemma":[0.9973868,0.00065644516,0.0002883434,0.0012183076,0.00014841756,0.0003016568],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00073399075,0.00058421236,0.001606667,0.00027046568,0.0001433891,0.00005192235,0.0002615557,0.00024351773,0.000021948003],"category_scores_gemma":[0.00065522623,0.00040672952,0.00027212768,0.0006250679,0.00031330626,0.00022782123,0.00035828594,0.0005305687,0.000002773381],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029260843,0.00097621913,0.99068964,0.00020447808,0.004073723,0.00026971154,0.0010269526,0.000031742085,0.00003069168,0.000022116516,0.000027062133,0.0023550524],"study_design_scores_gemma":[0.042235028,0.0025110827,0.94967616,0.001397416,0.0026255841,0.00001960466,0.00015154615,0.0003009367,0.00058387296,0.000020038198,0.00010434345,0.0003743975],"about_ca_topic_score_codex":0.0034755643,"about_ca_topic_score_gemma":0.008540049,"teacher_disagreement_score":0.04194242,"about_ca_system_score_codex":0.0021805281,"about_ca_system_score_gemma":0.0011499627,"threshold_uncertainty_score":0.9998385},"labels":[],"label_agreement":null},{"id":"W4405049461","doi":"10.1182/blood-2024-202565","title":"Inflammation in Myeloproliferative Philadelphia Chromosome Negative Neoplasms - Relationship with Biomarkers of Disease Activity","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Windsor Regional Hospital; Ottawa Hospital; University of Ottawa; Juravinski Cancer Centre; Population Health Research Institute; McMaster University","funders":"","keywords":"Inflammation; Disease; Philadelphia chromosome; Medicine; Polycythemia vera; Internal medicine; Immunology; Pathology; Oncology; Genetics; Biology; Chromosomal translocation","score_opus":0.016408615710562548,"score_gpt":0.26489348507884714,"score_spread":0.2484848693682846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405049461","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962173,0.00028070662,0.000054669952,0.0016243758,0.00004288206,0.00077359495,0.000040353447,0.000081256316,0.0008848448],"genre_scores_gemma":[0.99905646,0.00002269868,0.000481687,0.000011600135,0.000081524566,0.00011002785,0.00006069575,0.000026601585,0.00014867846],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989284,0.000070456284,0.00023120973,0.000307725,0.00028377632,0.00017842422],"domain_scores_gemma":[0.99920833,0.00028696368,0.00007794161,0.00024028146,0.00005707367,0.0001294006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011684518,0.00017554424,0.0002478314,0.00025236516,0.000035392695,0.000017226559,0.00004387112,0.0000744812,0.000057006502],"category_scores_gemma":[0.00018351055,0.00013724026,0.000058840113,0.0006423758,0.00010786601,0.0002679,0.000021659485,0.00020809677,0.000026089747],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007623493,0.002585151,0.9235204,0.002979463,0.003165939,0.0021332218,0.008739651,0.0004130507,0.03862183,0.0034269423,0.00015658264,0.0066343104],"study_design_scores_gemma":[0.0100802025,0.0007367688,0.91730946,0.0016169547,0.00076721073,0.00006440105,0.00015240161,0.0022588926,0.06606786,0.00066222344,0.00005284874,0.00023076756],"about_ca_topic_score_codex":0.000084524974,"about_ca_topic_score_gemma":0.00010061093,"teacher_disagreement_score":0.027446032,"about_ca_system_score_codex":0.000370756,"about_ca_system_score_gemma":0.0009968441,"threshold_uncertainty_score":0.5596496},"labels":[],"label_agreement":null},{"id":"W4405049588","doi":"10.1182/blood-2024-207213","title":"Impact of Adverse Events on Health-Related Quality of Life in Patients with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs) - Early Results of the Survey on Humanistic Burden of Intolerance to First or Second TKIs (SHIFT) Study","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Myeloid leukemia; Adverse effect; Quality of life (healthcare); Tyrosine kinase; Tyrosine-kinase inhibitor; Leukemia; Imatinib; Oncology; Internal medicine; Immunology; Cancer; Receptor","score_opus":0.0210851803101542,"score_gpt":0.2880698534737959,"score_spread":0.26698467316364166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405049588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99526316,0.0001692462,3.097241e-7,0.00003889303,0.00006042848,0.003125008,0.0012702488,0.000029112412,0.00004362191],"genre_scores_gemma":[0.9995285,0.000010242604,0.000013269543,0.000011315127,0.000025790376,0.00004265506,0.0001657252,0.000067338435,0.00013516391],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957991,0.0004895936,0.0017307495,0.00063890044,0.00094369485,0.00039794797],"domain_scores_gemma":[0.99706835,0.000482377,0.0009424645,0.0010394383,0.00025303708,0.000214338],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00076668477,0.00044943497,0.001349937,0.00035653036,0.000053717984,0.0000040558525,0.00024713206,0.00013371928,0.0000689702],"category_scores_gemma":[0.0004807027,0.00025799993,0.00015773693,0.0014795996,0.00015264173,0.000077829194,0.000076919285,0.00038250626,0.0000057905745],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02906135,0.0061758915,0.9550619,0.001050305,0.0013570567,0.000029785118,0.004928029,0.0017936343,0.00028670882,0.0000026367584,0.00007265596,0.00018004587],"study_design_scores_gemma":[0.04722404,0.03652993,0.9082095,0.0050389473,0.00023953318,0.0000012252914,0.00007797434,0.000025800286,0.0024606842,0.0000012792843,0.0000018571333,0.00018921353],"about_ca_topic_score_codex":0.08414847,"about_ca_topic_score_gemma":0.03300291,"teacher_disagreement_score":0.051145554,"about_ca_system_score_codex":0.0023871271,"about_ca_system_score_gemma":0.0026204449,"threshold_uncertainty_score":0.99998724},"labels":[],"label_agreement":null},{"id":"W4405050586","doi":"10.1182/blood-2024-202475","title":"Lamotrigine and Anti-Epileptic Medications in HLH: A Systematic Review","year":2024,"lang":"en","type":"review","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Dalhousie University","funders":"","keywords":"Lamotrigine; Medicine; Epilepsy; Pharmacology; Psychiatry","score_opus":0.030019270485542513,"score_gpt":0.34494958712287566,"score_spread":0.3149303166373331,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405050586","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000010593138,0.99375314,5.756297e-7,0.00018474364,0.00008673489,0.005228413,0.000032192802,0.00008940425,0.00061421434],"genre_scores_gemma":[0.000014606482,0.9968599,0.00010032434,0.00013080245,0.00011038173,0.0012505273,0.00022026166,0.00007791603,0.0012352923],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99750674,0.00016189563,0.0011992309,0.00052857527,0.00033075255,0.00027280903],"domain_scores_gemma":[0.9984791,0.0002189682,0.0002831754,0.000812165,0.000031572745,0.00017499724],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00047000733,0.00044214822,0.004205891,0.00034790486,0.000021788648,0.000019670953,0.00015317909,0.00023232172,0.00007624307],"category_scores_gemma":[0.0004198586,0.00029291338,0.0003568544,0.0007524283,0.000052973475,0.000028923447,0.00008730135,0.00052925147,0.000703071],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[2.0488852e-7,0.00021092093,0.000004342652,0.9890146,0.0010137287,0.00051344576,0.000017309665,1.1946739e-9,6.3219964e-8,0.000051217343,0.00044620284,0.00872791],"study_design_scores_gemma":[0.000895791,0.00004180185,0.0000034765696,0.8382578,0.07324846,0.002285388,0.000002626412,0.0000016748819,8.04023e-8,0.0000056892973,0.08508671,0.00017048011],"about_ca_topic_score_codex":0.000017774264,"about_ca_topic_score_gemma":0.000008740339,"teacher_disagreement_score":0.15075684,"about_ca_system_score_codex":0.00040314082,"about_ca_system_score_gemma":0.0010729843,"threshold_uncertainty_score":0.9999523},"labels":[],"label_agreement":null},{"id":"W4405050748","doi":"10.1182/blood-2024-208480","title":"Zelenirstat Nmt Inhibitor in Patients with Relapsed/Refractory B-Cell Lymphoma and Acute Myelogenous Leukemia: Mechanistic Insights and Clinical Outcomes","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Spinal Cord Injury BC; University of British Columbia; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Leukemia; Refractory (planetary science); Internal medicine; Lymphoma; Oncology; Cancer research; Biology","score_opus":0.008041097237837361,"score_gpt":0.24283727096826185,"score_spread":0.2347961737304245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405050748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99579126,0.002649098,0.00000815226,0.00005680294,0.00026061575,0.0007119831,0.00003433314,0.00011708207,0.00037064884],"genre_scores_gemma":[0.9974526,0.0009079262,0.0006585388,0.00018305545,0.00009842663,0.000029726803,0.00006934753,0.00007175844,0.00052860385],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980208,0.00006899879,0.0005039399,0.0006934001,0.00034905897,0.00036377093],"domain_scores_gemma":[0.9989081,0.00032023058,0.0000838661,0.0003630457,0.000049860424,0.00027489732],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012886061,0.00034931378,0.0006184299,0.0002012917,0.00007057507,0.00004876993,0.00006904455,0.00027081228,0.000014733091],"category_scores_gemma":[0.000065821194,0.0002451629,0.00007834718,0.00019502632,0.00013858998,0.00013659902,0.00010828455,0.00033918535,0.000040357274],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008464008,0.004766338,0.9708341,0.00052463217,0.0015212928,0.0038783478,0.0010375007,2.9698055e-7,0.00033813814,0.00014147686,0.00022909188,0.015882393],"study_design_scores_gemma":[0.075946644,0.0051381267,0.91235685,0.0005954528,0.0026032543,0.00020537278,0.00008905672,0.00009488904,0.00095990696,0.00019103958,0.001338375,0.00048102954],"about_ca_topic_score_codex":0.00011046155,"about_ca_topic_score_gemma":0.00012426918,"teacher_disagreement_score":0.07510024,"about_ca_system_score_codex":0.0006265222,"about_ca_system_score_gemma":0.0008161346,"threshold_uncertainty_score":0.9997453},"labels":[],"label_agreement":null},{"id":"W4405054996","doi":"10.1182/blood-2024-211186","title":"High-Dimensional Single-Cell Analysis of Clinical-Grade Flow Cytometry Explains the Unpredictable Complex Shifts of Patient-Specific Immunophenotypes during B-ALL Relapse Progression","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"","keywords":"Flow cytometry; Immunophenotyping; Medicine; Immunology","score_opus":0.03589947275361183,"score_gpt":0.3035207173792604,"score_spread":0.26762124462564857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405054996","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901196,0.0083228415,0.000019939585,0.00015006268,0.0003384008,0.00048088437,0.00014695748,0.000101479265,0.00031983],"genre_scores_gemma":[0.9934856,0.0002635151,0.0054589207,0.00003251764,0.00013307373,0.000024898101,0.00038901894,0.000047542293,0.00016487786],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99692655,0.00017308335,0.0012097228,0.0005296756,0.00081412354,0.00034682945],"domain_scores_gemma":[0.997958,0.0005772027,0.0003577432,0.00084377907,0.00012198428,0.00014130109],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004003707,0.0002707824,0.0009152496,0.00047121634,0.00009303913,0.000021346814,0.00020046285,0.00017298524,0.00042172562],"category_scores_gemma":[0.00010604712,0.00017724001,0.00053262524,0.001502693,0.00021486687,0.00008393826,0.00018171174,0.0003808323,0.00002626274],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031073035,0.032329913,0.1563946,0.002610843,0.037074905,0.0013709413,0.00521628,0.003221176,0.7245601,0.00038976767,0.003030887,0.030693278],"study_design_scores_gemma":[0.036846418,0.0050248345,0.48124138,0.0036666046,0.032990094,0.00011881936,0.000855153,0.015871488,0.41814533,0.00016160068,0.004112423,0.0009658512],"about_ca_topic_score_codex":0.00006520124,"about_ca_topic_score_gemma":0.000008215532,"teacher_disagreement_score":0.32484677,"about_ca_system_score_codex":0.00017598734,"about_ca_system_score_gemma":0.0002062952,"threshold_uncertainty_score":0.72276384},"labels":[],"label_agreement":null},{"id":"W4405126133","doi":"10.1182/blood-2024-205641","title":"A CD33-Deleted Allograft (Trem-cel) Enables Post-Hematopoietic Cell Transplant (HCT) Maintenance Dosing of Gemtuzumab Ozogamicin (GO) with Therapeutic Levels of Drug Exposure and Low Hematologic and Hepatic Toxicity in Patients with High-Risk Acute Myeloid Leukemia (AML)","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Gemtuzumab ozogamicin; Calicheamicin; Dosing; Medicine; Toxicity; CD33; Pharmacology; Hematopoietic cell; Hematopoietic stem cell transplantation; Drug; Haematopoiesis; Internal medicine; Transplantation; Stem cell; Myeloid leukemia; Biology; CD34","score_opus":0.0047083901957352845,"score_gpt":0.19473791786580147,"score_spread":0.19002952767006617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405126133","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994651,0.0035298613,0.00009228146,0.00007273488,0.000030281986,0.0012719752,0.00023641824,0.00007753273,0.0000379099],"genre_scores_gemma":[0.99768746,0.0006503815,0.0013340639,0.00006100389,0.00001047991,0.00004462385,0.000060970295,0.00007465963,0.00007635198],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974648,0.00013112827,0.00067456916,0.0007046389,0.0004934132,0.00053145795],"domain_scores_gemma":[0.9986888,0.00025782333,0.00029048033,0.0004736421,0.00014188871,0.00014735253],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020709369,0.00051504234,0.0010887128,0.00028816346,0.00006398545,0.000028585291,0.00013961007,0.00017654356,0.00002066482],"category_scores_gemma":[0.000017113021,0.00033934155,0.00008609163,0.00045877576,0.00033106864,0.00015085851,0.000050059465,0.00039003792,0.0000013950876],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030667204,0.0027638276,0.87729806,0.008340555,0.0024311098,0.0013133923,0.010129052,0.00008332601,0.09225197,0.00008906209,0.000009725759,0.0022232025],"study_design_scores_gemma":[0.055661716,0.007144388,0.6133929,0.010109494,0.005759753,0.00090498535,0.00086452084,0.00092776254,0.30418122,0.0001972148,0.0000059051863,0.0008501868],"about_ca_topic_score_codex":0.00059578405,"about_ca_topic_score_gemma":0.00038145066,"teacher_disagreement_score":0.2639052,"about_ca_system_score_codex":0.00033586915,"about_ca_system_score_gemma":0.0005452356,"threshold_uncertainty_score":0.9999059},"labels":[],"label_agreement":null},{"id":"W4405748861","doi":"10.1016/j.jval.2024.10.251","title":"CO175 Clinical Outcomes of Interventions in Patients With Newly Diagnosed Chronic Myeloid Leukemia: A Systematic Literature Review","year":2024,"lang":"en","type":"article","venue":"Value in Health","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Amorfix (Canada)","funders":"","keywords":"Medicine; Myeloid leukemia; Systematic review; Psychological intervention; Intensive care medicine; Chronic leukemia; Internal medicine; Oncology; Leukemia; MEDLINE; Acute leukemia; Psychiatry; Biology","score_opus":0.04815711128303091,"score_gpt":0.36623023945130506,"score_spread":0.31807312816827416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405748861","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.56187254,0.4290669,0.000033139906,0.0018638511,0.0005273023,0.0063718962,0.00007061925,0.00009138911,0.00010240384],"genre_scores_gemma":[0.9136427,0.08318002,0.00088857615,0.0009886218,0.00009083774,0.00043792452,0.00022363784,0.000075251715,0.00047242432],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9956278,0.00067710417,0.0023170009,0.00049320405,0.00047169498,0.00041317727],"domain_scores_gemma":[0.9978185,0.0008618521,0.00038417568,0.0006472066,0.00009239493,0.00019583208],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017098899,0.00028183399,0.0017284226,0.00038166842,0.000023849263,0.000019480462,0.00015033125,0.00015696819,0.000047158974],"category_scores_gemma":[0.00082032796,0.00018944536,0.00037263057,0.0010858711,0.00006589238,0.0001188585,0.000053228887,0.0007559698,0.000040798746],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006402106,0.00066812104,0.3988498,0.5964465,0.00023540367,0.00025388508,0.0004120769,0.00009904669,1.4012247e-7,0.00023694585,0.0007093728,0.002024678],"study_design_scores_gemma":[0.0062331636,0.0015006311,0.33592665,0.65515816,0.00019520946,0.00002213117,0.000021369324,0.00067938794,5.489644e-7,0.000019845149,0.00012470174,0.00011819697],"about_ca_topic_score_codex":0.000817641,"about_ca_topic_score_gemma":0.00029194515,"teacher_disagreement_score":0.3517702,"about_ca_system_score_codex":0.005131826,"about_ca_system_score_gemma":0.0028267922,"threshold_uncertainty_score":0.99868727},"labels":[],"label_agreement":null},{"id":"W4405963592","doi":"10.7150/thno.105729","title":"Shear stress unveils patient-specific transcriptional signatures in PAH: Towards personalized molecular diagnostics","year":2024,"lang":"en","type":"article","venue":"Theranostics","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Computational biology; Medicine; Nanotechnology; Chemistry; Biology; Materials science","score_opus":0.015962013516629393,"score_gpt":0.2670989557063386,"score_spread":0.2511369421897092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405963592","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8960963,0.09457394,0.0028077648,0.0015507946,0.0010257734,0.0011168593,0.00043505474,0.0006709215,0.001722607],"genre_scores_gemma":[0.99305797,0.004056679,0.0014228384,0.00058415503,0.00020514391,0.000052987358,0.00021026128,0.00015938561,0.00025058907],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99807346,0.00008771474,0.00037002104,0.00043560733,0.000613923,0.0004192578],"domain_scores_gemma":[0.9990995,0.00031097658,0.000031975327,0.00031641143,0.000078776415,0.00016234559],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000102324186,0.0003151634,0.00038160235,0.00019706927,0.00002886969,0.000058022422,0.000117359275,0.00021347601,0.00059863523],"category_scores_gemma":[0.0001125224,0.0002699135,0.000179906,0.000337892,0.00014633097,0.000064741995,0.000023884535,0.0004912752,0.000051468876],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005231837,0.007580101,0.012255544,0.0042277323,0.0042035435,0.04693176,0.050217725,0.008829899,0.37241617,0.16257021,0.0460967,0.2794388],"study_design_scores_gemma":[0.038049705,0.004620464,0.06463153,0.009942022,0.0020217772,0.0005292368,0.00267636,0.021155996,0.12273666,0.010145211,0.72019833,0.0032926816],"about_ca_topic_score_codex":0.000056410223,"about_ca_topic_score_gemma":0.000007507986,"teacher_disagreement_score":0.67410165,"about_ca_system_score_codex":0.0006824364,"about_ca_system_score_gemma":0.00044116427,"threshold_uncertainty_score":0.9999753},"labels":[],"label_agreement":null},{"id":"W4406158698","doi":"10.1182/blood.2024026515","title":"Introduction to a series of reflections on a quarter century of TKIs for CML","year":2025,"lang":"en","type":"review","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Series (stratigraphy); History; Medicine; Biology","score_opus":0.034431397373121723,"score_gpt":0.3589982414632105,"score_spread":0.3245668440900888,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406158698","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000061457526,0.99433726,0.00003935956,0.000491097,0.0005295015,0.002715292,0.00026725064,0.000036404945,0.0015223792],"genre_scores_gemma":[0.000017244301,0.9919932,0.002256131,0.000026863645,0.00083655067,0.0005624294,0.00026430303,0.000029194865,0.0040140953],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988343,0.000039815422,0.0004989472,0.00032952253,0.00014615494,0.00015125549],"domain_scores_gemma":[0.99896485,0.00010735863,0.00022118574,0.0005342328,0.000118817145,0.00005354466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008256627,0.00022211256,0.0012565759,0.0003358921,0.000026482889,0.0000030276753,0.00006915914,0.0001721408,0.00006007032],"category_scores_gemma":[0.00023430276,0.00017531535,0.00040875486,0.0004067973,0.000023982973,0.000020118741,0.0000232544,0.00013345352,0.000013945594],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047462608,0.0036351322,0.000008449329,0.19611463,0.004381111,0.000010941759,0.0005770975,7.3540787e-7,0.00023184987,0.0010728562,0.037983425,0.75550914],"study_design_scores_gemma":[0.001547701,0.0015720538,0.000004501352,0.014355369,0.005184474,0.000058348294,0.000037948343,5.127779e-8,0.00043720426,0.000013132627,0.97669274,0.00009649103],"about_ca_topic_score_codex":0.000021793294,"about_ca_topic_score_gemma":0.000016427826,"teacher_disagreement_score":0.9387093,"about_ca_system_score_codex":0.00029552003,"about_ca_system_score_gemma":0.0007533571,"threshold_uncertainty_score":0.7149152},"labels":[],"label_agreement":null},{"id":"W4406184503","doi":"10.1177/2050313x241311341","title":"A case of pityriasis rubra pilaris secondary to ponatinib","year":2025,"lang":"en","type":"article","venue":"SAGE Open Medical Case Reports","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne; Université Laval; Université de Sherbrooke","funders":"","keywords":"Medicine; Ponatinib; Pityriasis rubra pilaris; Dermatology; Nilotinib; Tyrosine-kinase inhibitor; Triamcinolone acetonide; Myeloid leukemia; Cancer; Surgery; Psoriasis; Internal medicine; Imatinib","score_opus":0.020616701878592623,"score_gpt":0.34450511325370575,"score_spread":0.32388841137511315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406184503","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9334459,0.0005285378,0.00035533507,0.0028008674,0.0005020643,0.0019969947,0.000051648156,0.00005783105,0.060260862],"genre_scores_gemma":[0.9884179,0.000042746782,0.0025565359,0.002832379,0.00009909515,0.00015336572,0.000056531506,0.000032335232,0.005809103],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9968905,0.00012231327,0.00115114,0.0007087736,0.00071991177,0.00040740246],"domain_scores_gemma":[0.99717987,0.00032180527,0.0002681974,0.0012051484,0.0001610027,0.00086395966],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016270139,0.0002744855,0.00087534677,0.00023680762,0.00013908342,0.000041665604,0.00015286647,0.0002801044,0.00885567],"category_scores_gemma":[0.0036866115,0.00023117842,0.00018098933,0.00064990396,0.0001400393,0.000119796845,0.0007745644,0.00052543706,0.000031987987],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013794468,0.00038732882,0.0013442778,0.00022616929,0.00027881406,0.8154151,0.0003449674,4.6242417e-7,0.0001169332,0.0000445523,0.0085576475,0.17314583],"study_design_scores_gemma":[0.0040594866,0.00037832002,0.001115474,0.0010892825,0.0004885173,0.9627398,0.00066578545,0.00005442153,0.0039884956,0.0002498695,0.024947165,0.00022332964],"about_ca_topic_score_codex":0.00610268,"about_ca_topic_score_gemma":0.0008750001,"teacher_disagreement_score":0.1729225,"about_ca_system_score_codex":0.0005695381,"about_ca_system_score_gemma":0.004465462,"threshold_uncertainty_score":0.99205035},"labels":[],"label_agreement":null},{"id":"W4406227864","doi":"10.1080/14796694.2024.2439178","title":"Asciminib versus bosutinib following 2 or more prior therapies in chronic myeloid leukemia: a plain language summary of the ASCEMBL study","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Bosutinib; Medicine; Myeloid leukemia; Oncology; Side effect (computer science); Internal medicine; Tyrosine-kinase inhibitor; Drug; Imatinib; Pharmacology; Nilotinib; Cancer","score_opus":0.017235741951038337,"score_gpt":0.3434522840867526,"score_spread":0.32621654213571427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406227864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97976744,0.004988883,0.0000016260575,0.0031967713,0.0020699808,0.002045688,0.0000139563645,0.000066189066,0.007849479],"genre_scores_gemma":[0.99293983,0.00016890554,0.00026578415,0.00057477236,0.0005348677,0.00021770629,0.0000262773,0.000037471924,0.005234357],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99774784,0.0003356924,0.00057086826,0.00049987907,0.00034873543,0.00049699534],"domain_scores_gemma":[0.99823296,0.0006201809,0.00019705776,0.00083537603,0.000043606182,0.00007080611],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047760163,0.0003296282,0.0008890213,0.00024144199,0.00012430978,0.000009324972,0.00040084412,0.00040124176,0.00018690765],"category_scores_gemma":[0.00026857137,0.00020432321,0.00026228785,0.00079734524,0.00014801319,0.000059118513,0.00025547,0.0007330067,0.000011337805],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.049244966,0.008422371,0.2517708,0.0019697223,0.011206975,0.0106235705,0.13682447,0.0001748746,0.03569643,0.0010369504,0.042035148,0.45099372],"study_design_scores_gemma":[0.15015338,0.010927065,0.5507828,0.0013949478,0.002163374,0.00012069149,0.1169752,0.00020153864,0.004838048,0.000034229095,0.16173495,0.0006737412],"about_ca_topic_score_codex":0.0005202632,"about_ca_topic_score_gemma":0.00855107,"teacher_disagreement_score":0.45031998,"about_ca_system_score_codex":0.008016142,"about_ca_system_score_gemma":0.006951465,"threshold_uncertainty_score":0.9986782},"labels":[],"label_agreement":null},{"id":"W4406414224","doi":"10.1016/s1553-3212(08)70261-9","title":"10.1016/s1553-3212(08)70261-9","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Natalizumab; Medicine; Immunology; Multiple sclerosis","score_opus":0.007462633821043905,"score_gpt":0.20388252322879102,"score_spread":0.19641988940774713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406414224","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0081647085,0.00017013148,4.2446098e-7,0.00063391717,0.000002270845,0.0004558535,0.000016206297,0.00022476412,0.9903317],"genre_scores_gemma":[0.0007789782,0.0000011892503,0.00030684014,0.00016159673,0.00026877125,0.0000412516,0.00006756852,0.00005259553,0.99832124],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986721,0.00002735351,0.00023318703,0.0003490883,0.00031101817,0.00040719946],"domain_scores_gemma":[0.99896646,0.000046779263,0.000030858224,0.0005767466,0.000045296507,0.00033386023],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000093473616,0.00021914454,0.00032357473,0.000090923146,0.00006351173,0.000018484454,0.00013587312,0.000101097045,0.9990768],"category_scores_gemma":[0.000047993446,0.00019529663,0.000105792285,0.00023520514,0.000040062067,0.00006331974,0.0000379152,0.00016219329,0.99872667],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029128665,0.00016007508,0.0000014311133,0.000017867878,0.00008948632,0.00009946616,0.00003053915,0.000013621599,0.00013819961,5.840535e-7,0.4742399,0.52491754],"study_design_scores_gemma":[0.0024012472,0.0004589835,0.0003411639,0.00007101819,0.000119458404,0.00011728323,0.0000012045681,0.00018849844,0.00038112508,0.0000035932749,0.99573547,0.00018093288],"about_ca_topic_score_codex":0.00006265257,"about_ca_topic_score_gemma":2.5278635e-7,"teacher_disagreement_score":0.52473664,"about_ca_system_score_codex":0.0005568755,"about_ca_system_score_gemma":0.00019475837,"threshold_uncertainty_score":0.79639655},"labels":[],"label_agreement":null},{"id":"W4406423607","doi":"10.1016/s1541-9800(07)70287-9","title":"10.1016/s1541-9800(07)70287-9","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Imatinib mesylate; Scleroderma (fungus); Medicine; Imatinib; Systemic scleroderma; Pharmacology; Internal medicine; Immunology; Disease","score_opus":0.00765759275118989,"score_gpt":0.20517258636614336,"score_spread":0.19751499361495348,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406423607","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008213336,0.00017052366,2.6973268e-7,0.0006459367,0.0000022168192,0.00045824432,0.000017147246,0.00022127753,0.99027103],"genre_scores_gemma":[0.00075162953,0.0000011712536,0.0003015597,0.00015918864,0.00026559463,0.000043078708,0.00006989937,0.00005184141,0.99835604],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99867254,0.000027872198,0.0002343531,0.00035106577,0.0003054255,0.00040875617],"domain_scores_gemma":[0.99896103,0.00004855794,0.000030467443,0.0005796446,0.000045673554,0.000334625],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000094437346,0.00021971695,0.00032425788,0.00008627643,0.000062855564,0.000018567003,0.00013573992,0.000102173435,0.9993064],"category_scores_gemma":[0.00004878119,0.00019571286,0.00010635564,0.00021265946,0.000039707953,0.000063405394,0.000038233757,0.00016269123,0.99899095],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028136457,0.00015844393,0.0000016235196,0.000017764107,0.00008825344,0.000102371916,0.000027615468,0.000012433013,0.00012680802,4.141794e-7,0.4532051,0.5459778],"study_design_scores_gemma":[0.0023843385,0.0004556854,0.00034619262,0.00007342533,0.00012112811,0.00012410794,0.0000011555197,0.00013273703,0.00037113053,0.0000040281266,0.9958047,0.00018131454],"about_ca_topic_score_codex":0.00007431059,"about_ca_topic_score_gemma":3.2817093e-7,"teacher_disagreement_score":0.54579645,"about_ca_system_score_codex":0.00056043436,"about_ca_system_score_gemma":0.00019590388,"threshold_uncertainty_score":0.79809386},"labels":[],"label_agreement":null},{"id":"W4406466198","doi":"10.1016/s1553-3212(08)70279-6","title":"10.1016/s1553-3212(08)70279-6","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Natalizumab; Medicine; Virology; Multiple sclerosis; Immunology","score_opus":0.007460975307699833,"score_gpt":0.20389334129048195,"score_spread":0.1964323659827821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406466198","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008235354,0.00017446227,4.0053487e-7,0.00064788107,0.0000022937818,0.00045694812,0.000016270475,0.00022533129,0.99024105],"genre_scores_gemma":[0.0007647417,0.0000011960511,0.00031382043,0.00016119012,0.00026737095,0.000041185085,0.00006689935,0.000052654952,0.99833095],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986753,0.000027081436,0.00023345242,0.0003491794,0.0003040595,0.00041094993],"domain_scores_gemma":[0.9989649,0.000047712078,0.00003088769,0.000576668,0.00004527859,0.00033457374],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00009303355,0.00021915522,0.00032361044,0.00009106798,0.00006333751,0.000018215924,0.00013604251,0.00010204416,0.99905735],"category_scores_gemma":[0.000048101978,0.00019535374,0.00010606605,0.00023584763,0.000039985967,0.00006333473,0.00003881768,0.00016230895,0.9986441],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002973927,0.00015932202,0.0000014495987,0.000017836468,0.000088828405,0.000098095115,0.00003007773,0.000013778535,0.00013657827,6.042475e-7,0.46632358,0.53283244],"study_design_scores_gemma":[0.0024049892,0.00045969296,0.00034707063,0.00007151139,0.00011779799,0.000118830525,0.000001218378,0.00019020982,0.00034485126,0.0000035276657,0.9957594,0.00018088323],"about_ca_topic_score_codex":0.000068485555,"about_ca_topic_score_gemma":2.8218847e-7,"teacher_disagreement_score":0.5326516,"about_ca_system_score_codex":0.0005766967,"about_ca_system_score_gemma":0.00019811957,"threshold_uncertainty_score":0.7966294},"labels":[],"label_agreement":null},{"id":"W4406473076","doi":"10.1016/s1541-9800(06)71246-7","title":"10.1016/s1541-9800(06)71246-7","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Imatinib; Myeloid leukemia; Medicine; Leukemia; Chronic myeloid leukaemia; Cancer research; Oncology; Internal medicine","score_opus":0.007566881897098721,"score_gpt":0.20452830817059248,"score_spread":0.19696142627349375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406473076","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008276194,0.00016460706,2.7061452e-7,0.00070354366,0.0000015528509,0.0004588225,0.000018843462,0.00022157426,0.99015456],"genre_scores_gemma":[0.00073524035,0.000001110288,0.00028541108,0.00016317451,0.0002897955,0.00004188789,0.000095548676,0.00005189111,0.99833596],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986807,0.000027868144,0.00023383043,0.00034939163,0.00029761824,0.00041057094],"domain_scores_gemma":[0.9989706,0.00004755907,0.00002975996,0.0005765052,0.00004545401,0.00033012187],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000094320676,0.00021938894,0.00032308305,0.00009125574,0.00006243564,0.000018331213,0.00013490187,0.00010234441,0.9988327],"category_scores_gemma":[0.000048870752,0.0001954553,0.000104876184,0.00023551565,0.000039502465,0.00006176711,0.00003833713,0.00016336389,0.998585],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021378395,0.00015280867,0.0000017834546,0.000017663293,0.000085259824,0.00008902779,0.00002661151,0.000014022502,0.00016473987,3.9251776e-7,0.5813278,0.4179061],"study_design_scores_gemma":[0.0023934213,0.00046736372,0.0002810082,0.00007440908,0.00012086574,0.00012035013,0.000001152153,0.00014748077,0.00035674198,0.0000035750952,0.9958526,0.00018103835],"about_ca_topic_score_codex":0.000061821105,"about_ca_topic_score_gemma":3.0074347e-7,"teacher_disagreement_score":0.41772506,"about_ca_system_score_codex":0.0005564313,"about_ca_system_score_gemma":0.0001922546,"threshold_uncertainty_score":0.7970436},"labels":[],"label_agreement":null},{"id":"W4406484983","doi":"10.1007/s11523-024-01123-3","title":"Bosutinib for the Treatment of CML—Using it Safely: a Podcast","year":2025,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Pfizer","keywords":"Medicine; Bosutinib; Oncology; Bioinformatics; Cancer research; Dasatinib; Imatinib","score_opus":0.050757151797893,"score_gpt":0.38388280706674194,"score_spread":0.33312565526884896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406484983","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93926936,0.009268949,0.0035778699,0.021102738,0.0017480005,0.005132581,0.00016539471,0.0001262741,0.019608852],"genre_scores_gemma":[0.98141515,0.0005444806,0.008502195,0.0014143629,0.00026931037,0.00028788374,0.00009316434,0.000029651474,0.0074437847],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99892646,0.00005109494,0.00036063505,0.00024874846,0.00009579842,0.0003172372],"domain_scores_gemma":[0.9985945,0.0007151829,0.00013141605,0.00039221774,0.000107628184,0.00005903473],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012538806,0.00017226631,0.00052598264,0.00011358092,0.00010815662,0.0000034734994,0.00009261834,0.00016454469,0.0002632842],"category_scores_gemma":[0.000113233495,0.000109786175,0.00019572832,0.00023104857,0.00013684448,0.000017497907,0.000025154195,0.00008314685,0.000012741308],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013536068,0.011187778,0.023496004,0.00070731825,0.009458895,0.00040261904,0.008235363,0.0005876986,0.103544846,0.007397165,0.049564004,0.77188224],"study_design_scores_gemma":[0.023133727,0.006535377,0.006359738,0.0001095946,0.0020574436,0.00009692601,0.0008588134,0.0063839615,0.025919953,0.00041353065,0.92797613,0.00015478434],"about_ca_topic_score_codex":0.00033274337,"about_ca_topic_score_gemma":0.00013455962,"teacher_disagreement_score":0.8784121,"about_ca_system_score_codex":0.0023948182,"about_ca_system_score_gemma":0.0016585905,"threshold_uncertainty_score":0.6262366},"labels":[],"label_agreement":null},{"id":"W4406517917","doi":"10.1101/2025.01.14.632811","title":"Stress Granules Underlie Acute Myeloid Leukemia Stem Cell Survival and Stress Adaptation","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Princess Margaret Cancer Centre; McMaster University; University of Toronto; University Health Network","funders":"","keywords":"Myeloid leukemia; Stem cell; Adaptation (eye); Stress (linguistics); Medicine; Biology; Neuroscience; Cancer research; Cell biology","score_opus":0.018953582981747815,"score_gpt":0.23751530100031207,"score_spread":0.21856171801856425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406517917","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98584795,0.0046258154,0.0013208475,0.0002195177,0.0016421922,0.0019678245,0.0035413215,0.00064932177,0.00018521717],"genre_scores_gemma":[0.9919741,0.0032490655,0.0034508836,0.000120931356,0.0004472084,0.00028791104,0.000017598091,0.000174029,0.0002782646],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99552405,0.00021931285,0.0008634217,0.0017360477,0.0008125746,0.00084460515],"domain_scores_gemma":[0.9963023,0.00021059762,0.0005783749,0.0018180535,0.0005429149,0.000547756],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036736726,0.0010799146,0.0013398003,0.00048760197,0.00024563694,0.00023333583,0.00047090458,0.0009979405,0.0000462115],"category_scores_gemma":[0.0000478839,0.0011201001,0.00025848605,0.0004939314,0.00021863566,0.00018263,0.00072991103,0.0012990076,0.000043476168],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037608175,0.004771539,0.34247333,0.052457664,0.018367281,0.0062967036,0.0011026437,0.0053675775,0.5542238,0.006681982,0.0034246545,0.0010720307],"study_design_scores_gemma":[0.015687698,0.0005384876,0.3375215,0.008356806,0.0063894573,3.561504e-7,0.00027491464,0.007802655,0.6166959,0.00001008026,0.0034131056,0.0033090634],"about_ca_topic_score_codex":0.00042147478,"about_ca_topic_score_gemma":0.000054401957,"teacher_disagreement_score":0.06247212,"about_ca_system_score_codex":0.0034490023,"about_ca_system_score_gemma":0.0044836537,"threshold_uncertainty_score":0.9991249},"labels":[],"label_agreement":null},{"id":"W4406546626","doi":"10.1016/s1541-9800(09)70074-2","title":"10.1016/s1541-9800(09)70074-2","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Imatinib; Multiple sclerosis; Medicine; Intensive care medicine; Oncology; Internal medicine; Immunology","score_opus":0.007720203464742671,"score_gpt":0.2056780698692173,"score_spread":0.19795786640447463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406546626","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0062588505,0.00022698093,2.8430284e-7,0.0006285558,0.0000022682052,0.00046209895,0.000017468978,0.00022104984,0.99218243],"genre_scores_gemma":[0.0004232458,0.0000015485224,0.0003027695,0.00012485796,0.00027559092,0.00004215146,0.00006939739,0.000051913845,0.99870855],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986691,0.000027607184,0.00023474617,0.00034981215,0.000307701,0.00041102082],"domain_scores_gemma":[0.9989608,0.000048718597,0.000030509864,0.000580318,0.000045602796,0.00033405697],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00009663847,0.00021970044,0.00032379583,0.000091759925,0.000062583415,0.00001828241,0.00013571953,0.00010273092,0.99898547],"category_scores_gemma":[0.0000477428,0.00019570751,0.000106289466,0.00023441117,0.000039828923,0.00006297062,0.00003828649,0.0001631893,0.9984226],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026082582,0.00014297127,0.0000013521744,0.000020891093,0.00007986296,0.000089192516,0.000026691328,0.000011009954,0.000106599226,3.0570916e-7,0.36874387,0.63051647],"study_design_scores_gemma":[0.0023964937,0.00045423722,0.00024913746,0.000072633906,0.000120478835,0.000119273755,0.0000012326677,0.00013314653,0.00038558326,0.000003862145,0.99588275,0.00018117533],"about_ca_topic_score_codex":0.00007752743,"about_ca_topic_score_gemma":3.8987002e-7,"teacher_disagreement_score":0.6303353,"about_ca_system_score_codex":0.00056793506,"about_ca_system_score_gemma":0.0001938502,"threshold_uncertainty_score":0.7980721},"labels":[],"label_agreement":null},{"id":"W4406547197","doi":"10.1016/s1541-9800(06)71204-2","title":"10.1016/s1541-9800(06)71204-2","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Natalizumab; Medicine; Risk analysis (engineering); Multiple sclerosis; Immunology","score_opus":0.007656082178041335,"score_gpt":0.20489843406515906,"score_spread":0.19724235188711772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406547197","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0093573015,0.00017070644,3.0551539e-7,0.00065664,0.00000155561,0.00046528687,0.000017873495,0.00021862284,0.9891117],"genre_scores_gemma":[0.0007181414,0.0000012329857,0.00032683188,0.00016390074,0.00026190936,0.000043669832,0.000092836584,0.000052597847,0.9983389],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998656,0.000028324868,0.00023669106,0.00035388547,0.0003090957,0.00041600407],"domain_scores_gemma":[0.99894834,0.000048832495,0.0000301871,0.00058313983,0.000046150115,0.00034333536],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00009595749,0.00022234501,0.00032762624,0.00009248636,0.00006346505,0.000018623203,0.00013691145,0.00010377442,0.99885905],"category_scores_gemma":[0.00004957234,0.00019816328,0.00010772056,0.00023960511,0.000040188213,0.00006398459,0.00003871037,0.0001651092,0.998615],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000223397,0.00015827859,0.0000022045667,0.000018140301,0.00008839571,0.00009295647,0.000027783337,0.00001525755,0.00014333746,4.0785721e-7,0.5202938,0.47893605],"study_design_scores_gemma":[0.0024005533,0.00040115498,0.00035030264,0.000074381795,0.000121984434,0.00011945375,0.0000012083545,0.00015659833,0.0003734801,0.0000036764995,0.9958136,0.00018359543],"about_ca_topic_score_codex":0.00006313183,"about_ca_topic_score_gemma":3.0659584e-7,"teacher_disagreement_score":0.47875246,"about_ca_system_score_codex":0.00056573236,"about_ca_system_score_gemma":0.00019983752,"threshold_uncertainty_score":0.8080864},"labels":[],"label_agreement":null},{"id":"W4406548693","doi":"10.1016/s1155-1984(20)30007-8","title":"10.1016/s1155-1984(20)30007-8","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine","score_opus":0.007156379452170288,"score_gpt":0.20379979904274226,"score_spread":0.19664341959057197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406548693","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0076980856,0.00023022022,2.6658844e-7,0.00067594653,0.0000022602715,0.0004649792,0.00002147215,0.00022831421,0.9906784],"genre_scores_gemma":[0.0005119248,0.000001403826,0.00027590222,0.00016414774,0.00027213013,0.000042942647,0.000087588414,0.000052432417,0.99859154],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998668,0.000027829044,0.00023609155,0.00035194465,0.00030187774,0.00041424023],"domain_scores_gemma":[0.99896353,0.000045640012,0.000025284553,0.00058184704,0.00004586224,0.0003378537],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00009607869,0.00021984302,0.00032421178,0.000094263865,0.0000630711,0.000013280124,0.00013786332,0.000103445855,0.9989505],"category_scores_gemma":[0.000044232653,0.00019710699,0.00010575441,0.00023629535,0.000039882758,0.00006622951,0.000037818347,0.00016340816,0.99816877],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029368585,0.00015054167,0.0000013650532,0.000017566097,0.000085214866,0.000099225756,0.000026354865,0.000024357616,0.00017419914,2.766329e-7,0.45049554,0.54863167],"study_design_scores_gemma":[0.0023347398,0.00045038568,0.00023128434,0.000074205374,0.00012220794,0.00012623725,0.000001111222,0.00018262472,0.00038467746,0.0000031203308,0.99590695,0.00018244251],"about_ca_topic_score_codex":0.00008151088,"about_ca_topic_score_gemma":6.529208e-7,"teacher_disagreement_score":0.5484492,"about_ca_system_score_codex":0.00057020516,"about_ca_system_score_gemma":0.00020903871,"threshold_uncertainty_score":0.80377895},"labels":[],"label_agreement":null},{"id":"W4406579341","doi":"10.1016/s1541-9800(11)70459-8","title":"10.1016/s1541-9800(11)70459-8","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Imatinib mesylate; Medicine; Scleroderma (fungus); Internal medicine; Imatinib; Pathology","score_opus":0.007389628929640152,"score_gpt":0.2037287731248015,"score_spread":0.19633914419516135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406579341","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013535638,0.00012692409,2.6547966e-7,0.00071513565,0.0000023577581,0.00045661718,0.000016501399,0.00021987408,0.9849267],"genre_scores_gemma":[0.00081207836,9.904071e-7,0.00033602692,0.00014870195,0.00027453006,0.000043682136,0.000068714726,0.000051772986,0.9982635],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99867743,0.00002824711,0.00023335373,0.00034976666,0.00030534132,0.00040585455],"domain_scores_gemma":[0.9989604,0.000052461695,0.000030347672,0.0005841361,0.000045038916,0.00032761128],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00009627872,0.00021838806,0.00032045104,0.000089004054,0.000062823885,0.00001836926,0.00013822054,0.00010088479,0.99901515],"category_scores_gemma":[0.00004989717,0.00019475257,0.00010490412,0.00023139724,0.000040802952,0.00006125738,0.000038918646,0.00013957989,0.9977823],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021929208,0.00016395323,0.00000392044,0.000018884535,0.000073566,0.00010338893,0.00002773907,0.000015658625,0.00011110683,5.175115e-7,0.48584327,0.51341873],"study_design_scores_gemma":[0.0023434688,0.0003718007,0.0004450304,0.000072999435,0.000118812124,0.00009637656,0.0000012119134,0.0001405968,0.00039075993,0.0000034487093,0.9958352,0.00018031202],"about_ca_topic_score_codex":0.000102472535,"about_ca_topic_score_gemma":5.9321377e-7,"teacher_disagreement_score":0.51323843,"about_ca_system_score_codex":0.000552321,"about_ca_system_score_gemma":0.00018765753,"threshold_uncertainty_score":0.79417795},"labels":[],"label_agreement":null},{"id":"W4407403711","doi":"10.3390/curroncol32020097","title":"Treatment-Emergent Resistance to Asciminib in Chronic Myeloid Leukemia Patients Due to Myristoyl-Binding Pocket-Mutant of BCR::ABL1/A337V Can Be Effectively Overcome with Dasatinib Treatment","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Dasatinib; Myeloid leukemia; Medicine; Tyrosine-kinase inhibitor; Tyrosine kinase; Imatinib; Point mutation; Cancer research; Mutation; Nilotinib; Mutant; ABL; Internal medicine; Genetics; Biology; Cancer; Gene; Receptor","score_opus":0.04295286157565735,"score_gpt":0.3621294882242877,"score_spread":0.31917662664863033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407403711","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886294,0.0013122985,0.00005617307,0.0011226042,0.0009446867,0.005051228,0.0003440258,0.00008312349,0.002456434],"genre_scores_gemma":[0.994727,0.00043403183,0.00068139756,0.00021059722,0.0001383153,0.0016533359,0.0003591095,0.000078336925,0.0017178529],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956491,0.00031422114,0.0010877891,0.001300652,0.00054565375,0.0011025565],"domain_scores_gemma":[0.9974395,0.0004440637,0.00037737386,0.0009562289,0.00024324506,0.00053956313],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021970694,0.00081754493,0.0018566346,0.0009501897,0.00015920127,0.000016051767,0.0002889106,0.00026342415,0.00015304807],"category_scores_gemma":[0.00022409653,0.0006489035,0.00024310728,0.0013884859,0.00015540443,0.00008014686,0.00017076015,0.00032077194,0.000048974493],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.017727578,0.013341743,0.5264824,0.001708939,0.0029249878,0.0013211159,0.011071652,0.0006751674,0.022256274,0.00074550323,0.0046408214,0.3971038],"study_design_scores_gemma":[0.088472895,0.04969392,0.54461616,0.0038293994,0.0019577432,0.00007431517,0.0010703318,0.00019935596,0.069928475,0.000070677175,0.23867558,0.001411147],"about_ca_topic_score_codex":0.0009781313,"about_ca_topic_score_gemma":0.008391998,"teacher_disagreement_score":0.39569265,"about_ca_system_score_codex":0.08460267,"about_ca_system_score_gemma":0.00627079,"threshold_uncertainty_score":0.99959624},"labels":[],"label_agreement":null},{"id":"W4407408614","doi":"10.51731/cjht.2025.1074","title":"Lebrikizumab (Ebglyss)","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.01890364514807176,"score_gpt":0.30303255137561497,"score_spread":0.2841289062275432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407408614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4562103,0.29132405,0.000584914,0.23895778,0.0013754945,0.0007462408,0.000018570438,0.00032292263,0.010459756],"genre_scores_gemma":[0.9961484,0.0006843315,0.0010546306,0.0012266452,0.000008898146,0.0000040371347,0.0000020873624,0.000009523739,0.0008614674],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99878806,0.000025965199,0.00051274814,0.00011964121,0.000121142475,0.0004324433],"domain_scores_gemma":[0.99915385,0.000042043248,0.00023258127,0.00031945662,0.00014950101,0.000102559774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031910776,0.00011764644,0.00044108368,0.0009413351,0.0001601219,0.000016743019,0.00022264085,0.00015041669,0.000047938523],"category_scores_gemma":[0.00063176634,0.00009625954,0.00009648146,0.00047010052,0.00017435645,0.000054667365,0.000017542476,0.00045915935,0.00001560221],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003078669,0.00002454199,0.015991852,0.00018658105,0.0001497624,0.00056861265,0.0000988462,0.000003747145,0.000027571652,0.0025079555,0.035792463,0.9446173],"study_design_scores_gemma":[0.003723827,0.00084552064,0.054857243,0.0015426455,0.000095671996,0.0016137485,0.0024498722,0.000017719894,0.0018615188,0.005813535,0.927027,0.00015173902],"about_ca_topic_score_codex":0.004903654,"about_ca_topic_score_gemma":0.0027704819,"teacher_disagreement_score":0.9444655,"about_ca_system_score_codex":0.0031310671,"about_ca_system_score_gemma":0.015776383,"threshold_uncertainty_score":0.98980325},"labels":[],"label_agreement":null},{"id":"W4407499244","doi":"10.1111/bjh.19995","title":"Fibrosis and treatment‐free remission in chronic myeloid leukaemia","year":2025,"lang":"en","type":"letter","venue":"British Journal of Haematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; Hôpital du Sacré-Cœur de Montréal; Hôpital Maisonneuve-Rosemont; MPB Technologies & Communications (Canada); Hôpital Charles-Le Moyne; McGill University","funders":"","keywords":"Chronic myeloid leukaemia; Medicine; Fibrosis; Hematology; Spontaneous remission; Internal medicine; Oncology; Pathology; Alternative medicine","score_opus":0.014648414883871719,"score_gpt":0.2689435423935965,"score_spread":0.2542951275097248,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407499244","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4656731,0.10548139,0.000022227652,0.42254636,0.0012600422,0.0012779585,0.00017232652,0.00006708664,0.0034995188],"genre_scores_gemma":[0.10674509,0.28355902,0.0132472105,0.4928982,0.019342853,0.00032452887,0.0019682862,0.00091139,0.08100341],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99691993,0.00024471697,0.0012705326,0.00052154926,0.0004053256,0.0006379479],"domain_scores_gemma":[0.9980078,0.0003954186,0.00072904705,0.00052639295,0.00016762603,0.00017376059],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00021050616,0.00047849293,0.002334134,0.0006682846,0.00008042396,0.000052165597,0.00032096865,0.0014262518,0.0002879039],"category_scores_gemma":[0.00040815014,0.0004712334,0.00037393047,0.000247266,0.00021329852,0.00011774374,0.00015357655,0.0022712748,0.0000108260865],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015171379,0.00007942187,0.0008646825,0.000805826,0.00041187712,0.2782619,0.000039047427,0.0000013416056,0.00013212129,0.000003863114,0.68528706,0.033961125],"study_design_scores_gemma":[0.012722346,0.001219231,0.0015755547,0.010021268,0.0007957715,0.47204688,0.000020896754,0.000019322852,0.00060431845,0.00026489206,0.5004087,0.00030081972],"about_ca_topic_score_codex":0.0008315776,"about_ca_topic_score_gemma":0.00042941727,"teacher_disagreement_score":0.358928,"about_ca_system_score_codex":0.0052432525,"about_ca_system_score_gemma":0.0035683205,"threshold_uncertainty_score":0.9998701},"labels":[],"label_agreement":null},{"id":"W4408159145","doi":"10.1038/s41375-025-02543-4","title":"Management of children and adolescents with chronic myeloid leukemia in chronic phase: International pediatric chronic myeloid leukemia expert panel recommendations","year":2025,"lang":"en","type":"review","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Ontario Clinical Oncology Group; BC Children's Hospital","funders":"","keywords":"Myeloid leukemia; Medicine; Leukemia; Immunology","score_opus":0.023016166871779986,"score_gpt":0.3202360191588415,"score_spread":0.2972198522870615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408159145","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0049916566,0.98571193,0.00012337136,0.00010753017,0.00083213084,0.0059044487,0.00050721684,0.00024661087,0.001575119],"genre_scores_gemma":[0.0087969,0.9790195,0.00077786046,0.000090314585,0.0017473759,0.0012899154,0.004523023,0.00030839493,0.003446718],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99157345,0.00030804976,0.002756061,0.0024730896,0.0013088264,0.0015805193],"domain_scores_gemma":[0.9954438,0.00022272741,0.0015490586,0.002068932,0.00020665242,0.0005088081],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00051994575,0.0020147497,0.0040612454,0.0020003074,0.00022764823,0.00011432269,0.0013484299,0.0011244932,0.00053269864],"category_scores_gemma":[0.000058724003,0.0017801127,0.0007956948,0.0021724286,0.00036201224,0.00040649076,0.00096396916,0.002217925,0.00013794217],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0002682418,0.00032040637,0.00068353984,0.050681103,0.0023962206,0.0004774974,0.00012569703,0.00014504175,0.000011662414,0.00009031751,0.0037018424,0.94109845],"study_design_scores_gemma":[0.07116379,0.002939818,0.0074918624,0.28008747,0.012210895,0.0015006567,0.000102142025,0.0011636273,0.00012022096,0.000031556854,0.61925906,0.003928883],"about_ca_topic_score_codex":0.0010549265,"about_ca_topic_score_gemma":0.0004101864,"teacher_disagreement_score":0.93716955,"about_ca_system_score_codex":0.15939522,"about_ca_system_score_gemma":0.03517355,"threshold_uncertainty_score":0.9992595},"labels":[],"label_agreement":null},{"id":"W4408194139","doi":"10.51731/cjht.2025.1092","title":"Alectinib (Alecensaro)","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Alectinib; Medicine; Internal medicine","score_opus":0.022852287882387443,"score_gpt":0.31484878507832437,"score_spread":0.2919964971959369,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408194139","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.47075966,0.260031,0.0005502192,0.25316116,0.001721344,0.0008522057,0.000019219351,0.00035443387,0.012550752],"genre_scores_gemma":[0.9957535,0.00070069416,0.0011972261,0.0014311431,0.000009282353,0.000003917161,0.000001916053,0.000009566632,0.0008927426],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99882126,0.000027273321,0.0004907783,0.0001183819,0.00011072403,0.00043158332],"domain_scores_gemma":[0.9991755,0.000052768148,0.000227398,0.00028690838,0.00015998301,0.000097426986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032354696,0.00011425908,0.00041373423,0.00092360773,0.00016731785,0.000014266107,0.00019559296,0.00014703028,0.000048977265],"category_scores_gemma":[0.0007965416,0.000094518655,0.000086763524,0.000538141,0.00016362514,0.000048547536,0.000014167281,0.00048282332,0.000013278902],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000032813794,0.00003187038,0.03793718,0.00021522884,0.00018131569,0.0005498393,0.0001423169,0.0000034140633,0.000059383663,0.0018055468,0.046397887,0.9126432],"study_design_scores_gemma":[0.0033731158,0.00090924825,0.05351337,0.0014677474,0.00008711509,0.0016770739,0.0022777454,0.000013886171,0.0029606358,0.004600419,0.92896986,0.00014980522],"about_ca_topic_score_codex":0.0034712292,"about_ca_topic_score_gemma":0.0029990354,"teacher_disagreement_score":0.9124934,"about_ca_system_score_codex":0.0025151426,"about_ca_system_score_gemma":0.0144408485,"threshold_uncertainty_score":0.9911464},"labels":[],"label_agreement":null},{"id":"W4408246053","doi":"10.1038/s41375-025-02548-z","title":"Living, not just surviving, with chronic myeloid leukemia – quality of life to the front of the line","year":2025,"lang":"en","type":"review","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Myeloid leukemia; Front line; Quality of life (healthcare); Leukemia; Medicine; Myeloid; Immunology; Biology; History","score_opus":0.05066295497651767,"score_gpt":0.338302432049059,"score_spread":0.28763947707254134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408246053","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002872861,0.9862673,0.00012591416,0.00030101833,0.0008064725,0.0047805826,0.0004288118,0.00010174945,0.004315261],"genre_scores_gemma":[0.008026431,0.96443105,0.00033750286,0.0006597907,0.0009241655,0.0005232404,0.00014352589,0.0001946723,0.0247596],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9929419,0.0009934223,0.0025023448,0.0011533888,0.0015393054,0.0008696413],"domain_scores_gemma":[0.9906274,0.0023408805,0.002083769,0.0041888007,0.00040001606,0.00035911903],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017654378,0.0011937162,0.0049496465,0.00031413845,0.00020768515,0.000032994238,0.001781091,0.00075897743,0.00047799025],"category_scores_gemma":[0.0022091956,0.00060075754,0.0014590283,0.001306149,0.00044977272,0.000068857626,0.0010572778,0.0016443598,0.00012551785],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00053864677,0.000452251,0.0023345924,0.22137387,0.0062083416,0.000038386504,0.0016897072,0.000621142,0.000047136575,0.00048928044,0.029915363,0.7362913],"study_design_scores_gemma":[0.0028205232,0.00072018936,0.0059324824,0.10999949,0.0057499446,0.00006056932,0.00010624257,0.00006274571,0.00012696032,0.000003962379,0.8736185,0.00079837727],"about_ca_topic_score_codex":0.006422456,"about_ca_topic_score_gemma":0.0059333006,"teacher_disagreement_score":0.84370315,"about_ca_system_score_codex":0.017152017,"about_ca_system_score_gemma":0.044220887,"threshold_uncertainty_score":0.9996444},"labels":[],"label_agreement":null},{"id":"W4408310298","doi":"10.1038/s41408-025-01242-8","title":"Switching TKIs during CML therapy is frequent, mostly driven by intolerance, and does not affect survival: a prospective Quebec registry study","year":2025,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; Centre Hospitalier Universitaire de Sherbrooke; Hôpital Charles-Le Moyne; Université de Sherbrooke; Hôpital du Sacré-Cœur de Montréal; McGill University Health Centre; McGill University; Université Laval; Centre Hospitalier de l’Université de Montréal; The Quebec Population Health Research Network; Université du Québec à Montréal; Université du Québec; Centre hospitalier universitaire de Québec; Université de Montréal; Institut universitaire en santé mentale de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Affect (linguistics); Medicine; Intensive care medicine; Prospective cohort study; Family medicine; Internal medicine; Psychology","score_opus":0.013173212410804247,"score_gpt":0.2912117035899546,"score_spread":0.2780384911791503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408310298","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85967255,0.008117373,0.000012790334,0.12781148,0.0013198041,0.0023108271,0.00027967524,0.00011644838,0.0003590779],"genre_scores_gemma":[0.79976875,0.014263232,0.00022813784,0.13251126,0.012092478,0.000935551,0.0000914876,0.0003961237,0.03971296],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99569017,0.00031763632,0.0008192682,0.0011464608,0.0011770717,0.0008493997],"domain_scores_gemma":[0.99766624,0.00017579917,0.0008357373,0.000804154,0.00027402584,0.00024401708],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0003327897,0.0009385001,0.0016253516,0.00033505078,0.00049106777,0.00033930232,0.0004210609,0.0006366092,0.00027726695],"category_scores_gemma":[0.000053130338,0.0006707989,0.00036471462,0.00030401113,0.00010773835,0.00022875355,0.0001418319,0.0048844297,0.0000028246045],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015419936,0.0014209825,0.59838223,0.0016829899,0.018656693,0.00979468,0.007334107,0.0000054769807,0.011540908,0.0000026503826,0.3420213,0.0076159933],"study_design_scores_gemma":[0.20485434,0.005839785,0.39687064,0.020596307,0.017186191,0.0064026727,0.0034889905,0.000056867444,0.06873456,0.0002822788,0.2699437,0.0057436614],"about_ca_topic_score_codex":0.012503898,"about_ca_topic_score_gemma":0.0031510147,"teacher_disagreement_score":0.20331234,"about_ca_system_score_codex":0.003095415,"about_ca_system_score_gemma":0.0022248027,"threshold_uncertainty_score":0.9995743},"labels":[],"label_agreement":null},{"id":"W4408650838","doi":"10.51731/cjht.2025.1100","title":"Tarlatamab (Imdelltra)","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.01959808958604087,"score_gpt":0.30008057881005523,"score_spread":0.28048248922401436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408650838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.45681325,0.2875144,0.0010077456,0.2450599,0.0014559138,0.0008009514,0.000027384967,0.00032610202,0.006994379],"genre_scores_gemma":[0.996011,0.00068766554,0.0013776359,0.0012561252,0.00000842919,0.0000034347602,0.0000027029894,0.000009190809,0.00064381864],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988296,0.000022723016,0.000496115,0.00011685629,0.00011753023,0.00041720015],"domain_scores_gemma":[0.9991934,0.000041828658,0.00021702526,0.0003131247,0.00013380879,0.000100834615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031632715,0.00011472319,0.00041261545,0.00087211514,0.00014732353,0.000015412354,0.00022134924,0.00014704042,0.000045716468],"category_scores_gemma":[0.0004933205,0.00009391081,0.000087450106,0.00043847182,0.00017162785,0.00005793952,0.000014773573,0.00046724375,0.000013831378],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000031485833,0.000033235097,0.031955946,0.00024614806,0.00018238339,0.00066739396,0.00013577218,0.000007793732,0.000049661438,0.0028904323,0.0426534,0.92114633],"study_design_scores_gemma":[0.0036899454,0.00087653013,0.060908467,0.0015644566,0.000097906675,0.0013463724,0.0021297405,0.00002758141,0.0021986773,0.0054654772,0.92153275,0.00016208015],"about_ca_topic_score_codex":0.004211151,"about_ca_topic_score_gemma":0.0022215184,"teacher_disagreement_score":0.92098427,"about_ca_system_score_codex":0.0024660584,"about_ca_system_score_gemma":0.013985466,"threshold_uncertainty_score":0.9916043},"labels":[],"label_agreement":null},{"id":"W4408860763","doi":"10.1016/j.pathol.2025.01.005","title":"Flow cytometric detection of BCR::ABL1 in T-lymphocytes in chronic myeloid leukaemia","year":2025,"lang":"en","type":"letter","venue":"Pathology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Health and Medical Research Council; Channel 7 Telethon Trust; Micropalaeontological Society; Novartis; Bristol-Myers Squibb; Bamfield Marine Sciences Centre","keywords":"Chronic myeloid leukaemia; Flow cytometry; breakpoint cluster region; Immunology; Medicine; Myeloid; Biology; Internal medicine; Receptor","score_opus":0.014225768257537281,"score_gpt":0.2707302698236099,"score_spread":0.25650450156607263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408860763","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89788634,0.027188392,0.00036444515,0.059152298,0.0028530376,0.0037225357,0.00022490519,0.00027517937,0.008332856],"genre_scores_gemma":[0.87311286,0.0051010693,0.0013829512,0.10625995,0.0030572135,0.0008932885,0.001548465,0.00023868588,0.008405536],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99661756,0.00031607196,0.0009801062,0.00090943207,0.00037063393,0.0008062105],"domain_scores_gemma":[0.99811697,0.00051776716,0.0003351496,0.00088158477,0.000094170224,0.000054387794],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00038760016,0.00052613043,0.0015492273,0.0039281584,0.000025979414,0.00000716849,0.0002733008,0.001989228,0.00021479183],"category_scores_gemma":[0.0005749683,0.0005240141,0.00023647999,0.0023051633,0.0001733943,0.00005481856,0.00016168859,0.0022077756,0.00011753943],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018984213,0.0011891822,0.082495,0.01831694,0.0011354198,0.09986342,0.0015748978,0.001270546,0.09089898,0.000019649804,0.22106196,0.48027557],"study_design_scores_gemma":[0.07753467,0.006211421,0.27300674,0.008211673,0.0018880015,0.0071021123,0.0001360008,0.010230332,0.104784474,0.00069585367,0.5071678,0.0030309216],"about_ca_topic_score_codex":0.00084046857,"about_ca_topic_score_gemma":0.0007007219,"teacher_disagreement_score":0.47724465,"about_ca_system_score_codex":0.015851576,"about_ca_system_score_gemma":0.0030362632,"threshold_uncertainty_score":0.99972117},"labels":[],"label_agreement":null},{"id":"W4409236985","doi":"10.1212/wnl.0000000000210618","title":"Tolebrutinib Versus Placebo in Non-relapsing Secondary Progressive Multiple Sclerosis: Efficacy and Safety Results from the Phase 3 HERCULES Trial (PL5.003)","year":2025,"lang":"en","type":"article","venue":"Neurology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Multiple sclerosis; Placebo; Medicine; Phase (matter); Internal medicine; Oncology; Pathology; Psychiatry; Physics; Alternative medicine","score_opus":0.03510587589231528,"score_gpt":0.30797596631425445,"score_spread":0.27287009042193916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409236985","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872399,0.0013469921,0.0000060571,0.0057557994,0.0013260077,0.0021741837,0.000119138196,0.000056005076,0.001975932],"genre_scores_gemma":[0.9974193,0.00018109802,0.00014978193,0.0015960027,0.00027051222,0.000110102985,0.00017936545,0.000023757304,0.000070094815],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99793833,0.0003154098,0.0005371682,0.0006573194,0.00015519279,0.0003965524],"domain_scores_gemma":[0.99597347,0.0032107127,0.0001574078,0.00053424394,0.00003321461,0.00009097488],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028311394,0.0002543629,0.00049038,0.00009919428,0.00014893638,0.000023897566,0.00015738045,0.00026646935,0.00006868614],"category_scores_gemma":[0.0014150006,0.0001906449,0.0000723727,0.00022804647,0.00025597154,0.000054878426,0.0001578138,0.00074785785,0.000019061683],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.914177,0.00091488176,0.0015831994,0.000020824164,0.00027075518,0.00042197437,0.000988113,0.000027736944,0.0013420737,0.000018662184,0.0022751172,0.07795964],"study_design_scores_gemma":[0.90478235,0.0046338355,0.07971342,0.00028247066,0.00028643213,0.000025830988,0.000098491946,0.0018426202,0.0006287984,0.000025339576,0.0075174556,0.0001629504],"about_ca_topic_score_codex":0.00073847955,"about_ca_topic_score_gemma":0.0005392939,"teacher_disagreement_score":0.07813022,"about_ca_system_score_codex":0.00016938518,"about_ca_system_score_gemma":0.0004644211,"threshold_uncertainty_score":0.7774273},"labels":[],"label_agreement":null},{"id":"W4409333523","doi":"10.51731/cjht.2025.1113","title":"Avapritinib (Ayvakyt)","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.021525077236918103,"score_gpt":0.31111903087100845,"score_spread":0.28959395363409035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409333523","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.42249128,0.26956034,0.0005122202,0.2894537,0.0014340074,0.00083419174,0.000026244381,0.00035217643,0.015335863],"genre_scores_gemma":[0.99552363,0.0006968969,0.0013290354,0.001571359,0.000010326192,0.000004515814,0.000002296472,0.000009561985,0.00085238455],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987838,0.000026241703,0.0005277928,0.00011755229,0.00011630475,0.00042828673],"domain_scores_gemma":[0.999166,0.000050306284,0.00022136673,0.00030128218,0.00015603552,0.00010500845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035930023,0.000114266615,0.0004229872,0.00087559567,0.00015637325,0.000016265223,0.00021708214,0.00015096502,0.000057871643],"category_scores_gemma":[0.00075371825,0.00009500079,0.00009022067,0.00042182568,0.00018265274,0.000052456307,0.000017159247,0.00047349566,0.000017502527],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025528696,0.000030354013,0.02721229,0.00024807887,0.00014265535,0.0006173337,0.0001062481,0.000002496126,0.000039673017,0.0036882835,0.043265145,0.92462194],"study_design_scores_gemma":[0.0032156126,0.00070641824,0.045182154,0.0016684334,0.00007210899,0.0011755191,0.0025986712,0.000011414814,0.0018202106,0.005828293,0.9375863,0.00013485154],"about_ca_topic_score_codex":0.003132523,"about_ca_topic_score_gemma":0.0020329626,"teacher_disagreement_score":0.92448705,"about_ca_system_score_codex":0.0023655486,"about_ca_system_score_gemma":0.014236989,"threshold_uncertainty_score":0.99135137},"labels":[],"label_agreement":null},{"id":"W4409578902","doi":"10.1038/s41408-025-01288-8","title":"Comment on: “Switching TKIs during CML therapy is frequent, mostly driven by intolerance, and does not affect survival: a prospective Quebec registry study” by Busque et al.","year":2025,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Affect (linguistics); Medicine; Prospective cohort study; Intensive care medicine; Internal medicine; Psychology","score_opus":0.013395953033813964,"score_gpt":0.2998396381446816,"score_spread":0.28644368511086765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409578902","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.32581744,0.0048101814,0.000018059485,0.6652881,0.0009174789,0.0021519987,0.00066801754,0.000084548155,0.00024421158],"genre_scores_gemma":[0.121612504,0.014189714,0.000112774665,0.8511717,0.0022609576,0.0007662776,0.00015265879,0.00024387226,0.009489561],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99522763,0.0005329394,0.00083859486,0.0012156791,0.0013457115,0.000839439],"domain_scores_gemma":[0.9975028,0.00028929068,0.00086361414,0.0008524951,0.00022396515,0.0002678602],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00048776326,0.0010448884,0.0016015865,0.00026867646,0.00046612415,0.00034739263,0.00044162563,0.000509386,0.00022958728],"category_scores_gemma":[0.00004371551,0.00075526873,0.0003371211,0.00024534695,0.00010769091,0.00018773097,0.00014460944,0.0055309907,0.0000027604735],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00075007655,0.0009773056,0.050489534,0.00035845765,0.0061267964,0.0018372508,0.0020682227,0.0000035223861,0.0027091247,0.0000032075734,0.9332629,0.0014136261],"study_design_scores_gemma":[0.04937047,0.0022281932,0.011419208,0.0058578225,0.0020410067,0.0006695891,0.00053986564,0.000012860566,0.018734373,0.000040721323,0.9077071,0.0013788225],"about_ca_topic_score_codex":0.014764773,"about_ca_topic_score_gemma":0.0018538396,"teacher_disagreement_score":0.20420492,"about_ca_system_score_codex":0.0041368385,"about_ca_system_score_gemma":0.0015758544,"threshold_uncertainty_score":0.9996861},"labels":[],"label_agreement":null},{"id":"W4409758955","doi":"10.53876/001aa.129525","title":"Spot on CML: Expanding Access to Chronic Myeloid Leukemia Diagnostics in Low- and Middle-Income Countries","year":2025,"lang":"en","type":"article","venue":"International Journal of Cancer Care and Delivery","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Max Bell Foundation","funders":"","keywords":"Myeloid leukemia; Medicine; Low and middle income countries; Chronic myeloid leukaemia; Internal medicine; Developing country; Economics; Economic growth","score_opus":0.015647805819151473,"score_gpt":0.33008856983299756,"score_spread":0.3144407640138461,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409758955","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9745455,0.022346165,0.000028400964,0.0013056888,0.0008922932,0.00015174158,0.000031916094,0.00000629732,0.00069204066],"genre_scores_gemma":[0.9713242,0.026296223,0.0000679194,0.0017388191,0.0004251975,0.000012563564,0.0000049497594,0.000009906021,0.00012024479],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989255,0.00001530181,0.0003504415,0.00016127131,0.00040090733,0.0001465833],"domain_scores_gemma":[0.9990439,0.00023578289,0.00012868062,0.00008127861,0.0004073185,0.000103041064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008391803,0.00013459536,0.0002678919,0.00045305438,0.000034248045,0.000095782634,0.00016735888,0.00006352497,0.000047702477],"category_scores_gemma":[0.000102359496,0.00011557914,0.000055281398,0.00011282842,0.00004640599,0.00020049352,0.00011475878,0.00020185106,0.000002215531],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003642909,0.0000783213,0.9068774,0.0010061568,0.0009477722,0.002068577,0.0020360174,0.0016510703,0.00037241715,0.00036126623,0.0017044891,0.07925364],"study_design_scores_gemma":[0.016654165,0.0013163565,0.9023451,0.042039745,0.00037901965,0.0003128635,0.0010132294,0.00026161317,0.019960882,0.00023154155,0.01510196,0.00038350312],"about_ca_topic_score_codex":0.00040941653,"about_ca_topic_score_gemma":0.00061027193,"teacher_disagreement_score":0.07887013,"about_ca_system_score_codex":0.0045364145,"about_ca_system_score_gemma":0.0013221978,"threshold_uncertainty_score":0.999285},"labels":[],"label_agreement":null},{"id":"W4409767758","doi":"10.51731/cjht.2025.1115","title":"Trastuzumab Deruxtecan (Enhertu)","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Trastuzumab; Medicine; Internal medicine; Breast cancer; Cancer","score_opus":0.019601184163762185,"score_gpt":0.30275716874635483,"score_spread":0.28315598458259267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409767758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.517793,0.25146335,0.0013265827,0.22010666,0.0013116295,0.00089924585,0.000023586368,0.0003540857,0.006721848],"genre_scores_gemma":[0.9960618,0.0005924825,0.0014249259,0.0012522717,0.000009232357,0.00000562777,0.0000022550898,0.000011798627,0.00063958234],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986729,0.00003097133,0.0005525666,0.00013475773,0.00012987279,0.00047890833],"domain_scores_gemma":[0.99913305,0.00004987763,0.00023524393,0.00031440068,0.00014431545,0.00012311901],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032616907,0.00013665731,0.00047136392,0.0009353974,0.00018027647,0.000018078488,0.00024070358,0.00016294312,0.000051372484],"category_scores_gemma":[0.00057172956,0.00011194573,0.000100118166,0.00049303344,0.00019111623,0.000056494166,0.000014997746,0.00049809803,0.000010678564],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000023428274,0.000028138275,0.010924467,0.00015514922,0.00013919649,0.00039040696,0.0001351596,0.000003293053,0.0000321319,0.0010839979,0.015332621,0.971752],"study_design_scores_gemma":[0.0048949514,0.0015306108,0.0683055,0.0021118799,0.00014253843,0.001848427,0.0056107496,0.00002349696,0.0028189037,0.009132374,0.90334976,0.00023078242],"about_ca_topic_score_codex":0.0053122975,"about_ca_topic_score_gemma":0.005873452,"teacher_disagreement_score":0.9715212,"about_ca_system_score_codex":0.0038962327,"about_ca_system_score_gemma":0.017676314,"threshold_uncertainty_score":0.99992764},"labels":[],"label_agreement":null},{"id":"W4410140470","doi":"10.1182/bloodadvances.2025016042","title":"Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Novartis Pharma; Astellas Pharma; National Institute for Health and Care Research; National Cancer Institute; Incyte; Sanofi; AstraZeneca; Pfizer; Bristol-Myers Squibb","keywords":"Bosutinib; Tolerability; Discontinuation; Medicine; Adverse effect; Internal medicine; Oncology; Myeloid leukemia; Imatinib; Dasatinib","score_opus":0.009538012546709346,"score_gpt":0.28064886711593745,"score_spread":0.2711108545692281,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410140470","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913312,0.005415776,0.000004290674,0.00048760898,0.00029172556,0.0006019541,0.000021821623,0.00004166082,0.0018039283],"genre_scores_gemma":[0.9930934,0.00057283114,0.0016272294,0.00027880876,0.000057644786,0.00010592898,0.000026743717,0.00002643374,0.004211008],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982035,0.000060959897,0.00060816045,0.0004428238,0.00027980778,0.00040474368],"domain_scores_gemma":[0.999148,0.00016899972,0.000095282034,0.00045410352,0.00005301309,0.000080567785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002311413,0.0002239775,0.0006659657,0.00034403978,0.000017914304,0.000011393996,0.0001463188,0.00013640127,0.00014669125],"category_scores_gemma":[0.00033164222,0.00021431284,0.00012410415,0.00070258166,0.000104107035,0.00017649005,0.00007958733,0.00024445608,0.000025105035],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00508619,0.001707172,0.93553185,0.0008116534,0.00031798042,0.0014062616,0.0022696494,0.00014771527,0.01142352,0.00016482545,0.00014564054,0.04098751],"study_design_scores_gemma":[0.042703643,0.0011106797,0.90922207,0.002393382,0.00033912485,0.000022333019,0.00035412319,0.00016866809,0.027245522,0.0005170871,0.0155397635,0.00038362172],"about_ca_topic_score_codex":0.000288923,"about_ca_topic_score_gemma":0.0016250007,"teacher_disagreement_score":0.040603887,"about_ca_system_score_codex":0.00022876283,"about_ca_system_score_gemma":0.00045726084,"threshold_uncertainty_score":0.8739424},"labels":[],"label_agreement":null},{"id":"W4410360799","doi":"10.1002/cncr.35880","title":"Has the time for treatment‐free remission in Philadelphia chromosome‐positive acute lymphoblastic leukemia arrived?","year":2025,"lang":"en","type":"editorial","venue":"Cancer","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Lymphoblastic Leukemia; Complete remission; Philadelphia chromosome; Pediatrics; Oncology; Spontaneous remission; Internal medicine; Leukemia; Chemotherapy; Pathology; Alternative medicine; Chromosomal translocation; Genetics","score_opus":0.014290293710790287,"score_gpt":0.29862862777721944,"score_spread":0.28433833406642917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410360799","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004876492,0.019942626,0.00008316364,0.0103251785,0.93433803,0.0105499765,0.014795472,0.00036885933,0.004720198],"genre_scores_gemma":[0.0024576988,0.009271277,0.00025933134,0.00055090466,0.87102365,0.005554786,0.00737575,0.00032706518,0.10317956],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99674696,0.000086277905,0.0006261174,0.0011006617,0.0006839433,0.00075603375],"domain_scores_gemma":[0.9961036,0.001705463,0.0003418207,0.0013230627,0.0003062249,0.00021984018],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014941179,0.00084581465,0.0013863964,0.00025349684,0.00025499592,0.00006905893,0.00053595053,0.0012001274,0.0005044076],"category_scores_gemma":[0.0007065788,0.0005629773,0.00045654125,0.00040269824,0.0002484476,0.00008391023,0.0001785215,0.0005240795,0.00006866962],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.001794619,0.00012999307,0.000022647631,0.00028094873,0.0015933788,0.00019744957,0.0003483009,0.00004840404,0.0011346079,0.00000414469,0.9903393,0.004106248],"study_design_scores_gemma":[0.024065776,0.0009733014,0.00013876932,0.0045272196,0.0038137753,0.000017420522,0.000024797182,0.00082724425,0.0032154408,0.0001282681,0.96175313,0.00051485107],"about_ca_topic_score_codex":0.0013613339,"about_ca_topic_score_gemma":0.00032577378,"teacher_disagreement_score":0.09845936,"about_ca_system_score_codex":0.03789302,"about_ca_system_score_gemma":0.01842461,"threshold_uncertainty_score":0.9996822},"labels":[],"label_agreement":null},{"id":"W4410809345","doi":"10.1200/jco.2025.43.16_suppl.6545","title":"A phase 2 study of olutasidenib in relapsed/refractory acute myeloid leukemia: Outcomes by number of prior treatment regimens.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Refractory (planetary science); Myeloid leukemia; Oncology; Internal medicine","score_opus":0.06511744294923902,"score_gpt":0.47775764935884624,"score_spread":0.4126402064096072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410809345","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99356085,0.00067572785,0.0000069653024,0.0020738246,0.0006787414,0.00083488406,0.000018255581,0.000009384813,0.0021413758],"genre_scores_gemma":[0.9937851,0.0012329571,0.0010037778,0.0005048252,0.000106860425,0.000020637937,0.0000054253883,0.000024561918,0.0033158618],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.993151,0.0006969352,0.00493717,0.00035169584,0.0005349195,0.00032824918],"domain_scores_gemma":[0.9920804,0.0034924159,0.0032334654,0.00055288925,0.00036632823,0.00027451006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018037414,0.00030746657,0.0038710365,0.0003096051,0.000027710494,0.0000033737151,0.00026170496,0.00057620043,0.00015369305],"category_scores_gemma":[0.0021259785,0.00021013623,0.0007153965,0.00035182555,0.00024947658,0.00009309793,0.00009329126,0.0010373541,0.000012359164],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.022072386,0.086342916,0.70699173,0.00008676691,0.008008614,0.003268714,0.0010921332,0.000020935937,0.0010962241,0.00003537046,0.009935264,0.16104893],"study_design_scores_gemma":[0.4308608,0.13406809,0.3899162,0.0005996774,0.0066619664,0.00048379033,0.0016768464,0.00006182505,0.0020044015,0.00022818008,0.03315618,0.00028203893],"about_ca_topic_score_codex":0.00046490706,"about_ca_topic_score_gemma":0.00019795785,"teacher_disagreement_score":0.4087884,"about_ca_system_score_codex":0.0039620693,"about_ca_system_score_gemma":0.0074204635,"threshold_uncertainty_score":0.99986154},"labels":[],"label_agreement":null},{"id":"W4410811788","doi":"10.1200/jco.2025.43.16_suppl.e18569","title":"Predictors of septic shock among BCR/ABL-positive chronic myeloid leukemia patients admitted for sepsis: A nationwide study and analysis.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brampton Civic Hospital","funders":"","keywords":"Medicine; Myeloid leukemia; Septic shock; Sepsis; Internal medicine; Myeloid; Oncology; Immunology","score_opus":0.03273359574235987,"score_gpt":0.40261378956548566,"score_spread":0.36988019382312576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410811788","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961201,0.0004344822,0.00034925822,0.00047542725,0.00068270264,0.0012700026,0.00002744245,0.000012688065,0.00062791957],"genre_scores_gemma":[0.99755794,0.00021239008,0.00081441575,0.00041339252,0.00031664618,0.000036514248,0.000030951705,0.000018884508,0.00059889344],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951318,0.00050348317,0.0032060891,0.00037177542,0.0004909698,0.00029587795],"domain_scores_gemma":[0.992001,0.0038412677,0.0023220186,0.00029484543,0.0012134986,0.00032739603],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020914003,0.0002406616,0.002523786,0.0006450646,0.00006987639,0.000010344833,0.00019297117,0.00042022613,0.000060289083],"category_scores_gemma":[0.005316726,0.00018300443,0.0008076929,0.00072773255,0.00027634695,0.00015163312,0.00010456666,0.00069305196,0.0000017612244],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026296715,0.0029176245,0.9638269,0.000090177346,0.014335003,0.00005952137,0.0002843308,0.0001229807,0.00003117104,0.000011636828,0.0009764896,0.014714501],"study_design_scores_gemma":[0.030389184,0.021389697,0.93064547,0.0002149389,0.0139866015,0.0000076138685,0.00027998292,0.0019910736,0.00007667961,0.0000634101,0.00085290935,0.000102421116],"about_ca_topic_score_codex":0.000066454435,"about_ca_topic_score_gemma":0.0002769547,"teacher_disagreement_score":0.033181407,"about_ca_system_score_codex":0.0024445704,"about_ca_system_score_gemma":0.005831801,"threshold_uncertainty_score":0.9998042},"labels":[],"label_agreement":null},{"id":"W4410823174","doi":"10.51731/cjht.2025.1136","title":"Momelotinib (Ojjaara)","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business","score_opus":0.021987287900746253,"score_gpt":0.3110414981013667,"score_spread":0.28905421020062044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410823174","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.48273635,0.22491169,0.00052490196,0.27961344,0.0014965974,0.0008023709,0.000020600231,0.00034117396,0.009552864],"genre_scores_gemma":[0.99616337,0.0005795391,0.0010896138,0.001260595,0.000008773198,0.000004405692,0.0000020237414,0.000009622211,0.0008820345],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987966,0.00002484258,0.00051293464,0.000117299365,0.00011916824,0.00042920274],"domain_scores_gemma":[0.99916714,0.00004701436,0.0002341173,0.00030178763,0.0001458437,0.00010409173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034989585,0.00011567934,0.00043482214,0.0010081913,0.00014914294,0.000015099977,0.00021935132,0.00014616115,0.00004793887],"category_scores_gemma":[0.0006624559,0.000094484145,0.00009024697,0.0005068519,0.00016996636,0.000052174324,0.000016786158,0.00045121822,0.0000128421125],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003047858,0.000034260036,0.03922418,0.00025354198,0.00018241037,0.00057128473,0.00013533956,0.0000055738037,0.00004158203,0.0035037901,0.039013434,0.9170041],"study_design_scores_gemma":[0.0037910342,0.00091839297,0.0837363,0.0016856536,0.000089932124,0.0012035848,0.0028420864,0.000019844563,0.0021609422,0.0060788626,0.897309,0.00016434805],"about_ca_topic_score_codex":0.003025705,"about_ca_topic_score_gemma":0.0017582291,"teacher_disagreement_score":0.9168398,"about_ca_system_score_codex":0.0023233877,"about_ca_system_score_gemma":0.013592431,"threshold_uncertainty_score":0.99199957},"labels":[],"label_agreement":null},{"id":"W4410924084","doi":"10.1101/2025.05.30.652226","title":"LIN28A-Dependent Kinome and Phosphoproteome Reprogramming Promotes Imatinib Resistance","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Ontario Ministry of Research and Innovation; Natural Sciences and Engineering Research Council of Canada","keywords":"Kinome; Reprogramming; Computational biology; Cell biology; Chemistry; Biology; Computer science; Kinase; Biochemistry; Cell","score_opus":0.013259966348604532,"score_gpt":0.24384343143647647,"score_spread":0.23058346508787192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410924084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9767812,0.014919556,0.00042162012,0.0009041615,0.0009332982,0.0044555655,0.00037015614,0.00104805,0.00016643075],"genre_scores_gemma":[0.95686245,0.00092741364,0.03963638,0.00023958409,0.0004420766,0.0011470208,0.000002038276,0.00016904253,0.00057398574],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99522465,0.000116302326,0.00096838485,0.0020891747,0.0007161548,0.0008853118],"domain_scores_gemma":[0.9956554,0.0001187021,0.00062707986,0.0025661855,0.0005418113,0.0004908245],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007836042,0.00093852205,0.0012986661,0.00038409128,0.00022738452,0.00024934404,0.0004291057,0.0008238207,0.000077828015],"category_scores_gemma":[0.0006708839,0.0009612788,0.0002415123,0.000554371,0.0002232526,0.00013150148,0.00094338064,0.0014156073,0.00004854479],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019735254,0.003051003,0.118714586,0.03595711,0.005613409,0.0045169382,0.00033544275,0.000037847865,0.8255792,0.0024506354,0.0014537096,0.00031656813],"study_design_scores_gemma":[0.010520761,0.00043181694,0.20380735,0.015364568,0.0023039936,7.298692e-7,0.000023141096,0.0005599739,0.7424975,0.000027213191,0.02148961,0.0029733193],"about_ca_topic_score_codex":0.00015303094,"about_ca_topic_score_gemma":0.000009005024,"teacher_disagreement_score":0.08509277,"about_ca_system_score_codex":0.001845336,"about_ca_system_score_gemma":0.0023555628,"threshold_uncertainty_score":0.9992838},"labels":[],"label_agreement":null},{"id":"W4410930154","doi":"10.7759/cureus.85196","title":"Impact of Tyrosine Kinase Inhibitors on Thyroid Function in Chronic Myeloid Leukemia: A Systematic Review","year":2025,"lang":"en","type":"review","venue":"Cureus","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Myeloid leukemia; Tyrosine kinase; Thyroid function; Cancer research; CD135; Tyrosine-kinase inhibitor; Internal medicine; Thyroid; Oncology; Cancer; Receptor","score_opus":0.0256158832034788,"score_gpt":0.3404401348374343,"score_spread":0.3148242516339555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410930154","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004989037,0.98954123,0.0000037331915,0.000015475183,0.0003862139,0.008418692,0.00010484531,0.00008174402,0.0013981715],"genre_scores_gemma":[0.0002403441,0.9959754,0.000013004835,0.00007452153,0.00028122924,0.001112473,0.00066844193,0.00010680656,0.0015278236],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99528384,0.00041979767,0.0022947183,0.0008293978,0.00060734025,0.00056492985],"domain_scores_gemma":[0.99612707,0.00042522032,0.0012511389,0.0018489376,0.0001448627,0.00020279255],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005991644,0.0010363279,0.0071059796,0.0005914891,0.000041032876,0.000015070418,0.0003248599,0.00066906336,0.00023722026],"category_scores_gemma":[0.0010836546,0.00069102505,0.0019524088,0.0014554576,0.00007175456,0.00008782209,0.00012725849,0.0009865642,0.00022439467],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000037496888,0.00022820763,0.0000073117035,0.9428882,0.0010534115,0.00011585992,0.000011585773,0.0000033857757,0.000004957356,0.000026520409,0.0039123804,0.051710688],"study_design_scores_gemma":[0.0019187529,0.0019487339,0.000026999067,0.9676227,0.013195146,0.00012614943,0.0000031509828,0.000008255787,0.000004875928,0.0000052103246,0.014751263,0.0003887624],"about_ca_topic_score_codex":0.00035539552,"about_ca_topic_score_gemma":0.0000590406,"teacher_disagreement_score":0.051321924,"about_ca_system_score_codex":0.041153938,"about_ca_system_score_gemma":0.011360521,"threshold_uncertainty_score":0.9995541},"labels":[],"label_agreement":null},{"id":"W4411460229","doi":"10.3324/haematol.2025.288065","title":"Olverembatinib in chronic myeloid leukemia: is less actually better?","year":2025,"lang":"en","type":"article","venue":"Haematologica","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myeloid leukemia; Medicine; Cancer research; Immunology","score_opus":0.02647662499174571,"score_gpt":0.2971282614366661,"score_spread":0.2706516364449204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411460229","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9539325,0.001652767,0.00008224186,0.0032324297,0.00017156138,0.0007682073,0.000010637709,0.00019621402,0.03995343],"genre_scores_gemma":[0.9901865,0.00028344762,0.0013035202,0.004011426,0.00006893226,0.0001499449,0.000040003804,0.0000253702,0.0039308346],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99777067,0.000072001814,0.00057707273,0.00065841427,0.0002964146,0.0006254094],"domain_scores_gemma":[0.998738,0.00020475547,0.00012635266,0.00074415474,0.00006362367,0.0001231366],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00017543105,0.00035737327,0.0008689142,0.00028193902,0.00009585705,0.000026283746,0.00027062822,0.00037795017,0.0010016473],"category_scores_gemma":[0.00015537404,0.00028606714,0.00017767843,0.0005823932,0.00015036577,0.000060374732,0.00018168733,0.00052444066,0.00038804955],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023585972,0.0020545728,0.3552573,0.0052967523,0.0021142324,0.014352934,0.004716166,0.00020871537,0.022782924,0.017326415,0.16199172,0.41153967],"study_design_scores_gemma":[0.06809964,0.0030060466,0.635715,0.008063315,0.0013729873,0.003103145,0.0026323714,0.009563877,0.118714534,0.01056215,0.13634497,0.0028219444],"about_ca_topic_score_codex":0.00021451767,"about_ca_topic_score_gemma":0.00021237691,"teacher_disagreement_score":0.40871772,"about_ca_system_score_codex":0.004502568,"about_ca_system_score_gemma":0.0019867586,"threshold_uncertainty_score":0.9999592},"labels":[],"label_agreement":null},{"id":"W4411749041","doi":"10.51731/cjht.2025.1156","title":"Tarlatamab (Imdelltra)","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Cancer Care Ontario","keywords":"Computer science","score_opus":0.01959808958604087,"score_gpt":0.30008057881005523,"score_spread":0.28048248922401436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411749041","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.45681325,0.2875144,0.0010077456,0.2450599,0.0014559138,0.0008009514,0.000027384967,0.00032610202,0.006994379],"genre_scores_gemma":[0.996011,0.00068766554,0.0013776359,0.0012561252,0.00000842919,0.0000034347602,0.0000027029894,0.000009190809,0.00064381864],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988296,0.000022723016,0.000496115,0.00011685629,0.00011753023,0.00041720015],"domain_scores_gemma":[0.9991934,0.000041828658,0.00021702526,0.0003131247,0.00013380879,0.000100834615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031632715,0.00011472319,0.00041261545,0.00087211514,0.00014732353,0.000015412354,0.00022134924,0.00014704042,0.000045716468],"category_scores_gemma":[0.0004933205,0.00009391081,0.000087450106,0.00043847182,0.00017162785,0.00005793952,0.000014773573,0.00046724375,0.000013831378],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000031485833,0.000033235097,0.031955946,0.00024614806,0.00018238339,0.00066739396,0.00013577218,0.000007793732,0.000049661438,0.0028904323,0.0426534,0.92114633],"study_design_scores_gemma":[0.0036899454,0.00087653013,0.060908467,0.0015644566,0.000097906675,0.0013463724,0.0021297405,0.00002758141,0.0021986773,0.0054654772,0.92153275,0.00016208015],"about_ca_topic_score_codex":0.004211151,"about_ca_topic_score_gemma":0.0022215184,"teacher_disagreement_score":0.92098427,"about_ca_system_score_codex":0.0024660584,"about_ca_system_score_gemma":0.013985466,"threshold_uncertainty_score":0.9916043},"labels":[],"label_agreement":null},{"id":"W4411938444","doi":"10.62347/coly8536","title":"Acute myolysis in patients on tyrosine kinase inhibitor therapy for chronic myeloid leukemia","year":2025,"lang":"en","type":"article","venue":"American Journal of Blood Research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Myeloid leukemia; Tyrosine-kinase inhibitor; Tyrosine kinase; Internal medicine; Oncology; Cancer research; Receptor; Cancer","score_opus":0.020225638861801228,"score_gpt":0.3526977058180067,"score_spread":0.33247206695620546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411938444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953881,0.0012983005,0.00001781862,0.0017095717,0.00015526624,0.00090163155,0.000019192641,0.000011219939,0.00049892283],"genre_scores_gemma":[0.9958925,0.0015008515,0.00068651786,0.000349974,0.00034344933,0.0000680156,0.000019234747,0.00004175,0.0010976706],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9969394,0.00025483436,0.00070419436,0.00035293872,0.0010408256,0.0007077606],"domain_scores_gemma":[0.99761665,0.0005607184,0.00028342864,0.0004697993,0.0008183403,0.00025106128],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010570026,0.00023422354,0.00078010256,0.0013670967,0.00012512565,0.000036477515,0.00032444604,0.00008523635,0.00005927662],"category_scores_gemma":[0.00037435567,0.00017768725,0.00027905678,0.0017030262,0.00038682699,0.00009882498,0.000075939846,0.00095883216,0.00001724978],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0254019,0.00619265,0.13585418,0.00022220105,0.004507428,0.00071635994,0.00062304555,0.00010367711,0.048894648,0.00010345126,0.015609932,0.76177055],"study_design_scores_gemma":[0.1630783,0.119358785,0.35270545,0.004252065,0.0012851104,0.00013108514,0.00090505445,0.00032839595,0.33406344,0.00032582504,0.022853423,0.0007130768],"about_ca_topic_score_codex":0.00013616047,"about_ca_topic_score_gemma":0.000019014435,"teacher_disagreement_score":0.76105744,"about_ca_system_score_codex":0.0036647199,"about_ca_system_score_gemma":0.0036685285,"threshold_uncertainty_score":0.9583115},"labels":[],"label_agreement":null},{"id":"W4412088532","doi":"10.3390/ijms26136533","title":"Identification of a PAK6-Mediated MDM2/p21 Axis That Modulates Survival and Cell Cycle Control of Drug-Resistant Stem/Progenitor Cells in Chronic Myeloid Leukemia","year":2025,"lang":"en","type":"article","venue":"International Journal of Molecular Sciences","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada; Terry Fox Research Institute; University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Myeloid leukemia; Cancer research; Stem cell; Progenitor cell; Gene knockdown; Cell cycle; Tyrosine kinase; Biology; CD34; Cell; Cell biology; Apoptosis; Signal transduction; Genetics","score_opus":0.008488524623078008,"score_gpt":0.26330592088899074,"score_spread":0.2548173962659127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412088532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936299,0.0039865733,0.0011151348,0.00042649155,0.00043956662,0.00022340393,0.000030832547,0.0000043533755,0.00014375994],"genre_scores_gemma":[0.9993529,0.00028772483,0.00019688979,0.000040958705,0.00003505155,0.0000045506195,0.000003306021,0.000007020849,0.00007160799],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977555,0.00010612666,0.00081043574,0.00021919965,0.0009447398,0.00016397324],"domain_scores_gemma":[0.9984156,0.00021064922,0.0007257045,0.00014014138,0.00043950585,0.00006842953],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008594019,0.00013457921,0.00037663846,0.00052558,0.000029566725,0.000035100045,0.00039870272,0.000060071212,0.000014988837],"category_scores_gemma":[0.00008526607,0.00011064669,0.00012379148,0.00032732406,0.00029501962,0.00016646358,0.00006227333,0.00014111455,0.0000015162166],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002954931,0.00014247239,0.01305194,0.00009135221,0.00020358048,0.00009512851,0.00022521471,0.001839214,0.9822194,0.00016337936,0.000014594887,0.001658215],"study_design_scores_gemma":[0.006207913,0.00028677363,0.030640831,0.00051525363,0.00012499017,0.000029046507,0.0006363399,0.009321467,0.9516592,0.00044173686,0.000037063186,0.00009938792],"about_ca_topic_score_codex":0.0002113238,"about_ca_topic_score_gemma":0.000034152075,"teacher_disagreement_score":0.030560218,"about_ca_system_score_codex":0.00094012084,"about_ca_system_score_gemma":0.0015474341,"threshold_uncertainty_score":0.4512041},"labels":[],"label_agreement":null},{"id":"W4412178506","doi":"10.3324/haematol.2025.288391","title":"Advancing quality of life research in chronic myeloid leukemia: where do we stand?","year":2025,"lang":"en","type":"article","venue":"Haematologica","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Pfizer","keywords":"Myeloid leukemia; Medicine; Quality of life (healthcare); Internal medicine; Oncology; Nursing","score_opus":0.07511564801604897,"score_gpt":0.3993944169620986,"score_spread":0.3242787689460496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412178506","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88772357,0.088368736,0.00007643029,0.003950424,0.00011340939,0.0009736548,0.000011854093,0.00009343658,0.018688517],"genre_scores_gemma":[0.98715913,0.010282397,0.0008954956,0.000062725805,0.000045224497,0.00011573752,0.0000056890203,0.000019024457,0.0014145453],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99663776,0.0004780346,0.00092381827,0.00059187127,0.0006241321,0.00074439857],"domain_scores_gemma":[0.9975966,0.0009650605,0.00017486632,0.0008645935,0.00022287012,0.00017599779],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016749613,0.00024110309,0.0011056224,0.00043403183,0.00010690775,0.00001570545,0.00027294326,0.00032809665,0.0004764306],"category_scores_gemma":[0.0010949679,0.00019157038,0.00014532589,0.0011533991,0.00030828477,0.00008264639,0.00026227027,0.0008105519,0.00008130277],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.008073397,0.002578928,0.6120024,0.04903852,0.0013740944,0.003581498,0.00302541,0.00068790745,0.040825427,0.0919862,0.06710193,0.11972431],"study_design_scores_gemma":[0.08202169,0.0052345535,0.4124309,0.04797193,0.00046133433,0.0005111664,0.015195068,0.002302175,0.06340337,0.035568986,0.3326932,0.002205629],"about_ca_topic_score_codex":0.00062436,"about_ca_topic_score_gemma":0.0006784315,"teacher_disagreement_score":0.26559126,"about_ca_system_score_codex":0.0063228887,"about_ca_system_score_gemma":0.0059038787,"threshold_uncertainty_score":0.9997317},"labels":[],"label_agreement":null},{"id":"W4412178530","doi":"10.3324/haematol.2025.287772","title":"Improving chronic myeloid leukemia management and quality of life: patient and physician survey on unmet needs from the CML SUN survey","year":2025,"lang":"en","type":"article","venue":"Haematologica","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Respiratory Research Network","funders":"","keywords":"Medicine; Tolerability; Family medicine; Quality of life (healthcare); Disease; Myeloid leukemia; Internal medicine; Nursing; Adverse effect","score_opus":0.036523565505358006,"score_gpt":0.28499122384251957,"score_spread":0.24846765833716156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412178530","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99381506,0.0031982802,0.00006403183,0.0002490835,0.00011952104,0.00085988926,0.00020054197,0.00005034378,0.0014432403],"genre_scores_gemma":[0.99788225,0.00044516788,0.00018045049,0.0009522776,0.000019733403,0.000043855198,0.00022984964,0.000016361008,0.0002300729],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997637,0.00067485997,0.000567889,0.00048314984,0.00031013196,0.000326972],"domain_scores_gemma":[0.99721867,0.0015920016,0.00028772358,0.00071324065,0.0000804772,0.00010788393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000840877,0.00029489605,0.0008158112,0.00009980863,0.00015274457,0.000029848625,0.00016275191,0.00013753198,0.000033032913],"category_scores_gemma":[0.0005471485,0.0001895769,0.00007475922,0.00040571898,0.000253955,0.0000407174,0.00031058313,0.00024284128,0.000009616262],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010611033,0.00030480078,0.944618,0.0006284471,0.0008711135,0.000035166886,0.0004296897,0.000011918312,0.00047152129,0.0021511414,0.0026457955,0.046771333],"study_design_scores_gemma":[0.0029815543,0.00036117836,0.9940142,0.00026152647,0.00013306897,0.0000019153822,0.0003002802,0.00016190558,0.0012177905,0.00013862713,0.00026755332,0.00016036881],"about_ca_topic_score_codex":0.016376844,"about_ca_topic_score_gemma":0.0025984787,"teacher_disagreement_score":0.04939626,"about_ca_system_score_codex":0.0006249066,"about_ca_system_score_gemma":0.00031556495,"threshold_uncertainty_score":0.99017316},"labels":[],"label_agreement":null},{"id":"W4412187071","doi":"10.1038/s41375-025-02664-w","title":"2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia","year":2025,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Discontinuation; Dosing; Intensive care medicine; Disease; Transplantation; Myeloid leukemia; Quality of life (healthcare); Tyrosine-kinase inhibitor; Disease management; MEDLINE; Family medicine; Internal medicine; Cancer","score_opus":0.023097088389205465,"score_gpt":0.2976016508790599,"score_spread":0.2745045624898544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412187071","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17136124,0.025076985,0.05013758,0.03213803,0.0064237867,0.017860556,0.00059244403,0.0013325824,0.6950768],"genre_scores_gemma":[0.85512626,0.00459281,0.012706597,0.0025528353,0.00066840864,0.0007724447,0.0007066008,0.00015676107,0.1227173],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975993,0.00009314606,0.00078882783,0.00060252764,0.00032440436,0.00059181615],"domain_scores_gemma":[0.9977212,0.00040307315,0.0002500763,0.0013444016,0.00015671941,0.00012451786],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00058023224,0.00038883157,0.0005206053,0.00021516129,0.00031705596,0.000037911675,0.00054454483,0.0001365803,0.00038602663],"category_scores_gemma":[0.000050860453,0.00029724167,0.00034069922,0.0006719565,0.00019727068,0.00009581506,0.0002727701,0.00038996723,0.00015934475],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000674419,0.00026479887,0.0012399158,0.0031393056,0.004561024,0.00011025156,0.0004171904,0.0013649729,0.0021876898,0.02288647,0.40679067,0.5563633],"study_design_scores_gemma":[0.015752638,0.00045773637,0.02345703,0.0020939256,0.0024459932,0.000038580016,0.0006176973,0.006985557,0.006436271,0.0007220234,0.9405519,0.00044067457],"about_ca_topic_score_codex":0.000230317,"about_ca_topic_score_gemma":0.000044744902,"teacher_disagreement_score":0.683765,"about_ca_system_score_codex":0.011787378,"about_ca_system_score_gemma":0.0024102784,"threshold_uncertainty_score":0.99994797},"labels":[],"label_agreement":null},{"id":"W4412557774","doi":"10.51731/cjht.2025.1173","title":"Lazertinib and Amivantamab (Lazcluze and Rybrevant)","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.014318388167044858,"score_gpt":0.2930609854070025,"score_spread":0.27874259723995765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412557774","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7032254,0.19786364,0.000056410045,0.09753202,0.00020111298,0.00029373317,0.00000952556,0.00007247199,0.00074573845],"genre_scores_gemma":[0.99440277,0.0034543045,0.0008870149,0.0009591036,0.000006060501,0.0000026889304,0.000001124721,0.000008190669,0.00027871705],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99902797,0.000024026896,0.00040056062,0.00013466725,0.00008089081,0.0003319113],"domain_scores_gemma":[0.9993745,0.00006707573,0.00017467946,0.00018687097,0.000077013035,0.00011985559],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002859442,0.00011658544,0.00040537099,0.00058290677,0.00015645208,0.000021370246,0.00009599912,0.0001226357,0.000009412166],"category_scores_gemma":[0.00052794407,0.0000928544,0.000032135267,0.0002151042,0.0002740681,0.000056788154,0.000027787375,0.0003574822,0.0000016143813],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000042567197,0.000015859176,0.06367069,0.00039319406,0.00011641508,0.00039513418,0.00018195916,3.5947858e-7,0.00006658053,0.0014331173,0.007558607,0.9261255],"study_design_scores_gemma":[0.0086065065,0.0020655345,0.32941988,0.0035760303,0.0002174405,0.0053762244,0.006479236,0.000054732027,0.0018434961,0.010139055,0.6319186,0.00030324864],"about_ca_topic_score_codex":0.002406092,"about_ca_topic_score_gemma":0.0023945416,"teacher_disagreement_score":0.92582226,"about_ca_system_score_codex":0.0007658196,"about_ca_system_score_gemma":0.004045656,"threshold_uncertainty_score":0.717682},"labels":[],"label_agreement":null},{"id":"W4412914018","doi":"10.3390/curroncol32080418","title":"BCMA CAR-T: From Multiple Myeloma to Light-Chain Amyloidosis","year":2025,"lang":"en","type":"review","venue":"Current Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; Occupational Cancer Research Centre; University of Calgary","funders":"","keywords":"Medicine; Plasma cell dyscrasia; Amyloidosis; AL amyloidosis; Multiple myeloma; Context (archaeology); Tolerability; Oncology; Plasma cell; Immunoglobulin light chain; Internal medicine; Immunology; Adverse effect; Antibody","score_opus":0.10932876447773028,"score_gpt":0.42902445077595547,"score_spread":0.3196956862982252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412914018","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001442149,0.9852578,0.000055064058,0.0006377598,0.0056282016,0.0036591855,0.0005795423,0.00021111724,0.0038271025],"genre_scores_gemma":[0.00003262977,0.99075615,0.00073535874,0.00023793864,0.0016208703,0.0015602579,0.0020701292,0.00010970855,0.0028769244],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957185,0.00041678277,0.0012335319,0.0014008335,0.00040487075,0.0008254733],"domain_scores_gemma":[0.9960378,0.001401383,0.00044390155,0.0013598279,0.00015248184,0.0006046094],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00021606723,0.0009791462,0.0046788678,0.0006774321,0.00010933396,0.000023179427,0.0005358165,0.0010130092,0.00071580295],"category_scores_gemma":[0.0008878511,0.0007995113,0.0010569674,0.00077485497,0.00007289792,0.000034832196,0.0005355989,0.001162137,0.0021569515],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005910834,0.0006177819,0.00020605647,0.01081863,0.0007191654,0.00020229821,0.00018242707,1.3830042e-7,0.000002914175,0.000022331817,0.044508636,0.9426605],"study_design_scores_gemma":[0.002821566,0.00049128884,0.00009577779,0.027520606,0.0045989216,0.00006236515,0.000024852874,0.000008233421,0.000010447967,0.000014913764,0.96384686,0.0005041363],"about_ca_topic_score_codex":0.00017040911,"about_ca_topic_score_gemma":0.00020326766,"teacher_disagreement_score":0.9421564,"about_ca_system_score_codex":0.008442564,"about_ca_system_score_gemma":0.005045512,"threshold_uncertainty_score":0.99944556},"labels":[],"label_agreement":null},{"id":"W4413127968","doi":"10.51731/cjht.2025.1189","title":"Quizartinib (Vanflyta)","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine","score_opus":0.022377522746083685,"score_gpt":0.3158917955807999,"score_spread":0.2935142728347162,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413127968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4949171,0.20502599,0.000582465,0.28669783,0.0014238801,0.00075887196,0.000018002886,0.00032703124,0.010248834],"genre_scores_gemma":[0.99618435,0.00043674465,0.0010731259,0.0015103603,0.000008804011,0.000004150194,0.0000017610797,0.000009209353,0.00077147473],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998781,0.00002722116,0.00053286727,0.00011482738,0.00011633498,0.00042770393],"domain_scores_gemma":[0.9991564,0.000047417296,0.0002449104,0.00030395002,0.00014463035,0.00010265177],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003767941,0.00011189013,0.00041417344,0.00084193115,0.00015234012,0.00001521443,0.00020412386,0.00013941027,0.000045967197],"category_scores_gemma":[0.00080248376,0.000091229245,0.00008735696,0.00045368637,0.00017313981,0.000054651187,0.000016679161,0.00042173144,0.00001584387],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003166573,0.00003251701,0.03418955,0.00021805971,0.00015455295,0.0005266087,0.00014871973,0.0000049801333,0.00005653462,0.0030559385,0.045745507,0.9158354],"study_design_scores_gemma":[0.00295113,0.000771727,0.04363069,0.0013657508,0.00007482749,0.0008650048,0.0025574125,0.000016784705,0.0022520071,0.0052561485,0.94012785,0.00013069512],"about_ca_topic_score_codex":0.0027053184,"about_ca_topic_score_gemma":0.0024348332,"teacher_disagreement_score":0.91570467,"about_ca_system_score_codex":0.0021439914,"about_ca_system_score_gemma":0.013436183,"threshold_uncertainty_score":0.99215674},"labels":[],"label_agreement":null},{"id":"W4413137955","doi":"10.1016/j.jaccao.2025.06.007","title":"Cardiovascular Disease in Patients With Chronic Myeloid Leukemia","year":2025,"lang":"fi","type":"article","venue":"JACC CardioOncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myeloid leukemia; Disease; Medicine; Cancer research; Internal medicine","score_opus":0.0075691149232449675,"score_gpt":0.23709939311828557,"score_spread":0.2295302781950406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413137955","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9132944,0.04998937,0.00018377572,0.0009839849,0.003094561,0.004490987,0.00017992446,0.00016778756,0.027615221],"genre_scores_gemma":[0.9879751,0.0017164805,0.0001281874,0.0005628252,0.000917542,0.00053770933,0.00040293075,0.00012850988,0.00763071],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99386126,0.00071027345,0.0009089058,0.0017891241,0.0010426756,0.0016877572],"domain_scores_gemma":[0.9957886,0.00033772003,0.0002189723,0.002702753,0.0003379374,0.00061403034],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00067809894,0.0009579557,0.0026916505,0.0007936492,0.00019352074,0.00004823472,0.0005032632,0.0007405573,0.0003185746],"category_scores_gemma":[0.00033943323,0.000872369,0.0011776326,0.0014773336,0.0005157656,0.00020214396,0.00044841532,0.0011935962,0.000500045],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0039439774,0.0007101146,0.8718382,0.0011295893,0.011395155,0.002431999,0.00020974602,0.011598719,0.000008879331,0.00026683282,0.0033031097,0.09316369],"study_design_scores_gemma":[0.039267562,0.0011178894,0.72566193,0.0009866066,0.0053994046,0.000011594107,0.000056035005,0.0004729347,0.000034981327,0.00002905862,0.22640154,0.0005604659],"about_ca_topic_score_codex":0.0016702324,"about_ca_topic_score_gemma":0.00039894207,"teacher_disagreement_score":0.22309843,"about_ca_system_score_codex":0.040995754,"about_ca_system_score_gemma":0.014784323,"threshold_uncertainty_score":0.9993727},"labels":[],"label_agreement":null},{"id":"W4413158372","doi":"10.2139/ssrn.5386791","title":"Nilotinib Versus Nilotinib Combined to Pegylated Interferon-Alpha2a as First-Line Therapy in Chronic Phase Chronic Myeloid Leukaemia. Final Results of the National Academic Phase Iii Petals Trial","year":2025,"lang":"en","type":"preprint","venue":"SSRN Electronic Journal","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Nilotinib; Chronic myeloid leukaemia; Medicine; Petal; Internal medicine; Phase (matter); First line therapy; Pegylated interferon; Oncology; Virology; Tyrosine kinase; Biology; Physics; Receptor; Virus","score_opus":0.06326698993351434,"score_gpt":0.38814694487369394,"score_spread":0.3248799549401796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413158372","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97076887,0.010983509,0.00016816246,0.00583188,0.0033036426,0.006925928,0.00048049787,0.00013840708,0.0013991016],"genre_scores_gemma":[0.9658884,0.022637948,0.000039677463,0.00030298534,0.0028377234,0.00040978074,0.0007262967,0.0001534716,0.0070037493],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98731905,0.0007262165,0.0039286003,0.0017019537,0.0023121813,0.004011992],"domain_scores_gemma":[0.9939703,0.00091514783,0.002421457,0.001344624,0.0008652468,0.00048323735],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.0050633764,0.0014857985,0.0025021408,0.0013461561,0.00040489624,0.00008735847,0.002146074,0.0013385037,0.00035834246],"category_scores_gemma":[0.00196683,0.0011974537,0.0012830368,0.001461217,0.00035010357,0.00023037243,0.0010053108,0.015216915,0.00006862843],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.91190755,0.005856322,0.00007018484,0.00046168183,0.0060279313,0.00010075809,0.0012995948,0.0066340417,0.0059297048,0.0019757051,0.0028090647,0.056927435],"study_design_scores_gemma":[0.90817976,0.059027392,0.00012369161,0.0042805336,0.0010072435,0.0005159125,0.00021662102,0.0029870395,0.00991052,0.0064747063,0.006119618,0.0011569558],"about_ca_topic_score_codex":0.00074121496,"about_ca_topic_score_gemma":0.002729401,"teacher_disagreement_score":0.05577048,"about_ca_system_score_codex":0.060117148,"about_ca_system_score_gemma":0.10245306,"threshold_uncertainty_score":0.999958},"labels":[],"label_agreement":null},{"id":"W4413389037","doi":"10.1016/j.leukres.2025.108087","title":"Pilot study: A prospective, real-world, feasibility study testing a decreased frequency paradigm in treatment free remission in chronic myeloid leukemia","year":2025,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Windsor; Windsor Regional Hospital","funders":"","keywords":"Myeloid leukemia; Medicine; Oncology; Internal medicine; Leukemia; Complete remission; Prospective cohort study; Chemotherapy","score_opus":0.12377204351037173,"score_gpt":0.4169045640463377,"score_spread":0.29313252053596595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413389037","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9574747,0.0007870226,0.0000035822018,0.00029923458,0.00012100629,0.017155303,0.000020034546,0.00026572548,0.023873407],"genre_scores_gemma":[0.9905799,0.00016693323,0.0005506595,0.000032794633,0.00019686662,0.0038687207,0.000046376535,0.00011447861,0.0044432683],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98936194,0.0020696335,0.0016991463,0.0026597993,0.0020353016,0.0021741688],"domain_scores_gemma":[0.9928367,0.0023631437,0.00016258976,0.0035789693,0.00043973746,0.0006188233],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0044074096,0.00088400766,0.00165334,0.0026902263,0.00047642319,0.00014105724,0.00096914184,0.000203018,0.00017758275],"category_scores_gemma":[0.0043383488,0.0007608905,0.00016155408,0.0078778155,0.00035693683,0.0002883527,0.00073548197,0.0024127604,0.00008511465],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.004090351,0.0113767935,0.96501744,0.00031567007,0.00029326478,0.0033524667,0.001534391,0.00014310218,0.00783446,0.00017320174,0.00025690766,0.005611946],"study_design_scores_gemma":[0.062685914,0.01992253,0.907919,0.0015232543,0.00015152234,0.000024050161,0.0015593285,0.0019843257,0.0013826905,0.002340274,0.000054828157,0.00045230406],"about_ca_topic_score_codex":0.27820495,"about_ca_topic_score_gemma":0.26437312,"teacher_disagreement_score":0.22903948,"about_ca_system_score_codex":0.2675933,"about_ca_system_score_gemma":0.038553838,"threshold_uncertainty_score":0.9998887},"labels":[],"label_agreement":null},{"id":"W4413431624","doi":"10.1080/10428194.2025.2536121","title":"Indolent chronic myeloid leukemia – a historical dinosaur?","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myeloid leukemia; Medicine; Immunology","score_opus":0.010352445609960795,"score_gpt":0.2465565217181639,"score_spread":0.2362040761082031,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413431624","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94429857,0.017809235,0.00042418358,0.0012288595,0.0019880915,0.0019673265,0.00005349028,0.0010656518,0.031164588],"genre_scores_gemma":[0.9561551,0.0037233562,0.0010153502,0.0034849944,0.0012144706,0.0005835514,0.00026838426,0.0002562325,0.033298563],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9912867,0.0002719406,0.0019655633,0.002641815,0.0014297582,0.0024042164],"domain_scores_gemma":[0.9948148,0.000574478,0.0005607753,0.0024090805,0.00033688667,0.001303984],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00059740705,0.0017920118,0.0024477646,0.0011628867,0.00086337887,0.00025244596,0.00087657623,0.0014316734,0.00032442276],"category_scores_gemma":[0.00035893996,0.001686599,0.0008829645,0.001866406,0.0006367924,0.00052359456,0.00081160036,0.00061409577,0.00044619056],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0032617943,0.0010249179,0.032716673,0.0027165022,0.0026160341,0.0034341016,0.0014443372,0.00018816002,0.017686995,0.0064585772,0.103773676,0.82467824],"study_design_scores_gemma":[0.08112467,0.0018093017,0.23851727,0.002729369,0.002359919,0.0037012869,0.000388192,0.010166973,0.020760553,0.0010851644,0.63457865,0.0027786824],"about_ca_topic_score_codex":0.0052707097,"about_ca_topic_score_gemma":0.0002991615,"teacher_disagreement_score":0.82189953,"about_ca_system_score_codex":0.2470424,"about_ca_system_score_gemma":0.030808602,"threshold_uncertainty_score":0.9998647},"labels":[],"label_agreement":null},{"id":"W4413774125","doi":"10.1016/s2152-2650(25)00753-0","title":"POSTER: CML-754 Improved Patient-Reported Outcomes (PROs) With Asciminib vs Investigator-Selected Tyrosine Kinase Inhibitors (IS-TKIs) in Newly Diagnosed Chronic Myeloid Leukemia (CML): ASC4FIRST Week 48 PROs Analysis","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Myeloid leukemia; Tyrosine kinase; Oncology; Internal medicine; Dasatinib; Imatinib","score_opus":0.01578916958822854,"score_gpt":0.2878932926959074,"score_spread":0.27210412310767884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413774125","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987176,0.0016438849,0.00004938317,0.0027549432,0.0011735081,0.0051863207,0.00016068674,0.0008574488,0.0009978318],"genre_scores_gemma":[0.9860473,0.00037999905,0.0014077128,0.005994605,0.00050602335,0.001220052,0.0012335883,0.00033246327,0.0028782121],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98476654,0.000779183,0.006013511,0.003974578,0.0018102068,0.0026559595],"domain_scores_gemma":[0.98866934,0.0019569357,0.002217061,0.0038863618,0.0011530406,0.0021172538],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0013570298,0.0022402613,0.0050341855,0.0020467849,0.00052210054,0.00031450385,0.0010967456,0.0018500772,0.0003296938],"category_scores_gemma":[0.0058448245,0.0018863259,0.0017022165,0.009153638,0.0015709361,0.0007114709,0.0007442796,0.0017900569,0.00026081654],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0052549965,0.0020691117,0.83990705,0.0005703797,0.0067431564,0.0035060481,0.0006299248,0.00009242733,0.0032234262,0.00004127752,0.007838319,0.13012388],"study_design_scores_gemma":[0.052822534,0.00384813,0.91240776,0.001521638,0.0058643534,0.00016462356,0.00017437091,0.0041752853,0.0117652295,0.00008265562,0.0054966896,0.0016767397],"about_ca_topic_score_codex":0.0045407885,"about_ca_topic_score_gemma":0.0033353264,"teacher_disagreement_score":0.12844715,"about_ca_system_score_codex":0.027275495,"about_ca_system_score_gemma":0.033830903,"threshold_uncertainty_score":0.99944574},"labels":[],"label_agreement":null},{"id":"W4413774548","doi":"10.1016/s2152-2650(25)00721-9","title":"POSTER: CML-124 Tracking the Rising Burden of Major Cardiovascular Disease-Related Mortality Among Chronic Myeloid Leukemia Patients: Epidemiological Trends and Disparities in United States Adults Aged 25 and Above (2010–2020)","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Continental (Canada)","funders":"","keywords":"Medicine; Myeloid leukemia; Epidemiology; Disease; Disease burden; Gerontology; Environmental health; Intensive care medicine; Internal medicine","score_opus":0.019942205254524992,"score_gpt":0.2947420931033744,"score_spread":0.2747998878488494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413774548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9832837,0.013523315,0.000016993887,0.0008221139,0.00045560888,0.0012954734,0.00019767326,0.00015732189,0.0002477934],"genre_scores_gemma":[0.99204403,0.005728515,0.000081416605,0.00042787855,0.00021481201,0.0001231957,0.0009064561,0.00007745913,0.00039620846],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9921392,0.0014956644,0.002936774,0.0016360244,0.00074318744,0.0010491351],"domain_scores_gemma":[0.9936611,0.0031499376,0.0006860547,0.0016064416,0.0002866478,0.0006097873],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0025315518,0.0008660222,0.002428106,0.00047069945,0.00032581665,0.00009182319,0.00046318347,0.0008155675,0.00005649901],"category_scores_gemma":[0.0032570371,0.0006303165,0.0008146358,0.0013414528,0.002205408,0.00031893462,0.00057998655,0.001020594,0.0000064569663],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011968544,0.0002102036,0.7869885,0.0006372031,0.0021505803,0.00036199647,0.0004162666,0.00041827426,0.000018336983,0.0000825601,0.00032667935,0.20719254],"study_design_scores_gemma":[0.019029753,0.00055803446,0.96258557,0.0024247786,0.0020507379,0.00003641186,0.00026058033,0.011524465,0.00004083738,0.00056514086,0.0004127085,0.00051096664],"about_ca_topic_score_codex":0.009476051,"about_ca_topic_score_gemma":0.00039570994,"teacher_disagreement_score":0.20668156,"about_ca_system_score_codex":0.004519782,"about_ca_system_score_gemma":0.0015122521,"threshold_uncertainty_score":0.99961483},"labels":[],"label_agreement":null},{"id":"W4413783181","doi":"10.1016/s2152-2650(25)01940-8","title":"CML-575: ENABLE: A Phase 1a/1b Study of ELVN-001, a Selective Active Site Inhibitor of BCR::ABL1, in Patients With Previously Treated Chronic Myeloid Leukemia","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Myeloid leukemia; Internal medicine; breakpoint cluster region; Oncology; Cancer research; Receptor","score_opus":0.012512351634301826,"score_gpt":0.3084303981712043,"score_spread":0.2959180465369025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413783181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896854,0.00060399715,0.00001066009,0.00004390787,0.00030949063,0.00652561,0.00019859223,0.00020133403,0.002420998],"genre_scores_gemma":[0.99650466,0.00017800009,0.00026067795,0.0001864992,0.0002451485,0.0005142615,0.0005092905,0.00017088388,0.0014305598],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99060637,0.0008488425,0.0036902742,0.002104065,0.0013152978,0.0014351567],"domain_scores_gemma":[0.99300057,0.0015107404,0.0016572837,0.001996742,0.0012440832,0.0005905743],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00093060575,0.0012217002,0.0036364184,0.0009956986,0.00017850516,0.000036932768,0.0006401129,0.0009096972,0.0001664429],"category_scores_gemma":[0.0012852754,0.0010234835,0.00053098274,0.0032842103,0.00079799467,0.00042617237,0.00044759273,0.0009999974,0.00006520779],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.04658964,0.029710017,0.55797935,0.0009957223,0.004113557,0.000574109,0.0021723344,0.00010172101,0.0013956156,0.000037593716,0.0020978902,0.35423243],"study_design_scores_gemma":[0.17617334,0.02603834,0.78254575,0.0021465037,0.0017085465,0.000023901146,0.0004431457,0.00060263765,0.008860115,0.000042745407,0.0007307586,0.00068420003],"about_ca_topic_score_codex":0.0030325463,"about_ca_topic_score_gemma":0.0012109625,"teacher_disagreement_score":0.35354823,"about_ca_system_score_codex":0.023720214,"about_ca_system_score_gemma":0.014356404,"threshold_uncertainty_score":0.99922156},"labels":[],"label_agreement":null},{"id":"W4413789968","doi":"10.1016/s2152-2650(25)01954-8","title":"CML-754: Improved Patient-Reported Outcomes (PROs) With Asciminib vs Investigator-Selected Tyrosine Kinase Inhibitors (IS-TKIs) in Newly Diagnosed Chronic Myeloid Leukemia (CML): ASC4FIRST Week 48 PROs Analysis","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Myeloid leukemia; Tyrosine kinase; Internal medicine; Tyrosine-kinase inhibitor; Oncology; Cancer; Receptor","score_opus":0.016278072813078547,"score_gpt":0.28991046760751565,"score_spread":0.27363239479443713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413789968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875882,0.0017052866,0.000088082255,0.0023817094,0.0011682657,0.0050650425,0.00013956506,0.00089293875,0.0009708672],"genre_scores_gemma":[0.98568183,0.00044864285,0.002137763,0.005180149,0.0005432283,0.0013849863,0.0011314128,0.00033221475,0.0031597733],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9847086,0.0007622276,0.0059912456,0.0040098596,0.0018467483,0.0026813378],"domain_scores_gemma":[0.9885674,0.00204877,0.002206414,0.0038940415,0.0011354645,0.0021478692],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0014343224,0.002232721,0.005097834,0.0020437483,0.0005409079,0.00029586724,0.0010920679,0.001875769,0.00036685116],"category_scores_gemma":[0.006772424,0.0018818349,0.0017111814,0.009932047,0.0016691359,0.000683737,0.0006931488,0.0018483107,0.00026729098],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.004753338,0.002212864,0.82094014,0.00058019516,0.007123999,0.0034258,0.0005823869,0.00017182673,0.0030264952,0.00006702722,0.010628622,0.14648731],"study_design_scores_gemma":[0.05259997,0.0033396026,0.9093338,0.0014414405,0.0059496863,0.00012889788,0.00019827415,0.0072083157,0.010529905,0.00011066166,0.007473646,0.001685752],"about_ca_topic_score_codex":0.0046440065,"about_ca_topic_score_gemma":0.0033163363,"teacher_disagreement_score":0.14480157,"about_ca_system_score_codex":0.028683757,"about_ca_system_score_gemma":0.036818054,"threshold_uncertainty_score":0.99942},"labels":[],"label_agreement":null},{"id":"W4414553272","doi":"10.3390/cimb47100797","title":"Antipsychotic Chlorpromazine Suppresses STAT5 Signaling, Overcomes Resistance Mediated by the Gatekeeper Mutation FLT3-ITD/F691L, and Synergizes with Quizartinib in FLT3-ITD-Positive Cells","year":2025,"lang":"en","type":"review","venue":"Current Issues in Molecular Biology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"Kanazawa University; Kindai University","keywords":"STAT5; Tyrosine kinase; Myeloid leukemia; Cell growth; ROR1; Mutation; Tyrosine; Tyrosine-kinase inhibitor; Phosphorylation; Receptor tyrosine kinase","score_opus":0.0134641986650306,"score_gpt":0.3534042259723151,"score_spread":0.33994002730728445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414553272","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0144288605,0.981575,0.00016236385,0.00022642061,0.00039010882,0.0026421465,0.00040105946,0.000052609674,0.00012142016],"genre_scores_gemma":[0.0047768215,0.9900294,0.0003704494,0.00007155289,0.00006554312,0.0004887726,0.0037362212,0.0000829193,0.00037832436],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958079,0.000941921,0.0010605826,0.0011956843,0.00030832537,0.00068560673],"domain_scores_gemma":[0.9976016,0.00095146697,0.0004864604,0.00070955354,0.0001259405,0.00012492668],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00038946755,0.00085633923,0.002292971,0.00047851208,0.00007091643,0.000043955843,0.0003535997,0.00047902868,0.0000658624],"category_scores_gemma":[0.00034981195,0.00056112546,0.00018731742,0.00087268645,0.00051888375,0.00006511142,0.00014520448,0.00086014153,0.000019653977],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004755911,0.0062699537,0.008991548,0.17795512,0.008552635,0.0070990156,0.006266783,0.000111137364,0.01396904,0.0020205758,0.014163769,0.7498445],"study_design_scores_gemma":[0.013647336,0.0016394949,0.00036840714,0.123450644,0.004375643,0.00026330553,0.0002470147,0.00007344953,0.011878749,0.00056425727,0.8412965,0.0021951834],"about_ca_topic_score_codex":0.00010898111,"about_ca_topic_score_gemma":0.00012941142,"teacher_disagreement_score":0.82713276,"about_ca_system_score_codex":0.00053445133,"about_ca_system_score_gemma":0.0006295837,"threshold_uncertainty_score":0.99968404},"labels":[],"label_agreement":null},{"id":"W4414853071","doi":"10.51731/cjht.2025.1249","title":"Cabozantinib","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Cabozantinib; Drug; Compassionate Use; Drug approval","score_opus":0.02085405706881028,"score_gpt":0.31206519005522676,"score_spread":0.2912111329864165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414853071","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.49920815,0.24345043,0.00047122157,0.2428029,0.0014115155,0.00067163835,0.000018077766,0.00026967868,0.011696372],"genre_scores_gemma":[0.9964726,0.0005620864,0.0010217376,0.0011678197,0.0000070253463,0.0000028224024,0.0000015183723,0.0000072949633,0.0007570733],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989835,0.000020056115,0.00044278282,0.000095733776,0.00009448323,0.0003634255],"domain_scores_gemma":[0.999292,0.000036995745,0.00020083766,0.0002560582,0.00013345317,0.00008065576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029886843,0.00009458261,0.00036977077,0.000808406,0.00013063551,0.000012447245,0.00017504518,0.00012217666,0.000036630874],"category_scores_gemma":[0.00059400557,0.00007585599,0.000073388896,0.0004151651,0.00014871251,0.000042618787,0.000013051248,0.0003806224,0.000011048891],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022424427,0.00002424586,0.04035926,0.00019595925,0.00013429881,0.00055847876,0.000106723855,0.0000024791657,0.00003637931,0.0037389048,0.0353369,0.91948396],"study_design_scores_gemma":[0.0025225237,0.00048808954,0.05460554,0.0011466886,0.000055121214,0.00089864363,0.0019304116,0.000008820919,0.0014918548,0.0028481383,0.93390864,0.00009553105],"about_ca_topic_score_codex":0.0040654573,"about_ca_topic_score_gemma":0.0022389577,"teacher_disagreement_score":0.9193884,"about_ca_system_score_codex":0.0014470415,"about_ca_system_score_gemma":0.0142207155,"threshold_uncertainty_score":0.99136776},"labels":[],"label_agreement":null},{"id":"W4414887486","doi":"","title":"Targeted Therapy for CML Patients on Imatinib: Role of Novel Variants of Human Organic Cationic Transporter 1 (hOCT1)","year":2024,"lang":"en","type":"book-chapter","venue":"HAL (Le Centre pour la Communication Scientifique Directe)","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"","keywords":"Targeted therapy; Transporter; Cancer therapy; Cationic polymerization; Organic cation transport proteins; DNA; Decoy","score_opus":0.014618142092230531,"score_gpt":0.23702902300175333,"score_spread":0.2224108809095228,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414887486","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.31681627,0.0042265286,0.00336716,0.0022243673,0.00044617022,0.0063742227,0.0027874187,0.00038672658,0.66337115],"genre_scores_gemma":[0.80512655,0.00047515339,0.0044042286,0.00007137539,0.000033748183,0.000092640636,0.004501195,0.00020193598,0.18509321],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99744827,0.0001574763,0.000928684,0.0006474296,0.000547918,0.00027022365],"domain_scores_gemma":[0.9950538,0.00051997363,0.00075764663,0.0015682093,0.001965327,0.00013498696],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009494692,0.00042629926,0.0007370501,0.0003033805,0.000120264725,0.000028476,0.00043799213,0.0003491284,0.0008604319],"category_scores_gemma":[0.00017511206,0.00040244777,0.00038562063,0.00014774241,0.00018871432,0.00006340109,0.00007303857,0.00035008372,0.00003445429],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007133922,0.008791017,0.0034168486,0.002561015,0.0034291197,0.000009374018,0.020088853,0.000008694141,0.16735505,0.731734,0.001836408,0.06005624],"study_design_scores_gemma":[0.0526385,0.00020923013,0.053332523,0.035540134,0.0032284656,0.000038215585,0.000237535,0.0047348854,0.7185688,0.039384354,0.08911661,0.002970719],"about_ca_topic_score_codex":0.00021516999,"about_ca_topic_score_gemma":0.000264829,"teacher_disagreement_score":0.6923496,"about_ca_system_score_codex":0.00041055243,"about_ca_system_score_gemma":0.00054408895,"threshold_uncertainty_score":0.99984276},"labels":[],"label_agreement":null},{"id":"W4415300473","doi":"10.1016/j.ejps.2025.107332","title":"Exposure-response analysis of oral and intravenous imatinib in critically ill patients with COVID-19 acute respiratory distress syndrome","year":2025,"lang":"en","type":"article","venue":"European Journal of Pharmaceutical Sciences","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Horizon 2020 Framework Programme; Innovative Medicines Initiative; Nederlandse Organisatie voor Wetenschappelijk Onderzoek; ZonMw; Netherlands Organization for International Cooperation in Higher Education; European Commission","keywords":"Critically ill; Acute respiratory distress; Imatinib; Clinical trial; Respiratory distress; MEDLINE","score_opus":0.0347348413691972,"score_gpt":0.36654711676754986,"score_spread":0.3318122753983527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415300473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99644464,0.00036482856,0.00047419177,0.0019393745,0.000060886054,0.00017019,0.000034294302,0.000007491265,0.00050408836],"genre_scores_gemma":[0.99568653,0.000040188577,0.0014728735,0.0027572603,0.0000067165497,9.176528e-7,0.00000204955,0.0000072588246,0.000026199952],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973853,0.0008026916,0.0006871937,0.0002477905,0.00059549557,0.00028152927],"domain_scores_gemma":[0.99834025,0.00048346617,0.0002071541,0.00013802334,0.0003891773,0.00044192275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002463521,0.00015238837,0.0005265811,0.0006600786,0.0000859978,0.00003571314,0.00025319782,0.000022672593,0.00011803857],"category_scores_gemma":[0.001951327,0.00009912137,0.00009625092,0.0013894879,0.00093023025,0.00014236255,0.00008475668,0.00026533232,0.000001762347],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008239541,0.0014310002,0.9468598,0.00018794346,0.0021657147,0.0062174816,0.00087685045,0.00037966823,0.003018836,0.00016996716,0.0001364775,0.030316725],"study_design_scores_gemma":[0.008103079,0.0030552587,0.98376954,0.0002228956,0.0021175463,0.00013102117,0.00020231403,0.00045687667,0.00036857984,0.000014012399,0.001442148,0.00011670492],"about_ca_topic_score_codex":0.000009799357,"about_ca_topic_score_gemma":0.0000058795276,"teacher_disagreement_score":0.03690977,"about_ca_system_score_codex":0.000292239,"about_ca_system_score_gemma":0.000609929,"threshold_uncertainty_score":0.4042052},"labels":[],"label_agreement":null},{"id":"W4415438756","doi":"10.51731/cjht.2025.1260","title":"Asciminib (Scemblix)","year":2025,"lang":"","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Myeloid leukemia; Cancer; Disease; Drug; Public health; Cancer treatment","score_opus":0.026783171320781837,"score_gpt":0.31906480387779484,"score_spread":0.292281632557013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415438756","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06255317,0.71722853,0.00036884757,0.20695774,0.0052875597,0.0009917399,0.00006040713,0.00015062767,0.00640135],"genre_scores_gemma":[0.98276496,0.01138161,0.00076305645,0.0022825778,0.00004573417,0.000009638265,0.000004689232,0.00003557131,0.002712144],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953046,0.00016796119,0.0021213454,0.00040260397,0.0003826641,0.0016208539],"domain_scores_gemma":[0.9965972,0.00023481814,0.0012639326,0.00097001,0.0005476543,0.00038640533],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015206479,0.00046651743,0.0015178842,0.0035735932,0.0006425043,0.000093603354,0.0009869435,0.0007044271,0.00030275542],"category_scores_gemma":[0.0029955653,0.00041815662,0.0003274437,0.0017778574,0.0009128873,0.00018803781,0.00008140066,0.0018775263,0.000085459265],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00006478106,0.00007753611,0.008695667,0.0008622678,0.0005862316,0.0018901424,0.0004081126,0.000010401857,0.000015117483,0.0031959545,0.063537404,0.9206564],"study_design_scores_gemma":[0.0059932675,0.0022157677,0.015457873,0.008334932,0.00041171748,0.0014846028,0.012048648,0.000049260125,0.0011136737,0.0057518277,0.9467745,0.00036395682],"about_ca_topic_score_codex":0.013451727,"about_ca_topic_score_gemma":0.008564414,"teacher_disagreement_score":0.92029244,"about_ca_system_score_codex":0.012086548,"about_ca_system_score_gemma":0.093339466,"threshold_uncertainty_score":0.999827},"labels":[],"label_agreement":null},{"id":"W4415474892","doi":"10.1681/asn.20250vvfbnxk","title":"Effects of Long-Term Burosumab Treatment on Kidney Health in X-Linked Hypophosphatemia: Results from the XLH Disease Monitoring Program","year":2025,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's Hospital of Eastern Ontario","funders":"","keywords":"Kidney disease; Nephrology; Kidney; MEDLINE; Disease","score_opus":0.016191490012767387,"score_gpt":0.3225959424205549,"score_spread":0.3064044524077875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415474892","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94720167,0.002386441,0.000008889823,0.049172267,0.0002653457,0.0009113187,0.000033036136,0.000011031343,0.000009995019],"genre_scores_gemma":[0.98531747,0.0054310113,0.0010438636,0.007822708,0.00023714869,0.000028635242,0.00000818903,0.000018483674,0.00009250846],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99801445,0.00028590002,0.0008373251,0.00022946262,0.00031105374,0.0003218257],"domain_scores_gemma":[0.9965129,0.0010620954,0.0015569759,0.00054070866,0.0000954696,0.00023184856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029808673,0.00022559449,0.0009565284,0.000054975408,0.00008595284,0.0000060310967,0.00032795034,0.00007053139,0.0000023924667],"category_scores_gemma":[0.00033701194,0.00012342105,0.00062983925,0.00043270222,0.00055532,0.000031106963,0.00008574564,0.00042493932,8.19553e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026946466,0.0081448015,0.64243096,0.0007437048,0.0059473505,0.00026847157,0.0057257693,0.00043822505,0.01888707,0.000015396154,0.044327307,0.24612448],"study_design_scores_gemma":[0.013456653,0.00372827,0.9754073,0.0013050591,0.00051016273,0.000015485004,0.0001847044,0.00007133048,0.0032450687,0.000049776594,0.0019587844,0.00006739688],"about_ca_topic_score_codex":0.0013290618,"about_ca_topic_score_gemma":0.000016309355,"teacher_disagreement_score":0.33297634,"about_ca_system_score_codex":0.0017215366,"about_ca_system_score_gemma":0.0019210957,"threshold_uncertainty_score":0.50329643},"labels":[],"label_agreement":null},{"id":"W4415496365","doi":"10.1136/bmjno-2025-anzan.61","title":"3478 Baseline characteristics in the tolebrutinib phase 3 primary progressive multiple sclerosis perseus clinical trial","year":2025,"lang":"","type":"article","venue":"","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Clinical trial; Multiple sclerosis; Baseline (sea); Phases of clinical research; Phase (matter)","score_opus":0.10261127870639473,"score_gpt":0.39413716447222413,"score_spread":0.2915258857658294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415496365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96237165,0.0039531784,0.00029724857,0.0072117443,0.004991927,0.010605673,0.0003642793,0.0001309038,0.0100734],"genre_scores_gemma":[0.9782008,0.0024723927,0.0011029057,0.008397474,0.002990681,0.0006914064,0.0008282639,0.00007197129,0.005244123],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98985344,0.0020884054,0.004015148,0.0016108478,0.0010831135,0.0013490618],"domain_scores_gemma":[0.9902323,0.006002952,0.0008791476,0.00207304,0.0004006448,0.0004119488],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0053898054,0.0009439454,0.0022560887,0.000383975,0.0003397513,0.00020695054,0.00090262515,0.0008244943,0.0026017153],"category_scores_gemma":[0.009494157,0.00064730924,0.0008558901,0.0012533708,0.00079844386,0.00020683536,0.00042686018,0.00198743,0.00036411444],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23460314,0.045184143,0.056375034,0.0007779141,0.0016396965,0.0017265318,0.0019758146,0.0000013139716,0.0003160405,0.00023764338,0.026250683,0.63091207],"study_design_scores_gemma":[0.8444032,0.008362092,0.08598728,0.003433027,0.0032589363,0.00005129178,0.0024659534,0.013378987,0.0003366885,0.000023695493,0.037444897,0.0008539677],"about_ca_topic_score_codex":0.00023935699,"about_ca_topic_score_gemma":0.00007177857,"teacher_disagreement_score":0.63005805,"about_ca_system_score_codex":0.0021169765,"about_ca_system_score_gemma":0.0055883573,"threshold_uncertainty_score":0.9995978},"labels":[],"label_agreement":null},{"id":"W4415906229","doi":"10.21203/rs.3.rs-7924728/v1","title":"New Pattern of Emerging Somatic Mutations in Optimal Responders Following Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia Patients","year":2025,"lang":"","type":"preprint","venue":"Research Square","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Western University; Princess Margaret Cancer Centre; University Health Network","funders":"Princess Margaret Cancer Foundation; Cancer Research Society","keywords":"Somatic cell; Myeloid leukemia; Tyrosine kinase; Somatic evolution in cancer; clone (Java method); Tyrosine-kinase inhibitor; Mutation; Myeloid","score_opus":0.038380338992016885,"score_gpt":0.3755469473889204,"score_spread":0.33716660839690354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415906229","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9775382,0.010887045,0.00035545373,0.00062867196,0.0008773392,0.008871538,0.0002459999,0.00006915078,0.00052659964],"genre_scores_gemma":[0.98942935,0.004784854,0.0007854677,0.000038239305,0.0004534365,0.0009816117,0.0012783223,0.00018938477,0.0020593419],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.984891,0.002435177,0.0033263923,0.0023763033,0.004100692,0.0028704228],"domain_scores_gemma":[0.9930954,0.0022524425,0.0006769653,0.0024363778,0.00076290796,0.0007758995],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0035464575,0.0013172887,0.0024757374,0.0061029494,0.0003461334,0.00015741524,0.0012659103,0.0011847066,0.0011993436],"category_scores_gemma":[0.0019305409,0.0013887606,0.0009104316,0.00434609,0.00036962688,0.00045011274,0.0017760989,0.005020811,0.00012853168],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0041774544,0.0033851052,0.45645282,0.01645758,0.0017594105,0.0018092475,0.037565295,0.0433411,0.008892905,0.00003656261,0.00094224093,0.4251803],"study_design_scores_gemma":[0.13007376,0.008334976,0.61065984,0.13806947,0.00048198656,0.000009801624,0.015209564,0.06218476,0.030819967,0.0005241524,0.0009439887,0.0026877315],"about_ca_topic_score_codex":0.023202375,"about_ca_topic_score_gemma":0.0034706497,"teacher_disagreement_score":0.42249256,"about_ca_system_score_codex":0.05566345,"about_ca_system_score_gemma":0.04028555,"threshold_uncertainty_score":0.99995786},"labels":[],"label_agreement":null},{"id":"W4416386476","doi":"10.1038/s41597-025-06284-y","title":"14,441 Genomics-Based Validated Automated Comprehensive Clinicopathologic Correlations for Myeloid Neoplasms","year":2025,"lang":"en","type":"article","venue":"Scientific Data","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nova Scotia Health Authority; Spinologics (Canada)","funders":"","keywords":"Myeloid; Myeloid leukemia; Dysplasia; Peripheral blood; Myeloid sarcoma; Blood cancer","score_opus":0.08826511586548723,"score_gpt":0.3756117539573349,"score_spread":0.2873466380918477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416386476","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9041184,0.0013392658,0.02480339,0.0046298276,0.015895722,0.008004274,0.033796154,0.0030935872,0.004319367],"genre_scores_gemma":[0.66515005,0.0000389517,0.07693612,0.002543989,0.00021157325,0.0003170578,0.21169826,0.00010640666,0.042997576],"study_design_codex":"not_applicable","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99719167,0.00008883787,0.00061636843,0.0012975927,0.00031309042,0.0004924459],"domain_scores_gemma":[0.9954462,0.00055318925,0.00020046049,0.0032204804,0.00041974752,0.00015994042],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008070871,0.00026379814,0.00046567575,0.00037720476,0.00053609046,0.00020145676,0.000858153,0.00018919475,0.00020814668],"category_scores_gemma":[0.00088639476,0.00023736194,0.000119954886,0.0009766392,0.00043852115,0.00018510106,0.00049668655,0.00022850659,0.00046090878],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005394813,0.0008883801,0.0050913775,0.00034450626,0.0003350335,0.00008392264,0.00014168289,0.001086758,0.026243601,0.00033652087,0.9561693,0.008739404],"study_design_scores_gemma":[0.012209726,0.00023836158,0.01602341,0.00031396782,0.0008892423,0.000037734495,0.00016107876,0.5022919,0.0064725955,0.0003175398,0.46067888,0.00036551282],"about_ca_topic_score_codex":0.000029640201,"about_ca_topic_score_gemma":0.000041460957,"teacher_disagreement_score":0.5012052,"about_ca_system_score_codex":0.00061122864,"about_ca_system_score_gemma":0.0024440042,"threshold_uncertainty_score":0.9679339},"labels":[],"label_agreement":null},{"id":"W4416570952","doi":"10.1093/stcltm/szaf062","title":"Tracking leukemic residuals: dissecting the inverse relationship between CD26+ stem cells and extracellular <i>BCR::ABL1</i> transcript in Chronic Myeloid Leukemia (CML)","year":2025,"lang":"en","type":"article","venue":"Stem Cells Translational Medicine","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada)","funders":"European Commission","keywords":"Myeloid leukemia; Stem cell; Extracellular; Leukemia; Myeloid; Messenger RNA; Haematopoiesis","score_opus":0.043256419966998,"score_gpt":0.2881562899616622,"score_spread":0.2448998699946642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416570952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.967447,0.021023119,0.0014709,0.0046142074,0.0006753184,0.0021803742,0.00006188169,0.00016283148,0.0023643794],"genre_scores_gemma":[0.9918141,0.00048262885,0.00026283736,0.0003208515,0.0006627651,0.00009949841,0.0001293491,0.00008691423,0.006141066],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99517334,0.0004114096,0.0016187311,0.0010110219,0.0009845502,0.0008009588],"domain_scores_gemma":[0.99548227,0.0030321544,0.00030654113,0.00070302706,0.00017888716,0.00029714286],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017528143,0.00066117937,0.0010566509,0.00059881556,0.0004511801,0.00004593998,0.00032335013,0.00044086148,0.00012474696],"category_scores_gemma":[0.00006319188,0.0005129987,0.00020464335,0.0012765973,0.00053640356,0.00032153339,0.000036552756,0.0013910357,0.00003050359],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013948835,0.00029248805,0.49625677,0.0059704976,0.0013188322,0.0005747489,0.020362908,0.007183132,0.38127166,0.0034080525,0.0051519,0.07681411],"study_design_scores_gemma":[0.075759724,0.0018799064,0.58704084,0.020355362,0.006043373,0.00030118143,0.011505491,0.014969504,0.23486389,0.004396755,0.04020139,0.0026825743],"about_ca_topic_score_codex":0.00047334755,"about_ca_topic_score_gemma":0.0007471294,"teacher_disagreement_score":0.14640778,"about_ca_system_score_codex":0.0029040119,"about_ca_system_score_gemma":0.0021406345,"threshold_uncertainty_score":0.99973214},"labels":[],"label_agreement":null},{"id":"W4416637234","doi":"10.1183/13993003.congress-2025.pa4104","title":"Second- and Third-generation BCR-ABL Tyrosine-Kinase Inhibitors and the Risk of Pulmonary Arterial Hypertension: A Prevalent new-user Population-based Cohort Study","year":2025,"lang":"","type":"article","venue":"","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Bosutinib; Imatinib; Dasatinib; Hazard ratio; Proportional hazards model; Ponatinib; Nilotinib; Confidence interval; Poisson regression","score_opus":0.011440583508801212,"score_gpt":0.24389225671694884,"score_spread":0.23245167320814764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416637234","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98424876,0.005613515,0.00010177649,0.0011929155,0.0014519265,0.006678007,0.000052386687,0.000048877646,0.0006118667],"genre_scores_gemma":[0.9918138,0.0007912307,0.0002166894,0.00048450995,0.0007340141,0.0001602223,0.00013234424,0.000041917006,0.0056252778],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958673,0.00076551037,0.0013208825,0.0010112692,0.00064460945,0.00039040582],"domain_scores_gemma":[0.9973864,0.0006181958,0.0004915632,0.0010133923,0.0002439056,0.00024656087],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011076466,0.0005985232,0.0011653266,0.00025764984,0.00043971086,0.00010449563,0.00012459954,0.00027643095,0.0007595063],"category_scores_gemma":[0.00041381462,0.00039501212,0.00017778315,0.00042061345,0.0002965984,0.00018911046,0.00018712357,0.0003673459,0.0000071159225],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003356583,0.0017245102,0.9780129,0.00033657197,0.0013054893,0.000055569337,0.0005612589,0.00013730198,0.0039726137,0.00013519371,0.00390957,0.006492439],"study_design_scores_gemma":[0.03616946,0.0006994105,0.9055828,0.00043070273,0.005030255,0.00002947512,0.00055723893,0.047798272,0.003036086,0.000078416604,0.00026891418,0.00031897178],"about_ca_topic_score_codex":0.0063444218,"about_ca_topic_score_gemma":0.0012937365,"teacher_disagreement_score":0.0724301,"about_ca_system_score_codex":0.00055053836,"about_ca_system_score_gemma":0.0010245834,"threshold_uncertainty_score":0.99985015},"labels":[],"label_agreement":null},{"id":"W4417001562","doi":"10.1182/blood-2025-2845","title":"Management of chronic myeloid leukaemia (CML) during pregnancy: A systematic review of maternal and foetal outcomes","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Observational study; Pregnancy; Watchful waiting; Systematic review; Disease; Evidence-based practice; Fetus; Evidence-based medicine","score_opus":0.007551844088013685,"score_gpt":0.258552774803317,"score_spread":0.2510009307153033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417001562","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7802462,0.21532463,0.000009248177,0.00009289658,0.000056322217,0.0018609766,0.000009872092,0.000031239273,0.0023686378],"genre_scores_gemma":[0.9640744,0.03195895,0.00040389644,0.000029900317,0.000009855768,0.00016078373,0.0000058198452,0.000017293065,0.0033391574],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99863064,0.00003530387,0.0006545324,0.0002269483,0.00026395376,0.00018860478],"domain_scores_gemma":[0.99912184,0.000032802927,0.00024748233,0.000502661,0.000045919478,0.000049282673],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009719657,0.0001814172,0.0009350757,0.00009648429,0.00002384515,0.000004500441,0.0001105435,0.000047095276,0.000043853455],"category_scores_gemma":[0.00003380233,0.0001367599,0.00014152782,0.00015291691,0.000048457503,0.000038141465,0.0001325879,0.000073521944,0.000006062838],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014040424,0.00025046142,0.02535684,0.9706752,0.0021558648,0.00019273009,0.000029822882,1.9406345e-7,0.0005991876,0.00031296775,0.0000071603868,0.00040557745],"study_design_scores_gemma":[0.008444144,0.0001435213,0.093317494,0.8689299,0.0064130723,0.00016448446,0.000026122076,0.000009280627,0.022417942,0.000027576541,0.0000043337272,0.00010208018],"about_ca_topic_score_codex":0.000023318547,"about_ca_topic_score_gemma":0.0000033029714,"teacher_disagreement_score":0.18382816,"about_ca_system_score_codex":0.00026519466,"about_ca_system_score_gemma":0.00013471585,"threshold_uncertainty_score":0.5576907},"labels":[],"label_agreement":null},{"id":"W4417001699","doi":"10.1182/blood-2025-75","title":"Somatic mutations at diagnosis in patients with chronic Phase CML receiving frontline imatinib are associated with a higher rate of treatment failure: First analysis from the international CML foundation (iCMLf) genomics alliance on the harmony platform","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Imatinib; Exome sequencing; Genomics; DNA sequencing; Precision medicine; Exome; Cohort; Germline mutation","score_opus":0.018647265839945644,"score_gpt":0.2530596419954415,"score_spread":0.23441237615549587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417001699","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944806,0.0001267009,0.000051724488,0.0036149789,0.000053106614,0.0012385873,0.0003131013,0.000028684726,0.00009251224],"genre_scores_gemma":[0.996369,0.00010125076,0.00033667602,0.00020888585,0.00003862316,0.00056596415,0.0020589728,0.000024869998,0.00029577626],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998627,0.00006616464,0.00044859565,0.00035095736,0.00029289862,0.00021438523],"domain_scores_gemma":[0.9978328,0.001002806,0.0005152738,0.00047407384,0.00013258363,0.00004250318],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014060487,0.0002602268,0.00044232744,0.00012151933,0.0001815104,0.00004386653,0.00018643879,0.00006836759,0.00044271292],"category_scores_gemma":[0.00016336051,0.00014135518,0.000113273294,0.0005893253,0.00007697497,0.00010221057,0.000043632048,0.00013439705,0.000014571323],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005559468,0.0032980726,0.98345184,0.000022151415,0.00875586,0.00001216195,0.0009831856,0.0018128933,0.00007603907,0.000020713009,0.00021718358,0.000793957],"study_design_scores_gemma":[0.034840196,0.00083291566,0.95073426,0.0008824581,0.004715355,3.8210524e-7,0.00012996107,0.0055346293,0.0018375322,0.000049068665,0.00029434654,0.00014891203],"about_ca_topic_score_codex":0.000807597,"about_ca_topic_score_gemma":0.022457635,"teacher_disagreement_score":0.034284253,"about_ca_system_score_codex":0.004524577,"about_ca_system_score_gemma":0.0003438656,"threshold_uncertainty_score":0.9992969},"labels":[],"label_agreement":null},{"id":"W4417002264","doi":"10.1182/blood-2025-4425","title":"A multinational study to explore patient preferences for chronic myeloid leukaemia treatments","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Tolerability; Logistic regression; Logit; Risk assessment; Myeloid leukaemia; Toxicity; Clinical trial; Mixed logit","score_opus":0.03774920091659433,"score_gpt":0.3201063048281047,"score_spread":0.28235710391151037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417002264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928325,0.00042483985,0.000069327776,0.000238075,0.00017038945,0.0041404776,0.000038833678,0.000098409095,0.0019871644],"genre_scores_gemma":[0.9923551,0.000016050259,0.0019441259,0.00019538708,0.000107467706,0.0022181352,0.00012247227,0.000022683707,0.0030185909],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984976,0.000033616103,0.00032864255,0.0005003091,0.00030865116,0.00033114944],"domain_scores_gemma":[0.99914515,0.000121415476,0.0000679284,0.0003863038,0.00014316222,0.00013602419],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000072364426,0.0002430294,0.00034010728,0.00018795172,0.00012532824,0.000021512291,0.00011820888,0.00005819481,0.00009074742],"category_scores_gemma":[0.00013917727,0.00019714111,0.00011082758,0.00026055082,0.000021775082,0.000054646913,0.00009294773,0.00008656636,0.000060635055],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016192372,0.048598297,0.71907765,0.0006125086,0.0071266023,0.00018306369,0.015079229,0.000089721114,0.0058348416,0.00025631321,0.0069917575,0.19453079],"study_design_scores_gemma":[0.09908282,0.021510733,0.80598146,0.00087435526,0.0040795016,0.000038128866,0.0053661396,0.00026762523,0.051953737,0.00043142418,0.009754063,0.00066000427],"about_ca_topic_score_codex":0.00008334127,"about_ca_topic_score_gemma":0.00008274088,"teacher_disagreement_score":0.19387078,"about_ca_system_score_codex":0.0011717264,"about_ca_system_score_gemma":0.0008878778,"threshold_uncertainty_score":0.8039181},"labels":[],"label_agreement":null},{"id":"W4417004801","doi":"10.1182/blood-2025-7294","title":"Feasibility of the edmonton symptom assessment system (ESAS) score as patient-reported outcomes (PROs) assessment in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor therapy: A pilot Study","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Discontinuation; Myeloid leukemia; Context (archaeology); Clinical trial; Cancer; Medical record; Palliative care; Tyrosine-kinase inhibitor","score_opus":0.02364250898800571,"score_gpt":0.30918438888542793,"score_spread":0.2855418798974222,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417004801","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98793423,0.000513206,0.0000057148936,0.00013121788,0.0006723171,0.008736565,0.000032154403,0.00014985933,0.0018247298],"genre_scores_gemma":[0.9984436,0.000042181542,0.00016732578,0.000108596374,0.00006417244,0.0007738886,0.00006490519,0.00006645304,0.0002688722],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99455917,0.0005395834,0.0017802682,0.0010893994,0.0013695242,0.00066205615],"domain_scores_gemma":[0.99628985,0.00023160999,0.0008472441,0.0019995545,0.00045994436,0.00017181692],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00079478504,0.0006516411,0.0012810065,0.00031673737,0.00021370116,0.000055833483,0.00039681094,0.00015910188,0.000039394003],"category_scores_gemma":[0.0002985676,0.00044901366,0.00024890975,0.0011149521,0.00012250723,0.0001656923,0.00041432623,0.0007064226,0.00000480776],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00040973647,0.0147052035,0.97383416,0.00055109424,0.00094455265,0.00008805556,0.00041133273,0.000034754838,0.0063607637,0.000050876595,0.000044940145,0.002564525],"study_design_scores_gemma":[0.047452305,0.0059509547,0.9363637,0.002095421,0.0007165602,0.000011296284,0.00070101564,0.00012125351,0.006259637,0.000014099219,0.000020875732,0.00029289615],"about_ca_topic_score_codex":0.00293632,"about_ca_topic_score_gemma":0.0009740458,"teacher_disagreement_score":0.047042567,"about_ca_system_score_codex":0.015661156,"about_ca_system_score_gemma":0.006859575,"threshold_uncertainty_score":0.99979615},"labels":[],"label_agreement":null},{"id":"W4417005181","doi":"10.1182/blood-2025-7274","title":"DNA methylation instability as a biomarker to predict resistance or progression to advanced disease Phase following tyrosine kinase inhibitor therapy in chronic myeloid leukemia","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"DNA methylation; Myeloid leukemia; Epigenetics; Methylation; Biomarker; CpG site; Genome instability; Myeloid","score_opus":0.016375076702198548,"score_gpt":0.33585564430109904,"score_spread":0.3194805675989005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417005181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98880285,0.004272023,0.00014432697,0.0013402677,0.00025125637,0.004407957,0.000050120772,0.00019869099,0.0005324956],"genre_scores_gemma":[0.9943171,0.00012309717,0.0024661392,0.0004895914,0.00012008921,0.0011357986,0.000120593155,0.00005173962,0.0011758384],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971267,0.00015312845,0.0006572484,0.00094790076,0.0005445712,0.00057042553],"domain_scores_gemma":[0.99818695,0.00015323922,0.000108187975,0.0009239904,0.00010832884,0.00051929534],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000429156,0.00040551194,0.0005812084,0.00042467943,0.00013300958,0.000039044517,0.00018180624,0.0001415023,0.00010027589],"category_scores_gemma":[0.0011189743,0.00032317016,0.00017662584,0.0016407499,0.000047707224,0.00022100894,0.00012700773,0.00021688531,0.000030749638],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033857808,0.0049549714,0.023354832,0.0007277499,0.00040525975,0.0011231783,0.0006547487,0.000047167443,0.6964357,0.000036132245,0.0007973076,0.23760517],"study_design_scores_gemma":[0.13520217,0.004304907,0.2306791,0.008118958,0.000658131,0.000007578042,0.00013052447,0.0004143482,0.5971207,0.00018363546,0.022354525,0.00082543393],"about_ca_topic_score_codex":0.000062034684,"about_ca_topic_score_gemma":0.00034735026,"teacher_disagreement_score":0.23677973,"about_ca_system_score_codex":0.005142279,"about_ca_system_score_gemma":0.003991757,"threshold_uncertainty_score":0.99992204},"labels":[],"label_agreement":null},{"id":"W4417011103","doi":"10.1182/blood-2025-1991","title":"Immune deconvolution from whole transcriptomic data suggests expansion of exhausted T-cells and natural killer cells following tyrosine kinase inhibitor therapy in chronic myeloid leukemia patients","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Immune system; Myeloid leukemia; Natural killer cell; Myeloid; Cell; Bone marrow; T cell; Mass cytometry","score_opus":0.010890297946859624,"score_gpt":0.24786212162729712,"score_spread":0.2369718236804375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417011103","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9810759,0.016445963,0.0000104036635,0.00005722392,0.00115067,0.0010627348,0.000114141,0.000050900875,0.000032104494],"genre_scores_gemma":[0.9962963,0.0011263395,0.00043115093,0.00007546414,0.00008597435,0.000028589726,0.0015173634,0.000042433247,0.00039639772],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977938,0.00008881982,0.00068800634,0.00070757046,0.00032365616,0.00039817198],"domain_scores_gemma":[0.99860626,0.000108054315,0.00015759053,0.0009647049,0.00006786801,0.000095516705],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017781078,0.00035094758,0.00066829595,0.00026370227,0.000068899135,0.00002145781,0.0002561029,0.00023030177,0.000035232286],"category_scores_gemma":[0.00003905741,0.00031781418,0.00012327808,0.00037813105,0.00008194721,0.00027420386,0.00015407041,0.00033789116,0.000011220583],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004688918,0.0007130751,0.022581343,0.00013789818,0.00032344673,0.000042062446,0.000306394,0.000009732726,0.9665637,0.0000013511516,0.00040251485,0.008449598],"study_design_scores_gemma":[0.05685184,0.00044362491,0.23995417,0.0014466346,0.00041789332,0.0000021779285,0.00008128207,0.0010526624,0.6988921,0.000011035458,0.0005860982,0.00026044494],"about_ca_topic_score_codex":0.0017495478,"about_ca_topic_score_gemma":0.0002802022,"teacher_disagreement_score":0.26767156,"about_ca_system_score_codex":0.0013151271,"about_ca_system_score_gemma":0.0009579384,"threshold_uncertainty_score":0.9999274},"labels":[],"label_agreement":null},{"id":"W4417011124","doi":"10.1182/blood-2025-1993","title":"ASC4OPT 96-week results: Asciminib once or twice daily continues to be highly efficacious and demonstrates favorable safety in patients with chronic myeloid leukemia and suboptimal response, resistance or intolerance to two or more tyrosine kinase inhibitors","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Discontinuation; Dosing; Cohort; Adverse effect; Clinical endpoint; Myeloid leukemia; Clinical trial; Cohort study; Tolerability","score_opus":0.009452666292112995,"score_gpt":0.2560672023998395,"score_spread":0.2466145361077265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417011124","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920874,0.001305746,0.00002598479,0.003250329,0.00009443647,0.0024499872,0.0003230444,0.00013446776,0.00032858035],"genre_scores_gemma":[0.9812446,0.00019254311,0.008520233,0.0009952615,0.00008772753,0.00019668993,0.00008980756,0.00007353179,0.008599592],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9961862,0.00019106866,0.00094700104,0.001301854,0.0005436462,0.00083024916],"domain_scores_gemma":[0.99733734,0.0008971037,0.00022735991,0.00080257363,0.0002722627,0.00046333752],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005750697,0.0006242177,0.0009990467,0.00040744693,0.00023436919,0.00011204749,0.00024046119,0.00019382752,0.00001582431],"category_scores_gemma":[0.0014650964,0.00043948274,0.000045455636,0.0015179571,0.00028771893,0.00025193495,0.00021367034,0.00042951482,0.0000075357307],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8061994,0.0039663524,0.13766952,0.0015710776,0.0008550639,0.0030764889,0.0067193727,0.00052984327,0.014962586,0.00005759218,0.006014582,0.018378168],"study_design_scores_gemma":[0.14679575,0.013583345,0.7690399,0.008323448,0.00073754566,0.00010471961,0.0009495342,0.00009901895,0.041814327,0.000004450879,0.017403454,0.0011445006],"about_ca_topic_score_codex":0.0005407875,"about_ca_topic_score_gemma":0.008810838,"teacher_disagreement_score":0.6594036,"about_ca_system_score_codex":0.0018870292,"about_ca_system_score_gemma":0.0026466092,"threshold_uncertainty_score":0.9998057},"labels":[],"label_agreement":null},{"id":"W4417011144","doi":"10.1182/blood-2025-1997","title":"Asciminib (ASC) demonstrates continued improvement in patient-reported outcomes (PROs) vs investigator-selected tyrosine kinase inhibitors (IS-TKIs) in newly diagnosed chronic myeloid leukemia (CML): ASC4FIRST week 96 analysis","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Adverse effect; Quality of life (healthcare); Clinical trial; Randomized controlled trial; Nilotinib; Myeloid leukemia; Clinical endpoint; Tyrosine-kinase inhibitor","score_opus":0.009302172277035474,"score_gpt":0.24516943866969315,"score_spread":0.23586726639265768,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417011144","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99288946,0.0020560743,0.000009513074,0.0014431826,0.00027676334,0.002637382,0.00006685286,0.000234058,0.00038673164],"genre_scores_gemma":[0.99622965,0.00025019774,0.00050270546,0.0010610366,0.00008919329,0.00069655967,0.00051029114,0.00008265377,0.00057770876],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9940906,0.00018521414,0.0022088254,0.0014674949,0.00081371516,0.0012341355],"domain_scores_gemma":[0.99680644,0.00039190837,0.00066875224,0.0012624674,0.00032777598,0.0005426735],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004405765,0.0008918439,0.0019276917,0.0017835895,0.00014519165,0.000102373546,0.00032801388,0.0004931075,0.00017168997],"category_scores_gemma":[0.0016682016,0.0008366787,0.0004750924,0.0058264583,0.00027147835,0.0002523118,0.00020874453,0.0008207255,0.000031643558],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00030487435,0.0028510038,0.95157796,0.00027249227,0.0031668565,0.0016103601,0.00068999914,0.000099437166,0.033014167,0.000022637474,0.0009854551,0.005404732],"study_design_scores_gemma":[0.049041953,0.0013098887,0.7507973,0.0008579047,0.0041450686,0.00002184386,0.00031376965,0.00092918985,0.191318,0.00006773391,0.0005027723,0.0006946108],"about_ca_topic_score_codex":0.0064908895,"about_ca_topic_score_gemma":0.008498489,"teacher_disagreement_score":0.20078073,"about_ca_system_score_codex":0.0048015127,"about_ca_system_score_gemma":0.0057762773,"threshold_uncertainty_score":0.99986005},"labels":[],"label_agreement":null},{"id":"W4417015862","doi":"10.1182/blood-2025-5549","title":"Improved long-term tolerability with asciminib (ASC) vs investigator-selected (IS) tyrosine kinase inhibitors (TKIs) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Week 96 exploratory analysis of the phase 3 ASC4FIRST trial","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Tolerability; Discontinuation; Adverse effect; Randomized controlled trial; Regimen; Multivariate analysis; Exploratory analysis","score_opus":0.012970421291537181,"score_gpt":0.26331847505347356,"score_spread":0.25034805376193636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417015862","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927673,0.0010031511,0.000021643813,0.00024056886,0.00021171929,0.005419162,0.00018102783,0.00011095558,0.000044484055],"genre_scores_gemma":[0.9976933,0.000109818095,0.00012925296,0.00027294568,0.00015889714,0.0008846742,0.00057388924,0.00009836715,0.00007886498],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9941127,0.0004718494,0.0017906466,0.0015367277,0.0010198808,0.0010682307],"domain_scores_gemma":[0.99582595,0.0003426556,0.00082472566,0.002059448,0.0004584324,0.00048876874],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00056674954,0.0009378734,0.002091211,0.0012294834,0.00017072832,0.000060937,0.00056871335,0.00041548256,0.00013168126],"category_scores_gemma":[0.0007304598,0.00067389716,0.0003972215,0.0077269175,0.0007024951,0.0003968842,0.00021628324,0.0010021077,0.0000053819244],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0602896,0.028727638,0.8762137,0.0011215147,0.0052481606,0.00037782965,0.0018364138,0.00066034397,0.017477421,0.0000071818095,0.0002722749,0.007767878],"study_design_scores_gemma":[0.6002503,0.014740609,0.25981167,0.0017972743,0.006552719,0.000004752005,0.00008806891,0.0016845491,0.11435849,0.0000046449413,0.000056061835,0.0006508471],"about_ca_topic_score_codex":0.0017165468,"about_ca_topic_score_gemma":0.013864325,"teacher_disagreement_score":0.6164021,"about_ca_system_score_codex":0.011931536,"about_ca_system_score_gemma":0.016903117,"threshold_uncertainty_score":0.9995712},"labels":[],"label_agreement":null},{"id":"W4417015865","doi":"10.1182/blood-2025-5548","title":"Beyond survival in chronic myeloid leukemia: A systematic review of secondary malignancies in the era of tyrosine kinase inhibitors","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Myeloid leukemia; Incidence (geometry); Systematic review; MEDLINE; Tyrosine kinase; Medical record; Concomitant; Tyrosine-kinase inhibitor; Nilotinib","score_opus":0.00854823276166846,"score_gpt":0.25125108441659944,"score_spread":0.24270285165493097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417015865","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.76078403,0.23312238,0.0000014476801,0.00048740595,0.00010148043,0.0021187002,0.000028203764,0.000014684398,0.0033416746],"genre_scores_gemma":[0.9891327,0.009778492,0.00007739146,0.0004481797,0.0000434577,0.0002253532,0.000039487946,0.000018430495,0.00023649623],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9976235,0.00026469995,0.0011630759,0.00027026123,0.00039966585,0.00027877573],"domain_scores_gemma":[0.99851066,0.00032226287,0.00030477342,0.00073199504,0.00009350383,0.00003681324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010504844,0.00023252219,0.0012606118,0.00020200788,0.000020912536,0.000005577685,0.00023584637,0.00011606404,0.00005700602],"category_scores_gemma":[0.0004893945,0.00015824605,0.00017491131,0.0009735271,0.000113941,0.000060558377,0.000080765894,0.0004171649,0.000006384774],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005828101,0.0010134421,0.008679114,0.9756633,0.00033312838,0.0002934308,0.00075024075,0.000005242695,0.01128121,0.0009817585,0.00048794452,0.00045292746],"study_design_scores_gemma":[0.02016935,0.00069606834,0.03357384,0.8779988,0.002470724,0.00013213106,0.0007923468,0.000032862245,0.06355199,0.00020734876,0.00008493124,0.00028954784],"about_ca_topic_score_codex":0.0004540394,"about_ca_topic_score_gemma":0.0004080528,"teacher_disagreement_score":0.22834869,"about_ca_system_score_codex":0.0011428751,"about_ca_system_score_gemma":0.002679212,"threshold_uncertainty_score":0.6453087},"labels":[],"label_agreement":null},{"id":"W4417016071","doi":"10.1182/blood-2025-724","title":"A comparison of real-world outcomes of asciminib versus ATP-competitive tyrosine kinase inhibitors as second-line treatment in patients with chronic myeloid leukemia in chronic phase","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Nilotinib; Myeloid leukemia; Comorbidity; Dasatinib; Tyrosine-kinase inhibitor; Retrospective cohort study; Sorafenib; Imatinib mesylate","score_opus":0.018380191646538056,"score_gpt":0.32513581636332595,"score_spread":0.3067556247167879,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417016071","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99278593,0.001189055,0.0000012224548,0.000089601104,0.00018443158,0.0019396461,0.00012991989,0.0000428598,0.003637352],"genre_scores_gemma":[0.9980325,0.0001180162,0.00018378491,0.000025028949,0.00005870711,0.00016539074,0.0003687338,0.00004828158,0.0009995286],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99704766,0.00009296532,0.0011813868,0.0006444555,0.000478719,0.0005548176],"domain_scores_gemma":[0.99821156,0.00030782112,0.0004597326,0.00072845427,0.00014891173,0.0001435468],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013355777,0.0005261125,0.0016395659,0.0008656854,0.000038391852,0.0000084836165,0.00017085618,0.00016472321,0.00025518125],"category_scores_gemma":[0.000078550336,0.00042514337,0.00018914661,0.0011407305,0.00022653455,0.000109376044,0.000092316324,0.0003098088,0.000013703765],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00653083,0.01224992,0.96872103,0.0006149002,0.0012545891,0.00013313856,0.0010197497,0.0002394991,0.0029076978,0.0003052594,0.00003974961,0.0059836083],"study_design_scores_gemma":[0.22748171,0.014757953,0.57489973,0.0015797465,0.0009146515,0.0000014971843,0.00020270771,0.00018602065,0.17913365,0.000007584783,0.00053775747,0.00029697688],"about_ca_topic_score_codex":0.0043434775,"about_ca_topic_score_gemma":0.025698442,"teacher_disagreement_score":0.39382133,"about_ca_system_score_codex":0.013465719,"about_ca_system_score_gemma":0.005097665,"threshold_uncertainty_score":0.99982005},"labels":[],"label_agreement":null},{"id":"W4417016277","doi":"10.1182/blood-2025-6761","title":"A case of co-mutation of SF3B1 and BCR::ABL1 demonstrating an MDS-phenotype","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; Concordia University; McGill University","funders":"","keywords":"Bone marrow; Myeloid leukemia; Missense mutation; Myeloid; Haematopoiesis; DNA sequencing; Myelodysplastic syndromes; Mutation; Germline mutation","score_opus":0.015709284618118984,"score_gpt":0.30291417144742494,"score_spread":0.28720488682930595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417016277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952724,0.0004570979,0.000067853856,0.000032240598,0.000020018535,0.0002253717,0.000013496496,0.00001835731,0.0038931787],"genre_scores_gemma":[0.9963317,0.000013377162,0.0034716018,0.000028873405,0.000018291503,0.000006370377,0.000022084587,0.0000071577088,0.0001005229],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9994296,0.000027673215,0.00022824561,0.00014025148,0.000080815254,0.0000934434],"domain_scores_gemma":[0.99953914,0.00007727347,0.000091471775,0.0001818339,0.00006304005,0.000047237965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000098406934,0.000077151526,0.00020588412,0.00007440762,0.000029737255,0.000003627604,0.000023705568,0.000055741006,0.000025852012],"category_scores_gemma":[0.000103892235,0.000070454684,0.000026086576,0.00012569275,0.00005867479,0.00004397328,0.000013506115,0.00006079976,0.0000012899027],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00058116706,0.0046996,0.5171173,0.0031869954,0.0018423762,0.0059951097,0.0052325716,0.00002990439,0.34030765,0.005081805,0.0001910121,0.11573451],"study_design_scores_gemma":[0.048925895,0.003477049,0.14042301,0.0014053419,0.0042275675,0.0083533665,0.003888359,0.0033364263,0.7842239,0.0012454551,0.000105293635,0.0003883334],"about_ca_topic_score_codex":0.0003484426,"about_ca_topic_score_gemma":0.00008415876,"teacher_disagreement_score":0.44391626,"about_ca_system_score_codex":0.0000391827,"about_ca_system_score_gemma":0.00025759137,"threshold_uncertainty_score":0.28730586},"labels":[],"label_agreement":null},{"id":"W4417016598","doi":"10.1182/blood-2025-6388","title":"The humanistic burden of patients with chronic myeloid leukemia (CML) treated with first line (1L) tyrosine kinase inhibitors (TKIs)","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Discontinuation; Myeloid leukemia; Adverse effect; Quality of life (healthcare); First line; Bosutinib; Cohort; Nilotinib; Population","score_opus":0.0057912680990299245,"score_gpt":0.21777353540926295,"score_spread":0.21198226731023304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417016598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99424505,0.0019707896,0.000022706912,0.00033573838,0.00007732706,0.0013025869,0.000054455577,0.00011421615,0.0018771155],"genre_scores_gemma":[0.99587166,0.00025404044,0.00015559238,0.00004635671,0.00019828243,0.00012088962,0.00025448916,0.00006426843,0.0030344354],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979369,0.000041732605,0.000507045,0.0004981324,0.0005165298,0.0004996404],"domain_scores_gemma":[0.9981564,0.00023142352,0.00025690682,0.0009049961,0.00030615806,0.000144087],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000101170685,0.00041877606,0.0005526993,0.00015712235,0.00031727206,0.00003446824,0.00022286142,0.00013664993,0.00007278378],"category_scores_gemma":[0.00011831078,0.00024045055,0.000096759504,0.0006488937,0.00033960812,0.000069291134,0.000093927105,0.00028481198,0.000024378118],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009276186,0.007717084,0.939174,0.0035090626,0.007981665,0.0008329876,0.0011333446,0.0012202639,0.005588727,0.001046029,0.005053712,0.017466927],"study_design_scores_gemma":[0.18758354,0.01916198,0.6048338,0.008666056,0.010537299,0.00009293859,0.00024355309,0.0006588963,0.13379784,0.00008388601,0.03294199,0.0013982472],"about_ca_topic_score_codex":0.0008664544,"about_ca_topic_score_gemma":0.001211078,"teacher_disagreement_score":0.33434024,"about_ca_system_score_codex":0.0015634595,"about_ca_system_score_gemma":0.0015738755,"threshold_uncertainty_score":0.98052883},"labels":[],"label_agreement":null},{"id":"W4417020718","doi":"10.1182/blood-2025-4273","title":"Relapse with post-transplant tyrosine kinase inhibitor (TKI) maintenance therapy in phliladelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) after allogeneic hematopoietic stem cell transplantation: Incidence and risk factor analysis","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saskatchewan Cancer Agency; Princess Margaret Cancer Centre","funders":"","keywords":"Cumulative incidence; Maintenance therapy; Hematopoietic stem cell transplantation; Incidence (geometry); Clinical endpoint; Acute lymphocytic leukemia; Transplantation; Tyrosine-kinase inhibitor; Retrospective cohort study; Stem cell","score_opus":0.005103187444848837,"score_gpt":0.21940240336575145,"score_spread":0.21429921592090262,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417020718","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932151,0.0041345954,0.00030537412,0.00024974556,0.0000546451,0.0010203851,0.00088060426,0.000074899595,0.00006466764],"genre_scores_gemma":[0.9902522,0.008177859,0.00043556094,0.00040124374,0.000036776546,0.00020364011,0.00019571738,0.000048482703,0.00024850597],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99742055,0.00013624527,0.0005860576,0.00087479287,0.00042274524,0.00055959984],"domain_scores_gemma":[0.9986815,0.00021331127,0.00019404883,0.0005327669,0.00014908848,0.0002292929],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012411692,0.00054271304,0.00085638446,0.0004986638,0.00009339158,0.000047542373,0.00015580913,0.00022651376,0.000069753354],"category_scores_gemma":[0.0000072863386,0.0004137021,0.00019078379,0.0010610052,0.00017213546,0.0001860564,0.0000310187,0.00035009033,0.000013458104],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009166304,0.0016124782,0.88151824,0.0008241196,0.007509936,0.012492575,0.007503129,0.00016628626,0.07825983,0.000027824904,0.000012520011,0.0009067256],"study_design_scores_gemma":[0.027633557,0.0015410446,0.82458186,0.0016138576,0.011179907,0.00081704964,0.00020412014,0.00014936822,0.13172337,0.000013379278,0.000011481412,0.0005310017],"about_ca_topic_score_codex":0.00054471416,"about_ca_topic_score_gemma":0.00092995464,"teacher_disagreement_score":0.056936413,"about_ca_system_score_codex":0.00087284524,"about_ca_system_score_gemma":0.00074274366,"threshold_uncertainty_score":0.9998315},"labels":[],"label_agreement":null},{"id":"W4417020775","doi":"10.1182/blood-2025-8178","title":"Real-world analysis of asciminib as first-line therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase: A chart review Study in the United States","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Discontinuation; Interim; Clinical trial; Myeloid leukemia; Interim analysis; Concordance; Nilotinib; Medical record","score_opus":0.017885212387219577,"score_gpt":0.3186096871335428,"score_spread":0.30072447474632324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417020775","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98599935,0.008444695,0.0000014106564,0.000542181,0.000024720975,0.004643597,0.000039065606,0.000031199488,0.00027376632],"genre_scores_gemma":[0.96193916,0.03552762,0.000021029737,0.00061645167,0.000028686729,0.00067537423,0.0009975018,0.000033750912,0.0001604041],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967147,0.0003824292,0.0010959394,0.0006391987,0.0006372767,0.00053047104],"domain_scores_gemma":[0.9978356,0.00051114266,0.0003183145,0.0011220364,0.00013657901,0.00007635651],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007812913,0.00042847803,0.0013883444,0.0019195797,0.00004962792,0.000016664244,0.00038487522,0.00008894771,0.00021667386],"category_scores_gemma":[0.00014152587,0.00028435714,0.00016168633,0.009717399,0.000096190306,0.00008983163,0.00006634398,0.0004681674,0.0000074689915],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009824235,0.011817371,0.97226745,0.0008602318,0.0028099853,0.00033091655,0.0020435296,0.0015880677,0.000026135072,0.000015494097,0.00018242351,0.0070760017],"study_design_scores_gemma":[0.110737786,0.0057206294,0.8735072,0.0043583047,0.0029241461,0.000001175592,0.00027001312,0.0010557852,0.00016910813,0.000008335405,0.0010061015,0.00024141403],"about_ca_topic_score_codex":0.017952312,"about_ca_topic_score_gemma":0.080293566,"teacher_disagreement_score":0.10975537,"about_ca_system_score_codex":0.0052809888,"about_ca_system_score_gemma":0.0025357157,"threshold_uncertainty_score":0.99996084},"labels":[],"label_agreement":null},{"id":"W4417021452","doi":"10.1182/blood-2025-3767","title":"Emergence of new somatic mutations in CML patients optimally responding to tyrosine kinase inhibitor therapy: Proposal of long-term genomic monitoring","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Somatic cell; Germline mutation; Epigenetics; RUNX1; Myeloid leukemia; Somatic evolution in cancer; Trisomy 8; Spliceosome; Myeloid; Imatinib mesylate","score_opus":0.016867897445763384,"score_gpt":0.29805066500865546,"score_spread":0.28118276756289207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417021452","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979259,0.00061739696,0.000050245086,0.0001122787,0.00016173536,0.00096600066,0.000008575568,0.000020852598,0.00013705599],"genre_scores_gemma":[0.9926669,0.000051611507,0.006696557,0.000013957422,0.000058225465,0.000040081104,0.000019288183,0.000019815758,0.00043356474],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99881107,0.000032850527,0.0005055631,0.00022919061,0.00021861288,0.00020272216],"domain_scores_gemma":[0.99934876,0.000048077265,0.00013039735,0.00029832913,0.00008443901,0.00008998836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000919042,0.0001461466,0.0003164477,0.0005607933,0.0000275243,0.0000058874407,0.000113578855,0.00005785878,0.000054266293],"category_scores_gemma":[0.00011982538,0.00013667012,0.00006240131,0.0006912135,0.000027028002,0.00006225414,0.00006197846,0.00008869886,0.00000793427],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002512891,0.001138041,0.7626321,0.00021635284,0.000118193566,0.00002597929,0.0010441267,0.000056020213,0.22936428,0.000016533797,0.000022947934,0.0051141954],"study_design_scores_gemma":[0.00723975,0.00041403878,0.62765074,0.0009800077,0.00011013688,0.0000019065901,0.00007624205,0.000019162397,0.36341962,0.000016709088,0.0000021914861,0.000069491485],"about_ca_topic_score_codex":0.00010129234,"about_ca_topic_score_gemma":0.000016124059,"teacher_disagreement_score":0.13498132,"about_ca_system_score_codex":0.00017673074,"about_ca_system_score_gemma":0.0007749255,"threshold_uncertainty_score":0.5573246},"labels":[],"label_agreement":null},{"id":"W4417069316","doi":"10.1182/blood-2025-7300","title":"Real-world data comparison of asciminib 40 mg twice daily vs. 80 mg once daily in chronic myeloid leukemia patients","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Discontinuation; Myeloid leukemia; Adverse effect; Tyrosine-kinase inhibitor; Survival analysis; Leukemia; Nilotinib; Myeloid; Clinical trial","score_opus":0.03434395425559256,"score_gpt":0.3315944448529916,"score_spread":0.29725049059739905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417069316","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98083776,0.001251544,0.000013593036,0.00025076003,0.00029551753,0.0010361209,0.00018799912,0.00011002687,0.01601669],"genre_scores_gemma":[0.99415946,0.00038736113,0.0014124124,0.00021586753,0.00016160205,0.00005459004,0.0013073529,0.000057736517,0.002243627],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99622035,0.00013661798,0.0011682893,0.0010442788,0.00070810324,0.0007223325],"domain_scores_gemma":[0.99636984,0.00032817613,0.00045028995,0.002505117,0.00015371169,0.00019289555],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00039655555,0.00045140568,0.0011950094,0.00050124835,0.000092671966,0.000029103008,0.000919216,0.00017936369,0.00010857339],"category_scores_gemma":[0.00031131686,0.00043980585,0.0001171224,0.0012964776,0.00022329218,0.00025840473,0.00073926576,0.0006104637,0.00009591601],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011266504,0.0032118035,0.9592624,0.00096108014,0.0006889829,0.00009517525,0.0006856537,0.000058079022,0.005145003,0.00021575238,0.010888894,0.017660582],"study_design_scores_gemma":[0.037159644,0.0011022681,0.9261214,0.0018256272,0.0011233458,0.0000062675563,0.000186367,0.002780099,0.014705061,0.000035024077,0.014525909,0.00042894532],"about_ca_topic_score_codex":0.0057060495,"about_ca_topic_score_gemma":0.0076867724,"teacher_disagreement_score":0.036032993,"about_ca_system_score_codex":0.0038735198,"about_ca_system_score_gemma":0.0034966178,"threshold_uncertainty_score":0.9999504},"labels":[],"label_agreement":null},{"id":"W4417342747","doi":"10.1182/blood.2025029210","title":"Asciminib demonstrates superior efficacy and safety in newly diagnosed chronic myeloid leukemia in the ASC4FIRST trial","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Novartis Pharma; EUSA Pharma; Astellas Pharma; Incyte; Syndax Pharmaceuticals; BeiGene; Gilead Sciences; Celgene; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer","keywords":"Discontinuation; Imatinib; Tolerability; Myeloid leukemia; Imatinib mesylate; Adverse effect; Hazard ratio; Clinical trial","score_opus":0.012407773810649187,"score_gpt":0.2700160286641859,"score_spread":0.2576082548535367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417342747","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98942626,0.0035541249,0.000002843124,0.0012229705,0.0001537359,0.002168498,0.000010908607,0.00004624459,0.0034144057],"genre_scores_gemma":[0.9976895,0.0010997258,0.00014871127,0.00032062383,0.00020954316,0.00021475014,0.00004319024,0.000021484455,0.00025248426],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99806404,0.0001646243,0.00055502146,0.00048772714,0.00025684683,0.00047174512],"domain_scores_gemma":[0.9983913,0.0009259879,0.00006274177,0.000513388,0.000021655966,0.0000849583],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000493701,0.00028277538,0.0005327779,0.00022625767,0.000095631316,0.00004845571,0.00021249858,0.00020215349,0.00006432444],"category_scores_gemma":[0.00045713063,0.00020610937,0.00008915122,0.000626098,0.0001616722,0.00008416207,0.00007739894,0.00047273946,0.000021448388],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06950366,0.013518281,0.66941357,0.0017384454,0.0019791485,0.007732013,0.012702587,0.00030430572,0.016471613,0.0026909073,0.0025032393,0.20144226],"study_design_scores_gemma":[0.4590309,0.0011942912,0.532043,0.00065194804,0.0004415583,0.00010466673,0.00051833317,0.00017678543,0.0022152187,0.00007313637,0.0033061747,0.00024403333],"about_ca_topic_score_codex":0.00078751164,"about_ca_topic_score_gemma":0.0016880088,"teacher_disagreement_score":0.38952723,"about_ca_system_score_codex":0.0014805009,"about_ca_system_score_gemma":0.002561342,"threshold_uncertainty_score":0.8404896},"labels":[],"label_agreement":null},{"id":"W643832206","doi":"10.71781/31540","title":"Étude fonctionnelle des complexes transcriptionnels SCL hématopoïétiques","year":2008,"lang":"fr","type":"dissertation","venue":"Papyrus : Institutional Repository (Université de Montréal)","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine","score_opus":0.011530259622935277,"score_gpt":0.20199570280732607,"score_spread":0.1904654431843908,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W643832206","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8659599,0.10219869,0.00091102073,0.00019649717,0.002578184,0.000986045,0.00016181,0.0003332396,0.02667461],"genre_scores_gemma":[0.8952664,0.014260552,0.0028419916,0.00013425288,0.00082352036,0.00008842864,0.0018943514,0.000114493494,0.084576026],"study_design_codex":"qualitative","study_design_gemma":"observational","domain_scores_codex":[0.99548197,0.00026381243,0.00088666216,0.0011453016,0.0011633834,0.0010588913],"domain_scores_gemma":[0.9970988,0.00019193864,0.0005333616,0.0006973174,0.0006279269,0.0008506453],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.0001803353,0.0010105724,0.0010598671,0.0005639163,0.0131801395,0.00006773293,0.0004730895,0.00094083435,0.0006609184],"category_scores_gemma":[0.00007688395,0.001162779,0.000861467,0.00057182316,0.0011157781,0.0006828255,0.00011071937,0.0008499792,0.00051957683],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0080794385,0.0045752563,0.15740237,0.0045400662,0.007931942,0.0312602,0.4528594,0.010136484,0.2612794,0.035464283,0.0056767063,0.02079447],"study_design_scores_gemma":[0.017488651,0.0013245103,0.5666424,0.0064919787,0.0050815446,0.021819832,0.17406857,0.0057136915,0.1364672,0.0010853051,0.061011396,0.0028049406],"about_ca_topic_score_codex":0.11499128,"about_ca_topic_score_gemma":0.026043037,"teacher_disagreement_score":0.40924,"about_ca_system_score_codex":0.03812885,"about_ca_system_score_gemma":0.005264946,"threshold_uncertainty_score":0.9990822},"labels":[],"label_agreement":null},{"id":"W657458426","doi":"10.71781/29825","title":"Fonctions du facteur de transcription SCL dans les cellules souches et les progéniteurs hématopoïétiques","year":2008,"lang":"fr","type":"dissertation","venue":"Open MIND","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute; Canadian Institutes of Health Research; Cancer Research Society","keywords":"Biology; Molecular biology","score_opus":0.05101705018096494,"score_gpt":0.32449002679090233,"score_spread":0.2734729766099374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W657458426","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94518566,0.0055141863,0.00081640604,0.0006779237,0.0008796186,0.0026323842,0.0003936962,0.000029382614,0.043870766],"genre_scores_gemma":[0.8970572,0.0097802775,0.00922485,0.000052304236,0.00062304846,0.0005070371,0.00958775,0.00021420763,0.07295332],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99605715,0.00055712886,0.0009341586,0.0010613528,0.00054327596,0.000846927],"domain_scores_gemma":[0.997961,0.0002673684,0.00049990835,0.00061415235,0.00026823583,0.00038935358],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00047018297,0.0009062885,0.0009837776,0.0002994961,0.00085496594,0.0002987566,0.0006367824,0.0011021402,0.0045011546],"category_scores_gemma":[0.00020824566,0.0009023117,0.00041955826,0.00030840412,0.00032570242,0.00058258796,0.000070727045,0.0011244585,0.00090307125],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012288399,0.003675367,0.15031189,0.00130911,0.0020309926,0.0011548378,0.20269899,0.0003032068,0.17213401,0.00075106346,0.0016530467,0.46274862],"study_design_scores_gemma":[0.010821843,0.001537311,0.23467383,0.0070361495,0.00459598,0.0014617612,0.105059974,0.0014926466,0.38808164,0.00013257771,0.2429099,0.00219638],"about_ca_topic_score_codex":0.012596836,"about_ca_topic_score_gemma":0.017048016,"teacher_disagreement_score":0.46055225,"about_ca_system_score_codex":0.0022266314,"about_ca_system_score_gemma":0.0029028633,"threshold_uncertainty_score":0.99987483},"labels":[],"label_agreement":null},{"id":"W65840692","doi":"10.1182/blood.v108.11.2153.2153","title":"Abnormally Small BCR-ABL Transcripts in CML Patients before and during Imatinib Treatment.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Biology; Exon; Imatinib mesylate; Fusion gene; Amplicon; ABL; Imatinib; Tyrosine kinase; Alternative splicing; breakpoint cluster region; Cancer research; Fusion transcript; Molecular biology; Genetics; Gene; Polymerase chain reaction; Myeloid leukemia; Receptor","score_opus":0.007286936200778216,"score_gpt":0.2101842660553204,"score_spread":0.20289732985454217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W65840692","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99349827,0.0003788016,0.0000012443337,0.00007119228,0.00004853801,0.0006724896,0.000031146992,0.00007163013,0.0052266954],"genre_scores_gemma":[0.9975626,0.0000721267,0.00084180094,0.000040490355,0.000096700474,0.000069936796,0.00014565636,0.00003823189,0.0011324706],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99872273,0.000024861316,0.00034328032,0.00034101898,0.00017134503,0.00039678474],"domain_scores_gemma":[0.99951226,0.00001892826,0.00006651318,0.00025771835,0.00003119424,0.000113384325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004237386,0.00025407202,0.00035000383,0.00014713137,0.00006165168,0.000018223158,0.000052987503,0.000105857136,0.00005184489],"category_scores_gemma":[0.000013063691,0.00021153674,0.00007779918,0.0001469483,0.00004113741,0.00008548532,0.000019276646,0.00010459464,0.0000211783],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012204974,0.0026484667,0.98996526,0.00014148197,0.00011396029,0.00032299556,0.0006194091,0.0000029580633,0.0018551414,0.000025906815,0.000011325205,0.0041710245],"study_design_scores_gemma":[0.040058736,0.00081069797,0.9489115,0.00015113401,0.0002856539,0.00010358921,0.00002935911,0.000023435743,0.009166579,0.00004163647,0.0002652428,0.00015247142],"about_ca_topic_score_codex":0.0014068389,"about_ca_topic_score_gemma":0.0023536088,"teacher_disagreement_score":0.041053817,"about_ca_system_score_codex":0.00036919958,"about_ca_system_score_gemma":0.00010665253,"threshold_uncertainty_score":0.8626218},"labels":[],"label_agreement":null},{"id":"W6921087809","doi":"10.6084/m9.figshare.19423839","title":"Restoration of miR-23a expression by chidamide sensitizes CML cells to imatinib treatment with concomitant downregulation of CRYAB","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Imatinib mesylate; Downregulation and upregulation; Myeloid leukemia; K562 cells; Imatinib; Bone marrow; Peripheral blood mononuclear cell; microRNA","score_opus":0.021716486450800803,"score_gpt":0.2620542990795985,"score_spread":0.2403378126287977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6921087809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89954954,0.00026427303,0.0000061117435,0.0001590774,0.000028920585,0.0014159366,0.097650744,0.00005147038,0.00087392743],"genre_scores_gemma":[0.9353647,0.000002646195,0.0009624246,0.000052439886,0.00003056187,0.00031925063,0.062611744,0.000027351887,0.000628836],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987784,0.00007483026,0.00031908622,0.00025365854,0.00041906902,0.00015494284],"domain_scores_gemma":[0.99903095,0.00010699202,0.0002808224,0.00037055078,0.00011644352,0.00009424002],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000039917653,0.00016973616,0.00034449494,0.000087983455,0.000075663964,0.00000575585,0.000059504953,0.00004558642,0.019413492],"category_scores_gemma":[0.000060315935,0.00013303256,0.00006486929,0.00018382758,0.000009212747,0.00005928763,0.00006197306,0.000069220354,0.000046654946],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009742103,0.00040610056,0.0002250234,0.00025835723,0.000092810726,0.000040770206,0.0014050667,0.0009594315,0.8597043,0.000002110842,0.13386685,0.0020649505],"study_design_scores_gemma":[0.0051883943,0.0032016365,0.004970502,0.0013823166,0.000089436384,0.00003318966,0.00036531192,0.00072208,0.96655923,0.0000031027914,0.017321834,0.00016295817],"about_ca_topic_score_codex":0.00008154526,"about_ca_topic_score_gemma":0.000012818378,"teacher_disagreement_score":0.116545014,"about_ca_system_score_codex":0.00090530625,"about_ca_system_score_gemma":0.0002650784,"threshold_uncertainty_score":0.9814829},"labels":[],"label_agreement":null},{"id":"W6929475867","doi":"10.48660/16040106","title":"Spin liquids on kagome lattice and symmetry protected topological phase","year":2016,"lang":"en","type":"other","venue":"PIRSA","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Perimeter Institute","funders":"","keywords":"Lattice (music); Quantum spin liquid; Symmetry (geometry); Topology (electrical circuits); Spin (aerodynamics); Phase (matter)","score_opus":0.023659873815580445,"score_gpt":0.32993698578780756,"score_spread":0.3062771119722271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6929475867","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0335979,0.0024382167,0.000039594644,0.0018804776,0.00032544287,0.0018923648,0.00011086301,0.0005373781,0.95917773],"genre_scores_gemma":[0.026610892,0.0004339002,0.0008813753,0.0010095412,0.0013131972,0.00015620346,0.00006405626,0.00038262084,0.9691482],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986518,0.0000531267,0.00019604329,0.0005070028,0.00026379223,0.0003282114],"domain_scores_gemma":[0.9991048,0.0000635152,0.00012052521,0.00048755013,0.000020525707,0.0002030852],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00007844189,0.00034645002,0.0005484202,0.00021234123,0.000029955096,0.000010826462,0.0000891668,0.0004958573,0.009496949],"category_scores_gemma":[0.00016697527,0.00021846218,0.000078102035,0.00009011808,0.00014333981,0.00001424268,0.000061939245,0.00032288866,0.0014761791],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002946087,0.0037320957,0.001173625,0.002053534,0.002072784,0.0032494294,0.0001638232,2.0424704e-8,0.0053061657,0.0061207674,0.78523123,0.18795042],"study_design_scores_gemma":[0.012584385,0.0029276987,0.00036303684,0.0016921769,0.0003519509,0.0001588993,0.000009220094,0.00000678231,0.0009992253,0.00013306677,0.9803855,0.00038806375],"about_ca_topic_score_codex":0.00012722604,"about_ca_topic_score_gemma":0.000015322243,"teacher_disagreement_score":0.19515425,"about_ca_system_score_codex":0.00052806205,"about_ca_system_score_gemma":0.00019489099,"threshold_uncertainty_score":0.9993013},"labels":[],"label_agreement":null},{"id":"W6929840282","doi":"10.5063/aa/dpennington.154.1","title":"IPCC Climate Change Data: CGCM1 A2a Model: 2050 Mean Temperature","year":2005,"lang":"en","type":"dataset","venue":"UC Santa Barbara","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Forcing (mathematics); Climate model; Albedo (alchemy); Climate change; Radiative forcing; Atmospheric model; Atmosphere (unit); Greenhouse gas","score_opus":0.058360804748945984,"score_gpt":0.3294717842198687,"score_spread":0.2711109794709227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6929840282","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00086451333,0.008516586,7.881558e-7,0.0005354288,0.0008951391,0.001789949,0.9859927,0.0002446267,0.001160245],"genre_scores_gemma":[0.00035161898,0.027689934,0.00048754967,0.0034400579,0.004868998,0.00021412654,0.96147114,0.00019630979,0.0012802485],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99450725,0.00011126534,0.00085259596,0.0020428202,0.0011388687,0.0013471929],"domain_scores_gemma":[0.9925681,0.00009833672,0.00034769042,0.0062639173,0.000119291886,0.00060266844],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00045707,0.0012259805,0.0016199508,0.00041096233,0.00023379615,0.00013023714,0.0015068764,0.0013764149,0.0035136945],"category_scores_gemma":[0.000112135705,0.0010445028,0.0002798383,0.00037581308,0.00015122326,0.00051471754,0.001288992,0.0019206622,0.004548982],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002508099,0.00040178906,0.000044562763,0.00078834814,0.00048005217,0.00092328456,0.0000985395,0.000008985849,0.000075331875,0.000008915336,0.99489737,0.0020220394],"study_design_scores_gemma":[0.004391133,0.0001680599,0.00014362707,0.0011893379,0.0022245112,0.00053667085,0.00003728526,0.0018716545,0.000036869347,0.000007769488,0.988511,0.00088203914],"about_ca_topic_score_codex":0.0007355876,"about_ca_topic_score_gemma":0.0010338019,"teacher_disagreement_score":0.024521567,"about_ca_system_score_codex":0.0016644096,"about_ca_system_score_gemma":0.00076420506,"threshold_uncertainty_score":0.99992},"labels":[],"label_agreement":null},{"id":"W6930364741","doi":"10.5281/zenodo.12483814","title":"bell 47 flight manual pdf","year":2024,"lang":"en","type":"other","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Frame (networking); Work (physics); Troubleshooting; Limiting; Nucleofection; Table (database)","score_opus":0.02382523739709335,"score_gpt":0.2698552478878796,"score_spread":0.24603001049078627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6930364741","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000082022096,0.0014268863,0.00009094002,0.0006610547,0.00030983455,0.00084864156,0.00040659343,0.001945374,0.99422866],"genre_scores_gemma":[0.001075469,0.0005094473,0.00024511266,0.00019493379,0.00090752577,7.959366e-8,0.005012144,0.015108719,0.9769466],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99776906,0.00013830377,0.00027838437,0.0007466347,0.00058932573,0.00047826706],"domain_scores_gemma":[0.99856037,0.000010223628,0.000119710785,0.00084006175,0.00016455406,0.00030509362],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00024873344,0.00033662166,0.00037612245,0.00057007786,0.0003909909,0.00033584176,0.00058311934,0.00026899064,0.4074516],"category_scores_gemma":[0.00018410679,0.00031962074,0.00013457768,0.00045936782,0.00016469565,0.00005233791,0.001014659,0.0006010888,0.53789306],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000046132485,0.00013602474,6.276785e-7,0.0005726747,0.00034224542,0.00034383262,0.00022752455,3.3557762e-7,0.00021808865,0.0005759412,0.9786409,0.018895641],"study_design_scores_gemma":[0.0011879215,0.00030570026,0.000023697714,0.000544856,0.00021015422,0.0005506754,0.00006333976,0.000024558793,0.00013275282,0.00005630492,0.9966407,0.00025936207],"about_ca_topic_score_codex":0.000050005758,"about_ca_topic_score_gemma":0.000001049003,"teacher_disagreement_score":0.13044147,"about_ca_system_score_codex":0.00087448594,"about_ca_system_score_gemma":0.000019708157,"threshold_uncertainty_score":0.9999256},"labels":[],"label_agreement":null},{"id":"W6930374553","doi":"10.5281/zenodo.11787771","title":"cuando cae la noche pdf niñera","year":2024,"lang":"es","type":"other","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Presentation (obstetrics); The Renaissance; Ven","score_opus":0.027030035487641442,"score_gpt":0.2703279150607218,"score_spread":0.24329787957308036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6930374553","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006021509,0.0037045947,0.00014916924,0.0010490192,0.0005740746,0.0013426194,0.0008939855,0.0015827041,0.9901017],"genre_scores_gemma":[0.018660245,0.0034423782,0.00022468585,0.0003071043,0.001934495,2.2836336e-7,0.007637911,0.020792462,0.9470005],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956139,0.0006909409,0.0005749504,0.0012815209,0.0009554707,0.00088326295],"domain_scores_gemma":[0.997363,0.00007389692,0.00025220573,0.0013259924,0.00043837554,0.0005465485],"candidate_categories":["metaepi_narrow","scholarly_communication","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0008542738,0.00065128214,0.0006818271,0.00076367613,0.0009892393,0.0014029653,0.0012349082,0.00052067824,0.42842525],"category_scores_gemma":[0.0009845176,0.0006235641,0.0002550422,0.00089782797,0.0004614785,0.00013260006,0.001959828,0.0013540026,0.639777],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014692674,0.00031417896,0.0000036374568,0.0012255498,0.00086221413,0.00067353225,0.0009919594,0.0000032021264,0.0009353236,0.0022420904,0.9218223,0.07077906],"study_design_scores_gemma":[0.002882895,0.0004935783,0.00009834132,0.0015569816,0.0004985383,0.00089006196,0.00025900052,0.00011062299,0.0002287767,0.00009413583,0.9923817,0.00050538266],"about_ca_topic_score_codex":0.00010910266,"about_ca_topic_score_gemma":9.854715e-7,"teacher_disagreement_score":0.21135172,"about_ca_system_score_codex":0.001833796,"about_ca_system_score_gemma":0.000059125097,"threshold_uncertainty_score":0.99963367},"labels":[],"label_agreement":null},{"id":"W6931041057","doi":"10.5281/zenodo.3264155","title":"JAMES: Junk Authorizations for Massive-scale Enterprise Services","year":2005,"lang":"en","type":"article","venue":"Figshare","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Authorization; Exploit; Firewall (physics); Access control; Server; Leverage (statistics); Intrusion detection system; Enforcement; Service-oriented architecture","score_opus":0.02255838915641465,"score_gpt":0.2930083918259466,"score_spread":0.27045000266953195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6931041057","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03212173,0.0038087806,0.0002296058,0.0132629955,0.00044336123,0.006820495,0.8943054,0.0013563776,0.047651246],"genre_scores_gemma":[0.40994006,0.000026075057,0.0098394165,0.0028851526,0.0018679617,0.0023857504,0.5471233,0.00013805025,0.025794188],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991501,0.000008997382,0.0001784545,0.00025614107,0.00015412919,0.00025215442],"domain_scores_gemma":[0.9992748,0.000071691145,0.00007489158,0.00030550326,0.00012117967,0.00015195434],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000016020258,0.0001475166,0.00018348171,0.000063135914,0.00008901274,0.00002564588,0.00011126649,0.00009987026,0.1022507],"category_scores_gemma":[0.00011794775,0.0001317774,0.00011178252,0.0001172043,0.0000041820144,0.00012391861,0.00004864517,0.00008547205,0.0030557935],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009332348,0.00031990276,0.0007775678,0.0010868704,0.00014808973,0.000022553115,0.0011904635,0.000095431475,0.00032944532,0.000017816472,0.96928126,0.026637297],"study_design_scores_gemma":[0.002801403,0.00013084078,0.0026913204,0.0019160495,0.000093738214,0.000021261218,0.00014011862,0.0054963543,0.0027638515,0.000015461605,0.98377365,0.00015597985],"about_ca_topic_score_codex":0.000006199722,"about_ca_topic_score_gemma":0.00003098497,"teacher_disagreement_score":0.37781835,"about_ca_system_score_codex":0.00037938022,"about_ca_system_score_gemma":0.00017775255,"threshold_uncertainty_score":0.9977204},"labels":[],"label_agreement":null},{"id":"W6955622395","doi":"10.58079/quc4","title":"Appel à propositions. \"Low tech et enjeux ecologiques: quels potentiels pour affronter les crises\". Revue La pensée ecologique","year":2019,"lang":"fr","type":"article","venue":"OpenEdition (OpenEdition)","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Context (archaeology); Work (physics); Feature (linguistics); Negotiation","score_opus":0.02276115515904761,"score_gpt":0.287470356177199,"score_spread":0.26470920101815143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6955622395","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14558315,0.012595477,0.010330522,0.49598682,0.020183329,0.018498896,0.00516101,0.0014946507,0.29016614],"genre_scores_gemma":[0.8437605,0.005547233,0.010241842,0.02739138,0.002632333,0.0022852276,0.0056867776,0.00027383643,0.10218086],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99159974,0.0020408435,0.0016976,0.0019821113,0.0009845989,0.0016951308],"domain_scores_gemma":[0.99411106,0.0013481939,0.0009559227,0.0016673163,0.0011598726,0.0007576481],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.002122001,0.0012976109,0.0016200521,0.00059058896,0.0006267879,0.00051128503,0.00088447134,0.0019095199,0.0494189],"category_scores_gemma":[0.0009054926,0.0013314867,0.0007168895,0.00063095544,0.0007286298,0.009269221,0.00055666006,0.002030111,0.02312011],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002085495,0.014725758,0.010921887,0.009641787,0.0030878366,0.0064879586,0.0013477936,0.0016921215,0.012520537,0.47803405,0.41970485,0.039749913],"study_design_scores_gemma":[0.043958653,0.010657756,0.2795869,0.031980243,0.004270539,0.009102963,0.0072179474,0.003126398,0.04034355,0.025700377,0.5375164,0.006538265],"about_ca_topic_score_codex":0.00045138903,"about_ca_topic_score_gemma":0.0015640421,"teacher_disagreement_score":0.69817734,"about_ca_system_score_codex":0.0050989133,"about_ca_system_score_gemma":0.003300622,"threshold_uncertainty_score":0.9999775},"labels":[],"label_agreement":null},{"id":"W6969371770","doi":"10.5281/zenodo.7919554","title":"Imatinib mesylate: Recent drug used in oncology","year":2023,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Imatinib; Imatinib mesylate; Chronic myeloid leukaemia; Drug; Myeloid leukemia; Bioequivalence; Clinical trial","score_opus":0.058338928146033704,"score_gpt":0.3151679195635627,"score_spread":0.256828991417529,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6969371770","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7597907,0.00012940091,0.00006053747,0.009633434,0.00022625428,0.0013930643,0.00010566936,0.0021536215,0.22650729],"genre_scores_gemma":[0.98432475,0.0010266544,0.0003830131,0.000405767,0.000188966,2.7200048e-7,0.0043747057,0.0019799848,0.007315855],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981683,0.00029485725,0.00031370626,0.00039627455,0.0003690781,0.00045778975],"domain_scores_gemma":[0.99897873,0.000053848365,0.00008107157,0.00044492434,0.00024102165,0.0002004287],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000792441,0.0001394092,0.00024893598,0.00040953883,0.00050056225,0.000108592874,0.0003648319,0.000078408775,0.017433476],"category_scores_gemma":[0.0008005866,0.00013814843,0.00004723339,0.0012493356,0.00009920776,0.0001052516,0.00063303456,0.00033457717,0.02895277],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032730977,0.0006146487,0.00025435936,0.0001775184,0.0001329324,0.0007528836,0.0057176617,0.00008300483,0.009627907,0.0009105426,0.556096,0.42530525],"study_design_scores_gemma":[0.0034300906,0.00030075843,0.0064458847,0.00005896398,0.000020495627,0.00017716418,0.00053742196,0.00069963746,0.0009124419,0.000095917734,0.987199,0.00012223094],"about_ca_topic_score_codex":0.000037250644,"about_ca_topic_score_gemma":0.0000018859557,"teacher_disagreement_score":0.431103,"about_ca_system_score_codex":0.001429933,"about_ca_system_score_gemma":0.000029542614,"threshold_uncertainty_score":0.9834647},"labels":[],"label_agreement":null},{"id":"W6977493977","doi":"10.6084/m9.figshare.c.7129672","title":"What are the views of Quebec and Ontario citizens on the tiebreaker criteria for prioritizing access to adult critical care in the extreme context of a COVID-19 pandemic?","year":2024,"lang":"en","type":"other","venue":"Figshare","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Polytechnique Montréal; University of Ottawa; École Nationale d'Administration Publique; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Hamilton Health Sciences; Université de Sherbrooke; Université du Québec à Montréal; McGill University Health Centre; Université de Montréal","funders":"","keywords":"Thematic analysis; Deliberation; Context (archaeology); Health care; Exploratory research; Public health; Session (web analytics); Qualitative research; Pandemic","score_opus":0.2145141307830252,"score_gpt":0.4039633390244587,"score_spread":0.1894492082414335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6977493977","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009901662,0.106761105,0.000004867941,0.046009794,0.0016450359,0.034595244,0.7267017,0.00032708226,0.074053526],"genre_scores_gemma":[0.54980636,0.00086993224,0.00019500226,0.09216861,0.0027737182,0.01722686,0.07826708,0.0020735974,0.25661886],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982444,0.00016244264,0.00041929376,0.0004883127,0.00038117624,0.00030434108],"domain_scores_gemma":[0.9973407,0.0013887717,0.00019150984,0.00077610585,0.00018170467,0.0001212297],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001658674,0.00037406493,0.0006840372,0.0001122298,0.00005459065,0.00015887538,0.0004534597,0.00028801826,0.025816163],"category_scores_gemma":[0.0027774053,0.00018590472,0.00019906691,0.0001654141,0.00006777982,0.0000604888,0.00019501598,0.00046435065,0.000079968166],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019458157,0.000048312475,0.00033172633,0.0066497484,0.00012330493,0.0000795193,0.018586537,1.1427101e-7,0.000008810887,0.00009293979,0.9709465,0.0029379122],"study_design_scores_gemma":[0.0016515265,0.00024169142,0.0012411203,0.04313363,0.00027024024,0.00006710194,0.018561263,0.0000063073553,0.00003229874,0.00006118753,0.9345133,0.00022037922],"about_ca_topic_score_codex":0.021263402,"about_ca_topic_score_gemma":0.6158338,"teacher_disagreement_score":0.6484346,"about_ca_system_score_codex":0.0011179715,"about_ca_system_score_gemma":0.0009728189,"threshold_uncertainty_score":0.9852541},"labels":[],"label_agreement":null},{"id":"W6985023507","doi":"","title":"Fonds Roger FARAUT","year":2016,"lang":"fr","type":"other","venue":"OpenEdition (OpenEdition)","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Context (archaeology); Period (music); Term (time); Quarter (Canadian coin)","score_opus":0.014728789562650347,"score_gpt":0.26823812356347354,"score_spread":0.2535093340008232,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6985023507","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00035235504,0.0067228773,0.0016064243,0.045522306,0.013870012,0.0033600426,0.0024649727,0.000437445,0.9256636],"genre_scores_gemma":[0.018134195,0.0034372704,0.001428735,0.026436526,0.013670216,0.0015791338,0.0065107206,0.0009202611,0.92788297],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9919653,0.00047078502,0.001636658,0.0021573678,0.00179072,0.0019791564],"domain_scores_gemma":[0.9943118,0.0005579667,0.0011349393,0.002143202,0.00054247334,0.0013095845],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0006456443,0.0017943985,0.0020000085,0.00079551607,0.0005671799,0.00028165852,0.00094768475,0.0017683241,0.6525033],"category_scores_gemma":[0.00040987393,0.0015536713,0.0008398997,0.0005582153,0.0007879813,0.006008232,0.00044306007,0.0010453463,0.24324422],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004806821,0.0015565689,0.0008023376,0.00094797014,0.0022313637,0.0016588939,0.00010875669,0.000011236103,0.0012476222,0.30329534,0.5997066,0.08795266],"study_design_scores_gemma":[0.012003962,0.0007322753,0.009439465,0.0060763657,0.0014791561,0.0006329269,0.00008540722,0.00007997084,0.0026302133,0.0018514419,0.96338147,0.0016073475],"about_ca_topic_score_codex":0.00020604754,"about_ca_topic_score_gemma":0.0008433492,"teacher_disagreement_score":0.40925908,"about_ca_system_score_codex":0.006429092,"about_ca_system_score_gemma":0.0023568827,"threshold_uncertainty_score":0.9995276},"labels":[],"label_agreement":null},{"id":"W6987313445","doi":"","title":"Stopping Study in Chronic Myeloid Leukemia: Defining a New Paradigm for Ontario","year":2024,"lang":"en","type":"article","venue":"Scholarship at UWindsor (University of Windsor)","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Limiting; Population; Subpoena; TSG101","score_opus":0.03506782913480756,"score_gpt":0.27198986227433225,"score_spread":0.2369220331395247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6987313445","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99307525,0.0022748248,0.00015313497,0.00063387357,0.0002754371,0.0017332565,0.000028049524,0.00017139589,0.001654801],"genre_scores_gemma":[0.9811642,0.00004409066,0.0015653982,0.00006112624,0.00013483888,0.000006008265,0.00009334534,0.000066557455,0.0168644],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99725944,0.0000988627,0.00039762113,0.00095516996,0.00056101853,0.00072789576],"domain_scores_gemma":[0.99847,0.00027603068,0.00014494132,0.0006732217,0.00006570379,0.00037007162],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007221267,0.0004062896,0.00078427145,0.0007155404,0.00028091943,0.000056603727,0.00040485995,0.00033342585,0.0008027521],"category_scores_gemma":[0.000090459354,0.00048054318,0.0003833754,0.0007533215,0.00011279822,0.00067972223,0.00026015576,0.0010106679,0.00023907296],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0029448697,0.0006963363,0.9210548,0.0011781304,0.001772513,0.0027682234,0.038584515,0.00055638514,0.0066929534,0.0011987805,0.0018511864,0.020701347],"study_design_scores_gemma":[0.023574336,0.0026184355,0.93841225,0.0019382574,0.001192015,0.00020275143,0.0036438562,0.00081800483,0.0006625249,0.0006758502,0.025522722,0.00073897344],"about_ca_topic_score_codex":0.01840844,"about_ca_topic_score_gemma":0.15062487,"teacher_disagreement_score":0.13221644,"about_ca_system_score_codex":0.019847957,"about_ca_system_score_gemma":0.0077090436,"threshold_uncertainty_score":0.9997646},"labels":[],"label_agreement":null},{"id":"W6989960970","doi":"","title":"Comparison of oncological outcomes of uterine adenocarcinoma and grade 3 endometrial carcinoma: a meta-analysis of observational studies","year":2021,"lang":"en","type":"other","venue":"OSF Preprints (OSF Preprints)","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Observational study; MEDLINE; Scopus; Randomized controlled trial; Systematic review; CINAHL; Clinical trial","score_opus":0.23301899082969843,"score_gpt":0.4186304807859091,"score_spread":0.18561148995621066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6989960970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7071765,0.003220903,0.00014856055,0.0005122541,0.0004129744,0.0036778683,0.0010357681,0.000100137106,0.283715],"genre_scores_gemma":[0.5857325,0.0004749375,0.004617027,0.00003271285,0.000051854837,0.00019163157,0.00025325184,0.00010788118,0.40853816],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9944219,0.00065276976,0.0018311371,0.0017808559,0.0010007211,0.00031259257],"domain_scores_gemma":[0.9924894,0.0021509032,0.0018881483,0.0029149249,0.0003805988,0.0001760415],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0017274136,0.0005915415,0.00706299,0.0010811862,0.0000330692,0.000009266776,0.00048623572,0.00048963365,0.36981797],"category_scores_gemma":[0.004460748,0.0004853261,0.001996282,0.00097065856,0.00056667026,0.000037301972,0.0014108659,0.00041366002,0.0012778399],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002581555,0.0014762401,0.7370847,0.0014143985,0.24932729,0.000053822157,0.00062769663,0.00007257476,0.0007859196,0.0002729746,0.008320801,0.00030542587],"study_design_scores_gemma":[0.0049485317,0.000031283635,0.7717215,0.00011879901,0.2040396,0.000024775858,0.00032807657,0.00016567823,0.0051183216,0.00009137254,0.013035537,0.00037651527],"about_ca_topic_score_codex":0.000920655,"about_ca_topic_score_gemma":0.00027369527,"teacher_disagreement_score":0.36854014,"about_ca_system_score_codex":0.00047163805,"about_ca_system_score_gemma":0.00048734774,"threshold_uncertainty_score":0.99975985},"labels":[],"label_agreement":null},{"id":"W6999706055","doi":"","title":"Design and mechanism of action of novel agents termed \"combi-molecules\" engineered for tandem targeting for Bcr-abl expressing leukemia cells","year":2007,"lang":"en","type":"dissertation","venue":"eScholarship@McGill (McGill)","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Mechanism of action; Mechanism (biology); Leukemia; Action (physics); Tandem; Cell culture","score_opus":0.040400814138701543,"score_gpt":0.29890560531261146,"score_spread":0.2585047911739099,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6999706055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98679024,0.00040178196,0.0037320992,0.0000040258806,0.0014092713,0.005520486,0.00093373586,0.00013921202,0.0010691201],"genre_scores_gemma":[0.89960593,0.00020921402,0.09512163,0.000053331,0.000070167815,0.00036267322,0.0021142347,0.0003302478,0.002132548],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9958996,0.00010460241,0.0014501858,0.0010206477,0.0007331502,0.00079180836],"domain_scores_gemma":[0.9961838,0.00082520256,0.0014188254,0.00055620197,0.000698079,0.00031790414],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012247609,0.00083930115,0.0014543262,0.0005924809,0.00038443602,0.000027651884,0.00027431923,0.0011113478,0.000031648815],"category_scores_gemma":[0.00091093767,0.0008912223,0.00047110993,0.0003009187,0.00005621853,0.00030816754,0.000059490034,0.00066141784,0.0000023936327],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015790238,0.00033878817,0.0000033409951,0.0033710247,0.0006528239,0.00001415087,0.000038257633,0.0002372476,0.9730855,0.00174176,0.000014527115,0.018923504],"study_design_scores_gemma":[0.012065083,0.0007345257,0.000078690595,0.0020965852,0.0013150534,0.000022395436,0.00032263575,0.0044316743,0.976055,0.0011866519,0.0010646104,0.00062706706],"about_ca_topic_score_codex":0.00007681461,"about_ca_topic_score_gemma":0.000021961941,"teacher_disagreement_score":0.09138953,"about_ca_system_score_codex":0.0026930508,"about_ca_system_score_gemma":0.00036668094,"threshold_uncertainty_score":0.9993538},"labels":[],"label_agreement":null},{"id":"W7001138198","doi":"","title":"Implementing pharmacokinetic guided dosing to support the safe use of tyrosine kinase inhibitors","year":2025,"lang":"en","type":"dissertation","venue":"Radboud Repository (Radboud University)","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"","keywords":"Dosing; Pharmacokinetics; Tyrosine kinase; Kinase; Drug; Tyrosine-kinase inhibitor; Protein kinase A","score_opus":0.0254750282925334,"score_gpt":0.2819994501147563,"score_spread":0.2565244218222229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7001138198","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9457184,0.0010793427,0.00006355718,0.00020507943,0.0040208604,0.0027372383,0.00012687568,0.0001826167,0.04586604],"genre_scores_gemma":[0.596714,0.00043557328,0.0008264987,0.00017325633,0.0007518342,0.000018548259,0.0017297443,0.00014929897,0.39920124],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99625,0.00022240492,0.0009641312,0.00091832003,0.0008218141,0.00082335173],"domain_scores_gemma":[0.9969267,0.00026236603,0.00078083493,0.0010996833,0.00058528245,0.00034512763],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000245825,0.00068876793,0.00097042223,0.0011562199,0.00068372564,0.0001302411,0.00049291,0.00039555578,0.00009464007],"category_scores_gemma":[0.00012683496,0.00063396915,0.0004738587,0.0013884165,0.00010847447,0.00022121977,0.00027062176,0.0006706017,0.000015377114],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009206807,0.0033683977,0.027527034,0.0088521885,0.011278307,0.016931636,0.009807444,0.0069765956,0.59933007,0.0053251176,0.24517164,0.056224756],"study_design_scores_gemma":[0.0074610757,0.0006753245,0.008923571,0.0026919397,0.006467525,0.0002307914,0.002674606,0.0005884355,0.14381197,0.0000036114197,0.825455,0.0010161379],"about_ca_topic_score_codex":0.0018176232,"about_ca_topic_score_gemma":0.00008973517,"teacher_disagreement_score":0.58028334,"about_ca_system_score_codex":0.0022807326,"about_ca_system_score_gemma":0.0021328754,"threshold_uncertainty_score":0.99961114},"labels":[],"label_agreement":null},{"id":"W7021049794","doi":"","title":"Novel Sensors for Improving Reinforced Concrete Design and Assessment","year":2018,"lang":"en","type":"dissertation","venue":"QSpace (Queen's University Library)","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Natural Sciences and Engineering Research Council of Canada; Queen's University","keywords":"Deflection (physics); Reinforced concrete; Stiffness; Finite element method; Beam (structure); Reinforcement; Cracking; Measure (data warehouse)","score_opus":0.012824831476142981,"score_gpt":0.2369344955355543,"score_spread":0.2241096640594113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7021049794","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90015554,0.00013365451,0.022243502,0.017289108,0.0014950796,0.011883281,0.0005479463,0.0014572359,0.04479464],"genre_scores_gemma":[0.024828233,0.0002975276,0.23078871,0.00018243778,0.00027101274,0.000013399455,0.003627251,0.00018096922,0.73981047],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99823654,0.000054315984,0.00022560934,0.00071886077,0.0003055687,0.00045909974],"domain_scores_gemma":[0.9984519,0.00024242107,0.00036310393,0.00047953526,0.00013477138,0.00032827447],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00007408132,0.00049286574,0.0006582477,0.00036245785,0.00026399593,0.00006833454,0.00019009861,0.0005420262,0.00023498239],"category_scores_gemma":[0.000055970657,0.0005292604,0.00020418632,0.00022235412,0.0000984037,0.0006297143,0.000095513606,0.0004126183,0.00001584334],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03764074,0.0002489792,0.0040178015,0.01792905,0.00876204,0.0026076478,0.010926404,0.0002185202,0.020455725,0.015223889,0.8677823,0.014186933],"study_design_scores_gemma":[0.07976625,0.011917886,0.020866128,0.005212111,0.012114368,0.00005187792,0.024192376,0.014555092,0.18443803,0.00014579948,0.6404165,0.0063235997],"about_ca_topic_score_codex":0.0016793819,"about_ca_topic_score_gemma":0.000008922998,"teacher_disagreement_score":0.87532735,"about_ca_system_score_codex":0.0007832112,"about_ca_system_score_gemma":0.0020556161,"threshold_uncertainty_score":0.9997159},"labels":[],"label_agreement":null},{"id":"W7065964632","doi":"","title":"Gender Differences in Inhaled Pharmacotherapy Utilization in Patients with Obstructive Airway Diseases (OADs): A Population-Based Study","year":2020,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"COPD; Pharmacotherapy; Logistic regression; Airway; Retrospective cohort study; Confidence interval; Cohort","score_opus":0.22564794592792126,"score_gpt":0.5035742338664726,"score_spread":0.27792628793855134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7065964632","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99533355,0.0018451808,0.000052336993,0.00008057772,0.0000979898,0.002396029,0.000056546596,0.00003174092,0.00010606925],"genre_scores_gemma":[0.99894726,0.0002709533,0.0000686725,0.0003507693,0.000057293746,0.00012725798,0.000112712565,0.000052815096,0.000012267336],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971012,0.00034888307,0.00079435005,0.00055126275,0.0008968508,0.00030744215],"domain_scores_gemma":[0.9984595,0.00019721176,0.0005657571,0.0002724167,0.0002097371,0.00029534477],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00017704739,0.0003588145,0.00091713865,0.0006736959,0.000082135724,0.00018821334,0.00060406915,0.000067206776,0.0038346783],"category_scores_gemma":[0.00017614543,0.00028003048,0.00008495416,0.0013924486,0.00004875886,0.00096422597,0.00013196688,0.0003069183,0.0000037279237],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032153395,0.002477573,0.9865746,0.00009664707,0.0002748588,0.000100530415,0.000812295,0.0003963003,0.00034434898,0.0000016553888,0.00011679018,0.005589075],"study_design_scores_gemma":[0.0154994195,0.000134443,0.98203886,0.0003193123,0.00017740359,8.2702167e-7,0.00020740982,0.0006367034,0.0006348002,0.00007414363,0.00001116302,0.0002654965],"about_ca_topic_score_codex":0.0010593033,"about_ca_topic_score_gemma":0.00016634361,"teacher_disagreement_score":0.0122840805,"about_ca_system_score_codex":0.0007266969,"about_ca_system_score_gemma":0.00044949347,"threshold_uncertainty_score":0.9999652},"labels":[],"label_agreement":null},{"id":"W7084580264","doi":"10.5281/zenodo.17262700","title":"CANADA 🇨🇦, AUSTRALIA 🇦🇺,UK 🇬🇧 WORK VISAS AVAILABLE CALL OR WHATSAPP MR PETER OBENDE ON ☎(08143870581).","year":2025,"lang":"en","type":"other","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Work (physics)","score_opus":0.04188366152382906,"score_gpt":0.2677908379448095,"score_spread":0.22590717642098046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7084580264","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00028925415,0.00022792142,0.00003556792,0.00066111627,0.0004175641,0.0012605829,0.00095800793,0.0007806949,0.9953693],"genre_scores_gemma":[0.006421593,0.0002689734,0.00022570947,0.0007625487,0.00046746872,2.5440988e-7,0.0041923528,0.005556504,0.9821046],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99676955,0.00022912308,0.00040272847,0.0009416192,0.0008916911,0.0007653065],"domain_scores_gemma":[0.9977213,0.000046140674,0.00021302464,0.0012458519,0.00032763387,0.00044606233],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00024440925,0.0005016706,0.00055988046,0.00046080528,0.0006328409,0.00036693306,0.0008634731,0.00030635737,0.463065],"category_scores_gemma":[0.0005715761,0.00044596996,0.00010926955,0.00070826354,0.00013945968,0.000056362336,0.00072386034,0.0007724814,0.053087886],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035428072,0.00015825931,0.00001523454,0.00031775178,0.00039419593,0.0004494539,0.000056625697,0.0000045323245,0.00005460237,0.0001700632,0.9917679,0.006257096],"study_design_scores_gemma":[0.0021222294,0.00037569206,0.00019959542,0.0010342571,0.00016337818,0.00010627966,0.00002782978,0.000009971418,0.0001419299,0.0000041208887,0.9954467,0.0003680428],"about_ca_topic_score_codex":0.057952017,"about_ca_topic_score_gemma":0.0040567773,"teacher_disagreement_score":0.4099771,"about_ca_system_score_codex":0.0030912517,"about_ca_system_score_gemma":0.00030691197,"threshold_uncertainty_score":0.9997992},"labels":[],"label_agreement":null},{"id":"W7108451088","doi":"10.1182/blood-2025-73","title":"Distinct patterns of mutant ASXL1 over time and their implications for treatment failure (TF) and BCR::ABL1 mutation development in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) treated with asciminib (ASC) vs investigator-selected tyrosine kinase inhibitors (IS-TKI) in the ASC4FIRST study","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Proportional hazards model; Myeloid leukemia; Mutation; Allele; Multivariate analysis; Genotype; Allele frequency; Survival analysis","score_opus":0.009043509721543675,"score_gpt":0.24678857015356734,"score_spread":0.23774506043202367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7108451088","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925463,0.00039995133,0.000011824551,0.00027669157,0.000010490905,0.0064599547,0.00024699685,0.000037389244,0.000010398129],"genre_scores_gemma":[0.99677724,0.00004803538,0.00016336484,0.000063181986,0.000023315828,0.0018803431,0.00096479163,0.00005180607,0.000027929147],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976259,0.00014583408,0.0007423425,0.0007655624,0.00023335908,0.00048699998],"domain_scores_gemma":[0.99857223,0.0003595034,0.00027490073,0.0004975351,0.00014270986,0.00015312844],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019790024,0.0005468475,0.00076593476,0.00044951492,0.00012650026,0.00004206561,0.00013222838,0.00013878837,0.000010628662],"category_scores_gemma":[0.00011150718,0.0003434796,0.000042161908,0.0011133172,0.00013756163,0.00014582569,0.00005050309,0.00018548514,8.718085e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00096984184,0.0052775354,0.97745514,0.0002488835,0.00047527847,0.00006729601,0.005223218,0.000039178365,0.0031818035,0.0000061664323,0.000018780109,0.0070369067],"study_design_scores_gemma":[0.11102009,0.0065826722,0.8627882,0.00097028306,0.00047180057,0.00001638069,0.00031566946,0.00032864185,0.01714522,0.000009963444,0.00006774991,0.00028335018],"about_ca_topic_score_codex":0.0024425494,"about_ca_topic_score_gemma":0.027515769,"teacher_disagreement_score":0.11466693,"about_ca_system_score_codex":0.0046096435,"about_ca_system_score_gemma":0.0034184044,"threshold_uncertainty_score":0.9999017},"labels":[],"label_agreement":null},{"id":"W7117159139","doi":"10.51731/cjht.2025.1316","title":"Quizartinib (Vanflyta)","year":2025,"lang":"","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cytarabine; Myeloid leukemia; Reimbursement; Drug; Food and drug administration","score_opus":0.024026374837483006,"score_gpt":0.3171629694084499,"score_spread":0.2931365945709669,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117159139","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06827554,0.7122403,0.00041638146,0.20762771,0.004682773,0.000993738,0.000057738554,0.00016417664,0.005541643],"genre_scores_gemma":[0.9862629,0.008292438,0.0006797499,0.00230895,0.000044756187,0.000009646174,0.000004298763,0.00003641495,0.0023608573],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951608,0.00018364968,0.0022493543,0.0003931126,0.00036613134,0.0016469316],"domain_scores_gemma":[0.99655914,0.00023124905,0.0013622025,0.00094698,0.00052399957,0.00037645467],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016044594,0.00045814484,0.0015022439,0.0028501211,0.00063733826,0.00008394618,0.0009011678,0.00065164274,0.00029515376],"category_scores_gemma":[0.0034050357,0.0004164475,0.00032211732,0.0015820762,0.0008928712,0.00018485055,0.00007956831,0.0017912916,0.000089465655],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0000681858,0.00008169053,0.017542282,0.000858218,0.00058799965,0.0012189435,0.00047909687,0.000015400467,0.000023373115,0.0033788998,0.05763973,0.9181062],"study_design_scores_gemma":[0.0056957733,0.0019687775,0.01780885,0.0079825455,0.0003706945,0.0008745273,0.011292256,0.00005659035,0.0014030631,0.0059615336,0.9462327,0.00035269494],"about_ca_topic_score_codex":0.012238087,"about_ca_topic_score_gemma":0.009037965,"teacher_disagreement_score":0.91798735,"about_ca_system_score_codex":0.010571383,"about_ca_system_score_gemma":0.07921841,"threshold_uncertainty_score":0.99982876},"labels":[],"label_agreement":null},{"id":"W7117359556","doi":"10.31640/ls-2025-4-24","title":"Management of chronic myeloid leukemia in children and adolescents: tyrosine kinase inhibitor efficacy, survivorship challenges, and long-term hemostatic safety","year":2025,"lang":"","type":"article","venue":"Likarska sprava","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Myeloid leukemia; Tyrosine-kinase inhibitor; Survivorship curve; Observational study; Disease; Tyrosine kinase; Bone marrow transplantation; Quality of life (healthcare); Leukemia","score_opus":0.010968381465590593,"score_gpt":0.25666972413100786,"score_spread":0.24570134266541727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117359556","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7892065,0.20510371,0.000032281812,0.0007718604,0.0005709077,0.0035190745,0.0000927032,0.0000622814,0.00064068],"genre_scores_gemma":[0.8338512,0.16404077,0.00015666739,0.0001405611,0.00021412001,0.000052777577,0.0001898589,0.00010396311,0.0012500881],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99375314,0.0004131495,0.0018694437,0.0018438937,0.00076027645,0.0013600831],"domain_scores_gemma":[0.99706525,0.00027466065,0.00053526287,0.0014977922,0.00011683337,0.0005102068],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00087677204,0.0011658426,0.0018254581,0.000750545,0.00017027046,0.00006661184,0.0004310319,0.00057349977,0.00011996447],"category_scores_gemma":[0.000104538325,0.0012064349,0.00019086864,0.00085578643,0.00073946564,0.00025670123,0.0009625209,0.000983968,0.000037420712],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032236394,0.0026234284,0.40715724,0.018979123,0.0023679778,0.0009987231,0.0016960409,0.000035867855,0.0005933025,0.0015266933,0.00014735812,0.5606506],"study_design_scores_gemma":[0.037235387,0.0009850397,0.92612326,0.030973742,0.0014002223,0.000095777454,0.00026888566,0.00023908801,0.0016902648,0.000059472666,0.00020700076,0.0007218473],"about_ca_topic_score_codex":0.0008471394,"about_ca_topic_score_gemma":0.0010701668,"teacher_disagreement_score":0.5599288,"about_ca_system_score_codex":0.006483763,"about_ca_system_score_gemma":0.001328804,"threshold_uncertainty_score":0.9990386},"labels":[],"label_agreement":null},{"id":"W7132961279","doi":"","title":"Identification and characterization of the signaling mechanisms downstream of Dok-R that mediate cell migration and actin reorganization","year":2004,"lang":"","type":"dissertation","venue":"TSpace","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bibliothèque et Archives nationales du Québec; University of Toronto","funders":"","keywords":"Cell migration; Signal transduction; Actin cytoskeleton; Phosphorylation; Phosphatidylinositol; Angiogenesis; Tyrosine kinase; Cell; Endothelial stem cell; Cell signaling","score_opus":0.009726748151795642,"score_gpt":0.25970563993510154,"score_spread":0.2499788917833059,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7132961279","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99448913,0.00062429317,0.001798098,0.0003674812,0.0006771615,0.0018621013,0.000056366585,0.000028200244,0.00009714704],"genre_scores_gemma":[0.99087435,0.0035995403,0.00023460691,0.0000191246,0.00008684691,0.000036946218,0.0025624228,0.00008613088,0.0025000223],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99713767,0.00019296184,0.00096011866,0.0006661695,0.00077454455,0.00026853167],"domain_scores_gemma":[0.9959094,0.00012437436,0.0027742533,0.00057738484,0.000492557,0.000122008954],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00042541567,0.0005052951,0.0007107834,0.00028662645,0.00020997965,0.00005450111,0.00016294284,0.0005600588,0.00010897813],"category_scores_gemma":[0.0001936877,0.0004313113,0.00010574961,0.0006007011,0.00014170933,0.00028700972,0.000059638693,0.00031298812,0.000005697506],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023175775,0.00019900576,0.0034998364,0.0021103835,0.00013294346,0.0000014841738,0.024392651,0.00002868815,0.9672567,0.00018599795,0.0000020986108,0.0019584105],"study_design_scores_gemma":[0.002656011,0.00020131687,0.06838983,0.001725272,0.0013514704,0.000011522567,0.0069232234,0.00053808995,0.9177422,0.00019593468,0.000008049149,0.00025710577],"about_ca_topic_score_codex":0.00068495754,"about_ca_topic_score_gemma":0.00023087909,"teacher_disagreement_score":0.06489,"about_ca_system_score_codex":0.0005535912,"about_ca_system_score_gemma":0.0007364232,"threshold_uncertainty_score":0.99981385},"labels":[],"label_agreement":null},{"id":"W97160107","doi":"10.1182/blood.v116.21.3397.3397","title":"Analysis of BCR-ABL1 Tyrosine Kinase Domain Mutations In Primitive Chronic Myeloid Leukemia Cells Identifies a Unique Mutator Phenotype.","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Imatinib mesylate; Myeloid leukemia; Biology; Mutation; Cancer research; Phenotype; Tyrosine kinase; Leukemia; Molecular biology; ABL; Imatinib; Genetics; Gene; Receptor","score_opus":0.007657762070300278,"score_gpt":0.2521590659268038,"score_spread":0.24450130385650354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W97160107","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972042,0.00042751315,0.000092599905,0.00009303289,0.00015279496,0.0006513264,0.00016373981,0.00006992732,0.0011448914],"genre_scores_gemma":[0.996457,0.000076320706,0.0023657705,0.00005672225,0.000114988354,0.00009165017,0.000388242,0.000046078327,0.00040325432],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979477,0.000088889596,0.0006341772,0.0005155583,0.00038353464,0.00043014862],"domain_scores_gemma":[0.99835354,0.00026759994,0.00026575872,0.0007320065,0.00019224247,0.00018885378],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00028636682,0.00030267125,0.0007698078,0.00083421636,0.00007141156,0.000024593419,0.00017972548,0.00022458196,0.0005832822],"category_scores_gemma":[0.00019522212,0.00028804192,0.00028041014,0.0017164735,0.00026185665,0.00013203756,0.00007591613,0.00046863576,0.00005645042],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012789336,0.0015973754,0.02331757,0.00018302516,0.0024636313,0.00041878098,0.002501282,0.00023342049,0.96747065,0.0006392285,0.00006070354,0.0009864714],"study_design_scores_gemma":[0.014097742,0.00029774633,0.32647026,0.00020369302,0.006968372,0.000039346483,0.0005543276,0.0006709261,0.64980257,0.00027731658,0.00024427936,0.00037343102],"about_ca_topic_score_codex":0.0012344761,"about_ca_topic_score_gemma":0.005454045,"teacher_disagreement_score":0.31766805,"about_ca_system_score_codex":0.0010000337,"about_ca_system_score_gemma":0.0016836683,"threshold_uncertainty_score":0.99995714},"labels":[],"label_agreement":null}]}